[{"CaseStudyId":"989","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"3175395","Name":"Italy"},{"GeoNamesId":"2921044","Name":"Germany"},{"GeoNamesId":"1269750","Name":"India"}],"Funders":[],"ImpactDetails":"\u000d\u000a    \u000d\u000a    Exploiting nanomaterials for drug delivery\u000d\u000a    The Kent research into nanoparticulate magnetite (described in section 2)\u000d\u000a      laid the foundation for EryDel's (http:\/\/www.erydel.com\/)\u000d\u000a      preliminary studies into stability, functionality and delivery of iron\u000d\u000a      base contrast agents using Erythrocyte ghosts.\u000d\u000a    EryDel is an SME, founded in 2007 by the University of Urbino, Italy as a\u000d\u000a      direct result of the Kent- led European Commission NACBO project. The Kent\u000d\u000a      research was conducted in close collaboration with the Healthcare Division\u000d\u000a      of Royal Philips Electronics at Hamburg, Germany using their experimental\u000d\u000a      medical imaging platforms for small mammals. It led to the signature of a\u000d\u000a      joint accord between Phillips and EryDel relating to the development and\u000d\u000a      exploitation of the processes and materials involved. These processes and\u000d\u000a      materials are unique, covered by international patents, and possess the\u000d\u000a      potential to significantly impact a global market estimated to be worth in\u000d\u000a      excess of &#8364;11 billion by 2015. Together, Royal Philips Electronics and\u000d\u000a      EryDel are actively pursuing the commercial development and exploitation\u000d\u000a      of the materials and processes involved. As a consequence of this work and\u000d\u000a      optimisation of the erythroctye encapsulation process, the company has\u000d\u000a      developed the erythrocyte ghost system into a platform for drug delivery.\u000d\u000a      It has successfully concluded the Phase II Proof of Concept Study \"Evaluation\u000d\u000a        of Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate (EryDex)\u000d\u000a        on Neurological Symptoms in Ataxia- Teleangectasia (A-T) Patients\",\u000d\u000a      EudraCT Number 2010-022315-19 and has just announced (June 2013) that the\u000d\u000a      European Medicinal Agency has approved\u000d\u000a        Orphan Drug Designation for EryDex for the treatment of Ataxia\u000d\u000a      Telangiectasia. A-T is a rare, neurodegenerative, inherited disease\u000d\u000a      causing severe disability. Orphan Drug status allows the company 10 years\u000d\u000a      of marketing exclusivity from the time of approval.\u000d\u000a    EryDex also has the potential for use in the treatment for a variety of\u000d\u000a      other conditions and clinical pilot studies have already been conducted in\u000d\u000a      Europe in patients with chronic obstructive pulmonary disease, cystic\u000d\u000a      fibrosis, ulcerative colitis and Crohn's disease.\u000d\u000a    The Kent research team and EryDel's founders (Prof Magnami) were\u000d\u000a      co-collaborators on three European Commission nanotechnology grants\u000d\u000a      (section 3), have published a number of joint publications since 2004\u000d\u000a      (including the key reference 6, section 3) and have jointly presented at\u000d\u000a      numerous conferences.\u000d\u000a    Molecular diagnostics and forensics\u000d\u000a    The nanomaterials produced at Kent as part of the NACBO project have\u000d\u000a      underwritten the development of, and have been incorporated into, a number\u000d\u000a      of molecular diagnostic kits for the extraction of nucleic acids, e.g.\u000d\u000a      Bacterial DNA isolation (MBK0005),\u000d\u000a      Listeria monocytogenes DNA (MBK0002),\u000d\u000a      and the detection of microorganisms e.g. Legionella (MBK0051) and\u000d\u000a      microalga (MBK0003).\u000d\u000a      The diagnostic kits are marketed worldwide by Diatheva (www.diatheva.com),\u000d\u000a      an SME founded in 2002, for research and therapeutic applications in the\u000d\u000a      field of cancer, microbial infection and pharmacogenics. Reference 3,\u000d\u000a      section 3 is the key joint publication between Kent and Diatheva's\u000d\u000a      founders, outlining the joint research and potential impact. In 2012 a 51%\u000d\u000a      share of Diatheva was acquired\u000d\u000a        by the SOL Group. The SOL\u000d\u000a        Group is an Italian based multinational group present in 20 European\u000d\u000a      countries and India, employing over 2,350 people and has an annual revenue\u000d\u000a      of &#8364;555 million.\u000d\u000a    In 2011, the European Commission summed up the impact from the Kent-led\u000d\u000a      NACBO project as follows: \"Materials and processes generated by the\u000d\u000a      [NACBO] consortium, particularly surface activation strategies, materials\u000d\u000a      for use as contrast agents and\/or in drug delivery and diagnostic kits,\u000d\u000a      are already being commercially exploited by partners or in later stages of\u000d\u000a      clinical evaluation. Future revenues over the next 5 years are estimated\u000d\u000a      at least around &#8364; 35 million and projected additional future revenue based\u000d\u000a      on market penetration by project outputs could be in the region of between\u000d\u000a      &#8364;100 million to &#8364;500 million over the next 5 to 10 years.\"\u000d\u000a    \"Outputs from the project are already positively contributing to the\u000d\u000a      improvement of diagnostics (health and forensics), not only within the\u000d\u000a      European Union but also worldwide. In the context of forensics, improved\u000d\u000a      detection limit sensitivities and better robustness in genetic profiling\u000d\u000a      using materials and procedures developed in the project are already\u000d\u000a      helping to solve criminal cases and increase individuals' security and\u000d\u000a      protection from crime. Finally, the surface activation approaches\u000d\u000a      developed in the project are already making fine chemical manufacturing\u000d\u000a      processes (involved in the production of ultra-high quality pharmaceutical\u000d\u000a      grade materials) more robust and reproducible reducing associated cost,\u000d\u000a      time and undesirable environmental consequences.\"\u000d\u000a    ","ImpactSummary":"\u000d\u000a    The nanobiotechnology research group at the University of Kent (Bruce et\u000d\u000a        al.) has pioneered the ability to control, manipulate and\u000d\u000a      commercially process magnetite nanoparticles. Two spinout companies,\u000d\u000a      EryDel and Dietheva have been formed, with a &#8364;6 million venture capital\u000d\u000a      grant, as a direct result of the Kent-led research. EryDel (in\u000d\u000a      collaboration with Philips Healthcare) are exploiting the materials\u000d\u000a      worldwide for drug delivery (Erydex), with US and European approval for\u000d\u000a      Orphan drug designation given in 2013 for genetic diseases, and Diatheva\u000d\u000a      are marketing the technology for forensic diagnostic kits. The predicted\u000d\u000a      five-year revenue is &#8364;35 million with a potential market of &#8364;17 billion.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a\u0009\u000d\u000a\u0009University of Kent\u000d\u000a    \u000d\u000a\u0009","Institutions":[{"AlternativeName":"Kent (University of)","InstitutionName":"University of Kent","PeerGroup":"B","Region":"South East","UKPRN":10007150}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    References [1], [2] and [6] best indicate the quality of the underpinning\u000d\u000a      research):\u000d\u000a    \u000a1. Bruce IJ, Sen T \"Surface modification of magnetic\u000d\u000a      nanoparticles with alkoxysilanes and their application in magnetic\u000d\u000a      bioseparations\", Langmuir, 2005, 21(15), 7029-7035, DOI: http:\/\/dx.doi.org\/10.1021\/la050553t\u000d\u000a    \u000a\u000a2. Sen T, Sebastianelli A, Bruce IJ \"Mesoporous silica-magnetite\u000d\u000a      nanocomposite: Fabrication and applications in magnetic bioseparations\", Journal\u000d\u000a        of the American Chemical Society, 2006, 128(22), 7130-7131 DOI:\u000d\u000a      http:\/\/dx.doi.org\/10.1021\/ja061393q\u000d\u000a    \u000a\u000a3. Amagliani G, Omiccioli E, Del Campo A, Bruce IJ, Brandi G,\u000d\u000a      Magnani M, \"Development of a magnetic capture hybridization-PCR assay for\u000d\u000a      Listeria monocytogenes direct detection in milk samples\", Journal of\u000d\u000a        Applied Microbiology, 2006, 100(2), 375-383. DOI: http:\/\/dx.doi.org\/10.1111\/j.1365-2672.2005.02761.x\u000d\u000a    \u000a\u000a4. Sen T, Bruce IJ, \"Mesoporous silica-magnetite nanocomposities:\u000d\u000a      Fabrication, characterization and applications in biosciences\", Microporous\u000d\u000a        and Mesoporous Materials, 2009, 120(3), 246-251, DOI: http:\/\/dx.doi.org\/10.1016\/j.micromeso.2008.11.012\u000d\u000a    \u000a\u000a5. Van De Waterbeemd M, Sen T, Biagini S, Bruce IJ, \"Surface\u000d\u000a      functionalisation of magnetic nanoparticles: Quantification of surface to\u000d\u000a      bulk amine density\", Micro and Nano Letters, 2010, 5(5), 282-285.\u000d\u000a      DOI: http:\/\/dx.doi.org\/10.1049\/mnl.2010.0112\u000d\u000a    \u000a\u000a6. Antonelli A, Sfara C, Manuali E, Bruce IJ, Magnani M\u000d\u000a      \"Encapsulation of superparamagnetic nanoparticles into red blood cells as\u000d\u000a      new carriers of MRI contrast agents\", Nanomedicine, 2011, 6(2),\u000d\u000a      211-223. DOI: http:\/\/dx.doi.org\/10.2217\/NNM.10.163\u000d\u000a    \u000aKey competitive research grants\u000d\u000a    &#8226; EU FP6 Integrated Project \"NACBO: Novel and improved\u000d\u000a      nanomaterials, chemistries and apparatus for nanobiotechnology\". &#8364;11.5\u000d\u000a      million, 13 partner 6 country consortium 2004- 2009. NMP4-CT-2004-500804 Led\u000d\u000a        by Prof Bruce, University of Kent\u000d\u000a    &#8226; European Union FP6 Network \"SELECTNANO: Development of\u000d\u000a      multifunctional nanometallic particles using a new process -\u000d\u000a      sonoelectrochemistry\" 2005-2009 &#8364;3.3 million, 13 partner, 7 country\u000d\u000a      consortium. Project Partner, (2nd) Prof\u000d\u000a        Bruce, University of Kent, &#8364;270K\u000d\u000a    &#8226; European Union FP6 Integrated Project \"CHILL ON\" 2006 - 2011\u000d\u000a      &#8364;15Million, 32 partner, 12 country consortium. Project partner (7th),\u000d\u000a        Prof Bruce, University of Kent, &#8364;807K\u000d\u000a    \u000d\u000a      ","ResearchSubjectAreas":[{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"3","Subject":"Macromolecular and Materials Chemistry"},{"Level1":"9","Level2":"12","Subject":"Materials Engineering"}],"Sources":"\u000d\u000a    Despite assurances of REF confidentially the company was only willing to\u000d\u000a      offer statements already in the public domain.\u000d\u000a    \u000d\u000a      \"Successful European nanotechnology research: Outstanding science and\u000d\u000a        technology to match the needs of a future society\", Directorate-General\u000d\u000a        for Research and Innovation, 2011, ISBN 978-92-79-15623-6:\u000d\u000a      http:\/\/ec.europa.eu\/research\/industrial_technologies\/pdf\/successful-eu-nanotech-\u000d\u000a        research_en.pdf \u000d\u000a      EU document highlighting successful EU projects in nanotechnology, the\u000d\u000a      NACBO project and its impact are highlighted on pages 44-46, Spotlight on\u000d\u000a      NACBO.\u000d\u000a      NACBO Final Activity Report, 2010:\u000d\u000a      http:\/\/cordis.europa.eu\/publication\/rcn\/12321_en.html\u000d\u000a      The final report summarising all final outcomes and outputs of the NACBO\u000d\u000a      project. The spin-out company EryDel is highlighted on pages 5, 10, 16, 28\u000d\u000a      and 48.\u000d\u000a      EryDel's press releases for Orphan Drug approval in Europe and the US,\u000d\u000a        2013:\u000d\u000a      http:\/\/www.erydel.com\/en\/press-releases\u000d\u000a      U.S. Department of Health and Human Services Orphan Drug List:\u000d\u000a      www.hrsa.gov\/opa\/programrequirements\/orphandrugexclusion\/orphandruglist.pdf\u000d\u000a      EryDel product listed on page 24.\u000d\u000a      European Commission list of official designated Orphan Drugs:\u000d\u000a      http:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/alforphreg.htm\u000d\u000a      EU designation EU\/3\/13\/1158.\u000d\u000a      SOL Group acquires majority of Diatheva as further step in the biotech\u000d\u000a        sector, 2012:\u000d\u000a      http:\/\/www.diatheva.com\/newsDettaglio.aspx?id=120\u000d\u000a      Novel and Improved Nanomaterials, Chemistries and apparatus for\u000d\u000a        Nanobiotechnology: the NACBO project - Special Report, Nanomedicine,\u000d\u000a        2011, 6(2), 187-193, ISSN 1743-5889\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000aNanoparticles for Biomedical Applications\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    The underpinning research originated from an &#8364;11.5 million European\u000d\u000a      Commission funded FP6 project called \"NACBO\" - Novel and Improved\u000d\u000a        Nanomaterials, Chemistries and Apparatus for Nano-Biotechnology,\u000d\u000a      which ran from 2004-2009. The integrated research project, part of the NMP\u000d\u000a      (nanotechnology) thematic priority, was led by Prof Ian Bruce at the\u000d\u000a      University of Kent and brought together six universities (Shanghai,\u000d\u000a      Moscow, Urbino, Tel Aviv, Jerusalem and Kent), three Government agencies\u000d\u000a      (Central Public Health Laboratory in the UK and Criminalpol and Istituto\u000d\u000a      Zooprofilattico in Italy) and three companies (Phillips, Proligo and\u000d\u000a      Savyon). The project designed, synthesized and characterized a broad range\u000d\u000a      of biological and non-biological nanocomposite silica, magnetite and\u000d\u000a      carbon materials and their hybrids. Robust scale-up methodologies were\u000d\u000a      developed leading to commercially viable applications in drug delivery,\u000d\u000a      molecular diagnostics and forensics.\u000d\u000a    Kent Research Focus\u000d\u000a    \u000d\u000a      Understanding and controlling the variables involved in producing\u000d\u000a        defined geometry, composite, silica-iron oxide (magnetite) nanoparticles\u000d\u000a        of sizes between 10 to 100nm diameters (2, 4).\u000d\u000a      Understanding and controlling the variables involved in the surface\u000d\u000a        modification of such materials with organosilanes and ligands that would\u000d\u000a        render them useful and stable in biological and biomedical applications\u000d\u000a        (1, 3, 5, 6).\u000d\u000a      Scale-up production of the resultant materials (once best variants had\u000d\u000a        been selected and evaluated in desired applications) to a level and cost\u000d\u000a        that would render them commercially viable.\u000d\u000a    \u000d\u000a    Underpinning Research Outcomes\u000d\u000a    \u000d\u000a      A library of composite silica-magnetite particles were successfully\u000d\u000a        synthesized and produced on large scale.\u000d\u000a      Detailed understanding of their compositions and surface geometries\u000d\u000a        and chemistries was obtained and how they could be chemically activated\u000d\u000a        to amino-functionality in a controlled and measurable manner by\u000d\u000a        treatment with aminosilanes.\u000d\u000a      Detailed knowledge of and ability to modify the particles surfaces\u000d\u000a        with bioligands in a controlled fashion was obtained.\u000d\u000a    \u000d\u000a    All basic and applied research was conducted between 2004 and 2011 at\u000d\u000a      Kent, by the following key researchers (dates refer to period of\u000d\u000a      employment at Kent):\u000d\u000a    \u000d\u000a      \u000aProf\u000d\u000a          Ian Bruce, 2004-2011, Head of Nanobiotechnology Group, University\u000d\u000a        of Kent. Currently Emeritus Professor of Nanobiotechnology.\u000a\u000d\u000a      Dr Tapas Sen, 2003-2008, Postdoctoral Research Assistant,\u000d\u000a        Nanobiotechnology Group.\u000d\u000a      Dr Stephen Bagshaw, 2005-2006, Postdoctoral Research Assistant,\u000d\u000a        Nanobiotechnology Group.\u000d\u000a      \u000aDr\u000d\u000a          Stefano Biagini, 1999 - present, Senior Lecturer in Organic\u000d\u000a        Chemistry, Functional Materials Group.\u000d\u000a      Dr Marion Van De Waterbeem, 2005-2009, , PhD student, Functional\u000d\u000a        Materials Group and Nanobiotechnology Group, co-supervised by Prof Ian\u000d\u000a        Bruce and Dr Stefano Biagini.\u000d\u000a      Dr Antonio Sebastianelli, PhD student, Nanobiotechnology Group,\u000d\u000a        supervised by Prof Ian Bruce.\u000d\u000a    \u000d\u000a    The project has been used as an exemplar of European excellence in\u000d\u000a      science meetings across the World by the European Commission. The project\u000d\u000a      was recently nominated a success story for Europe (page 44):\u000d\u000a    http:\/\/ec.europa.eu\/research\/industrial_technologies\/pdf\/successful-eu-nanotech-research_en.pdf).\u000d\u000a    The 2011 report stated that \"NACBO was a highly successful project that\u000d\u000a      reached or exceeded all of its objectives... NACBO hit on a key that\u000d\u000a      seemed to unlock a treasure box, namely that certain well- made and\u000d\u000a      characterized materials, their surfaces and architectures possess the\u000d\u000a      ability to be used almost universally in a very wide range of\u000d\u000a      applications\".\u000d\u000a    Subsequent fundamental research has been funded by two further European\u000d\u000a      Commission nanotechnology grants, detailed in section 3.\u000d\u000a    "},{"CaseStudyId":"990","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"6252001","Name":"United States"}],"Funders":["Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000d\u000a    Hilger Crystals Ltd (Hilger) manufactures a range of synthetic crystals\u000d\u000a      for X-ray and Infra-red applications. The collaboration between Hilger and\u000d\u000a      the School of Physical Sciences (SPS) dates back more than 10 years and\u000d\u000a      builds on the expertise of Prof. Chadwick and Dr Mountjoy in defect\u000d\u000a      chemistry and analysis of their local structure using XAFS measurements\u000d\u000a      [2,3]. The latest KTP project [4] (co-ordinated by Dr. Alfredsson)\u000d\u000a      followed a CASE-studentship between Prof. Chadwick and Hilger (Drs.\u000d\u000a      Telfer, Hutton and Blacklocks). This is an on-going collaboration and\u000d\u000a      further results are to be expected.\u000d\u000a    The new growth method stemming from SPS's collaboration with Hilger is\u000d\u000a      robust for producing moderate volumes of low afterglow (Tl,Cs)I in\u000d\u000a      relatively low capital cost plant, permitting Hilger to be competitive\u000d\u000a      with low cost manufacturers in China etc. Only a few crystal growers\u000d\u000a      worldwide have been able to achieve this and it has given the company a\u000d\u000a      competitive advantage. This has allowed Hilger to expand its market and\u000d\u000a      seek customers in high-end applications of X-ray imaging such as air\u000d\u000a      transport and sea cargo screening and medical diagnostic devices.\u000d\u000a    Despite the disadvantages detailed above the rare-earth doped crystals\u000d\u000a      are also of interest for some specialist applications.\u000d\u000a    As a result of the new product, derived from the collaboration with the\u000d\u000a      University, the company has recruited new staff, including one new\u000d\u000a      research scientist as well as other high-quality technical staff &#8212; a key\u000d\u000a      requirement for future growth.\u000d\u000a    The new material enables great market penetration for high-performance\u000d\u000a      end sales to X-ray imaging companies throughout the world. All of the\u000d\u000a      company's current customers are located outside the UK. Hence, all sales\u000d\u000a      are export sales, mostly to the USA. The new material increased the annual\u000d\u000a      sales turnover by c.&#163;45k the first year it was launched in 2012 and is\u000d\u000a      projected (based on past experience, by the company) to improve the annual\u000d\u000a      sales turnover in the next three years' time to &#163;250k, which corresponds\u000d\u000a      to about 35% of the company's annual export volume.\u000d\u000a    \u000d\u000a      \u000d\u000a   Detectors and Imaging Arrays Cs(Tl)I from the Hilger Crystals Website.\u000d\u000a      http:\/\/www.hilger-crystals.co.uk\/prior\/detectors.htm\u000d\u000a    \u000d\u000a    A positive effect on the reputation and advertisement of Hilger Crystals\u000d\u000a      Ltd, resulted in the company being acquired by one of their largest\u000d\u000a      competitors in 2010, becoming a partner of the Dynasil group, which\u000d\u000a      specialises in advanced materials for a broad range of applications, with\u000d\u000a      markets in the medical, industrial, defence, as well as the homeland\u000d\u000a      security, sectors. This occurred while the product described in this case\u000d\u000a      study was under development and hence the potential future profits from\u000d\u000a      this product will have contributed to Hilger's attractiveness to Dynasil.\u000d\u000a    Hilger Crystals grow crystals for other companies to use in x-ray\u000d\u000a      scanners and other devices. These are sold into, and employed in, the\u000d\u000a      security and medical industries. Hence societal impact is \"downstream\" and\u000d\u000a      we can only describe this aspect of the impact in general terms.\u000d\u000a    Principal Impact\u000d\u000a    \u000d\u000a      A new product has successfully been developed with a low afterglow\u000d\u000a        that exceeded original expectations.\u000d\u000a      While the new crystals only became available for sale in 2012, Hilger\u000d\u000a        already has four client companies which have purchased the crystals and,\u000d\u000a        thereby, have been able to manufacture and sell cheaper scanners that\u000d\u000a        yield higher quality images.\u000d\u000a      Hilger's managing director informed the University that currently\u000d\u000a        (June 2013) there are about 50 detectors using these crystals in use in\u000d\u000a        security and medical diagnostic roles.\u000d\u000a    \u000d\u000a    Subsidiary Impact\u000d\u000a    \u000d\u000a      Indirectly this work contributes to improved security at national\u000d\u000a        entry points.\u000d\u000a      This work contributes to improved medical diagnostics (particularly\u000d\u000a        mammography).\u000d\u000a      The product is currently around 7%, and projected to reach 35%, of the\u000d\u000a        company's sales.\u000d\u000a      As all of the company's current customers are located outside the UK,\u000d\u000a        all sales are export sales and hence it produces income and tax revenue\u000d\u000a        to the UK.\u000d\u000a      Current customers have been retained, and new customers secured, by\u000d\u000a        the company.\u000d\u000a      New staff has been hired, including a research scientist and high\u000d\u000a        quality technical staff to expand the company's research base.\u000d\u000a      Exclusion of rare-earth dopants makes the material less expensive than\u000d\u000a        the originally proposed product.\u000d\u000a      In 2010 Hilger was incorporated into the Dynasil group, based in the\u000d\u000a        USA, improving the company's research profile with the aim to develop\u000d\u000a        new X-ray imaging materials.\u000d\u000a      A number of academic-related benefits including: (i) Hilger acting as\u000d\u000a        industrial partners in the EU-funded Interreg projects and (ii) SPS is\u000d\u000a        organising the international meeting EURODIM2014. The collaboration with\u000d\u000a        Hilger is assisting the University in attracting world-leading speakers\u000d\u000a        from industrial and academic backgrounds.\u000d\u000a      Generated research income to the University of Kent: (directly)\u000d\u000a        &#163;150,000 and (indirectly) &#163;300,000-&#163;350,000.\u000d\u000a    \u000d\u000a    ","ImpactSummary":"\u000d\u000a    X-ray scanners are a staple of the security industry: their use at ports\u000d\u000a      and airports is a key component of national security. In order to function\u000d\u000a      effectively, these scanners require state-of-the- art scintillator\u000d\u000a      materials and, given the size of the global market and importance of the\u000d\u000a      industry, there is a drive to make these materials work more effectively\u000d\u000a      to achieve better clarity in object identification and faster scanning\u000d\u000a      times.\u000d\u000a    This case study describes the development of a new scintillator product\u000d\u000a      for Hilger Crystals Ltd which was based on a long-term collaboration with\u000d\u000a      materials researchers at the University of Kent. This represents a\u000d\u000a      substantial contribution to: improving security at country entry\/exit\u000d\u000a      points; the commercial success of Hilger and the company's ability to\u000d\u000a      enter new markets (for example medical diagnostic uses). In addition to\u000d\u000a      the downstream security and diagnostic impact arising from this work there\u000d\u000a      have been a number of concomitant benefits to the country, the company and\u000d\u000a      the University.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    University of Kent\u000d\u000a    ","Institutions":[{"AlternativeName":"Kent (University of)","InstitutionName":"University of Kent","PeerGroup":"B","Region":"South East","UKPRN":10007150}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    Underpinning and background research was undertaken by staff at Kent as\u000d\u000a      evidenced below (references [1], [2] and [3] best indicate the quality of\u000d\u000a      the underpinning research). All references are to work led by staff from\u000d\u000a      the School of Physical Sciences at the University of Kent, and all have an\u000d\u000a      author from the University of Kent as first and\/or corresponding author.\u000d\u000a      Bold indicates a Kent author.\u000d\u000a    \u000a1. \"Investigation into thallium sites and defects in doped scintillation\u000d\u000a      crystals\", Blacklocks, A. N.; Chadwick, A. V.; Jackson, R. A.;\u000d\u000a      Hutton, K. B., Physica Status Solidi C &#8212; Current Topics in Solid State\u000d\u000a      Physics, 4, 1008-1011 (2007) DOI: http:\/\/dx.doi.org\/10.1002\/pssc.200673704\u000d\u000a    \u000a\u000a2. \"Solid state NMR and X-ray studies of the structural evolution of\u000d\u000a      nanocrystalline zirconia\", Chadwick, AV; Mountjoy, G; Nield, VM;\u000d\u000a      Poplett, IJF; Smith, ME (Kent 1992-1998); Strange, JH; Tucker, MG,\u000d\u000a      Chemistry of Materials, 13, 1219-1229 (2001) DOI: http:\/\/dx.doi.org\/10.1021\/cm001152w\u000d\u000a    \u000a\u000a3. \"A combined EXAFS and diffraction study of pure and doped\u000d\u000a      nanocrystalline tin oxide\", Davis, SR; Chadwick, AV; Wright, JP,\u000d\u000a      Journal of Physical Chemistry B, 101, 9901-9908 (1997) DOI: http:\/\/dx.doi.org\/10.1021\/jp971756w\u000d\u000a    \u000a4. Grants: KTP project (PI, Dr. M. Alfredsson; co-investigators Prof.\u000a        AV Chadwick and Dr G. Mountjoy); EPSRC-CASE award (PI, Prof AV\u000d\u000a        Chadwick; co-investigator Dr G. Mountjoy); INTERREG II, III\u000d\u000a      (PI;AV Chadwick, co-investigators, Drs G. Mountjoy and P.\u000d\u000a        Lindan) and INTERREG IV (PI, M. Alfredsson; co-investigators;\u000d\u000a        Prof. AV Chadwick and Dr. G. Mountjoy\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"7","Subject":"Theoretical and Computational Chemistry"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"9","Level2":"12","Subject":"Materials Engineering"}],"Sources":"\u000d\u000a    \u000d\u000a      Jim Telfer, Hilger Crystals, Managing Director. [Contact 1]\u000d\u000a      Keith Hutton, Hilger Crystals, Materials Development Scientist.\u000d\u000a        [Contact 2]\u000d\u000a      Aaron Blacklocks, Hilger Crystals, KTP Fellow. [Contact 3]\u000d\u000a      Knowledge Transfer Partnerships Final Report Form, 08\/11\/2011.\u000d\u000a        Partnership: KTP007000, Partners: University of Kent, Hilger Crystals\u000d\u000a        Limited.\u000d\u000a      KTP Local Management Committee meetings, minutes and reports,\u000d\u000a        29\/8\/2008, 7\/1\/2009, 27\/4\/2009, 21\/9\/2009, 14\/1\/2010, 17\/5\/2010,\u000d\u000a        1\/9\/2010, 9\/2\/2011, 18\/5\/2011 (HIGHLY CONFIDENTIAL)\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Crystals for National Security and Biomedical Diagnostics\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    An on-going collaboration between Hilger Crystals and physicists\/chemists\u000d\u000a      in the School of Physical Sciences at the University of Kent (principally\u000d\u000a      A.V. Chadwick [Kent 1970-present] and G. Mountjoy [Kent 1996-present] and\u000d\u000a      later Alfredsson [Kent 2007-present] and Ph.D\/KTP Associate A Blacklocks\u000d\u000a      [Kent 2004-2011]) has been in existence for more than a decade. This case\u000d\u000a      study describes one successful project that has arisen from this\u000d\u000a      collaboration. Not all of the research described here was published in the\u000d\u000a      academic literature for reasons of confidentiality. Publication [1] is\u000d\u000a      directly relevant to this proposal, Publications [2,3] describe\u000d\u000a      underpinning technique development pioneered by Kent staff, that was later\u000d\u000a      employed in this case. Theoretical work performed by Kent staff (M.\u000d\u000a      Alfredsson [Kent lecturer 2007-present]) was also key to the success of\u000d\u000a      this project. The SPS contribution can be verified by Hilger Crystals\u000d\u000a      [5.1].\u000d\u000a    There is a large worldwide market in scintillator materials for X-ray\u000d\u000a      scanners. However, images produced during scanning are blurred due to an\u000d\u000a      electronic process known as `afterglow'. Understanding the origin of the\u000d\u000a      afterglow in scintillators allows for the production of novel materials\u000d\u000a      with improved properties, resulting in sharper images.\u000d\u000a    The objectives of the collaboration between Hilger Crystals Ltd (Hilger)\u000d\u000a      and the School of Physical Sciences (SPS) were to:\u000d\u000a    (i) establish the origin of the afterglow process in Thallium-doped\u000d\u000a      Caesium Iodide (Tl,Cs)I scintillator single crystals;\u000d\u000a    (ii) develop an industrial process in which high-quality crystals could\u000d\u000a      be grown reliably, with significantly reduced afterglow, using standard\u000d\u000a      commercial materials;\u000d\u000a    (iii) investigate co-doping with rare-earth elements[1] to establish\u000d\u000a      whether these elements are critical for the afterglow reduction in\u000d\u000a      (Tl,Cs)I.\u000d\u000a    (i) Origin of the afterglow process.\u000d\u000a    It is generally accepted that the afterglow is caused by trapping of the\u000d\u000a      carriers that re-combine with the excited defect centres. The theoretical\u000d\u000a      work led by Alfredsson proposed unusual behaviour of the Cs-I interactions\u000d\u000a      in the system. Contrary to the general observation that band gaps decrease\u000d\u000a      with increasing pressure it was found that the band gap in CsI increases\u000d\u000a      if pressure or stress is applied. This was originally explained as a\u000d\u000a      relativistic effect in the material, but our simulations showed this be a\u000d\u000a      hybridisation effect. The observation is important in the understanding of\u000d\u000a      the origin to the afterglow, as the relaxation time of the material is\u000d\u000a      crucial for low afterglow. Thallium doping reduces the band gap\u000d\u000a      significantly, but the band gap behaviour remains. Understanding and\u000d\u000a      controlling this behaviour decreases the afterglow in the material\u000d\u000a    (ii) Reliable growth of high quality crystals.\u000d\u000a    New scaled-up crystal growth techniques were investigated at Hilger.\u000d\u000a      These were performed in collaboration with, and guided by Density\u000d\u000a      Functional Theory simulations and a number of material characterisation\u000d\u000a      experiments (e.g. IR, TGA, XRD and SEM-EDX) undertaken at SPS. The\u000d\u000a      quality of the crystal was found to be critically dependent on crystal\u000d\u000a      growth parameters, particularly temperature gradient and soaking times:\u000d\u000a      these were optimised. Processing of the final material, including heat\u000d\u000a      treatment and storage time, were found to reduce the afterglow, as the\u000d\u000a      material is allowed to relax after processing. Allowing the material to\u000d\u000a      relax means storage costs for the company. The result was a new crystal\u000d\u000a      growth method that yields new types of (TlCs)I crystals with substantially\u000d\u000a      fewer defects. These crystals are much clearer and more reproducible than\u000d\u000a      previously, and have dramatically reduced afterglow.\u000d\u000a    (iii) Co-doping with rare-earth elements.\u000d\u000a    Rare-earth doped CsI single crystals were initially grown at the SPS and\u000d\u000a      Hilger. In 2006 Blacklocks (Ph.D) and Chadwick[1] measured the afterglow\u000d\u000a      using X-ray excitation using combined techniques developed by Chadwick,\u000d\u000a      Mountjoy and others [2,3]. Short- and long-life relaxations times were\u000d\u000a      monitored for crystals with and without the presence of Eu and Sm. It was\u000d\u000a      found that there are two distinct afterglows, long-term and short-term and\u000d\u000a      that doping by rare-earths is only effective for short-term afterglow\u000d\u000a      reduction. Further, different growth conditions were explored. It had been\u000d\u000a      proposed that Tl is a determining factor controlling the afterglow in CsI\u000d\u000a      as this element may form Tl-dimers or defects in the structure. For this\u000d\u000a      purpose the local structure of CsI(Tl) structure was determined using\u000d\u000a      X-ray absorption spectroscopy (XAFS) [1-3] in combination with atomistic\u000d\u000a      simulations [unpublished, performed by M. Alfredsson and A. Blacklocks].\u000d\u000a      The introduction of rare-earth dopants decreases afterglow substantially,\u000d\u000a      but other properties such as hydroscopicity increase, limiting the range\u000d\u000a      of applications.\u000d\u000a    "},{"CaseStudyId":"1667","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"660013","Name":"Finland"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Engineering and Physical Sciences Research Council","Medical Research Council"],"ImpactDetails":"\u000d\u000a    Intelligent Fingerprinting Ltd., a spin-out company created from\u000d\u000a      the research of Professor David Russell [corroborating source A], has\u000d\u000a      developed a unique in vitro diagnostic technology platform that\u000d\u000a      non-invasively screens for metabolites present in fingerprint sweat while\u000d\u000a      simultaneously enabling determination of personal identity. Using a\u000d\u000a      hand-held device, the test can determine recent drug history within 10\u000d\u000a      minutes. This technology has substantial potential in rapid point-of-care\u000d\u000a      in vitro diagnostic testing. The Intelligent Fingerprinting\u000d\u000a      test offers a direct link between individual (biometrics) and result\u000d\u000a      (diagnostics), by clearly identifying drug metabolites found in the sweat\u000d\u000a      deposited in the unique patterns on the ridges of each fingerprint. The\u000d\u000a      test is therefore unequivocally linked to an individual. Results can be\u000d\u000a      rapidly rechecked to confirm any diagnosis. The core competency of the\u000d\u000a      company is the antibody-functionalised nanoparticles and fluorescence\u000d\u000a      imaging detection. A person places a fingerprint on the hand-held device,\u000d\u000a      the device then dispenses the reagents. Following incubation and removal\u000d\u000a      of excess particles, the device images the fingerprint to determine the\u000d\u000a      presence of drug metabolites. The key industry sectors for the company are\u000d\u000a      Criminal Justice &#8212; drug rehabilitation and roadside screening for drug\u000d\u000a      driving; Institutional testing &#8212; prisons, military and commercial\u000d\u000a      companies; and Healthcare &#8212; patient testing, hospital admissions and drug\u000d\u000a      compliance. Current screening methods using urine, blood or saliva have\u000d\u000a      restricted usefulness linked to invasive collection of hazardous samples,\u000d\u000a      donor dignity, transport and disposal of bio-hazardous waste and, most\u000d\u000a      importantly, problems associated with the ability of tested individuals to\u000d\u000a      cheat the system. The Intelligent Fingerprinting test overcomes\u000d\u000a      all of these limitations.\u000d\u000a    Intelligent Fingerprinting Ltd. was founded in 2007. A Proof of\u000d\u000a      Concept award from the East of England Development Agency (EEDA)\u000d\u000a      [corroborating source B], with a supporting contribution from UEA,\u000d\u000a      (totalling &#163;48K) was used to pay for market research, performed by two\u000d\u000a      independent companies. Having established considerable market potential in\u000d\u000a      several sectors, the ICENI Seedcorn University Challenge Fund invested\u000d\u000a      &#163;221K in 2009 for a share of equity in Intelligent Fingerprinting Ltd.\u000d\u000a      based on milestones around the further development of the reagent\u000d\u000a      chemistry and business plans. All milestones were achieved ahead of\u000d\u000a      schedule. In December 2010, Porton Capital Inc., a venture capital\u000d\u000a      investor company, together with their UK company Synergis Technologies\u000d\u000a      Ltd. made a &#163;250K investment in Intelligent Fingerprinting Ltd.\u000d\u000a      [corroborating source C]. At the same time, a further &#163;50K was invested by\u000d\u000a      ICENI Seedcorn University Challenge Fund. This second round funding was\u000d\u000a      used to hire a small team of staff and to develop a prototype hand- held\u000d\u000a      instrument that could dispense the reagents onto the fingerprint and then\u000d\u000a      image the resultant prints to establish drug use. In February 2012, a\u000d\u000a      consortium of US-based individuals invested &#163;2M in Intelligent\u000d\u000a        Fingerprinting Ltd. for a share of equity [corroborating source D].\u000d\u000a      The third round funding provided for expansion of the company's staff and\u000d\u000a      research and development activities. Key products are the\u000d\u000a      antibody-particle reagents and the self-contained, hand-held device that\u000d\u000a      applies the reagents to a fingerprint through microfluidics and then\u000d\u000a      fluorescently images the fingerprint. In 2013, US investors provided a\u000d\u000a      fourth funding round of &#163;750K for the manufacture of demonstrator\u000d\u000a      products. To date, total investment in the company has been in excess of\u000d\u000a      &#163;3.2M.\u000d\u000a    Intelligent Fingerprinting Ltd. has signed a North American\u000d\u000a      distribution agreement with Texas-based SmarTox Inc. with ambitious sales\u000d\u000a      targets of both the hand-held device and antibody-particle based reagent\u000d\u000a      cartridges [corroborating source E]. Intelligent Fingerprinting Ltd.\u000d\u000a      received its first purchase order for services from the UK Home Office in\u000d\u000a      2012 [corroborating source F].\u000d\u000a    In 2012, as part of on-going product development in conjunction with key\u000d\u000a      end-users, Intelligent Fingerprinting Ltd. applied for, and won,\u000d\u000a      two research grants totalling &#163;425K from the MRC\/TSB `Biomedical Catalyst'\u000d\u000a      scheme for pilot studies with the Accident and Emergency Department at the\u000d\u000a      Leicester Royal Infirmary and H. M. Coroner's Office in Sheffield\u000d\u000a      respectively. The first project assessed the feasibility of the technology\u000d\u000a      for fast, non-invasive drug screening of hospital A&amp;E patients on\u000d\u000a      admission. The second project, working with the Sheffield coroner, has\u000d\u000a      been trialling Intelligent Fingerprinting's non-invasive drug\u000d\u000a      testing device to establish cause of death without the need for full,\u000d\u000a      invasive toxicological screens. Additionally, in 2013, Intelligent\u000d\u000a        Fingerprinting Ltd. won a &#8364;982K EU Eurostars grant with the\u000d\u000a      University of Eastern Finland and Finnish SME Addoz Oy to develop a remote\u000d\u000a      diagnostic monitor for opiate-substitution treatment [corroborating source\u000d\u000a      G].\u000d\u000a    The fingerprint methods developed by Russell are included in the new Fingermark\u000a        Visualisation Manual (publication and distribution in January 2014)\u000d\u000a      [corroborating source H]. This manual, produced by the Home Office Centre\u000d\u000a      for Applied Science and Technology (CAST), is distributed to all UK police\u000d\u000a      forces. It is the definitive source of fingerprinting methods and\u000d\u000a      their application for police and forensic use in the UK. Importantly, as\u000d\u000a      the key fingerprint information source, the Manual is also used by Police\u000d\u000a      Forces across Europe, USA, Australasia and Asia.\u000d\u000a    Based in dedicated offices and laboratories at the Norwich Research Park\u000d\u000a      Innovation Centre, Intelligent Fingerprinting Ltd. now employs 11\u000d\u000a      staff: Dr Jerry Walker (Chief Executive), Dr Paul Yates (Business\u000d\u000a      Development Manager), Dr Mark Hudson (Development Director), Su Mace\u000d\u000a      (Finance Officer), 6 technical\/scientific staff (4 Ph.D.s and 2 graduates)\u000d\u000a      and a PA. In addition, the company has bought out Professor Russell from\u000d\u000a      his University duties (2011-2013 inclusive) for 40% FTE, to enable him to\u000d\u000a      work as the Chief Technical Officer.\u000d\u000a    Intelligent Fingerprinting Ltd. has already received considerable\u000d\u000a      recognition for its activities, including [corroborating source I]:\u000d\u000a    \u000d\u000a      In four consecutive years, 2010-2013 inclusive, Intelligent\u000d\u000a          Fingerprinting Ltd. was highlighted as one of 50 companies with\u000d\u000a        future potential in the East of England through the Eastern Daily Press\u000d\u000a        (EDP) `Future50' competition.\u000d\u000a      In 2012, Intelligent Fingerprinting Ltd. won the `One to\u000d\u000a        watch' category at the EDP Business Awards.\u000d\u000a      \u000aIntelligent Fingerprinting Ltd. was shortlisted in the 2010\u000d\u000a        Times Higher Education Awards in the `Outstanding Contribution to\u000d\u000a        Innovation and Technology' category.\u000d\u000a    \u000d\u000a    The original science behind the company has also been recognised by\u000d\u000a      EPSRC, with the science of the fingerprinting research developed as part\u000d\u000a      of the original grant (grant (i) above) highlighted in the EPSRC `Pioneers'\u000d\u000a      magazine 2009 and within the EPSRC `Impact Case Studies' (Case study 08)\u000d\u000a      in 2010 [corroborating source J].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    The spin-out company Intelligent Fingerprinting Ltd. was founded\u000d\u000a      in 2007, based on Professor David Russell's research. The company develops\u000d\u000a      novel technologies using antibody-nanoparticle reagents to detect drugs\u000d\u000a      and drug metabolites in latent fingerprints whilst simultaneously\u000d\u000a      providing high resolution fingerprint images for identification purposes.\u000d\u000a      Combining these technologies with a fluorescence-based hand-held reader\u000d\u000a      provides a non-invasive diagnostic platform for use in the criminal\u000d\u000a      justice sector, institutional testing and hospital environments.\u000d\u000a    Total funding to date for the company has been &gt;&#163;3.2M in four\u000d\u000a      investment rounds. The company employs 11 staff, who work in dedicated\u000d\u000a      office and laboratory premises within the Norwich Research Park Innovation\u000d\u000a      Centre.\u000d\u000a    The company received its first purchase order from the UK Home Office in\u000d\u000a      2012. A distribution agreement is in place with Dallas-based SmarTox Inc.\u000d\u000a      for North American sales of Intelligent Fingerprinting products\u000d\u000a      for `Drugs of Abuse' testing.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    University of East Anglia\u000d\u000a    ","Institutions":[{"AlternativeName":"East Anglia (University of)","InstitutionName":"University of East Anglia","PeerGroup":"B","Region":"East","UKPRN":10007789}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    (UEA authors in bold)\u000d\u000a    \u000a1. Patent: WO 2007\/110605: Fluorescence-based detection of\u000d\u000a      substances\u000d\u000a      D. A. Russell, R. Leggett, E. E. Lee-Smith, S. M.\u000d\u000a      Jickells and B. Daniel\u000d\u000a    \u000a\u000a2. \"Intelligent\" fingerprinting: Simultaneous identification of\u000d\u000a      drug metabolites and individuals by using antibody-functionalized\u000d\u000a      nanoparticles\u000d\u000a      R. Leggett, E. E. Lee-Smith, S. M. Jickells and D. A.\u000d\u000a        Russell\u000d\u000a      Angewandte Chemie International Edition, 2007, 46,\u000d\u000a      4100-4103.\u000d\u000a      doi: 10.1002\/anie.200700217\u000d\u000a    \u000aThis paper was highlighted by: Nature (2007, 447, 119); Nature\u000d\u000a      Nanotechnology (2007, 2, 388); New Scientist, Chemistry World;\u000d\u000a      Chemistry &amp; Industry; C&amp;E News; Analytical Chemistry; National\u000d\u000a      newspapers &#8212; Sunday Telegraph; Daily Mirror; International media &#8212; CNN\u000d\u000a      On-line; Interviewed by German and BBC radio.\u000d\u000a    \u000a3. Imaging of latent fingerprints through the detection of drugs\u000d\u000a      and metabolites\u000d\u000a      P. Hazarika, S. M. Jickells, K. Wolff and D. A. Russell\u000d\u000a      Angewandte Chemie International Edition, 2008, 47,\u000d\u000a      10167- 10170 (plus inside cover).\u000d\u000a      doi: 10.1002\/anie.200804348\u000d\u000a    \u000aThis paper was highlighted by: Angewandte Chemie as a `Very Important\u000d\u000a      paper'; Nature Materials (2009, 8, 5); Discovery Channel on-line; Chemical\u000d\u000a      and Engineering News (Dec 22, 2008, p34); Interviewed for BBC World\u000d\u000a      Service Radio.\u000d\u000a    \u000a4. Multiplexed detection of metabolites of narcotic drugs from a\u000d\u000a      single latent fingermark\u000d\u000a      P. Hazarika, S. M. Jickells, K. Wolff and D. A. Russell\u000d\u000a      Analytical Chemistry, 2010, 82, 9150-9154.\u000d\u000a      doi: 10.1021\/ac1023205\u000d\u000a    \u000aGrants Awarded:\u000d\u000a    i. Light it up: A nanotechnology approach for the acquisition of\u000d\u000a      forensic evidence\u000d\u000a      D. A. Russell (UEA); S. Jickells and B. Daniel (King's College,\u000d\u000a      London)\u000d\u000a      EPSRC, 2006-2009, &#163;426,569 (UEA &#8212; &#163;247,956)\u000d\u000a    ii. Nanoconjugates for the detection of forensic residues\u000d\u000a      D. A. Russell\u000d\u000a      EPSRC Follow on Fund, 2009-2010, &#163;100,047\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"15","Subject":"Pharmacology and Pharmaceutical Sciences"},{"Level1":"3","Level2":"1","Subject":"Analytical Chemistry"},{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"}],"Sources":"\u000d\u000a    A Registration of Intelligent Fingerprinting Ltd. Company number\u000d\u000a      06409298 - Companies House. Company website: http:\/\/www.intelligentfingerprinting.com\/\u000d\u000a    B Nanotechnology for fingerprint and metabolite detection\u000d\u000a      East of England Development Agency (EEDA), Proof of Concept Award;\u000d\u000a      2007-2008; &#163;38.5K\u000d\u000a      together with &#163;10K contribution from UEA.\u000d\u000a    C Investment agreement with venture capital funder `Porton Capital Inc.'\u000d\u000a      (copy held on file at UEA).\u000d\u000a    D Investment agreement and audited accounts filed with Companies House\u000d\u000a      April 2013, showing &#163;2M investment by US investment consortium. (Copies\u000d\u000a      held on file at UEA)\u000d\u000a    E Intelligent Fingerprinting Ltd. `Distribution agreement' with\u000d\u000a      SmarTox Inc., Dallas, Texas, USA (subsidiary of SmartStart Inc.). (Copy\u000d\u000a      held on file at UEA)\u000d\u000a    F UK Home Office Purchase Order 2012 (Copy held on file at UEA)\u000d\u000a    G Research grant awards:\u000d\u000a    a. Biomedical Catalyst Feasibility Award: Medical Research Council \/\u000d\u000a      Technology Strategy Board; &#163;135,000; 2012-2013; Intelligent\u000d\u000a        Fingerprinting Ltd. and A&amp;E Department (Professor Tim Coates)\u000d\u000a      Leicester Royal Infirmary.\u000d\u000a    b. Biomedical Catalyst Early Stage Award: Medical Research Council \/\u000d\u000a      Technology Strategy Board; &#163;290,000; 2012-2014; Intelligent\u000d\u000a        Fingerprinting Ltd. and Sheffield Coroner's Office.\u000d\u000a    c. EU Eurostars Award: &#8364;982K; 2013-2015; Fingerprint Recording in Opiate\u000d\u000a      Substitution Treatment (FR-OST) &#8212; Non-invasive Diagnostic Monitoring' Intelligent\u000a        Fingerprinting Ltd. with the University of Eastern Finland and Addoz\u000d\u000a      Oy.\u000d\u000a    (All details held on file at UEA)\u000d\u000a    H Fingermark Visualisation Manual, Home Office Centre for Applied\u000d\u000a      Science and Technology (CAST). Publication and distribution to UK Police\u000d\u000a      Forces, January 2014. (Notices of publication and inclusion held on file\u000d\u000a      at UEA)\u000d\u000a    I Awards to Intelligent Fingerprinting Ltd.\u000d\u000a    a. EDP Future 50; 2010-2013 inclusive (copies of articles held on file at\u000d\u000a      UEA)\u000d\u000a    b. EDP `One to Watch' business awards winner 2012 - Video of Professor\u000d\u000a      Russell\u000d\u000a      collecting the award on behalf of Intelligent Fingerprinting Ltd.\u000d\u000a      http:\/\/www.intelligentfingerprinting.com\/news.html\u000d\u000a    c. Shortlisting for 2010 Times Higher Education Award:\u000d\u000a      http:\/\/www.timeshighereducation.co.uk\/story.asp?storycode=413567\u000d\u000a    J EPSRC `Pioneers' magazine (2009) and EPSRC Impact Case Study number 08\u000d\u000a      (2010). (Copies of both documents held on file at UEA) \u000d\u000a    ","Title":"\u000d\u000a    Intelligent Fingerprinting Ltd.&#8212; a spin out company from\u000d\u000a        the School of Chemistry\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2641181","Name":"Norwich"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    Professor David Russell's research is focused within bioanalytical\u000d\u000a      chemistry, particularly in developing nanoscale-based approaches for novel\u000d\u000a      chemical measurements. As part of this research, gold nanoparticles were\u000d\u000a      synthesised and then stabilised with a monolayer of Protein A.\u000d\u000a      Anti-cotinine antibody was then bound to the Protein A on the\u000d\u000a      nanoparticles to provide a conjugate that was used to detect cotinine, the\u000d\u000a      major metabolite of nicotine, in the fingerprints of smokers. The antibody\u000d\u000a      conjugates bound to the cotinine antigens, while a fluorescently-tagged\u000d\u000a      secondary antibody fragment was used to image the fingerprints. Not only\u000d\u000a      did the reagents detect the drugs and drug metabolites in fingerprints,\u000d\u000a      but they simultaneously provided a high resolution image of the print to\u000d\u000a      establish the identity of the individual.\u000d\u000a    Initial research was performed by M.Chem. student Emma Lee-Smith\u000d\u000a      during her final year research project in 2005 under the supervision of\u000d\u000a      Professor Russell. Her work and subsequent Ph.D. research studies by Richard\u000a        Leggett (Ph.D. awarded in 2007), also from the Russell laboratory,\u000d\u000a      were patented (1) and then published (2). Following publication, there was\u000d\u000a      considerable media attention as this was the first report that drug\u000d\u000a      metabolites, and therefore drug usage, could be determined from the sweat\u000d\u000a      deposited in a fingerprint. These results also provided preliminary data\u000d\u000a      for a collaborative EPSRC research grant (i) with Dr Sue Jickells and Dr\u000d\u000a      Barbara Daniel from the Department of Forensic Science and Drug Monitoring\u000d\u000a      at King's College London.\u000d\u000a    The EPSRC research grant supported Dr Pompi Hazarika\u000d\u000a      (post-doctoral research associate at UEA, 2006-2010) who developed iron\u000d\u000a      oxide based particles which were functionalised with Protein A\/G. Protein\u000d\u000a      A\/G is a recombinant fusion protein that combines IgG-binding domains of\u000d\u000a      both Protein A and Protein G. This created an exceptionally versatile\u000d\u000a      platform on which numerous classes of antibodies could be bound. The\u000d\u000a      platform technology was used to conjugate various antibodies that\u000d\u000a      specifically bind to their target antigen. These antibody-particle\u000d\u000a      conjugates were used to detect: 03949- tetrahydrocannabinol (THC), the\u000d\u000a      main psychoactive component of marijuana; methadone, a synthetic opioid\u000d\u000a      generally prescribed as a substitute pharmacotherapy to heroin-dependent\u000d\u000a      patients; 2-ethylidene- 1,5-dimethyl 3,3-diphenylpyrrolidine (EDDP), the\u000d\u000a      major metabolite of methadone; and benzoylecgonine, the major metabolite\u000d\u000a      of cocaine in the fingerprints of volunteers attending a methadone\u000d\u000a      maintenance programme (3). Publication of paper (3) prompted further\u000d\u000a      significant media attention since the paper highlighted the detection of\u000d\u000a      illegal drugs and drug metabolites using the antibody-magnetic particle\u000d\u000a      conjugates.\u000d\u000a    An EPSRC Follow-on Fund grant (ii) was awarded to Russell in 2009 to\u000d\u000a      further develop the antibody-particle conjugates for forensic\u000d\u000a      applications. Results from this study reported the multiplexed detection\u000d\u000a      of two drug metabolites (from heroin and cocaine) in a single\u000d\u000a      fingerprint (4).\u000d\u000a    The University of East Anglia patented the technology, focused on the\u000d\u000a      antibody-particle conjugates for the combination of drug detection and\u000d\u000a      personal identity, in 2007 (1). Patents were granted in the European Union\u000d\u000a      (2011), Australia (2012) and United States (2013). Other territories are\u000d\u000a      pending. The University maintained the family of patents until they were\u000d\u000a      assigned to Intelligent Fingerprinting Ltd in February 2012.\u000d\u000a    "},{"CaseStudyId":"1668","Continent":[],"Country":[],"Funders":["Biotechnology and Biological Sciences Research Council","Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000a    In the period 2001 to 2009, Chameleon Biosurfaces Ltd. received a\u000a      total of &#163;1.48M of venture capital and seedcorn funding from a number of\u000a      sources: the ICENI University Seedcorn Fund; Rainbow Venture Capital;\u000a      Aitua; London Seed Capital; Great Eastern Investment and Create Ventures.\u000a      The activities of Chameleon Biosurfaces Ltd. at UEA were funded by\u000a      &#163;1.13M of this venture capital, secured between 2005 - 2009.\u000a    Initial work focussed on showing that the electropolymers developed by\u000a      Pickett's group were well tolerated in vivo. Subsequently there\u000a      was considerable industrial interest in the development of the\u000a      electropolymers as coatings for implantable medical devices &#8212; for which\u000a      there is a multi-billion $US global market &#8212; where the aim of the\u000a      technology is to address key limitations of current devices such as\u000a      foreign body reactions, stability and long-term electrical performance.\u000a    In 2009 and 2010, Chameleon Biosurfaces Ltd. completed contracts\u000a      with two international medical device companies [text removed for publication]\u000a      (2009) and [text removed for publication] (2009 and 2010) to study the\u000a      electropolymer coatings on stents and pacemaker implants respectively. The\u000a      latter study resulted in IPR on the coating methodology for use in heart\u000a      stimulation applications. [corroborating source A]\u000a    A second patent was filed in 2010 that detailed the preparation and\u000a      biophysical characterisation of low thrombogenicity electropolymer\u000a      materials that could be used in coronary stent applications.\u000a      [corroborating source B]\u000a    Following the successful conclusion of these contracts, in 2011 Biotectix\u000a        LLC, a leading developer of implantable medical devices based in Ann\u000a      Arbor Michigan, acquired all Chameleon Biosurfaces Ltd. issued and\u000a      pending US and international patents [corroborating sources A to C]\u000a      together with all technical and commercial data on the electropolymers for\u000a      an undisclosable sum.\u000a    Biotectix LLC, a wholly-owned subsidiary of Allied Minds,\u000a      is developing a new class of conducting polymer materials and coatings,\u000a      for implantable medical devices and sensors. The goal is to improve the\u000a      safety, longevity, reliability, biological integration and function of\u000a      implantable biomedical devices for electro-stimulation and sensing\u000a      applications. Following the acquisition, all Chameleon Biosurfaces\u000a        Ltd.'s materials technology transferred to Ann Arbor. Biotectix\u000a        LLC continues to maintain the granted IPR and is actively pursuing\u000a      applications of the electropolymers in implantable medical devices for\u000a      cardiovascular, cochlear and neuro-modulation.\u000a    The General Manager at Biotectix LLC, James Arps, stated at the\u000a      time that:\u000a    \"the Chameleon technology is highly complementary to the conductive\u000a      thiophene-based polymer materials we are actively commercializing.\u000a      Importantly, the acquisition further solidifies our leading IP position in\u000a      this field while giving us additional materials options with our\u000a      co-development partners in the medical device field.\"\u000a    [corroborating source D]\u000a    The continuing importance of this acquisition in increasing the\u000a      commercial opportunities available to Biotectix LLC is clear from\u000a      the statements by the Director of R&amp;D provided in 2012:\u000a    `Implantable medical devices for cardiovascular and neuromodulation\u000a      applications, together represent a multi-billion dollar global market.\u000a      Hence there is a significant commercial opportunity for value-added\u000a      technologies including BT's [Biotectix's] medical coatings that\u000a      address the needs for smaller, safer, multifunctional next generation\u000a      clinical medical devices.'\u000a    `The acquisition of Chameleon Biosurfaces assets further\u000a      solidifies BT's leading IP position in this field...'\u000a    [corroborating source E]\u000a    In 2011, following the acquisition of IPR from Chameleon Biosurfaces\u000a        Ltd., Biotectix LLC funded further electropolymer studies at\u000a      UEA which have already been of considerable benefit to Biotectix LLC\u000a      producing more than 5 new molecular species that continue to be evaluated\u000a      for further development by Biotectix LLC. [corroborating source E]\u000a    ","ImpactSummary":"\u000a    Our research has shown that functionalised poly(pyrroles) grown\u000a      electrochemically on medical steels and other alloys as adherent, highly\u000a      conformal coatings can enhance surface biocompatibility and provide a\u000a      platform for implantable medical devices. Chameleon Biosurfaces Ltd.\u000a      was founded to exploit this research by producing coatings for medical\u000a      devices, including coronary artery stents and pacemaker implants. Up to\u000a      2009, Chameleon Biosurfaces Ltd. received &#163;1.48M of venture\u000a      capital and seedcorn funding. In 2011 all assets of Chameleon\u000a        Biosurfaces Ltd. were sold to the US biomedical company Biotectix\u000a        LLC.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of East Anglia\u000a    ","Institutions":[{"AlternativeName":"East Anglia (University of)","InstitutionName":"University of East Anglia","PeerGroup":"B","Region":"East","UKPRN":10007789}],"Panel":"B         ","PlaceName":[],"References":"\u000a    (UEA authors in bold)\u000a    \u000a(1) Electropolymeric materials incorporating subsite structures related\u000a      to iron-only hydrogenase: active ester functionalised poly(pyrroles) for\u000a      covalent binding of {2Fe3S}-carbonyl\/cyanide assemblies\u000a      Ibrahim, SK; Liu, XM; Tard, C;\u000a      Pickett, CJ\u000a      Chemical Communications 2007, 1535-1537.\u000a      doi: 10.1039\/b617399c\u000a    \u000a\u000a(2) Artificial hydrogenases: assembly of an H-cluster analogue within a\u000a      functionalised poly(pyrrole) matrix\u000a      Ibrahim, S; Woi, PM; Alias, Y; Pickett,\u000a      CJ\u000a      Chemical Communications 2010, 46, 8189-8191.\u000a      doi: 10.1039\/c0cc02962a\u000a    \u000a\u000a(3) Novel surface modification for reducing polymer burden on\u000a      drug-eluting stents is highly compatible with pig coronary arteries\u000a      Shinke, T; Brants, I; Robinson, KA; Tolland, J; Knott,\u000a      J; Ibrahim, S; Jabara, R; Chronos, N; Mackenzie,\u000a      IA; Pickett, CJ.\u000a      American J. Cardiology 2007, 100, issue 8A, Supp.S, 161L-161L\u000a      Conference Abstract. Presented at 19th Annual Transcatheter Cardiovascular\u000a      Therapeutics Symposium, Washington DC (USA), Oct 20-25, 2007.\u000a    \u000a(4) Patent: Polymer coatings on medical devices\u000a      EP2155275 (A2) (Publication date: 2010)\u000a      Inventors: CJ Pickett, TJ Boote, SK Ibrahim, JM\u000a        Knott, JD Tolland\u000a    Key Research Funding:\u000a    Anti-thrombolytic electropolymers (2006 to 2010)\u000a      EPSRC ICASE Studentship\u000a      Pickett, CJ\u000a      &#163;60,864\u000a    In vitro biocompatibility and release characteristics of\u000a      polypyrrole -bupivacaine coatings for neurostimulators (2006 to 2007)\u000a      BBSRC Follow-on Fund\u000a      Pickett, CJ\u000a      &#163;87,962\u000a    Biotectix LLC contract with Chameleon Biosurfaces Ltd.\u000a      (2011)\u000a      &#163;35,100\u000a    ","ResearchSubjectAreas":[{"Level1":"9","Level2":"3","Subject":"Biomedical Engineering"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"3","Subject":"Macromolecular and Materials Chemistry"}],"Sources":"\u000a    [A] Coating on titanium nitride\u000a      UK patent application 1012808.0 (Submitted: 2010)\u000a      US patent: Implantable Electrode US 2012\/0029585 (publication\u000a      date: 2012)\u000a      Inventor: CJ Pickett\u000a      This patent application covers applications of Chameleon Biosurfaces\u000a        Ltd. electropolymers for heart stimulation applications.\u000a    (details held on file at UEA)\u000a    [B] Polymer coatings on medical devices\u000a      EP2155275 (A2) (Publication date: 2010)\u000a      Inventors: CJ Pickett, TJ Boote, SK Ibrahim, JM Knott, JD Tolland\u000a      This patent describes low thrombogenicity electropolymer materials\u000a        including their preparation and biophysical characterisation.\u000a    (details held on file at UEA)\u000a    [C] Electro-release systems, modified electrodes and their use\u000a      US 6,132,752 (publication date: 2000)\u000a      Also EU, Canadian, Australian and other derived granted patents.\u000a      Inventors: CJ Pickett , SK Ibrahim\u000a      This patent family described how electrical stimulation of an implanted\u000a        electropolymer device containing a bound drug could control the release\u000a        of that drug.\u000a    (details held on file at UEA)\u000a    [D] Press releases posted on 28th March 2011 regarding the Biotectix\u000a        LLC acquisition of assets and technology from Chameleon\u000a        Biosurfaces Ltd.:\u000a    http:\/\/www.pharmiweb.com\/pressreleases\/pressrel.asp?ROW_ID=38278\u000a    http:\/\/www.businessweekly.co.uk\/biomedtech-\/11596\u000a    (Accessed on 7th November 2013 and held on file at UEA)\u000a    [E] Supporting letter from Biotectix LLC\u000a    (held on file at UEA)\u000a    ","Title":"\u000a    Medical implants with biocompatible electropolymer surfaces\u000a    ","UKLocation":[{"GeoNamesId":"2643743","Name":"London"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    The research underpinning this impact spans the period 1993 to 2013.\u000a      Initial research undertaken by Professor Chris Pickett's research\u000a      group was based at the John Innes Centre on the Norwich Research Park. A\u000a      change of research direction coincided with Professor Pickett's move to\u000a      the School of Chemistry, University of East Anglia (UEA) in 2005.\u000a    The academic research programme addressed the construction of electrode\u000a      interfaces in which bioinorganic reaction centres were confined within an\u000a      electropolymer matrix. It was found that such electropolymers could be\u000a      grown on medical stainless steels, which opened the possibility for\u000a      biomedical implant applications. A spin-out company, Chameleon\u000a        Biosurfaces Ltd., was established to pursue these applications. In\u000a      2003, Chameleon Biosurfaces Ltd. performed an initial rabbit\u000a      dorsal muscle implant study with four types of electropolymer,\u000a      establishing that the materials were well tolerated in the in vivo\u000a      environment. This result, together with their high conformality and\u000a      adhesion to medical steels, suggested that the electropolymers could be of\u000a      benefit in the area of polymer-coated drug-eluting coronary stents.\u000a      However, while commercially available coronary drug eluting stents were\u000a      successful in inhibiting restenosis, in 2005 there were significant\u000a      emerging problems with late stent thrombosis. This was variously\u000a      attributed to polymer detachment, poor biocompatibility and delayed\u000a      re-endothelialisation.\u000a    Late stent thrombosis defined the medical problem which Chameleon\u000a        Biosurfaces Ltd. sought to address when the company relocated to UEA\u000a      in 2005. Dedicated laboratory and office space was provided within the\u000a      School of Chemistry and four personnel employed by Chameleon\u000a        Biosurfaces Ltd.: Dr Jane Knott was employed to undertake synthesis\u000a      of innovative pyrroles; Dr Steven Ryley was appointed as a senior\u000a      scientist and worked on the project until December 2008; Dr John Tolland\u000a      undertook biophysical studies of the electropolymer coatings; Mr Christian\u000a      Greef was employed as a research technician in 2007 for 20 months.\u000a    The research at UEA led to the synthesis and electropolymerisation of\u000a      unprecedented, highly functionalised poly(pyrroles), bearing cysteine and\u000a      other motifs capable of binding synthetic ferredoxin and hydrogenase\u000a      clusters (references 1 and 2). In 2007, a histological study of\u000a      functionalised poly(pyrrole) coated stents following implantation in\u000a      porcine coronary arteries was undertaken in conjunction with the St Joseph\u000a      Medical Center, Atlanta (USA). This showed that the new functionalised\u000a      poly(pyrrole) coatings were biocompatible in vivo over a period of\u000a      three months, presenting a low polymer burden (reference 3).\u000a    Subsequent research on antithrombolytic electropolymers led to the\u000a      synthesis of pyrrole monomers, with molecular motifs related to allicins,\u000a      and studies of their electropolymerisation. These studies showed that such\u000a      surface functionality resulted in low levels of platelet binding,\u000a      agglomeration and thrombus formation. Real-time dynamic studies of the\u000a      behaviour of the electropolymer coatings were carried out on whole blood\u000a      samples, in collaboration with Professor Richard Farndale at Cambridge\u000a      University. Importantly, sulfur and\/or allyl functionality of these\u000a      pyrroles conferred excellent adhesion to medical steel substrates. The\u000a      research on these innovative, low thrombogenicity electropolymer materials\u000a      was patented (reference 4).\u000a    Follow-on fund support from the BBSRC (2006 - 2007) enabled studies of\u000a      drug confinement in the electropolymer matrices for neurostimulator\u000a      coatings. Alongside this, Biotectix LLC funding supported research\u000a      on the functionalisation of poly(3,4-ethylenedioxythiophene) (PEDOT)\u000a      electropolymers also for application in the neurostimulator area.\u000a    UEA Research Personnel:\u000a    Professor Chris Pickett: UEA 2005 to date\u000a      Dr Jane Knott: Post-doctoral research associate (2006-2007) BBSRC\u000a      Follow-on Funding\u000a      Dr Tim Boote: PhD student (2006 - 2010) funded on an ICASE award\u000a      (Antithrombolytic Electropolymers); postdoctoral research associate (2010\u000a      to 2011) funded by Chameleon Biosurfaces Ltd. and Biotectix\u000a        LLC.\u000a    "},{"CaseStudyId":"1669","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"2750405","Name":"Netherlands"},{"GeoNamesId":"102358","Name":"Saudi Arabia"}],"Funders":[],"ImpactDetails":"\u000d\u000a    World polyolefin production has risen from 25.6M tonnes in 1983 to an\u000d\u000a      estimated 150M tonnes in 2010, with a total market value of several\u000d\u000a      billion US$. Research at UEA has focussed on single-site polymerisation\u000d\u000a      catalysts and this market sector shows an annual growth rate of more than\u000d\u000a      10% p.a.\u000d\u000a    A key route to economic impact for the UEA research on olefin\u000d\u000a      polymerisation catalysis has been through industry funded IPR protection.\u000d\u000a      For example, within the butyl rubber polymerisation area, research has\u000d\u000a      resulted in 5 world-wide `patent families' each containing 5-7 filings and\u000d\u000a      naming UEA academics as the inventors [corroborating source A].\u000d\u000a      Importantly, these patents were all financed and continue to be maintained\u000d\u000a      by the industrial partner.\u000d\u000a    The specific uptake of UEA research results within the industrial sector\u000d\u000a      is a matter of commercial secrecy. However, statements from key industrial\u000d\u000a      partners, DSM and Sabic, indicate quite clearly the importance of the UEA\u000d\u000a      research.\u000d\u000a    DSM is a Dutch-based global life sciences and materials company with a\u000d\u000a      wide range of products including a range of ultra high molecular weight\u000d\u000a      polyethylene (UHMwPE) applications such as knee implants and high-tensile\u000d\u000a      strength fibres (`Dyneema'&#174; used for nets and ropes for the\u000d\u000a      commercial fishing \/ shipping industry, and personal ballistic\u000d\u000a      protection). In 2012 DSM had net sales figures of &#8364;9.13B.\u000d\u000a    Bochmann's research on the trityl effect has been instrumental in\u000d\u000a      the development of commercially viable polyolefin products at DSM, as\u000d\u000a      shown by the following statement from [text removed for publication]:\u000d\u000a    `If I was asked to be specific on a particular theme that has had\u000d\u000a      industrial significance and that can be easily linked to $$$ then it would\u000d\u000a      be his [Professor Bochmann's] work on the `trityl effect' .... This work\u000d\u000a      has long been regarded as a step change in our knowledge and has led to\u000d\u000a      the commercial success of a family of polyolefin products that only became\u000d\u000a      commercially viable by the addition of an extra equivalent of\u000d\u000a      `co-catalyst' [text removed for publication] which resulted in the products\u000d\u000a      becoming economically attractive to produce. . . . The \"trityl\" effect and\u000d\u000a      the mechanistic review papers also aided the development of commercial\u000d\u000a      heterogeneous catalysts.' [corroborating source B]\u000d\u000a    Sabic, one of the World's top 10 petrochemical companies, is based in\u000d\u000a      Riyadh, Saudi Arabia. In Europe, Sabic is a major producer of plastics and\u000d\u000a      chemicals with approximately 6,300 employees. Sabic-Europe operates 13\u000d\u000a      petrochemical production sites, including a site at Geleen in The\u000d\u000a      Netherlands which produces large volumes of polyethylene (940 ktpa), and\u000d\u000a      polypropylene (620 ktpa). Geleen's output is used in the automotive,\u000d\u000a      luggage, and food packaging industries.\u000d\u000a    A supporting statement from [text removed for publication] shows the\u000d\u000a      importance of Bochmann's research on weakly coordinating anions\u000d\u000a      (WCA) to the operation of [text removed for publication]:\u000d\u000a    `To the best of my knowledge, almost all low pressure\/high temperature\u000d\u000a      solution phase processes currently operated by industry make use of such\u000d\u000a      WCA's as activators for polyolefins. It is especially in this important\u000d\u000a      area where Professor Bochmann and his co-workers have played a major role\u000d\u000a      in the discovery, fundamental understanding and subsequent further\u000d\u000a      development of boron containing WCA's as activators for polyolefins that\u000d\u000a      allowed commercialization of this groundbreaking technology. [text removed for\u000d\u000a      publication]\u000d\u000a    Without the introduction of these speciality olefins it is hard to\u000d\u000a        envisage that [text removed for publication] would still be in\u000d\u000a        operation today.'\u000d\u000a    [corroborating source C]\u000d\u000a    The packaging market accounts for nearly a third of all Sabic-Europe's\u000d\u000a      polymer sales within Europe. For the production of food packaging\u000d\u000a      materials, it is crucial that all polymers comply with EU Plastics\u000d\u000a      Regulations, including the catalysts. Bochmann's research on [text removed for\u000d\u000a      publication] has been important within such polymer production, as shown\u000d\u000a      by the statement from [text removed for publication]:\u000d\u000a    `The commercial relevance of [text removed for publication] was not very well\u000d\u000a      recognized because of the generally encountered low productivity. For\u000d\u000a      this, pioneering publications on the performance of [text removed for\u000d\u000a      publication] catalysts by Professor Bochmann's group.... were and still\u000d\u000a      are leading references ...Although not able to go into details, the large\u000d\u000a      economic relevance of [text removed for publication] EU's positive list for\u000d\u000a      substances allowed in Food Contact Applications.'\u000d\u000a    [corroborating source C]\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Research at UEA over a 20 year period in the area of olefin\u000d\u000a      polymerisation catalysis has had significant economic impact\u000d\u000a      through:\u000d\u000a    \u000d\u000a      industrial uptake of new activator systems crucial for solution phase\u000d\u000a        polymerisation processes\u000d\u000a      improvement in catalyst performance by the `trityl effect' which is\u000d\u000a        now implemented in industrial processes\u000d\u000a      patents taken out and maintained by industry.\u000d\u000a    \u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    University of East Anglia\u000d\u000a    ","Institutions":[{"AlternativeName":"East Anglia (University of)","InstitutionName":"University of East Anglia","PeerGroup":"B","Region":"East","UKPRN":10007789}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"108410","Name":"Riyadh"}],"References":"\u000d\u000a    (UEA authors in bold)\u000d\u000a    \u000aWeakly Coordinating Anions\u000d\u000a    1. Synthesis, Structures and Reactivity of Weakly Coordinating Anions\u000d\u000a      with Delocalized Borate Structure: The Assessment of Anion Effects in\u000d\u000a      Metallocene Polymerization Catalysts J. Zhou, S. J. Lancaster, D.\u000a        A. Walker, S. Beck, M. Thornton-Pett and M. Bochmann\u000d\u000a      J. Am. Chem. Soc. 2001, 123, 223 - 237 (154\u000d\u000a      citations) doi: 10.1021\/ja002820h\u000d\u000a    \u000a\u000a2. Cationic Group IV Metallocene Complexes and Their Role in\u000d\u000a      Polymerisation Catalysis: The Chemistry of Well-defined Ziegler Catalysts\u000d\u000a      M. Bochmann\u000d\u000a      J. Chem. Soc., Dalton Trans. 1996, 255 - 270 (855\u000d\u000a      citations)\u000d\u000a      doi: 10.1039\/DT9960000255\u000d\u000a    \u000a\u000aTrityl Effect\u000d\u000a      3. Activator Effects in Metallocene-Based Alkene Polymerizations:\u000d\u000a      Unexpectedly Strong Dependence of Catalyst Activity on Trityl\u000d\u000a      Concentration\u000d\u000a      F. Song, R. D. Cannon, S. J. Lancaster and M.\u000d\u000a        Bochmann\u000d\u000a      J. Mol. Catal. 2004, 218, 21-28 (36 citations)\u000d\u000a      doi: 10.1016\/j.molcata.2004.03.042\u000d\u000a    \u000a\u000aTrimethylaluminium and Hafnium Catalysis\u000d\u000a      4. Monomer-Dimer Equilibria in Homo-and Heterodinuclear Cationic\u000d\u000a      Alkylzirconium Complexes and Their Role in Polymerization Catalysis\u000d\u000a      M. Bochmann and S.J. Lancaster\u000d\u000a      Angew. Chem. Int. Ed. Engl. 1994, 33, 1634 - 1637\u000d\u000a      (258 citations)\u000d\u000a      doi: 10.1002\/anie.199416341\u000d\u000a    \u000a\u000a5. Cationic Group IV Metal Alkyl Complexes and their Role as Olefin\u000d\u000a      Polymerization Catalysts &#8212; The Formation of Ethyl-bridged Dinuclear and\u000d\u000a      Heteronuclear Zirconium and Hafnium Complexes\u000d\u000a      M. Bochmann and S. J. Lancaster\u000d\u000a      J. Organomet. Chem. 1995, 497, 55-59 (86 citations)\u000d\u000a      doi: 10.1016\/0022-328X(95)00109-4\u000d\u000a    \u000a\u000aCationic Polymerisation and Butyl Rubber Production\u000d\u000a      6. Highly Electrophilic Organometallics for Carbocationic Polymerizations:\u000d\u000a      From Anion Engineering to New Polymer Materials\u000d\u000a      M. Bochmann\u000d\u000a      Acc. Chem. Res. 2010, 43, 1267 - 1278 (9 citations)\u000d\u000a      doi: 10.1021\/ar100044s\u000d\u000a    \u000aKey Grants and Personnel (all with Bochmann as PI):\u000d\u000a    [text removed for publication]\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"},{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"}],"Sources":"\u000d\u000a    [A] Patent details:\u000d\u000a    I.Polymerization process using zinc halide initiators\u000d\u000a      M. Bochmann, A. Guerrero, K. Kulbaba\u000d\u000a      Canadian CA 2578679 (15.2.2007); EP1834964 (19\/9\/2007); US2007238843\u000d\u000a      (22.2.2007); JP2007246902 (27.2.2007) (Lanxess Inc., Canada)\u000d\u000a    II.Process for the Production of Butyl Rubber\u000d\u000a      M. Bochmann and S. Garratt\u000d\u000a      Canadian Pat. Applic. 2,441,079 (16.3.2005); China CN 1654487 (17.8.2005);\u000d\u000a      EP 1516883 (23.3.2005); JP 2005089756 (7.4.2005); US 7,041,760 (31.3.2005)\u000d\u000a      (Bayer Inc., Canada)\u000d\u000a    III.Process for Preparing Isobutylene-based Polymers\u000d\u000a      M. Bochmann, M. Schormann and S. Garratt\u000d\u000a      Canadian Pat. Applic. 2,368,724 (filing date 21.1.02); Eur. Pat. Appl.\u000d\u000a      1470167 A2 (27.10.2004); JP 2005515276 (26.5.2005); RU2004125857\u000d\u000a      (27.5.2005); US2005165182 (28.7.2005); WO03\/062284 (31.7.2003) (Bayer\u000d\u000a      Inc., Canada)\u000d\u000a    IV.Process for the Preparation of Polyisoolefins via New Initiator\u000d\u000a        Systems of the Metallocene Type\u000d\u000a      G. Langstein, M. Bochmann, D. Dawson, A.G. Carr and R. Commander\u000d\u000a      German DE 19836663.9 (13.8.98). (Bayer Inc. Canada)\u000d\u000a    V. Process for the Preparation of Polyisoolefins via New Initiator\u000d\u000a        Systems of the Metallocene-Type\u000d\u000a      G. Langstein, M. Bochmann and D. Dawson\u000d\u000a      German Pat. Appl. DE 1961003331 (30.1.96); Eur. Pat. Appl. 0787748; US\u000d\u000a      5703182 (Bayer AG, Germany)\u000d\u000a    (copies of all patents held on file at UEA)\u000d\u000a    [B] Supporting letter from [text removed for publication] DSM (held on file\u000d\u000a      at UEA)\u000d\u000a    [C] Supporting letter from [text removed for publication] SABIC-Europe (held\u000d\u000a      on file at UEA)\u000d\u000a    ","Title":"\u000d\u000a    Industrially relevant olefin polymerisation catalysis at UEA\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    From 1993 to present, the research group of Bochmann has carried\u000d\u000a      out a series of research programmes into the activation chemistry and\u000d\u000a      mechanisms of single-site catalysts for olefin polymerisation, mainly\u000d\u000a      metallocenes. This research has been undertaken alongside industrial\u000d\u000a      partners and with industrial funding, thus maximising the opportunity for\u000d\u000a      knowledge transfer to the manufacturing industry throughout the period.\u000d\u000a      The research can be described under the following broad headings:\u000d\u000a    Weakly Coordinating Anions\u000d\u000a      Early work (93-96) was on the identification and spectroscopic\u000d\u000a      characterisation of cationic, 14-electron group 4 metallocenes as active\u000d\u000a      species. This was followed by the development of activators that led to\u000d\u000a      ultra-active catalysts of a type that are presently used in industrial\u000d\u000a      solution phase processes. This included the development of \"super-weakly\u000d\u000a      coordinating\" anions for generating highly active soluble catalysts.\u000d\u000a    Trityl Effect\u000d\u000a      From 2000-2007, studies on polymerisation kinetics, the solution dynamics\u000d\u000a      and on aggregation phenomena of metallocenes catalysts led to the\u000d\u000a      discovery of the \"trityl effect\", which can increase the activity of\u000d\u000a      metallocene catalysts by up to an order of magnitude without the need for\u000d\u000a      expensive modification of the metallocene component.\u000d\u000a    Trimethylaluminium and Hafnium Catalysis\u000d\u000a      Research into the role of trimethylaluminium (TMA) in polymerisation\u000d\u000a      catalysis includes the first identification of TMA association equilibria\u000d\u000a      and their influence on catalyst activity in zirconocene and hafnocene\u000d\u000a      polymerisation catalysts.\u000d\u000a    Cationic Polymerisation and Butyl Rubber Production\u000d\u000a      In addition, in collaboration with Bayer and Lanxess (95-08), Bochmann\u000d\u000a      developed an alternative to the, then current, process for producing butyl\u000d\u000a      rubber, originally developed before WWII, which requires extremely low\u000d\u000a      operating temperatures (-100 &#176;C) and consequently high energy costs.\u000d\u000a      Using his weakly coordinating anion chemistry, Bochmann was able to\u000d\u000a      provide a more energy-friendly alternative which delivers\u000d\u000a      industry-standard polymers at -30 &#176;C.\u000d\u000a    Total industrial investment in Professor Bochmann's olefin polymerisation\u000d\u000a      catalysis research from BP, Bayer Leverkusen, Bayer Canada, Lanxess, BASF\u000d\u000a      and Exxon has been ca. &#163;1M, supporting 7 postdoctoral researchers and 6\u000d\u000a      PhD students.\u000d\u000a    "},{"CaseStudyId":"2547","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"3017382","Name":"France"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":[],"ImpactDetails":"\u000a    The research was supported by the Heritage Lottery Fund through an award\u000a      to Professor AV Chadwick, University of Kent that was administered by the\u000a      Mary Rose Trust. The project was specifically targeted to solve an\u000a      existing problem in the treatment of waterlogged wood that is described\u000a      above. Eleanor Schofield was appointed as a postdoctoral research\u000a      assistant during the period of the award. As a result of the training she\u000a      obtained at the University of Kent, and the progress she made with the\u000a      development of new chemical treatments, she subsequently became\u000a      Conservation Manager for the Mary Rose Trust, with overall responsibility\u000a      for chemistry related conservation. She has overseen the implementation of\u000a      the University of Kent technology to treat numerous salvaged items. The\u000a      figure below shows one of the many gun carriages on display that were\u000a      treated using the University of Kent method. These items would not be on\u000a      display if the University of Kent research had not been carried out. \u000a    Beneficiaries and Significance of the Conservation of the Mary Rose\u000a    The work led by the University of Kent has a local impact on the economy\u000a      of Portsmouth and the South East, a national impact in the position of the\u000a      Mary Rose within British history, and an international impact on the\u000a      conservation and heritage industry.\u000a    The restored Mary Rose forms a centrepiece attraction in Portsmouth's\u000a      Historic Dockyard: in its new purpose-built museum it is a major visitor\u000a      attraction and cultural asset to its region. The Dockyard attracts around\u000a      500,000 visitors a year, approximately 15-20% from overseas and it is\u000a      anticipated that these numbers will grow further with the opening of the\u000a      Mary Rose (Portsmouth Historic Dockyard Ltd.). The Mary Rose Trust\u000a      received &#163;2m from visitors, in donations and trading income in 2012; it\u000a      also has an active learning and outreach programme (Mary Rose Trust Annual\u000a      Review 2013). \u000a    \u000a      \u000a      \u000a       Kent research enabled the conservation of artefacts, such as\u000a        the gun carriages (left) that would otherwise not be on display. The Mary\u000a          Rose project is a lasting legacy to Tudor life that will be\u000a        enjoyed for many generations to come. The uniqueness of the exhibition\u000a        (right) prompted historian David Starkey to describe it as the \"British\u000a        Pompeii\" \u000a    \u000a     The preservation of Mary Rose has major historical significance as a\u000a      well-preserved example of Tudor history. Without the preservation of the\u000a      artefacts - of which the ship itself if the greatest - it would not be\u000a      possible for the museum to tell the full story of this period of history:\u000a      \"In the original museum less than 10% of the recovered artefacts were on\u000a      display. In the new museum many thousands more artefacts will be displayed\u000a      in context, many never seen before. Preparing all this material has been a\u000a      huge task. The remarkable state of preservation of some of these articles\u000a      can be confusing because everything wooden on display in the new museum is\u000a      a conserved original. There are no organic replicas on display.\" (Mary\u000a      Rose Trust Annual Review 2013). The impact of the work is also evidenced\u000a      by interest from other conservators. Dr Emma Hocker, a conservator at the\u000a      Vasa commented on the research at the University of Kent: \"We at the Vasa\u000a      Museum are always interested in new treatments to neutralise acids in\u000a      wood. What is intriguing about the University of Kent's method is that it\u000a      is not a one-off treatment, but since the nano-particles remain in the\u000a      wood, they act as a buffer ready to neutralise any new acidic outbreaks.\"\u000a    \u000a    ","ImpactSummary":"\u000a    The warship Mary Rose served Henry VIII's navy for 34 years, including\u000a      spells as the flagship. She sank while engaging the French navy in the\u000a      Solent in 1545, and unsuccessful salvage bids meant the ship remained on\u000a      the seabed for almost half a millennium. The University of Kent has been\u000a      the central academic partner of the 30-year and &#163;35 million Mary Rose\u000a      salvage and conservation project. It received Heritage Lottery funds,\u000a      which the University of Kent used to develop new conservation chemistry,\u000a      underpinned by synchrotron studies. Kent researchers have subsequently\u000a      taken up permanent employment with the Mary Rose Trust to implement this\u000a      new technology. The Mary Rose exhibition opened at Portsmouth Historic\u000a      Dockyard in May 2013, is one of the most important additions to UK culture\u000a      in recent times. The research at Kent was critical to this achievement,\u000a      and the new chemical technology is subsequently finding new areas of\u000a      impact.\u000a    ","ImpactType":"Cultural","Institution":"\u000a    University of Kent\u000a    ","Institutions":[{"AlternativeName":"Kent (University of)","InstitutionName":"University of Kent","PeerGroup":"B","Region":"South East","UKPRN":10007150}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"3170335","Name":"Pompei"}],"References":"\u000a    The conservation section of the Mary Rose website (http:\/\/www.maryrose.org\/archaeology-and-conservation\/mary-rose-publications\/)\u000a        describes a total of 5 research publications (references [2]-[6]\u000a      below) directly impacting on the restoration of the warship. All 5\u000a      articles are work carried out in the School of Physical Sciences at the\u000a      University of Kent, and all have an author from the University of Kent as\u000a      first author, as well as the corresponding author. The work at the\u000a      University of Kent constitutes all of the research done to preserve the\u000a      Mary Rose. References [1], [5] and [6] best indicate the quality of the\u000a      underpinning research). \u000a    \u000a1. Wetherall, K. M.*, Moss, R. M., Jones, A. M., Smith,\u000a      A. D., Skinner, T., Pickup, D. M.,&#160; Goatham, S. W.,\u000a        Chadwick, A. V. and Newport, R. J. \"Sulfur and Iron Speciation in\u000a      recently recovered timbers of the Mary Rose revealed via X-ray absorption\u000a      spectroscopy\", J. Archaeological Science, 35, 1317 (2008) \u000a    \u000a\u000a2. Berko, A., Smith, A.D. Jones, A. M., Schofield, E.J.,\u000a      Mosselmans, J. F. W. and Chadwick, A.V.* \"XAS studies of\u000a      the effectiveness of iron chelating treatments of Mary Rose timbers\",\u000a      Journal of Physics Conference Series: 14th International Conference on\u000a      X-ray Absorption Fine Structure (XAFSI 4), 190, 012147 (2009). \u000a    \u000a\u000a3. Chadwick, A.V.*, Berko, A., Schofield, E.J.,\u000a      Jones, A.M., Mosselmans, J. F. W., Smith, A. D. \"How X-rays are helping\u000a      defeat the effects of micro-organisms in the preservation of Mary Rose\"\u000a      L'Actualite Chimique, 356-357, 106 (2011). \u000a    \u000a\u000a4. Schofield, E.J., Sarangi, R., Mehta, A., Jones, A. M. and Chadwick,\u000a        A. V.* \"Nanotechnology and Synchroton light in the service of Henry\u000a      VIII: preserving the Mary Rose\" Materials Today,14, 354 (2011). \u000a    \u000a\u000a5. Chadwick, A. V.*, Berko, A., Schofield, E.J.,\u000a      Jones, A. M., Mosselmans, J. F. W., Smith, A. D. \"Application of\u000a      Microfocus X-ray Beams from Synchrotrons in Heritage Conservation\"\u000a      International Journal of Architectural Heritage, 6, 228 (2012). \u000a    \u000a\u000a6. Chadwick, A. V.*, Schofield, E.J., Jones, A. M.,\u000a      Cibin, G. and Mosselmans, J. W. F., \"Ionic Nanoparticles in Heritage\u000a      Conservation\", Solid State Ionics, 225, 742-746 (2012) \u000a    \u000a* Corresponding author. Bold signifies author from University of\u000a      Kent. \u000a    Key funding: \u000a    &#8226; Chadwick, A.V., Newport, R.J., \"An investigation of remediation methods\u000a    for the sulphur problem in Mary Rose timbers.\", Heritage Lottery Fund grant\u000a    administered by the Mary Rose Trust, 01\/07\/2008 to 30\/06\/2011. \u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"},{"Level1":"4","Level2":"2","Subject":"Geochemistry"},{"Level1":"3","Level2":"7","Subject":"Theoretical and Computational Chemistry"}],"Sources":"\u000a    1. Professor Mark Jones, Head of Collections of the Mary Rose Trust.\u000a      [Contact 1]. Who can confirm the relationship of the underpinning research\u000a      from Kent to the Mary Rose project and the impact on the Mary Rose Trust.\u000a    \u000a    2. Dr Eleanor Schofield, Conservation Manager at the Mary Rose Trust.\u000a      [Contact 3]. Who can confirm the detailed relationship between the\u000a      technical aspects of the Kent research and the conservation of the Mary\u000a      Rose ship. \u000a    3. Emma Hocker, Conservator, Vasa Museum. [Contact 2]. Who can confirm\u000a      the wider impact of the research on international conservation efforts,\u000a      and specifically for the Vasa ship. \u000a    4. The Mary Rose Trust has an extensive website describing the\u000a      extraordinary history of the ship, including a large section on the\u000a      Archaeology and Conservation process, a link is provided in the section 3\u000a      above. A section of the website is quoted below, that corroborates the\u000a      involvement of the University of Kent: \"University of Kent -\u000a        development of strontium carbonate nanoparticle treatment to sequester\u000a        sulfate and neutralise the wood \/ exploration of chelating agents to\u000a        remove iron from the wood and therefore eliminate the catalyst for\u000a        sulphur oxidation and acid production.\" http:\/\/www.maryrose.org\/archaeology-and-conservation\/mary-rose-research\/\u000a         \u000a    5. Interview with Eleanor Schofield from the University of Kent on\u000a      nanoparticle preservation. The transcript of an interview with Eleanor\u000a      Schofield in Materials Today on the use of nanoparticles in the\u000a      conservation of the Mary Rose is given at : http:\/\/www.materialstoday.com\/blog\/2013\/1\/30\/interview-with-eleanor-schofield-nanoparticle-preservation\/783.aspx\u000a        A recording of the actual interview is given at : http:\/\/about.elsevier.com\/media\/MT_Schofield_maryrose.mp3\u000a        \u000a    6. Website:\u000a        http:\/\/www.maryrose.org\/archaeology-and-conservation\/mary-rose-publications\/\u000a        All 5 articles are work carried out in the School of Physical\u000a      Sciences at the University of Kent, and all have an author from the\u000a      University of Kent as first author, as well as the corresponding author. \u000a    ","Title":"\u000a    Mary Rose: Protecting our Heritage through Chemistry  \u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Context and Traditional Conservation projects \u000a    Salvage projects, such as the Mary Rose, UK and the Vasa, Sweden, have\u000a      shown wooden ships can remain relatively intact while buried within silt\u000a      under sea beds for hundreds of years. However, this does not mean that the\u000a      environment is benign, which was first highlighted during the restoration\u000a      of the Vasa. The Swedish warship spent 333 years under the Stockholm\u000a      archipelago after collapsing on her maiden voyage. She was salvaged in\u000a      1961 and put on display in 1990; a project approximately 20 year ahead of\u000a      the Mary Rose. Although the oak beams were seemingly in excellent\u000a      condition when first raised above the surface, the ship dramatically\u000a      deteriorated while in the museum [Nature 415 893 (2002)]. The problem lay\u000a      in the nature of the treatment used to stabilise the wood after salvage.\u000a      In this process, a preservation solution of boric acid and sodium borate\u000a      was applied to neutralise the acidity, along with polyethylene glycol to\u000a      replace the water and prevent warping as the wood dries. What quickly\u000a      became apparent was that the acidity of the wood increased and sulphate\u000a      salts began to coat the surfaces, which \"threatened the continued\u000a      preservation of the Vasa\". It was suggested that the problem originated\u000a      from hydrogen sulphide produced by bacteria within the waterlogged wood\u000a      while submerged. The preservation solution initially lowered the acidity\u000a      on treatment, but the slow oxidation of the sulphur containing material,\u000a      catalysed by the presence of iron from structural bolts etc, was creating\u000a      an ongoing acidity problem, which \"could produce 5,000kg of sulphuric acid\u000a      when fully oxidised.\" The University of Kent solved this issue by\u000a      understand the oxidation process [1, 2, 5], and developed a completely\u000a      different treatment that neutralises both the inherent acidity, as well as\u000a      acting as a buffer for the ongoing sulphur-related problem [3, 4, 6]. \u000a    Key Research Findings at University of Kent\u000a    Dr Eleanor Schofield was appointed a postdoctoral research\u000a      scientist by Professor Alan Chadwick [Kent 1970-present] of the\u000a      School of Physical Sciences, University of Kent between January 2009 and\u000a      June 2011 to study \"abiotic production of acid in waterlogged\u000a      archaeological wood and remediation strategies\". She focused on addressing\u000a      the sulphur issue, while Aaron Berko, University of Kent, focussed\u000a      on iron removal for his PhD during the same time. The Kent team developed\u000a      detailed chemical mechanisms of how sulphates, naturally present in sea\u000a      water, interacted with bacteria to form reduced sulphur compounds, such as\u000a      hydrogen sulphide, which can undergo further reactions with iron to form\u000a      iron sulphides [1]. Although not particularly harmful themselves, lifting\u000a      the wood out of the water sets off a new set of reactions, where the air\u000a      oxidises the plethora of sulphur compounds formed under the seabed into\u000a      harmful sulphuric acid that attacks the wood. Using this knowledge, the\u000a      Kent scientists studied a number of alternative treatments, making use of\u000a      synchrotron beam lines at Stanford, USA and Diamond, UK, to characterise\u000a      their effectiveness [2]. It was shown that strontium carbonate\u000a      nanoparticles (in an isopropanol solution) reduced both the inherent\u000a      acidity (as achieved by the Vasa treatment), as well as the ongoing\u000a      acidity originating from the reduced sulphur compounds [4, 6]. This new\u000a      technique has been extensively implemented on the Mary Rose project and\u000a      represents a major achievement as the new treatment developed at the\u000a      University of Kent permanently stabilises waterlogged items, preventing\u000a      further degradation and requires no addition treatments.\u000a    "},{"CaseStudyId":"3264","Continent":[],"Country":[],"Funders":[],"ImpactDetails":"\u000a    Nearly all solid medicines like tablets and capsules contain drugs in\u000a      crystalline form; and all crystals have the potential to `morph' into not\u000a      one but many alternative forms. The likelihood of the crystals actually\u000a      changing and becoming a danger to patients is very small but it can and\u000a      does happen, with catastrophic consequences.\u000a    In 1988, a clinical failure of Tegretol (carbamazepine) tablets, the\u000a      anticonvulsant widely used with epilepsy, was observed. It was believed to\u000a      be caused by a phase conversion from the anhydrate to dehydrate form. In\u000a      1998 Abbott Laboratories withdrew Norvir (ritonavir), essential at that\u000a      time in the treatment of HIV\/AIDS, because the capsules unexpectedly\u000a      failed dissolution tests. The public were without an essential drug while\u000a      researchers investigated. They finally identified that the drug crystals\u000a      had changed into a more stable, less soluble polymorph which contaminated\u000a      laboratories and effectively halted production processes. They had to\u000a      completely reformulate the drug and develop a new capsule product. The\u000a      case cost Abbott hundreds of millions of dollars and over 600 scientists\u000a      working for nearly a year to resolve the issue. The estimated loss in\u000a      sales in 1998 alone is $250m.\u000a    Pfizer experienced similar problems with two drugs in development and\u000a      concluded that a deeper scientific knowledge of polymorphism was an\u000a      emerging need in the pharmaceutical industry. The consequences were\u000a      typically catastrophic, hard to predict, clinically and economically\u000a      unacceptable, and damaging to patients' trust in the company to produce\u000a      the quality products they relied on.\u000a    Pfizer identified internal and external drivers for the need to\u000a      understand polymorphism on a more scientifically rigorous basis. These\u000a      drivers included:\u000a    \u000a      emphasis on the chemical rather than physical attributes of drugs and\u000a        excipients;\u000a      the instrumentation used to characterise polymorphism was relatively\u000a        simplistic and unable to predict the potential for phase transition;\u000a      the existing protocols to test physical performance required large\u000a        quantities of expensive pure solid drug, and occurred too late in the\u000a        development process to stimulate the re-engineering of defective\u000a        crystalline drug forms;\u000a      an industry-wide drive for more rapid drug development and clinical\u000a        testing.\u000a    \u000a    Pfizer turned to the University of Greenwich to develop the scientific\u000a      methodology to:\u000a    \u000a      produce small quantities of highly purified drug crystals, alone and\u000a        in drug product matrices, from side streams of conventional pilot\u000a        batches;\u000a      use the pure drugs to develop tests on single crystals, a process\u000a        which is much cheaper and can be performed at the start rather than end\u000a        of the drug development process;\u000a      develop tests that could predict polymorph instability and how they\u000a        behave during manufacture, and in turn allow the engineering and\u000a        understanding of new solid-state forms for development.\u000a    \u000a    Since 2008 Pfizer has been able to apply the resulting methodologies,\u000a      systematically to the development of crystalline APIs for use in solid\u000a      oral and inhalation dosage forms. The company has also applied them to\u000a      understand the risk for products licensed from other companies not using\u000a      this scientific paradigm. Pfizer has invested &#163;2.4m in the university to\u000a      date. The programme has resulted in critical technology and human resource\u000a      transfer to the company as well as 27 refereed publications. To date 24\u000a      researchers have progressed through the scheme; 40% have taken up posts\u000a      within Pfizer and 42% with other leading pharmaceutical companies.\u000a    The larger impacts are that Pfizer has vastly reduced the risk of\u000a      polymorphism in its drugs, increasing the confidence of patients and\u000a      health professionals. Examples of what might have happened without the\u000a      university's pioneering research abound, for instance to UCB with\u000a      Parkinson's disease drug rotigotine. Filed in 2003 as a drug that did not\u000a      exhibit polymorphism, rotigotine was delivered through Neupro skin patches\u000a      and many patients experienced an improved quality of life. In 2008,\u000a      dendritic structures were observed: a new form polymorph had crystallised\u000a      which reduced the patches' efficacy. The product was withdrawn in the US\u000a      in 2008 and did not return to the market until 2012. Similarly, in 2010\u000a      BMS withdrew 64 million Avalide tablets (hydrochlorthiazide and\u000a      irbesartan) over concerns that irbesartan crystals had converted to a less\u000a      soluble polymorph. Avalide sales were calculated to be $310 million in the\u000a      first nine months of 2010. Pfizer is able to safeguard its patients and\u000a      avoid the cost associated with recalls and the redevelopment and relaunch\u000a      of clinically essential products.\u000a    ","ImpactSummary":"\u000a    Nearly all solid dosage forms contain drugs in crystalline form; and all\u000a      crystals have the potential to `morph', suddenly, into different forms\u000a      which can affect the safety and efficacy of the medicinal product. A\u000a      number of high-profile cases in which marketed medicines had to be\u000a      withdrawn [Lee, et al., Annu. Rev. Chem. Biomol. Eng. 2011,\u000a      2, 259-280] led multinational drug company Pfizer to conclude that\u000a      a greater understanding of polymorphism was required to enable drug\u000a      product design for the 21st Century. The University of\u000a      Greenwich pioneered methods to predict crystal behaviour on the shelf and\u000a      during manufacture that were affordable, timely and effective. It enabled\u000a      Pfizer to select the optimal polymorphic drug form and manage risk\u000a      associated with uncontrolled solid-state transformations, thereby\u000a      safeguarding patients and avoiding huge costs.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Greenwich\u000a    ","Institutions":[{"AlternativeName":"Greenwich (University of)","InstitutionName":"University of Greenwich","PeerGroup":"D","Region":"London","UKPRN":10007146}],"Panel":"B         ","PlaceName":[],"References":"\u000a    \u000a3.1.1 Mathews, B. T., Higginson, P. D., Lyons, R., Mitchell, J. C.,\u000a      Sach, N. W., Snowden, M. J., Taylor, M. R., &amp; Wright, A.G.\u000a      (2004). Improving Quantitative Measurements for the Evaporative Light\u000a      Scattering Detector. Chromatographia, 60(11-12), 625-633.\u000a      http:\/\/dx.doi.org\/10.1365\/s10337-004-0441-3\u000a    \u000a\u000a3.1.2 Dubant, S., Mathews, B., Higginson, P., &amp; Crook, R., Snowden\u000a        M.J., Mitchell, J.C., (2008). Practical solvent system selection for\u000a      counter-current separation of pharmaceutical compounds. Journal of\u000a        Chromatography A, 1207(102), 190-192.\u000a      http:\/\/dx.doi.org\/10.1016\/j.chroma.2008.08.113\u000a        \u000a    \u000a\u000a3.2.1 Johnson, M. N., &amp; Feeder, N. (2004). dl-Histidine dl-tartrate.\u000a      Acta Crystallographica Section E: Structure Reports Online, 60(7),\u000a      1273-1274.\u000a      http:\/\/dx.doi.org\/10.1107\/S1600536804015296\u000a    \u000a\u000a3.2.2 Johnson, M. N., &amp; Feeder, N. (2004). d-Histidinium\u000a      (2S,3S)-tartrate. Acta Crystallographica Section E: Structure Reports\u000a        Online, 60(8), 1374-1375.\u000a      http:\/\/dx.doi.org\/10.1107\/S1600536804017088\u000a    \u000a\u000a3.2.3 Johnson, M. N., Feeder, N., &amp; Snowden, M.J.\u000a      (2004). Effects of chirality on the salt formation of histidine. Journal\u000a        of Pharmacy and Pharmacology, 56(S1), 24-25.\u000a      http:\/\/dx.doi.org\/10.1211\/002235704777489212\u000a    \u000a\u000a3.3.1 Taylor L. J., Papadopoulos D. G., Dunn P. J., Bentham A. C., Dawson\u000a      N. J., Mitchell J. C. &amp; Snowden M. J. (2004).\u000a      Predictive milling of pharmaceutical materials using nanoindentation of\u000a      single crystals, Organic Process Research &amp; Development, 8(4),\u000a      675-679. http:\/\/dx.doi.org\/10.1021\/op0300241\u000a    \u000a\u000a3.3.2 Taylor L. J., Papadopoulos D. G., Dunn P. J., Bentham A. C., Mitchell\u000a        J. C., &amp; Snowden M. J. (2004), Mechanical\u000a      characterisation of powders using nanoindentation, Powder Technology,\u000a      143-144, 179-185. http:\/\/dx.doi.org\/10.1016\/j.powtec.2004.04.012\u000a    \u000a\u000a3.3.3 Taylor L. J., Papadopoulos D. G., Dunn P. J., Mitchell J. C.,\u000a      &amp; Snowden M. J. (2004). Milling Made Easy: Nanoindentation as\u000a      a predictor of bulk properties, Pharmaceutical Technology Europe,\u000a        16(12), 51-54.\u000a      http:\/\/www.pharmtech.com\/pharmtech\/article\/articleDetail.jsp?id=138086&amp;sk=&amp;date=&amp;pageID=2\u000a    \u000a\u000a3.4.1 &#352;a&#353;i&#263;, S., Clark, D. A., Mitchell, J. C., &amp; Snowden,\u000a        M. J. (2005). Raman line mapping as a fast method for analyzing\u000a      pharmaceutical bead formulations. Analyst, 130(11),\u000a      1530-1536.\u000a      http:\/\/dx.doi.org\/10.1039\/B506523B\u000a    \u000a\u000a3.4.2 &#352;a&#353;i&#263;, S., Clark D. A., Mitchell, J. C. and Snowden M.\u000a        J., (2005). Analysing Raman images of pharmaceutical products by\u000a      sample-sample 2D correlation, Appl. Spec., 59, (5),\u000a      630-638.\u000a      http:\/\/dx.doi.org\/10.1366\/0003702053946047\u000a    \u000a\u000a3.4.3 &#352;a&#353;i&#263;, S., Clark, D. A., Mitchell, J. C., &amp; Snowden,\u000a        M. J. (2004). A comparison of Raman chemical images produced by\u000a      univariate and multivariate data processing&#8212;a simulation with an example\u000a      from pharmaceutical practice. Analyst, 129(11), 1001-1007.\u000a      http:\/\/dx.doi.org\/10.1039\/B409879J\u000a    \u000a\u000a3.4.4 Brody, R.H., Kierstan, K.T.E., Clark, D.A., Mitchell, J.C.\u000a      &amp; Snowden, M.J. (2003). Analysis of challenging pharmaceutical\u000a      samples using chemical and elemental images. Microscopy and\u000a        Microanalysis, 9 (Suppl. 02), 1108-1109.\u000a      http:\/\/journals.cambridge.org\/article_S1431927603445546\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"},{"Level1":"3","Level2":"1","Subject":"Analytical Chemistry"}],"Sources":"\u000a     \u000a    5.1 Letter of Corroboration from Pfizer Inc. A\u000a      corroborating letter is available from the R&amp;D Director, Pfizer Ltd.\u000a      The contact for communication the Senior Director and Head of Materials\u000a      Science Pfizer Ltd.\u000a    5.2 Corroborating Pfizer Publications. The following\u000a      publications, by Pfizer lead authors, confirm the application and\u000a      development of the tools and techniques developed by the Pfizer-University\u000a      of Greenwich partnership.\u000a    5.2.1. Extracting process-related information from pharmaceutical\u000a        dosage forms using near infrared microscopy, Fiona Clarke,\u000a      Vibrational Spectroscopy 2004 34 25-35\u000a    5.2.2. Evaluating particle hardness of pharmaceutical solids using AFM\u000a        nanoindentation Victoria M. Masterson, Xiaoping Cao International\u000a      Journal of Pharmaceutics 2008 362 163-171.\u000a    5.2.3. Chemical imaging of pharmaceutical granules by Raman global\u000a        illumination and near- infrared mapping platforms Slobodan Sasic\u000a      Analytica Chimica Acta 2008 611 73-79.\u000a    5.2.4. Scalable Technology for the Extraction of Pharmaceutics\u000a        (STEP): The transition from academic know how to industrial reality,\u000a      Ian Sutherland, Svetlana Ignatova, Peter Hewitson, Lee Janaway, Philip\u000a      Wood, Neil Edwards, Guy Harris, Hacer Guzlek, David Keay, Keith Freebairn,\u000a      David Johns, Nathalie Douillet, Chris Thickitt, Elsa Vilminot, Ben\u000a      Mathews, Journal of Chromatography A, 2011 1218 6114- 6121. \u000a    ","Title":"\u000a    Managing risk associated with crystal polymorphism in pharmaceutical\u000a      development\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Polymorphism is a phenomenon where drug molecules can adopt multiple\u000a      crystalline packing arrangements or conformations in the solid state. It\u000a      affects manufacturing performance, the stability of formulated medicines\u000a      and the extent of oral absorption and hence the dose. An optimal\u000a      polymorphic drug form must be selected that is thermodynamically stable.\u000a      Pfizer did not have the analytical tools to provide a deep knowledge of\u000a      the emerging importance of polymorphism. Pfizer identified Martin\u000a        Snowden, with expertise in surface and colloid chemistry, and John\u000a        Mitchell, a physical organic chemist, to lead research to develop\u000a      the technology in four areas. Stephen Wicks, Vice President of\u000a      Pharmaceutical Science and Technology and UK Development Director at\u000a      Pfizer, led the technology transfer project.\u000a    2.1 Production of highly pure crystals for physical and mechanical\u000a        evaluation\u000a    Flash-Liquid Chromatography is a purification method of choice for\u000a      preparative separations of drug molecules. Flash-LC had limited ability to\u000a      produce pure fractions for routine solid-state characterisation because of\u000a      its reliance on UV detection: important organic solvents used to achieve\u000a      high purity levels had high UV cut-offs; many new drug candidates lacked\u000a      significant chromophores. The Evaporative Light Scattering Detector (ELSD)\u000a      was adapted for use with Flash-LC to allow the routine preparation of\u000a      Active Pharmaceutical Ingredients (APIs) for materials science analysis\u000a      when UV detection was not possible. [3.1.1 and 3.1.2]\u000a    2.2 Characterisation of crystal disorder to predict catastrophic\u000a        solid-state transitions\u000a    Single-crystal X-ray diffraction produces a complete model of a\u000a      material's molecular and solid-state structure. Ab.initio\u000a      prediction of crystal structure is also possible. The practice was\u000a      considered using a combination of structural information and structure\u000a      prediction methodologies to develop powerful structure prediction\u000a      procedures for drug crystals and more complex solid-state forms, e.g.\u000a      salts. [3.2.1-3.2.3]\u000a    2.3 Prediction of processing properties of pharmaceutical powders\u000a        using single crystals\u000a    Manufacturing processes can be problematic when drug crystals deform\u000a      elastically in production machinery. Particle physics investigations\u000a      required large quantities of pure, expensive crystalline drug.\u000a      Consequently such studies were deferred to a point in the development\u000a      programme where change, however desirable, was impractical. Indentation\u000a      techniques were developed using highly purified single crystals to\u000a      investigate the processing performance of drug candidate crystals, very\u000a      early in the development process, to provide the opportunity to engineer\u000a      and substitute improved solid-state variants to avoid processing problems.\u000a      [3.3.1-3.3.3]\u000a    2.4 Chemical imaging of pharmaceutical products\u000a    Conventional analytical techniques sample the average bulk\u000a      characteristics of pharmaceutical products. It is possible to determine\u000a      the total drug content in a tablet but not the distribution of particles\u000a      within a matrix formed with other formulation excipients. With spatial and\u000a      chemical information, obtained using near infrared and Raman spectroscopy,\u000a      it is possible to generate chemical images of each ingredient within the\u000a      formulation. The physicochemical form of drug, in the presence of\u000a      excipient particles, in the sample can be determined along with the size\u000a      of any material clustering and spatial position relative to other\u000a      components. The interface with processing machinery can also be\u000a      determined. This research increased process understanding and material\u000a      attributes associated with the clinical performance of the product.\u000a      [3.4.1-3.4.4]\u000a    "},{"CaseStudyId":"3461","Continent":[{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"102358","Name":"Saudi Arabia"}],"Funders":["Royal Academy of Engineering"],"ImpactDetails":"\u000d\u000a    Advances in bisphosphine ligand synthesis carried out at Cardiff\u000d\u000a      University have enabled industrial scale application of a cost-effective\u000d\u000a      new process, the Alpha Process, for the production of methyl methacrylate\u000d\u000a      monomer for acrylic resins and Perspex production.\u000d\u000a    The economic impact is demonstrated by investment of US$230 million by\u000d\u000a      Lucite International, part of the Mitsubishi Group, in a new plant in\u000d\u000a      Singapore which has been producing 120 kilotonnes of MMA per annum since\u000d\u000a      2008.\u000d\u000a    This process brings major environmental benefits, as it produces only\u000d\u000a      environmentally benign waste products and does not rely on the use of\u000d\u000a      toxic feedstocks, such as hydrogen cyanide and sulphuric acid, commonly\u000d\u000a      used in alternative processes.\u000d\u000a    Enabling increased end-user applications and industrial production\u000d\u000a    The success of the Alpha Process was enabled by a patented process\u000d\u000a      developed by Cardiff University [3.5] to scale-up Lucite International's\u000d\u000a      production of the bisphosphine ligand for production of Perspex. Dr.\u000d\u000a      Graham Eastham (Senior Research Scientist for ALPHA Technology, Lucite\u000d\u000a      International) recognised the significance of the Cardiff contribution in\u000d\u000a      developing \"a commercially viable synthetic route to produce the phosphine\u000d\u000a      ligand...without this early innovation the Alpha process may well not have\u000d\u000a      become the unqualified success that it is\" [5.1].\u000d\u000a    The key to the process is the remarkable efficiency of the catalyst for\u000d\u000a      the addition of carbon monoxide to ethylene, which is fast (producing 13\u000d\u000a      kg of methyl propanoate for 1 g of palladium metal per hour of operation)\u000d\u000a      and cost efficient with regard to the amount of expensive and rare\u000d\u000a      palladium metal consumed (10 tonnes of product produced for 1 g of metal\u000d\u000a      consumed). The remarkable selectivity and efficiency of the catalyst\u000d\u000a      allows reliable production under milder reaction conditions, which has a\u000d\u000a      significant beneficial impact on operating costs, safety and energy\u000d\u000a      efficiency. Lucite International estimates that the Alpha process reduces\u000d\u000a      costs by 30-40% compared to the established acetone-cyanohydrin (ACH)\u000d\u000a      process, the mainstay of US and European MMA production, which has\u000d\u000a      remained largely unchanged since the 1930s.\u000d\u000a    The Alpha process has removed constraints on plant size allowing\u000d\u000a      significantly improved operating economies. As a result of the industrial\u000d\u000a      viability of the process, Lucite invested US$230 Million in 2008 in a\u000d\u000a      manufacturing plant in Singapore to produce 120 kilotonnes of MMA per\u000d\u000a      annum [5.2]. The plant has been running at 100% capacity to date, and\u000d\u000a      accounts for around 3% of global MMA production. Based on the success of\u000d\u000a      the Singapore plant, Mitsubishi Group signed a Letter of Intent with Saudi\u000d\u000a      Basic Industries Corporation, with the tender to issue in 2013, to build\u000d\u000a      the largest MMA plant in the world, costing US$500 million and producing\u000d\u000a      250 kilotonnes annually (around 6% of global production) [5.3].\u000d\u000a    The Alpha Process also produces purer MMA, which increases end-user\u000d\u000a      applications. Lucite Perspex is in demand for high margin applications\u000d\u000a      such as screens for mobile phones, televisions and computer monitors,\u000d\u000a      since Alpha process Perspex offers maximum light transmission without\u000d\u000a      disturbing surface hot spots. Growing demand in this area complements\u000d\u000a      conventional uses, including glazing, signage and lighting, moulding and\u000d\u000a      extrusion compounds for automotive, medical and optical industries,\u000d\u000a      surface coatings, emulsion polymers, adhesives, and enamels. Lucite\u000d\u000a      International is the world leader in MMA and PMMA production, with around\u000d\u000a      25-30% of the global market share, which is valued in excess of US$7\u000d\u000a      Billion annually and projected to show annual growth of 6.5% up to 2017\u000d\u000a      [5.4].\u000d\u000a    Environmental benefits\u000d\u000a    The Alpha process brings environmental benefits compared to conventional\u000d\u000a      manufacturing technologies, such as the ACH process, which rely on the use\u000d\u000a      of feedstocks that are highly toxic (hydrogen cyanide) and highly\u000d\u000a      corrosive (sulfuric acid). For example, Alpha Process production at the\u000d\u000a      Lucite Singapore plant produces annual savings of 19 kilotonnes of\u000d\u000a      hydrogen cyanide and annual savings of 360 kilotonnes of spent acid,\u000d\u000a      including sulfuric acid and ammonium sulphate, compared to the\u000d\u000a      conventional ACH route.\u000d\u000a    A further supply chain benefit of the Alpha Process is that it uses\u000d\u000a      cheap, relatively non- hazardous and readily available feedstocks (carbon\u000d\u000a      monoxide, ethylene, formaldehyde and methanol). The atom-efficiency of the\u000d\u000a      process also brings waste management benefits, as it means that there are\u000d\u000a      no toxic wastes or by-products [5.2].\u000d\u000a    These environmental benefits also have an impact on manufacturing\u000d\u000a      efficiencies through, for example, the reduced use of solvents and reduced\u000d\u000a      storage and waste management facilities required at the Singapore and\u000d\u000a      Saudi facilities. A purer MMA product also has knock-on benefits for\u000d\u000a      downstream users and applications industries in minimising requirements\u000d\u000a      for further purification as well as providing assurance of a dependable\u000d\u000a      supply of higher quality plastics from readily available feedstocks.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Cardiff University, through developing and patenting a commercially\u000d\u000a      viable synthetic route to a catalyst, has enabled the application of a new\u000d\u000a      process, the Alpha Process, for the production of methyl methacrylate\u000d\u000a      (MMA), a key commodity precursor to Perspex. The Alpha Process has had\u000d\u000a      economic and environmental impacts.\u000d\u000a    Lucite International, the world's leading MMA producer, has invested in\u000d\u000a      major Alpha Process production facilities in Singapore and Saudi Arabia,\u000d\u000a      benefitting from a production route which is more efficient, more reliable\u000d\u000a      and cheaper than conventional routes.\u000d\u000a    The Alpha Process also brings environmental benefits, as it does not rely\u000d\u000a      on the use of corrosive and toxic feedstocks, such as hydrogen cyanide,\u000d\u000a      which are associated with conventional MMA processes.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    Cardiff University\u000d\u000a    ","Institutions":[{"AlternativeName":"Cardiff University","InstitutionName":"Cardiff University","PeerGroup":"A","Region":"Wales","UKPRN":10007814}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"1880252","Name":"Singapore"}],"References":"\u000d\u000a    [3.1] Research grant: Catalytic reactions of carbon monoxide with\u000d\u000a        alkenes and alkynes, ICI Acrylics (name change to Ineos Acrylics),\u000d\u000a      &#163;125,000, 9\/12\/1996-30\/10\/1999, PI: Prof. P. G. Edwards.\u000d\u000a    \u000a[3.2] Comments on the Catalytic Alkoxycarbonylation of Alkynes, A.\u000d\u000a      Dervisi, P. G. Edwards, P. D. Newman, R. P. Tooze, S. J.\u000d\u000a      Coles and M. B. Hursthouse, J. Chem. Soc., Dalton Trans., 1999,\u000d\u000a      1113-1120. Publication date: 01\/01\/1999.\u000d\u000a      http:\/\/dx.doi.org\/10.1039\/a809624d\u000d\u000a    \u000a\u000a[3.3] Synthesis and chemistry of diphenyl-2-pyridylphosphine complexes of\u000d\u000a      palladium(0). X-Ray characterisation of Pd(Ph2Ppy)2-(03b72-DMAD)\u000a      and transPd(Ph2Ppy)2(PhC=CH2)(CF3CO2)\u000d\u000a      A. Dervisi, P.G. Edwards, P.D. Newman and R.P.\u000d\u000a      Tooze, J. Chem. Soc., Dalton Trans., 2000, 523-528. Publication\u000d\u000a      date: 22\/01\/2000.\u000d\u000a      http:\/\/dx.doi.org\/10.1039\/a908050c\u000d\u000a    \u000a\u000a[3.4] Acrylics for the future, B. Harris, Ingenia, issue 45,\u000d\u000a      December 2010, Royal Academy of Engineering,\u000d\u000a      http:\/\/www.ingenia.org.uk\/ingenia\/issues\/issue45\/harris.pdf\u000d\u000a    \u000a\u000a[3.5] Patent: Process for the preparation of bisphosphines, Paul\u000a        D. Newman, Richard A. Campbell, Robert P. Tooze, Graham R. Eastham,\u000d\u000a      Jamie M. Thorpe, Peter G. Edwards. GB\/9805348; PCT\/GB\/99\/00797;\u000d\u000a      WO99\/47528; US\/6376715. Patent assigned to Ineos then transferred to\u000d\u000a      Lucite and maintained to present.\u000d\u000a      http:\/\/www.freepatentsonline.com\/6376715.pdf\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"},{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"},{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"}],"Sources":"\u000d\u000a    [5.1] Personal Confirmation of Cardiff's contribution, including through\u000d\u000a      developing patented technology, to the commercial viability of the Alpha\u000d\u000a      process from the Senior Research Scientist for ALPHA Technology, Lucite\u000d\u000a      International. (Letter on file at UoA)\u000d\u000a    [5.2] Confirmation of Lucite investment in Alpha process, together with\u000d\u000a      environmental and other benefits, as part of a feature on the Alpha\u000d\u000a      process as a finalist in the Royal Academy of Engineering MacRobert Award\u000d\u000a      2010,\u000d\u000a    Acrylics for the future, B. Harris, Ingenia, issue 45,\u000d\u000a      December 2010, Royal Academy of Engineering,\u000d\u000a      http:\/\/www.ingenia.org.uk\/ingenia\/issues\/issue45\/harris.pdf\u000d\u000a    [5.3] Confirmation of agreement between Sabic and Mitsubishi Rayon to\u000d\u000a      build the largest MMA plant in the world in Saudi Arabia (capital\u000d\u000a      expenditure of $500 million), using the Alpha process.\u000d\u000a      http:\/\/www.2b1stconsulting.com\/sabic-and-mitsubishi-to-tender-jubail-mma-pmma-epc-\u000a      contract\/.\u000d\u000a    [5.4] Confirmation of global value of MMA production\u000d\u000a      http:\/\/www.marketsandmarkets.com\/PressReleases\/polymethyl-methacrylate.asp\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Enabling the cost-effective and environmentally friendly production of\u000d\u000a        Perspex\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2653822","Name":"Cardiff"}],"UKRegion":[{"GeoNamesId":"2634895","Name":"Wales"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    In 1996 Lucite International (then Ineos Acrylics Ltd., and since\u000d\u000a      incorporated into the Mitsubishi Group) provided a research grant to\u000d\u000a      Professor Peter G. Edwards (Professor of Inorganic Chemistry, Cardiff\u000d\u000a      University) to investigate novel synthetic routes to phosphine ligands for\u000d\u000a      palladium of relevance to the catalysis of the addition of carbon monoxide\u000d\u000a      to ethylene, for the production of MMA and derivative plastics (i.e.,\u000d\u000a      PMMA, Perspex or Lucite) [3.1]. This research was carried out in\u000d\u000a      conjunction with Dr Paul Newman (post-doctoral researcher, 1996-99).\u000d\u000a    Fundamental studies into the reaction and mechanistic chemistry that\u000d\u000a      contributed to the understanding of ligand behaviour and key catalyst\u000d\u000a      design concepts were performed under this grant leading to high-quality\u000d\u000a      outputs in a leading journal [3.2, 3.3]. This work resulted in a much\u000d\u000a      improved synthetic route to the key catalyst ligand component, 1,2-bis(di-t-\u000d\u000a      butylphosphinomethyl)benzene. Palladium complexes of this ligand are\u000d\u000a      remarkably active and selective and also show excellent stability\u000d\u000a      (longevity) under reaction conditions; it provides 99.99% efficiency for\u000d\u000a      the addition of carbon monoxide to ethylene in methanol to give the\u000d\u000a      intermediate methyl propanoate.\u000d\u000a    The new technology this catalyst supports leads to several major\u000d\u000a      advantages:\u000d\u000a    a) it utilises the efficient conversion of cheap readily available\u000d\u000a      feedstocks (ethylene and methanol),\u000d\u000a    b) it avoids the requirement for the highly toxic liquid hydrogen cyanide\u000d\u000a      used in the conventional (competitor) process,\u000d\u000a    c) it is intrinsically more environmentally benign with no toxic waste\u000d\u000a      products,\u000d\u000a    d) it produces a purer higher quality acrylic resin product for higher\u000d\u000a      value end applications, and\u000d\u000a    e) it is economically cheaper to operate under milder conditions saving\u000d\u000a      up to 40% on operating costs over the main competitor technologies [3.4].\u000d\u000a    This methodology was the basis for a patent application, with a priority\u000d\u000a      date of 16th March 1998, naming the Cardiff researchers as inventors\u000d\u000a      [3.5]. Patents have been granted world- wide and are maintained to the\u000d\u000a      present.\u000d\u000a    In view of its impact, the Alpha process has been recognised by several\u000d\u000a      awards:\u000d\u000a    The Biennial Kirkpatrick Chemical Engineering Award 2009 - Winner\u000d\u000a    Chemical Industry Association 2009 Innovation Award - Winner\u000d\u000a    ICIS Innovations Awards 2009 - Short-listed for Best Product Innovation\u000d\u000a    The Royal Academy of Engineering MacRobert Award 2010 - Finalist\u000d\u000a    "},{"CaseStudyId":"3462","Continent":[{"GeoNamesId":"6255150","Name":"South America"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"3469034","Name":"Brazil"},{"GeoNamesId":"1814991","Name":"China"},{"GeoNamesId":"1861060","Name":"Japan"},{"GeoNamesId":"1668284","Name":"Taiwan"},{"GeoNamesId":"798544","Name":"Poland"},{"GeoNamesId":"2017370","Name":"Russia"}],"Funders":[],"ImpactDetails":"\u000d\u000a    The research outcomes above and the related body of research (see\u000d\u000a      reference 3.1) have been\u000d\u000a      embodied in the Molpro software (http:\/\/www.molpro.net),\u000d\u000a      which has been developed, supported\u000d\u000a      and distributed under licence since 2004. Since 2008, there have been\u000d\u000a      three major releases of the\u000d\u000a      software (2008, 2010 and 2012) at which new capabilities have been added\u000d\u000a      as a result of research\u000d\u000a      in theory and methods.\u000d\u000a    Impact on Practitioners and Professional Services\u000d\u000a    The value of Molpro is that it offers key functionality (in particular\u000d\u000a      local correlation for large\u000d\u000a      molecules; multireference methods for chemical reactions and excited\u000d\u000a      states) that are not available\u000d\u000a      in Gaussian (the industry-standard general purpose code) or any other code\u000d\u000a      [5.1]. A wide range of\u000d\u000a      companies, each operating on an international basis, has opted to use\u000d\u000a      Molpro, as a new process\u000d\u000a      that offers enhanced capabilities, to enable the development and\u000d\u000a      production of a plethora of\u000d\u000a      products that are marketed to industries including agriculture, aerospace,\u000d\u000a      construction, automotive,\u000d\u000a      pharmaceutical, packaging and personal care. The list includes BASF,\u000d\u000a      Sasol, Schr&#246;dinger, Bristol-Myers-Squibb,\u000d\u000a      Mitsubishi Chemical Group and Nissan Chemical Industries. BASF, for\u000d\u000a      example\u000d\u000a      (an organisation that has over 380 production sites worldwide and produces\u000d\u000a      a range of products\u000d\u000a      for eight industries), purchased Molpro in 2011. Ansgar Sch&#228;fer, the Group\u000d\u000a      Leader in Quantum\u000d\u000a      Chemistry at BASF, states that \"Molpro, and in particular its capability\u000d\u000a      for very accurate\u000d\u000a      computations on large molecules, has become a valuable tool for estimating\u000d\u000a      thermochemical and\u000d\u000a      kinetic data for substances and reactions involved in our development of\u000d\u000a      new materials and\u000d\u000a      processes\" [5.2]. Similarly, Bristol-Myers-Squibb (BMS), which has 26\u000d\u000a      facilities in 10 countries and\u000d\u000a      manufactures prescription drugs to treat diseases such as cancer,\u000d\u000a      HIV\/AIDS, cardiovascular\u000d\u000a      disease, diabetes, hepatitis and rheumatoid arthritis, acquired Molpro in\u000d\u000a      2008. Dan Cheney,\u000d\u000a      Group Leader at BMS, commented that \"In the Bristol-Myers Squibb CADD\u000d\u000a      group, we believe that\u000d\u000a      effective drug design rests on an affordable and acceptable level of\u000d\u000a      scientific rigor. Among\u000d\u000a      quantum chemistry programs, Molpro is unique in enabling us to do this by\u000d\u000a      offering coupled cluster\u000d\u000a      code that can be applied to drug-like systems using reasonable\u000d\u000a      computational resources\" [5.3]. No\u000d\u000a      other package is competitive on this basis. Molpro has significantly\u000d\u000a      progressed industrial\u000d\u000a      knowledge and capabilities.\u000d\u000a    Economic Gain\u000d\u000a    Molpro has resulted in significant economic gain, manifested in a) the\u000d\u000a      number of licences sold, and\u000d\u000a      b) the augmentation of corporations authorised to resell the software.\u000d\u000a    a) Licences sold\u000d\u000a    Between 1\/1\/2008 and 31\/7\/2013, 780 paid-for Molpro licences were issued.\u000d\u000a      Total sales, including\u000d\u000a      those effected by sales agents and net of their commission, amounted to\u000d\u000a      &#163;1,783,714. As a result\u000d\u000a      of this, several posts have been created in Cardiff to support the work,\u000d\u000a      to achieve further sales and\u000d\u000a      to develop activities in Stuttgart, Lund, Regensburg, Bristol and Uppsala.\u000d\u000a      Sales are continuing to\u000d\u000a      increase, as demonstrated by the six monthly income figures; in October\u000d\u000a      2012, the amount was\u000d\u000a      &#163;179,535, but by April 2013 this had risen to &#163;290,132 [5.4].\u000d\u000a    b) Companies reselling the software\u000d\u000a    There are presently twelve authorised resellers of the software that have\u000d\u000a      reaped considerable\u000d\u000a      financial gain from the sale of Molpro. Examples are Beijing Hongcam\u000d\u000a      Software Technologies Co.\u000d\u000a      and Ryoka Systems, Inc. Ryoka Systems have stated that, during the REF\u000d\u000a      period, sales of Molpro\u000d\u000a      amounted to &#163;145,143 [5.5]. Molpro sales have continued to increase; there\u000d\u000a      was a 19% increase\u000d\u000a      for the period 2008-2010 compared to 2005-2007, while in the last two and\u000d\u000a      a half years the\u000d\u000a      software has remained a source of ongoing profit for Ryoka. Similarly,\u000d\u000a      Beijing Hongcam Software\u000d\u000a      Technologies has accumulated sizeable financial benefit from distributing\u000d\u000a      Molpro; during the REF\u000d\u000a      period, sales amounted to &#163;82,705 [5.4].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Research in quantum-mechanical methods, conducted at the School of\u000d\u000a      Chemistry at Cardiff\u000d\u000a      University, has resulted in the creation of an innovative software package\u000d\u000a      called Molpro. Molpro\u000d\u000a      provides the ability to calculate from first principles (ab initio) the\u000d\u000a      properties of molecular matter. It\u000d\u000a      is unique and differs from other quantum chemistry packages because, using\u000d\u000a      local electron\u000d\u000a      correlation methods, it significantly reduces the increase of the\u000d\u000a      computational cost with molecular\u000d\u000a      size. This means highly accurate computations can be performed for much\u000d\u000a      larger molecules than\u000d\u000a      with most other programs, and the screening of far wider libraries of\u000d\u000a      potential new materials is\u000d\u000a      enabled. Consequently, Molpro is extremely valuable to the global chemical\u000d\u000a      and pharmaceutical\u000d\u000a      industries and has been endorsed and applied by major international\u000d\u000a      corporations that\u000d\u000a      manufacture products that are used by a wide range of industries\u000d\u000a      (including cosmetics, automotive\u000d\u000a      and construction). Examples are BASF, Mitsubishi Chemical Group, Sasol and\u000d\u000a      Nissan Chemical\u000d\u000a      Industries.\u000d\u000a    The software is distributed under licence through Cardiff University and\u000d\u000a      resellers, operating in\u000d\u000a      China, Japan, Brazil, Taiwan, Russia, Poland and the USA. During the REF\u000d\u000a      period, it has\u000d\u000a      generated over &#163;1.75M in revenue, and is used by over 650 organisations\u000d\u000a      worldwide. Accordingly\u000d\u000a      the impact claimed is extensive economic gain and impact on practitioners\u000d\u000a      and professional\u000d\u000a      services.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    Cardiff University\u000d\u000a    ","Institutions":[{"AlternativeName":"Cardiff University","InstitutionName":"Cardiff University","PeerGroup":"A","Region":"Wales","UKPRN":10007814}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"2666199","Name":"Uppsala"},{"GeoNamesId":"2849483","Name":"Regensburg"}],"References":"\u000d\u000a    \u000a[3.1] Molpro: a general-purpose quantum chemistry program package. H-J.\u000d\u000a      Werner, P.J. Knowles,\u000d\u000a      G. Knizia, F.R. Manby, and M. Sch&#252;tz, Wiley Interdisciplinary Reviews:\u000d\u000a        Computational Molecular\u000d\u000a        Science, 2012, 2, 242-253. ISSN 1759-0876 (http:\/\/dx.doi.org\/10.1002\/wcms.82)\u000d\u000a    \u000a\u000a[3.2] Fast Hartree-Fock theory using local density fitting\u000d\u000a      approximations.\u000d\u000a      R. Polly, H.-J. Werner, F.R. Manby, and P.J. Knowles, Molecular\u000d\u000a        Physics, 2004, 102 (21-22). pp.\u000d\u000a      2311-2321. ISSN 0026-8976 (http:\/\/dx.doi.org\/10.1080\/0026897042000274801).\u000d\u000a    \u000a\u000a[3.3] Improved version of parallel programming interface for distributed\u000d\u000a      data with multiple helper\u000d\u000a      servers. M. Wang, A.J. May and P.J. Knowles,\u000d\u000a      Computer Physics Communications, 2011, 182 (7). pp. 1502-1506. ISSN\u000d\u000a      0010-4655\u000d\u000a      (http:\/\/dx.doi.org\/10.1016\/j.cpc.2011.03.020)\u000d\u000a    \u000a\u000a[3.4] Breaking Multiple Covalent Bonds with Hartree-Fock-based\u000d\u000a        Quantum Chemistry: Quasi-Variational\u000d\u000a        Coupled Cluster Theory with Perturbative Treatment of Triple Excitations.\u000d\u000a      J.B. Robinson and P.J. Knowles,\u000d\u000a      Phys. Chem. Chem. Phys., 2012, 14(19). pp. 6729-6732. ISSN 0021-9606\u000d\u000a      (http:\/\/dx.doi.org\/10.1039\/C2CP40698E)\u000d\u000a    \u000a\u000a[3.5] A linked electron pair functional. P.J. Knowles and\u000d\u000a      B. Cooper,\u000d\u000a      Journal of Chemical Physics, 2010, 133 (22) 224106. ISSN 00219606\u000d\u000a      (http:\/\/dx.doi.org\/10.1063\/1.3507876)\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"8","Level2":"2","Subject":"Computation Theory and Mathematics"},{"Level1":"8","Level2":"3","Subject":"Computer Software"},{"Level1":"10","Level2":"6","Subject":"Computer Hardware"}],"Sources":"\u000d\u000a    [5.1] Molpro User's Manual, version 2012.1, http:\/\/www.molpro.net\/info\/2012.1\/doc\/manual.pdf,\u000d\u000a      Describes the functionality of the software.\u000d\u000a    [5.2] Group Leader in Quantum Chemistry, BASF. Corroborates the use\u000d\u000a        of the research by BASF\u000d\u000a        and resulting impact. Letter on file at UoA.\u000d\u000a    [5.3] Group Leader at BMS. Corroborates the use of the research by\u000d\u000a        BMS and resulting impact.\u000d\u000a        Letter on file at UoA.\u000d\u000a    [5.4] Digests of company accounts, University College Cardiff Consultants\u000d\u000a      Ltd. Corroborates the\u000d\u000a        sales and financial data connected to Molpro. On file at UoA.\u000d\u000a    [5.5] Ryoka Systems, Inc, Science and Technology System Division. Corroborates\u000d\u000a        the impact of\u000d\u000a        Molpro on this company. Letter on file at UoA.\u000d\u000a    [5.6] Vice President of Business Development, Beijing Hongcam Software\u000d\u000a      Technologies Co.\u000d\u000a      Corroborates the impact of Molpro on this corporation. Letter on file\u000d\u000a        at UoA.\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Transforming quantitative prediction of molecular properties through\u000d\u000a        software - Molpro\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2654675","Name":"Bristol"},{"GeoNamesId":"2653822","Name":"Cardiff"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"},{"GeoNamesId":"2634895","Name":"Wales"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    The research that has generated the Molpro software has been carried out\u000d\u000a      over a long time period\u000d\u000a      by a number of collaborating researchers, led by Peter Knowles (Professor\u000d\u000a      of Theoretical\u000d\u000a      Chemistry, Cardiff University, since 2004) and Hans-Joachim Werner\u000d\u000a      (Stuttgart). Some of the\u000d\u000a      computational methods that have been invented and then embodied in the\u000d\u000a      software have been\u000d\u000a      very extensively used, reflected, for example, in the heavy citation of\u000d\u000a      http:\/\/dx.doi.org\/10.1016\/0009-2614(94)00815-9,\u000d\u000a      http:\/\/dx.doi.org\/10.1063\/1.465990\u000d\u000a      and\u000d\u000a      http:\/\/dx.doi.org\/10.1063\/1.1564816.\u000d\u000a      An overview can be found in reference 3.1.\u000d\u000a    Three specific research advances made at Cardiff University have been\u000d\u000a      major contributors to the\u000d\u000a      impact.\u000d\u000a    A. Linear-scaling Hartree-Fock methodology using local orbitals\u000d\u000a      [3.2]. This 2004 paper\u000d\u000a      showed for the first time how to compute molecular orbitals for large\u000d\u000a      molecules, including\u000d\u000a      the exchange interaction exactly, with effort that scales linearly with\u000d\u000a      the size of the\u000d\u000a      molecule. This was a key step in making more accurate correlated\u000d\u000a      linear-scaling methods\u000d\u000a      feasible, since before this work was done, Hartree-Fock was the\u000d\u000a        computational\u000d\u000a        bottleneck. The distinctive feature of the Cardiff contribution, essential\u000d\u000a        to the success of\u000d\u000a        the project, was the use of innovative basis sets based on the\u000d\u000a        solutions of Poisson's\u000d\u000a        equation, which provides a speed-up by a factor of approximately two.\u000d\u000a    B. Portable one-sided remote memory access in parallel scientific\u000d\u000a      computing [3.3]. This work,\u000d\u000a      conducted in Cardiff between 2007 and 2011, addressed an important\u000d\u000a      challenge in the use\u000d\u000a      of parallel computers for computations involving large intermediate data\u000d\u000a      structures. In most\u000d\u000a      of the electronic structure methods embodied in Molpro, very large\u000d\u000a      matrices are distributed\u000d\u000a      across the processors of a parallel machine, and data must sometimes be\u000d\u000a      accessed by a\u000d\u000a      process that is remote from the node on which the data are stored. The MPI\u000d\u000a      parallelisation\u000d\u000a      standard does not provide properly for this, and until this work it was\u000d\u000a      necessary to use non-\u000d\u000a      standard libraries to achieve this function. In this work, new algorithms\u000d\u000a      for managing data\u000d\u000a      were designed, implemented completely portably within the MPI standard,\u000d\u000a      and\u000d\u000a      performance-analysed. This research and its deployment is crucial for the\u000d\u000a      operation of the\u000d\u000a      whole Molpro software system on the high-performance computers of today\u000d\u000a      and tomorrow,\u000d\u000a      where parallelism becomes more and more important, and all Molpro\u000d\u000a        calculations on\u000d\u000a        large machines now depend on this work.\u000d\u000a    C. New theories and approximations for breaking chemical bonds\u000d\u000a      [3.4, 3.5]. This work, started\u000d\u000a      in 2008, brings new capabilities to predict the energetics of covalent\u000d\u000a        bond breaking,\u000d\u000a        crucial for the simulation of chemical reactions. The new methods\u000d\u000a      allow `black-box'\u000d\u000a      calculations that ultimately will scale linearly with system size.\u000d\u000a    "},{"CaseStudyId":"3712","Continent":[{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6252001","Name":"United States"}],"Funders":["Biotechnology and Biological Sciences Research Council","Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000a    The body of research published by the Cosstick group from the 1990's\u000a      through to the present, has described a wealth of information relating to\u000a      the chemistry and biochemistry of the 3'-sp linkages. Oligonucleotides\u000a        containing this 3'-sp linkage are an essential component in a DNA\u000a      sequencing method known as SOLiD&#8482; (Sequencing by Oligonucleotide Ligation\u000a      and Detection). SOLiD sequencing was launched by Applied Biosystems Inc\u000a      (ABI, now incorporated into Life Technologies as of 2008) in 2007 and the\u000a      SOLiD sequencing instruments became commercially available in 2008.6,7\u000a      The SOLiD method is based on sequencing by ligation and uses universal\u000a      sequencing primers (essentially short oligonucleotides containing the 3-sp\u000a      linkage) to interrogate the DNA template to be sequenced. The sequence is\u000a      read through rounds of hybridisation, ligation, detection and cleavage.\u000a      The cleavage step removes the fluorescent label (required for the\u000a      detection step) from the 5'-end of the oligonucleotide and resets the\u000a      system for the next round of hybridisation and ligation, so that the next\u000a      nucleotide can be sequenced. The specific cleavage step of the 3'-sp\u000a      linkage, which is conducted under mild conditions compatible with the\u000a      requirements of the SOLiD method using aqueous silver ions as demonstrated\u000a      by Cosstick,1 is crucial: at the time when the method was\u000a      developed, no other of DNA modification was known to work in SOLiD\u000a      sequencing. Details of the sequencing method and the role of the 3'-sp\u000a      linkage are clearly evident from the patents of McKernan8 and\u000a      from a review article on sulfur analogues of nucleic acids by Zon.9\u000a      Cosstick's chemistry was thus decisive in enabling implementation of SOLiD\u000a      sequencing. It was subsequently shown that SOLiD sequencing can also be\u000a      performed in what is known as \"the reverse direction\" using the isomeric\u000a      5'-sp linkages,8,9 but in this case an additional step is\u000a      necessary to remove the 3'-phosphate prior to ligation.\u000a    In 2006, ABI were working on the development of their SOLiD sequencing\u000a      method and needed to produce oligonucleotides containing the 3'-sp\u000a      linkages on a large-scale, as these were essential reagents for the SOLiD\u000a      instruments. Their synthetic approach to the large-scale synthesis of\u000a      these oligonucleotides was principally based on scaling-up the synthetic\u000a      procedures published by Cosstick in 2004.2 On invitation from\u000a      Dr Gerry Zon (then director of sequencing chemistry), Cosstick visited the\u000a      ABI chemistry labs (Foster City, CA, USA) in October 2006 for detailed\u000a      discussions relating to some of the difficulties the chemistry sequencing\u000a      group had encountered with the synthesis of 3'-sp modified\u000a      oligonucleotides. At that time there was considerable urgency to establish\u000a      an efficient method for the production of the 3'-sp modified\u000a      oligonucleotides in order to meet the demand for these reagents when the\u000a      instruments became commercially available.\u000a    In terms of their performance, the latest SOLiD instruments (5500 series\u000a      genetic analysers) deliver greater than 90 giga base-pairs of sequence\u000a      information in one day and a 7 day run can complete the sequence of the\u000a      human genome. The two-base encoding, which is unique to the SOLiD method,\u000a      provides exceptional sequencing accuracy at &gt;99.94%, (for\u000a      further information see: http:\/\/tools.lifetechnologies.com\/content\/sfs\/brochures\/cms_057511.pdf),10\u000a      as each nucleotide in the sequence is essentially read twice. The SOLiD\u000a      technology is one of several so-called second\/next-generation sequencing\u000a      systems (together with instruments from Illumina, Roche and to a lesser\u000a      extent Helicos) which were available as of 2008. Each of these sequencing\u000a      systems seems to have its own advantages and limitations, although in 2011\u000a      the SOLiD system was reported to have the lowest reagent cost needed\u000a        to reassemble a human genome11 and came top in the J.P.\u000a      Morgan Next Generation Sequencing Survey12 (published in 2010)\u000a      for accuracy. Accuracy was also shown to be the most important attribute\u000a      when choosing a DNA sequencing system.12\u000a    The estimated sales value of SOLiD sequencing systems to Life\u000a        Technolgies is also presented in the J.P. Morgan survey12\u000a        and rose from zero in 2007 to $68 million in 2008, $100million in 2009\u000a        and predicted sales of $136.9 million in 2010, $178 million in 2011 and\u000a        $222.5 million in 2012 (figures based on J.P. Morgan estimates and\u000a      company reports12). In 2010, only two years after becoming\u000a      commercially available, the SOLiD instrument was estimated to have about\u000a      20% market share for second\/next-generation sequencing and was predicted\u000a      to rise to 22.6% (second largest market share after Illumina) by 2012.12\u000a      New jobs created by commercialization of SOLiD sequencing include\u000a      USA-based manufacturing of consumable reagents, world-wide hiring of\u000a      technical specialists to support customers, and (especially) world-wide\u000a      sample preparation, sequencing and bioinformatics analysis at\u000a      service-provider facilities.\u000a    The benefit of the SOLiD sequencing system goes beyond that of generating\u000a      economic impact, as the technology is now enabling patients to benefit\u000a        from personalised medicine derived from DNA sequence information.\u000a      For example, whole genome sequencing (conducted with the SOLiD 4\u000a      instrument) of twins with dopamine-responsive dystonia, a clinically\u000a      complex neurological movement disorder, that is normally treated with\u000a      L-dopa, identified unexpected mutations in the gene encoding sepiapterin\u000a      reductase. This enzyme is responsible for the synthesis of co-factors\u000a      required for the synthesis of dopamine and seratonin. Supplement of the\u000a      L-dopa therapy with a serotonin precursor resulted in considerable\u000a      clinical improvements in both twins.13\u000a    The exceptional accuracy of the 2-base encoding means that SOLiD\u000a      sequencing is ideally suited to cancer research\/diagnosis, because tumors\u000a      contain mixed sub-populations with different mutations. Deep-sequencing on\u000a      the SOLiD platform has revealed differential expression of microRNAs in\u000a      favourable versus unfavourable neuroblastoma (the most common extracranial\u000a      solid tumor of childhood) and provides a reliable method to assess the\u000a      aggressiveness and hence prognosis of the tumor.14 Whilst just\u000a      two specific examples are presented here, they indicate the tremendous\u000a      scope of the SOLiD sequencing technique to aid diagnosis and treatment of\u000a      a wide range of diseases.\u000a    There is a list of over 100 publications resulting from SOLiD sequencing\u000a      at the Life Technologies website which cover applications on: sequencing\u000a      accuracy, bioinformatics, de novo sequencing, targeted resequencing and\u000a      transcriptome analysis (further details available at: http:\/\/www.invitrogen.com\/site\/us\/en\/home\/Products-and-Services\/Applications\/Sequencing\/Next-Generation-Sequencing\/Publications-Literature.html\u000a      )10\u000a    The wealth of research that was conducted by the Cosstick group on DNA\u000a      containing the 3'-S-phosphorothiolate linkage has been absolutely\u000a      crucial to the development of SOLiD sequencing. The contribution that the\u000a      work in Liverpool made to the SOLiD programme has been corroborated by Dr\u000a      Gerry Zon15 (letter available) who was directing the ABI\u000a      chemistry sequencing group in Foster City (USA) at the time SOLiD\u000a      sequencing was being developed. To quote from Dr Zon's letter, \"the\u000a        scale-up of the synthesis of the phosphorothiolate-containing DNA\u000a        reagents had to be done in a very short period of time, because of\u000a        competing sequencing techniques which were due to come on the market. It\u000a        was an enormous benefit therefore to be able to use and adapt your\u000a        published procedures, particularly the automated synthesis of the\u000a        phosphorothiolate oligomers you published in 2004\" (reference 2). To\u000a      quote further, \"from the work you had published (reference 3 is\u000a      quoted in the letter, it was apparent that) the phosphorothiolate\u000a        reagents would be fully compatible with all aspects of the sequencing\u000a        technique (and) gave ABI confidence to commit to the technique\".\u000a    ","ImpactSummary":"\u000a    This case study describes both economic and healthcare benefits that have\u000a      resulted from a new DNA (gene) sequencing technique known as SOLiD\u000a      sequencing. Through the 1990s until the present, Cosstick (University of\u000a      Liverpool since 1984) has both developed the synthesis and studied the\u000a      properties of chemically modified DNA in which a single oxygen atom is\u000a      replaced by sulfur; we have termed this a 3'-phosphorothiolate (3'-sp)\u000a      modification. Chemically prepared DNA containing the 3'-sp modification is\u000a      a key enabling component of the Applied Biosystems SOLiD DNA sequencing\u000a      instrument which is able to produce extremely rapid, cost-effective and\u000a      exceptionally accurate DNA sequence information. The impact of this very\u000a      powerful sequencing technology extends beyond economic benefits as it has\u000a      many healthcare applications which have impacted medical practice.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Liverpool\u000a    ","Institutions":[{"AlternativeName":"Liverpool (University of)","InstitutionName":"University of Liverpool","PeerGroup":"A","Region":"North West","UKPRN":10006842}],"Panel":"B         ","PlaceName":[],"References":"\u000a    * = Three references to indicate the quality of the research.\u000a    \u000a1. Vyle, J.S., Kemp, D., Cosstick, R., and Connolly, B.A. Sequence and\u000a      strand specific cleavage in oligonucleotides and DNA containing\u000a      3'-thiothymidine. Biochemistry 31, 3012 - 3018 (1992).\u000a      DOI: 10.1021\/bi00126a024\u000a    \u000a\u000a2*. Sabbagh, G., Fettes, K.J., Gossain, R., O'Neil, I.A. and Cosstick, R.\u000a      Synthesis of phosphorothioamidites derived from 3'-thio-3'-deoxy-thymidine\u000a      and 3'-thio-2',3'-dideoxycytidine and the automated synthesis of\u000a      oligodeoxynucleotides containing a 3'-S-phosphorothiolate linkage.\u000a      Nucl. Acids Res. 32, 495-501 (2004). DOI:\u000a      10.1093\/nar\/gkh189\u000a    \u000a\u000a3*. Beevers, A.P.G., Fettes, K.J., Roberts, S.M., O'Neil, I.A., Arnold,\u000a      J.R.P., Cosstick, R. and Fisher, J. Probing the effect of a 3'-S-phosphorothiolate\u000a      link on the conformation of a DNA:RNA hybrid; Implications for antisense\u000a      drug design, J. Chem. Soc., Chem.Commun. 1458-1459 (2002). DOI:\u000a      10.1039\/B203582K\u000a    \u000a\u000a4*. Bentley, J., Brazier, J.A., Fisher, J. and Cosstick, R. Duplex\u000a      stability of DNA&#183;DNA and DNA&#183;RNA duplexes containing 3'-S-phosphorothiolate\u000a      linkages. Org. Biomol. Chem. 5, 3698-3702 (2007). DOI:\u000a      10.1039\/b713292a\u000a    \u000a5. Cosstick PI on all grants. EPSRC: EP\/F011938\/1, Increasing the potency\u000a      of RNA interference using RNA mimetics, 2007-10, &#163;299,576; BBSRC: B05097,\u000a      Synthesis and application of nucleic acid analogues containing\u000a      3'-S-phosphorothiolate linkages, 1995-98, &#163;136,725; BBSRC: B18146,\u000a      Oligonucleotides containing phosphorothiolate linkages, 2003-06, &#163;192,736.\u000a    ","ResearchSubjectAreas":[{"Level1":"6","Level2":"1","Subject":"Biochemistry and Cell Biology"}],"Sources":"\u000a    \u000a      \u000ahttp:\/\/en.wikipedia.org\/wiki\/ABI_Solid_Sequencing10\u000a\u000a      Metzker, M. Application of next-generation sequencing. Nature\u000a          Reviews Genetics 11, 31-46 (2010). DOI: 10.1038\/nrg2626\u000a      McKernan, K., Blanchard, A., Kotler, L. &amp; Costa, G. Reagents,\u000a        methods, and libraries for bead-based sequencing. US Patent Application\u000a        11\/345,979 (2005).\u000a      Zon, G. Automated synthesis of phosphorus-sulfur analogs of nucleic\u000a        acids-25 years on. New J. Chem., 34, 795-804 (2010).\u000a        DOI: 10.1039\/b9nj00577c\u000a      Web references can alternatively be found at: http:\/\/tinyurl.com\/livchemref\u000a\u000a      Niedringhaus, T. P. et al. Landscape of next generation\u000a        sequencing methodologies. Anal. Chem. 83, 4327-4341\u000a        (2011). DOI: 10.1021\/ac2010857\u000a      Peterson T.W., Nam, S.J., Darby, A. J.P. Morgan Next Generation\u000a        Sequencing Survey, 12 May 2010. Available at: http:\/\/www.genomicslawreport.com\/wp-content\/uploads\/2011\/04\/JP-Morgan-NGS-Report.pdf\u000a        10. Sales figures taken from Appendix 1 of this survey.\u000a      Genome study solves twins' mystery condition, Nature News, 15 June\u000a        2011 DOI: 10.1038\/news.2011.368. (This story has been featured on Good\u000a        Morning America, the Today show, the New York Times and about 240 other\u000a        publications worldwide.)\u000a      Schulte, J.H. Deep sequencing reveals differential expression of\u000a        microRNAs of favorable versus unfavorable neuroblastoma. Nucl. Acids\u000a          Res., 38, 5919-5928 (2010). DOI:10.1093\/NAR\/gkq342\u000a      Letter of corroboration available from the Director of Business\u000a        Development now at TriLink Biotech (details at: http:\/\/zon.trilinkbiotech.com\/about-jerry-zon\/)10.\u000a        Between 1999 and 2011 he was at Applied Biosystems (subsequently Life\u000a        Technologies) as detailed in reference 9 above.\u000a    \u000a    ","Title":"\u000a    Impact on DNA (gene) sequencing based on chemically modified DNA\u000a    ","UKLocation":[{"GeoNamesId":"2644210","Name":"Liverpool"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    The chemical modification to DNA that is required for the SOLiD\u000a      sequencing technology involves replacing a single oxygen atom in the\u000a      phosphodiester linkage of the DNA with sulfur to produce the\u000a      3'-phosphorothiolate (3'-sp) linkage (Figure). This modification was\u000a      originally designed by Cosstick (then lecturer in Chemistry, University of\u000a      Liverpool) as a DNA analogue that was expected to be resistant to cleavage\u000a      by enzymes that process and manipulate DNA, but susceptible to cleavage by\u000a      mild chemical reagents. The motivation for this research was to provide\u000a      new approaches to manipulate DNA that might find applications in\u000a      biotechnology. The chemical synthesis of oligonucleotides (short pieces of\u000a      DNA) containing this modification was first reported by the Cosstick\u000a      Group. An important step towards realising the potential application of\u000a      the 3'-sp modification was the subsequent report by Cosstick and\u000a      co-workers that a DNA molecule with 7250 natural phosphate linkages could\u000a      be specifically cleaved at the site of a single 3'-sp linkage by aqueous\u000a      solutions of silver ions.1 It was apparent at this time that in\u000a      order to fully explore the potential applications of the 3'-sp\u000a      modification greatly improved methods were required for its preparation\u000a      and thus through the 1990s and 2000s the Cosstick group reported a number\u000a      of methods for the chemical synthesis of DNA sequences containing the\u000a      3'-sp modification. These studies culminated in the key report (2004) of a\u000a      preparative method based on the use of 3'-S-phosphorothioamidites\u000a      which was compatible with standard automated procedures for the chemical\u000a      synthesis of DNA. This method therefore made oligonucleotides containing\u000a      the 3'-sp linkage much more readily accessible by routine DNA synthesis\u000a      procedures.2\u000a\u0009  \u000a      \u000a      \u000a    The resulting improved access to these 3'-sp DNA analogues made it\u000a      possible to investigate their interactions with complementary sequences of\u000a      DNA or RNA in much greater detail. It was shown that a DNA strand\u000a      containing this modification could form duplex structures with either\u000a      complementary DNA or RNA strands and indeed the 3'-sp modification\u000a      actually stabilised some of these structures.3,4 Significantly,\u000a      it was established that the effect of the 3'-sp modification had a\u000a      predictable effect on the thermal melting temperature of complementary\u000a      oligonucleotides. This was important in establishing that DNA containing\u000a      the 3'-sp modification would be compatible with the hybridisation steps in\u000a      the SOLiD sequencing technique.\u000a    In summary, the work conducted by the Cosstick group at Liverpool has\u000a      covered the synthesis of the 3'-sp DNA analogues, the effect that this\u000a      modification has on duplex and higher order DNA\/RNA structures and their\u000a      mild chemical and enzymatic cleavage. This work established information on\u000a      all the important chemical properties of this modification and thus\u000a      provided the necessary background from which the chemical\/biochemical\u000a      aspects of the sequencing method could be developed. Much of this work was\u000a      performed though national and international collaborations. The work has\u000a      been supported by both the EPSRC5 and the BBSRC.5\u000a    "},{"CaseStudyId":"3914","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6251999","Name":"Canada"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":[],"ImpactDetails":"\u000d\u000a    Accelerated Carbonation Technology (ACT) is a single, elegant and\u000d\u000a      powerful solution to a lot of serious environmental threats - CO2\u000d\u000a      emissions, reliance on sending waste to landfill, extraction of virgin\u000d\u000a      stone for construction, and managing the impact of emissions on the\u000d\u000a      environment.\u000d\u000a    Colin Hills and the University of Greenwich proved that ACT is a cost\u000d\u000a      effective technology, which can help organisations meet their\u000d\u000a      responsibilities, through its commercialisation with spin-out company Carbon8\u000d\u000a        Systems (C8S). Now they have taken hazardous residues from the\u000d\u000a      bottom of the waste hierarchy to the top by commercialising ACT's\u000d\u000a      application to UK-derived APCR to produce building materials, via spin-out\u000d\u000a      company Carbon8 Aggregates (C8A). By 2012 C8A had\u000d\u000a      commissioned the world's first commercial plant using ACT to produce\u000d\u000a      aggregate from APCR in Brandon, Suffolk, at a cost of &#163;1M [5.1]. Today the\u000d\u000a      plant is producing 32,000 tonnes of carbonated aggregate (C8Agg) per year,\u000d\u000a      which block manufacturer Lignacite turns into the world's first carbon\u000d\u000a      negative concrete blocks with values as low as-40 kg CO \/ tonne of\u000d\u000a      product.2 The way is now open to apply ACT to many other waste streams,\u000d\u000a      including contaminated soil.\u000d\u000a    ACT delivers five main benefits by:\u000d\u000a    \u000d\u000a      reducing the risks associated with hazardous waste and contaminated\u000d\u000a        soil\u000d\u000a      capturing and stores significant volumes of greenhouse gas CO2\u000a\u000d\u000a      recycling waste into a valuable aggregate\u000d\u000a      reducing waste going to landfill\u000d\u000a      producing aggregates in minutes rather than months, making the process\u000d\u000a        commercially viable.\u000d\u000a    \u000d\u000a    The CO2 used in ACT comes from industrial processes, thereby\u000d\u000a      recycling gas, which would otherwise pollute the atmosphere. However to\u000d\u000a      date it has been supplied in tankers from a sugar beet manufacturing\u000d\u000a      plant. C8A is now working with key UK waste management companies to `close\u000d\u000a      the loop' by using the actual CO2 produced by the incineration\u000d\u000a      of municipal solid waste (MSW) that also produces the APCRs: thus the\u000d\u000a      gaseous and solid wastes are valorised simultaneously. This is a perfectly\u000d\u000a      sustainable method for managing the 185,000 tonnes of MSW APCRs produced\u000d\u000a      in the UK every year; if adopted it would offset the CO2\u000d\u000a      produced by 10,000 cars.\u000d\u000a    Two more ACT plants will be built in 2014 and another is in planning,\u000d\u000a      increasing production capacity to &gt;100,000 tonnes by the end of 2014.\u000d\u000a      UK incinerator operators have included ACT treatment of APCRs in tenders\u000d\u000a      for new-build MSW incinerators, allowing them to demonstrate improved\u000d\u000a      sustainability credentials (zero landfill) and lower costs. C8S\u000d\u000a      has also identified potential for simultaneous valorisation of other key\u000d\u000a      waste streams.\u000d\u000a    C8S developed the technology to optimise the continuous treatment\u000d\u000a      of ashes through strategic partnerships with Viridor Waste Management,\u000d\u000a      Kent County Council and the Environment Agency, together with funding from\u000d\u000a      Knowledge Transfer Partnership (KTP) and the Technology Strategy Board. As\u000d\u000a      a result a new company C8A was formed to treat Air Pollution\u000d\u000a      Control Residues (APCr) and a commercial-scale plant was built in 2010 at\u000d\u000a      Brandon in Suffolk. More than 200T of aggregate was made and tested by two\u000d\u000a      major UK block manufacturers. It was this proof of concept that led to the\u000d\u000a      UK's largest independent waste management company, Grundon, investing in\u000d\u000a      C8A. Grundon were looking for an alternative to the landfill disposal of\u000d\u000a      APCRs.\u000d\u000a    The significance of ACT was quickly recognised. C8S won several\u000d\u000a      prestigious awards in quick succession including the 2008 national Shell\u000d\u000a        Springboard competition, established to identify the UK's next `big\u000d\u000a      idea' in low carbon enterprise and innovation. The Shell prize\u000d\u000a      money helped paid for a pilot-scale facility to treat waste at a Kent\u000d\u000a      County Council landfill site in 2010 using the CO2 generated by\u000d\u000a      the site itself. The C8S team, were invited to No.10 Downing Street four\u000d\u000a      days before critical global climate change negotiations in Copenhagen in\u000d\u000a      2009. Prime Minister Gordon Brown said: \"Our transition to a low carbon\u000d\u000a      economy will be a key driver of our future economic prosperity. Carbon8\u000d\u000a      Systems...are at the forefront of this transformation. Their innovation\u000d\u000a      and expertise demonstrates why the UK is one of best places in the world\u000d\u000a      for low carbon business.\" [5.3]. C8S has also been one of UK Trade &amp;\u000d\u000a      Investment's (UKTI) case studies for UK low carbon innovation.\u000d\u000a    Overseas potential for ACT appears significant and, with UKTI support,\u000d\u000a      discussions are on-going to market ACT in Australasia. Other overseas\u000d\u000a      markets including Europe and Canada are also being explored. C8S is\u000d\u000a      partnering Canadian low carbon company, CarbonCure Technologies, in a\u000d\u000a      submission to the $35M Alberta Grand (Carbon) Challenge 2013, and has\u000d\u000a      successfully completed the first-round of the application process. C8A's\u000d\u000a      aggregate was recognised Best Recycled Product at the 2013 UK National\u000d\u000a      Recycling Awards.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Accelerated Carbonation Technology (ACT) is an innovative solution to\u000d\u000a      several key environmental issues - CO2 emissions to the\u000d\u000a      atmosphere, sustainable use of resources and the reliance on use of virgin\u000d\u000a      stone for construction. ACT rapidly stabilises industrial waste recycling\u000d\u000a      it into valuable aggregate, thereby reducing the amount going to landfill.\u000d\u000a      ACT simultaneously captures the greenhouse gas CO2, via the\u000d\u000a      rapid production of carbonate, which solidifies the waste into a hardened\u000d\u000a      product. ACT has been commercialised through two spin-out companies\u000d\u000a      leading to the first commercial production of carbon negative concrete\u000d\u000a      blocks, taking hazardous waste from the bottom to the top of the waste\u000d\u000a      hierarchy.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    University of Greenwich\u000d\u000a    ","Institutions":[{"AlternativeName":"Greenwich (University of)","InstitutionName":"University of Greenwich","PeerGroup":"D","Region":"London","UKPRN":10007146}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"5883102","Name":"Alberta"},{"GeoNamesId":"2618425","Name":"Copenhagen"}],"References":"\u000d\u000a    (REF1 submitted staff in bold, **REF2 Outputs) *Joint\u000d\u000a      UCL\/UoG doctoral student.\u000d\u000a    \u000a3.1 Fern&#225;ndez Bertos, M.*, Simons, S. J. R., Hills, C. D., &amp;\u000d\u000a      Carey, P. J. (2004). A review of accelerated carbonation technology in the\u000d\u000a      treatment of cement-based materials and sequestration of CO2. Journal\u000d\u000a        of Hazardous Materials, B112, 193-205. \u000d\u000a        http:\/\/dx.doi.org\/10.1016\/j.jhazmat.2004.04.019\u000d\u000a    \u000a\u000a3.2 Fern&#225;ndez Bertos, M.*, Li, X., Simons, S. J. R., Hills, C. D.,\u000d\u000a      &amp; Carey, P. J. (2004). Investigation of accelerated carbonation for\u000d\u000a      the stabilisation of MSW incinerator ashes and the sequestration of CO2.\u000d\u000a      Green Chemistry, 6, 428-436. http:\/\/dx.doi.org\/10.1039\/B401872A\u000d\u000a    \u000a\u000a3.3 Scuzzarella, A., Simons, S.J.R., Hills, C. D., &amp; Carey,\u000d\u000a      P.J. (2005). Investigation on Assisted Fluidization of a Cohesive Powder,\u000d\u000a      Trans. IChemE, Part A, Chemical Engineering Research and Design,\u000d\u000a        83(A11), 1319-1324. http:\/\/dx.doi.org\/10.1205\/cherd.05098\u000d\u000a    \u000a\u000a3.4 Scuzzarella, A., Fernandez Bertos, M*., Simons, S. J. R., Hills,\u000d\u000a        C. D., &amp; Carey, P. J. (2006). Expansion of Cohesive Gas\u000d\u000a      Fluidized Binary Solid Systems, Powder Tech., 163, 18-22.\u000d\u000a      http:\/\/dx.doi.org\/10.1016\/j.powtec.2006.01.002\u000d\u000a    \u000a\u000a3.5 Li X., Fern&#225;ndez Bertos M*, Hills, C. D., Carey, P. J.,\u000d\u000a      &amp; Simons, S. J. R. (2007). Accelerated carbonation of municipal solid\u000d\u000a      waste incineration fly ashes, Waste Management, 27,\u000d\u000a      1200-6. \u000d\u000a        http:\/\/dx.doi.org\/10.1016\/j.wasman.2006.06.011\u000d\u000a    \u000a\u000a**3.6 Gunning, P., Hills, C. D., &amp; Carey, P. J. (2009)\u000d\u000a      Production of Lightweight Aggregates from Waste and Carbon Dioxide. Waste\u000d\u000a        Management, 29(10), 2722-2728. http:\/\/dx.doi.org\/10.1016\/j.wasman.2009.05.021\u000d\u000a    \u000aExample Research Grants\u000d\u000a    1. C. D. Hills. Artificial Aggregates from Waste and Recycled CO2.\u000d\u000a      Grant Ref. B197. Biffaward. 2002-2005. &#163;370,000. In collaboration with\u000d\u000a      UCL, Onyx, Millennium Chemicals and Tarmac.\u000d\u000a    2. P.Carey. CarbATTACT: Carbon abatement through accelerated\u000d\u000a        carbonation. Grant Ref. 130028 [PPBR007H] Technology Strategy Board,\u000d\u000a      Energy Generation and Supply: Carbon Abatement Technologies Programme.\u000d\u000a      2009-2011. &#163;150,000. Collaboration with Carbon8 Systems Ltd and BRE.\u000d\u000a    3. C. D. Hills. To develop a novel accelerated carbonation process\u000d\u000a        for the treatment of ashes from paper recycling and municipal waste\u000d\u000a        incineration. Grant Ref. KTP0006243. Technology Strategy Board,\u000d\u000a      Knowledge Transfer Partnership. 2007-2010. &#163;104,508.\u000d\u000a    4. A. Maries. Feasibility study. Grant Ref. BT223L. Technology\u000d\u000a      Strategy Board, Energy Generation and Supply: Carbon Abatement\u000d\u000a      Technologies Programme. 2009-2010. &#163;32,000. In collaboration with Carbon8\u000d\u000a      Systems Ltd and MIRO (Greenwich, sub-contractor to C8S).\u000d\u000a    5. C. D. Hills. Sustainable Aggregate Production with Imbibed Carbon\u000d\u000a        Dioxide (SAPICO2). Grant Ref. 4188. INTERREG IVA (Channel).\u000d\u000a      2013-2015. &#8364;860,000.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"9","Level2":"7","Subject":"Environmental Engineering"},{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"},{"Level1":"9","Level2":"4","Subject":"Chemical Engineering"}],"Sources":"\u000d\u000a    Prizes and awards for Carbon8 Systems Ltd.:\u000d\u000a     \u000d\u000a      \u000d\u000a        \u000d\u000a          Dates\u000d\u000a          Detail of prize or ward\u000d\u000a          Awarding\/electing body\u000d\u000a        \u000d\u000a        \u000d\u000a          &#160; 2006\u000d\u000a          &#160;Kent Innovative Climate Change Technology Award\u000d\u000a          &#160;Kent County Council\u000d\u000a        \u000d\u000a        \u000d\u000a          &#160; 2006\u000d\u000a          &#160;Kent Environment Business of the Year, 2006\u000d\u000a          &#160;Kent County Council\u000d\u000a        \u000d\u000a        \u000d\u000a          &#160; 2006\u000d\u000a          &#160;IChemE Green Technology Award (Chemistry\u000d\u000a            &#160;Innovation)\u000d\u000a          &#160;IChemE\u000d\u000a        \u000d\u000a        \u000d\u000a          &#160; 2007\u000d\u000a          &#160;Winner, Kent Innovation Challenge\u000d\u000a          &#160;Kent County Council\u000d\u000a        \u000d\u000a        \u000d\u000a          &#160; 2008\u000d\u000a          &#160;National winner (and winner of South-East final),\u000d\u000a            &#160;Shell Springboard\u000d\u000a          &#160;Shell plc\u000d\u000a        \u000d\u000a        \u000d\u000a          &#160; 2008\u000d\u000a          &#160;Times Higher Education Award for Outstanding\u000d\u000a            &#160;Contribution to Innovation and Technology\u000d\u000a          &#160;Times HE\u000d\u000a        \u000d\u000a        \u000d\u000a          &#160; 2013\u000d\u000a          &#160;Best Recycled Product (for C8Agg)\u000d\u000a          &#160;National Recycling\u000d\u000a            &#160;Awards\u000d\u000a        \u000d\u000a        \u000d\u000a          &#160;2013\u000d\u000a          &#160;CIWM, Murphy Innovative Practice SME Award\u000d\u000a            &#160;Winner\u000d\u000a          &#160;Chartered Institution of\u000d\u000a            &#160;Wastes Management\u000d\u000a        \u000d\u000a      \u000d\u000a    \u000d\u000a    Press releases\u000d\u000a    \u000d\u000a      www.agg-net.com\/news\/lignacite-launch-world-s-first-carbon-negative-block?source=search&amp;highlight=lignacite\u000d\u000a      www.agg-net.com\/news\/carbon8-achieve-a-world-first\u000d\u000a      http:\/\/www.theargus.co.uk\/news\/4793103.print\/\u000d\u000a      http:\/\/www.agg-net.com\/news\/lignacite-launch-world-s-first-carbon-negative-block\u000d\u000a      http:\/\/www.mrw.co.uk\/best-recycled-product-carbon8-aggregates\/8650293.article\u000d\u000a    \u000d\u000a    Reports:\u000d\u000a    \u000d\u000a      A reference to ACT and the work at UCL was made in the\u000d\u000a        Intergovernmental Panel on Climate Change (IPCC) Special Report on\u000d\u000a        \"Carbon Dioxide Capture &amp; Storage\", 2005. http:\/\/www.ipcc.ch\/publications_and_data\/publications_and_data_reports.shtml\u000a\u000d\u000a      Technology Strategy Board \"Collaboration nation; Carbon abatement\u000d\u000a        feasibility studies\", 2008. http:\/\/www.innovateuk.org\/publications\/competition-and-project-documents.ashx\u000a\u000d\u000a      Technology Strategy Board \"Energy Portfolio, 2009\/10. http:\/\/www.innovateuk.org\/publications\/competition-and-project-documents.ashx\u000a\u000d\u000a    \u000d\u000a    Selected national press articles:\u000d\u000a    http:\/\/www.telegraph.co.uk\/finance\/2789256\/Bringing-waste-not-want-not-to-life.html;\u000d\u000a      http:\/\/www.thesundaytimes.co.uk\/sto\/business\/energy_and_environment\/article347620.ece\u000d\u000a    Organisations who could corroborate claims:\u000d\u000a    Carbon8 Systems Ltd.\u000d\u000a    Shell Springboard, http:\/\/www.shellspringboard.org\/home\/\u000d\u000a    Kent County Council.\u000d\u000a    IChemE.\u000d\u000a    Grundon Waste Management Ltd.\u000d\u000a    ","Title":"\u000d\u000a    Treating waste with carbon dioxide\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    Government regulations have encouraged both the diversion of waste from\u000d\u000a      landfill and the development of alternative aggregate sources. These\u000d\u000a      include the EU Landfill Directive 2004, requiring hazardous wastes to be\u000d\u000a      treated before disposal to landfill, Waste Acceptance Criteria; the UK\u000d\u000a      Landfill Tax escalator, and Aggregate Levy on the extraction of primary\u000d\u000a      aggregates. The European Union Emissions Trading Scheme 2005 has focused\u000d\u000a      attention on ways of managing emissions, including geological carbon\u000d\u000a      capture and storage. New technologies that can redirect hazardous air\u000d\u000a      pollution control residues (APCRs) into inert products with commercial\u000d\u000a      value, using the carbon emitted in their production - the closing of the\u000d\u000a      `loop' -therefore have an important place in the market.\u000d\u000a    Dr Colin Hills, Director of the Centre for Contaminated Land\u000d\u000a      Remediation at the University of Greenwich, showed that certain\u000d\u000a      contaminants inhibit the hardening of cements used to stabilise and\u000d\u000a      solidify contaminated soil and waste but that this retardation can be\u000d\u000a      overcome by exposure to CO2 gas. The `accelerated carbonation'\u000d\u000a      reaction produces solid carbonates rapidly in contrast to the slow\u000d\u000a      development of `normal' hydrated phases. Having shown that the carbon\u000d\u000a      dioxide concentration and water-to-solid ratio (w\/s) were important he\u000d\u000a      patented Accelerated Carbonation Technology (ACT). Hills saw the\u000d\u000a      opportunity to sequester significant quantities of CO2 into\u000d\u000a      solid waste streams, thereby minimising industrial emissions. The major\u000d\u000a      advance he made was the discovery that the 100% CO2 atmosphere\u000d\u000a      thought necessary to drive carbonation reactions to a rapid conclusion &#8212;\u000d\u000a      under 15 minutes, rather than the weeks or months required for natural\u000d\u000a      carbonation &#8212; was erroneous [unpublished work, due to IP considerations].\u000d\u000a      He established that lower gas concentrations as found in flue gases, are\u000d\u000a      often optimal for a rapid, substantially complete reaction, and that\u000d\u000a      optimal conditions also depend on the particle size distribution of the\u000d\u000a      waste and w\/s ratio.\u000d\u000a    Following these and other advances in waste processing, the spin-out\u000d\u000a      company Carbon8 Systems (C8S) was established in 2006 to\u000d\u000a      commercialise both ACT as a waste treatment step and the CO2\u000d\u000a      capture process. Carbon8 Aggregates (C8A) was founded in 2010\u000d\u000a      specifically to commercialise the engineering applications of the\u000d\u000a      technology to UK-derived APCR.\u000d\u000a    The first major grant, which was to research the use of ACT to treat\u000d\u000a      Municipal Solid Waste (MSW) APCRs, was received in 2002. Supported\u000d\u000a      with additional industrial funding, Hills examined the properties of\u000d\u000a      carbonated APCRs: their physical and chemical stability, including\u000d\u000a      leaching properties; and suitability either for disposal, at non-hazardous\u000d\u000a      landfill sites, or for re-use as an aggregate in construction. The\u000d\u000a      research investigated a number of UK APCRs with varying physical and\u000d\u000a      chemical characteristics, and defined the key characteristics affecting\u000d\u000a      the efficacy of carbonation and product properties. It was quickly\u000d\u000a      established that ACT is an effective treatment method, which renders the\u000d\u000a      APCRs non-hazardous and stable over long time periods. Following\u000d\u000a      substantial grant income from TSB, KTP and others, the most recent award\u000d\u000a      to Hills (&#8364;860,000) is to evaluate French and UK waste streams\u000d\u000a      for incorporation in new sustainable building materials.\u000d\u000a    "},{"CaseStudyId":"4894","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"2921044","Name":"Germany"},{"GeoNamesId":"289688","Name":"Qatar"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"6252001","Name":"United States"}],"Funders":[],"ImpactDetails":"\u000a    The research described above has underpinned the development of the first\u000a      smaller-scale, modular gas-to-liquids (GTL) and biomass-to-liquids (BTL)\u000a      Fischer-Tropsch (FT) reactors, launched by Oxford Catalysts Group in 2010.\u000a      Several orders for reactors have been taken; the company has attracted\u000a      very substantial investment as a result of the novel technology it offers,\u000a      and has one of the world's largest patent portfolios in this area.\u000a    After its spin-out from the University of Oxford in 2004, Oxford\u000a      Catalysts Ltd. concentrated on the creation of highly active and efficient\u000a      cobalt-based FT catalysts based on Green's research. Such was the\u000a      perceived potential of this new technology that the company's Initial\u000a      Public Offering of 2006 raised &#163; 15M and was over-subscribed. Oxford\u000a      Catalysts' patented technology, known as Organic Matrix Combustion (OMX),\u000a      allows highly active cobalt-based catalysts to be produced with a reduced\u000a      need for precious metal promoters, without any loss of performance and in\u000a      fact with superior activity, selectivity and stability to conventional\u000a      catalysts. In 2008, the company merged with Velocys, a US company\u000a      specialising in microchannel chemical reactors (using channels with\u000a      diameters in the range 0.1 - 10 mm, far smaller than those in conventional\u000a      reactors). These small channels dissipate heat more quickly than\u000a      conventional reactors so a more active catalyst can be used, and the mass\u000a      and heat transfer limitations of conventional FT reactors are overcome.\u000a      Importantly, this allowed Oxford Catalysts to take advantage of the highly\u000a      active cobalt catalysts developed by Green [6]. The use of microchannel\u000a      processing technology makes it possible to greatly intensify chemical\u000a      reactions, enabling them to occur at rates significantly higher than\u000a      conventional processes, thus enabling smaller-scale FT reactors for GTL\u000a      and BTL. The merged company became known as Oxford Catalysts Group\u000a      (re-named Velocys from September 2013) and is the only company working in\u000a      this field to maintain in-house research in both catalyst and reactor\u000a      development.\u000a    The company has capitalised on the potential of smaller and more\u000a      versatile FT reactors. Existing FT plants are huge, designed for\u000a      production levels of around 30,000 barrels of liquid fuel per day (BPD),\u000a      and cannot be scaled down economically. They require vast sources of gas,\u000a      and so are confined to a small number of locations (primarily in Qatar),\u000a      and cost billions of dollars, putting them beyond the reach of all but the\u000a      largest companies. Gas associated with oil production is usually wasted;\u000a      it is frequently disposed of by flaring (burning) - an environmentally\u000a      unfriendly process that is increasingly subject to regulation - or by\u000a      re-injection back into the reservoir at considerable expense. According to\u000a      the World Bank, 140 billion cubic meters of associated gas - enough to\u000a      power Germany - was flared in 2011. An equivalent amount or more was\u000a      re-injected simply to avoid flaring. Gas located at remote locations is\u000a      often not developed; it is not economically viable to pipe the gas to\u000a      where it is needed. Biomass resources such as agricultural and municipal\u000a      solid waste are another important potential syngas for the FT process: the\u000a      alternative being that they are disposed of as waste. Because biomass\u000a      feedstock is not very dense, it is not economic to transport it over long\u000a      distances to centralised production facilities. Therefore, BTL plants in\u000a      particular need to be relatively small and located near the source of the\u000a      feedstock. The technology developed by Oxford Catalysts Group makes it\u000a      possible to take advantage of these `wasted resources' to produce liquid\u000a      fuels by using the biomass-to-liquids (BTL) or gas-to-liquids (GTL)\u000a      processes. An added advantage is that the process creates synthetic clean\u000a      fuels free from sulphur and aromatics (unlike those produced in\u000a      conventional refinery processes), and can be tailored to produce\u000a      high-value hydrocarbons such as jet fuel [7].\u000a    Oxford Catalysts Group has demonstrated that its reactors operate\u000a      economically when producing as little as 1,000 BPD of FT products. The\u000a      reactors are small enough that modules incorporating the reactors can be\u000a      transported in standard-size shipping containers and easily delivered to\u000a      where they are needed. This has opened up the market to smaller companies,\u000a      smaller gas fields and more remote locations, enabling the distributed\u000a      production (production at or near the source of the feedstock) of clean\u000a      liquid fuels from stranded and associated gas, both on- and off-shore, and\u000a      from biomass. For example, Oxford Catalysts Group has established a\u000a      partnership with offshore-facility developers MODEC and the global\u000a      engineering firm Toyo Engineering to develop small-scale GTL facilities\u000a      based on microchannel reactors and designed for use offshore [14].\u000a    The huge potential of the reactors has generated a high level of\u000a      investment in the company. Between 2008 and the end of 2012, the group\u000a      achieved revenue of &#163; 30M and received over &#163; 60M in investment. &#163; 30.6M\u000a      of the investment was raised in January 2013, at which time Roman\u000a      Abramovich invested &#163; 4.3M in the company, generating press and television\u000a      news coverage. Oxford Catalysts' stock increased by around 200% between\u000a      June 2012 and June 2013. Throughout this period, the company has been able\u000a      to maintain its levels of employment (80 - 90 staff) in the UK and the US\u000a      [8], and has offices in the UK near Oxford and in the USA in Texas and\u000a      Ohio.\u000a    In May 2012, Oxford Catalysts announced the sale and start-up of a\u000a      commercial scale FT reactor at an integrated energy company facility [9].\u000a      The Group's technology has been selected for 4 commercial-scale projects\u000a      including:\u000a    \u000a      A 1,000 BPD commercial GTL plant for Calumet Specialty Product\u000a        Partners, L.P., a major US-based producer of speciality petroleum\u000a        products, for use in the expansion of Calumet's Karns City, Pennsylvania\u000a        facility [10].\u000a      GreenSky London waste-biomass to jet fuel commercial plant, in\u000a        partnership with BA. Like many airlines, BA is concerned about carbon\u000a        taxes and is, therefore, interested in securing a low-carbon-footprint\u000a        fuel based on biomass. The plant will provide enough fuel for BA at City\u000a        Airport [11] - reportedly 50,000 tonnes of jet fuel annually over 10\u000a        years equating to $ 500M at today's prices.\u000a      A 2,800 BPD GTL plant being developed by Pinto Energy in Ohio, USA, to\u000a        convert low-cost natural gas into high value specialty products\u000a        (solvents, lubricants and waxes), as well as ultra clean transportation\u000a        fuels [12].\u000a    \u000a    In November 2012, Oxford Catalysts Group was named as the preferred\u000a      supplier of FT technology for Ventech Engineers LLC, a global leader in\u000a      the design and construction of modular refineries. The deal raised &#163; 1.2M\u000a      for the Group, and in April 2013, Ventech placed an order worth $ 8M for\u000a      FT reactors for a plant of sufficient capacity to produce approximately\u000a      1,400 BPD. This gives an indication of the expected income from the\u000a      projects listed above. Kevin Stanley, CEO of Ventech Engineers commented,\u000a      `After an extensive search of available technologies we identified Oxford\u000a      Catalysts' FT product as the leading offering in the industry for modular\u000a      GTL plants' [13].\u000a    Oxford Catalysts Group has established collaborations for the\u000a      engineering, manufacturing and deployment of its technology with companies\u000a      such as MODEC, Toyo Engineering, Haldor Topose and Ventech. The range of\u000a      partnerships reflects the fact that Oxford Catalysts group is regarded as\u000a      a leading player in the field of FT technology [14].\u000a    ","ImpactSummary":"\u000a    Research carried out by Malcolm Green's group in the UOA led to the\u000a      spin-out of Oxford Catalysts Ltd. A large part of the company's technology\u000a      is based on Green's transition-metal catalysis research, which has enabled\u000a      them to develop a highly efficient Fischer-Tropsch (FT) catalyst to\u000a      convert natural gas to liquid hydrocarbons. In 2010, Oxford Catalysts\u000a      Group (now Velocys) demonstrated the world's first smaller-scale, modular\u000a      gas-to-liquids and biomass-to-liquids FT plants which made use of the\u000a      catalyst for the efficient conversion of low-value or waste gas to liquid\u000a      hydrocarbon fuels. Since then, orders worth &#163; 8M have been taken and the\u000a      company has been selected to provide FT technology for 4 commercial\u000a      projects. From 2008 - 2012, the company raised over &#163; 60M, achieved\u000a      revenue of &#163; 30M and now employs around 90 people.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Oxford\u000a    ","Institutions":[{"AlternativeName":"Oxford (University of)","InstitutionName":"University of Oxford","PeerGroup":"A","Region":"South East","UKPRN":10007774}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"6254927","Name":"Pennsylvania"},{"GeoNamesId":"5165418","Name":"Ohio"},{"GeoNamesId":"4736286","Name":"Texas"}],"References":"\u000a    Asterisked outputs denote best indicators of quality; University of\u000a      Oxford authors are underlined.\u000a    \u000a[1] A study of carbon deposition on catalysts during the partial\u000a      oxidation of methane to synthesis gas. Claridge, J. B.; Green,\u000a        M. L. H.; Tsang, S. C.; York, A. P. E.; Ashcroft,\u000a        A. T.; Battle, P. D. Catalysis Letters 22 (4),\u000a      299-305, 1993. DOI: 10.1007\/BF00807237\u000a    \u000a\u000a[2] Molybdenum and tungsten carbides as catalysts for the conversion of\u000a      methane to synthesis gas using stoichiometric feedstocks. York, A. P.\u000a        E.; Claridge, J. B.; Brungs, A. J.; Tsang, S. C.;\u000a      Green, M. L. H. Chemical Communications 1, 39-40, 1997.\u000a      DOI: 10.1039\/A605693H\u000a    \u000a\u000a[3]* New catalysts for the conversion of methane to synthesis gas:\u000a      Molybdenum and tungsten carbide. Claridge, J. B.; York, A. P.\u000a        E.; Brungs, A. J.; Marquez-Alvarez, C.; Sloan,\u000a        J.; Tsang, S. C.; Green, M. L. H. Journal of\u000a        Catalysis 180 (1), 85-100, 1998. DOI: 10.1006\/jcat.1998.2260. Paper\u000a        illustrates the underpinning expertise in carbide catalyst technology of\u000a        the Oxford Research Group.\u000a    \u000a\u000a[4]* Study on the mechanism of partial oxidation of methane to synthesis\u000a      gas over molybdenum carbide catalyst. Xiao, T. C.; Hanif, A.;\u000a      York, A. P. E.; Nishizaka, Y.; Green, M. L. H. Physical\u000a        Chemistry Chemical Physics 4 (18), 4549-4554, 2002. DOI:\u000a      10.1039\/b204347e. Underpinning expertise in carbide catalyst\u000a        technology of the Oxford research group in combination with a\u000a        microreactor.\u000a    \u000a\u000a[5] Methane combustion over supported cobalt catalysts. Xiao, T. C.;\u000a      Ji, S. F.; Wang, H. T.; Coleman, K. S.; Green, M. L.\u000a        H. Journal of Molecular Catalysis A-Chemical 175 (1-2),\u000a      111-123, 2001. DOI: 10.1016\/S1381-1169(01)00205-9\u000a    \u000a\u000a[6]* A supported cobalt-containing catalyst used in the partial oxidation\u000a      of hydrocarbons or Fischer-Tropsch reaction. Green, M. L. H. and Xiao,\u000a        T. C. Int. Appl. (2003), WO 2003002252. Assignee: Isis Innovation\u000a      Limited, UK (a wholly-owned subsidiary of the University of Oxford,\u000a      managing technology transfer). http:\/\/www.google.com\/patents\/WO2003002252A1?cl=en\u000a      One of the base patents underpinning Oxford Catalysts Ltd. FT\u000a        technology.\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"},{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"}],"Sources":"\u000a    [7] http:\/\/www.velocys.com\/our_business_overview.php\u000a      Oxford Catalyst Group (now Velocys) Business webpage, corroborating\u000a        details of the technology offered by the company and its performance.\u000a    [8] Details of investment\/employment can be corroborated by Oxford\u000a        Catalysts Group (Velocys).\u000a    [9] http:\/\/www.oxfordcatalysts.com\/financial\/fa\/ocgfa20120524.php\u000a      May 2012 press release from Oxford Catalysts, confirming sale and\u000a        successful start-up of a commercial scale FT Reactor with an anonymous\u000a        integrated energy company.\u000a    [10] http:\/\/calumetspecialty.investorroom.com\/2012-09-06-Calumet-Specialty-Products-Partners-L-P-Announces-Plan-to-Expand-its-Karns-City-PA-Specialty-Products-Facility\u000a      September 2012 press release from Calumet, confirming that it has\u000a        commissioned Oxford Catalysts\/Velocys to supply FT technology for 1,000\u000a        BPD commercial GTL plant for Calumet at its Karns City, Pennsylvania\u000a        site.\u000a    [11] http:\/\/www.solenafuels.com\/index.php\/in-the-news\/10-solena-makes-the-news-items\/10-british-airways-pledges-10-year-offtake-agreement-as-greensky-project-with-solena-gathers-momentum-on-greenair-online\u000a      November 2012 press release from Solena, confirming the selection of\u000a        Oxford Catalysts to provide FT technology to GreenSky London, Europe's\u000a        first commercial scale sustainable jet fuel facility, being developed in\u000a        partnership with British Airways.\u000a    [12] http:\/\/pintogtl.com\/partner\/\u000a      Pinto Energy webpage confirming details of the joint project with\u000a        Oxford Catalysts (Velocys).\u000a    [13] http:\/\/www2.ventech-eng.com\/2012\/11\/oxford-catalysts-secures-1-3m-from-ventech\/\u000a      November 2012 press release on the Ventech website confirming the\u000a        Ventech\/Oxford Catalysts collaboration and the fact that Ventech regards\u000a        Oxford Catalysts' FT technology as at the forefront of the GTL industry.\u000a    [14] http:\/\/www.velocys.com\/our_business_partners.php\u000a      Oxford Catalyst Group (now Velocys) Partners webpage, corroborating\u000a        details of the companies with whom the group has active partnerships.\u000a    \u000a    ","Title":"\u000a    UOA08-01: Oxford Catalysts Group - a successful company built on the\u000a        development and application of highly-active catalysts for the\u000a        conversion of natural gas to liquid hydrocarbons\u000a    ","UKLocation":[{"GeoNamesId":"2643743","Name":"London"},{"GeoNamesId":"2640729","Name":"Oxford"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    The Fischer-Tropsch (FT) process is a collection of chemical reactions\u000a      that converts a mixture of carbon monoxide and hydrogen (`synthesis gas'\u000a      or syngas) into synthetic crude that can be upgraded to high-quality motor\u000a      fuel. Developed in Germany in the 1920s, the process was used in World War\u000a      II to enable Germany to produce liquid fuels from coal when oil was not\u000a      available, and again in South Africa where it was subject to sanctions\u000a      during the apartheid era. The production of synthetic crude via the FT\u000a      synthesis has not been adopted widely owing to the availability of cheap\u000a      oil. However concern about diminishing oil supplies, combined with an\u000a      increasing need to make use of `wasted' resources, such as gas produced\u000a      from waste biomass or the gas associated with oil production, is leading\u000a      to a renewed and growing interest in FT catalysis.\u000a    The key technology behind the catalysts used by Oxford Catalysts is the\u000a      result of nearly two decades of research at the Wolfson Catalysis Centre\u000a      (part of the University of Oxford's Department of Chemistry). The focus\u000a      has been on the use of transition-metal carbides as catalysts for the\u000a      partial oxidation of methane to syngas, and as highly active, selective\u000a      and stable FT catalysts for the conversion of syngas to synthetic crude.\u000a      This work was led by Green, the co-founder of Oxford Catalysts Ltd. who\u000a      was Head of Inorganic Chemistry at Oxford (to October 2003).\u000a    In 1993, Green reported a systematic investigation into the carbon\u000a      deposition caused by a range of transition metals acting as catalysts for\u000a      the partial oxidation of methane (POM). This built on his previous\u000a      serendipitous finding that a lanthanide ruthenium oxide catalyst gave a\u000a      remarkable 90% yield of syngas from methane via POM catalysis. Prior to\u000a      this discovery, it had been considered impossible to convert methane to\u000a      syngas in this way. Although only a thin film of carbon formed in the\u000a      process, Green was aware that carbon deposition could potentially `kill' a\u000a      catalyst and render it useless for industrial exploitation. The 1993 study\u000a      showed that nickel attracted the most carbon deposition and iridium the\u000a      least, but the ruthenium and iridium catalysts, although effective, were\u000a      too expensive for commercial use, and this prompted Green to look for\u000a      alternatives [1]. He subsequently developed less expensive, non-precious\u000a      metal, molybdenum and tungsten carbide catalysts [2, 3, 4], which,\u000a      importantly, showed no macroscopic deposition of carbon.\u000a    In 2001, Green developed a non-carbide cobalt methane oxidation catalyst\u000a      with activities comparable to noble-metal catalysts under comparable\u000a      conditions [5]. Green's research continued to develop carbide catalysts\u000a      towards industrial exploitation using micro-reactors and, in 2002, he\u000a      reported catalysts that were stable at high temperatures and pressures\u000a      using this technology [4]. The final critical development with regard to\u000a      the commercial systems currently used by Oxford Catalysts Ltd. was\u000a      described in a patent application filed in 2001 [6], in which cobalt salt\u000a      precursors to the supported active catalysts are activated in a process\u000a      involving hydrocarbon reductants. These catalysts have superior activity\u000a      and are less susceptible to deactivation over time. This method of\u000a      activation of the catalyst precursor forms a mixture of metallic cobalt\u000a      and cobalt carbides. Critically, these catalysts are not only effective\u000a      for POM, but also for FT catalysis that converts syngas into hydrocarbons\u000a      [6]. Moreover, they do not promote carbon deposition and are selective to\u000a      form hydrocarbons with five or more carbon atoms. A high selectivity is\u000a      required for an economic commercial process.\u000a    In 2004, Green spun-out the company Oxford Catalysts Ltd. with the aim of\u000a      developing a number of novel metal-carbide catalysts and catalysed\u000a      processes that could lead to marketable products based in particular on\u000a      the new FT catalyst technology.\u000a    "},{"CaseStudyId":"4902","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":[],"ImpactDetails":"\u000a    Robinson's novel modification of Micromass' original Q-ToF mass\u000a      spectrometer, a proposal arising directly from her research needs, has\u000a      generated a new area of mass spectrometry research in industry as well as\u000a      academia, in which intact protein complexes can be studied and the\u000a      chemistry of small molecules and drugs investigated. Using earlier designs\u000a      of mass spectrometer optimised for proteomics and small-molecule drug\u000a      analysis, it was not possible to maintain the non-covalent interactions in\u000a      the gas phase since the pressure regimes and mass range of the\u000a      instrumentation were not sufficient.\u000a    The prototype instrument described in Section 2 outperformed all\u000a      anticipated specifications; the suite of initial papers that Robinson\u000a      published (including references [2] and [3], and also reported in May 2001\u000a      at the ASMS Conference [7]) contained solid evidence that the new design\u000a      could record the mass spectra of large intact molecules, and resulted in a\u000a      high level of interest from other laboratories. This, in turn, created a\u000a      demand for the modified Q-ToF mass spectrometer to be made commercially\u000a      available. The Senior Director of Mass Spectrometry Research at Micromass\u000a      UK Ltd, part of Waters Corporation, confirms that `the first [commercially\u000a      available] extended mass quadrupole units for the Q-ToF were developed in\u000a      2000, following the suggestions of Professor Robinson', and based on the\u000a      prototype tested by Robinson at Oxford University [8]. Two model classes\u000a      of mass spectrometers manufactured by Waters contain Robinson's\u000a      modification: the Q- ToF and the SYNAPT. A rival company, now AB Sciex,\u000a      also thought the new design was sufficiently commercially viable to invest\u000a      in, and manufactured their own version, the QStar, in 2006. However, only\u000a      a few QStar instruments have been sold, most likely because these were\u000a      significantly more expensive than Micromass' instruments.\u000a    Whilst initial sales of the modified mass spectrometers were confined to\u000a      academia, the research demonstrating the ability of mass spectrometry to\u000a      preserve protein complexes and to study the effects of drug binding\u000a      (including [4] above) has led to purchases by industry, notably by\u000a      pharmaceutical companies. The benefits for such customers within the\u000a      pharmaceutical industry are illustrated by the three examples below.\u000a    The biotechnology and pharmaceutical company Amgen bought their second\u000a      SYNAPT instrument in 2008 as a tool for analysing drug-like molecules. A\u000a      recent Amgen white paper confirms that the instrument's increased\u000a      quadrupole mass range allows for `mass selection, transmission and\u000a        ultimately activation and fragmentation of large protein complexes. This\u000a        fragmentation allows for protein subunit complex stoichiometry\u000a        determination, which has proven incredibly valuable if the stoichiometry\u000a        of the protein complex is unknown, or if the complex is heterogeneous'\u000a      [9]. Amgen has used ion mobility-mass spectrometry to analyze polyethylene\u000a      glycol and PEGylated polypeptides, IgG2 monoclonal antibodies and most\u000a      recently the detection of large multimeric charge-reduced protein\u000a      complexes [10]. Novo Nordisk, a global healthcare company with particular\u000a      expertise in diabetes care, has purchased a SYNAPT and used it to carry\u000a      out a joint collaborative study to monitor insulin aggregation [11]. A\u000a      senior Novo Nordisk scientist confirms that the mass spectrometer\u000a      modifications suggested by Robinson have given them `insight into the\u000a        structure and function of protein pharmaceuticals that would otherwise\u000a        be difficult or impossible to obtain' [12]. In addition, GSK is\u000a      working with Pentraxin, a spin-out company from University College London,\u000a      to develop small molecules that stabilise transthyretin, a blood protein\u000a      linked to a rare but fatal disease called amyloidosis. This research\u000a      programme has also used the modified spectrometers to perform analysis of\u000a      the macromolecules and determine the efficacy of potential inhibitors in\u000a      regulating the assembly and disassembly of transthyretin, directly\u000a      building on Robinson's demonstration that it was possible to use the new\u000a      instrumentation to study interactions within protein assemblies,\u000a      particularly in relation to the effect of drugs.\u000a    Many of these experiments are not possible on standard mass\u000a      spectrometers, since the required accuracy, resolution and pressure\u000a      regimes cannot be achieved. Thus, Robinson's modified ESI- MS design has\u000a      led to significant improvements in potential drug identification and\u000a      analysis, since multimeric drug targets can be observed intact and the\u000a      effect of potential inhibitors can consequently be revealed in an entirely\u000a      new environment.\u000a    To give an indication of the context for sales of the new mass\u000a      spectrometers, in 2012 Waters achieved net sales of over $ 1.8 billion, an\u000a      increase of 17% since 2008 [13]. 45% of these sales were of instrument\u000a      systems including its mass spectrometer range. Overall, Q-ToF and SYNAPT\u000a      instruments containing the modification proposed by Robinson constitute\u000a      about half of all Q-ToF instruments sold by the Waters Corporation [8].\u000a      There has thus been a significant impact on the commercial success of a\u000a      leading multinational instrument manufacturer, worth many millions of\u000a      dollars.\u000a    ","ImpactSummary":"\u000a    Carol Robinson's research at the University of Oxford in the mid-1990s\u000a      led directly to her proposing a new type of mass spectrometer to enable\u000a      more detailed analyses of larger molecular assemblies than previously\u000a      possible. The design is marketed worldwide by Micromass UK Ltd (part of\u000a      Waters Corporation), generating a new area of research within industry and\u000a      academia in which intact protein complexes can be analysed by mass\u000a      spectrometry and the chemistry of small molecules and drugs bound to them\u000a      investigated, thus contributing to the search for novel pharmaceuticals.\u000a      Since 2008, Waters' successful commercialisation of the new technology has\u000a      led to sales worth many millions of dollars.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Oxford\u000a    ","Institutions":[{"AlternativeName":"Oxford (University of)","InstitutionName":"University of Oxford","PeerGroup":"A","Region":"South East","UKPRN":10007774}],"Panel":"B         ","PlaceName":[],"References":"\u000a    Asterisked outputs denote best indicators of quality; University of\u000a      Oxford authors are underlined.\u000a    \u000a1. Robinson CV, Gross M, Eyles SJ, Ewbank JJ,\u000a      Mayhew M, Hartl FU, Dobson CM &amp; Radford SE.\u000a      Conformation of GroEL-bound &#945;-lactalbumin probed by mass spectrometry. Nature\u000a      372, 646-651 (1994). DOI:10.1038\/372646a0\u000a    \u000a\u000a2. * Rostom AA &amp; Robinson CV. Detection of the intact\u000a      GroEL chaperonin assembly by mass spectrometry. J Am Chem Soc 121,\u000a      4718-4719 (1999). DOI: 10.1021\/ja990238r\u000a      First analysis of GroeEl as an intact molecular assembly using the\u000a        modified mass spectrometer.\u000a    \u000a\u000a3. * Rostom AA, Fucini P, Benjamin DR, Juenemann\u000a      R, Nierhaus KH, Hartl FU, Dobson CM, Robinson CV.\u000a      Detection and selective dissociation of intact ribosomes in a mass\u000a      spectrometer. PNAS 97, 5185-5190 (2000). DOI:\u000a      10.1073\/pnas.97.10.5185\u000a      First mass spectrum of an intact ribosome using the modified mass\u000a        spectrometer.\u000a    \u000a\u000a4. Improvements in, or relating to, microfluidic sample preparation and\u000a      mass spectrometry. Patent application number WO2000050880 A3, filed 22nd\u000a      February 2000. Inventors: Carol Robinson and Mark Tito. https:\/\/www.google.com\/patents\/WO2000050880A3\u000a    \u000a\u000a5. * Zhou M, Morgner N, Barrera NP, Politis A, Isaacson\u000a        SC, Matak-Vinkovi&#263; D, Murata T, Bernal RA, Stock D, Robinson CV.\u000a      Mass spectrometry of intact V-type ATPases reveals lipid binding and the\u000a      effects of nucleotide binding. Science 344, 380-385 (2011). DOI:\u000a      10.1126\/science.1210148\u000a      First report of a membrane motor with structural consequences for lipid\u000a        and nucleotide binding.\u000a    \u000a\u000a6. Marcoux J, Wang S, Politis A, Reading E,\u000a      Ma J, Biggin P, Zhou M, Tao H, Zhang Q, Chang G, Morgner\u000a        N &amp; Robinson CV. Mass spectrometry reveals synergistic\u000a      effects of nucleotides, lipids, and drugs binding to a multidrug\u000a      resistance efflux pump. PNAS 110, 9704-9709 (2013). DOI:\u000a      10.1073\/pnas.1303888110\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"6","Level2":"1","Subject":"Biochemistry and Cell Biology"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"}],"Sources":"\u000a    \u000a      Conference paper, `Structure and Subunit Dynamics of Small Heat Shock\u000a        Proteins studied by Nanoflow ESI-MS', 49th ASMS Conference on\u000a        Mass Spectrometry and Allied Topics, May 2001 (held on file). Corroborates\u000a          the use at Oxford University of the custom-built mass spectrometer\u000a          provided by Micromass to record mass spectra of large intact\u000a          molecules.\u000a\u000a      Letter from the Senior Director of Mass Spectrometry Research at\u000a        Micromass\/Waters (held on file); corroborates Robinson's suggestion\u000a          of the extended-mass QToF instrument, and the impacts on\u000a          Micromass\/Waters' commercial success.\u000a\u000a      Amgen White Paper, `Advantages of the High-Mass QTOF for intact\u000a        protein detection' (held on file), confirming the advantages of the\u000a          modified mass spectrometer for the characterisation of\u000a          biopharmaceutical products.\u000a\u000a       Campuzano IDG, Schnier PD. Coupling electrospray corona discharge,\u000a        charge reduction and ion-mobility mass spectrometry: From peptides to\u000a        large macromolecular protein complexes. International Journal for Ion\u000a        Mobility Spectrometry, 16, 51-60 (2013). DOI: 10.1007\/s12127- 013-0120-x\u000a        Paper published by Amgen, in which the analyses were conducted using\u000a          the modified mass spectrometer.\u000a\u000a      Rune Salbo et al. Traveling-wave ion mobility mass spectrometry of\u000a        protein complexes: accurate calibrated collision cross-sections of human\u000a        insulin oligomers. Rapid Communications in Mass Spectrometry 26,\u000a        1181-1193 (2012). DOI: 10.1002\/rcm.6211 Paper co-published by Novo\u000a          Nordisk; confirms in the Methods Section the use of Waters SYNAPT\u000a          instruments to analyse insulin molecules.\u000a\u000a      Statement from a Senior Research Scientist at Novo Nordisk (held on\u000a        file), corroborating the ways in which the modified mass\u000a          spectrometer design has enabled insights in the development of protein\u000a          pharmaceuticals.\u000a\u000a      \u000ahttp:\/\/www.waters.com\/waters\/nav.htm?cid=134619461&amp;locale=en_US\u000a          Link to list of Waters Annual Reports; the 2012 Annual Report\u000a        confirms the sales figures, and 2011 Annual Report confirms the\u000a          increase in sales growth on page 18.\u000a    \u000a    ","Title":"\u000a    UOA08-02: A modified mass spectrometer provides a new tool for\u000a        structural biology.\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Carol Robinson was employed at the University of Oxford's Department of\u000a      Chemistry between 1991 - 2001 and 2009 - present, and at the University of\u000a      Cambridge between 2001 - 2009. From 1993 onwards, Robinson has used\u000a      electrospray-ionisation mass spectrometry (ESI-MS) to decipher protein\u000a      structure and function. Research by Robinson and colleagues in 1994\u000a      investigated GroEL, a molecular chaperone that catalyses protein-folding,\u000a      by directly monitoring its hydrogen exchange kinetics [1]. This work\u000a      provided new insights into the GroEL mechanism, and supported the\u000a      potential of ESI-MS for studying non-covalent protein complexes.\u000a      Importantly, it showed that large protein assemblies (800 kDa) could be\u000a      transferred intact into a vacuum even though they were not\u000a      directly detected by the existing MS instruments. Quadrupole\u000a      time-of-flight (Q-ToF) mass spectrometers (in which an ion's\u000a      mass-to-charge ratio (m\/z) is determined via a time measurement)\u000a      could not directly detect the intact complexes because the high m\/z\u000a      ratio of large molecules was beyond the operating limits of commercial\u000a      quadrupoles. Two specific instrument advances were required for the large\u000a      complexes to be analysed; first, there needed to be improved transmission\u000a      of high-mass molecules through Q-ToF mass spectrometers, and second there\u000a      needed to be improved selectivity between ions with high m\/z\u000a      values.\u000a    In 1998, Robinson approached Micromass UK Ltd, who had launched their\u000a      Q-ToF mass spectrometer in 1996, with a proposal to modify the instrument\u000a      to enable more detailed investigation of the molecular system outlined in\u000a      her 1994 paper. Proof-of-principle research using prototype and\u000a      home-improvements on commercial instruments was performed, revealing that\u000a      transmission of very large protein assemblies was possible, including\u000a      GroEL (800 kDa) [2] , ribosomes (2.3 MDa) [3], and a virus (2.5 MDa). The\u000a      virus analysis demonstrated that 180 protein subunits could remain intact\u000a      during flight through the mass spectrometer and be dissociated to give\u000a      monomeric units and assemblies, thus indicating that the packing of other\u000a      viruses could be addressed using ESI-MS. The mass spectra of intact\u000a      ribosomes revealed that not only the 70S particle but also the 30S and 50S\u000a      complexes could be observed with charge-state resolution. These findings\u000a      had huge consequences since, at the time, preservation of non-covalent\u000a      interactions in such large complexes was completely unexpected. This key\u000a      step towards obtaining mass spectra of intact protein complexes was\u000a      achieved on both time-of-flight (ToF) and Q-ToF instruments by making\u000a      adjustments to collisional cooling (via the differential pressure regimes)\u000a      in the instrument, reducing the internal energy of the complexes and hence\u000a      reducing their tendency to fragment. A patent for this method was filed in\u000a      2000 [4].\u000a    The second aspect of Robinson's instrumentation conceived at Oxford was\u000a      to reduce the radio- frequency of the guiding field applied to the\u000a      quadrupole. She was confident that this would optimise analysis of\u000a      macromolecular complexes, and better exploit the ability of ESI-MS to\u000a      preserve interactions between proteins and other molecules in the gas\u000a      phase. The quadrupole frequency was reduced such that an m\/z value\u000a      of 32,000 could be isolated and transmitted. This was the first time that\u000a      such a modification had been made to a Q-ToF instrument, and it was\u000a      considered to be high-risk; it was not clear to Micromass, or others, that\u000a      sufficient mass resolution would be achieved with a lower frequency\u000a      quadrupole. Initially, therefore, they produced only one mass spectrometer\u000a      for Robinson's use, delivered to her Oxford laboratory in December 2000.\u000a    The first research results from the prototype instrument, obtained in\u000a      Oxford in early 2001 and first reported in May 2001 at the 49th\u000a      ASMS Conference on Mass Spectrometry and Allied Topics (Chicago,\u000a      Illinois), showed unequivocally that intact macromolecular assemblies\u000a      could be maintained and transmitted through the mass spectrometer, their\u000a      masses measured with high accuracy using the new low-frequency quadrupole,\u000a      and their overall topology examined. It was evident that with Robinson's\u000a      innovative modification ESI-MS could now be used to analyse not just small\u000a      proteins and modest non-covalent complexes but also macromolecular\u000a      assemblies with masses as large as 1,000,000 Da.\u000a    In 2008, while at Cambridge, Robinson found that by releasing a\u000a      membrane-protein complex from a detergent micelle transported into the gas\u000a      phase, she could record the mass spectrum of an intact membrane-protein\u000a      complex, further supporting the initial proposal made at Oxford in 1998.\u000a      Unexpectedly, these complexes also carried with them specifically bound\u000a      lipid molecules. After Robinson returned to Oxford in 2009 she developed\u000a      this research to show the consequences of lipid binding to\u000a      membrane-embedded complexes [5]. This work is particularly important for\u000a      the discovery of new drugs, since many drugs target membrane-bound\u000a      proteins and lipid binding can either prevent the entry of drugs into the\u000a      cell or adapt the cavity for drug recognition.\u000a    Robinson continues to pursue cutting-edge research into drug binding to a\u000a      broad range of membrane-protein complexes. Research published in 2013\u000a      again used ESI-MS to study the binding in P-gp, a membrane-embedded pump\u000a      which is responsible for clearing xenotoxins from the cell.\u000a      Over-expression of P-gp in tumour cells impairs targeted drug delivery,\u000a      since the pump recognises chemotherapeutics as toxins and exports them.\u000a      Robinson and colleagues were able to probe the effect of a combination of\u000a      drugs and lipids on the equilibrium in P-gp and detect independent and\u000a      simultaneous binding, with important consequences for studying drug\u000a      binding in general [6].\u000a    "},{"CaseStudyId":"5577","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1814991","Name":"China"},{"GeoNamesId":"2658434","Name":"Switzerland"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000d    The new AVADA catalyst developed by BP (EP0757027, 1997) consists of a\u000d      bed of silica beads impregnated with silicotungstic HPA. The catalyst\u000d      showed excellent initial activity in the synthesis of ethyl acetate, but\u000d      unfortunately deactivated very quickly and with irreversible loss of\u000d      activity. The main cause of deactivation was extensive catalyst coking\u000d      which blocked catalyst acid sites leading to the loss of acidity. As a\u000d      result, the catalyst life was too short to be economically viable, which\u000d      put the AVADA project at risk of closure.\u000d    Kozhevnikov made the crucial suggestion of an alternative approach to the\u000d      problem of catalyst deactivation, viz prevention of catalyst coking and\u000d      poisoning by adding n-donors to the reaction feed, rather than attempting\u000d      a `cure' (regeneration). Kozhevnikov demonstrated that addition of water\u000d      to the olefin feedstock was an extremely effective coke inhibitor over HPA\u000d      catalysts (Appl. Catal. A 214, 47-58 (2001)).\u000d    Based on these results, the first advance implemented was co-feeding 3-8%\u000d      of water (steam) together with ethylene and acetic acid to the catalytic\u000d      reactor. This reduced dramatically the amount of coke deposited on the\u000d      catalyst surface. It also improved the stability of the heteropoly acid on\u000d      the silica surface. The second measure developed was the installation of a\u000d      silico-alumina guard bed to protect the HPA catalyst from poisoning by\u000d      basic impurities in the feed and corrosion metal ions. Altogether these\u000d      measures, originating from collaborative research between Kozhevnikov's\u000d      group and BP Chemicals, allowed significant prolongation of catalyst life\u000d      to about one year and were crucial to the commercial success of the AVADA\u000d      process.\u000d    The ethyl acetate plant at Hull achieved continuous sustained operation\u000d      during its first year in commercial production. The purity of the product\u000d      was excellent - 99.98%, the best ever. The low volatility of the HPA\u000d      helped the catalyst to survive the reactor's extremes of heat and\u000d      pressure, thus allowing long periods of uninterrupted operation for the\u000d      plant. Interestingly, the HPA catalyst, which is now produced by Johnson\u000d      Matthey, is practically unchanged from the one used in the initial stage\u000d      of process development. It is the implementation of the right process\u000d      conditions, based on fundamental research, that has made the great\u000d      improvement to the process efficiency.\u000d    Regarding its environmental friendliness, the AVADA process is by far\u000d      ahead of conventional ethyl acetate syntheses (Green Chemistry,\u000d      2003, 5, G78-C81; DOI: 10.1039\/b304290c). Traditional ethanol\u000d      esterification units produce as much water as they do ethyl acetate and\u000d      therefore require treatment and disposal of this waste stream. In the\u000d      AVADA process, elimination of ethanol as intermediate eliminated the\u000d      transport of some 60,000 tonnes of ethanol by road and removed more than\u000d      100,000 tonnes p.a. of wastewater stream. The other main technology in the\u000d      market, Tischenko condensation, uses an acetaldehyde feedstock. This is\u000d      less efficient than producing ethyl acetate directly from a modern\u000d      ethylene cracker and also produces waste streams from the aluminium salts\u000d      used as catalyst. Compared to conventional processes, AVADA's energy\u000d      consumption is about 20% lower and feedstock losses are some 35% less than\u000d      in conventional esterification with benefits to CO2 emissions (Green\u000a        Chemistry, 2003, 5, G78-C81).\u000d    The AVADA technology is potentially interesting for other acid-catalysed\u000d      processes such as the manufacturing of fuels, detergents and lubricants\u000d      using heterogeneous acid catalysis. The AVADA process won the AstraZeneca\u000d      Award in Green Chemistry and Engineering in 2002 (Green Chemistry,\u000d      5, G78-C81 (2003)).\u000d    In 2008, BP sold the ethyl acetate and related vinyl acetate monomer\u000d      businesses to INEOS Enterprise, a Swiss headquartered petrochemical group,\u000d      for an undisclosed amount. At that time each facility had 250,000 tonnes\u000d      p.a. capacity and together employed around 40 people (www.knak.jp\/big\/ineos.htm).\u000d    According to the recent ICIS Chemical Business report (October 2011), the\u000d      INEOS (former BP) plant at Hull (245,000 tonnes p.a. production capacity,\u000d      $340m p.a. factory gate value) by far dominates ethyl acetate production\u000d      in Europe (56% of the total 440,000 tonnes p.a.), being the second largest\u000d      in the world after the Zhenjiang 270,000 tonnes p.a. capacity ethyl\u000d      acetate plant in China (http:\/\/www.icis.com\/Articles\/2011\/10\/24\/9501870\/european+chemical+profile+ethyl+acetate.html).\u000d    Over the REF period from 2008 to 2013, the AVADA process produced 1.2\u000d      million tonnes of ethyl acetate of the total value of $1.7 billion and\u000d      reduced the wastewater stream by 0.5 million tonnes compared to the\u000d      conventional ethanol esterification process.\u000d    In his letter of corroboration, Dr Mark Howard, Technology Vice\u000d      President, Conversion Technology Centre, BP International Ltd., Saltend,\u000d      Hull, states \"Kozhevnikov's group, in close cooperation with BP's team\u000d        at Sunbury, set out to investigate coking and regeneration of HPA\u000d        catalysts. This contributed to the development of effective strategies\u000d        for maintaining the stability of the HPA catalyst which were implemented\u000d        to achieve economically viable catalyst lifetime. Recently sold to INEOS\u000d        as part of BP's rationalisation of its portfolio, the AVADA plant is\u000d        still in operation.\"\u000d    ","ImpactSummary":"\u000d    Studies into the deactivation and regeneration of heteropoly acid\u000d      catalysts, which took place in the group of Professor Ivan Kozhevnikov at\u000d      Liverpool University since 1996, resulted in the large-scale industrial\u000d      application of these catalysts in BP's process for the synthesis of the\u000d      widely used solvent ethyl acetate, thus making significant economic and\u000d      environmental impact. This process, trademarked AVADA (for AdVanced\u000a      Acetates by Direct Addition of acetic acid to\u000d      ethylene), was launched in 2001 at Hull, UK, on a scale of 220,000 tonnes\u000d      p.a., then the world's largest ethyl acetate production plant. The impact\u000d      continued through the REF period from 2008 to 2013. In October 2011, the\u000d      AVADA process produced 56% of the ethyl acetate in Europe (245,000 tonnes\u000d      p.a. production capacity and $340m p.a. factory gate value), being the\u000d      second largest in the world after the Zhenjiang 270,000 tonnes p.a. ethyl\u000d      acetate plant in China. Over the REF period, the AVADA process produced\u000d      1.2 million tonnes of ethyl acetate worth $1.7 billion. The AVADA process\u000d      makes ethyl acetate with 100% atom efficiency, avoiding the use of ethanol\u000d      as an intermediate. It beats conventional processes in environmental\u000d      friendliness by reducing energy consumption by 20% and feedstock losses by\u000d      35%, thus removing more than 100,000 tonnes p.a. of wastewater stream. At\u000d      the heart of the AVADA process is a highly efficient heteropoly acid\u000d      catalyst that is responsible for its superior performance. Implementation\u000d      of measures improving catalyst stability and resistance to coking, which\u000d      originated from collaboration between the Kozhevnikov group and BP\u000d      Chemicals, prevented otherwise fast catalyst deactivation to create an\u000d      economically viable process.\u000d    ","ImpactType":"Technological","Institution":"\u000d    University of Liverpool\u000d    ","Institutions":[{"AlternativeName":"Liverpool (University of)","InstitutionName":"University of Liverpool","PeerGroup":"A","Region":"North West","UKPRN":10006842}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"1784642","Name":"Zhenjiang"}],"References":"\u000d    * Three references to indicate the quality of the research.\u000d    \u000a1. *Siddiqui, M.R.H., Holmes, S., He, H., Smith, W., Coker, E.N., Atkins,\u000d      M.P., Kozhevnikov, I.V. Coking and regeneration of palladium-doped H3PW12O40\/SiO2\u000d      catalysts. Catal. Lett. 66, 53-57 (2000). DOI:\u000d      10.1023\/A:1019083103395 (citation score 24).\u000d    \u000a\u000a2. *Kozhevnikov, I.V., Holmes, S., Siddiqui, M.R.H. Coking and\u000d      regeneration of H3PW12O40\/SiO2\u000d      catalysts. Appl. Catal. A 214, 47-58 (2001). DOI:\u000d      10.1016\/S0926-860X(01)00469-0 (citation score 48).\u000d    \u000a\u000a3. *Kozhevnikov, I.V. Sustainable heterogeneous acid catalysis by\u000d      heteropoly acids. J. Mol. Catal. A 262, 86-92 (2007). DOI:\u000d      10.1016\/j.molcata.2006.08.075 (citation score 87).\u000d    \u000a\u000a4. Alsalme, A.M., Wiper, P.V., Khimyak, Y.Z., Kozhevnikova, E.F.,\u000d      Kozhevnikov, I.V. Solid acid catalysts based on H3PW12O40\u000d      heteropoly acid: Acid and catalytic properties at a gas-solid interface. J.\u000a        Catal. 276, 181-189 (2010). DOI: 10.1016\/j.jcat2010.09.014\u000d      (citation score 18).\u000d    \u000a5. BP Chemicals as the Industrial Affiliate with the Leverhulme Centre\u000d      for Innovative Catalysis at Liverpool University (1987 to 1998) supported\u000d      this project through their membership fee (&#163;25,000 p.a.). In addition,\u000d      they also supported two post-docs and provided support in kind including\u000d      access to facilities and staff time. Support from EPSRC: Novel solid acid\u000d      materials based on polyoxometalates, grant EP\/F014686\/1, 2007-2010\u000d      (&#163;99,174).\u000d    6. Web references can alternatively be found at: http:\/\/tinyurl.com\/livchemref\u000d    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"},{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"}],"Sources":"\u000d    The contribution of the Leverhulme Centre for Innovative Catalysis at the\u000d      Department of Chemistry, University of Liverpool, to the success of AVADA\u000d      process is acknowledged in a special publication by the General Technology\u000d      Manager, BP Chemicals (Dobson, I.D., \"Leaps of innovation\", Green\u000d        Chemistry, 5, G78-C81 (2003) (DOI: 10.1039\/b304290c)).\u000d      Similar publication appeared earlier in the BP journal Frontiers,\u000d      August 2002, p. 12-14. Both state \"the ethyl acetate development work was\u000d      ... widely collaborative ..., calling on the cooperation of chemists,\u000d      chemical engineers process developers, catalyst manufacturers and research\u000d      departments in several universities, particularly the Leverhulme\u000d        Centre of Liverpool University in the UK and Waterloo University in\u000d      Canada.\"\u000d    The letter of corroboration is provided by the Technology Vice President,\u000d      Conversion Technology Centre, BP International Ltd., Saltend, Hull. \u000d    ","Title":"\u000d    Economical and beneficial environmental impact on industrial production\u000d      of ethyl acetate\u000d    ","UKLocation":[{"GeoNamesId":"2645425","Name":"Hull"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d    Catalysis by heteropoly acids (HPAs), also known as polyoxometalates, has\u000d      attracted much interest both in fundamental and applied research because\u000d      of its potential to generate significant economic and environmental\u000d      benefits (Kozhevnikov, I.V., Catalysis by Polyoxometalates, Wiley,\u000d      Chichester, 2002). Systematic studies of HPA catalysts at the molecular\u000d      level have led to a series of large-scale industrial applications, such as\u000d      the hydration of olefins and the oxidation of methacrolein to methacrylic\u000d      acid. Prof. Kozhevnikov is a world-leading expert in catalysis by HPAs; he\u000d      became involved with HPA catalysis early on, since the mid-1970s, and\u000d      published over 150 widely recognized research outputs in this field,\u000d      including the pioneering work on acid catalysis by HPAs (Kozhevnikov,\u000d      I.V., Chemical Reviews, 98, 171-198 (1998); J. Mol.\u000d        Catal. A 262, 86-92 (2007); J. Mol. Catal. A 305,\u000d      104-111 (2009), total citation score 1436). The majority of HPA catalytic\u000d      applications use the most stable and easy available Keggin HPAs comprising\u000d      heteropolyanions of the formula [XM12O ]n-, where X\u000d      is the heteroatom (e.g. P5+, Si4+) and M is the 40\u000d      addendum atom (e.g. Mo6+, W6+). HPAs are\u000d      non-volatile compounds possessing very strong Br&#248;nsted acidity which is\u000d      superior to that of mineral acids and conventional solid acid catalysts.\u000d      This makes them promising solid acid catalysts for various reactions both\u000d      in gas and liquid phases. However, the relatively low thermal stability of\u000d      HPAs and difficulty of catalyst regeneration had always been obstacles to\u000d      their commercialisation, rendering their use in heterogeneous acid\u000d      catalysis rather limited. The key problem was catalyst lifetime, since the\u000d      heteropoly acids usually suffered rapid deactivation and loss of activity.\u000d    In the 1990s, BP Chemicals were facing the challenge of relocating ethyl\u000d      acetate manufacturing capacity around Europe to a more efficient site, by\u000d      implementing a significantly improved production process. Ethyl acetate is\u000d      manufactured on a large scale and is used in surface coatings, inks, and\u000d      pharmaceuticals. The state-of-the-art BP site at Hull was chosen as the\u000d      new location for the commercial plant.\u000d    BP Chemicals came up with a new solution for ethyl acetate production,\u000d      trademarked AVADA. The new technology converts ethylene and acetic acid in\u000d      the gas phase with 100% atom efficiency directly into ethyl acetate using\u000d      a highly active HPA catalyst, without the usual intermediate stage of\u000d      esterification which would have required another feedstock chemical,\u000d      ethanol. By avoiding ethanol the new technology represents a significant\u000d      advance &#8212; a true step change. Exploratory work on the AVADA process was\u000d      carried out at BP Sunbury-on-Thames Research Centre by the team led by Dr\u000d      Martin Atkins and at BP Research and Technology Centre at Hull by the\u000d      technology team led by Dr Mark Howard. Their progress was hampered by the\u000d      short catalyst lifetime due to fast deactivation of the HPA catalyst\u000d      caused by its coking and poisoning.\u000d    In 1996, Kozhevnikov, then Senior Research Fellow in the Leverhulme\u000d      Centre for Innovative Catalysis (LCIC), Department of Chemistry,\u000d      University of Liverpool, was invited by BP Chemicals, an Industrial\u000d      Affiliate with the LCIC at that time, to collaborate with their team at\u000d      Sunbury on the development of the HPA catalyst for the AVADA process.\u000d      Kozhevnikov set up a research group in Liverpool, which included two\u000d      PDRA's, Dr S. Holmes and Dr M. R. H. Siddiqui, funded by BP Chemicals. The\u000d      aim of their research was to gain an insight into the nature of the coke\u000d      formed on the surface of supported HPA catalysts and the effect of the\u000d      coke on the HPA. This was investigated using 13C and 31P\u000d      solid state NMR, XPS and TPO\/TGA in combination with fixed-bed reactor\u000d      studies of aerobic coke gasification. It was found that catalyst\u000d      modification with platinum group metals, such as palladium, significantly\u000d      reduced the temperature of coke removal to allow for catalyst regeneration\u000d      without HPA degradation (Catal. Lett. 66, 53-57 (2000)).\u000d      Particularly important was the finding that addition of polar molecules\u000d      (n-donors) such as water, methanol etc. to the feed could greatly reduce\u000d      coking of HPA catalysts thus improving catalyst life without the need for\u000d      frequent catalyst regeneration (Appl. Catal.A 214, 47-58\u000d      (2001)).\u000d    The result of this collaborative research was the development of\u000d      effective methods to improve the stability and lifetime of the HPA\u000d      catalysts. These processes include both prevention of catalyst coking as\u000d      well as regeneration of HPA catalysts. The main results of these studies\u000d      have been published in the papers listed below.\u000d    "},{"CaseStudyId":"6327","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"2658434","Name":"Switzerland"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2921044","Name":"Germany"}],"Funders":["Wellcome Trust","Biotechnology and Biological Sciences Research Council","Engineering and Physical Sciences Research Council","Royal Society"],"ImpactDetails":"\u000a    Context: Dental decay is the most common of all diseases\u000a      (prevalence: ~10% of the population p.a. in the western world i.e. 100\u000a      million lesions p.a.), yet the principles of treatment have remained\u000a      unchanged for almost 100 years (J. Dent. 2003, 31,\u000a      395-405). Most adults worldwide suffer from dental caries (tooth decay),\u000a      many of which go untreated because of patients' fear of the dental drill.\u000a      The earliest sign of tooth decay is the \"white spot\" lesion, visible to\u000a      the clinician on the tooth surface. There is no current consensus view\u000a      regarding treatment, and clinicians have three choices: (a) to monitor the\u000a      lesion, and then to excavate and fill; (b) to apply fluoride treatments,\u000a      and then to proceed as in (a); and (c) to place a small restoration.\u000a      Ultimately, all restorations fail and need to be replaced with larger\u000a      fillings, and will eventually lead to tooth loss and replacement.\u000a      Treatment currently costs the UK NHS ca &#163;2bn pa (roughly half the\u000a      budget for dental care; Office of the Government Auditor). Drilling is\u000a      feared by many patients, inhibiting their attendance at the dentist and so\u000a      precluding opportunities for early diagnosis and treatment of decay as\u000a      well as diseases such as oral cancer. Leeds' self-assembling peptide\u000a      technology provides a simple and cost-effective alternative to current\u000a      treatments that avoids a subsequent need for larger fillings; this\u000a      technology removes the clinician's dilemma of whether to treat decay, and\u000a      removes the need for drilling and thus the fear of visiting the dentist.\u000a    Societal impact\u000a      Public interest was stimulated through promotional material from\u000a      EPSRC; in a story featuring Prof. Kirkham on Channel 4 News; and in an\u000a      article in the Daily Mail (A).\u000a    Economic impacts\u000a      A company was established (\"Credentis AG\", Switzerland;\u000a      www.credentis.com) in January 2010, in which the University of Leeds is a\u000a      major stakeholder, to exploit under license Leeds' IP on self- assembling\u000a      peptides in the dental domain (B,C). Jobs have been created for\u000a      highly-skilled researchers at both Credentis in Switzerland (2010, 0.5\u000a      FTEs; 2011, 2 FTEs; 2012, 3 FTEs; 2013, 4 FTEs) and at the University of\u000a      Leeds (3 FTEs in 2013) (C). In its first two years of operation, the\u000a      company has raised external investment of ca 4.75M Swiss\u000a      francs (ca &#163;3M) in three rounds (2010, 0.25M CHF; 2011, 2.5M CHF;\u000a      2013, 2.0M CHF) (C).\u000a    Leeds' IP has enabled the adoption of disruptive technology\u000a      within dental care. The platform technology for self assembling peptide\u000a      design developed in Leeds was patented (D, currently maintained), and\u000a      underpins diverse applications including the design of biomimetic\u000a      scaffolds in tissue engineering. Following Leeds research using self\u000a      assembling peptide technology to treat decay lesions in extracted teeth,\u000a      an applications patent was granted in 2009 (E) and is currently\u000a      maintained. Subsequent Leeds research comparing the ability of different\u000a      peptide designs to nucleate mineral crystals and to regenerate bone led to\u000a      the filing of a patent in the US (F).\u000a    Credentis was recognised as one of the top 100 Swiss start-up companies\u000a      in 2011, 2012 and 2013 (http:\/\/www.startup.ch\/index.cfm?CFID=241786181&amp;CFTOKEN=45081364&amp;page=129572&amp;profilesEntr\u000a        y=1) by a panel of start-up company experts in conjunction with\u000a      Handelszeitung. In 2012, Credentis opened at UK office in Leeds,\u000a      reflecting the continuing close collaboration with researchers in the\u000a      University. Support for this collaborative research programme includes a\u000a      new &#163;1.2M award via the Leeds EPSRC Medical Technologies Innovation and\u000a      Knowledge Centre (EP\/I019103\/1) to develop second-generation peptides for\u000a      further dental applications to increase the Credentis product range (G).\u000a      Leeds researchers (Aggeli, Kirkham) are developing new technology and\u000a      minimising commercial risk via the provision of access to a full and\u000a      validated pipeline screening facility including (a) rational peptide\u000a      design; (b) characterisation of self-assembly processes; (c) computational\u000a      modelling; (d) theology testing; (e) screening for capacity to induce\u000a      mineralisation; (f) cytotoxicity testing; (g) in situ (ex vivo)\u000a      testing; (h) clinical trials; and (i) process development.\u000a    A new product (initially CurodontTM, and now CurodontTM\u000a        Repair (H)) containing peptide P11-4, based on patents of Leeds\u000a      researchers, was granted its CE certificate in January 2012 (C) and has\u000a      now entered the European market for clinical use as a class IIa medical\u000a      device; the product has also been approved for clinical use in Australia,\u000a      and Health Canada approval is pending. Large scale production of CurodontTM\u000a        provides a fully GMP-compliant product (50,000 patient treatments\u000a      in the first run) for which patient acceptability has been shown to be\u000a      very high. Leeds researchers contributed to this outcome by conducting\u000a      first in man safety trials for P11-4, demonstrating a clear clinical\u000a      improvement over treatment of class 5 lesions with the peptide (6). The\u000a      product has been launched in Germany and Switzerland in Q1\/2013. Credentis\u000a      has engaged a UK dental specialist company, Optident, who will distribute\u000a      and supply the products within the UK market from October 2013 (I). A\u000a      second product, Curodont&#8482; Protect, was approved(H) in April 2013, is\u000a      regulated as a cosmetic and has been launched in selected markets in 2013;\u000a      here, the formulation of the peptide has been adapted for the treatment of\u000a      dentin hypersensitivity and the prevention of tooth decay.\u000a    There has been significant investment in research and development\u000a      of this peptide technology (including P11-4) by overseas industry. In\u000a      addition to support from Credentis AG (G), a collaborative project with\u000a      Geistlich Biomaterials (Switzerland) demonstrated that self-assembling\u000a      peptides can promote highly efficient bone regeneration in an animal\u000a      model.\u000a    Health impact\u000a      A new clinical intervention - a medical device for restoration of\u000a      early enamel caries - has been developed, trialled in patients and a\u000a      definite positive outcome demonstrated (6). Leeds researchers were\u000a      involved in all stages of the product development from laboratory to\u000a      chairside (C). The resulting marketed products launched in 2013 are seen\u000a      by the profession to fill the previously unfilled gap between prevention\u000a      and surgical intervention (J).\u000a    ","ImpactSummary":"\u000a    A new class of synthetic self-assembling peptides has been developed at\u000a      Leeds into a product that allows the enamel in the dental cavities to be\u000a      regenerated. The peptides assemble to form gels that have been shown to be\u000a      promising biocompatible materials with applications in regenerative\u000a      medicine, for example in the regeneration of bone. Credentis AG\u000a      (Switzerland) was founded in January 2010 to commercialise the technology\u000a      in the dental care domain. Its first product Curodont&#8482; Repair - the first\u000a      product of its kind in dental care - has completed first-in-man safety\u000a      trials (also at Leeds); has received regulatory approval for clinical use\u000a      in Switzerland, Europe and Australia; and was launched in Switzerland and\u000a      Germany in Q1\/2013. The product has tremendous promise because most adults\u000a      suffer from dental caries which often go untreated because of patients'\u000a      fear of the dental drill. A second product Curodont&#8482; Protect, approved in\u000a      April 2013 and regulated as a cosmetic, has been launched in 2013 for the\u000a      treatment of dentin hypersensitivity. Credentis has established a UK base\u000a      in Leeds and has engaged a UK company as distributor of its products from\u000a      October 2013.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Leeds\u000a    ","Institutions":[{"AlternativeName":"Leeds (University of)","InstitutionName":"University of Leeds","PeerGroup":"A","Region":"Yorkshire And Humberside","UKPRN":10007795}],"Panel":"B         ","PlaceName":[],"References":"\u000a    \u000a1) Aggeli, A, Bell, M, Boden, N, Keen, J, Knowles, PF, McLeish, TCB,\u000a      Pitkeathly, M &amp; Radford, SE., Responsive gels formed by the\u000a      spontaneous self-assembly of peptides into polymeric 03b2- sheet tapes, Nature,\u000a      1997, 386, 259-262, (500 citations; Source: Scopus, 24\/10\/13)\u000a      http:\/\/dx.doi.org\/10.1038\/386259a0\u000a      The paper describes the detailed characterisation of organogel and\u000a      hydrogel peptide tape- based materials.\u000a    \u000a\u000a2) Aggeli, A., Nyrkova, I., Bell, M., Harding, R., Carrick, L., McLeish,\u000a      TCB, Semenov, A. &amp; Boden, N., Hierarchical self-assembly of chiral\u000a      rod-like molecules as a model for peptide beta-sheet tapes, ribbons,\u000a      fibrils and fibres, Proc. Natl. Acad.Sci. USA 2001, 98,\u000a      11857-11862 (462 citations; Source: Scopus, 24\/10\/13) http:\/\/dx.doi.org\/10.1073\/pnas.191250198\u000a      The hierarchical route to self-assembly of peptide tapes was described,\u000a      together with a theoretical framework for the self-assembly process.\u000a    \u000a\u000a3) Aggeli A, Bell M, Carrick LM, Fishwick CWG, Harding R, Mawer PJ,\u000a      Radford SE, Strong AE, Boden N., pH as a trigger of peptide beta-sheet\u000a      self-assembly and reversible switching between nematic and isotropic\u000a      phases, J. Am. Chem. Soc. 2003, 125, 9619-9628 (201\u000a      citations; Source: Scopus, 24\/10\/13) http:\/\/dx.doi.org\/10.1021\/ja021047i\u000a      This paper describes pH-responsive peptides whose self assembly is\u000a      controlled by a specific external trigger\u000a    \u000a\u000a4) Kirkham, J, Zhang, J, Wallwork, ML, Smith, DA, Brookes, SJ, Shore, RC,\u000a      Wood, SR and Robinson, C., Evidence for Charge Domains on Developing\u000a      Enamel Crystal Surfaces, J. Dental Research. 2000, 79,\u000a      1943-1947 (38 citations; Source: Scopus, 24\/10\/13)\u000a      http:\/\/dx.doi.org\/10.1177\/00220345000790120401\u000a    \u000a\u000a5) Kirkham, J., Firth, A, Vernals, D., Boden, N, Robinson, C., Shire, RC,\u000a      Brookes, SJ and Aggeli, A, Self-assembling peptide scaffolds promote\u000a      enamel remineralization, J. Dental Research 2007, 86,\u000a      426-430 (59 citations; Source: Scopus, 24\/10\/13)\u000a      http:\/\/dx.doi.org\/10.1177\/154405910708600507\u000a      The paper presents for the first time the potential of peptide gels for\u000a      the treatment of dental- caries like lesions.\u000a    \u000a\u000a6) Brunton, PA, Davies, RWP, Burke, JL, Smith, A, Aggeli, A., Brookes, SJ\u000a      and Kirkham, J, Treatment of early caries lesions using biomimetic self\u000a      assembling peptides, British Dental Journal 2013, 215, E6.\u000a        http:\/\/dx.doi.org\/10.1038\/sj.bdj.2013.741 The paper describes the\u000a      results of the first-in-man safety trials.\u000a    \u000aAll papers are in internationally-leading peer-reviewed journals and are\u000a      hence &#8805;2*, but references 1-3 are particularly highlighted by the UoA to\u000a      demonstrate the quality of the underpinning research.\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"3","Subject":"Macromolecular and Materials Chemistry"},{"Level1":"6","Level2":"1","Subject":"Biochemistry and Cell Biology"},{"Level1":"2","Level2":"99","Subject":"Other Physical Sciences"}],"Sources":"\u000a    (A) For example: (a) \"Tooth technology\", EPSRC Growth Story, May 2013;\u000a      (b) Story on Channel 4 news, 22nd August 2011 ( http:\/\/www.channel4.com\/news\/no-more-dental-drilling-and-filling;\u000a      accessed 28.10.13); (c) Daily Mail, 22nd August 2011 (http:\/\/www.dailymail.co.uk\/health\/article-\u000a        2029014\/Painless-tooth-fillings-drilling-make-dentist-trips-irksome.html;\u000a      accessed 28.10.13).\u000a    (B) License agreements between University of Leeds and Credentis,\u000a      06.01.2011 and 02.01.2013.\u000a    (C) Letters, Chief Executive Officer, Credentis, 2013, 13th June\u000a      2013 and 30th August 2013.\u000a    (D) Platform technology patent: \"Beta Sheet Forming Peptides\"; Proprietor\u000a      : UoL, Inventors : N. Boden, A. Aggeli, T. C. B. McLeish, Priority Date:\u000a      28\/3\/1996, European Patent No: EP 0 759 933,B1, granted 08\/05\/2002 and\u000a      being currently maintained. The patent recognised at an early stage the\u000a      potential applications of the new materials\u000a    (E) \"Beta-sheet forming peptides and materials made thereof\", Proprietor:\u000a      UoL, Inventors : N. Boden, A. Aggeli, E. Ingham, J. Kirkham, Priority\u000a      Date: 17\/07\/2003, European Patent No: EP 1 523 494 B1, granted 23\/12\/2009\u000a      and being currently maintained.\u000a    (F) \"Beta Sheet Tapes Ribbons in Tissue Engineering\", Assignee: UoL,\u000a      Inventors: N. Boden, A. Aggeli, E. Ingham, J. Kirkham, US Patent No: US\u000a      7700721, granted 20\/4\/2010 and being currently maintained.\u000a    (G) Collaborative agreement with Credentis AG, 29th April\u000a      2013.\u000a    (H) \"Curodont&#8482; Repair and Curodont Protect&#8482; for the treatment and\u000a      prevention of tooth decay\", NIHR Horizon Scanning Centre, University of\u000a      Birmingham, July 2013.\u000a    (I) Letter, Commercial Director, Optident Ltd., 24th September\u000a      2013.\u000a    (J) \"Curolux Technology: Regenerative Cutting-Edge Technology\", brochure\u000a      containing quotes from independent dental practitioners who have used\u000a      CurodontTM Repair, 2013. \u000a    ","Title":"\u000a    \"Filling without drilling\": A new class of product for the treatment of\u000a      early stage dental decay based on hydrogels of self-assembling peptide\u000a      tapes\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000a    This new regenerative therapy for the treatment of early enamel decay\u000a      developed from an interdisciplinary, collaborative research programme at\u000a      the University of Leeds led by Aggeli (School of Chemistry and\u000a      Centre for Self-Organising Molecular Systems, SOMS\/Centre for Molecular\u000a      Nanoscience, CMNS) and Kirkham (Leeds Dental Institute).\u000a    The initial underpinning research formed part of a major programme on\u000a      peptide self-assembly within the SOMS Centre at Leeds led by Boden.\u000a      In 1995, Aggeli, then a PhD student in the School of Chemistry at Leeds\u000a      supervised by Boden, described for the first time the ability of peptides\u000a      to aggregate to form supramolecular nanotapes and gels (A. Aggeli, Spectroscopic\u000a        studies of self-assembling peptides in solution and in lipid bilayers,\u000a      PhD thesis, University of Leeds, 1995). Subsequently, supported by EPSRC,\u000a      Aggeli and Boden, together with Fishwick, Radford (Faculty of\u000a      Biological Sciences) and McLeish (School of Physics), established (between\u000a      1995 and 2003) the underlying principles required for peptide\u000a      self-assembly into nanotapes and gels (1); a theoretical framework to\u000a      explain the experimental behaviour of self-assembled peptides (2); and the\u000a      principles to design in responsiveness to external triggers in order to\u000a      control the assembly process (3). Under specific conditions, peptides\u000a      undergo hierarchical self-assembly through formation of micrometer-long\u000a      f062-sheet \"nanotapes\", which stack in pairs to form ribbons, further\u000a      assemble to form fibrils, and then entwine to form fibres. This assembly\u000a      process is principally driven by intermolecular hydrogen bonding between\u000a      peptide backbones, together with additional interactions between specific\u000a      backbones, and offered the potential for a new generation of biomaterials\u000a      with many different applications. This research was described in three\u000a      seminal papers(1-3) in high-impact journals that have collectively accrued\u000a      over 1100 citations.\u000a    Kirkham's group [funded from 1998 through Wellcome Trust programme and\u000a      project grants (088908\/Z\/09\/Z) and BBSRC (9709001; ABY08147; REI18424)\u000a      equipment grants] utilised enamel development as a paradigm for\u000a      understanding how extracellular matrix proteins control crystal\u000a      nucleation, disposition and tissue architecture in mammalian\u000a      biomineralisation. This research established the principles that underpin\u000a      the control of crystal growth in developing enamel, leading to the\u000a      hypothesis that domains of negative charge on extracellular matrix\u000a      proteins were responsible for crystal nucleation during enamel\u000a      biomineralisation (4).\u000a    Kirkham and Aggeli's collaboration since 2003 has used the knowledge of\u000a      the structure-function relationships of self-assembling peptides and the\u000a      mechanism of mineralised tissue formation to address clinical challenges\u000a      in dental cavity healing. Peptides were selected that would be monomeric\u000a      at pH &gt;7.5, providing a low viscosity, injectible fluid that would\u000a      spontaneously assemble to form a three-dimensional fibrillar scaffold\u000a      under physiological conditions. In addition, the peptides were designed to\u000a      provide, via their amino acid side chains, domains of negative charge once\u000a      assembled. The resulting three-dimensional structures were therefore\u000a      designed to mimic the biological macromolecules found in extracellular\u000a      matrices of the mammalian skeleton.\u000a    Applied collaborative research between the two groups [funded by an EPSRC\u000a      CASE award, a Leeds Teaching Hospitals Trust research award, Leeds' EPSRC\u000a      Medical Technologies Innovation Knowledge Centre (EP\/I019103\/1) and\u000a      Geistlich Biomaterials, Switzerland] tested the hypotheses that rationally\u000a      designed self assembling synthetic peptides could nucleate mineral\u000a      crystals in vitro and in situ within artificial decay\u000a      lesions in extracted human teeth and were both biocompatible and\u000a      non-allergenic in animals (5). Taking this information together, a\u000a      first-in-man clinical trial (National Research Ethics System project\u000a      number 10\/H1207\/75) was carried out in 2010 (led by Brunton, Professor of\u000a      Restorative Dentistry, Leeds) applying one of the peptides (P11-4) to\u000a      early enamel decay lesions in patients. The results provided unequivocal\u000a      evidence of efficacy following a single treatment of the lesions with the\u000a      peptide material (6).\u000a    Key personnel\u000a      Centre for Self-Organising Molecular Systems\/School of Chemistry\u000a      Amalia Aggeli (PhD student, 1992-1995; Royal Society Dorothy Hodgkin\u000a      Fellow, 1997-2001; Royal Society University Research Fellow, 2001-9;\u000a      Lecturer, 2009-)Neville Boden (Lecturer 1966-81; Reader 1981-91;\u000a      Professor 1991-2001; Research Professor 2001-2005; now retired)Colin\u000a      Fishwick (Lecturer 1985-1997, Senior Lecturer 1997-2006, Professor 2006-)\u000a      PhD students: Mark Bell (1995-2000); Lisa Carrick (1998-2002); Richard\u000a      Harding (1993-1997); Peter Mawer (1997-2002); A Firth (2003-2008).\u000a    Leeds Dental Institute: Jen Kirkham (Lecturer then Senior Lecturer\u000a      then Reader, 1980-; Professor of Oral Biology 1999-)\u000a    School of Physics: Tom McLeish (Professor of Polymer Physics,\u000a      1993-2008)\u000a    Faculty of Biological Sciences: Sheena Radford (Lecturer, 1995-8;\u000a      Reader, 1998-2000; Professor of Structural Molecular Biology, 2000-)\u000a    "},{"CaseStudyId":"6328","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":[],"ImpactDetails":"\u000a    Context - a large market\u000a      Chronic wounds such as infected leg ulcers represent a significant burden\u000a      to patients and to healthcare systems throughout the world. A study in Nursing\u000a        Times (Nursing Times 2008, 104, 44- 45) describes the\u000a      impact of chronic wounds on a representative healthcare system:\u000a      approximately 200,000 patients in the UK have a chronic wound and the cost\u000a      of caring for these patients is conservatively estimated at &#163;2.3-3.1\u000a      billion per year i.e. around 3% of total NHS expenditure. The cost of\u000a      treating those patients with venous ulceration, mostly in primary care and\u000a      through community nursing services, is over &#163;168-198 million per year.\u000a      Pain and odour can affect quality of life, and these common symptoms are\u000a      frequently associated with poor sleep, loss of mobility and social\u000a      isolation.\u000a    As described in Section 2, the candidate photodynamic therapeutic PPA904\u000a      stems from the discovery and initial evaluations of the new class of\u000a      photosensitising dye by Brown, Griffiths and colleagues. Subsequent\u000a      studies by the Leeds team revealed that these dyes have properties which\u000a      made them suitable for photodynamic therapy (PDT). The candidate agent\u000a      PPA904 was identified as part of targeted chemical modifications led by\u000a      Griffiths and laboratory antimicrobial screening studies led by Brown (5).\u000a      The intellectual property generated by the two research groups was\u000a      transferred to the spin-out Photopharmica for further development in 2001.\u000a      Patents have been granted in all major territories in the world,\u000a      all of which are current and are owned by Photopharmica, covering the\u000a      application of specific phenothiazinium photosensitisers in photodynamic\u000a      treatment (A,B,C,D)\u000a    Commercial impact - job creation\u000a      Photopharmica successfully raised &#163;11.5M of external investment from IP\u000a      Group PLC and others to support its research and development programme,\u000a      &#163;6.25M million of which has been deployed since 2008 (E,F) (see below).\u000a      Some of these funds have supported further research and development of\u000a      PPA904 and other candidate photosensitisers by researchers at the\u000a      University of Leeds (outlined in Section 2).\u000a    The establishment of Photopharmica as a viable spin-out company\u000a      has also created jobs. Since 2008, Photopharmica has employed on\u000a      average 8 employees according to the needs of its R&amp;D cycle, and\u000a      additional personnel have been employed at contract research organisations\u000a      providing services to support its clinical trials (F).\u000a    Health benefits - reducing infectious bacteria\u000a      Between 2009 and 2011, Photopharmica deployed around &#163;6.0M to fund a Phase\u000a      IIb trial of antimicrobial photodynamic therapy involving PPA904 in the\u000a      treatment of chronic leg ulcers. Thus, a new drug was trialled with\u000a        patients. This trial involved 11 leading UK institutes and recruited\u000a      57 patients at seven sites across the UK (G).\u000a    The trial showed that subjects receiving weekly PPA904 treatment (with\u000a      light activation) showed a statistically greater reduction in the total\u000a      load of bacteria in the wound compared to placebo and light. Crucially,\u000a      significantly fewer PPA904-treated patients (compared to placebo)\u000a      experienced post-treatment bacterial load levels above the recognised\u000a      clinical threshold for prevention of wound healing. Significantly fewer\u000a      PPA904-treated patients experienced very high post-treatment bacterial\u000a      load levels, suggesting that PPA904 may reduce the risk of acquiring an\u000a      infection. All bacterial species, including MRSA, were substantially and\u000a      significantly reduced (H).\u000a    The trial reported that the treatment was well tolerated and no safety\u000a      concerns were raised by the independent Data Safety Monitoring Board.\u000a      Analysis of wound area and quality of life scores showed that the\u000a      treatment had no adverse effect on either (H).\u000a    Commenting on this trial, the Head of Wound Healing at Cardiff University\u000a      Medical School, Chief Investigator on the trial and Editor-in-Chief of\u000a      International Wound Journal commented: \"In 30 years in the wound\u000a        healing field, I have never seen a topical treatment with efficacy\u000a        anywhere near that which Photopharmica has demonstrated. Very few\u000a        significant advances have been made in this field over the last decade;\u000a        I believe the Photopharmica technology is the disruptive change needed.\"\u000a      (I).\u000a    Following these promising Phase IIb clinical trial results, in December\u000a      2012, Photopharmica raised a further &#163;250K in external investment to\u000a      source an acquisition and\/or co-development partner to help bring a novel\u000a      photodynamic antimicrobial to market (E,F).\u000a    ","ImpactSummary":"\u000a    Leeds researchers discovered a novel class of tissue penetrating,\u000a      light-activated dyes that were selectively and rapidly taken up by\u000a      bacteria. Based on the dyes' promising antimicrobial activity, the\u000a      University of Leeds span-out Photopharmica Ltd. Further research at Leeds\u000a      has progressed the development of a targeted antimicrobial for chronic\u000a      wound infections. Photopharmica has raised &#163;11.5M in external investment,\u000a      around &#163;6.0M of which has been deployed since 2009 to support a 57 patient\u000a      phase IIb clinical trial. The results, which showed substantially reduced\u000a      loads of all bacterial species, led to a further &#163;250K investment in 2012\u000a      to support Photopharmica's strategy to bring an antimicrobial drug to the\u000a      market.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Leeds\u000a    ","Institutions":[{"AlternativeName":"Leeds (University of)","InstitutionName":"University of Leeds","PeerGroup":"A","Region":"Yorkshire And Humberside","UKPRN":10007795}],"Panel":"B         ","PlaceName":[],"References":"\u000a    \u000a1. S.A. Gorman, A. L. Bell, J. Griffiths, D. Roberts, S.B. Brown, The\u000a      synthesis and properties of unsymmetrical 3,7-diaminophenothiazin-5-ium\u000a      iodide salts: Potential photosensitisers for photodynamic therapy, Dyes\u000a        and Pigments 2006, 71, 153-160. (10 citations; Source:\u000a      Scopus, 24\/10\/13)\u000a        http:\/\/dx.doi.org\/10.1016\/j.dyepig.2005.06.011\u000a    \u000a\u000a2. D J Ball, S Mayhew, S R Wood, J Griffiths, D I Vernon and S B Brown, A\u000a      comparative study of the cellular uptake and photodynamic efficacy of\u000a      three novel zinc phthalocyanines of differing charge, Photochemistry\u000a        and Photobiology, 1999, 69, 390-396. (51 citations; Source:\u000a      Scopus, 24\/10\/13) http:\/\/dx.doi.org\/10.1111\/j.1751-1097.1999.tb03303.x\u000a    \u000a\u000a3. K J Mellish, R D Cox, D I Vernon, J Griffiths and S B Brown, In\u000a        Vitro Photodynamic activity of series of Methylene Blue analogues, Photochemistry\u000a        and Photobiology, 2002, 75, 392-397. (79 citations; Source:\u000a      Scopus, 24\/10\/13) http:\/\/dx.doi.org\/10.1562\/0031-8655(2002)0750392IVPAOA2.0.CO2\u000a    \u000a\u000a4. A. Minnock, D.I. Vernon, J. Schofield, J. Griffiths, J. H. Parish and\u000a      S. B. Brown., Photoinactivation of bacteria. Use of a cationic\u000a      water-soluble zinc phthalocyanine to photoinactivate both Gram-negative\u000a      and Gram-positive bacteria, J. Photochem. Photobiol. (B) 1996, 32,159-164.\u000a      (206 citations; Source: Scopus, 24\/10\/13) http:\/\/dx.doi.org\/10.1016\/1011-1344(95)07148-2\u000a    \u000a\u000a5. S. B. Brown and C. C. O'Grady, Biologically active methylene blue\u000a      derivatives, International PCT application WO02096896. This application\u000a      established a filing date in all contracting states and was followed up by\u000a      the filing and granting of national and regional patents (see\u000a      corroborative evidence A).\u000a    \u000a\u000a6. S. Morley, J. Griffiths, G. Philips, H. Moseley, C. O'Grady, K.\u000a      Mellish, C. L. Lankester, B. Faris, R. J. Young, S. B. Brown and L. E.\u000a      Rhodes, Phase IIa randomized, placebo-controlled study of antimicrobial\u000a      photodynamic therapy in bacterially colonized, chronic leg ulcers and\u000a      diabetic foot ulcers: a new approach to antimicrobial therapy, Brit.\u000a        J. Dermatol. 2013, DOI: 10.1111\/bjd.12098. (0 citations; Source:\u000a      Scopus, 24\/10\/13) \u000a        http:\/\/dx.doi.org\/10.1111\/bjd.12098\u000a    \u000aAll papers are in internationally-leading peer-reviewed journals and are\u000a      hence &#8805;2*, but references 2-4 are particularly highlighted by the UoA to\u000a      demonstrate the quality of the underpinning research.\u000a    ","ResearchSubjectAreas":[{"Level1":"6","Level2":"1","Subject":"Biochemistry and Cell Biology"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"},{"Level1":"6","Level2":"5","Subject":"Microbiology"}],"Sources":"\u000a    A. The international PCT application WO02096896 (S. B. Brown, C. C.\u000a      O'Grady, J. Griffiths, K. J. Mellish, R. G. Tunstall, D. J. H. Roberts and\u000a      D. I. Vernon, \"Biologically Active Methylene Blue Derivatives\")\u000a      established a filing date (30.5.2002) in all contracting states. It was\u000a      followed up by a range of regional and national applications, including\u000a      the following granted patents: (a) AU2002256784 (Austrailia; filed\u000a      30.5.2002, granted 12.7.2007); (b) AU2007221946 (Australia; filed\u000a      11.10.2007, granted 1.4.2010; (c) CA2448303 (Canada; filed 25.11.2003,\u000a      granted 13.7.2010); (d) CN100491362 (China; filed: 30.5.2002, granted\u000a      27.5.2009); (e) EP1392666 (Europe; filed 30.5.2002, granted 28.2.2007);\u000a      (f) HK1063788 (Hong Kong; filed 1.9.2004, granted 29.6.2007); (g)\u000a      JP4554198 (Japan; filed 30.5.2002, granted 29.9.2010); (h) KR100957260\u000a      (Korea; filed 15.1.2009, granted 12.5.2010); (i) NO324321 (Norway; filed\u000a      28.11.2003, granted 24.9.2007); (j) NZ529682 (New Zealand; filed\u000a      24.11.2003, granted 13.7.2006); (k) US7915254 (US; filed 4.4.2008, granted\u000a      29.3.2011); (l) US7855197 (US; filed 28.6.2008, granted 21.12.2010); (m)\u000a      US8188074 (US; filed 12.5.2008, granted 29.5.2012); (n) US7732439 (US;\u000a      filed 10.7.2008, granted 10.5.2010); (o) US7371744 (US; filed 26.11.2003,\u000a      granted 13.5.2006); (p) ZA200309215 (South Africa; filed 26.11.2003,\u000a      granted 25.5.2005).\u000a    B. The international PCT application WO2006032848 (J. Griffiths, S. A.\u000a      Gorman and A. L. Bell, \"Photosensitisers and Their Uses\") established a\u000a      filing date (14.9.2005) in all contracting states. It was followed up by a\u000a      range of regional and national applications, including the granted patent\u000a      US7407948 (US; filed 20.3.2007, granted 5.8.2005), which are currently\u000a      being maintained.\u000a    C. The international PCT application WO0224226 (S. B. Brown, A. L. Bell,\u000a      J. Griffiths and J. Schofield, \"Photosensitisers\") established a filing\u000a      date (21.9.2001) in all contracting states. It was followed up by a range\u000a      of regional and national applications, including the following granted\u000a      patents: (a) AU2001287915 (Australia; filed 21.9.2001, granted\u000a      24.11.2005); (b) CA2423252 (Canada; filed 20.3.2003, granted 20.1.2009);\u000a      (c) EP1320383 (Europe; filed 21.9.2001, granted 13.6.2007); (d) US7276494\u000a      (US; filed 21.3.2003, granted 2.10.2007).\u000a    D. The international PCT application WO2006032847 (S. B. Brown and C. C.\u000a      O'Grady, \"Wound Healing\") established a filing date (14.9.2005) in all\u000a      contracting states. It was followed up by a range of regional and national\u000a      applications, including the following granted patents: (a) EP1797053\u000a      (Europe; filed 15.9.2005, granted 3.11.2010); (b) JP5118967 (Japan; filed\u000a      14.9.2005, granted 16.1.2013); (c) US7407953 (US; filed 20.3.2007, granted\u000a      5.8.2005).\u000a    E. Statement, Business Development Manager, IP Group PLC, 1st\u000a      February 2013.\u000a    F. Statement, Senior Programme Manager, Photopharmica Ltd, 1st\u000a      February 2013.\u000a    G. \"Clinical Trial to Investigate Treatment With Photodynamic Therapy to\u000a      Reduce Levels of Bacteria in Leg Ulcers\", ClinicalTrials.gov identifier:\u000a      NCT825760.\u000a    H. Statement, Chief Investigator, Phase IIb clinical trial; Director,\u000a      Institute for Translation, Innovation, Methodology and Engagement,\u000a      University of Cardiff; and Head, Wound Healing Research Unit, Dept. of\u000a      Dermatology and Wound Healing, Univ of Cardiff, 29th January\u000a      2013).\u000a    I. Press releases: (a) http:\/\/www.photopharmica.com\/latest_news.htm\u000a      (accessed 4.12.12); and (b) http:\/\/www.ipgroupplc.com\/media-centre\/ip-group-news\/2011\/2011-10-05\u000a      (accessed 25.9.13). \u000a    ","Title":"\u000a    Establishment of Photopharmica Ltd. to exploit novel photosensitising\u000a      dyes as photoactivatable antibacterial therapeutics\u000a    ","UKLocation":[{"GeoNamesId":"2644688","Name":"Leeds"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    A new class of bioactive photosensitising dyes\u000a      In the mid-1990s, an interdisciplinary research collaboration at the\u000a      University of Leeds between the groups of Professor John Griffiths\u000a      (Department of Colour Chemistry then School of Chemistry) and Professor\u000a      Stan Brown (Department of Biochemistry at the time) led to the discovery\u000a      of novel photosensitising dyes that were capable of generating singlet\u000a      oxygen efficiently with (red) light of a wavelength needed for good tissue\u000a      penetration.\u000a    Recognising the potential of these dyes in photodynamic therapy (PDT),\u000a      the researchers received substantial grants from Yorkshire Cancer Research\u000a      from 1998 (&#163;3.5M, including a programme grant). PDT requires the\u000a      combination of light and a photosensitiser drug to achieve a therapeutic\u000a      effect; the mechanism involves absorption of light by the photosensitiser,\u000a      activation of molecular oxygen by the excited photosensitiser, and damage\u000a      by the resulting highly reactive singlet oxygen leading to cell death. The\u000a      need for a light source ensures that the process can be targeted precisely\u000a      to the site of disease. This funding supported research by Griffiths and\u000a      his colleagues to develop synthetic methods for the systematic preparation\u000a      of water-soluble photosensitising dyes including phenothiaziniums(1) and\u000a      phthalocyanines (2,3) In parallel with these synthetic studies, between\u000a      1996 and 2001, Brown's research group carried out experiments to evaluate\u000a      the cellular uptake and in vitro photodynamic activity of these\u000a      compounds for potential applications as anticancer or antimicrobial\u000a      agents.\u000a    The collaborative team demonstrated the value of the novel\u000a      photosensitisers as photoactivatable antimicrobial agents, and optimised\u000a      their activity. Bacteria can be classified into two broad groups - Gram\u000a      positive and Gram negative bacteria - and dangerous pathogens are found in\u000a      both classes. Although it was well known that some photosensitising dyes\u000a      were active against Gram positive bacteria, none had previously been found\u000a      active against Gram negative bacteria. The novel photosensitisers are\u000a      active against Gram negative bacteria, Gram positive bacteria (including\u000a      antibiotic resistant bacteria such as methicillin-resistant Staphylococcus\u000a        Aureus, MRSA) and fungi. Research conducted at Leeds showed that\u000a      both Gram positive and Gram negative bacteria could be killed provided\u000a      that the photosensitiser was cationic (4). Through a process of systematic\u000a      structural modification, with parallel in vitro and in vivo\u000a      screening, detailed structure-activity relationships were established.\u000a      Specific phenothiaziniums, with far superior antibacterial activities\u000a      compared to other known photosensitisers, were discovered, including the\u000a      subsequent candidate agent PPA904 (5). A crucial advantage of these\u000a      compounds, which made them suitable for treating infected tissue, was\u000a      their highly selective uptake by bacteria compared to mammalian cells.\u000a    This intellectual property was transferred to the University spin-out\u000a      company Photopharmica Limited and followed up by a range of national and\u000a      regional applications. Photopharmica was established in 2001 to continue\u000a      the clinical development of the candidate agent PPA904. The class of\u000a      photosensitising dyes were patent protected worldwide through a patent\u000a      cooperation treaty (PCT) application (5), with Brown and O'Grady as named\u000a      inventors.\u000a    Phase IIa clinical trial\u000a      The first clinical trial, funded by Photopharmica, focused on the\u000a      treatment of chronic infected leg and foot ulcers; it took place in 2004\u000a      under the `DDX' (`Doctors and Dentists Exemption') rules which allowed\u000a      clinicians to use the experimental therapy on a named patient basis. This\u000a      DDX study involved nine patients, and led to regulatory approval of a\u000a      Phase IIa clinical trial. The Phase IIa clinical trial, involving 32\u000a      patients from three centres (16 with chronic leg ulcers and 16 with\u000a      diabetic foot ulcers), was led by Professor Lesley Rhodes (University of\u000a      Manchester) and was undertaken in 2005-2007. Clinicians from Dundee,\u000a      Manchester and Leeds carried out the clinical work with support from both\u000a      Griffiths and Brown. This trial demonstrated a significant reduction of\u000a      bacterial load in patients (6).\u000a    Key personnel\u000a      Department of Colour Chemistry\/School of Chemistry Professor John\u000a      Griffiths (Lecturer 1969-81, Senior Lecturer 1981-99, Professor 1999-2004,\u000a      Research Professor (part time) 2004-12) Stephen Gorman (2001-8), Russell\u000a      Cox (1998-2000), Jack Schofield (1992-2004) (Research Fellows)\u000a    Department of Biochemistry\/Faculty of Biological Sciences\u000a      Professor Stan Brown (Professor of Biochemistry 1971-2009) David Vernon\u000a      (1995-2010), Simon Wood (1991-1996), Kirste Mellish (1998-2003), Denise\u000a      Ball (1998-1999) (Research Fellows), Andrea Bell (Technician 1998-2002,\u000a      Research Fellow 2002-10) Andrew Minnock (1991-1995), Cassandra O'Grady\u000a      (2000-3) (PhD students)\u000a    Key research grants and funding\u000a    i. \"Programme grant\", Yorkshire Cancer Research, PI: Prof. S. Brown,\u000a      1998-2003, &#163;2.3M.\u000a    ii. \"Photodynamic therapy\", Yorkshire Cancer Research, PI: Prof. S.\u000a      Brown, 1998-2005, &#163;500k.\u000a    iii. \"Lasers for photodynamic therapy\", Yorkshire Cancer Research, PI:\u000a      Prof. S. Brown, 1998-2003, &#163;150k.\u000a    iv. Yorkshire Cancer Research, PI: Prof. S. Brown, 1998-2005, &#163;500k.\u000a    v. Yorkshire Cancer Research, PI: Prof. S. Brown, 2002-2006, &#163;230k.\u000a      Grants from Yorkshire Cancer Research are awarded following extensive peer\u000a      review on a competitive basis, provided the proposed research meets\u000a      stringent quality criteria.\u000a    "},{"CaseStudyId":"6329","Continent":[{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1814991","Name":"China"}],"Funders":[],"ImpactDetails":"\u000a    The ability to predict potential significant toxicity of pharmaceutical\u000a      impurities is of vital importance to the pharmaceutical industry because\u000a      many drug candidates fail in development due to toxicity problems. Early\u000a      toxicity testing can prevent the costs associated with unnecessary R&amp;D\u000a      and the late failure of drug candidates.\u000a    Universally accepted by regulators\u000a      In 2008 the US Food and Drug Administration (FDA) published guidance on \"a\u000a        variety of ways to characterize and reduce the potential lifetime cancer\u000a        risk associated with patient exposure to genotoxic and carcinogenic\u000a        impurities both during clinical development and after approval.\"\u000a      Derek Nexus is specifically cited as a recommended prediction tool to\u000a      inform decision-making (A). Although a number of methods are mentioned\u000a      alongside Derek Nexus for this initial toxicity evaluation, in practice,\u000a      the use of Derek Nexus by large pharmaceutical companies is effectively\u000a      universal (B). In a survey of eight leading pharmaceutical companies in\u000a      2012, Derek Nexus was the method of choice for all eight companies in\u000a      assessing genotoxic risk; in half of cases, Derek Nexus was the only\u000a      commercial product used (C). An article from 2013 co-authored by\u000a      representatives from 15 companies confirms the on-going value of Derek\u000a      Nexus in the drug development process (D). Changes to guidelines have\u000a        been informed and the pharmaceutical sector has adopted\u000a      Derek Nexus as a tool for toxicology prediction.\u000a    Faster to market to increase revenues\u000a      The universal application (C,D) of the Derek Nexus system between 2008 and\u000a      2013 derives from its excellent success rate in identifying structures\u000a      that represent a genotoxicity risk and providing supporting evidence for\u000a      its assertions (C,D). The success of Derek Nexus has embedded the software\u000a      in the workflow industry-wide as a means of reducing costly and\u000a      time consuming experimental evaluation. An article co-authored by\u000a      representatives from 13 major pharmaceutical companies explains how Derek\u000a      Nexus can accelerate the development process, whilst still ensuring the\u000a      regulatory requirements to ensure patient safety are met; the article\u000a      places the success of in silico approaches (judged using the\u000a      industry-accepted negative prediction value) at 94%, which increases to\u000a      99% with interpretation by an expert user (Regulatory Toxicology and\u000a        Pharmacology, 2006, 44, 198-211).\u000a    One pharmaceutical company shared some experiences of two development\u000a      programmes that led to launched products over a 5-year period before the\u000a      industry-wide acceptance of toxicology prediction tools. In each\u000a      programme, the regulatory authorities raised concerns about the\u000a      genotoxicity profile of a low level impurity, leading to a 1-3 month delay\u000a      while the safety of the impurity was established experimentally. In each\u000a      case, a Derek Nexus-based assessment would have been negative, and would\u000a      have avoided any delay. As it was, based on a conservative estimate of the\u000a      delay (1 month) and a conservative estimate of the annual sales figure for\u000a      the launched products during their patent period of exclusivity (each\u000a      &#163;200M), the use of Derek Nexus, now embedded in current practice, would\u000a      have increased revenues by &#163;30M. If this scenario is common to all large\u000a      pharmaceutical companies, then the increased revenues across the sector\u000a      over a 5-year period (using a conservative scaling factor of five-fold)\u000a      can be estimated at &#163;150M. The Director of Computational Toxicology at\u000a      GlaxoSmithKline corroborated in 2012 that the impact of embedding\u000a      prediction tools (in particular Derek Nexus) for genotoxicity in current\u000a      practice was broadly in line with his experience and a realistic\u000a      assessment for the sector as a whole (E). The performance of a sector\u000a        was thus improved.\u000a    Reduced costs during development\u000a      The embedding of predictive toxicity tools has also had a significant\u000a        bearing on cost and resource. Each year, on average, a major\u000a      pharmaceutical company might perform 100 Derek Nexus screens on impurities\u000a      to adhere to regulatory guidelines for genotoxic impurities. Of these, a\u000a      significant proportion (&gt;50%) will generate a clean signal and, as a\u000a      result, development can proceed without further safety testing. In the\u000a      absence of a reliable predictive tool embedded in industry practice,\u000a      experimental screening would require substantial resource for synthesis,\u000a      purification, analysis and testing. Assuming an FTE rate of &#163;100K, and\u000a      applying a conservative resource requirement of 0.25 FTE-year, a cost\u000a      saving of &#163;25K per example can be estimated. Scaling for 50 clean signals\u000a      per year, and applying a conservative scaling factor for the industry of\u000a      5-fold, this corresponds to an estimated cost saving of &#163;30M over a five\u000a      year period. The Director of Computational Toxicology at GlaxoSmithKline\u000a      corroborated in 2012 that the impact of embedding toxicology prediction\u000a      tools (in particular Derek Nexus) in current practice was broadly in line\u000a      with his experience and a realistic assessment for the sector as a whole\u000a      (E).\u000a    Employment and revenue\u000a      Lhasa Ltd. is a not-for-profit company (and a registered charity) and is\u000a      responsible for the continued support of cheminformatic research\u000a      undertaken at the University of Leeds in support of its charitable aims.\u000a      There are currently 254 organisations who are members of Lhasa Ltd.,\u000a      including all of the top 20 pharmaceutical companies in the world (F).\u000a    In 2005, the research capacity supporting Lhasa Ltd's development had\u000a      grown substantially, and the staff left the employment of the University\u000a      and became employees of Lhasa Ltd. Lhasa Ltd.'s growth has accelerated\u000a      dramatically in the last five years (see Table below) (G,H). In 2012,\u000a      Lhasa Ltd. reported an annual turnover of &gt;&#163;5.4M; the Derek Nexus\u000a      system contributed 56% of turnover, with Meteor Nexus (18%) and other more\u000a      recent products based on Leeds research providing further major\u000a      contributions (G). In 2012, Lhasa Ltd. employed 71 highly qualified staff\u000a      (G). The company has therefore established its viability and generated\u000a        revenue.\u000a    Table of income and staff numbers at Lhasa Ltd., 2007-2012\u000a    \u000a      \u000a        \u000a          Year\u000a          Income (&#163;000s)\u000a          Staff\u000a        \u000a        \u000a          2007\u000a          3,0287a\u000a\u000a          51\u000a        \u000a        \u000a          2008\u000a          3,819a\u000a\u000a          58\u000a        \u000a        \u000a          2009\u000a          4,379a\u000a\u000a          59\u000a        \u000a        \u000a          2010\u000a          4,442a\u000a\u000a          61\u000a        \u000a        \u000a          2011\u000a          5,063a\u000a\u000a          69\u000a        \u000a        \u000a          2012\u000a          5,416b\u000a\u000a          71\u000a        \u000a      \u000a    \u000a    a. Audited accounts.\u000a    b. Management accounts.\u000a    The introduction of Meteor Nexus alongside Derek Nexus adds a layer of\u000a      sophistication which addresses a key gap in toxicity prediction: the\u000a      ability to predict potential metabolic routes, together with the\u000a      prediction of the toxicity of the predicted metabolites. Lhasa Ltd.'s\u000a      strategy for continued growth focuses on Meteor Nexus as a key product\u000a      alongside further development of Derek Nexus to meet the needs of\u000a      end-users in the pharmaceutical industry.\u000a    ","ImpactSummary":"\u000a    Research at the University of Leeds has underpinned the company Lhasa\u000a      Ltd. which has made widely available the toxicity prediction software\u000a      currently known as Derek Nexus. The use of Derek Nexus by large\u000a      pharmaceutical companies to support drug development is effectively\u000a      universal. Toxicology prediction software has led to changes in guidelines\u000a      issued by regulatory authorities and to industry-wide changes to the\u000a      investigation of the toxicity of trace impurities. These changes have\u000a      reduced the resources needed for experimental investigation of toxicity,\u000a      and have increased revenues derived from launched drugs by extending their\u000a      patent period of exclusivity. Lhasa Ltd. derives income in support of its\u000a      charitable aims from Derek Nexus , and a related product Meteor Nexus\u000a      (Meteor) also based on research undertaken in Leeds. The company reported\u000a      revenues over &#163;5.4M in 2012 and employs 71 highly qualified staff.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Leeds\u000a    ","Institutions":[{"AlternativeName":"Leeds (University of)","InstitutionName":"University of Leeds","PeerGroup":"A","Region":"Yorkshire And Humberside","UKPRN":10007795}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"1280737","Name":"Lhasa"}],"References":"\u000a    \u000a1. Long, A. and Combes, R.D. (1995). Using Derek to Predict the Activity\u000a      of Some Carcinogens and Mutagens Found in Foods. Toxicology in vitro,\u000a      1995, 9, 563-569. (10 citations; Source: Source: Scopus, 24\/10\/13)\u000a      http:\/\/dx.doi.org\/10.1016\/0887-2333(95)00040-F\u000a    \u000a\u000a2. Ridings, J.E., Barratt, M.D., Cary, R., Earnshaw, C.G., Eggington,\u000a      C.E., Ellis, M.K., Judson, P.N., Langowski, J.J., Marchant, C.A., Payne,\u000a      M.P., Watson, W.P. and Yih, T.D. (1996).\u000a      Computer Prediction of Possible Toxic Action From Chemical Structure &#8212; an\u000a      Update on the Derek System. Toxicology, 1996, 106, 267-279. (110\u000a      citations; Source: Scopus, 24\/10\/2013)\u000a      http:\/\/dx.doi.org\/10.1016\/0300-483X(95)03190-Q\u000a    \u000a\u000a3. Greene N; Judson PN; Langowski JJ; et al. Knowledge-based expert\u000a      systems for toxicity and metabolism prediction: Derek, StAR and Meteor\u000a      (1999) SAR and QSAR in Environmental Research Vol. 10 2-3 pp 299\u000a      (107 citations; Source: Scopus, 24\/10\/2013)\u000a      http:\/\/dx.doi.org\/10.1080\/10629369908039182\u000a    \u000a\u000a4. Tonnelier, C.A.G., Fox, J., Judson, P.N., Krause, P.J., Pappas, N. and\u000a      Patel, M. (1997). Representation of Chemical Structures in Knowledge-based\u000a      Systems: The StAR System.\u000a      Journal of Chemical Information and Computer Sciences, 1997, 37,\u000a      117-123. (11 citations; Source: Scopus, 24\/10\/2013)\u000a      http:\/\/dx.doi.org\/10.1021\/ci960094p\u000a    \u000a\u000a5. Button, W. G.; Judson, P. N.; Long, A.; Vessey, J. D. (2003). Using\u000a      Absolute and Relative Reasoning in the Prediction of the Potential\u000a      Metabolism of Xenobiotics. Journal of Chemical Information and\u000a        Computer Science, 2003, Vol. 43, No. 5, pp. 1371-1377. (39\u000a      citations; Source:\u000a      Scopus, 24\/10\/2013)\u000a      http:\/\/dx.doi.org\/10.1021\/ci0202739\u000a    \u000a\u000a6. Balmat, A-L.; Judson, P.; Long, A. and Testa, B. Predicting Drug\u000a      Metabolism &#8212; An Evaluation of the Expert System Meteor. Chemical and\u000a        Biodiversity. 2005, Vol. 2, No. 7, pp. 872-885 (42 citations;\u000a      Source: Scopus 24\/10\/13)\u000a      http:\/\/dx.doi.org\/10.1002\/cbdv.200590064.\u000a    \u000aAll papers are in internationally-leading peer-reviewed journals and are\u000a      hence &#8805;2*, but references 2, 3 and 5 are particularly highlighted to\u000a      demonstrate the quality of the underpinning research.\u000a    ","ResearchSubjectAreas":[{"Level1":"8","Level2":"1","Subject":"Artificial Intelligence and Image Processing"},{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"},{"Level1":"8","Level2":"6","Subject":"Information Systems"}],"Sources":"\u000a    A. \"Guidance for Industry Genotoxic and Carcinogenic Impurities in Drug\u000a      Substances and Products: Recommended Approaches\", U.S. Department of\u000a      Health and Human Services, Food and Drug Administration, 2008.\u000a      http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/u\u000a        cm079235.pdf\u000a    B. \"New Horizons in Predictive Toxicology: Current Status and\u000a      Application\", ed. Alan G.E. Wilson, RSC Drug Discovery Series No. 12., RSC\u000a      Publishing, Cambridge, 2012. ISBN: 978-1-84973-051-8 (Section 5, reference\u000a      5, page 91).\u000a    C. \"In silico methods combined with expert knowledge rule out mutagenic\u000a      potential of pharmaceutical impurities: An industry survey\", Regulatory\u000a      Toxicology and Pharmacology, 2012, 62, 449-455. http:\/\/dx.doi.org\/10.1016\/j.yrtph.2012.01.007.\u000a    D. \"Use of in silico systems and expert knowledge for\u000a      structure-based assessment of potentially mutagenic impurities\", Regulatory\u000a        Toxicology and Pharmacology 2013, 67, 39-52. \u000a        http:\/\/dx.doi.org\/10.1016\/j.yrtph.2013.05.001\u000a    E. Statement, Director of Computational Toxicology, GlaxoSmithKline, 11th\u000a      December 2012.\u000a    F. List of current members of the Lhasa Ltd.: http:\/\/www.lhasalimited.org\/membership\/current-members.htm\u000a      (accessed 11.9.2013).\u000a    G. Statement, CEO, Lhasa Ltd, 5thFebruary 2013.\u000a    H. Lhasa Ltd accounts, dated December 2012.\u000a    ","Title":"\u000a    Knowledge-based genotoxicity prediction tools used universally in\u000a      pharmaceutical development\u000a    ","UKLocation":[{"GeoNamesId":"2644688","Name":"Leeds"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    A heritage of chemical informatics\u000a      A long-running collaboration involving the research group of Johnson\u000a      at the University of Leeds and partners from the chemical and\u000a      pharmaceutical industries led to the establishment in 1983 of Lhasa Ltd.\u000a      (initially Lhasa UK Ltd.). This not-for-profit charity and company limited\u000a      by guarantee, in which Johnson was a Director, was initially formed to\u000a      develop tools, based on `Logic and Heuristics Applied to Synthetic\u000a      Analysis' (LHASA), that could automatically identify synthetic routes to\u000a      complex organic molecules. Lhasa Ltd. secured subscriptions from a wide\u000a      range of members from industry which was deployed by Johnson to fund\u000a      academic research at the University of Leeds.\u000a    A member of Lhasa, Schering Agrochemicals, realised that adaptations to\u000a      the LHASA approach could create a knowledge-based system to predict the\u000a      toxic hazard of organic chemicals. An early prototype known as DEREK was\u000a      developed in 1986 in collaboration between Lhasa UK Ltd. and Schering\u000a      Agrochemicals. An account of the development of the Derek prototype has\u000a      been published (Chapter 9 in \"Knowledge-Based Expert Systems in\u000a      Chemistry\", P. Judson, RSC Theoretical and Computational Chemistry Series\u000a      No. 1, RSC Publishing, Cambridge, 2009. ISBN: 978-0-85404-160-2).\u000a    Underpinning research to develop Derek Nexus into a mature system\u000a      Academic research undertaken by researchers at the University of Leeds\u000a      between 1993 and 2005 enabled DEREK (subsequently Derek for Windows and\u000a      now, Derek Nexus) to be developed into a mature system that is accepted\u000a      industry-wide.\u000a    A key study was undertaken by Long in collaboration with FRAME\u000a      (Fund for the Replacement of Animals in Medical Experiments) to evaluate\u000a      the viability of Derek's approach for toxicity prediction. Tested with a\u000a      panel of food-based carcinogens and mutagens, the potential of the system\u000a      was demonstrated, whilst also highlighting the need to enhance reliability\u000a      through exploitation of larger experimental datasets (1). This study\u000a      highlighted the accuracy and reliability of Derek for industry and drove a\u000a      new phase of the model's refinement.\u000a    Research undertaken between 1993 and 1996 led to a refined model with\u000a      improved predictive capabilities, particularly in the areas of\u000a      genotoxicity and skin sensitisation (2). This highly-cited work was\u000a      undertaken principally by Marchant, with Langowski and Judson,\u000a      and involved collaboration with industrial partners. The refinement of\u000a      rules improved substantially the ability of Derek to predict the toxicity\u000a      of compounds (3).\u000a    In addition, through expert software engineering, the interface and data\u000a      processing capabilities of the Derek tools were enhanced with a simple\u000a      graphical interface for the input of structures and display of results.\u000a      Leeds researcher Patel also led the development of a graphical\u000a      language (StAR) for the representation of generic structures within the\u000a      Derek platform (4).\u000a    Underpinning research to extend to metabolism prediction\u000a      Alongside the continued research to improve Derek, Leeds researchers Vessey,\u000a      Long, Button, Greene and Judson developed\u000a      and applied knowledge-based prediction techniques to create a\u000a      complementary system called METEOR (currently Meteor Nexus). Meteor uses a\u000a      similar rule-based approach to predict the metabolic fate of compounds.\u000a      Meteor provides a further level of sophistication to toxicity prediction\u000a      by identifying potential sites and routes of metabolism (5,6).\u000a    The underpinning research was published in leading cheminformatic and\u000a      toxicology journals and the six cited references have collectively amassed\u000a      well over 250 citations (1-6).\u000a    Key personnel\u000a      Peter Johnson, Lecturer, 1980-4 then Senior Lecturer, 1984-95 then\u000a      Professor, 1995-2004 then Research Professor, 2004-.\u000a      Anthony Long, Project Officer, 1990-2005.\u000a      Jonathan Vessey, Project Officer, 1995-2005.\u000a      William Button, Computer Scientist, 1999-2002.\u000a      Nigel Greene, Software Assistant, 1998-1999.\u000a      Mukesh Patel, Project Assistant, 1995-2005.\u000a      Carol Marchant, Project Officer, 1993-2005.\u000a      Jan Langowski, Senior Project Officer, 1986-2005.\u000a      Philip Judson, Research Fellow then Manager, 1991-1998.\u000a    "},{"CaseStudyId":"6413","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1819730","Name":"Hong Kong"},{"GeoNamesId":"2661886","Name":"Sweden"}],"Funders":["Natural Environment Research Council"],"ImpactDetails":"\u000d\u000a    According to a 2010 report of the House of Commons Environmental Audit\u000d\u000a      Committee \"Poor air quality reduces the life expectancy of everyone in\u000d\u000a        the UK by an average of 7-8 months and up to 50,000 people a year die\u000d\u000a        prematurely because of it.' Defra estimates that poor health due to\u000d\u000a      air pollution costs the UK f07e&#163;19 bn p.a. (http:\/\/www.defra.gov.uk\/environment\/quality\/air\/air-quality\/eu\/).\u000aThe\u000a      Health and Environment Alliance commented in 2013 \"For the first time,\u000d\u000a        the Global Burden of Disease assessment has ranked an environmental\u000d\u000a      [health risk] factor [outdoor air pollution] among the more\u000d\u000a        widely discussed `life-style' risk factors, such as tobacco and alcohol\"\u000d\u000a      (Lin et al, Lancet 2012, 380, 2224-60).\u000d\u000a    4.1 MCM informs policy. Action to manage and improve air quality\u000d\u000a      in the UK is largely driven by EU legislation. The 2008 ambient air\u000d\u000a      quality directive sets legally binding limits for concentrations\u000d\u000a      in outdoor air of major air pollutants that impact public health. The EU\u000d\u000a      also sets national emissions ceilings. VOC oxidation, to form ozone and\u000d\u000a      secondary particulate matter (PM), presents particular problems because of\u000d\u000a      its long range and therefore transnational nature. The Head of the Air\u000d\u000a      Quality Programme at Defra (Department for Environment, Food and Rural\u000d\u000a      Affairs) (2005-2010) (previously, Head of the Air Quality Science Unit,\u000d\u000a      Defra, 1993-2005) stated that \"The MCM formed the core of the modelling\u000d\u000a        research to inform policy related to ozone in Defra. As part of the PTM\u000d\u000a        (Photochemical Trajectory Model), and as a benchmark against which other\u000d\u000a        mechanisms were evaluated, it played a crucial role in ensuring that the\u000d\u000a        UK's policy positions were founded on the basis of the best available\u000d\u000a        science, on EU Directives such as the National Emissions Ceilings\u000d\u000a        Directive and the Solvent Emissions Directive and the UNECE `Gothenburg\u000d\u000a        Protocol'. Over the period during which Defra supported the MCM it\u000d\u000a        became a world-wide benchmark for chemical mechanisms and we in Defra\u000d\u000a        were therefore able to feel great confidence in our international\u000d\u000a        negotiations having based our positions on such excellent science\"\u000d\u000a      (A). A detailed review for Defra provides a discussion of the MCM and of\u000d\u000a      its application in policy related work (A review of the Master Chemical\u000d\u000a        Mechanism, prepared for Defra, July 2007). Developments between\u000d\u000a      2007-2009 can be found in a 2009 project report to Defra (B) that\u000d\u000a      outlines the use of the MCM to model the formation of secondary organic\u000d\u000a      particulate matter (termed \"secondary organic aerosol\" in the report).\u000d\u000a    4.2 MCM as the gold standard to benchmark atmospheric pollution\u000d\u000a        models. Because of the need to accommodate detailed atmospheric\u000d\u000a      transport, models of air pollution for policy purposes simplify the\u000d\u000a      chemistry and reduce the number of species involved to make the\u000d\u000a      atmospheric modelling more manageable. Because of its fundamental nature,\u000d\u000a      and the quality of its response to experimental evaluation, the MCM has\u000d\u000a      contributed substantially to policy applications through its use as a reference\u000d\u000a        mechanism that can be used to test the smaller, less fundamentally\u000d\u000a      based mechanisms that are used in atmospheric policy models. In their\u000d\u000a      report to Defra on modelling tools for policy applications (Review of\u000d\u000a        tools for modelling tropospheric ozone formation and assessing impacts\u000d\u000a        on human health &amp; ecosystems, Report to Defra, November 2007),\u000d\u000a      Monks et al. stated: \"the traceability of chemical schemes\" (i.e.\u000d\u000a      mechanisms) \"to an explicit basis is a more robust methodology than the\u000d\u000a        use of tuned generic schemes\" (i.e. mechanisms not directly linked\u000d\u000a      to fundamental chemistry) \"and the MCM should be used as a reference\u000d\u000a        benchmark for this process.\" The Head of the Air Quality Programme\u000d\u000a      at Defra (2005-2010) has stated that the impact of MCM has been sustained\u000d\u000a      since 2008: \"The MCM has continued to provide a benchmark or standard\u000d\u000a      against which other, simpler, mechanisms are judged. Models using these\u000d\u000a        mechanisms are in continual use within Defra to inform and evaluate\u000d\u000a        policy, as demonstrated by the revision of the UNECE\/CLRTAP 'Gothenburg'\u000d\u000a        Protocol in 2012 and the forthcoming negotiations on a revision of the\u000d\u000a        EU National Emissions Ceilings Directive later this year\" (A). This\u000d\u000a      ongoing position was confirmed in 2013 by the current Head of the Air\u000d\u000a      Quality Science and Evidence Team at Defra (A).\u000d\u000a    A similar recommendation has also been made in the United States where\u000d\u000a      the Environmental Protection Agency now considers that the MCM \"is the\u000d\u000a        `gold standard' of chemical mechanisms. Both of the chemical mechanisms\u000d\u000a        that US EPA recommends for regulatory actions since 2008 have drawn from\u000d\u000a        the mechanism sequences in MCM. If our mechanisms are consistent with\u000d\u000a        MCM, we are confident they will hold up to scrutiny\" (C).\u000d\u000a    4.3 PTM\/MCM informs policy\u000d\u000a      Section 2.2 outlined the importance of the MCM in a photochemical\u000d\u000a      trajectory model (PTM), which allowed the contribution of individual VOCs\u000d\u000a      to ozone formation in Europe and the UK to be quantified through\u000d\u000a      Photochemical Ozone Creation Potentials (POCPs). The PTM\/MCM has been used\u000d\u000a      since 2008:\u000d\u000a    \u000d\u000a      by Defra to ensure that the UK's policy positions are founded on the\u000d\u000a        basis of the best available science. This included the evaluation of\u000d\u000a        policy strategies based on VOC reactivity, implications of multiday\u000d\u000a        ozone formation in Europe and the impacts of large VOC releases from\u000d\u000a        industrial plant (A).\u000d\u000a      by the Hong Kong Environmental Protection Department to identify key\u000d\u000a        ozone precursors. \"Policy debate on the environment has been\u000d\u000a          stimulated and informed by ... research evidence using the master\u000d\u000a          chemical mechanism (MCM) as the chemical mechanism within a\u000d\u000a          photochemical trajectory model (PTM). We are currently assessing the\u000d\u000a          potential of using the MCM\/PTM model as a new tool in the development\u000d\u000a          of those policies\" (D).\u000d\u000a      by the European Solvents Industry group in 2009 (E) to highlight the\u000d\u000a        effectiveness of the Solvents Emissions Directive in reducing ozone\u000d\u000a        since 1990, while also establishing that further restrictions under the\u000d\u000a        2004\/42\/EC Directive (Paints) would not contribute to a significant\u000d\u000a        further ozone reduction in Europe.\u000d\u000a      by Derwent et al. (F) to attribute improvements in peak episodic ozone\u000d\u000a        concentrations in the UK 1990-2010 to EU Air Quality Policies. They also\u000d\u000a        established that the upward trend in the annual mean daily maximum could\u000d\u000a        be attributed to intercontinental transport of pollutants, emphasising\u000d\u000a        the need for global policies to abate ozone, as discussed by the UNECE\u000d\u000a        Task force on Hemispheric Air Pollution (G).\u000d\u000a    \u000d\u000a    ","ImpactSummary":"\u000d\u000a    Air pollution is a major health concern and government policy driver.\u000d\u000a      Leeds researchers and colleagues have developed a detailed chemical\u000d\u000a      mechanism which describes reactions in the lower atmosphere leading to the\u000d\u000a      formation of ozone and secondary particulate matter, key air pollutants.\u000d\u000a      The so-called `master chemical mechanism' (MCM) is considered the `gold\u000d\u000a      standard' and has been used by the UK government and industry groups to\u000d\u000a      inform their position on EU legislation and by the US EPA to validate and\u000d\u000a      extend their regulatory models. The Hong Kong Environmental Protection\u000d\u000a      Department has used the MCM to identify key ozone precursors and provide\u000d\u000a      evidence for abatement strategies.\u000d\u000a    ","ImpactType":"Political","Institution":"\u000d\u000a    University of Leeds\u000d\u000a    ","Institutions":[{"AlternativeName":"Leeds (University of)","InstitutionName":"University of Leeds","PeerGroup":"A","Region":"Yorkshire And Humberside","UKPRN":10007795}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"1819729","Name":"Hong Kong"},{"GeoNamesId":"2711537","Name":"Gteborg"}],"References":"\u000d\u000a    \u000a1. \"The tropospheric degradation of volatile organic compounds: A\u000d\u000a      protocol for mechanism development\", M. E. Jenkin, S. M. Saunders,\u000d\u000a      and M. J. Pilling, Atmospheric Environment, 1997, 31,\u000d\u000a      81 -104 (334 citations; Source: Scopus, 24\/10\/13) http:\/\/dx.doi.org\/10.1016\/S1352-2310(96)00105-7\u000d\u000a    \u000a\u000a2. \"Photochemical ozone creation potentials for organic compounds in\u000d\u000a      northwest Europe calculated with a master chemical mechanism\", R. G.\u000d\u000a      Derwent, M. E. Jenkin, S. M. Saunders and M. J. Pilling, Atmospheric\u000d\u000a        Environment 1998, 32, 2429-2441 (194 citations; Source: Scopus,\u000d\u000a      24\/10\/13) http:\/\/dx.doi.org\/10.1016\/S1352-2310(98)00053-3\u000d\u000a    \u000a\u000a3. \"Development of a detailed chemical mechanism (MCMv3.1) for the\u000d\u000a      atmospheric oxidation of aromatic hydrocarbons\", C. Bloss, V. Wagner,\u000d\u000a      M. E. Jenkin, R. Volkamer, W. J. Bloss, J. D. Lee, D. E. Heard, K.\u000d\u000a      Wirtz, M. Martin-Reviejo, G. Rea, J. C. Wenger and M. J. Pilling,\u000d\u000a      Atmospheric Chemistry and Physics 2005, 5, 641-664. (143\u000d\u000a      citations; Source: Scopus, 24\/10\/13) http:\/\/dx.doi.org\/10.5194\/acp-5-641-2005\u000d\u000a    \u000a\u000a4. \"Measurement of OH and HO2 in the troposphere\", D. E. Heard\u000d\u000a      and M. J. Pilling, Chem. Rev., 2003, 103, 5163 -\u000d\u000a      5198 (145 citations; Source: Scopus, 24\/10\/13) http:\/\/dx.doi.org\/10.1021\/cr020522s\u000d\u000a    \u000a\u000a5. OH and HO2 chemistry during NAMBLEX: roles of oxygenates, halogen\u000d\u000a      oxides and heterogeneous uptake R. Sommariva, W. J. Bloss,\u000d\u000a      N. Brough, N. Carslaw, M. Flynn, A.-L. Haggerstone, D. E. Heard,\u000d\u000a      J. R. Hopkins, J. D. Lee, A. C. Lewis, G. McFiggans, P. S. Monks, S. A.\u000d\u000a      Penkett, M. J. Pilling, J. M. C. Plane, K. A. Read, A. Saiz-Lopez,\u000d\u000a      A. R. Rickard, and P. I. Williams, Atmospheric Chemistry and Physics,\u000d\u000a      2006, 6, 1135 - 1153 (42 citations; Source: Scopus, 24\/10\/13)) http:\/\/dx.doi.org\/10.5194\/acp-6-1135-2006\u000d\u000a    \u000a\u000a6. \"Space-based formaldehyde measurements as constraints on volatile\u000d\u000a      organic compound emissions in east and south Asia and implications for o\u000d\u000a      zone\", T.-M. Fu, D. J. Jacob, P. I. Palmer, K. Chance, Y. X. Wang, B.\u000d\u000a      Barletta, D. R. Blake, J. C. Stanton and M. J. Pilling, Journal\u000d\u000a        of Geophysical Research: Atmospheres 2007, 112, D06312. (74\u000d\u000a      citations; Source: Scopus, 24\/10\/13)) http:\/\/dx.doi.org\/10.1029\/2006JD007853\u000d\u000a    \u000aAll Leeds researchers in bold. Citation data from web of\u000d\u000a      knowledge, accessed 03.09.2012. All papers are in internationally-leading\u000d\u000a      peer-reviewed journals and are hence &#8805;2*, but references 1-3 are\u000d\u000a      particularly highlighted by the UoA to demonstrate the quality of the\u000d\u000a      underpinning research. Reference 1 was awarded the Haagen-Smit Prize in\u000d\u000a      2010 as an \"outstanding publication\".\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"},{"Level1":"3","Level2":"7","Subject":"Theoretical and Computational Chemistry"}],"Sources":"\u000d\u000a    A. Letter, Head of the Air Quality Programme at Defra (2005-2010)\u000d\u000a      (previously, Head of the Air Quality Science Unit, Defra, 1993-2005), 19th\u000d\u000a\u0009  April 2013, and confirmation from current Head of Air Quality\u000d\u000a      Science and Evidence Team at Defra, Sep 2013. Available on request from\u000d\u000a      HEI.\u000d\u000a    B. \"Modelling of Tropospheric Ozone: Project Summary Report\", 2007-2009,\u000d\u000a      AEA, 2009. http:\/\/uk-air.defra.gov.uk\/reports\/cat05\/1003151144_ED48749_Final_Report_tropospheric_ozone_AQ0704.pdf\u000d\u000a    C. Letter, Physical Scientist and CMAQ Atmospheric Chemistry Workgroup\u000d\u000a      Lead, US Environmental Protection Agency, April 26th 2013.\u000d\u000a      Available on request from HEI\u000d\u000a    D. Letter, Senior Environmental Protection Officer, Hong Kong\u000d\u000a      Environmental Protection Department. Available on request from HEI, 22nd\u000d\u000a\u0009  April 2013. Available on request from HEI.\u000d\u000a    E. \"The Ozone Challenge\", European Solvents VOC Coordination Group, ESIG,\u000d\u000a      Februrary 2009. http:\/\/www.esig.org\/en\/regulatory-information\/ozone-modelling\u000d\u000a    F. \"Ozone in Central England: the impact of 20 years of precursor\u000d\u000a      emission controls in Europe\", R.G. Derwent, C. S. Witham, S. R. Utembe, M.\u000d\u000a      E. Jenkin and N. R. Passant, Environmental Science and Policy\u000d\u000a      2010, 13, 195-204. http:\/\/dx.doi.org\/10.1016\/j.envsci.2010.02.001\u000d\u000a    G. UNECE Task force on Hemispheric Air Pollution. Report. http:\/\/www.htap.org\/index.htm\u000d\u000a      (2010) \u000d\u000a    ","Title":"\u000d\u000a    Development of abatement strategies and policies for air pollutants\u000d\u000a      facilitated by the Master Chemical Mechanism\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2644688","Name":"Leeds"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    Ozone and particulate matter (PM) are important atmospheric pollutants.\u000d\u000a      Ozone is formed from the photo-oxidation, in the presence of nitrogen\u000d\u000a      oxides (NOx), of the large number of volatile organic compounds\u000d\u000a      (VOCs) that are emitted both naturally and from man-made sources.\u000d\u000a      Oxidation of VOCs also contributes substantially to PM formation. The master\u000a        chemical mechanism (MCM) describes these complex mechanisms\u000d\u000a      quantitatively. It is based on our current understanding of atmospheric\u000d\u000a      oxidation chemistry; is traceable to experimental measurements and\u000d\u000a      estimates of reaction rates and mechanisms; represents a synthesis of\u000d\u000a      current knowledge; and provides a web-based resource for atmospheric\u000d\u000a      chemistry modelling applications. Section 4 outlines the impact of the MCM\u000d\u000a      on the development of air quality policies in the UK and internationally.\u000d\u000a    2.1 MCM creation &#8212; synthesis of knowledge. The development of the\u000d\u000a      MCM was instigated by Dr R Derwent (Defra) in 1993 as the government\u000d\u000a      recognised that it required more understanding of how different organic\u000d\u000a      compounds in the atmosphere influence ozone formation. The project was\u000d\u000a      initiated following collaboration between Defra and Pilling on VOC\u000d\u000a      kinetics and ambient measurements of VOCs in cities. The MCM research was\u000d\u000a      co-led by Prof Mike Pilling (University of Leeds, 1989-) (mechanism\u000d\u000a      development and evaluation, website development) and Dr Mike Jenkin\u000d\u000a      (UKAEA\/AEA Technology 1981-2001, then Imperial College 2001-2008, then\u000d\u000a      Atmospheric Chemistry Services, 2008-) (protocol and mechanism\u000d\u000a      development, and application).\u000d\u000a    The mechanisms are based on a protocol (e.g. (1) from 1997), developed on\u000d\u000a      the basis of a fundamental understanding of the detailed chemistry of\u000d\u000a      atmospheric oxidation, and incorporate reaction rate and mechanism data\u000d\u000a      from laboratory experiments. The project was funded by Defra (1993-2010),\u000d\u000a      with funding for specific applications and subsequent development being\u000d\u000a      secured through research grants (Grants: NERC(i), EU (ii)). The MCM is now\u000d\u000a      supported by the National Centre for Atmospheric Chemistry (Dr Andrew\u000d\u000a      Rickard), and may be accessed via a Leeds website (http:\/\/mcm.leeds.ac.uk\/MCM\/).\u000d\u000a      In addition to representation of the mechanism, together with rate\u000d\u000a      coefficients, the website provides output for incorporation into\u000d\u000a      atmospheric models.\u000d\u000a    2.2 MCM as a basis for policy modelling. Derwent, Jenkin and the\u000d\u000a      Leeds group also developed a predictive pollution model &#8212; the\u000d\u000a      photochemical trajectory model (PTM) &#8212; published in 1998 that combines\u000d\u000a      atmospheric transport and chemical reactions (2). The PTM models ozone\u000d\u000a      formation in an air parcel, driven by winds from central Europe to the UK,\u000d\u000a      and incorporates VOC and nitrogen oxide emissions from the surface. The\u000d\u000a      MCM is a key component of the model, allowing the different contributions\u000d\u000a      to ozone formation from specific VOCs to be quantified. A new VOC\u000d\u000a      characteristic &#8212; the photochemical ozone creation potential (POCP) -\u000d\u000a      provides a relative measure of the impact of different VOCs on ozone\u000d\u000a      formation.\u000d\u000a    2.3 MCM evaluation and application. The complexity of the MCM\u000d\u000a      demands direct experimental testing of its mechanistic predictions.\u000d\u000a      Pilling has led developments in the use of atmospheric simulation chambers\u000d\u000a      to evaluate the MCM in a series of European consortia (EXACT, 1999-2002;\u000d\u000a      EUROCHAMP-1, 2004-2009; EUROCHAMP-2, 2009-2013, Integrated Infrastructures\u000d\u000a      Initiative; grants ii) (3). Experimental field measurements, coupled with\u000d\u000a      the MCM, have also been used to develop and test our understanding of\u000d\u000a      atmospheric chemistry. The construction in Leeds and application in the\u000d\u000a      field of an instrument to measure OH and HO2 radicals by\u000d\u000a      Heard,(4) and modelling of their concentrations with the MCM (e.g. (5)\u000d\u000a      published in 2006) have been central to these developments.\u000d\u000a    2.4 MCM: a validation tool for simplified models. The MCM is a\u000d\u000a      very large mechanism that is too large and complex for use in global or\u000d\u000a      even regional atmospheric models that include detailed atmospheric\u000d\u000a      transport. The MCM is however widely used to validate models of\u000d\u000a      atmospheric pollution that typically incorporate simpler, less\u000d\u000a      fundamentally based chemical mechanisms. For example, in a collaboration\u000d\u000a      between Leeds and US scientists in 2005-7, the MCM was used to evaluate\u000d\u000a      the chemical mechanism in a 3D global model, to interpret satellite\u000d\u000a      measurements of formaldehyde and to evaluate emissions of anthropogenic\u000d\u000a      and biogenic VOCs in S E Asia (6).\u000d\u000a    Key personnel\u000d\u000a      Professor Mike Pilling, Professor of Physical Chemistry, 1989-2007 and\u000d\u000a      Research Professor 2013.\u000d\u000a      Professor Dwayne Heard, University Research Fellow, 1994-2002 then Reader,\u000d\u000a      2002-4 then\u000d\u000a      Professor of Atmospheric Chemistry, 2004-.\u000d\u000a      Dr Sandra Saunders, postdoctoral researcher, 1991-2002.\u000d\u000a      Dr V Wagner, postdoctoral researcher, 1999 - 2001.\u000d\u000a      Dr Roberto Sommariva, graduate student, 2000-2004 and postdoctoral\u000d\u000a      researcher, 2011-2012.\u000d\u000a      Dr Claire Bloss, postdoctoral researcher, 2001-2003.\u000d\u000a      Dr Jenny Young (n&#233;e Stanton), graduate student, 2002-2006 and postdoctoral\u000d\u000a      researcher, 2007-.\u000d\u000a    Competitively-awarded funding following peer review\u000d\u000a    i. NERC: (a) \"Highly instrumented reactor for atmospheric chemistry,\u000d\u000a      HIRAC\", NEC513493\/1, PI: M. J. Pilling, &#163;248k, 2004-2006; (b) \"Integration\u000d\u000a      and co-development of the MCM and IUPAC databases and websites\",\u000d\u000a      NE\/E002668\/1, PI: M. J. Pilling, &#163;130k, 2006-2009; (c) \"Laboratory\u000d\u000a      measurements of photochemical and kinetic processes of atmospheric\u000d\u000a      significance\", RES20732, PI: M. J. Pilling, &#163;118k, 2003-2006.\u000d\u000a    ii. EU: (a) EXACT, PI: M. J. Pilling, 1999-2002, &#8364;176k; (b) \"Integration\u000d\u000a      of EUROpean Simulation CHAMbers for Investigating Atmospheric Processes\"\u000d\u000a      (EUROCHAMP-1), PI: M. J. Pilling, 2004- 2009, &#8364;279k; (c) \"Integration of\u000d\u000a      EUROpean Simulation CHAMbers for Investigating Atmospheric Processes\"\u000d\u000a      (EUROCHAMP-2), PI: M. J. Pilling, 2009-2013, Integrated Infrastructures\u000d\u000a      Initiative, &#8364;422k.\u000d\u000a    Note: NERC and EU grants are awarded following extensive peer review on a\u000d\u000a      competitive basis, provided the proposed research meets stringent quality\u000d\u000a      criteria.\u000d\u000a    "},{"CaseStudyId":"7260","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000d\u000a    Polar polymers such as polyesters, polyamides, polycarbonates, acrylates\u000d\u000a      and methacrylates are traditionally used in commodity applications such as\u000d\u000a      in textiles and engineering. The Warwick research was recognized by\u000d\u000a      Haddleton, Warwick Ventures Ltd and investors as having potential to\u000d\u000a      create new high-technology applications in the area of \"effect polymers\"\u000d\u000a      i.e. polymers as fine rather than bulk chemicals. Therefore the spin-out\u000d\u000a      company Warwick Effect Polymers Limited (WEP) was formed in 2001 with the\u000d\u000a      initial purpose of exploiting the new Warwick living radical\u000d\u000a      polymerization technology with end users. With a DTI SMART award, &#163;5k from\u000d\u000a      1st prize at a Cambridge Enterprise Launch Pad event and\u000d\u000a      investment from a US business angel [10] the company started trading in\u000d\u000a      2002. In 2013 WEP is still based in its own laboratories on the University\u000d\u000a      of Warwick Science Park employing 10-15 people on average [11]. The\u000d\u000a      company has also funded over 20 students and research fellows.\u000d\u000a    The relevant Warwick\/Haddleton IP was assigned to WEP, and a pipeline\u000d\u000a      agreement (2002-12) facilitated collaborative work with several companies\u000d\u000a      including Unilever, Courtaulds, ICI, BP, Geltex (Genzyme), Biocompatibles,\u000d\u000a      Syngenta, Elf AtoChem in exploiting the underpinning research. With\u000d\u000a      Unilever, for example, work on ABA triblocks led to patents relating to\u000d\u000a      personal care products which were subject to large scale customer trials\u000d\u000a      in the US and UK (2002-2006) [12] and this collaboration is ongoing (see\u000d\u000a      below). A director of a VC fund management company and private investor in\u000d\u000a      WEP (2003-2012) notes that the company \"had a strong track record of\u000d\u000a      undertaking paid research for large corporations\" [13]. During a\u000d\u000a      collaborative project the company caught the attention of a Vice President\u000d\u000a      of a multinational biotechnology company because of its \"potential for\u000d\u000a      impact in far-ranging areas\" and \"belief in the broad potential\" of WEP\u000d\u000a      technology [10] and this individual became a director and private investor\u000d\u000a      in WEP. In 2005 the company won the Lord Stafford award for best\u000d\u000a      University spin out in the West Midlands and Haddleton was awarded the RSC\u000d\u000a      Chemistry World Entrepreneur of the year. In 2013 the founder of another\u000d\u000a      VC Fund Management company described WEP as \"an exemplar of the high\u000d\u000a      quality research innovations with disruptive global potential.\" [11]\u000d\u000a    During the REF2014 period, the focus of the company was the development\u000d\u000a      of the Warwick technology in polymers for therapeutics and nanomedicine\u000d\u000a      [13]; markets that could stand the increased costs of production of\u000d\u000a      precision polymers from living radical polymerization. The pegylation and\u000d\u000a      glycopolymer work described in section 2 became a strategic activity with\u000d\u000a      the aim of improving aspects of protein, peptide and subsequently siRNA\u000d\u000a      (small interfering RNA) therapeutics- classes of biological drug. Building\u000d\u000a      on the collaboratively generated intellectual property, specific protein\u000d\u000a      and peptide therapeutics identified by biotech partners were optimised\u000d\u000a      with the new conjugation and polymerisation technology. WEP's comb\u000d\u000a      polymers (PolyPEGTM) have the advantage of \"lower viscosity\u000d\u000a      compared to conventional PEG polymer [that] is utilised to extend the in\u000a        vivo half-life of protein therapeutics by reducing the clearance\u000d\u000a      rate.\" This advantage \"has been demonstrated [in projects throughout the\u000d\u000a      REF2014 period] by WEP's partners within the pharmaceutical industry\" [14]\u000d\u000a      and was one of the key drivers for WEP's eventual acquisition (see below).\u000d\u000a    To support its R&amp;D programme, WEP received &#163;3.77M since 2001 in\u000d\u000a      venture capital funding (angel investors plus national, international and\u000d\u000a      regional venture capital trusts) [15,16] and the company now holds three\u000d\u000a      patent families for targeting polymers; \"a very important segment of\u000d\u000a      intellectual property\" [10]. As a measure of activity, total expenditure\u000d\u000a      over the REF2014 period was &#163;3.0M spread evenly over that period [15].\u000d\u000a      Since 2008, WEP has supplemented its capital investment through a\u000d\u000a      portfolio of more than 10 multi-contract projects with major companies.\u000d\u000a      For example, with Unilever, a new technology in protein conjugation of\u000d\u000a      polymers has been developed to protect human hair against damaging\u000d\u000a      treatments [17]. New synthetic glycopolymer technologies, transferred to\u000d\u000a      WEP under the pipeline agreement and developed as GlycoPolTM\u000d\u000a      and ZenoPolTM (trademarked 2009 and 2011 respectively) are\u000d\u000a      being tested by a global pharmaceuticals leader for gene delivery [14,\u000d\u000a      18].\u000d\u000a    In 2012 WEP was acquired by PolyTherics Ltd in a substantial\u000d\u000a      (undisclosed) share-for-share deal and is now a wholly owned subsidiary\u000d\u000a      still based at the Warwick Science Park. Polytherics explains that their\u000d\u000a      interest was driven by WEPs patent portfolio and the existence of \"a\u000d\u000a      number of programmes with one of the top 5 pharmaceutical companies\"\u000d\u000a      [14,19]. The deal \"brought together complementary technologies...to extend\u000d\u000a      the pharmacokinetics of biological therapeutics through polymer\u000d\u000a      conjugation\" [14]. An industry expert notes, \"the continuing evolution of\u000d\u000a      PolyPEG by large pharma companies, and the increased interest in\u000d\u000a      GlycoPol...by some of the same players, continues to validate the\u000d\u000a      strategy\" [10]. Products utilising PolyTherics and WEP technologies are\u000d\u000a      \"expected to enter clinical development in 2014 and the company will\u000d\u000a      receive milestone payments and royalties from the successful development\u000d\u000a      and commercialisation of these products\" [14]. The acquisition has thereby\u000d\u000a      allowed WEP to attain the security required for its long term partner\u000d\u000a      projects in drug delivery and development. The specialist polymer team and\u000d\u000a      laboratory continues with some PolyTherics activities relocating from\u000d\u000a      London to WEP's premises. For the Polytherics group, WEP provides the\u000d\u000a      effect polymers technology and expertise that it was established to\u000d\u000a      create.\u000d\u000a    In July 2013, following PolyTherics acquisition of WEP and Antitope Ltd,\u000d\u000a      &#163;13.5M further investment was raised from some of WEP's funders (Mercia\u000d\u000a      Fund Management and Advantage Enterprise &amp; Innovation Fund) and\u000d\u000a      Invesco Perpetual. The group now employs more than 80 staff. Revenues of\u000d\u000a      the combined Polytherics businesses exceeded &#163;8.5M last financial year\u000d\u000a      with WEP \"making an increasing contribution to revenues as more\u000d\u000a      significant licence payments are received and as the technology becomes\u000d\u000a      established.\"[14]\u000d\u000a    The underpinning research at Warwick by Haddleton and his research team\u000d\u000a      thus led to the establishment of a spin-out company that during the\u000d\u000a      REF2014 period has created a large number of jobs, attracted substantial\u000d\u000a      investment, implemented strategic industry-collaborative projects and\u000d\u000a      developed valuable intellectual property. Acquisition of WEP and its IP\u000d\u000a      portfolio by Polytherics Ltd was accompanied by substantial new investment\u000d\u000a      and forms a key part of the group's nanomedicine strategy.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Research at Warwick by Professor David Haddleton's team led to the\u000d\u000a      discovery of a new family of catalysts for living radical polymerisation.\u000d\u000a      A spin-out company, Warwick Effect Polymers Ltd (WEP), was established to\u000d\u000a      develop this research and received a total of &#163;3.77M investment.\u000d\u000a      Supplemented by income from contracts, and operating in purpose-built\u000d\u000a      laboratories on the Warwick Science Park, WEP employed 10-15 people and\u000d\u000a      spent &#163;3.0M over the REF2014 period developing a substantial patent\u000d\u000a      portfolio. WEP's commercial success and intellectual property in polymer\u000d\u000a      therapeutics and nanomedicine led to its acquisition by PolyTherics Ltd in\u000d\u000a      2012.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    University of Warwick\u000d\u000a    ","Institutions":[{"AlternativeName":"Warwick (University of)","InstitutionName":"University of Warwick","PeerGroup":"A","Region":"West Midlands","UKPRN":10007163}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    Articles\u000d\u000a    \u000a[1] Atom transfer Radical Polymerisation of MMA by Alkyl Bromide and\u000d\u000a        2-Pyridinecarbaldehyde Copper(I) Complexes, D. M. Haddleton, C. B.\u000d\u000a      Jasieczek, M. J. Hannon, A. J. Shooter, Macromolecules 1997,\u000d\u000a      30, 2190, DOI: 10.1021\/ma961074r.\u000d\u000a    \u000a\u000a[2] Monohydroxyl terminally functionalised polymethyl methacrylate\u000d\u000a        from atom transfer radical polymerisation (ATRP), D. M. Haddleton,\u000d\u000a      C. Waterson, P. J. Derrick, C. B. Jasieczek, A. J. Shooter, Chem.\u000d\u000a        Comm. 1997, 683, DOI: 10.1039\/A700677B.\u000d\u000a    \u000a\u000a[3] A new approach to bioconjugates for proteins and peptides\u000d\u000a        (\"pegylation\") utilising living radical polymerization, F. Lecolley,\u000d\u000a      L. Tao, G. Mantovani, I. Durkin, S. Lautru, D. M. Haddleton, Chem.\u000d\u000a        Comm. 2004, 18, 2026-2027, DOI: 10.1039\/B407712A.\u000d\u000a    \u000a\u000a[4] Alpha-aldehyde Terminally Functional Methacrylic Polymers from\u000d\u000a        Living Radical Polymerization: Application in Protein Conjugation\u000d\u000a        \"Pegylation\", L. Tao, G. Mantovani, F. Lecolley, D. M. Haddleton, J.\u000a        Am. Chem. Soc. 2004, 126, 13220-13221, DOI: 10.1021\/ja0456454.\u000d\u000a    \u000a\u000a[5] Design and Synthesis of N-Maleimido-Functionalized Hydrophilic\u000d\u000a        Polymers via Copper-Mediated Living Radical Polymerization: A Suitable\u000d\u000a        Alternative to PEGylation Chemistry. G. Mantovani, F. Lecolley, L.\u000d\u000a      Tao, D. M. Haddleton, J. Clerx, J. J. L. M. Cornelissen, K. Velonia, J.\u000a        Am. Chem. Soc. 2005, 127, 2966-2973, DOI: 10.1021\/ja0430999.\u000d\u000a    \u000a\u000a[6] Synthesis of Neoglycopolymers by a Combination of \"Click\u000d\u000a        Chemistry\" and Living Radical Polymerization. V. Ladmiral, G.\u000d\u000a      Mantovani, G. J. Clarkson, S. Cauet, J. L. Irwin, D. M. Haddleton, J.\u000d\u000a        Am. Chem. Soc. 2006, 128, 4823-4830, DOI: 10.1021\/ja058364k.\u000d\u000a    \u000aResearch Council grants\u000d\u000a    [7] Living Free Radical Polymerisation, EPSRC (GR\/K04606),\u000a      Oct 1994 - Sep 1996, &#163;80,612.\u000d\u000a    [8] Synthesis and Role in Atom Transfer Chemistry, EPSRC (GR\/K90364),\u000a      Oct 1996 - Sep 1998, &#163;87,052.\u000d\u000a    [9] Atom transfer living free radical polymerisation, EPSRC (GR\/L10314),\u000a      Oct 1996 - Sep 1998, &#163;88,433.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"3","Subject":"Macromolecular and Materials Chemistry"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"7","Subject":"Theoretical and Computational Chemistry"}],"Sources":"\u000d\u000a    [10] Vice President of a multinational biotech company; statement dated\u000d\u000a      June 27th 2013.\u000d\u000a    [11] Mercia Fund Management; statement dated 20 June 2013.\u000d\u000a    [12] Unilever; statement dated 24 June 2013.\u000d\u000a    [13] Longwall Ventures; statement dated 21 June 2013.\u000d\u000a    [14] Polytherics Ltd; statement dated 02 Sept 2013.\u000d\u000a    [15] FAME report, Warwick Effect Polymers Limited, registered number\u000d\u000a      04182449. Retrieved 24 Sept 2013 (available on request).\u000d\u000a    [16] Press release: 31 March 2009 (Catapult Venture Managers Limited,\u000d\u000a      Mercia Technology Seed Fund, WEP), Warwick Effect Polymers raises &#163;2\u000d\u000a        million in investment (contains summary of historical investments),\u000d\u000a      web\u000a        link.\u000d\u000a    [17] Patent WO2011\/134785, Hair care composition (Unilever Plc,\u000d\u000a      priority date Apr 28, 2010) https:\/\/www.google.com\/patents\/WO2011134785A3.\u000d\u000a    [18] Patent WO2011007133, Polymer modified macromolecules (WEP\u000d\u000a      Ltd, priority date Jul 13, 2009)\u000d\u000a      https:\/\/www.google.com\/patents\/WO2011007133A3.\u000d\u000a    [19] Press release: 15 Oct 2012 (Polytherics), PolyTherics expands\u000d\u000a        collaboration with a top five pharmaceutical company to enhance the\u000d\u000a        clinical properties of biopharmaceuticals using PolyPEG, web\u000a        link. \u000d\u000a    ","Title":"\u000d\u000a    Warwick Effect Polymers Ltd\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2643743","Name":"London"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    A family of pyridine imine and diazabutadiene copper catalysts for living\u000d\u000a      radical polymerization were discovered by Professor David Haddleton and\u000d\u000a      his research team at Warwick [1]. A key design feature of these catalysts\u000d\u000a      is that they stabilise Cu(I) relative to Cu(II) allowing control over the\u000d\u000a      equilibrium position of the key reaction step - radical chain-end\u000d\u000a      formation. The concentration of radicals is thus controlled, preventing\u000d\u000a      termination by radical-radical reaction events, and the result is a\u000d\u000a      so-called living polymerization. In particular the method was unusually\u000d\u000a      successful with methacrylate (as opposed to acrylate) monomers. Funded by\u000d\u000a      the EPSRC [7-9] and others, over 100 papers have been published by\u000d\u000a      Haddleton and group in this area.\u000d\u000a    This Warwick living radical polymerization catalysis is generally\u000d\u000a      unaffected by the presence of functional groups either in the monomer or\u000d\u000a      the initiator from which the polymer grows. The use of new classes of\u000d\u000a      functionalized initiator was thereby feasible. A range of hydroxy\u000d\u000a      functionalized polymers from standard condensation and ring opening\u000d\u000a      polymerizations were shown to provide useful macro-initiators providing a\u000d\u000a      facile route to AB and ABA block copolymers. These gave new combinations\u000d\u000a      of functional properties in the polymers, such as adhesion, pH\u000d\u000a      sensitivity, thermal response and hydrophobicity\/hydrophilicity [2].\u000d\u000a    Pegylation - the covalent attachment of poly(ethylene glycol) groups to\u000d\u000a      active pharmaceutical ingredients - was a topical strategy in the early\u000d\u000a      2000s for improvement of drug delivery and pharmacokinetics. Warwick's\u000d\u000a      catalyst technology could provide many new hydrophilic and functional\u000d\u000a      polymer conjugates with highly tuneable properties via living radical\u000d\u000a      polymerization processes. It was further realized that one of the\u000d\u000a      deficiencies of conventional single-site pegylation is that, as the\u000d\u000a      molecular weight of the PEG is increased, clearance from the body becomes\u000d\u000a      a problem. Ranges of new polymers with comb-like architectures and\u000d\u000a      cleavable ester groups were thus developed for this application [3,4,5].\u000d\u000a      Among the advantages of these new systems are that viscosity is\u000d\u000a      essentially independent of molecular weight (allowing clearance from the\u000d\u000a      body), and that there is a low tendency to crystallise, thus reducing\u000d\u000a      damage to liver, spleen and brain [3,4].\u000d\u000a    The work was expanded by Haddleton and group to the preparation of\u000d\u000a      synthetic glycopolymers from functional initiators for bioconjugation. The\u000d\u000a      approach used was to add simple sugars to a preformed polymer backbone\u000d\u000a      facilitating the synthesis of the glycopolymers and exploiting the\u000d\u000a      glyco-cluster effect; enhanced binding and lectin (carbohydrate-binding\u000d\u000a      protein) recognition as a result of proximity of a number of sugar units.\u000d\u000a      The majority of this research was conducted with salmon calcitonin - a\u000d\u000a      clinical drug for osteoporosis. This work proved to be a landmark with\u000d\u000a      many research groups and companies now looking at synthetic glycopolymers\u000d\u000a      for a range of glycocode applications; Haddleton's first publication on\u000d\u000a      the subject in 2006 has received &gt;340 citations to date [6].\u000d\u000a    "},{"CaseStudyId":"7262","Continent":[{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6252001","Name":"United States"}],"Funders":[],"ImpactDetails":"\u000d\u000a    During the EPSRC's 2009 Chemistry International Review, a senior officer\u000d\u000a      of the Index Ventures- backed company Funxional Therapeutics Ltd with a\u000d\u000a      substantial track record in the `biotech' industry described the company's\u000d\u000a      interaction with Fox at Warwick as \"the life-blood of FXT\" [5]. In the\u000d\u000a      period 2006-13 the Fox group at Warwick has been the de facto\u000d\u000a      chemistry group for FXT and was involved in all aspects of medicinal\u000d\u000a      chemistry and biological investigation; exploratory synthesis,\u000d\u000a      lead-optimisation, compound selection and preclinical chemical development\u000d\u000a      [6]. The identification of FX125L as the lead candidate, underpinned by\u000d\u000a      the continuing confidence borne of the medicinal and biological mechanism\u000d\u000a      research at Warwick [1-4] led to FXT's decision to push FX125L into\u000d\u000a      clinical trials [5,7] and, \"made the key chemistry contribution to the\u000d\u000a      success of this programme\" [6].\u000d\u000a    In 2008 Fox acted on behalf of FXT as lead chemistry consultant for the\u000d\u000a      synthesis of multiple kilograms of FX125L. The synthetic route developed\u000d\u000a      at Warwick (see Section 2) was transferred to a contract research\u000d\u000a      organisation employed by FXT. Fox subsequently provided the scientific\u000d\u000a      direction and substantial new experimental input, and, \"convincingly\u000d\u000a      solved several problems that emerged during scale-up\" [6] including\u000d\u000a      unwanted racemisation and the suspected crystallisation of FX125L as\u000d\u000a      different polymorphs. As part of the consultancy, analytical standards\u000d\u000a      were also developed at Warwick to test the long-term chemical and\u000d\u000a      stereochemical stability of FX125L [5]. A second Funxional Therapeutics\u000d\u000a      senior officer states that, \"the underpinning work commissioned by FXT at\u000d\u000a      Warwick was used in the initiation of clinical trials,\" and following the\u000d\u000a      FDA approved Investigational New Drug (IND) application of FX125L for the\u000d\u000a      treatment of asthma (January 2009) and access to large quantities of pure\u000d\u000a      FX125L from the Warwick route, Phase 1 trials were started [8]. Studies in\u000d\u000a      an animal model of allergic asthma quickly showed that FX125L exhibits a\u000d\u000a      superior efficacy profile to dexamethasone or montelucast [9].\u000d\u000a    As part of Phase 1 trials, 66 healthy participants in the USA received a\u000d\u000a      wide range of doses (0.03 mg to 3 g of FX125L), and the study was\u000d\u000a      completed in July 2009. FX125L was safe and well tolerated at all dose\u000d\u000a      levels. No serious adverse events or patient withdrawal were observed\u000d\u000a      [10]. The pharmacokinetic profile of FX125L was linear over the wide range\u000d\u000a      of doses studied, which led to the development of a convenient once-daily\u000d\u000a      oral dosing regimen. \"The results in humans are consistent with the\u000d\u000a      preclinical data, suggesting that FX125L has a very wide safety margin,\u000d\u000a      and confirmed the excellent drug-like profile of FX125L\" [8].\u000d\u000a    In January 2010 a second Phase 1 study in which US patients received\u000d\u000a      multiple ascending doses was completed and the results were \"entirely\u000d\u000a      consistent with those of the single dose study and confirmed the excellent\u000d\u000a      drug-like profile of FX125L\" [11].\u000d\u000a    Phase 2 clinical trials studying the effects of FX125L on asthma, COPD,\u000d\u000a      rheumatoid arthritis and psoriasis were announced [11] and in May 2010,\u000d\u000a      FXT reported that it had raised &#8364;10M in a private Series B financing round\u000d\u000a      to fund these initial Phase 2 clinical studies in inflammatory disease\u000d\u000a      [12].\u000d\u000a    FXT have stated that as a result of the underpinning Warwick research\u000d\u000a      \"FX125L has optimal CMC (chemistry, manufacturing and controls)\u000d\u000a      characteristics and is obtained by a straightforward 3-step chemical\u000d\u000a      synthesis with an extremely low cost of goods\" [5,7]. In addition FX125L\u000d\u000a      was described as an \"ideal pharmaceutical\" by potential large\u000d\u000a      pharmaceutical firm investors [5]. The collaboration with\u000d\u000a      Warwick was therefore vital for the success of Phase 1 clinical trials and\u000d\u000a      the continuing funding and progress of Phase 2 trials [5,6].\u000d\u000a    In July 2012 Boehringer Ingelheim and Funxional Therapeutics announced\u000d\u000a      acquisition by the former of FX125L and the somatotaxin portfolio to treat\u000d\u000a      inflammation. This sale generated an undisclosed multi-million pound\u000d\u000a      return for FXT and its investors [13]. \"The confidence that Funxional was\u000d\u000a      thereby able to create in the synthetic route and analytical standards,\u000d\u000a      alongside the novel and highly favourable performance of the drug,\u000d\u000a      underpinned BI's decision to acquire FX125L and the somatotaxin portfolio\"\u000d\u000a      [6].\u000d\u000a    The Warwick research thus provided the synthetic and medicinal chemistry\u000d\u000a      that allowed phase 1 and phase 2 clinical trials in humans and underpinned\u000d\u000a      investor confidence. This led to substantial economic impact in the\u000d\u000a      pharmaceutical industry and will lead to important health impacts in a\u000d\u000a      disease area that affects the majority of families. The success of FX125L\u000d\u000a      and the identification of the SSTR2 as its molecular target has led to\u000d\u000a      Index Ventures employment of Fox as their lead medicinal chemist in their\u000d\u000a      new biotech companies E3Bio Ltd and Purple Pharmaceuticals Ltd [5].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    A new anti-inflammatory molecule FX125L was developed by David Fox at\u000d\u000a      Warwick, in collaboration with David Grainger (Department of Medicine,\u000d\u000a      Cambridge) and Funxional Therapeutics Ltd (FXT). Research in lead\u000d\u000a      optimization, mechanistic preclinical chemistry, synthetic route\u000d\u000a      development (for scale-up), and CMC (chemistry, manufacturing and\u000d\u000a      controls) was conducted at Warwick. As a result FX125L completed Phase 1\u000d\u000a      and entered Phase 2 clinical trials in humans for the treatment of asthma\u000d\u000a      or other inflammatory diseases. Its sale to Boehringer Ingelheim generated\u000d\u000a      a multi-million pound return for FXT and its investors.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    University of Warwick\u000d\u000a    ","Institutions":[{"AlternativeName":"Warwick (University of)","InstitutionName":"University of Warwick","PeerGroup":"A","Region":"West Midlands","UKPRN":10007163}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    \u000a[1] D. J. Grainger (Cambridge) and D. J. Fox (Coventry), Anti-inflammatory\u000a        composition comprising\u000d\u000a        3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one\u000d\u000a      US200900364862009, priority date 02 Aug 2007, http:\/\/www.google.com\/patents\/US20090036486.\u000d\u000a      This compound selection patent presents a great deal of detailed\u000d\u000a      information as required by patent granting bodies (here the USPTO) in\u000d\u000a      order to allow protection of a specific compound that was included within\u000d\u000a      a previous patent application without being synthesised. This class of\u000d\u000a      patent application comes under extremely close scrutiny as it effectively\u000d\u000a      extends the patent coverage for the compound. It was granted because the\u000d\u000a      specific named compound 3-(2',2'-\u000d\u000a        dimethylpropanoylamino)-tetrahydropyridin-2-one possesses unexpected\u000d\u000a      and non-obviously- predictable, highly desirable pharmaceutical properties\u000d\u000a      that other members of the general class do not. This work will be\u000d\u000a      re-published in a journal once the structure can be revealed.\u000d\u000a    \u000a\u000a[2] D. J. Grainger (Cambridge) and D. J. Fox (Coventry), Anti-inflammatory\u000a        agents WO 2011154696 2011, priority date 08 June 2010. http:\/\/www.google.com\/patents\/WO2011154696A1.\u000d\u000a      This patent describes the use of arenecarbonylamino-lactams as `back-up'\u000d\u000a      compounds for FX125L some of which are even more potent than FX125L but\u000d\u000a      are further behind in clinical development.\u000d\u000a    \u000a\u000a[3] D. J. Grainger (Cambridge) and D. J. Fox (Coventry), Anti-inflammatory\u000a        agents WO 2011154695 2011, priority date 08 Jun 2010, http:\/\/www.google.com\/patents\/WO2011154695A1.\u000d\u000a      This patent describes the use of arenesulfonylamino-lactams as `back-up'\u000d\u000a      compounds for FX125L some of which are even more potent than FX125L but\u000d\u000a      are further behind in clinical development.\u000d\u000a    \u000a\u000a[4] Royall, Sophie C. (2012) Anti-inflammatory SSTR2 ligands.\u000d\u000a      PhD thesis, University of Warwick. http:\/\/wrap.warwick.ac.uk\/51776\/.\u000d\u000a      Once necessary IP restrictions are lifted - see ref [1] - publications\u000d\u000a      will follow.\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"15","Subject":"Pharmacology and Pharmaceutical Sciences"},{"Level1":"11","Level2":"7","Subject":"Immunology"},{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"}],"Sources":"\u000d\u000a    [5] Senior officer #1, Funxional Therapeutics Ltd; statement 23 Sept\u000d\u000a      2013.\u000d\u000a    [6] Senior officer #2, Funxional Therapeutics Ltd; statement 25 Sept\u000d\u000a      2013.\u000d\u000a    [7] Funxional Therapeutics Ltd website on FX125L, web\u000a        link, retrieved 20 June 2013.\u000d\u000a    [8] Funxional Therapeutics Ltd press release 08 July 2009, web\u000a        link.\u000d\u000a    [9] FX125L, a novel small molecule chemokine inhibitor, attenuates\u000d\u000a        neutrophil accumulation in a model of allergic asthma and exhibits a\u000d\u000a        superior efficacy profile to dexamethasone or monteleukast, J.\u000d\u000a      Reckless, V. Piercy, K. Langley, I. Purvis, D. Fox, D. Grainger, Allergy,\u000d\u000a      64 (s90), 539-550, DOI: 10.1111\/j.1398-9995.2009.02077.x.\u000d\u000a    [10] First clinical experience with FX125L, an anti-inflammatory oral\u000d\u000a        small molecule with an entirely novel mechanism of action, P.\u000d\u000a      Wieser, R. Cooper, L. Wang-Smith, J. Reckless, K.J. Champion, V.\u000d\u000a      Petrolese, D. Grainger, Ann. Allergy Asthma Immunol. 2009; 103[5]\u000d\u000a      [suppl 3]: abstract 5] http:\/\/dx.doi.org\/10.1016\/S1081-1206(10)60675-8\u000d\u000a    [11] Funxional Therapeutics Ltd press release 08 Jan 2010, web\u000a        link.\u000d\u000a    [12] Funxional Therapeutics Ltd press release 26 May 2010, web\u000a        link.\u000d\u000a    [13] Funxional Therapeutics Ltd\/Boehringer Ingelheim press release 23\u000d\u000a      July 2012, web\u000a        link. \u000d\u000a    ","Title":"\u000d\u000a    An anti-inflammatory molecule for the pharmaceutical industry\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    Warwick research has underpinned the development of a potent\u000d\u000a      anti-inflammatory drug for oral administration in a disease area where,\u000d\u000a      according Transparency Market Research (2013) the market will reach $27Bn\u000d\u000a      in 2017. This includes a wide range of disorders including asthma, chronic\u000d\u000a      obstructive pulmonary disease, rheumatoid arthritis, inflammatory bowel\u000d\u000a      disease, psoriasis and acne.\u000d\u000a    Beginning in 2006, Dr David Fox (Assistant then Associate Professor at\u000d\u000a      Warwick) worked with `biotech' SME Funxional Therapeutics Ltd to identify\u000d\u000a      and develop a lead clinical candidate from a ca 150 molecule\u000d\u000a      library of Broad-Spectrum Chemokine Inhibitors (BSCIs) for the treatment\u000d\u000a      of inflammatory disease. Fox had previously synthesised these compounds in\u000d\u000a      Cambridge (Fox et al., J. Med. Chem. 2009, 52,\u000d\u000a      3591). Significant funding to support the Warwick work (&#163;411K) came from\u000d\u000a      FXT, supporting four PhD students (alongside university funding) and two\u000d\u000a      research assistants. On the basis of biological data from the research\u000d\u000a      group of David Grainger (Department of Medicine, Cambridge and FXT), an\u000d\u000a      analysis of the IP position and an assessment of synthetic tractability,\u000d\u000a      Fox created a short list of compounds. Fox and his research team\u000d\u000a      determined structure activity relationships within the library and added a\u000d\u000a      further ca 150 pure compounds made at Warwick, evaluating the\u000d\u000a      particular advantages and disadvantages of various substructures (e.g.\u000d\u000a      lactam ring size and side chain branching) [1]. The short-listed molecules\u000d\u000a      were tested in collaboration with Funxional Therapeutics in a range of\u000d\u000a      preclinical experiments to determine their ADMET (absorption,\u000d\u000a      distribution, metabolism, excretion and toxicity) properties and in\u000d\u000a        vitro and in vivo efficacy. Fox and Grainger analysed these\u000d\u000a      results and two potential candidates were selected; FX97L and FX125L.\u000d\u000a      While both compounds contained the same 2,2-dimethylpropionylamino\u000d\u000a      sidechain, Fox developed at Warwick a new and highly efficient one-pot,\u000d\u000a      three step synthesis of the piperidinone FX125L as a single enantiomer.\u000d\u000a      This was a far easier process than that required for the synthesis of the\u000d\u000a      enantiomerically pure seven-membered ring of FX97L and was subsequently\u000d\u000a      taken forward. The results of all this research were published as a highly\u000d\u000a      detailed patent incorporating extensive data [1]. While the structure of\u000d\u000a      the chemical compound that is FX125L has thus been published, it has not\u000d\u000a      been explicitly labelled as such for reasons of commercial sensitivity and\u000d\u000a      in accord to the wishes of Funxional Therapeutics Ltd.\u000d\u000a    The identification of FX125L as a potential anti-inflammatory clinical\u000d\u000a      candidate prompted Fox and group to design and synthesise new classes of\u000d\u000a      both arylcarbonylamino- and arylsulfonylamino- lactams as back-up drug\u000d\u000a      candidates. Various arene substitution patterns were investigated\u000d\u000a      including fluoro and trifluoromethyl substitutions, and various of the\u000d\u000a      compounds were found to have potencies in an in vitro cell\u000d\u000a      migration assay equivalent or better than FX125L (in collaboration with\u000d\u000a      Grainger). Two patent applications concerning the use of these compounds\u000d\u000a      as anti-inflammatory agents have been published [2,3].\u000d\u000a    The proposal from Grainger that the biological target of BSCIs is the\u000d\u000a      somatostatin G protein coupled receptor SSTR2, prompted Fox and group to\u000d\u000a      design and synthesise hybrid lactam containing compounds and traditional\u000d\u000a      non-lactam SSTR2 agonists and antagonists [4]. This resulted in\u000d\u000a      development of a `split binding' or allosteric model for the active site\u000d\u000a      of SSTR2 (i.e. that both somatostatin and FX125L can induce receptor\u000d\u000a      signalling). It was also determined that some non-lactam derivatives can\u000d\u000a      act as cell migration inhibitors [4]. This research suggests that the\u000d\u000a      biochemistry of somatostain is far more complex than previously thought.\u000d\u000a      The activity of these peptide analogues (i.e. that both series act as\u000d\u000a      BSCIs) strongly supported the first-in-class status of FX125L, boosting\u000d\u000a      investor confidence (Section 4).\u000d\u000a    "},{"CaseStudyId":"7263","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"3175395","Name":"Italy"},{"GeoNamesId":"3190538","Name":"Slovenia"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"2750405","Name":"Netherlands"},{"GeoNamesId":"2921044","Name":"Germany"},{"GeoNamesId":"1814991","Name":"China"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"1861060","Name":"Japan"},{"GeoNamesId":"2661886","Name":"Sweden"}],"Funders":["Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000a    Catalytic hydrogenation is a pivotal chemical transformation which\u000a      underpins the synthesis of numerous high-value target molecules, materials\u000a      and intermediates. Wills tethered catalysts &#8212; invented at Warwick and\u000a      commercialized by collaborators and competitor businesses &#8212; have been\u000a      shown to have significant commercial advantages over the Noyori system. A\u000a      rapidly growing number of impacts are reported here with commercial\u000a      catalyst producers, suppliers and pharmaceutical companies in several\u000a      countries.\u000a    Commercialisation of the `tethered' catalysts by Johnson Matthey\u000a    The Wills catalyst was tested by Johnson Matthey Catalysis and Chiral\u000a      Technologies (JM CCT) and the system \"emerged [...] as the only transfer\u000a      hydrogenation catalysts providing activity on the difficult substrate\u000a      under study\" and offering \"remarkably increased activity when compared to\u000a      previous generations of catalysts while retaining high enantioselectivity\"\u000a      [10]. A team of nine inventors worked at JM CCT on a scalable synthetic\u000a      route to the catalysts, which was later demonstrated on multi-100s gram\u000a      scale and kg-scale at Alfa Aesar; a Johnson Matthey company [10]. A patent\u000a      was filed in 2009 [11].\u000a    Since 2009 JM CCT &#8212; through Alfa Aesar, SigmaAldrich and Strem &#8212; has sold\u000a      four Wills tethered catalysts in the family, either individually or as a\u000a      part of a `kit' (catalogue prices &#163;368-&#163;560 per gram). JM CCT also uses\u000a      the material in collaborative projects with client companies worldwide\u000a      [10].\u000a    While specific details of JM CCT customers and sales are confidential,\u000a      they state that Wills catalysts have been made (2009 &#8212; June 2013) \"on\u000a      multi Kg scale for several international customers involved in the\u000a      production of pharmaceutical intermediates\" [10]. JM CCT also states that\u000a      \"1 kg of catalyst may be sufficient for making tonnes of a particular\u000a      target\" [10]. The catalysts are used in large scale processes.\u000a    Use of Wills catalysts by pharmaceutical companies in research, scale-up and production\u000a    A large number of pharmaceutical and related companies have used the\u000a      catalysts in the synthesis of target molecules, as evidenced below, with\u000a      several quoting the use of the JM CCT supplier, and all describing\u000a      specific Wills catalysts or directly citing Wills papers. The Wills\u000a      catalyst system is readily available and easy to apply.\u000a      Enantioselectivity, functional group tolerance and catalyst stability are\u000a      all more favourable than in the untethered Noyori system. Hence, there has\u000a      been rapid take-up of the catalysts by industry. The examples below almost\u000a      certainly represent a small proportion of the number of actual uses,\u000a      patents, and the economic and healthcare impacts of the Warwick research.\u000a    \u000a      AstraZeneca (Sweden &amp; UK), one of the largest pharmaceutical\u000a        companies in the world, describes in a process patent the use of (S,S)-teth-TsDpen-RuCl\u000a        (a JM CCT trade name for a Wills catalyst) in the catalytic asymmetric\u000a        synthesis of a class of anti-asthmatic bronchodilator drugs [12].\u000a      Synthon BV (Netherlands) report the use of a Wills catalyst in the key\u000a        chirality-inducing reduction step in their synthesis of the\u000a        anti-asthmatic drug montelukast (singulair), a drug which in 2010 was\u000a        the fourth most prescribed drug in the US (24.7 M). They conclude, \"It\u000a        has now been discovered that the use of [Wills catalyst] can provide a\u000a        more suitable process for the asymmetric transfer hydrogenation\u000a        reaction\" [13].\u000a      Archimica GMBH (Germany) patented the use of a Wills tethered catalyst\u000a        in the key chirality-generating step of their synthesis of the third\u000a        generation antiepileptic drug Eslicarbazepine [14].\u000a      Boehringer Ingelheim (Germany), one of the largest pharmaceutical\u000a        companies in the world, describe their route to certain chemokine\u000a        inhibitors via the reduction of an early-stage intermediate using a\u000a        Wills tethered catalyst [15].\u000a      Lek Pharmaceuticals (Slovenia), part of the Sandoz group, has reported\u000a        an improved process for the preparation of intermediates on route to\u000a        non-steroidal selective estrogen receptor modulators such as\u000a        lasofoxifene using the Wills catalyst [16].\u000a      In collaboration with Eli Lilly (USA), one of the largest\u000a        pharmaceutical companies in the world, JM CCT have developed an achiral\u000a        version of the Wills tethered catalysts and have applied this to racemic\u000a        reductions [10].\u000a    \u000a    Additional examples from a rapidly growing list further demonstrate the\u000a      international commercial reach of the Wills catalysts, in e.g. China\u000a      (Hunan Fangsheng Pharma, patent CN102978253A), USA (Ambit Biosciences,\u000a      patent US2012053193A1) and Italy (Zach Systems\/Zambon Chemicals, patent\u000a      WO2012120086).\u000a    Commercialisation of Wills tether catalysts by others\u000a    With Dr Reddys Ltd (DRL), the Wills group investigated the development of\u000a      a further class of tethered catalyst containing an ether linkage (2007-11)\u000a      [17]. At this time another industrial lab (Takasago, Japan) disclosed work\u000a      on this specific variant [18] and this tethered catalyst has subsequently\u000a      been commercialised by Takasago under the trade name DENEB [19]. A\u000a      representative of DRL notes in respect of this commercialisation,\u000a      \"Takasago have clearly invested a great deal of funding in DENEB\" [17].\u000a    Further companies have developed catalysts that use the Wills tether\u000a      concept: a nitrogen atom tether system was reported by PhosPhoenix SARL\u000a      researchers (Org. Lett. 2013, 15, 1614-1617); a\u000a      polymer-supported version of a Wills tethered catalysts was commercialised\u000a      by PolyAn [20].\u000a    Continuing research at Warwick and commercial collaboration with JM\u000a          CCT\u000a    JM CCT recognized the commercial need for the use of dihydrogen as the\u000a      primary reducing agent and will develop this area with Wills through a\u000a      TSB-funded collaborative grant Development of the future generation of\u000a        catalysts for asymmetric reduction (TSB ref: 101330, Mar 2013, &#163;216k\u000a      plus &#163;108K from JM CCT), extending the range of catalysts and their\u000a      applications. In a further development, a new synthetic route to the Wills\u000a      catalysts and novel variants is the subject of a patent application filed\u000a      by Warwick (UK patent application 1219716.6, 02 Nov 2012;\u000a      PCT\/GB2013\/05286901, 01 Nov 2013); licensing negotiations are ongoing.\u000a    The Wills catalyst class has thus had very significant impact in a\u000a      critical chemical transformation practised very frequently in a major\u000a      global industry and leading to high value products on a large scale. The\u000a      Warwick research also underpinned the development and commercialisation of\u000a      competitor catalysts of the same essential design. As noted by JM CCT,\u000a      Warwick Chemistry has, \"provided modern catalysis with a truly powerful\u000a      synthetic tool\".\u000a    ","ImpactSummary":"\u000a    A process for the commercial production of a family of Warwick-invented\u000a      organometallic catalysts has been developed and patented by Johnson\u000a      Matthey (JM). The catalysts &#8212; which have been sold internationally to\u000a      several fine chemical and pharmaceutical companies in kilogram quantities,\u000a      capable of producing tonnes of product &#8212; are in widespread industrial use\u000a      for synthesis and scale-up. Other companies have protected, and are\u000a      marketing, similar `copycat' catalysts. JM continues to work in\u000a      collaboration with Warwick Chemistry on the next generation of catalysts.\u000a    ","ImpactType":"Technological","Institution":"\u000a    The University of Warwick\u000a    ","Institutions":[{"AlternativeName":"Warwick (University of)","InstitutionName":"University of Warwick","PeerGroup":"A","Region":"West Midlands","UKPRN":10007163}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"1806691","Name":"Hunan Sheng"}],"References":"\u000a    \u000a[1] A New Class of `Tethered' Ruthenium(II) Catalysts for Asymmetric\u000a        Transfer Hydrogenation Reactions, J. Hannedouche, G. J. Clarkson and\u000a      M. Wills; J. Am. Chem. Soc. 2004, 126, 986-987,\u000a      DOI: 10.1021\/ja0392768.\u000a    \u000a\u000a[2] A Class of Ruthenium(II) catalyst for Asymmetric Transfer\u000a        Hydrogenations of Ketones; A. M. Hayes, D. J. Morris, G. J. Clarkson\u000a      and M. Wills; J. Am. Chem. Soc. 2005, 127,\u000a      7318-7319, DOI: 10.1021\/ja051486s.\u000a    \u000a\u000a[3] A Stereochemically Well-Defined Rhodium(III) Catalyst for\u000a        Asymmetric Transfer Hydrogenation of Ketones, D. S. Matharu, D. J.\u000a      Morris, A. M. Kawamoto, G. J. Clarkson, and M. Wills; Org. Lett. 2005,\u000a      7, 5489-5491, DOI: 10.1021\/ol052559f.\u000a    \u000a\u000a[4] An Unexpected Directing Effect in the Asymmetric Transfer\u000a        Hydrogenation of f061, f061-Disubstituted\u000a        Ketones; R. Soni, J.-M. Collinson, G. J. Clarkson and M. Wills; Org.\u000a        Lett. 2011, 13, 4304-4307, DOI: 10.1021\/ol201643v.\u000a    \u000a\u000a[5] An investigation into the tether length and substitution pattern\u000a        of arene-substituted complexes for asymmetric transfer hydrogenation of\u000a        ketones, F. K. Cheung, C. Lin, F. Minissi, A. L. Crivill&#233;, M. A.\u000a      Graham, D. J. Fox and M. Wills, Org. Lett. 2007, 9,\u000a      4659-4662, DOI: 10.1021\/ol702226j.\u000a    \u000a\u000a[6] Application of Tethered Ruthenium Catalysts to Asymmetric\u000a        Hydrogenation of ketones, and the Selective Hydrogenation of Aldehydes,\u000a      K. E. Jolley, A. Zanotti-Gerosa F. Hancock, A. Dyke, D. M. Grainger, J. A.\u000a      Medlock, H. G. Nedden, J. J. M. Le Paih, S. J. Roseblade, A. Seger, V.\u000a      Sivakumar, I. Prokes, D. J Morris and M. Wills; Adv. Synth. Catal.\u000a      2012, 354, 2545-2555, DOI: 10.1002\/adsc.201200362.\u000a    \u000aResearch Council Grants\u000a    [7] Stereochemically Well-Defined Ruthenium(II) Catalysts For\u000a        Asymmetric Transfer Hydrogenation; EPSRC GR\/S72214\/01,\u000a      Jul 2004 &#8212; Dec 2007, &#163;183,371, M Wills.\u000a    [8] Asymmetric Transfer Hydrogenation Using Tethered Ligands;\u000a      EPSRC EP\/D031168\/1,\u000a      Jan 2006 &#8212; Mar 2009, &#163;186,531, M. Wills.\u000a    [9] Asymmetric Transfer Hydrogenation of Imines; EPSRC EP\/F019424\/1,\u000a      Jan 2008 &#8212; Mar 2011; &#163;301,135; M. Wills.\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"},{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"}],"Sources":"\u000a    [10] Johnson Matthey, Catalysis and Chiral Technologies; statement 17\u000a      June 2013.\u000a    [11] Process patent WO2010106364A2 (Johnson Matthey, priority date 17 Mar\u000a      2009), web link.\u000a    [12] Process patent WO2012156693A1, Processes for the preparation of\u000a        the compound of formula (II) and intermediate compounds for use in the\u000a        processes (AstraZeneca Ab and AstraZeneca UK Ltd, priority date 13\u000a      May 2011), web\u000a        link.\u000a    [13] Process patent WO2009130056A1, Process for making montelukast\u000a        intermediates (Synthon BV., priority date Apr 25, 2008), web\u000a        link.\u000a    [14] Process patent WO2011131315A1, Process for the asymmetric\u000a        transfer hydrogenation of ketones (Archimica GMBH, priority date 23\u000a      Apr 2010), web\u000a        link.\u000a    [15] Patent US20130217728, New CCR2 Antagonists (Boehringer\u000a      Ingelheim International GMBH, priority date 01 June 2010), web\u000a        link.\u000a    [16] Patent EP2644603A1, Synthetic route for the preparation of\u000a        substituted 2-phenyl-1,2,3,4-tetrahydronaphthalene-1-ols (LEK\u000a      Pharmaceuticals d.d., priority date 30 Mar 2012), web\u000a        link.\u000a    [17] Dr Reddy's, Chirotech Technology Ltd; statement 13 Aug 2013.\u000a    [18] Patent WO 2012\/026201 Ruthenium-diamine complexes and method for\u000a        producing optically active compounds (Tagasago Int. Corporation,\u000a      priority date 01 Aug 2010), web\u000a        link. See also J. Am. Chem. Soc. 2011, 133,\u000a      14960-14963, DOI: 10.1021\/ja207283t.\u000a    [19] Takasago website and presentation on DENEB, retrieved 11 Sept 2013\u000a      from web\u000a        link or available on request.\u000a    [20] PolyAn catalogue entry for heterogenised Wills catalyst, retrieved\u000a      31 July 2013 from web\u000a        link or available on request. See also Adv. Synth. Catal.\u000a      2010, 352, 2497-2506, DOI: 10.1002\/adsc.201000340\u000a    \u000a    ","Title":"\u000a    Wills Catalysts: commercialised systems for enantioselective production\u000a      of pharmaceutical intermediates\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000a    In the mid-1990s, R. Noyori (Nagoya, Japan) reported a series of\u000a      ruthenium-based catalysts containing an arene and chiral diamine that\u000a      demonstrated high reactivity and selectivity for the asymmetric reduction\u000a      of ketones to alcohols &#8212; versatile intermediates in pharmaceutical\u000a      manufacture. At Warwick, Professor Martin Wills and his research team have\u000a      been carrying out research in the area of asymmetric reduction using\u000a      organometallic catalysts, with a focus on their applications, as described\u000a      in over 40 publications since 1997. A major project carried out as part of\u000a      this research was directed at the development of improved variants of the\u000a      `Noyori catalysts'. The resulting `Wills catalysts' [1-6] have\u000a      substantially higher activity, use lower catalyst loadings and cause fewer\u000a      side reactions. This reduces cost, waste and energy usage.\u000a    In 2004, Wills was awarded the first of three EPSRC grants to support his\u000a      research in this area [7-9]. This led to the development of a series of\u000a      novel Ru(II)-based catalysts, in which a covalent tether from the chiral\u000a      diamine component to the 03b76-arene unit was incorporated.\u000a      This tether &#8212; the essential motif of the Wills catalyst family &#8212; provides\u000a      conformational and chemical stability as well as the unprecedented\u000a      potential to create derivatives with a predictable structure. Wills\u000a      established the principle of tethering in this system in 2004 [1], and\u000a      systems with exceptional activity and versatility were reported in 2005\u000a      [2]. The tethering concept was further extended to analogous Rh catalysts\u000a      [3].\u000a    Wills and his group further developed the new Ru(II) tethered catalysts,\u000a      and reported their mechanisms and wider applications in the following\u000a      years (11 additional papers). In particular, the research resulted in the\u000a      development of a catalyst for the reduction of a wide range of ketone\u000a      substrates to alcohols under transfer-hydrogenation conditions (formic\u000a      acid being the most commonly used source of hydrogen) [4,5], and later\u000a      to the extension of the catalyst to pressure-hydrogenation\u000a      reactions (where hydrogen gas is used as the reducing agent) [6]. It was\u000a      this class of highly engineered catalysts that led to the enhanced\u000a      reaction rates and increased compatibility needed for the key substrate\u000a      classes used in industry. These include &#945;-chloroacetophenones and\u000a      2-ketopyridines (which are prone to side reactions leading to catalyst\u000a      deactivation), and highly hindered substrates (which are normally\u000a      unreactive).\u000a    "},{"CaseStudyId":"11775","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2921044","Name":"Germany"},{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"1835841","Name":"South Korea"},{"GeoNamesId":"3175395","Name":"Italy"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"1814991","Name":"China"},{"GeoNamesId":"6252001","Name":"United States"}],"Funders":["Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000d\u000a    Research at Durham aimed at developing an open-flow cryostat capable of\u000d\u000a      cooling below liquid\u000d\u000a      nitrogen temperatures [1] was performed as part of an EPSRC-funded project\u000d\u000a      in collaboration with\u000d\u000a      Oxford Cryosystems (OC). OC is an Oxfordshire based company which employs\u000d\u000a      20 staff and has\u000d\u000a      an annual turnover of &#163;3-&#163;3.5M. The prototype was completed in 1998 and\u000d\u000a      the commercial\u000d\u000a      version was launched by OC as the HeliX at the IUCr Congress in Glasgow,\u000d\u000a      1999. IP for the Helix\u000d\u000a      is owned by OC who have sold around 20 units in the 2008-2013 period to\u000d\u000a      academic institutions\u000d\u000a      and central facilities globally [Im1].\u000d\u000a    \u000d\u000a    \u000d\u000a     \u000d\u000a     \u000d\u000a       \u000d\u000a    \u000d\u000a   Figure: N-HeliX (far left) and pHeniX (middle) cryostats\u000d\u000a        commercialised by Oxford Cryosystems [2,3]; Olex2 and\u000d\u000a        Topas Academic crystallography software (right).\u000d\u000a     \u000d\u000a    The successful development of the HeliX suggested similar technology\u000d\u000a      could provide a 12-310 K\u000d\u000a      cryostat for powder diffraction experiments, filling a market gap for\u000d\u000a      apparatus that was (a) easy to\u000d\u000a      use and low maintenance, (b) compatible with a range of diffractometer\u000d\u000a      configurations and (c)\u000d\u000a      usable by those without cryogen expertise and did not require expensive\u000d\u000a      liquid He. A prototype\u000d\u000a      pHeniX powder cryostat [4] was co-developed with OC, installed in Durham\u000d\u000a      in 2002, and the\u000d\u000a      commercial version launched later that year. pHeniX units have been sold\u000d\u000a      to industry in South\u000d\u000a      Korea, China, United States, mainland Europe and the UK as well as to\u000d\u000a      national facilities and\u000d\u000a      academic institutions directly by OC and through the X-ray manufacturers\u000d\u000a      PANalytical and Bruker\u000d\u000a      AXS. Approximately eight units are sold annually. The Director of Sales\u000d\u000a      and Marketing at Oxford\u000d\u000a      Cryosystems, said: \"it is fair to say that without the research excellence\u000d\u000a      of Durham University, we\u000d\u000a      would not be manufacturing and selling these cooling devices as we are\u000d\u000a      today. OC's product range\u000d\u000a      has expanded greatly over the past ten years and being able to offer these\u000d\u000a      products is very\u000d\u000a      important in allowing us to move into new applications.\" [Im1]\u000d\u000a    EPSRC \"Age Concern\" funding to JAKH enabled development of Olex2 software\u000d\u000a      [5, Im2], a\u000d\u000a      modern, powerful and easy to use package for the solution, analysis and\u000d\u000a      refinement of single\u000d\u000a      crystal X-ray data. The open source version is available free of charge\u000d\u000a      from the internet and has\u000d\u000a      been downloaded extensively, providing an estimation that there are over\u000d\u000a      5000 users worldwide.\u000d\u000a      The original paper has been cited &gt; 650 times, demonstrating impact on\u000d\u000a      the global academic\u000d\u000a      community and in training students, future academics and industrial\u000d\u000a      scientists. Future development\u000d\u000a      of Olex2 has been secured through the Durham spinout company OlexSys\u000d\u000a      [Im2]. OlexSys was\u000d\u000a      established in December 2010 (Company No 07465154) with the legal\u000d\u000a      assistance of Durham\u000d\u000a      University Business and Innovation Services. It has been trading since\u000d\u000a      June 2011 has a growing\u000d\u000a      turnover, employs full and part time staff and is chaired by JAKH. OlexSys\u000d\u000a      has two complementary\u000d\u000a      and parallel work strands. To keep Olex2 at the scientific cutting-edge\u000d\u000a      they maintain and develop\u000d\u000a      the open source version for and on behalf of the global academic\u000d\u000a      community. They also provide\u000d\u000a      bespoke software solutions for industry and have commercial contracts with\u000d\u000a      instrument\u000d\u000a      manufacturers Agilent, Rigaku and the Cambridge Crystallographic Data\u000d\u000a      Centre.\u000d\u000a    One commercial contract is with Agilent [Im3], who install Olex2 with all\u000d\u000a      of their X-ray systems\u000d\u000a      (each typically costing &gt; ~&#163;300K). Agilent commissioned OlexSys to\u000d\u000a      create the exclusive bespoke\u000d\u000a      commercial product AutoChem. Autochem provides automated, intelligent,\u000d\u000a      real-time structure\u000d\u000a      solution and refinement during data collection. Although Agilent company\u000d\u000a      policy states that specific\u000d\u000a      sales figures can't be released, the University believes a significant\u000d\u000a      number of licences have been\u000d\u000a      sold to date. A major update, Autochem2.0 was commissioned in 2011. It is\u000d\u000a      derived from Durham\u000d\u000a      research and OlexSys developments, and described on the Agilent website\u000d\u000a      as: \"The ultimate\u000d\u000a      productivity tool for chemical crystallography, AutoChem &#8212; now as\u000d\u000a      AutoChem2.0 &#8212; provides fast,\u000d\u000a      fully automated structure solution and refinement during data collection.\u000d\u000a      Developed exclusively for\u000d\u000a      Agilent by the authors of Olex2, AutoChem2.0 is a seamlessly integrated,\u000d\u000a      optional plug-in for\u000d\u000a      CrysAlisPro, offering an advanced approach for automatic structure\u000d\u000a      determination, and now with\u000d\u000a      an even higher rate of success.\"\u000d\u000a    JSOE has been heavily involved in the development of Topas &#8212; the leading\u000d\u000a      software for analysis of\u000d\u000a      powder diffraction data and Rietveld refinement (e.g. [6]). He has worked\u000d\u000a      closely with Alan Coelho\u000d\u000a      and Bruker in implementing new ideas and methodologies in this software\u000d\u000a      [Im4,5]. In particular his\u000d\u000a      methods for analysing variable temperature\/time\/chemical environment data\u000d\u000a      are used worldwide\u000d\u000a      and the time-of-flight neutron and distortion mode\/magnetism methods he\u000d\u000a      introduced underpin\u000d\u000a      numerous experiments at UK central facilities (e.g. [7]). The jEdit\u000d\u000a      interface he developed and\u000d\u000a      distributes for \"power-use\" of the software is used by many academic and\u000d\u000a      industrial groups, and\u000d\u000a      Durham has trained in excess of 500 people in its use at predominantly\u000d\u000a      industrial workshops\u000d\u000a      worldwide (USA, Germany, Italy, UK, Australia). Many of these innovations\u000d\u000a      are now incorporated\u000d\u000a      in the commercial version of Topas [Im4], which has a list price around\u000d\u000a      &#163;10K. Sales figures for\u000d\u000a      Topas are commercially sensitive information that Bruker cannot release.\u000d\u000a      Many licenses have\u000d\u000a      been sold and that their distribution would be approximately 50:50 between\u000d\u000a      industry and academia.\u000d\u000a      Many copies of the academic version have been sold to groups worldwide\u000d\u000a      (80% in REF period)\u000d\u000a      [Im5]. The Topas community wiki site and discussion forum is run through\u000d\u000a      Durham\u000d\u000a      (topas.dur.ac.uk\/dokuwiki.php) and has a vibrant and expanding community\u000d\u000a      with about 300\u000d\u000a      members. This includes industrial members from industries in the chemicals\u000d\u000a      (e.g. Johson Mathey,\u000d\u000a      BASF), cement, pharmaceutical and mining sectors.\u000d\u000a    Our structural expertise also has significant and direct impact on\u000d\u000a      industry via the\u000d\u000a      service\/consultancy work we perform under the auspices of the departmental\u000d\u000a      services. Within the\u000d\u000a      REF period the Department has performed many single crystal, powder\u000d\u000a      diffraction and related\u000d\u000a      analyses. We have also supported industrial users with structure-related\u000d\u000a      problems via Durham's\u000d\u000a      industry-funded solid state NMR service, helping 49 companies with work\u000d\u000a      between January 2008\u000d\u000a      and July 2013.\u000d\u000a    The impact of all our crystallographic research is enhanced by regular\u000d\u000a      international training schools\u000d\u000a      run in Durham [Im6], e.g. the Powder Diffraction and Rietveld refinement\u000d\u000a      School (biennial since\u000d\u000a      2004) and BCA X-Ray Single Crystal Structure Analysis Intensive Training\u000d\u000a      School (biennial in\u000d\u000a      Durham since 1995), targeting both academics and industry on an\u000d\u000a      international scale. Since 2008\u000d\u000a      the X-ray Single crystal school has trained over 250 participants over 3\u000d\u000a      schools held biennially and\u000d\u000a      the powder school has trained &gt;200 delegates from around the world. An\u000d\u000a      overseas PhD student at\u000d\u000a      the 2008 powder school stated \"I think it was one of the best teaching\u000d\u000a      courses I have ever\u000d\u000a      attended\" and a UK academic \"I would have no hesitation in recommending it\u000d\u000a      to any academics or\u000d\u000a      students....there is a huge need for this in the UK\"; the International\u000d\u000a      Union of Crystallography\u000d\u000a      powder commission described it as a \"school others should aspire to\". The\u000d\u000a      problem-based\u000d\u000a      learning example set for the powder school features many examples derived\u000d\u000a      from Durham\u000d\u000a      research ( http:\/\/www.dur.ac.uk\/john.evans\/topas_workshop\/pcg_workshop_menu.htm\u000d\u000a      ) to help\u000d\u000a      train others in our methods.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Durham Chemistry has a long history of research in cutting edge\u000d\u000a      crystallographic methods and\u000d\u000a      innovative instrument design which has led to the commercialisation of\u000d\u000a      scientific apparatus and\u000d\u000a      software with significant sales value. Durham-developed apparatus and\u000d\u000a      crystallographic software\u000d\u000a      are used globally by both industry and academia. Autochem2, for example,\u000d\u000a      is sold exclusively to\u000d\u000a      Agilent via the spin-out company OlexSys, and hundreds of researchers rely\u000d\u000a      on Durham's\u000d\u000a      contributions to the Topas software pacakge. Crystallographic research for\u000d\u000a      pharmaceutical and\u000d\u000a      other companies, research-based consultancy, commercial analytical\u000d\u000a      services and provision of\u000d\u000a      international PhD+ level training schools have led to further significant\u000d\u000a      impact.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    Durham\u000d\u000a    ","Institutions":[{"AlternativeName":"Durham (University of)","InstitutionName":"University of Durham","PeerGroup":"B","Region":"North East","UKPRN":10007143}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    \u000a[1] R.C.B.Copley, A.E. Goeta, C.W. Lehmann, J.C. Cole, D.S. Yufit, J.A.K.\u000d\u000a      Howard and J.M.\u000d\u000a      Archer, \"The Fddd four-circle diffractometer for single-crystal X-ray\u000d\u000a      studies at temperatures\u000d\u000a      down to 9K\", J. Appl. Cryst., 1997, 30, 413-417. DOI:\u000d\u000a      10.1107\/S0021889897002525. [8\u000d\u000a        citations]\u000d\u000a    \u000a\u000a[2] A.E. Goeta, L.K. Thompson, C.L. Sheppard, S.T. Tandon, C.W. Lehmann,\u000d\u000a      J. Cosier, C.\u000d\u000a      Webster and J.A.K. Howard, \"[Cu2{1,4-bis[(3-methyl-2-pyridyl)amino]-phthalazine-H}(N3)3]\u000d\u000a      at\u000d\u000a      40K\", Acta Cryst., 1999, C55, 1243-1246. DOI:\u000d\u000a      10.1107\/S0108270199005648. [19]\u000d\u000a    \u000a\u000a[3] V.A. Money, I.R. Evans, M.A. Halcrow, A.E. Goeta and J.A.K. Howard,\u000d\u000a      \"Light induced excited\u000d\u000a      high spin-state trapping in [FeL2](BF4)2\u000d\u000a      (L = 2,6-di(pyrazol-1-yl)pyridine)\", Chem. Commun.,\u000d\u000a      2003, 158-9. DOI: 10.1039\/B210146G. [53]\u000d\u000a    \u000a\u000a[4] S. Allen and J.S.O. Evans, \"The kinetics of oxygen migration in\u000d\u000a      ZrWMoO8\", J. Mater. Chem.,\u000d\u000a      2004, 14,151-156, RSC Hot Article. DOI: 10.1039\/B310137A.\u000d\u000a      [18]\u000d\u000a    \u000a\u000a[5] O.V. Dolomanov, L.J. Bourhis, R.J. Gildea, J.A.K. Howard, H.\u000d\u000a      Puschmann, \"OLEX2: A\u000d\u000a      complete structure solution, refinement and analysis program\", J. App.\u000d\u000a        Cryst., 2009, 42, 339-341.\u000d\u000a\u0009\u0009DOI:10.1107\/S0021889808042726. [650]\u000d\u000a    \u000a\u000a[6] A.A. Coelho, J.S.O. Evans, I.R. Evans, A. Kern, and S. Parsons, \"The\u000d\u000a      TOPAS symbolic\u000d\u000a      computation system\", Powder Diffraction, 2011, 26, S22-S25. DOI:\u000d\u000a      10.1154\/1.3661087. [8]\u000d\u000a    \u000a\u000a[7] G.W. Stinton, J.S.O. Evans, \"Parametric Rietveld refinement\", J.\u000d\u000a        Appl. Cryst., 2007, 40, 87-95.\u000d\u000a\u0009\u0009DOI:10.1107\/S0021889806043275. [40]\u000d\u000a    \u000aSelected research funding:\u000d\u000a    [F1] EPSRC Grant GR\/L16903\/01 (1996-1999), &#163;180K, JAKH. \"Open Heart\u000d\u000a      Crystallography at\u000d\u000a      (virtually) Helium Temperatures\".\u000d\u000a    [F2] EPSRC Grant GR\/N00524 (2000-2003), &#163;270K, JSOE. \"Negative Thermal\u000d\u000a      Expansion and\u000d\u000a      Oxygen Mobility in Framework Materials\".\u000d\u000a    [F3] EPSRC GR\/M35222 (1999-2002), &#163;121K. JSOE, JAKH, &amp; AEG. Joint\u000d\u000a      Research Equipment\u000d\u000a      Initiative grant leading to development of the pHeniX cryostat.\u000d\u000a    [F4] EPSRC EP\/C536274\/1 (2005-2011), &#163;1.2M (&#163;943K Durham). \"Age Concern;\u000d\u000a      Crystallographic Software for the Future\" led to Olex2, spin-out OlexSys\u000d\u000a      and other outputs.\u000d\u000a    The quality of the research described in section 1 is evidenced in\u000d\u000a      several ways. Much of it was\u000d\u000a      enabled by peer-reviewed EPSRC grants (listed F1-F4) above. When required,\u000d\u000a      final reviewed\u000d\u000a      reports on these received outstanding\/internationally-leading grades.\u000d\u000a      Several of the papers cited\u000d\u000a      above were returned in previous RAE exercises and, we infer, were graded\u000d\u000a      &gt; 2*. Several of the\u000d\u000a      references listed have also been highly cited. Reference [5] has been\u000d\u000a      cited over 850 times and\u000d\u000a      reference [7] over 40 times and we have received numerous invitations to\u000d\u000a      present research at\u000d\u000a      international meetings. Our software user base (&gt;5000 for single\u000d\u000a      crystal, &gt;650 for jEdit\/Topas\u000d\u000a      Academic) attests to the quality of these research-derived packages.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"},{"Level1":"2","Level2":"99","Subject":"Other Physical Sciences"}],"Sources":"\u000d\u000a    [Im1] Helix and pHenix: Director of Marketing &amp; Sales, Oxford\u000d\u000a      Cryosystems\u000d\u000a      (http:\/\/www.oxcryo.com; http:\/\/www.oxcryo.com\/coolers-for-diffraction\/n-helix\/;\u000d\u000a      http:\/\/www.oxcryo.com\/coolers-for-diffraction\/phenix\/)\u000d\u000a    [Im2] Olex2: Olex2 CEO &#8212; OlexSys (http:\/\/www.olexsys.org);\u000d\u000a      UK registered company 07465154.\u000d\u000a    [Im3] Olex2 and Autochem2.0: Oliver Presley, Program Marketing Manager\u000d\u000a      (XRD), Agilent\u000d\u000a      (www.agilent.com). (http:\/\/www.chem.agilent.com\/en-US\/products-services\/software-\u000d\u000a        informatics\/autochem\/Pages\/default.aspx).\u000d\u000a    [Im4] Topas: Head of Global Product Management XRD, Bruker AXS has\u000d\u000a      provided information\u000d\u000a      confirming JSOE's contribution to Topas. See also: http:\/\/www.bruker.com\/products\/x-ray-diffraction-and-elemental-analysis\/x-ray-diffraction\/xrd-software\/applications\/xrd-software-applications\/topas.html.\u000d\u000a    [Im5] Topas Academic: Alan Coelho has provided information confirming\u000d\u000a      TOPAS sales and\u000d\u000a      impact. http:\/\/www.topas-academic.net;\u000d\u000a      http:\/\/www.dur.ac.uk\/john.evans\/topas_academic\/topas_main.htmtopas.dur.ac.uk\/dokuwiki.php\u000d\u000a    [Im6] Powder diffraction and Rietveld refinement school: EPSRC proposals,\u000d\u000a      testaments of\u000d\u000a      previous delegates and comments of referees in school funding\u000d\u000a      applications.\u000d\u000a    ","Title":"\u000d\u000a    Structural science &#8212; equipment and software for industry\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    Research in the development of crystallographic methods at Durham has\u000d\u000a      been carried out by the\u000d\u000a      groups of Professor Judith A K Howard (JAKH, 1991-), Dr. Andres Goeta\u000d\u000a      (AEG, 1998-2011dc),\u000d\u000a      Professor John S.O. Evans (JSOE, 1998-) and Dr Ivana Evans (IRE, 1999-).\u000d\u000a      Their work forms\u000d\u000a      part of our Research Grouping in Materials Synthesis and Structure (MSS),\u000d\u000a      and is supported and\u000d\u000a      exploited by others working in structural science and, in particular,\u000d\u000a      solid state NMR.\u000d\u000a    Durham Chemistry has a strong focus on the synthesis and understanding of\u000d\u000a      functional materials.\u000d\u000a      Examples include superconductors, molecular magnets, materials with\u000d\u000a      electronic and magnetic\u000d\u000a      phase transitions, gas storage materials, structural materials and\u000d\u000a      molecular switches. In order to\u000d\u000a      understand, develop and exploit structure-property relationships in these\u000d\u000a      materials, high resolution\u000d\u000a      X-ray-derived structural information is required across a wide temperature\u000d\u000a      range. Low\u000d\u000a      temperatures also provide higher quality structural information than\u000d\u000a      ambient studies and allow\u000d\u000a      study of otherwise unstable systems. JAKH therefore designed, constructed\u000d\u000a      and developed the\u000d\u000a      unique Fddd diffractometer [1] integrating closed cycle cryo-refrigeration\u000d\u000a      and a high intensity X-ray\u000d\u000a      beam to enable crystallographic studies of very small crystals down to 9\u000d\u000a      K. Single crystal X-ray\u000d\u000a      diffraction studies in the UK had been restricted previously to\u000d\u000a      temperatures above 100K using\u000d\u000a      liquid nitrogen temperatures as coolant. The unique facilities developed\u000d\u000a      in Durham enabled low\u000d\u000a      temperature studies on a number of important systems with exploitable\u000d\u000a      macroscopic properties,\u000d\u000a      but, using a point detector, experiments were slow and only a limited\u000d\u000a      number of temperatures\u000d\u000a      could be studied.\u000d\u000a    The advent of CCD detectors for laboratory diffractometers provided a\u000d\u000a      solution to the speed\u000d\u000a      problem, but the data quality obtainable at sub 100 K temperatures was\u000d\u000a      severely limited by the\u000d\u000a      complex cryostat environment, with heat shields and windows severely\u000d\u000a      attenuating the beam and\u000d\u000a      giving rise to their own strong X-ray scatter. JAKH therefore initiated\u000d\u000a      research into the development\u000d\u000a      of an open-flow cooling device, similar to the now ubiquitous liquid\u000d\u000a      nitrogen devices, but capable of\u000d\u000a      reaching much lower temperatures [F1]. The cryostat developed, the HeliX,\u000d\u000a      allowed the first rapid\u000d\u000a      full structural investigations of novel systems maintained at sub 100 K\u000d\u000a      temperatures in an open\u000d\u000a      environment, allowing rapid data acquisition. The design also enabled\u000d\u000a      laser excitation of samples\u000d\u000a      allowing full structural investigations of thermally trapped, optically\u000d\u000a      induced, excited spin state\u000d\u000a      complexes [2,3].\u000d\u000a    Many of the new materials prepared and studied in Durham are in\u000d\u000a      polycrystalline (powdered) form,\u000d\u000a      but there is still a need to study their low temperature structural\u000d\u000a      properties. Examples of materials\u000d\u000a      include those showing negative thermal expansion behaviour [F2],\u000d\u000a      electronic phase transitions or\u000d\u000a      light-induced changes. The need to study these materials [3,4] led to [F3]\u000d\u000a      research by JSOE\/AEG\u000d\u000a      to develop and exploit the pHeniX cryostat for powder diffraction. The\u000d\u000a      design incorporated novel\u000d\u000a      features to allow operation on a range of lab-based instruments with a\u000d\u000a      variety of different sample\u000d\u000a      types.\u000d\u000a    The experimental structural and materials science undertaken at Durham\u000d\u000a      has required parallel\u000d\u000a      development of computational methods and software tools. In the area of\u000d\u000a      single crystal diffraction\u000d\u000a      the JAKH group has an extensive research programme in the development of\u000d\u000a      computational tools\u000d\u000a      for data analysis. With EPSRC funding they designed and delivered an\u000d\u000a      innovative, future-proof,\u000d\u000a      toolbox based software suite (Olex2) based on Python-integration of a\u000d\u000a      series of small modules [F4]\u000d\u000a      using fit-for-purpose programming codes, informed by X-ray crystallography\u000d\u000a      expertise. This\u000d\u000a      approach allows the efficient use of established routines and the parallel\u000d\u000a      development of new\u000d\u000a      algorithms [5]. In the area of powder diffraction, JSOE has been involved\u000d\u000a      in the development of the\u000d\u000a      Topas suite of software and its application for novel data analysis since\u000d\u000a      the late 1990s. He has\u000d\u000a      developed data analysis methods for parametric fitting of huge bodies of\u000d\u000a      diffraction data, for\u000d\u000a      analysing neutron and energy dispersive diffraction data, and\u000d\u000a      distortion-mode modelling of\u000d\u000a      functional materials; these are used by industry and academics [6,7].\u000d\u000a    "},{"CaseStudyId":"11776","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"1861060","Name":"Japan"}],"Funders":["Engineering and Physical Sciences Research Council","Royal Society"],"ImpactDetails":"\u000d\u000a    In 1992 BNFL established a spin-out company, BNFL Fluorochemicals Ltd,\u000d\u000a      later F2 Chemicals Ltd,\u000d\u000a      to develop new markets in the fine chemicals sector using their expertise\u000d\u000a      in the production and\u000d\u000a      handling of F2 developed from nuclear power generation\u000d\u000a      applications. A research team (3 PDRA\u000d\u000a      employees, 3 years) from the company was seconded to the Chemistry\u000d\u000a      Department at Durham\u000d\u000a      (1992-1995) in order to establish a skill base, expertise and IPR in the\u000d\u000a      field. The company also\u000d\u000a      provided funds for building and equipping a new, purpose-built research\u000d\u000a      laboratory for handling F2\u000d\u000a      within the Chemistry Department and RDC subsequently became a\u000d\u000a      non-executive Director of the\u000d\u000a      company. The following period (1993-1996) resulted in a suite of over 20\u000d\u000a      patent applications which\u000d\u000a      were filed, granted and maintained by F2 Chemicals arising from the Durham\u000d\u000a      research\u000d\u000a      collaboration. Most importantly, development of new selective fluorination\u000d\u000a      methodology of &#946;-ketoesters\u000d\u000a      in high dielectric constant media was investigated and exemplified at\u000d\u000a      Durham on a 1 g\u000d\u000a      scale and published by the DU research team in collaboration with F2\u000d\u000a      Chemicals in 1996 [2]\u000d\u000a      following IPR protection [Im1]. Subsequently, Durham direct fluorination\u000d\u000a      reaction methodology\u000d\u000a      using F2 [2] was adopted and scaled up to a manufacturing\u000d\u000a      process by F2 Chemicals Ltd [Im2] with\u000d\u000a      the design, investment and construction of a 1000 litre Selective Direct\u000d\u000a      Fluorination (SDF) plant\u000d\u000a      (Fig. 1a) at their headquarters in Preston to synthesise products for\u000d\u000a      customers in the life science\u000d\u000a      industries.\u000d\u000a    V-FEND (Voriconazole, Pfizer, Fig. 1b) is the world-wide best-selling\u000d\u000a      systemic, antifungal agent\u000d\u000a      and has a 5-fluoropyrimidine sub-unit 1 as part of its structure.\u000d\u000a      Manufacture of fluoropyrimidine\u000d\u000a      intermediate 1 had been carried out previously by multi-step,\u000d\u000a      resource intensive strategies\u000d\u000a      described by Pfizer scientists [Im3] but new Durham methods for selective\u000d\u000a      direct fluorination of &#946;-ketoesters\u000d\u000a      using F2 [2] provided the opportunity for a more efficient\u000d\u000a      2-step process, that is far less\u000d\u000a      expensive and generates less waste than other procedures. Given this new\u000d\u000a      business opportunity,\u000d\u000a      Durham direct fluorination methodology [2] for the synthesis of\u000d\u000a      &#946;-fluoroketoester 2 (Fig. 1b), as the\u000d\u000a      key starting material for the manufacture of 5-fluoropyrimiide system 1,\u000d\u000a      was developed and scaled-up\u000d\u000a      by F2 Chemicals and used through all the clinical trial, launch and\u000d\u000a      commercialization periods of\u000d\u000a      V-FEND by Pfizer [Im3]. In the period from January 2008 to July 2013,\u000d\u000a      multi-tonne quantities of F-ketoester\u000d\u000a      1 were manufactured by F2 Chemicals Ltd [Im2] as the exclusive\u000d\u000a      supplier for Pfizer using\u000d\u000a      Durham direct fluorination chemistry [2]. World-wide sales of V-FEND in\u000d\u000a      the 2008-2012 REF period\u000d\u000a      total $4.65 billion [Im4] making this product one of the global top 100\u000d\u000a      best-selling pharmaceuticals.\u000d\u000a     \u000d\u000a     Figure: impact of Durham selective direct fluorination methodology. Left: Selective Direct Fluorination plant at F2 Chemicals (Preston). Right: new strategy for the synthesis of a fluoro-ketoester, a key intermediate of Pfizer&#8217;s V-Fend antifungal agent.\u000d\u000a\u000d\u000a    V-FEND's economic and societal impact arises from its use as a triazole\u000d\u000a      antifungal medication\u000d\u000a      [Im5] active against serious, invasive fungal infections such as\u000d\u000a      candidiasis, aspergillosis, and\u000d\u000a      certain emerging fungal infections [Im6]. Aspergillosis is primarily an\u000d\u000a      infection of the lungs caused\u000d\u000a      by the inhalation of airborne spores of the fungus Aspergillus\u000d\u000a      which is commonly found growing on\u000d\u000a      dead leaves, stored grain, compost piles, or in other decaying vegetation.\u000d\u000a      There are several forms\u000d\u000a      of aspergillosis: pulmonary aspergillosis is an allergic reaction to the\u000d\u000a      fungus that usually develops\u000d\u000a      in people who already have lung problems (such as asthma or cystic\u000d\u000a      fibrosis); aspergilloma is a\u000d\u000a      growth (fungus ball) that develops in an area of past lung disease or lung\u000d\u000a      scarring (such as\u000d\u000a      tuberculosis or lung abscess) and pulmonary aspergillosis (invasive type)\u000d\u000a      is a serious infection\u000d\u000a      associated with pneumonia that can spread to other parts of the body. This\u000d\u000a      infection almost always\u000d\u000a      occurs in people with a weakened immune system due to cancer, AIDS,\u000d\u000a      leukaemia, an organ\u000d\u000a      transplant, chemotherapy, or other conditions or medications that lower\u000d\u000a      the number of normal\u000d\u000a      white blood cells or weaken the immune system. For example, invasive\u000d\u000a      pulmonary aspergillosis\u000d\u000a      (IPA) is estimated to occur in 5-13% of people who have a bone marrow\u000d\u000a      transplant, 5-25% of\u000d\u000a      people with a heart or lung transplant and 10-20% of people who undergo\u000d\u000a      high-dose radiotherapy\u000d\u000a      for leukaemia.\u000d\u000a    Durham selective fluorination chemistry [2, Im1] has therefore played a\u000d\u000a      significant role in impacting\u000d\u000a      many patients treated by V-FEND, giving world-wide health benefits in the\u000d\u000a      treatment of fungal\u000d\u000a      infections for a wide range of disease control.\u000d\u000a    In order to further develop the use of Durham F2 chemistry for\u000d\u000a      fine chemical manufacture, a\u000d\u000a      Durham University spin-out company, Brock Fine Chemicals Ltd [Im7], was\u000d\u000a      established in April\u000d\u000a      2011 by Graham Sandford with assistance and legal expertise from Durham\u000d\u000a      Business Innovation\u000d\u000a      Services (DBIS). Brock (UK registered company 7610103) attracted proof of\u000d\u000a      concept funding\u000d\u000a      (&#163;100K) from the NorthStar regional investment group [Im8] to further\u000d\u000a      exploit the use of fluorine for\u000d\u000a      fine chemical manufacturing, particularly for the synthesis of a range of\u000d\u000a      iodo-aromatic derivatives\u000d\u000a      using Durham fluorine-mediated iodination chemistry [4]. The company now\u000d\u000a      employs 2 FTE\u000d\u000a      chemists and associated marketing and finance expertise. It has made sales\u000d\u000a      of over 100 fine\u000d\u000a      chemical products to chemical distributors such as Fluorochem, Acros, Alfa\u000d\u000a      Aesar, Apollo Scientific\u000d\u000a      and Shigematsu since trading began. Sales in Year 1 were &#163;8K growing to\u000d\u000a      &#163;40K in Year 2 and\u000d\u000a      within the proof-of-concept business plan.\u000d\u000a    Multi-channel continuous flow microreactor techniques developed at Durham\u000d\u000a      [3] were patented by\u000d\u000a      Durham University [Im9] and a world-wide exclusive license negotiated by\u000d\u000a      the University (DBIS)\u000d\u000a      and granted to the Asahi Glass Co., Japan for a significant fee and a\u000d\u000a      subsequent royalty stream.\u000d\u000a      This acquisition formed a core part of the IP knowledge base in flow\u000d\u000a      reactor technology at Asahi\u000d\u000a      Glass.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Durham selective direct fluorination methodology using fluorine gas has\u000d\u000a      been scaled up by F2\u000d\u000a      Chemicals Ltd to supply the Pfizer company with multi-tonne quantities of\u000d\u000a      a key pharmaceutical\u000d\u000a      intermediate used in the synthesis of V-Fend (voriconazole). This\u000d\u000a      antifungal agent has achieved\u000d\u000a      global sales of $4.65bn from 2008-present and is used extensively for the\u000d\u000a      treatment of invasive\u000d\u000a      pulmonary aspergillosis. Multi-channel continuous flow gas\/liquid\u000d\u000a      microreactor technology for direct\u000d\u000a      fluorination was licensed to the Asahi Glass Co (Japan) and other\u000d\u000a      transformations enabled by\u000d\u000a      fluorine gas are being exploited by a DU spin-out company, Brock Fine\u000d\u000a      Chemicals Ltd.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    Durham University\u000d\u000a    ","Institutions":[{"AlternativeName":"Durham (University of)","InstitutionName":"University of Durham","PeerGroup":"B","Region":"North East","UKPRN":10007143}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    \u000a[1] R. D. Chambers, C. J. Skinner, J. Hutchinson and J. Thomson,\u000d\u000a      Synthesis of fluoroaromatic\u000d\u000a      compounds. J. Chem. Soc., Perkin Trans. I, 1996, 605-609. DOI:\u000d\u000a      10.1039\/P19960000605.\u000d\u000a      [27 citations]\u000d\u000a    \u000a\u000a[2] R. D. Chambers, M.P. Greenhall and J. Hutchinson. Direct fluorination\u000d\u000a      of 1,3-dicarbonyl\u000d\u000a      compounds. Tetrahedron, 1996, 1-8. DOI:\u000d\u000a      10.1016\/0040-4020(95)00883-A [57]\u000d\u000a    \u000a\u000a[3] R.D. Chambers, M.A. Fox, D. Holling, T. Nakano, T. Okazoe and G.\u000d\u000a      Sandford. Versatile thin-film gas-liquid multi-channel microreactors for effective scale-out. Lab.\u000d\u000a        Chip, 2005, 5, 191-198.\u000d\u000a      DOI: 10.1039\/B416400 [53]\u000d\u000a    \u000a\u000a[4] R.D. Chambers, C.J. Skinner, M.J. Atherton and J.S. Moilliet. Use of\u000d\u000a      elemental fluorine for\u000d\u000a      the halogenation of aromatics. J. Chem. Soc., Perkin Trans 1,\u000d\u000a      1996, 1659-1664. DOI:\u000d\u000a      10.1039\/P19960001659. [17]\u000d\u000a    \u000aThe research quality of the elemental fluorine research programme\u000d\u000a      (1993-present) led by Prof RD\u000d\u000a      Chambers (RDC) and Prof G Sandford (GS) is supported by: RDC's election to\u000d\u000a      FRS in 1997; and\u000d\u000a      the 2003 award of the Prix Moissan to RDC in 2003 (the premier\u000d\u000a      international award in Fluorine\u000d\u000a      Chemistry). GS and RDC have given many plenary and keynote lectures at\u000d\u000a      major international\u000d\u000a      conferences (European Symposium on Fluorine Chemistry, ACS Winter Fluorine\u000d\u000a      Symposium, ACS\u000d\u000a      National Meetings and International Symposium on Fluorine Chemistry). R.D.\u000d\u000a      Chambers, Fluorine\u000d\u000a        in Organic Chemistry (1st edition: 1973; 2nd\u000d\u000a      edition: 2004) remains the standard textbook in the\u000d\u000a      field.\u000d\u000a    Research funding allowing the fluorination programme to be established\u000d\u000a      included: industrial\u000d\u000a      support from BNFL Fluorochemicals (three employees seconded to Durham for\u000d\u000a      3 years; 3 year\u000d\u000a      PDRA; 2 PhD studentships); the Asahi Glass Co. Japan (2 PhD studentships\u000d\u000a      including one\u000d\u000a      employee from Japan seconded to Durham); and the Royal Society (URF to GS,\u000d\u000a      1996-2001). The\u000d\u000a      development of single and multi-channel microreactors was funded by: EPSRC\u000d\u000a      ROPA (1 PDRA, 3\u000d\u000a      years) and EPSRC Crystal Faraday (1 PDRA, 3 years) schemes, both in\u000d\u000a      collaboration with F2\u000d\u000a      Chemicals.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"},{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"}],"Sources":"\u000d\u000a    [Im1] Fluorination of &#946;-ketoesters patent: R.D. Chambers, M.P.\u000d\u000a      Greenhall, J. Hutchinson, J.S.\u000d\u000a      Moilliet, J. Thomson, PCT Intl Appl WO 95\/14646 (June 1st\u000d\u000a      1995); Chem. Abstr. 1995, 123,\u000d\u000a      339705.\u000d\u000a    [Im2] F2 Chemicals: Managing Director, F2 Chemicals Ltd, www.f2chemicals.com.\u000d\u000a    [Im3] V-FEND application: the use of Durham\/F2 Chemicals direct\u000d\u000a      fluorination methods for the\u000d\u000a      synthesis of V-FEND is described by Pfizer scientists in M. Butters and\u000d\u000a      co-workers, Org.\u000d\u000a        Proc. Res. Dev., 2001, 5, 28-36.\u000d\u000a    [Im4] V-FEND sales: annual global sales of V-FEND are given in successive\u000d\u000a      Pfizer Annual reports:\u000d\u000a      2008: http:\/\/www.pfizer.com\/files\/annualreport\/2008\/financial\/financial2008.pdf\u000d\u000a      (p 2)\u000d\u000a      2009: http:\/\/www.pfizer.com\/files\/annualreport\/2009\/financial\/financial2009.pdf\u000d\u000a      (p 21)\u000d\u000a      2010: http:\/\/www.pfizer.com\/files\/annualreport\/2010\/financial\/financial2010.pdf\u000d\u000a      (p 25)\u000d\u000a      2011: http:\/\/www.pfizer.com\/files\/annualreport\/2011\/financial\/financial2011.pdf\u000d\u000a        (p 21)\u000d\u000a      2012: http:\/\/www.pfizer.com\/files\/annualreport\/2012\/financial\/financial2012.pdf (p115)\u000d\u000a    [Im5] V-FEND (Pfizer): trade name of Voriconazole: http:\/\/en.wikipedia.org\/wiki\/Voriconazole;\u000d\u000a      http:\/\/www.pfizer.com\/products\/rx\/rx_product_vfend.jsp.\u000d\u000a    [Im6] V-FEND applications: for details on the various types of\u000d\u000a      aspergillosis and treatment regimes,\u000d\u000a      see: http:\/\/www.nhs.uk\/conditions\/Aspergillosis\/Pages\/Introduction.aspx.\u000d\u000a    [Im7] Brock Fine Chemicals Ltd: UK registered company 7610103, April 19th\u000d\u000a      2011,\u000d\u000a      www.brockfinechemicals.com; sales\u000d\u000a      figures contained in Annual Reports registered with\u000d\u000a      Companies House.\u000d\u000a    [Im8] Brock investment: investment analyst, NorthStar http:\/\/www.northstarei.com.\u000d\u000a    [Im9] Flow systems: multi-channel microreactors patented by DU: R.D.\u000d\u000a      Chambers, G. Sandford\u000d\u000a      and D. Holling, U.K. Pat Appl. 0210809.0, 11th May 2002.\u000d\u000a    ","Title":"\u000d\u000a    Elemental fluorine for fine chemical manufacture\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    Research in elemental fluorine for organic synthesis at DU was led by\u000d\u000a      Prof R.D. Chambers FRS\u000d\u000a      (Durham staff 1960-2000) and continued by Prof G Sandford (Durham staff\u000d\u000a      1993-present).\u000d\u000a      Elemental fluorine gas (F2) has long been considered to be too\u000d\u000a      reactive and uncontrollable for use\u000d\u000a      as a reagent in organic synthesis and this perception still predominates.\u000d\u000a      General comments in\u000d\u000a      standard organic chemistry textbooks such as \"Direct fluorination of\u000d\u000a      aromatic rings with F2 is not\u000d\u000a      feasible at room temperature because of the extreme reactivity of F2....is\u000d\u000a      not yet of preparative\u000d\u000a      significance (J. March, Advanced Organic Chemistry)\" are typical.\u000d\u000a    Despite this background, research into the use of F2 for\u000d\u000a      controlled organic synthesis began a new\u000d\u000a      phase in 1993 after encouragement from Durham led British Nuclear Fuels\u000d\u000a      (BNFL) to exploit its\u000d\u000a      expertise in handling F2 for non-nuclear purposes and to create\u000d\u000a      a subsidiary company, BNFL\u000d\u000a      Fluorochemicals Ltd (Preston, UK), later F2 Chemicals Ltd. Considerable\u000d\u000a      research funding from\u000d\u000a      the company to Durham allowed the development of a wide ranging blue-skies\u000d\u000a      research\u000d\u000a      programme into the use of F2 for organic synthesis and this\u000d\u000a      continues at Durham to the present.\u000d\u000a      Expertise was developed to overcome the many problems of using F2\u000d\u000a      for the safe synthesis of fine\u000d\u000a      chemicals. In particular, techniques involving the use of dilute F2\u000d\u000a      in nitrogen, appropriate solvent\u000d\u000a      choice (high dielectric constant media such as formic acid, sulfuric acid\u000d\u000a      or acetonitrile) [1], reactor\u000d\u000a      vessel design, gas flow regulator systems and stainless steel\/monel\u000d\u000a      fluorine gas handling lines\u000d\u000a      have been developed over the years in Durham. This has allowed selective\u000d\u000a      direct fluorination of a\u000d\u000a      range of aliphatic, dicarbonyl [2], aromatic, heteroaromatic,\u000d\u000a      heterocyclic, steroid and carbohydrate\u000d\u000a      derivatives to be established and the mechanism (regiochemistry,\u000d\u000a      stereochemistry, selectivity) of\u000d\u000a      these processes to be explored. Indeed, we have shown that controlled\u000d\u000a      direct fluorination of\u000d\u000a      aromatic rings is now feasible at room temperature [1].\u000d\u000a    The control of F2 reactivity by promoting selective\u000d\u000a      electrophilic reactions using high dielectric\u000d\u000a      constant media [1] was particularly important, and F2 can now\u000d\u000a      be considered to act as a typical\u000d\u000a      electrophilic reagent for a range of electrophilic aliphatic and aromatic\u000d\u000a      substitution processes. In\u000d\u000a      particular, efficient direct selective fluorination processes of\u000d\u000a      &#946;-dicarbonyl and &#946;-ketoester\u000d\u000a      substrates were established for the first time using acetonitrile or\u000d\u000a      formic acid as reaction media [2]\u000d\u000a      to give various fluoro-dicarbonyl and fluoro-ketoester systems in high\u000d\u000a      yield.\u000d\u000a    Further control of selective fluorination reactions was achieved by the\u000d\u000a      design, fabrication and\u000d\u000a      commissioning of single and multi-channel continuous flow reactor systems,\u000d\u000a      establishing the use of\u000d\u000a      convenient and inexpensive flow reactors for gas\/liquid processes in the\u000d\u000a      laboratory [3]. Key new\u000d\u000a      techniques for the supply of individual gas (F2) and liquid\u000d\u000a      reagents from single sources to a parallel\u000d\u000a      array of many flow channels at the same flow rate and pressure whilst\u000d\u000a      maintaining laminar flow\u000d\u000a      within the reactor channels were incorporated into the reactor designs.\u000d\u000a    Fluorine gas can also be used an enabler of other chemical\u000d\u000a      transformations. For example, reaction\u000d\u000a      of fluorine in situ with iodine leads to iodine monofluoride which\u000d\u000a      has been used in highly efficient\u000d\u000a      electrophilic iodination processes [4] within acidic reaction media for\u000d\u000a      the synthesis of iodoaromatic\u000d\u000a      systems directly from corresponding aromatic substrates.\u000d\u000a    "},{"CaseStudyId":"11777","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"3017382","Name":"France"},{"GeoNamesId":"1269750","Name":"India"}],"Funders":["Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000d\u000a    Following the first publications on emissive lanthanide complexes in the\u000d\u000a      late 1990s, several companies independently contacted the Durham chemists\u000d\u000a      and began to support research in Durham. These included: Sensors for\u000d\u000a      Medicine and Science (1999-2001, Gaithersburg USA; Parker became a\u000d\u000a      foundation shareholder); Molecular Devices (2004-7, Sunnyvale,\u000d\u000a      California); and CISbio Bioassays (2005-2014, Codolet, France). In 2007\/8,\u000d\u000a      Molecular Devices marketed an assay [Im1] for high throughput screening of\u000d\u000a      kinase inhibitors using a nanoparticle labelled with a Tb complex\u000d\u000a      developed in Durham [6], a five-figure deal was agreed with the\u000d\u000a      University, and it was protected by a primary patent (US Patent 7,517,701,\u000d\u000a      3 named Durham inventors) [Im1]. Consecutive direct grant support from the\u000d\u000a      French firm CISbio developed new bright Eu complexes for time-resolved\u000d\u000a      assays protected by 4 patents (most importantly: \"Nouveaux agents\u000d\u000a      complexants et complexes de lanthanide correspondant et leur utilisation\u000d\u000a      comme marquers luminescents\", French Pat. No. 1000118536; filed January\u000d\u000a      2013). These products, based on Durham research [5], are being considered\u000d\u000a      for commercialisation [Im3] as potential replacements for the emissive Eu\u000d\u000a      cryptate complexes used since the mid-1990s in high throughput,\u000d\u000a      time-resolved assays for the pharmaceutical industry.\u000d\u000a    A Durham University spin-out company FScan Ltd [Im2] (company number\u000d\u000a      6550089), was set up in 2009 to examine the use of various anions as\u000d\u000a      screening biomarkers using responsive luminescent probes. Initial support\u000d\u000a      was via the EPSRC follow-on-fund (EP\/G004773; &#163;99K) and subsequent support\u000d\u000a      was raised from the regional NStar Finance company (&#163;190K), the Northern\u000d\u000a      Universities N8 METRC fund (&#163;50K), and Ocean Optics Inc. ($10K). Granted\u000d\u000a      patents include EP 2041571 B1 and US patent 8193174.\u000d\u000a    The FScan-related research led to a test of Durham complexes in screening\u000d\u000a      men for prostate cancer, by measuring citrate levels initially in\u000d\u000a      prostatic then in seminal fluid samples (1 microlitre only needed) [4,7].\u000d\u000a      Ethical approval in late 2009 allowed an NHS study of 60 patients to be\u000d\u000a      undertaken in 2010\/2011 with the James Cook University Hospital, Teesside\u000d\u000a      [Im4]. This showed that a distinction could be made between patients with\u000d\u000a      high or intermediate grade prostate cancer from those with low-grade\u000d\u000a      cancer or benign hyperplasia. The first UCLH trial (Mark Emberton,\u000d\u000a      clinical lead, 240 patients) is underway, 80 samples have been measured\u000d\u000a      (Oct. 2013) and it will compare citrate screening with more expensive\u000d\u000a      methods such as those based on MRI and MRSI.\u000d\u000a    International publicity in 2009 [Im5] for the citrate test for prostate\u000d\u000a      cancer raised significant public &amp; commercial awareness. The story was\u000d\u000a      carried by Reuters and reported in over 50 countries and in at least 30\u000d\u000a      magazines and papers (e.g. as a front page lead in the Daily Express; page\u000d\u000a      3 of the Sun; also in the Hindu in India). Live interviews were given on 5\u000d\u000a      radio stations in the UK and Eire and it was covered in Channel 4 News and\u000d\u000a      on the BBC web site.\u000d\u000a\u000d\u000aFigure 1. Publicity and science behind the FSCan prostate cancer diagnostic test and FScan&#8217;s Robert\u000d\u000aPal undertaking related outreach demonstrations.\u000d\u000a\u000d\u000a    The optical instrumentation developed in this work has also been\u000d\u000a      incorporated into the \"Spectroscopy in a Suitcase\" outreach project. This\u000d\u000a      allows the distribution of portable spectroscopy equipment to schools\u000d\u000a      throughout the UK. Since September 2010, over 5000 pupils and members of\u000d\u000a      the public have been educated and entertained by 35 on-site demonstrations\u000d\u000a      by a team led by Dr A Beeby. Examples include demonstrations of Eu\u000d\u000a      emission (e.g. on the &#8364;10 note) following UV excitation, and the\u000d\u000a      biomedical applications of emissive complexes are explained to attendees.\u000d\u000a      Durham's research-derived expertise in lanthanide coordination chemistry\u000d\u000a      has also had major impact in the healthcare arena, particularly through\u000d\u000a      changes in FDA regulations surrounding Gd contrast agents used in millions\u000d\u000a      of MRI scans every year. This arose from the key scientific arguments and\u000d\u000a      insight Parker provided between 2008 &amp; 2013 [Im6,8] to Cleveland\u000d\u000a      lawyers developing the plaintiffs' case in a multi-district litigation\u000d\u000a      around the recently defined disease, nephrogenic systemic fibrosis (NSF).\u000d\u000a    In 1993, Parker stated [8] that macrocyclic contrast agents, \"are more\u000d\u000a      kinetically stable in vivo than DTPA-based ligands, and should\u000d\u000a      avert long term (i.e. chronic, rather than acute) toxicity problems\".\u000d\u000a      These concerns proved prophetic. In 2005\/6, the fatal condition,\u000d\u000a      nephrogenic systemic fibrosis emerged, mostly in diseased renal patients.\u000d\u000a      A link was made to the \"unsafe\" use of DTPA-based Gd contrast agents that\u000d\u000a      are susceptible to acid promoted dissociation, particularly GE\u000d\u000a      Healthcare's Omniscan and the related Optimark product.\u000d\u000a    Durham advised the Ohio law firm involved via an initial 12 page report\u000d\u000a      followed by a formal court deposition involving 8 hours of video\/oral\u000d\u000a      defence in London in September 2010. On January 24 2011 GE Healthcare\u000d\u000a      acknowledged these arguments and settled the first and four subsequent\u000d\u000a      \"bellwether trials\" out of Court; each was linked to scores of cases with\u000d\u000a      undisclosed settlements [Im 6,7]. Parker continued to advise the\u000d\u000a      prosecution for the first case involving a single individual to come to\u000d\u000a      Court in March 2013. The Court asked GE Healthcare to pay $5M to Mr Paul\u000d\u000a      Decker, who had been rendered an invalid following one Omniscan MRI scan\u000d\u000a      in 2005 [Im7,8].\u000d\u000a    In December 2009, the FDA issued new guidelines to the radiology\u000d\u000a      community advising against the use of DTPA based systems in renal\u000d\u000a      patients. This minimised risk to the 40 million patients each year that\u000d\u000a      undergo a Gd-assisted MRI scan. Since its launch, the DTPA-diamide\u000d\u000a      contrast agent Omniscan has been used in over 50 million MRI procedures at\u000d\u000a      a cost of around $30 per scan. Omniscan's share of the Gd contrast agent\u000d\u000a      market fell from 32% in 2005-7 (ca $130M) to just 10% in 2012. Macrocyclic\u000d\u000a      contrast agents are likely to dominate this market in future.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    This case describes the impact of new emissive metal complexes, the\u000d\u000a      development of associated optical equipment and knowledge dissemination\u000d\u000a      based on lanthanide chemistry. Luminescent lanthanide complexes have been\u000d\u000a      commercialised for drug-screening assays (France, USA); responsive probes\u000d\u000a      have been developed to measure bicarbonate, citrate, lactate and urate in\u000d\u000a      bio-fluids using ratiometric analysis of metal-based emission; and\u000d\u000a      clinical studies are underway assessing the use of citrate as a metabolic\u000d\u000a      marker for prostate cancer. Knowledge developed in Durham has led to\u000d\u000a      expert witness work that has helped determine the outcome of hundreds of\u000d\u000a      litigation cases. The first open settlement in the USA was $5 million; and\u000d\u000a      there have been scores of undisclosed settlements. This has contributed to\u000d\u000a      new FDA guidance that reduced the sales of one problematic gadolinium\u000d\u000a      contrast agent by $90 million in the USA alone. Finally, a related\u000d\u000a      \"Spectroscopy in a Suitcase\" outreach project was launched for UK\u000d\u000a      schoolchildren and shown to over 5000 pupils, helping them link our basic\u000d\u000a      research to societal impact.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    Durham University\u000d\u000a    ","Institutions":[{"AlternativeName":"Durham (University of)","InstitutionName":"University of Durham","PeerGroup":"B","Region":"North East","UKPRN":10007143}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"5165418","Name":"Ohio"},{"GeoNamesId":"5332921","Name":"California"},{"GeoNamesId":"5150529","Name":"Cleveland"}],"References":"\u000d\u000a    \u000a[1] J. I. Bruce, R. S. Dickins, T. Gunnlaugsson, S. Lopinski, M. P. Lowe,\u000d\u000a      D. Parker, R. D. Peacock, J. J. B. Perry, S. Aime and M. Botta, \"The\u000d\u000a      selectivity of reversible oxy-anion binding in aqueous solution at a\u000d\u000a      europium and terbium centre; signalling of carbonate chelation by changes\u000d\u000a      in the form and circular polarisation of luminescence emission\", J. Am.\u000d\u000a        Chem. Soc., 2000, 122, 9674-9684. DOI:\u000d\u000a      10.1021\/ja001797x. [193 citations]\u000d\u000a    \u000a\u000a[2] R. S. Dickins, J. A. K. Howard, A. S. Batsanov, M. Botta, J. I.\u000d\u000a      Bruce, C. S. Love, D. Parker, R. D. Peacock, and H. Puschmann,\u000d\u000a      \"Structural, luminescence and NMR studies of the reversible binding of\u000d\u000a      acetate, lactate, citrate and selected amino-acids to chiral di-aqua\u000d\u000a      ytterbium and europium complexes\", J. Am. Chem. Soc., 2002, 124,\u000d\u000a      12697-12705. DOI: 10.1021\/ja020836x. [160]\u000d\u000a    \u000a\u000a[3] A. Beeby, I.M. Clarkson, R.S. Dickins, S. Faulkner, D. Parker, L.\u000d\u000a      Royle, A.S. de Sousa, J.A.G. Williams and M. Woods, \"Non-radiative\u000d\u000a      deactivation of the excited states of europium, terbium and ytterbium\u000d\u000a      complexes by energy matched OH, NH and CH oscillators: an improved\u000d\u000a      luminescence method for establishing solution hydration states\", J.\u000d\u000a        Chem. Soc., Perkin Trans. 2, 1999, 493-504. DOI:\u000d\u000a      10.1039\/A808692C. [670]\u000d\u000a    \u000a\u000a[4] R. Pal, L. C. Costello and D. Parker, \"A europium luminescence assay\u000d\u000a      of lactate and citrate in biological fluids\", Org. Biomol. Chem.\u000d\u000a      2009, 7, 1525-1528. DOI: 10.1039\/b901251f. [55]\u000d\u000a    \u000a\u000a[5] J. W. Walton, M. Soulie, A. Bourdolle, S. J. Butler, M. Delbianco, L.\u000d\u000a      Lamarque, C. Andraud O. Maury, B. K. McMahon, R. Pal, H. Puschmann, J. M.\u000d\u000a      Zwier and D. Parker, Very bright europium complexes that stain cellular\u000d\u000a      mitochondria, Chem. Commun. 2013, 49, 1600-1602. DOI:10.1039\/C2CC35247H.\u000a      [6]\u000d\u000a    \u000a\u000a[6] P.A. Atkinson, K.S. Findlay, F. Kielar, R. Pal, D. Parker, R.A.\u000d\u000a      Poole, H. Puschmann, P.A. Stenson, A.L. Thompson and J. Yu, \"Azaxanthones\u000d\u000a      and azathiaxanthones as sensitisers for europium and terbium\u000d\u000a      luminescence\", Org. Biomol. Chem., 2006, 4, 1707-1722. DOI\u000d\u000a      10.1039\/B601357K. [37]\u000d\u000a    \u000a\u000a[7] R. Pal, A. Beeby and D. Parker, \"Rapid and accurate analysis of\u000d\u000a      citrate in low-volume seminal fluid samples using a time-gated and\u000d\u000a      ratiometric measurement of europium luminescence\", J. Pharmaceut.\u000d\u000a        Biomed. Anal. 2011, 56, 352-358. DOI:10.1016\/j.jpba.2011.05.023.\u000a      [12]\u000d\u000a    \u000a\u000a[8] K. P. Pulukkody, T. J. Norman, D. Parker, L. Royle and C. J. Broan,\u000d\u000a      \"Synthesis of charged and uncharged complexes of gadolinium and yttrium\u000d\u000a      with cyclic polyazaphosphinic acid ligands for in vivo\u000d\u000a      applications\", J. Chem. Soc. Perkin Trans 2, 1993, 605-620. DOI:\u000d\u000a      10.1039\/P29930000605. [72]\u000d\u000a    \u000aThe work described was supported by successive EPSRC grants to Parker\u000d\u000a      over the period 1998-2011 including: GR\/M04594, &#163;173K, 1998-2001;\u000d\u000a      GR\/S15952, &#163;94K, 2004-7; EP\/D061873, &#163;281K, 2006-2009; EP\/I010319\/1,\u000d\u000a      &#163;642K, 2011-14. Industrial funding includes ongoing support from CISbio\u000d\u000a      Bioassays, Codolet, France of &#163;415K, 2005-2014. EU support included\u000d\u000a      invited participation in two EC Networks of Excellence: EMIL (2004-9) &#163;47K\u000d\u000a      and DIMI (2005-10) &#163;215K. Parker also won an ERC Advanced Investigator\u000d\u000a      Grant of &#8364;2.5M (FCC-266804; 2011-16) on \"Functional Coordination\u000d\u000a      Chemistry\" to support research in metal complex systems and develop\u000d\u000a      mechanistic understanding and exploitation of function.\u000d\u000a    The academic research quality and international esteem is attested by 23\u000d\u000a      named, plenary and keynote lectures on this topic in the period, various\u000d\u000a      awards (e.g. 2011\/12, RSC Ludwig Mond medal; 2012 triennial Lecoq de\u000d\u000a      Boisbaudran Award in rare earth science) and invited consultancy work for\u000d\u000a      commercial companies (CISbio; Molecular Devices; Guerbet, Bracco s.a.).\u000d\u000a      Parker was awarded an FRS in 2002 based in part on his contributions in\u000d\u000a      this area of science. He was also appointed as an expert witness on\u000d\u000a      lanthanide chemistry for international patent litigation cases (2005\u000d\u000a      Taylor-Wessing London; 2003 Two Birds London) and for a major on-going\u000d\u000a      multi-district litigation (2008 to present) for Spangenberg-Shibley and\u000d\u000a      Liber (Cleveland, USA).\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"7","Subject":"Theoretical and Computational Chemistry"}],"Sources":"\u000d\u000a    [Im1] Molecular Devices assay: www.moleculardevices.com.\u000d\u000a      US Patent 7517701 (granted April 2009) contains details of IMAP assay\u000d\u000a      method; independent validation is in Nature Protocols, 2008, 3,\u000d\u000a      1350. The former Vice President of Molecular Devices oversaw commercial\u000d\u000a      development of the IMPA assay and will confirm use of the Durham Tb\u000d\u000a      complex.\u000d\u000a    [Im2] FScan company: www.fscanltd.co.uk\u000d\u000a      UK registered company 6550089, 31 March 2009. FSCan hold 4 patents.\u000d\u000a    [Im3] CISbio high throughput arrays: www.cisbio.com\u000d\u000a      Contact CISbio (gmathis@cisbio.com)\u000d\u000a      for corroboration of the status of emissive Eu complexes bring developed.\u000d\u000a    [Im4] Clinical trials: details of the pilot clinical work at the James\u000d\u000a      Cook University Hospital that recruited patients to assess the scope and\u000d\u000a      sensitivity\/specificity of citrate as a metabolic marker in seminal fluid\u000d\u000a      can be traced via: www.cancerhelp.org.uk\/trials\/trials-search\/study-looking-new-test-diagnose-prostate-cancer-measuring-citrate\u000d\u000a    [Im5] Prostate screening: Details of publicity associated with the 2009\u000d\u000a      press release (syndicated worldwide by Associated Press and Reuters) can\u000d\u000a      be traced via:\u000d\u000a      www.nhs.uk\/news\/2009\/05May\/Pages\/3MinuteProstateCancerTest.aspx\u000d\u000a      This links to press articles published (inter alia) in the Daily\u000d\u000a      Express (front page lead), Sun, Hindu, Daily Mail, Daily Telegraph, Men's\u000d\u000a      Health, BBC News, Channel 4 www sites (&gt;500,000 hits).\u000d\u000a    [Im6] Law case settlement: details of the first out of court GE\u000d\u000a      Healthcare settlement presided over by Judge Dan Polster in the Ohio Court\u000d\u000a      on January 24 2011 can be traced via:\u000d\u000a      http:\/\/gadoliniumlawsuit-info.com\/2011\/03\/judge-dan-polster-key-ruling-gadolinium-lawsuit\/\u000d\u000a      For updates see: http:\/\/gadoliniumlawsuit-info.com\/2011\/05\/gadolinium-multidistrict-litigation-lawsuits-settlements\u000d\u000a      Details of the amended FDA guidance (09\/12\/09) following realisation of\u000d\u000a      the NSF problem can be traced at: http:\/\/www.fda.gov\/drugs\/drugsafety\/ucm223966.htm\u000d\u000a    [Im7] Trial settlement: details of the first case to proceed to trial,\u000d\u000a      completing on March 22 2013, can be found at:\u000d\u000a      \u000d\u000ahttp:\/\/finance.yahoo.com\/news\/ashcraft-gerel-llp-jury-orders-160500877.html\u000d\u000a      The story is related in the Washington Post at\u000d\u000a      \u000d\u000ahttp:\/\/washpost.bloomberg.com\/Story?docId=1376-MK2PHO6S972W01-4NJQJIG0GSPKRHIAN399NB7SBS\u000d\u000a    [Im8] Expert witness contributions: a signed letter from the Cleveland\u000d\u000a      law firm Spangenburg, Liber and Shipley attests to the key role played by\u000d\u000a      Parker in developing the scientific case for the prosecution in these\u000d\u000a      litigation cases. \u000d\u000a    ","Title":"\u000d\u000a    Lanthanide complexes in analysis and diagnosis\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2643743","Name":"London"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    The rare earth elements are ubiquitous in modern society. A mobile phone\u000d\u000a      contains 9 different lanthanide elements (ca 120 mg), and they are widely\u000d\u000a      used in security printing (Eu) and as phosphors in displays (Eu, Tb).\u000d\u000a      Since 1993, Durham research led by Parker (Durham staff 1982-present) and\u000d\u000a      Beeby (Durham staff 1992-present) has addressed the synthesis, structure,\u000d\u000a      mechanism of action and function of lanthanide coordination complexes\u000d\u000a      [1-7]. Applications range from highly emissive lanthanide complexes to\u000d\u000a      paramagnetic complexes of Gd used as contrast agents for MRI. Parker, for\u000d\u000a      example, served as a consultant (1994-2007) for the contrast agent\u000d\u000a      companies, Guerbet (Paris) and Bracco (Milan), and Beeby worked closely\u000d\u000a      with Horiba Jobin-Yvon on instrumentation development (e.g. integrating\u000d\u000a      sphere for quantum yield determinations) to help understand these\u000d\u000a      materials.\u000d\u000a    Luminescent complexes of Eu and Tb whose emission profile is a sensitive\u000d\u000a      function of the local pH, pO2 or concentration of key bioactive\u000d\u000a      anions or macromolecules were created in Durham between 1998 &amp; 2011\u000d\u000a      [1,2]. These typically work via reversible anion binding to the metal\u000d\u000a      centre displacing water and changing the spectral form and relative\u000d\u000a      intensity of the emitted light. Ion affinity and selectivity can be\u000d\u000a      controlled by varying the effective charge and steric demand at the metal\u000d\u000a      centre. Using a mixture of Eu and Tb complexes, or by analysing the\u000d\u000a      intensity ratio of two well-separated bands in the Eu emission spectrum,\u000d\u000a      ratiometric analyses are enabled, allowing accurate calibration (WO\u000d\u000a      2008\/007089, granted 2010 in Europe: EP 2041571 B1; US patent 8,501,398\u000d\u000a      (2013)). This has allowed optical sensors to be devised that can be\u000d\u000a      calibrated to measure directly bicarbonate, urate, lactate and citrate in\u000d\u000a      a variety of bio-fluids including serum, urine and seminal fluid (original\u000d\u000a      filing by Durham University for citrate: US patent 8,193,174 granted\u000d\u000a      05.06.2012; for citrate and lactate: WO 2010\/086615 A1 published in USA as\u000d\u000a      US 2011\/0287558A1 and in Europe as EP 2391610 A0).\u000d\u000a    Factors that limit the optical brightness of these probes have also been\u000d\u000a      studied, especially processes that quench the excited states along the\u000d\u000a      photochemical pathway [4]. For example, details of the quenching of the\u000d\u000a      ligand and metal-based excited states by energy and electron transfer\u000d\u000a      processes were examined, using time-resolved spectroscopic methods.\u000d\u000a      Between 2005 and 2011 the research was extended beyond in vitro\u000d\u000a      work, by developing spectral imaging in optical microscopy of pH and\u000d\u000a      anion-induced changes in cellulo, paving the way for applications\u000d\u000a      in cell biology. New portable optical instrumentation has been developed\u000d\u000a      by Beeby and Dr Robert Pal to measure the optical signal selectively. A\u000d\u000a      hand-held, time-gated emission spectrometer is being developed, in\u000d\u000a      partnership with Ocean Optics (USA) [7]. Ethical approval was given in\u000d\u000a      November 2009 for clinical studies to begin assessing citrate as a\u000d\u000a      screening marker in prostate cancer.\u000d\u000a\u0009  Parker has also been developing the\u000d\u000a      chemistry of contrast agents for MRI since 1991, creating new families of\u000d\u000a      kinetically stable macrocyclic complexes that resist premature\u000d\u000a      dissociation of the metal ion in vivo. [8] In addition, he has been\u000d\u000a      creating new series of very bright Eu and Tb complexes [5,6], designing\u000d\u000a      new sensitising moieties, such as azaxanthones\/azathiaxanthones and with\u000d\u000a      Olivier Maury (Lyon) and CISbio, he has developed Eu complexes with a\u000d\u000a      brightness of the same order as that of green fluorescent protein [5].\u000d\u000a    "},{"CaseStudyId":"11778","Continent":[{"GeoNamesId":"6255150","Name":"South America"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2960313","Name":"Luxembourg"},{"GeoNamesId":"2963597","Name":"Ireland"},{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"2802361","Name":"Belgium"},{"GeoNamesId":"2510769","Name":"Spain"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"1814991","Name":"China"},{"GeoNamesId":"1643084","Name":"Indonesia"},{"GeoNamesId":"3469034","Name":"Brazil"},{"GeoNamesId":"2623032","Name":"Denmark"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"2921044","Name":"Germany"},{"GeoNamesId":"1269750","Name":"India"},{"GeoNamesId":"99237","Name":"Iraq"},{"GeoNamesId":"1605651","Name":"Thailand"},{"GeoNamesId":"3865483","Name":"Argentina"}],"Funders":["Engineering and Physical Sciences Research Council","Royal Society"],"ImpactDetails":"\u000a    The Durham research described in Section 2 has been transferred to\u000a      industry through three different business models (income generated growth,\u000a      corporate venturing, and venture capital). The transfer methods are\u000a      summarized in the flow chart below and an example of impact generated\u000a      through each method is given in the following sections.\u000a\u000a\u000a\u000a    (a) Income Generated Growth (Surface Innovations Ltd, Durham, UK):\u000a      Atomized-Spray Plasma Deposition (ASPD) described in [6] is capable of\u000a      producing a wide variety of thin, high quality, functional coatings, at\u000a      throughputs attractive to a large number of markets. The approach allows\u000a      lost-cost substrates to exhibit the surface properties and performance of\u000a      far more expensive materials. To exploit this technology Badyal and Dr\u000a      Luke Ward (a former PhD student) founded the IP-ownership company Surface\u000a      Innovations Ltd. in 2001 [Im1]. Durham University agreed to assign\u000a      non-industrially sponsored intellectual property developed within the\u000a      Badyal group to the company in return for an equity stake. 14 core patent\u000a      families were filed during the period 2001-2010 on surface\u000a      functionalization for applications including: filtration; antifogging;\u000a      bioarrays; antibacterial; antifouling; high dielectric constant;\u000a      super-repellency; fog harvesting; and rewritability. The company was\u000a      funded by loans and income generated from prototype development amounting\u000a      to &#163;824K for industrial partners including: Siemens (Germany); Arcelor\u000a      (Belgium); Procter &amp; Gamble (USA); Sauflon (UK); Federal Moghul\u000a      (Luxembourg); Dow Corning (USA); IRD Fuel Cells (Denmark); Kimberly-Clark\u000a      (USA); Gillette (USA); Calgon (USA); Porvair (UK); and SMB Microfluidic\u000a      Devices (Denmark). The company had 5 employees when it was bought out by\u000a      P2i Ltd in July 2010 [Im2] for ca &#163;737K (P2i 2010 Annual report\u000a      [Im8]). The Department's share of the income has been used to fund\u000a      undergraduate research internships in Durham and abroad to highlight\u000a      entrepreneurship opportunities and benefits to our students. Badyal has\u000a      utilized proceeds to help alleviate extreme child poverty in India and\u000a      Africa.\u000a    (b) Corporate Venturing (Dow Corning Plasma Ltd, Cork, Ireland):\u000a      The atomised spray plasmachemical deposition (ASPD) technique developed in\u000a      Durham [5] was patented in collaboration with Dow Corning and a start-up\u000a      company [Im3,Im4] was set up in Ireland with an initial investment of &#8364;3.3\u000a      million made by Dow Corning Corporation (USA). Its managing director was\u000a      Dr Alan Hynes (a former Badyal PhD student). Large scale (up to 2.8 m\u000a      width roll-to-roll) industrial manufacturing machines were built based\u000a      upon the Durham ASPD equipment design and sold for significant sums. The\u000a      company employed 28 people, and in 2008 the business became fully\u000a      integrated into Dow Corning Corporation. Current licensees of the ASPD\u000a      technology include Invexus (USA) which is supplying to the &gt;&#163;2 billion\u000a      global market for antibacterial surfaces.\u000a    (c) Venture Capital (P2i Ltd, Abingdon, UK): In 1996 Badyal was\u000a      approached by the UK MoD concerning the dehydration of British soldiers in\u000a      the desert during the 1990 conflict with Iraq. In particular, the military\u000a      wanted to reduce the number of layers of clothing that soldiers had to\u000a      wear in the battle field. Badyal proposed the utilization of pulsed\u000a      plasmachemical deposition (PPD) which led to the funding of a PhD student\u000a      (Stephen Coulson). The idea was successful, a patent for treating fabric\u000a      was filed (GB Pat Appl. 9712338.4, 1997) and the research published\u000a      [4,Im5,Im6]. Upon completion of his PhD, Stephen Coulson moved to the MoD\u000a      and in 2004 helped found P2i Ltd (UK Company 04814350), where he has\u000a      remained as Chief Technology Officer (CTO). P2i has raised &#163;40 million\u000a      investment from Swarraton Partners, NAXOS Capital Partners, Porton Capital\u000a      Limited, Unilever Ventures, OMBU Group, and the Rainbow Seed Fund,\u000a      including &#163;31.75M since 2008. The company headquarters are in Abingdon,\u000a      and it currently has offices in Savannah (USA), Oregon (USA), Singapore,\u000a      and an applications centre in China. In 2010, having undergone very rapid\u000a      growth, P2i purchased Surface Innovations from DU and Badyal in order to\u000a      broaden its portfolio of functional nanocoatings [Im2,8].\u000a    P2i has built its business by developing and commercialising the Durham\u000a      plasma deposited liquid repellent nanocoatings described in [4]. It has\u000a      commercialised treatments as the Ion Mask&#8482; brand for footwear,\u000a      clothing and accessories, and as Aridion&#8482; for electronics\u000a      applications [Im7]. These ultra-low surface energy nanocoatings impart\u000a      numerous benefits to consumer products. For footwear and filtration media,\u000a      treated products no longer absorb liquids but instead remain dry, clean\u000a      and lightweight. For complex three dimensional products such as\u000a      smartphones, and computer tablets, the low surface energy prevents liquids\u000a      from being drawn into the device by means of capillary action.\u000a\u000aFigure: Some examples of product applications using Durham-derived plasma nanocoatings.\u000a\u000a    Over 150 commercial plasma coatings units based on the Durham design have\u000a      been manufactured by P2i and installed with customers in Argentina,\u000a      Australia, Brazil, China, Germany, India, Indonesia, Singapore, Spain,\u000a      Thailand, UK, and the USA for the surface treatment of products in the electronics, lifestyle,\u000a      life sciences, filtration,\u000a        energy, military,\u000a        and institutional sectors. Examples of the use of Ion Mask&#8482;\u000a      and Aridion&#8482; technologies are given in the figure above and the\u000a      table below. This is sourced from Case Studies described in P2i open\u000a      literature [Im8] in July 2013, and is not a comprehensive list of\u000a      applications.\u000a    \u000a      \u000a        \u000a          Application\u000a          Examples: Brand\u000a              (models)\u000a          Notes\u000a        \u000a        \u000a          Phones\u000a          Alcatel (ONE TOUCH 997 and 992D); Plantronics (Headsets Voyager\u000a            legend, Backbeat GO); Motorola (RAZR and Moto X smartphones and\u000a            Xyboard tablet)\u000a          8 million units &gt;&#163;4M retail\u000a        \u000a        \u000a          Hearing Aids\u000a          Hearing Lab Technology (HLT) &#8211; GN Resound 60% of the\u000a            world&#8217;s hearing aids\u000a          6 million units &gt;&#163;3M retail\u000a        \u000a        \u000a          Footwear\u000a          Hi-Tec (V-Lite Mach 4, V-Lite Infinity, Sierra Lite); Teva (Links\u000a            Mtb, Mush Frio Lace, Fuse-ion, Reforge-Ionmask); K-Swiss (Kwicky\u000a            Blade Light, California); Timberland (Tall Zip Boot, Desert Boot,\u000a            City 6IN Boot, Formentor Boot); Scott (Eride Icerunner); Van Dal\u000a            (suede shoe range); Mizuno (Weathers golf); MAGNUM (Sidewinder\u000a            Combat Desert Boot, Elite Force Boot); Nike; Adidas\u000a          3 million pairs of shoes &gt;&#163;2M retail\u000a        \u000a        \u000a          Clothing\u000a          Kangol Headwear (Tropic Jacquard 507, Zig Duke, Pole Stripe);\u000a            Trekmates (Mountain Lite Mitt); Global Armour (G Tech Vest)\u000a          Potential market of &gt;&#163;1 billion\u000a        \u000a        \u000a          Filtration and Energy\u000a          Porvair (filtration and separation equipment) Crowcon\u000a            (gas detection equipment, STAY-CLIR) Eppendorf (Pipette tips)\u000a          55,000 ft of filter media\u000a            100 million pipette tips\u000a        \u000a      \u000a    \u000a    P2i company turnover has grown rapidly since 2008 (see table), exceeding\u000a      &#163;8.8M in 2011-12 with 93% of revenues generated in geographic markets\u000a      outside of the UK, leading to the creation of &gt;100 new jobs and the\u000a      establishment of wholly owned subsidiaries in China, Hong Kong, USA and\u000a      Singapore. P2i currently own a portfolio of over 60 patent families to\u000a      protect their core businesses.\u000a    \u000a      \u000a        \u000a          \u000a          2008\u000a          2009\u000a          2010\u000a          2011\u000a          2012\u000a          Totals*\u000a        \u000a        \u000a          VC raised (&#163;M)\u000a          2.0\u000a          6.1\u000a          5.5\u000a          11.4\u000a          6.75\u000a          31.75\u000a        \u000a        \u000a          Turnover(&#163;M)\u000a          0.862\u000a          1.035\u000a          3.180\u000a          6.021\u000a          8.886\u000a          19.984\u000a        \u000a        \u000a          Employees\u000a          15\u000a          27\u000a          48\u000a          90\u000a          115\u000a          115\u000a        \u000a      \u000a    \u000a    * Company report for January - July 2013 unavailable at time of writing\u000a    P2i is widely recognized as being the world leader in plasmachemical\u000a      deposited functional nanocoatings and has won numerous awards including:\u000a      International Business Award for \"Most Innovative Company in Europe\", 2011\u000a      and 2012; \"Footwear Innovation\" category at the 2009 Company Clothing\u000a      Awards, London, 2009; \"Borderless Business\" category, Management Today,\u000a      2011; \"Best of Show\" award, American Academy of Audiology, 2011; Global\u000a      Business Excellence Award 2012; and 27th fasted growing UK technology\u000a      company in the 2012 Sunday Times Tech Track 100 league table. The Durham\u000a      research has featured extensively in the media, including: the Sunday\u000a      Times newspaper; the national BBC Evening TV News; BBC Radio 4 Today\u000a      Programme; Channel 5's Gadget Show; and the Discovery Channel.\u000a    ","ImpactSummary":"\u000a    Super-repellent surfaces created by plasmachemical techniques invented at\u000a      Durham University have been exploited by P2i as the Ion-mask&#8482;\u000a      and Adiron&#8482; brands and used to protect the surfaces of millions\u000a      of products worldwide including: 3 million pairs of footwear (Timberland,\u000a      Hi- Tec); 8 million mobile phones (Nokia, Motorola, Alcatel); 60% of the\u000a      world's hearing aids (HLT, GN Resound); 55,000 feet of filter media\u000a      (Porvair); and 100 million pipette tips (Eppendorf). This has earned P2i\u000a      industry awards including the 2011 and 2012 International Business Award\u000a      for \"Most Innovative Company in Europe\" and the \"Global Business\u000a      Excellence Award\" 2012. The combined turnover of P2i since 2008 was ca.\u000a      &#163;20M, it received external investment of &#163;31.75M and has created 115 new\u000a      jobs. A DU IP-holding spin-out company, Surface Innovations, was purchased\u000a      by P2i in 2010, and further applications of DU plasmachemical\u000a      functionalization were commercialized by Dow Corning Plasma Solutions Ltd\u000a      and exploited in-period.\u000a    ","ImpactType":"Technological","Institution":"\u000a    Durham University\u000a    ","Institutions":[{"AlternativeName":"Durham (University of)","InstitutionName":"University of Durham","PeerGroup":"B","Region":"North East","UKPRN":10007143}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"304081","Name":"Mus"},{"GeoNamesId":"5744337","Name":"Oregon"},{"GeoNamesId":"1819729","Name":"Hong Kong"},{"GeoNamesId":"1880252","Name":"Singapore"},{"GeoNamesId":"5332921","Name":"California"}],"References":"\u000a    \u000a[1] J. Hopkins and J. P. S. Badyal, \"Nonequilibrium Glow Discharge\u000a      Fluorination of Polymer Surfaces\", J. Phys. Chem., 1995, 99,\u000a      4261-4264. DOI: 10.1021\/j100012a056 [60 citations]\u000a    \u000a\u000a[2] I. S. Woodward, W. C. E. Schofield, V. Roucoules and J. P. S. Badyal,\u000a      \"Super-Hydrophobic Surfaces Produced by Plasma Fluorination of\u000a      Polybutadiene Films\", Langmuir, 2003,19, 3432-3438. DOI:\u000a      10.1021\/la020427e [203]\u000a    \u000a\u000a[3] M. E. Ryan, A. M. Hynes and J. P. S. Badyal, \"Pulsed Plasma\u000a      Polymerization of Maleic Anhydride\", Chem. Mater., 1996, 8,\u000a      37-42. DOI: 10.1021\/cm9503691 [135]\u000a    \u000a\u000a[4] S. R. Coulson, I. S. Woodward, S. A. Brewer, C. Willis and J. P. S.\u000a      Badyal, \"Ultra-Low Surface Energy Plasma Polymer Films\", Chem. Mater.,\u000a      2000, 12, 2031-2038. DOI: 10.1021\/cm000193p [141]\u000a    \u000a\u000a[5] L. J. Ward, W. C. E. Schofield, A. J. Goodwin, P. J. Merlin and J. P.\u000a      S. Badyal, \"Atmospheric Pressure Plasma Deposition of Structurally\u000a      Well-Defined Polyacrylic Acid Films\", Chem. Mater., 2003, 15,\u000a      1466-1469. DOI: 10.1021\/cm020289e [82]\u000a    \u000a\u000a[6] L. J. Ward and J. P. S. Badyal, \"Method and Apparatus for Forming a\u000a      Coating on a Substrate\", Patent WO 2006\/092614, 8 September 2006.\u000a    \u000aThe quality of this research is evidenced by several major awards to\u000a      Badyal including: the Harrison Prize of the Royal Society of Chemistry;\u000a      the Burch Prize of the British Vacuum Council; and the International\u000a      Association of Advanced Materials Medal for \"Outstanding and Notable\u000a      Contribution in the Field of Nanomaterials and Nanotechnology\". He has\u000a      given 13 plenary\/keynote and 12 invited lectures at overseas international\u000a      conferences since 2008 (in countries including Australia, Austria,\u000a      Belgium, Canada, Czech Republic, Denmark, France, Germany, Greece, India,\u000a      Italy, Luxembourg, Mexico, Netherlands, New Zealand, Poland, Portugal, and\u000a      USA). The surface science described in this study was funded by a variety\u000a      of research grants from several sources including EPSRC, British Gas, EU,\u000a      Mupor Ltd, DERA and Dow Corning.\u000a    ","ResearchSubjectAreas":[{"Level1":"2","Level2":"2","Subject":"Atomic, Molecular, Nuclear, Particle and Plasma Physics"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"9","Level2":"12","Subject":"Materials Engineering"}],"Sources":"\u000a    [Im1] Surface innovations: www.surface-innovations.com\u000a      and annual reports filed with Companies House 2008-2013.\u000a    [Im2] P2i acquisition of Surface Innovations: P2i Press Release, 13 July,\u000a      2010.\u000a    [Im3] Dow coatings: Dow Corning Plasma Solutions Application Note, 2005.\u000a    [Im4] Dow coatings: Chem. Eng. News, October 16, 2006, 84 (42), 18-20.\u000a    [Im5] Fabric coating: DSTL Annual Report and Accounts, 2004\/2005, p17.\u000a    [Im6] Fabric coating: Sunday Times main section, 11th October 1998.\u000a    [Im7] P2i brands: Financial Times, March 4, 2012.\u000a    [Im8] P2i awards: www.p2i.com, P2i\u000a      Media Information Pack and Annual reports filed with Companies House\u000a      2008-2013. \u000a    ","Title":"\u000a    Super-repellent surfaces by plasmachemical functionalization\u000a    ","UKLocation":[{"GeoNamesId":"2657780","Name":"Abingdon"},{"GeoNamesId":"2643743","Name":"London"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Research focused on understanding and controlling chemical reaction\u000a      pathways at plasma-solid interfaces was led by Professor Jas Pal Badyal\u000a      (Durham staff, 1989-present).\u000a    Surface engineering and modification techniques are being used in all\u000a      sectors of the materials, engineering, electronics and health-care\u000a      industries to provide devices with specific functional properties such as\u000a      waterproofing, antifouling and corrosion-resistance properties. This\u000a      industry has an estimated value of $50 billion per annum and new\u000a      technologies to enhance surface properties of all types of materials are\u000a      highly valued.\u000a    The plasma state was discovered in 1879 by the English scientist William\u000a      Crookes and, despite being used for technological applications such as\u000a      lighting for over 100 years, very little progress had previously been made\u000a      in relation to achieving high chemical reaction pathway selectivities\u000a      within this 4th state of matter. Durham research has, however, developed\u000a      methods to use plasmachemical techniques to selectively functionalise the\u000a      surfaces of a wide range of different materials. Two particular areas of\u000a      research which underpin the impact described in Section 4 are:\u000a    (a) Synthon theory for plasmachemical surface functionalization:\u000a      this theory allows rational prediction of the surface functionalization of\u000a      polymers by electrical gas discharges. It uses a synthon approach to\u000a      correlate the reactivity of chemical groups located at a polymer substrate\u000a      surface with the impinging plasma species. In this way, desired\u000a      functionalities can be incorporated into a surface by the judicious choice\u000a      of electrical discharge and polymer substrate. Structure- behaviour\u000a      relationships were developed which explain the interfacial plasma-solid\u000a      chemical reaction pathways [1,2].\u000a    (b) Structurally well-defined functional nanofilms: Most\u000a      established surface treatment methods are substrate-specific and cannot be\u000a      easily adapted to different materials or geometries (making them no more\u000a      than an academic curiosity in many cases). Durham research showed that\u000a      plasmachemical deposition offers the potential to address this limitation\u000a      by exploiting the inherent substrate activation by the electrical\u000a      discharge prior to the onset of film growth. This allows\u000a      substrate-independent surface functionalization. Furthermore, this\u000a      approach is single-step, solventless, operates at ambient temperature, and\u000a      requires very low energy input. Two methods utilized by Durham have been\u000a      shown to achieve extremely high chemical selectivity at the plasma- solid\u000a      interface during functional nanolayer deposition:\u000a    \u000a      \u000aPulsed Plasmachemical Deposition (PPD): By pulsing the\u000a        electrical discharge on ms-03bcs timescales, two distinct reaction\u000a        regimes can be constructed: firstly activation of precursor molecules by\u000a        UV irradiation, ion, or electron collisions during the plasma duty cycle\u000a        on-period (typically 03bcs), and then conventional chemistry (e.g.\u000a        cyclisation or polymerisation) proceeding in the absence of any damaging\u000a        plasma species during a much longer off-period (typically ms). This has\u000a        been shown to lead to extremely high levels of surface functionality\u000a        [3,4].\u000a      \u000aAtomised Spray Plasma Deposition (ASPD):\u000a        Structurally well-defined functional nanofilms can also be obtained by\u000a        the nebulisation of precursor molecules into an electrical discharge.\u000a        Mechanistically, this proceeds by highly excited metastable atoms\u000a        possessing sufficient energies to activate precursor molecules (Penning\u000a        type reactions) which initiate conventional chemical reaction pathways\u000a        during the impact of the supersonically expanding atomised liquid\u000a        droplets onto the substrate surface [5]. It has also been shown that\u000a        well-defined nanocomposite films can be created by utilizing\u000a        nanoparticle slurries [6].\u000a    \u000a    "},{"CaseStudyId":"11779","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"3175395","Name":"Italy"},{"GeoNamesId":"2658434","Name":"Switzerland"},{"GeoNamesId":"3077311","Name":"Czech Republic"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"2623032","Name":"Denmark"},{"GeoNamesId":"2782113","Name":"Austria"},{"GeoNamesId":"2921044","Name":"Germany"}],"Funders":["Biotechnology and Biological Sciences Research Council","Engineering and Physical Sciences Research Council","Medical Research Council","Royal Society"],"ImpactDetails":"\u000a    The global research market for cell culture is estimated to be worth\u000a      $600m annually and is growing at 10% a year. Around 35 million cell\u000a      culture plates are used each year world-wide for simple 2D cell growth for\u000a      many applications in basic research, drug discovery and life science\u000a      sectors; i.e. in all areas where scientists need to better understand\u000a      growth, function and disease mechanisms of cells in vivo.\u000a    Durham University spin-out company, Reinnervate Limited [Im1] (UK Company\u000a      04468747), was established in 2002 by Pryzborski with the aid of the\u000a      Durham Business &amp; Innovation Services team as a vehicle to\u000a      commercialise technology in the bioscience sector and, specifically, to\u000a      develop enabling technology to improve the growth and function of cultured\u000a      cells stemming from Durham research in the porous polymer scaffold [3,6]\u000a      and synthetic retinoid fields [1]. The Company raised seedcorn funding\u000a      (~&#163;60K) from a variety of different initiatives, including awards from the\u000a      Regional Development Agency and the Department of Trade and Industry, to\u000a      support R&amp;D and perform corporate duties. In 2005, a commercial loan\u000a      (&#163;0.5M) to expedite the development and translation of the basic research\u000a      into marketable products was raised. A further ~&#163;8M of research funding\u000a      was raised from investors (Venture Capital funds, high net-worth\u000a      individuals, Angel funds) to support R&amp;D, IP protection and marketing.\u000a      In its early stages Reinnvervate was incubated within the Chemistry\u000a      Department, but by 2009 it had grown to such an extent that it established\u000a      its own independent premises outside the University. It completed this\u000a      process in 2010 by acquiring 5000 sq ft of space in the NETPark Incubator,\u000a      Sedgefield, in which the University has an equity stake. In 2011, the\u000a      Company became fully operational and independent of the University. By\u000a      2012 the business employed 27 personnel at NetPark, a further 9 at Durham\u000a      University and had an experienced management team consisting of a CEO,\u000a      CSO, CFO, Production Director, Commercial Director, and Marketing and\u000a      Product Development managers, as well as a Board headed by a Chairman with\u000a      experience in the life science sector.\u000a    All the products developed and marketed by Reinnervate (ec23&#174; retinoids\u000a      and the Alvetex&#174; 3D scaffold range) have their origins in DU Chemistry\u000a      research [1-6].\u000a    The stable synthetic retinoids for predictable stem cell differentiation\u000a      designed, synthesised and described in [1] were patented by DU in 2006\u000a      (WO2008025965 \"Retinoid compounds and their use\", Przyborski, Whiting and\u000a      Marder) and the IP rights assigned to Reinnervate. The syntheses of the\u000a      retinoid compounds were scaled-up and manufactured at High Force Research\u000a      Ltd (Durham) and are currently marketed through Reinnervate's commercial\u000a      partners including Tocris, Enzo Life Sciences, LGC Standards and Amsbio as\u000a      ec23&#174; [Im2].\u000a    The 3D polyHIPE scaffolds derived from porous polystyrene described in\u000a      references [5] and [6] were patented by DU (WO200712588 \"Substrate for\u000a      growth of cultured cell in three dimensions\", Przyborski &amp; Cameron)\u000a      and the IP assigned to Reinnervate. An extensive development phase within\u000a      Reinnervate, involving re-engineering and scale-up of the technology,\u000a      optimization for 3D cell culture and development of further applications\u000a      of the 3D scaffolds in bioscience was carried out. This allowed creation\u000a      of the first Alvetex&#174; products which were launched in November 2010 [Im3].\u000a      Since the first scaffold entered the market (see Figure), several other\u000a      formats of the technology such as a 12-well, 24-well and 96-well culture\u000a      plate and 6\/12-well inserts were introduced. There are currently 18\u000a      distributors including ThermoFisher Scientific, Generon (UK), Biozol GmbH\u000a      (Germany), Chemie Brunschwig AG (Switzerland), THP Medical Products\u000a      (Austria), In Vitro AS (Denmark), Euroclone (Italy), and Bio Connect (the\u000a      Benelux region) that market the Alvetex&#174; brand in different territories\u000a      around the world and over 1500 customers world-wide. Growing sales\u000a      currently amount on average to approximately &#163;15K per month for the first\u000a      two quarters of 2013.\u000a    \u000a    \u000a    \u000a   \u000a  Figure: porous polystyrene Alvetex&#174; 3D scaffold microstructure (left) and marketed 96-well plate format for cell culture studies (right)\u000a  \u000a\u000a    The ultimate beneficiaries of these developments are the life science end\u000a      users who buy and use the scaffold technology. Whilst some of the\u000a      technologies are specialised and will benefit discrete groups of\u000a      scientists (e.g. stem cell differentiation, cancer cell biology), other\u000a      products are more generic, and have far greater penetration and use (e.g.\u000a      3D cell culture &#8212; applicable to almost any cell biologist currently\u000a      practising conventional 2D culture techniques). Improving the growth,\u000a      differentiation and function of cultured cells has many advantages,\u000a      including decreasing R&amp;D costs, reducing animal usage, improving the\u000a      predictive accuracy during development of drug candidates, and advancing\u000a      basic research.\u000a    A published BBSRC Impact evidence report [Im4] confirms that \"Reinnervate\u000a      now has more than 1,500 customers around the world, including cell\u000a      biologists and other researchers in academic institutions, government\u000a      labs, hospitals and the biotech and pharmaceutical industries, making it a\u000a      leading company in the 3D cell-culture market. The company's technologies\u000a      have several applications in life sciences, including stem cell research\u000a      and tissue engineering in vitro, cancer cell biology, liver\u000a      toxicology, models of human skin, as well as drug discovery and product\u000a      development in the academic, biotechnology and pharmaceutical sectors.\"\u000a    Testimonials [Im5] from scientists using the Alvetex&#174; products recorded\u000a      on the http:\/\/www.reinnervate.com\u000a      website attest to the effectiveness of the Alvetex&#174; technology for cell\u000a      biology. These include: \"The ability to use Alvetex&#174; Scaffold\u000a      to create a genuine 3D cell culture enabled us to provide a favourable\u000a      environment in which our cells could grow, differentiate and proliferate\",\u000a      Professor of Cardiothoracic Surgery, Stanford University, USA; \"Oncotest\u000a      are particularly pleased at the ease of isolation of protein for\u000a      downstream assays and potential biomarker validation\", Head, Throughput\u000a      Screening Laboratory and Investigator, Oncotest GmbH; \"We have been using\u000a      Alvetex&#174; Scaffold for growing our prostate and colon epithelial\u000a      cell line [and] have observed some striking differences between 2D and 3D\u000a      prostate and colon cells surface marker expression\", Senior Scientist,\u000a      Inst. of Biophysics, Czech Republic. In addition, collaborations with\u000a      various industrial organisations including Tecan, Roslinn Cellab,\u000a      Medicyte, Kirkstall and Mirus Bio to develop new uses of Alvetex&#174;\u000a      scaffolds in a variety of healthcare areas are underway.\u000a    The Durham scientists involved in the Reinnervate project were awarded\u000a      the RSC Rita and John Cornforth award in 2012, which recognises excellence\u000a      in inter-disciplinary research at the boundaries of chemistry and biology,\u000a      for developing Alvetex&#174;.\u000a    Alvetex&#174; has also won numerous technology awards. These include: an\u000a      R&amp;D 100 Award in June 2011, identifying it as among the top 100 most\u000a      technologically significant products introduced into the marketplace over\u000a      the previous year; and \"The Scientist\" magazine's Top 10 Life Science\u000a      Innovations of 2010. The judging panel for the latter award commented that\u000a      \"Alvetex&#174; Scaffold is an example of innovation to move us\u000a      closer to better models for mimicking in vivo behaviour of cells\u000a      with the control offered by in vitro conditions\" (Neil Kelleher,\u000a      Northwestern University Chicago, USA) and \"Alvetex&#174; Scaffold\u000a      should enable the routine and reproducible creation of 3D cell cultures in\u000a      the laboratory and extend the concept of 3D culture beyond simple,\u000a      reconstituted extracellular matrices to complex cellular structures\"\u000a      (Steven Wiley, Environmental Molecular Sciences Laboratory, Richland WA,\u000a      USA) [Im6].\u000a    ","ImpactSummary":"\u000a    3D polyHIPE scaffold materials and synthetic retinoids developed at\u000a      Durham University for applications in cell biology have been\u000a      commercialized by Reinnervate, a Durham spin-out company, using a\u000a      patent\/licensing strategy. Reinnervate has raised &#163;8m venture capital\u000a      investment and has employed an average of 12 FTE staff since 2008, peaking\u000a      at 27 in 2012. Polystyrene-based highly porous polyHIPE materials which\u000a      act as 3D in vitro cell culture scaffolds were launched under the\u000a      Alvetex&#174; brand in November 2010 and a retinoid derivative, designed to\u000a      control cellular development including stem cell differentiation down\u000a      neural pathways, was launched as ec23&#174;. The products have won several\u000a      awards and Alvetex&#174; was voted one of \"The Scientist\" magazine's top 10\u000a      Life Science Innovations of 2010.\u000a    ","ImpactType":"Technological","Institution":"\u000a    Durham University\u000a    ","Institutions":[{"AlternativeName":"Durham (University of)","InstitutionName":"University of Durham","PeerGroup":"B","Region":"North East","UKPRN":10007143}],"Panel":"B         ","PlaceName":[],"References":"\u000a    \u000a[1] J. H. Barnard, C. E. Bridgens, A. Botsanov, E. B. Cartmell, V. B.\u000a      Christie, J. C. Collings, T. B. Marder, S. Przyborski, C. P. F. Redfern\u000a      and A. Whiting, \"Synthesis and evaluation of selective stem cell\u000a      differentiation agents based on synthetic retinoid derivatives\", Org.\u000a        Biomol. Chem., 2008, 6, 3497-3507. DOI:\u000a      10.1039\/b808574a. [15 citations]\u000a    \u000a\u000a[2] A. Barbetta, N.R. Cameron and S.J. Cooper, \"High internal phase\u000a      emulsion (HIPEs) containing divinylbenzene and 4-vinylbenzyl chloride and\u000a      the morphology of the resulting PolyHIPE materials\", Chem. Commun.,\u000a      2000, 221-222. DOI: 10.1039\/a909060f. [74]\u000a    \u000a\u000a[3] M. W. Hayman, K. H. Smith, N. R. Cameron and S. A. Przyborski,\u000a      \"Enhanced neurite outgrowth by human neurons grown on solid\u000a      three-dimensional scaffolds\", Biochem. Biophys. Res. Commun.,\u000a      2004, 314, 483-488. DOI: 10.1016\/j.bbrc.2003.12.135\u000a        [54]\u000a    \u000a\u000a[4] R. J. Carnachan, M. Bokhari, S. A. Przyborski and N. R. Cameron,\u000a      \"Tailoring the morphology of emulsion-templated porous polymers\", Soft\u000a        Matter, 2006, 2, 608-616. DOI: 10.1039\/b603211g. [68]\u000a    \u000a\u000a[5] M. Bokhari, R. Carnachan, S.A. Przyborski and N.R. Cameron, \"Effect\u000a      of synthesis parameters on emulsion-templated porous polymer formation and\u000a      evaluation for 3D cell culture scaffolds\", J. Mater. Chem., 2007,\u000a      17, 4088-4094. DOI: 10.1039\/b707499a. [28]\u000a    \u000a\u000a[6] M. Bokhari, R. Carnachan, N.R. Cameron and S.A. Przyborski, \"Novel\u000a      cell culture device enabling three-dimensional cell growth and improved\u000a      cell function\", Biochem. Biophys. Res. Commun., 2007, 354,\u000a      1095-1100. DOI: 10.1016\/j.bbrc.2007.01.105. [39]\u000a    \u000aThis research was funded by various UK research councils including: EPSRC\u000a      (GR\/T24043, 2005-2006); MRC; and 3 &#215; BBSRC and 1 &#215; EPSRC Industrial CASE\u000a      studentships The quality and international esteem of the research\u000a      programme is supported by citations of the original papers and a number of\u000a      invitations to give plenary and keynote lectures at major international\u000a      conferences (for example, NRC: 32nd Australasian Polymer\u000a      Symposium, 2011; 23rd European Congress on Biomaterials, 2010;\u000a      11th Pacific Polymer Conference, 2009; AW: 1st\u000a      Annual World Congress on Asymmetric Synthesis, Beijing, 2010; 6th\u000a      International Conference on Green and Sustainable Chemistry, UK, 2013; SB:\u000a      Form and Function in Regenerative Medicine, Dublin, 2013; Neurological\u000a      Disorders, London, 2013).\u000a    The Reinnervate team was awarded the 2012 Rita and John Cornforth Award\u000a      of the Royal Society of Chemistry. This recognises research achievements\u000a      by scientists working in interdisciplinary collaborative research teams in\u000a      both the chemistry and life science sectors.\u000a    ","ResearchSubjectAreas":[{"Level1":"6","Level2":"1","Subject":"Biochemistry and Cell Biology"},{"Level1":"9","Level2":"3","Subject":"Biomedical Engineering"}],"Sources":"\u000a    [Im1] Company details: Reinnervate Limited (Registered Company No.\u000a      04468747), NETPark Incubator, Thomas Wright Way, Sedgefield, TS21 3FD.\u000a      Corporate headquarters: 5000sq.ft facility, comprising manufacturing\u000a      suite, clean room, product development laboratory, process development,\u000a      administration offices, warehousing. See:\u000a      http:\/\/www.reinnervate.com\/.\u000a    [Im2] Synthetic retinoids: for additional marketing material see:\u000a      http:\/\/www.tocris.com\/dispprod.php?ItemId=272185#.UYej_oJcSHk,\u000a      http:\/\/www.enzolifesciences.com\/BML-EC23\/ec23\/\u000a      and http:\/\/www.amsbio.co.uk\/ec23-synthetic-retinoid-ATRA.aspx.\u000a    [Im3] Alvetex&#174;: see http:\/\/www.reinnervate.com\/\u000a      and\u000a      http:\/\/www.fishersci.com\/ecomm\/servlet\/fsproductdetail?storeId=10652&amp;aid=4370711&amp;store\u000a=Scientific&amp;segment=lifeScience&amp;WTPromo=%20Spotlight%20Alvetex%20Scaffold.\u000a    [Im4] BBSRC Impact evidence reports: http:\/\/www.bbsrc.ac.uk\/publications\/impact\/novel-3d-cell-culture-system.aspx.\u000a    [Im5] Customer feedback: for quotations directly from beneficiaries and\u000a      users of Alvetex&#174; products see the comprehensive list at: http:\/\/reinnervate.com\/alvetex\/testimonials\/.\u000a    [Im6] Technology awards: see information on the web at: http:\/\/www.nebusiness.co.uk\/business-\u000anews\/science-and-technology\/2011\/10\/27\/bio-tech-firm-reinnervate-wins-major-r-d-award-51140-29669230\/,\u000a      http:\/\/classic.the-scientist.com\/2010\/12\/1\/47\/1\/,\u000a      http:\/\/www.biospace.com\/news_story.aspx?NewsEntityId=204209&amp;Source=MoreNews\u000a      and\u000a      http:\/\/www.reinnervate.com.\u000a    ","Title":"\u000a    Chemical and Materials Technologies for Cell Biology\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Interdisciplinary research between Durham University chemists Profs Neil\u000a      Cameron (DU staff 1997-present), Andy Whiting (DU 2001-present) and Todd\u000a      Marder (DU 1996-2012) and cell biologist Prof Stefan Przyborski (DU\u000a      Department of Biological and Biomedical Sciences, returned in UoA 5) began\u000a      following the creation of the DU Bioactive Chemistry Centre in 2004.\u000a    Initial BBSRC-funded research (2001-2004) by Prof. Przyborski led to the\u000a      creation of stem cell lines and their subsequent differentiation into\u000a      neural derivatives. This methodology was improved through the application\u000a      of synthetic retinoids designed in collaboration with Profs Whiting and\u000a      Marder. Whilst naturally occurring retinoids may be used in a variety of\u000a      cell differentiation techniques, their inherent instability due to\u000a      isomerisation in culture media provides opportunities for the use of\u000a      synthetic retinoids that can control cellular development but also have\u000a      long term stability. A new class of synthetic retinoids was designed and\u000a      synthesised at Durham [1] in which an arene carboxylic acid, acetylene and\u000a      saturated ring replaced the normal retinoic acid system. These retinoids\u000a      were found to be stable to degradation over extended periods under normal\u000a      laboratory conditions. The ability of the synthetic retinoids to modulate\u000a      tissue development, particularly the induction of cell differentiation in\u000a      a stem cell model of human embryogenesis, was demonstrated [1].\u000a    Research into mechanisms controlling stem cell differentiation in\u000a        vitro and the beneficial formation of 3D neuroprogenitor aggregates\u000a      by the Przyborski group led to the concept of developing technology that\u000a      would enable the study of cultured cells in 3D models. The shape and\u000a      function of a cultured cell is significantly affected by the physical\u000a      environment in which it grows. Cells grown in two dimensions have a large\u000a      proportion of their surface exposed to the typically flat polystyrene\u000a      substrate surface and interaction between adjacent cells is therefore\u000a      localised primarily to their edges. In a 3D scaffold system, however,\u000a      there is significantly greater scope for cell interaction and signalling\u000a      which more accurately resembles how cells constitute a tissue, providing\u000a      far more precise information about cell function. Such in vitro\u000a      assays and models are more effective at modelling the in vivo\u000a      growth of cells. A suitable sterile, inert, solid scaffold would offer\u000a      several advantages to scientists for 3D cell culture growth including\u000a      reproducibility, robustness, stability and reduced sample preparation\u000a      time.\u000a    Cameron's research in materials chemistry has a strong focus on the\u000a      preparation and application of polymers synthesised by high internal phase\u000a      emulsion (polyHIPE) techniques [2]. Following discussions as part of an\u000a      internal DU Bioactive Chemistry Centre symposium, Cameron and Przyborski\u000a      recognised that polyHIPEs offered excellent potential as scaffolds for 3D\u000a      cell culture since the high porosity of the materials would allow healthy\u000a      cells to grow within a network of size-controlled pores in the solid\u000a      polymeric material. Research funded by an EPSRC grant awarded to\u000a      Professors Przyborski and Cameron (GR\/T24043) allowed initial proof of\u000a      concept research to demonstrate the effectiveness of new 3D polyHIPEs with\u000a      tailored morphology synthesised by emulsion templating [3,4]. The cells\u000a      cultured in the pores of the 3D polyHIPE material were not only more\u000a      functional, but also expressed different proteins which act as markers of\u000a      neural network development compared to cells grown in conventional 2D\u000a      culture. Further optimisation enabled polystyrene-based scaffold materials\u000a      to be tailored to provide improved 3D polyHIPE supports [5] and the\u000a      engineering of polyHIPE materials into thin membranes [6]. In all cases,\u000a      cells cultured in 3D were shown to be more functional and more viable than\u000a      those grown in 2D culture.\u000a    "},{"CaseStudyId":"18127","Continent":[{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"1814991","Name":"China"},{"GeoNamesId":"2077456","Name":"Australia"}],"Funders":["Wellcome Trust"],"ImpactDetails":"\u000a    The breakthrough discoveries on oxygenases have had specific impacts\u000a      including the following.\u000a    Identification\/validation of new drug targets for diseases ranging\u000a        from anaemia to cancer that are being pursued by multiple companies [7 -\u000a        10].\u000a    Enabling work in the Oxford University laboratories (1996-2002) followed\u000a      by that in the spin-out ReOx (2002 onwards), demonstrated that\u000a      small-molecule mediated inhibition of the HIF prolyl-hydroxylases\u000a      upregulates proteins of major medicinal relevance (e.g. EPO and vascular\u000a      endothelial growth factor, VEGF), thus validating the HIF hydroxylases as\u000a      drug targets (see Section 2). Subsequently, pharmaceutical companies,\u000a      including GSK, Merck, Bayer, Fibrogen\/Astellas, Akebia, and Johnson and\u000a      Johnson have targeted the prolyl hydroxylase domain enzymes (PHDs),\u000a      demonstrating very widespread interest in them as targets for the\u000a      treatment of anaemia, and ischaemia-related diseases including heart\u000a      disease and diabetes. At least 2 of these companies have PHD inhibitors\u000a      which were progressed during 2008-2013 such that they are now in\u000a      late-stage clinical trials, including for anaemia (worldwide market &gt; &#163;\u000a      50 billion). For example, FibroGen, Inc. and Astellas Pharma Inc. have\u000a      reported the initiation of clinical studies in the Phase 3 clinical\u000a      development program of FG-4592\/ASP1517, an orally administered small\u000a      molecule inhibitor of the HIF prolyl-hydroxylases, for treatment of\u000a      anaemia associated with chronic kidney disease in patients, to support\u000a      approval in the U.S. and Europe [7]. Phase 2 clinical studies showed that\u000a      FG-4592\/ASP1517 demonstrated \"anaemia correction in treatment-na&#239;ve CKD\u000a      patients not on dialysis as well as maintenance of hemoglobin in CKD\u000a      patients on dialysis and not on dialysis.\" GSK have reported a \"Phase IIa,\u000a      Randomised, Single-Blind, Placebo-Controlled, Parallel-Group clinical\u000a      study to Evaluate the Safety, Pharmacokinetics, and Efficacy of 28-day\u000a      Repeat Oral Doses of GSK1278863A, a HIF prolyl-hydroxylase inhibitor, in\u000a      anemic pre-dialysis and hemodialysis-dependent patients.\" [8]. At Bayer,\u000a      \"a Phase IIb program with the investigational new drug Molidustat (BAY\u000a      85-3934) is under initiation in patients with anaemia associated with\u000a      chronic kidney disease and\/or end-stage renal disease. Molidustat is a\u000a      novel inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase (PH)\u000a      which stimulates erythropoietin (EPO) production and the formation of red\u000a      blood cells. Phase I data have shown that inhibition of HIF-PH by\u000a      Molidustat results in an increase in endogenous production of EPO.\" [9]\u000a      Akebia report that \"AKB-6548 and AKB-4924 are 2 selective HIF-PH [HIF\u000a      prolyl-hydroxylase] inhibitors\" .....\"have profound effects for anaemia,\u000a      wound healing and anti-microbial therapy. Akebia's HPTP03b2 inhibitors\u000a      modulate Angiopoietin-2 activity and represent an exciting new approach in\u000a      the treatments for vascular leak, retinopathy, cancer and critical limb\u000a      ischemia (CLI)\" [10]\u000a    Oxford's identification of one of the HIF hydroxylases as a JmjC protein\u000a      stimulated work leading to their assignment as histone\/chromatin\u000a      demethylases acting on all 3 N-epsilon methylation states of\u000a      lysine. Because of the fundamental role of histone methylation in the\u000a      regulation of gene expression, sometimes in an epigenetic manner, the JmjC\u000a      histone demethylases have also attracted considerable attention as\u000a      potential targets for diseases ranging from cancer to genetic diseases (by\u000a      several companies including GSK, Genentech, and Epitherapeutics). Andrea\u000a      Cochran of Genentech states [11] \"Oxford is one of a very small number of\u000a      academic institutions at the leading edge of early-stage drug discovery\u000a      and target validation in epigenetics\" and \"Each of the specific examples\u000a      cited [relating to oxygenases and bromodomains] addresses problems that I\u000a      have heard discussed internally multiple times and that have real impact\u000a      on our ability to develop drugs against these targets.\"\u000a    Commercial sale of products including (i) small-molecules arising\u000a        directly from Oxford work, (ii) antibodies arising directly and\u000a        indirectly from Oxford work [12-13].\u000a    Oxford Chemistry work and that of its collaborators has directly or\u000a      indirectly resulted in commercially available products for biomedical\u000a      research. With respect to 2OG oxygenase\/demethylase inhibitors, the\u000a      Schofield group initiated a joint Wellcome Trust-funded project with the\u000a      Structural Genomics Consortium, the NIH and (ultimately) more than 10\u000a      industrial partners and the National Institutes of Health, USA, to\u000a      identify and distribute small molecule inhibitors of `epigenetic'\u000a      enzymes\/proteins for use in probing biological function. Duncan Crawford,\u000a      CSO of Tocris Bioscience, says [13] \"This research has helped to open up\u000a      an entirely new product line for (Tocris) in the past 3 or 4 years by\u000a      generating small molecule probes for epigenetic research. We think this is\u000a      likely to remain a very exciting field for us for the next decade or\u000a      longer.\"\u000a    Some of the oxygenase\/demethylase inhibitors arising from work in the\u000a      Oxford Chemistry laboratories (in most cases in collaboration) are now\u000a      commercially available, for example:\u000a    \u000a      Tocris Biosciences sells the following small molecules relating to\u000a        Oxford precompetitive work on oxygenases and epigenetics: Daminozide,\u000a        IOX1, IOX2, JQ1, DMOG, GSK J1, GSK J4 (arising from collaboration with\u000a        GSK), OXFBD 02 and OXFBD 03.\u000a      Cayman Chemical Company sells the following small molecules:\u000a        Daminozide, IOX1, IOX2, JQ1 and DMOG.\u000a      Selleck Chemicals sells the following small molecules: IOX2, JQ1, GSK\u000a        J1 and GSK J4.\u000a      SIGMA-ALDRICH sells the following small molecules: Daminozide, IOX1,\u000a        IOX2, DMOG, GSK-J1 and GSK-J4.\u000a      Millipore sells the following small molecules: Daminozide, IOX1, DMOG,\u000a        GSK J1 and GSK J4.\u000a      BioVision Inc. sells the following small molecules: IOX1, DMOG, GSK J1\u000a        and GSK J4.\u000a      Axon Medchem sells the following small molecules: IOX2, GSK J1 and GSK\u000a        J4.\u000a      Bertin Pharma sells IOX1.\u000a      Enzo Life Sciences sells DMOG.\u000a      Many companies sell antibodies based on our discoveries relating to\u000a        the hydroxylation of HIF: Hydroxy-HIF-1&#945; (Pro564) (D43B5) XP&#174;\u000a        Rabbit mAb #3434 through Cell Signaling; Anti-HIF1 alpha (Hydroxy P402)\u000a        antibody (ab72775) through Abcam; Anti-HIF-1-alpha Antibody,\u000a        hydroxyproline (Pro402) through Millipore; HIF-1 alpha hydroxy P564\u000a        Antibody through Rockland.\u000a    \u000a    Representative sales figures for probes (for oxygenases and bromodomains)\u000a      based on Oxford University research from individual retailers (to\u000a      September 2013): Tocris Biosciences [13] have distributed a total of 280\u000a      units (9 units of IOX1, 21 units of IOX2, 62 units of GSK J1, 121 units of\u000a      GSK J4, and 59 units of JQ1), generating total revenue based on list\u000a      prices in excess of &#163; 50000. Cayman Chemical Company has distributed 453\u000a      units of JQ1, 17 units of IOX1, and 26 units of IOX2, generating a total\u000a      revenue in excess of &#163;25000. Millipore has distributed 21 units of IOX1,\u000a      generating a total revenue based on list prices of &#163;2499. Note IOX1, IOX2,\u000a      GSK J1, are oxygenase inhibitors; JQ1 is bromodomain inhibitor; further\u000a      (&gt;5) oxygenase and bromodomain inhibitors will be available in 2014.\u000a      The geographical spread of sales includes 16 countries in North America,\u000a      Australia, the Far East and Europe, with the purchases being approximately\u000a      equally divided between academia and industry\/government.\u000a    ","ImpactSummary":"\u000a    Breakthrough structural and mechanistic work at Oxford University\u000a      investigating how enzymes catalyse oxidising reactions has had major\u000a      impacts in biomedicinal fields, including how humans adapt to changes in\u000a      oxygen availability. Impacts arising from the work since 2008 include the\u000a      identification of new drug targets for major diseases ranging from anaemia\u000a      to cancer that are being clinically pursued by pharmaceutical companies\u000a      (including GSK, Bayer, Astellas, Akebia) and smaller companies (including\u000a      the Oxford spin out ReOx), and the sale of products including\u000a      small-molecule probes (e.g. by Tocris, Millipore, Selleck Chem) that are\u000a      of use in biomedicinal\/pharmaceutical research, especially in the emerging\u000a      field of epigenetics.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Oxford\u000a    ","Institutions":[{"AlternativeName":"Oxford (University of)","InstitutionName":"University of Oxford","PeerGroup":"A","Region":"South East","UKPRN":10007774}],"Panel":"B         ","PlaceName":[],"References":"\u000a    Asterisked outputs denote best indicators of quality;\u000a    \u000a1. Structural origins of the selectivity of the\u000a      trifunctional oxygenase clavaminic acid synthase, Zhang ZH, Ren JS,\u000a      Stammers DK, Baldwin JE, Harlos K, Schofield CJ, Nature Structural Biology\u000a      7: 127-133, 2000. DOI: 10.1038\/72398. Pioneering structural studies of\u000a        a 2-oxoglutarate enzyme-substrate complex.\u000a    \u000a\u000a2. The obesity-associated FTO gene encodes a\u000a      2-oxoglutarate-dependent nucleic acid demethylase, Gerken T, et al.,\u000a      Science 318: 1469-1472, 2007. DOI: 10.1126\/science.1151710.\u000a    \u000a\u000a3. *C. elegans EGL-9 and mammalian homologs define a family of\u000a      dioxygenases that regulate HIF by prolyl hydroxylation, Epstein\u000a      ACR, et al., Cell 107: 43-54, 2001. DOI: 10.1016\/S0092-8674(01)00507-4.\u000a        Identification of the HIF prolyl-hydroxylases &#8212; the work enabled the\u000a        prosecution of new therapeutic targets by small-molecule pharmaceuticals.\u000a    \u000a\u000a4. *Hypoxia-inducible factor (HIF) asparagine hydroxylase is\u000a      identical to factor inhibiting HIF (FIH) and is related to the cupin\u000a      structural family, Hewitson KS, et al, J. Biol. Chem. 277: 26351-26355,\u000a      2002. DOI: 10.1074\/jbc.C200273200. Identification of a FIH, as the HIF\u000a        Asn-hydroxylase, and consequently of the family of JmjC proteins\/enzymes\u000a        as oxygenases, opening up a new field in transcriptional regulation.\u000a    \u000a\u000a5. *Oxygen sensing by HIF hydroxylases, Schofield CJ and\u000a      Ratcliffe PJ, Nat. Rev. Mol. Cell Biol. 5: 343-354, 2004. DOI:\u000a      10.1038\/nrm1366. Exemplary studies on the role of oxygenases in the\u000a        regulation of gene expression.\u000a    \u000a\u000a6. Jmjd6 Catalyses Lysyl-Hydroxylation of U2AF65, a Protein\u000a      Associated with RNA Splicing, Webby CJ, et al., Science 325: 90-93,\u000a      2009. DOI: 10.1126\/science.1175865.\u000a    \u000aFive Patent families relating to Oxford work on oxygenases have been\u000a      filed by ISIS Innovation.\u000a    ","ResearchSubjectAreas":[{"Level1":"6","Level2":"1","Subject":"Biochemistry and Cell Biology"},{"Level1":"6","Level2":"4","Subject":"Genetics"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000a    [7] Clinical trials by Fibrogen \/Astellas using HIF prolyl\u000a      hydroxylases as targets:\u000a      http:\/\/www.businesswire.com\/news\/home\/20121211006761\/en\/FibroGen-Astellas-Announce-Initiation-Phase-3-Trial\u000a      and Phase 2 trials at Fibrogen:\u000a      http:\/\/www.fibrogen.com\/press\/release\/pr_1352127487.\u000a    [8] GSK clinical trials using HIF prolyl hydroxylases as targets:\u000a      http:\/\/www.gsk-clinicalstudyregister.com\/protocol_detail.jsp;jsessionid=8CD9309F891F132231AB97DBE2D4AC09?protocolId=112844&amp;studyId=81B449A5-23FF-4617-BAAE-FC6065229339&amp;compound=GSK1278863.\u000a    [9]:Phase 1 trials at Bayer Pharma:\u000a      http:\/\/www.bayerpharma.com\/en\/research-and-development\/development-pipeline\/index.php?phase=1\u000a\u0009  (http:\/\/www.investor.bayer.com\/news\/investor-news\/investor-news\/showNewsItem\/1627\/1381211700\/d884bbd065\/).\u000a    [10] Use of target by Akebia: http:\/\/www.akebia.com\/research.html.\u000a      For a summary of industrial work on HIF hydroxylase inhibitors, see:\u000a      Expert Opin. Ther. Pat. 2010, 20, 219-45. doi:\u000a      10.1517\/13543776.2010.510836 .\u000a    [11] Letter from Genentech Principal Scientist (Nov 3rd,\u000a      2013) concerning Oxford's work on demethylases\/oxygenases and bromodomains\u000a      (held on file).\u000a    [12] Tocris Biosciences website, http:\/\/www.tocris.com\/\u000a        under hydroxylase and demethylase categories; Cayman Chemical\u000a      Company, http:\/\/www.caymanchem.com;\u000a      Selleck Chemicals, www.selleckchem.com;\u000a      SIGMA-ALDRICH, http:\/\/www.sigmaaldrich.com;\u000a      Millipore, http:\/\/www.millipore.com\/;\u000a      BioVision Inc., http:\/\/www.biovision.com;\u000a      Axon Medchem, http:\/\/axonmedchem.com;\u000a      Bertin Pharma, http:\/\/bioreagent.bertinpharma.com\/product-18511.aspx;\u000a      Enzo Life Sciences, http:\/\/www.enzolifesciences.com\/BML-EI347\/dimethyloxaloylglycine\/\u000a    [13] Letter from Tocris Bioscience CSO (Oct 4th, 2013)\u000a      concerning Oxford's work on target validation and inhibitors (held on\u000a      file). \u000a    ","Title":"\u000a    UOA08-03: Oxygenases - from Chemistry to Medicine\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Work from the Schofield group and collaborators at Oxford University on\u000a      oxygenases &#8212; enzymes that can catalyse transformations not presently\u000a      possible using synthetic methodology &#8212; has led to structural and\u000a      mechanistic insights of widespread academic, medicinal, and commercial\u000a      interest. Studies on bacterial enzymes in antibiotic biosynthesis resulted\u000a      in pioneering structure determinations including of substrate complexes\u000a      for oxygenases, e.g. [1]. With a desire to apply their skills to human\u000a      biology and disease the group focused its activities (1996 onwards) to\u000a      address mechanisms, structures and functions of the f07e60 human\u000a      2-oxoglutarate (2OG) oxygenses with assigned and unassigned roles (at the\u000a      time the majority were unassigned). Initial work on oxygenases involved in\u000a      chlorophyll metabolism resulted in pathophysiological insights by\u000a      correlating chemical and clinical data. This work placed the group in an\u000a      excellent position to address functions of unassigned 2OG oxygenases in an\u000a      interdisciplinary approach employing synthesis, biochemistry, structural\u000a      and cell biology, methods of genetic and chemical intervention,\u000a      structure-informed bioinformatics, and clinical data. The results have had\u000a      major impact by identifying new signalling mechanisms and therapeutic\u000a      targets. Studies on metabolic oxygenases included assignment of the\u000a      fat-mass and obesity-associated protein FTO (mutations of which correlate\u000a      with obesity) as a demethylase [2], raising the possibility that\u000a      metabolism is regulated by nucleic acid methylation, a finding that has\u000a      stimulated research worldwide.\u000a    Working with Peter Ratcliffe (Dept of Medicine, Oxford University), a\u000a      joint programme from 2000 onwards was initiated to elucidate molecular\u000a      mechanisms by which animals respond to hypoxia, a long-standing\u000a      physiological problem. Arising in this programme, the finding that\u000a      oxygenases act as oxygen sensors [3 - 5] was a landmark discovery\u000a      (&gt;&gt; 10000 citations for related papers). Following the discovery\u000a      that the hypoxia inducible transcription factors (HIF) are O2\u000a      regulated (by Semenza in the U.S.), an objective was to identify\u000a      mechanisms of O2 -dependent HIF-degradation.\u000a      Prolyl-hydroxylation was shown to regulate HIF levels, via increasing its\u000a      binding to the von Hippel-Lindau protein, a ubiquitin ligase component.\u000a      Structural knowledge enabled identification of candidates encoding for HIF\u000a      prolyl-hydroxylases, leading to identification of 3 human HIF hydroxylase\u000a      enzymes, PHD1-3, which act as hypoxia sensors [3]. When O2 is\u000a      limiting, HIF-hydroxylation slows, causing its concentration to rise, so\u000a      triggering the hypoxic response. Crucially, work of the Oxford University\u000a      team in 2000 demonstrated that small-molecules (developed by Oxford\u000a      Chemistry) mediate HIF prolyl-hydroxylase inhibition, leading to\u000a      upregulation of HIF target genes, including those of major therapeutic\u000a      benefit such as erythropoietin (EPO).\u000a    Following the finding that O2-dependent HIF Asn hydroxylation\u000a      reduces its transcriptional activity, Oxford work revealed that\u000a      factor-inhibiting HIF (FIH), a JmjC protein, is the HIF Asn-hydroxylase\u000a      [4]. Contrary to the paradigm, subsequent work demonstrated that\u000a      hydroxylation of intracellularly localised proteins is common, opening a\u000a      new protein-research field. Sequence analyses, informed by structures\u000a      determined in Oxford, revealed that many genes encode for oxygenases\u000a      involved in chromatin regulation. Following the discovery that many JmjC\u000a      enzymes are histone demethylases, a programme to investigate oxygenase\u000a      roles in epigenetics was initiated. Highlights include structures for\u000a      demethylases complexed with substrates, discovery of splicing factor\u000a      hydroxylases, identification of a demethylase associated with X-linked\u000a      mental retardation \/ cleft lip palate diseases [6], and of the ribosomal\u000a      oxygenases. The collective results suggest all steps in protein expression\u000a      are regulated by oxygen availability, and have opened up new therapeutic\u000a      targets.\u000a    Key Oxford University contributors: C.J. Schofield, S. J. Conway, B. G.\u000a      Davis, E. Flashman and A. Kawamura groups in Chemistry Department; P.J.\u000a      Ratcliffe and C.W. Pugh in Medicine Department (work on hypoxia); C.\u000a      Bountra and colleagues in the Structural Genomics Consortium (work on\u000a      epigenetic probes). Schofield and Ratcliffe\/Pugh collaborated from 2000\u000a      onwards; Schofield and SGC from 2005 on probe research.\u000a    "},{"CaseStudyId":"18128","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Engineering and Physical Sciences Research Council","Royal Society"],"ImpactDetails":"\u000a    Following the patenting of the Compton group's chilli sensor technology\u000a      by Isis Innovation in early 2008, there were well over a hundred worldwide\u000a      media reports on the potential of the new technique in newspapers,\u000a      magazines, journals and online forums (including the Guardian, Nature, the\u000a      Royal Society of Chemistry News, many chemistry journals and specialist\u000a      chilli industry publications) [7]. Interest focussed particularly on the\u000a      objectivity and precision of the measurements obtained, and on the greatly\u000a      reduced costs in contrast to the traditional method of using teams of\u000a      tasters [8, 9]. Isis Innovation prepared the chilli sensor project for\u000a      commercialisation, and the English Provender Company (EPC) subsequently\u000a      expressed an interest in the technology for commercial purposes. Using\u000a      EPSRC Pathway to Impact funds, prototypes were built and a PDRA employed\u000a      to assist with field trials. The Compton group showed EPC staff how to use\u000a      the tester on their food samples, and followed up with several visits to\u000a      monitor progress. Isis licensed the technology to EPC on a non-exclusive\u000a      basis in 2012 [10].\u000a    EPC, a company with a turnover of &#163; 63.6 M in 2012 and 323 employees\u000a      [11], produces a wide range of sauces and condiments for use in domestic\u000a      food, such as their Very Lazy range of pre-prepared ingredients, and is a\u000a      key supplier of ready meals for the UK's major food retailers. It makes\u000a      around 250 tonnes of cooked products (ready meals) each month containing\u000a      chilli, and approximately 200,000 jars of chilli-containing foods.\u000a      Typically it uses up to 10 tonnes of chillies every month, which vary\u000a      dramatically in heat; there is thus a need to ensure consistency in both\u000a      raw materials and finished product. Extensive tests by EPC in its\u000a      production facilities confirmed that Compton's electrochemical device was\u000a      accurate and reliable and matched Scoville Test results, a key part of\u000a      validating the device and convincing the industry to use the method.\u000a      Following this, EPC has routinely used the sensor as a quality assurance\u000a      monitor on the incoming raw ingredients. The company can now offer its\u000a      customers (which include Marks and Spencer, 2 Sisters Food Group and\u000a      Greencore Group) improved consistency in the products it delivers, and\u000a      this has been well received by the customers concerned [12]. According to\u000a      the Head of Technical at EPC, `the device [chilli tester] has a\u000a        massive place in our future'.\u000a    In February 2013 the Singapore-based company Bio-X (S) Pte. Ltd. obtained\u000a      an exclusive licence for the chilli sensor patent in Asia-Pacific and a\u000a      non-exclusive licence in the rest of the world (again through Isis\u000a      Innovation). Bio-X works with technologies and products (including\u000a      chemical sensors) targeted at the measurement of spiciness in food, and\u000a      aims to establish standardisation for heat in the food industry. Following\u000a      licensing, Bio-X is designing and building a new commercially available\u000a      chilli sensor, and demonstration units have been sold prior to full-scale\u000a      launch. Nestl&#233; have been involved in a trial in which data from Bio-X's\u000a      Chilli Tester matched with their own data from high performance liquid\u000a      chromatography &#8212; an extremely promising outcome [13, 14]. The CEO of Bio-X\u000a      has stated the advantages to them of the chilli sensor technology: `Both\u000a        suppliers and users of chillies can be assured of the quality by using a\u000a        simple handheld device. Initially, we expect to see the Chilli Tester\u000a        being used by food manufacturers to determine the quality of their raw\u000a        materials and chilli farms to grade their products &#8212; but the real\u000a        potential of the Chilli Tester will be realised in giving the consumer a\u000a        number that they can use in deciding on sauces and other food products.'\u000a      [10]\u000a    The science behind the chilli sensors has been the subject of significant\u000a      outreach activities at several UK schools. Since July 2012 a consortium of\u000a      seven Yorkshire schools, led by Shelley College in Huddersfield and also\u000a      involving the University of Huddersfield, has been engaged in an ongoing\u000a      collaboration and outreach programme with the Compton group, aimed at\u000a      increasing science applications from such students to research-intensive\u000a      universities. Students aged 14-15 have successfully used research-level\u000a      equipment based on the technology described in section 2 to investigate\u000a      capsaicin levels in fresh chillies and chilli products. They have also\u000a      used Compton's voltammetry techniques to investigate and quantify the\u000a      amount of ascorbic acid in supplements and soft drinks. The programme has\u000a      now expanded to incorporate a chilli-growing project, and selected\u000a      students have taken part in residential visits to Oxford. The links with\u000a      the GCSE chemistry curriculum are significant and include reinforcement of\u000a      topics such as atomic structure and bonding, ionic compounds, covalent\u000a      structures (carbon), electrolysis, redox reactions and nanoscience. In\u000a      practical terms the activities give students the chance to improve skills\u000a      in risk assessment, collection of data, processing and interpreting data,\u000a      and development of hypotheses and explanations. In addition it assists in\u000a      preparing them for aspects of the A level Chemistry syllabus, especially\u000a      in the topics identified above.\u000a    The Director of Science at Shelley College confirms that the programme is\u000a      encouraging more students to pursue chemistry seriously: `The students\u000a        from Shelley and the other schools involved in the project could not be\u000a        more enthusiastic about taking their [chemistry] studies further. The\u000a        whole nation recognises the importance of producing first class\u000a        scientists for the future and this project is helping to further that\u000a        aim in a way that should not be underestimated.' The outreach has\u000a      been supported by funds from St John's College and the Department of\u000a      Chemistry, University of Oxford, and from the Royal Society of Chemistry\u000a      [15].\u000a    A second schools programme started in early 2013 at Cheltenham Ladies\u000a      College in Gloucestershire, aided by a Partnership Grant from the Royal\u000a      Society. Again, with active support from the Compton group, students have\u000a      used the techniques described in the research section to devise their own\u000a      experiments investigating capsaicin levels within chilli plants (the\u000a      strength of dried versus fresh chillies, and which solvent will extract\u000a      capsaicin more readily). The College's Head of Chemistry feels the project\u000a      `has helped push science to the top of the school agenda. A significant\u000a        proportion of the school's cohort has become engaged with the project.'\u000a      In addition the Cheltenham students have particularly benefited from the\u000a      high proportion of female researchers from the Compton group visiting the\u000a      school, which has `served as an excellent motivator for young female\u000a        scientists' [16].\u000a    Over 100 students in all have so far taken part across the schools\u000a      involved, and both programmes are continuing.\u000a    ","ImpactSummary":"\u000a    Richard Compton's group at the University of Oxford has developed an\u000a      electrochemical sensor which uses multi-walled carbon nanotube electrodes\u000a      to detect capsaicin molecules and related capsaicinoids &#8212; the chemicals\u000a      responsible for the hot taste of chilli peppers. The technology, patented\u000a      in 2008, has been licensed to the English Provender Company, which uses\u000a      the sensors to perform quality assurance on 10 tonnes of incoming chillies\u000a      every month, as well as monitoring reproducibility of finished products.\u000a      In February 2013 Singapore-based Bio-X obtained an exclusive licence for\u000a      the patent in Asia to develop, build and sell devices on a global basis.\u000a      The science behind the technology has been the subject of significant\u000a      outreach activities at UK schools, and has attracted extensive media\u000a      interest.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Oxford\u000a    ","Institutions":[{"AlternativeName":"Oxford (University of)","InstitutionName":"University of Oxford","PeerGroup":"A","Region":"South East","UKPRN":10007774}],"Panel":"B         ","PlaceName":[],"References":"\u000a    Asterisked outputs denote best indicators of quality; University of\u000a      Oxford authors are underlined.\u000a    \u000a1. Kachoosangi, R.T., Wildgoose, G.G., Compton, R.G.\u000a      Sensitive adsorptive stripping voltammetric determination of paracetamol\u000a      at multiwalled carbon nanotube modified basal plane pyrolytic graphite\u000a      electrode. Analytica Chimica Acta 2008, 618, 54-60. DOI:\u000a      10.1016\/j.aca.2008.04.053.\u000a    \u000a\u000a2. Kachoosangi, R.T., Wildgoose, G.G., Compton, R.G.\u000a      Adsorptive stripping voltammetric determination of 4-hexylresorcinol in\u000a      pharmaceutical products using multiwalled carbon nanotube based\u000a      electrodes. Electroanalysis 2008 20, 1714-1718. DOI:\u000a      10.1002\/elan.200804258\u000a    \u000a\u000a3. * Kachoosangi, R.T., Wildgoose, G.G., Compton,\u000a        R.G. Carbon nanotube-based electrochemical sensors for quantifying\u000a      the 'heat' of chilli peppers: The adsorptive stripping voltammetric\u000a      determination of capsaicin. Analyst 2008,133, 888-895. DOI:\u000a      10.1039\/b803588a This paper reports the analytical protocol employed\u000a        in the `chillimeter'.\u000a    \u000a\u000a4. * Kachoosangi, R.T., Wildgoose, G.G., Compton,\u000a        R.G. Chilli Sensor Patent, EP 09723101.3 , priority date 18 March\u000a      2008 (Isis Project 3670).\u000a      https:\/\/www.google.com\/patents\/EP2257795A1?cl=en\u000a      This patents the analytical procedure for the determination of\u000a        capsaicin via adsorptive stripping voltammetry using carbon nanotubes.\u000a    \u000a\u000a5. * Martindale, B. C. M., Aldous, L., Rees, N. V.,\u000a      Compton, R. G. Towards the electrochemical quantification of the\u000a      strength of garlic. Analyst 2011,136,128-133. DOI:\u000a      10.1039\/c0an00706d This paper reports work stimulated by discussion\u000a        with the food technology industry into the electrochemical measurement\u000a        of garlic flavour.\u000a    \u000a\u000a6. Aldous, L., Compton, R. G., Martindale, B. C. M.,\u000a      Rees, N. V. Garlic Sensor Patent, GB 1017625.3, priority date 19\u000a      October 2010 (Isis Project 7513).\u000a      https:\/\/www.google.com\/patents\/WO2012052755A1?cl=en\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"},{"Level1":"10","Level2":"7","Subject":"Nanotechnology"}],"Sources":"\u000a      \u000a      A full list of media sources which ran the chilli sensor story is held\u000a      on file.\u000a    \u000ahttp:\/\/www.nature.com\/news\/2008\/080512\/full\/news.2008.817.html\u000a      May 2008 Nature News article detailing the advantages of the chilli sensor\u000a      technique and the chemistry behind it.\u000a    \u000ahttp:\/\/www.theguardian.com\/technology\/2008\/jun\/12\/news.sciencenews\u000a      June 2008 article in the Guardian describing Compton's development of the\u000a      chilli sensor technique and its commercial potential.\u000a    Isis Innovation can corroborate the details of the licence with the\u000a      English Provender Company and with Bio-X, details of patent-related income\u000a      for the University of Oxford, and quotes from the Bio-X CEO on the\u000a      benefits to them of the chilli sensor technology.\u000a    Details of English Provender turnover 2012 at\u000a      http:\/\/www.worksmart.org.uk\/company\/company.php?id=02593588\u000a        .\u000a    The Head of Technical at English Provender Company can corroborate the\u000a      use of the Chilli Meter in quality assurance of incoming raw materials,\u000a      and the importance placed on the device by the company and its customers.\u000a    The Bio-X webpage at http:\/\/biox.com.sg\/data-book\/\u000a        confirms the link with the Compton research. The homepage shows the\u000a      chilli sensor: http:\/\/biox.com.sg\/ .\u000a    Bio-X June 2013 progress report to Isis Innovation (held on file),\u000a      corroborating progress towards a commercially-available chilli sensor, and\u000a      results of trials including the trial with Nestl&#233;.\u000a    15. Letter from the Director of Science at Shelley College (held on\u000a      file), corroborating details of Compton group outreach activities and\u000a      impact on students.\u000a    Email from the Head of Chemistry at the Cheltenham Ladies' College (held\u000a      on file), corroborating details of Compton group activities and impact on\u000a      female students.\u000a    \u000a    ","Title":"\u000a    UOA08-04: Measuring chilli heat with electrochemistry\u000a    ","UKLocation":[{"GeoNamesId":"2646458","Name":"Huddersfield"},{"GeoNamesId":"2653261","Name":"Cheltenham"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    The `heat' or piquancy of chillies is a result of the molecule capsaicin\u000a      (8-methyl-N-vanillyl-6-nonenamide) and related compounds called\u000a      capsaicinoids. Chillies are used ubiquitously throughout the food\u000a      industry, and in order to ensure consistency there is a need to assess\u000a      chilli strength &#8212; or, more technically, capsaicin content. Such\u000a      measurements are traditionally performed using organoleptic (taste)\u000a      testing: chilli pepper extract is diluted in sugar solution until the\u000a      `heat' is no longer detectable to a panel of five tasters. The degree of\u000a      dilution gives a measurement on the Scoville scale, which dates back to\u000a      1912, and yields numbers which range from 0 to 16,000,000. By means of\u000a      illustration, a Jalapeno pepper scores 2,500, Tabasco sauce 30,000-50,000,\u000a      and pure capsaicin 16,000,000. The Scoville test can give accurate results\u000a      when performed by expert tasters. However results are entirely dependent\u000a      on the capsaicin sensitivity of the tasters, and the test is\u000a      time-consuming and costly to perform since it requires a panel of five\u000a      experts for every measurement of chilli heat. More consistent scientific\u000a      methods of measuring capsaicin content involve cumbersome and expensive\u000a      high-performance liquid chromatographs, which also require trained staff\u000a      and involve time for sample preparation and results analysis.\u000a    In the mid-2000s Richard Compton and colleagues in the Department of\u000a      Chemistry, University of Oxford began to undertake fundamental studies of\u000a      adsorptive stripping voltammetry (AdSV) at multiwalled carbon nanotube\u000a      modified basal plane pyrolytic graphite electrodes (MWCNT-BPPGE) &#8212;\u000a      electrodes coated in carbon nanotubes. The Compton group applied the\u000a      technique to a variety of analytes; with paracetamol [1] they obtained a\u000a      detection limit of 10 nM, almost certainly the lowest limit of detection\u000a      thus far reported for paracetamol using electrochemical techniques,\u000a      showing that the technique was extremely sensitive. In a similar study on\u000a      4-hexylresorcinol (an anaesthetic and antiseptic used in pharmaceutical\u000a      products) [2], Compton and colleagues experimented with MWCNT-BPPGE\u000a      modified screen-printed electrodes, thereby demonstrating that the AdSV\u000a      technique could easily be incorporated into a simple and inexpensive\u000a      electrochemical sensor.\u000a    Compton and colleagues also studied food anayltes, specifically capsaicin\u000a      molecules, which they observed to spontaneously adsorb onto a MWCNT-BPPGE.\u000a      Further, when the voltage at the electrode was adjusted appropriately, the\u000a      molecules were oxidised and stripped from its surface. This finding led to\u000a      the development of an AdSV technique which built on the fact that, if\u000a      deposition and stripping conditions were kept constant, the process could\u000a      be calibrated to link the voltammetric stripping current to solution\u000a      concentration [3]. The Compton group then developed an innovative\u000a      electrochemical technique to reliably quantify the concentration of\u000a      capsaicin in a sample.\u000a    The technique was refined by the group so that the multi-wall carbon\u000a      nanotube-based electrode could be screen-printed and used with a hand-held\u000a      sensor to assess capsaicin concentration outside the laboratory. To use\u000a      the device, food extracts containing chilli are diluted in a ratio of\u000a      1:100 with 0.05M Britton-Robinson buffer at pH 1.0 and then placed on the\u000a      carbon nanotube electrode. The voltage is scanned, and the variation in\u000a      voltammetric stripping current is recorded. The result is then converted\u000a      into a measurement corresponding to the Scoville scale. The technology was\u000a      patented in 2008 by Isis Innovation Ltd, the University of Oxford's\u000a      technology transfer division [4].\u000a    The Compton group also developed a similar electrochemical technique\u000a      using carbon-based electrodes to measure the strength of garlic by\u000a      identifying the presence of disulfides [5]. This technology was patented\u000a      in the UK, and by Isis Innovation, in 2010 [6].\u000a    Richard Compton has been on the academic staff of the Department of\u000a      Chemistry from 1985 to the present day.\u000a    "},{"CaseStudyId":"18129","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Royal Society"],"ImpactDetails":"\u000a    The research described above has underpinned the formation of a very\u000a      successful company, Oxford Nanopore Technology (ONT), which has attracted\u000a      more than &#163; 105M investment, &#163; 97.8M of this since 1st January 2008. This\u000a      very high level of investment arises as a direct result of ONT's\u000a      pioneering technology, which has the potential to revolutionise the fields\u000a      of DNA sequencing and single-molecule analysis.\u000a    ONT was spun-out of the Department of Chemistry in 2005, founded on\u000a      intellectual property from the University of Oxford, to exploit the\u000a      technology developed by the Bayley laboratory and develop it into a\u000a      robust, commercial product. From the outset the company aimed to create\u000a      `disruptive technology' (one that establishes an entirely new market or\u000a      new behaviours in an existing market, thus disrupting the old one). From\u000a      2008 onwards, ONT forged collaborations with leading nanopore researchers\u000a      at other institutions including Harvard University, the University of\u000a      California Santa Cruz and Boston University, in addition to the company's\u000a      existing relationship with the University of Oxford. This work has\u000a      generated an IP portfolio for the company comprising &gt;300 issued\u000a      patents and patent applications in &gt;80 patent families, including 12\u000a      key patents arising from Bayley's work at Oxford [7]. A new agreement in\u000a      2010, renewed in 2012, strengthened ONT's collaboration with the\u000a      University of Oxford through funding (&gt;&#163; 2M) for the Bayley laboratory.\u000a      The deliberate decision to engage multiple institutions with relevant IP\u000a      has given ONT a world-leading position in nanopore sensing and ensured\u000a      that a UK-based company stands to profit from the enormous potential of\u000a      this technology, with associated benefits to the UK economy.\u000a    In February 2012, ONT revealed the GridION system at the Advances in\u000a      Genome Biology and Technology conference in Florida. GridION is a\u000a      nanopore-based platform that utilises key elements of Bayley's research,\u000a      in addition to research from other ONT partners. The primary emphasis of\u000a      GridION is efficient DNA\/RNA strand sequencing (efficient both in time and\u000a      cost), but it can also be adapted for the direct electronic analysis of\u000a      target proteins, with applications in the discovery and validation of\u000a      disease biomarkers and the development of subsequent diagnostics (e.g. in\u000a      relation to drug response or status of a disease). ONT has revealed that\u000a      the technology within the GridION platform can be miniaturised into\u000a      MinION, a portable device for electronic single-molecule sensing that\u000a      plugs into a PC and is the size of a USB memory stick. These devices\u000a      measure single molecules directly, without the need for amplification of\u000a      the target molecule, fluorescent or chemical labelling, or optical\u000a      instrumentation; in addition analysis of data can be performed in real\u000a      time, and multiple nanopore measurements can be made in parallel, making\u000a      it both cheaper and faster than current sequencing technologies [8].\u000a      MinION will be made available to selected researchers to use, assess and\u000a      evaluate from late November 2013 [9].\u000a    Currently, ONT's nanopore-sensing technology is the only near-market\u000a      method which looks set to break the $ 1,000 barrier (it is expected that\u000a      MinION will be marketed at around $ 900), and importantly it will provide\u000a      extremely fast and robust sequencing, differentiating it from other\u000a      sequencing technologies [9]. ONT calculates that if 20 of its\u000a      second-generation GridION nodes were used together, a human genome could\u000a      be sequenced in 15 minutes at a highly competitive cost (since the\u000a      single-molecule techniques developed at ONT do not require the cyclic\u000a      addition of reagents) [9]. Application of this technology will not just be\u000a      in human health and personalised medicine but also in agriculture and crop\u000a      science, environmental science (e.g. detection of toxins in water), energy\u000a      and defence (e.g. detection of explosives). The potential global market\u000a      for `next generation sequencing' is significant: in 2012 it stood at $\u000a      232M and is expected by market researchers such as BCC Research to be\u000a      approximately $ 7.6bn by 2018. The announcement of GridION and MinION\u000a      attracted considerable worldwide media attention from national and\u000a      international newspapers including the New York Times, Guardian, Sunday\u000a      Times and Financial Times, as well as from scientific journals including\u000a      Science. These reports highlighted the low cost and high speed of ONT's\u000a      devices, and the two sequencers were described as `impressive, credible,\u000a      possibly amazing' and as a potential `game-changer' [10, 11].\u000a    The enormous potential of ONT's new technology, coupled with its wide\u000a      intellectual property portfolio and product pipeline, has generated a very\u000a      high level of investment during the impact period. Seed funding that\u000a      enabled ONT to be established was obtained in two rounds from IP Group in\u000a      2005, and in June 2006 the company raised &#163; 7.75M. Since 1st January 2008,\u000a      ONT has raised a further &#163; 97.8M (representing 92% of total investment\u000a      since company start-up) from a range of sources in the UK and the US. Over\u000a      a third of this (&#163; 34.1M) was raised in May 2012 almost entirely from\u000a      existing investors in the company &#8212; a clear indication of the extent to\u000a      which investors see the potential for GridION and MinION to become highly\u000a      successful. ONT is currently well funded for the next phase of corporate\u000a      development [12].\u000a    The success of ONT is also reflected in its workforce. During the impact\u000a      period the number of people ONT employed increased nearly 6-fold, from 25\u000a      in 2008 to 145 in July 2013. The vast majority of current staff are\u000a      employed in research and development; they have backgrounds in multiple\u000a      disciplines including nanopore science, molecular biology and\u000a      applications, informatics, engineering, electronics, manufacturing and\u000a      commercialisation. ONT has UK offices in Oxford and Cambridge and US\u000a      offices in Boston and New York, and is building a commercial team in\u000a      advance of the launch of the products. Since 2008, ONT has also benefited\u000a      from the transfer of 3 highly-skilled staff from the Bayley laboratory.\u000a      Two of these bring academic research expertise to an industrial R&amp;D\u000a      setting and work in application development and advanced research, and the\u000a      third works for ONT's IP team [9]. The company was valued at $ 2bn by a\u000a      Numis Securities analyst in November 2012 [13].\u000a    ONT made an important contribution to the 2008 - 09 House of Lords\u000a      Science and Technology Committee session on Genomic Medicine. ONT provided\u000a      evidence to the effect that the new technologies were advancing so rapidly\u000a      that the government needed to take action. This evidence helped to shape\u000a      the recommendations in the 2009 final report [14], which are now being\u000a      taken forward by the Government (for example, via the Human Genomics\u000a      Strategy Group, established by the government to address questions raised\u000a      by the report [15]). This influence further reflects ONT as a pioneering\u000a      leader in the field of new generation sequencing.\u000a    ","ImpactSummary":"\u000a    Hagan Bayley's research on nanopore sensing for DNA sequencing at the\u000a      University of Oxford led to the formation of the spin-out company Oxford\u000a      Nanopore Technologies Ltd (ONT) in 2005. Since 2008, ONT has raised &#163;\u000a      97.8M to support research and product development. This level of\u000a      investment arises as a direct result of the pioneering technology ONT has\u000a      developed, based on research in the UOA, which has the potential to\u000a      revolutionise DNA sequencing and other single molecule analyses. ONT\u000a      currently employs 145 people, nearly six times as many as in 2008, and was\u000a      recently valued at $ 2 billion. Evidence from ONT was used in a 2009 House\u000a      of Lords report on genomic medicine, demonstrating ONT's position at the\u000a      forefront of this new technology.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Oxford\u000a    ","Institutions":[{"AlternativeName":"Oxford (University of)","InstitutionName":"University of Oxford","PeerGroup":"A","Region":"South East","UKPRN":10007774}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"4930956","Name":"Boston"},{"GeoNamesId":"4155751","Name":"Florida"},{"GeoNamesId":"5128638","Name":"New York"}],"References":"\u000a    Asterisked outputs denote best indicators of quality; University of\u000a      Oxford authors are underlined.\u000a    1. * Xie, H., Braha, O., Gu, L.-Q., Cheley, S., \u000aBayley, H.\u000a    Single-molecule observation of the catalytic subunit of cAMP-dependent\u000a    protein kinase binding to an inhibitor peptide. Chemistry and Biology 12,\u000a    109-210 (2005). DOI: 10.1016\/j.chembiol.2004.11.013 \u000aDemonstrates how\u000a      stochastic sensing can be used in an engineered pore to detect binding\u000a      events at the single-molecule level.\u000a    \u000a2. Astier, Y., Braha, O. and Bayley, H. Toward single\u000a      molecule DNA sequencing: direct identification of ribonucleoside and\u000a      deoxyribonucleoside 5f0a2-monophosphates by using an engineered protein\u000a      nanopore equipped with a molecular adapter. J. Am. Chem. Soc. 128,\u000a      1705-1710 (2006). DOI: 10.1021\/ja057123+.\u000a    \u000a\u000a3. * Stoddart, D., Heron, A., Mikhailova, E., Maglia,\u000a        G. and Bayley, H. Single nucleotide discrimination in\u000a      immobilized DNA oligonucleotides with a biological nanopore. Proc. Natl.\u000a      Acad. Sci. USA 106, 7702-7707 (2009). DOI: 10.1073\/pnas.0901054106 Paper\u000a        describing how an engineered &#945;HL pore containing 3 recognition sites can\u000a        be used to identify all 4 DNA bases in an immobilized single-stranded\u000a        DNA molecule.\u000a    \u000a\u000a4. Stoddart, D., Maglia, G., Mikhailova, E., Heron,\u000a        A. and Bayley, H. Multiple base-recognition sites in a\u000a      biological nanopore: two heads are better than one. Angew. Chem. Int. Ed.\u000a      49, 556-559 (2010). DOI: 10.1002\/anie.200905483.\u000a    \u000a\u000a5. * Hall, A.R., Scott, A., Rotem, D., Mehta, K.K., Bayley,\u000a        H. and Dekker, C. Hybrid pore formation by directed insertion of\u000a      alpha hemolysin into solid-state nanopores. Nature Nanotechnology 5,\u000a      874-877 (2010). DOI: 10.1038\/nnano.2010.237 Paper describing the\u000a        creation of hybrid nanopores suitable for integration into wafer-scale\u000a        devices.\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"6","Level2":"4","Subject":"Genetics"},{"Level1":"6","Level2":"1","Subject":"Biochemistry and Cell Biology"}],"Sources":"\u000a      \u000a    \u000ahttps:\/\/www.google.com\/patents\/US7939270\u000a      The first Bayley patent to be licensed to ONT, US 7939270 B2, granted May\u000a      2011: `Delivery of molecules to a lipid bilayer', part of the technology\u000a      underpinning GridION and MinION.\u000a    \u000ahttps:\/\/www.nanoporetech.com\/technology\/introduction-to-nanopore-sensing\/introduction-to-nanopore-sensing\u000a      ONT webpage confirming details of the GridION and MinION technology and\u000a      what it can do.\u000a    The Corporate and Communications Director at ONT can corroborate details\u000a      of the `15 minute genome', the projected cost of MinION, its availability\u000a      to researchers from late 2013, details of company employees, and the role\u000a      of staff who have joined ONT from the Bayley laboratory.\u000a    \u000a\u000a      http:\/\/www.nytimes.com\/2012\/02\/18\/health\/oxford-nanopore-unveils-tiny-dna-sequencing-device.html?_r=0\"&gt;\u000a      February 2012 article in the New York Times, announcing the release of\u000a      MinION and corroborating the descriptions of the device quoted here.\u000a    \u000a\u000a     http:\/\/www.sciencemag.org\/content\/336\/6081\/534.full?sid=9d6cc8c3-4c55-443d-9818-3cebd1228d27\"&gt;\u000a      May 2012 article in Science News, announcing the release of MinION and\u000a      corroborating the descriptions of the device quoted here.\u000a    \u000ahttps:\/\/www.nanoporetech.com\/about-us\/for-investors\u000a      ONT webpage, confirming investments in the company.\u000a    \u000ahttp:\/\/www.bio-itworld.com\/2012\/11\/29\/numis-reiterates-2billion-valuation-oxford-nanopore.html\u000a      BioIT World report corroborating the $ 2 billion valuation of ONT.\u000a    \u000ahttp:\/\/www.publications.parliament.uk\/pa\/ld200809\/ldselect\/ldsctech\/ldsctech.htm\u000a      Reports from the House of Lords Science and Technology Committee session\u000a      on Genomic Medicine, confirming the evidence provided by ONT to the\u000a      committee.\u000a    \u000ahttps:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/213705\/dh_132382.pdf\"&gt;\u000a      Human Genomics Strategy Group report, January 2012, confirming actions as\u000a      a result of the report cited at [14].\u000a\u0009  \u000a    ","Title":"\u000a    UOA08-05: Oxford Nanopore Technologies: a successful company built on innovative\u000a        DNA sequencing\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Nucleic acid sequencing is likely to become a core part of personalised\u000a      medicine and has many additional applications including in agriculture and\u000a      crop science, food safety and security, and defence. However, it is\u000a      currently an expensive and time-consuming enterprise. In 2004, the US\u000a      National Human Genome Research Institute (NHGRI) announced a series of\u000a      grants to support research with the aim of sequencing a human genome for\u000a      the cost of $ 1000 or less. At this cost, the technology should become\u000a      affordable enough to enable routine use in personalised medicine. The\u000a      speed and reliability of sequencing is also important for use in the\u000a      clinic. Conventional high-throughput sequencing technologies are\u000a      relatively slow; most require DNA samples to be amplified, cut to an\u000a      appropriate length, attached to a bead or surface and labelled with a\u000a      fluorescent tag which is read with expensive optical imaging equipment.\u000a      There is thus a need for `new generation sequencing' technologies which\u000a      use different approaches to sequencing and can therefore transform the\u000a      speed and reliability of genome sequencing, and hence the utility of\u000a      `personal' genome sequencing.\u000a    Hagan Bayley joined the Department of Chemistry in 2003 to carry out\u000a      fundamental research on membrane proteins. His research led to\u000a      breakthrough developments in the area of `new generation DNA sequencing';\u000a      specifically, his group worked on perfecting techniques to permit the\u000a      sensing of individual molecules using engineered membrane protein pores.\u000a      Bayley established that staphylococcal alpha-haemolysin, a bacterial\u000a      pore-forming toxin, could be modified by protein engineering to bind a\u000a      wide variety of partial blockers and that these pores might be used to\u000a      detect many different analytes at the single-molecule level. For example,\u000a      a paper published in 2005 (with researchers at Texas A&amp;M University)\u000a      demonstrated how an engineered pore could be used to detect binding events\u000a      to monitor the concentration of a critical cell signalling enzyme,\u000a      cAMP-dependent protein kinase [1]. This research built on previous work by\u000a      Bayley at Texas A&amp;M on the assembly, structure and functional\u000a      properties of the alpha-haemolysin protein pore, and made use of the\u000a      technique of `stochastic sensing', in which the modulation by an analyte\u000a      of the ionic current flowing through a single protein pore produces a\u000a      signal that reveals both the concentration of the analyte and its\u000a      identity. Bayley has also used stochastic sensing to distinguish between\u000a      enantiomeric drug molecules. In 2005, Oxford Nanopore Technologies Ltd\u000a      (ONT) was formed to support and further translate his research to\u000a      applications in sequencing and sensing.\u000a    The work on engineered pores suggested that DNA and RNA might be\u000a      sequenced by pulling single DNA strands through a nanopore and detecting\u000a      nucleobases (including non-canonical bases) through their different\u000a      effects on the ion current passing through the channel pore. In 2006, a\u000a      breakthrough paper from the Bayley group demonstrated for the first time\u000a      that the four bases of DNA could be distinguished using an\u000a      alpha-haemolysin pore equipped with a cyclodextrin adapter [2]. Following\u000a      this result, in 2009 -10 his group addressed one of the key issues in\u000a      strand sequencing: the need to be able to sense several different DNA\u000a      bases within the nanopore at once. The group showed for the first time\u000a      that an alpha-haemolysin pore could be engineered to contain more than one\u000a      recognition site, and thus identify groups of different nucleobases\u000a      simultaneously in an immobilised DNA strand [3, 4]. This marked a\u000a      critically important step towards continuous strand sequencing.\u000a    In 2010, the Bayley group demonstrated that it was possible to create\u000a      solid-state nanopores suitable for integration into wafer-scale devices,\u000a      by attaching a double strand of DNA to a single alpha-haemolysin pore and\u000a      threading it into a solid-state nanopore by electrophoretic translocation.\u000a      This research, in collaboration with Delft University of Technology,\u000a      showed that the hybrid nanopore remained functional in terms of ability to\u000a      sense individual DNA molecules [5]. It formed the foundation for the\u000a      development of ONT's GridION and MinION devices for electronic single\u000a      molecule sensing and DNA and RNA sequencing. In parallel with the\u000a      DNA-focused research, the Bayley group has worked on similar methods to\u000a      enable nanopore sensing of protein molecules [1].\u000a    In 2005, the Bayley laboratory was awarded an NHGRI `$ 1,000 Genome'\u000a      grant, which was renewed in 2010 &#8212; the only such grant outside the USA.\u000a      The total award has been in the region of US$ 10M. In 2009, Bayley was\u000a      awarded the Royal Society of Chemistry World Entrepreneur of the Year\u000a      Award in recognition of his contribution to the commercialisation of\u000a      nanopore research.\u000a    "},{"CaseStudyId":"18137","Continent":[{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6252001","Name":"United States"}],"Funders":[],"ImpactDetails":"\u000a    The calibration-free pH measurement system invented by the Compton group\u000a      is a truly innovative\u000a      technology which represents a landmark in the field of pH sensing. It has\u000a      led directly to the\u000a      commercial success of Senova Systems Inc, [text removed for publication].\u000a    In September 2008 Isis Innovation Ltd. exclusively licensed the patent\u000a      for calibration-free pH\u000a      sensing to San Francisco-based Senova Systems Inc [6]. The company was\u000a      founded in 2007 with\u000a      the sole aim of developing a commercial pH meter based on the Compton\u000a      research; Professor\u000a      Compton sits on Senova's advisory board. Based on the potential of the\u000a      technology and the high\u000a      value of the IP, Senova secured initial seed funding of $ 3M and raised a\u000a      further $ 6.7M in Series B\u000a      financing by January 2012 [7]. During the three years between licensing\u000a      and finalising funding, the\u000a      company developed a smart sensor platform capable of being produced on a\u000a      commercial scale. In\u000a      the first instance Senova designed a prototype hand-held pH sensor &#8212; the\u000a      pHit Scanner &#8212; which\u000a      offered a number of significant advantages over current standard glass\u000a      electrodes: it requires no\u000a      calibration, is temperature stable, does not suffer signal drift, can be\u000a      stored dry with no need for\u000a      electrolyte solution, can be sterilised, is physically robust and is\u000a      inexpensive to mass produce.\u000a      The scanner was previewed at Pittcon 2012, the world's largest annual\u000a      conference and expo for\u000a      laboratory science [8], and in September 2012 won the Frost &amp; Sullivan\u000a      2012 North American New\u000a      Product Innovation Award [9]. In March 2013, the pHit Scanner was\u000a      recognized with the Pittcon\u000a      Editors' Gold Award for the best new product at Pittcon 2013 [10].\u000a    Feedback from an early adoption programme (EAP) evaluating the hand-held\u000a      meter has confirmed\u000a      the effectiveness of the technology and enabled Senova to embark on the\u000a      development of a larger-\u000a      scale meter aimed at the high-tech market, which will be more profitable\u000a      than the hand-held meter\u000a      [11]. [text removed for publication] [11]. Additional venture capital\u000a      funding (from Phoenix Venture\u000a      Partners and Harris &amp; Harris Group Inc) for Senova is ongoing [12];\u000a      the continued investment\u000a      underlines the potential the technology has to revolutionise this field,\u000a      and the expectation that\u000a      Senova's products will be a commercial success.\u000a    As a result of the collaborative research between Oxford University and\u000a      Schlumberger described in\u000a      Section 2, Schlumberger filed a similar patent at roughly the same time as\u000a      [4]. This has led to a\u000a      mutually beneficial situation in which each party has rights on each\u000a      other's patent. [text removed for publication].\u000a    [text removed for publication][13].\u000a    ","ImpactSummary":"\u000a    Richard Compton's group at the University of Oxford has developed the\u000a      world's first calibration-free\u000a      pH meter, representing the first major advance in pH measurement for 80\u000a      years. In 2008, the\u000a      technology was licensed to Senova Systems Inc, who subsequently produced a\u000a      prototype hand-\u000a      held calibration-free pH meter. In September 2012 the device won the Frost\u000a      &amp; Sullivan 2012 North\u000a      American New Product Innovation Award, and in March 2013 it won Best New\u000a      Product award at\u000a      Pittcon 2013, the world's largest annual conference and expo for\u000a      laboratory science. Following\u000a      successful field trials with end-users in diverse sectors, Senova is now\u000a      developing a commercial\u000a      product. Senova has already secured $ 9.7M to commercialise the\u000a      technology, with additional\u000a      ongoing venture capital investments. [text removed for publication].\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Oxford\u000a    ","Institutions":[{"AlternativeName":"Oxford (University of)","InstitutionName":"University of Oxford","PeerGroup":"A","Region":"South East","UKPRN":10007774}],"Panel":"B         ","PlaceName":[],"References":"\u000a    Asterisked outputs denote best indicators of quality; University of\u000a      Oxford authors are underlined.\u000a    \u000a1. * Anthraquinone-derivatised carbon powder: reagentless voltammetric pH\u000a      electrodes. GG\u000a        Wildgoose, M Pandurangappa, NS Lawrence, L Jiang,\u000a      TGJ Jones and RG Compton. Talanta\u000a      60 (2003) 887-893. DOI: 10.1016\/S0039-9140(03)00150-4\u000a      Reports the methodology for derivatising carbon surfaces with\u000a        anthraquinone moieties.\u000a    \u000a\u000a2. Derivatised carbon powder electrodes: reagentless pH sensors. HC\u000a        Leventis, I Streeter, GG\u000a        Wildgoose, NS Lawrence, L Jiang, TGJ Jones and RG\u000a        Compton. Talanta 63 (2004) 1039-1051.\u000a      DOI: 10.1016\/j.talanta.2004.01.017\u000a    \u000a\u000a3. A sensitive reagentless pH probe with a ca 120 mV\/pH unit response. I\u000a        Streeter, HC Leventis,\u000a      GG Wildgoose, M Pandurangappa, NS Lawrence, L\u000a      Jiang, TGJ Jones and RG Compton. J\u000a      Solid State Electrochem 8 (2004) 718-721. DOI: 10.1007\/s10008-004-0536-7\u000a    \u000a\u000a4. * Patent WO 2005085825 A1. Electrochemical sensors. SP McCormack\u000a        and RG Compton,\u000a      Assignee: Isis Innovation Ltd, UK. https:\/\/www.google.com\/patents\/WO2005085825A1\u000a      The patent describes the principle of calibration-free measurement and\u000a        identifies chemical\u000a        systems for use in pH meters using such an approach.\u000a    \u000a\u000a5. *Investigating the reactive sites and the anomalously large changes in\u000a      surface pKa values of\u000a      chemically modified carbon nanotubes of different morphologies. AT\u000a        Masheter, P Abiman, GG\u000a        Wildgoose, E Wong, L Xiao, NV Rees, R\u000a      Taylor, GA Attard, R Baron, A Crossley, JH Jones\u000a      and RG Compton. J. Materials Chemistry 17 (2007) 2616-2626. DOI:\u000a      10.1039\/b702492d\u000a      This paper reports the 2e, 2H+reduction of\u000a        anthraquinone-modified carbon nanotubes across\u000a        the full aqueous pH range up to 14.\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"3","Level2":"1","Subject":"Analytical Chemistry"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"}],"Sources":"\u000a      \u000a    \u000a\u000a        http:\/\/senovasystems.com\/press-release\/oxford-university-licenses-ph-sensor-technology-senova-systems\u000a      August 2008 press release on the Senova website, confirming that the\u000a      calibration-free pH\u000a      meter is based on the Compton research and licensed to Senova.\u000a    \u000ahttp:\/\/senovasystems.com\/press-release\/senova-systems-closes-6-7m-series-financing\u000a      January 2012 press release on the Senova website, confirming details of\u000a      Series B investment\u000a      in Senova.\u000a    \u000ahttp:\/\/senovasystems.com\/press-release\/phit-ph-meter-introduction\u000a      January 2012 press release on the Senova website, confirming preview of\u000a      the pHit Scanner at\u000a      Pittcon 2012.\u000a    \u000ahttp:\/\/www.frost.com\/prod\/servlet\/press-release.pag?docid=266584923\u000a      Frost &amp; Sullivan webpage confirming the New Product Innovation Award\u000a      made to Senova for\u000a      its pHit Scanner.\u000a    \u000ahttp:\/\/www.pittconshowpreview-digital.com\/pittconshowpreview\/post201303?pg=1#pg1\u000a      Pittcon 2013 webpage corroborating the Editors' Gold Award made to Senova\u000a      Systems for its\u000a      pHit Scanner.\u000a    Statement from the President and CEO of Senova (held on file),\u000a      corroborating details of field\u000a      trials and feedback from customers on the pHit Scanner.\u000a    \u000ahttp:\/\/senovasystems.com\/about-us\/investors\u000a      Senova webpage confirming Phoenix Venture Partners and Harris and Harris\u000a      Group Inc as\u000a      current venture capital investors in the company.\u000a    [text removed for publication]\u000a\u0009\u000a    ","Title":"\u000a    UOA08-06: The first method of calibration-free pH measurement\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000a    The electrochemical measurement of pH is a ubiquitous and routine tool\u000a      used in industries ranging\u000a      from pharmaceuticals to brewing. The standard apparatus for measuring pH\u000a      has not changed\u000a      significantly since it was developed by Beckman in the 1930s, and consists\u000a      of a glass electrode\u000a      connected to an electronic meter that measures and displays the pH\u000a      reading. The electrodes are\u000a      expensive and fragile, pH measurements are easily corrupted, and for\u000a      precise work the meter\u000a      needs calibration before every single measurement. Over the past eight\u000a      decades, vast amounts of\u000a      time (and therefore money) have been spent on pH meter calibration in both\u000a      academia and\u000a      industry. Incorrect calibration and other errors can also lead to huge\u000a      costs for companies in terms\u000a      of wasted supplies and products. These factors underline the pressing need\u000a      for a pH meter that\u000a      does not require calibration.\u000a    In 2001, Professor Richard Compton (Department of Chemistry, 1985 -\u000a      present) and his research\u000a      group at the University of Oxford sought to establish if it was possible\u000a      to derivatise carbon\u000a      nanotubes coated on an electrode surface in a way that made them\u000a      reproducibly and predictably\u000a      pH responsive. If his team could identify a molecule whose electrochemical\u000a      properties varied\u000a      consistently with pH, Compton believed it would be possible to create a\u000a      new breed of pH sensors.\u000a      Compton's team demonstrated that anthraquinone-derivatised carbon\u000a      (AQcarbon) nanotube\u000a      surfaces were in fact pH sensitive, accepting protons as pH conditions\u000a      changed and hence\u000a      exhibiting changing electrochemical properties. His team developed a\u000a      simple pH probe based upon\u000a      the covalent derivatisation of carbon particles with anthraquinone, and\u000a      found that its amperometric\u000a      response provided a Nernstian, linear response over the pH range 1 - 14\u000a      and over a temperature\u000a      range from 20 - 70&#176;C [1, 2, 5].\u000a    The broad range of observed pH sensitivity using AQcarbon suggested that\u000a      an effective,\u000a      calibration-free pH sensor could be created. Compton and his team\u000a      developed electrodes which\u000a      were coated with carbon nanotubes functionalised with anthraquinone.\u000a      Alongside, they also\u000a      developed redox probes which were rigorously pH insensitive when similarly\u000a      deployed. Then, by\u000a      modifying electrodes with both pH sensitive and pH insensitive probes and\u000a      measuring the potential\u000a      difference between the two signals, it was possible to directly assess the\u000a      pH of the solution in\u000a      which the electrodes were immersed [3]. The research described in [1], [2]\u000a      and [3] was conducted\u000a      in collaboration with Schlumberger.\u000a    Compton and his team showed that the AQcarbon pH measurement technique\u000a      has distinct\u000a      advantages over existing glass electrodes. Firstly, the amperometric\u000a      signal shows a linear\u000a      relationship with the tiny currents used, which offers far higher\u000a      sensitivity than the logarithmic\u000a      voltage relationships exhibited by potentiometric glass electrodes.\u000a      Secondly, it is unaffected by\u000a      alkali errors which can corrupt the results provided by present\u000a      techniques. Thirdly (and most\u000a      importantly), because it is a potential difference that is measured, the\u000a      need for an ultra-stable\u000a      reference electrode is eliminated, in turn leading to calibration-free pH\u000a      measurement. Combined\u000a      with practical benefits &#8212; such as durability and speed &#8212; the newfound\u000a      theoretical insights provided\u000a      a promising springboard for the development of a new, revolutionary,\u000a      `disruptive' technology for pH\u000a      sensing. For these reasons, the concept was patented in 2005 by Richard\u000a      Compton and Isis\u000a      Innovation Ltd., the technology transfer arm of the University of Oxford\u000a      [4].\u000a    "},{"CaseStudyId":"18138","Continent":[],"Country":[],"Funders":[],"ImpactDetails":"\u000d\u000a    Since 2008 the research of the Compton group in the field of\u000d\u000a      heterogeneous reaction mechanisms has had a significant impact at Syngenta\u000d\u000a      AG, the company with which it has collaborated. Syngenta is the world's\u000d\u000a      biggest manufacturer of crop chemicals and a major global supplier of\u000d\u000a      insecticides, fungicides and herbicides. In 2012 it achieved sales of $\u000d\u000a      14.2 billion [6]; fungicides alone accounted for 23% &#8212; over $ 3 billion &#8212;\u000d\u000a      of total revenues [7] and insecticides for $ 1.8 billion [8].\u000d\u000a      Azoxystrobin, sold by Syngenta principally under the trade name Amistar,\u000d\u000a      is the world's leading fungicide by sales, while thiamethoxam is the\u000d\u000a      active ingredient developed by Syngenta and used in its product Actara,\u000d\u000a      the best selling insecticide worldwide. Manufacturing processes for both\u000d\u000a      these products, as well as others made by Syngenta, have benefited from\u000d\u000a      important changes as a result of the Compton group research. In the words\u000d\u000a      of a Senior Fellow at Syngenta UK, \"The fundamental science behind the\u000d\u000a        processes described above has been key to the development of scalable,\u000d\u000a        robust, optimised manufacturing processes where, although the chemical\u000d\u000a        fundamentals (rate constant, equilibrium constant, etc.) are scale\u000d\u000a        insensitive, the mass transfer components are not. The overall thinking\u000d\u000a        and methodology used is the primary scientific value (transferable to\u000d\u000a        all and any solid-liquid system, helping to direct technology\u000d\u000a        exploitation and raising the awareness of the need for such\u000d\u000a        methodology). However, the specific systems studied have proved of\u000d\u000a        particular value to Syngenta since 2008 in terms of process changes, and\u000d\u000a        have helped our process chemists from laboratory synthesis to include\u000d\u000a        more physical quantitative chemistry in the development process.\"\u000d\u000a      [10]\u000d\u000a    Impact of studies on sparingly soluble inorganic bases in polar\u000d\u000a        aprotic solvents\u000d\u000a    Research by the Compton group in this area clearly showed that key\u000d\u000a      processes, especially at full scale, can be controlled by the physical\u000d\u000a      process of inorganic base dissolution, and drew attention to the fact that\u000d\u000a      organic chemistry transformations cannot be studied in isolation from the\u000d\u000a      inorganic transformations. As such, care needs to be taken when designing,\u000d\u000a      scaling and running larger scale manufacture of the specific base used,\u000d\u000a      the physical form of the base used and the processing conditions. This had\u000d\u000a      substantial impact for Syngenta since 2008. They manufacture Amistar (the\u000d\u000a      world's largest selling fungicide) via a sequence, the final step of which\u000d\u000a      employs K2CO3 to deprotonate an acid, HA, in a\u000d\u000a      polar aprotic solvent, to produce a nucleophilic A-K+ salt.\u000a      This subsequently reacts with an electrophilic chloro-heterocycle to\u000d\u000a      produce the active ingredient (Ai). The rate limiting `step' in the\u000d\u000a      overall process can switch from being the covalent-bond-forming reaction\u000d\u000a      to the rate of carbonate dissolution, depending on the carbonate salt\u000d\u000a      being used. Understanding this has allowed Syngenta to optimise the\u000d\u000a      robustness of the process and appreciate fully the potential impact of\u000d\u000a      using alternative carbonate sources.\u000d\u000a    The production of Actara, Syngenta's world-leading insecticide, also uses\u000d\u000a      K2CO3 in the final Ai stage in an analogous manner.\u000d\u000a      For environmental reasons, Syngenta desired to switch from K2CO3\u000d\u000a      to Na2CO3, but Na2CO3 failed\u000d\u000a      in process development with much lower rates, lower conversions, longer\u000d\u000a      cycle times and increased by-products. Compton's work showed that the\u000d\u000a      solubility of Na2CO3 and rate of dissolution into\u000d\u000a      polar aprotic solvents is an order of magnitude less than K2CO3.\u000d\u000a      With this insight, Syngenta found that the solution-phase reactivity of\u000d\u000a      the A-K+ and A- Na+ salts were\u000d\u000a      comparable (slight differentiation due to ion-pairing effects) and that\u000d\u000a      the failure with Na2CO3 was due to the process being\u000d\u000a      controlled by the slow rate of dissolution. With this knowledge in hand,\u000d\u000a      alternative processes were rapidly developed.\u000d\u000a    In both of these examples, water can be produced. In some cases the\u000d\u000a      system then switches from involving solid-liquid mass transfer to\u000d\u000a      solid-liquid-liquid transfer as the water produced becomes saturated in\u000d\u000a      the inorganic base and phase separates from the polar aprotic solvent.\u000d\u000a      This produces a gelatinous mass, which at full production scale requires\u000d\u000a      control of agitation and active removal of the water. Otherwise, again,\u000d\u000a      the rate of inorganic base mass transfer from the solid phase through the\u000d\u000a      aqueous liquid phase to the continuous organic solvent (in which the\u000d\u000a      reactant resides) becomes rate limiting. The methods devised by Compton\u000d\u000a      have been used by Syngenta to study and control precisely such a process\u000d\u000a      for an important recently-developed herbicide. A conversion of &gt;98%\u000d\u000a      without rate-limiting mass transfer is now obtained in manufacture, versus\u000d\u000a      a previous figure of ~75% [10].\u000d\u000a    Impact of studies on sparingly soluble organic molecules reacting with\u000d\u000a        solubilised reactants\u000d\u000a    Triazine-based herbicides such as Atrazine (used in Syngenta's product\u000d\u000a      Gesaprim) are crucial to agriculture; it is estimated triazine-based\u000d\u000a      herbicides currently save US consumers &gt;$ 3 billion p.a. in decreased\u000d\u000a      producer costs and increased yield and support 85,000 US jobs [9].\u000d\u000a      Cyanuric chloride forms the basis of triazine-based herbicides, and within\u000d\u000a      Syngenta the science behind the research of the Compton group has\u000d\u000a      subsequently been used to optimise the process for manufacture of\u000d\u000a      herbicides like Gesaprim. Prior to the research of the Compton group, this\u000d\u000a      had suffered from scale up issues; the work helped identify that the root\u000d\u000a      cause of the problems was coating of the reactant solid with an even more\u000d\u000a      insoluble product. [10]\u000d\u000a    Targeted removal of metal ions from waste streams\u000d\u000a    Homogeneous Pd catalysis is important in major industrial coupling\u000d\u000a      reactions. The downside of large scale Pd use beyond the laboratory-scale\u000d\u000a      is the large amounts of solubilised Pd that have to be recovered and\u000d\u000a      removed from waste streams &#8212; for both cost and environmental reasons. The\u000d\u000a      methods and concepts developed by the Compton group have been used by\u000d\u000a      Syngenta since 2008 to plan how to address the issue and optimise\u000d\u000a      recovery. [10]\u000d\u000a    The cost of goods is an especially important issue in the agrochemical\u000d\u000a      industry [11]. Syngenta are unable to quantify the precise financial\u000d\u000a      benefits to them of the Compton research concerning individual steps in\u000d\u000a      multi-stage overall manufacturing processes. However, in the context of\u000d\u000a      yearly revenues of billions of dollars, the financial impact for the\u000d\u000a      company is likely to be very substantial. According to the Senior Fellow\u000d\u000a      at Syngenta UK, \"Overall the research of the Compton group has been of\u000d\u000a        great benefit to Syngenta, enabling significant improvements in the\u000d\u000a        company's development of processes, and sustainably increasing its\u000d\u000a        capability in quantitative physical chemistry. The extension of this has\u000d\u000a        been broad impact into Syngenta's production processes.\" [10]\u000d\u000a    ","ImpactSummary":"\u000d\u000a    The cost of goods is an especially important issue in developing\u000d\u000a      commercially available agrochemicals, which must be manufactured on a\u000d\u000a      large scale. Richard Compton's research at the University of Oxford has\u000d\u000a      led to a step change in the understanding of heterogeneous reaction\u000d\u000a      mechanisms for liquid &#8212; organic solid or liquid &#8212; inorganic solid\u000d\u000a      processes involved in large-scale manufacturing processes. Compton's work\u000d\u000a      has had particular impact on optimising the processes used by Syngenta AG\u000d\u000a      in its manufacturing of agrochemicals. Since 2008 the insights gained on\u000d\u000a      inorganic-base dissolution have been of great benefit to Syngenta in its\u000d\u000a      development of scalable robust manufacturing processes, particularly in\u000d\u000a      relation to production of its fungicide Amistar and insecticide Actara,\u000d\u000a      which are two of the world's largest selling products of this type. In\u000d\u000a      2012 Syngenta achieved total sales of over $ 14 billion, $ 4.8 billion of\u000d\u000a      this from fungicide and insecticide revenues.\u000d\u000a    ","ImpactType":"Economic","Institution":"\u000d\u000a    University of Oxford\u000d\u000a    ","Institutions":[{"AlternativeName":"Oxford (University of)","InstitutionName":"University of Oxford","PeerGroup":"A","Region":"South East","UKPRN":10007774}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    Asterisked outputs denote best indicators of quality; University of\u000d\u000a      Oxford authors are underlined.\u000d\u000a    \u000a1. * Booth, J., Compton, R.G., Atherton, J.H. Mechanism\u000d\u000a      of solid\/liquid interfacial reactions. Atomic force microscopy studies of\u000d\u000a      the self-passivating reaction between solid p-chloranil and aqueous phase\u000d\u000a      N,N-dimethylphenylenediamine. J Phys Chem B, 1998, 102, 3980. DOI:\u000d\u000a      10.1021\/jp980895q\u000d\u000a      The hydrodynamic flow cell was used to measure the rate of a soluble\u000d\u000a        reaction with the surface of an organic solid and to simultaneously\u000d\u000a        image the formation of the insoluble product on the solid surface so\u000d\u000a        providing a kinetic model for a process used by Syngenta.\u000d\u000a    \u000a\u000a2. Compton, R.G., Harding, M.S., Atherton, J.H., Brennan,\u000d\u000a      C.M. Mechanism of a solid\/liquid interfacial reaction. The reaction of an\u000d\u000a      aqueous solution of an aromatic amine with cyanuric chloride. J. Phys.\u000d\u000a      Chem., 1993, 97, 4677. DOI: 10.1021\/j100120a020\u000d\u000a    \u000a\u000a3. * Tam, K.Y., Compton, R.G., Atherton, J.H., Brennan,\u000d\u000a      C.M., Docherty, R. Mechanism of solid\/liquid interfacial reactions. The\u000d\u000a      hydrolytic dissolution of solid triphenylmethyl chloride in aqueous\u000d\u000a      solution. JACS, 1996, 118, 4419. DOI: 10.1021\/ja9529145\u000d\u000a      Channel flow cell measurements, as pioneered by the Compton Group, were\u000d\u000a        used to show that the rate of chemical reaction (hydrolysis) changed\u000d\u000a        markedly between different crystal faces of an organic solid so\u000d\u000a        providing a key stimulus for Syngenta to characterise reactivity at the\u000d\u000a        individual crystal face scale.\u000d\u000a    \u000a\u000a4. * Forryan, C.L., Compton, R.G., Klymenko, O.V.,\u000d\u000a      Brennan, C.M., Taylor, C.L., Lennon, M. Comparative solubilisation of\u000d\u000a      potassium carbonate, sodium bicarbonate and sodium carbonate in hot\u000d\u000a      dimethylformamide: Application of cylindrical particle surface-controlled\u000d\u000a      dissolution theory. Phys. Chem. Chem. Phys., 2006, 8, 633. DOI:\u000d\u000a      10.1039\/b512463h\u000d\u000a    \u000a\u000a5. Abiman, P., Wildgoose, G.G., Crossley, A., Compton,\u000a        R.G. Removal of palladium ions from aqueous systems by chemically\u000d\u000a      modified cysteine carbon powder. J. Mater. Chem., 2008, 18, 3948. DOI:\u000d\u000a      10.1039\/b805804k\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"},{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"}],"Sources":"\u000d\u000a    [6] Syngenta webpage confirming the company's sales profile:\u000d\u000a      http:\/\/www.syngenta.com\/global\/corporate\/en\/investor-relations\/company-profile\/Pages\/key-facts.aspx(downloaded\u000a      06-11-2013).\u000d\u000a    [7] Bloomberg news item corroborating the percentage of Syngenta sales\u000d\u000a      represented by fungicides: http:\/\/www.bloomberg.com\/news\/2013-04-17\/bayer-claims-syngenta-s-fungicide-appear-infringes-patent.html(downloaded\u000a      06-11-2013).\u000d\u000a    [8] Syngenta webpage corroborating sales of its products:\u000d\u000a      http:\/\/www.syngenta.com\/global\/corporate\/en\/investor-relations\/company-profile\/Pages\/products-and-brands.aspx.\u000d\u000a    [9] Syngenta webpage corroborating statistics relating to Atrazine:\u000d\u000a      http:\/\/www.atrazine.com\/AtraMain.aspx(downloaded 11-10-2013).\u000d\u000a    [10] The Senior Fellow at Syngenta UK will corroborate impacts relating\u000d\u000a      to process changes for manufacture of fungicide, insecticide and herbicide\u000d\u000a      products at Syngenta and the consequent benefits to Syngenta. He will also\u000d\u000a      corroborate impacts in relation to targeted removal of metal ions from\u000d\u000a      waste streams.\u000d\u000a    [11] A recent article by Syngenta scientists highlights the importance of\u000d\u000a      agrochemical costs in addressing food security for an estimated world\u000d\u000a      population of 9 billion by 2050.\u000d\u000a      http:\/\/www.sciencemag.org\/content\/341\/6147\/742.abstract\u000d\u000a    ","Title":"\u000d\u000a    UOA08-07: Understanding solid-liquid reactions to improve\u000d\u000a        manufacturing processes for agrochemicals at Syngenta\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    Science &amp; methodology\u000d\u000a      The fundamental science underpinning this case study involves the study of\u000d\u000a      solid-liquid mass transfer and coupled chemical reactions. The work\u000d\u000a      described has been carried out since 1993 under the supervision of Richard\u000d\u000a      Compton at Oxford University. It has involved development of experimental\u000d\u000a      and modelling methodologies to interrogate and quantify chemical and\u000d\u000a      physical processes occurring directly at the solid-liquid interface rather\u000d\u000a      than inferring them from remote indirect methods. Examples of the methods\u000d\u000a      developed include the channel flow cell with numerous in situ\u000d\u000a      analysis methodologies (this has been adopted and adapted by others, but\u000d\u000a      was conceptualised and developed first by Compton), dynamic in situ\u000d\u000a      AFM [1] and numerous novel electrochemical techniques. Modelling of the\u000d\u000a      mass transfer processes between detector and solid-liquid interfaces under\u000d\u000a      controlled and defined fluid-dynamic regimes has enabled direct\u000d\u000a      measurement of the solid-liquid interfacial processes involved.\u000d\u000a      Importantly, the new methods enable classes of differentiated mechanisms\u000d\u000a      to be quantified, varying from those where reaction occurs solely in the\u000d\u000a      solution phase following dissolution, through processes occurring in the\u000d\u000a      interfacial regime, to true heterogeneous reactions that occur directly\u000d\u000a      either at or within the solid surface. The methodology has been applied to\u000d\u000a      both reactive dissolution processes and precipitation processes. Examples\u000d\u000a      of particular value to Syngenta include:\u000d\u000a    (i) Studies on sparingly soluble organic molecules reacting with\u000d\u000a        solubilised reactants\u000d\u000a      Cyanuric chloride (CC) is used in the manufacture of dyestuffs and\u000d\u000a      agrochemicals at the thousands of tonnes per annum scale. CC is sparingly\u000d\u000a      soluble in water. The Compton group has quantified the reactive\u000d\u000a      dissolution of CC with amines including competitive hydrolysis [2], which\u000d\u000a      occurs in parallel with dissolution. Similarly, a mechanistic\u000d\u000a      understanding of the reaction of the insoluble p-chloranil with\u000d\u000a      amines has been developed. In this case, the mechanism is further\u000d\u000a      complicated by formation of a product of even lower solubility which\u000d\u000a      \"coats\" the reactant, inhibiting the process [1]. The hydrolysis of\u000d\u000a      crystalline trityl chloride has also been quantified and shown to be truly\u000d\u000a      interfacial, driven by the specific orientation and concentration of C-Cl\u000d\u000a      bonds at the substrate crystal surface; this is an unambiguous example of\u000d\u000a      how Compton's methodologies can clearly characterise surface reactivity\u000d\u000a      that is dependent upon the specific crystal face exposed to the reacting\u000d\u000a      liquid medium [3]. This research was carried out in collaboration with\u000d\u000a      Zeneca Ltd (who merged into Syngenta AG in 2000).\u000d\u000a    (ii) Studies on sparingly soluble inorganic bases in polar aprotic\u000d\u000a        solvents\u000d\u000a      A significant extension of Compton's work was to refocus the research from\u000d\u000a      organic to inorganic solids. Inorganic bases such as K2CO3\u000d\u000a      are used routinely with solvents such as DMF to generate the reactive\u000d\u000a      anion of an acid in solution for subsequent reaction with a solubilised\u000d\u000a      electrophile. The research conducted on K2CO3\u000d\u000a      clearly showed that very low base solubility can, and indeed does, lead to\u000d\u000a      the dissolution of the base into the solvent becoming rate limiting,\u000d\u000a      rather than any subsequent chemical step. Establishing this fact has had\u000d\u000a      significant impact on operation at full scale. Work by Compton (in\u000d\u000a      collaboration with Syngenta AG) quantified the dissolution rates of\u000d\u000a      inorganic bases and how they vary depending upon conditions, between\u000d\u000a      related structures (e.g. K+ vs Na+ base), and the\u000d\u000a      crystal structure [4]. The methods developed were readily transferable to\u000d\u000a      Syngenta's processes for agrochemical production (see Section 4) and had a\u000d\u000a      major impact on their choice of base in manufacturing processes.\u000d\u000a    (iii) Targeted removal of metal ions from waste streams\u000d\u000a      Metal catalysed processes, especially using palladium, are becoming\u000d\u000a      increasingly important in industry. The detection, removal and recovery of\u000d\u000a      pollution from waste streams is important for cost reasons and to minimise\u000d\u000a      environmental impact. The Compton group developed methods using simple\u000d\u000a      functionalisation of cheap carbon to recover precious metals such as\u000d\u000a      palladium from water, including detailed characterisation of the surface\u000d\u000a      physical properties that control the removal processes [5].\u000d\u000a    "},{"CaseStudyId":"18144","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Royal Society"],"ImpactDetails":"\u000d\u000a    The Oxford University Botanic Garden is the oldest botanic garden in the\u000d\u000a      UK and a major tourist attraction in the city, with over 100,000 visitors\u000d\u000a      from all over the world every year (ranked 16th of 92 tourist\u000d\u000a      attractions in Oxford on TripAdvisor, July 2013). The research link\u000d\u000a      between the UOA and the Botanic Garden goes back more than 100 years\u000d\u000a      including the work of Sir Robert Robinson (who pioneered the isolation and\u000d\u000a      study of bioactive compounds from plants in the early 20th\u000d\u000a      Century); the Chemistry at the Garden public project has taken inspiration\u000d\u000a      from this historical link and built on it to provide a public engagement\u000d\u000a      project with contemporary relevance.\u000d\u000a    The series of collaborative outreach projects started in 2011,\u000d\u000a      International Year of Chemistry, when an enthusiastic group of staff and\u000d\u000a      research students from the Chemistry Department hosted a poster exhibition\u000d\u000a      at the Garden. The posters told stories about the chemistry of\u000d\u000a      plant-derived compounds, with titles such as \"Poisonous plants: an\u000d\u000a      unlikely source of medicine!\", \"History molecules; plants and\u000d\u000a      archaeology\", \"When life gives you lemons...take some Miraculin\", \"Natural\u000d\u000a      Solar Fuels\". The exhibition was in a prominent location near the entrance\u000d\u000a      to the Garden and there were over 14,000 visitors to the garden during the\u000d\u000a      four-month exhibition (as recorded by ticket sales) [7]. The launch event\u000d\u000a      for the exhibition was attended by the Lord Mayor of Oxford and other\u000d\u000a      local councillors, as well as senior representatives from industry,\u000d\u000a      business and the University. Comments from the Exhibition's visitors' book\u000d\u000a      included: \"Fascinating information and communicated in a simple style\u000d\u000a        for us non-chemists. Brilliant!\"; \"A very interesting exhibition\u000d\u000a        and well presented. Found lots of information on plants found in my\u000d\u000a        garden.\" [8]\u000d\u000a    From September 2012, highlights of this exhibition were developed into an\u000d\u000a      ongoing Chemistry Discovery Audio Trail, which includes Anderson, Vincent,\u000d\u000a      Parkin and McCullagh talking about aspects of their research described in\u000d\u000a      Section 2. Acting on some of the feedback from the poster exhibition, each\u000d\u000a      audio feature, delivered via an interactive map of the Garden, is\u000d\u000a      accompanied by a chemical structure model of the compound being described.\u000d\u000a      Over 400 visitors and 200 post-16 students and teachers have so far taken\u000d\u000a      the trail [9] and there have been at least 1,700 downloads of the trail\u000d\u000a      audio podcasts from iTunesU and the University of Oxford podcast page [9].\u000d\u000a      A video about the project is publicly available, featuring extracts from\u000d\u000a      the chemistry audio trail and researchers talking about how highly they\u000d\u000a      value the opportunity to engage with new audiences. The trail reaches an\u000d\u000a      audience that might otherwise not engage with research of this kind, as\u000d\u000a      evidenced by comments such as a 2012 review on TripAdvisor: \"The\u000d\u000a        Chemistry trail &#8212; an audio system that accompanies you [on your\u000d\u000a        visit] &#8212; ... gives some fascinating insights into the plants and why\u000d\u000a        they are significant.\" [10]. After a visit with his class a\u000d\u000a      secondary school teacher commented \"Very interesting chemical stories\u000d\u000a        told by real scientists. Excellent to see the molecular models next to\u000d\u000a        the plants\" [11].\u000d\u000a    \u000d\u000a    A molecular model on the audio trail\u000d\u000a    \u000d\u000a    The next development was to introduce more face-to-face contact between\u000d\u000a      academics and the general public. During May to July 2013, academics from\u000d\u000a      the Chemistry Department (Davies, Anderson, Vincent, Sartbaeva and Cooper)\u000d\u000a      delivered a series of guided walks around the Botanic Garden, using plants\u000d\u000a      to explain key aspects of their research as in Section 2. Over 50\u000d\u000a      individuals attended the talks, and the intimate setting meant visitors\u000d\u000a      were able to engage with the chemists in ways that had meaningful impact\u000d\u000a      on their perception of science. Detailed written feedback was collected\u000d\u000a      from all attendees, with one example stating \"I feel that what I have\u000d\u000a        picked up \"in small bits\" has helped me read the science sections of\u000d\u000a        public media in a more informed way.\" [12]\u000d\u000a    One of the major themes from the Chemistry at the Garden project was\u000d\u000a      selected for an interactive stand at the prestigious one-week Royal\u000d\u000a      Society Summer Science Exhibition in July 2013. The topic, \"Solving the\u000d\u000a      Energy Crisis &#8212; from Ancient to Future Solar Fuels\", linked directly to\u000d\u000a      Armstrong and Parkin's research on artificial photosynthesis (see Section\u000d\u000a      2). During the week-long exhibition over 30 volunteers from the Department\u000d\u000a      and the Botanic Garden, led by Rhiannon Evans (PDRA in the Armstrong\u000d\u000a      group), worked on the stand. Always led by a member of the solar fuels\u000d\u000a      research group, the exhibition received over 12,500 visitors, including\u000d\u000a      11,400 from the media, schools and the general public (official figures\u000d\u000a      from the RS). The Oxford Chemistry team spoke directly with at least 3,000\u000d\u000a      visitors, measured by handing out stickers to everyone who engaged with\u000d\u000a      the stand over the course of the week. The team also engaged online\u000d\u000a      through social media, podcasts, the RSSE website (which received 83,000\u000d\u000a      unique visitors over the course of the exhibition), and the blog, where\u000d\u000a      aspiring scientists posted results from a take-home chlorophyll experiment\u000d\u000a      after visiting the exhibit, continuing after July 2013 [13]. The\u000d\u000a      popularity of the stand was enhanced by a `hands-on' approach with\u000d\u000a      interactive demonstrations and experiments completed by hundreds of\u000d\u000a      people. The activities linked to several aspects of primary and secondary\u000d\u000a      school Science, Maths and Geography curricula and A-level Biology and\u000d\u000a      Chemistry curricula. The strong impact of the exhibition on school pupils\u000d\u000a      and their teachers was evidenced by requests for follow-up resource packs\u000d\u000a      which were delivered to 84 UK schools, the majority of which had never\u000d\u000a      been in contact with the Department of Chemistry before [13]. Since the\u000d\u000a      exhibition the Department has been approached directly by students asking\u000d\u000a      for further information about solar fuels science, including one Year 13\u000d\u000a      student at North London Collegiate School who wrote \"I was fascinated\u000d\u000a        by your display at the Royal Society Summer Science Exhibition, and I\u000d\u000a        believe others at my school would love to hear about your work too. We\u000d\u000a        would be delighted if you would be able to talk to us about 'Ancient to\u000d\u000a        Future Solar Fuels'.\" [14].\u000d\u000a \u000d\u000aA Chemistry Department volunteer engaging with school students at the RSSE\u000d\u000a\u000d\u000a    The Department raised over &#163; 30,000 in sponsorship for the RSSE stand.\u000d\u000a      One of the sponsors, the Royal Society of Chemistry (RSC), gave support\u000d\u000a      for the Future Solar Fuels stand since the focus aligned with their own\u000d\u000a      programme of activities, in particular the goal of raising public and\u000d\u000a      political awareness of the environmental and economic potential of fuels\u000d\u000a      produced using sunlight, as well as with the strength of UK research in\u000d\u000a      this area. The RSC provided both funding and relevant materials for\u000d\u000a      distribution, taking advantage of the stall as a `channel to a wider\u000d\u000a      audience', and welcoming the fact that the UOA planned to `create a legacy\u000d\u000a      from the stand' and promote future solar fuels beyond the RSSE. The RSC\u000d\u000a      also valued the involvement of practising researchers on the stand, as\u000d\u000a      well as the collaboration with the University of York researchers [15].\u000d\u000a    Finally, this sustained series of engagement beyond academia has\u000d\u000a      established links with the outreach ambitions of industry. Since 2011,\u000d\u000a      industry sponsors have included BP, Syngenta, Johnson Matthey, Infineum,\u000d\u000a      AZ, Evotech, GSK, Basildon Chemicals and the Society of Chemical Industry\u000d\u000a      (SCI), plus the donation of equipment by Locktronics\/Matrix. Syngenta and\u000d\u000a      SCI both sponsored the event because they saw its value in informing and\u000d\u000a      enthusing the general public about the society benefits of plant chemistry\u000d\u000a      [16, 17]. BP's Chief of Staff stated: \"The summer exhibition is a\u000d\u000a        great way to engage current and future scientists and the general public\u000d\u000a        and to raise awareness of science in general. Your exhibition on\u000d\u000a        `Solving the Energy Crisis  From Ancient to Future Solar Fuels' will be\u000d\u000a        an interesting and informative example.\" [18] The generous donations\u000d\u000a      in support of the project have provided sustainability &#8212; the RSSE exhibit\u000d\u000a      will be taken to the 2014 Big Bang Fair (estimated 60k visitors).\u000d\u000a    ","ImpactSummary":"\u000d\u000a    A portfolio of Oxford University research, relating to the chemistry of\u000d\u000a      natural products extracted from plants, has formed the basis of a\u000d\u000a      substantial and multifaceted programme of outreach activity targeted at\u000d\u000a      schools and the general public from 2011-2013. Research students and staff\u000d\u000a      have collaborated with the Oxford University Botanic Garden to deliver\u000d\u000a      multiple events including a poster exhibition, an audio trail, interactive\u000d\u000a      guided walks and a `solar fuels' stand at the prestigious 2013 Royal\u000d\u000a      Society Summer Science Exhibition, with the emphasis on face-to-face\u000d\u000a      in-depth interaction where possible and a strong link to Oxford Chemistry\u000d\u000a      research. The events have educated thousands of people and helped to\u000d\u000a      inform their views on, and enthusiasm for, plant-related chemistry. They\u000d\u000a      have also engaged the interest and support of industry.\u000d\u000a    ","ImpactType":"Societal","Institution":"\u000d\u000a    University of Oxford\u000d\u000a    ","Institutions":[{"AlternativeName":"Oxford (University of)","InstitutionName":"University of Oxford","PeerGroup":"A","Region":"South East","UKPRN":10007774}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    Asterisked outputs denote best indicators of quality; University of\u000d\u000a      Oxford authors are underlined.\u000d\u000a    \u000a[1]* A Palladium-mediated Cascade Cyclisation Approach to the CDE Cores\u000d\u000a      of Rubriflordilactone A and Lancifodilactone G. Cordonnier M-CA,\u000d\u000a      Kan SBJ, and Anderson EA, Chem. Commun. 23 (2008) 5818. The\u000d\u000a        natural product target for the Anderson laboratory research described in\u000d\u000a        this publication is isolated from the Chinese herbal plant Schisandra\u000d\u000a        rubriflora, which is grown at the University of Oxford Botanic Garden.\u000d\u000a    \u000a\u000a[2]* Danyal K, Inglet BS, Vincent KA, Barney BM, Hoffman BM, Armstrong\u000a        FA, Dean DR, Seefeldt LC. Uncoupling Nitrogenase: Catalytic\u000d\u000a      Reduction of Hydrazine to Ammonia by a MoFe Protein in the Absence of Fe\u000d\u000a      Protein-ATP. J. Am. Chem. Soc. 133 (2010) 13197. DOI: 10.1021\/ja1067178 This\u000d\u000a        paper describes a technique for delivering low potential electrons to\u000d\u000a        nitrogenase, which will enable new studies to understand the mechanism\u000d\u000a        by which this important enzyme fixes atmospheric nitrogen into forms\u000d\u000a        accessible to plants and its role in the global N cycle.\u000d\u000a    \u000a\u000a[3]* Bachmeier A, Wang VCC, Woolerton TW, Bell S,\u000d\u000a      Fontecilla-Camps JC, Can M, Ragsdale SW, Chaudhary YS, Armstrong\u000d\u000a        FA. How light-harvesting semiconductors can alter the bias of\u000d\u000a      reversible electrocatalysts in favor of H2 production and CO2\u000d\u000a      reduction. J. Am. Chem. Soc. Accepted September 2013. DOI:\u000d\u000a      10.1021\/ja4042675 This paper shows how the capability of a biological\u000d\u000a        catalyst to produce solar fuels or feedstocks such as CO and hydrogen\u000d\u000a        can be favoured by the semiconductor used as the source of electrons.\u000d\u000a    \u000a\u000a[4] Wait AF, Parkin A, Morley GM, dos Santos L, Armstrong\u000a        FA. Characteristics of Enzyme-Based Hydrogen Fuel Cells Using an\u000d\u000a      Oxygen-Tolerant Hydrogenase as the Anodic Catalyst. J. Phys. Chem. C 114\u000d\u000a      (2010) 12003. DOI: 10.1021\/jp102616m\u000d\u000a    \u000a\u000a[5] Marom A, McCullagh JSO, Higham TFG, Sinitsyn AA, Hedges REM.\u000d\u000a      Single amino acid radiocarbon dating of Upper Palaeolithic modern humans.\u000d\u000a      PNAS 18th April 2012. DOI: 10.1073\/pnas.1116328109\u000d\u000a    \u000a\u000a[6] Davies S G, Lee J A, Roberts PM, Stonehouse\u000a        JP, Thomson JEJ. Asymmetric syntheses of the homalium\u000d\u000a      alkaloids (-)-(S,S)-homaline and (-)-(R,R)-hopromine. Org. Chem. 77 (2012)\u000d\u000a      7028. DOI: 10.1021\/jo3012732\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"},{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"}],"Sources":"\u000d\u000a    [7] Spreadsheet (on file) corroborating visitor numbers to the Botanic\u000d\u000a      Garden during the poster exhibition.\u000d\u000a    [8] Poster exhibition visitors' book (held on file) corroborating the\u000d\u000a      impact on visitors and increase in understanding of, and interest in, the\u000d\u000a      chemistry presented.\u000d\u000a    [9] Corroboration of numbers of people taking the Chemistry Trail and\u000d\u000a      audio downloads (on file).\u000d\u000a    [10] The TripAdvisor review appeared on 10 November 2012 and can be found\u000d\u000a      at http:\/\/www.tripadvisor.co.uk\/Attraction_Review-g186361-d531741-Reviews-or70-University_of_Oxford_Botanic_Garden-Oxford_Oxfordshire_England.html#REVIEWS.\u000d\u000a    [11] Teacher from Redborne Upper School and Community College,\u000d\u000a      corroborating the positive impact of the Chemistry Trail (feedback form,\u000d\u000a      held on file).\u000d\u000a    [12] Feedback corroborating the personal impact of the Summer Strolls\u000d\u000a      event (held on file).\u000d\u000a    [13] Corroboration of numbers of visitors posting results on RSSE blog,\u000d\u000a      and evidence of numbers of schools requesting packs, is held on file.\u000d\u000a    [14] Email from Year 13 student at North London Collegiate School (held\u000d\u000a      on file), corroborating their continuing interest in the RSSE exhibition\u000d\u000a      topic, and requesting a visit.\u000d\u000a    [15] The Senior Programme Manager at the RSC can be contacted to\u000d\u000a      corroborate the reasons for the RSC's support of the RSSE stall.\u000d\u000a    [16] The Senior Research Chemist at Syngenta can be contacted to\u000d\u000a      corroborate the reasons for Syngenta's support of the Chemistry at the\u000d\u000a      Garden project.\u000d\u000a    [17] The Chairman of SCI Horticulture Group can be contacted to\u000d\u000a      corroborate the reasons for SCI's support of the Chemistry at the Garden\u000d\u000a      project.\u000d\u000a    [18] Quote from BP's Chief of Staff in sponsorship letter, and\u000d\u000a      corroborating interest from UK Fuel industry (letter held on file). \u000d\u000a    ","Title":"\u000d\u000a    UOA08-08: Chemistry at the Garden: using living collections to\u000d\u000a        generate public interest in chemistry research.\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2656194","Name":"Basildon"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    A substantial body of research conducted at Oxford University since\u000d\u000a      January 1993 has explored a range of themes relating to plant-derived\u000d\u000a      natural products including complex natural product synthesis, artificial\u000d\u000a      photosynthesis, nitrogenases, crystallographic analysis and asymmetric\u000d\u000a      catalysis, mineral components of soil, studies on plant signalling and\u000d\u000a      defence, measuring isotopes for archaeology, synthetic materials and the\u000d\u000a      biological importance of plant-derived compounds. Five examples at the\u000d\u000a      heart of the public engagement work (described in sections 1 and 4) are\u000d\u000a      highlighted below.\u000d\u000a    Edward Anderson (Lecturer) has worked on a family of natural antivirals\u000d\u000a      derived from Schisandra rubriflora, a Chinese plant used in\u000d\u000a      traditional medicine which grows in the Oxford Botanic Garden. This work\u000d\u000a      not only includes total synthesis efforts towards these antiviral\u000d\u000a      molecules, but also the development of new synthetic methodology that was\u000d\u000a      only conceived because of the chemical \/ structural relevance to these\u000d\u000a      plant-derived natural products [1].\u000d\u000a    Kylie Vincent (Lecturer) is developing new tools for understanding small\u000d\u000a      molecule activation by metallo-enzymes including dinitrogen reduction by\u000d\u000a      nitrogenase in soil and plant roots. The groups of Vincent and Armstrong\u000d\u000a      (both Oxford) and Lance Seefeldt (Utah State University) used the control\u000d\u000a      of electron transfer to nitrogenase via low-potential reductants or an\u000d\u000a      electrode to study catalysis and ligand binding [2].\u000d\u000a    Fraser Armstrong (Professor) and Alison Parkin (Research Fellow at Oxford\u000d\u000a      2008-12) have applied the chemical principles of bio-catalysis to\u000d\u000a      developing `artificial photosynthesis' systems. The three fundamental\u000d\u000a      components of such systems (light capture, electron source and fuel\u000d\u000a      production systems) are studied as separate entities in the Armstrong Labs\u000d\u000a      (e.g. enzyme-based bio-catalytic hydrogen production), with the ultimate\u000d\u000a      aim of integrating these components into a scalable system with extended\u000d\u000a      efficiencies and lifetimes. While at Oxford Dr Parkin pioneered the\u000d\u000a      electrochemical characterisation of these bio-catalytic systems which are\u000d\u000a      helping to develop an understanding of how to harness non-platinum metals\u000d\u000a      in proof-of-concept energy devices [3, 4].\u000d\u000a    James McCullagh (Head of Mass Spectrometry) has explored plants in\u000d\u000a      relation to archaeological chemistry. He has focussed on developing\u000d\u000a      strategies for compound-specific palaeodietary reconstruction using mass\u000d\u000a      spectrometry, and shown that carbon isotope ratios of amino acids from\u000d\u000a      archaeological proteins can provide useful information about an\u000d\u000a      individual's diet. In other studies his development of compound specific\u000d\u000a      radiocarbon dating has made a significant contribution to understanding of\u000d\u000a      the dispersal of anatomically modern humans into Europe [5].\u000d\u000a    Steve Davies' (Waynflete Professor of Chemistry) research since 1993 has\u000d\u000a      included the development of asymmetric synthetic methods and total\u000d\u000a      synthesis of natural products, including many derived from plants. X-ray\u000d\u000a      crystallography is a key analytical tool for this research and is used for\u000d\u000a      both characterisation of chemical structure and the determination of\u000d\u000a      absolute stereochemistry of products [6]. The development and application\u000d\u000a      of such crystallographic methods are a major focus of research within\u000d\u000a      Chemical Crystallography in Oxford.\u000d\u000a    "},{"CaseStudyId":"18224","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"6252001","Name":"United States"}],"Funders":["Royal Society"],"ImpactDetails":"\u000a    Since 2008, InhibOx Ltd. has made important contributions to\u000a      computational chemistry in the field\u000a      of drug discovery. Taking advantage of cloud computing techniques, the\u000a      natural successor to\u000a      Screensaver Lifesaver, to increase the scale and speed of its virtual\u000a      screening methods, InhibOx\u000a      has helped to drive down costs of searching for leads in a way that has\u000a      enabled much smaller\u000a      companies to enter the field of drug development. InhibOx's key product is\u000a      the drug database\u000a      Scopius.\u000a    After spin-out in 2001, Isis Innovation Ltd. (the technology transfer arm\u000a      of the University of Oxford)\u000a      exclusively licensed the software technology developed by the Richards\u000a      group to InhibOx. From\u000a      2004 to 2008, a new round of investment enabled InhibOx to develop initial\u000a      versions of the Scopius\u000a      database and novel software methods, informed by the lessons learned\u000a      regarding the issues of\u000a      large scale database construction obtained with Screensaver; in this\u000a      period the level of commercial\u000a      activity was minimal. At the start of 2008, Scopius consisted of\u000a      approximately 3 million molecules;\u000a      by the end of the assessment period it contained &gt;112 million\u000a      molecules, making it the world's\u000a      largest high-quality database of candidate compounds, either commercially\u000a      available or\u000a      synthesisable in a few steps. InhibOx has also produced an array of more\u000a      focused databases for\u000a      specialist applications. Since 2008, InhibOx has used ElectroShape, the\u000a      ultrafast technique\u000a      invented by the Richards Group which incorporates chiral shape\u000a      recognition, to further develop the\u000a      search software. InhibOx's CEO states that \"InhibOx has developed a\u000a        comprehensive array of\u000a        computer-aided drug design technologies that helped to advance\u000a        real-world commercial drug\u000a        discovery projects. The contribution of Richards has been fundamental to\u000a        this achievement both\u000a        through the development of new science and his experience in bridging\u000a        the gap between basic and\u000a        applied research.\" [7]\u000a    Rather than developing a software product to sell, InhibOx has focussed\u000a      on running targeted\u000a      database searches for customers, producing lists of potential molecules\u000a      that they can use as drug\u000a      leads. This has had a particular impact for SMEs. In some fields of drug\u000a      discovery, it can cost\u000a      billions to bring a drug to market, including an estimated &#163; 400,000 for a\u000a      company to build its own\u000a      molecule database in order to find the right molecules to experiment with,\u000a      and typically &gt;&#163; 50M -100M\u000a\u0009  to develop compounds suitable for use in clinical trials. These high\u000a      costs have hindered the\u000a      pre-clinical trial phases of drug development, restricting them to very\u000a      large, well-financed\u000a      companies. InhibOx has enabled increased competition in early-stage drug\u000a      R&amp;D by making\u000a      compound searching more affordable for SMEs; a target search of molecules\u000a      using Scopius costs\u000a      around &#163; 20,000 - a fraction of what it would cost a small company to\u000a      build its own database.\u000a      InhibOx's client base demonstrates the way in which it has helped to open\u000a      up early-stage\u000a      development to smaller companies: 75% of its clients are SMEs, e.g.\u000a      DormaTarg, Mission\u000a      Therapeutics, Lauras and Cephalon, and 25% are corporates, e.g. Bristol\u000a      Myers Squibb and\u000a      Colgate Palmolive. This reflects and supports a shift in the way the\u000a      market operates; big pharma\u000a      will in some cases buy drug leads from small companies rather than develop\u000a      leads themselves.\u000a      Lauras' Vice President for R&amp;D commented that InhibOx has helped\u000a        redesign the company's drug\u000a        targeting programmes and suggested new lines of derivatisation that have\u000a        delivered compounds\u000a        with the properties they wanted [8]. Likewise DormaTarg worked with\u000a      InhibOx on in silico\u000a      screening, testing several of the hits predicted by InhibOx, and finding\u000a      that several showed the kind\u000a      of novel activity they were seeking [9].\u000a    In 2010 InhibOx designed a programme to develop Tumour Necrosis Factor-&#945;\u000a      Converting Enzyme\u000a      inhibitors for inflammatory disease starting from a non-selective weak\u000a      lead molecule. Using\u000a      InhibOx structure-based design technology and project management\u000a      expertise, a cost-effective\u000a      semi-virtual discovery project delivered a novel compound series and\u000a      optimised a lead candidate\u000a      requiring the synthesis of only 33 compounds within a 6-month timescale.\u000a      The series (based on\u000a      bicyclosulfonyl acid compounds) was patented by InhibOx [10], and the\u000a      programme was sold in\u000a      December 2010 to a large EU-based pharmaceutical company. This is an\u000a      example of InhibOx\u000a      providing the initial screening of compounds that are now being taken\u000a      forward in further research.\u000a    More recently InhibOx has taken advantage of the experience developed in\u000a      its pioneering use of\u000a      cloud computing for large-scale molecular modelling. The availability of\u000a      new and powerful cloud\u000a      computing services which can be leveraged on demand has enabled InhibOx to\u000a      provide large-\u000a      scale virtual screening throughput at low cost for specific purposes. In\u000a      2012, the company created\u000a      a corporate virtual library for a major corporation based on their\u000a      available chemistry. The result\u000a      contained over 28 million drug-like molecules and was completed in just\u000a      over 4 days using cloud\u000a      computing facilities from Amazon Web Services (AWS). The computational\u000a      cluster constructed\u000a      would have ranked the project in the Top 500 Supercomputers, with a speed\u000a      to 240 TFlop\/s.;\u000a      constructing this level of hardware infrastructure in-house would have\u000a      cost InhibOx around $ 200k,\u000a      so the use of AWS led to considerable cost savings. This work was\u000a      highlighted in a case study on\u000a      the AWS web site [11]. Company expertise in this area is reflected in a\u000a      recent review by InhibOx\u000a      authors analysing the applications of cloud computing to molecular\u000a      modelling [12].\u000a    InhibOx has made a conscious decision to remain focussed and concentrate\u000a      on core areas of\u000a      expertise, a strategy which has helped it to weather the upheaval in the\u000a      pharmaceutical industry\u000a      while many larger biotechs have gone out of business. It has maintained\u000a      steady business during\u000a      the impact period; income and investment since 2008 has totalled around &#163;\u000a      2.8M, including sales\u000a      revenue of &#163; 250,000 in 2012. It is an export-led company with 60% of\u000a      sales in the US, 25% in\u000a      Europe and 15% within the UK [7]. Since 2008, it has established an\u000a      additional office in Princeton,\u000a      USA and since 2010 developed commercial partnerships with the Cambridge\u000a      Crystallographic\u000a      Data Centre, Intelligensys, COSMIC Discoveries and Molport [13]. These\u000a      companies provide\u000a      complementary expertise in virtual screening, computer-aided drug\u000a      discovery and chemical\u000a      compound manufacture. The Scientific Director of Intelligensys has\u000a      outlined the benefits to them\u000a      (and to drug discovery generally) of the partnership: `We have seen,\u000a        over many years, too many\u000a        seemingly promising lead compounds fail to make it through preclinical\u000a        tests. This has been\u000a        expensive to the industry and is largely avoidable. This collaboration\u000a        is delivering the capability to\u000a        stem these losses and deliver much more cost-effective drug discovery as\u000a        a result.' [14].\u000a    InhibOx's innovation, underpinned by the Richards' Group work, has led to\u000a      it being selected as a\u000a      partner on several high-profile EU projects such as a recent FP7 framework\u000a      grant worth &#8364; 1M to\u000a      InhibOx [15], and its innovation\/international excellence was recognised\u000a      in May 2011 with InhibOx\u000a      being short listed for the prestigious Red Herring 100 Award &#8212; a mark of\u000a      distinction for identifying\u000a      promising new companies and entrepreneurs. Red Herring is a global media\u000a      company with a focus\u000a      on technology innovation [16].\u000a    ","ImpactSummary":"\u000a    Since 2008, pioneering contributions to the field of computational\u000a      chemistry for drug discovery\u000a      have been made by InhibOx Ltd., a spin-out company based on the research\u000a      of Graham Richards\u000a      and co-workers at the University of Oxford. InhibOx launched Scopius, the\u000a      world's largest\u000a      searchable virtual database of small-molecules (&gt;112 million compounds)\u000a      and pioneered the use\u000a      of cloud computing for large-scale molecular modelling. The key impact for\u000a      customers of InhibOx\u000a      has been the reduced costs in identifying molecular leads for new drugs.\u000a      InhibOx's work has\u000a      helped to open up early stages of drug development to smaller companies;\u000a      75% of InhibOx's\u000a      clients are SMEs. Since 2008, InhibOx has received &#163; 2.8M in income and\u000a      investment.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Oxford\u000a    ","Institutions":[{"AlternativeName":"Oxford (University of)","InstitutionName":"University of Oxford","PeerGroup":"A","Region":"South East","UKPRN":10007774}],"Panel":"B         ","PlaceName":[],"References":"\u000a    Asterisked outputs denote best indicators of quality; University of\u000a      Oxford authors are underlined.\u000a    \u000a1. *Richards, W. G., Virtual screening using grid computing: the\u000a      screensaver project. Nature\u000a      Reviews Drug Discovery, 1 (7), 551-5, 2002. DOI:10.1038\/nrd841. The\u000a        article describes how\u000a        massively distributed computing using screensavers has allowed databases\u000a        of billions of\u000a        compounds to be screened against protein targets in a matter of days.\u000a    \u000a\u000a2. Ballester, P. J.; Richards, W. G., Ultrafast shape\u000a      recognition for similarity search in molecular\u000a      databases. Proceedings of the Royal Society A: Mathematical Physical and\u000a      Engineering\u000a      Sciences 463 (2081), 1307-1321, 2007. DOI: 10.1098\/rspa.2007.1823\u000a    \u000a\u000a3. Ballester, P. J.; Finn, P. W.; Richards, W. G.,\u000a      Ultrafast shape recognition: Evaluating a new\u000a      ligand-based virtual screening technology. Journal of Molecular Graphics\u000a      &amp; Modelling 27 (7),\u000a      836-845, 2009. DOI: 10.1016\/j.jmgm.2009.01.001\u000a    \u000a\u000a4. *Ballester, P. J.; Westwood, I.; Laurieri, N.;\u000a      Sim, E., Richards, W.G. Prospective virtual\u000a      screening with Ultrafast Shape Recognition: the identification of novel\u000a      inhibitors of arylamine N-\u000a      acetyltransferases. Journal of the Royal Society Interface 7 (43),\u000a      335-342, 2010. DOI:\u000a      10.1098\/rsif.2009.0170. A virtual screening technique (USR) is\u000a        described based on ligand-\u000a        receptor shape complementarity and is applied to discover a novel\u000a        inhibitor by screening\u000a        almost 700 million molecular conformers.\u000a    \u000a\u000a5. Richards, W. G., Patent no 03700921.4-2201-GB0300241 (2007);\u000a      Method for binding site\u000a      identification using a multi-scale approach.\u000a      https:\/\/www.google.com\/patents\/EP1468392B1\u000a    \u000a\u000a6. *Armstrong, M. S.; Morris, G. M.; Finn, P. W.; Sharma, R.; Moretti,\u000a        L.; Cooper, R. I.; Richards,\u000a      W. G., ElectroShape: fast molecular similarity calculations incorporating\u000a      shape, chirality and\u000a      electrostatics. Journal of Computer Aided Molecular Design 24 (9),\u000a      789-801, 2010. DOI:\u000a      10.1007\/s10822-010-9374-0. The paper describes a novel ligand-based\u000a        virtual screening\u000a        method that combines shape and electrostatic information into a single\u000a        unified framework.\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"15","Subject":"Pharmacology and Pharmaceutical Sciences"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"9","Subject":"Neurosciences"}],"Sources":"\u000a      \u000a    The CEO of InhibOx can corroborate the benefits to the company of the\u000a      Richards Group\u000a      research, details relating to the Scopius database, and income, investment\u000a      and sales figures.\u000a    \u000ahttp:\/\/www.inhibox.com\/node\/23\u000a      Quote on the InhibOx website from the VP for R&amp;D at Lauras AS,\u000a      corroborating the fact that\u000a      InhibOx's in silico screening has helped Lauras advance its drug\u000a      discovery pipeline.\u000a    \u000ahttp:\/\/www.inhibox.com\/dormatarg-endorses-inhibox\u000a      Quote on the InhibOx website from the President and CSO of DormaTarg,\u000a      Inc., corroborating\u000a      the fact that InhibOx's in silico screening has helped DormaTarg's\u000a      drug discovery programme.\u000a    \u000ahttp:\/\/www.google.com\/patents\/US20100311741\u000a      Patent number PCT\/GB2008\/001683 relating to the TACE inhibitor work at\u000a      InhibOx.\u000a    \u000ahttp:\/\/aws.amazon.com\/solutions\/case-studies\/inhibox\/\u000a      InhibOx case study on the AWS\u000a      website, corroborating creation of a corporate virtual library using cloud\u000a      computing.\u000a    The emerging role of cloud computing in molecular modelling. Ebejer JP,\u000a      Fulle S, Morris GM,\u000a      Finn PW. J Mol Graph Model. 44:177-87 (2013). Review with InhibOx authors\u000a      analysing the\u000a      applications of cloud computing to molecular modelling, corroborating\u000a      InhibOx's expertise in\u000a      this area. http:\/\/www.sciencedirect.com\/science\/article\/pii\/S1093326313001137\u000a\u000a    \u000ahttp:\/\/www.inhibox.com\/commercial-partners\u000a      InhibOx webpage confirming commercial partners.\u000a    \u000ahttp:\/\/www.inhibox.com\/inhibox-intelligensys-partnership\u000a      Quote on the InhibOx website from the Scientific Director of\u000a      Intelligensys, corroborating the\u000a      benefits to them of the partnership with InhibOx.\u000a    \u000ahttp:\/\/www.inhibox.com\/node\/92\u000a      23 July 2013 announcement on the InhibOx website, confirming the FP7\u000a      framework grant.\u000a    \u000ahttp:\/\/www.redherring.com\/events\/red-herring-europe\/2011-red-herring-europe-finalists\/\u000a      Red Herring website, confirming InhibOx as a 2011 finalist for the Red\u000a      Herring 100 Award.\u000a\u0009  \u000a    ","Title":"\u000a    UOA08-09: Computational chemistry to facilitate drug development\u000a    ","UKLocation":[{"GeoNamesId":"2654675","Name":"Bristol"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    A common problem in small-molecule drug discovery is identifying useful\u000a      hits and leads.\u000a      Researchers have a difficult task in selecting compounds with therapeutic\u000a      potential from the billions\u000a      of possible starting points. Improving the selection of which molecules to\u000a      work with is a key part of\u000a      improving return on investment from early stage R&amp;D spend, especially\u000a      for SME companies.\u000a      Computer-based screening is a potentially valuable tool for predicting\u000a      which molecules warrant\u000a      further investigation. Drug companies hold internal databases which may\u000a      hold tens of millions of\u000a      real or virtual molecules; however:\u000a    \u000a      they are often narrowly concentrated around that company's areas of\u000a        expertise;\u000a      it can take 2-3 weeks to search the database (depending on computer\u000a        power available) to\u000a        predict whether a molecule has potential for binding to a particular\u000a        target;\u000a      developing a database in house is a specialised task and may be too\u000a        expensive for small\u000a        organisations (typically requiring two full-time staff for 5 years, or\u000a        around &#163;400,000).\u000a    \u000a    With these limitations in mind, in 2001, a project known as Screensaver\u000a      Lifesaver led by Graham\u000a      Richards set out to build a database of millions of drug-like molecules.\u000a      The database has two\u000a      sections: CSPACE, all molecules available commercially and VSPACE, virtual\u000a      molecules but with\u000a      known synthetic route. Software developed by the Richards group used the\u000a      idle processing power\u000a      of volunteers' computers around the globe to screen molecules and assess\u000a      whether they are\u000a      candidate inhibitors of human proteins for cancer treatment. The concept\u000a      was simple: ruling out\u000a      molecules that were unlikely to be pharmaceutically beneficial meant that\u000a      resources could be\u000a      efficiently concentrated on a smaller number of more promising molecules.\u000a      Screensaver Lifesaver\u000a      was an early example of a computational chemistry project of this kind and\u000a      remains the largest\u000a      such experiment ever conducted. It was very successful, with over 3.5\u000a      million personal computers\u000a      in more than 200 countries used to screen 3.5 billion separate molecules\u000a      for their inhibitory\u000a      potential. The project produced a wealth of potential cancer drug leads\u000a      for 12 target proteins and,\u000a      importantly, revealed for the first time the viability of virtual\u000a      screening using a grid of PCs [1].\u000a      Screensaver Lifesaver led directly to the spin-out of the company InhibOx\u000a      Ltd in late 2001, based\u000a      on the Richards-group research.\u000a    Subsequent research focused on improving effectiveness in searching the\u000a      billions of virtually\u000a        accessible compounds. In particular, this focused on enabling\u000a      searches with virtual molecules\u000a      which `look like' known drug candidates (e.g. a natural drug or an\u000a      existing commercial synthetic\u000a      compound). The Richards Group made two important advances:\u000a    \u000a      Novel ultrafast computing techniques were needed to help whittle down\u000a        the millions of\u000a        molecular options more quickly. Techniques were developed to search\u000a        databases efficiently\u000a        for molecules of similar shape [2, 3]. In particular they used an\u000a        approach based on the\u000a        moments of distance distributions which improved the speed of\u000a        molecular-shape\u000a        recognition by at least 3 orders of magnitude. A prospective screening\u000a        application of the\u000a        method to identify novel inhibitors of arylamine N-acetyltransferases\u000a        had a 40% hit rate (ie.\u000a        active above a critical limit) and was amongst the most cited articles\u000a        in the Journal of the\u000a        Royal Society Interface in 2010 [4]. In order to be useful as an\u000a        antagonist or agonist of a\u000a        target, a small molecule must bind to a specific site on the target. The\u000a        method for\u000a        identification of this site was the subject of a patent granted to\u000a        Richards in 2007 [5].\u000a      Virtual screening requires the search procedure to group molecules\u000a        with strong\u000a        resemblances in terms of electrostatics and lipophilicity as well as\u000a        shape. In 2010 - 2011\u000a        the Richards Group developed and published innovative solutions to this\u000a        problem [6]. At the\u000a        time, the most widely-used methods for this type of virtual screening\u000a        involved a molecular\u000a        alignment step that was computationally intensive and thus provided a\u000a        constraint on the\u000a        size of database that could be searched. The new methods developed an\u000a        alignment-free\u000a        approach that was orders of magnitude faster, while maintaining\u000a        accuracy. By introducing\u000a        partial charge information as a 4th dimension the\u000a        electrostatics was handled very efficiently.\u000a    \u000a    These key advances, together with additional developments at InhibOx\u000a      allowing chirality to be\u000a      incorporated into molecular similarity searching (i.e. distinguishing\u000a      enantiomers), made it possible\u000a      to perform extremely fast searches of a database of billions of compounds\u000a      for molecular similarity\u000a      incorporating shape, chirality, electrostatics and lipophilicity, all\u000a      critical components when\u000a      determining potential drug molecules.\u000a    Richards was a member of the academic staff at Oxford University until\u000a      his retirement in Dec 2007;\u000a      the research was continued in the UOA by two University-employed\u000a      post-doctoral researchers,\u000a      Ballester and Moretti, in collaboration with Richards (at InhibOx since\u000a      2008).\u000a    "},{"CaseStudyId":"18586","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"953987","Name":"South Africa"},{"GeoNamesId":"2921044","Name":"Germany"}],"Funders":[],"ImpactDetails":"\u000a    Sullivan's research [1-6] led to a range of patented products [7, 8] that\u000a      were brought to market by the spin-out company PhosphonicS [a]. The\u000a      company, which was established in 2003 and has shown substantial growth\u000a      throughout the REF period, manufactures and supplies these products at the\u000a      metric tonne scale around the globe. Current applications of Sullivan's\u000a      technology by PhosphonicS clients include precious metal recovery in the\u000a      mining, pharmaceutical and petrochemical markets.\u000a    The initial phase of translation of Sullivan's research into commercially\u000a      viable products began in 2003 with the formation of PhosphonicS Ltd\u000a      (Founders Sullivan and Wilson) supported by Dr Malcolm Sims then Director\u000a      of Queen Mary Innovation and Enterprise (now Queen Mary Innovation Ltd).\u000a      The first staff and lab space were paid for using funds from a DTI Smart\u000a      Award and the Combined London Colleges University Challenge Seed Fund.\u000a    PhosphonicS' development progressed through a series of stages focused on\u000a      product development in the chemistry laboratories at Queen Mary during\u000a      2003-2006 and continued, following Series A funding totalling &#163;1.5\u000a      million, with a move to premises at Milton Park, Abingdon, Oxford.\u000a      Sullivan maintained her academic position at Queen Mary while acting in an\u000a      advisory capacity to the company.\u000a    The company continued to grow with the benefit of long-term investor\u000a      support from the original investor-shareholders who provided additional\u000a      amounts of &#163;1.3M in 2008 and &#163;450k in 2009.\u000a    PhosphonicS is a cleantech company that provides novel technology to\u000a      recover precious metals from process, waste and effluent streams and\u000a      providing both financial and environmental benefits to industrial end\u000a      users and metal refiners. The innovative chemistry underpinning\u000a      PhosphonicS materials [1-6] gives them leading performance for the\u000a      recovery of precious metals such as platinum and rhodium from large volume\u000a      low concentration (parts per million) waste streams, making recovery both\u000a      cleaner and more economic than alternative options. PhosphonicS' materials\u000a      are also applied in the metric-tonne volumes as next-generation metal and\u000a      organic scavengers in the pharmaceutical, and fine and speciality chemical\u000a      industries for product purification purposes.\u000a    `Case study' examples of the application of PhosphonicS materials are\u000a      available from the company website [b, c] and include the recovery of\u000a      rhodium from a waste stream that was previously being transported and\u000a      burned with no precious metal recovery. PhosphonicS provided the plant\u000a      with innovative materials that remove 95% of the rhodium from the waste\u000a      stream, of which 97% can then be reclaimed from the scavenger. Another\u000a      PhosphonicS client utilises the materials in the manufacture of active\u000a      pharmaceutical ingredients. The client uses platinum as a catalyst, which\u000a      must be removed from the product before use, with final concentrations no\u000a      greater than 10 ppm. The PhosphonicS scavenger removes 98% of the\u000a      platinum, 98% of which can be recovered.\u000a    In 2010 the company secured second round financing of &#163;3.5m (US$5.75m),\u000a      led by French venture capital company Seventure Partners (Press Release\u000a      April 2010). The new capital allowed the company to expand its core team\u000a      into larger premises, increase the number of international agents and\u000a      secure further manufacturing options for its products.\u000a    In 2011 PhosphonicS also forged a strategic liaison with multinational\u000a      company W.C. Heraeus [d], who offer batch refinery. W.C. Heraeus is\u000a      offering PhosphonicS' scavenger processes to its customers with low-grade\u000a      waste streams to enable them to capture and recycle more of their precious\u000a      metal waste.\u000a    Building on the success of Sullivan's novel technology, the number of\u000a      PhosphonicS employees had grown from six in 2005 to 25 in March 2012; the\u000a      majority at PhD level. The company has also been able to support PhD CASE\u000a      students at Queen Mary University of London. According to publically\u000a      available accounts, the average net worth (net asset value) of PhosphonicS\u000a      over the last three years (averaging end of year returns for 2010 - 2012)\u000a      was &#163;1.3m [g].\u000a    In February 2013 Seventure Partners invested a further &#163;2.1 million into\u000a      PhosphonicS. To date, the company has raised approximately &#163;9 million of\u000a      private equity investment over 10 years of trading. The investment is\u000a      facilitating ongoing acceleration of the launch of the precious metal\u000a      scavenger product range in numerous international markets, especially\u000a      mining and petrochemical, and to invest in co-developing some major\u000a      catalyst applications with industry clients.\u000a    ","ImpactSummary":"\u000a    The technology in this impact study is based on organofunctionalised\u000a      silica materials that can address market needs for high purity in\u000a      compounds that underpin many areas of the pharma, electronic and medical\u000a      sectors as well as the recovery of limited resources such as precious\u000a      metals that are used in diverse industries. Since the launch of the\u000a      product portfolio in 2006, the materials have become embedded in\u000a      purification or recovery steps in commercial production processes of\u000a      leading mining (South Africa), pharmaceutical (UK) and petrochemical\u000a      (Germany) companies and make a significant impact on the business of these\u000a      companies as well as limiting waste of limited resources.\u000a    ","ImpactType":"Technological","Institution":"\u000a    Queen Mary University of London (QMUL)\u000a    ","Institutions":[{"AlternativeName":"Queen Mary, University of London","InstitutionName":"Queen Mary, University of London","PeerGroup":"A","Region":"London","UKPRN":10007775}],"Panel":"B         ","PlaceName":[],"References":"\u000a    Publications\u000a    \u000a1. M. Jurado-Gonzalez, Duan Li Ou, Alice C. Sullivan, J.R.H. Wilson.\u000a      `Synthesis, characterisation and catalytic activity of porous\u000a      vanadylphosphonate modified silicas'. J. Mater. Chem., 2002, 12,\u000a      3605-3609\u000a    \u000a\u000a2. M. Jurado-Gonzalez, Alice C. Sullivan, J.R.H. Wilson. `Oxidation of\u000a      allylic olefins using cobalt (II) alkyl phosphonate modified silica', Tetrahedron\u000a        Letters, 2003, 44, 4283-4286\u000a    \u000a\u000a3. M. Jurado-Gonzalez, Alice C. Sullivan, J.R.H. Wilson. `Selective\u000a      oxidations of allylic alcohols using vanadyl and cobalt(II) alkyl\u000a      phosphonate modified silicas', Tetrahedron Letters, 2004, 45,\u000a      4465-4468\u000a    \u000a\u000a4. E. Fisset, M. Al-Hashimi, J. Wilson, AC Sullivan. `Selective\u000a      oxidations of sulfides to sulfoxides using immobilised metal alkyl\u000a      phosphonate', Tetrahedron Letters, 2006, 46, 8017-8019\u000a    \u000a\u000a5. Al-Hashimi M., Sullivan A.C. and Wilson J.R.H. `Palladium\u000a      ethylthioglycolate modified silica &#8212; a new heterogeneous catalyst for\u000a      Suzuki and Heck cross-coupling reactions', J. Mol. Catal. A Chemical,\u000a      2007, 273, 298-30\u000a    \u000a\u000a6. Qazi and A.C. Sullivan, `Mesoporous silica-bis(ethylsulfanyl)propane\u000a      palladium catalysts for hydrogenation and one-pot two-step Suzuki\u000a      cross-coupling followed by hydrogenation', Dalton Trans. 2011, 40\u000a      (40),10637-10642\u000a    \u000aPatents\u000a    7. Patent Title: Organopolysiloxanes containing phosphonic groups,\u000a      methods for the production and use thereof.\u000a      SULLIVAN, A. C., &amp; Wilson, J. R. H. (2002, July 18). WO02055587 (A1),\u000a      Granted US as US 7,728,159 B2, , Date of Patent: 20th June 2006\u000a      Granted Europe as EP 1360222B, Date of Patent: 10th August 2006\u000a    8. Patent Title: Substituted organopolysiloxanes, and use thereof.\u000a      Wilson, J. R. H., SULLIVAN, A. C., &amp; Man, S. P. (2006, February 9).\u000a      WO\/2006\/013060,\u000a      Granted: In Europe as EP 1786850B on 26th November 2008; also granted in\u000a      China.\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"},{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"},{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"}],"Sources":"\u000a    a) Spin-out company website: www.phosphonics.com\u000a    b) Details of Precious Metal Recovery Case Studies from PhosphonicS\u000a      clients:\u000a      www.phosphonics.com\/pmr-case-studies.html\u000a    c) Details of purification of small molecules case studies from\u000a      PhosphonicS clients, which include Astra Zenica, Global Pharmaceutical\u000a      Company, Exelixis and Clauson Kaas:\u000a      www.phosphonics.com\/purification-case-studies.html\u000a    d) Strategic agreement with Hiraeus: www.phosphonics.com\/1\/post\/2011\/08\/first-post.html\u000a    e) PhosphonicS company profile: www.rsc.org\/chemistryworld\/2012\/05\/support-specialists\u000a    f) PhosphonicS product overview: www.sigmaaldrich.com\/technical-documents\/articles\/chemfiles\/phosphonics-heterogeneous.html\u000a    g) PhosphonicS publically available account information for the company\u000a      showing net worth:\u000a      www.duedil.com\/company\/04829817\/phosphonics-limited\u000a    ","Title":"\u000a    CS1 &#8212; Innovative chemistry reduces the environmental impact of mining and\u000a      pharmaceutical manufacture\u000a    ","UKLocation":[{"GeoNamesId":"2657780","Name":"Abingdon"},{"GeoNamesId":"2643743","Name":"London"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Organic-inorganic hybrid materials have applications in health care,\u000a      sustainable chemistry and energy transport and generation.\u000a    Many organic-inorganic hybrid materials are formed through organic\u000a      modifications to common metal oxide surfaces. This process imparts novel\u000a      properties that are useful in a host of applications such as in the\u000a      fabrication of new biomaterials, chemical sensors, solid phase catalysts\u000a      and media that are used for purification or capture of high value chemical\u000a      entities including pharma intermediates\/products or precious metals.\u000a    Professor Alice Sullivan has worked and published in this field for more\u000a      than twenty years. While working on organically modified silicas and\u000a      silica type materials (during the period 1995-2003) it became apparent to\u000a      Sullivan (Professor of Inorganic Chemistry at QM) and research associate\u000a      Dr John Wilson (PDRA and Academic Visitor at QM 2001-2005) that the\u000a      development of these materials for a range of potential applications was\u000a      severely hampered both in terms of cost and performance by the limited\u000a      methods then used for surface modifier synthesis. Modifiers were largely\u000a      derived from a single chloroalkylsilane source. This meant that the\u000a      resulting compounds had a very limited range of functionality.\u000a    Prof. Sullivan and Dr Wilson realised that a novel approach, based on\u000a      radical addition chemistry, would lead to products with better\u000a      performance, lower costs at scale, and which could be applied to a wider\u000a      range of problems. The process that they developed is amenable to large\u000a      scale manufacture. A series of papers demonstrating some of the catalytic\u000a      applications of the materials including different types of oxidation,\u000a      carbon-carbon coupling and hydrogenation chemistries were published by the\u000a      team between 1998 and 2011 [1-6]. These novel organic modifiers and the\u000a      derived materials formed the inventive steps of a series of patent\u000a      applications submitted between 2001 and 2006 [7, 8].\u000a    An initial patent application on phosphonate modified silicas was\u000a      submitted by Sullivan and Wilson from Queen Mary in 2001 proceeding to\u000a      grant in the US and Europe in 2006. Patents covering the other families of\u000a      modified materials followed, including those with sulfur rich or nitrogen\u000a      rich surface modifiers. The portfolio provided materials with excellent\u000a      metal binding affinities covering the hard or soft metals in common use in\u000a      the pharmaceutical, petrochemical, mining and fine chemicals sectors and\u000a      supporting applications in areas of solid phase catalysis and purification\u000a      and embracing ideas of sustainable chemical processing.\u000a    "},{"CaseStudyId":"18587","Continent":[{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6252001","Name":"United States"}],"Funders":["Biotechnology and Biological Sciences Research Council","Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000d\u000a    The American Dental Association estimates that there are around 300\u000d\u000a      million periodontal examinations undertaken in the USA every year,\u000d\u000a      representing ca. 30% of the examinations undertaken world-wide. Based on\u000d\u000a      Watkinson and Krause's research, QMUL's spin-out company Degrasense\u000d\u000a      (established in January 2008) has developed a system with the likely\u000d\u000a      capability to accurately identify periods of active inflammation in\u000d\u000a      relation to periodontal disease that is inexpensive to mass produce. The\u000d\u000a      meter (Figure 1) is a point of care system that is designed to allow\u000d\u000a      rapid, in-house diagnosis of periodontal disease, precluding the need to\u000d\u000a      outsource assays to external laboratories. It has been estimated that the\u000d\u000a      consumables associated with this novel technology, will have a market\u000d\u000a      value of approximately 450m GBP per annum (Oraldent &#8212; see below). The\u000d\u000a      technology will improve the targeting of treatment to patients with active\u000d\u000a      periodontitis and ultimately improve clinical outcomes and enhance patient\u000d\u000a      experience.\u000d\u000a    The device developed by spin-out company Degrasense is shown in Figure 1.\u000d\u000a      Briefly, the meter works by samples of gingival crevicular fluid (GVC)\u000d\u000a      from the gums, being loaded onto the capillary sensor chip, which contains\u000d\u000a      electrodes coated with the QMUL patented technology. This sensor is then\u000d\u000a      loaded into the machine, where protelytic activity of the clinically\u000d\u000a      relevant proteases in the GVC is measured through changes in electrical\u000d\u000a      impedance.\u000d\u000a    \u000d\u000a    Figure 1: Meter used to detect protease activity in patients with periodontal disease\u000d\u000a    \u000d\u000a    Companies and charities influenced by the research\u000d\u000a    To reach the point of a clinical trial [below, and 1 in section 5]\u000d\u000a      required collaboration with a number of industrial partners. Supported by\u000d\u000a      Technology Strategy Board funding, Watkinson coordinated the industrial\u000d\u000a      partners to develop the technology specifically for the clinical\u000d\u000a      diagnostics market. These partners are:\u000d\u000a    \u000d\u000a      Oraldent (Oraldent: www.oraldent.co.uk)\u000d\u000a        who assessed the size of the potential periodontal market to be 450m GBP\u000d\u000a        per annum in consumables (value of disposable capillary sensor chip).\u000d\u000a      Industrial Design consultancy (IDC: www.idc.uk.com)\u000d\u000a        [2 in section 5] who designed the meter (see Figure 1)\u000d\u000a      AND Technology Research (AND: http:\/\/andtr.com)\u000d\u000a        who developed the electronics in the meter [3 in section 5].\u000d\u000a      Gwent Electronic Materials Ltd. (www.gwent.org\/gem_index.html)\u000d\u000a        who manufactured the interdigitated electrodes used in the clinical\u000d\u000a        trial [4 in section 5].\u000d\u000a      Barts Charity (www.bartscharity.org.uk)\u000d\u000a        who are currently funding Gwent Electronic Materials to further refine\u000d\u000a        the electrodes based on insights gained through the clinical trial.\u000d\u000a    \u000d\u000a    Collectively, these industrial partners contributed over &#163;340k to the\u000d\u000a      project.\u000d\u000a    Development of a new clinical diagnostic tool and its application\u000d\u000a          in a clinical trial\u000d\u000a    The efficacy of the Degrasense technology is currently being assessed via\u000d\u000a      a clinical trial involving 30 patients suffering from chronic\u000d\u000a      periodonitis. This is an important step on the road to delivery of this\u000d\u000a      diagnostic technology to market. The clinical trials are being undertaken\u000d\u000a      by staff within the School of Clinical Dentistry at the University of\u000d\u000a      Sheffield, in partnership with Sheffield Teaching Hospitals NHS Foundation\u000d\u000a      Trust. The aim of the trial is to assess whether the device can be used to\u000d\u000a      detect active periodontal disease.\u000d\u000a    The initial 12-month stage of the trial necessitated the appointment of a\u000d\u000a      dental hygienist to collect patient samples. The patients were recruited\u000d\u000a      from a number of sources within the partnering hospital, including the\u000d\u000a      undergraduate periodontology teaching clinic, staff hygienist clinics and\u000d\u000a      consultant clinics. All patients were selected by the clinician in charge\u000d\u000a      [1 in section 5] according to criteria that include; aged 18 or over; a\u000d\u000a      diagnosis of chronic periodontitis but otherwise healthy and; one healthy\u000d\u000a      gingival crevice, one deep bleeding and one deep non-bleeding periodontal\u000d\u000a      pocket.\u000d\u000a    Data from the first 12 months of the trial have revealed that the\u000d\u000a      interdigitated electrodes produced by Gwent Electronics need further\u000d\u000a      refinement. The company, funded by Barts Charity, are currently modifying\u000d\u000a      the electrodes to increase reliability. All patient samples from the first\u000d\u000a      stage of the trial have been retained for re-testing once these\u000d\u000a      refinements are in place.\u000d\u000a    Application of Degrasense technology in other clinical settings\u000d\u000a    Krause and Watkinson's technology has already attracted significant\u000d\u000a      interest and investment from multiple industrial partners and its use in a\u000d\u000a      clinical setting has been demonstrated through application in a clinical\u000d\u000a      trial. In addition to increasing the efficacy of diagnostic tools for\u000d\u000a      assessing periodontal disease, the technology has significant potential in\u000d\u000a      a number of other clinical applications where elevated levels of\u000d\u000a      proteolytic enzymes are linked to disease states. Investigations into\u000d\u000a      these applications are ongoing (and are sensitive at this stage) but\u000d\u000a      include: (i) home monitoring of haemophilia; (ii) clinical monitoring of\u000d\u000a      sepsis and trauma; (iii) home monitoring of multiple sclerosis and (iv)\u000d\u000a      the monitoring of arterial ageing and the role of proteinases in\u000d\u000a      hypertension. All of these areas are associated with very significant\u000d\u000a      patient numbers and cost to the NHS. The generic technology that Watkinson\u000d\u000a      and Krause have developed is capable of providing significant improvements\u000d\u000a      in the quality of patient monitoring and consequently also reduction in\u000d\u000a      treatment costs.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    The spin-out company, Degrasense, has developed and protected\u000d\u000a      intellectual property of technology capable of quantifying specific\u000d\u000a      proteolytic enzymes through changes in electrochemical responses\u000d\u000a      (impedance) at electrodes due to the enzymatic degradation of polymer\u000d\u000a      coatings. The company has detected several specific proteases that are\u000d\u000a      relevant to the monitoring and treatment of a number of conditions\u000d\u000a      including: periodontal disease, multiple sclerosis, haemophilia and\u000d\u000a      hypertension. The technology is currently being validated in a clinical\u000d\u000a      trial as a point of care sensor for the detection of active periodontal\u000d\u000a      disease. Point-of-care sensors provide immediate, low-cost test results in\u000d\u000a      non-laboratory settings, offering a more patient-centred approach to\u000d\u000a      healthcare and earlier detection of disease.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    Queen Mary University of London (QMUL)\u000d\u000a    ","Institutions":[{"AlternativeName":"Queen Mary, University of London","InstitutionName":"Queen Mary, University of London","PeerGroup":"A","Region":"London","UKPRN":10007775}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    Peer Reviewed Papers\u000d\u000a    \u000a1. J. Stair, M. Watkinson and S. Krause, \"A generic protease sensor\u000d\u000a      material based on the degradation of peptide cross-linked dextran\u000d\u000a      hydrogels\", Biosensors and Bioelectronics, 2009, 24, 2113-2118.\u000d\u000a    \u000a\u000a2. X. Zheng, J. Cook, S. Yang, S. Krause, M. Watkinson, I. Douglas and A.\u000d\u000a      Rawlinson, \"Generic protease detection technology for monitoring\u000d\u000a      periodontal disease\", Faraday Disc., 2011,149, 37-47.\u000d\u000a    \u000aPatents\u000d\u000a    3. S. Krause, D. Kamarun, M. Watkinson and J. Stair, \"Sensor coatings for\u000d\u000a      protease detection\", European patent number 07824180.9-1223\u000d\u000a      PCT\/GB2007\/003929, granted 10.06.2009 currently at the national phase in\u000d\u000a      the US (WO2008047095(A1)) and the regional phase in Europe\u000d\u000a      (EP2082057(A1)).\u000d\u000a    4. S. Krause, X. Zheng, and M. Watkinson, A second UK priority\u000d\u000a      application following on from Patent 1 was filed on July 30th 2010 and is\u000d\u000a      entitled \"Sensor Coating Layer, Device and Method\" (App No. 1012902.1).\u000d\u000a    Funding\u000d\u000a    &#163;124,876 to G. Giovannoni (PI), S. Krause (co-I), M. Watkinson (co-I), D.\u000d\u000a      Baker (co-I) and A Nassim (co-I) for a project entitled \"MMP-9 detector\u000d\u000a      for inflammation monitoring in autoimmune diseases and solid organ graft\u000d\u000a      rejection\" (NSCG1L3R), January 2012-December 2014.\u000d\u000a    &#163;738,583 EPSRC\/DTI Technology Strategy Board to S. Krause (PI) and M.\u000d\u000a      Watkinson (co-I) for a project entitled \"Prototype sensor for periodontal\u000d\u000a      disease monitoring\" (TP\/8\/BIO\/6\/I\/Q0020H) April 2008-.December 2011\u000d\u000a    &#163;18,952 Queen Mary Innovations Ltd to M. Watkinson (PI) and S. Krause\u000d\u000a      (co-I) for a project entitled \"Sensor Platform for the Detection of\u000d\u000a      Coagulation Factors\" December 2010-March 2011.\u000d\u000a    &#163;109,710 BBSRC follow-on fund awarded to S. Krause (PI) and M. Watkinson\u000d\u000a      (co-I) for a project entitled \"Disposable low cost sensor for periodontal\u000d\u000a      disease\", BB\/E525877\/1 (co-investigator) April 2006-March 2008.\u000d\u000a    &#163;95,839 Heptagon Fund awarded to S. Krause (PI) for a project entitled\u000d\u000a      \"Disposable low cost periodontal disease diagnostic\", (QMUL\/AL05), June\u000d\u000a      2006-May 2008\u000d\u000a    &#163;48,000 IP2IPO Ltd GRUB funding awarded to Degrasense for a project\u000d\u000a      entitled \"Prototype sensor for periodontal disease monitoring\" July\u000d\u000a      2008-June 2009\u000d\u000a    &#163;12,000 Combined London Colleges University Challenge Partnerships (CLUC)\u000d\u000a      awarded to Degrasense for a project entitled \"Disposable low cost\u000d\u000a      periodontal disease diagnostic\", July 2008-June 2009\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"5","Subject":"Dentistry"},{"Level1":"11","Level2":"15","Subject":"Pharmacology and Pharmaceutical Sciences"},{"Level1":"6","Level2":"1","Subject":"Biochemistry and Cell Biology"}],"Sources":"\u000d\u000a    \u000d\u000a      Professor and NHS Consultant, The University of Sheffield and\u000d\u000a        Sheffield Teaching Hospitals NHS Foundation Trust: the clinician\u000d\u000a        currently undertaking the clinical trial.\u000d\u000a      Programmes Director, AND Technology Research Ltd: this company\u000d\u000a        developed the meter being used in the clinical trial through the TSB\u000d\u000a        project.\u000d\u000a      Project Manager, Industrial Design Consultancy: AND Technology\u000d\u000a        Research Ltd sub-contracted the meter design to Industrial Design\u000d\u000a        Consultancy Ltd.\u000d\u000a      Technical Director, Gwent Electronic Materials: GEM Ltd manufactured\u000d\u000a        the interdigitated electrodes currently being used in the clinical trial\u000d\u000a        in Sheffield and are printing new electrodes coated with the degradable\u000d\u000a        polymer for the ongoing multiple sclerosis study.\u000d\u000a      Director, QED Biosciences: QED provided an independent assessment of\u000d\u000a        the technology for the IP-Group.\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    CS2 &#8212; The development of low-cost point of care sensors for the detection\u000d\u000a      of protease enzymes\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    Staff leading the underpinning research\u000d\u000a    Dr Steffi Krause (School of Engineering and Materials Science) and\u000d\u000a      Professor Michael Watkinson (School of Biological and Chemical Sciences)\u000d\u000a      have been collaborating since 2006 on the development of new, generic, low\u000d\u000a      cost and non-invasive sensor arrays for the specific detection and\u000d\u000a      quantitation of a number of proteolytic enzymes, which are clinically\u000d\u000a      relevant markers for a number of disease states. They have established the\u000d\u000a      spin-out company Degrasense, which owns the underpinning intellectual\u000d\u000a      property and are developing the technology via clinical trials.\u000d\u000a    Other notable QMUL researchers working with Watkinson and Krause include\u000d\u000a      Dr Jacqueline Stair (BBSRC-funded PDRA, 2008-2009), Dr Xingewi Zheng\u000d\u000a      (IP2IPO Ltd-funded PDRA, 2008-2010) and Dr Joseph Cook (Technology\u000d\u000a      Strategy Board-funded PDRA, 2008-2009).\u000d\u000a    Research underpinning the new technology\u000d\u000a    The technology is based on the preparation of hydrogel polymers that are\u000d\u000a      cross-linked with short peptide sequences containing amino acid sequences\u000d\u000a      cleaved by the specific proteolytic enzymes being targeted [references\u000d\u000a      1-4].\u000d\u000a    Through BBSRC-funded research, Krause, Watkinson and Stair developed new\u000d\u000a      peptide cross- linked dextran hydrogels, which, they demonstrated using a\u000d\u000a      quartz crystal micro-balance, can sense protease cleavage [see publication\u000d\u000a      1]. The underpinning work involved the preparation of suitably\u000d\u000a      functionalised peptides, which could be used to cross-link dextran to form\u000d\u000a      degradable hydrogel polymers. The key synthetic challenges were to\u000d\u000a      identify both the functional group which could be cross-linked and the\u000d\u000a      nature of the polymeric matrix which would allow degradation by the\u000d\u000a      individual protease in question, at clinically relevant concentrations and\u000d\u000a      within a short time-frame, without non-specific protein binding. Several\u000d\u000a      approaches were investigated including the in situ radical\u000d\u000a      polymerisation of peptides and the cross-linking of highly functionalised\u000d\u000a      dendronised polymers. Ultimately it was found that a partially oxidised\u000d\u000a      dextran in combination with amine-functionalised peptides provided\u000d\u000a      suitable substrates which met the technical specification required.\u000d\u000a      Consequently they were able to coat individual electrodes with different\u000d\u000a      polymers so that each electrode is able to detect a specific enzyme. This\u000d\u000a      aspect of the research is central to the technology &#8212; without it no point\u000d\u000a      of care device could have been produced.\u000d\u000a    In a second publication [2], Watkinson, Krause, Zheng and Cook\u000d\u000a      demonstrated the efficacy of this technology in the selective detection of\u000d\u000a      a number of proteases (Human Neutrophil Elastase, Cathepsin-G, and MMP8)\u000d\u000a      that are clinically relevant to periodontal disease. Periodontal disease\u000d\u000a      (periodontitis) is an inflammatory disease that affects the periodontum,\u000d\u000a      the tissues that surround and support the teeth. If left untreated,\u000d\u000a      chronic periodontitis leads to degradation of bone and ultimately to the\u000d\u000a      loss of teeth. However, progression of the disease is not uniform across\u000d\u000a      infected sites and accurate clinical methods for distinguishing areas\u000d\u000a      where the disease is active, rather than inert, are currently lacking. As\u000d\u000a      a result much unnecessary treatment of periodontal sites that are\u000d\u000a      quiescent occurs. This is both costly and potentially causes additional\u000d\u000a      damage to teeth attachments.\u000d\u000a    The research, led by Krause and Watkinson [1, 2], clearly established the\u000d\u000a      potential for a new technology, as a point-of-care clinical diagnostic\u000d\u000a      tool of protease activity associated with periodontal disease. The\u000d\u000a      intellectual property underpinning the technology was protected by a\u000d\u000a      European patent [3] and a further patent application has been filed [4].\u000d\u000a    The potential of this technology led to follow-on funding secured from\u000d\u000a      the BBSRC and the Heptagon fund in 2006. Then with support from the\u000d\u000a      Technology Strategy Board, and in collaboration with a number of key\u000d\u000a      industrial partners, Watkinson and Krause were able to develop the\u000d\u000a      technology to the point where it could be tested in a clinical trial. They\u000d\u000a      have also secured Venture Capital (VC) funding and, most recently, funding\u000d\u000a      from the Barts and the London Charity.\u000d\u000a    "},{"CaseStudyId":"20083","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Biotechnology and Biological Sciences Research Council","Royal Society"],"ImpactDetails":"\u000d\u000aImpact on Commerce\u000d\u000aA spinout company has been created and established its viability by generating revenue or\u000d\u000aprofits:\u000d\u000aOn the basis of high resolution by X-ray crystallographic structures of fragments that bound to\u000d\u000aprotein targets carried out in the Blundell and Abell laboratories, a spinout company, Astex\u000d\u000aTechnology Ltd, was created in 1999 (Company No. 03751674, incorporated 14\/4\/1999). The\u000d\u000auniversity-based research provided the basis of all subsequent work in Astex, including\u000d\u000aapproximately thirty \"campaigns\" against many targets, mainly of interest in fighting cancer. In\u000d\u000a2001 the University of Cambridge invested &#163;250k and was given equity in the company. The\u000d\u000acompany has signed deals in excess of $1.8bn (approximately &#163;1bn) between 1999 and 2011.\u000d\u000aInvestments in Astex have included Abingworth, Apax, Oxford (Boston), Advent, Alta and others\u000d\u000awith &#163;80 million equity in multiple financing rounds. Astex has also had major collaborations, which\u000d\u000ainvolved investments of up to a total of &#163;25 million from GSK, Johnson and Johnson, Novartis and\u000d\u000aAstra Zeneca, of these the GSK investment occurred after 1\/1\/2008.1, LC1, LC2 In 2011 Astex\u000d\u000aTherapeutics was purchased by NASDAQ-listed oncology company SuperGen, Inc. for $150\u000d\u000amillion (ca &#163;100 million). The new company was named Astex Pharmaceuticals, to reflect the\u000d\u000astrong brand name of Astex.LC1\u000d\u000aJobs have been created\/protected:\u000d\u000aOver the past decade, the company has secured constant employment for between 70 and 120\u000d\u000aworkers in Cambridge.LC1 The current number of employees in the UK and US is ~120.\u000d\u000aHighly skilled people have taken up specialist roles:\u000d\u000aAstex employs predominantly PhD students from industry and academia (including some from the\u000d\u000aAbell Group). Employees from Astex have gone on to major roles in academia (Paul Wyatt,\u000d\u000aDirector of the Drug Discovery Unit, Dundee), and industry (Miles Congreve, Vice President of\u000d\u000aChemistry, Heptares). Professor Abell was a member of the Astex Board from 1999 - 2000 and\u000d\u000ahas been on its Scientific Advisory Board continuously since its foundation.LC1\u000d\u000aA business or sector has adopted a new technology or process:\u000d\u000aAstex changed the way that drug discovery is carried out not only within its own labs but also in\u000d\u000aother small companies and large pharmaceuticals. The former Head of Worldwide Discovery for\u000d\u000aPfizer states: \"As a consequence of Astex success, fragment-based approaches are common\u000d\u000aplace throughout Pharma and Biotech, and the power of the technology is also recognised by\u000d\u000aacademia and drug discovery institutes through the UK 3D Fragment consortium, for example.\u000d\u000aWhile many companies have in-house capabilities, it is perhaps telling that GSK established a\u000d\u000amajor fragment collaboration with Astex as their internal expertise was apparently not competitive.\u000d\u000aImportantly, fragments may open the door to blocking protein-protein interactions which would lead\u000d\u000ato totally new classes of therapeutic agents designed to meet the medical needs of the 21st\u000d\u000aCentury.\" LC3\u000d\u000aMost pharmaceutical companies now use fragment-based methods in early discovery. They\u000d\u000ainclude J&amp;J, GSK and Astra Zeneca, all of whom have first collaborated with Astex; and UCB,\u000d\u000aHeptares and Evotec, where Astex employees and\/or former members of the Abell and Blundell\u000d\u000alaboratories have moved to take posts.LC1 &amp; LC2\u000d\u000aImpact on Health\u000d\u000aNew clinical interventions have been developed:\u000d\u000aAstex has developed a strong pipeline2 and three drugs that were developed using the fragment-based approach (AT13387, an HSP90 inhibitor; AT7519M, a CDK inhibitor; and AT9283, a\u000d\u000aJAK\/Aurora Inhibitor) are now in Phase II clinical trials for the conditions Gastrointestinal Stromal\u000d\u000aTumour (NCT01294202), Mantle Cell Lymphoma (NCT01652144), Chronic Lymphocytic Leukemia\u000d\u000a(NCT01652144) and Multiple Myeloma (NCT01145989).3,4,5,6 The same drugs have completed\u000d\u000aPhase I and are about to enter Phase II for other related clinical conditions (Multiple Myeloma\u000d\u000a(NCT01183949), Non-Small Cell Lung Cancer (NCT01712217), and Prostate Cancer\u000d\u000a(NCT01685268)), and in combination with other drugs.7,8,9\u000d\u000aEarly discovery candidates from Astex structure-guided fragment-based drug discovery that are\u000d\u000anow being taken forward in Phase I trials through collaborating companies include: FGFR Inhibitor\u000d\u000aJNJ 42756493 (NCT01703481, against Solid Tumours or Lymphoma, taken forward by Janssen\u000d\u000aResearch &amp; Development, LLC), CDK4 Inhibitor LEE011 (eg NCT01747876, against MRT and\u000d\u000aNeuroblastoma, taken forward by Novartis), PKB\/Akt Inhibitor AZD 5363 (eg NCT01692262,\u000d\u000aagainst Prostate Cancer, taken forward by Astra Zeneca) and BACE Inhibitor AZD 3293 (eg\u000d\u000aNCT01795339, against Alzheimers, taken forward by Astra Zeneca).10\u000d\u000a","ImpactSummary":"\u000d\u000aIn 1999, Chris Abell (Chemistry), Tom Blundell (Biochemistry), and Harren Jhoti co-founded Astex\u000d\u000aTechnology Ltd. to develop an X-ray structure-guided, `fragment-based' approach to drug\u000d\u000adiscovery. This led to a significant change in how the pharmaceutical industry approached drug\u000d\u000adiscovery. Astex Technology Ltd developed four molecules in-house using this approach, which\u000d\u000ahave in 2013 reached Phase I\/II clinical trials for various tumours. Four further molecules have\u000d\u000abeen taken into Phase I through collaborations between Astex and Janssen, Novartis and Astra\u000d\u000aZeneca. In 2011 the company was sold to SuperGen, Inc., for $150 million (ca &#163;100 million),\u000d\u000acreating Astex Pharmaceuticals, Inc., currently with ~120 employees, and a value of &gt;$500 million\u000d\u000a(&gt; &#163;320 million).\u000d\u000a","ImpactType":"Technological","Institution":"\u000d\u000aUniversity of Cambridge\u000d\u000a","Institutions":[{"AlternativeName":"Cambridge (University of)","InstitutionName":"University of Cambridge","PeerGroup":"A","Region":"East","UKPRN":10007788}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"4930956","Name":"Boston"}],"References":"\u000d\u000a\u000a1. Albert, A., Dhanaraj, V., Genschel, U., Khan, G., Ramjee, M. K., Pulido, R., Sibanda, B. L., von\u000d\u000aDelft, F., Witty, M., Blundell, T. L., Smith, AG and Abell, C. (1998) Crystal structure of\u000d\u000aaspartate decarboxylase at 2.2&#197; resolution provides evidence for an ester in protein self-processing. Nature Structural &amp; Molecular Biology 5(4): 289-293. DOI: 10.1038\/nsb0498-289.\u000d\u000a(*)\u000d\u000a\u000a\u000a2. The crystal structure of E. coli pantothenate synthetase: a new member of the aminoacyl-tRNA\u000d\u000asynthetase superfamily. F von Delft, A Lewendon, V Dhanaraj, T L Blundell, C Abell &amp; A G\u000d\u000aSmith. Structure 2001, 9, 439-450. (*)\u000d\u000a\u000a\u000a3. Crystal structure of E. coli ketopantoate reductase at 1.7A and insight into the mechanism. D\u000d\u000aMatak-Vinkovic, M Vinkovic, S A Saldanha, J L Ashurst, F von Delft, T Inoue, R Nunez Miguel,\u000d\u000aA G Smith, T L Blundell &amp; C Abell. Biochemistry 2001, 40, 14493-14500. (*)\u000d\u000a\u000a\u000a4. Blundell T.L., Abell C., Cleasby A., Hartshorn M.J., Tickle I.J., Parasini E. and Jhoti, H. (2002)\u000d\u000aHigh-throughput X-ray crystallography for drug discovery. Drug Design: Cutting Edge\u000d\u000aApproaches. Darren Flower, Ed. Royal Society Chemistry, 53-59.\u000d\u000aDOI: 10.1039\/9781847550705\u000d\u000a\u000a\u000a5. Blundell, T.L., Jhoti, H. and Abell, C. (2002) High-throughput crystallography for lead discovery\u000d\u000ain drug design. Nature Reviews Drug Discovery 1, 45-54. DOI: 10.1038\/nrd706\u000d\u000a\u000a(*) References that best indicate the quality of the research. Reference 5 is a review that contains\u000d\u000aimportant original unpublished work.\u000d\u000aGrant Information:\u000d\u000a&#8226; PIs: Chris Abell, Tom Blundell and Alison Smith; Grant Title: Structural and biochemical studies\u000d\u000aon pantothenate biosynthesis enzymes; Sponsor: BBSRC; Period of Grant: 01\/10\/98 -01\/10\/01; Value of Grant: &#163;161,086.\u000d\u000a&#8226; PIs: Chris Abell and Tom Blundell; Grant Title: Sponsored Research Agreement; Sponsor:\u000d\u000aAstex Technology Ltd; Period of Grant: 01\/10\/99 - 30\/09\/00; Value of Grant: &#163;279,370.\u000d\u000a","ResearchSubjectAreas":[{"Level1":"6","Level2":"1","Subject":"Biochemistry and Cell Biology"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"3","Subject":"Macromolecular and Materials Chemistry"}],"Sources":"\u000d\u000aLetters of corroboration available for audit\u000d\u000aLC1 President of Astex Pharmaceuticals.\u000d\u000aLC2 Vice President Respiratory Therapy Area, GSK.\u000d\u000aLC3 Former Head of Worldwide Discovery at Pfizer.\u000d\u000aReferences in the public domain\u000d\u000a\u000d\u000aAstex corporate partnering information: http:\/\/astx.com\/partners\/corporate-partnering\/\u000a\u000d\u000aAstex pipeline: http:\/\/astx.com\/pipeline\/products\/\u000a\u000d\u000a\u000aDrug: AT13387 and Imatinib; Phase: II; Study title: A Study to Investigate the Safety and\u000d\u000aEfficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST. Sponsor \/\u000d\u000acollaborators: Astex Pharmaceuticals; Trial dates: 1\/3\/2011- 1\/8\/2013\u000d\u000aTrial information link: http:\/\/ClinicalTrials.gov\/show\/NCT01294202\u000a\u000d\u000a\u000aDrug: AT7519M; Phase: II; Study title: A Phase II Study of AT7519M, a CDK Inhibitor, in\u000d\u000aPatients With Relapsed Mantle Cell Lymphoma. Sponsor \/ collaborators:\u000d\u000aNCIC Clinical Trials Group; Novartis Pharmaceuticals previously: Astex Pharmaceuticals; Trial\u000d\u000adates: 1\/8\/2012 - 1\/2\/2015\u000d\u000aTrial information link: http:\/\/ClinicalTrials.gov\/show\/NCT01652144\u000a\u000d\u000a\u000aDrug: AT7519M; Phase: II; Study title: A Phase II Study of AT7519M, a CDK Inhibitor, in\u000d\u000aPatients With Relapsed and\/or Refractory Chronic Lymphocytic Leukemia. Sponsor \/ collaborators:\u000d\u000aNCIC Clinical Trials Group; Novartis Pharmaceuticals, previously: Astex Pharmaceuticals; Trial\u000d\u000adates: 1\/8\/2012 - 1\/7\/2014\u000d\u000aTrial information link: http:\/\/ClinicalTrials.gov\/show\/NCT01627054\u000a\u000d\u000a\u000aDrug: AT9283; Phase: II; Study title: A Study of AT9283 in Patients With Relapsed or Refractory\u000d\u000aMultiple Myeloma. Sponsor \/ collaborators: NCIC Clinical Trials Group; Trial dates: 1\/6\/2010 - 1\/10\/2013\u000d\u000aTrial information link: http:\/\/ClinicalTrials.gov\/ct2\/show\/\u000a\u000d\u000a\u000aDrug: AT7519M, Bortezomib; Phase: I&amp;II; Study title: Effect of AT7519M Alone and AT7519M\u000d\u000aPlus Bortezomib in Patients With Previously Treated Multiple Myeloma; Sponsor \/ collaborators:\u000d\u000aAstex Pharmaceuticals; Multiple Myeloma Research Consortium; Trial dates: 1\/11\/2010 - 1\/10\/2013\u000d\u000aTrial information link: http:\/\/ClinicalTrials.gov\/show\/NCT01183949\u000a\u000d\u000a\u000aDrug: AT13387, Crizotinib; Phase: I&amp;II; Study title: A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib; Sponsor \/\u000d\u000acollaborators: Astex Pharmaceuticals; Trial dates: 1\/10\/2012 - 1\/11\/2014\u000d\u000aTrial information link: http:\/\/ClinicalTrials.gov\/show\/NCT01712217\u000a\u000d\u000a\u000aDrug: AT13387 and abiraterone | AT13387 alone; Phase: I&amp;II; Study title: A Study of HSP90\u000d\u000aInhibitor AT13387 Alone or in Combination With Abiraterone Acetate; Sponsor \/ collaborators:\u000d\u000aAstex Pharmaceuticals; Trial dates: 1\/9\/2012 - 1\/1\/2015\u000d\u000aTrial information link: http:\/\/ClinicalTrials.gov\/show\/NCT01685268\u000a\u000d\u000ahttp:\/\/astx.com\/pipeline\/products\/preclinical\/\u000d\u000a\u000d\u000a\u000d\u000a","Title":"\u000d\u000aStructure-Guided and Fragment-Based Drug Discovery\u000d\u000a","UKLocation":[{"GeoNamesId":"2653941","Name":"Cambridge"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000aThe underpinning research was a collaboration between Professor Chris Abell (Professor in\u000d\u000aBiological Chemistry since 2002; Department of Chemistry since 1984) and Professor Sir Tom\u000d\u000aBlundell (Sir William Dunn Professor of Biochemistry, Department of Biochemistry, 1996-2009, and\u000d\u000anow Research Director), who developed their combined expertise in structural biology and organic\u000d\u000achemistry to better understand protein-ligand interactions.\u000d\u000aThroughout his research career Professor Abell has maintained a strong interest in the mechanism\u000d\u000aand inhibition of enzymes. This led to increasing collaborative and consultancy involvement with\u000d\u000aIndustry in the 1990s, where high throughput screening was the prevalent method for discovering\u000d\u000anew hits for drug development. Abell was frustrated by the randomness of this approach, and this\u000d\u000afuelled his interest in structure-based approaches to enzyme inhibition. This was facilitated by a\u000d\u000amajor, BBSRC funded collaboration with Professor Tom Blundell on the mechanism, inhibition and\u000d\u000astructure of enzymes involved in pantothenate biosynthesis.1,2,3\u000d\u000aIn 1998, Blundell and Abell, together with Dr H Jhoti (at the time working at GSK), suggested a\u000d\u000anovel approach to drug discovery, which underpinned the formation in May 1999 of the spinout\u000d\u000acompany Astex Technology Ltd. The approach was to develop novel therapeutics from very small\u000d\u000achemical fragments (MW&lt;300) using high-throughput methods with powerful X-ray sources,\u000d\u000atogether with roboticised data collection, to define at high-resolution complexes of small molecules\u000d\u000a(fragments). They hypothesised that a library of 300-1000 small fragments could explore chemical\u000d\u000aspace more efficiently than a million-compound library of larger drug-like molecules. The approach,\u000d\u000aknown as fragment-based drug discovery, depended on identifying the positions of fragments\u000d\u000abound to the protein by X-ray crystallography and then using knowledge of their positions and the\u000d\u000astructure of the targets to iteratively elaborate these into potent inhibitors.\u000d\u000aResearch in the laboratories of Abell and Blundell was funded in the University during 1999-2000\u000d\u000aby a research grant from Astex Technology. The research was carried out by a post-doctoral\u000d\u000aresearcher in the Department of Chemistry (Dr Martyn Frederickson) in collaboration with two post-doctoral researchers in the Department of Biochemistry (Dr Emil Parasini and Dr Anne Cleasby).\u000d\u000aMultiple crystals of target proteins were screened with a small fragment library in 1999. They\u000d\u000ademonstrated in 1999-2000 that binding of very small molecules (MW&lt;300) could be detected, and\u000d\u000atheir positions, including orientation, could be defined at high resolution by X-ray crystallography. In\u000d\u000atwo papers, Abell, Blundell and Jhoti describe the concept of X-ray structure-based fragment\u000d\u000ascreening, and the linking and \"growing\" of fragments across the binding site using X-ray structures\u000d\u000aas guides.4,5 The significance of their results enabled Abell, Blundell, and Jhoti to raise substantial\u000d\u000afurther funding and develop the spinout company Astex Technology Ltd. Due to commercial\u000d\u000asensitivity, from 2001 further research and development was carried out at Astex Technology Ltd,\u000d\u000aand the early results were not published until 2002.\u000d\u000a"},{"CaseStudyId":"20084","Continent":[],"Country":[],"Funders":["Engineering and Physical Sciences Research Council","Natural Environment Research Council","Royal Society"],"ImpactDetails":"\u000d\u000a    Microsoft Research has supported, built, and collaborated on a large\u000d\u000a      number of Office extensions in a number of scientific domains, but the\u000d\u000a      Chemistry Add-in for Word remains the most highly downloaded project\u000d\u000a      developed to date, that number exceeding 400,000 as of July 2012. (See\u000d\u000a      Corroboration Letter LC1).\u000d\u000a    Chem4Word enables both humans and machines to understand the underlying\u000d\u000a      semantics of the documented chemistry and expose semantically rich\u000d\u000a      chemical information across the global chemistry and chemical information\u000d\u000a      community.\u000d\u000a    The Chemistry Add-in for Word has been widely recognised by educators,\u000d\u000a      publishers and software developers as making it easier for students,\u000d\u000a      educators, and chemists to insert and modify semantically searchable\u000d\u000a      chemical information, such as labels, formulae and 2D depictions, from\u000d\u000a      within Microsoft Office Word. Designed for and tested on both Word 2007\u000d\u000a      and Word 2010, it makes chemistry documents open, readable and easily\u000d\u000a      accessible, not just to other chemists, but also to other (robotic)\u000d\u000a      technologies using the widely adopted extensible markup language (XML).\u000d\u000a      The Chemistry Add-in supports both publishing and data-mining scenarios.1\u000d\u000a    Impact on Publishing\u000d\u000a      Chem4Word has been widely welcomed by publishers. The following\u000d\u000a      testimonials serve as an example of this: \"The future of research will be\u000d\u000a      powered not only by ever more rapid dissemination of ever large quantities\u000d\u000a      of data, but also by software tools that 'understand' something about\u000d\u000a      science. These tools will behave intelligently with respect to the\u000d\u000a      information they process, and will free their human users to spend more\u000d\u000a      time doing the things that humans do best: generating ideas, designing\u000d\u000a      experiments and making discoveries. Chem4Word is one of the best examples\u000d\u000a      so far of this important new development at the interface between science\u000d\u000a      and technology.\" Managing Director, Digital Science, Macmillan Publishers.2\u000d\u000a    \"The IUCr is delighted to see the release of v.1 of Chemistry Add-in\u000d\u000a        for Word under an open-source development license &#8212; this has great\u000d\u000a        potential for authors to enrich the semantic content of their articles,\u000d\u000a        and for publishers to leverage this semantic content in creating ever\u000d\u000a        more useful and powerful active publications.\" Research and\u000d\u000a      Development Officer, International Union of Crystallography.2\u000d\u000a    Impact on Education\u000d\u000a      Chem4Word is promoted by Microsoft as a tool for teachers and students as\u000d\u000a      a Chemistry teaching and learning aid.3 &amp; 4\u000d\u000a    Impact on Open Source Publishing\u000d\u000a      Much of the work of science depends on having appropriate tools available\u000d\u000a      to analyse experimental data and to interact with theoretical models.\u000d\u000a    The Chem4Word research collaboration was unique at the time, with\u000d\u000a      software development happening both within Microsoft and the University of\u000d\u000a      Cambridge, and it provided a model for future collaborations between\u000d\u000a      Microsoft Research and academic institutions worldwide. Additionally, the\u000d\u000a      Chem4Word project was one of the first Microsoft Research projects for\u000d\u000a      which it sought public release under an open source licence from the\u000d\u000a      project's inception. Releasing software in this way was extremely rare for\u000d\u000a      Microsoft at the time, but was recognised as an important component in\u000d\u000a      building long-term collaborative development communities. The Chem4Word\u000d\u000a      project was instrumental in formulating new policy at Microsoft Research\u000d\u000a      to define and grow a broader open-source strategy, and contributed to the\u000d\u000a      establishment of the Outercurve Foundation, whose mission is to enable the\u000d\u000a      exchange of code and understanding among software companies and open\u000d\u000a      source communities. As a direct result the source code for the Chem4Word\u000d\u000a      Add-in was released under an open-source licence and the intellectual\u000d\u000a      property was assigned to the Outercurve Foundation to facilitate broader\u000d\u000a      community involvement and governance, leading the way for future releases\u000d\u000a      of Open software via Microsoft and other previously closed vendors.\u000d\u000a    \"Releasing software under open source licenses was extremely rare for\u000d\u000a        Microsoft at the time, but was recognized as an important component in\u000d\u000a        building long-term collaborative development communities.\u000d\u000a        The Chem4Word project helped Microsoft Research to define and grow a\u000d\u000a        broader open-source strategy, which has led to a large\u000d\u000a        number of open source releases, and ultimately to the establishment of\u000d\u000a        the Outercurve Foundation.\" Quote from Director Scholarly\u000d\u000a      Communication Microsoft Research (see Corroboration Letter, LC1).\u000d\u000a    Impact on Chemical Informatics\u000d\u000a      In 2012, Peter Murray-Rust was a joint recipient (with Henry Rzepa) of the\u000d\u000a      Herman Skolnik Award presented by the American Chemical Society Division\u000d\u000a      of Chemical Information, an award that recognises outstanding\u000d\u000a      contributions to and achievements in the theory and practice of chemical\u000d\u000a      information science and related disciplines. According to the ACS \"Their\u000a        work has had a huge impact in the fields of chemical document analysis,\u000d\u000a        chemistry on the Internet, and in the orchestration of a viable strategy\u000d\u000a        for making electronic chemistry information as widely accessible and\u000d\u000a        usable as possible in our information age.\"5\u000d\u000a    ","ImpactSummary":"\u000d\u000a    From 2008-2010, Peter Murray-Rust developed a Chemistry Add-in for\u000d\u000a      Microsoft Office Word, which enables users to insert and modify\u000d\u000a      searchable, semantically rich chemical information within a Microsoft word\u000d\u000a      document and for the data to be stored and manipulated in a semantically\u000d\u000a      rich manner. The Add-in has been downloaded over 400,000 times. It was one\u000d\u000a      of the first projects from Microsoft Research for which a public release\u000d\u000a      under an open source license was obtained. This project demonstrated to a\u000d\u000a      wide audience new semantic approaches to computing in chemistry. Chem4Word\u000d\u000a      has impacted on education, publishing and science in industry and\u000d\u000a      academia.\u000d\u000a    ","ImpactType":"Societal","Institution":"\u000d\u000a    University of Cambridge\u000d\u000a    ","Institutions":[{"AlternativeName":"Cambridge (University of)","InstitutionName":"University of Cambridge","PeerGroup":"A","Region":"East","UKPRN":10007788}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    \u000a1. Chemical markup, XML, and the world wide web. 6. CMLReact, an XML\u000d\u000a      vocabulary for chemical reactions. Holliday GL, Murray-Rust P, Rzepa HS. J\u000d\u000a      Chem Inf Model. 2006 Jan-Feb; 46(1): 145-57. (*)\u000d\u000a    \u000a\u000a2. CML: Evolution and design. Peter Murray-Rust and Henry Rzepa. J\u000d\u000a      Cheminform. 2011 Oct 14; 3(1): 44. doi: 10.1186\/1758-2946-3-44. (*)\u000d\u000a    \u000a\u000a3. The semantics of Chemical Markup Language (CML): dictionaries and\u000d\u000a      conventions. Peter Murray-Rust et al. J Cheminform. 2011 Oct 14; 3:43.\u000d\u000a      doi: 10.1186\/1758-2946-3-43.\u000d\u000a    \u000a4. Chemistry Add-in for Word. Microsoft Research. http:\/\/research.microsoft.com\/en-us\/projects\/chem4word\/\u000d\u000a    5. http:\/\/www-pmr.ch.cam.ac.uk\/wiki\/Funded_CML_Projects.\u000d\u000a    (*) References that best indicate the quality of the research.\u000d\u000a    Grant Information:\u000d\u000a    &#8226; Grant No: MAZA042, RG50497; PI: Peter Murray-Rust; Grant title:\u000d\u000a      Chem4Word; Sponsor: Microsoft; Period of Grant: 1-10-2007 to 30-9-2009;\u000d\u000a      Value of Grant: &#163;106,404.80.\u000d\u000a    &#8226; Grant No: MAZA056, RG59518; PI: Peter Murray-Rust; Grant title:\u000d\u000a      Chem4Word; Sponsor: Microsoft; Period of Grant: 31-3-2010 to 31-3-2013;\u000d\u000a      Value of Grant: &#163;115,445.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"8","Level2":"6","Subject":"Information Systems"},{"Level1":"8","Level2":"1","Subject":"Artificial Intelligence and Image Processing"},{"Level1":"8","Level2":"3","Subject":"Computer Software"}],"Sources":"\u000d\u000a    Letter of corroboration available for audit\u000d\u000a      LC1 Director Scholarly Communication, Microsoft Research, Redmond, WA\u000d\u000a      98052\u000d\u000a    References in the public domain\u000d\u000a    \u000d\u000a      http:\/\/chem4word.codeplex.com\/\u000d\u000a      What people are saying about the Chemistry Add-in for Word http:\/\/research.microsoft.com\/en-us\/projects\/chem4word\/quotes.aspx\u000a\u000d\u000a      http:\/\/www.decd.sa.gov.au\/it\/files\/links\/Bringing_a_1_to_1_Progra_1.pdf\u000d\u000a      http:\/\/cie.acm.org\/articles\/microsoft-research-connections-collaborating-reinvent-education\/\u000d\u000a      http:\/\/bulletin.acscinf.org\/node\/245\u000d\u000a    \u000d\u000a    Users\/Beneficiaries who can be contacted to corroborate claims\u000d\u000a      Manager Informatics, Royal Society of Chemistry Publishing (verify benefit\u000d\u000a      to publishers) Managing Director, Digital Science, Macmillan Publishers\u000d\u000a      (see Reference 3) Research and Development Manager, International Union of\u000d\u000a      Crystallography (see Reference 3) \u000d\u000a    ","Title":"\u000d\u000a    Chem4Word\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    Peter Murray-Rust joined Cambridge as a lecturer in the Department of\u000d\u000a      Chemistry in 2000, and then Reader in (2004) until retirement (2008),\u000d\u000a      remaining research-active in the Department thereafter. Together with\u000d\u000a      Henry Rzepa (Imperial College London, since 1995) they established the\u000d\u000a      first fully operational system for managing complex chemical content\u000d\u000a      entirely in Extensible Markup Language (XML), which defines a set of rules\u000d\u000a      for encoding documents in a format\u000d\u000a      that is both human- and machine-readable.\u000d\u000a      Chemical Markup Language (CML), which adapts XML to chemistry, is the\u000d\u000a      first and the most ambitious application of semantic computing in\u000d\u000a      chemistry. CML is the pioneering XML-based language for chemistry,\u000d\u000a      providing a uniform, extensible system for representing, storing, and\u000d\u000a      transmitting chemical information. CML supports 4 main methods of creating\u000d\u000a      semantic chemistry: 1) human authoring (as in conventional articles,\u000d\u000a      reports, laboratory notebooks, etc.), 2) conversion of chemical data from\u000d\u000a      legacy formats, 3) creation of semantic chemistry through computer program\u000d\u000a      output and 4) machine extraction of chemistry from unstructured and\u000d\u000a      semi-structured material (e.g. electronic chemistry publications). CML\u000d\u000a      also enables a range of concepts to be modelled, including molecules,\u000d\u000a      reactions, and chemical metadata. CML has become an important component of\u000d\u000a      many chemical information systems, including toolkits, structure editors,\u000d\u000a      and other software.1,2&amp;3\u000d\u000a    Based on the CML framework and Murray-Rust's vision of creating a simple\u000d\u000a      way for chemists worldwide to insert \"semantically intelligent\" chemical\u000d\u000a      information into documents using existing desktop applications such as\u000d\u000a      Microsoft Office Word, the Chemistry Add-In for Word (Chem4Word) Project\u000d\u000a      was initiated in 2008 in a collaboration between the Department of\u000d\u000a      Chemistry and Microsoft Research. The new Microsoft Office Word format\u000d\u000a      (.DOCX) would allow for chemical entities to be authored, manipulated, and\u000d\u000a      stored as CML files within a DOCX package in a user-friendly manner, and\u000d\u000a      the resulting files could easily be queried and mined for chemical data\u000d\u000a      whether that was expressed in the document as a name, formula, image, or\u000d\u000a      bold number reference.\u000d\u000a    Other chemical drawing tools are available, such as ChemDraw, which is\u000d\u000a      used by many chemists to create publication-ready, scientifically\u000d\u000a      meaningful drawings. A limitation of software like ChemDraw is that\u000d\u000a      individuals, groups and organisations now have a large number of Word\u000d\u000a      Documents containing embedded ChemDraw objects that cannot easily be\u000d\u000a      searched in a chemically meaningful way. Additionally, only humans can\u000d\u000a      create and interpret the chemical structures created by ChemDraw. Other\u000d\u000a      limitations of some of the currently available software include\u000d\u000a      limitations on the types of chemical structures that can be created, e.g.\u000d\u000a      some are limited to only generating organic molecules. The Chem4Word\u000d\u000a      project set out to simplify the process of inserting and modifying\u000d\u000a      chemical information from within Microsoft Office Word, and also to have\u000d\u000a      the chemical information stored and manipulated in a semantically rich\u000d\u000a      manner. Working closely with Microsoft engineers, Murray-Rust and\u000d\u000a      colleagues provided the underlying research for the design, semantic\u000d\u000a      descriptions and ontology, software algorithms, and chemical knowledge for\u000d\u000a      the program. Microsoft funded a postdoctoral scientist, Dr. Joe Townsend,\u000d\u000a      to design and implement the software.\u000d\u000a    Murray-Rust and his group, together with Microsoft Research and the\u000d\u000a      Microsoft Office Word team, jointly defined and developed the features\u000d\u000a      that led to beta (March 2010) and version 1.0 (February 2011) releases of\u000d\u000a      the Chemistry Add-in for Microsoft Office Word. This Add-in makes it\u000d\u000a      possible not only to author chemical content in Word, but also to include\u000d\u000a      the meta-data behind the structures, which means that the chemical\u000d\u000a      information can be represented in a variety of ways: 2D chemical\u000d\u000a      structures, names, chemical formulae and importantly, a variety of\u000d\u000a      semantically encoded data. In other words, instead of a static picture one\u000d\u000a      can search and select with a few clicks what information should appear in\u000d\u000a      the embedded fields.4\u000d\u000a    Chemical Mark-Up Language\u000d\u000a      In addition to Chem4Word, the following projects (in whole or part\u000d\u000a      involving the Department of Chemistry Unilever Centre for Molecular\u000d\u000a      Informatics) have included development of CML specifications, software or\u000d\u000a      applications: Molecular Standards for the Grid (DTI\/EPSRC) 2002-2005,\u000d\u000a      eMinerals (NERC), Materials Grid (DTI\/Unilever\/Accelrys), Sciborg (EPSRC),\u000d\u000a      eCrystals, (JISC\/Soton), SPECTRa (JISC), SPECTRa-T (JISC), Crystal editor\u000d\u000a      (IUCr), Crystal repository (Dept of Chemistry), Polymer Informatics\u000d\u000a      (Unilever), MDL2CML (MDL), Openbabel (Merck).5\u000d\u000a    "},{"CaseStudyId":"20087","Continent":[{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6252001","Name":"United States"}],"Funders":["Royal Society"],"ImpactDetails":"\u000d\u000a    The LAG method developed by the Jones Group is routinely used by industry\u000d\u000a      to search for new solid forms; in particular with regard to poorly soluble\u000d\u000a      drugs, which will have limited bioavailability. The approach allows a\u000d\u000a      complete search of the phase diagram associated with the formation of new\u000d\u000a      solid forms. In addition, intellectual property can exist for each new\u000d\u000a      solid form entity. When searching for new forms drug companies want to be\u000d\u000a      able to screen for all possible forms and develop that form which has the\u000d\u000a      best physical or chemical attributes. By means of this LAG approach the\u000d\u000a      phase space can be more efficiently explored, in a shorter time scale,\u000d\u000a      with smaller amounts of material (important in early stages of development\u000d\u000a      when sample quantities are small). As a result candidates, which might not\u000d\u000a      otherwise be suitable for commercialisation, can be developed into\u000d\u000a      effective solid forms for formulation into drug products. LAG\u000d\u000a      significantly impacts on how the pharmaceutical industry is able to screen\u000d\u000a      for and discover new solid drug forms.\u000d\u000a    A number of pharmaceutical companies are known to currently use LAG as\u000d\u000a      part of their drug development process, as evidenced by 3 corroborating\u000d\u000a      statements provided by Amgen, Eli Lilly and Renova Research, and patents\u000d\u000a      that cite the methodology. Further names of companies that can be\u000d\u000a      approached to corroborate that they use the technique are listed in\u000d\u000a      Section 5 and include Pfizer and Vertex Pharmaceuticals.\u000d\u000a    Quote from Senior Research Advisor, Eli Lilly corroborating letter: \"(W)e\u000a        have successfully leveraged LAG in recent years to discover new,\u000d\u000a        metastable crystal forms, many of which evaded solution-state\u000d\u000a        crystallization screening...(I)t has been your work around adding small\u000d\u000a        (catalytic) amounts of solvent that has paved the way for us to access\u000d\u000a        more highly crystalline and phase pure crystal forms in high yield. In\u000d\u000a        fact, as a result of your contributions, I am pleased to confirm that\u000d\u000a        LAG has now been incorporated into our solid form screening strategy for\u000d\u000a        enabling forms.\" LC1\u000d\u000a    Quote from President and CSO, Renova Research, Atlanta, USA,\u000d\u000a      corroborating letter: \"Through my direct interactions and\u000d\u000a        collaborations with Bill Jones I was able to take advantage of the LAG\u000d\u000a        concept to create high throughput LAG screening equipment that would\u000d\u000a        produce 96 experiments in a parallel reaction process. The assistance of\u000d\u000a        the Jones lab was essential to the success of this effort to produce a\u000d\u000a        screening platform that could be used in a production contract research\u000d\u000a        environment.\" LC2\u000d\u000a    A search of US Issued patents referring to methods for co-crystallisation\u000d\u000a      reveals a number of patents that reference the use of LAG and the Jones\u000d\u000a      Group in their methodology indicating that the technique has been adopted\u000d\u000a      across a number of Pharmaceutical industries.\u000d\u000a    \u000d\u000a      US7927613 Filed Sept 2003; Issued April 2011; Assignee: TransForm\u000d\u000a        Pharmaceuticals, Inc. acquired by Johnson &amp; Johnson\u000d\u000a      US7790905 Filed Dec 2003; Issued Sept 2010; &amp; US8183290 Filed July\u000d\u000a        10; Issued May 2012; Assignee: McNEIL-PPC, Inc.\u000d\u000a      US8241371 Filed Feb 2008; Issued August 2012; &amp; US8241371 Filed\u000d\u000a        Feb 2007; Issued Aug 2012; Assignee: Thar Pharmaceuticals\u000d\u000a      US8212079 Filed Sept 2008; Issued July 2012; Assignee: Aptuit LLC\u000d\u000a        Pharmaceuticals\u000d\u000a    \u000d\u000a    Some of the reasons LAG has been so readily adopted by the pharmaceutical\u000d\u000a      industry are listed below:\u000d\u000a    \u000d\u000a      Drugs, which might otherwise fail because of property issues (e.g.\u000d\u000a        poor solubility), can be saved by the development of new solid forms and\u000d\u000a        the LAG method allows rapid screening of a range of potential molecules\u000d\u000a        to cocrystallise with the drug (the screening step).\u000d\u000a      The time needed to produce a crystalline form of the drug suitable for\u000d\u000a        large-scale manufacture is significantly reduced. With typical drug sale\u000d\u000a        revenues of the top 10 major drug products each being between 6 and 13\u000d\u000a        billion US$ per annum, a six month increased revenue can be significant\u000d\u000a        for profits and therefore further support of R &amp; D in other disease\u000d\u000a        areas.\u000d\u000a      Approval of the solid form by regulators (e.g. FDA) can be accelerated\u000d\u000a        by evidence that the proposed marketed form is robust and that a full\u000d\u000a        screening has been undertaken.\u000d\u000a      Small amounts of material are required: In initial stages of drug\u000d\u000a        discovery only small amounts of material are available. The amounts\u000d\u000a        needed for LAG experiments are small &#8212; of the order of milligrams,\u000d\u000a        representing a significant cost savings.\u000d\u000a      There is no need to use large amounts of solvent typical of a solution\u000d\u000a        screening approach &#8212; with such solvents then being incinerated. This\u000d\u000a        cuts down on waste and lost revenue.\u000d\u000a    \u000d\u000a    Evidence of some of the advantages of using LAG, and how LAG has resulted in\u000d\u000a    economic impacts such as improved business operations, competitiveness and\u000d\u000a    profitability of industry; as well as environmental impacts through\u000d\u000a    reductions in solvent and consumable waste streams are available in the\u000d\u000a    letters of corroboration, with selected quotes listed below:\u000d\u000a    Quote from Preclinical Director, Amgen, Cambridge MA, U.S.A,\u000d\u000a      corroborating letter: \"(T)his reduction in the number of experiments\u000d\u000a        has led to tremendous efficiencies in terms of the amount of compound\u000d\u000a        required, solvent and consumables waste streams, data organization\u000d\u000a        efforts and time required to conduct and complete experiments.\" LC3\u000d\u000a    Quotes from President and CSO, Renova Research, Atlanta, USA,\u000d\u000a      corroborating letter: \"The High Throughput (HT) LAG equipment has had a\u000d\u000a        significant and positive impact on my business operations. To date I\u000d\u000a        have used the HT-LAG equipment to produce 16,128 samples (based on the\u000d\u000a        number of samples logged into the database used to track screening\u000d\u000a        processes). The time savings compared to performing individual reactions\u000d\u000a        is enormous. The `hands on' time required to do 16,128 reactions\u000d\u000a        individually would be approximately 8064 hours, while the number of\u000d\u000a        hours actually spent creating and analyzing these samples using the\u000d\u000a        HT-LAG approach was only 1680 hours.\u000d\u000a    \"Without the HT-LAG system the core operational efficiency required to\u000d\u000a        profitably operate Renovo Research would simply not exist. The LAG\u000d\u000a        screening process constitutes about half of the sample output in a\u000d\u000a        typical commercial screening project, thus a significant portion of the\u000d\u000a        contract research income to Renovo is directly dependent on this\u000d\u000a        technology. The demonstrated ability to perform rapid and comprehensive\u000d\u000a        cocrystal screening was instrumental in the acquisition of $500k USD in\u000d\u000a        investment by a commercial group that contracted with Renovo to rapidly\u000d\u000a        identify cocrystals of key pharmaceutical ingredients that were\u000d\u000a        approaching the end of the patent protected lifecycle. Without the\u000d\u000a        HT-LAG system, Renovo would not have been awarded this contract and\u000d\u000a        could not have completed it within the aggressive time period required\u000d\u000a        by the investors.\"LC2\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Research by Professor Jones, Department of Chemistry, University of\u000d\u000a      Cambridge, resulted in the development of a new method for preparing\u000d\u000a      composite solids, involving the grinding of two or more crystalline solids\u000d\u000a      in the presence of small volumes of liquid. This so called \"liquid\u000d\u000a      assisted grinding\" (LAG) which produces novel solids with bespoke physical\u000d\u000a      and chemical properties, is now routinely used by the major pharmaceutical\u000d\u000a      companies to screen for new drug forms as part of their drug product\u000d\u000a      development process.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    University of Cambridge\u000d\u000a    ","Institutions":[{"AlternativeName":"Cambridge (University of)","InstitutionName":"University of Cambridge","PeerGroup":"A","Region":"East","UKPRN":10007788}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"4180439","Name":"Atlanta"},{"GeoNamesId":"6254926","Name":"Massachusetts"}],"References":"\u000d\u000a    \u000a1. Shan, N., Toda, F., &amp; Jones, W. (2002) Mechanochemistry and\u000d\u000a      co-crystal formation: effect of solvent on reaction kinetics. Chemical\u000d\u000a        Communications, 2372- 2373. (*)\u000d\u000a    \u000a\u000a2. Batchelor, E., Klinowski, J., &amp; Jones, W. (2000) Crystal\u000d\u000a      engineering using co-crystallisation of phenazine with dicarboxylic acids.\u000d\u000a      Journal of Materials Chemistry, 10: 839-848.\u000d\u000a    \u000a\u000a3. Trask, A. V., van de Streek, J., Motherwell, W. D. S., &amp; Jones, W.\u000d\u000a      (2005) Achieving Polymorphic and Stoichiometric Diversity in Cocrystal\u000d\u000a      Formation: Importance of Solid-State Grinding, Powder X-ray Structure\u000d\u000a      Determination, and Seeding. Crystal Growth &amp; Design, 5 (6),\u000d\u000a      2233-2241. (*)\u000d\u000a    \u000a\u000a4. Karki, S., Frisci&#263;, T., Jones., &amp; Motherwell, W. D. S. (2007)\u000d\u000a      Screening for pharmaceutical cocrystal hydrates via neat and\u000d\u000a      liquid-assisted grinding. Molecular Pharmaceutics 4 (3): 347-354.\u000d\u000a      (*)\u000d\u000a    \u000a\u000a5. Trask, A. V., Haynes, D. A., Motherwell, W. D. S., &amp; Jones, W.\u000d\u000a      (2006) Screening for crystalline salts via mechanochemistry. Chemical\u000d\u000a        Communications, 51-53.\u000d\u000a    \u000a\u000a6. Fucke, K., Myz, S. A., Shakhtshneider, T. P., Boldyreva, E. V., and\u000d\u000a      Griesser, U. J. (2012) How good are the crystallisation methods for\u000d\u000a      co-crystals? A comparative study of piroxicam. New Journal of\u000d\u000a        Chemistry 36, 1969-1977.\u000d\u000a    \u000a(*) References that best indicate the quality of the research.\u000d\u000a    Grant Information\u000d\u000a      &#8226; Grant No: RG34605 MAAG\/163; PI: Prof W Jones; Grant Title: Ab initio\u000d\u000a      structure prediction; Sponsor: Pfizer; Period of Grant: 2002-2003; Value\u000d\u000a      of Grant: &#163;289,173\u000d\u000a    &#8226; Grant No: RG44738 MAAG\/411; PI: Prof W Jones; Grant Title: Cocrystal\u000d\u000a      design for non-polar (weak synthon) molecules; Sponsor: Pfizer; Period of\u000d\u000a      Grant: 2005-2007; Value of Grant: &#163;199,599\u000d\u000a    &#8226; Grant No: RG44738 MAAG\/411; PI: Prof W Jones; Grant Title: Preparative\u000d\u000a      methods for co-crystal screen development; Sponsor: Pfizer; Period of\u000d\u000a      Grant: 2006-2009; Value of Grant: &#163;103,100\u000d\u000a    &#8226; Grant No: RG36191 MAAG\/163; PI: Prof W Jones; Grant Title: Excipient\u000d\u000a      co-crystals; Sponsor: Pfizer; Period of Grant: 2002-2006; Value of Grant:\u000d\u000a      &#163;66,600\u000d\u000a    &#8226; Grant No: RG36191 MAAG\/163; PI: Prof W Jones; Grant Title: Crystal\u000d\u000a      engineering: salt selection and counter ion motifs; Sponsor: Pfizer;\u000d\u000a      Period of Grant: 2002-2005; Value of Grant: &#163;186,975\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"3","Subject":"Macromolecular and Materials Chemistry"},{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"}],"Sources":"\u000d\u000a    Letters of corroboration available for audit\u000d\u000a      LC1 Senior Research Advisor, Lilly Research Laboratories, Indianapolis,\u000d\u000a      Indiana, U.S.A\u000d\u000a    LC2 President and Chief Scientific Officer, Renovo\u000a        Research, Atlanta, Georgia, U.S.A\u000d\u000a    LC3 Preclinical Director, Amgen Inc, Cambridge, Massachusetts, U.S.A\u000d\u000a    Users\/Beneficiaries who can be contacted to corroborate claims\u000d\u000a    \u000d\u000a      Head of Materials Sciences in Drug Product Design, Pfizer, UK\u000d\u000a      Senior Director, Vertex Pharmaceuticals Inc, Cambridge, Massachusetts,\u000d\u000a        U.S.A\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Liquid Assisted Grinding\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    Liquid Assisted Grinding (LAG) was developed by Prof William Jones who\u000d\u000a      has been employed as a member of staff in the Chemistry Department,\u000d\u000a      University of Cambridge, since 1978 (SAIR, 1978; ADR 1985; Reader, 1999;\u000d\u000a      Professor, 2006 onwards) and leads a research group focused on Materials\u000d\u000a      Chemistry. The discovery of LAG as an effective screening method was made\u000d\u000a      in 2001 and published in the Royal Society of Chemistry journal Chemical\u000d\u000a      Communications in 2002.1 This work demonstrated how the\u000d\u000a      kinetics of the solid-solid reaction could be accelerated. Prior to this\u000d\u000a      work solution crystallisation was the main method of doing solid form\u000d\u000a      screening.\u000d\u000a    The discovery resulted from work in the Jones Group on understanding how\u000d\u000a      organic molecules pack and interact in the solid state. To expand in a\u000d\u000a      systematic way the number and types of interactions that were possible\u000d\u000a      between molecules within an organic crystal structure, from 1995 onwards\u000d\u000a      the Jones Group investigated methods for preparing crystalline solids with\u000d\u000a      two or more distinct molecular entities within them.2 This\u000d\u000a      meant, for example, that to understand how an acid function interacted\u000d\u000a      with an amine function in a crystal lattice, it was not necessary to have\u000d\u000a      both functionalities present on the same molecule. To obtain such\u000d\u000a      multicomponent solids is difficult if the solubility of the two molecules\u000d\u000a      which are being co-crystallised is very different &#8212; they will simply\u000d\u000a      crystallise as separate pure phases.\u000d\u000a    Solid-state grinding had been explored previously by others for producing\u000d\u000a      co-crystals, but in 2001 the Jones Group embarked on a series of studies\u000d\u000a      to see whether a small amount of liquid added to the solids during mixing\u000d\u000a      could have an effect on the outcome. It was discovered in 2001 that not\u000d\u000a      only did small amounts of liquid speed up the solid-solid reaction but in\u000d\u000a      numerous cases it allowed the formation of new solid forms that could not\u000d\u000a      otherwise be made. The method has now been termed \"liquid assisted\u000d\u000a      grinding\". The group disclosed this discovery in 2002 where the enhanced\u000d\u000a      kinetics was noted.1 Between 2002 and 2005 the Jones Group\u000d\u000a      discovered that the exact outcome of the solid state grinding could be\u000d\u000a      controlled by careful choice of the added liquid.3Between\u000d\u000a      2005 and 2007 it was further demonstrated that this LAG approach is\u000d\u000a      significantly more effective in searching for alternate solid forms of\u000d\u000a      drug candidates than other previously used methods, e.g. conventional\u000d\u000a      solution crystallisation or melt growth.4&amp;5 LAG is a method\u000d\u000a      that requires very small amounts of material, essential for preformulation\u000d\u000a      pharmaceutical development, is rapid, and environmentally friendly because\u000d\u000a      it eliminates the need to use large amounts of solvents.\u000d\u000a    A recent independent study comparing the effectiveness of the various\u000d\u000a      approaches to screening for new forms of the drug piroxicam is given by\u000d\u000a      Fucke, et al (2012).6 The authors conclude that: \"Solvent-drop\u000a        grinding showed the highest absolute number of experiments resulting in\u000d\u000a        co-crystals\" and \"\"For an initial screening solvent drop grinding\u000d\u000a        should be preferred, as this method produced reliably co-crystal forms.\"\u000d\u000a    In the pharmaceutical industry many drug candidates in their pure form\u000d\u000a      suffer from very poor physical and chemical attributes. An example is the\u000d\u000a      increasingly common problem of poor solubility and bioavailability. To\u000d\u000a      improve solubility the pharmaceutical industry routinely searches for\u000d\u000a      alternative solid forms of the drug, e.g. formation of salt and\/or\u000d\u000a      co-crystal forms. The prior established practice of screening by\u000d\u000a      conventional crystallisation from solution is particularly difficult\u000d\u000a      because drug and coformer will tend to crystallise separately.\u000d\u000a    The LAG research was supported by Pfizer grants. The following staff\u000d\u000a      members working in the Jones Group contributed to the underpinning\u000d\u000a      research: Delia Haynes (PDRA 2002-2005) and Tomislav Frisic (PDRA\u000d\u000a      2005-2007). Additionally, Dr Sam Motherwell from the Cambridge\u000d\u000a      Crystallographic Data Centre (1992-present) provided database support; and\u000d\u000a      Professor Fumio Toda (Matsuyama, Japan (deceased)) provided background\u000d\u000a      information on solid-solid grinding. Members of the Jones Group also\u000d\u000a      included PhD students Ning Shan (PhD 2000-2003), Andrew Trask (PhD 2002\u000d\u000a      -2005) and Shyam Karki (PhD 2006 -2009).\u000d\u000a    "},{"CaseStudyId":"20089","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"1269750","Name":"India"},{"GeoNamesId":"6252001","Name":"United States"}],"Funders":["Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000d\u000a    Chemical synthesis is at the heart of modern society, being essential in\u000d\u000a      the development and\u000d\u000a      manufacture of everything from modern electronics to pharmaceutical\u000d\u000a      agents. The research\u000d\u000a      programme started by Ley in the mid 1990s sought to provide a sea change\u000d\u000a      in the way molecules\u000d\u000a      could be assembled in a multi-step fashion.1 Key to the success\u000d\u000a      of the approach was the use of an\u000d\u000a      ensemble of immobilised reagents and scavengers to synthesise molecules\u000d\u000a      without the\u000d\u000a      requirement for extensive downstream processing techniques, which are\u000d\u000a      wasteful in terms of\u000d\u000a      materials, energy, time and labour costs. Moving from conventional\u000d\u000a      batch-mode chemical\u000d\u000a      production to continuous flow-based processing has had worldwide impact,\u000d\u000a      with companies across\u000d\u000a      the chemical space &#8212; from research operations to full-scale production &#8212;\u000d\u000a      now realising the benefits\u000d\u000a      and implementing continuous flow processing techniques within their\u000d\u000a      facilities. Substantial benefits\u000d\u000a      have been accrued in terms of safety, energy savings, scale-up and low\u000d\u000a      solvent usage, all leading\u000d\u000a      to more sustainable chemical practices.\u000d\u000a    Technology Seeded New Companies\u000d\u000a    This technology helped to seed the formation of a number of UK start-up\u000d\u000a      companies largely\u000d\u000a      focused on flow methods. Many new UK start-up companies, such as Vapourtec\u000d\u000a      (2003, Suffolk,\u000d\u000a      UK), Uniqsis (2007, Cambridge, UK), Cyclofluidic (2008, Welwyn Garden\u000d\u000a      City, UK), Microsaic\u000d\u000a      (2004, Woking, UK), and HEL (1987, Borehamwood, UK) were set up to exploit\u000d\u000a      the potential of\u000d\u000a      flow chemistry. These companies continue to trade and the UK is now\u000d\u000a      leading the world in\u000d\u000a      developing new, innovative equipment for flow chemistry. Ley has had\u000d\u000a      direct input into Cyclofluidic\u000d\u000a      as a member of its Scientific Advisory Board.\u000d\u000a    In 2005, Steven Ley set up the spin-out company Reaxa to exploit work on\u000d\u000a      the nickel, palladium,\u000d\u000a      platinum and osmium encapsulated reagents EnCat, and QuadraPure reaction\u000d\u000a      clean-up\u000d\u000a      scavengers. These provide a unique solution to minimise waste during\u000d\u000a      chemical reactions, and\u000d\u000a      allow precious spent catalysts to be easily recovered, facilitating\u000d\u000a      recycling and being ideal for flow\u000d\u000a      chemistry applications. The scavengers are now sold by Johnson Matthey\u000d\u000a      after it acquired the\u000d\u000a      patent in 2011, and Reaxa itself was acquired by Indian company S. Amit\u000d\u000a      Speciality Chemicals Pvt\u000d\u000a      Ltd, also in 2011, which has continued to support and promote these\u000d\u000a      important reagents, now sold\u000d\u000a      through Sigma-Aldrich.\u000d\u000a    Adoption and Application of Technology in the Commercial Sector\u000d\u000a    There are numerous examples of the use of these reagents in the\u000d\u000a      commercial sector. Two\u000d\u000a      examples published in 2012 are Pfizer's use of palladium EnCat to effect a\u000d\u000a      Suzuki cross-coupling\u000d\u000a      reaction in the synthesis of potent inhibitors of LpxC that have potential\u000d\u000a      as antibiotics2, and the use\u000d\u000a      of the same EnCat in the synthesis of a range of orally available CHK1\u000d\u000a      inhibitors by a team at the\u000d\u000a      Institute of Cancer Research.3\u000d\u000a    The QuadraPure scavengers have also been employed in industrial\u000d\u000a      processes. Novartis, for\u000d\u000a      example, published work on the clean-up of Heck reactions in 2008, which\u000d\u000a      concluded that\u000d\u000a      QuadraPure TU was the most effective adsorbent.4 Another\u000d\u000a      example is Pfizer's use of QuadraPure\u000d\u000a      TU to remove traces of palladium in the process scale-up of\u000d\u000a      [beta]2-adrenoceptor agonist PF-00610335.5\u000d\u000a    New Products Created and Commercialised\u000d\u000a    Further evidence of the impact of Ley's work on polymer supported\u000d\u000a      reagents and scavengers\u000d\u000a      under flow chemistry conditions is that a local company, Cambridge Reactor\u000d\u000a      Design have\u000d\u000a      commercialised two products which had their genesis in his laboratories.\u000d\u000a      These are the\u000d\u000a      \"Gastropod\" for conducting mixed gas\/liquid flow reactions with in-line\u000d\u000a      supported catalysts and\u000d\u000a      \"Polar Bear\" for achieving low temperatures (-89&#186;C) without cryogens for\u000d\u000a      flow mode multi-step\u000d\u000a      synthesis. Both these units have attracted wide interest as judged by ISI\u000d\u000a      citations to this work\u000d\u000a      (Gastropod 145, Polar Bear 30).\u000d\u000a    Similarly, in collaboration with Mettler Toledo, Ley's flow chemistry\u000d\u000a      techniques have driven the\u000d\u000a      need for improved in-line analysis, which has resulted in further\u000d\u000a      commercial products for flow IR\u000d\u000a      monitoring being introduced to the market.6 The impact on his\u000d\u000a      work in this area has also aided the\u000d\u000a      development of mini-mass spectrometers for in-line flow analysis. The\u000d\u000a      details of this joint\u000d\u000a      collaboration with Microsaic Systems are reported.7&amp;8 This\u000d\u000a      equipment is now commercially\u000d\u000a      available giving the UK a lead in the development of these new advances in\u000d\u000a      mass spectrometer\u000d\u000a      design.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    The pioneering work of Steven Ley on polymer-supported reagents and\u000d\u000a      continuous-flow reaction\u000d\u000a      technology has helped change the way we achieve cleaner chemical\u000d\u000a      processes. The concepts and\u000d\u000a      techniques invented in Cambridge allow more sustainable processes to be\u000d\u000a      developed, with\u000d\u000a      concomitant reduction in purification steps, shorter reaction times and\u000d\u000a      diminished solvent usage.\u000d\u000a      The work has led to a spin-out company (Reaxa), seeded the creation of a\u000d\u000a      number of other\u000d\u000a      companies, and resulted in the development of several devices for\u000d\u000a      continuous flow synthesis that\u000d\u000a      are now commercially available via Mettler-Toledo (USA) and Cambridge\u000d\u000a      Reactor Design (UK).\u000d\u000a      This technology is having an impact in industry, with continuous flow\u000d\u000a      processing increasingly being\u000d\u000a      used for full-scale commercial production.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    University of Cambridge\u000d\u000a    ","Institutions":[{"AlternativeName":"Cambridge (University of)","InstitutionName":"University of Cambridge","PeerGroup":"A","Region":"East","UKPRN":10007788}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    \u000a1. Polymer-Supported Perruthenate (PSP): A New Oxidant for Clean Organic\u000d\u000a      Synthesis, B.\u000d\u000a      Hinzen and S.V. Ley, J. Chem. Soc., Perkin Trans. I, 1997,\u000d\u000a      1907-1908.\u000d\u000a    \u000a\u000a2. Clean Six-Step Synthesis of a Piperidino-thiomorpholine Library using\u000d\u000a      Polymer-Supported\u000d\u000a      Reagents, J. Habermann, S.V. Ley and J.S. Scott, J. Chem. Soc., Perkin\u000d\u000a        Trans. I, 1998, 3127-3130.\u000d\u000a      (*)\u000d\u000a    \u000a3. Patent No. WO 99\/58475, Preparation of compounds using polymer\u000d\u000a      supported reagents.\u000d\u000a    \u000a4. Multistep Organic Synthesis using Solid Supported Reagents and\u000d\u000a      Scavengers: A New\u000d\u000a      Paradigm in Chemical Library Generation, S.V. Ley, I.R. Baxendale, R.N.\u000d\u000a      Bream, P.S.\u000d\u000a      Jackson, A.G. Leach, D.A. Longbottom, M. Nesi, J.S. Scott, R.I. Storer and\u000d\u000a      S.J. Taylor, J.\u000d\u000a        Chem. Soc., Perkin Trans. I, 2000, 3815-4195.\u000d\u000a    \u000a\u000a5. A Total Synthesis of Epothilones using Solid-Supported Reagents and\u000d\u000a      Scavengers, R.I. Storer,\u000d\u000a      T. Takemoto, P.S. Jackson and S.V. Ley, Angew. Chem. Int. Edn,\u000d\u000a      2003, 42, 2521-2525. (*)\u000d\u000a    \u000a\u000a6. New Tools and Concepts in Modern Organic Synthesis, S.V. Ley and I.R.\u000d\u000a      Baxendale, Nature\u000d\u000a        Reviews, 2002, 1, 573-586.\u000d\u000a    \u000a\u000a7. A Flow Process for the Multi-Step Synthesis of the Alkaloid Natural\u000d\u000a      Product Oxomaritidine: A\u000d\u000a      New Paradigm for Molecular Assembly, I.R. Baxendale, J. Deeley, C.M.\u000d\u000a      Griffiths-Jones, S.V.\u000d\u000a      Ley, S. Saaby and G. Tranmer, J. Chem. Soc., Chem. Commun, 2006,\u000d\u000a      2566-2568.\u000d\u000a    \u000a\u000a8. Encapsulation of\u000d\u000a        Palladium in Polyurea Microcapsules, C. Ramarao, S.V. Ley, S.C.\u000d\u000a      Smith, I.M.\u000d\u000a      Shiley and N. DeAlmeida, J. Chem. Soc., Chem. Commun, 2002, 1132.\u000d\u000a      (*)\u000d\u000a    \u000a9. EnCat patent: Microencapsulated catalyst, methods of preparation and\u000d\u000a      methods of use thereof.\u000d\u000a      July 9 2002 WO203006151.\u000d\u000a    (*) References that best indicate the quality of the research.\u000d\u000a    Grant Information\u000d\u000a    &#8226; Grant No: GR\/M50614\/01; PI: Professor Steven V Ley; Grant Title: ROPA:\u000d\u000a      Orchestrated\u000d\u000a      Multistep Organic Synthesis Using Polymer Bound Reagents; Period of Grant:\u000d\u000a      01 April 1999 - 31\u000d\u000a      March 2001; Grant Value: &#163;103,821\u000d\u000a    &#8226; Grant No: GR\/N02030\/01; PI: Professor Steven V Ley; Grant Title:\u000d\u000a      Multistep Organic Synthesis\u000d\u000a      Using Solid Supported Reagents: A New Paradigm in Chemical Library\u000d\u000a      Generation; Period of\u000d\u000a      Grant: 01 June 2000 - 31 May 2003; Grant Value: &#163;410,911\u000d\u000a    &#8226; Grant No: GR\/S40343\/01; PI: Professor Steven V Ley; Grant Title: An\u000d\u000a      Organic Synthesis\u000d\u000a      Programme in Cambridge; Period of Grant: 1 October 2003 - 30 September\u000d\u000a      2008); Grant\u000d\u000a      Value: &#163;3,552,215\u000d\u000a    &#8226; Grant No: EP\/K009494\/1; PI: Professor Steven V Ley; Grant Title:\u000d\u000a      Fully-Integrated Continuous\u000d\u000a      Flow Processes for Access to Forbidden Chemistries, New Reactivities and\u000d\u000a      Sequential\u000d\u000a      Complexity Generation; Grant Period: 1 January 2013 - 31 December 2013;\u000d\u000a      Grant Value:\u000d\u000a      &#163;2,559,199\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"},{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"},{"Level1":"3","Level2":"1","Subject":"Analytical Chemistry"}],"Sources":"\u000d\u000a    References in the public domain\u000d\u000a    \u000d\u000a      Clean Six-Step Synthesis of a Piperidino-thiomorpholine Library using\u000d\u000a        Polymer-Supported\u000d\u000a        Reagents, J. Habermann, S.V. Ley and J.S. Scott, J. Chem. Soc.,\u000d\u000a          Perkin Trans. I, 1998,\u000d\u000a        3127-3130.\u000d\u000a      Potent Inhibitors of LpxC for the Treatment of Gram-Negative\u000d\u000a        Infections, M.F. Brown, U.\u000d\u000a        Reilly, J.A. Abramite, J.T. Arcari, R. Oliver, R.A. Barham, Y. Che, J.M.\u000d\u000a        Chen, E.M.\u000d\u000a        Collantes, S.W. Chung, C. Desbonnet, J. Doty, M. Doroski, J.J.\u000d\u000a        Engtrakul, T.M. Harris, M.\u000d\u000a        Huband, J.D. Knafels, K.L. Leach, S. Liu, A. Marfat, A. Marra, E.\u000d\u000a        McElroy, M. Melnick, C.A.\u000d\u000a        Menard, J.I. Montgomery, L. Mullins, M.C. Noe, J. O'Donnell, J. Penzien,\u000d\u000a        M.S. Plummer,\u000d\u000a        L.M. Price, V. Shanmugasundaram, C. Thoma, D.P. Uccello, J.S. Warmus,\u000d\u000a        and D.G.\u000d\u000a        Wishka, J. Med. Chem., 2012, 55(2), 914-923.\u000d\u000a      Discovery of\u000d\u000a        3-Alkozyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as\u000d\u000a        Selective,\u000d\u000a        Orally Bioavailable CHK1 Inhibitors, M. Lainchbury, T.P. Matthews, T.\u000d\u000a        McHardy, K.J.\u000d\u000a        Boxall, M.I. Walton, P.D. Eve, A. Hayes, M.R. Valenti, A.K. de Haven\u000d\u000a        Brandon, G. Box,\u000d\u000a        G.W. Aherne, J.C. Reader, F.I. Reynaud, S.A. Eccles, M.D. Garrett, I.\u000d\u000a        Collins, J. Med.\u000d\u000a          Chem., 2012, 55(22), 10229-40.\u000d\u000a      Removal of Soluble Palladium Complexes from Reaction Mixtures by\u000d\u000a        Fixed-Bed\u000d\u000a        Adsorption, M.J. Girgis, L.E. Kuczynski, S.M. Berberena, C.A. Boyd, P.L.\u000d\u000a        Kubinski, M.L.\u000d\u000a        Scherholz, D.E. Drinkwater, X. Shen, S. Babiak and B.G. Lefebvre, Org.\u000d\u000a          Proc. Res. Dev.,\u000d\u000a        2008, 12, 1209-1217.\u000d\u000a      Development of a Potential Manufacturing Route to PF-00610355: A Novel\u000d\u000a        Inhaled 03b22-Adrenoreceptor\u000d\u000a        Agonist, P. D. de Koning, N. Castro, I.R. Gladwell, N.A. Morrison, I.B.\u000d\u000a        Moses, M.S. Panesar, A.J. Pettman, and N.M. Thomson, Org. Proc. Res.\u000d\u000a          Dev., 2011, 15,\u000d\u000a        1256).\u000d\u000a      ReactIRTM Flow Cell &#8212; A New Analytical Tool for Continuous\u000d\u000a        Flow Chemistry Processing,\u000d\u000a        C.F. Carter, H. Lange, I.P. Baxendale, S.V. Ley, J. Goode, N. Gaunt, B.\u000d\u000a        Wittkamp, Org.\u000d\u000a          Proc. Res. Dev., 2010, 14, 393-404.\u000d\u000a      Microsaic Systems (http:\/\/www.microsaic.com).\u000d\u000a      Continuous Flow Reaction Monitoring using an On-Line Miniature Mass\u000d\u000a        Spectrometer, D.L.\u000d\u000a        Browne, S. Wright, B.J. Deadman, S. Dunnage, I.R. Baxendale, R.M. Turner\u000d\u000a        and S.V. Ley,\u000d\u000a        Rapid Commun. Mass Spectrom, 2012, 26, 1999-2010.\u000d\u000a    \u000d\u000a    Users\/Beneficiaries who can be contacted to corroborate claims\u000d\u000a    \u000d\u000a      Director, Cambridge Reactor Design Ltd, Cottenham, UK.\u000d\u000a      Technical Applications Consultant, Mettler Toledo Ltd, Leicester, UK.\u000d\u000a      SVP, Head of Worldwide Medicinal Chemistry Pfizer, Cambridge MA, USA.\u000d\u000a      Fellow, Novartis Pharma AG, Basel, Switzerland.\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Enabling Methods for Cleaner Chemical Synthesis\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2634552","Name":"Welwyn Garden City"},{"GeoNamesId":"2633709","Name":"Woking"},{"GeoNamesId":"2655186","Name":"Borehamwood"},{"GeoNamesId":"2653941","Name":"Cambridge"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    Steven Ley (1702 Professor of Chemistry at the University of Cambridge\u000d\u000a      since 1992) and his group\u000d\u000a      began work in the mid 1990s to discover improved enabling methods for\u000d\u000a      cleaner and more\u000d\u000a      sustainable chemical synthesis. Using recyclable polymer supported\u000d\u000a      reagents in combination with\u000d\u000a      flow chemistry methods, he was able to conduct multi-step synthesis\u000d\u000a      sequences leading to the\u000d\u000a      synthesis of complex biologically active compounds. This was achieved\u000d\u000a      without recourse to\u000d\u000a      techniques such as chromatography, crystallisation, distillation or\u000d\u000a      reaction quenching, common to\u000d\u000a      more conventional synthesis methods at the time. The first paper\u000d\u000a      describing some of these\u000d\u000a      methods appeared in 19971 and within one year he had shown that\u000d\u000a      the concept could be extended\u000d\u000a      to up to six linear steps (a world record at the time) without recourse to\u000d\u000a      conventional and wasteful\u000d\u000a      downstream processing.2 This work attracted modest research\u000d\u000a      funding from the EPSRC through a\u000d\u000a      ROPA grant (GR\/M50614\/01) and a more substantial follow-up grant\u000d\u000a      (GR\/N02030\/01). The\u000d\u000a      concept for this work and its potential application for multi-step\u000d\u000a      synthesis using polymer supported\u000d\u000a      reagents with flow chemistry was the subject of a patent from his first\u000d\u000a      spin-out company in 1999.3\u000d\u000a    The grants awarded to Ley's group facilitated very rapid development of\u000d\u000a      the techniques and\u000d\u000a      resulted in a highly cited review.4 The methods were promptly\u000d\u000a      adopted by the academic community\u000d\u000a      (as evidenced by ISI listing 700 citations in 2011 alone) and by industry\u000d\u000a      with Ley's own company\u000d\u000a      leading the charge (see above). His spectacular synthesis of epothilone C,\u000d\u000a      a potent anti-tumour\u000d\u000a      agent, in just 15 linear steps using only polymer supported reagents, was\u000d\u000a      a true demonstration of\u000d\u000a      the technology and a landmark publication because it changed many people's\u000d\u000a      attitudes towards\u000d\u000a      organic synthesis using cleaner and more efficient methods.5\u000d\u000a    More significantly Ley then went on to show even further advances were\u000d\u000a      possible by using these\u000d\u000a      polymer supported reagents and related scavenger materials. This was\u000d\u000a      achieved by constructing\u000d\u000a      packed cartridges containing these species and, by appropriate machinery,\u000d\u000a      passing substrates\u000d\u000a      through these tubes in a flow chemistry manner; multi-step flow synthesis\u000d\u000a      was made possible.6 By\u000d\u000a      2006 he developed flow chemistry and immobilised reagents to deliver\u000d\u000a      pharmaceutical agents and\u000d\u000a      complex natural products such as oxomaritidine in just seven steps using\u000d\u000a      this machine-assisted\u000d\u000a      approach.7 This seminal paper opened up a whole new set of\u000d\u000a      opportunities for molecular assembly\u000d\u000a      as a result of Ley's work. It also generated substantial interest at the\u000d\u000a      EPSRC, who began to fund\u000d\u000a      initiatives in the area and a large EPSRC grant in 2003 (GR\/S40343\/01), to\u000d\u000a      support further\u000d\u000a      research in Ley's group.\u000d\u000a    As these techniques were being developed and adopted worldwide, further\u000d\u000a      underpinning research\u000d\u000a      in Cambridge from Ley's group led to the discovery of a new range of\u000d\u000a      encapsulated reagents and\u000d\u000a      greatly improved polymer supported scavengers, some of which were\u000d\u000a      patented.8&amp;9 Further\u000d\u000a      research support for this area has been recently awarded to Ley's group\u000d\u000a      from the EPSRC\u000d\u000a      (EP\/K009494\/1). These immobilised systems were very effective in batch and\u000d\u000a      flow conditions and\u000d\u000a      this discovery led to the formation of a second spin-out company, Reaxa,\u000d\u000a      based in Manchester in\u000d\u000a      2005. The products are now marketed and sold worldwide for green chemistry\u000d\u000a      applications.\u000d\u000a    "},{"CaseStudyId":"21352","Continent":[],"Country":[],"Funders":[],"ImpactDetails":"\u000a    The Newcastle University spin-out company NewChem Technologies, which was\u000a      founded in 2002, is primarily a drug development company working in\u000a      association with industrial partners. The company is the route by which\u000a      the academic research of Golding and his group is commercialised. In 2008,\u000a      as the result of steady growth, NewChem invested in new laboratories\u000a      within the School of Chemistry which are adjacent to Golding's research\u000a      group, thus enabling continuous and fruitful exchange of information and\u000a      expertise. In the period 2008-2013, NewChem has provided employment for\u000a      high quality chemists (&gt;60 FTE) and has achieved annual sales of\u000a      greater than &#163;1 million, thus making a significant contribution to\u000a      employment in the North East region [E1].\u000a    The impacts of Newcastle University research through the vehicle of\u000a      NewChem include contributions to the science of the drug anagrelide\u000a      (Xagrid), a core product of Shire, as well as development of prodrugs of\u000a      several therapeutic agents [e.g. galanthamine (Alzheimer's disease) ,\u000a      guanfacine (ADHD), meptazinol and oxycodone (pain) [E2, E3].\u000a      NewChem developed several customised release mechanisms for prodrugs that\u000a      aimed to resolve disadvantageous drug properties, e.g. poor intestinal\u000a      absorption, poor bioavailability due to extensive 1st pass\u000a      metabolism, high abuse potential, local GI toxicity, colonic delivery etc.\u000a      According to the Former Head of New Product Discovery (Small molecules) at\u000a      Shire: \"The positive impact of that relationship [NewChem and\u000a      Shire] on the research output of Shire cannot be overstated and\u000a        singularly contributed to the development of over 40 patents on\u000a        potential new drug products\" [E3].\u000a    Anagrelide (Xagrid or Agrylin&#174;) which is used to treat the\u000a      myeloproliferative disorder called essential thrombocythemia (ET) has\u000a      annual peak sales of $97 million [E4]. Individuals with raised\u000a      platelet counts have a higher risk of adverse thrombotic and haemorrhagic\u000a      events. Previous investigations identified a metabolite\u000a      3-hydroxyanagrelide, derived from oxidation of anagrelide. Whilst\u000a      anagrelide and 3-hydroxyanagrelide are similarly potent against ET, the\u000a      metabolite is nearly 40-fold more potent against\u000a      phosphodiesterase-III (PDE-III), which causes severe cardiovascular\u000a      side-effects. Based on prior Newcastle research a synthetic route to\u000a      3-hydroxyanagrelide was devised [P2] which made this biologically\u000a      potent molecule reliably available for the first time and enabled a full\u000a      determination of its pharmacological profile. An analogue of anagrelide\u000a      was developed (3,3-dimethylanagrelide, `Rafingrelide') [E4], which\u000a      retains potency against ET, but has much reduced activity against PDE-III.\u000a      This compound \"has completed phase 2 clinical testing...current\u000a        estimates of its market potential in the anti-thrombotic market exceed\u000a        $500 million\" [E3 Former Head of New Product Discovery (Small\u000a      molecules) at Shire]. Phase 2 clinical trials represent an average of\u000a      $19,300 per patient investment into the drug [E6].\u000a    During 2008-2012, a major contribution has been made to the Shire drug\u000a      guanfacine which is used to treat attention deficit hyperactivity disorder\u000a      (ADHD) [E1]. Children with ADHD are deficient in normal social\u000a      skills and lack the ability to focus on tasks. Current sales for the\u000a      established ADHD drug Vyvanse approach $1030 million per annum [E4].\u000a      The alternative ADHD drug guanfacine has been converted into a novel\u000a      carbamate prodrug. Shire recently invested substantial effort via NewChem\u000a      in research for new prodrugs for alleviating pain. This has resulted in\u000a      the development of carbamate prodrugs of meptazinol and oxycodone, which\u000a      were produced by the synthetic methodologies analogous to those described\u000a      [P3]. NewChem studies for Shire have also created novel prodrugs of\u000a      the anti-Alzheimer drug galanthamine [E2]. Shire has requested that\u000a      the details of these prodrugs be kept confidential but we can disclose \"that\u000a        three compounds (not to be named) that...[NewChem researchers] worked on\u000a        were nominated for IND [Investigational New Drug] studies (2009-2012)\u000a        and two of these went into man [phase 1 trials in humans]\" [E5,\u000a      Senior Director Exploratory Projects, Shire]. Phase 1 trials represent on\u000a      average an investment per patient of $15700 (USD) [E6].\u000a    During 2012\/2013 NewChem has provided invaluable assistance to two SMEs.\u000a      This assistance included the synthesis of key intermediates and products\u000a      that could not be sourced elsewhere. A key step in the synthesis of\u000a      complex nucleotides for the company QuantuMDX was accomplished based on\u000a      Golding's knowledge of protecting group chemistry arising from his\u000a      Newcastle research on nucleosides and nucleotides [P3]. QuantuMDx\u000a      have \"...secured &#163;1.4 million from the Technology Strategy Board\u000a        `biomedical catalyst fund' for developing a handheld device for rapid\u000a        tumour profiling...and ... a &#163;3.5 million EU FP7 grant for\u000a        developing a handheld diagnostic test for Malaria...\" [E7,\u000a      Chief Operating Officer, QuantuMDx Group Limited]. In another notable\u000a      achievement, Golding's Newcastle research has also assisted the company\u000a      Glythera in the synthesis of heterocyclic derivatives that are the basis\u000a      of therapeutic applications. \"Based on the success of these studies\u000a      Glythera has...secured its second tranche of funding of &#163;700,000 from its\u000a      investors\" [E8, Chief Operating Officer, Glythera Ltd.].\u000a\u0009  In all of\u000a      the projects described above prior Newcastle research on prodrugs,\u000a      protecting groups, heterocyclic chemistry, nucleosides and reaction\u000a      mechanisms was critical to success.\u000a    ","ImpactSummary":"\u000a    Newcastle research is the driving force behind NewChem, a Newcastle\u000a      University spin-out company which provides creative molecular design and\u000a      synthetic\/analytical services for the pharmaceutical\/chemical industry.\u000a      During 2008-2013, NewChem assisted Shire, a global pharmaceutical company,\u000a      in the quest for new drugs for treating a range of therapeutic\u000a      indications, including pain, cardiovascular disorders, ADHD and\u000a      Alzheimer's disease. Since 2008, NewChem has provided employment for &gt;\u000a      60 FTE's and achieved sales exceeding &#163;1 million per annum.\u000a    ","ImpactType":"Technological","Institution":"\u000a    Newcastle University\u000a    ","Institutions":[{"AlternativeName":"Newcastle upon Tyne (University of)","InstitutionName":"Newcastle University","PeerGroup":"A","Region":"North East","UKPRN":10007799}],"Panel":"B         ","PlaceName":[],"References":"\u000a    (Newcastle personnel are italicised)\u000a    \u000a[P1] *A J Pierik, D Ciceri, G Br&#246;ker, C H Edwards, W\u000a        McFarlane, J Winter, W Buckel, and B T Golding, Rotation of\u000a      the exo-methylene Group of (R)-3-methylitaconate catalyzed\u000a      by coenzyme B12-dependent 2-methyleneglutarate mutase from Eubacterium\u000a        barkeri, Journal of the American Chemical Society, 2002, 124,\u000a      14039-14048 (DOI: 10.1021\/ja020340f).Detailed study of the mechanism of\u000a        a coenzyme B12-dependent enzyme. Shows the\u000a        value of selective isotopic labelling for uncovering complex enzyme\u000a        mechanisms.\u000a    \u000a\u000a[P2]*R B Scott, K M Downey, K P Healy, A P Henderson, C L\u000a        Robinson, W Clegg, R W Harrington, R Franklin, B T Golding,\u000a      Synthesis and stability of 3-hydroxyanagrelide, a biologically potent\u000a      metabolite of anagrelide, Heterocycles, 2012, 86, 1637-1646 (DOI:\u000a      10.3987\/COM-12-S(N)115 ). First synthesis of 3-hydroxyanagrelide, the\u000a        key metabolite of anagrelide, and a study of its stability in pH 7.4\u000a        buffer. Research that laid the groundwork for the subsequent discovery\u000a        of Rafingrelide.\u000a    \u000a\u000a[P3] K Saravanan, H C Barlow, M Barton, A H Calvert, B T\u000a        Golding, D R Newell, J S Northen, N J Curtin, H D Thomas, R J Griffin,\u000a      Nucleoside transport inhibitors: structure-activity relationships for\u000a      pyrimido [5,4-d]pyrimidine derivatives that potentiate pemetrexed\u000a      cytotoxicity in the presence of f0611-acid glycoprotein, Journal of\u000a        Medicinal Chemistry, 2011, 54, 1847-1859 (DOI: 10.1021\/jm101493z).\u000a    \u000a\u000a[P4] *Munter,T; Cottrell, L; Hill, S; Kronber, L;\u000a      Watson, WP; Golding, BT, Identification of adducts derived from\u000a      reactions of (1-chloroethenyl)oxirane with nucleosides and calf thymus\u000a      DNA, Chemical Research in Toxicology, 2002, 15, 1549-1560 (DOI:\u000a      10.1021\/tx020070e).Research that unravelled the complex adduct\u000a        chemistry arising from the reactions of a chloroprene epoxide with\u000a        2&#162;-deoxyguanosine, 2&#162;-deoxyadenosine, 2&#162;-deoxycytidine, thymidine and\u000a        calf thymus DNA. First comprehensive study relevant to chloroprene\u000a        mutagenesis and has been much cited in subsequent work on chloroprene.\u000a    \u000a\u000a[P5] A W White, R Almassy, A H Calvert, N J Curtin, R J\u000a        Griffin, Z Hostomsky, K Maegley, D R Newell, S Srinivasan,\u000a        and B T Golding, Synthesis and biological properties of\u000a      benzimidazole inhibitors of the DNA repair enzyme\u000a      poly(ADP-ribose)polymerase (PARP), Journal of Medicinal Chemistry,\u000a      2000, 43, 4084-4097 (DOI: 10.1021\/jm000950v).\u000a    \u000a\u000a[P6] J S Northen, F T Boyle, W Clegg, N J Curtin, A J\u000a        Edwards, R J Griffin, and B T Golding, Controlled stepwise\u000a      conversion of 2,4,6,8-tetrachloropyrimido[5,4-d]pyrimidine into\u000a      2,4,6,8-tetrasubstituted pyrimido[5,4-d]pyrimidines', Journal\u000a        of the Chemical Society Perkin Transactions 1, 2002, 108-115 (DOI:\u000a      10.1039\/b102224p).\u000a    \u000a* = 3 papers that best indicate the quality of the\u000a      research\u000a    Selected grants\u000a    CEFIC-LRI: 2000 - 2003 \"Molecular toxicology of industrially important\u000a      dienes and the relevance for human cancer\". Awarded: &#163;95,538\u000a    Commission of the European Communities: 2002 - 2005 \"Reactions with\u000a      Cobalamins and their mimics: mechanisms, synthetic applications and\u000a      relevance to human health\". Awarded: &#163;146,923\u000a\u0009  Newchem Technologies\u000a      Limited: 2003 \"Development of Processes for the Preparation of Pure\u000a      BCH24426 and its Isomer BCH29732\" Awarded: &#163;12,842\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"}],"Sources":"\u000a    [E1] Corroborating contact: Newchem Managing Director\u000a    [E2] Patents (searched and accessed on http:\/\/worldwide.espacenet.com\/searchResults?compact=false&amp;ST=singleline&amp;query=Golding%2C+Bernard&amp;locale=en_EP&amp;DB=worldwide.espacenet.com)\u000a    [E3] Testimonial from the Former Head of New Product Discovery\u000a      (Small molecules) at Shire\u000a    [E4] Shire annual report 2012\u000a    [E5] Email from the Senior Director Exploratory Projects, Shire\u000a    [E6] Pellegrino, J. &amp; Smith, R. 2009. Predictive Modeling in\u000a      Clinical Trial Enrollment. Acurian, Horsham, Pennsylvania, USA.\u000a        www.acurian.com\u000a    [E7] Testimonial from the Chief Operating Officer, QuantuMDx Group\u000a      Ltd.\u000a    [E8] Testimonial from the Chief Operating Officer, Glythera Ltd. \u000a    ","Title":"\u000a    The provision of novel compounds for the healthcare industry via the\u000a      Newcastle University based company NewChem\u000a    ","UKLocation":[{"GeoNamesId":"2641673","Name":"Newcastle-upon-Tyne"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    The application of synthesis to the solution of problems in biology and\u000a      medicine has been the central tenet of Newcastle University research led\u000a      by Professor Golding (1983 to date &#8212; Professor of Organic\u000a        Chemistry) in the period 1993-present as exemplified by over 160\u000a      research papers. Post-1993, a portfolio of powerful synthetic\u000a      methodologies applicable to a range of therapeutic targets were developed\u000a      [P1 - P4]. This work included the accumulation of expertise in\u000a      selective isotopic labelling [P1], which was subsequently applied\u000a      to the synthesis of specifically labelled drug metabolites. Studies of\u000a      some of the most challenging problems in mechanistic enzymology [P1]\u000a      underpinned key innovations in drug design, most notably leading to the\u000a      development of the anticancer agent Rucaparib. These fundamental studies\u000a      created a unique research environment from which emerged seminal\u000a      discoveries relevant to the treatment of some of the most challenging\u000a      medical conditions including cancers, cardiovascular diseases, dementias,\u000a      attention deficit hyperactivity disorder (ADHD) and infections arising\u000a      from Clostridium difficile. This invaluable experience derived\u000a      from wide-ranging research achievements led to the creation of prodrugs\u000a      that are structurally fine-tuned to release their parent drug under either\u000a      chemical or enzymatic conditions.\u000a    Examples of Newcastle research in the context of drug development are:\u000a    \u000a      Knowledge derived from research requiring selective isotopic labelling\u000a        [P1] applied to the synthesis of labelled drugs for metabolism\u000a        studies.\u000a      Fundamental research on the anagrelide metabolite 3-hydroxyanagrelide\u000a        leading to new anagrelide analogues (e.g. 3,3-dimethylanagrelide,\u000a        `Rafingrelide') resistant to metabolism [P2] One critical aspect\u000a        of this research was the application of X-ray crystallography at\u000a        Newcastle to the identification of a previously unrecognised isomer of\u000a        3-hydroxyanagrelide.\u000a      Extensive experience of the synthesis of prodrugs [P3] enabling\u000a        an array of new prodrugs to be developed.\u000a      Wide ranging nucleoside and nucleotide research [P4]\u000a        underpinning the synthesis of complex nucleotides for medical detection\u000a        devices.\u000a      Diverse heterocyclic chemistry exemplified in &gt; 50 research papers\u000a        since 1993 [e.g. P5, P6].\u000a    \u000a    Key Researchers\u000a    Daniele Ciceri (2000 to 2001 &#8212; Research Associate)\u000a    Julian S Northen (2000 to 2001 &#8212; Research Associate)\u000a    Dr Tony Munter (1998 to 2000 &#8212; Research Associate)\u000a    Alex W White (1998 to 2000 &#8212; Research Associate)\u000a    "},{"CaseStudyId":"21354","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"6252001","Name":"United States"}],"Funders":[],"ImpactDetails":"\u000d\u000a    Overview\u000d\u000a    The primary impact of the Newcastle PARP project is the development of\u000d\u000a      the anticancer drug\u000d\u000a      Rucaparib. In addition, the Newcastle research has stimulated PARP\u000d\u000a      research worldwide, which\u000d\u000a      has led to further potent inhibitors. PARP research now embraces the\u000d\u000a      global pharmaceutical\u000d\u000a      industry (over 10 companies), with 33 cancer trials involving PARP\u000d\u000a      inhibitors completed and an\u000d\u000a      additional 52 trials currently open. Through these trials (50 Phase I, 33\u000d\u000a      Phase II and 2 Phase III)\u000d\u000a      more than 7000 patients exhibiting 8 types of cancer have been treated\u000d\u000a      with a PARP-1 inhibitor so\u000d\u000a      far, including more than 200 patients who have received Rucaparib. The\u000d\u000a      successful exploitation of\u000d\u000a      PARP has established:\u000d\u000a    \u000d\u000a      \u000aStructure-based drug design (SBDD) as a major tool in cancer\u000d\u000a        drug discovery.\u000d\u000a      DNA damage repair as a viable target.\u000d\u000a    \u000d\u000a    Beneficiaries\u000d\u000a    The research has had a significant impact on the global pharmaceutical\u000d\u000a      industry, with companies\u000d\u000a      such as AstraZeneca, Clovis, Sanofi-Aventis, Abbott, Merck, Biomarin,\u000d\u000a      Eisai, Cephalon and\u000d\u000a      Genentech having invested heavily in clinical trials and clinical PARP\u000d\u000a      inhibitor programmes [E1].\u000d\u000a      Since the initial clinical trials in Newcastle in which patients were\u000d\u000a      treated with a PARP inhibitor for\u000d\u000a      the first time, there has been a twenty-fold increase in the commencement\u000d\u000a      of trials testing PARP\u000d\u000a      inhibitors [data extracted from E1].\u000d\u000a    Since the initial Phase 1 trial in 2003, more than 7000 cancer patients\u000d\u000a      (approximately 750 of which\u000d\u000a      have been recruited to more than one phase) have entered clinical trials\u000d\u000a      involving PARP inhibitors\u000d\u000a      [E1]. Five thousand six-hundred of these patients were enrolled\u000d\u000a      since 2008. These trials include\u000d\u000a      patients with ovarian cancer (incidence rate in the UK: 21 cases for every\u000d\u000a      100,000 women), breast\u000d\u000a      cancer (157 new breast cancer cases for every 100,000 women and 1 for\u000d\u000a      every 100,000 males in\u000d\u000a      the UK) and prostate cancer (134 new prostate cancer cases for every\u000d\u000a      100,000 males in the UK;\u000d\u000a      [E2]). Thirty-three cancer trials involving PARP inhibitors have\u000d\u000a      been completed with an additional\u000d\u000a      52 trials currently open, totalling 50 Phase I, 33 Phase II and 2 Phase\u000d\u000a      III trials [E1]. In 2011 the\u000d\u000a      average per patient cost associated with a Phase I, II and III trial in\u000d\u000a      Oncology were reported to be\u000d\u000a      $21,883, $73,303 and $65,900 respectively [E3]. Therefore, an\u000d\u000a      estimated $385 million US dollars\u000d\u000a      has been invested into PARP inhibitor trials in the period 2008-2013.\u000d\u000a    In the earliest clinical trials of Rucaparib (2003 and 2005), although\u000d\u000a      some patients had a life\u000d\u000a      expectancy of only a few months, two treated in 2003 in the first clinical\u000d\u000a      trial and five from a 2005\u000d\u000a      Phase II study with one exception are still alive and cancer-free [E4].\u000d\u000a      In one Phase II trial,\u000d\u000a      treatment with the PARP inhibitor olaparib has significantly reduced the\u000d\u000a      size of tumours in 38 % of\u000d\u000a      breast cancer patients (9 of 24 patients) [E5]. Similarly, a Phase\u000d\u000a      II trial showed that this drug was\u000d\u000a      well tolerated in ovarian cancer patients with hereditary breast-ovarian\u000d\u000a      cancer syndrome, with 33%\u000d\u000a      (11 of 33 patients) showing reduced tumour size [E6].\u000d\u000a    As a consequence of Newcastle's PARP research, several other DNA damage\u000d\u000a      and repair targets\u000d\u000a      are now being explored and Newcastle is involved in many of these, e.g.\u000d\u000a      ATM, ATR, CHK1\/2 and\u000d\u000a      DNA PK.\u000d\u000a    Timeline for the Impact of the Newcastle PARP Inhibitor Programme\u000d\u000a    1995 - 2000 &#8212; Discovery of potent small molecule PARP inhibitors and\u000d\u000a      initiation of a pre-clinical\u000d\u000a      collaboration with Agouron Pharmaceuticals resulting in the identification\u000d\u000a      of the first-in-class PARP\u000d\u000a      inhibitor for clinical evaluation in cancer patients.\u000d\u000a    2000 - 2005 &#8212; Initiation of the first clinical trials of a PARP inhibitor\u000d\u000a      in cancer in conjunction with\u000d\u000a      Cancer Research UK and multiple UK clinical centres (Belfast, Oxford,\u000d\u000a      Glasgow, Manchester,\u000d\u000a      Birmingham), and Pfizer.\u000d\u000a    2005 - 2010 &#8212; Demonstration of the synthetic lethal interaction of PARP\u000d\u000a      inhibition and BRCA\u000d\u000a      deficiency, and the initiation of clinical trials in defined at risk\u000d\u000a      patient groups in collaboration with\u000d\u000a      Cancer Research UK and Pfizer.\u000d\u000a    2010 &#8212; Worldwide clinical trials of multiple PARP inhibitors in a range\u000d\u000a      of cancers.\u000d\u000a    2010 &#8212; The Newcastle team were the recipients of the first Cancer\u000d\u000a      Research UK Translational\u000d\u000a      Research Award [E7].\u000d\u000a    2012 &#8212; Pfizer licence clinical development of Rucaparib to Clovis\u000d\u000a      Oncology (Boulder, USA) [E8].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Newcastle University research discovered the first potent inhibitors of\u000d\u000a      the DNA repair enzyme poly\u000d\u000a      (ADP-ribose) polymerase 1 (PARP-1) through medicinal chemistry and\u000d\u000a      preclinical work leading to\u000d\u000a      first-in-man clinical studies. This research led to the development of\u000d\u000a      Rucaparib, an agent that\u000d\u000a      inhibits the ability of cancer cells to survive drug treatments or\u000d\u000a      radiotherapy. As a result of\u000d\u000a      Newcastle's research a further 8 PARP inhibitors are in development. Major\u000d\u000a      pharmaceutical\u000d\u000a      companies have invested an estimated $385 million in clinical trials, with\u000d\u000a      at least 7000 patients\u000d\u000a      enrolled in PARP inhibitor trials since 2008. Cancer patients worldwide\u000d\u000a      have already been\u000d\u000a      successfully treated with these new anti-cancer drugs.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    Newcastle University\u000d\u000a    ","Institutions":[{"AlternativeName":"Newcastle upon Tyne (University of)","InstitutionName":"Newcastle University","PeerGroup":"A","Region":"North East","UKPRN":10007799}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    \u000a[P1] *R J Griffin, L C Pemberton, D Rhodes, C Bleasdale, K Bowman,\u000d\u000a      A H Calvert, N J Curtin, B W\u000d\u000a      Durkacz, D R Newell, J K Porteous, B T Golding, Novel potent inhibitors of\u000d\u000a      the DNA repair enzyme\u000d\u000a      poly(ADP-ribose)polymerase (PARP), Anti-Cancer Drug Design, 1995,\u000d\u000a      10, 507 - 514. This paper\u000d\u000a        was the first to describe benzimidazole carboxamides as potent PARP-1\u000d\u000a        inhibitors.\u000d\u000a    \u000a\u000a[P2] R J Griffin, S Srinivasan, K Bowman, A H Calvert, N J Curtin,\u000d\u000a      D R Newell, L C Pemberton, and\u000d\u000a      B T Golding, Resistance-modifying agents. 5. Synthesis and biological\u000d\u000a      properties of quinazolinone\u000d\u000a      inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP), J\u000d\u000a        Med Chem, 1998, 41,\u000d\u000a      5247-5256 (DOI: 10.1021\/jm980273t).\u000d\u000a    \u000a\u000a[P3] *A W White, R Almassy, A H Calvert, N J Curtin, R J Griffin,\u000d\u000a      Z Hostomsky, K Maegley, D R\u000d\u000a      Newell, S Srinivasan, and B T Golding, `Resistance-modifying agents. 9.\u000d\u000a      Synthesis and biological\u000d\u000a      properties of benzimidazole inhibitors of the DNA repair enzyme\u000d\u000a      poly(ADP-ribose)polymerase\u000d\u000a      (PARP), J Med Chem, 2000, 43, 4084-4097 (DOI: 10.1021\/jm000950v).This\u000d\u000a        is the seminal paper\u000d\u000a        on benzimidazole carboxamides as PARP-1 inhibitors showing that a\u000d\u000a        substituted phenyl group at\u000d\u000a        the 2-position of the imidazole ring gave enhanced potency. This study\u000d\u000a        confirmed a predicted\u000d\u000a        binding mode by X-ray analysis, in particular the importance of three\u000d\u000a        hydrogen bonds from the\u000d\u000a        carboxamide moiety.\u000d\u000a    \u000a\u000a[P4] *S S Canan Koch, L H Thoresen, J G Tikhe, K A Maegley, J Li,\u000d\u000a      X.-H Yu, S E Zook, R A\u000d\u000a      Kumpf, C Zhang, R N Mansour, K E Zhang, A Ekker, C R Calabrese, N J\u000d\u000a      Curtin, H D Thomas, L-Z\u000d\u000a      Wang, A H Calvert, B T Golding, R J Griffin, S E Webber, and Z Hostomsky,\u000d\u000a      Novel tricyclic\u000d\u000a      poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer\u000d\u000a      chemopotentiating activity: design,\u000d\u000a      synthesis, and X-ray cocrystal structure, J Med Chem, 2002, 45,\u000d\u000a      4961-4974 (DOI:\u000d\u000a      10.1021\/jm02059n). This paper was the first to show that tricylic\u000d\u000a        systems related to the\u000d\u000a        benzimidazole carboxamides gave improved properties as PARP-1 inhibitors\u000d\u000a        and led the way to\u000d\u000a        rucaparib.\u000d\u000a    \u000a\u000a[P5] D J Skalitzky, J T Marakovits, K A Maegley, A Ekker, X H Yu,\u000d\u000a      Z Hostomsky, S E Webber, B W\u000d\u000a      Eastman, R Almassy, J K Li, N J Curtin, D R Newell, A H Calvert, R J\u000d\u000a      Griffin, and B T Golding,\u000d\u000a      Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1\u000d\u000a      inhibitors, J Med Chem, 2003,\u000d\u000a      46, 210-213 (DOI: 10.1021\/jm0255769).\u000d\u000a    \u000a\u000a[P6] Tikhe JG, Webber SE, Hostomsky Z, Maegley KA, Ekkers A, Li\u000d\u000a      JK, Yu XH, Almassy RJ,\u000d\u000a      Kumpf RA, Boritzki TJ, Zhang C, Calabrese CR, Curtin NJ, Kyle S, Thomas\u000d\u000a      HD, Weng LZ, Calvert\u000d\u000a      AH, Golding BT, Griffin RJ, Newell DR, Design, synthesis, and evaluation\u000d\u000a      of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of\u000d\u000a      poly(ADP-ribose)\u000d\u000a      polymerase, J Med Chem, 2004, 47, 5467-5481 (DOI: 10.1021\/jm030513r).\u000d\u000a    \u000aSelected grants\u000d\u000a    Cancer Research UK: Drug development Programme &#8212; 2007 - 2008: Awarded &#8212;\u000d\u000a      &#163;1,401,647; 2008\u000d\u000a      - 2009: Awarded &#8212; &#163;986,663; 2009 - 2012: Awarded &#8212; &#163;2,196,361; 2012 -\u000d\u000a      2015: Awarded &#8212;\u000d\u000a      &#163;738,433\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"12","Subject":"Oncology and Carcinogenesis"}],"Sources":"\u000d\u000a    [E1] Search of clinical trials of PARP inhibitors indicating\u000d\u000a      cancer disease types being studied and\u000d\u000a      companies involved in the development of PARP inhibitors &#8212; www.clinicaltrials.gov.\u000d\u000a      Search term\u000d\u000a      `PARP inhibitor', excluding withdrawn and terminated trials. For patient\u000d\u000a      numbers, trials not yet\u000d\u000a      recruiting were also excluded.\u000d\u000a    [E2] Search of prevalence rate for ovarian, breast and prostate\u000d\u000a      cancers\u000d\u000a      http:\/\/www.cancerresearchuk.org\/cancer-info\/cancerstats\/types\/\u000d\u000a    [E3] http:\/\/www.pharmalive.com\/clinical-trial-costs-are-rising-rapidly\u000d\u000a      (data sourced from \"Oncology\u000d\u000a      Clinical Trials: Drug Development Resources and Case Studies\");\u000d\u000a    [E4] Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A,\u000d\u000a      Curtin N, Boddy A, McHugh\u000d\u000a      P, Newell D, Harris A, Johnson P, Steinfeldt H, Dewji R, Wang D, Robson L,\u000d\u000a      Calvert H. (2008)\u000d\u000a      Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in\u000d\u000a      combination with\u000d\u000a      temozolomide in patients with advanced solid tumors. Clinical Cancer\u000d\u000a      Research, 14:7917-7923.\u000d\u000a      DOI: 10.1158\/1078-0432.CCR-08-1223.\u000d\u000a    [E5] Tutt, A et al. Phase II trial of the oral PARP inhibitor\u000d\u000a      olaparib in BRCA-deficient advanced\u000d\u000a      breast cancer. Journal of Clinical Oncology, 2009 ASCO Annual Meeting\u000d\u000a      Proceedings (Post-Meeting\u000d\u000a      Edition). Vol 27, No 18S (June 20 Supplement)\u000d\u000a    [E6] Audeh, MW et al. Phase II trial of the oral PARP inhibitor\u000d\u000a      olaparib (AZD2281) in BRCA-deficient\u000d\u000a      advanced ovarian cancer. Journal of Clinical Oncology, 2009 ASCO Annual\u000d\u000a      Meeting\u000d\u000a      Proceedings (Post-Meeting Edition). Vol 27, No 15S (May 20 Supplement)\u000d\u000a    [E7] Award to Newcastle of the inaugural Cancer Research UK\u000d\u000a      Translational Research Team Prize\u000d\u000a      in 2010 &#8212; http:\/\/science.cancerresearchuk.org\/news\/prize-winners-2010-announced.\u000d\u000a    [E8] http:\/\/www.clovisoncology.com\/products-companion-diagnostics\/rucaparib\/\u000d\u000a    ","Title":"\u000d\u000a    Development of the first-in-class poly(ADP-ribose) polymerase-1 (PARP-1)\u000d\u000a      inhibitor Rucaparib for the treatment of cancer\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2655603","Name":"Birmingham"},{"GeoNamesId":"2655984","Name":"Belfast"},{"GeoNamesId":"2641673","Name":"Newcastle-upon-Tyne"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"},{"GeoNamesId":"2641364","Name":"Northern Ireland"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    Although many cancer patients are successfully treated with drugs there\u000d\u000a      is an urgent need for\u000d\u000a      better drugs for some of the most prevalent cancers including breast,\u000d\u000a      ovarian and prostate. Prior to\u000d\u000a      1993, inhibitors of PARP-1 were studied by Professor B Durkacz (1982-2009\u000d\u000a        &#8212; Professor of\u000d\u000a        Experimental Cancer Therapeutics; Northern Institute of Cancer\u000d\u000a        Research (NICR), Newcastle\u000d\u000a        University), but were of insufficient potency for clinical use.\u000d\u000a      Following these initial observations, a\u000d\u000a      translational research effort was instituted between the NICR and Golding\u000d\u000a      (1983 to date &#8212;\u000d\u000a        Professor of Organic Chemistry) and Griffin (1990 to date\u000d\u000a        &#8212; Professor of Medicinal Chemistry) in\u000d\u000a      the School of Chemistry. After considering the mode of action of PARP-1,\u000d\u000a      we conceived\u000d\u000a      benzimidazole and quinazolinone derivatives as possible effective\u000d\u000a      inhibitors [P1, P2] A synthetic\u000d\u000a      program was initiated, which led by 1995 to potent benzimidazole and\u000d\u000a      quinazolinone inhibitors.\u000d\u000a      These were much more effective than previously studied compounds and led,\u000d\u000a      in collaboration with\u000d\u000a      industrial partners (initially Agouron Pharmaceuticals), to the\u000d\u000a      first-in-class clinical candidate by\u000d\u000a      2000 [P3-P6].\u000d\u000a    The primary contributions from Newcastle research was thus the design of\u000d\u000a      new structural motifs for\u000d\u000a      inhibition of PARP-1 and devising efficient synthetic routes to libraries\u000d\u000a      of drug-like molecules\u000d\u000a      needed to exemplify the concept. The discovery of potent benzimidazole\u000d\u000a      inhibitors of PARP-1\u000d\u000a      enabled the support of a major pharmaceutical partner to be secured:\u000d\u000a      initially Agouron\u000d\u000a      Pharmaceuticals, world leaders in structure-based drug design (SBDD),\u000d\u000a      which was an emerging\u000d\u000a      technique in the 1990s. With the help of crystal structures of Newcastle\u000d\u000a      inhibitors bound to PARP-1\u000d\u000a      protein, the number of molecules synthesised through the collaboration\u000d\u000a      between the School of\u000d\u000a      Chemistry and Agouron chemists led to the identification of the clinical\u000d\u000a      candidate Rucaparib\u000d\u000a      (AG014699, PF-01367338). This partnership was noteworthy because it came\u000d\u000a      at a time when drug\u000d\u000a      resistance modifiers and chemo-\/radio-potentiators were considered to be\u000d\u000a      of limited commercial\u000d\u000a      value by the pharmaceutical sector. Our persistence and research therefore\u000d\u000a      validated PARP as a\u000d\u000a      viable target despite this prevailing attitude.\u000d\u000a    Preclinical research by the NICR validated the identified compounds as\u000d\u000a      inhibitors of the target\u000d\u000a      enzyme. Potentiation of the activity of alkylating agents (e.g.\u000d\u000a      temozolomide) and topoisomerase I\u000d\u000a      inhibitors (e.g. topotecan) was demonstrated in cell lines and also in\u000d\u000a      xenograft models. The much\u000d\u000a      wider clinical potential for PARP-1 inhibitors was shown by potentiation\u000d\u000a      of ionising radiation and of\u000d\u000a      cytotoxic drugs in a range of tumour types. After the clinical candidate\u000d\u000a      Rucaparib had been\u000d\u000a      identified, the Newcastle clinical team, with the support of Cancer\u000d\u000a      Research UK (Drug\u000d\u000a      Development Office), designed and executed a first-in-human,\u000d\u000a      first-in-class Phase I study of this\u000d\u000a      compound in combination with temozolomide. This study was designed to\u000d\u000a      provide both safety data\u000d\u000a      and proof-of-mechanism of action in a surrogate tissue and also in tumour\u000d\u000a      biopsies. It was one of\u000d\u000a      the first Phase I studies to rely on a therapeutic (pharmacodynamic)\u000d\u000a      endpoint rather than toxicity\u000d\u000a      and pharmacokinetics alone. The Newcastle PARP-1 team was also closely\u000d\u000a      involved in the\u000d\u000a      preclinical research that first demonstrated synthetic lethality with PARP\u000d\u000a      inhibitors in BRCA\u000d\u000a      defective cell lines and proposed the first proof-of-principal Phase II\u000d\u000a      study investigating this aspect.\u000d\u000a    In 2010, the PARP research team won Cancer Research UK's Translational\u000d\u000a      cancer research prize\u000d\u000a      which \"...recognises a team who have made a significant impact on the\u000d\u000a        continuing effort to\u000d\u000a        prevent, diagnose and cure cancer, and whose research is at the cutting\u000d\u000a        edge of scientific novelty\"\u000d\u000a      (http:\/\/science.cancerresearchuk.org\/news\/prize-winners-2010-announced).\u000d\u000a      The intramural\u000d\u000a      Newcastle PARP team that initiated the project embraced medicinal\u000d\u000a      chemistry (Golding, Griffin),\u000d\u000a      molecular, cell and in vivo pharmacology (Curtin, 1989-date &#8212;\u000d\u000a        Professor of Experimental\u000d\u000a        Therapeutics; Newell, 1989-date &#8212; Professor of Cancer Therapeutics) and\u000d\u000a        medical oncology\u000d\u000a        (Calvert, 1990-2009 &#8212; Professor of Medical Oncology; Plummer &#8212; 2001-date\u000d\u000a        &#8212; Professor of\u000d\u000a        Experimental Cancer Medicine).\u000d\u000a    "},{"CaseStudyId":"21355","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"3017382","Name":"France"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"6252001","Name":"United States"}],"Funders":["Engineering and Physical Sciences Research Council","Science and Technology Facilities Council","Council for the Central Laboratory of the Research Councils"],"ImpactDetails":"\u000a    Station 9.8, with its unique design developed by Newcastle University\u000a      researchers, was the first dedicated facility of its kind in the world.\u000a      Its rapid and large oversubscription prompted the decision by SRS to\u000a      establish a second similar station by reallocation of an underused powder\u000a      diffraction beamline (16.2) a few years later. Both facilities operated\u000a      until mid-2008 and provided the model, inspiration and (through high\u000a      demand from users) justification for current facilities in the UK and\u000a      worldwide. Impact from commercial work using these facilities typically\u000a      develops over many subsequent years, as illustrated by specific examples\u000a      given below.\u000a    Impact on the development of other synchrotron facilities\u000a    The success of Station 9.8 led to the design principles being used\u000a      subsequently in plans for other similar facilities worldwide, particularly\u000a      the beamline I19 at Diamond Light Source (DLS), effectively a direct UK\u000a      replacement for Station 9.8 from 2008 [E1], and the Advanced Light Source\u000a      in California, USA (ALS, conversion of beamline 11.3.1 from threatened\u000a      closure in 2006 to the most productive beamline from 2009), and to the\u000a      successful cases for development of these facilities as a result of its\u000a      immense popularity and success. These two are the only current dedicated\u000a      beamlines of their kind in the world and are unrivalled in their output by\u000a      any shared- use facilities [E2, E3]; such other facilities include\u000a      beamlines at APS (USA) and Soleil (France), themselves influenced\u000a      indirectly by the design principles and the success of Station 9.8.\u000a    DLS is the largest UK Government-funded science project in a generation,\u000a      costing around &#163;400M in its construction to date and with an annual\u000a      operating budget rising from the initial &#163;23M in 2007-2008 as beamlines\u000a      are added; it provides a high level of employment and contribution to the\u000a      local economy. The I19 beamline had a construction budget of around &#163;5M\u000a      and its annual operating budget is &#163;430K excluding support for an average\u000a      of 3 PhD students per year; it has a full-time staff of 4 scientists and\u000a      technical support equivalent to 1.25 FTE.\u000a    In addition to providing the model for such facilities, the original\u000a      research has also produced leading scientists to manage and operate them.\u000a      Of grant-funded research staff employed for the construction and\u000a      commissioning stages of SRS 9.8, one is now Staff Scientist for ALS 11.3.1\u000a      (Dr Simon Teat, previously beamline scientist at SRS and Principal\u000a      Beamline Scientist for DLS I19), and another is a director of the\u000a      EPSRC-funded NCS (Dr Simon Coles). Major users\/beneficiaries of SRS 9.8\u000a      who are now in commercial and public service employment include Dr David\u000a      Allan (Principal Beamline Scientist for DLS I19), Dr Neil Feeder (Pfizer\u000a      then CCDC), and Dr Elizabeth Shotton (Industrial Liaison Manager, DLS).\u000a      Clegg has also helped provide training for over 150 staff and users of\u000a      synchrotron facilities from many countries through Synchrotron Radiation\u000a      Summer Schools, formerly at Chester\/Daresbury [E4 p.69] and currently at\u000a      Oxford\/Diamond.\u000a    Impact through commercial use of facilities\u000a    Around 10 commercial companies made use of SRS Station 9.8 up to 2008,\u000a      including all the major UK pharmaceutical firms; 5 companies from the\u000a      pharmaceutical and chemical sectors of UK industry currently use DLS\u000a      beamline I19 (one reason for the lower number is company mergers). These\u000a      companies are prepared to pay full-cost-recovery commercial rates for\u000a      access, since there is usually no other feasible way for them to obtain\u000a      vital structural information for the development and marketing of their\u000a      products when the available materials are poorly diffracting [E5].\u000a      Confidentiality agreements between the facilities and commercial customers\u000a      make it impossible to provide details of such usage, but we give some\u000a      examples here where results have been published or approved by company\u000a      representatives, or where the work is commercially-sponsored research by\u000a      academic partner teams; they are undoubtedly typical of other work. At\u000a      DLS, as previously at SRS, several days of beamtime in each 6-month\u000a      operating schedule are allocated to commercial work and a day of beamtime\u000a      can deliver up to 10 or more data sets, as an indication of overall usage.\u000a      Without the original Newcastle underpinning research, these opportunities\u000a      would probably not exist and the key structures would remain unknown.\u000a    For example, Organon (now Merck) used SRS 9.8 to investigate the\u000a      structure of a cyclodextrin complexed with a drug used as a neuromuscular\u000a      blocker, to confirm its mode of action. Sugammadex is now marketed as\u000a      Bridion; it was approved for use in the EU in 2008 and sales to date have\u000a      been around &#163;300M [E6; E4 pp. 7 &amp; 93].\u000a    Roche Discovery Welwyn, part of Hoffman LaRoche, carried out structural\u000a      studies at SRS 9.8, concentrating on active pharmaceutical ingredients,\u000a      intermediates and impurities in support of anti-inflammatory and\u000a      anti-viral programmes. This work contributed to the development of the\u000a      influenza neuraminidase inhibitor Tamiflu (oseltamivir phosphate) and the\u000a      first-generation HIV protease inhibitor Invirase (saquinavir mesylate),\u000a      both originally licensed for use in the 1990s and in continued use today\u000a      [E7]. Tamiflu has had particularly high public profile and impact in\u000a      recent years as a major treatment during several big flu outbreaks around\u000a      the world. In the UK alone the NHS has spent an average of around &#163;70M per\u000a      year maintaining stocks of Tamiflu; annual worldwide sales peaked in 2009\u000a      and 2010 at around &#163;550M, then reduced by over 50%.\u000a    Commercial use of the SRS facilities was taken over by DLS I19 beamline\u000a      from 2009. Anhydrous sodium diclofenac was a key structure obtained by\u000a      SAFC Pharmorphix (Sigma-Aldrich) using DLS I19, enabling a thorough study\u000a      of relative stability of hydrates and other crystalline forms of this\u000a      common painkiller, which is one of the top 100 drugs in international use,\u000a      with an estimated annual value of about &#163;820M in 2009 [E7, E8 p.5, E9].\u000a      This work is typical of polymorphism and solvate studies carried out by\u000a      pharmaceutical companies, requiring synchrotron facilities for unstable\u000a      and poorly crystalline forms of important drugs and drug candidates in\u000a      order to secure and protect intellectual property rights attributable to\u000a      particular solid forms [E7].\u000a    Other major pharmaceutical firms who have confirmed their use of these\u000a      facilities in order to obtain or improve vital drug development structures\u000a      and to support regulatory and patent processes are Pfizer and\u000a      GlaxoSmithKlyne.\u000a    Impact through commercialisation or Government use of academic\u000a        research\u000a    Zeolites and metal-organic framework materials studied by St Andrews\u000a      chemists at SRS, DLS and ALS have led to Chevron Texaco patents on two\u000a      materials, SSZ-23 and SSZ-51, for use in oil refineries, three patents\u000a      related to storage and release of nitric oxide, and two spin-out\u000a      companies, Zeomedix LLC (started in 2009 with over $1M of external\u000a      investment to date) and MOFgen Ltd (started in 2013 with 14 commercial\u000a      agreements with other companies) [P3, E4 p.51, E10]. Metal-organic\u000a      frameworks have become popular research projects, of interest for\u000a      potential in hydrogen and other gas storage and energy applications. Work\u000a      is often industrially sponsored, such as that by Nottingham University\u000a      supported by General Motors [E7, p.17].\u000a    ALS 11.3.1 is used in projects of the US Department of Energy, including\u000a      gas separations for clean air technology, extraction of uranium from sea\u000a      water, and nuclear reprocessing [E2].\u000a    ","ImpactSummary":"\u000a    This case study describes impact from the Newcastle-led research project\u000a      to construct the world's first dedicated single-crystal diffraction\u000a      synchrotron beamline for chemistry and materials science at Daresbury\u000a      Laboratory Synchrotron Radiation Source (SRS). The result was an\u000a      innovative and productive facility that has served as the model for the\u000a      development of other facilities internationally, especially at Diamond\u000a      Light Source (UK) and the Advanced Light Source (USA). The original\u000a      Newcastle University research has helped produce scientists now employed\u000a      by industry and public service sectors around the world. Major new and\u000a      beneficial drugs and catalysts have been developed with the aid of the\u000a      synchrotron beamlines and work conducted at these facilities has been\u000a      critically important for the advancement of the global chemical and\u000a      pharmaceutical industries and US Government energy development programmes.\u000a    ","ImpactType":"Technological","Institution":"\u000a    Newcastle University\u000a    ","Institutions":[{"AlternativeName":"Newcastle upon Tyne (University of)","InstitutionName":"Newcastle University","PeerGroup":"A","Region":"North East","UKPRN":10007799}],"Panel":"B         ","PlaceName":[],"References":"\u000a    \u000a[P1] Cernik, R. J., Clegg, W., Catlow, C. R. A., Bushnell-Wye, G.,\u000a      Flaherty, J. V., Greaves, G. N., Burrows, I., Taylor, D.J., Teat, S.J.,\u000a      &amp; Hamichi, M. (1997). A new high-flux chemical and materials\u000a      crystallography station at the SRS Daresbury. 1. Design, construction and\u000a      test results. J. Synchrotron Rad. 4, 279-286. Corrigendum J.\u000a        Synchrotron Rad. (2000), 7, 40. The principal technical\u000a        description of the SRS facility.190 citations. [* Key reference]\u000a    \u000a\u000a[P2] Clegg, W. (2000). Synchrotron chemical crystallography. J. Chem.\u000a        Soc. Dalton Trans. 3223-3232. Describes the context of the\u000a        research, with specific references to the use of the SRS facility.\u000a      46 citations.\u000a    \u000a\u000a[P3] Camblor, M. A., D&#237;az-Caba&#241;as, M. J., Perez-Pariente, J., Teat, S.\u000a      J., Clegg, W., Shannon, I. J., Lightfoot, P., Wright, P. A. &amp; Morris,\u000a      R. E. (1998). SSZ-23: an odd zeolite with pore openings of seven and nine\u000a      tetrahedral atoms. Angew. Chem. Int. Ed. Engl. 37, 2122-2126. Early\u000a        publication of results from the initial project &amp; an example of work\u000a        that has led to commercial impact. 68 citations. [* Key\u000a      reference]\u000a    \u000a\u000a[P4] Li, X.-C., Sirringhaus, H., Garnier, F., Holmes, A. B., Moratti, S.\u000a      C., Feeder, N., Clegg, W., Teat, S. J. &amp; Friend, R. H. (1998). A\u000a      highly f070-stacked organic semiconductor for thin film transistors based\u000a      on fused thiophenes. J. Am. Chem. Soc. 120, 2206-2207. Early\u000a        publication of results from the initial project. 320 citations. [*\u000a      Key reference]\u000a    \u000a\u000a[P5] Hamilton, D. G., Sanders, J. K. M., Davies, J. E., Clegg, W., &amp;\u000a      Teat, S. J. (1997). Neutral [2] catenanes from oxidative coupling of\u000a      f070-stacked components. Chem. Commun. 897-898. Early\u000a        publication of results from the initial project. 76 citations.\u000a    \u000a\u000a[P6] Francis, R.J., Drewitt, M. J., Halasyamani, P. S., Ranganathachar,\u000a      C., O'Hare, D., Clegg, W. &amp; Teat, S. J. (1998). Organically templated\u000a      layered uranium(VI) phosphates: hydrothermal syntheses and structures of\u000a      [NHEt3][(UO2)2(PO4)(HPO4)]\u000a      and [NPr4][(UO2)3(PO4)(HPO4)2].\u000a      Chem. Commun. 279-280. Early publication of results from the\u000a        initial project. 52 citations.\u000a    \u000aKey grants awarded to Newcastle University:\u000a    W. Clegg (PI), C. R. A. Catlow (CI; Royal Institution). A high-flux\u000a      synchrotron station for single-crystal diffraction. EPSRC. 1994-1997.\u000a      &#163;1,283,069.\u000a    W. Clegg. CLRC Joint Appointment. CCLRC. 1995-1998. &#163;68,500.\u000a    W. Clegg. National X-ray Crystallography Service: a synchrotron\u000a      component. EPSRC. 2001-2006. &#163;527,964.\u000a    W. Clegg. Joint Appointment at Daresbury Laboratory. CCLRC. 2001-2007.\u000a      &#163;84,467.\u000a    W. Clegg. National Crystallography Service 2006 renewal. EPSRC.\u000a      2006-2010. &#163;345,239.\u000a    Quality assurance:\u000a    All the EPSRC grant final reports were recognised as Outstanding and\u000a      Internationally Leading; the NCS synchrotron component was singled out by\u000a      reviewers for special commendation.\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"}],"Sources":"\u000a    [E1] Nowell,\u000a      H., Barnett,\u000a      S. A., Christensen, K. E., Teat, S. J. &amp; Allan, D. R. (2012). I19, the\u000a      small-molecule single-crystal diffraction beamline at Diamond Light\u000a      Source. J. Synchrotron Rad. 19, 435-441\u000a    [E2] Supporting statement: Staff Scientist at Advanced Light Source\u000a      (formerly Principal Beamline Scientist at SRS and at Diamond Light Source)\u000a    [E3] Supporting statement: Principal Beamline Scientist at DLS\u000a    [E4] New Light on Science: The Social &amp; Economic Impact of the\u000a      Daresbury Synchrotron Radiation Source 1981-2008. Science &amp; Technology\u000a      Facilities Council (2010). https:\/\/www.stfc.ac.uk\/resources\/PDF\/SRSImpact.pdf\u000a    [E5] Supporting statement: Industrial Liaison Manager at DLS (and\u000a      previously at SRS)\u000a    [E6] Bom, A., Bradley, M., Cameron, K., Clark, J. K., van Egmond, J.,\u000a      Feilden, H., MacLean, E. J., Muir, A. W., Palin, R., Rees, D. C. &amp;\u000a      Zhang, M.-Q. (2002). A novel concept of reversing neuromuscular block:\u000a      chemical encapsulation of rocuronium bromide by a cyclodextrin-based\u000a      synthetic host. Angew. Chem. Int. Ed. Engl. 41, 265-270\u000a    [E7] Supporting statement: Chief Scientific Officer at SAFC Pharmorphix\u000a      Solid-State Services\u000a    [E8] Diamond Industrial Liaison Office case studies. DLS, 2013. http:\/\/www.diamond.ac.uk\/Home\/industry\/casestudies.html\u000a    [E9] Top 200 Pharmaceutical Products by Worldwide Sales in 2009. Poster.\u000a      (Diclofenac is 86th) http:\/\/cbc.arizona.edu\/njardarson\/group\/sites\/default\/files\/Top200PharmaceuticalProductsByWorld\u000a        wideSalesin2009.pdf\u000a    [E10] Supporting statement from Professor of Chemistry, EASTCHEM, St\u000a      Andrews University\u000a    ","Title":"\u000a    International synchrotron facilities for crystal structure determination\u000a    ","UKLocation":[{"GeoNamesId":"2640729","Name":"Oxford"},{"GeoNamesId":"2634552","Name":"Welwyn Garden City"},{"GeoNamesId":"2653228","Name":"Chester"},{"GeoNamesId":"2641673","Name":"Newcastle-upon-Tyne"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Crystal structure determination is crucial to our understanding of the\u000a      properties of materials and is of fundamental importance in physical and\u000a      life sciences. The technique faces ever-increasing demands for the study\u000a      of more complex molecular systems. The years 1994-1997 were the main\u000a      period of a major Newcastle-led research project to design, construct and\u000a      commission a single-crystal diffraction beamline (Station 9.8) at the SRS,\u000a      recognising the need for a facility that could greatly extend the range of\u000a      materials not otherwise amenable to conventional laboratory equipment.\u000a      Before Station 9.8 was built there were no dedicated facilities available\u000a      for the study of crystals with one or more dimensions on the micron scale\u000a      or other very weak scatterers, as laboratory facilities were not\u000a      sufficient, and so many important structural insights were lost.\u000a    The project team, led by Clegg, designed and set up Station 9.8 using a\u000a      modified laboratory diffractometer and detector system with X-ray optical\u000a      components in a novel combination to ensure that the equipment would\u000a      function successfully with the synchrotron source and also to combat\u000a      constraints of the available space. Other challenges overcome were the\u000a      needs for appropriate control and processing procedures and software, and\u000a      requirements for handling a wide range of samples, including air-sensitive\u000a      materials, to ensure maximum applicability [P1]. A primary objective was\u000a      to offer a familiar setup to a non-specialist first-time synchrotron user.\u000a    Overall project leadership and direction was maintained throughout by\u000a      Clegg, on site half-time at Daresbury from 1995 to 1998 through formal\u000a      Joint Appointments financed as research grants to Newcastle University to\u000a      cover 50% of salary costs; he was responsible for key decisions regarding\u000a      the choice of equipment, software and postdoctoral staffing as well as\u000a      conducting the extensive commissioning work using samples provided by\u000a      chemists from around the UK and abroad. Station 9.8 was the first\u000a      dedicated facility of its kind anywhere in the world [P2] and has enjoyed\u000a      immense success and productivity from the first commissioning data\u000a      measurement. In 1997, in accordance with the original plan and EPSRC grant\u000a      conditions, it was formally handed over by Newcastle University as a full\u000a      SRS user facility, on schedule, within budget, and with performance\u000a      exceeding the design specifications. It quickly became one of the most\u000a      heavily oversubscribed beamlines at Daresbury, with academic and\u000a      commercial users, generating between 10 and 20% of SRS-based publications\u000a      in subsequent years [P3, P4, P5 &amp; P6].\u000a    Continued use of the facility beyond 1997, and of its direct successor at\u000a      Diamond Light Source after 2008, by Clegg's Newcastle research group\u000a      included the establishment of a synchrotron-based component of the EPSRC\u000a      National Crystallography Service (NCS) in 2001, which further raised the\u000a      profile of the beamline and introduced its benefits to a wide range of UK\u000a      chemists, some of whom subsequently became commercial users, while others\u000a      were carrying out research projects with industrial partners; this\u000a      attraction of a large user community contributed hugely to the success of\u000a      the proposal to construct Diamond beamline I19.\u000a    "},{"CaseStudyId":"25834","Continent":[{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1861060","Name":"Japan"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000a    Current practices for therapeutic management of asthma and chronic\u000a      obstructive pulmonary disease (COPD) rely heavily on treatment with\u000a      corticosteroids and 03b22-agonists, the former to control\u000a      underlying inflammatory dysfunction and the latter to afford symptomatic\u000a      relief for airway constriction. However, long-term use of corticosteroids\u000a      can produce adverse side effects, and the safety of long-acting &#946;2-agonists\u000a      is also currently under scrutiny. New safer and effective options for the\u000a      treatment of respiratory disease are therefore highly significant in their\u000a      potential societal and economic impact.\u000a    To pursue this goal, in 2000 Kyorin entered into an agreement with\u000a      Scottish Biomedical (SB), a technology management company founded jointly\u000a      by Scottish Universities in 1994, to set up a PDE biology research\u000a      facility, the Kyorin-Scotland Research Laboratory (KSRL), with an initial\u000a      project of &#163;5.2M. Consultancy oversight came from Prof. Miles Houslay\u000a      (University of Glasgow), one of the foremost authorities in the global PDE\u000a      biology community, while the medicinal chemistry direction was provided by\u000a      Adams. KSRL functioned to screen compounds initially provided largely by\u000a      Adams' medicinal chemistry group and the promising activity of emerging\u000a      compounds was central to the success of this initial programme, which\u000a      cemented the Kyorin-SB partnership. According to a senior manager of\u000a      Scottish Biomedical:\u000a    \"Prof Adams' group provided compound series and informed advice on all\u000a        aspects of the medicinal chemistry associated with the SB\/Kyorin\u000a        project. Prof Adams was one of the academic advisors employed for the\u000a        original project. His role allowed Kyorin to be confident that the\u000a        chemistry element of the project was being managed well and that\u000a        informed advice for the critical decision stages was available. Prof\u000a        Adams continued to play a vital role in the success of the first PDE\u000a        project which allowed a follow up project 3 years later. Prof Adams\u000a        contribution was essential to the success of the PDE programme (that)...\u000a        helped cement the partnership between Kyorin and SB.\"\u000a    In July 2002 a second &#163;5.2M project by Kyorin was agreed to extend the\u000a      KSRL portfolio to development of therapeutics for type 2 diabetes, and the\u000a      respiratory disease programme was extended for 3 years with a further\u000a      tranche of funding (&#163;4.5M) from 2003. Adams contributed medicinal\u000a      chemistry support throughout the period to 2006, eventually assisting SB\u000a      with the appointment of their own medicinal chemistry team. This completed\u000a      the transition of SB to a fully independent preclinical drug discovery\u000a      services company [text removed for publication].\u000a    The Adams group played an important role in establishing the PDE\u000a      medicinal chemistry research direction for Kyorin, and the success of the\u000a      work provided the basis for a major PDE drug development programme at\u000a      Kyorin's central Discovery Research Laboratories from 2004 and through the\u000a      current REF assessment period, employing 3 chemists and 6 biologists to\u000a      develop the work begun at HWU. The programme has generated 22 patents (18\u000a      published within the current REF assessment period) with a direct link to\u000a      the foundational work and direction contributed by HWU. A senior manager\u000a      at Kyorin's Discovery Research Laboratory in Japan stated that:\u000a    \"The work undertaken at Heriot-Watt University provided a substantive\u000a        benefit to Kyorin's PDE programme.\"\u000a    Throughout the current REF period Adams has continued to work with\u000a      Kyorin, developing a multi- part series of papers to disclose details of\u000a      the PDE programme and raise the company profile.1-6 These\u000a      papers evince the impact of the work performed in the Adams group in\u000a      shaping the direction of Kyorin's PDE programme. The success of the PDE\u000a      programme and establishment of a partnership with SB was also\u000a      strategically important to Kyorin in establishing a research network and\u000a      presence in Europe.\u000a    There is still considerable scope for bringing new best-in-class PDE4\u000a      inhibitors to the market as drugs with improved efficacy and reduced side\u000a      effect profiles for a range of inflammatory conditions in the respiratory\u000a      field and beyond. The first PDE4-selective inhibitor to reach the market,\u000a      roflumilast, was developed by the competitor company, Nycomed. Roflumilast\u000a      is indicated as a treatment for a subset of severe COPD cases and was\u000a      approved in the EU only in June 2010. It was subsequently also approved by\u000a      the FDA for use in the US (March 2011). A second PDE4 inhibitor,\u000a      apremilast from Celgene, will be launched in the near future as treatment\u000a      for psoriatic arthritis, with predicted annual sales of $1.5-2bn by 2017.\u000a      The global market for asthma\/COPD drugs, $38bn pa in 2012, is set to rise\u000a      to $47bn pa by 2017 [BCC Research]. Kyorin's own PDE programme therefore\u000a      remains an important asset in its portfolio of inflammatory and\u000a      respiratory disease research.\u000a    ","ImpactSummary":"\u000a    Phosphodiesterase (PDE) research by Prof. David Adams of Heriot-Watt\u000a      University (HWU) has discovered compounds with potent combined\u000a      anti-inflammatory and bronchorelaxant activity, relevant to asthma and\u000a      chronic obstructive pulmonary disease (COPD). This fuelled a major\u000a      therapeutic development programme by the Japanese company, Kyorin\u000a      Pharmaceutical Co. Ltd, resulting in 22 patents (18 published since 2008)\u000a      with a direct link to the foundational work at HWU. The work was a key\u000a      factor in Kyorin's continued commissioning of projects with Scottish\u000a      Biomedical (SB) up to &#163;14.9M, a technology management company founded by\u000a      Scottish Universities, enabling SB's transition into a fully independent\u000a      drug-discovery services company, [text removed for publication].\u000a    ","ImpactType":"Health","Institution":"\u000a    Heriot Watt University\u000a    ","Institutions":[{"AlternativeName":"Heriot-Watt University","InstitutionName":"Heriot-Watt University","PeerGroup":"B","Region":"Scotland","UKPRN":10007764}],"Panel":"B         ","PlaceName":[],"References":"\u000a    (* = best indicates the quality of the underpinning research)\u000a\u0009\u000a[1]* K. A. Johnston, R. W. Allcock, Z. Jiang, I. D. Collier, H. Blakli,\u000a      G. M. Rosair, P. D. Bailey, K. M. Morgan, Y. Kohno and D. R. Adams \"Concise\u000a        routes to pyrazolo[1,5-a]pyridin-3-yl pyridazin-3-ones.\" Org.\u000a      Biomol. Chem. 2008, 6, 175-186. [doi: http:\/\/dx.doi.org\/10.1039\/b713638b]\u000a    \u000a\u000a[2]* R. W. Allcock, H. Blakli, Z. Jiang, K. A. Johnston, K. M. Morgan, G.\u000a      M. Rosair, K. Iwase, Y. Kohno and D. R. Adams \"Phosphodiesterase\u000a        inhibitors. Part 1: Synthesis and structure-activity relationships of\u000a        pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast.\"\u000a      Bioorg. Med. Chem. Lett. 2011, 21, 3307-12. [doi: http:\/\/dx.doi.org\/10.1016\/j.bmcl.2011.04.021]\u000a    \u000a\u000a[3]* K. Ochiai, N. Ando, K. Iwase, T. Kishi, K. Fukuchi, A. Ohinata, H.\u000a      Zushi, T. Yasue, D. R. Adams, and Y. Kohno \"Phosphodiesterase\u000a        inhibitors. 2: Design, synthesis and structure-activity relationships of\u000a        dual PDE3\/4-inhibitory pyrazolo [1,5-a]pyridines with anti-inflammatory\u000a        and bronchodilatory activity.\" Bioorg. Med. Chem. Lett. 2011, 21,\u000a      5451-46. [doi: http:\/\/dx.doi.org\/10.1016\/j.bmcl.2011.06.118]\u000a    \u000a\u000a[4] K. Ochiai, S. Takita, T. Eiraku, A. Kojima, K. Iwase, T. Kishi, K.\u000a      Fukuchi, T. Yasue, D. R. Adams, R. W. Allcock, Z. Jiang and Y. Kohno \"Phosphodiesterase\u000a        inhibitors. Part 3: Design, synthesis and structure-activity\u000a        relationships of dual PDE3\/4-inhibitory fused bicyclic\u000a        heteroaromatic-dihydropyridazinones with anti-inflammatory and\u000a        bronchodilatory activity.\" Bioorg. Med. Chem. 2012, 20, 1644-58.\u000a      [doi: http:\/\/dx.doi.org\/10.1016\/j.bmc.2012.01.033].\u000a    \u000a\u000a[5] K. Ochiai, S. Takita, A. Kojima, T. Eiraku, N. Ando, K. Iwase, T.\u000a      Kishi, A. Ohinata, Y. Yageta, T. Yasue, D. R. Adams and Y. Kohno \"Phosphodiesterase\u000a        inhibitors. Part 4: Design, synthesis and structure-activity\u000a        relationships of dual PDE3\/4-inhibitory fused bicyclic\u000a        heteroaromatic-4,4-dimethylpyrazolones.\" Bioorg. Med. Chem. Lett.\u000a      2012, 22, 5833-38. [http:\/\/dx.doi.org\/10.1016\/j.bmcl.2012.07.088]\u000a    \u000a\u000a[6] K. Ochiai, S. Takita, A. Kojima, T. Eiraku, K. Iwase, T. Kishi, A.\u000a      Ohinata, Y. Yageta, T. Yasue, D. R. Adams and Y. Kohno \"Phosphodiesterase\u000a        inhibitors. Part 5: Hybrid PDE3\/4 inhibitors as dual\u000a        bronchorelaxant\/anti-inflammatory agents for inhaled administration.\"\u000a      Bioorg. Med. Chem. Lett. 2012, 22, 375-81. [http:\/\/dx.doi.org\/10.1016\/j.bmcl.2012.08.121].\u000a    \u000aGrants\u000a    Medical Research Council MRC\/G0400053, &#163;1.9m, 1\/10\/2006, 48 months;\u000a      Exploration of PDE4 structure and function (PI Houslay, with Adams a named\u000a      collaborator)\u000a    Thera-cAMP (EU FP6\/037189), 1\/10\/2006 - 30\/9\/2009; Identification of\u000a      therapeutic molecules to target compartmentalised cAMP signalling networks\u000a      in human disease (PI Houslay, with Adams a named collaborator)\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"15","Subject":"Pharmacology and Pharmaceutical Sciences"},{"Level1":"6","Level2":"1","Subject":"Biochemistry and Cell Biology"}],"Sources":"\u000a    A senior manager, SB Drug Discovery\u000a    A senior manager, Discovery Research Laboratories, Kyorin Pharmaceutical\u000a      Co., Ltd.\u000a    Press releases from The Scotland Office (09\/07\/01) and Kyorin\u000a      Pharmaceutical Co., Ltd (31\/07\/02).\u000a    Newspaper articles from The Sunday Herald (12\/11\/00 and 01\/07\/0), The\u000a      Scotsman (01\/08\/2002 and 27\/11\/03) and The Herald (01\/08\/02).\u000a    ","Title":"\u000a    Inhibitors for respiratory disease\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate\u000a      (cGMP) are key messenger molecules that are vital to cell function. The\u000a      intracellular levels of these species are regulated by as many as 11\u000a      phosphodiesterase gene families (PDE1-11). Prof. David Adams has worked on\u000a      phosphodiesterase at HWU for &gt;13 years and has collaborated with\u000a      internationally leading molecular biology groups to unravel key aspects of\u000a      PDE regulation and subcellular targeting. Work on mapping protein-binding\u000a      interfaces on PDE4 for key signalling complexes has been funded by MRC, EU\u000a      and Scottish Enterprise and has been carried out in collaboration with the\u000a      Houslay group (Glasgow and Strathclyde Universities).\u000a    PDE4 inhibitors have long been known to exhibit good anti-inflammatory\u000a      activity and modest bronchodilatory activity, and this prompted interest\u000a      in their development as a treatment option for respiratory disease. In the\u000a      1980s Kyorin developed ibudilast for use in asthma therapy and stroke in\u000a      Japan, the drug's pharmacological activity issuing, in part, from it being\u000a      a non-selective PDE inhibitor. Kyorin further developed the drug in the\u000a      1990s by coupling the ibudilast pyrazolopyridine core to a pyridazinone to\u000a      provide a new prototype compound, KCA-965. However, it remained unclear\u000a      what overall PDE-inhibitory profile was optimal for achieving dual\u000a      anti-inflammatory and bronchodilatory action in a single compound. The\u000a      company therefore sought partnerships and as part of this between 2000 and\u000a      2006 they awarded ca. &#163;1.8M to Adams, allowing him to establish a\u000a      medicinal chemistry programme to develop PDE inhibitors from KCA-965.\u000a    Having developed appropriate synthetic methodology,1 Adams\u000a      brought a hypothesis-driven medicinal chemistry approach to develop a\u000a      series of novel pyrazolopyridine-pyridazinone inhibitors for enzymes of\u000a      the PDE3 and PDE4 families. By undertaking a structure-activity\u000a      relationship survey and employing conformationally constrained molecular\u000a      probes, the Adams group discovered that compounds within the series bind\u000a      to the catalytic pocket of PDE3 and PDE4 enzymes in a fundamentally\u000a      distinct manner, and that optimisation required structural reorganisation\u000a      of the pyrazolopyridine-pyridazinone core.2 This discovery\u000a      allowed the activity of compounds to be fine-tuned so as to provide either\u000a      potent selective PDE4 inhibitors or dual PDE3\/4-selective inhibitors with\u000a      promising biological activity.\u000a    An important feature of the programme at HWU was that it provided the\u000a      molecular tools to investigate the pharmacological benefit from targeting\u000a      both PDE3 and PDE4. At the outset of the work PDE4 inhibitors were already\u000a      known to exhibit modest bronchodilatory activity in addition to possessing\u000a      good anti-inflammatory activity. The bronchodilatory activity arises\u000a      because PDE inhibition leads to elevated cAMP levels in the airway smooth\u000a      muscle and so promotes relaxation. Both PDE4 and PDE3 mediate cAMP\u000a      hydrolysis, however, and inhibition of PDE3 is more effective than\u000a      inhibition of PDE4 for inducing airway smooth muscle relaxation. By\u000a      unlocking the structural determinants that control PDE3- and\u000a      PDE4-inhibitory selectivity in the HWU chemical series it was possible to\u000a      develop compounds with promising dual anti-inflammatory and\u000a      bronchorelaxant activity.2-6\u000a    Biological assessment of the compounds developed from the Adams group\u000a      medicinal chemistry programme was undertaken by the Kyorin-Scotland\u000a      Research Laboratory (KSRL), a facility set up in 2000 between Scottish\u000a      Biomedical (SB) and Kyorin with an initial &#163;5.2M investment.\u000a    "},{"CaseStudyId":"25835","Continent":[],"Country":[],"Funders":["Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000a    NiTech Solutions Ltd was spun off from Heriot-Watt University in Dec\u000a      2004, aided by a SMART\u000a      award from Scottish Enterprise, with plug-flow crystallisation and\u000a      reaction as the key technologies\u000a      for chemical, pharmaceutical and food industries. A second SMART award on\u000a      continuous\u000a      crystallisation supported Dr Anting Liao, Xiongwei Ni's ex-PhD student\u000a      from HWU, to be employed\u000a      at NiTech to carry out the designed trials. Excellent results were\u000a      generated; for example,\u000a      consistent crystal morphology\/size distribution\/enhanced yield,\u000a      significantly reduced process time\u000a      and waste, and elimination of the use of milling machines. An example of\u000a      the impact of the\u000a      technology is the continuous crystallisation of one of the AstraZeneca's\u000a      blockbuster drug\u000a      ingredients. In their operation in traditional crystallisers, it takes 9\u000a      hours and 40 minutes for the\u000a      crystallisation step; the filtration rate is poor because of uneven sizes\u000a      of crystals generated due to\u000a      the difficulties, identified above, of controlling the crystallisation\u000a      environment. In order to obtain the\u000a      required size a milling machine is used as one of the key downstream unit\u000a      operations. When\u000a      applying NiTech continuous crystallising technology, the overall process\u000a      was shown to take only 12\u000a      minutes with uniform sizes, enhanced filtration rates (which eliminate the\u000a      use of the milling\u000a      machine) and significant savings in capital and operational costs (see ref\u000a      [6] above).\u000a    Another leading example is the production of a biopharmaceutical drug in\u000a      Genzyme (now Sanofi).\u000a      In less than two years from conception in 2005, full production was\u000a      commissioned at the Haverhill\u000a      site in April 2007 after successful trials and design at NiTech as well as\u000a      the certification of the\u000a      process by the FDA. NiTech technology was used to launch production of a\u000a      new active\u000a      pharmaceutical ingredient (API) via a three-phase reaction on the scale of\u000a      multi-hundred tons p.a.\u000a      with a value of multi-&#163;100M p.a. The reaction is approximately 40 times\u000a      faster than a batch\u000a      process, with good flexibility to control throughput. The reactor was able\u000a      to fit into a small footprint\u000a      in an existing building, avoiding the traditional alternative of two large\u000a      pressure reactors and a new\u000a      building. There was a resultant saving of several million pounds in\u000a      capital expenditure and\u000a      approximately four times faster construction. Simplicity of operation and\u000a      reduced maintenance\u000a      costs have been sustained. Product quality is higher, with the ability to\u000a      continuously monitor and\u000a      control the reaction leading to a zero reject rate for this reaction step,\u000a      all contributing to a\u000a      competitive commercial advantage. Quoting a Senior Manager of Genzyme:\u000a    \"This is believed to be the largest scale continuous manufacturing\u000a        plant for a patented API in the\u000a        world. Importantly, we were able to supply the market many months\u000a        earlier than would have been\u000a        the case with conventional batch processing. This was one of the best\u000a        investment decisions that I\u000a        have made! \"\u000a    [text removed for publication]\u000a    NiTech has filed key patents on continuous crystallisation, worked with a\u000a      large number of chemical,\u000a      food and pharmaceutical companies on continuous crystallisation, including\u000a      seven out of the top\u000a      ten global pharma giants and two out of the top three global food\u000a      companies on edible oils. It has\u000a      received investments over &#163;3M and employed more than 16 people.\u000a    Following discussions between NiTech, GSK, and members of the ScotCHEM\u000a      research pooling\u000a      and Chemical Sciences Scotland industry-academia collaborative initiatives\u000a      on how to further\u000a      exploit this technology, a joint demonstration project was established in\u000a      mid-2009. GSK provided\u000a      `model' crystallisation process and materials. Outstanding results were\u000a      obtained in these trials. It\u000a      was seen as an opportunity for Scotland to take the lead in meeting the\u000a      challenges facing chemical\u000a      manufacturing globally. This led to continuous crystallisation being the\u000a      platform technology in the\u000a      GSK-led Continuous Manufacture and Crystallisation (CMAC) consortium. CMAC\u000a      was established\u000a      in 2010 with &#163;1M cash injection and &#163;1M in kind each from GSK,\u000a      AstraZeneca and Novartis as the\u000a      tier-one members, plus &#163;250k from tier two members including Fujifilm,\u000a      Genzyme, Croda,\u000a      Syngenta, Evonik, NiTech itself and others. In 2010\/11, NiTech changed its\u000a      business model to\u000a      become an integrator and facilitator, focussing on collaboration with an\u000a      engineering company\u000a      rather than manufacturing the reactors itself. It is a critical part of\u000a      CMAC, indeed, according to a\u000a      member of the Board\u000a    \"NiTech's technology is the technology that started it all off\".\u000a    CMAC has now grown into a &gt;&#163;60M consortium with research grants from\u000a      EPSRC Centre for\u000a      Innovative Manufacturing (&#163;9.1M), ESPRC DTC (&#163;6.9M), Scottish Funding\u000a      Council (&#163;1.5M), TSB\u000a      (1.75M), EPSRC ICT Platform (&#163;4M), EU (&#163;0.5M), and EPSRC RPIF (&#163;34M). CMAC\u000a      is now the\u000a      largest and the most comprehensive centre in the world on continuous\u000a      crystallisation. It is focused\u000a      on helping industry to evaluate and trial leading edge process solutions\u000a      against their requirements\u000a      and to accelerate the introduction of new process-intensification\u000a      technologies to meet wider\u000a      industry needs.\u000a    ","ImpactSummary":"\u000a    Research at Heriot-Watt University (HWU) has led to the development of a\u000a      new continuous\u000a      oscillatory baffled reactor and crystalliser technology. This has direct\u000a      economic and environmental\u000a      impact in the chemical, pharmaceutical and food industries. Waste is\u000a      substantially reduced, while\u000a      the scale of the equipment and plant is dramatically decreased, reducing\u000a      time to market, start-up\u000a      and maintenance costs and on-going energy usage. The reactor\/crystalliser\u000a      was taken to market\u000a      through a spinout, NiTech Solutions Ltd, with a peak of 16 employees in\u000a      the REF period. Genzyme\u000a      (now Sanofi) has implemented NiTech's technology for biopharmaceutical\u000a      manufacture since\u000a      2007, with multi-100 ton production and sales of multi-&#163;100M pa. The\u000a      technology now underpins\u000a      the larger-scale joint venture, the Continuous Manufacture and\u000a      Crystallisation (CMAC) consortium,\u000a      launched in 2010. CMAC has attracted over &#163;60M investment, much of it from\u000a      three major\u000a      industrial partners, GSK, AstraZeneca and Novartis, with additional\u000a      second-tier investors. CMAC is\u000a      accelerating the introduction of new process-intensification technologies\u000a      in the process industries.\u000a    ","ImpactType":"Technological","Institution":"\u000a    Heriot Watt University\u000a    ","Institutions":[{"AlternativeName":"Heriot-Watt University","InstitutionName":"Heriot-Watt University","PeerGroup":"B","Region":"Scotland","UKPRN":10007764}],"Panel":"B         ","PlaceName":[],"References":"\u000a    (* = best indicates the quality of the underpinning research)\u000a    \u000a1.* Ni X and Pereira NE, Parameters affecting fluid dispersion in a\u000a        continuous oscillatory\u000a        baffled tube. AIChemE Journal 46: 37-45 (2000). \u000a\u0009\u0009http:\/\/dx.doi.org\/10.1002\/aic.690460106\u000a    \u000a\u000a2. Ni X, Jian H and Fitch AW, Evaluation of turbulent integral length\u000a        scale in an oscillatory\u000a        baffled column using large-eddy simulation and digital particle image\u000a        velocimetry. Trans\u000a        IChemE 81: 842-853 (2003). http:\/\/dx.doi.org\/10.1205\/026387603322482086\u000a    \u000a\u000a3. Ni X, Valentine A, Liao A, Sermage SBC, Thomson GB and Roberts KJ, On\u000a        the crystal polymorphic forms of L-glutamic acid following temperature programmed\u000a        crystallisation in a batch oscillatory baffled crystalliser. Crystal Growth and\u000a        Design 4: 1129-1135 (2004).\u000a      http:\/\/dx.doi.org\/10.1021\/cg049827l\u000a    \u000a\u000a4.* Ni X and Liao A, Effects of cooling rate and solution\u000a        concentration on solution crystallisation\u000a        of L-glutamic acid in an oscillatory baffled crystalliser. Crystal\u000a        Growth and Design 8: 2875-2881\u000a      (2008). http:\/\/dx.doi.org\/10.1021\/cg7012039\u000a    \u000a\u000a5. Ni X, Laird I and Liao A, Improved apparatus and method for\u000a        temperature controlled processes. EU patent WO 2007060412 A8 (22 November 2006).\u000a    \u000a\u000a6.* Lawton S, Steele G, Shering P, Zhao L, Laird I and Ni X, Continuous\u000a        crystallisation of\u000a        pharmaceuticals using a continuous oscillatory baffled crystalliser.\u000a      Organic Process\u000a        Research &amp; Development 13: 1357-1363 (2009). http:\/\/dx.doi.org\/10.1021\/op900237x\u000a    \u000aResearch grants:\u000a    1998 - 2001 EPSRC GR\/M31309\/01 &#163;233,423 with Bonar Polymers Ltd\u000a      and Professor David\u000a      Sherrington of Chemistry, Strathclyde University on application of the\u000a        oscillatory baffled reactor to\u000a        continuous polymerisation processes\u000a    2000 - 2003 EPSRC GR\/M63447\/01 &#163;193,175 on fluid flow\u000a        measurement using high resolution\u000a        digital particle image velocimetry\u000a    2000 - 2002 &#163;36,000 Yorkshire Water on continuous coagulation\u000a        using an oscillatory baffled\u000a        Reactor\u000a    2003 - 2003 &#163;100,000 Department of Trade and Industry (DTI) and\u000a      James Robinson Ltd on\u000a      continuous production of a photochemical using oscillatory baffled\u000a        reactor\u000a    2004 - 2005 &#163;50,000 SMART: Scotland Award on a feasibility\u000a        study of continuous production of\u000a        a family of nano particles using an oscillatory-baffled reactor\u000a    2005 - 2006 &#163;40,897 SMART: Scotland Award on a feasibility\u000a        study of continuous crystallisation\u000a        of l-glutamic acid using an oscillatory-baffled crystalliser\u000a    2009 - 2010 &#163;55,819 Technology Strategy Board (TSB) Award on achieving\u000a        greater consistency\u000a        in the modification of human recombinant proteins through scaleable\u000a        continuous-production\u000a        process technology\u000a    2009 - 2011 &#8364;28,245 out of &#8364;958,429 from a FP7 Project on development\u000a        of continuous\u000a        oscillatory baffled reactor to enable the creation of graduated radar\u000a        absorbing multi-layer structures\u000a        for wind turbine applications\u000a    2010 - 2014 &#163;148,384 two PhD studentship by the Scottish Founding\u000a      Council on probing into\u000a      how nucleation was generated without seeds in oscillatory baffled\u000a      crystalliser while seeding was\u000a      essential in traditional batch crystalliser\u000a    2012 - 2012 &#163;53,048 from Continuous Manufacturing and\u000a      Crystallisation (CMAC) Industrial\u000a      Consortium on the effect of seed size and quantity on crystal\u000a        properties\u000a    ","ResearchSubjectAreas":[{"Level1":"9","Level2":"4","Subject":"Chemical Engineering"},{"Level1":"9","Level2":"15","Subject":"Interdisciplinary Engineering"},{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"}],"Sources":"\u000a    A senior manager with technical responsibilities, Genzyme.\u000a    A member of the Board of NiTech Solutions.\u000a    A member of the Board of Chemical Sciences Scotland.\u000a    A senior manager in Investigational Materials Supply, GlaxoSmithKline.\u000a    www.nitechsolutions.co.uk\u000a    ","Title":"\u000a    Baffled Reactors for Continuous Reaction and Crystallisation\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Traditional batch technologies for manufacture of fine chemicals are\u000a      inherently inefficient due to\u000a      the difficulties of consistently meeting product specifications. This\u000a      incurs significant financial\u000a      penalties and generates waste. The current norm is that for every 1 kg of\u000a      active pharmaceutical\u000a      ingredient (API) harvested, 50 to 200 kg of waste is produced. The typical\u000a      raw material cost for a\u000a      single batch of API is &#163;1 to &#163;5M. Many of these products (over 90% of\u000a      pharmaceuticals and 80%\u000a      of fine chemicals) are of crystalline form and involve a crystallisation\u000a      step in their production cycle.\u000a      The control of crystal purity, morphology and size distribution therefore\u000a      has a significant impact on\u000a      the efficiency and profitability of the overall production.\u000a    Research of Prof Xiongwei Ni at Heriot-Watt University has successfully\u000a      addressed the\u000a      underpinning physical principles that are responsible for these\u000a      limitations of traditional batch\u000a      reactors and crystallisers. The work was stimulated, in part, by the\u000a      results of a 9-year EPSRC-\u000a      funded project (part of which was carried out at HWU) `Chemicals Behaving\u000a      Badly'. This identified\u000a      that the key to delivering consistent product specifications included the\u000a      control of cooling (linear)\u000a      profile and the attainment of uniform mixing. However, neither of these\u000a      features is achievable in\u000a      industrial batch systems, due to the facts that mixing becomes less\u000a      efficient and the specific area\u000a      per unit volume for heat transfer decreases dramatically with scale. This\u000a      makes any controlled\u000a      cooling profiles problematic to implement in any industrial production.\u000a    Ni's research has focused on understanding the science of achieving\u000a      uniform mixing at all scales in\u000a      plug flow under laminar flow conditions1, 2 The\u000a      continuous oscillatory baffled reactor and crystalliser\u000a      technology developed as a result of this research combines both uniform\u000a      mixing with precise\u000a      temperature control, allowing any desired cooling profiles, e.g. linear,\u000a      nonlinear, step function,\u000a      parabolic, etc., to be achieved from lab to full scales. The applicability\u000a      of the technology has been\u000a      demonstrated for transport processes, reactions and crystallisation.3, 4\u000a\u0009  Major patents have been\u000a      filed on both apparatus and method.5 The technology eliminates\u000a      the two fundamental problems\u000a      encountered in traditional industrial scale crystallisers identified\u000a      above. It also enables kinetic\u000a      reaction time to be executed at all scales, shrinking the space required.\u000a      Unlike standard batch\u000a      systems, laboratory monitoring tools have been shown to be capable of\u000a      being implemented on\u000a      industrial scales without modification, facilitating smooth, direct and\u000a      fast transition from the\u000a      laboratory to production. Knowledge gained in the laboratory can be\u000a      applied directly in production,\u000a      again unlike in traditional full-scale operations due to the effects of\u000a      non-scalable mixing.\u000a    Trials with a large number of chemical, food and pharmaceutical compounds\u000a      (&gt;60) from various\u000a      industrial companies have firmly reinforced that the technology delivers\u000a      consistent product quality,\u000a      e.g. size distribution, morphology, yield and purity, with significant\u000a      reductions (&gt;90%) in process\u000a      time, waste and unwanted products, as well as in energy, utility, plant\u000a      size and inventory.6\u000a      Continuous reaction and crystallisation are now identified as critical\u000a      steps in process-intensification\u000a      drives to improve manufacturing in the chemical and pharmaceutical\u000a      industries, through more\u000a      efficient use of reagents, solvents and energy while minimizing side\u000a      reactions, unwanted products\u000a      and waste materials.\u000a    "},{"CaseStudyId":"25836","Continent":[{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1861060","Name":"Japan"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000a    Current practices for therapeutic management of asthma and chronic\u000d\u000a      obstructive pulmonary disease (COPD) rely heavily on treatment with\u000d\u000a      corticosteroids and &#946;2-agonists, the former to control\u000d\u000a      underlying inflammatory dysfunction and the latter to afford symptomatic\u000d\u000a      relief for airway constriction. However, long-term use of corticosteroids\u000d\u000a      can produce adverse side effects, and the safety of long-acting &#946;2-agonists\u000a      is also currently under scrutiny. New safer and effective options for the\u000d\u000a      treatment of respiratory disease are therefore highly significant in their\u000d\u000a      potential societal and economic impact.\u000d\u000a    To pursue this goal, in 2000 Kyorin entered into an agreement with\u000d\u000a      Scottish Biomedical (SB), a technology management company founded jointly\u000d\u000a      by Scottish Universities in 1994, to set up a PDE biology research\u000d\u000a      facility, the Kyorin-Scotland Research Laboratory (KSRL), with an initial\u000d\u000a      project of &#163;5.2M. Consultancy oversight came from Prof. Miles Houslay\u000d\u000a      (University of Glasgow), one of the foremost authorities in the global PDE\u000d\u000a      biology community, while the medicinal chemistry direction was provided by\u000d\u000a      Adams. KSRL functioned to screen compounds initially provided largely by\u000d\u000a      Adams' medicinal chemistry group and the promising activity of emerging\u000d\u000a      compounds was central to the success of this initial programme, which\u000d\u000a      cemented the Kyorin-SB partnership. According to a senior manager of\u000d\u000a      Scottish Biomedical:\u000d\u000a    \"Prof Adams' group provided compound series and informed advice on all\u000d\u000a        aspects of the medicinal chemistry associated with the SB\/Kyorin\u000d\u000a        project. Prof Adams was one of the academic advisors employed for the\u000d\u000a        original project. His role allowed Kyorin to be confident that the\u000d\u000a        chemistry element of the project was being managed well and that\u000d\u000a        informed advice for the critical decision stages was available. Prof\u000d\u000a        Adams continued to play a vital role in the success of the first PDE\u000d\u000a        project which allowed a follow up project 3 years later. Prof Adams\u000d\u000a        contribution was essential to the success of the PDE programme (that)...\u000d\u000a        helped cement the partnership between Kyorin and SB.\"\u000d\u000a    In July 2002 a second &#163;5.2M project by Kyorin was agreed to extend the\u000d\u000a      KSRL portfolio to development of therapeutics for type 2 diabetes, and the\u000d\u000a      respiratory disease programme was extended for 3 years with a further\u000d\u000a      tranche of funding (&#163;4.5M) from 2003. Adams contributed medicinal\u000d\u000a      chemistry support throughout the period to 2006, eventually assisting SB\u000d\u000a      with the appointment of their own medicinal chemistry team. This completed\u000d\u000a      the transition of SB to a fully independent preclinical drug discovery\u000d\u000a      services company [text removed for publication].\u000d\u000a    The Adams group played an important role in establishing the PDE\u000d\u000a      medicinal chemistry research direction for Kyorin, and the success of the\u000d\u000a      work provided the basis for a major PDE drug development programme at\u000d\u000a      Kyorin's central Discovery Research Laboratories from 2004 and through the\u000d\u000a      current REF assessment period, employing 3 chemists and 6 biologists to\u000d\u000a      develop the work begun at HWU. The programme has generated 22 patents (18\u000d\u000a      published within the current REF assessment period) with a direct link to\u000d\u000a      the foundational work and direction contributed by HWU. A senior manager\u000d\u000a      at Kyorin's Discovery Research Laboratory in Japan stated that:\u000d\u000a    \"The work undertaken at Heriot-Watt University provided a substantive\u000d\u000a        benefit to Kyorin's PDE programme.\"\u000d\u000a    Throughout the current REF period Adams has continued to work with\u000d\u000a      Kyorin, developing a multi-part series of papers to disclose details of\u000d\u000a      the PDE programme and raise the company profile.1-6 These\u000d\u000a      papers evince the impact of the work performed in the Adams group in\u000d\u000a      shaping the direction of Kyorin's PDE programme. The success of the PDE\u000d\u000a      programme and establishment of a partnership with SB was also\u000d\u000a      strategically important to Kyorin in establishing a research network and\u000d\u000a      presence in Europe.\u000d\u000a    There is still considerable scope for bringing new best-in-class PDE4\u000d\u000a      inhibitors to the market as drugs with improved efficacy and reduced side\u000d\u000a      effect profiles for a range of inflammatory conditions in the respiratory\u000d\u000a      field and beyond. The first PDE4-selective inhibitor to reach the market,\u000d\u000a      roflumilast, was developed by the competitor company, Nycomed. Roflumilast\u000d\u000a      is indicated as a treatment for a subset of severe COPD cases and was\u000d\u000a      approved in the EU only in June 2010. It was subsequently also approved by\u000d\u000a      the FDA for use in the US (March 2011). A second PDE4 inhibitor,\u000d\u000a      apremilast from Celgene, will be launched in the near future as treatment\u000d\u000a      for psoriatic arthritis, with predicted annual sales of $1.5-2bn by 2017.\u000d\u000a      The global market for asthma\/COPD drugs, $38bn pa in 2012, is set to rise\u000d\u000a      to $47bn pa by 2017 [BCC Research]. Kyorin's own PDE programme therefore\u000d\u000a      remains an important asset in its portfolio of inflammatory and\u000d\u000a      respiratory disease research.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Phosphodiesterase (PDE) research by Prof. David Adams of Heriot-Watt\u000d\u000a      University (HWU) has discovered compounds with potent combined\u000d\u000a      anti-inflammatory and bronchorelaxant activity, relevant to asthma and\u000d\u000a      chronic obstructive pulmonary disease (COPD). This fuelled a major\u000d\u000a      therapeutic development programme by the Japanese company, Kyorin\u000d\u000a      Pharmaceutical Co. Ltd, resulting in 22 patents (18 published since 2008)\u000d\u000a      with a direct link to the foundational work at HWU. The work was a key\u000d\u000a      factor in Kyorin's continued commissioning of projects with Scottish\u000d\u000a      Biomedical (SB) up to &#163;14.9M, a technology management company founded by\u000d\u000a      Scottish Universities, enabling SB's transition into a fully independent\u000d\u000a      drug-discovery services company, [text removed for publication].\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    Heriot Watt University\u000d\u000a    ","Institutions":[{"AlternativeName":"Heriot-Watt University","InstitutionName":"Heriot-Watt University","PeerGroup":"B","Region":"Scotland","UKPRN":10007764}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    (* = best indicates the quality of the underpinning research)\u000d\u000a    \u000a[1]* K. A. Johnston, R. W. Allcock, Z. Jiang, I. D. Collier, H. Blakli,\u000d\u000a      G. M. Rosair, P. D. Bailey, K. M. Morgan, Y. Kohno and D. R. Adams \"Concise\u000a        routes to pyrazolo[1,5-a]pyridin-3-yl pyridazin-3-ones.\" Org.\u000d\u000a      Biomol. Chem. 2008, 6, 175-186. [doi: http:\/\/dx.doi.org\/10.1039\/b713638b]\u000d\u000a    \u000a\u000a[2]* R. W. Allcock, H. Blakli, Z. Jiang, K. A. Johnston, K. M. Morgan, G.\u000d\u000a      M. Rosair, K. Iwase, Y. Kohno and D. R. Adams \"Phosphodiesterase\u000d\u000a        inhibitors. Part 1: Synthesis and structure-activity relationships of\u000d\u000a        pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast.\"\u000d\u000a      Bioorg. Med. Chem. Lett. 2011, 21, 3307-12. [doi: http:\/\/dx.doi.org\/10.1016\/j.bmcl.2011.04.021]\u000d\u000a    \u000a\u000a[3]* K. Ochiai, N. Ando, K. Iwase, T. Kishi, K. Fukuchi, A. Ohinata, H.\u000d\u000a      Zushi, T. Yasue, D. R. Adams, and Y. Kohno \"Phosphodiesterase\u000d\u000a        inhibitors. 2: Design, synthesis and structure-activity relationships of\u000d\u000a        dual PDE3\/4-inhibitory pyrazolo [1,5-a]pyridines with anti-inflammatory\u000d\u000a        and bronchodilatory activity.\" Bioorg. Med. Chem. Lett. 2011, 21,\u000d\u000a      5451-46. [doi: http:\/\/dx.doi.org\/10.1016\/j.bmcl.2011.06.118\u000d\u000a      ]\u000d\u000a    \u000a\u000a[4] K. Ochiai, S. Takita, T. Eiraku, A. Kojima, K. Iwase, T. Kishi, K.\u000d\u000a      Fukuchi, T. Yasue, D. R. Adams, R. W. Allcock, Z. Jiang and Y. Kohno \"Phosphodiesterase\u000a        inhibitors. Part 3: Design, synthesis and structure-activity\u000d\u000a        relationships of dual PDE3\/4-inhibitory fused bicyclic\u000d\u000a        heteroaromatic-dihydropyridazinones with anti-inflammatory and\u000d\u000a        bronchodilatory activity.\" Bioorg. Med. Chem. 2012, 20, 1644-58.\u000d\u000a      [doi: http:\/\/dx.doi.org\/10.1016\/j.bmc.2012.01.033].\u000d\u000a    \u000a\u000a[5] K. Ochiai, S. Takita, A. Kojima, T. Eiraku, N. Ando, K. Iwase, T.\u000d\u000a      Kishi, A. Ohinata, Y. Yageta, T. Yasue, D. R. Adams and Y. Kohno \"Phosphodiesterase\u000a        inhibitors. Part 4: Design, synthesis and structure-activity\u000d\u000a        relationships of dual PDE3\/4-inhibitory fused bicyclic\u000d\u000a        heteroaromatic-4,4-dimethylpyrazolones.\" Bioorg. Med. Chem. Lett.\u000d\u000a      2012, 22, 5833-38. [http:\/\/dx.doi.org\/10.1016\/j.bmcl.2012.07.088]\u000d\u000a    \u000a\u000a[6] K. Ochiai, S. Takita, A. Kojima, T. Eiraku, K. Iwase, T. Kishi, A.\u000d\u000a      Ohinata, Y. Yageta, T. Yasue, D. R. Adams and Y. Kohno \"Phosphodiesterase\u000a        inhibitors. Part 5: Hybrid PDE3\/4 inhibitors as dual\u000d\u000a        bronchorelaxant\/anti-inflammatory agents for inhaled administration.\"\u000a      Bioorg. Med. Chem. Lett. 2012, 22, 375-81. [http:\/\/dx.doi.org\/10.1016\/j.bmcl.2012.08.121].\u000d\u000a    \u000aGrants\u000d\u000a    Medical Research Council MRC\/G0400053, &#163;1.9m, 1\/10\/2006, 48 months;\u000d\u000a      Exploration of PDE4 structure and function (PI Houslay, with Adams a named\u000d\u000a      collaborator)\u000d\u000a    Thera-cAMP (EU FP6\/037189), 1\/10\/2006 - 30\/9\/2009; Identification of\u000d\u000a      therapeutic molecules to target compartmentalised cAMP signalling networks\u000d\u000a      in human disease (PI Houslay, with Adams a named collaborator)\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"15","Subject":"Pharmacology and Pharmaceutical Sciences"},{"Level1":"6","Level2":"1","Subject":"Biochemistry and Cell Biology"}],"Sources":"\u000d\u000a    A senior manager, SB Drug Discovery\u000d\u000a    A senior manager, Discovery Research Laboratories, Kyorin Pharmaceutical\u000d\u000a      Co., Ltd.\u000d\u000a    Press releases from The Scotland Office (09\/07\/01) and Kyorin\u000d\u000a      Pharmaceutical Co., Ltd (31\/07\/02).\u000d\u000a    Newspaper articles from The Sunday Herald (12\/11\/00 and 01\/07\/0), The\u000d\u000a      Scotsman (01\/08\/2002 and 27\/11\/03) and The Herald (01\/08\/02).\u000d\u000a    ","Title":"\u000d\u000a    Inhibitors for respiratory disease\u000d\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate\u000d\u000a      (cGMP) are key messenger molecules that are vital to cell function. The\u000d\u000a      intracellular levels of these species are regulated by as many as 11\u000d\u000a      phosphodiesterase gene families (PDE1-11). Prof. David Adams has worked on\u000d\u000a      phosphodiesterase at HWU for &gt;13 years and has collaborated with\u000d\u000a      internationally leading molecular biology groups to unravel key aspects of\u000d\u000a      PDE regulation and subcellular targeting. Work on mapping protein-binding\u000d\u000a      interfaces on PDE4 for key signalling complexes has been funded by MRC, EU\u000d\u000a      and Scottish Enterprise and has been carried out in collaboration with the\u000d\u000a      Houslay group (Glasgow and Strathclyde Universities).\u000d\u000a    PDE4 inhibitors have long been known to exhibit good anti-inflammatory\u000d\u000a    activity and modest bronchodilatory activity, and this prompted interest in\u000d\u000a    their development as a treatment option for respiratory disease. In the\u000d\u000a    1980s Kyorin developed ibudilast for use in asthma therapy and stroke in\u000d\u000a    Japan, the drug's pharmacological activity issuing, in part, from it being a\u000d\u000a    non-selective PDE inhibitor. Kyorin further developed the drug in the 1990s\u000d\u000a    by coupling the ibudilast pyrazolopyridine core to a pyridazinone to provide\u000d\u000a    a new prototype compound, KCA-965. However, it remained unclear what overall\u000d\u000a    PDE-inhibitory profile was optimal for achieving dual anti-inflammatory and\u000d\u000a    bronchodilatory action in a single compound. The company therefore sought\u000d\u000a    partnerships and as part of this between 2000 and 2006 they awarded ca.\u000d\u000a    &#163;1.8M to Adams, allowing him to establish a medicinal chemistry programme to\u000d\u000a    develop PDE inhibitors from KCA-965.\u000d\u000a    Having developed appropriate synthetic methodology,1 Adams\u000d\u000a      brought a hypothesis-driven medicinal chemistry approach to develop a\u000d\u000a      series of novel pyrazolopyridine-pyridazinone inhibitors for enzymes of\u000d\u000a      the PDE3 and PDE4 families. By undertaking a structure-activity\u000d\u000a      relationship survey and employing conformationally constrained molecular\u000d\u000a      probes, the Adams group discovered that compounds within the series bind\u000d\u000a      to the catalytic pocket of PDE3 and PDE4 enzymes in a fundamentally\u000d\u000a      distinct manner, and that optimisation required structural reorganisation\u000d\u000a      of the pyrazolopyridine-pyridazinone core.2 This discovery\u000d\u000a      allowed the activity of compounds to be fine-tuned so as to provide either\u000d\u000a      potent selective PDE4 inhibitors or dual PDE3\/4-selective inhibitors with\u000d\u000a      promising biological activity.\u000d\u000a    An important feature of the programme at HWU was that it provided the\u000d\u000a      molecular tools to investigate the pharmacological benefit from targeting\u000d\u000a      both PDE3 and PDE4. At the outset of the work PDE4 inhibitors were already\u000d\u000a      known to exhibit modest bronchodilatory activity in addition to possessing\u000d\u000a      good anti-inflammatory activity. The bronchodilatory activity arises\u000d\u000a      because PDE inhibition leads to elevated cAMP levels in the airway smooth\u000d\u000a      muscle and so promotes relaxation. Both PDE4 and PDE3 mediate cAMP\u000d\u000a      hydrolysis, however, and inhibition of PDE3 is more effective than\u000d\u000a      inhibition of PDE4 for inducing airway smooth muscle relaxation. By\u000d\u000a      unlocking the structural determinants that control PDE3- and\u000d\u000a      PDE4-inhibitory selectivity in the HWU chemical series it was possible to\u000d\u000a      develop compounds with promising dual anti-inflammatory and\u000d\u000a      bronchorelaxant activity.2-6\u000d\u000a    Biological assessment of the compounds developed from the Adams group\u000d\u000a      medicinal chemistry programme was undertaken by the Kyorin-Scotland\u000d\u000a      Research Laboratory (KSRL), a facility set up in 2000 between Scottish\u000d\u000a      Biomedical (SB) and Kyorin with an initial &#163;5.2M investment.\u000d\u000a    "},{"CaseStudyId":"25837","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Research Councils UK","Engineering and Physical Sciences Research Council","Particle Physics and Astronomy Research Council","Royal Society"],"ImpactDetails":"\u000d\u000a    Stars `r' Us! uses highly interactive exhibits to show how information\u000d\u000a      obtained from telescopic\u000d\u000a      observations, laboratory experiments and computer modelling is used to\u000d\u000a      infer clues about the\u000d\u000a      possible chemical origins of life. McCoustra led the development of the\u000d\u000a      exhibition, with\u000d\u000a      contributions from UCL, the OU, Leiden Observatory and Royal Observatory\u000d\u000a      Greenwich. Over\u000d\u000a      &#163;25,000 was initially secured from various sources to fund the exhibition\u000d\u000a      including grant [A] above.\u000d\u000a      However this initial investment was supplemented by addition funding in\u000d\u000a      2006 ([B] and [C] above to\u000d\u000a      an estimated total of &#163;10,000) and most recently in 2010 (from [D] to a\u000d\u000a      value estimated at &#163;7,500).\u000d\u000a      Operating costs for SRU activities come from sources including the British\u000d\u000a      Council, RSC, ESF and\u000d\u000a      SRU partners.\u000d\u000a    Resources created to accompany SRU include a comprehensive teacher's pack\u000d\u000a      which has been\u000d\u000a      distributed to hundreds of schools. The team has also developed a session\u000d\u000a      for school\u000d\u000a      engagement. Stars `r' Us! is a key plank of Heriot-Watt University's\u000d\u000a      public engagement strategy,\u000d\u000a      during a period which has seen annual applications for undergraduate\u000d\u000a      places on Chemistry degree\u000d\u000a      programmes increase from 547 in 2004 to 734 in 2013. There has also been a\u000d\u000a      commensurate rise\u000d\u000a      in quality of students accepted into our Chemistry courses, demonstrated\u000d\u000a      by the increase in UCAS\u000d\u000a      tariff by fifty points over the same period.\u000d\u000a    4.1 In depth engagement with adults of all socioeconomic groups\u000d\u000a      The Stars `r' Us! team has actively sought engagement with audiences from\u000d\u000a      a wide range of\u000d\u000a      different demographics. With this in mind, we have toured the exhibition\u000d\u000a      around shopping centres\u000d\u000a      as part of an RSC programme, and took it to the International Scout\u000d\u000a      Jamboree. More recently the\u000d\u000a      exhibition has featured at Our Dynamic Earth (ODE) three times during the\u000d\u000a      REF period as part of\u000d\u000a      the Edinburgh International Science Festival (EISF) and once at Cheltenham\u000d\u000a      Science Festival. A\u000d\u000a      senior UK academic astronomer states:\u000d\u000a    \"Stars `r' Us! has been a highly effective piece of work with an\u000d\u000a        enduring life and one that works for\u000d\u000a        diverse audiences of all ages and backgrounds\".\u000d\u000a    EISF at Our Dynamic Earth Science Centre in 2008, 2009 and 2011\u000d\u000a      Exhibiting at ODE offers a great opportunity for scientists to engage with\u000d\u000a      families and independent\u000d\u000a      adults across the social spectrum (a quarter of ODE's visitors are from\u000d\u000a      socioeconomic group\u000d\u000a      C2DE). For example, in 2009, this included a group of Hibernian football\u000d\u000a      fans! The SRU team\u000d\u000a      invites experts to collaborate in the exhibition and programme. Over the\u000d\u000a      weekend of operation in\u000d\u000a      ODE in 2011 some 1000 visits were recorded (an average of 330 per day for\u000d\u000a      the Friday to Sunday\u000d\u000a      period). Taking this as a realistic average footfall per day at each of\u000d\u000a      our activities then a total\u000d\u000a      footfall of 11,000 can be estimated, excluding the additional auditable\u000d\u000a      earlier figures from the Royal\u000d\u000a      Society Summer Exhibitions and more recently (see below) at the Cheltenham\u000d\u000a      Science Festival.\u000d\u000a      The Public Astronomer, from the Royal Observatory Greenwich comments:\u000d\u000a    \"The Stars `r' Us! activity has been an amazingly effective piece of\u000d\u000a        public engagement and I've\u000d\u000a        enjoyed helping to present it on a number of occasions. As an astronomer\u000d\u000a        and a professional\u000d\u000a        science communicator I've been very impressed by the excellent mix of\u000d\u000a        exhibits, pictures,\u000d\u000a        interpretation and live demos that comprise Stars `r' Us! This variety\u000d\u000a        and flexibility has ... allowed it\u000d\u000a        to engage a huge number of people in a wide range of different venues.\u000d\u000a        One of its great strengths\u000d\u000a        has been the way in which it has been used to bring together researchers\u000d\u000a        from a variety of different\u000d\u000a        institutes and fields of expertise and it has also proved itself as an\u000d\u000a        excellent training ground for\u000d\u000a        students and young researchers, allowing them to hone their creativity\u000d\u000a        and public engagement\u000d\u000a        skills.\"\u000d\u000a    One former SRU helper has gone on to join the staff of the Royal\u000d\u000a      Observatory Greenwich as an\u000d\u000a      assistant to the Public Astronomer.\u000d\u000a    Cheltenham Science Festival 2013 (Area 42 - for over 14s)\u000d\u000a      Over 900 people visited Stars'r'Us! at Cheltenham Science Festival. The\u000d\u000a      Festival attracts a broad\u000d\u000a      social mix with approximately half of visitors coming from socio-economic\u000d\u000a      group C2DE. SRU\u000d\u000a      visitors enjoyed in-depth interactions (6-7 minutes on average) with\u000d\u000a      researchers that led to a wide\u000d\u000a      range of new learning from specific details on complex theories such as\u000d\u000a      gravity waves to how\u000d\u000a      different colours of light relate to the composition of stars.\u000d\u000a    Visitors reported particular appreciation for being able to talk directly\u000d\u000a      to researchers and\u000d\u000a      discovering subjects that would not be covered by mainstream media. They\u000d\u000a      felt strongly that giving\u000d\u000a      young people the opportunity to meet researchers informs and influences\u000d\u000a      their education and\u000d\u000a      career choices. Having visited SRU, visitors also voiced clear support for\u000d\u000a      publicly-funded, curiosity\u000d\u000a      driven research (57% expressed a positive attitude; 30% had no strong\u000d\u000a      opinion; 13% expressed\u000d\u000a      support with caveats). The Programme Director, Cheltenham Science\u000d\u000a      Festival, said:\u000d\u000a    \"Cheltenham Science Festival really values the contribution that\u000d\u000a        exhibitions such as Stars `r' Us!\u000d\u000a        make to Times Area 42. These exhibitions offer a fantastic opportunity\u000d\u000a        for visitors to discuss cutting\u000d\u000a        edge contemporary research with the scientists who are undertaking the\u000d\u000a        work and are a rare\u000d\u000a        opportunity for an in-depth exchange of information and views on\u000d\u000a        everything from fundamental\u000d\u000a        scientific principles to funding.\"\u000d\u000a    4.2 Engagement with schools\u000d\u000a      Stars `r' Us! has provided information about contemporary science and\u000d\u000a      science careers to\u000d\u000a      thousands of young people. In recent years, this has included\u000d\u000a      participation in HWU's Get SET\u000d\u000a      widening-participation days. These popular events are an exciting and\u000d\u000a      stimulating opportunity to\u000d\u000a      inspire girls to consider study and careers in science and engineering.\u000d\u000a    McCoustra has also run Stars `r' Us! schools' sessions with over 600\u000d\u000a      students in Scotland and\u000d\u000a      northern England. Feedback from teachers shows that these activities have\u000d\u000a      encouraged\u000d\u000a      numerous young people, including many in remote geographical locations, to\u000d\u000a      change their\u000d\u000a      perceptions of science and has influenced their educational choices.\u000d\u000a    \u000d\u000a      \"[Our students] thoroughly enjoyed it and some were more motivated\u000d\u000a          to go on and study\u000d\u000a          ..[science]... at a higher level\" Teacher, James Young High\u000d\u000a        School, Livingston\u000d\u000a      \"They were more aware of other courses (rather than just physics or\u000d\u000a          chemistry) to study at\u000d\u000a          university and not just the same three as at school\". Teacher,\u000d\u000a        Earlston High School\u000d\u000a      \"We are a small island school. We very much benefit from programmes\u000d\u000a          where visiting\u000d\u000a          speakers can show our students a little of the opportunities that\u000d\u000a          exist on the mainland.\"\u000d\u000a        Teacher, Islay High School\u000d\u000a    \u000d\u000a    4.3 Engagement with EU policy makers &#8212; Astrochemistry &#8212; The Cradle of\u000d\u000a        Life event\u000d\u000a      In 2011, Stars `r' Us! was invited by the European Science Foundation\u000d\u000a      (ESF) and European\u000d\u000a      Cooperation in Science to take part in an astrochemistry event organised\u000d\u000a      for the EU Commission\u000d\u000a      and Parliament and held at the Natural History Museum in Brussels. EU\u000d\u000a      politicians and civil\u000d\u000a      servants attended a reception to raise awareness of astrochemistry at a\u000d\u000a      trans-national level.\u000d\u000a    \"Bringing Stars `r' Us! to an audience of European Commissioners and\u000d\u000a        the general public helped to\u000d\u000a        raise the profile of astrochemistry in the EC. I believe that activities\u000d\u000a        of this kind are an important\u000d\u000a        contributory factor to the favourable discussions regarding\u000d\u000a        astrochemistry in the development of\u000d\u000a        Horizon 2020\/Framework Programme 8.\" Chair of European Science\u000d\u000a      Foundation\u000d\u000a    In February 2013, The European Commission Consultation On Possible Topics\u000d\u000a      For Future\u000d\u000a      Activities For Integrating And Opening Existing National Research\u000d\u000a      Infrastructures Report cited\u000d\u000a      (page 24) European Laboratory Astrophysics as a topic with high potential\u000d\u000a      and with merit for future\u000d\u000a      Horizon 2020 actions for integrating and opening existing national\u000d\u000a      research infrastructures.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Stars `r' Us! (SRU) is a touring exhibition conceived in 2004 by\u000d\u000a      Professor Martin McCoustra to\u000d\u000a      engage the public with astrochemistry. SRU has been updated frequently,\u000d\u000a      most recently in 2010 to\u000d\u000a      include on-going work at Heriot-Watt University (HWU). SRU has contributed\u000d\u000a      regularly to major\u000d\u000a      science festivals, with independently corroborated strong impact on public\u000d\u000a      attitudes. Over its\u000d\u000a      lifetime, active researchers have interacted directly with an estimated\u000d\u000a      11,000 visitors, most of\u000d\u000a      whom were teenagers. SRU has further indirect reach through a widely\u000d\u000a      distributed teacher's pack.\u000d\u000a      It is also a valuable element of the public engagement programme at HWU\u000d\u000a      which has seen\u000d\u000a      demonstrably improved recruitment to chemistry programmes over recent\u000d\u000a      years. SRU has\u000d\u000a      engaged with the EU Commission through an ESF co-sponsored event:\u000d\u000a      laboratory astrochemistry\u000d\u000a      has recently achieved preferred status in a Horizon 2020 foresighting\u000d\u000a      exercise.\u000d\u000a    ","ImpactType":"Societal","Institution":"\u000d\u000a    Heriot- Watt University\u000d\u000a    ","Institutions":[{"AlternativeName":"Heriot-Watt University","InstitutionName":"Heriot-Watt University","PeerGroup":"B","Region":"Scotland","UKPRN":10007764}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"2800867","Name":"Bruxelles-Capitale"}],"References":"\u000d\u000a    (* = best indicates the quality of the underpinning research )\u000d\u000a    \u000a*[1] Applying Laboratory Thermal Desorption Data in an Interstellar\u000d\u000a        Context: Sublimation of\u000d\u000a        Methanol Thin Films. S. D. Green, A. S. Bolina, R. Chen, M. P.\u000d\u000a      Collings, W. A. Brown and M. R. S.\u000d\u000a      McCoustra Mon. Not. Roy. Astron. Soc., 2009, 398, 357-367.\u000d\u000a    \u000a\u000a[2] Laboratory Investigations of the Interaction between Benzene and\u000d\u000a        Bare Silicate Grain Surfaces.\u000d\u000a      J. D. Thrower, M. P. Collings, F. J. M. Rutten and M. R. S. McCoustra,\u000d\u000a      Mon. Not. Roy. Astron.\u000d\u000a      Soc., 2009, 394, 1510-1518.\u000d\u000a    \u000a\u000a*[3] Thermal Desorption of C6H6 from Surfaces\u000d\u000a        of Astrophysical Relevance. J. D. Thrower, M. P.\u000d\u000a      Collings, F. J. M. Rutten, and M. R. S. McCoustra, J. Chem. Phys., 2009,\u000d\u000a      131, 244711.\u000d\u000a    \u000a\u000a*[4] Desorption of Hot Molecules from Photon Irradiated Interstellar\u000d\u000a        Ices. J. D. Thrower, D. J.\u000d\u000a      Burke, M. P. Collings, A. Dawes, P. J. Holtom, F. Jamme, P. Kendall, W. A.\u000d\u000a      Brown, I. P. Clark, H.\u000d\u000a      J. Fraser, M. R. S. McCoustra, N. J. Mason and A. W. Parker, Astrophys.\u000d\u000a      J., 2008, 673, 1233-1239.\u000d\u000a    \u000a\u000a[5] Photon- and Electron-stimulated Desorption from Laboratory Models\u000d\u000a        of Interstellar Ice Grains.\u000d\u000a      J. D. Thrower, A. G. M. Abdulgalil, M. P. Collings, and M. R. S.\u000d\u000a      McCoustra, D. J. Burke, W. A.\u000d\u000a      Brown, A. Dawes, P. J. Holtom, P. Kendall, N. J. Mason, F. Jamme, H. J.\u000d\u000a      Fraser and F. J. M.\u000d\u000a      Rutten, J. Vac. Sci. Technol. A, 2010, 28, 799-806\u000d\u000a    \u000a\u000a[6] Highly Efficient Electron-stimulated Desorption of Benzene from\u000d\u000a        Amorphous Solid Water Ice.\u000d\u000a      J.D. Thrower, M. P. Collings, F. J. M. Rutten, and M. R. S. McCoustra,\u000d\u000a      Chem. Phys. Lett., 2011,\u000d\u000a      505, 106-111.\u000d\u000a    \u000aTo support the operation of SRU, we have utilised funding from RCUK\u000d\u000a      sources both directly and\u000d\u000a      indirectly. Since 2010, SRU is has been supported by the LASSIE ITN under\u000d\u000a      Framework 7. The\u000d\u000a      awards that have supported SRU activities are listed below;\u000d\u000a      [A] Stars R Us! An Exhibit at the Royal Society Summer Exhibition.\u000d\u000a      2004, PPARC PP\/B5Q1017\/1\u000d\u000a      to McCoustra (HWU, PI) with Brown and Viti (UCL), Mason (OU), Fraser\u000d\u000a      (Leiden) and Massey\u000d\u000a      (RGO); &#163;4,000.\u000d\u000a    [B] AstroSurf: A Network in Surface Science Applications in\u000d\u000a        Laboratory Astrophysics. 2004 - 2007;\u000d\u000a      EPSRC GR\/T05004\/01 and GR\/T05004\/02 to McCoustra (HWU, PI) with Brown and\u000d\u000a      Viti (UCL),\u000d\u000a      Mason (OU) and Darling (Liverpool); &#163;66,934.\u000d\u000a    [C] Stars `r' Us!; The Cosmic Chemistry Connection. 2006,\u000d\u000a      EP\/E022693\/1 to McCoustra (HWU,\u000d\u000a      PI); Linked to EP\/E022413\/1 and EP\/E022081\/1 awarded to Brown (UCL) and\u000d\u000a      Fraser (Strathclyde); &#163;2,598.\u000d\u000a    [D] Laboratory Astrochemical Surface Science in Europe (LASSIE).\u000d\u000a      2010, Framework 7 PEOPLE\u000d\u000a      Work Programme 2008 Grant Agreement Number 235258 to McCoustra (HWU,\u000d\u000a      coordinator) with\u000d\u000a      colleagues from 12 other centres; 6, 053,548 Euro.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"2","Level2":"1","Subject":"Astronomical and Space Sciences"},{"Level1":"3","Level2":"1","Subject":"Analytical Chemistry"}],"Sources":"\u000d\u000a    [1] A senior Astronomer within the UK will state Stars `r' Us! has been a\u000d\u000a      highly effective piece of\u000d\u000a      work with an enduring life and one that works for diverse audiences of all\u000d\u000a      ages and backgrounds\u000d\u000a    [2] The Marketing Manager from Our Dynamic Earth for numbers of visitors\u000d\u000a      and their perception of\u000d\u000a      the impact of SRU when it ran at the Edinburgh International Science\u000d\u000a      Festival.\u000d\u000a    [3] Public Astronomer at the Royal Observatory in Greenwich can confirm\u000d\u000a      the effectiveness of the\u000d\u000a      approach in SRU, and its impact on participants\u000d\u000a    [4] Chair, European Science Foundation, on the impact of the event in\u000d\u000a      Brussels in 2011.\u000d\u000a    [5] Final Report to PPARC PP\/B5Q1017\/1.\u000d\u000a    [6] Final Reports to EPSRC EP\/E022081\/1, EP\/E022413\/1 and EP\/E022693\/1.\u000d\u000a    [7] Evaluation of Stars `r' Us! at the 2013 Cheltenham Science Festival,\u000d\u000a      Graphic Science Ltd 2013\u000d\u000a    ","Title":"\u000d\u000a    Stars `r' Us! Engaging the Public with Astrochemical Research\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2653261","Name":"Cheltenham"},{"GeoNamesId":"2650225","Name":"Edinburgh"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"},{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    Stars `r' Us! (SRU, http:\/\/www.stars-r-us.org\u000d\u000a      ) can trace it roots back to the early 2000s and the\u000d\u000a      publication of a short popular article by McCoustra, Fraser and Williams\u000d\u000a      in the Royal Astronomical\u000d\u000a      Society (RAS) house magazine Astronomy and Geophysics [DOI http:\/\/dx.doi.org\/10.1111\/j.1365-2966.2009.15144.x]\u000d\u000a\u0009  and to the astrochemical science behind a publication for teachers in the\u000d\u000a      Royal Society of Chemistry (RSC) journal Education in Chemistry. The\u000d\u000a      activities of SRU are\u000d\u000a      underpinned and informed today by the wide-ranging science originating\u000d\u000a      from within the HWU\u000d\u000a      Laboratory Astrochemistry Group (http:\/\/www.astrochemistry.hw.ac.uk)\u000d\u000a      and from other members of\u000d\u000a      the Framework 7 Initial Training Network (ITN) Laboratory Astrochemical\u000d\u000a      Surface Science In\u000d\u000a      Europe (LASSIE). SRU is broadly based and draws on the activities of all\u000d\u000a      its partners. The key\u000d\u000a      themes that SRU explores are:\u000d\u000a    \u000d\u000a      The role of spectroscopy in observing the chemical composition of the\u000d\u000a        local and more\u000d\u000a        distant universe;\u000d\u000a      The importance of small molecules in controlling the formation of\u000d\u000a        small, long-lived stars;\u000d\u000a      The interplay between chemistry in the gas phase and on dust grains;\u000d\u000a      The role of surface and solid state chemistry in developing a rich\u000d\u000a        organic chemistry in star-forming\u000d\u000a        regions;\u000d\u000a      The importance of that rich organic chemistry in seeding the galaxy\u000d\u000a        and the universe with\u000d\u000a        the chemical potential for life.\u000d\u000a    \u000d\u000a    The work of the HWU Astrochemistry Group focuses on the broad theme of\u000d\u000a      the role of surface and\u000d\u000a      solid-state physics and chemistry in evolving the chemical complexity of\u000d\u000a      the regions where stars\u000d\u000a      and planets are formed towards the chemical progenitors of life; this has\u000d\u000a      a direct impact on the\u000d\u000a      final three bullet points listed above. That complexity can be observed to\u000d\u000a      a very limited extent in\u000d\u000a      the solid state, but infrared spectroscopy is insufficiently sensitive and\u000d\u000a      characteristic to provide\u000d\u000a      information on anything but the most abundant chemical species in the\u000d\u000a      solid state. However,\u000d\u000a      desorption and release of complex organic molecules into the gas phase\u000d\u000a      allows many more of the\u000d\u000a      chemical species present in these distant environments to be detected. The\u000d\u000a      on-going development\u000d\u000a      of sensitive new observational platforms such as ALMA is revealing the\u000d\u000a      details of the complex\u000d\u000a      molecular inventory of the Universe. The key publications from the\u000d\u000a      activities of McCoustra and the\u000d\u000a      HWU Astrochemistry Group that are relevant to the development and\u000d\u000a      implementation of SRU are\u000d\u000a      listed below. The work listed highlights the role of laboratory\u000d\u000a      measurements of both thermal [1 - 3]\u000d\u000a      and non-thermal desorption [4 - 6] of molecules under conditions that\u000d\u000a      mimic the interstellar\u000d\u000a      medium. The first set of three publications relate to the development of\u000d\u000a      an understanding of the\u000d\u000a      thermal desorption of icy grain mantles [1 - 3], a process that is crucial\u000d\u000a      to the chemical control of\u000d\u000a      the star formation process. On the basis of this work at HWU, these\u000d\u000a      processes are better\u000d\u000a      described in physicochemical models of such environments. The latter three\u000d\u000a      papers describe\u000d\u000a      recent and on-going work on desorption processes induced by light and\u000d\u000a      charged particles [4 - 6]\u000d\u000a      that are crucial in returning complex organic species to the interstellar\u000d\u000a      gas and compete effectively\u000d\u000a      with chemical evolution within radiation-rich environments. These\u000d\u000a      discoveries and the\u000d\u000a      understanding they provide of the processes that enrich the interstellar\u000d\u000a      gas with complex organic\u000d\u000a      molecules directly inform our discussion of the chemical evolution of the\u000d\u000a      Universe when engaging\u000d\u000a      with the public.\u000d\u000a    "},{"CaseStudyId":"28086","Continent":[{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1861060","Name":"Japan"}],"Funders":[],"ImpactDetails":"\u000a    Context\u000a    Despite the advantageous electroluminescent and photoluminescent\u000a      properties of quantum dot nanoparticles, their incorporation into\u000a      next-generation consumer electronics has been precluded by the absence of\u000a      a means to manufacture both sufficient quantities and materials that are\u000a      free of toxic heavy metals in-order to comply with `Restriction of\u000a      Hazardous Substances' (RoHS) legislation.\u000a    Pathways to impact\u000a      The research conducted at the University of Manchester enabled the\u000a      preparation of bulk quantities of quantum dots free of toxic heavy metals,\u000a      which led to the spinout of Nanoco Technologies in 2001-2 from the School\u000a      of Chemistry based on its proprietary technology covered, by 19 patents\u000a      [4,5].\u000a    Whilst located within the School of Chemistry building, Nanoco grew to\u000a      10-12 workers before moving to dedicated premises where it experienced\u000a      extraordinary growth between 2004-2013. Currently, Nanoco operates from\u000a      the company's headquarters and R&amp;D facility in Manchester, a\u000a      production plant in Runcorn and sales offices located in Japan and the\u000a      United States.[A]\u000a    Impact.\u000a      During the period 1st January 2008 to 31st July 2013, Nanoco Technologies\u000a      established itself as the world's leading manufacturer and supplier of\u000a      commercial quantities of RoHS compliant (RoHS 2002\/95\/EC) quantum dots,\u000a      employing approximately 95 staff at a total cost of over &#163;3m per year and\u000a      generating over &#163;10.5m revenue since 1st August 2008 [B].\u000a    On the 1st May 2009 Nanoco Group plc began trading on the Alternative\u000a      Investment Market of the London Stock Exchange and since this time has\u000a      grown its market capitalisation to &#163;384m (31\/7\/2013).\u000a    Nanoco's strategic partnerships have generated significant secondary\u000a      impact through job creation throughout its associated supply chain and\u000a      within its partner companies. Currently, Nanoco's quantum dot's are being\u000a      developed with its strategic partners in several areas including displays\u000a      and photovoltaic solar cells as follows:-\u000a    1. Displays\u000a      Display technology has progressed from bulky cathode ray tubes to plasma\u000a      screens, liquid crystal displays and more recently to energy efficient\u000a      organic light emitting diodes (OLED). OLED technology has provided low\u000a      power, lightweight, thinner displays of improved user experience through\u000a      wider viewing angles and improved contrast. However, OLED\u000a      display technology is limited to the fabrication of small displays\u000a      employing wasteful and energy inefficient evaporation procedures with a\u000a      high discard rates.\u000a    Quantum dot electroluminescent display technology (QD TV&#8482;) offers a\u000a      tremendous advantage over existing OLED-technology. Quantum dots have been\u000a      printed using facile low cost techniques into various sizes of lightweight\u000a      flexible displays. High photoluminescence quantum yields render the\u000a      displays energy efficient, narrow emission band-width provides displays of\u000a      superior optical resolution, whilst the high stability of inorganic\u000a      quantum dots provides displays with improved lifetimes.\u000a    Since 2011, Nanoco has delivered 1kg batches of both red and green\u000a      coloured quantum dots worth &#163;2.5m and achieved performance milestones that\u000a      have generated an additional &#163;1.1M. In January 2013 Nanoco entered into an\u000a      exclusive licensing agreement with Dow Electronic Materials' who are\u000a      opening a production facility in the far-east to manufacture quantum dots\u000a      and have exclusive worldwide rights for the sale, marketing and\u000a      manufacture of Nanoco's quantum dots for use in electronic displays [C].\u000a    2. Photovoltaic solar cells\u000a      The world's growing demand for power is met predominantly by the\u000a      combustion of fossil fuels (13TW, 87%). As fossil fuels become depleted\u000a      and the demand for cleaner, greener energy increases it is imperative that\u000a      renewable energy becomes a more significant proportion of our energy mix.\u000a      Currently, solar power contributes a negligible 0.03% toward the global\u000a      energy mix despite the earth receiving sufficient energy from the sun to\u000a      meet its current and future energy demand (&gt;120,000 TW). The widespread\u000a      adoption of solar power has been impeded by the high cost of cells,\u000a      principally of silicon fabricated by expensive methods.\u000a    In partnership with a Japanese automotive firm that has invested\u000a      approximately &#163;1m and `Tokyo Electron' who have invested an undisclosed\u000a      amount, Nanoco has exploited its proprietary intellectual property and\u000a      expertise to prepare a range of novel copper indium gallium diselenide and\u000a      copper indium diselenide quantum dot inks that have been fabricated into\u000a      solar cell devices of good efficiencies using conventional low cost\u000a      printing techniques [D].\u000a    ","ImpactSummary":"\u000a    Nanoco, is a University of Manchester spin out company having a current\u000a      market capitalisation of &#163;384m (31\/7\/2013). Nanoco's proprietary processes\u000a      enable, for the first time, commercial quantities of high-quality quantum\u000a      dot nanoparticles, free of toxic heavy-metals, to be manufactured\u000a      economically &#8212; for incorporation into next-generation displays &amp;\u000a      solar-cells.\"\u000a\u0009  As a result of its world-leading disruptive technology,\u000a      Nanoco has, in the REF period, forged down-stream global business\u000a      partnerships that have generated around &#163;11m revenue, creating 95 jobs\u000a      with Nanoco (at a cost of over &#163;3m\/year), substantial secondary employment\u000a      in the supply chain, and underpinning technology to enable the delivery of\u000a      more energy-efficient electronic devices.\u000a    ","ImpactType":"Technological","Institution":"\u000a    The University of Manchester\u000a    ","Institutions":[{"AlternativeName":"Manchester (University of)","InstitutionName":"University of Manchester","PeerGroup":"A","Region":"North West","UKPRN":10007798}],"Panel":"B         ","PlaceName":[],"References":"\u000a    All of the papers appear in peer-reviewed international journals that led\u000a      to Professor O'Brien being invited to present his research\u000a      internationally. The patents capture the underpinning research that forms\u000a      the basis of Nanoco Technologies. Professor O'Brien was made FRS in 2013\u000a      largely for his contributions to the development of the chemistry\u000a      described in this Impact Case.\u000a    Key references\u000a    \u000a1. Investigation of the internal heterostructure of highly luminescent\u000a      quantum dot-quantum well nanocrystals, Santra, P. K. Viswanatha, R.\u000a      Daniels, S. M. Pickett, N. L. Smith, J. M. O'Brien, P., Sarma, D. D., J.\u000a      Am. Chem. Soc., 2009, 131, 470-7 DOI:\u000a        10.1021\/ja8033075\u000a    \u000a\u000a2. Power law carrier dynamics in semiconductor nanocrystals at nanosecond\u000a      timescales. Sher, P. H., Smith, J. M., Dalgarno, P. A., Warburton, R. J.,\u000a      Chen, X., Dobson, P. J., Daniels, S. M., Pickett, N. L., O'Brien, P.,\u000a      Appl. Phys. Lett., 2008, 92, 101111, DOI:\u000a        10.1063\/1.2894193\u000a    \u000a\u000a3. New synthetic routes for quantum dots, Crouch, D., Norager, S.,\u000a      O'Brien, P., Park, J-H., Pickett, N. L., Phil. Trans. R. Soc. Lond. A.,\u000a      2003, 361, 297-310. DOI: 10.1098\/rsta.2002.1129\u000a    \u000aOther references\u000a    \u000a4. Preparation of nanoparticle materials, O'Brien, P.,Pickett, N., PCT\u000a      Int. Appl. (2005), WO\u000a        2005106082\u000a        A1 20051110.\u000a    \u000a\u000a5. Nanoparticles, Pickett, N., Daniels, S., O'Brien, P., PCT Int. Appl.\u000a      (2007), WO\u000a        2007020416 A1 20070222\u000a    \u000a\u000a6. Synthesis and characterization of CdS quantum dots in polystyrene\u000a      microbeads, Li, Y., Liu, E. C. Y., Pickett, N., Skabara, P. J., Cummins,\u000a      S. S., Ryley, S., Sutherland, A., O'Brien, P., J. Mat. Chem., 2005, 15,\u000a      1238-1243. DOI:\u000a        10.1039\/b412317d.\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"3","Subject":"Macromolecular and Materials Chemistry"}],"Sources":"\u000a    A) Corroboration of Nanoco startup timeline and individual involvement.\u000a      Letter of support (CEO Nanoco)\u000a    B) Nanoco 2013 Interim Report.\u000a    C) Press Release re Dow use for LCD displays.\u000a    D) Press Release re Tokyo Electron use of solar ink\u000a    ","Title":"\u000a    Nanoco Grp Ltd\u000a    ","UKLocation":[{"GeoNamesId":"2643123","Name":"Manchester"},{"GeoNamesId":"2638960","Name":"Runcorn"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Research conducted at the University of Manchester developed novel\u000a      processes to prepare, reproducibly, bulk quantities of high-quality\u000a      quantum dot nanoparticles from non-heavy metal precursors. [4,5]\u000a    The research was carried out by key Manchester researchers:\u000a    \u000a      Paul O'Brien &#8212; Professor of Materials Chemistry (1999-present);\u000a      Nigel Picket &#8212; PDRA (2000-2004);\u000a      Steve Daniels &#8212; PhD student (2001-2004).\u000a    \u000a    Most often, quantum dots have been prepared by `hot-injection methods'\u000a      rapidly introducing solutions of often hazardous precursor compounds into\u000a      a vast excess of hot solvent, resulting in nucleation and subsequent\u000a      growth of the quantum dot nanoparticles by `heating-up' methodologies. The\u000a      approach can be severely limited by being non-reproducible in terms of the\u000a      stability, size and colour of the quantum dot nanoparticles produced.\u000a    The molecular seeding process developed at Manchester circumvented these\u000a      limitations. In this approach, the precursor compounds are heated in the\u000a      presence of a molecular-cluster in a single-pot reaction. The molecular\u000a      cluster serves as a prefabricated template to nucleate nanoparticle\u000a      growth, offering more accurate control over the size and associated\u000a      emission wavelength of the resulting quantum dots. [3]\u000a    This seeding process was then further developed at Manchester, coating\u000a      the quantum dot nanoparticles with a wide band-gap inorganic shell in\u000a      order to confine the exciton generated within the quantum dot, upon\u000a      irradiation, from the external environment. This improved both the\u000a      stability and brightness of the quantum dot nanoparticles. [1,2,6]\u000a    "},{"CaseStudyId":"28087","Continent":[{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1814991","Name":"China"}],"Funders":["Royal Society"],"ImpactDetails":"\u000a    Context\u000a    Fluorine is one of the most reactive elements in the periodic table, yet\u000a      its compounds are some of the most useful, this is exemplified in\u000a      agrochemicals and pharmaceuticals where more than 1\/5th of\u000a      compounds on the market are fluorine containing, including 30% of the\u000a      top-thirty best sellers. [O'Hagan, J. Fluorine Chem. 2010, 131,\u000a      1071]\u000a    The presence of a fluorine atom can confer advantageous potency,\u000a      selectivity and\/or metabolic stability attributes to prospective drug\u000a      candidate molecules. This desirability is tempered by the harsh and\u000a      hazardous nature of conventional fluorinating agents; many different\u000a      electrophilic fluorinating agents have been investigated, but most are\u000a      insufficiently reactive, too hazardous or too expensive for large-scale\u000a      applications. Selectfluor&#174; was developed at Manchester, and between 1993\u000a      and 2004 was demonstrated to fluorinate complex molecules, to the point\u000a      where it has now been adopted as the method of choice in industry for the\u000a      synthesis of a wide range of products, including being the preferred\u000a      fluorinating reagent in medicinal chemistry drug discovery projects within\u000a      Pfizer \"SelectFluor&#174; is a milder, safer and more easily\u000a        handled alternative to DAST (diethylaminosulfur trifluoride) and, as\u000a        such, it is a preferred fluorinating reagent in medicinal chemistry drug\u000a        discovery projects within Pfizer\" (Senior Director, Worldwide\u000a      Medicinal Chemistry &#8212; Oncology, Pfizer) [A], and used to prepare one of\u000a      the most prescribed billion-dollar fluorosteroid products in the modern\u000a      pharmaceutical industry. \"Prior to Selectfluor&#174;'s discovery and\u000a        development, only a very few companies would dare face the challenges of\u000a        producing fluorinated steroids because of the necessity to obtain and\u000a        handle perchlorylfluoride, the only reagent available at the time to\u000a        provide electrophilic fluorination.\u000a    [Previously] perchlorylfluoride used in the production of\u000a        fluorosteroids had resulted in the fatalities of 2 production workers,\u000a        and as a result, the industry refused to consider commercial production\u000a        using the reagent. With the development of Selectfluor&#174; chemistry,\u000a        this stable, safe, and readily handled white solid made it possible for\u000a        any company wishing to introduce electrophilic fluorination to do so.\u000a        Selectfluor&#174; was a game-changing innovation for commercial\u000a        production of fluorinated steroids\" (Research Fellow, Arkema &#8212;\u000a      formerly at Air Products) [B].\u000a    Pathways to impact\u000a    Selectfluor&#174; was developed in Manchester by Professor R. Eric Banks in\u000a      collaboration with, and funded by, Air Products Inc. Following its\u000a      development the research carried out in Manchester determined and\u000a      exemplified the reactivity and conditions of use for Selectfluor&#174; which\u000a      has subsequently led to it becoming the world's most widely adopted\u000a      electrophilic fluorinating agent to date.\u000a    Our publications of Selectfluor&#174;'s reactivity and protocols for its use\u000a      were published between 1994 and 1999, shortly afterwards patents\u000a      describing the application of Selectfluor&#174; started to appear. In total\u000a      from 1993 to 2012, there have been 134 patents published which cite\u000a      Selectfluor&#174; (SciFinder search 07.01.2013), that cover a wide range of\u000a      multinational companies, countries and scientific areas.\u000a    Impact\u000a    As the chemistry and applications of Selectfluor&#174; were developed and the\u000a      industrial relevance of this compound became obvious Selectfluor&#174;\u000a      production was developed over a 5 year period onto a commercial scale. It\u000a      is now produced on a multi-tonne quantity in America, China and other\u000a      countries, with estimated annual production and sales figures of ca. 25\u000a      tonnes and $7.5m (USD) per annum [C].\u000a    `Selectfluor&#174;'s widespread availability at commercial volumes\u000a        and its acceptance by both academic and industrial chemists changed the\u000a        way researchers and process development chemists in pharmaceutical and\u000a        agricultural industries think about fluorination. Selectfluor&#174; became\u000a        the first tool of choice for any process requiring electrophilic\u000a        fluorination and even today it remains the most popular reagent used'\u000a      (Research Fellow, Arkema &#8212; formerly at Air Products) [B].\u000a    This has impacted on some of the largest pharmaceutical companies, for\u000a      example: Bayer for the application and processes for the preparation of\u000a      halogen-substituted compounds, for controlling animal pests, especially\u000a      arthropods, arachnids and nematodes; Pfizer for the synthesis of fluorine-\u000a      containing morpholine compounds as therapeutic mineralocorticoid receptor\u000a      antagonists to control hypertension, congestive heart failure and chronic\u000a      kidney disease; Glaxo Group Ltd for Napththyrdin-2(1H) based compounds of\u000a      use as antibacterials, for example in the treatment of tuberculosis;\u000a      AstraZeneca AB for the synthesis of compounds used as selective\/potent\u000a      GSK3 (glycogen synthase kinase 3) inhibitors of relevance to treatment in\u000a      chronic and acute neurodegenerative diseases, Alzhimer's disease,\u000a      Schizophrenia and bipolar disorders, diabetes, inflammatory diseases and\u000a      cancers.\u000a    The area in which the chemistry of Selectfluor&#174; has had the most\u000a      significant impact is as the electrophilic fluorinating agent of choice\u000a      for the generation of fluorine-substituted corticosteroids used as\u000a      anti-inflammatory drugs [D,E]. It is estimated that ca. 80 % of the\u000a      currently produced fluorinated steroids, critical for the improvement in\u000a      quality of many people's lives, are produced using Selectfluor&#174; and this\u000a      is backed up by the patent literature [O'Hagan, J. Fluorine Chem. 2010, 131,\u000a      1071].\u000a    Fluticasone propionate (from flumethasone or flumetasone) is the active\u000a      ingredient in a very wide range of pharmaceutical products for the\u000a      treatment of asthma and chronic obstructive pulmonary disease symptoms.\u000a      This fluorinated ingredient was first developed and patented in the early\u000a      1960's, based on small scale routes involving the use of anhydrous\u000a      HF\/Pb(OAc)4, SF4 or ClO3F (perchloryl\u000a      fluoride) to introduce fluorine, all of which are hazardous and difficult\u000a      to handle. Since the development of Selectfluor&#174;'s chemistry companies,\u000a      such as Hovione, Taro and Farmabios, have patented Selectfluor&#174;-based\u000a      methods as their preferred routes, including (but not limited to) EP\u000a      1207166 (2002), WO 02\/100878 (2002) [F], US 7098328 (2006) [G], and US\u000a      7718793 (2010) [H]. These described (and cite) methods based on references\u000a      [1], [2] and R. E. Banks et al J. Fluorine Chem. 1998, 87, 1-17, as the\u000a      preferred method for the generation of this, and other corticosteroid\u000a      anti-inflammatory agents.\u000a    This fluorinated steroid produced in this way is sold-on and formulated\u000a      into a number of products which sell under tradenames such as Flixonase,\u000a      Flixotide, Flonase, Flovent HFA and Advair Diskus. The latter two GSK\u000a      products are in the top 25 selling drugs. Data from: www.drugs.com\/top200.html\u000a      (accessed 8.1.2013) or from the IMS Institute for Healthcare Informatics\u000a      (which covers US sales alone) shows that these pharmaceuticals for the\u000a      years 2009-2012 had total sales of over $17bn, corresponding to ca. 75\u000a      million units for Advair Diskus alone. The reach of this\u000a      Selectfluor-prepared fluorine-containing drug is truly international and\u000a      benefits many millions of users per annum.\u000a    ","ImpactSummary":"\u000a    The development of the chemistry of Selectfluor&#174; (F-TEDA-BF4)\u000a      has resulted in this Manchester-discovered reagent becoming the world's\u000a      most widely used commercial electrophilic fluorinating agent to introduce\u000a      fluorine into a range of pharmaceuticals and agrochemicals. Annual\u000a      worldwide production is ca. 25 tonnes and sales estimated to be US$7.5m.\u000a      Selectfluor is used in the synthesis of fluticasone, a fluorinated\u000a      corticosteroid which is the active ingredient in GSK's Advair ($3.6bn\u000a      sales in 2010) used in the treatment of asthma and chronic obstructive\u000a      pulmonary disease symptoms; top 25 selling drugs Flixonase, Flixotide,\u000a      Flonase, Flovent HFA and Advair Diskus which had total sales of over $17bn\u000a      between 2009-2012.\u000a    ","ImpactType":"Technological","Institution":"\u000a    The University of Manchester\u000a    ","Institutions":[{"AlternativeName":"Manchester (University of)","InstitutionName":"University of Manchester","PeerGroup":"A","Region":"North West","UKPRN":10007798}],"Panel":"B         ","PlaceName":[],"References":"\u000a    All of the papers appear in peer-reviewed international journals,\u000a      including two of the foremost Royal Society of Chemistry journals, and the\u000a      specialist journal for fluorine chemists, the Journal of Fluorine\u000a      Chemistry. Citations are from Google Scholar.\u000a    Key references:\u000a    \u000a[1] N-Halogeno compounds. Part 18.\u000a      1-Alkyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane salts: user-friendly\u000a      site-selective electrophilic fluorinating agents of the N-fluoroammonium\u000a      class, R. E. Banks, M. K. Besheesh, S. N. Mohialdin-Khaffaf, I. Sharif, J.\u000a      Chem. Soc., Perkin 1, 1996, 2069-2076 (doi: 10.1039\/P19960002069)\u000a      - 96 citations\u000a    \u000a\u000a[2] Efficient electrophilic fluorination of 03b2-dicarbonyl compounds\u000a      with the selectfluor reagent F-TEDA-BF4\u000a      {1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane\u000a      bis(tetrafluoroborate)}, R.E. Banks, N. J. Lawrence, A. L. Popplewell, J.\u000a      Chem. Soc., Chem. Commun., 1994, 343-344. (doi: 10.1039\/C39940000343)\u000a      - 66 citations\u000a    \u000a\u000a[3] Oxidation of benzylic alcohols and benzaldehydes with the Selectfluor\u000a      reagent F-TEDA-BF4\u000a      {1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane\u000a      bis(tetrafluoroborate)}, R.E. Banks, N. J. Lawrence, A. L. Popplewell,\u000a      Synlett. 1994, 831-832 (doi: 10.1055\/s-1994-23021)\u000a      &#8212; 26 citations\u000a    \u000aOther references\u000a    \u000a[4] Remote functionalization of (-)-menthol&#8212;synthesis of\u000a      4a,5,6,7,8,8a-hexahydro-4H-benzo[1,3]oxazine derivatives with the\u000a      SelectfluorTM reagent F-TEDA-BF4, R.E. Banks, N. J.\u000a      Lawrence, M. K. Besheesh, A. L. Popplewell, R.G. Pritchard, Chem. Commun.,\u000a      1996, 1629-1630. (doi: 10.1039\/CC9960001629)\u000a    \u000a\u000a[5] N-Halogeno compounds. Part 20. Vicarious electrophilic\u000a      fluorodemethylation of 1,3,5-trimethoxybenzene and 2,4,6-trimethoxytoluene\u000a      with 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane\u000a      bis(tetrafluoroborate) (Selectfluor&#8482; reagent F-TEDA-BF4), R. E.\u000a      Banks, M. K. Besheesh, R. W. Gorski, N. J. Lawrence, A. J. Taylor, J.\u000a      Fluorine Chem., 1999 , 96, 129-133. (doi: 10.1016\/S0022-1139(99)00064-0)\u000a    \u000a\u000a[6] N-Halogeno compounds. Part 14. \"Transfer fluorination\" of\u000a      quinuclidine using F-TEDA-BF4 (SelectfluorTM\u000a      reagent): laboratory synthesis of N-fluoroquinuclidinium salts not\u000a      requiring the use of elemental fluorine, M. Abdul-Ghani, R. E. Banks, M.\u000a      K. Besheesh, I. Sharif, R. G. Syvret, J. Fluorine Chem., 1995, 73,\u000a      255-257. (doi: 10.1016\/0022-1139(94)03225-O)\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"}],"Sources":"\u000a    A) Corroboration of Selectfluor&#174; impact. Letter from Senior Director,\u000a      Pfizer.\u000a    B) Corroboration of commercial impact of Selectfluor&#174;. Letter from\u000a      Research Fellow at Arkema.\u000a    C) An email discourse with scientist who was at Air Products when\u000a      Selectfluor&#174; was commercialised.\u000a    D) C. G. Pozzoli, F. La Loggia, F. Malanga, Farmabios SpA, Synthesis of\u000a      Fluoro-corticosteroids, La Chimica, L'Industria, 2013, 124 - 128.\u000a    E) Dabbling with Fluorine, C&amp;E News, 90(9), 27th February 2012 pp.\u000a      10-17.\u000a    F) Villax, Z. Mendes, WO 02\/100878,, June\u000a      11, 2002, Preparation of flumethasone and its 17- carbonyl androsten\u000a      analogue, assigned to Hovione Limited.\u000a    G) S. Chernyak, M. Zarbov, D. Gutman, US7098328,\u000a      August 29 2006, Method for the Preparation of 6&#945;-fluoro corticosteroids,\u000a      assigned to Taro Pharmaceutical Industries.\u000a    H) S. Chernyak, M. Zarbov, D. Gutman, US7718793,\u000a      May 18, 2010, Method for the Preparation of 6-&#945; fluoro corticosteroids,\u000a      assigned to Taro Pharmaceutical Industries \u000a    ","Title":"\u000a    The development of Selectfluor&#174; as a commercial electrophilic\u000a      fluorinating agent\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000a    The research was carried out in the UoA between 1993-2004. The key\u000a      Manchester researchers were:\u000a    Professor R. E. Banks (professor 1993-1994, emeritus professor 1994-2004)\u000a      Dr N. J. Lawrence (lecturer 1993-1997, senior lecturer 1997-2000)\u000a      Dr M. Besheesh (PhD student 1993-1994, PDRA 1994-2001)\u000a      Dr I. Sharif (PDRA, 1993-1994)\u000a      A.L. Popplewell (PhD student, 1994-1997)\u000a    In particular work was undertaken to show the effectiveness, range of\u000a      applications and utility of Selectfluor&#174; as an electrophilic fluorinating\u000a      agent, an oxidising agent and as a fluorine-transfer reagent. The key\u000a      steps in demonstrating these classes of reactivity were\u000a    \u000a      Use as a fluorinating agent for 1,3-diketones and keto-amides,\u000a        demonstration that fluorination with Selectfluor&#174; occurs more rapidly\u000a        for compounds which exist in their enolic form, and that Selectfluor&#174;\u000a        was as effective as DesMarteau's reagent, but more advantageous, because\u000a        of its lower cost and less hazardous nature.[2]\u000a      Demonstration of the use of Selectfluor&#174; as an oxidising agent for\u000a        alcohols via acid fluorides[3] and how this may be used to effect\u000a        remote-functionalisation.[4]\u000a      Establishing that Selectfluor&#174; can be used under a fluorine-transfer\u000a        protocol to prepare other fluorinating agents of the N-F class, which\u000a        has subsequently led to asymmetric fluorinating agents and [18-F]\u000a        variants for PET work.[6]\u000a      Detailing the properties of Selectfluor&#174; compared with other N-F\u000a        reagents, how modification of counter-ions impacts on solubility and\u000a        protocols for fluorination of a wide range of substrates, including how\u000a        to activate otherwise unreactive substrates.[1]\u000a    \u000a    Some of the limitations of the reagent, due to fluorodemethylation\u000a      side-reactions, and hence how to protect against this eventuality.[5]\u000a    "},{"CaseStudyId":"28089","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"660013","Name":"Finland"},{"GeoNamesId":"1835841","Name":"South Korea"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2802361","Name":"Belgium"}],"Funders":[],"ImpactDetails":"\u000a    The following exemplifies OMIC impact in teems of policy and up\u000a        skilling industry as well as\u000a        two examples of economic impact based upon research with SME deriving\u000a        from basic\u000a        research performed within the UoA.\u000a    OMIC [A,B,C,D]\u000a    Context: The Organic Materials Innovation Centre (OMIC) was\u000a      established by initial funding of\u000a      &#163;4.25m from the Department of Trade and Industry in 2002 to the University\u000a      of Manchester for\u000a      work on knowledge transfer from academe to industry in the thematic areas\u000a      of Complex Fluids,\u000a      Organic Electronics, Biomaterials and High Performance\u000a        Materials. Its success [A] led to an award\u000a      from the North West Development Agency of over &#163;8m (ca. &#163;3m to\u000a      Manchester) in October 2008\u000a      to start the North West Knowledge Centre for Materials Chemistry (KCMC,\u000a      2008-2012) [B]. In the\u000a      first four years of operation (2008-12), the KCMC in Manchester has\u000a      carried out 100 projects with\u000a      industry for a value of over &#163;5.4m which includes over &#163;3.2M of industry\u000a      income [C].\u000a    Pathways to Impact: OMIC enables effective knowledge transfer to\u000a      industry through a flexible\u000a      engagement model, which is attractive for the smallest SME through to the\u000a      largest multinational.\u000a      Flexibility is enabled through the ability to engage in projects as short\u000a      as a few weeks with the\u000a      ability through UoM procedures to put in place agreements between parties\u000a      on a very short time\u000a      scale. Projects have included embedding industrial researchers in the OMIC\u000a      laboratories as well as\u000a      OMIC scientists into industrial laboratories. Knowledge transfer is also\u000a      facilitated through tailored\u000a      CPD and training events for industry in thematic areas where OMIC has\u000a      recognized academic\u000a      excellence.\u000a    Impact: Through its position as one of the UK's four academic,\u000a      plastic electronics centres of\u000a      excellence, as recognised in the House of Commons Select Report in 2008\u000a      [D], OMIC is a\u000a      founding member of the Plastic Electronics Leadership Group and these\u000a      activities are helping to\u000a      advocate and shape the UK strategy in this emerging field and direct TSB\u000a      funding in the area.\u000a      Internationally, OMIC through Professor Yeates was invited to contribute\u000a      as experts to the\u000a      international White Paper from the Chemical Sciences and Society Summit\u000a      (CS3) on `Organic\u000a      Electronics for a Better Tomorrow: Innovation, Accessibility,\u000a      Sustainability' 2012 and also the EU\u000a      project on developing the roadmap for digital fabrication `Diginova'. As\u000a      part of this advocacy, OMIC\u000a      has hosted inward investment missions from Finland, Korea and Belgium as\u000a      well as providing\u000a      training to over 250 people in industry since 2008. Events have included\u000a      `Future generation solar\u000a      cells' in 2008, `Opportunities in printed solar cells', 2009, and\u000a      `Chemicals and materials for printed\u000a      electronics', 2011. A recent survey by the Plastic Electronics Leadership\u000a      Group confirmed that\u000a      while the industry is still in its infancy, there are now over 150\u000a      businesses in the UK with activities\u000a      in this field, more than double that of four years ago. Most of those are\u000a      SMEs developing materials\u000a      and devices but there are already some end-users such as De La Rue and\u000a      Reckitt-Benckiser\u000a      working to apply the technology in their products.\u000a    ACAL Energy [E]\u000a    Context: Fuel cells produce electrical power directly from\u000a      chemicals and offer the potential to be a\u000a      more efficient and clean way to generate power when compared to the\u000a      combustion of fuels.\u000a      Hydrogen-fuelled 10-100 kW fuel cells provide a cost-effective method for\u000a      power production\u000a      particularly at sites where lower life-cycle costs, cleaner and quieter\u000a      operation, longer runtimes,\u000a      and lower maintenance requirements are important. However concerns over\u000a      cost and lifetime have\u000a      limited their adoption. ACAL Energy is an UK SME developing a novel\u000a      approach to the fuel cell\u000a      cathode &#8212; the FlowCath&#174; technology.\u000a    Pathways to Impact: ACAL Energy collaborated with the Collison and\u000a      May (2) group by\u000a      embedding a company scientist within the group and by consultancy from\u000a      2006, because of their\u000a      expertise on polyoxometallates. This research led to the initial FlowCath&#174;\u000a      technology. Collaboration\u000a      with the Turner and Proctor groups (5) through a combination of the\u000a      flexible OMIC model, KTP and\u000a      PhD funding on novel nitrogen-containing ligands is enabling more\u000a      efficient fuel cells to be\u000a      developed.\u000a    Impact: Since 2008 ACAL Energy has received &#163;15m of venture\u000a      capital investment, created in\u000a      excess of 20 jobs and won the Carbon Trust's Polymer Fuel Cell Challenge.\u000a      ACAL Energy's\u000a      patented FlowCath&#174; technology is the first example of a non-Pt\u000a      based fuel cell cathode system and\u000a      the first installation is now located in at the Solvay Interox Chemical\u000a      Plant, UK. ACAL Energy fuel\u000a      cells using a polyoxometallate catalyst compete with conventional\u000a      electricity generators by\u000a      reducing the platinum content by up to 80% which represents 20-25 % of the\u000a      total cost of a system.\u000a      These fuel cells show no deterioration in performance after 10,000 hrs of\u000a      rigorous automotive test\u000a      cycles (equivalent to 300,000 miles). This is comparable to the best\u000a      light-weight diesel engines\u000a      (100kW equivalent to a 2 L diesel engine) and exceeds the 2017 US\u000a      Department of Energy (DoE)\u000a      industry target for fuel cell powered vehicles. The durability of the fuel\u000a      cells allows the system to be\u000a      applied to stationary power applications where 40,000 hrs (10 years of\u000a      product lifetime) operation\u000a      is required. As a result ACAL Energy fuel cell units will be installed at\u000a      the UK's first open access H2\u000a      refuelling station to be located at Honda's manufacturing site in Swindon.\u000a    Byotrol [F]\u000a    Context: Cleaning products, such as bleach and alcohol-based\u000a      products, stop working as soon as\u000a      they dry, which allows bacteria and other microbes to quickly recolonize;\u000a      a single surviving\u000a      bacterium can produce up to 8 million descendants by the next day. In\u000a      contrast, Byotrol technology\u000a      which is based upon surfactant-polymer mixtures kills and destroys\u000a      instantaneously bacteria and\u000a      viruses and then dries to form a long-lasting antimicrobial barrier that\u000a      stops germs from\u000a      re-populating for up to 24 hrs.\u000a    Pathways to Impact: In 2007, Byotrol approached the University of\u000a      Manchester based upon our\u000a      previous work in the area of complex aqueous surfactant mixtures [3], and\u000a      our then unpublished\u000a      work on complex aqueous polymer-surfactant mixtures [6] with the aim of\u000a      understanding the\u000a      mechanism of long-lasting antimicrobial performance and of developing more\u000a      effective and\u000a      reproducible formulations which in turn could lead to a stronger IP\u000a      position in this highly\u000a      competitive market. This resulted in the filing of patent WO2010043863,\u000a      which covers and\u000a      exemplifies novel formulation classes, addressing the dual challenges of\u000a      effective antimicrobial kill\u000a      coupled with long term follow-on performance. This was continued by a one\u000a      year Molecular\u000a      Engineering Translational Research Centre (METRC) proof of concept grant\u000a      in 2009-2010 and\u000a      supported by a direct funded iCASE PhD 2009-13.\u000a    Impact: The research performed under the above engagement modes\u000a      has contributed to the\u000a      technology being further developed and optimized to provide reproducible,\u000a      fast acting and powerful\u000a      performance across all microbial classes [E]: bacteria, viruses, fungi,\u000a      moulds &amp; algae killing up to\u000a      99.99% of germs in 30 seconds when tested against the most stringent test\u000a      methodologies\u000a      including BS:EN 1276 Standard, BS:EN 13697 Standard, BS:EN 1650 Standard,\u000a      BS:EN 14476\u000a      Standard and Residual Abrasion Testing methodologies. In 2013, Byotrol\u000a      reported sales of &#163;2.19m\u000a      with a year-on-year growth of 12% per annum. Byotrol technology has been\u000a      introduced into a wide\u000a      range of consumer products across the healthcare, food and beverage and\u000a      consumer goods\u000a      sectors [E], through both direct sales and partnership with some of the\u000a      world's leading brands\u000a      including Boots, PZ Cussons, Heinz, Kimberley Clark, Marks and Spencer and\u000a      Rentokil Initial\u000a      Group (UltraProtect&#8482;).\u000a    ","ImpactSummary":"\u000a    The activities of the Organic Materials Innovation Centre (OMIC) at the\u000a      University of Manchester\u000a      generate impact from its research activities through knowledge transfer to\u000a      industry. This is\u000a      exemplified by:\u000a    \u000a      Enabled UK SME ACAL Energy, through technology transfer and\u000a        development, to create in\u000a        excess of 20 jobs, raise &#163;15m of venture capital investment to develop\u000a        their FlowCath&#174;\u000a        fuel-cell technology.\u000a      Enabled UK SME Byotrol, through improved understanding to develop\u000a        novel anti-microbial\u000a        technology which has been licensed to global fast moving consumer goods\u000a        companies with\u000a        sales of &#163;2.19m per annum.\u000a    \u000a    Provision of research-based training in the field of printed electronics\u000a      and sensors to over 250\u000a      people from 2008 onwards.\u000a    ","ImpactType":"Technological","Institution":"\u000a    The University of Manchester\u000a    ","Institutions":[{"AlternativeName":"Manchester (University of)","InstitutionName":"University of Manchester","PeerGroup":"A","Region":"North West","UKPRN":10007798}],"Panel":"B         ","PlaceName":[],"References":"\u000a    Publications are in leading journals in the respective fields, having led\u000a      to invitations to speak at\u000a      international conferences. Citations are from Google Scholar.\u000a    Key Publications\u000a    \u000a1. Real-time vapour sensing using an OFET-based electronic nose and\u000a      genetic programming.\u000a      D.C. Wedge, A. Das, R. Dost, J. Kettle, M-B. Madec, J.J. Morrison, M.\u000a      Grell, D.B. Kell, T.H.\u000a      Richardson, S.G. Yeates, M.L. Turner, Sensors and Actuators, B: Chemical\u000a      (2009),\u000a      B143(1), 365-372. [citations = 11] DOI\u000a        10.1016\/j.snb.2009.09.030\u000a    \u000a\u000a2. A rare structural characterisation of the phosphomolybdate lacunary\u000a      anion, [PMo 11O39]7-.\u000a      Crystal structures of the Ln(III) complexes, A.J. Gaunt, I. May, M. J.\u000a      Sarsfield, D. Collison, M.\u000a      Helliwell, and I. S. Denniss, Dalton Trans., 2003, 2767. [citations = 55]\u000a      DOI\u000a      10.1039\/B301995K\u000a    \u000a\u000a3. Micellisation and Gelation of Mixed Copolymers P123 and F127 in\u000a      Aqueous Solution. C.\u000a      Chaibundit, N.M.P.S. Ricardo, F. de M.L.L.C. Costa, S.G. Yeates, C. Booth,\u000a      Langmuir\u000a      (2007), 23(18), 9229-9236. [citations = 47] DOI: 10.1021\/la701157j\u000a    \u000aOther Publications\u000a    \u000a4. High performance, Acene-Based Organic Thin Film Transistors, G. Rincon\u000a      Llorente, M-B\u000a      Dufourg-Madec, D.J. Crouch, R.G. Pritchard, S. Ogier and S.G. Yeates,\u000a      Chem.Comm.,\u000a      (2009), (21), 3059-3061. [citations = 25] DOI: 10.1039\/B901448A\u000a    \u000a\u000a5. A Fluorous, Pummerer Cyclative-Capture Strategy for the Synthesis of\u000a      N-Heterocycles, L. A.\u000a      McAllister, R. A. McCormick, K. M. James, S. Brand, N. Willetts, and D. J.\u000a      Procter, Chem.\u000a      Eur. J., 2007, 13, 1032-1046. [citations = 25] DOI: 10.1002\/chem.200601429\u000a    \u000a\u000a6. The effect of polymeric additives on the solubilisation of a\u000a      poorly-soluble drug in micellar\u000a      solutions of Pluronic F127. C.P. Oliveira, L.C.G. Vasconcellos, M.E.N.P.\u000a      Ribeiro, N.M.P.S.\u000a      Ricardo, T.V. de P. Souza, F. de M.L.L.C. Costa, C. Chaibundit, S.G.\u000a      Yeates, and D.\u000a      Attwood, International Journal of Pharmaceutics (2011), 409(1-2), 206-208.\u000a      [citations = 9]\u000a      DOI:\u000a        10.1016\/j.ijpharm.2011.02.025\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"3","Subject":"Macromolecular and Materials Chemistry"},{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"}],"Sources":"\u000a    A) Evaluation of University Innovation Centre's, Report for BERR, Tribal\u000a      Consulting, March\u000a      2009. Independent report on success of OMIC over the funding period\u000a      2004-2008.\u000a    B) NW Science Strategy 2007-2010, NWDA, 2010. Establishment of KCMC and\u000a      key partner\u000a      role of OMIC.\u000a    C) KCMC report.2012. Report on performance of KCMC against agreed metrics\u000a      from 2009-\u000a      2012.\u000a    D) House of Commons Select Committee report on Plastic Electronics 2008.\u000a      Recognition of\u000a      OMIC of one of four UK centre's of excellence in printed electronics.\u000a    E) ACAL Energy, Chief Technology Officer. Corroboration of UoM and OMIC\u000a      technology\u000a      translation and support to ACAL Energy and ensuing impact.\u000a    F) Byotrol, Chief Scientist. Corroboration of UoM and OMIC technology\u000a      translation and support\u000a      to Byotrol and ensuing impact.\u000a    \u000a    ","Title":"\u000a    Organic Materials Innovation Centre (OMIC)\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000a    The impact is based on research that took place at the University of\u000a      Manchester between the\u000a      following key researchers:\u000a    \u000a      Professor Michael Turner (2004-date)\u000a      Professor Stephen Yeates (2004-date)\u000a      Dr Colin Booth (1993-1999)\u000a      Dr Iain May (2000-2006) - lecturer\u000a      Professor David Collison (1993-date)\u000a      Professor David Procter (2004-date)\u000a      Dr Andromachi Malandraki (2009) -PDRA\u000a    \u000a    Electronic nose (1): Demonstration that arrays of organic field\u000a      effect transistors can selectively\u000a      detect airborne analytes in real time. The use of multiple parameters &#8212; on\u000a      resistance, off current\u000a      and mobility &#8212; collected from multiple transistors coated with different\u000a      semiconducting polymers\u000a      gives dramatic improvements in the sensitivity, specificity and speed of\u000a      sensing.\u000a    Polyoxometallate chemistry (2): Research on the coordination\u000a      chemistry of polymolybdate\u000a      anions with zirconium, lanthanide or actinide heteroatoms. Careful\u000a      manipulation of the Keggin ion\u000a      structure [PMo 12O40]3- lead to loss of {M=O]4+\u000a      and gave the monovacant lacunary anion [PMo 11O39]7-, which has\u000a      four unsaturated oxygen atoms available for coordination to a positive\u000a      metal centre. This was confirmed in the solid state by single-crystal and\u000a      powder X-ray diffraction\u000a      studies and in solution by NMR, FT-IR and UV-VIS spectroscopy.\u000a    Micellisation and gelation behaviour of mixed surfactants (3):\u000a      Investigation of the nature of the\u000a      interaction of surfactant mixtures in aqueous solution on formation of\u000a      hierarchical structures and\u000a      subsequent gelation behavior.\u000a    Materials for organic electronics (4): The synthesis of\u000a      substituted pentacene derivatives having\u000a      optimised crystal structure for high hole mobility and their subsequent\u000a      use in organic field effect\u000a      transistors.\u000a    Heterocyclic chemistry (5): Central to the chemistry described in\u000a      [4] is a new Pummerer process\u000a      that provided rapid access to fluorous-tagged, heterocyclic frameworks\u000a      that can be modified using\u000a      a variety of approaches, easily purified by retention on fluorous-silica\u000a      and the fluorous-tag cleaved\u000a      reductively or oxidatively to give access to a diverse range of N-heterocyclic\u000a      systems.\u000a    Effect of polymer additives on drug solubilisation in micellar systems\u000a        (6): Investigation of the\u000a      effect water soluble polymers on the uptake of hydrophobic drugs in\u000a      micellar solutions. Increased\u000a      drug uptake is rationalized in terms of synergistic interaction between\u000a      the water soluble polymer\u000a      and the micelle corona.\u000a    "},{"CaseStudyId":"28090","Continent":[],"Country":[],"Funders":["Engineering and Physical Sciences Research Council","Medical Research Council","Royal Society"],"ImpactDetails":"\u000d\u000a    Context\u000d\u000a    Nuclear magnetic resonance is one of the most important and powerful\u000d\u000a      analytical tools used by chemists. It is able to determine, for example,\u000d\u000a      the composition of a mixture, the structures of complex molecules, and the\u000d\u000a      mobilities of these molecules. However, to direct the complex and\u000d\u000a      precisely-timed sequences of radiofrequency and magnetic field pulses that\u000d\u000a      are used in an NMR spectrometer to measure these different properties of\u000d\u000a      substances is a science in itself. The Impact described in this case\u000d\u000a      relates to the development and commercial exploitation of one such family\u000d\u000a      of pulse sequences, known as DOSY, that is able to analyse complex\u000d\u000a      mixtures in a unique manner that has proved vital to industrial research\u000d\u000a      and product development.\u000d\u000a    Pathways to impact\u000d\u000a    The initial impetus for our developments in DOSY came from an industrial\u000d\u000a      collaboration with Pfizer Global Research, and led to dedicated processing\u000d\u000a      software which was initially shared widely but informally with other\u000d\u000a      users. The subsequent development of DOSY software for the proprietary\u000d\u000a      operating system of the major NMR manufacturer Varian (now Agilent) gave\u000d\u000a      both the opportunity to exploit the intellectual property generated, and\u000d\u000a      an effective vehicle for disseminating the results to a wide range of\u000d\u000a      users including many industrial research organisations. Key contributors\u000d\u000a      to this Impact were the School policy of maintaining shared\u000d\u000a      high-resolution NMR facilities, and the assistance of UMIP (University of\u000d\u000a      Manchester Intellectual Property management agent) in negotiating the\u000d\u000a      licensing of DOSY software. In parallel, open-source DOSY processing code\u000d\u000a      was made available through the DOSY Toolbox, which is now in use in 68\u000d\u000a      countries and has contributed to a significant shift in practice and\u000d\u000a      capacity in industrial research.\u000d\u000a    Since the commercialisation of this technique many of the 100 or so papers\u000d\u000a    on DOSY published each year are from industry, but inevitably only a small\u000d\u000a    proportion of industrial use of DOSY is captured by such a metric. \"... the\u000a      interest in, and use of, DOSY in the pharmaceutical industry is far\u000d\u000a      greater than that evidenced by publications in the public domain. The\u000d\u000a      majority of applications are at later stages of product development, when\u000d\u000a      information on mixture composition is most valuable, and here publishing\u000d\u000a      opportunities are very limited because of confidentiality concerns.\"\u000d\u000a    (Vice-President R&amp;D, Mestrelab Research) [A]\u000d\u000a    In addition to the widespread use of our data processing software, DOSY\u000d\u000a      experiments developed at Manchester have now been incorporated into the\u000d\u000a      software of almost all commercial high-resolution NMR equipment. \"The\u000d\u000a        overwhelming majority of DOSY users are dealing with mixtures of small\u000d\u000a        organic or inorganic molecules but there are scientists at bio-NMR sites\u000d\u000a        where DOSY is regularly used to monitor molecular associations.\"\u000d\u000a      (Applications Scientist, Agilent) [B]\u000d\u000a    DOSY NMR has had fundamental impact in a diverse range of important\u000d\u000a      sectors that include pharmaceuticals, fine chemicals, petrochemicals, and\u000d\u000a      flavours and fragrances. \"Mixture analysis using NMR is a large,\u000d\u000a        diverse problem that relies on a number of techniques. DOSY is widely\u000d\u000a        perceived to be vital technology for this purpose.\" (Vice-President\u000d\u000a      R&amp;D, Mestrelab Research) [A]\u000d\u000a    Impact\u000d\u000a    The principal impacts associated with DOSY NMR are:\u000d\u000a    1 \"The performance of an existing business has been improved through\u000d\u000a        the introduction of new ... products\". Our DOSY experimental methods\u000d\u000a      and data processing software have allowed new products to be developed,\u000d\u000a      with major economic impact. For example, the flavourings and fragrances\u000d\u000a      manufacturer Givaudan used DOSY to discover a new flavour ingredient,\u000d\u000a      generating a total sales growth for that product alone of more than 50M\u000d\u000a      CHF (&#163;35m) over the REF period, which is more than 20 % compared to the\u000d\u000a      status quo. (Researcher, Givaudan) [C]\u000d\u000a    2 \"A business or sector has adopted a new or significantly changed\u000d\u000a        technology\". Our DOSY methods have generated major changes in\u000d\u000a      capacity and practice in industrial research; the last time industry\u000d\u000a      changed its use of NMR to such an extent was with the introduction of\u000d\u000a      multidimensional methods in the 1980s. For example, Givaudan now analyse\u000d\u000a      approximately 20 % of all NMR samples using DOSY. Syngenta, one of the\u000d\u000a      world's leading agricultural science companies, uses DOSY to assist in\u000d\u000a      reducing the environmental impact associated with the use of its\u000d\u000a      plant-protection products by optimising plant protection formulations, and\u000d\u000a      \" ... to measure the rate of diffusion of plant protection compounds in\u000d\u000a        water which will help us understand their breakdown in the environment\u000d\u000a        ... The `One-Shot' sequence [reference 3 above] ... is our\u000d\u000a        preferred method of acquiring DOSY NMR spectra because it increases\u000d\u000a        throughput on our NMR spectrometers.\" (Researcher, Syngenta) [D]. At\u000d\u000a      the multinational chemical manufacturer DuPont, DOSY is now used in \"30%\u000a        of our projects ... mostly fluorochemical studies, but really studying\u000d\u000a        all kinds of reaction mixtures\" (Researcher, DuPont) [E].\u000d\u000a    3 \"The performance of an existing business has been improved through\u000d\u000a        ... the adoption of new, updated or enhanced technical standards and\/or\u000d\u000a        protocols\".Manchester's collaborative research and development of\u000d\u000a      DOSY NMR software with Varian (now Agilent) has positioned that company as\u000d\u000a      a leading global supplier of commercial DOSY NMR software. Software\u000d\u000a      developed specifically for Varian spectrometers was first licensed to them\u000d\u000a      in 2001 in a barter deal. In 2010, Varian licensed through the University\u000d\u000a      of Manchester's exclusive intellectual property company, UMIP Ltd, updated\u000d\u000a      software developed at the University of Manchester for incorporation into\u000d\u000a      their VnmrJ software, giving Varian\/Agilent a key competitive advantage. \"Since\u000a        incorporation of the advanced tools supplied by your group for DOSY data\u000d\u000a        collection and analysis into our software suite in 2009 we have licensed\u000d\u000a        51 copies of your program to academic and 31 copies to industrial\u000d\u000a        customers in connection with new instrument sales ... The 82\u000d\u000a      instruments referred to here cost between US$250k and several $m each and,\u000d\u000a      therefore, DOSY has given this manufacturer of NMR equipment a competitive\u000d\u000a      advantage that has contributed to several $10m's of instrument sales since\u000d\u000a      2009. It is rare, almost exceptional, that beyond producing breaking\u000d\u000a        scientific results and first class publications, a research group puts\u000d\u000a        so much extra effort into making their developments widely accessible\u000d\u000a        and usable by the whole NMR community.\" (Applications Scientist,\u000d\u000a      Agilent) [B].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Pioneering research in the UoA has driven significant advances in\u000d\u000a      diffusion-ordered nuclear magnetic resonance spectroscopy (DOSY),\u000d\u000a      resulting in pulse sequence and analysis software that has been\u000d\u000a      commercialised under licence by Agilent, and distributed as open-source\u000d\u000a      software across 68 countries. DOSY has given a manufacturer of NMR\u000d\u000a      equipment a competitive advantage that has contributed to several $10m's\u000d\u000a      of instrument sales since 2009. These advances have changed practice\u000d\u000a      and capacity in industry, through the introduction of new\u000d\u000a        products and processes: one of the world's largest chemical\u000d\u000a      companies is using the technique in about 30 % of all formulation\u000d\u000a      projects. DOSY is having significant economic impact: one food industry\u000d\u000a      company reporting sales growth of &#163;35m in the REF period as a direct\u000d\u000a      result of the use of DOSY.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    The University of Manchester\u000d\u000a    ","Institutions":[{"AlternativeName":"Manchester (University of)","InstitutionName":"University of Manchester","PeerGroup":"A","Region":"North West","UKPRN":10007798}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    The awards of the Royal Society of Chemistry Award in Magnetic Resonance\u000d\u000a      Spectroscopy to Morris and of the BRSG\/NMRDG Award for Excellent\u000d\u000a      Contribution to Magnetic Resonance by an Early Career Researcher to\u000d\u000a      Nillson were based in part on references 1-2 and 4-6 below respectively.\u000d\u000a      Citation numbers taken from Google Scholar (16\/9\/13).\u000d\u000a    Key references\u000d\u000a    \u000a1. H. Barjat, G.A. Morris, S. Smart, A.G. Swanson, and S.C.R. Williams,\u000d\u000a      \"High Resolution Diffusion Ordered 2D Spectroscopy (HR-DOSY) &#8212; A New Tool\u000d\u000a      for the Analysis of Complex Mixtures\", J. Magn. Reson., Ser. B, 108,\u000d\u000a      170-172 (1995). [154 citations]. DOI: dx.doi.org\/10.1006\/jmrb.1995.1118.\u000d\u000a    \u000a\u000a2. M.D. Pelta, H. Barjat, G.A. Morris, A.L. Davis and S.J. Hammond,\u000d\u000a      \"Pulse Sequences for High Resolution Diffusion-Ordered Spectroscopy\u000d\u000a      (HR-DOSY)\", Magn. Reson. in Chem., 36, 706-714 (1998). [167 citations].\u000d\u000a      DOI: dx.doi.org\/10.1002\/(SICI)1097-458X(199810)36:10&lt;706::AID-OMR363&gt;3.0.CO;2-W.\u000d\u000a    \u000a\u000a3. M.D. Pelta, G.A. Morris, M.J. Stchedroff and S.J. Hammond, \"A One-Shot\u000d\u000a      Sequence for High Resolution Diffusion Ordered Spectroscopy\", Magn. Reson.\u000d\u000a      in Chem. 40, S147-S152 (2002). [107 citations]. DOI: dx.doi.org\/10.1002\/mrc.1107.\u000d\u000a    \u000aOther references\u000d\u000a    \u000a4. M. Nilsson and G.A. Morris, \"Pure shift Proton DOSY: Diffusion-Ordered\u000d\u000a      1H Spectra without multiplet structure\", Chem. Commun. 2007, 933-935. [28\u000d\u000a      citations]. DOI: dx.doi.org\/10.1039\/b617761a.\u000d\u000a    \u000a\u000a5. S. Faulkner, M. Nilsson and G.A. Morris, \"Pure Shift Proton NMR: a\u000d\u000a      Resolution of the Resolution Problem?\", Angew. Chem. Int. Ed. 49,\u000d\u000a      3901-3903 (2010). [35 citations]. DOI: dx.doi.org\/10.1002\/anie.201001107.\u000d\u000a    \u000a\u000a6. R. Evans, S. Haiber, M. Nilsson and G.A. Morris, \"Isomer Resolution by\u000d\u000a      Micelle-Assisted Diffusion-Ordered Spectroscopy\", Anal. Chem. 81,\u000d\u000a      4548-4550 (2009). [30 citations]. DOI: dx.doi.org\/10.1021\/ac9005777.\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"6","Level2":"1","Subject":"Biochemistry and Cell Biology"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"1","Subject":"Analytical Chemistry"}],"Sources":"\u000d\u000a    The following users of DOSY have provided corroborative factual\u000d\u000a      statements.\u000d\u000a    A. Vice-President R&amp;D, MestreLab (Spain, industry). Corroboration of\u000d\u000a      impact in the pharmaceutical industry.\u000d\u000a    B. Applications Scientist, Agilent (Germany, industry). Corroboration of\u000d\u000a      incorporation in commercial instrumentation.\u000d\u000a    C. Researcher, Givaudan (Netherlands, industry). Corroboration of role in\u000d\u000a      identifying new flavour ingredients and resultant sales revenue.\u000d\u000a    D. Researcher, Syngenta (UK, industry). Corroboration of role in plant\u000d\u000a      protection formulations.\u000d\u000a    E. Researcher, DuPont (US, industry). Corroboration of utilisation in\u000d\u000a      industrial projects.\u000d\u000a    ","Title":"\u000d\u000a    Diffusion-Ordered Spectroscopy\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    The key Manchester researchers were:\u000d\u000a    \u000d\u000a      Professor Gareth Morris (Reader in Physical Chemistry 1994-1997,\u000d\u000a        Professor of Physical Chemistry 1998 to date);\u000d\u000a      Dr Mathias Nilsson (postdoctoral research associate 2005-2007, EPSRC\u000d\u000a        Advanced Research Fellow 2007-2012, Lecturer 2012, Reader 2013 to date).\u000d\u000a    \u000d\u000a    The rapid analysis of mixtures of samples by spectroscopic means is a\u000d\u000a      very important chemical function. One method that has been developed at\u000d\u000a      the University of Manchester exploits differences in diffusion rates\u000d\u000a      between mixture components to distinguish their characteristic NMR\u000d\u000a      spectra. The underpinning research has advanced significantly the\u000d\u000a      knowledge and understanding of DOSY NMR techniques and their applications\u000d\u000a      in determining the compositions of multi-component mixtures.\u000d\u000a    The key to mixture analysis using NMR is to be able to distinguish\u000d\u000a      between signals from different species. One distinctive characteristic of\u000d\u000a      a molecule (determined by its size) that can be measured with NMR is its\u000d\u000a      diffusion coefficient, and extending previous work by Charles Johnson we\u000d\u000a      developed methods to produce very high resolution spectra, for example\u000d\u000a      separating the signals of all the different components in a brain extract\u000d\u000a      (e.g. acetate, alanine, lactate, N-acetyl aspartate, glutamate) according\u000d\u000a      to size [1-3].\u000d\u000a    The power of DOSY was greatly increased by our introduction of broadband\u000d\u000a      homonuclear decoupling (\"pure shift\") methods, which can increase spectral\u000d\u000a      resolution by nearly an order of magnitude [4,5].\u000d\u000a    Our introduction of \"matrix-assisted DOSY\" [6] extended the method to\u000d\u000a      allow the analysis of mixtures in which species diffuse at the same rate,\u000d\u000a      for example those of isomers, by exploiting differential strengths of\u000d\u000a      interaction with a slowly-diffusing matrix.\u000d\u000a    "},{"CaseStudyId":"28111","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"1861060","Name":"Japan"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2661886","Name":"Sweden"}],"Funders":["Research Councils UK","Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000a    Context\u000a    Traditionally SIMS was limited primarily to the analysis of inorganic\u000a      materials due to the aggressive\u000a      nature of the primary ion beam employed, which caused significant damage\u000a      to the underlying\u000a      surface of the material and restricted the amount of meaningful\u000a      information that could be obtained\u000a      to less than 1% of the sample surface. In addition the low yield of\u000a      diagnostic secondary ions\u000a      limited the spatial resolution available in SIMS imaging of molecular\u000a      materials\u000a    Pathways to impact\u000a    In 1998 Professor Vickerman at the University of Manchester secured\u000a      3-years EPSRC funding\u000a      (&#163;190k,) to develop a primary ion beam based on buckminsterfullerene C60+.\u000a      Between 2000-2003,\u000a      in collaboration with Ionoptika a commercial C60+\u000a      ion beam system was developed that is protected\u000a      by 3 patents. The C60+ ion beam system has both\u000a      enabled the development of the next generation\u000a      of secondary ion mass spectrometers and Ionoptika to establish itself as\u000a      the world leading\u000a      manufacturer and supplier of commercial C60+ ion\u000a      beam systems.\u000a    In addition, further funding from RCUK and Ionoptika Ltd was secured to\u000a      evaluate the capabilities\u000a      of the C60+ ion beam and more recently to develop a\u000a      high-resolution time-of-flight SIMS instrument\u000a      that fully exploits the unique capabilities of C60+\u000a      for the study of biological and similarly complex\u000a      chemical systems. The C60+ primary ion beam\u000a      technology experienced immediate and rapid growth\u000a      from a specialist academic research interest to influence the whole\u000a      direction of SIMS and XPS\u000a      analysis and establish a whole new field of organic materials depth\u000a      profiling in life-sciences and\u000a      materials science. Applications for chemical imaging of tissues and in\u000a      disease research have\u000a      brought intense interest from the medical community, according to the\u000a      Director of the National\u000a      ESCA and Surface Analysis Centre for Biomedical Problems in the USA [A].\u000a      Such was the\u000a      paradigm shift in the research field that within 5 years of our\u000a      introduction of the C60 source almost\u000a      every SIMS lab in the world was seeking to follow our lead [B].\u000a    Impact\u000a    Commercial C60+ primary ion beam systems for SIMS\u000a      that were developed at Manchester in\u000a      collaboration with Ionoptika have led to the sale of ~70 C60+\u000a      ion beam units during 2008-2013 with\u000a      revenue &gt;&#163;2m that created 5 employment positions [D]. Furthermore, the\u000a      new ion beam\u000a      technology has been incorporated into a completely new type of Secondary\u000a      Ion Mass\u000a      Spectrometer that fully exploits the capability of the C60+\u000a      ion beam system. In 2012 two new C60+\u000a      SIMS instruments were sold to the US and Sweden with associated revenues\u000a      of &#163;2.5m [D]\u000a    Additionally, technology transfer to Ulvac-Phi inc, a Japanese\u000a      manufacturer of XPS and SIMS\u000a      instrumentation also included the C60+ ion beams in\u000a      their systems at an early stage, giving them an\u000a      initial competitive advantage in the organic surface analysis market and\u000a      contributing towards\u000a      instrument sales of several &#163;10m's of instrument sales [C]. C60+\u000a      bombardment resulted in new,\u000a      enhanced analysis protocols adopted across many sectors including the\u000a      semiconductor industry,\u000a      chemical industry, biotechnology industries, automobile companies, and\u000a      drug companies, in\u000a      addition to governmental and academic research labs. The CEO of Omicron\u000a      (formerly from Ulvac-Phi)\u000a      is of the opinion that all of these organisations were able to use cluster\u000a      beam analysis to\u000a      develop new products that could be life-changing for many people. (D).\u000a      Subsequently all other\u000a      manufacturers of SIMS instruments for molecular analysis have adopted C60+\u000a      beams in their\u000a      systems.\u000a    The breadth of impact is illustrated by the diverse range of important\u000a      application areas including\u000a      tissue and cell imaging, atmospheric sciences, drug delivery,\u000a      anti-bacterial coatings, polymer\u000a      composites, biomaterials, microelectronic fabrication, organic electronics\u000a      and nanoparticles,\u000a      according to a Fellow at the National Physical Laboratory [E]\u000a    \"The pioneering work at Manchester has revolutionised the imaging\u000a        capability, especially in 3D, for\u000a        SIMS and XPS. It has had a diverse impact on many industrial sectors as\u000a        well as fundamental\u000a        scientific understanding and has led to an important boost in the UK\u000a        instrument sector.\" [E]\u000a    As a direct result of the success of C60+ ion beams\u000a      for SIMS analysis a number of alternative\u000a      second-generation polyatomic ion beams are under development including Arn+\u000a      and (H2O)n+\u000a      (where 10&lt;n&lt;5000). We are currently developing this technology with\u000a      Ionoptika Ltd.\u000a    ","ImpactSummary":"\u000a    Pioneering research at the University of Manchester developed a primary ion\u000a    beam system based\u000a    on buckminsterfullerene C60+ for secondary ion mass\u000a    spectrometry (SIMS) that has revolutionized\u000a    the field by providing unprecedented insight into the 3D depth profiling of\u000a    organic materials, and\u000a    spawned the development of second-generation polyatomic sources. A\u000a    commercial C60+ ion beam\u000a    has been developed in collaboration with Ionoptika Ltd that has lead to: the\u000a    sale of 70 units with\u000a    value greater than &#163;2m; the development of a new spectrometer with sales of\u000a    &#163;2.5m; the creation\u000a    of five employment positions. Technology has been transferred to a Japanese\u000a    instrument\u000a    manufacturer contributing to &#163; tens of millions sales.\u000a    ","ImpactType":"Technological","Institution":"\u000a    The University of Manchester\u000a    ","Institutions":[{"AlternativeName":"Manchester (University of)","InstitutionName":"University of Manchester","PeerGroup":"A","Region":"North West","UKPRN":10007798}],"Panel":"B         ","PlaceName":[],"References":"\u000a    In 2004 JCV was awarded the Rivi&#232;re Prize of the UK Surface Analysis\u000a      Forum , in 2009 the Royal\u000a      Society of Chemistry Theophilus Redwood Award ' and in 2012 JCV the\u000a      M&#233;daille Chevenard by\u000a      the French Society for Metals and Materials for the contributions to the\u000a      SIMS field including the\u000a      work described in references 1-6 below. This research has been published\u000a      in the topmost\u000a      journals within the field of analytical chemistry and have each been\u000a      highly cited. JCV and NPL\u000a      have given between them 27 invited conference talks since the introduction\u000a      of the C60 source in\u000a      2003.\u000a    Key Publications\u000a    \u000a1. D. Weibel, S. Wong, N. Lockyer, P. Blenkinsopp, R. Hill, J.C.\u000a      Vickerman, A C-60 primary ion\u000a      beam system for time of flight secondary ion mass spectrometry: Its\u000a      development and\u000a      secondary ion yield characteristics, Analytical Chemistry 75\u000a      (2003) 1754-1764. - 350 citations.\u000a      DOI: 10.1021\/ac026338o.\u000a    \u000a\u000a2. E.A. Jones, N.P. Lockyer, J.C. Vickerman, Mass spectral analysis and\u000a      imaging of tissue by\u000a      ToF-SIMS - The role of buckminsterfullerene, C-60(+), primary ions, International\u000a        Journal of\u000a        Mass Spectrometry 260 (2007) 146-157. - 68 citations. DOI: 10.1016\/j.ijms.2006.09.015.\u000a    \u000a\u000a3. E.A. Jones, N.P. Lockyer, J.C. Vickerman, Depth profiling brain tissue\u000a      sections with a 40 keV\u000a      C-60(+) primary ion beam, Analytical Chemistry 80 (2008)\u000a      2125-2132. &#8212; 53 citations.\u000a      DOI: 10.1021\/ac702127q.\u000a    \u000aOther relevant Publications\u000a    \u000a4. J.S. Fletcher, N.P. Lockyer, S. Vaidyanathan, J.C. Vickerman, TOF-SIMS\u000a      3D biomolecular\u000a      imaging of Xenopus laevis oocytes using buckminsterfullerene (C-60)\u000a      primary ions, Analytical\u000a        Chemistry 79 (2007) 2199-2206. 148 citations. DOI: 10.1021\/ac061370u.\u000a    \u000a\u000a5. J.S. Fletcher, S. Rabbani, A. Henderson, P. Blenkinsopp, S.P.\u000a      Thompson, N.P. Lockyer, J.C.\u000a      Vickerman, A New Dynamic in Mass Spectral Imaging of Single Biological\u000a      Cells, Analytical\u000a        Chemistry 80 (2008) 9058-9064. &#8212; 86 citations. DOI: 10.1021\/ac8015278.\u000a    \u000aNote: citation numbers taken from Web of Science (20\/9\/13).\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"2","Level2":"2","Subject":"Atomic, Molecular, Nuclear, Particle and Plasma Physics"},{"Level1":"2","Level2":"99","Subject":"Other Physical Sciences"}],"Sources":"\u000a    A. Director, National ESCA and Surface Analysis Center for Biomedical\u000a      Problems, University of\u000a      Washington. Evidence on the benefits of the C60+ ion\u000a      beam system in organic and bio-organic\u000a      research.\u000a    B. Evan Pugh Professor of Chemistry, Penn State University. Evidence as\u000a      to the impact of the\u000a      C60+ ion beam system on the direction of SIMS\u000a      research and application.\u000a    C. Managing Director, Ionoptika Ltd. Information on the commercial\u000a      benefits of the instrument -\u000a      the number and value of ion beams manufactured and supplied.\u000a    D. CEO, Omicron, Japan. Evidence of the impact of the development in the\u000a      Japanese analytical\u000a      instrument market.\u000a    E. Director, National Centre of Excellence in Mass Spectrometry Imaging,\u000a      National Physical\u000a      Laboratory, Teddington UK. Evidence of wider impact of C60+\u000a      ion beam.\u000a    \u000a    ","Title":"\u000a    Development and exploitation of a buckminsterfullerene, C60+\u000a      based primary ion beam system for\u000a      secondary ion mass spectrometry (SIMS)\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000a    The key Manchester researchers were\u000a    \u000a      Professor John Vickerman (Professor in Surface Chemistry 1970-to date)\u000a      Dr Nicholas Lockyer (PDRA 1996-2000, Lecturer in Physical Chemistry\u000a        2000-2008, Senior\u000a        Lecturer 2008 to date)\u000a      Dr Daniel Weibel (PDRA 2000-2002)\u000a      Dr Stephen Wong (PhD student 1997-2002)\u000a    \u000a    SIMS is a very powerful tool for accurately analysing the chemical\u000a      make-up of a solid material in\u000a      order to build up a three-dimensional chemical map. The principle of the\u000a      technique is to bombard\u000a      the surface with a beam of ions (the primary ion beam) and then analyse\u000a      the emitted particles (in\u000a      the form of `secondary ions') that is ejected from the sample, using mass\u000a      spectrometry.\u000a    Previously, for in-depth or 3D analysis, SIMS had been limited to the\u000a      analysis of inorganic\u000a      materials due to the aggressive nature of the primary ion beam employed.\u000a      Traditional primary ion\u000a      beams based on Ar+, Ga+, Cs+ and more\u000a      recently Aun+n and Bin+\u000a      cause significant damage to the\u000a      underlying surface of the material, which restricted the amount of\u000a      meaningful information that could\u000a      be obtained to less than 1% of the sample surface.\u000a    Fundamental research in the late 1980's suggested that cluster molecules\u000a      may serve as a more\u000a      effective primary ion beam system than the simple atomic ions in use at\u000a      the time. Research by the\u000a      Vickerman group led to the development of a prototype C60+\u000a      primary ion beam system for SIMS .\u000a      The C60+ primary ion beam is generated by ionising C60\u000a      molecules with a stream of electrons. The\u000a      resultant positively charged C60+ particles are\u000a      accelerated to collide with the surface of the sample.\u000a      Through the first application of C60+ bombardment\u000a      for practical SIMS analysis we demonstrated a\u000a      ~1000 fold increase in secondary ion yields of `molecular' ions enabling\u000a      high sensitivity surface\u000a      analysis [1]. This pioneering development yields sub-micron spatial\u000a      resolution for examination of\u000a      organic materials and systems in life sciences [2-5]. Moreover, a\u000a      substantial reduction in\u000a      bombardment-induced damage of the sample permitted up to 100% of the\u000a      sample to be analysed\u000a      providing unprecedented depth profiling of successive layers and 3D\u000a      chemical imaging of organic\u000a      materials [2,3] including the first 3D molecular SIMS analysis of a single\u000a      biological cell [4]. Beyond\u000a      SIMS, the rather gentle molecular erosion under C60 bombardment\u000a      allows other 'surface analysis'\u000a      methods including X-ray Photoelectron spectroscopy (XPS) to probe\u000a      sub-surface chemistry.\u000a    "},{"CaseStudyId":"28939","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"2921044","Name":"Germany"},{"GeoNamesId":"2750405","Name":"Netherlands"},{"GeoNamesId":"1668284","Name":"Taiwan"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"1814991","Name":"China"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"1269750","Name":"India"},{"GeoNamesId":"2802361","Name":"Belgium"},{"GeoNamesId":"719819","Name":"Hungary"},{"GeoNamesId":"1835841","Name":"South Korea"},{"GeoNamesId":"6251999","Name":"Canada"},{"GeoNamesId":"294640","Name":"Israel"}],"Funders":[],"ImpactDetails":"\u000a    Key impacts have been:\u000a    \u000a      2 new businesses (Chemtrix BV and ChemtrixUSA).\u000a      13 jobs created including 4 PhDs, 3 MScs and 4 engineers.\u000a      The development of 3 innovative products (Labtrix&#174;&#9633;\u000a        KiloFlow&#174; and Plantrix&#174;) with a growing\u000a        international industrial and academic customer base.\u000a    \u000a    New businesses: After receiving substantial investment from Dutch\u000a      investors, the Headquarters of\u000a      Chemtrix was established in Geleen (Netherlands) in April 2008; and\u000a      product development and\u000a      sales actively commenced. Chemtrix Ltd.[A] remains the holding\u000a      company trading under the name\u000a      `Chemtrix BV'. In 2009 Chemtrix USA was registered to facilitate sales in\u000a      North America and\u000a      Canada whilst management and product development\/engineering remains in\u000a      the Netherlands and\u000a      R&amp;D at The University of Hull where 2 full-time employees (Drs Wiles\u000a      and Ngamsom, previous Hull\u000a      postdoctoral workers) develop customer-initiated processes\/products\u000a      related to process\u000a      optimisation. In total Chemtrix BV employs 11 full time staff (split\u000a      between the Netherlands and UK)\u000a      and Chemtrix USA has 2 employees. In addition Chemtrix has sales\u000a      representatives in Europe,\u000a      Taiwan, India, Israel, Korea and China; and is actively investigating\u000a      other worldwide market\u000a      opportunities with the Asian market developing rapidly.\u000a    Instrumental in securing initial investment were two patent families\u000a      licensed from the University of\u000a      Hull and two patents licensed from Lionix, BV. Since then, Chemtrix has\u000a      applied for two patents\u000a      [B,C] with two more patent applications are in progress, IP generation\u000a      remains key to the on-going\u000a      technical development of the Company.\u000a    New innovative products: Based on early research conducted at\u000a      Hull, the commercial advantages\u000a      of micro-reactor technology, as it relates to organic synthesis under flow\u000a      conditions, has underpinned\u000a      the development of new products which now meet previously unfulfilled\u000a      industry needs [D] (Figures 1-3).\u000a      Competitor analysis reveals that other micro-reactor companies either\u000a      specialise in small scale\u000a      screening equipment (e.g. Syrris, Mikroglas, Future Chemistry) or\u000a      large scale production systems\u000a      (e.g. Corning, Alfa Lafal) and it is not facile to directly\u000a      translate research from one system to another.\u000a      Chemtrix believes that it is the only Company currently developing\u000a      equipment to directly link both\u000a      markets; specifically using the slogan `scalable flow chemistry'.\u000a    The first product launched was Labtrix&#174; (2009), a fully\u000a      automated flow reactor platform (Figure 1a)\u000a      containing a glass micro-reactor (Figure 1b) (volume 1-20 &#181;L), allowing\u000a      processes to be optimized\u000a      using minute quantities of reagent (200 experiments day-1 using\u000a      10's mg of material[C]).\u000a      Furthermore, the equipment enables researchers to conduct organic\u000a      synthesis more safely[D] as\u000a      well as generating less chemical waste. Independent evidence is reported\u000a      by Ley.[E] In addition,\u000a      Chemtrix is the only micro-reactor supplier to manufacture a reactor\u000a      (Figure 1c) that enables the\u000a      incorporation of heterogeneous catalysts.[D]\u000a\u000a\u000a\u000aFigure 1. (a) Labtrix&#174; system (launched 2009) and (b\/c)\u000a      micro reactors.\u000a\u000a    Through discussions with industry it was identified that although process\u000a      chemists are content\u000a      using fully automated computer controlled equipment, many bench chemists\u000a      prefer manual\u000a      equipment. Consequently, reacting to market demand, Chemtrix in 2010\u000a      launched Labtrix&#174; Start\u000a      (Figure 2). Sales of this product have been particularly high, both within\u000a      academia and industry\u000a      (independent evidence reported by Kappe[F]) with more than 40\u000a      units of this type sold to date ~\u000a      40:60 academic to industrial end users.\u000a\u000aFigure 2 Labtrix&#174; Start (launched 2010).\u000a\u000a    Scale up production from Labtrix&#174;using `meso' scale reactors\u000a      (KiloFlow&#174; launched 2011, 3 installed and 2 in production)\u000a      which consists of mm-size channels (Figure 3a). Through\u000a      carrying out detailed ongoing research into available static\u000a      mixer technology, the Company has developed the ability to\u000a      translate the reaction conditions identified in micro-channels to\u000a      meso-channels, where combination of these modules (Figure\u000a      4b) affords access to production-scale quantities (g-kg's) within\u000a      a standard laboratory fume cupboard.[G,H] A partnership with\u000a      ESK has enabled Chemtrix to develop silicon carbide reactors\u000a      capable of achieving production rates at the tonne-scale (Figure\u000a      3b) which will service a growing industrial market estimated to\u000a      be &#8364; 50million.[I] This partnership was strategic in giving\u000a      Chemtrix access to larger production units and ESK access to\u000a      the continuous flow reaction knowledge of Chemtrix.\u000a\u000a\u000aFigure 3. (a) KiloFlow&#174; system (launched 2011) and (b)\u000a      Plantrix&#174; system.\u000a\u000a    Chemtrix is working closely with major international pharmaceutical and\u000a      fine chemical companies\u000a      (under CDAs and NDAs), with publicised examples including Sanofi-Aventis\u000a      (Hungary),[J] DSM\u000a      Pharmaceutical Products (NL), Janssen Phamaceutica NV (Belgium) and\u000a      Iolitec GmbH (Germany)\u000a      who presented results at a Symposia held at CPhI 2011 and Flow Chemistry\u000a      Europe, Munich,\u000a      2011. The work focuses on access to new processing conditions (higher\u000a      temperatures &amp; pressure)\u000a      with simplified synthetic processes that can be transferred from R&amp;D\u000a      to production. In one\u000a      example, a new route for an API was identified at the lab-scale, resulting\u000a      in an increase in product\u000a      purity which upon transfer to the production plant led to significant cost\u000a      savings due to a reduction\u000a      in the complexity of the downstream separation process. In addition to the\u000a      publicised work,\u000a      Chemtrix are currently working on multiple projects with industrial\u000a      partners focussing on the\u000a      translation of batch processes to continuous flow, with the aim of\u000a      developing sustainable, cost\u000a      effective production processes. Chemtrix maintains its links to the\u000a      University of Hull, collaborating\u000a      in the development of new chemical processes beyond those initially\u000a      identified as having\u000a      commercial interest; this includes for example the synthesis of inorganic\u000a      nanoparticles with Dr\u000a      Grazia Francesconi.[K]\u000a    ","ImpactSummary":"\u000a    Chemtrix Ltd. was established in February 2006 as a 50-50 joint venture\u000a      between the University of\u000a      Hull and Lionix Ltd. In 2008 the company attracted investment from Limburg\u000a      Ventures BV,\u000a      Panthera, Technostartersfund, Microfix BV and Hugo Delissen (&#8364;2 million)\u000a      that led to the creation\u000a      of Chemtrix BV. In 2009 the Company launched Chemtrix USA and a second\u000a      investment round\u000a      followed with investors Particon BV. In 2012 ESK Ceramics GmbH &amp; Co.\u000a      KG, acquired a minority\u000a      interest (30%) in Chemtrix BV based on a valuation of &#8364;5.3 million.\u000a    The three products developed and marketed by Chemtix, Labtrix&#174;,\u000a      KiloFlow&#174; and Plantrix&#174;, are\u000a      differentiated from competitor products as they offer `scalable flow\u000a      chemistry', such that optimised\u000a      reaction conditions can be easily scaled from R&amp;D to production. In\u000a      addition to the employees and\u000a      investors in Chemtrix the main non-academic beneficiaries of the research\u000a      have been industrial\u000a      customers such as Janssen Pharmaceutica NV, Edward Air Force Base, Iolitec\u000a      GmbH and DSM.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Hull\u000a    ","Institutions":[{"AlternativeName":"Hull (University of)","InstitutionName":"University of Hull","PeerGroup":"C","Region":"Yorkshire And Humberside","UKPRN":10007149}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"2867714","Name":"Mnchen"},{"GeoNamesId":"2867714","Name":"Munich"}],"References":"\u000a    \u000a(1) Development of a micro flow injection manifold for the determination\u000a      of orthophosphate,\u000a      R.N.C. Daykin and S.J. Haswell, Analytica Chimica Acta, 1995, 313,\u000a      155-159.\u000a    \u000a\u000a(2) Theoretical investigation into the rates of chemical reactions in\u000a      micro-total analytical systems\u000a      (&#181;TAS) operating under electroosmotic and electrophoretic control,\u000a      P.D.I. Fletcher, S.J. Haswell and V.N. Paunov, Analyst, 1999, 124,\u000a      1273-1282.\u000a    \u000a\u000a(3) The use of novel microreactors for high throughput continuous flow\u000a      organic synthesis, G.M.\u000a      Greenway, S.J. Haswell, D.O. Morgan, V. Skelton and P. Styring, Sensors\u000a        and Actuators B,\u000a      2000, 63, 153-158.\u000a    \u000a\u000a(4) Micro reactors: principles and applications in organic synthesis,\u000a      P.D.I. Fletcher, S.J. Haswell,\u000a      E. Pombo-Villar, B.H. Warrington, P. Watts, S.Y.F. Wong and X.L. Zhang, Tetrahedron,\u000a      2002, 58, 4735-4757.\u000a    \u000a\u000a(5) Electrokinetic control of a chemical reaction in a lab-on-a- chip\u000a      micro-reactor: measurement\u000a      and quantitative modelling, P.D.I. Fletcher, S.J. Haswell and X.L. Zhang,\u000a      Lab on a Chip,\u000a      2002, 2, 102-112.\u000a    \u000a\u000a(6) Pressure-driven and electroosmotic flows and electrical currents in\u000a      Lab-on-a-chip micro\u000a      reactor devices, I. Broadwell, P.D.I. Fletcher, S.J. Haswell, X.L. Zhang,\u000a      R.W.K. Allen, J.M.\u000a      MacInnes and X. Du, Trends in Physical Chemistry, 2004, 10,\u000a      117-133.\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"9","Level2":"15","Subject":"Interdisciplinary Engineering"},{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"},{"Level1":"9","Level2":"4","Subject":"Chemical Engineering"}],"Sources":"\u000a    [A] www.chemtrix.com\/company-profile\u000a      (corroboration of the establishment of Chemtrix BV and ChemtrixUSA)\u000a    [B] Patent Application - `A microfluidic system and the use thereof'\u000a      EP2010\/002777.\u000a    [C] Patent Application &#8212; `A new design microfluidic device, a kit of\u000a      parts comprising such\u000a      microfluidic devices and a modular system comprising such microfluidic\u000a      devices'\u000a      EP10008784.0.\u000a    [D] Microreactors as tools for high-throughput synthesis, C. Wiles and P.\u000a      Watts,\u000a      Speciality Chemicals Magazine, 2009, 40-41.; The evaluation of the\u000a      heterogeneously\u000a      catalysed Strecker reaction conducted under continuous flow, C. Wiles and\u000a      P. Watts,\u000a      Eur. J. Orgc. Chem., 2008, 5597-5613.\u000a    [E] The flow synthesis of heterocycles for natural product and medicinal\u000a      chemistry, M. Baumann,\u000a      I. R. Baxendale and S. V. Ley, Mol. Divers., 2011, 5,\u000a      613-630.\u000a    [F] The microwave to flow paradigm: Translating high-temperature batch\u000a      microwave chemistry\u000a      to scalable continuous flow processes, T. Glasnov and C.O. Kappe, Chem.\u000a        Eur. J., 2011, 17,\u000a      11956-11968.\u000a    [G] Chemtrix' KiloFlow: The turn-key kilo-lab in your fume hood, C.\u000a      Wiles,\u000a      Chem. Today, 2011, 29, 32-33.\u000a    [H] Flexible Durchflussreaktoren f&#252;r das schnelle Scale-up von\u000a      Produktionsprozessen, C. Wiles\u000a      and M. Seipel, Process, 2012, 1, 42-44.\u000a    [I] Innovative solutions to fulfill the flow chemistry potentials in\u000a      Europe, L. Pichon, 4th\u000a      Symposium on continuous flow reactor technology for industrial\u000a      applications, 2012, Lisbon.\u000a    [J] Formation of aromatic amidoximes with hydroxylamine using\u000a      microreactor technology',\u000a      Voros, Z. Baan, P. Mizsey and Z. Finta, Org. Proc. Res. Dev.,\u000a      2012, 16, 1717-1726.\u000a    [K] The preparation of magnetic iron oxide nanoparticles in\u000a      microreactors, M. Simmons, C.\u000a      Wiles, V. Rocher, M. G. Francesconi and P. Watts, J. Flow Chem.,\u000a      2013, 3, 7-10.\u000a    ","Title":"\u000a    Chemtrix - Scalable Flow Chemistry\u000a    ","UKLocation":[{"GeoNamesId":"2645425","Name":"Hull"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    In the early 1990s a small number of researchers (7-8 academics) mainly\u000a      from Europe, the USA\u000a      and Japan started to develop microfluidic based methodology which built on\u000a      techniques drawn\u000a      from the semiconductor industry (in particular photolithography and wet\u000a      etching) in an attempt to\u000a      produce so called micro total analytical systems. Professor Haswell, one\u000a      of these pioneers,\u000a      published the first micron-scale flow injection analysis system in 1995\u000a      and started to develop micro\u000a      reactor technology.1 This activity became instrumental in\u000a      securing a prestigious multi\u000a      university\/industry &#163;5 million Foresight LINK grant in 1999 that in turn\u000a      was used by the DTI (now\u000a      TSB) to establish a strategic national focus for the micro- and\u000a      nano-technology. The research of\u000a      Professor Haswell since 1993 has lead to over 180 peer reviewed\u000a      publications and 10 patents in\u000a      the field which have focused on establishing the fundamental design and\u000a      operational parameters of\u000a      flow reactors which gives the methodology significant advantages in the\u000a      fields of synthetic and\u000a      analytical chemistry.2-6 These advantages can be attributed to\u000a      the unique operating conditions\u000a      associated with meso\/micro flow-reactor devices in which the spatial and\u000a      temporal control of\u000a      reagents is achieved under a non-turbulent, diffusion limited mixing\u000a      regime. Within such systems\u000a      the control of hydrostatic and other pressure gradients, the\u000a      immobilization of catalysts (Pd, Pt,\u000a      sulphated zirconia, zeolites and enzymes) and the monitoring of reactants\u000a      and products have\u000a      featured strongly. A range of chemical reaction types have been carried\u000a      out to demonstrate the\u000a      advantages meso\/micro flow-reactors offer in terms of stereoselective\u000a      product control, multi-step\u000a      synthesis and in-situ separations. In addition, mathematical\u000a      models of reactions in meso\/micro\u000a      flow-reactors under electrokinetic and hydrodynamic control have been\u000a      successfully constructed\u000a      and validated using in-situ measurements of spatially and\u000a      temporally resolved concentration\u000a      profiles.\u000a    In 2002 a previous postdoctoral fellow of Professor Haswell, Dr Paul\u000a      Watts (Lecturer, University of\u000a      Hull; 2002 to 2013) and a former PhD student and postdoctoral researcher\u000a      Dr Charlotte Wiles\u000a      (PhD Student, University of Hull; 2000 to 2003 and post doctoral\u000a      researcher, University of Hull;\u000a      2003 to 2005) seized the opportunity to commercially develop the\u000a      underpinning research carried\u000a      out at Hull, focusing in particular on the up-scaling (volume increase) of\u000a      micro-reactor methodology\u000a      whilst retaining the inherent operational advantages of excellent reaction\u000a      control and efficiency. In\u000a      partnership with the University of Hull and Lionix, Chemtrix BV was\u000a      established to develop micro-reactor\u000a      based operating systems for industrial applications of flow chemistry.\u000a      Charlotte Wiles is\u000a      now the Chief Executive Officer with Chemtrix BV. The research carried out\u000a      at Hull in the field of\u000a      micro-reactors has therefore been instrumental in establishing the core\u000a      technology on which\u000a      Chemtrix has now developed innovative products that have lead to a\u000a      significant growth and\u000a      internationalisation of the business; with industrial customers in Europe,\u000a      UK, USA, Israel, India,\u000a      Taiwan, Korea, China and Australia.\u000a    "},{"CaseStudyId":"28949","Continent":[],"Country":[],"Funders":[],"ImpactDetails":"\u000a    The non-academic beneficiaries in terms of positive economic impacts from\u000a      the underpinning\u000a      research are Nalco &#8212; which has a successful and effective commercial\u000a      product line specifically\u000a      developed with the problem in mind, and its customers who use this product\u000a      (Clean n Cor). Clean\u000a      n Cor helps to decrease integrity risks by mitigating the potential for\u000a      under deposit corrosion in\u000a      production pipelines which has added benefits for the environment in\u000a      reducing the instances of\u000a      corrosion failures in high pressure lines and therefore ensuring a safer\u000a      working environment for\u000a      oilfield personnel.\u000a    Since 2008, Nalco has sold in excess of 17,000,000 kg of the product to\u000a      over 300 customers\u000a      including many of the super-major and major oil companies around the\u000a      world. In the 5 years since\u000a      2008, the Clean n Cor technology has been Nalco's fastest growing new\u000a      product. The success of\u000a      the original product has prompted several additional derivative products\u000a      utilizing the Clean n Cor\u000a      technology to address more specific niche applications.\u000a    Clean n Cor has been used extensively at over 300 oil production\u000a      locations worldwide, to impart\u000a      corrosion protection in aging production infrastructure and to maximize\u000a      water injectivity, with the\u000a      following economic and other benefits:\u000a    \u000a      Clean n Cor is injected into fluids at very low concentrations of the\u000a        active materials (40 - 100\u000a        ppm) which ensures the application is extremely cost-effective.\u000a      From a corrosion control perspective, the technology allows operating\u000a        companies to utilize\u000a        lower cost steel alloys for the fabrication of injection systems thereby\u000a        reducing capital costs\u000a        dramatically.\u000a      Clean n Cor also protects against corrosion from naturally occurring\u000a        microbes in the system,\u000a        minimising impact to the environment and protecting personnel in\u000a        oilfield operations. More\u000a        specifically Clean n Cor helps to minimize the deposition of solids\u000a        build up in the production\u000a        infrastructure and provides the protective film that mitigates\u000a        corrosion. Minimizing the effects of\u000a        corrosion results in less failures, and ultimately safer working\u000a        conditions for employees.\u000a      Oil companies often operate in environmentally sensitive areas and the\u000a        improvement in\u000a        corrosion protection will ensure the potential for pipeline failures and\u000a        the resulting exposure of\u000a        production fluids into the environment is minimized. This in turn\u000a        assists oil and gas companies\u000a        in preserving their licence to operate and protecting their corporate\u000a        brand.\u000a      Maximizing water injectivity has a dramatic impact on increasing oil\u000a        and gas production and this\u000a        is critical today as the global demand for oil and gas approaches the\u000a        global supply curve. By\u000a        cleaning the hydrocarbon based deposits that build up in injection\u000a        systems, the injection\u000a        differential pressure into the formation is reduced therefore allowing\u000a        more water to be injected to\u000a        balance crude oil production and ensure reservoir production pressure is\u000a        maximized. This has\u000a        resulted in increases of oil production that ranges between 50 - 100%.\u000a      Clean n Cor also minimizes operational costs that otherwise would be\u000a        incurred through having\u000a        to clean out injection wells as they start to plug up over time. This is\u000a        not only a savings in\u000a        operational cost, but also a safety advantage. The cleaning process\u000a        involves the use of heavy\u000a        machinery and employees operating on highly pressurized flow lines.\u000a        Clean n Cor helps to keep\u000a        the pipes clean chemically as opposed to manually.\u000a\u0009\u0009\u000a      To date, there are no other competing technologies to Clean n Cor in\u000a        the oilfield market place.\u000a      Although commercial sensitivity limits the range of specific impact\u000a        details that can be given here,\u000a        however the significance of this development and the important role\u000a        played by Hull researchers\u000a        was marked by the presentation by Nalco of a plaque to the Department of\u000a        Chemistry, University of\u000a        Hull in December 2011. The award is \"for collaboration in the area of\u000a        Surfactant Science that led to\u000a        the successful development of Clean n Cor\".\u000a      ","ImpactSummary":"\u000a    In partnership with the US company Nalco, the University's Surfactant\u000a      &amp; Colloid Group developed\u000a      a new multifunctional technology (Clean n Cor) for the oil industry that\u000a      both removes accumulated\u000a      deposits at a metal surface (enabling \"break-through\" of corrosion\u000a      inhibitor to the metal surface)\u000a      and inhibits corrosion. Clean n Cor technology not only protects assets\u000a      such as oil pipelines\u000a      against corrosion but also maximises oil production through enhancing\u000a      water injectivity (water flow\u000a      per unit pressure drop). Since its launch in 2007, it is currently one of\u000a      Nalco's fastest growing new\u000a      technologies and is used at over 100 production locations worldwide.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Hull\u000a    ","Institutions":[{"AlternativeName":"Hull (University of)","InstitutionName":"University of Hull","PeerGroup":"C","Region":"Yorkshire And Humberside","UKPRN":10007149}],"Panel":"B         ","PlaceName":[],"References":"\u000a    \u000a(1) Displacement of oil by aqueous surfactant solutions from capillaries\u000a      sealed at one end.\u000a      R. Aveyard, B.P. Binks, S. Clark and P.D.I. Fletcher, Colloids &amp;\u000a      Surfaces A, 1996, 113, 295.\u000a    \u000a\u000a(2) Adhesion under water: surface energy considerations. J.H. Clint and\u000a      A.C. Wicks, Int. J.\u000a      Adhesion &amp; Adhesives, 2001, 21, 267.\u000a    \u000a\u000a(3) Adhesion and components of solid surface energies. J.H. Clint, Curr.\u000a      Opinion Colloid &amp;\u000a      Interface Sci., J.H. Clint, 2001, 6, 28. (Although a review\u000a      article, this reference is included\u000a      here as it contains original analyses by Clint of data published by other\u000a      authors.)\u000a    \u000a\u000a(4) \"I put it in, but where does it go?\" - The fate of corrosion\u000a      inhibitors in multiphase systems.\u000a      D.I. Horsup, J.C. Clark, B.P. Binks, P.D.I. Fletcher and J.T. Hicks, NACE\u000a      Corrosion\u000a      Conference 2007, paper 06717, 1-32.\u000a    \u000a\u000a(5) A break-through corrosion inhibitor technology for heavily fouled\u000a      systems. D.I. Horsup, T.S.\u000a      Dunstan and J.H. Clint, Corrosion, 2009, 65, 527.\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"},{"Level1":"9","Level2":"12","Subject":"Materials Engineering"}],"Sources":"\u000a      [A] Vice President, Research and Development, Energy Services at Nalco\u000a        &#8212; corroborating the\u000a        economic impacts of Clean n Cor for the company since 1st January\u000a        2008.\u000a      [B] A break-through technology for maximizing water injectivity and\u000a          asset integrity &#8212; SPE\u000a        Production and Operations, #108675, May 2009 - corroborating the\u000a        benefits of the Clean n\u000a        Cor technology.\u000a      [C] Integrity control in heavily fouled systems - Phase II -\u000a          Environmentally sustainable solutions - D.I. Horsup, R. Meyer, L.\u000a        Tiwari, T. Dunstan - NACE 2008, Paper #08623 - corroborating\u000a        the benefits of the Clean n Cor technology.\u000a      \u000a      ","Title":"\u000a    A break-through corrosion inhibitor technology for heavily fouled systems\u000a    ","UKLocation":[{"GeoNamesId":"2645425","Name":"Hull"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Organic corrosion inhibitors with surfactant properties are widely used\u000a      to inhibit the corrosion of\u000a      oilfield equipment. Injected into piped liquids, they work by adsorbing at\u000a      the aqueous solution-\u000a      corroding metal surface where they commonly reduce the corrosion rate by\u000a      &gt;95%, thereby saving\u000a      cost\/environmental impact. However, their performance over time\u000a      deteriorates due to the\u000a      accumulation of oily deposits mixed with clays, corrosion products and\u000a      biomass (so-called\u000a      \"schmoo\") at the metal surface. The accumulation of schmoo on internal\u000a      pipe surfaces not only\u000a      prevents the corrosion inhibitor reaching the metal surface but also\u000a      adversely affects water\u000a      injectivity (e.g. by reducing the effective internal diameter of a pipe)\u000a      and thereby causes problems\u000a      with many oilfield operations.\u000a    The key research from Hull underpinning Clean n Cor development was in\u000a      several stages. The first\u000a      stage was to realise that the behaviour of surfactant-like corrosion\u000a      inhibitor-schmoo-water systems\u000a      follows the patterns of microemulsion phase behaviour of conventional\u000a      surfactant-oil-water\u000a      systems enabled the exploitation of Hull's leading work in this area.\u000a      Early work (published pre-1993\u000a      and so not included here) at Hull had significantly advanced the\u000a      understanding of how oil\u000a      solubilisation can be maximised and how the oil-water tension can be made\u000a      ultra-low by \"tuning\"\u000a      the tendency of the adsorbed surfactant monolayer to curve &#8212; both factors\u000a      are of critical\u000a      importance in maximising schmoo removal from corroding metal surfaces.\u000a    Secondly, the post-1993 research that underpinned the development of\u000a      Clean n Cor1-4 investigated\u000a      the inter-relationships between the solid-oil, solid-water and oil-water\u000a      interfacial tensions to\u000a      understand the surface chemistry relating to the removal of oil from\u000a      capillaries and the adhesion of\u000a      different materials to solid surfaces. It identified the key factors\u000a      responsible for the adhesion of the\u000a      schmoo to the metal surface and how they could be manipulated, using the\u000a      understanding of\u000a      microemulsion behaviour, to ensure good removal. The research described in\u000a      Ref. 5 then\u000a      developed a laboratory-based schmoo removal test cell which (i) enabled\u000a      validation of the\u000a      fundamental concepts described above and (ii) showed excellent correlation\u000a      with in-field\u000a      performance of the multifunctional inhibitor systems. It was used to\u000a      provide a rapid screening of\u000a      different complex formulations and thereby enable the product launch of\u000a      the optimised Clean n Cor\u000a      system.\u000a    Thirdly, although very successful in most oilfield application sites, it\u000a      emerged that Clean n Cor was\u000a      not sufficiently effective against the schmoos formed in some particular\u000a      oilfields and Nalco\u000a      commissioned further research at Hull in 2012-13 to investigate. The Hull\u000a      team successfully\u000a      showed that schmoo from the problem sites contained additional solid\u000a      components which caused\u000a      the main removal mechanism to switch from \"roll-up\" and emulsification (as\u000a      seen in 5) to one of\u000a      solubilisation. Additional principles governing the design of Clean n Cor\u000a      formulations for such\u000a      problem sites were established and experiments demonstrated the enhanced\u000a      performance of new\u000a      formulation. This recent work is fully described in a commercially\u000a      sensitive and confidential report.\u000a    The underpinning research was undertaken at the University of Hull from\u000a      1993 to 2013 by Paul\u000a      Fletcher (Professor, since 1984), Robert Aveyard (Professor, 1965 to\u000a      2001), Bernard Binks\u000a      (Reader 1988 to 2002, Professor 2002 to present) and John Clint (Reader\u000a      1993 to 2006).\u000a    "},{"CaseStudyId":"28977","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"1861060","Name":"Japan"},{"GeoNamesId":"6252001","Name":"United States"}],"Funders":["Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000d\u000a    The beneficiaries of the underpinning research have been:\u000d\u000a    \u000d\u000a      Merck's Liquid Crystals business unit, which increased turnover by\u000d\u000a        8.0% to &#8364;1,094 million in 2011 from &#8364;1,013 million in 2010. \"This\u000d\u000a        [growth] stemmed from the ongoing demand, particularly for IPS (in-plane\u000d\u000a        switching) technologies for smart-phone touch-screens and PS-VA\u000d\u000a        (polymer-stabilized vertical alignment) as well as VA (vertical\u000d\u000a        alignment) technologies for TV displays.\"[A,B]\u000a\u000d\u000a      Manufacturers of LCDs, who produced LCDs worth $99.4 billion in 2011\u000d\u000a        rising to a turnover of $107.7 billion in 2012 including 216 million\u000d\u000a        LCD-TVs.[C-G]\u000a\u000d\u000a      Micron Technology, USA, and Forth Dimension Displays, UK, which are\u000d\u000a        the two main manufacturers of F-LCOS microdisplays in a market worth\u000d\u000a        $250 million in 2011.[H,I]\u000a\u000d\u000a      Kingston Chemicals Limited, which had a turnover of &#163;200k in 2011.\u000d\u000a      The users of devices with VAN-LCDs, such as banks, who benefit from\u000d\u000a        the significantly lower energy consumption of LCDs (10%-25%) compared to\u000d\u000a        that required for CRTs.[J]\u000a\u000d\u000a      Purchasers of consumer devices, such as LCD TVs, laptops, with better\u000d\u000a        LCD screens.\u000d\u000a    \u000d\u000a    The two LCD applications that have benefited most from liquid crystals\u000d\u000a      based on the ortho-difluorophenyl unit developed and optimised at\u000d\u000a      the University of Hull during the assessment period, in collaboration with\u000d\u000a      the MoD and E. Merck, are VAN-LCDs for LCD-TVs, which is a multi-billion\u000d\u000a      pound market involving very large LCDs in TVs and laptop computers, and\u000d\u000a      F-LCOS LCDs, primarily used in camera viewfinders, which is a niche, but\u000d\u000a      very important market, using small LCDs. Vertically Aligned Nematic\u000d\u000a      technology encompasses several variants, such as Polymer-stabilised-,\u000d\u000a      Multidomain- and Patterned-VA-LCDs.[D-F]\u000d\u000a    VAN-LCDs have replaced bulky cathode ray tube displays as well as earlier\u000d\u000a      LCDs and provide the majority of the 216 million LCD-TVs sold in 2012,\u000d\u000a      from manufacturers such as Samsung, Sharp and Sony.[C] The\u000d\u000a      advantageous VAN-LCD technology is increasingly (2008 to present time)\u000d\u000a      being employed in smaller displays for desktop and laptop displays, which\u000d\u000a      is a very high volume market. Additionally, because of the lower power\u000d\u000a      consumption and cheaper production costs, VAN-LCD technology is now being\u000d\u000a      introduced into the mobile phone and tablet markets. No other current\u000d\u000a      design of material can match those based on the ortho-difluorophenyl\u000a      unit for the combination of liquid crystallinity, low viscosity and high\u000d\u000a      negative dielectric anisotropy required for VAN displays. [D-G]\u000d\u000a    \"Liquid Crystals generate more than 70% of the [E. Merck performance\u000d\u000a        materials] division's sales [&#8364;1,719 million]. Based on a market share of\u000d\u000a        between 50% and 60%, this business has for many years commanded the\u000d\u000a        number one market position for liquid crystal mixtures used in liquid\u000d\u000a        crystal displays (LCDs). With the broadest offering in the industry, the\u000d\u000a        business unit's product portfolio comprises liquid crystals tailored to\u000d\u000a        match the individual requirements of the full range of LCDs, from small\u000d\u000a        displays in smart phones to ultra-large televisions. The portfolio\u000d\u000a        includes liquid crystals based on polymer stabilized vertical alignment\u000d\u000a        (PS-VA) technologies, primarily used in mid- and large-sized\u000d\u000a        televisions, as well as liquid crystals based on in-plane switching\u000d\u000a        (IPS) technology, which are also used in televisions as well as\u000d\u000a        increasingly in mobile devices such as tablet PCs and smart phones. The\u000d\u000a        Liquid Crystals business unit operates in a highly consolidated market\u000d\u000a        with a total of only three suppliers, indicating the high barriers to\u000d\u000a        entry as a result of the scientific complexity of liquid crystals and\u000d\u000a        their high quality requirements. Liquid Crystals supplies all seven\u000d\u000a        major LCD panel manufacturers that serve television manufacturers or\u000d\u000a        other consumer electronics companies.\"[B]\u000d\u000a    The ortho-difluorophenyl unit is also present in smectic\u000d\u000a      liquid crystals, developed and optimised at the University of Hull in the\u000d\u000a      assessment period, that are essential components of smectic\u000d\u000a      mixtures used in Ferroelectric Liquid Crystal on Silicon (F-LCOS)\u000d\u000a      microdisplays, which are small LCDs with a cell thickness of less than a\u000d\u000a      micron. The amount of liquid crystal material used is very small when\u000d\u000a      compared with that used in VAN-LCDs, but nevertheless the commercial\u000d\u000a      impact is still very significant. F-LCOS microdisplays provide very high\u000d\u000a      resolution and extremely fast switching, and are employed in head-mounted\u000d\u000a      displays for training simulators and computer games, and in camera\u000d\u000a      viewfinders for the film, military and medical industries. The high\u000d\u000a      value-added nature of the liquid crystals used in F-LCOS microdisplays\u000d\u000a      provides an ideal business for Kingston Chemicals Limited, which\u000d\u000a      manufactures ortho-difluorophenyl liquid crystals and formulates\u000d\u000a      ferroelectric liquid crystal mixtures containing them for Display Tech and\u000d\u000a      Forth Dimension Displays. Citizen Finetech Mijota Japan, which now owns\u000d\u000a      Display Tech,[H] and Forth Dimension Displays, are two of the\u000d\u000a      main manufacturers of F-LCOS microdisplays in a global microdisplays\u000d\u000a      market expected to reach $995 million by 2016 from $250 million in 2011.[I]\u000d\u000a    ","ImpactSummary":"\u000d\u000a    216 million LCD-TVs were sold in 2012 many of which incorporate liquid\u000d\u000a      crystals invented in Hull. Research on the design, synthesis and\u000d\u000a      evaluation of liquid crystals of negative dielectric anisotropy and the\u000d\u000a      formulation of liquid crystalline mixtures incorporating them enabled the\u000d\u000a      successful commercialisation of two types of Liquid Crystal\u000d\u000a      Displays (LCDs), i.e., Vertically Aligned Nematic (VAN)-LCDs for\u000d\u000a      televisions, desktop monitors and laptop computers and Ferroelectric\u000d\u000a      Liquid Crystals on Silicon (F-LCOS) microdisplays used in head-mounted\u000d\u000a      displays for training simulators, computer games and in camera\u000d\u000a      viewfinders. Kingston Chemicals Limited, a spinout from the University of\u000d\u000a      Hull, supplies ferroelectric liquid crystals to LCD manufacturers.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    University of Hull\u000d\u000a    ","Institutions":[{"AlternativeName":"Hull (University of)","InstitutionName":"University of Hull","PeerGroup":"C","Region":"Yorkshire And Humberside","UKPRN":10007149}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    \u000a(1) Fluorinated Oligophenyls and Their Use in Liquid Crystal Materials.\u000d\u000a      U. Finkenzeller, T. Geelhaar, G. W. Gray, M. Hird, J. Krause, D. Lacey, V.\u000d\u000a      Reiffenrath, K. J. Toyne and A. W&#228;chtler, EP 0329752 B1, filed 13\u000d\u000a      Aug 1988 by E. Merck; Difluorinated Terphenyls and their Use in Liquid\u000d\u000a      Crystal Materials. G. W. Gray, M. Hird, D. Lacey, K. J. Toyne, V.\u000d\u000a      Reiffenrath, A. W&#228;chtler, J. Krause, U. Finkenzeller and T. Geelhaar, UK\u000d\u000a        Patent 2 227 742 B, filed 9 Mar 1989 by Defence Re-search Agency;\u000d\u000a      The synthesis and transition temperatures of some 4,4\"-dialkyl- and\u000d\u000a      4,4\"-alkoxy-alkyl-1,1':4',1\"-terphenyls with 2,3- or 2',3'-difluoro\u000d\u000a      substituents and of their biphenyl analogues. G.W. Gray, M. Hird, D.\u000d\u000a      Lacey, K.J. Toyne, J. Chem. Soc., Perkin Trans. 2, 1989,\u000d\u000a      2041-2053.\u000d\u000a    \u000a\u000a(2) Synthesis, mesomorphic behaviour and optical anisotropy of some novel\u000d\u000a      materials for nematic mixtures of high birefringence, J. Mat. Chem.\u000d\u000a      2000, 10, 1555-1563.\u000d\u000a    \u000a\u000a(3) The synthesis and mesomorphic properties of 4,4\"-dialkyl-2,2',3- and\u000d\u000a      2,2',3-trifluoro-1,1':4',1\"-terphenyls for high dielectric biaxiality\u000d\u000a      ferroelectric mixtures. M.E. Glendenning, J.W. Goodby, M. Hird, K.J.\u000d\u000a      Toyne, J. Chem. Soc., Perkin Trans. 2, 2000, 27-34.\u000d\u000a    \u000a\u000a(4) Synthesis, mesomorphic behaviour and optical anisotropy of some novel\u000d\u000a      materials for nematic mixtures of high birefringence. M. Hird, K. J.\u000d\u000a      Toyne, J. W. Goodby, G. W. Gray, V. Minter, R. P. Tuffin and D. G.\u000d\u000a      McDonnell, J. Mater. Chem., 2004, 11, 1731-1743.\u000d\u000a    \u000a\u000a(5) The dramatic influence of the location of bend and of lateral fluoro\u000d\u000a      substitution on the mesomorphic properties of angular chiral esters based\u000d\u000a      on a 1,3-disubstituted benzene ring, K.M. Fergusson, M. Hird, J.\u000d\u000a        Mater, Chem., 2010, 20, 3069-3078\u000d\u000a    \u000a\u000a(6) Fluorinated liquid crystals &#8212; properties and applications. M. Hird, Chem.\u000a        Soc. Rev., 2008, 36, 2070-2095. Molecular complexity and the control\u000d\u000a      of self-organising processes, J.W. Goodby, I.M. Saez, S.J. Cowling, J.S.\u000d\u000a      Gasowska, R.A. MacDonald, S. Sia, P. Watson, K.J. Toyne, M. Hird, R.A.\u000d\u000a      Lewis, S.E. Lee, V. Vaschenko, Liquid Crystals, 2009, 36,\u000d\u000a      567-605.\u000d\u000a    \u000a\u000a(7) The synthesis and mesomorphic properties of 2,2',3-Tri- and\u000d\u000a      2,2',3,3'-Tetra-fluoro-1,1':4',1\"-terphenyls for high dielectric\u000d\u000a      biaxiality ferroelectric liquid crystal mixtures. M. E. Glendenning, J. W.\u000d\u000a      Goodby, M. Hird and K. J. Toyne, J. Chem. Soc., Perkin Trans. 2,\u000d\u000a      1999, 481-491.\u000d\u000a    \u000a\u000a(8) The synthesis and mesomorphic properties of liquid crystals with\u000d\u000a      bulky terminal groups designed for bookshelf geometry ferroelectric\u000d\u000a      mixtures. I.A. Radini, M. Hird, Liquid Crystals, 2009, 36,\u000d\u000a      1417-1430.\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"9","Level2":"12","Subject":"Materials Engineering"}],"Sources":"\u000d\u000a    [A] Merck Annual Report 2011.\u000d\u000a    [B] Merck Annual Report 2012.\u000d\u000a    [C] Quarterly Global TV Shipment and Forecast Report, 2012, NPD Display\u000d\u000a      Search;\u000d\u000a      http:\/\/www.displaysearch.com\/.\u000d\u000a    [D] Advanced Liquid Crystals for Television. D. Pauluth and K. Tarumi, J.\u000a        Mater. Chem., 2004, 14, 1219-1227 &amp; \"Optimization of\u000d\u000a      Liquid Crystals for Television.\"\u000d\u000a      J. SID., 2005, 18\/8, 693-702.\u000d\u000a    [E] New liquid crystal materials for active matrix displays with negative\u000d\u000a      dielectric anisotropy and low rotational viscosity. M. Klasen, M. Bremer\u000d\u000a      and K. Tarumi,\u000d\u000a      Jpn. J. Appl. Phys., 2000, 39, L1180-L1182.\u000d\u000a    [F] Liquid crystals for TV screens. M. Bremer, M. Klasen-Memmer and K.\u000d\u000a      Tarumi, Adv. Mater., 2004, 16, 1882-1885.\u000d\u000a    [G] http:\/\/itersnews.com\/?p=14292.\u000d\u000a    [H] http:\/\/displaydaily.com\/2009\/05\/20\/micron-buys-displaytech-key-validation-of-pico-market\/.\u000d\u000a    [I] http:\/\/www.marketsandmarkets.com\/Market-Reports\/micro-displays-market-430.html.\u000d\u000a    [J] http:\/\/en.wikipedia.org\/wiki\/Comparison_of_CRT,_LCD,_Plasma,_and_OLED.\u000d\u000a    ","Title":"\u000d\u000a    Liquid crystals based on the ortho-difluorophenyl unit\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2645425","Name":"Hull"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    Pre-1993 research at the University of Hull had focussed on the synthesis\u000d\u000a      and evaluation of the physical properties of smectic liquid\u000d\u000a      crystals, such as the ortho-difluoroterphenyls 1 and 2,\u000d\u000a      for F-LCOS applications and other types of ferroelectric LCDs for LCD-TVs.\u000d\u000a      Prototypes were fabricated, but not manufactured on a large scale due to\u000d\u000a      fabrication and shock-stability problems. This joint research carried out\u000d\u000a      between the University of Hull, E. Merck, and funded by the Defence\u000d\u000a      Evaluation and Research Agency (DERA) led to joint patents owned by DERA,\u000d\u000a      covering this generic class of compounds.1,2\u000d\u000a    Post-1993 research between the University of Hull, Merck and DERA\u000d\u000a      focussed on designing modified terphenyl-type structures, such as 1-6,\u000d\u000a      with exclusively nematic mesophases for VAN-LCDs in order\u000d\u000a      to facilitate the large scale manufacture of LCD-TVs. The design of nematic\u000d\u000a      liquid crystals with a large lateral dipole &#8212; and hence a significant\u000d\u000a      negative dielectric anisotropy &#8212; was a major, unresolved challenge at that\u000d\u000a      time.3,4\u000d\u000a\u000d\u000a\u000d\u000a\u000d\u000a    Post-1993 research at the University of Hull focussed on completely\u000d\u000a      suppressing the smectic (layered) nature of the\u000d\u000a      ortho-difluoroterphenyls and replacing it with the desired (non-layered) nematic\u000d\u000a      phase required for VAN-LCDs for LCD TVs. The presence of a smectic phase\u000d\u000a      even at very low temperatures, e.g., at &#8212;50 oC, below a\u000d\u000a      nematic phase can result in a high viscosity of the nematic phase above it\u000d\u000a      at room temperature. The smectic and nematic phases of terphenyl\u000d\u000a      derivatives synthesised up to that point were highly viscous and exhibited\u000d\u000a      very high melting points and poor solubility in liquid crystal mixtures.\u000d\u000a      The post-1993 research at the University of Hull led to the synthesis of\u000d\u000a      ortho-difluoroterphenyls with a broad nematic phase, low melting points, a\u000d\u000a      high nematic clearing point and most importantly, generated a high\u000d\u000a      negative dielectric anisotropy (-2.5 &gt; &#916;&#949; &gt; -7) and a high\u000d\u000a      birefringence (&#916;n &gt; 0.20). Nematic mixtures containing them,\u000d\u000a      developed with colleagues at DERA and Merck, exhibit low viscosity\u000d\u000a      (&#947; 1 ~ 100), a wide operating temperature range\u000d\u000a      (typically -50 oC to 120 oC), appropriate elastic\u000d\u000a      constant ratios (k11, k22,\u000d\u000a      and k33), moderate birefringence (&#916;n ~ 0.08)\u000d\u000a      and dielectric anisotropy (-3 &gt; &#916;&#949; &gt; -4) values, a short\u000d\u000a      optical path (d&#916;n &lt; 0.3), high pre-tilt angles (1o - 5o),\u000d\u000a      high voltage holding ratios (VHR), fast response times (ca. 20 ms),\u000d\u000a      wide viewing angles with high optical contrast at low operating voltages\u000d\u000a      (2-3 V) in very large, full-colour, video-rate VAN-LCDs for LCD TVs.2-6\u000d\u000a      Many of these objectives are mutually exclusive and many non-linear\u000d\u000a      effects and non-ideal behaviour are observed, especially in complex\u000d\u000a      mixtures with between 10 - 20, sometimes 50, individual components.\u000d\u000a      Another key aspect of the successful commercialisation of VAN-LCDs for the\u000d\u000a      TV market was the development at the University of Hull of optimised\u000d\u000a      reaction conditions for the Suzuki aryl-aryl cross-coupling reaction to\u000d\u000a      synthesise difluoro-substituted liquid crystals on a cost-effective\u000d\u000a      industrial scale.4\u000d\u000a    A substantial body of related research between 2000-2004, funded by the\u000d\u000a      Ministry of Defence (UK) and the EPSRC, and 2004-2007, funded by the DTI\u000d\u000a      and Kingston Chemicals, led to structures such as 7 and 8,\u000d\u000a      which were designed to generate a bookshelf molecular alignment to further\u000d\u000a      optimize liquid crystal mixtures for F-LCOS applications.7-8\u000d\u000a\u000d\u000a\u000d\u000a\u000d\u000a    "},{"CaseStudyId":"29359","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"953987","Name":"South Africa"},{"GeoNamesId":"1269750","Name":"India"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000a    Research at Bangor on ultra-fast DSC co-sensitization has directly\u000a      influenced the commercial sector. Since 2006, Holliman's group has focused\u000a      on large scale, low cost PV working with TATA, Dyesol and G24i on\u000a      roll-to-roll PV manufacturing with the aim of becoming market competitive\u000a      (cost, efficiency and lifetime) versus the market-leading\u000a      crystalline silicon. Line trials have been carried out with TATA and\u000a      Dyesol (Shotton) using their &#163;1.5M roll-to-roll pilot line.[5.1-5.4]\u000a      Holliman's group are scaling ultra-fast DSC sensitization, increasing DSC\u000a      efficiencies (by 30-40%) by improving spectral response using four dyes in\u000a      minutes. This avoids longer processing and large dye baths containing\u000a      100's g of expensive dye (ca. &#163;500\/g). Following the launch of the\u000a      SPECIFIC IKC (2011) Bangor has linked with Swansea partners to develop\u000a      building-integrated modules (roof mounted, windows etc.).[5.4-5.6] This\u000a      is important because roll-to-roll lines run at the speed of the slowest\u000a      process, so doubling dyeing time halves productivity making ultra-fast\u000a      sensitization essential for roll-to-roll DSC manufacture.\u000a    Since 2008, in addition to the six industry-facing PDRAs at Bangor, three\u000a      new jobs were created at the joint TATA\/Dyesol PV Accelerator in Shotton,\u000a      employing ex-Bangor researchers Rugen- Hankey, Vaca Velasco and\u000a      Ketipearachchi. Holliman is Bangor PI on an Industry\/Welsh\u000a      Government\/TSB\/EPSRC funded Innovation Knowledge Centre opened at Swansea\u000a      University in 2011 (SPECIFIC).[5.5-5.6] SPECIFIC works at\u000a      Technology Readiness Levels (TRL) 3-7 on \"Buildings as Power Stations\" to\u000a      functionalise the building envelope. Hence, SPECIFIC is an exploitation\u000a      vehicle between invention (TRL1-3) and commercialisation (TRL 6-9).\u000a      Scaling and line trials of Bangor-generated IP (working with TATA, Dyesol,\u000a      G24i and\/or SPECIFIC) have taken the sintering and dyeing inventions from\u000a      TRL1-3 to TRL 4-5 using large substrates (A4 size) which are larger than\u000a      that required for fully scaling this technology into modules (see\u000a      Technology Roadmap below).\u000a    Another example of an impact of Bangor's research is WG-supported STRIP\u000a      initiative (Steel Training Research and Innovation Partnership) to deliver\u000a      high quality University research to industry to improve industry\u000a      competitiveness.[5.8]\u000a    Holliman has undertaken two funded secondments (Oct-Dec 2011 and July\u000a      2012-Jan 2013) to work with senior TATA and SPECIFIC management and\u000a      economists (Mr. Kevin Bygate and Mr. Kian Woodward, TATA and Prof. Dave\u000a      Worsley, SPECIFIC) on a PV Technology Roadmap (TRM). [5.1]\u000a      These were based at TATA (Shotton) and SPECIFIC (Swansea) and involved\u000a      visits to TATA sites in the UK and India and SPECIFIC partners (e.g.\u000a      NSG). The roadmap is a strategy for PV commercialisation which compares PV\u000a      technologies in terms of feasibility, manufacturing, processing and\u000a      lifetime issues as well as current\/predicted markets and product form. It\u000a      has been developed through SPECIFIC and its industrial partners (e.g.\u000a      TATA, NSG, BASF who have staff seconded into the centre) and the recently\u000a      Welsh Government-funded Ser Cymru Solar project (&#163;6M, 2013-2018) working\u000a      between Swansea, Imperial College and Bangor.\u000a    Thus, the research carried out at the School of Chemistry in Bangor has\u000a      been contributing to the evolving global PV sector through the development\u000a      of scaled PV manufacturing by accelerating dye sensitization by ca.\u000a      2000 times (24h becoming 1 min) and reducing processing temperatures (from\u000a      450-550&#176;C to room temperature). We have scaled these inventions to A4 size\u000a      and carried out feasibility and lifetime testing with G24i, Dyesol and\u000a      TATA and line trials with Tata\/Dyesol proving low temperature processes\u000a      can also take place much faster (30 min becoming 4 min). These process are\u000a      now being utilised by our industrial partners.[5.1]\u000a    Holliman has established a strong partnership with TATA Steel (scaling,\u000a      route to market) and Prof Worsley (SPECIFIC- rapid processing, lifetime\u000a      testing) working on PV commercialisation particularly that based on the\u000a      results of his research on DSC. Holliman has developed a Technology\u000a      Roadmap for PV[5.1] which sets the strategy\/targets to develop\u000a      scaled building integrated PV (BIPV) to replace bolt-on crystalline\u000a      silicon modules. TATA have already produced BIPV roofs based on this\u000a      strategy which are undergoing outdoor testing.[5.8]\u000a    Associated with this research, using EPSRC support (Holliman, 2008-2010),\u000a      the bilingual English- Welsh language schools lecture Chemistry Show-Sioe\u000a      Cemeg was presented to over 2000 children annually by Dr Robyn\u000a      Wheldon-Williams.[5.9] In 2013, Dr Matthew Davies (SPECIFIC\u000a      PDRA in Dr Holliman's group) led a 15 strong team to South Africa showing\u000a      how to make dye- sensitized solar cells from natural dyes to over 1300\u000a      school children over a 2-week visit.[5.9]\u000a    ","ImpactSummary":"\u000a    In 2012, it is estimated the $145bn was invested in solar photovoltaic\u000a      technology. Dye-Sensitized Solar Cells (DSC) are expected to play an\u000a      increasing role in renewable energy generation over the next decade and\u000a      beyond, but several practical issues need to be overcome to facilitate\u000a      large-scale economic production. Fundamental research at Bangor has laid\u000a      the ground for collaborative work with industry which has overcome several\u000a      of the key production constraints in their manufacture, increasing\u000a      production speed and efficiency and substantially reducing costs. As a\u000a      result, we have developed a Technology Roadmap with a major multinational\u000a      partner (TATA) which has led to significant investment in plant and to the\u000a      production of pilot products in the form of photovoltaic roofs, currently\u000a      undergoing outdoor testing.\u000a    ","ImpactType":"Technological","Institution":"\u000a    010007857 Bangor University\u000a    ","Institutions":[{"AlternativeName":"Bangor University","InstitutionName":"Bangor University","PeerGroup":"B","Region":"Wales","UKPRN":10007857}],"Panel":"B         ","PlaceName":[],"References":"\u000a    (Bangor authors in Boldface)\u000a    \u000a3.1 P. J. Holliman, M. Mohsen, A. Connell, M. L. Davies, K.\u000a        Al-Salihi, M. B. Pitak, G. J. Tizzard, S. J. Coles, R.W. Harrington,\u000a      W. Clegg, C. Serpa, O. H. Fontes, C. Charbonneau, M. J. Carnie, Ultra-fast\u000a      Co-Sensitization and Tri-Sensitization of Dye-Sensitized Solar Cells with\u000a      N719, SQ1 and Triarylamine Dyes, J. Mater. Chem., 2012,\u000a      22, 13318-13327. DOI: 10.1039\/c2jm31314f [Citations: 8]. (Submitted to\u000a      REF2014, ID 0810).\u000a    \u000a\u000a3.2 P. J. Holliman, M. L. Davies, A. Connell, B. V. Velasco and\u000a      T. M. Watson, Ultra-fast dye sensitisation and co-sensitisation for dye\u000a      sensitized solar cells. Chem. Commun., 2010, 46,\u000a      7256-7258. DOI: 10.1039\/c0cc02619k [Citations: 22]. (Submitted to REF2014,\u000a      ID 0809).\u000a    \u000a\u000a3.3 T. Watson, P. Holliman, D. Worsley, Rapid, continuous in situ\u000a      monitoring of dye sensitisation in dye-sensitized solar cells. J.\u000a        Mater. Chem., 2011, 21, 4321-4325. DOI:\u000a      10.1039\/c0jm03607b [Citations: 11]. (Submitted to REF2014, ID 0811).\u000a    \u000a\u000a3.4 P. J. Holliman, M. L. Davies, A. Connell, M. J. Carnie and T.\u000a      M. Watson, Rapid, Low Temperature Processing of Dye Sensitized Solar\u000a      Cells. Peer reviewed chapter in Functional Materials for Energy\u000a        Applications, Eds. J. A. Kilner, S. J. Skinner, S. J. C. Irvine, P.\u000a      P. Edwards 2012, Woodhead Publishers, Cambridge, pp. 42-66.\u000a      ISBN-13: 978-0-87509-059-1.\u000a      (http:\/\/www.woodheadpublishing.com\/en\/book.aspx?bookID=2340)\u000a    \u000a\u000a3.5 P. J. Holliman, D. Al-Husenawi, A. Connell and E.\u000a        Jones. Low temperature sintering of dye sensitized solar cells using\u000a      peroxides. PCT\/GB 2013\/050308. Filed 10th February 2012.\u000a    \u000a3.6 EPSRC research Grants:\u000a    (a) \"Metal Substrate Mounted Flexible Dye Sensitized Semiconductor Solar\u000a      Cells\", EP\/E03585X\/1, 2007-2010. Total &#163;282,362;\u000a    (b) \"Sustainable Product Engineering Centre for Innovative Functional\u000a      Industrial Coatings - SPECIFIC\", EP\/I019278\/1, 2011-2016. Total to\u000a      Bangor: &#163;465,673.\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"9","Level2":"12","Subject":"Materials Engineering"},{"Level1":"9","Level2":"6","Subject":"Electrical and Electronic Engineering"}],"Sources":"\u000a    5.1 PV pilot line trials and collaborative work on PV Technology\u000a        Roadmap with TATA and SPECIFIC can be verified by letter on file\u000a      from Director of Business Development, TATA Colors and CEO SPECIFIC,\u000a      Baglan.\u000a    5.2 PV pilot line trials, scale-up and collaborative work with\u000a      Dyesol can be verified by letter on file from Technical Manager, Dyesol,\u000a      St Asaph.\u000a    5.3 Collaborative work with TATA STRIP on novel surface lubricity\u000a      treatment can be verified by letter on file from Senior Technologist,\u000a      Product Technology, TATA Steel STRIP, Port Talbot. See also: http:\/\/www.welshcountry.co.uk\/index.php\/news-from-around-wales\/232-south-east-wales\/5570-forward-looking-partnership-supports-steel-industrys\u000a    5.4 DSC technology on prototype steel roofing material\u000a      (18.09.2012): http:\/\/www.dyesol.com\/posts\/cat\/corporate-news\/post\/watch-video-dyesols-dye-solar-cell-dsc-technology-on-tata-steels-roofing-material\/\u000a    5.5 Dr Holliman interview \"SPECIFIC: An opportunity to make a\u000a      real product\":\u000a      http:\/\/www.youtube.com\/watch?v=4SjSz43i5G8\u000a    5.6 For Bangor partnership with SPECIFIC see:\u000a      http:\/\/www.dailypost.co.uk\/business\/business-news\/20m-scheme-turn-wales-buildings-\u000a        2649375\u000a      http:\/\/www.walesonline.co.uk\/news\/local-news\/20m-scheme-turn-wales-buildings-2022427\u000a      http:\/\/www.plusplasticelectronics.com\/buildingsinfrastructure\/work-on-coatings-for-low-carbon-buildings-gets-underway-41833.aspx\u000a      http:\/\/www.tatasteeleurope.com\/en\/news\/news\/2010\/2010_specific\u000a    5.7 http:\/\/www.building4change.com\/page.jsp?id=723\u000a    5.8 BIPV Development Project (17.06.2011):\u000a      http:\/\/www.slideshare.net\/PVaccel\/bipv-development-projectppt-8335044\u000a    5.9 Schools outreach work in the UK is evidenced by final\u000a      reports, evaluation forms and pictures sent to EPSRC as funding body\u000a      (reports for 2009 and 2010 are on file as examples). Web reports of the\u000a      schools work in South Africa (2013) are also held on file.\u000a    ","Title":"\u000a    Dye-Sensitised Solar Cells\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"2634895","Name":"Wales"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Materials chemistry and renewable energy are important research themes\u000a      within the School of Chemistry and this is exemplified by research on\u000a      dye-sensitized solar cells (DSC) led by Dr. P.J. Holliman (appointed\u000a      1995).\u000a    Since 2002, Holliman's group has carried out research on functional\u000a      coatings and photovoltaics focussing on three issue of major importance\u000a      for the commercialisation of the cells:\u000a    \u000a      design and synthesis of low cost dye sensitizers and studies of their\u000a        co-sensitization;[3.1-3.2]\u000a\u000a      investigations of dye chemisorption for a fast sensitisation process;[3.1-3.3]\u000a\u000a      research on low temperature processing of DSC.[3.4-3.5]\u000a\u000a    \u000a    This research has led to long-term collaborations between Bangor\u000a      Chemistry with Engineers at Swansea University (ultra-fast sintering,\u000a      weathering) and TATA Steel (process engineering\/scale- up). The research\u000a      has been supported by a series of Welsh Government, EU, EPSRC and\u000a      EPSRC\/TSB industrially co-sponsored projects.\u000a    2.1. Dye sensitizers and co-sensitization of DSC.\u000a      The research was carried by 2 postdoctoral research assistants and 3 PhD\u000a      students, under the direction of Holliman, in search of efficient, low\u000a      cost sensitizers which work together to harvest more sunlight by DSC\u000a      (2003-2013). This has produced 5 dye families, clay-stabilized pigments\u000a      and the patented synthesis of infrared absorbing DSC dyes. We have also\u000a      demonstrated that co- sensitizing dyes broadens spectral absorption and\u000a      increases DSC efficiency by 30-40%, whilst reducing dye costs by more than\u000a      50%, compared to the widely used Ru-bipy dyes, by reducing raw material\u000a      costs, and simplifying synthetic steps and purification.[3.1-3.2]\u000a    2.2 Ultra-fast process of dye sensitization and co-sensitization for\u000a        DSC.\u000a      Conventional TiO2 dyeing in DSC takes a long time, making it a\u000a      critical issue for DSC manufacturing. Working with 2 PDRAs and 2 PhD\u000a      students, Holliman has developed rapid dyeing methods leading to\u000a      ultra-fast sensitization, reducing processing time from 18-24h to\u000a          &lt;5 mins. This work resulted in 3 patents from 2009-2012\u000a      (PCT\/EP2010\/051135, PCT\/EP2011\/059551 and PCT\/GB2013\/050171), with\u000a      subsequent journal publication.[3.1-3.3]\u000a    This approach was further developed to demonstrate the world's first\u000a      examples of ultra-fast co- sensitization of up to 4 dyes in less than\u000a      5min, eliminating oxidative degradation by air, reducing dye solution\u000a      volume by ~100 times (significantly reducing costs of expensive dyes) and\u000a      enhancing spectral response and device efficiency by controlling multiple\u000a      dye loading (impossible using conventional dyeing).[3.1-3.3] This\u000a      work was funded by Welsh Government Academia for Business (A4B) Proof of\u000a      Concept funding supporting a PDRA in Bangor from 2010-2011, and from 2011,\u000a      by EPSRC support for a PDRA in Bangor as part of a Swansea University-led\u000a      innovation &amp; knowledge centre SPECIFIC (Sustainable Product\u000a      Engineering Centre for Innovation in Functional Industrial Coatings),[3.6b]\u000a      as well as 2 PhD students.\u000a    2.3 Low-temperature processing of DSC.\u000a      Conventional DSC photo-anode manufacturing requires sintering of TiO2\u000a      at &gt;450&#176;C. A consortium EPSRC project (2007-2010)[3.6a]\u000a      comprising Bangor Chemistry (Holliman), TATA, Imperial College,London\u000a      (Prof. J. Durrant &#8212; device characterisation), University of Bath (Prof. L.\u000a      Peter - electrolyte development) and Swansea University (Prof. D. Worsley\u000a      &#8212; lifetime testing) led to us producing the first examples of low\u000a          temperature sintering of binder-containing TiO2\u000a          colloids. We demonstrated that the binder is essential for\u000a      commercial manufacture, although previous approaches had simply left this\u000a      out[3.4]. We developed combustion catalysts\/promoters and\u000a      chemical binders to reduce sintering to room temperature for longer\u000a      sintering times leading to 3 patents, the most recent in 2012 [3.5].\u000a    Our work with support from the Welsh Energy Research Council (PDRAs\u000a      2006-2009), led to a patented room temperature platinisation\u000a      procedure, to supplant a previous process carried out at 400&#176;C.\u000a    Further Welsh Government A4B funding (PDRAs, 2010-2013), enabled us to\u000a      scale-up the low temperature sintering and platinisation processes to A4\u000a      size. With EU (ERDF) support through the Low Carbon Research Institute,\u000a      the Solar Photovoltaic Academic Research Consortium brought together\u000a      researchers from Bangor (Holliman &#8212; sensitization and low temperature\u000a      processing), Swansea (Dr. P. Igic &#8212; power electronics, Prof. D. Worsley &#8212;\u000a      materials), Glyndwr (Prof. S. Irvine - thin film photovoltaics) and\u000a      several companies to scale up photovoltaic manufacture leading to pilot\u000a      line trials (2012) of the Bangor low temperature processes.\u000a    In total, 9 patents have been filed (7 through Bangor University and 2\u000a      through TATA) on metal surface treatments for inherent lubricity,\u000a      development of DSC sensitizers, ultra-fast and precision controlled\u000a      multiple dye sensitisation for DSC and rapid low temperature processing.\u000a    "},{"CaseStudyId":"31276","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Wellcome Trust","Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000a    UoN's novel method of using supercritical carbon dioxide as a medium for\u000a      the synthesis and\u000a      modification of polymeric materials has resulted in the development of new\u000a      drug-delivery devices\u000a      and millions of pounds' worth of investment and research collaborations\u000a      for the spin-out company,\u000a      Critical Pharmaceuticals Ltd (CP).\u000a    The method developed from the initial patent [3.i], marketed by CP as\u000a      CriticalMix TM, has been used\u000a      to produce a human growth hormone (hGH), product CP016. In October 2008\u000a      this sustained\u000a      release formulation of the synthetic hGH somatropin successfully completed\u000a      preclinical studies in\u000a      non-human primates, confirming that CriticalMix TM enables\u000a      sustained release of active species &#8212; as\u000a      predicted &#8212; and that the therapeutic plasma levels are maintained for\u000a      days, weeks or even\u000a      months following a single injection [5.1- 5.3].\u000a    Given the inherent shortcomings of the conventional hGH treatment\u000a      regimen, these results are\u000a      highly significant. hGH is used therapeutically to treat a variety of\u000a      diseases &#8212; from growth hormone\u000a      deficiency in children and adults to Turners Syndrome and HARS, a syndrome\u000a      associated with HIV\u000a      infection &#8212; but, due to various physical and biological barriers, it needs\u000a      to be injected\u000a      subcutaneously every day. The regimen is strongly disliked by patients and\u000a      carers, with studies\u000a      showing up to 66% of the former do not adhere to the prescribed routine,\u000a      leading to reduced\u000a      efficacy and increased healthcare costs. CP016 needs to be injected only\u000a      once every two weeks,\u000a      improving clinical outcomes through enhanced efficacy, greater patient\u000a      compliance and reduced\u000a      side-effects. A Non-Executive director of CP noted \"despite the marked\u000a      improvements in needle\u000a      and injector pen technology, there remains a sizeable number of patients\u000a      who have \"needle\u000a      phobia\" and fail to adhere to the prescribed regimen\" and that the\u000a      technology \"would be an\u000a      important addition to the clinician's armamentarium\" [5.4].\u000a    CP is also engaged in several new projects to increase the utility of\u000a      CriticalMix TM including\u000a      collaboration with UK biotechnology company PolyTherics Ltd. This\u000a      partnership, launched in 2011\u000a      and backed by &#163;350k of Technology Strategy Board funding [5.4], was\u000a      initiated to produce a\u000a      clinically superior sustained release product that could be administered\u000a      less frequently than\u000a      currently marketed products, resulting in reduced side-effects and\u000a      improved overall efficacy. The\u000a      Chief Executive Officer of PolyTherics has described the collaboration as\u000a      \"an opportunity to\u000a      develop a unique technology... to produce a better product for patients\"\u000a      [5.5]. In addition in a\u000a      collaboration with Ferring Pharmaceuticals which began in 2011, from\u000a      pre-clinical results,\u000a      CriticalMixTM technology has been shown to \"overcome issues of\u000a      release of Ferring's molecule\u000a      which could not be overcome using standard drug delivery\" [5.6]. Both of\u000a      these examples\u000a      demonstrate the significant impact CriticalMix TM has for\u000a      patients.\u000a    Working with the UoN research team, CP has developed a second proprietary\u000a      technology,\u000a      CriticalSorb TM, which allows hGH and other drugs to be\u000a      administered using a nasal spray.\u000a      CriticalSorb TM is a pharmaceutically acceptable excipient\u000a      approved by the Food and Drug\u000a      Administration as GRAS (\"generally regarded as safe\"). It has a Drug\u000a      Master File and is used in\u000a      currently marketed products as a solubility enhancer for intravenous and\u000a      oral administration. It was\u000a      found to be non-toxic in preclinical toxicology studies and was well\u000a      tolerated by the nasal mucosa\u000a      in acute, 14-day and six-month repeated dose chronic toxicity studies. It\u000a      is not mutagenic to\u000a      bacteria, mammalian cells and mammals, and no developmental toxicity or\u000a      teratogenicity has been\u000a      found. hGH could previously not be absorbed through the nasal mucosa, but\u000a      CriticalSorb TM has\u000a      been shown to allow it to be administered intra-nasally &#8212; thereby\u000a      completely removing the need for\u000a      daily injections.\u000a    CriticalSorb TM nderpinned the development of the hGH\u000a      treatment CP024, which in July 2012\u000a      successfully completed Phase I clinical trials in which it exhibited\u000a      similar performance and safety to\u000a      marketed products [5.7]. The trials also showed CP024 to be the first\u000a      intra-nasal growth hormone\u000a      to induce the insulin-like growth factor IGF-1. This represents a\u000a      significant advance in efforts to\u000a      treat the disorders related to hGH deficiency outlined above while\u000a      obviating the need for injections.\u000a      The growth hormone market is currently worth $3.1bn, with more than 10\u000a      major manufacturers of\u000a      branded and generic daily injectable products. CP024 is the only\u000a      non-invasive growth hormone\u000a      product in development, and feedback from leading endocrinologists and\u000a      franchise holders\u000a      indicates it is an attractive product for patients and physicians.\u000a    CriticalSorb TM has also been used in two revenue-generating\u000a      research collaborations with\u000a      biotechnology companies and in a major collaborative project with\u000a      Nottingham's Queen's Medical\u000a      Centre, the largest hospital in the UK and Europe's largest teaching\u000a      hospital, to evaluate a new\u000a      nasal delivery formulation for Teriparatide, a treatment for osteoporosis\u000a      [5.8]. This new formulation\u000a      is expected to improve the efficacy of the drug and make it more easily\u000a      administered as it\u000a      eliminates the current need for daily subcutaneous injection. To date the\u000a      collaboration has\u000a      demonstrated excellent outcomes in preclinical studies and will start\u000a      Phase I clinical trials in\u000a      October 2013. The Head of The Clinical Gerontology Research Unit at\u000a      Nottingham University\u000a    Hospitals NHS Trust [5.9] expects the nasal teriparatide product to\u000a      `significantly benefit patients,\u000a      their families, carers and clinicians with improved clinical outcomes and\u000a      greatly enhanced ease of\u000a      use' and `enable patients to live independently for longer so reducing the\u000a      cost of treatment'.\u000a      The progress made in exploiting these technologies is in line with the\u000a      drug discovery and\u000a      development timeline expected when bringing a new drug\/therapy to market &#8212;\u000a      specifically, up to 15\u000a      years from inception.\u000a    UoN's research has enabled CP to safeguard nine jobs and has also allowed\u000a      expansion, with a\u000a      further six staff recruited since 2008. In the period 2008-2013, CP has\u000a      attracted &#163;2.7m in private\u000a      investment and venture capital and another &#163;1.9m in R&amp;D funding,\u000a      including &#163;1.5m from the\u000a      Wellcome Trust (October 2009) [5.10] to develop CriticalSorb TM.\u000a      Investors have described CP as\u000a      \"an exciting opportunity\" and \"an ideal showcase for the region's\u000a      excellence in pharmaceutical\u000a      services\" [5.11]. A number of revenue-generating research collaborations\u000a      have been secured using\u000a      the CriticalMixTM technology, including with a leading\u000a      European pharmaceutical company, seven\u000a      biopharmaceutical companies and two drug-delivery companies.\u000a    ","ImpactSummary":"\u000a    The University of Nottingham's School of Chemistry has developed a novel\u000a      method of\u000a      incorporating thermally or chemically labile biologically active\u000a      substances into polymers. This has\u000a      been achieved by using supercritical carbon dioxide as a medium for the\u000a      synthesis and\u000a      modification of polymeric materials. The method has been employed as the\u000a      basis for new drug-delivery\u000a      devices whose viability in the healthcare sphere has been confirmed by\u000a      patient trials. The\u000a      spin-out company, Critical Pharmaceuticals Ltd, has delivered a range of\u000a      economic benefits,\u000a      including job creation, the securing of millions of pounds' worth of\u000a      investment and a number of\u000a      revenue-generating research collaborations.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Nottingham\u000a    ","Institutions":[{"AlternativeName":"Nottingham (University of)","InstitutionName":"University of Nottingham","PeerGroup":"A","Region":"East Midlands","UKPRN":10007154}],"Panel":"B         ","PlaceName":[],"References":"\u000a    Publications:\u000a      \u000a1. Howdle, S. M., Watson, M., Whitaker, M., Shakesheff, K. M., Davies, M.\u000a      C., Mandel, F. S.,\u000a      Wang, J. D., and Popov, V. K, Supercritical fluid mixing: preparation of\u000a      thermally sensitive\u000a      polymer composites containing bioactive materials, Chemical\u000a        Communications, 2001, 109-\u000a      110, DOI: 10.1039\/b008188o\u000a    \u000a\u000a2. Watson, M. S., Whitaker, M. J., Howdle, S. M., and Shakesheff, K. M.,\u000a      Incorporation of\u000a      proteins into polymer materials by a novel supercritical fluid processing\u000a      method, Advanced\u000a        Materials, 2002, 14, 1802-1804, DOI: 10.1002\/adma.200290003\u000a    \u000a\u000a3. Kanczler, J. M., Barry, J. J. A., Ginty, P., Howdle, S. M.,\u000a      Shakesheff, K. M., and Oreffo, R.\u000a      O. C., Supercritical carbon dioxide generated vascular endothelial growth\u000a      factor\u000a      encapsulated poly(DL-lactic acid) scaffolds induce angiogenesis in\u000a        vitro, Biochemical and\u000a        Biophysical Research Communications, 2007, 352, 135-141,\u000a      DOI:\u000a      10.1016\/j.bbrc.2006.10.187\u000a    \u000aGrants:\u000a      a. EPSRC Materials Processing for Engineering Applications Grant\u000a      GR\/M38759\/01,\u000a      Manufacturing of Bio-interactive Scaffolds for Tissue Engineering Using\u000a      Supercritical Fluid\u000a      Technology, P.I Steven M. Howdle, 1999-2001, &#163;251,328\u000a    Patents:\u000a      i. Steven Melvyn Howdle Biofunctional polymers prepared in supercritical\u000a      fluid WO9851347\u000a    ii. Andrew Naylor, Andrew Lester Lewis, Lisbeth Illum Process for\u000a      preparing microparticles\u000a      WO2010004287\u000a    iii. Lisbeth Illum, Michael Faron Jordan, Andrew Lester Lewis\u000a      Improvements in the absorption of\u000a      therapeutic agents across mucosal membranes or the skin WO2010029374\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"3","Subject":"Macromolecular and Materials Chemistry"},{"Level1":"9","Level2":"3","Subject":"Biomedical Engineering"},{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"}],"Sources":"\u000a    \u000a      Preclinical results of CriticalMixTM hGH product\u000a        http:\/\/www.criticalpharmaceuticals.com\/latest\/news\/critical-pharmaceuticals-enter-sustained-release-hgh-arena (published 1\/10\/08, accessed 25\/9\/12)\u000a      Jordan, F., Naylor, A., Kelly, C., Howdle, S., Lewis, A., and Illum,\u000a        L., Sustained release hGH\u000a        microsphere formulation produced by a novel supercritical fluid\u000a        technology: in vivo studies,\u000a        Journal of Controlled Release, 2010, 141, 153-160, DOI:\u000a        10.1016\/j.jconrel.2009.09.013\u000a      Kelly C., Naylor A., Illum L., Shakesheff K. M., and Howdle S.,\u000a        Supercritical CO2: A Clean and\u000a        Low Temperature Approach to Blending PDL LA and PEG, Advanced\u000a          Functional Materials,\u000a        2012, 22,1684-1691, DOI: 10.1002\/adfm.201101889\u000a      Letter of support from Non-Executive director of Critical\u000a        Pharmaceuticals (11\/10\/13)\u000a      Critical Pharmaceuticals\/PolyTherics Ltd TSB-funded collaboration\u000a        http:\/\/www.criticalpharmaceuticals.com\/latest\/news\/polytherics-and-critical-pharmaceuticals-collaboration (published 5\/4\/11, accessed 25\/9\/12)\u000a      Senior Vice President Global Pharmaceutical R&amp;D Ferring\u000a        Pharmaceuticals (14\/10\/13)\u000a      CP024 Phase I clinical trial outcomes\u000a        http:\/\/www.criticalpharmaceuticals.com\/latest\/news\/cp024-presentation-at-endo (published\u000a        7\/6\/12, accessed 25\/9\/12)\u000a      TSB and EPSRC funding to develop nano-enabled nasal spray for\u000a        osteoporosis\u000a        http:\/\/www.criticalpharmaceuticals.com\/latest\/news\/nasal-pth-collaboration (published 16\/2\/12,\u000a        accessed 25\/9\/12)\u000a      Letter of support from the Head of The Clinical Gerontology Research\u000a        Unit at Nottingham\u000a        University Hospitals NHS Trust (18\/9\/2013)\u000a      Wellcome Trust funding http:\/\/www.criticalpharmaceuticals.com\/latest\/news\/wellcome-trust-funding-for-cp024-nasal-hgh (published 14\/10\/09, accessed 25\/9\/12)\u000a      Investment round results http:\/\/www.criticalpharmaceuticals.com\/latest\/news\/critical-pharmaceuticals-raise-650k (published 10\/11\/08, accessed 25\/9\/12)\u000a    \u000a    ","Title":"\u000a    Supercritical Fluids &#8212; Critical Pharmaceuticals Ltd (CS1)\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000a    The effective use of polymers in bio-materials has traditionally involved\u000a      a number of significant\u000a      challenges. In particular, maintaining the structure and activity of\u000a      biological materials within\u000a      polymers using conventional processing methods &#8212; for example,\u000a      organic\/aqueous solvent\u000a      interfaces, elevated temperatures or the mechanical agitation of solutions\u000a      &#8212; is difficult. In 1996,\u000a      after a study of the literature (including the foaming and processing of\u000a      polymers in tissue\u000a      engineering) highlighted areas in which improvements in bio-materials\u000a      processing were needed,\u000a      the School of Chemistry at the University of Nottingham (UoN) began\u000a      investigating the application\u000a      of supercritical fluids for incorporating thermally or chemically labile\u000a      biologically active substances\u000a      into polymers.\u000a    Supercritical carbon dioxide (scCO2) is known to be a \"green\"\u000a      solvent with a broad range of\u000a      environmentally sustainable chemistry applications. Working in\u000a      collaboration with Vladimir Popov,\u000a      of Moscow's Russian Academy of Sciences, Professor Steven Howdle\u000a      (Professor of Chemistry,\u000a      1989-present) discovered that scCO2 plasticises polymers and\u000a      can be used not only to generate\u000a      porous scaffolds but also to incorporate thermally labile molecules\u000a      without loss of their activity.\u000a      Examples included growth hormone yielding polymeric materials suitable for\u000a      tissue engineering\u000a      applications in the field of bone repair. This finding is the subject of a\u000a      patent application [3.i] filed by\u000a      UoN.\u000a    The researchers showed that the use of this supercritical fluid mixing\u000a      method for producing a\u000a      sustained release formulation had considerable advantage over existing\u000a      commercial technologies\u000a      as the drug is not chemically modified during the process. As a result\u000a      there are no changes in\u000a      activity, stability, safety and distribution of the active ingredients.\u000a      Moreover, the process of\u000a      encapsulation operates at ambient temperatures meaning that the technique\u000a      could be applied to a\u000a      range of thermally sensitive molecule such as proteins. The process is\u000a      also solvent-free so there\u000a      is no possibility of solvent residues contaminating the formulations and\u000a      causing potentially harmful\u000a      side-effects in patients.\u000a    The key finding that polymer-drug scaffolds could be formed using scCO2\u000a      and without using any\u000a      hazardous chemical solvents\/reagents made the technology immediately\u000a      amenable to biomedical\u000a      applications. Howdle collaborated with UoN's School of Pharmacy (Professor\u000a      Kevin Shakesheff,\u000a      Professor of Advanced Drug Delivery and Tissue Engineering, 1997-present;\u000a      Professor Martyn\u000a      Davies, Professor of Biomedical Surface Chemistry, 1985-present) to\u000a      explore these possibilities\u000a      further and secured an EPSRC Materials Processing for Engineering\u000a      Applications grant (MaPEA)\u000a      [3.a] to investigate scale-up and commercialisation. This research\u000a      included the optimisation of the\u000a      supercritical mixing method and the testing of new polymer scaffolds for\u000a      tissue engineering [3.1-\u000a      3.3].\u000a    It was found that proteins could be mixed with plasticised polymers under\u000a      scCO2 conditions and\u000a      the mixture sprayed to produce polymeric microparticles loaded with active\u000a      protein. This could then\u000a      be injected and would deliver the biologically active substance in a\u000a      controlled release manner.\u000a      Protein activity was also found to be unaffected by the supercritical\u000a      mixing process [3.1]. A process\u000a      was subsequently developed to allow encapsulation of delicate\u000a      protein-based drugs or hormones\u000a      into a biodegradable polymeric matrix, either as a scaffold for tissue\u000a      engineering applications or as\u000a      microparticles for controlled drug release.\u000a    The MaPEA research highlighted the commercial potential of using\u000a      supercritical fluids as a reaction\u000a      medium for the manufacture of polymer-based biomaterials. Dr Martin\u000a      Whitaker, the PhD\u000a      researcher on the grant, became a Business Science Fellow within the\u000a      School's Business\u000a      Partnership Unit and developed a business plan to establish a spin-out\u000a      company, leading to the\u000a      founding in 2002 of Critical Pharmaceuticals Ltd.\u000a      Research findings were published in 2002 &amp; 2007 [3.2 &amp; 3.3] and\u000a      two further patents were filed by\u000a      Critical Pharmaceuticals [3.ii &amp; 3.iii].\u000a    "},{"CaseStudyId":"31279","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"337996","Name":"Ethiopia"},{"GeoNamesId":"2328926","Name":"Nigeria"},{"GeoNamesId":"2275384","Name":"Liberia"}],"Funders":["Engineering and Physical Sciences Research Council","Royal Society"],"ImpactDetails":"\u000d\u000a    The University of Nottingham (UoN) has led the way in addressing the key\u000d\u000a      challenge of\u000d\u000a      establishing Green Chemistry in the developing world. The joint paper with\u000d\u000a      Ethiopian researchers\u000d\u000a      on the cleaner extraction of essential oils from Artemisia Afra\u000d\u000a      stimulated considerable interest\u000d\u000a      among the chemistry community in Ethiopia, with subsequent discussions\u000d\u000a      highlighting not only the\u000d\u000a      benefits Green Chemistry could bring to the country but also the need to\u000d\u000a      raise awareness of the\u000d\u000a      topic among the public, government and industry. Poliakoff and Licence\u000d\u000a      have participated in a\u000d\u000a      range of activities that have changed the curriculum in universities,\u000d\u000a      informed government policy\u000d\u000a      and influenced training and services offered by professional bodies and\u000d\u000a      learned societies.\u000d\u000a      Increasingly, the benefits of these efforts have been felt across Africa.\u000d\u000a    Four Green Chemistry Workshops have been organised by UoN, AAU and the\u000d\u000a      Chemical Society of\u000d\u000a      Ethiopia during the 2008-2013 period [5.1]. Held in Ethiopia, each has\u000d\u000a      attracted up to 100 high\u000d\u000a      school\/university students, chemists, chemical engineers from Ethiopian\u000d\u000a      industry and members of\u000d\u000a      the general public. Researchers from Poliakoff and Licence's team have\u000d\u000a      given talks on their work &#8212; including\u000d\u000a      research into ionic liquids, reaction optimisation and hydrogenation using\u000d\u000a      supercritical\u000d\u000a      fluids &#8212; and have held discussions with students to share experiences.\u000d\u000a      According to AAU's Dr\u000d\u000a      Nigist Asfaw, these events have been fundamental in raising Green\u000d\u000a      Chemistry's wider profile, even\u000d\u000a      featuring on Ethiopian national television and in the national print\u000d\u000a      media. Asfaw has remarked: \"It\u000d\u000a      has been great to see Green Chemistry, which was once an unknown topic in\u000d\u000a      our country, being\u000d\u000a      discussed and employed across my country.\" [5.2]\u000d\u000a    Building on the success of the initial research collaboration and the\u000d\u000a      subsequent workshops, a\u000d\u000a      British Council DelPHE-funded partnership between AAU's Science Faculty\u000d\u000a      and UoN's School of\u000d\u000a      Chemistry was secured. Showcased as a DelPHE case study in 2010 [5.3], the\u000d\u000a      arrangement has\u000d\u000a      continued to deliver benefits throughout the impact period. Knowledge\u000d\u000a      transfer between the two\u000d\u000a      universities, coupled with Licence's appointment as an Adjunct Professor\u000d\u000a      at AAU, has resulted in a\u000d\u000a      new course, Introduction to Green Chemistry, for the undergraduate\u000d\u000a      curriculum. In addition, PhD\u000d\u000a      students trained by Poliakoff and Licence have taken up positions at other\u000d\u000a      Ethiopian universities,\u000d\u000a      including Jimma, Haramaya, Hawassa and Bahir Dar, where they are now\u000d\u000a      promoting and initiating\u000d\u000a      Green Chemistry research. Licence has also hosted four visiting\u000d\u000a      researchers in Nottingham as part of\u000d\u000a      their PhD studies in Ethiopia. In 2013 the British Council's Director of\u000d\u000a      Science observed: \"A little\u000d\u000a      over a decade ago the field of Green Chemistry was virtually unknown in\u000d\u000a      Ethiopia. Now, as a direct\u000d\u000a      result of the University of Nottingham's pioneering efforts, it is taught\u000d\u000a      across the country. We\u000d\u000a      consider this to be one of our most successful recent DelPHE projects.\u000d\u000a      Your work... has given\u000d\u000a      Ethiopian chemists a sense of empowerment and confidence.\" [5.4]\u000d\u000a    In 2012 the Ethiopian Ministry of Education and UoN reached an agreement\u000d\u000a      for jointly funded\u000d\u000a      scholarships for outstanding young Ethiopian academics to undertake\u000d\u000a      one-year research\u000d\u000a      programmes at UoN in areas likely to advance the country's development.\u000d\u000a      Green Chemistry is one\u000d\u000a      of these areas. In an August 2013 letter to Poliakoff &#8212; who twice met with\u000d\u000a      Ethiopia's Deputy Prime\u000d\u000a      Minister, His Excellency Derek Mekonnen, in 2011 &#8212; the Ethiopian\u000d\u000a      Ambassador to the UK said:\u000d\u000a      \"His Excellency was most impressed to hear how the ideas of Green\u000d\u000a      Chemistry are being\u000d\u000a      incorporated into the curriculum at AAU and other universities... [He] and\u000d\u000a      I would like to thank you\u000d\u000a      and your colleagues for your great efforts over nearly 10 years in\u000d\u000a      increasing the understanding of\u000d\u000a      science and science education in my country.\" [5.5]\u000d\u000a    The influence of UoN's work has also been felt beyond Ethiopia. As a\u000d\u000a      result of his connections with\u000d\u000a      Nottingham, Royal Society of Chemistry (RSC) President Simon Campbell\u000d\u000a      attended the inaugural\u000d\u000a      Federation of African Societies of Chemistry (FASC) congress in 2006,\u000d\u000a      where he announced RSC\u000d\u000a      would be the first learned and professional organisation to provide\u000d\u000a      developing countries with free\u000d\u000a      access to science journal archives. The current RSC Chief Executive has\u000d\u000a      described UoN's input as\u000d\u000a      \"critical\" to this move, noting: \"Your work has transformed how the\u000d\u000a      concept of Green Chemistry is\u000d\u000a      perceived and pursued in Africa.\" [5.6] Between 2008 and 2013 more than\u000d\u000a      49,000 journal articles\u000d\u000a      have been downloaded and 25,000 textbooks and RSC journals distributed to\u000d\u000a      universities in 12\u000d\u000a      different African countries &#8212; including 800 to aid the reconstruction of\u000d\u000a      Liberia University &#8212; under the\u000d\u000a      Journals for Africa initiative.\u000d\u000a    The success of the collaboration between FASC and RSC led to the\u000d\u000a      formation of the Pan-African\u000d\u000a      Chemistry Network (PACN), including the establishment in 2008 of two hubs\u000d\u000a      &#8212; one in Addis Ababa.\u000d\u000a      PACN aims to enhance cooperation between governments, universities,\u000d\u000a      industry and communities\u000d\u000a      to help build a sustainable science base across the continent. The RSC's\u000d\u000a      CEO has acknowledged\u000d\u000a      UoN's \"significant input\" into PACN [5.6], including its contribution to\u000d\u000a      Wealth Not Waste: Green\u000d\u000a      Science and Engineering for Sustainable Growth in Africa [5.7], a report\u000d\u000a      whose cover featured\u000d\u000a      Poliakoff's Thirteen Principles for Green Chemistry for Africa. According\u000d\u000a      to RSC, Wealth Not Waste\u000d\u000a      has reached an estimated 20,000 scientists and 2,500 global policymakers\u000d\u000a      since its launch at\u000d\u000a      launch at the United Nations UNECA CODIST-2 meeting. Further UoN support\u000d\u000a      for PACN has\u000d\u000a      included Licence's participation on the PACN Advisory Board since 2009. He\u000d\u000a      has also lectured at\u000d\u000a      the PACN Sustainable Water Conference, University of Nairobi (August\u000d\u000a      2009), been a member of\u000d\u000a      the organising committee for the 1st PACN Green Chemistry Congress\u000d\u000a      (November 2010) held in\u000d\u000a      Addis Ababa and sat on the organising group of PACN, Nigeria &#8212; Health\u000d\u000a      Water and Waste, Lagos\u000d\u000a      (July 2012). These interactions have seen Green Chemistry research feature\u000d\u000a      at the heart of PACN\u000d\u000a      activities further raising awareness of the topic across Africa.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    University of Nottingham researchers have been at the forefront in\u000d\u000a      promoting and establishing\u000d\u000a      Green Chemistry in developing nations. Working with and influencing\u000d\u000a      colleagues and policymakers\u000d\u000a      in both the UK and Africa, they have increased awareness of the importance\u000d\u000a      of introducing\u000d\u000a      sustainable technologies that meet local communities' needs. As a result,\u000d\u000a      they have invigorated\u000d\u000a      the chemistry teaching curriculum in Ethiopia, placing Green Chemistry at\u000d\u000a      its core, and helped\u000d\u000a      shape the approaches of professional bodies, including the Royal Society\u000d\u000a      of Chemistry, for the\u000d\u000a      benefit of the developing world. This has led to what the British Council\u000d\u000a      has described as \"a sense\u000d\u000a      of empowerment and confidence\" among Ethiopian chemists.\u000d\u000a    ","ImpactType":"Societal","Institution":"\u000d\u000a    University of Nottingham\u000d\u000a    ","Institutions":[{"AlternativeName":"Nottingham (University of)","InstitutionName":"University of Nottingham","PeerGroup":"A","Region":"East Midlands","UKPRN":10007154}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"2332459","Name":"Lagos"},{"GeoNamesId":"343137","Name":"Hawassa"},{"GeoNamesId":"444178","Name":"Adis Abeba Astedader"},{"GeoNamesId":"342884","Name":"Bahir Dar"},{"GeoNamesId":"184745","Name":"Nairobi"},{"GeoNamesId":"333772","Name":"Jima"}],"References":"\u000d\u000a    Publications:\u000d\u000a    \u000a1. M. G. Hitzler and M. Poliakoff, Continuous hydrogenation of organic\u000d\u000a      compounds in\u000d\u000a      supercritical fluids, Chemical Communications, 1997, 17,\u000d\u000a      1667-1668, DOI: 10.1039\/a704371f\u000d\u000a    \u000a\u000a2. P. Licence, J. Ke, M. Sokolova, S. K. Ross and M. Poliakoff, Chemical\u000d\u000a      reactions in\u000d\u000a      supercritical carbon dioxide: from laboratory to commercial plant, Green\u000d\u000a        Chemistry, 2003, 5(2),\u000d\u000a      99-104, DOI: 10.1039\/b212220k\u000d\u000a    \u000a\u000a3. E. F. Smith, I. J. Villar Garcia, D. Briggs and P. Licence, Ionic\u000d\u000a      liquids in vacuo; solution-phase\u000d\u000a      X-ray photoelectron spectroscopy, Chemical Communications, 2005,\u000d\u000a      5633-5635, DOI:\u000d\u000a      10.1039\/B512311A\u000d\u000a    \u000a\u000a4. S. J. Craythorne, K. Anderson, F. Lorenzini, C. McCausland, E. F.\u000d\u000a      Smith, P. Licence, A. C.\u000d\u000a      Marr and P. C. Marr, The Co-Entrapment of a Homogeneous Catalyst and an\u000d\u000a      Ionic Liquid by a\u000d\u000a      Sol-Gel Method: Recyclable Ionogel Hydrogenation Catalysts, Chemistry\u000d\u000a        &#8212; A European\u000d\u000a        Journal, 2009, 15, 7094-7100, DOI: 10.1002\/chem.200801809\u000d\u000a    \u000a\u000a5. N. Asfaw, P. Licence, A. A. NovitskiiI and M. Poliakoff, Green\u000d\u000a      Chemistry in Ethiopia: The\u000d\u000a      Cleaner Extraction of Essential Oils From Artemisia Afra: A Comparison Of\u000d\u000a      Clean Technology\u000d\u000a      With Conventional Methodology, Green Chemistry, 2005, 7, 352-356.\u000d\u000a      DOI 10.1039\/b417961g\u000d\u000a    \u000a\u000a6. A. Ejigu, A. Asfaw, N. Asfaw and P. Licence, Moringa stenopetala\u000d\u000a      seed oil as a potential\u000d\u000a      feedstock for biodiesel production in Ethiopia, Green Chemistry,\u000d\u000a      2010,12, 316-320 DOI:\u000d\u000a      10.1039\/B916500B\u000d\u000a    \u000aGrants:\u000d\u000a    a. EPSRC Grant (GR\/H95464\/01),Organometallic Chemistry in\u000d\u000a        Supercritical Fluids, P.I.\u000d\u000a      Poliakoff, 1993-1996, &#163;154,124\u000d\u000a    b. EPSRC Grant (GR\/M73644\/010), The Continuous Production of Fine\u000d\u000a        Chemicals in\u000d\u000a        Supercritical Carbon Dioxide, P.I. Poliakoff, 2000-2003, &#163;194,772\u000d\u000a    c. EPSRC Platform Grant (GR\/S87409\/01),Cleaner Chemistry &amp;\u000d\u000a        Processing in Supercritical\u000d\u000a        Fluids, P.I. Poliakoff, 2004-2009, &#163;430,004\u000d\u000a    d. EPSRC Advanced Fellowship (EP\/D073014\/1), Ionic Liquids in-vacuo;\u000d\u000a        marrying Surface\u000d\u000a        Science with Solution Chemistry, P.I. Licence, 2006-2011, &#163;870,688\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"},{"Level1":"3","Level2":"1","Subject":"Analytical Chemistry"}],"Sources":"\u000d\u000a    \u000d\u000a      Green Chemistry Workshops in Ethiopia (information supplied by Dr\u000d\u000a        Nigist Asfaw, Addis Ababa\u000d\u000a        University)\u000d\u000a      Letter from Dr Nigist Asfaw, Addis Ababa University\u000d\u000a      British Council (2010): Development Partnerships in Higher Education &#8212;\u000d\u000a        case study of Green\u000d\u000a        Chemistry in Ethiopia\u000d\u000a        http:\/\/www.britishcouncil.org\/delphe-case-studies-2010.pdf\u000a\u000d\u000a      Letter from Director of Science, British Council\u000d\u000a      Letter from Ambassador, Embassy of the Federal Democratic Republic of\u000d\u000a        Ethiopia, London\u000d\u000a      Letter from Chief Executive, Royal Society of Chemistry\u000d\u000a      Royal Society of Chemistry (2011): Wealth Not Waste: Green Science and\u000d\u000a        Engineering for\u000d\u000a        Sustainable Growth in Africa\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Empowering Chemists in Africa Through Green Chemistry (CS4)\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    One of the principal aims of Green Chemistry is to bring the benefits of\u000d\u000a      modern chemical\u000d\u000a      manufacture to developing countries without imposing the environmental\u000d\u000a      burden that has plagued\u000d\u000a      the industrialised world. Green Chemistry is particularly relevant to the\u000d\u000a      needs of African countries,\u000d\u000a      which have little indigenous oil to rely on yet face increasing demand for\u000d\u000a      chemicals from rapidly\u000d\u000a      expanding populations.\u000d\u000a    The School of Chemistry at the University of Nottingham (UoN) has a\u000d\u000a      long-established track record\u000d\u000a      of research excellence in Green Chemistry [3.1-3.4]. The work of Professor\u000d\u000a      Martyn Poliakoff CBE,\u000d\u000a      FRS (now Research Professor of Chemistry, University of Nottingham,\u000d\u000a      1979-present) and\u000d\u000a      Professor Peter Licence (now Professor of Chemistry, University of\u000d\u000a      Nottingham, 2005-present)\u000d\u000a      covers a range of sustainable methodologies that focus on reducing the\u000d\u000a      environmental impact of\u000d\u000a      chemical processes. Their research includes cleaner reaction chemistry in\u000d\u000a      supercritical fluids [3.1],\u000d\u000a      continuous reactions in supercritical carbon dioxide from lab-scale to\u000d\u000a      commercial plant [3.2] and\u000d\u000a      UHV spectroscopic techniques for the characterisation and in-situ\u000d\u000a      monitoring of catalytic processes\u000d\u000a      in ionic liquids [3.3-3.4]. Poliakoff and Licence have also disseminated\u000d\u000a      their findings and\u000d\u000a      communicated the importance of Green Chemistry to a wider scientific\u000d\u000a      audience through a number\u000d\u000a      of review articles in high-profile journals and participation in\u000d\u000a      influential conferences\/policymaking\u000d\u000a      working groups.\u000d\u000a    In 2003 Poliakoff was invited to present his research on Green Chemistry\u000d\u000a      at an event in Ethiopia.\u000d\u000a      After his lecture, which focused on the hydrogenation of organic compounds\u000d\u000a      in supercritical fluids\u000d\u000a      [3.1], he was approached by Dr Nigist Asfaw (University of Addis Ababa\u000d\u000a      (AAU)), who expressed\u000d\u000a      her concern that Green Chemistry did not feature in AAU's curriculum.\u000d\u000a      Discussions about further\u000d\u000a      collaboration to help raise awareness of the discipline in Ethiopia\u000d\u000a      resulted in Asfaw spending three\u000d\u000a      months in UoN's laboratories, where, alongside Licence, she completed the\u000d\u000a      first comparative study\u000d\u000a      of Greener methods for the extraction of essential oils from Ethiopian\u000d\u000a      plants [3.5].\u000d\u000a    This area of research is a major focus for academics in Ethiopia, as it\u000d\u000a      offers unique opportunities to\u000d\u000a      discover new biologically active molecules &#8212; for use in pharmaceuticals or\u000d\u000a      agrochemicals &#8212; from\u000d\u000a      the wide variety of flora endemic to the region. The plant at the centre\u000d\u000a      of this work, Artemisia Afra,\u000d\u000a      has for many generations been traditionally employed as a fragrance, an\u000d\u000a      insect repellent and a\u000d\u000a      treatment for minor ailments such as coughs and heart murmurs.\u000d\u000a      Conventional techniques for the\u000d\u000a      collection of essential oils (e.g. hydrodistillation) are expensive in\u000d\u000a      terms of equipment and energy,\u000d\u000a      and the oils' components are known to decompose during such\u000d\u000a      high-temperature processes. The\u000d\u000a      sustainable, low-energy methods used in this study, which was published in\u000d\u000a      2005, were shown to\u000d\u000a      extract the essential oils rapidly, reducing energy costs and resulting in\u000d\u000a      differing compositions that\u000d\u000a      could subsequently lead to the discovery of biologically interesting\u000d\u000a      molecules.\u000d\u000a    Continued collaboration between Licence and Asfaw investigated the use of\u000d\u000a      the seed oil of the\u000d\u000a      Ethiopian indigenous plant Moringa stenopetala as biodiesel [3.6].\u000d\u000a      These two publications\u000d\u000a      highlighted the impact Green Chemistry could have in Ethiopia &#8212; in doing\u000d\u000a      so laying the foundations\u000d\u000a      for a wider appreciation of the School's other work in this vital field.\u000d\u000a    "},{"CaseStudyId":"31280","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Engineering and Physical Sciences Research Council","Royal Society"],"ImpactDetails":"\u000a    Since 2008 the University of Nottingham's School of Chemistry has\u000a      undertaken a sustained\u000a      programme of public engagement, both through face to face events and via\u000a      the internet, to\u000a      communicate its world-leading research in nanoscience and materials for\u000a      energy applications. The\u000a      team has been motivated by a desire to enable the public to debate\u000a      scientific issues of societal\u000a      importance, enthuse a sufficient number of school pupils to pursue careers\u000a      in science and\u000a      engineering to sustain our national infrastructure in the future and to\u000a      communicate new discoveries\u000a      for their inherent excitement.\u000a    The School's innovative use of online media has enabled it to share its\u000a      research with a global\u000a      audience via our award-winning YouTube channel, \"The Periodic Table of\u000a      Videos\" (PTOV) [5.1].\u000a      (www.periodicvideos.com). The\u000a      PTOV team is led by Professor Martyn Poliakoff CBE, FRS\u000a      (Research Professor of Chemistry, 1979-present), in collaboration with Dr\u000a      Samantha Tang (Public\u000a      Awareness scientist 2004-present) and journalist Brady Haran. It is one of\u000a      the most popular\u000a      chemistry focused sites on the internet, with greater than 325,000\u000a      subscribers and 47.5 million\u000a      views and for this work Poliakoff was recognised with the 2011 Royal\u000a      Society of Chemistry Nyholm\u000a      Prize for Education. This ground-breaking project has earned critical\u000a      acclaim and a wealth of\u000a      positive feedback has been recognised by awards from IChemE, Science (Science,\u000a      2011, 332,\u000a      1046) and a prestigious US Webby Award in 2012. In the 2009 International\u000a      Review of UK\u000a      Chemistry Research \"Chemistry for the next decade and beyond\" it was\u000a      highlighted that by using\u000a      PTOV to communicate science to school age students \"such an approach to\u000a      community outreach\u000a      was extremely cost effective, reaching more than a thousand individuals\u000a      per pound invested\" [5.2].\u000a      We have regularly used this medium to communicate the School's research\u000a      with about a quarter of\u000a      the research staff contributing to the production of scientific videos.\u000a      The research topics on\u000a      `nanoscience' and `materials for energy applications' feature in some of\u000a      the series' highly popular\u000a      entries alongside videos that describe e.g. research into chemical\u000a      knots, X-ray photon\u000a      spectroscopy of ionic liquids and self-optimised reactions.\u000a    Using the PTOV platform, Liddle has communicated his work on uranium\u000a      [3.6] through the videos\u000a      `New Uranium Bond' (60,000+ views) and `Magnetic Uranium' (105,000+).\u000a      These build on an\u000a      earlier clip, `Uranium' (399,000+), in which he describes the element's\u000a      general properties and\u000a      dispels some of the misconceptions surrounding it. Other videos feature\u000a      Khlobystov's work with\u000a      C60 (`Buckyballs'; 70,000+) and graphene (`Graphene'; 44,000+) whilst the\u000a      use of scandium-based\u000a      metal organic frameworks for hydrogen storage [3.5] is included in a video\u000a      about Scandium\u000a      (107,000+). The original `Uranium' video is one of 34 PTOV films used in\u000a      products supplied by\u000a      Pearson to support GCSE-level chemistry in around 600 schools in the UK.\u000a      Pearson UK's Senior\u000a      Manager (Science) has confirmed the \"very positive feedback\" generated by\u000a      PTOV, remarking:\u000a      \"[Its] use added to the educational value and engagement for students.\"\u000a      [5.3]\u000a    The School of Chemistry team continually evaluate their outreach\u000a      activities and a study of 179\u000a      teachers and 229 students by Dr Andrew Clapham (UoN Department of\u000a      Education) further\u000a      highlighted PTOV's educational benefits [5.4]. The independent study noted\u000a      that 77% of students\u000a      associated uranium with nuclear energy before watching Liddle's New\u000a      Uranium Bond video,\u000a      whereas afterwards 84% associated uranium with chemical bonds. Some 80% of\u000a      students said the\u000a      video had changed their understanding of uranium and related research.\u000a      Similarly a study of\u000a      teacher's use of PTOV showed more than 70% of those questioned used it in\u000a      lessons. Interviews\u000a      and focus group data suggested it influenced teachers' subject content\u000a      knowledge (89%) and\u000a      pedagogical content knowledge (42%). Clapham observed: \"PTOV impacted both\u000a      on how teachers\u000a      taught and, crucially, their own fundamental conceptions of nanoscience\u000a      and materials.\"\u000a    In 2008, the School's research into metal organic frameworks [3.4] and\u000a      nanotubes [3.1] was\u000a      presented to thousands of visitors at the NanoWhat? Totally Tiny\u000a      Technology exhibition. This\u000a      event, organised by the East Midlands Development Agency (EMDA), ran for\u000a      17 days in\u000a      Nottingham, Leicester, Loughborough, Derby, Lincoln and Northampton. More\u000a      than 24,000 people\u000a      - including nearly 1,300 pupils, most aged 11 to 13, from 40 schools -\u000a      attended. Each schoolchild\u000a      was engaged for an estimated six hours, including follow-up work with a\u000a      special activity pack. An\u000a      independent study [5.5] concluded the event \"fully met the targets defined\u000a      by EMDA and\u000a      significantly exceeded the estimates for public participation... [and]\u000a      served as a valuable curriculum\u000a      enrichment opportunity for the schools that attended\". Several\u000a      accompanying short films, including\u000a      one in which Champness discussed his and Schr&#246;der's work on new materials\u000a      for hydrogen\u000a      storage, were shown to visitors and at participating schools and later won\u000a      the Best Corporate\/Non-\u000a      Broadcast Programme prize at the Royal Television Society Midland Awards\u000a      [5.6].\u000a    `Wonder in Carbon Land', an exhibit designed to communicate the School's\u000a      development of\u000a      nanotubes [3.1, 3.2], used interactive displays to convey both simple\u000a      concepts (e.g. bonding\u000a      between atoms) and complex ideas (e.g. the laws of quantum mechanics) to a\u000a      range of audiences.\u000a      It debuted at the 2008 Royal Society Summer Exhibition (RSSE), which\u000a      attracted 4,323 attendees,\u000a      including 894 schoolchildren. Feedback compiled by the Royal Society [5.7]\u000a      showed 86% of adult\u000a      visitors felt their interest in science increased as a result of the\u000a      exhibition, while 62% of school\u000a      pupils said the experience made them more interested in a career in\u000a      science. The EPSRC's then\u000a      Public Engagement Manager subsequently invited the School to exhibit\u000a      `Wonder in Carbon Land'\u000a      at the 2008 British Science Festival, noting: \"Your department is highly\u000a      successful in terms of\u000a      EPSRC-funded research and public engagement.\" [5.8] Almost 29,000 people,\u000a      3,755 of them\u000a      schoolchildren aged eight to 16, attended the event, with feedback [5.9]\u000a      indicating 88% rated the\u000a      exhibits \"excellent\" or \"good\" in terms of their ability to educate or\u000a      inform. In 2010 the EPSRC used\u000a      the exhibit again, this time at a showcase event for EPSRC staff.\u000a    At the 2012 RSSE Liddle presented `The Wonder of Chemistry', a series of\u000a      nine public lectures.\u000a      This allowed him to communicate his uranium research to a total audience\u000a      of around 750 people,\u000a      including more than 600 14-to-18-year-old students. Some 80% of attendees\u000a      said their knowledge\u000a      increased as a result [5.7]. A video of the lecture [5.10] was later\u000a      posted on the Royal Society\u000a      website to sustain public engagement. At the 2010 RSSE, which was attended\u000a      by almost 50,000\u000a      people, including more than 1,000 schoolchildren, the School's research\u000a      into novel hydrogen\u000a      storage materials [3.4] was part of the Diamond Light Source exhibit.\u000a    Champness's work on molecular networks [3.3] has also been a key\u000a      component of `Seeing the\u000a      Unseeable', a series of annual masterclasses to encourage students &#8212;\u000a      particularly those unable to\u000a      pursue higher education without support &#8212; to study science at degree\u000a      level. Since 2008, 134\u000a      students have attended; 48 have applied to attend the University of\u000a      Nottingham, with 13 enrolling.\u000a      Feedback from the past four years [5.11] shows 83% felt the programme\u000a      raised their interest in\u000a      science, with comments including \"It has encouraged me to go on to HE\" and\u000a      \"It has opened my\u000a      mind\".\u000a    ","ImpactSummary":"\u000a    The School of Chemistry has a long track record of pioneering and\u000a      innovative outreach activities\u000a      aimed at stimulating public interest and understanding in chemistry\u000a      research and its societal\u000a      impact. During the period 2008-2013 it successfully communicated to a\u000a      wide-ranging audience the\u000a      significance of a series of \"firsts\" in the areas of nanoscience and\u000a      materials for energy applications.\u000a      Using YouTube, Royal Society Summer Science Exhibitions, roadshows and\u000a      science festivals, this\u000a      award-winning approach has engaged hundreds of thousands through digital\u000a      media and thousands\u000a      more face-to-face, raising public awareness, inspiring interest in science\u000a      and delivering educational\u000a      benefits for students and teachers alike.\u000a    ","ImpactType":"Societal","Institution":"\u000a    University of Nottingham\u000a    ","Institutions":[{"AlternativeName":"Nottingham (University of)","InstitutionName":"University of Nottingham","PeerGroup":"A","Region":"East Midlands","UKPRN":10007154}],"Panel":"B         ","PlaceName":[],"References":"\u000a    Publications:\u000a    \u000a1. D.A. Britz, A.N. Khlobystov, K. Porfyrakis, A. Ardavan and G.A.D.\u000a      Briggs, Chemical Reactions\u000a      Inside Single-Walled Nano Test-Tube, Chemical Communications,\u000a      2005, 37-39 (cover page\u000a      article). DOI: 10.1039\/B414247K\u000a    \u000a\u000a2. T.W. Chamberlain, A. Camenisch, N.R. Champness, G.A.D. Briggs, S.C.\u000a      Benjamin, A. Ardavan\u000a      and A.N. Khlobystov, Toward Controlled Spacing in One-Dimensional\u000a      Molecular Chains: Alkyl-\u000a      Chain-Functionalized Fullerenes in Carbon Nanotubes, Journal of the\u000a        American Chemical\u000a        Society, 2007, 129, 8609-8614. DOI: 10.1021\/ja071803q\u000a    \u000a\u000a3. M.O. Blunt, J.C. Russell, M.C. Gim&#233;nez-L&#243;pez, J.P. Garrahan, X. Lin,\u000a      M. Schr&#246;der, N.R.\u000a      Champness and P.H. Beton, Random tiling and topological defects in a\u000a      two-dimensional\u000a      molecular network, Science, 2008, 322, 1077-1081. DOI:\u000a      10.1126\/science.1163338\u000a    \u000a\u000a4. X. Lin, J. Jia, X. Zhao, K.M. Thomas, A.J. Blake, G.S. Walker, N.R.\u000a      Champness, P. Hubberstey\u000a      and M. Schr&#246;der, High H2 adsorption by coordination-framework materials, Angewandte\u000aChemie\u000a        International Edition, 2006, 45, 7358-7736. DOI:\u000a      10.1002\/anie.200601991\u000a    \u000a\u000a5. I.A. Ibarra, S. Yang, X. Lin, A.J. Blake, P.J. Rizkallah, H. Nowell,\u000a      D.R. Allan, N.R. Champness,\u000a      P. Hubberstey and M. Schr&#246;der, Highly Porous and Robust Scandium-based\u000a      Metal-Organic\u000a      Frameworks for Hydrogen Storage, Chemical Communications, 2011,\u000a      47, 8304-8306. DOI:\u000a      10.1039\/c1cc11168j\u000a    \u000a\u000a6. D.M. King, F. Tuna, E.J.L. McInnes, J. McMaster, W. Lewis, A.J. Blake\u000a      and S.T. Liddle,\u000a      Synthesis and Structure of a Terminal Uranium Nitride Complex, Science,\u000a      2012, 337, 717-720.\u000a      DOI: 10.1126\/science.1223488\u000a    \u000aGrants:\u000a    a. Royal Society University Research Fellowship, Royal Society,\u000a      Professor A. Khlobystov,\u000a      October 2005 - September 2013, &#163;541,874.\u000a    b. EPSRC Grant GR\/S97521, Surface supramolecular assembly: molecular\u000a        entrapment &amp;\u000a        nanostructure fabrication, P.I. Professor N. Champness, October 2004\u000a      - March 2008,\u000a      &#163;296,425.\u000a    c. EPSRC Grant EP\/E040071\/1, United Kingdom Sustainable Hydrogen\u000a        Energy Consortium\u000a        (UK-SHEC) CORE PROGRAMME, C.I. Professor M. Schr&#246;der &amp; Professor\u000a      N. Champness,\u000a      October 2007 - June 2012, &#163;5.94M.\u000a    d. ERC Starting Grant (ERC StG239621), UNCLE: Uranium in\u000a        Non-Conventional Ligand\u000a        Environments, P.I. Professor S.T. Liddle, 2009 - 2015, &#8364;1M.\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"9","Level2":"12","Subject":"Materials Engineering"}],"Sources":"\u000a    \u000a      Periodic Table of Videos (http:\/\/www.youtube.com\/periodicvideos)\u000a        http:\/\/www.youtube.com\/watch?v=bk_D4mSgMsQ;\u000a        http:\/\/www.youtube.com\/watch?v=2qZycn7o7Po;\u000a        http:\/\/www.youtube.com\/watch?v=B8vVZTvJNGk;\u000a\u0009\u0009http:\/\/www.youtube.com\/watch?v=ljF5QhD5hnI;\u000a        http:\/\/www.youtube.com\/watch?v=prKi2TI0TVw;http:\/\/www.youtube.com\/watch?v=KkKv5ilmRjY\u000a\u000a      EPSRC International Review of Chemistry p30-31\u000a      Senior Manager (Science), Pearson UK - corroboration of PTOV's\u000a        educational benefits\u000a        (22\/1\/2013)\u000a      Analysis of PTOV surveys, Dr Andrew Clapham, University of Nottingham\u000a      Independent evaluation of NanoWhat? Totally Tiny Technology exhibition\u000a        (7\/09)\u000a      Royal Television Society award for nanotechnology film - press release\u000a        (3\/11\/08)\u000a      Feedback report on 2008, 2010 and 2012 Royal Society Summer\u000a        Exhibitions\u000a      Public Engagement Programme Manager, EPSRC - corroboration of success\u000a        in communicating\u000a        research to wider audiences (4\/7\/2008)\u000a      Feedback report on 2008 British Science Festival\u000a      Video of Liddle lecture, The Wonder of Chemistry, Royal Society\u000a        website (accessed 26\/9\/13) -\u000a        https:\/\/royalsociety.org\/events\/2012\/wonders-chemistry\/\u000a\u000a      Feedback from University of Nottingham Widening Participation Team on\u000a        Get on 4 Uni\u000a        masterclasses\u000a    \u000a    ","Title":"\u000a    Informing public understanding of nanoscience and materials for energy\u000a      applications (CS5)\u000a    ","UKLocation":[{"GeoNamesId":"2641430","Name":"Northampton"},{"GeoNamesId":"2651347","Name":"Derby"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Research into nanoscience and materials for energy applications is\u000a      increasingly fundamental to\u000a      addressing many of the major challenges facing humanity, yet it is either\u000a      not widely understood by\u000a      the general public or, as particularly evidenced by the case of uranium,\u000a      has received significant\u000a      negative media coverage. The test for scientists is to communicate novel,\u000a      cutting-edge research in\u000a      these areas in such a way that the public gains maximum understanding,\u000a      confidence and benefit.\u000a    Researchers from the School of Chemistry have undertaken a sustained\u000a      programme of activities to\u000a      engage the public with their work in these vital fields. Their approach\u000a      reflects the recommendations\u000a      contained in Chapter 3 (Public Understanding of Science) of the Select\u000a      Committee on Science and\u000a      Technology's Third Report, published in 2000, which said: \"Grant-giving\u000a      bodies should give\u000a      researchers every encouragement to share their research with the public...\u000a      and should support and\u000a      reward those who do so.\" Comprising of Professor Neil Champness (now\u000a      Professor of Chemical\u000a      Nanoscience and Head of Inorganic and Materials Chemistry, 1995-present),\u000a      Professor Andrei\u000a      Khlobystov (now Professor of Nanomaterials, 2004-present), Professor\u000a      Martin Schr&#246;der (now\u000a      Dean of Science and Professor of Inorganic Chemistry, 1995-present) and\u000a      Professor Steve Liddle\u000a      (now Professor of Inorganic Chemistry, 2007-present), the team has\u000a      achieved a number of\u000a      scientific \"firsts\" that have underpinned its engagement efforts.\u000a    In 2005 Khlobystov developed the world's smallest test tube by using a\u000a      single-walled carbon\u000a      nanotube (SWNT) as a nano-sized reaction vessel. This technique allows the\u000a      synthesis of linear\u000a      polymers to be controlled and could find application in the synthesis of\u000a      industrially important\u000a      polymers such as polyethylene [3.1]. Two years later further research by\u000a      Khlobystov showed\u000a      fullerenes bearing organic groups could be encapsulated within a SWNT and\u000a      that the distance\u000a      between the C60 units could be controlled [3.2].\u000a    In work with important applications in areas such as magnetism and\u000a      sensing devices, Champness\u000a      and others discovered new methods for arranging molecules on surfaces. In\u000a      particular, they built a\u000a      molecular network on graphite surfaces and showed how a rhombus tiling\u000a      effect is created [3.3].\u000a      This work was first published in 2008.\u000a    The development of new porous materials by Schr&#246;der and Champness\u000a      resulted in the discovery\u000a      of a metal organic framework (MOF) with remarkable hydrogen storage\u000a      capacity and led to two\u000a      world-record values for such materials &#8212; the first in 2006 (7.5 wt%) and\u000a      the second in 2009 (10\u000a      wt%) [3.4]. These materials, the development of which generated\u000a      considerable publicity, including\u000a      leading articles in Science and Nature, exceed the US\u000a      Department of Energy's 2010 target for\u000a      hydrogen storage materials (6 wt%). More recent developments have looked\u000a      at the use of\u000a      scandium-based systems for hydrogen storage [3.5].\u000a    In 2012, after decades of failed international attempts, Liddle reported\u000a      the preparation and isolation\u000a      of a landmark molecular terminal uranium-nitride [3.6] - widely credited\u000a      by others as \"the ultimate\u000a      target in synthetic actinide chemistry\". The U&#8801;N triple bond represents a\u000a      benchmark for uranium\u000a      chemical bonding; a potential low-temperature route to\u000a      difficult-to-prepare uranium nitride materials\u000a      that exhibit superior physicochemical properties to uranium oxides used in\u000a      nuclear reactors; and a\u000a      way to model the long-term stability of [UN]n as a ceramic nuclear fuel.\u000a    "},{"CaseStudyId":"31377","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"3017382","Name":"France"},{"GeoNamesId":"3144096","Name":"Norway"},{"GeoNamesId":"2661886","Name":"Sweden"},{"GeoNamesId":"660013","Name":"Finland"},{"GeoNamesId":"3175395","Name":"Italy"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"6252001","Name":"United States"}],"Funders":["Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000a    Worldwide, cervical cancer is the second most common cancer of women5.3,\u000a      resulting in an estimated 225,000 deaths in 20105.4. Since the\u000a      introduction of widespread screening with the Papanicolaou cervical smear\u000a      (Pap) test, the mortality rate in the USA has declined by an estimated 74%5.3.\u000a      Like many other biomedical staining processes, the pap test is not a\u000a      patented process and dye manufacture is a cottage industry of small\u000a      producers of variable quality. The market for biomedical stains is\u000a      relatively small compared to uses of dyes in textiles and cosmetics, often\u000a      leading to sharp fluctuations in cost and availability of key compounds5.5.\u000a    In the 1990s, CellPath Ltd, a small family business focussing on\u000a      laboratory supplies, such as plasticware, decided to seek assistance from\u000a      Bangor University chemistry researchers to advise on the development of\u000a      processes for the manufacture of high-quality laboratory stains, in\u000a      particular for the Pap test.\u000a    During a 3-year collaboration, funded by an EPSRC Teaching Company Scheme\u000a      Grant (later KTP)5.6, researchers from Bangor University under\u000a      the supervision of Professor Mark Baird developed a new approach to\u000a      compounds for the Pap test and other biomedical special stains. A new\u000a      process was also developed for the synthesis of the Light Green SF\u000a      Yellowish stain, which had become virtually unobtainable commercially3.3.\u000a      These Ortho Stains were more effective, economical and readily available\u000a      than existing formulations. In the course of the collaborations, we also\u000a      advised on the setting up of appropriate laboratory facilities for the\u000a      manufacture of the stains, and assisted the company in optimising their\u000a      processes, including enhanced quality control and safety and reduced\u000a      production costs. For example, it was found that the reaction temperature\u000a      for haematoxylin production could be lowered, saving 2.5% of total\u000a      production costs, while reduction in Alum concentration produced\u000a      additional efficiencies. A stabilized form of Haematoxylin was developed\u000a      for commercial scale production, as Haematoxylin Z, which remains on the\u000a      market.\u000a    The company invested &#163;170k in production facilities and hired two\u000a      production workers5.7. The MSc student Oram was later hired to\u000a      carry our further research and development within the company.\u000a    Results were immediate, with an increase in turnover from &#163;1.1M to &#163;1.5M\u000a      in the first year following completion of the project (1996)5.7.\u000a      The project was a Finalist at the Teaching Company Scheme Awards in 19975.1.\u000a    The company, previously mainly known for manufacture and sales of\u000a      laboratory plastics etc, rapidly become the UK market leader in cytology\u000a      stains, with over 50% of the domestic market, and exports to Finland,\u000a      France, Italy, Japan, Norway and Sweden5.7.\u000a    Ortho stains remain a mainstay of the company's business. Since\u000a      collaborating with Bangor Chemistry researchers, the turnover of the\u000a      company has grown by 400% and the workforce increased from 5 to 65\u000a      employees5.2.\u000a    From 2008-2012, the value of the company has doubled5.8. From\u000a      2012, the company began trading in the USA5.9, indicating its\u000a      continuing dynamism.\u000a    ","ImpactSummary":"\u000a    Through research carried out under an EPSRC Teaching Company (KTP) award,\u000a      we assisted an SME, CellPath, to develop the capacity to manufacture a\u000a      novel set of dyes (Ortho Stains) for use in the Papanicolaou cervical\u000a      smear test and other histological procedures. The company, previously\u000a      mainly known for manufacture and sales of laboratory plastics etc, rapidly\u000a      become the UK market leader in cytology stains, with over 50% of the\u000a      domestic market, and exports to Finland, France, Italy, Japan, Norway,\u000a      Sweden and the USA. As a result the company has increased turnover by 400%\u000a      and the workforce has grown from 5 to 65 employees.\u000a    ","ImpactType":"Technological","Institution":"\u000a    10007857 Bangor University\u000a    ","Institutions":[{"AlternativeName":"Bangor University","InstitutionName":"Bangor University","PeerGroup":"B","Region":"Wales","UKPRN":10007857}],"Panel":"B         ","PlaceName":[],"References":"\u000a    \u000a1. Salaun J &amp; Baird MS 1995 Biologically active cyclopropanes\u000a      and cyclopropenes. Current Medicinal Chemistry, 2, 511-542\u000a      [reviews research developments in the cyclopropane field, including Bangor\u000a      work, over 250 citations].\u000a    \u000a\u000a2. Baird MS &amp; Grehan B 1993. A new approach to cyclopropene\u000a      fatty acids involving 1,2- deiodination. J. Chem Soc. Perkin Trans.\u000a      1, 14, 1547-1548. DOI: 10.1039\/p19930001547. [example of\u000a      contemporaneous Bangor research on this class of molecules]\u000a    \u000a\u000a3. Oram SJ 1997. Formulation and manufacture of cytodiagnostic\u000a      stains and reagents. University of Wales, Bangor, MSc thesis.\u000a      [integral to the CellPath TCS work]\u000a    \u000a\u000a4. Davies RA 1997. Theoretical and computational aspects of\u000a      organic chemistry. University of Wales, Bangor, PhD thesis.\u000a      [contains unpublished modelling research, supporting the design of ortho\u000a      stains]\u000a    \u000a\u000a5. O'Sullivan AC 1995. Modelling of cellulose-molecule\u000a      interactions. University of Wales, Bangor, PhD thesis. [modelling\u000a      research, some later published as 3.6]\u000a    \u000a\u000a6. Baird MS, Hamlin\u000a          JD, O'Sullivan\u000a          A, Whiting\u000a          A 2008. An insight into the mechanism of the cellulose\u000a      dyeing process: Molecular modelling and simulations of cellulose and its\u000a      interactions with water, urea, aromatic azo-dyes and aryl ammonium\u000a      compounds. Dyes &amp; Pigments 76, 406-416\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"}],"Sources":"\u000a    \u000a      Letter on file from Deputy Director, Teaching Company Scheme, 4 Nov\u000a        1997.\u000a      Letter on file from a director of CellPath, (11 November 2013).\u000a      Armstrong EP (2010). Prophylaxis of cervical cancer and related\u000a        cervical disease: a review of the cost-effectiveness of vaccination\u000a        against oncogenic HPV types. Journal of Managed Care Pharmacy 16:\u000a        217-30.\u000a      Lozano, R (2012). Global and regional mortality from 235 causes of\u000a        death for 20 age groups in 1990 and 2010: a systematic analysis for the\u000a        Global Burden of Disease Study 2010. Lancet 380:\u000a        2095-128.\u000a      Dapson RW (2010) Dye quality and implications for biomedical staining.\u000a        Chapter 5 in Special Stains Education Guide, pp45-48. Dako (Agilent\u000a        Ltd).\u000a      \u000ahttp:\/\/info.ktponline.org.uk\/action\/details\/partnership.aspx?id=4101\u000a        [summary of EPSRC Teaching Company\/KTP award]\u000a      Teaching Company Scheme #1402, Final Report 1997.\u000a      Company accounts summary: http:\/\/companycheck.co.uk\/company\/01831261\u000a\u000a      http:\/\/www.cellpath.co.uk\/\u000a    \u000a    ","Title":"\u000a    Cervical Cancer Diagnostics\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000a    The Papanicolaou cervical smear test used in cytological laboratories\u000a      around the world was developed in the 1930s. The stain, which is itself a\u000a      mixture of four dyes and various ingredients, was developed with\u000a      apparently little rational design. Although certain dyes were chosen to\u000a      react with specific entities, e.g. with cell cytoplasm (collagens \/\u000a      keratins); two of the ingredients, Bismarck Brown Y and phosphotungstic\u000a      acid appear to interfere with each other.\u000a    During the late 1980s and early 1990s, a series of smear test\u000a      misdiagnoses were reported in the national press as a result of both the\u000a      approach, which was not suitable for automation, and human error in\u000a      misinterpreting cellular structures. Coincidentally, a worldwide shortage\u000a      in one of the key ingredients, Light Green SF Yellowish was reported. This\u000a      was largely due to the high costs of waste disposal as the dye itself was\u000a      a suspected carcinogen and its production involved lead oxide.\u000a    CellPath, innovators in cytological pathology based in Newtown, Mid Wales\u000a      were interested in:\u000a    i) Large scale synthesis of Light Green SF Yellowish\u000a    ii) Large scale synthesis of possible analogues, e.g. Fast Green\u000a      FCF used as a replacement in Masson's trichrome stain\u000a    iii) Rational design of Papanicolaou cytological stains using molecular\u000a      modelling\u000a    iv) Prediction of the UV-Vis spectra of known and novel cytological\u000a      stains using molecular modelling\u000a    v) Investigation of key stain-cell interactions using molecular modelling\u000a    Bangor University was well-placed to carry out this research, as a result\u000a      of Professor Mark Baird's expertise in synthetic organic chemistry and\u000a      structure determination, in particular, in relation to cyclopropanes and\u000a      cyclopropenes3.1, 3.2.\u000a    The company approached us because of our research experience in organic\u000a      synthesis, on the advice of the Welsh Development Agency. Synthetic work\u000a      including synthesis optimization was successfully carried out at both\u000a      Bangor and Cellpath by Dr. Jeremy Tomkinson, supported by an EPSRC\u000a      Teaching Company Scheme award and Simon Oram3.3, whose MSc\u000a      thesis was funded by Cellpath. Dr Tomkinson had worked on the synthesis of\u000a      aromatic systems for his PhD and was ideally suited to take on the\u000a      challenge of developing and improving synthesis of stains (containing\u000a      aromatic systems) for application in cervical cancer smears.\u000a    During this time much of the underpinning basic science was carried out\u000a      by R.A. Davies as part of his PhD, focussing on modelling of structures of\u000a      the stains. This work re-confirmed Dahne's triad theory for organic\u000a      chromophores, allowing dyes to be categorized with differing amounts of\u000a      polyenic, aromatic and polymethinic character. Linear regressions were\u000a      developed for the three families allowing accurate quantitative\u000a      predictions of the UV-VIS spectra of cytological dyes. Initial stain-cell\u000a      (e.g. haematoxylin-DNA) interactions used in both the cervical smear test\u000a      and other staining procedures such as the widely used Gram test for\u000a      bacteria, were modelled using smaller analogues.\u000a    In addition, as part of her PhD3.5, Ms A.O'Sullivan began a\u000a      programme modelling the structures of natural polymers- then a very\u000a      complex exercise -to understand the bonding of stains to such systems. Mr\u000a      Oram's work was nearer-market, carefully optimising reaction conditions\u000a      for appropriate commercial scales, with a view to the economics of\u000a      production.\u000a    Much of the work in these research theses was considered commercially\u000a      sensitive at the time, and therefore was not published in refereed\u000a      journals. Some of the modelling work of O'Sullivan was eventually\u000a      published in collaboration with Prof A. Whiting at Durham in 20083.6.\u000a    The modelling approaches devised in the PhD thesis are currently used by\u000a      the Davies research group, e.g. hydrogen bond containing polhydroxy\u000a      napthoquinone dyes (James Maskery, Knowledge Exchange Scholarship PhD in\u000a      collaboration with CAST Ltd).\u000a    "},{"CaseStudyId":"31942","Continent":[{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6251999","Name":"Canada"}],"Funders":["Natural Environment Research Council"],"ImpactDetails":"\u000d\u000a    The underpinning research contributed directly to national and\u000d\u000a      international discussions and agreements on the phase-out of ozone\u000d\u000a      depleting gases. A major impact has been via contributions to the Montreal\u000d\u000a      Protocol, EU legislation, advisory roles and dissemination.\u000d\u000a    The World Meteorological Organisation and the Montreal Protocol\u000d\u000a      The World Meteorological Organisation (WMO) has published 7 Scientific\u000d\u000a        Assessment of Ozone Depletion reports since 1987. The most recent in\u000d\u000a      2010 (published spring 2011), contains over 35 citations to underpinning\u000d\u000a      research performed in the Department of Chemistry.1 On the\u000d\u000a      evidence of their ongoing research contributions, the group led by Pyle\u000d\u000a      was asked to contribute scientific evidence to all the WMO assessments.\u000d\u000a      Pyle was a lead author on the 1985, 1991, 1998 and 2002 assessments and\u000d\u000a      contributing author and Assessment Co-Chair of the 2010 report. The\u000d\u000a      earlier reports all feed into the on-going Montreal Protocol regulation\u000d\u000a      process. In addition, Harris contributed to all reports and was a lead\u000d\u000a      author on the1994 report as well as the report currently being prepared\u000d\u000a      for publication in 2014. On the basis of their expert knowledge and\u000d\u000a      research contribution, the Cambridge team were also selected to contribute\u000d\u000a      to the shaping of the reports' accompanying executive summaries, which\u000d\u000a      include information for policymakers, most recently in 2010.LC1\u000d\u000a    Pyle was also a lead author in the special report for the UNEP\/WMO\u000d\u000a      Intergovernmental Panel on Climate Change (IPCC) on \"Safeguarding the\u000d\u000a      Ozone layer and the Global Climate System\" in 2005.2 This\u000d\u000a      report had a major impact on the direction of subsequent research on the\u000d\u000a      climate impact of CFC replacements, which is now starting to be reflected\u000d\u000a      in international regulation and which is a major topic in the current WMO\u000d\u000a      Scientific Assessment where Harris is a lead author of the chapter on\u000d\u000a      `Scenarios, Information and Options for Policymakers'. The WMO assessment\u000d\u000a      reports (most recent 2010, published in 2011), and in particular their\u000d\u000a      summaries, have also been used internationally to monitor the success of\u000d\u000a      the Montreal Protocol in protecting the ozone layer and climate, for\u000d\u000a      example, by comparing the rate of halocarbon reduction with that observed,\u000d\u000a      and to inform the wider public about the process.\u000d\u000a    The Montreal Protocol on Substances that Deplete the Ozone Layer came\u000d\u000a      into force in 1987, in response to the scientific evidence that\u000d\u000a      human-induced depletion of the ozone layer was indeed occurring. The\u000d\u000a      Protocol mandates that the measures it introduced must be regularly\u000d\u000a      assessed (now every 4 years) on the basis of available scientific,\u000d\u000a      environmental, technical, and economic information. In particular, it\u000d\u000a      specifies a scientific assessment process by which panels of experts are\u000d\u000a      required to prepare reports to guide policymakers in their decisions\u000d\u000a      regarding the protocol. The original Montreal Protocol in 1987 called for\u000d\u000a      modest regulation on the emission of CFCs and allowed for on-going\u000d\u000a      revision based on scientific evidence. The 10 subsequent amendments and\u000d\u000a      adjustments to the Protocol, based on the Scientific Assessments, brought\u000d\u000a      about more rapid phase-out of the CFCs and also added new controls for\u000d\u000a      many more ozone-depleting compounds. The most recent adjustments were made\u000d\u000a      in 2007, were enacted in the following years and remain current (see below\u000d\u000a      for on-going EU legislation). The impact of these amendments and\u000d\u000a      adjustments (reduced ozone depletion) will be felt for many decades. Pyle\u000d\u000a      and Harris have worked to ensure their research has been widely reported\u000d\u000a      in the media since 2008, thereby contributing both to the public\u000d\u000a      understanding of the importance of climate change and the role of\u000d\u000a      environmental policy. 3,4,5,6,7&amp;8\u000d\u000a    On the basis of his significant research contribution, since 2008\u000d\u000a      Professor Pyle has been one of four international Co-Chairs of the Science\u000d\u000a      Assessment Panel (SAP), who provide direct advice to the Meetings of the\u000d\u000a      Parties to the Montreal Protocol1. By undertaking these roles,\u000d\u000a      it has been possible to ensure that the group's research findings are\u000d\u000a      effectively communicated to the policymakers. The Chief Officer,\u000d\u000a      Multilateral Fund for the Implementation of the Montreal Protocol\u000d\u000a      Secretariat, provided the following statement about the role of the SAP: \"The\u000a        SAP plays an invaluable role in analysing, interpreting, and presenting\u000d\u000a        atmospheric trends. The clarity of this work has enabled global\u000d\u000a        political\/regulatory decisions that have resulted in a continuing\u000d\u000a        improvement of stratospheric ozone levels since the inception of the\u000d\u000a        Montreal Protocol in 1987, as well as aiding the many amendments to\u000d\u000a        accelerate the Protocol's progress. I would like to thank Professor Pyle\u000d\u000a        and his team for their continued dedicated efforts to provide a sound\u000d\u000a        scientific basis for our work in protecting the environment\".LC2\u000d\u000a    Pyle's involvement in the Montreal Protocol has been funded since 2007 by\u000d\u000a      DEFRA, to whom he provides ad hoc advice.\u000d\u000a    Impacts on Health The Montreal Protocol has had a major impact in\u000d\u000a      avoiding ozone depletion, in avoiding climate change thanks to the phase\u000d\u000a      out of those ozone-depleting substances which are also greenhouse gases,\u000d\u000a      and in preventing UV-related health issues. A recent paper, using model\u000d\u000a      calculations by the Pyle group, indicates that, by 2030, the Protocol will\u000d\u000a      have prevented two million cases of skin cancer annually, and further\u000d\u000a      reinforces the case for the Montreal Protocol.9 Ensuring that\u000d\u000a      the Protocol is adjusted and amended according to the latest scientific\u000d\u000a      developments is essential to their continuing impact.\u000d\u000a    EU Legislation The various assessments, informed by Cambridge\u000d\u000a      research and that of the international community, led to a strengthening\u000d\u000a      of the regulations covering production and emission of ozone depleting\u000d\u000a      substances. EU legislation was introduced in 2008 to speed up the phase\u000d\u000a      out of the HCFC family of halocarbons, replacements for the CFCs.10\u000d\u000a      Hydrofluorocarbons (HFCs), another family of halocarbons, are replacement\u000d\u000a      gases for the ODS which have the attractive property that they do not lead\u000d\u000a      to any ozone depletion. They are, however, strong greenhouse gases and so\u000d\u000a      there are very good reasons to limit their future growth. Based on the\u000d\u000a      halocarbon research, Dr Harris gave evidence to the European Parliament in\u000d\u000a      June 2011 during a special session of the ENV committee on `Reduction of\u000d\u000a      non-CO2 Emissions'. This session was part of the process which led to a\u000d\u000a      resolution passed by the European Parliament and, in 2013, to the\u000d\u000a      introduction of EU legislation on Fluorinated Greenhouse Gases limiting\u000d\u000a      future HFC usage.11\u000d\u000a    The Senior Administrator for the European Parliament, Committee for\u000d\u000a      Environment, Public Health and Food Safety writes: \"since 2008 I have\u000d\u000a        appreciated the impact of its pioneering research and assessment\u000d\u000a        influence in the regulatory process of the Environment, Public Health\u000d\u000a        and Food Safety Committee of the European Parliament...Overall, research\u000d\u000a        by the Cambridge group made a significant impact to both policy actions\u000d\u000a        and environmental protection.LC3\u000d\u000a    Working with Industry Pyle continues to provide informal,\u000d\u000a      independent advice to industries producing and using halocarbons (e.g.\u000d\u000a      3M).\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Atmospheric science research in the Department of Chemistry, University\u000d\u000a      of Cambridge has played a leading role in demonstrating the depletion of\u000d\u000a      the ozone layer following anthropogenic emissions of halogenated compounds\u000d\u000a      and other Ozone Depleting Substances (ODS). This research has been a key\u000d\u000a      input into the series of assessment reports that have made the case to\u000d\u000a      policy makers for the strengthening of the Montreal Protocol. The research\u000d\u000a      underpinning these reports has made a vital contribution to a number of\u000d\u000a      changes to the Protocol that have ensured a more rapid phase-out of a\u000d\u000a      wider range of ODS and their replacements, leading to significant global\u000d\u000a      health and climate benefits during the REF period. Researchers at\u000d\u000a      Cambridge have helped to raise global awareness of these benefits, helping\u000d\u000a      to maintain support for the Protocol among policy makers and the public,\u000d\u000a      and supported European legislation to limit the environmental impact of\u000d\u000a      ODS and their replacements.\u000d\u000a    ","ImpactType":"Environmental","Institution":"\u000d\u000a    University of Cambridge\u000d\u000a    ","Institutions":[{"AlternativeName":"Cambridge (University of)","InstitutionName":"University of Cambridge","PeerGroup":"A","Region":"East","UKPRN":10007788}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"6077243","Name":"Montral"}],"References":"\u000d\u000a    \u000a1. Gostlow B., A.D. Robinson, N.R.P. Harris, L. O'Brien, D.E. Oram, G.P.\u000d\u000a      Mills, H.M. Newton, S.E. Yong and J.A. Pyle, Micro-DIRAC: An Autonomous\u000d\u000a      Instrument for Halocarbon Measurements, Atmos. Meas. Tech., 3,\u000d\u000a      507-521, 2010.\u000d\u000a    \u000a\u000a2. Large loss of total ozone during the Arctic winter of 1999\/2000. B.M.\u000d\u000a      Sinnhuber, M.P. Chipperfield, S. Davies, J.P. Burrows, K.U. Eichmann, M.\u000d\u000a      Weber, P. von der Gathen, M. Guirlet, G.A. Cahill, A.M. Lee, and J.A.\u000d\u000a      Pyle, Geophys. Res. Lett., 27, 3473-3476, 2000. (*)\u000d\u000a    \u000a\u000a3. Chemical depletion of ozone observed in the Arctic Vortex during the\u000d\u000a      1991\/1992 winter. P. von der Gathen, M. Rex, N.R.P. Harris, D. Lucic, B.\u000d\u000a      Knudsen, G.O. Braathen, H. De Backer, R. Fabian, H. Fast, M. Gil, E. Kyro,\u000d\u000a      I.S. Mikkelsen, M. Rummukainen, J. Staehelin and C. Varotsos, Nature,\u000d\u000a      375, 131-134, 1995. (*)\u000d\u000a    \u000a\u000a4. Ozone Trends at northern mid- and high latitudes: a European\u000d\u000a      perspective. N.R.P.Harris, E.Kyr&#246;, J.Staehelin, D.Brunner, S-B.Andersen,\u000d\u000a      S.Godin-Beekmann, S.Dhomse, P.Hadjinicolaou, G.Hansen, I.Isaksen, A.Jrrar,\u000d\u000a      A.Karpetchko, R.Kivi, B.Knudsen, P.Krizan, J.Lastovicka, J.Maeder,\u000d\u000a      Y.Orsolini, J.A.Pyle, M.Rex, Ann. Geophys, 26, 1207-1220,\u000d\u000a      2008.\u000d\u000a    \u000a\u000a5. Decline and recovery of total column ozone using a multimodel time\u000d\u000a      series analysis. J. Austin, J. Scinocca, D. Plummer, L. Oman, D. Waugh, H.\u000d\u000a      Akiyoshi, S. Bekki, P. Braesicke, N. Butchart, M. Chipperfield, D. Cugnet,\u000d\u000a      M. Dameris, S. Dhomse, V. Eyring, S. Frith, R.R. Garcia, H. Garny, A.\u000d\u000a      Gettelman, S.C. Hardiman, D. Kinnison, J.F. Lamarque, E. Mancini, M.\u000d\u000a      Marchand, M. Michou, O. Morgenstern, T. Nakamura, S. Pawson, G. Pitari, J.\u000d\u000a      Pyle, E. Rozanov, T.G. Shepherd, K. Shibata, H. Teyss&#232;dre, R.J. Wilson and\u000d\u000a      Y. Yamashita, J. Geophys. Res., 115, D00M10, doi:\u000d\u000a      10.1029\/2010JD013857, 2010.\u000d\u000a    \u000a\u000a6. The world avoided by the Montreal Protocol. O. Morgenstern, P.\u000d\u000a      Braesicke, M.M. Hurwitz, F.M. O'Connor, A.C. Bushell, C.E. Johnson and\u000d\u000a      J.A. Pyle, Geophys. Res. Lett., 35, L16811,\u000d\u000a      doi:10.1029\/2008GL034590, 2008.\u000d\u000a    \u000a\u000a7. A three-dimensional model calculation of the ozone depletion potential\u000d\u000a      of 1-bromopropane (1-C3H7Br). C.H.Bridgeman,\u000d\u000a      J.A.Pyle and D.E.Shallcross, J. Geophys. Res., 105,\u000d\u000a      26,493-26,502, 2000. (*)\u000d\u000a    \u000a(*) References that best indicate the quality of the research.\u000d\u000a    Grant Information\u000d\u000a    &#8226; PI: Harris; Grant Title: The Role of Short-lived Species in the\u000d\u000a      Tropical Atmosphere (NERC Advanced Research Fellowship for Dr Neil\u000d\u000a      Harris); Sponsor: NERC; Period of Grant: Jan 2010-Dec 2014; Grant Value:\u000d\u000a      &#163;474,458.\u000d\u000a    &#8226; PI: Pyle; Grant Title: The Lower Stratosphere: Interactions with the\u000d\u000a      Tropospheric Chemistry\/Climate System; Sponsor: NERC; Period of Grant:\u000d\u000a      July 2007 &#8212; July 2011; Grant Value: &#163;154,026.\u000d\u000a    &#8226; PI: Pyle; Grant Title: Stratosphere-Climate Links with Emphasis on the\u000d\u000a      UTLS (SCOUT); Sponsor: EC; Period of Grant: May 2005 &#8212; August 2009; Grant\u000d\u000a      Value: &#163;1,588,101.\u000d\u000a    &#8226; PI: Pyle; Grant Title: Current and Future Stratospheric Ozone Depletion\u000d\u000a      and Implications for Climate Change; Sponsor: Department of the\u000d\u000a      Environment; Period of Grant: Jan 97 &#8212; Dec 12; Grant Value: &#163;265,126.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"},{"Level1":"2","Level2":"2","Subject":"Atomic, Molecular, Nuclear, Particle and Plasma Physics"},{"Level1":"3","Level2":"7","Subject":"Theoretical and Computational Chemistry"}],"Sources":"\u000d\u000a    Letters of corroboration available for audit\u000d\u000a    LC1 Senior Scientific Officer at World Meteorological Organization,2028\u000d\u000a      Switzerland.\u000d\u000a    LC2 Chief Officer, Multilateral Fund for the Implementation of the\u000d\u000a      Montreal Protocol Secretariat, 2028 Canada.\u000d\u000a    LC3 Senior Administrator, European Parliament, Committee for Environment,\u000d\u000a      Public Health and Food Safety, Belgium.\u000d\u000a    References in the public domain\u000d\u000a    \u000d\u000a      WMO (World Meteorological Organization), Scientific Assessment of\u000d\u000a          Ozone Depletion: 2010, Global Ozone Research and Monitoring\u000d\u000a        Project-Report No. 52, 516 pp., Geneva, Switzerland, 2011.\u000d\u000a        http:\/\/ozone.unep.org\/Assessment_Panels\/SAP\/Scientific_Assessment_2010\/index.shtml\u000d\u000a        Earlier reports, to which Pyle and Harris contributed, are available via\u000d\u000a        ozone.unep.org\u000d\u000a      UNEP\/WMO Intergovernmental Panel on Climate Change (IPCC)\u000d\u000a        \"Safeguarding the Ozone layer and the Global Climate System\" (2005).\u000d\u000a        http:\/\/www.ipcc.ch\/pdf\/special-reports\/sroc\/sroc_full.pdf\u000a\u000d\u000a      Relating to Cambridge research on the world avoided by the Montreal\u000d\u000a        Protocol: SBS Australia: http:\/\/www.sbs.com.au\/news\/article\/1693247\/Ozone-layer-agreement-saved-human-lives\u000a\u000d\u000a      Special Issue of \"The Conversation\" (Australian online science\u000d\u000a        magazine links)\u000d\u000a        http:\/\/theconversation.edu.au\/saving-the-ozone-layer-saved-human-lives-9494\u000a\u000d\u000a      Naked Scientist:http:\/\/www.thenakedscientists.com\/HTML\/content\/interviews\/interview\/1569\/\u000a\u000d\u000a      Sunday Times\u000d\u000a        http:\/\/www.thesundaytimes.co.uk\/sto\/news\/uk_news\/Environment\/article1127288.ece\u000a\u000d\u000a      Chemistry World http:\/\/www.rsc.org\/chemistryworld\/2012\/07\/storm-horizon-ozone-levels\u000a\u000d\u000a      Newsweek Magazine: A Climate Cure's Dark Side by Sharon Begley\u000d\u000a        http:\/\/www.thedailybeast.com\/newsweek\/2011\/01\/30\/a-climate-cure-s-dark-side.html\u000a\u000d\u000a      Skin cancer risks avoided by the Montreal protocol &#8212; worldwide\u000d\u000a        modelling integrating coupled chemistry-climate models with a risk model\u000d\u000a        for UV. A Van Dijk, H Slaper, PN den Outer, O Morgenstern, P Braesicke,\u000d\u000a        JA Pyle, H Garny, A Stenke, M Dameris, A Kazantzidis, K Tourpali, AF\u000d\u000a        Bais. Photochemistry and Photobiology, 89, 234-246, 2013.\u000d\u000a      EU legislation from 2008 on more rapid phase-out of HCFCs:\u000d\u000a        http:\/\/europa.eu\/legislation_summaries\/other\/l28064_en.htm\u000a\u000d\u000a      The European Parliament HFC proposals can be found at:\u000d\u000a        http:\/\/www.europarl.europa.eu\/oeil\/popups\/ficheprocedure.do?reference=2012\/0305(COD)&amp;l=en\u000a\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Impact on International Measures to Control Ozone-Depleting Substances\u000d\u000a      and their Replacements.\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    The Centre for Atmospheric Science, established in 1993, is a joint\u000d\u000a      venture within the University of Cambridge between the University\u000d\u000a      Departments of Chemistry, Applied Mathematics and Theoretical Physics and\u000d\u000a      Geography. Co-directed by Professor John Pyle (1920 Professor of Physical\u000d\u000a      Chemistry, University of Cambridge, in Cambridge since 1985), the centre\u000d\u000a      has since its inception been among the world leaders in stratospheric\u000d\u000a      ozone science. Pyle played a leading role in the development of\u000d\u000a      state-of-the-art chemistry\/climate models for the stratosphere. The\u000d\u000a      physical and chemical processes in his numerical models have been\u000d\u000a      evaluated successfully against atmospheric observations and so can be used\u000d\u000a      to explain the role of ozone depleting substances in past changes in\u000d\u000a      atmospheric composition and can be used to project future changes. Dr Neil\u000d\u000a      Harris (Dept of Chemistry since 1990, NERC Advanced Fellow since 2010) has\u000d\u000a      been a pioneer in the analysis of existing atmospheric ozone data to\u000d\u000a      understand long-term changes in ozone, and in conducting field experiments\u000d\u000a      in the Arctic to quantify the detailed chemical processes leading to ozone\u000d\u000a      loss each winter. He has been making atmospheric measurements of\u000d\u000a      ozone-depleting halocarbons including chlorofluorocarbons (CFCs) and\u000d\u000a      shorter-lived compounds since the mid-1990s.1\u000d\u000a    Together these researchers have made substantial contributions to the\u000d\u000a      understanding of global ozone loss and to the contribution of ozone\u000d\u000a      depleting substances. Examples of relevant underpinning research performed\u000d\u000a      between 1993 and 2013 are listed below:\u000d\u000a    A) Model calculations performed by the Pyle group have demonstrated that\u000d\u000a      CFCs and other halogenated compounds have led to depletion of ozone in the\u000d\u000a      Arctic; they confirmed that severe Arctic ozone loss occurs in some\u000d\u000a      winters, following the same chemical mechanism as found in Antarctica,2\u000d\u000a      in agreement with observational analyses that the Pyle group helped to\u000d\u000a      develop.3\u000d\u000a    B) Harris has explained the observed decadal changes in ozone in middle\u000d\u000a      latitudes, showing that both chemical and dynamical processes play a role\u000d\u000a      in the observed ozone changes.4\u000d\u000a    C) Pyle's calculations project the future evolution of ozone, explaining\u000d\u000a      how atmospheric ozone concentrations should respond to regulation, with\u000d\u000a      slow `recovery' this century,5 and how these chemistry-climate\u000d\u000a      model projections show that, had the Montreal Protocol not been enacted,\u000d\u000a      ozone depletion would have been even more severe and that consequently\u000d\u000a      large changes in surface temperature and UV radiation would have occurred.6\u000d\u000a    D) The Pyle group has shown that the scientific framework for regulation\u000d\u000a      of short-lived ozone depleting substances is different to that of the\u000d\u000a      longer-lived gases, like the CFCs. For short-lived gases, the Ozone\u000d\u000a      Depletion Potential (ODP), a concept enshrined in legislation, varies with\u000d\u000a      region and season of emission, whereas for long-lived gases the ODP is a\u000d\u000a      constant.7\u000d\u000a    Key researchers in Cambridge that contributed to the research include: Dr\u000d\u000a      Martyn Chipperfield (PDRA and Temporary Assistant Lecturer 1993-1999, now\u000d\u000a      Professor at the University of Leeds) and Dr Peter Braesicke (Senior\u000d\u000a      Researcher, Centre for Atmospheric Science, Cambridge, 1999-2013,\u000d\u000a      Professor at the Karlsruhe Institute of Technology, Germany since August\u000d\u000a      2013).\u000d\u000a    "},{"CaseStudyId":"32236","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2658434","Name":"Switzerland"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Biotechnology and Biological Sciences Research Council"],"ImpactDetails":"\u000a    University of Huddersfield studies in the field of physical organic\u000a      chemistry have led to widespread\u000a      economic, industrial and societal benefits, in large part through the\u000a      continued success of IPOS, the\u000a      formation of which was a direct result of research carried out since the\u000a      early 1990s. Much of the\u000a      impact arising from the research described above has been generated\u000a      directly through the work of\u000a      IPOS with the chemical industry in the period since 2008.\u000a    Although the Innovative Physical Organic Solutions unit (IPOS) was formed\u000a      in 2006, major\u000a      expansion has occurred since 2009 with the award of &#163;3.6M of European\u000a      Regional Development\u000a      Fund support [G1]. IPOS has moved to new purpose-built laboratories (\"Page\u000a      Laboratory\" &#8212; 200\u000a      m2); Agilent has added investment of ca. &#163;3M, and the Page\u000a      Laboratory is now an \"Agilent Centre\u000a      of Excellence\". IPOS now consists of five academics (Page and Atherton,\u000a      with Charsley, Sinnott\u000a      and Maskill [last three Emeritus\/Visiting]). Co-workers include Dr N\u000a      Powles (Senior Research\u000a      Fellow, 2006-present), Dr M Stirling (Senior Research Fellow,\u000a      2006-present), Dr M Chadha\u000a      (Quality Manager, 2010-present), and four Research Fellows, six PhD\u000a      students and four\u000a      technicians. Atherton, Powles and Stirling have more than 60 years'\u000a      industry experience between\u000a      them.\u000a    IPOS has become self-financing, with income of &#163;0.6M p.a. Income from\u000a      consultancy and training\u000a      for the chemical and related industries in particular has grown\u000a      significantly, from around &#163;150,000\u000a      and &#163;8,000 respectively in 2008\/2009 to around &#163;385,000 and &#163;34,000 in\u000a      2012\/2013. IPOS now\u000a      provides full-time employment for 11 members of research staff [5.1].\u000a    IPOS has so far carried out research projects for more than 150\u000a      companies, of which over 70 have\u000a      been SMEs. The large majority of projects and enquiries are from within\u000a      the Yorkshire\/Humberside\u000a      region, where regeneration is critically dependent on new,\u000a      non-traditional, high-technology\u000a      companies, meaning IPOS's expertise has been vital to economic growth in\u000a      the area. Around 30\u000a      enquiries are now received each month from throughout the UK. Of the many\u000a      successful projects,\u000a      one example is their 15-month collaboration on gas-liquid kinetics with\u000a      ACAL Energy, of Runcorn,\u000a      which has led to a &#163;15M venture capital investment [SL1].\u000a    The Society of Chemical Industry has officially recognised the scale and\u000a      significance of Page and\u000a      Atherton's contributions to the industry, most recently through the\u000a      activities of IPOS. Atherton\u000a      received an SCI Chemistry for Industry Award in 2013 in recognition of his\u000a      \"contribution to process\u000a      chemistry\", and Page received the same honour in 2011 for work \"which\u000a      provides a potential major\u000a      benefit to society\" [5.2].\u000a    Specific areas of work undertaken by the research team before and after\u000a      the establishment of\u000a      IPOS have benefited a wide range of stakeholders and end-users, the most\u000a      notable being the\u000a      following.\u000a    i. Synthetic oligonucleotides for therapy\u000a    Huddersfield's work in the area of synthetic oligonucleotides,\u000a      particularly in terms of improving the\u000a      economics of the large-scale synthesis of small interfering RNA (siRNA)\u000a      oligonucleotides, has\u000a      enhanced industry practice. The findings were first applied by Avecia,\u000a      which sponsored early\u000a      research in this field, and later by Pfizer [SL2]. Huddersfield's findings\u000a      [3.1-3.2] have improved\u000a      efficiency and delivered cost benefits by highlighting key considerations\u000a      in the large-scale\u000a      manufacture of oligonucleotide-based therapeutics particularly with regard\u000a      to solvent selection and\u000a      reactant stoichiometries; the large scale synthesis of oligonucleotides\u000a      traditionally involved\u000a      considerable volumes of solvents and excessive amounts of expensive and\u000a      fragile\u000a      phosphoramidite reagents.\u000a    Since 2012 GlaxoSmithKline has supported and drawn on Huddersfield's\u000a      continuing research in\u000a      this area as part of the company's efforts to develop a substantial\u000a      portfolio of oligonucleotide-based\u000a      therapeutics, many of which are in late-stage clinical trials. GSK has\u000a      been guided by Huddersfield's\u000a      studies in devising the synthesis technologies required for stage 3\u000a      trials. GSK's Oligonucleotide\u000a      Synthesis Group has confirmed: \"Your research provides the fundamental\u000a      chemistry understanding\u000a      that we need in order to develop robust, scalable and sustainable\u000a      oligonucleotide manufacturing\u000a      processes.\" [SL3] This further underlines the research's contribution to\u000a      the health of society, as\u000a      therapeutically important mRNAs are used for treating diseases arising\u000a      from genetic disorders.\u000a    ii. Providing solutions to antimicrobial resistance\u000a    Huddersfield's research in the area of antimicrobial resistance (AMR) has\u000a      also led to improvements\u000a      in healthcare by helping companies to design new products. The finding\u000a      that the &#946;-lactam ring is\u000a      not inherently reactive [3.4] has contributed to a shift towards novel\u000a      designs of alternative\u000a      antibacterials and Huddersfield's outputs describing the mechanism by\u000a      which &#946;-lactamases\u000a      catalyse the hydrolysis of &#946;-lactams [3.5-3.6] has influenced the\u000a      development of new therapeutics\u000a      such as those developed by Basilea Pharmaceutics, of Basel, Switzerland\u000a      [SL4]. This work has\u000a      anticipated key elements of the Department for Health's `UK Five-Year\u000a      Antimicrobial Resistance\u000a      Strategy', introduced in 2013, one of the principal strategic aims of\u000a      which is to improve knowledge\u000a      and understanding of AMR. Such advances also deliver economic benefits,\u000a      given that AMR is\u000a      currently estimated by the European Centre for Disease Prevention and\u000a      Control to cost &#8364;1.5bn in\u000a      healthcare expenses and lost productivity each year.\u000a    iii. Chemical reactions in liquid ammonia\u000a    Huddersfield's work on solvolysis reactions, most notably the finding\u000a      that liquid ammonia can be\u000a      considered a \"green\" solvent, has influenced the industrial manufacture of\u000a      chemicals. The\u000a      technology has been adopted by Syngenta, which has used it to develop \"new\u000a      route options\" and\u000a      has begun transferring these to the company's laboratories [SL5]. Research\u000a      in this area has also\u000a      formed the basis of an IPOS patent application for the conversion of fatty\u000a      acids to amides [5.3].\u000a    ","ImpactSummary":"\u000a    University of Huddersfield research in physical organic chemistry has\u000a      delivered economic,\u000a      industrial and societal benefits. It has led to process improvements in\u000a      chemical manufacturing,\u000a      most notably in the optimisation of the synthesis of antisense\u000a      oligonucleotides and in the use of\u000a      liquid ammonia as a solvent. It has also led to the development of new\u000a      inhibitors of bacterial &#946;-lactamases\u000a      for use as antibacterials. The research team's expertise has been\u000a      reflected in the\u000a      success of IPOS (Innovative Physical Organic Solutions), a unit\u000a      established in 2006 to carry out\u000a      research in process and other areas of chemistry for the chemical\u000a      industry. IPOS expanded\u000a      significantly from 2009 to 2013 and has now collaborated with more than\u000a      150 companies, many of\u000a      them based in Yorkshire\/Humberside where regeneration is critically\u000a      dependent on the success of\u000a      new, non-traditional, high-technology firms and industries. Through these\u000a      collaborative projects,\u000a      IPOS has contributed to the growth and prosperity of both regional and\u000a      national industry.\u000a    ","ImpactType":"Technological","Institution":"\u000a    The University of Huddersfield\u000a    ","Institutions":[{"AlternativeName":"Huddersfield (University of)","InstitutionName":"University of Huddersfield","PeerGroup":"D","Region":"Yorkshire And Humberside","UKPRN":10007148}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"2661604","Name":"Basel"}],"References":"\u000a    \u000a[3.1] M. A. Russell, A. P. Laws, J. H. Atherton and M. I. Page; The\u000a        kinetics and mechanism of the\u000a        acid catalysed detritylation of nucleotides in non-aqueous solution,\u000a      (2009), Org. Biomol. Chem., 7,\u000a      52-57. DOI: 10.1039\/b816235b\u000a    \u000a\u000a[3.2]* N. Powles, J. H. Atherton, and M.I. Page; Reactive\u000a        intermediates in the H-phosphonate\u000a        synthesis of oligonucleotides, (2012), Org. Biomol. Chem., 10,\u000a      5940-5947. DOI: 10.1039\/c2ob07130d\u000a    \u000a\u000a[3.3]* A. P. Laws, and M. I. Page; The\u000a          mechanism of catalysis and the inhibition of &#946;-lactamases, \u000a      (1998), Chem. Commum., 16, 1609-1617. DOI:\u000a      10.1039\/a803578d\u000a    \u000a\u000a[3.4] A. P. Laws, and M. I. Page; The\u000a          chemical reactivity of &#946;-lactams, &#946;-sultams and &#946;-phospholactams,\u000a      (2000), Tetrahedron 56(31), 5631-5638. DOI:\u000a      10.1016\/S0040-4020(00)00412-9\u000a    \u000a\u000a[3.5] A. Badarau, A. Llin&#225;s, A. P. Laws, C. Damblon and M. I. Page;\u000a        Inhibitors of metallo-&#946;-&#946;lactamase\u000a        generated from &#946;-lactam antibiotics, (2005), Biochemistry, 45,\u000a      8578-8589.\u000a      DOI: 10.1155\/2008\/576297\u000a    \u000a\u000a[3.6]* P. Ji, J. H. Atherton and M. I. Page; The kinetics and\u000a        mechanisms of organic reactions in\u000a        liquid ammonia, (2010), Faraday Discuss., 145,\u000a      15-25. DOI: 10.1039\/b912261n\u000a    \u000a\u000a[3.7] J. H. Atherton, M. I. Page and H. Sun; Reaction kinetics in\u000a        liquid ammonia up to 120oC:\u000a        techniques and some solvolysis and substitution reactions, (2013), J.\u000a        Phys.Org. Chem., 26, 1038-1043.\u000a      DOI: 10.1002\/poc.3150\u000a    \u000aIndicators of the quality of the research: The vast majority of\u000a      the studies performed by the physical\u000a      organic chemistry team at Huddersfield, including the bulk of the projects\u000a      described in the\u000a      references above, have been in collaboration with international\u000a      pharmaceutical companies\u000a      (AstraZeneca, GlaxoSmithKline, Avecia, Syngenta, James Robinson, British\u000a      Biotech, ICI Pharm.,\u000a      Fisons, PanTherix, Proteus and NPilPharma). Page's contribution to the\u000a      development of the subject\u000a      was recognised through the award of the RSC Organic Reaction Mechanisms\u000a      Prize in 2003.\u000a    Grants\u000a    [G1] European Regional Development Fund, Product and process\u000a        development, project 903993,\u000a      &#163;2.3M plus &#163;1.3M matched funding, 2008-2013, PI: Page.\u000a    [G2] Avecia direct support for PhD studentships: Powles (01-04) and\u000a      Russell (04-07), &#163;105,000,\u000a      2001-2007, PIs: Page and Laws.\u000a    [G3] Scotson BBSRC Case Award with GSK, &#163;114,000, 2012-2016, PI: Laws.\u000a    [G4] European Network Funding, MEBEL &#8212; metallo-&#946;-lactamases,\u000a      contract no. HPRN-CT-2002-00264,\u000a      820,000 Euros, PI: Page.\u000a    [G5] Syngenta direct funding, Liquid ammonia research, &gt;&#163;125k,\u000a      2008-, PIs: Powles and Stirling.\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"},{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"}],"Sources":"\u000a    [5.1] IPOS website http:\/\/www.hud.ac.uk\/research\/researchcentres\/ipos\/\u000a      and list of ERDF outputs,\u000a      confirm the impact that the physical organic chemistry team has had on the\u000a      employment of staff at\u000a      Huddersfield and the economic impact on SMEs in the Yorkshire and Humber\u000a      Region.\u000a    [5.2] http:\/\/www.soci.org\/News\/Awards\/Other\/Awards-Yorks-RD-Page.aspx\u000a    [5.3] H. Sun, J. Atherton and N. Powles, (2013), Method and apparatus\u000a        for the conversion of\u000a        glycerides into amides, British patent application 1319751.2.\u000a    Supporting Letters\/Factual Statements:\u000a    [SL1] Chief Technology Officer, ACAL Energy Ltd. In receipt of Factual\u000a      Statement confirming\u000a      IPOS's contribution to gas\/liquid kinetics research, and their crucial\u000a      part played in securing venture\u000a      capital.\u000a    [SL2] Director, Bio-Manufacturing Sciences Group, Pfizer. In receipt of\u000a      Factual Statement\u000a      confirming that Huddersfield's Oligonucleotide work has directed\u000a      manufacturing practice at Pfizer.\u000a    [SL3] GlaxoSmthKline, Oligonucleotide Synthesis Group, API Chemistry and\u000a      Analysis, UK. In\u000a      receipt of Factual Statement confirming that Huddersfield's\u000a      oligonucleotide work has directed\u000a      process development at GSK.\u000a    [SL4] Head of Biology, Basilea Pharmaceuticals. In receipt of Factual\u000a      Statement confirming that\u000a      Huddersfield's &#946;-lactam and &#946;-lactamases outputs have been used in\u000a      directing their R and D.\u000a    [SL5] Senior Research Scientist, Syngenta Limited, Jealott's Hill. In\u000a      receipt of Factual Statement\u000a      confirming their use of the liquid ammonia technology developed at\u000a      Huddersfield.\u000a    \u000a    ","Title":"\u000a\u0009The Impact of Physical Organic Chemistry\u000a        Research at Huddersfield\u000a    ","UKLocation":[{"GeoNamesId":"2646458","Name":"Huddersfield"},{"GeoNamesId":"2636910","Name":"Stirling"},{"GeoNamesId":"2638960","Name":"Runcorn"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"},{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    The University of Huddersfield's studies in the area of physical organic\u000a      chemistry have been driven\u000a      by the ever-growing demand for academic research to meet the needs of\u000a      industry and, in turn, the\u000a      people industry serves. Professors M. Page (Dean of School 1989-2004;\u000a      Deputy VC 2004-2010;\u000a      Managing Director, IPOS, 2006-present), J. Atherton (2007-present) and A.\u000a      Laws (1992-present;\u000a      submitted in UoA 5) have each contributed research outputs describing\u000a      fundamental research\u000a      undertaken in collaboration with, and sponsored by, industry. Reflecting\u000a      the rapid and sustained\u000a      expansion of activity in this area, Innovative Physical Organic Solutions\u000a      (IPOS), a research unit\u000a      offering analytical and chemical process development services to the\u000a      chemical industry, was\u000a      established in the Department of Chemistry in 2006. IPOS entered a period\u000a      of rapid expansion in\u000a      2009 with the award of European Regional Development Funding (ERDF) of\u000a      &#163;3.6M [G1]. Some of\u000a      the underpinning research described here was carried out in IPOS. The IPOS\u000a      team has both\u000a      furthered existing strands of research (e.g. in liquid ammonia) and also\u000a      initiated a number of new\u000a      themes (e.g. in catalyst development).\u000a    i. Synthetic oligonucleotides for therapy (2001-present)\u000a    Small interfering RNA (siRNA) and antisense oligonucleotides have been\u000a      demonstrated as\u000a      powerful tools for chemotherapy. There is currently no efficient synthesis\u000a      of oligonucleotides on an\u000a      industrial scale. Huddersfield's studies of the mechanisms of the chemical\u000a      synthesis of\u000a      oligonucleotides have provided an understanding of the synthetic\u000a      parameters that can be used to\u000a      optimise large-scale synthesis. The first part of this work was funded\u000a      directly by Avecia\u000a      Biotechnology through PhD studentships for Powles (2001-2004) and Russell\u000a      (2004-2007) [G2].\u000a      Powles' work explored the mechanism of H-phosphonate coupling of\u000a      oligonucleotides [3.1], while\u000a      Russell's examined several steps involved in the oligonucleotide synthesis\u000a      cycle employing\u000a      phosphoramidite chemistry [3.2]. More recently this work has been taken up\u000a      by GlaxoSmithKline\u000a      who have continued to support this research through a CASE award for\u000a      Scotson [G3].\u000a    ii. Providing solutions to antimicrobial resistance (1993-present)\u000a    The rise of bacterial resistance to antibiotics has been highlighted in\u000a      recent years. Huddersfield's\u000a      work on &#946;-lactams was initiated by Page, who went on to continue research\u000a      in this area with Laws.\u000a      The team has published more than 50 papers since 1993 that contribute to\u000a      understanding how\u000a      bacteria are able to evade the action of &#946;-lactam antibiotics. The work\u000a      has focused on\u000a      demonstrating that &#946;-lactams are not particularly \"strained\" four-membered\u000a      rings, a notion\u000a      facilitating the design of novel alternative antibacterials [3.3]. Through\u000a      measurement of the intrinsic\u000a      reactivity of a number of small ring systems including &#946;-lactams,\u000a      &#946;-sultams and\u000a      azaphosphetidienes, the work at Huddersfield has facilitated the design of\u000a      novel alternative\u000a      enzyme inhibitors of bacterial enzymes [3.4]. Investigations into serine\u000a      and metallo-&#946;-lactamase\u000a      enzymes, which are increasingly important causes of bacterial resistance\u000a      to &#946;-lactam antibiotics,\u000a      has raised the possibility of developing novel methods of inhibition\u000a      [3.5]. The work has been\u000a      funded through collaboration with pharmaceutical companies (including\u000a      AstraZeneca and GSK)\u000a      and engagement in European Networks [G4].\u000a    iii. Chemical reactions in liquid ammonia (2007-present)\u000a    The use of liquid ammonia as a reaction solvent is advantageous because\u000a      product isolation and\u000a      solvent recycling are greatly facilitated, meaning ammonia can be\u000a      considered an environmentally\u000a      \"green\" solvent. Fundamental research in Huddersfield on the use of\u000a      ammonia as a reaction\u000a      solvent has revealed the scope of reactions that can be transferred to a\u000a      liquid ammonia medium,\u000a      with both catalysed [3.6] and non-catalysed [3.7] reactions showing\u000a      potential benefits. Supported\u000a      by funding from Syngenta [G5], current research portfolios include\u000a      continuous flow processes and\u000a      biotransformations in liquid ammonia.\u000a    "},{"CaseStudyId":"32237","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2658434","Name":"Switzerland"}],"Funders":["Engineering and Physical Sciences Research Council","Royal Society"],"ImpactDetails":"\u000a    Impact has been generated by two routes. The first is through the\u000a      synthesis of porous solids and the capability for tuning porosities in\u000a      both adsorbent and catalyst synthesis. The second is through improvements\u000a      to thermal analytical techniques and the new information available on the\u000a      structure\/function relationships in solid-state systems. The techniques\u000a      have been used in the characterisation of catalytic materials and\u000a      pyrotechnic materials, with the associated benefits to users and to\u000a      manufacturers, including global companies and the defence industry.\u000a    We have been working with Johnson Matthey (JM) since 1999 (as ICI\/Synetix\u000a      in the early years), applying controlled-rate techniques to catalysts and\u000a      catalyst precursors with a view both to strengthening the understanding of\u000a      the processes that occur in the preparation of solid catalysts and to\u000a      improving the properties of solid catalysts prepared by thermal methods.\u000a      Our (Parkes' and Barnes') work with JM, based on that reported in\u000a      references A1-A3 above, has illustrated the potential for controlling\u000a      catalyst morphology, especially in calcined materials, so offering the\u000a      prospect to tune key catalyst properties. Through both our early\u000a      fundamental work and the continuing collaboration with JM, knowledge\u000a      transfer to JM has occurred. Impact has been felt by JM throughout the\u000a      assessment period and continues to be felt today. The Catalysis R and D\u000a      Director at JM, describes the research as \"crucial for our\u000a          understanding of how to scale and optimise manufacturing processes for\u000a          materials development. This has clear implications for economic and\u000a          environmental benefits for our manufacturing processes and end-users\u000a          of our products\".[S1]\u000a    Joint research with Dstl, Porton Down over a similar period (Parkes and\u000a      Brown) has been aimed at the use of controlled-rate techniques to tailor\u000a      porosity characteristics in activated carbons. The objectives were to\u000a      increase understanding of the synthesis\/preparative factors that control\u000a      the properties of carbon adsorbents, and also to improve the extent to\u000a      which activated carbons can be characterised. This work (reference A3\u000a      above) was ultimately aimed at improving carbon adsorbents for personal\u000a      respirator use by improving the balance between effective adsorption\u000a      performance and resistance to airflow. The benefits in these directions\u000a      were witnessed at Dstl in the 2008-2010 period and the Chief Scientist\u000a      (Physical Sciences Dept), Porton Down, reports that:.... (Our\u000a        collaborative work) \"has greatly increased our understanding of the\u000a        factors that affect the performance of activated carbons used in\u000a        respirator filters including the influence of metal impregnants and pore\u000a        structure on removal of toxic chemicals from contaminated airstreams. In\u000a        particular the controlled-rate activation methods developed\u000a          at Huddersfield have enable excellent control over the properties of\u000a          activated carbons, resulting in significant improvements in adsorbent\u000a          performance and their long-term stability\".[S2]\u000a    A similar approach to tuning carbon pore structures using controlled-rate\u000a      techniques has recently been applied to carbon adsorbents for use in\u000a      cigarette filters (2008-date, funded by BAT). [B1] The joint research\u000a      (Parkes) has shown that it is possible to change the internal structure of\u000a      an activated carbon derived from an environmentally-preferred\u000a      vegetable-based source to maximise its adsorption properties when\u000a      operating under high flow rates. The Research Manager at BAT confirms that\u000a      in the period since 2010 \"significant enhancements in the adsorption of\u000a        some key smoke toxicants were achieved (using the methods developed\u000a      in Huddersfield) compared to the use of conventional materials\".[S3]\u000a      An international patent with BAT has been granted. [B2]\u000a    Our expertise and unique capability in adsorption calorimetric techniques\u000a      have been applied to work with MEL Chemicals (Brown). Over the period from\u000a      2003 we have been using these techniques, based on references A4 and A5\u000a      above, to characterise modified zirconia catalysts, significantly\u000a      increasing the company's understanding of the structure\/function\u000a      relationship in these materials. Impact has been felt in two areas. The\u000a      first is in designing doped zirconias with controlled acidity\/basicity for\u000a      use mainly in auto catalysts but also in gas clean-up catalysts [B3]\u000a      (2008-2011). The second is in the design of lithium zirconate catalysts\u000a      for biodiesel synthesis (2011-13). A patent was filed on our joint work on\u000a      lithium ziroconate in 2012 [B4] and the work has been presented at\u000a      numerous conferences. The Divisional Research and Development Director\u000a      says that this work has \"strengthened our product range. In\u000a          monetary terms, the joint research has certainly brought benefit to\u000a          MEL\".[S4]\u000a    Over the period 2000 to date, Charsley has been carrying out research\u000a      with the Defence Evaluation and Research Agency, QinetiQ Ltd, armasuisse,\u000a      Switzerland and the Finnish Defence Forces. In this work a series of\u000a      advanced and unique thermal analytical techniques (based on reference A6\u000a      above) have been used to characterise the strongly exothermic reactions of\u000a      a range of pyrotechnic compositions, with a view to designing new\u000a      materials using more benign compounds than those that have traditionally\u000a      been used, particularly perchlorates. [B5] This has resulted in a series\u000a      of new formulations (introduced 2008-2010) based on magnesium alloy-sodium\u000a      nitrate-calcium resinate compositions. The overall programme was sponsored\u000a      by the Strategic Environmental Research and Development Programme (SERDP),\u000a      US Department of Defence and in 2009 was awarded the SERDP Project of\u000a        the Year Prize. The Principal Capability Group Leader at QinetiQ\u000a      involved in this work confirms that the contribution of Huddersfield \"was\u000a        pivotal to the consortium being awarded the project (in competition with\u000a        US research laboratories) and the prize\", adding that \"the\u000a        reputation of your team and quality of work performed at Huddersfield\u000a        has allowed the UK to benefit from a number of long term international\u000a        collaborative studies on pyrotechnics and novel materials\". [S5]\u000a      Through facilitating the study of these reactive materials, says QinetiQ,\u000a      the University has \"contributed to defence research both in the UK\u000a          and internationally\".\u000a    ","ImpactSummary":"\u000a    Methods to improve control over thermally-induced solid state\u000a      transformations have been developed in Huddersfield and applied to\u000a      materials synthesis and materials characterisation. Impact is being felt\u000a      by catalyst and adsorbent manufacturers, where feedback-controlled thermal\u000a      and microwave methods allow improved control of morphology, surface area\u000a      and porosity, and possibly the nature of surface sites. New thermal\u000a      characterisation methods, some based on these principles, plus\u000a      calorimetric adsorption, modulated differential calorimetric and high\u000a      speed thermal methods, are being applied to catalytic\/adsorbent materials.\u000a      The information arising from these studies is bringing economic benefit to\u000a      manufacturers. The same techniques are also being applied to pyrotechnic\u000a      materials, in work which has been credited with making a significant\u000a      contribution to defence research in the UK and overseas.\u000a    ","ImpactType":"Technological","Institution":"\u000a    The University of Huddersfield\u000a    ","Institutions":[{"AlternativeName":"Huddersfield (University of)","InstitutionName":"University of Huddersfield","PeerGroup":"D","Region":"Yorkshire And Humberside","UKPRN":10007148}],"Panel":"B         ","PlaceName":[],"References":"\u000a\u0009(key papers bold\/starred)\u000a    \u000a[A1]* M Tiernan, P A Barnes, and G Parkes, Reduction of iron\u000a        oxide catalysts: the investigation of kinetic parameters using rate\u000a        perturbation and linear heating thermoanalytical techniques, (2001),\u000a      J. Phys. Chem. B, 105, 220. 10.1021\/jp003189+\u000a    \u000a\u000a[A2]* E A Fesenko, P A Barnes, G M B Parkes, D R Brown and M\u000a      Naderi, A New Approach to the Study of the Reactivity of Solid-Acid\u000a        Catalysts: The Application of Constant Rate Thermal Analysis to the\u000a        Desorption and Surface Reaction of Isopropylamine from NaY and HY\u000a        Zeolites, (2001), J. Phys. Chem. B, 105, 6178. 10.1021\/jp004587f\u000a    \u000a\u000a[A3] E A Dawson, G Parkes, P A Barnes, M Chinn, A Pears and C Hindmarsh,\u000a      A study of evolved gas control and its effect on carbon yield during\u000a        the activation of carbon fibres by controlled rate methods, (2002),\u000a      Carbon, 40, 2897. 10.1016\/S0008-6223(02)00220-8\u000a    \u000a\u000a[A4] H E Cross, G M Parkes and D R Brown, Microwave calcination of\u000a        Cu\/Mg\/Al hydrotalcite catalyst precursor, (2012), Appl. Catal.,\u000a      439-430, 24. 10.1016\/j.apcata.2012.03.046\u000a    \u000a\u000a[A5]* M P Hart and D R Brown, Surface Acidities and Catalytic\u000a        Activities of Acid-Activated Clays, (2004), J. Mol. Catal. A:\u000a        Chem., 212, 315. 10.1016\/j.molcata.2003.11.013\u000a    \u000a\u000a[A6] I M Tuukkanen, E L Charsley, S J Goodall, P G Laye, J J Rooney, T T\u000a      Griffiths, H Lemmetyinen, An investigation of strontium nitrite and\u000a        its role in the ageing of the magnesium-strontium nitrate pyrotechnic\u000a        system using isothermal microcalorimetry and thermal analysis techniques,\u000a      (2006), Thermochim. Acta, 443, 116. 10.1016\/j.tca.2006.02.004\u000a    \u000aExternal funding supporting underpinning research:\u000a    [G1] EPSRC: 1997-2001 (&#163;182,000) Enhanced thermal methods and their\u000a        application in catalysis (PI: P A Barnes). GR\/66069\/01.\u000a    [G2] ICI (now JM): 1998-2001 (&#163;156,000) Controlled rate thermal\u000a        methods in catalyst preparation (PI: P A Barnes).\u000a    [G3] DERA, MOD: 1997-2000 (&#163;440,000) Novel modified carbon adsorbents\u000a      (P A Barnes)\u000a    [G4] Dstl: 2003-05 (&#163;80,000) Activated carbon porosity using\u000a        controlled rate thermal methods (PI: P A Barnes).\u000a    [G5] Dstl: 2012- (&#163;25,000) The use of gas adsorption calorimetry to\u000a        characterise the interaction of selected TICs on carbon and other\u000a        adsorbents (PI: G M B Parkes and D R Brown).\u000a    [G6] BAT Ltd 2008-10 and 2010-2012 (&#163;199,000) Creation of mesopores\u000a        in activated coconut carbon (PI: G M B Parkes).\u000a    [G7] Royal Society of Chemistry: 1999-2002 (&#163;33,000) Microwave\u000a        thermal analysis (PI: P A Barnes).\u000a    [G8] EPSRC: 1997-1999 (&#163;85,000) New methods of thermal analysis using\u000a        microwave heating\/detection (PI: P A Barnes). GR\/K99862\/02.\u000a    [G9] EPSRC: 2002-05 (&#163;249,000) An instrument for the\u000a        quasi-simultaneous measurement of the temperature dependence of\u000a        dielectric parameters (PI: P A Barnes). GR\/R38460\/01.\u000a    [G10] Home Office CBRN S&amp;T: 2005-8 (&#163;340,000) Removal of toxic\u000a        gases from air streams using pulsed microwave activation of novel\u000a        catalytic materials (PIs: G M B Parkes, P A Barnes) Project ref:\u000a      TR23\/04\/02.\u000a    [G11] DTI\/EPSRC LINK: Catalysis and catalytic processes 1998-00\u000a      (&#163;494,000) Sulfonated organic resin acid catalysts (PI: D R Brown\u000a      with Purolite Intl). GR\/L87859\/01.\u000a    [G12] MEL Chemicals: 2008 (&#163;18,000) Modified zirconia auto catalysts\u000a      (PI: D R Brown).\u000a    [G13] MEL Chemicals: 2011 (&#163;25,000) New applications of Li2ZrO3\u000a      (PI: D R Brown).\u000a    [G14] DERA \/ QinetiQ Ltd: UK 1998-2009 (&#163;800,000) Thermal\u000a        characterisation of pyrotechnic systems (PI: E.L.Charsley).\u000a    [G15] armasuisse, Switzerland: 2001-2010 (&#163;133,000) Thermal studies\u000a        on pyrotechnic systems (PI: E.L.Charsley).\u000a    [G16] Finnish Defence Forces 2001-2005 (&#163;102,500) Ageing behaviour of\u000a        magnesium pyrotechnic compositions (PI: E.L.Charsley).\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"},{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"},{"Level1":"9","Level2":"4","Subject":"Chemical Engineering"}],"Sources":"\u000a    References (from section 4)\u000a    [B1] E A Dawson, G M B Parkes and P Branton, Synthesis of\u000a        vegetable-based activated carbons with mixed micro-and mesoporosity for\u000a        use in cigarette filters, (2012), Ads.Sci.Technol., 30,\u000a      859. Joint Huddersfield\/BAT(Branton). http:\/\/eprints.hud.ac.uk\/16683\/\u000a    [B2] P Branton, E Dawson and G Parkes, Method of preparing porous\u000a        carbon, PCT\/GB2011\/050882. Patent authors from Huddersfield and BAT\u000a      (Branton).\u000a    [B3] H Stephenson, E Dvininov, D R Brown, Alkaline zirconate for\u000a        biodiesel production, Patent MEL (Stephenson, Dvininov). Search\u000a      report received. Decision pending on re-filing.\u000a    [B4] Several papers\/reports were published jointly by MEL and VTT,\u000a      Finland on the gasification of biomass. Our work on zirconia catalyst\u000a      characterisation was used in these projects. E.g. T Viinikainen, H\u000a      Ronkkonen, H Bradshaw, H Stephenson, S Airaksinen, M Reinikainen, P Simell\u000a      and O Krause, Acidic and basic surface sites of zirconia-based biomass\u000a        gasification gas clean-up catalysts. (2009), Appl. Catal. A,\u000a      362, 169.\u000a    [B5] Charsley (Huddersfield) and Griffiths (QinetiQ) presented joint work\u000a      at numerous conferences and events. E.g. T T Griffiths, E L Charsley, H M\u000a      Markham and J J Rooney, 36th International Pyrotechnics\u000a      Seminar, Rotterdam, TNO Defence, Security and Safety, 2009, 377. Pyrotechnic\u000a        incendiary compositions.\u000a    Sources of supporting letters (referred to in section 4). Names\u000a        provided separately.\u000a    [S1] Technology Manager and Catalysis R and D Director, Johnson Matthey\u000a      PCT. Oversaw all the collaborative projects with ICI Katalco, Synetix and\u000a      now Johnson Matthey, on application of controlled-rate methods to catalyst\u000a      synthesis, including carbon-supported materials, and can speak on the\u000a      outcomes and impact of the work.\u000a    [S2] Chief Scientist, Dstl, Porton Down. Responsible for research on\u000a      adsorbents for gas filtration and can verify impact of controlled-rate\u000a      thermal methods on activated carbon adsorbent preparative methods, and can\u000a      confirm importance of adsorption calorimetric methods in characterising\u000a      adsorbent materials.\u000a    [S3] Research Manager, Group Research and Development, British American\u000a      Tobacco. Can verify impact of controlled-rate thermal methods on the\u000a      tuning of carbon adsorbent properties for toxin adsorption from tobacco\u000a      smoke.\u000a    [S4] Divisional Research and Development Director, MEL Chemicals. Can\u000a      describe the influence our research, especially adsorption calorimetric\u000a      methods, has had on design of doped zirconias for both auto and other\u000a      catalytic applications, and can also verify impact of joint development of\u000a      lithium zirconate biodiesel catalysts.\u000a    [S5] Principal Capability Group Leader, QinetiQ, Fort Halstead. Can\u000a      verify the impact of our work on pyrotechnic storage and on\u000a      environmentally improved pyrotechnic compositions, and can also confirm\u000a      the importance of SERDP prize to QinetiQ and UK defence research.\u000a    ","Title":"\u000a    New Thermal Methods for Materials Preparation and Characterisation\u000a    ","UKLocation":[{"GeoNamesId":"2646458","Name":"Huddersfield"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    P A Barnes (Emeritus Professor, retired 2007, Professor 1997-2007), E L\u000a      Charsley (Emeritus Professor, retired 2010, Professor 1997-2010), D R\u000a      Brown (Professor 2003- and Reader 1997-2003) and G M Parkes (Reader 2011-,\u000a      Senior Lecturer 2002-2011, Research Fellow 1997-2002) have been developing\u000a      new thermal techniques for both solid materials preparation (thermal\u000a      processing), and materials characterisation (thermal analysis) since 1997.\u000a      The reason this work is important is that, when using standard or\u000a      conventional thermal methods, variations in temperature across the bulk of\u000a      solid materials limit 1) the control that is available in materials\u000a      synthesis and 2) the information that is available from characterisation\u000a      techniques. The new thermal techniques (including various\u000a        \"controlled-rate\" processes, using both conventional and microwave\u000a        heating) have allowed increased control in synthesis, and increased\u000a        precision in characterisation, leading to finer control of material\u000a        properties and better understanding of many thermally-induced\u000a        solid-state processes.\u000a    Barnes and Parkes (1997-2009) developed controlled-rate methods of\u000a      thermal analysis in which the heating regime is continuously controlled by\u000a      feedback from the rate of the thermally-induced reaction of a solid\u000a      sample, [A1, A2] greatly improving the quality of information provided.\u000a      The techniques were extended to control not just heating programmes but\u000a      also, for example, over-gas compositions. [Grants G1, G2]\u000a    The techniques were scaled-up for materials preparation, firstly in\u000a      carbon and impregnated carbon activation (Dstl 1997-, BAT 2003-), and\u000a      latterly through controlling calcination techniques for catalyst synthesis\u000a      more generally. [A3] [Grants G3-G6] Barnes, Parkes and Charsley, over\u000a      1997-2004, applied controlled-rate algorithms to microwave thermal\u000a      analytical techniques [Grants G7-G10], where they offer the particular\u000a      benefit of precise temperature control even when sample dielectric\u000a      properties are changing. Adapting microwave controlled-rate methods to\u000a      semi- preparative and then preparative scale took place over 2004-2009.\u000a      Current work (Brown and Parkes) is focussed on microwave-induced\u000a      controlled production of mixed metal oxide catalysts through calcination\u000a      of the hydroxides. [A4] These dehydration processes involve large changes\u000a      in microwave coupling and, without controlled-rate technology, temperature\u000a      control is not possible.\u000a    More widely, solid materials characterisation has been facilitated by the\u000a      development and refinement of adsorption calorimetric techniques by Brown\u000a      (1997-). [A5] [Grants G11-G13] These techniques provide unique information\u000a      on the abundance, strength and strength distribution of active sites on\u000a      the surfaces of solid catalysts and adsorbents. Two approaches have been\u000a      used, based on 1) the progressive adsorption of probe gases from a flowing\u000a      carrier gas and 2) the progressive adsorption under static conditions\u000a      where adsorption equilibrium is achieved at each stage of the addition of\u000a      probe gas. The unique capability in this area held at Huddersfield has led\u000a      to almost 40 papers, and many academic and industrial collaborations.\u000a    In another area in which our novel thermal methods have been applied to\u000a      chemical systems in new ways, Charsley has studied metal-oxidant\u000a      pyrotechnic reactions (1997-date). He has used both the new thermal\u000a      methods described above and other specialised thermal techniques designed\u000a      for studying these very reactive materials, such as modulated temperature\u000a      differential calorimetry and sample ignition-controlled thermal analysis.\u000a      [Grants G14-G16] The use of these techniques, in conjunction with chemical\u000a      analysis, has proved to be an effective approach to investigating the\u000a      reaction mechanisms of a wide range of pyrotechnic systems and has been\u000a      extended to studying the mechanism of ageing under ambient conditions in\u000a      collaboration with industrial partners (e.g. QinetiQ, 1998-2009). [A6]\u000a    "},{"CaseStudyId":"33268","Continent":[],"Country":[],"Funders":["Research Councils UK"],"ImpactDetails":"\u000d\u000a    Prior to the impacts described in this section the UK's e-infrastructure\u000d\u000a      suffered from a fragmented funding regime, with resources being funded by\u000d\u000a      a variety of bodies representing diverse user groups. There was also a\u000d\u000a      distinct lack of a coordinated policy and strategy for UK\u000d\u000a      e-infrastructure, and no single coordinating body that represented all\u000d\u000a      relevant stakeholders. This fragmented organisation of the national\u000d\u000a      infrastructure, together with no guarantee of future provision,\u000d\u000a      discouraged business from becoming involved, inhibited collaboration\u000d\u000a      between organisations and resulted in the UK losing its ability to compete\u000d\u000a      internationally in the field.\u000d\u000a    In 2011, as a result of the strength of UCL research in the field,\u000d\u000a      Coveney was asked by the UK e-Science Institute to lead on the publication\u000d\u000a      of a report into the UK's e-infrastructure, with the objective to develop\u000d\u000a      a strategy to overcome the problems of fragmented funding and\u000d\u000a      coordination. The Strategy for the UK Research Computing Ecosystem\u000d\u000a      report [A], published in October 2011, was the result of a number of\u000d\u000a      meetings (with the involvement of UK Science and Universities Minister Rt\u000d\u000a      Hon David Willetts MP in July 2011). It set out a holistic approach for\u000d\u000a      the UK's e-infrastructure involving the different Research Councils,\u000d\u000a      funding bodies and user communities in a coherent collaboration.\u000d\u000a      Non-university users of the e-infrastructure include automotive,\u000d\u000a      pharmaceutical, software and hardware industry sectors; charity-funded\u000d\u000a      research laboratories (for example, the London Research Institute); and\u000d\u000a      many publicly funded research institutes, including the Met Office, Culham\u000d\u000a      and AWE (Atomic Weapons Establishment). Specific recommendations made in\u000d\u000a      the Strategy report were to (i) set up an independent coordinating\u000d\u000a      body to govern the e-infrastructure that reports directly to the\u000d\u000a      Government, (ii) drive the development of software, hardware and\u000d\u000a      networking for all stakeholders (including national supercomputing service\u000d\u000a      providers and Research Councils) in the e-infrastructure, and (iii) offer\u000d\u000a      e-science training to develop the next generation of computationally aware\u000d\u000a      researchers who are able to use the improved e-infrastructure. Coveney's\u000d\u000a      role in directing and shaping these recommendations was directly\u000d\u000a      consequent on the UCL team's research in computational science, including\u000d\u000a      computational chemistry.\u000d\u000a    This document in turn fed into and informed a key policy document\u000d\u000a      entitled A Strategic Vision for UK e-Infrastructure, commissioned\u000d\u000a      by Willetts and published by the Department for Business, Innovation and\u000d\u000a      Skills (BIS) in January 2012 [B]. This document addressed the advanced\u000d\u000a      computational capacity of the UK as a system (i.e. as an\u000d\u000a      e-infrastructure), and proposed a series of recommendations on software,\u000d\u000a      hardware, networks, data storage and skills to help develop this\u000d\u000a      e-infrastructure. In particular, the Vision report took forward\u000d\u000a      the specific recommendations made in the Strategy report,\u000d\u000a      demonstrating that the Strategy report informed Government\u000d\u000a      understanding of the issues. As a direct result of the first of these\u000d\u000a      recommendations the Government created the UK E-Infrastructure Leadership\u000d\u000a      Council (ELC) in March 2012 [C]. The ELC has the responsibility to advise\u000d\u000a      the Government on e-infrastructure development and to develop a wider plan\u000d\u000a      for stakeholder engagement. It is currently working on mechanisms for\u000d\u000a      engaging industry and healthcare with the newly funded e-infrastructure,\u000d\u000a      including an \"On Ramp\" programme that seeks to identify and remove\u000d\u000a      barriers to the uptake of e-infrastructure by UK PLCs. The strong\u000d\u000a      influence of the Strategy report on the Vision report is\u000d\u000a      clearly evidenced in the Chairman's foreword and the references of the\u000d\u000a      latter report [B]. For example, the Chairman wrote: \"I was commissioned by\u000d\u000a      the Minister to write a report on how we might create an e-infrastructure\u000d\u000a      that would support a strong public-private partnership. [...] We have been\u000d\u000a      able to move quickly by building on some excellent analysis. I think\u000d\u000a      particularly of the work of the academic community summarised in the\u000d\u000a      report by Peter Coveney Strategy for the UK Research Computing\u000d\u000a        Ecosystem\" [B].\u000d\u000a    As a result of these two policy documents (mainly the Strategy\u000d\u000a      report, which was already published at the time), in October 2011 the\u000d\u000a      Government earmarked &#163;145 million (increased to &#163;165 million in early\u000d\u000a      2012) to improve the UK's HPC capabilities and wider e-infrastructure [D,\u000d\u000a      E]. This investment has resulted in improvements to existing\u000d\u000a      e-infrastructure such as the UK academic network JANET and high-capacity\u000d\u000a      data storage across the Research Councils, and has funded a number of HPC\u000d\u000a      activities in the UK including Emerald, one of the largest Graphics\u000d\u000a      Processing Unit systems in Europe, now located in the Rutherford Appleton\u000d\u000a      Laboratory in Daresbury, and IRIDIS, a conventional 100-teraFLOPS\u000d\u000a      supercomputer, located at the University of Southampton. These activities\u000d\u000a      have vastly increased the computing capacity and capability in the UK.\u000d\u000a      This has wide-ranging industrial and economic impact, including allowing\u000d\u000a      the NHS and UK PLCs to use these resources, and attracting hi-tech\u000d\u000a      industry from overseas. For example, companies including IBM, Intel and\u000d\u000a      Cisco have already made investments into the UK following this Government\u000d\u000a      investment in e-infrastructure [F].\u000d\u000a    The Vision report (and therefore the Strategy report) has\u000d\u000a      further influenced Government spending, with the Government's on-going\u000d\u000a      commitment to improving UK e-infrastructure demonstrated by the allocation\u000d\u000a      of an additional &#163;189 million in capital funding to this area in December\u000d\u000a      2012. This investment was part of the &#163;600 million capital funding for\u000d\u000a      science announced in the Chancellor's 2012 Autumn Statement, and the\u000d\u000a      amount allocated to e-infrastructure was communicated by Willetts at\u000d\u000a      Policy Exchange in January 2013, where he described e-infrastructure &#8212; or\u000d\u000a      \"Big Data\" &#8212; as one of the \"eight great technologies\" which will propel\u000d\u000a      the UK to future growth [F]. The &#163;189 million, to be invested over the\u000d\u000a      next two years, has been allocated to areas including \"e-Infrastructure\u000d\u000a      for Biosciences\" and \"Administrative Data Research Centres\" [G]; it was\u000d\u000a      announced in February 2013 that &#163;30 million has already been awarded to\u000d\u000a      the Hartree Centre in Daresbury and its academic and industrial partners,\u000d\u000a      in part to develop new technology to make supercomputers more efficient\u000d\u000a      [H].\u000d\u000a    The work of the UCL team has also informed policy debate. In June 2013,\u000d\u000a      Coveney was invited to speak at a House of Lords meeting about scientific\u000d\u000a      infrastructure [I], as part of an inquiry into that topic launched by the\u000d\u000a      Science and Technology Committee in May 2013. He reminded the audience of\u000d\u000a      the recommendations for UK e-infrastructure made in the Strategy\u000d\u000a      report, and explained that whilst the initial Government investments and\u000d\u000a      formation of the ELC are excellent outcomes of this report, there are a\u000d\u000a      number of critical recommendations that have yet to be implemented. These\u000d\u000a      include holistic management of investments in e-infrastructure, a focus on\u000d\u000a      software development in addition to investments in hardware, and the\u000d\u000a      provision of appropriate training across a wide range of disciplines. His\u000d\u000a      presentation sparked considerable discussion and debate amongst meeting\u000d\u000a      attendees about these and other issues relating to UK e-infrastructure.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    In 2011, a leading role was given to Peter Coveney in UCL's Department of\u000d\u000a      Chemistry in defining the future strategy for the UK's e-infrastructure,\u000d\u000a      based on the department's expertise and research in this field. This\u000d\u000a      appointment led to the publication of the Strategy for the UK Research\u000d\u000a        Computing Ecosystem document, which has since stimulated debate\u000d\u000a      amongst policy makers and informed government policy. On the basis of its\u000d\u000a      recommendations, the government has set up an advisory E-Infrastructure\u000d\u000a      Leadership Council and allocated &#163;354 million to improving the UK's\u000d\u000a      high-performance computing capabilities and wider e-infrastructure, a move\u000d\u000a      that is having wide-ranging industrial and economic impact in the UK. Most\u000d\u000a      recently, in June 2013 the Strategy document stimulated further\u000d\u000a      debate about the UK's e-infrastructure at the House of Lords.\u000d\u000a    ","ImpactType":"Political","Institution":"\u000d\u000a    University College London (UCL)\u000d\u000a    ","Institutions":[{"AlternativeName":"University College London","InstitutionName":"University College London","PeerGroup":"A","Region":"London","UKPRN":10007784}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    \u000a[1] The application hosting environment: Lightweight middleware for\u000d\u000a      grid-based computational science, P. V. Coveney, R. S. Saksena, S. J.\u000d\u000a      Zasada, M. McKeown and S. Pickles, Comp. Phys. Commun., 176,\u000d\u000a      406-418 (2007) doi:10.1016\/j.cpc.2006.11.011\u000d\u000a    \u000a\u000a[2] Virtualizing access to scientific applications with the Application\u000d\u000a      Hosting Environment, S. J. Zasada and P. V. Coveney, Comp. Phys.\u000d\u000a        Commun., 180, 2513-2525 (2009) doi:10.1016\/j.cpc.2009.06.008\u000d\u000a    \u000a\u000a[3] Computer simulation study of the structural stability and materials\u000d\u000a      properties of DNA-intercalated layered double hydroxides, M. A. Thyveetil,\u000d\u000a      P. V. Coveney, H. C. Greenwell and J. L. Suter, J. Am. Chem. Soc.,\u000d\u000a      130, 14, 4742-4756 (2008) doi:10.1021\/ja077679s\u000d\u000a    \u000a\u000a[4] Rapid and accurate prediction of binding free energies for\u000d\u000a      saquinavir-bound HIV-1 proteases, I. Stoica, S. K. Sadiq and P. V.\u000d\u000a      Coveney, J. Am. Chem. Soc., 130, 8, 2639-2648 (2008) doi:10.1021\/ja0779250\u000d\u000a    \u000a\u000a[5] Accurate ensemble molecular dynamics binding free energy ranking of\u000d\u000a      multidrug-resistant HIV-1 proteases, S. K. Sadiq, D. W. Wright, O. A.\u000d\u000a      Kenway and P. V. Coveney, J. Chem. Inf. Mod., 50, 890-905 (2010)\u000d\u000a      doi:10.1021\/ci100007w\u000d\u000a    \u000aReferences [3], [4] and [5] best indicate the quality of the\u000d\u000a        underpinning research.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"8","Level2":"3","Subject":"Computer Software"},{"Level1":"8","Level2":"2","Subject":"Computation Theory and Mathematics"},{"Level1":"1","Level2":"3","Subject":"Numerical and Computational Mathematics"}],"Sources":"\u000d\u000a    [A] Strategy for the UK Research Computing Ecosystem (2011),\u000d\u000a      available online:\u000d\u000a      http:\/\/wiki.esi.ac.uk\/w\/files\/f\/f5\/ResearchComputing-glossy.pdf\u000d\u000a      &#8212; corroborates the recommendations of the report and Coveney's role in\u000d\u000a      producing it.\u000d\u000a    [B] A Strategic Vision for UK e-Infrastructure (2012), available\u000d\u000a      online:\u000d\u000a      http:\/\/www.bis.gov.uk\/assets\/BISCore\/science\/docs\/S\/12-517-strategic-vision-for-uk-e-infrastructure.pdf\u000d\u000a      &#8212; corroborates the influence of the Strategy report on the Vision\u000d\u000a      report.\u000d\u000a    [C] ELC website: https:\/\/www.gov.uk\/government\/policy-advisory-groups\/122\u000d\u000a      &#8212; corroborates the creation of the ELC in March 2012 and what it does.\u000d\u000a    [D] BIS: Innovation and Research Strategy for Growth (2011),\u000d\u000a      available online:\u000d\u000a      https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/32450\/11-1387-innovation-and-research-strategy-for-growth.pdf\u000d\u000a      &#8212; corroborates that the Government allocated &#163;145 million to\u000d\u000a      e-infrastructure in October 2011.\u000d\u000a    [E] Transcript of David Willetts' oral statement \"Science and the City\"\u000d\u000a      (2012), available online:\u000d\u000a      https:\/\/www.gov.uk\/government\/speeches\/science-and-the-city--2\u000d\u000a      &#8212; corroborates the increase in Government funding for e-infrastructure to\u000d\u000a      &#163;165 million in early 2012.\u000d\u000a    [F] Transcript of David Willetts' speech at Policy Exchange (2013),\u000d\u000a      available online:\u000d\u000a      https:\/\/www.gov.uk\/government\/speeches\/eight-great-technologies\u000d\u000a      &#8212; corroborates that the Government allocated &#163;189 million \"Big Data\" in\u000d\u000a      January 2013, and corroborates that investments into the UK have been made\u000d\u000a      by companies including IBM, Intel and Cisco.\u000d\u000a    [G] Research Councils UK press release (2013), available online:\u000d\u000a      http:\/\/www.rcuk.ac.uk\/media\/news\/2013news\/Pages\/130124.aspx\u000d\u000a      &#8212; corroborates how the &#163;189 million has been allocated.\u000d\u000a    [H] George Osborne press release (2013), available online:\u000d\u000a      https:\/\/www.gov.uk\/government\/news\/chancellor-announces-boost-for-state-of-the-art-computing\u000d\u000a      &#8212; corroborates the award to the Hartree Centre of &#163;30 million from the\u000d\u000a      &#163;189 million.\u000d\u000a    [I] Agenda for Scientific Infrastructure seminar at House of Lords (11\u000d\u000a      June 2013) &#8212; corroborates the attendance of Coveney at the meeting and the\u000d\u000a      discussion questions. Available on request.\u000d\u000a    ","Title":"\u000d\u000a    Impact on UK Government funding and decisions relating to the improvement\u000d\u000a      of UK e-infrastructure\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2637487","Name":"Southampton"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    E-infrastructures are connected systems of computational technology and\u000d\u000a      resources that can facilitate distributed collaboration and computation. A\u000d\u000a      single e-infrastructure may involve the interoperation of high-performance\u000d\u000a      computing (HPC), cloud computing, mid-range computer systems, databases,\u000d\u000a      networks, image resources, instruments, software and people, which may all\u000d\u000a      be geographically dispersed across a nation or even across the world.\u000d\u000a    A research group in UCL's Department of Chemistry makes use of\u000d\u000a      e-infrastructures to access globally distributed computational resources,\u000d\u000a      including some of the world's largest supercomputers. In addition to\u000d\u000a      carrying out their own research using computational science, the group\u000d\u000a      also researches the use and development of computational resources. This\u000d\u000a      includes the development of tools that enable users to make use of\u000d\u000a      e-infrastructures more easily.\u000d\u000a    The unification of distributed computational resources within and between\u000d\u000a      e-infrastructures to solve challenging problems is known as grid\u000d\u000a      computing. It is conducted through the use of software &#8212; referred to as\u000d\u000a      middleware &#8212; which ties together the resources from the e-infrastructures\u000d\u000a      that constitute the grid; however, these middleware are usually complex\u000d\u000a      and difficult for end users to deploy, with the result that the full power\u000d\u000a      of computational grids is rarely realised. To tackle this problem and\u000d\u000a      encourage the integrated use of dispersed resources, the UCL group\u000d\u000a      developed the Application Hosting Environment (AHE), a lightweight (i.e.\u000d\u000a      simpler than other middleware tools) but powerful middleware tool that\u000d\u000a      hides much of the complexity of the grid from the user.\u000d\u000a    The first version of the AHE was developed in 2006 by the UCL group and\u000d\u000a      collaborators at the University of Manchester (McKeown and Pickles) [1].\u000d\u000a      The Manchester team helped to define the architecture; the implementation\u000d\u000a      and deployment were performed by UCL. Version 2.0, with enhanced features\u000d\u000a      and usability, was developed by the UCL group's Peter Coveney (Professor\u000d\u000a      2002-present) in 2009 [2]. The AHE consists of an ensemble of programs\u000d\u000a      written in Perl with command-line and Graphical User Interface client\u000d\u000a      tools, and is a form of \"non-invasive\" middleware, meaning that it is not\u000d\u000a      necessary for grid management teams to usually even be aware that the AHE\u000d\u000a      is interfacing with the lower-level middleware resident on the different\u000d\u000a      e-infrastructures. The AHE provides the user with a single interface to\u000d\u000a      all computing resources (e.g. different supercomputers) on which they have\u000d\u000a      accounts, enabling them to perform all manner of complex workflows on\u000d\u000a      these resources, from the most basic form of single job submission to\u000d\u000a      complex orchestrated sets of applications.\u000d\u000a    Previous research conducted by the UCL group included international\u000d\u000a      leading work on soft matter and computational chemistry, all using\u000d\u000a      high-performance computing, visualisation and computational steering to\u000d\u000a      make new discoveries in these domains of the chemical sciences. The AHE\u000d\u000a      was developed to facilitate these investigations, and has since been\u000d\u000a      exploited by the UCL group to conduct further research pertaining to the\u000d\u000a      chemical and biomedical sciences, which is leading to broad impact in\u000d\u000a      medical applications. For example, it enabled them to use grid computing\u000d\u000a      resources in both Europe and the US in 2008 to apply molecular dynamics\u000d\u000a      techniques to study the structure and stability of DNA intercalated in\u000d\u000a      layered double hydroxides (LDHs) [3]. Their simulations indicate that DNA\u000d\u000a      intercalated into LDHs is endowed with enhanced structural stability, a\u000d\u000a      finding which gives support to the origins-of-life theory that LDHs could\u000d\u000a      have acted as a protective environment for the first nucleic acids in\u000d\u000a      extreme environmental conditions. In another example, in 2008-10 the AHE\u000d\u000a      enabled the group to use combined UK and US computational resources to\u000d\u000a      estimate and rank the binding affinities of inhibitors with the wild type\u000d\u000a      and variants of HIV-1 protease, an attractive target for HIV\/AIDS therapy\u000d\u000a      [4, 5]. This research showed that molecular dynamics can achieve accurate\u000d\u000a      and rapid relative binding affinity ranking. Indeed, the concerted use of\u000d\u000a      computing resources and automated workflow enabled through the AHE make\u000d\u000a      turnaround of an array of binding affinities feasible within three days;\u000d\u000a      such rapidity is crucial for enhancing patient-specific clinical decision\u000d\u000a      support.\u000d\u000a    UCL owes its prominence in the field to the strength of its published\u000d\u000a      research, which has led to Coveney and others being appointed to\u000d\u000a      leadership positions relating to the use of computers in research,\u000d\u000a      including Coveney's chairmanship of the Collaborative Computational\u000d\u000a      Projects Steering Panel (since 2006) and membership of the UK High-End\u000d\u000a      Computing Strategy Committee (2006-2010). These pivotal positions as a\u000d\u000a      spokesperson for the community have enabled the impacts described in\u000d\u000a      section 4.\u000d\u000a    "},{"CaseStudyId":"33269","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1269750","Name":"India"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Royal Society"],"ImpactDetails":"\u000a    RS is used extensively and is valued as one of the analysis techniques of\u000a      choice by heritage scientists. It is a highly specific, non-destructive\u000a      analytical technique that can be applied in situ, and is highly\u000a      sensitive both to the structure and composition of the sample. Clark's\u000a      fundamental studies, collaboration activities and continuing work in this\u000a      field provided a vital contribution to the adoption and widespread use of\u000a      RS in heritage science and museums. His significant contribution has been\u000a      recognised by The Royal Society, who awarded him the 2008 Bakerian Lecture\u000a      for \"his pioneering work using the technique of RS as applied to artwork\u000a      and artefacts\". The society added:\u000a    \"The research is having a profound effect on the art, archaeology and\u000a      museum worlds; he [Clark] has shown that numerous profound and critical\u000a      issues which could not previously be addressed can now not only be\u000a      addressed but resolved. This has influenced major institutions such as the\u000a      Louvre, the Getty, the Metropolitan of New York and the British Museum\u000a      (among others) to install Raman microscope systems in recognition of their\u000a      striking effectiveness as analytical tools.\" [A] Additionally, his work\u000a      has been further recognised by a number of eminent scientific and\u000a      scholarly organisations (American Philosophical Society, the Royal Society\u000a      of Chemistry, the Fondation de la Maison de la Chimie and the Chemical\u000a      Heritage Foundation) in the last five years, each of which has\u000a      acknowledged Clark's contribution to bridging the science world with the\u000a      humanities and arts, and demonstrating chemistry's role in shaping society\u000a      [B].\u000a    The Indianapolis Museum of Art (IMA) and the Victoria &amp; Albert Museum\u000a      (V&amp;A) in London have both employed former members of the Clark group.\u000a      Their expertise in RS, developed whilst at UCL, benefits analysis of art\u000a      and historic artefacts at the institutions. The IMA established a\u000a      Conservation Science Laboratory in 2011 and one of the first instruments\u000a      purchased for the new facility was a Raman spectrometer [C], an instrument\u000a      that vastly expanded the museum's conservation and analytical\u000a      capabilities. Prior to this, only optical and polarised light spectroscopy\u000a      were available, techniques that are not only time consuming to use but are\u000a      of limited value in pigment identification. Around 50 objects are analysed\u000a      in the facility per year, and RS analysis is applied to all of them at\u000a      some point during their study [C]. In 2012, in partnership with Cincinnati\u000a      Art Museum, a combination of RS and X-ray fluorescence spectroscopy were\u000a      used to map the location of specific pigments and, following a computer\u000a      reconstruction, revealed the original appearance of the white flowers in\u000a      Vincent van Gogh's painting of 1890 Undergrowth with Two Figures;\u000a      this reconstruction is now displayed to the public [C].\u000a    In 2009, in collaboration with Clark, five miniatures at the V&amp;A were\u000a      unambiguously confirmed to be modern forgeries (five `Spanish Forger'\u000a      paintings), and the detection of metallic bismuth on an illuminated\u000a      Bourdichon miniature added to the knowledge of trade routes and pigment\u000a      availability in medieval Europe [D]. Subsequently, in 2010, having\u000a      benefited from access to the Raman facilities and collaborating with the\u000a      team at UCL, the V&amp;A purchased its own Raman spectrometer, a resource\u000a      that is used on a weekly basis [E]. Having a Raman spectrometer available\u000a      at the V&amp;A has made it possible to analyse non-destructively and in\u000a        situ museum objects that were, until recently, off-limits due to\u000a      restrictions to their sampling. Furthermore, where inorganic pigments,\u000a      minerals and gemstones are concerned, analyses now take a few seconds or\u000a      minutes to complete, bringing about considerable savings in terms of staff\u000a      time and increasing productivity. In all, around 150 objects are now\u000a      studied each year using the technique at the V&amp;A, with analysis\u000a      results not only enabling dating and authentication of collections, but\u000a      also informing curators as to whether objects are appropriate for proposed\u000a      exhibitions and impacting upon their conservation [E]. Utilising their own\u000a      system in 2012, V&amp;A staff were able to investigate distinct\u000a      \"fingerprints\" of pigments for different artists, which led to changes in\u000a      the attributions of three portrait miniatures: the original Tudor\u000a      portraits of \"Mr and Mrs Croker\", which have suffered from troubled\u000a      attribution histories, were attributed to Nicholas Hilliard or his\u000a      workshop; and a third portrait miniature (miniature 630-1882) was\u000a      reattributed from Isaac Oliver to Hilliard or his workshop [F].\u000a    UK libraries (Bodleian Library and BL) have also benefited from\u000a      collaborating with the UCL group and implementing RS analysis. By using RS\u000a      to ascertain and understand the chemical behaviour of specific pigments,\u000a      conservators are now able to control the display and storage schedule to\u000a      reduce degradation of objects, understand and update conservation records,\u000a      add support to conservation strategies, and also provide instructions to\u000a      readers about certain items for which there may be a health and safety\u000a      impact; for example, the requirement to wear gloves where poisonous\u000a      arsenic-containing pigments are identified (especially in the case of\u000a      Indian manuscripts). Furthermore, the collaboration between UCL and the BL\u000a      (1996 to 2008) was highlighted in the House of Lords Science and\u000a      Technology Committee Science and Heritage report as an example of how\u000a      academics and curators can work together to develop academic agendas\u000a      whilst answering both curatorial and conservation questions. This same\u000a      report concluded that collaboration between university and museum-based\u000a      scientists is crucial to heritage science. Subsequently, the Science and\u000a      Heritage Programme (established to take forward the recommendations from\u000a      these reports) has promoted further collaboration of this nature through\u000a      research clusters and networking funding, with examples reported in the\u000a      most recent review (2012) [G].\u000a    The pigment database developed by UCL is also valued by researchers and\u000a      is considered significant to the conservation science field because it was\u000a      one of the first online reference spectra collections for art materials.\u000a      The Museum of Fine Arts in Boston (MFA) printed out the set of UCL Raman\u000a      spectra as a reference when they purchased their Raman spectrometer in\u000a      2008, and still regularly consult the printouts today [H]. The images of\u000a      67 of the Raman reference spectra generated by UCL, along with links to\u000a      the UCL Raman Spectroscopic Library website, are included in the\u000a      Conservation &amp; Art Materials Encyclopedia Online (CAMEO) database that\u000a      was developed by the MFA &#8212; a database that is regularly accessed\u000a      worldwide. The Schorr Family Associate Research Scientist at the MFA said\u000a      in May 2013: \"in the last year, 80,000 unique visitors provided over\u000a      250,000 page views. The hits came from 165 countries. A random check of\u000a      several pigment pages that include UCL reference spectra gave the\u000a      following hit results over the past year: berberine (14), lazurite (31),\u000a      malachite (298), orpiment (93), vermilion (219).\" [H]\u000a    The UCL research has also had an impact on the sale of Raman\u000a      spectrometers by Renishaw, a world leader in the manufacture and supply of\u000a      these instruments. The company's International Sales Manager and\u000a      Applications Specialist said: \"From a commercial aspect the importance of\u000a      this field of interest [the use of RS in heritage work] has led to a\u000a      significant number of sales that one could argue would not have been\u000a      possible without Professor Clark's fundamental studies\". Renishaw was the\u000a      first supplier of a high-end bench Raman microscope and today enjoys a\u000a      dominant position in the marketplace. It sells instruments worldwide [text\u000a      removed for publication] [I].\u000a    ","ImpactSummary":"\u000a    The Department of Chemistry at UCL has pioneered the use of Raman\u000a      spectroscopy (RS) for the identification of pigments in and the in\u000a        situ examination of objects that are of artistic, cultural, or\u000a      historical importance. Until recently this was a relatively unknown and\u000a      rarely used technique in heritage science. RS is now used regularly by\u000a      conservators worldwide and has become an important analysis tool in\u000a      museums and libraries including the Victoria &amp; Albert Museum, the\u000a      Indianapolis Museum of Art and the Museum of Fine Arts in Boston.\u000a      Collaboration between the British Library and UCL was highlighted by the\u000a      House of Lords Science and Technology Committee, helping to promote\u000a      further collaboration between universities and museums. The use of RS in\u000a      heritage science has also benefited manufacturers of RS equipment, and has\u000a      led to enhanced understanding of the histories and care requirements of a\u000a      wide range of artefacts.\u000a    ","ImpactType":"Cultural","Institution":"\u000a    University College London (UCL)\u000a    ","Institutions":[{"AlternativeName":"University College London","InstitutionName":"University College London","PeerGroup":"A","Region":"London","UKPRN":10007784}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"4508722","Name":"Cincinnati"},{"GeoNamesId":"4259418","Name":"Indianapolis"},{"GeoNamesId":"4930956","Name":"Boston"},{"GeoNamesId":"5128638","Name":"New York"}],"References":"\u000a    \u000a[1] Synthesis, structural characterisation and Raman spectroscopy of the\u000a      inorganic pigments lead tin yellow types I and II and lead antimonate\u000a      yellow: their identification on medieval paintings and manuscripts, R.J.H.\u000a      Clark, L. Cridland, B.M. Kariuki, K.D.M. Harris and R. Withnall, J.\u000a        Chem. Soc. Dalton Trans., 2577-2582 (1995) doi:10\/chthzg\u000a    \u000a\u000a[2] Library of FT-Raman spectra of pigments, minerals, pigment media and\u000a      varnishes, and supplement to existing library of Raman spectra of pigments\u000a      with visible excitation, L. Burgio and R.J.H. Clark, Spectrochim. Acta\u000a        A, 57(7), 1491-1521 (2001) doi:10\/dfc4n2\u000a    \u000a\u000a[3] Raman spectroscopy as a means for the identification of plattnerite\u000a      (PbO2), of lead pigments and of their degradation products, L.\u000a      Burgio, R.J.H. Clark and S. Firth, Analyst, 126, 222-227 (2001)\u000a      doi:10\/c52773\u000a    \u000a\u000a[4] The Lindisfarne Gospels and two other 8th century Anglo-Saxon\/Insular\u000a      manuscripts: pigment identification by Raman microscopy, K.L. Brown and\u000a      R.J.H. Clark, J. Raman Spectrosc., 35(1), 4-12 (2004) doi:10\/d4dmbq\u000a    \u000a\u000a[5] Raman spectroscopic analysis of selected astronomical and\u000a      cartographic folios from the early 13th century Islamic `Book of\u000a      Curiosities of the Sciences and Marvels for the Eyes', T.D. Chaplin,\u000a      R.J.H. Clark, A. McKay and S. Pugh, J. Raman Spectrosc., 37(8),\u000a      865-877 (2006) doi:10\/fqz458\u000a    \u000a\u000a[6] Pigment identification by spectroscopic means: evidence consistent\u000a      with the attribution of the Painting `Young Woman Seated at a Virginal' to\u000a      Vermeer, L. Burgio, R.J.H. Clark, L. Sheldon and G.D. Smith, Anal.\u000a        Chem., 77, 1261-1267 (2005) doi:10\/b3vt6j\u000a    \u000aReferences [1], [4] and [6] best indicate the quality of the\u000a        underpinning research.\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"11","Level2":"9","Subject":"Neurosciences"},{"Level1":"2","Level2":"99","Subject":"Other Physical Sciences"}],"Sources":"\u000a    [A] Supporting statement from The Royal Society &#8212; corroborates the impact\u000a      of the UCL research on the art, archaeology and museum worlds, and that\u000a      Clark was awarded the Bakerian Lecture for this contribution. Available on\u000a      request.\u000a    [B] Corroboration of the awards won by Clark 2008-13 can be found online:\u000a      http:\/\/bit.ly\/17uSG4h.\u000a    [C] A supporting statement from Senior Conservation Scientist at the IMA\u000a      is available on request &#8212; corroborates the impact that RS has made at the\u000a      IMA in the last 5 years. For further corroboration of the impact on the\u000a      van Gogh painting work see the Artdaily.org article: http:\/\/bit.ly\/17qISux.\u000a    [D] Information relating to the `Spanish Forger' paintings and the\u000a      Bourdichon Nativity miniature is available on the V&amp;A website at http:\/\/bit.ly\/1cpil2r\u000a      and http:\/\/bit.ly\/HqQ0vb respectively\u000a      &#8212; corroborates that the paintings are now labelled as forgeries and that\u000a      RS analysis (along with other techniques) changed knowledge of trade\u000a      routes and pigment availability in medieval Europe.\u000a    [E] The Senior Object Analysis Scientist at the V&amp;A can be contacted\u000a      to corroborate the application of RS by the V&amp;A and its impact on the\u000a      museum. Contact details are provided separately.\u000a    [F] Comparison of English portrait miniatures using Raman microscopy and\u000a      other techniques, L. Burgio, A. Cesaratto and A. Derbyshire, J. Raman\u000a        Spectrosc., 43, 1713-1721 (2012) doi:10\/ppv\u000a      &#8212; corroborates the use of RS at the V&amp;A in the attribution of three\u000a      portrait miniatures to Hilliard.\u000a    [G] House of Lords Science and Technology Committee Reports on Science\u000a      and Heritage available online: http:\/\/bit.ly\/1adiBtS\u000a      and http:\/\/bit.ly\/1itnXpT &#8212;\u000a      corroborates that the BL collaboration was highlighted by the committee\u000a      and that the earlier report led to the establishment of the Science and\u000a      Heritage Programme, which has promoted further collaboration of this\u000a      nature.\u000a    [H] Supporting statement from Schorr Family Associate Research Scientist\u000a      at MFA &#8212; corroborates the use of the pigment database at MFA and through\u000a      the CAMEO database. Available on request.\u000a    [I] Supporting statement from the International Sales Manager and\u000a      Applications Specialist at Renishaw &#8212; corroborates the impact that the UCL\u000a      research has had on sales of Renishaw Raman spectrometers. Available on\u000a      request.\u000a    ","Title":"\u000a    Raman spectroscopy benefiting the authentication, conservation, display\u000a      and handling of historic objects\u000a    ","UKLocation":[{"GeoNamesId":"2643743","Name":"London"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Using his extensive experience of transition metal chemistry, UCL\u000a      Department of Chemistry researcher Robin Clark (Ramsay Professor\u000a      1989-2008; Emeritus Ramsay Professor 2008-present) realised that RS could\u000a      be used to investigate artists' materials and their degradation products\u000a      in a novel way. Therefore, he undertook research to enable the full\u000a      realisation of the potential of RS in the non-destructive technical\u000a      examination of art objects. The research carried out at UCL has provided a\u000a      major contribution to this field since 1993, demonstrating the sensitivity\u000a      and precision of the technique in identifying pigments and other\u000a      materials, both rapidly and without ambiguity.\u000a    RS is a non-destructive technique, making it ideal for the analysis of\u000a      organic and inorganic pigments in artworks and artefacts on which\u000a      destructive or sampling techniques &#8212; such as powder X-ray diffraction and\u000a      scanning electron microscopy &#8212; may not be permitted. Furthermore, since\u000a      each distinct material gives rise to a unique Raman spectrum, the\u000a      technique can be used to identify unambiguously which pigments are\u000a      present.\u000a    One of the Clark group's important contributions to the emerging field\u000a      was a 1995 study in which they showed that RS is an ideal technique for\u000a      distinguishing between lead-based yellow pigments used in antiquity. When\u000a      previous conventional non-destructive spectroscopic analyses were used,\u000a      these pigments &#8212; the two types of lead tin yellow, Pb2SnO4\u000a      and PbSn1-xSixO3, and the\u000a      similarly coloured and structured lead antimonate, Pb2Sb2O7\u000a      &#8212; were difficult to identify unambiguously in the presence of other\u000a      compounds commonly found on artefacts, due to their similar, broad\u000a      electronic spectra. The Clark group demonstrated that the pigments could,\u000a      however, be readily distinguished in situ using RS by comparing\u000a      the Raman spectra of laboratory-synthesised lead tin oxides and typical\u000a      contemporary primer and binding agents with those obtained from medieval\u000a      paintings and manuscripts [1].\u000a    During the early work, Clark identified the lack of reference databases\u000a      for the analysis of pigments using RS and proceeded to collect the first\u000a      set of pigment reference spectra at several different excitation\u000a      wavelengths in 1995. This was immediately popular, and both it and an\u000a      updated database published in 2001 are still extensively used by Raman\u000a      scientists all over the world working at the arts-science interface. The\u000a      2001 work [2] also introduced Fourier-Transform (FT) Raman as another\u000a      option for the analysis of organic materials, particularly common binders\u000a      and varnishes, which either show little response to conventional Raman\u000a      excitation or fluoresce.\u000a    In 2001, the Clark group determined under which conditions of laser\u000a      wavelength, power and irradiation time PbO2 and common lead\u000a      pigments Pb3O4, PbO and 2PbCO3&#8226;Pb(OH)2\u000a      degrade, and through which pathways [3]. Their results revealed how to\u000a      correctly identify lead pigments originally used on an artwork, and how to\u000a      recognise when unwanted degradation is occurring during RS analysis. This\u000a      work also validated previous studies on the identification of lead\u000a      pigments by RS, and further confirmed that RS could be used in situ\u000a      on such artefacts without causing degradation, allowing other groups to\u000a      conduct RS studies on lead pigments with confidence.\u000a    Contributions to the field also included many studies conducted jointly\u000a      with cultural heritage institutions [4, 5, 6]. In collaboration with the\u000a      British Library (BL), the Lindisfarne Gospels (from AD 715-721) were\u000a      analysed using RS as, although well studied from a palaeographical\u000a      standpoint, much less was known about the materials used on the\u000a      manuscripts and the methods used in their construction. The details\u000a      regarding the use of pigments in such works were previously identifb01ed\u000a      purely by a visual inspection and had become accepted as fact. As such,\u000a      important information ascribing to date or point of origin for the greater\u000a      understanding in an historical context remained undiscovered. The analysis\u000a      performed on the Lindisfarne Gospels revealed the presence of pigments\u000a      including calcite CaCO3, indigo C16H10N2O2,\u000a      orpiment As2S3, vergaut (indigo mixed with\u000a      orpiment), verdigris (uncertain variant), red lead Pb3O4,\u000a      white lead 2PbCO3&#8226;Pb(OH)2 and gold, confirming that\u000a      most of the pigments that were considered to be there were indeed present\u000a      [4]. Importantly, however, the blue pigment lazurite Na8[Al6Si6O24]Sn\u000a      was not found on the manuscript; instead, all the blue colouring in the\u000a      gospels came from indigo (which was readily available in England at the\u000a      time). Earlier studies of the gospels had implied that there was a trade\u000a      route in the 8th century between Afghanistan &#8212; the location of\u000a      the only source of lazurite at the time &#8212; and Northumberland; in fact, the\u000a      UCL work found the earliest use of lazurite on an English manuscript to be\u000a      more than two centuries later [4]. Interesting studies of astronomical and\u000a      cartographic Islamic folios held at the Bodleian Library, Oxford, were\u000a      also made [5]. In a further study, the identification of key pigments on\u000a      \"Young Woman Seated on a Virginal\" supported work from the History of Art\u000a      Department at UCL, by providing persuasive evidence consistent with\u000a      reattribution of this painting to Vermeer [6]. The research led to the\u000a      sale of this painting by Sotheby's for &#163;16.2 million.\u000a    "},{"CaseStudyId":"34373","Continent":[],"Country":[],"Funders":["Wellcome Trust"],"ImpactDetails":"\u000d\u000a    The Abraham solvation model is a well-known and well-used equation for\u000d\u000a      the description of relationships between structure and both\u000d\u000a      physicochemical and biochemical properties, which can be applied to\u000d\u000a      biological, chromatographic and environmental partition systems. As such,\u000d\u000a      Abraham descriptors and the Abraham solvation parameter approach are\u000d\u000a      widely used in the chemical industries, where they provide a rapid and\u000d\u000a      efficient way to compare and characterise partition systems and solutes,\u000d\u000a      and allow the determination of unknown properties of solutes without\u000d\u000a      conducting an actual experiment or even synthesising the molecule. In the\u000d\u000a      pharmaceutical industry, the model is used for predicting the\u000d\u000a      pharmacokinetics (absorption, distribution, metabolism, excretion, and\u000d\u000a      toxicity; or ADMET) of chemical agents, which is vital in determining\u000d\u000a      their performance and pharmacological activity as drugs. Meanwhile,\u000d\u000a      agri-businesses use the method to create bioavailability profiles for\u000d\u000a      agrochemicals, which informs not only on efficacy but also the fate of the\u000d\u000a      chemicals in terms of environmental risk assessment.\u000d\u000a    In recent years, commercial, open source and \"in-house\" computational\u000d\u000a      modelling software has been developed and made available to users\u000d\u000a      worldwide based upon the Abraham solvation model, in order to provide a\u000d\u000a      framework with which to analyse, rationalise and quantify problems such as\u000d\u000a      solubility and partitioning. For example, the Absolv software is used by\u000d\u000a      chemists to calculate various solvation-associated properties from\u000d\u000a      equations (LFERs) involving transfer from the gas phase to a condensed\u000d\u000a      phase or between different condensed phases, and to carry out\u000d\u000a      structure-based prediction of the solvation parameters required for those\u000d\u000a      calculations [A]. Absolv was first commercialised by Sirius, then later by\u000d\u000a      Pharma Algorithms, who in 2009 partnered with ACD\/Labs; in 2011, the\u000d\u000a      latter launched the \"Percepta Platform\", which includes the Absolv\u000d\u000a      prediction module. From a commercial perspective, Absolv has been, and\u000d\u000a      continues to be, a very important component in ADMET and physicochemical\u000d\u000a      property prediction. As such, Percepta is recognised as a core component\u000d\u000a      of the drug discovery toolkit and is highly valued by research\u000d\u000a      institutions and industrial groups worldwide [A]. In many drug discovery\u000d\u000a      teams at multinational pharmaceutical companies &#8212; [text removed for\u000d\u000a      publication] &#8212; the use of such software, and thus the Abraham model, has\u000d\u000a      become a fundamental part of the way that they understand and optimise\u000d\u000a      drug candidate solubility and partitioning. It has also become fundamental\u000d\u000a      to how they establish vital parameters for determining whether a candidate\u000d\u000a      can be formulated and delivered in sufficient quantities to be effective\u000d\u000a      as a drug. The alternative approach is simply calculating the number of\u000d\u000a      hydrogen-bond donor and acceptor groups and the size of the molecules,\u000d\u000a      which often gives inferior information to the Abraham approach. The useful\u000d\u000a      information provided by the Abraham approach means that scientists need to\u000d\u000a      make fewer compounds before a candidate is selected and do not often make\u000d\u000a      the wrong compounds [text removed for publication].\u000d\u000a    [text removed for publication]\u000d\u000a    In 2010, a team from Pfizer developed an in silico model of rat\u000d\u000a      biliary excretion &#8212; an important property in drug discovery &#8212; with the\u000d\u000a      help of the Abraham approach [D]. When Sanofi sought an improvement in the\u000d\u000a      solubility of the main compound used in an oncology program in 2008,\u000d\u000a      commercial software proved unsatisfactory at predicting more soluble\u000d\u000a      compounds; however, the team was able to build their own local models\u000d\u000a      using Abraham descriptors. The model built at pH = 4 was a success,\u000d\u000a      achieving an 82% correct prediction rate of the solubility [text removed\u000d\u000a      for publication] [E]. The results obtained from the work in these and\u000d\u000a      other examples have made a significant contribution to internal research\u000d\u000a      at pharmaceutical companies and have helped to streamline discovery\u000d\u000a      efforts over the last five years.\u000d\u000a    Outside of the pharmaceutical industry, physical chemists supporting\u000d\u000a      Syngenta, one of the world's leading bioscience companies, measure a\u000d\u000a      diverse range of organic\/water partition coefficients to enable the\u000d\u000a      experimental determination of Abraham descriptors and prediction of\u000d\u000a      difficult-to-measure properties such as water\/air, soil\/water and\u000d\u000a      plant-related partitioning processes from LFERs. A significant benefit of\u000d\u000a      this work to Syngenta is that it offers its scientists an alternative way\u000d\u000a      of thinking about and addressing chemical design issues related to\u000d\u000a      expression of activity and environmental fate for agrochemicals, beyond\u000d\u000a      conventional physical chemical properties [F].\u000d\u000a    [text removed for publication]\u000d\u000a    The RP-HPLC methods for determining lipophilicity expressed as CHI and ElogP\/ElogD,\u000d\u000a      which were co-developed at UCL, are now in routine use within drug\u000d\u000a      discovery at [text removed for publication], Pfizer, Merck and other drug\u000d\u000a      discovery companies. These techniques allow scientists to measure more\u000d\u000a      quickly and accurately the lipophilicities of potential drug candidates,\u000d\u000a      which helps them assess whether the candidates would be suitable for use in\u000a        vivo. The high-throughput HPLC methods are also useful when\u000d\u000a      scientists wish to modify the lipophilicity (alongside other\u000d\u000a      physicochemical properties) of drug candidates systematically in order to\u000d\u000a      optimise a series and find the most promising compound to progress to\u000d\u000a      further testing. Most uses of the methods are confidential; however, there\u000d\u000a      are a few published examples that demonstrate how this method has helped\u000d\u000a      drug discovery teams to optimise series of compounds. These include novel\u000d\u000a      GPR119 agonists (for a potential treatment for type 2 diabetes) in 2011\u000d\u000a      and ghrelin receptor agonists (for the relief of symptoms of gastroparesis\u000d\u000a      in both type 1 and type 2 diabetes) in 2012 by drug discovery teams at\u000d\u000a      Pfizer [H]; and novel cannabinoid CB2 receptor agonists and novel TRPV1\u000d\u000a      antagonists (both investigated as potential treatments of pain) in 2011 by\u000d\u000a      teams at Merck and MSD respectively [I].\u000d\u000a    Additionally, the biomimetic HPLC systems are also now in use at GSK\u000d\u000a      [text removed for publication] and other companies. They provide\u000d\u000a      scientists with fast and automated methods for modelling the membrane\u000d\u000a      interaction and protein binding of drug candidates. Again, most uses are\u000d\u000a      confidential; however, a few examples of impacts on drug discovery\u000d\u000a      programs have been published. These include the use of the CHI IAM and HSA\u000d\u000a      biomimetic systems, as well as CHI, by a GSK team in 2012 in a successful\u000d\u000a      attempt to find novel antimicrobially inactive anti-inflammatory\u000d\u000a      macrolides; and the use of the two biomimetic systems by a Novartis team\u000d\u000a      in 2011 to confirm the superior physicochemical properties of the useful\u000d\u000a      2-amino-5-tert-butylpyridine fragment compared to the currently\u000d\u000a      used fragment [J].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    The Abraham solvation parameter approach developed at UCL has become\u000d\u000a      integral to the work carried out by drug discovery teams at [text removed\u000d\u000a      for publication] and other major pharmaceutical companies, as well as\u000d\u000a      research and development groups at international chemical companies\u000d\u000a      including Syngenta and [text removed for publication]. It enables chemists\u000d\u000a      to predict physicochemical and biochemical properties of chemicals,\u000d\u000a      including drugs and agrochemicals, rapidly and efficiently, without the\u000d\u000a      need to conduct time-consuming experiments. The method helps drug\u000d\u000a      discovery teams to identify and optimise the most promising compounds, and\u000d\u000a      often results in fewer compounds being made before a candidate is\u000d\u000a      selected, saving time and resources. The approach has been integrated into\u000d\u000a      software used for drug discovery [text removed for publication].\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    University College London (UCL)\u000d\u000a    ","Institutions":[{"AlternativeName":"University College London","InstitutionName":"University College London","PeerGroup":"A","Region":"London","UKPRN":10007784}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    \u000a[1] Estimation of molecular linear free energy relation descriptors using\u000d\u000a      a group contribution approach, J.A. Platts, D. Butina, M.H. Abraham and A.\u000d\u000a      Hersey, J. Chem. Inf. Comput. Sci., 39, 835-845 (1999) doi:10.1021\/ci980339t\u000d\u000a    \u000a\u000a[2] Determination of solvation descriptors for ionic species: Hydrogen\u000d\u000a      bond acidity and basicity, M.H. Abraham and Y.H. Zhao, J. Org. Chem.,\u000d\u000a      69, 4677-4685 (2004) doi:10.1021\/jo049766y\u000d\u000a    \u000a\u000a[3] Evaluation of human intestinal absorption data and subsequent\u000d\u000a      derivation of a quantitative structure&#8212;activity relationship (QSAR) with\u000d\u000a      the Abraham descriptors, Y.H. Zhao, J. Le, M.H. Abraham, A. Hersey, P.J.\u000d\u000a      Eddershaw, C.N. Luscombe, D. Boutina, G. Beck, B. Sherborne, I. Cooper and\u000d\u000a      J.A. Platts, J. Pharm. Sci., 90, 749-784 (2001) doi:10.1002\/jps.1031\u000d\u000a    \u000a\u000a[4] Rapid gradient RP-HPLC method for lipophilicity determination: A\u000d\u000a      solvation equation based comparison with isocratic methods, C. My Du, K.\u000d\u000a      Valko, C. Bevan, D. Reynolds and M.H. Abraham, Anal. Chem., 70,\u000d\u000a      4228-4234 (1998) doi:10.1021\/ac980435t\u000d\u000a    \u000a\u000a[5] ElogPoct: A tool for lipophilicity determination in drug\u000d\u000a      discovery, F. Lombardo, M.Y. Shalaeva, K.A. Tupper, F. Gao and M.H.\u000d\u000a      Abraham, J. Med. Chem., 43, 2922-2928 (2000) doi:10\/cfqkpq\u000d\u000a    \u000a\u000a[6] Rapid-gradient HPLC method for measuring drug interactions with\u000d\u000a      immobilized artificial membrane: Comparison with other lipophilicity\u000d\u000a      measures, K. Valko, C. My Du, C.D. Bevan, D.P. Reynolds and M.H. Abraham,\u000d\u000a      J. Pharm. Sci., 89, 1085-1096 (2000) &#8212; PDF available on request\u000d\u000a    \u000a\u000a[7] Determination of sets of solute descriptors from chromatographic\u000d\u000a      measurements, M.H. Abraham, A. Ibrahim and A.M. Zissimos, J.\u000d\u000a        Chromatogr. A, 1037, 29-47 (2004) doi:10\/bzn5hz\u000d\u000a    \u000aReferences [1], [2] and [3] best indicate the quality of the\u000d\u000a        underpinning research.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"7","Subject":"Theoretical and Computational Chemistry"},{"Level1":"6","Level2":"1","Subject":"Biochemistry and Cell Biology"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"}],"Sources":"\u000d\u000a    [A] Supporting statement from Academic Account Manager at ACD\/Labs, and a\u000d\u000a      particular example cited on the ACD\/Labs website:\u000d\u000a      http:\/\/www.acdlabs.com\/download\/docs\/poster_absolv_syngenta.pdf\u000d\u000a      &#8212; corroborates the use and value of the Absolv software. The statement is\u000d\u000a      available on request.\u000d\u000a    [text removed for publication]\u000d\u000a    [D] Structure-pharmacokinetic relationship of in vivo rat biliary\u000d\u000a      excretion, Y. Chen et al., Biopharm. Drug Dispos., 31, 82-90\u000d\u000a      (2010) doi:10\/bppvcq &#8212; corroborates\u000d\u000a      the use of the Abraham approach in the development of the in silico\u000d\u000a      model at Pfizer.\u000d\u000a    [E] Supporting statement from a scientist in the Molecular Modeling Team,\u000d\u000a      Sanofi &#8212; corroborates that Sanofi built a successful local model using\u000d\u000a      Abraham descriptors. Available on request.\u000d\u000a    [F] Supporting statement from former (left in August 2012) Senior\u000d\u000a      Physical Chemistry Consultant at Syngenta &#8212; corroborates the impact of the\u000d\u000a      Abraham approach on agrochemical research at Syngenta. Available on\u000d\u000a      request.\u000d\u000a    [text removed for publication]\u000d\u000a    [H] V. Mascitti et al., Bioorg. Med. Chem. Lett., 21, 1306-1309\u000d\u000a      (2011) doi:10\/b4ss3x; and D.W. Kung et\u000d\u000a      al., Bioorg. Med. Chem. Lett., 22, 4281-4287 (2012) doi:10\/pvd\u000d\u000a      &#8212; corroborate Pfizer's use of the ElogP\/ElogD method to optimise series of\u000d\u000a      compounds.\u000d\u000a    [I] M. van der Stelt et al., J. Med. Chem., 54, 7350-7362 (2011)\u000d\u000a      doi:10\/ckp8z7; and P. Ratcliffe et\u000d\u000a      al., Bioorg. Med. Chem. Lett., 21, 2559-2563 (2011) doi:10\/dgzvkj\u000d\u000a      &#8212; corroborate Merck and MSD's use of the ElogP\/ElogD method to optimise\u000d\u000a      series of compounds.\u000d\u000a    [J] M. Bosnar et al., J. Med. Chem., 55, 6111-6123 (2012) doi:10\/pvg; and C.G. Thomson et al., Bioorg.\u000d\u000a        Med. Chem. Lett., 21, 4281-4283 (2012) doi:10\/fwts42\u000d\u000a      &#8212; corroborate GSK and Novartis' use of CHI IAM and HSA biomimetic systems.\u000d\u000a    ","Title":"\u000d\u000a    Abraham solvation parameter approach benefiting the chemical industries\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    Solvation processes have been a subject of interest for many decades,\u000d\u000a      because dramatic changes in reaction rates can be observed in different\u000d\u000a      solvents. The Abraham solvation parameter approach uses linear free energy\u000d\u000a      relationships (LFERs) to describe solvent-solute interactions. It revolves\u000d\u000a      around a set of Abraham descriptors, which characterise the solute and are\u000d\u000a      part of the LFERs. The approach enables systems and solutes to be\u000d\u000a      characterised using multiple linear regression analysis, and in turn\u000d\u000a      predicts solvation properties (such as logP) without the need for an\u000d\u000a      actual experiment. The Abraham approach was first developed within the\u000d\u000a      Department of Chemistry at UCL before the REF research period; however,\u000d\u000a      its application by and subsequent impact on the pharmaceutical,\u000d\u000a      agri-chemical and chemical industries in recent years are underpinned by\u000d\u000a      the department's establishment of the approach and continued work in this\u000d\u000a      area since 1993.\u000d\u000a    Since 1993, the Abraham group at UCL has published more than 300 papers\u000d\u000a      in peer-reviewed journals, detailing the underlying research, application\u000d\u000a      of the method and numerous enhancements to the approach. Key findings\u000d\u000a      documented in these publications include a method (developed together with\u000d\u000a      the Science Development Group at Glaxo Wellcome R&amp;D) for calculating\u000d\u000a      Abraham descriptors from molecular fragment structures [1], which allows\u000d\u000a      drug discovery teams to rapidly assess the solvation properties of drug\u000d\u000a      candidates that have not yet been synthesised; an extension of the Abraham\u000d\u000a      approach to allow for ionic solutes, since many drug candidate molecules\u000d\u000a      are ionised [2]; and the determination (in work conducted with researchers\u000d\u000a      from Glaxo Wellcome, Roche Products and Cardiff University) of solvation\u000d\u000a      equations (LFERs) that characterise important biological processes for\u000d\u000a      drug delivery, such as skin permeation, blood-brain distribution, and\u000d\u000a      intestinal absorption [3], allowing drug discovery teams to predict these\u000d\u000a      properties for drug candidates rapidly.\u000d\u000a    In the late 1990s, this UCL group also collaborated with teams at Glaxo\u000d\u000a      Wellcome Medicines Research Centre [4] and Pfizer's Central Research\u000d\u000a      Division [5] to develop high-throughput reversed-phase high-performance\u000d\u000a      liquid chromatography (RP-HPLC) methods for determining lipophilicity\u000d\u000a      (expressed as the chromatographic hydrophobicity index, CHI, and\u000d\u000a      ElogP\/ElogD respectively), an important property in drug discovery. These\u000d\u000a      methods were developed to replace the time-consuming traditional\u000d\u000a      determination of lipophilicity from a measurement of the partition of\u000d\u000a      molecules in the octanol-water system. Advantages of these newer methods\u000d\u000a      include increased accuracy and rapid measurements. The Abraham solvation\u000d\u000a      parameter approach was crucial in validating and refining these faster\u000d\u000a      methods, and was used to confirm that both CHI and ElogP encode the same\u000d\u000a      information as other measures of lipophilicity. Further work, in the early\u000d\u000a      2000s &#8212; again in collaboration with Glaxo Wellcome &#8212; led to the\u000d\u000a      development of biomimetic HPLC systems that measure human serum albumin\u000d\u000a      binding (HSA) and immobilised artificial membrane interaction (CHI IAM)\u000d\u000a      [6], enabling chemists to easily assess a drug candidate's protein binding\u000d\u000a      and membrane affinity &#8212; both important properties for drug discovery.\u000d\u000a    In 2004, the Abraham group concluded that for processes that entail\u000d\u000a      transfer of a solute from one phase to another, no more than fb01ve or six\u000d\u000a      solute descriptors are required to provide a reasonably accurate analysis\u000d\u000a      of a given process [7]. This work has been cited over 300 times since,\u000d\u000a      contributing to the development of ab initio and empirical\u000d\u000a      software for predicting solvation energies and profiling of chemicals used\u000d\u000a      for a number of applications. In summary, this UCL research group and its\u000d\u000a      collaborators have made significant progress in defining transport-related\u000d\u000a      or dependent processes for a diverse set of chemicals, utilising only a\u000d\u000a      few descriptors.\u000d\u000a    Key UCL researchers: Michael Abraham (Honorary Reader 1994-2002;\u000d\u000a      Honorary Professor 2002-present) and the following Postdoctoral Research\u000d\u000a      Fellows: Chau My Du (1996-1998), James Platts (1997-1999), Andreas\u000d\u000a      Zissimos (2000-2003) and Yuan Zhao (1999-2001 and 2003-2006).\u000d\u000a    "},{"CaseStudyId":"34975","Continent":[],"Country":[],"Funders":["Science and Technology Facilities Council","Council for the Central Laboratory of the Research Councils","Royal Society"],"ImpactDetails":"\u000a    Catalytic processes underpin production in the chemicals and\u000a      pharmaceuticals industries; as such, the value of the goods and products\u000a      manufactured by catalysts is estimated at $15 trillion worldwide1.\u000a      It is well recognised that improvements in the efficiency of catalytic\u000a      processes &#8212; resulting in added value of the products manufactured and\u000a      minimisation of environmental impact &#8212; require a science-led approach. The\u000a      UCL\/RI team has made significant contributions to development processes\u000a      and products globally, fostered through deep and long-standing\u000a      interactions with UK and international industry. These relationships have\u000a      enabled the translation of the pioneered techniques and their subsequent\u000a      application in product and process optimisation.\u000a    Contribution to commercial software development: The translation\u000a      to industry of QM\/MM techniques has been realised through commercial\u000a      software development. Professor Catlow was one of the lead scientific\u000a      advisors to the Catalysis and Sorption Consortium and subsequently,\u000a      between 2008 and 2011, advisor to the Nanotechnology Consortium. This\u000a      latter consortium, in collaboration with the STFC, developed a QM\/MM\u000a      module (QMERA) for Accelrys' Materials Studio&#174; modelling and simulation\u000a      environment software [A]. Materials Studio enables investigators to relate\u000a      product performance with material properties and behaviour at the\u000a      molecular, atomic, and meso scales. QMERA was first included in Materials\u000a      Studio 4.3 in 2008 [A]. In 2011, Accelrys released a new version of this\u000a      software &#8212; Materials Studio&#174; 6.0 [B] &#8212; that included a significantly\u000a      enhanced QMERA module [A]. [text removed for publication]\u000a    Knowledge transfer of techniques and highly skilled specialists:\u000a      At Johnson Matthey (JM), adoption of new techniques developed by UCL\/RI\u000a      and integration of UCL\/RI-trained scientists has shortened research\u000a        projects, aided understanding and improved the company's competitiveness\u000a      [C]. Transfer of synchrotron radiation-based techniques to industry has\u000a      been facilitated through Royal Society industrial fellowships, such as the\u000a      secondment of Professor Sankar from UCL to JM between 2007 and 2011.\u000a      During this period, Sankar shared his significant experimental know-how of\u000a      diffraction and synchrotron radiation (SR) techniques with JM research and\u000a      development (R&amp;D), enabling the implementation of these techniques\u000a      across a range of catalysts, from zeolite-based systems to supported oxide\u000a      materials. The introduction of SR techniques at JM has been invaluable\u000a        to the company's catalytic technology and materials processing [C].\u000a      Furthermore, a range of in situ methodologies has been designed\u000a      and developed for JM, which has helped make its analytical science and\u000a      technology highly competitive with other similar chemical companies\u000a      around the world [text removed for publication] [C]. The relationship with\u000a      Sankar has continued through a consultancy arrangement. Alongside this, JM\u000a      has recruited seven UCL\/RI-trained scientists over the last 10\u000a      years; one is now in a senior management role and three were hired in\u000a        the REF impact period. Of the latter group, one is now managing\u000a      projects incorporating modelling, while the other two are full-time\u000a      practitioners [D].\u000a    New product development: Collaborative projects with JM &#8212; for\u000a      example, those described in outputs [3] and [6], above &#8212; have led to\u000a      commercial benefits for the company. Here, work has primarily focused on\u000a      applying the techniques developed by the UCL\/RI team to the field of bulk\u000a      industrial chemical production, particularly in the development of\u000a      inorganic oxides. These are important industrial catalysts used in the\u000a      annual worldwide production of 130 million tonnes of ammonia, 50 million\u000a      tonnes of hydrogen, 60 million tonnes of nitric acid and 100 million\u000a      tonnes of methanol [E]. Catalyst development is a continuous process aimed\u000a      at enhancing operational efficiency and in turn resulting in major\u000a      financial benefits for the end users. Historically, the approach was\u000a      mainly empirical, but new computational and experimental tools have\u000a      provided major opportunities to enhance understanding and suggest new\u000a      avenues for research. Computational modelling, backed by access to\u000a      advanced X-ray techniques such as X-ray absorption spectroscopy (XAS) at\u000a      SR sources, has been applied to a range of doped and defect-containing\u000a      catalytic inorganic oxide materials of relevance to the bulk chemical\u000a      interests of JM (including the former ICI Katalco) [E]. In turn, this work\u000a      has contributed to novel materials design, cost-effective synthesis of\u000a        catalysts and understanding of their application under aggressive\u000a      chemical process conditions [E]. [text removed for publication]\u000a    [text removed for publication]\u000a    Impact on environmental policy: In 2011, in collaboration with JM\u000a      and other international organisations, the application of XAS techniques\u000a      (e.g. output [5] above) provided essential learning for members of the\u000a      International Platinum Group Metals Association (IPA) who were seeking\u000a      evidence to retain the use of platinum as the active component in vehicle\u000a      emission catalysts. [text removed for publication] the global emission\u000a      control catalyst market reached $6.7 billion in 2012 [C]. These catalysts,\u000a      and platinum-containing systems in particular, were under scrutiny by the\u000a      United States Environmental Protection Agency (EPA) as a potential source\u000a      of chloroplatinates in the environment [G]. The work was used in 2012 as\u000a      part of the science case that demonstrated that the major industrial use\u000a      of platinum in the catalysts was not a direct source of chloroplatinates;\u000a      in turn, the work recommended a prospective, evidence-based approach to\u000a      both occupational and public exposure assessment to legislators in Europe\u000a      and North America [C].\u000a    \u000a      \u000aTopics in Catalysis 52(8), 924-934 (2009) http:\/\/doi.org\/cd2hgx\u000a\u000a    \u000a    ","ImpactSummary":"\u000a    The development and application, by a UCL and Royal Institution (UCL\/RI)\u000a      team, of a powerful range of computational and experimental techniques has\u000a      had a major impact on understanding of catalysis at the molecular level.\u000a      The translation of these approaches to industry &#8212; achieved through\u000a      fellowships, collaborations and employment of trained UCL\/RI scientists &#8212;\u000a      has had substantial impact on the development and optimisation of key\u000a      catalytic systems used in energy, environmental, bulk and fine chemicals\u000a      production. Computational modelling software has been commercialised by\u000a      Accelrys following interaction with the UCL\/RI team. Products and\u000a      processes at Johnson Matthey have been developed and enhanced over a\u000a      shorter timescale, ultimately leading to good returns and a sustained\u000a      market position. The approaches also provided evidence that\u000a      platinum-containing vehicle emission catalysts are not a source of\u000a      chloroplatinates in the environment and can therefore continue to be used.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University College London (UCL)\u000a    ","Institutions":[{"AlternativeName":"University College London","InstitutionName":"University College London","PeerGroup":"A","Region":"London","UKPRN":10007784}],"Panel":"B         ","PlaceName":[],"References":"\u000a    \u000a[1] De novo design of structure-directing agents for the\u000a      synthesis of microporous solids, D. W. Lewis, D. J. Willock, C. R. A.\u000a      Catlow, J. M. Thomas and G. J. Hutchings, Nature, 382, 604-606\u000a      (1996) doi.org\/dqqdhf (In\u000a      collaboration with the University of Liverpool)\u000a    \u000a\u000a[2] QUASI: A general purpose implementation of the QM\/MM approach and its\u000a      application to problems in catalysis, P. Sherwood, A. H. de Vries, M. F.\u000a      Guest, G. Schreckenbach, C. R. A. Catlow, et al., J. Mol. Str.\u000a        Theochem., 632, 1-28 (2003) doi.org\/fgjpj7\u000a      (In collaboration with the CLRC Daresbury Laboratory, Max-Planck-Institut\u000a      Mulheim, ICI, Synetix, Norsk Hydro Oil and Energy Research Centre and\u000a      BASF)\u000a    \u000a\u000a[3] Combined experimental and computational modelling studies of the\u000a      solubility of nickel in strontium titanate, A. M. Beale, M. Paul, G.\u000a      Sankar, R. J. Oldman, C. R. A. Catlow, S. French and M. Fowles, J.\u000a        Mater. Chem., 19, 4391-4400 (2009) doi.org\/bz76g3\u000a      (In collaboration with Johnson Matthey)\u000a    \u000a\u000a[4] Probing the onset of crystallization of a microporous catalyst by\u000a      combined X-ray absorption spectroscopy and X-ray diffraction, G. Sankar,\u000a      J. M. Thomas, F. Rey and G. N. Greaves, J. Chem. Soc., Chem. Commun.,\u000a      2549-2550 (1995) doi.org\/drt8zz (In\u000a      collaboration with the CCLRC Daresbury Laboratory)\u000a    \u000a\u000a[5] X-ray absorption spectroscopic studies of platinum speciation in\u000a      fresh and road aged light-duty diesel vehicle emission control catalysts,\u000a      T. I. Hyde, P. W. Ash, D. A. Boyd, G. Randlshofer, K. Rothenbacher and G.\u000a      Sankar Platinum Met. Rev., 55(4), 233-245 (2011) doi.org\/d9h9gs\u000a      (In collaboration with Johnson Matthey, International Platinum Group\u000a      Metals Association and European Precious Metals Federation)\u000a    \u000a\u000a[6] Computational modeling study of the solubility of cerium at LaCoO3\u000a      perovskite surfaces, S. Khan, R. J. Oldman, C. R. A. Catlow, S. A. French\u000a      and S. A. Axon, J. Phys. Chem. C, 112(32), 12310-12320 (2008) doi.org\/cvr8qb (In collaboration with\u000a      Johnson Matthey)\u000a    \u000aReferences [1], [3] and [4] best indicate the quality of the\u000a        underpinning research.\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"},{"Level1":"3","Level2":"3","Subject":"Macromolecular and Materials Chemistry"}],"Sources":"\u000a    [A] Supporting correspondence from Senior Product Manager, Accelrys Ltd.\u000a      &#8212; corroborates the contribution of UCL's Prof Catlow to software\u000a      development at Accelrys [text removed for publication]. Available on\u000a      request.\u000a    [B] Accelrys press release: http:\/\/ir.accelrys.com\/releasedetail.cfm?ReleaseID=627761\u000a      &#8212; corroborates the release of the new Materials Studio&#174; 6.0 software in\u000a      2011.\u000a    [C] Supporting correspondence from Technology Manager, Johnson Matthey\u000a      PLC &#8212; corroborates the contribution that Prof Sankar and the UCL\/RI team\u000a      have made to the programs of work at JM. Available on request.\u000a    [D] Supporting statement from Technology Manager, Emissions Control\u000a      Research, Johnson Matthey PLC &#8212; corroborates the recruitment of the\u000a      UCL\/RI-trained scientists by JM. Available on request.\u000a    [E] Supporting correspondence from Catalyst Research Associate, Johnson\u000a      Matthey PLC &#8212; corroborates the contribution that the UCL team has made to\u000a      the development of inorganic oxides and the impact that the UCL\/RI team\u000a      has had at JM. Available on request.\u000a    [text removed for publication]\u000a    [G] IRIS Toxicological Review of Halogenated Platinum Salts and Platinum\u000a      Compounds (External Review Draft) http:\/\/ofmpub.epa.gov\/eims\/eimscomm.getfile?p_download_id=513625\u000a      by the US Environmental Protection Agency.\u000a    ","Title":"\u000a    Industrial application of computational models and experimental\u000a      techniques for catalyst development and optimisation\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Research teams at UCL and the Royal Institution (RI) &#8212; which is\u000a      affiliated with UCL and was returned jointly with UCL in previous RAE\u000a      exercises &#8212; have for over two decades pursued major programmes exploiting\u000a      the concerted use of computation and experiment in catalytic science. The\u000a      aim of this work has been to develop detailed models of catalytic\u000a      structures and processes at the molecular level. The synergistic\u000a      computational and experimental exploration of catalysts has elucidated and\u000a      probed the structures, properties and reactivities of these complex\u000a      materials, helping to develop and direct the design of industrially\u000a      relevant catalysts. The application of both computational models and\u000a      experimental techniques has generated a significant body of work, and the\u000a      UCL\/RI team has published over 500 outputs in the field of catalytic\u000a      science that have provided the underpinning research for industry.\u000a    The computational expertise developed has employed both force field and\u000a      quantum mechanical techniques; for example, in 1996 the ZEBEDDE (ZEolites\u000a      By Evolutionary De novo DEsign) code was developed by UCL\/RI in\u000a      collaboration with the University of Liverpool, primarily to support the\u000a      synthesis and development of microporous materials. This code provides a\u000a      method for the de novo design of template molecules, thus avoiding\u000a      long and exhaustive searches and trial-and-error modifications of known\u000a      templates in order to identify new structure-directing agents [1]. The\u000a      UCL\/RI team was also an integral part of the EU project QUASI (Quantum\u000a      Simulation in Industry) that aimed to encourage and facilitate the\u000a      adoption and implementation of simulation programs. In this project, in\u000a      collaboration with the other project partners, UCL\/RI researchers\u000a      investigated robust QM\/MM (quantum mechanics\/molecular mechanics)\u000a      procedures for modelling active sites and reaction mechanisms in catalytic\u000a      processes, in turn demonstrating the wide applicability of QM\/MM\u000a      procedures to industrial modelling problems [2].\u000a    Complementary to the development and exploitation of advanced\u000a      computational models, the UCL\/RI team concurrently conducted experimental\u000a      research on microporous catalyst structure determination using X-ray\u000a      diffraction (XRD) and absorption spectroscopic (XAS) techniques, employing\u000a      both laboratory and synchrotron radiation sources. In particular, UCL\/RI\u000a      researchers have pioneered the use of powder diffraction and X-ray\u000a      absorption fine structure spectroscopy (XAFS) for the simultaneous\u000a      elucidation of local and long-range structure [3, 4]. The combined use of\u000a      these techniques offers a viable, atom-specific analysis of\u000a      non-crystalline gels and crystalline solids when other techniques, such as\u000a      DAFS (diffraction anomalous fine structure), are inapplicable.\u000a      Furthermore, it enables a greater understanding of the formation of, and\u000a      specific environment at, the active sites of microporous catalysts [3, 4].\u000a      Additionally, XAS techniques have been used to assess the environmental\u000a      impact of platinum catalysts [5]. It was found that the use of platinum in\u000a      vehicle emission catalysts is not likely to generate chloroplatinate\u000a      species, which are of environmental concern; rather it was shown that Pt\u000a      is coordinated to oxygen atoms.\u000a    A significant amount of research has been conducted in collaboration with\u000a      industry, in particular with Johnson Matthey. For example, investigations\u000a      into the solubility of metal ions in known catalysts for industrially\u000a      relevant reactions, including the partial oxidation of methane and\u000a      high-temperature catalytic oxidation processes, have been performed [3,\u000a      6]. Such studies are important because the size and morphology of metal\u000a      particles (like Ni and Ce) supported on inorganic oxides impact upon the\u000a      catalytic activity of the material for a specific reaction. A\u000a      comprehensive understanding of how a synthetic route influences the size\u000a      of a metal dopant and its most favourable conformation within a host\u000a      lattice informs on both catalytic performance and lifetime.\u000a    Overall, this combined computational and experimental approach has\u000a      enabled an increasingly detailed understanding at the molecular level of\u000a      the synthesis and catalytic operation of oxide and microporous catalysts.\u000a    Key UCL researchers: Richard Catlow (Professor 1993-present),\u000a      Gopinathan Sankar (Professor, RI 2004-2007; Professor, UCL 2007-present),\u000a      Nora de Leeuw (Reader, Computational Materials Science 2004-2007;\u000a      Professor 2007-present) and Dewi Lewis (Lecturer 1998-2003; Senior\u000a      Lecturer 2003-present).\u000a    "},{"CaseStudyId":"35254","Continent":[],"Country":[],"Funders":["Natural Environment Research Council"],"ImpactDetails":"\u000a    Public Policy: Air quality and climate change science and policy\u000a      actions have complex linkages. The research above provided both the sound\u000a      scientific evidence base and expert interpretation of that science for the\u000a      UK government and regulatory agencies to establish air quality measurement\u000a      standards and policy actions.[S1]\u000a    NO2 The research in Section 2(A) underpinned\u000a      major parts of the standardisation and improvement in protocols for the\u000a      measurement of NO2 by passive diffusion tube in the UK. Heal\u000a      was an invited member on the working group for 'Harmonisation of Diffusion\u000a      Tube Methods' and references [1-3] are cited in the 2008 Defra report. 'Diffusion\u000a      tubes for ambient NO2 monitoring: practical guidance for\u000a      laboratories and users.'[S2]\u000a      The beneficiaries are Defra and the Local Authorities which are required\u000a      to measure ambient NO2 in their areas under the legal framework\u000a      of the UK Air Quality Strategy, and the commercial laboratories contracted\u000a      to provide these measurements for the Local Authorities. These procedures\u000a      are now compulsory for air quality reviews to be accepted by Defra.\u000a      The 2011 AEA group report [S3] indicates that the implementation of these\u000a      standardised procedures is slowly making improvements to the measurement\u000a      of NO2 by passive diffusion tube.\u000a      The impact of Heal's research is testified by the Senior Air Quality\u000a      Consultant at AEA Technology plc a corroborating letter [F1] which also\u000a      states:\u000a      \"Dr Heal was an active and productive member of the working group. In\u000a        particular, Dr Heal's research findings in this field were important\u000a        contributions to the desired impact of harmonised protocols for\u000a        application by users of NO2 passive sampler measurement across the UK...\u000a      The measurement results often feed into potentially expensive decisions\u000a        (such as declaration of an Air Quality Management Area). It is therefore\u000a        important that the results of these measurements are consistent and\u000a        reliable...Dr Heal's ongoing research in this field (in particular, the\u000a        effects of meteorological factors on diffusion tube performance)\u000a        continues to provide important input to the scientific community's\u000a        understanding of this much-used measurement technique...\"\u000a    PM2.5 The research quantifying sources of carbon\u000a      in PM2.5 described in Section 2(B), and ref 5 (section 3) is\u000a      cited in the report 'Fine particulate matter (PM2.5) in the\u000a      United Kingdom' 2012, PB13837,[S4] written for Defra for assessment and\u000a      recommendations on the concentrations, sources and trends of PM2.5\u000a      in the UK. The research is also part of evidence contained within the 2010\u000a      report commissioned by the UK environment agencies (EA, SEPA and DENI) 'PM2.5\u000a      in the UK'.[S5] The research described in Section 2(B) on emission sources\u000a      potentially controllable within Scotland is part of the 2012 report 'PM2.5\u000a      in Scotland' presented to SEPA which analyses potential policy levers\u000a      available to SEPA for amelioration of PM2.5.[S6] SEPA is\u000a      currently considering this report; SEPA's Local Air Quality Management\u000a      Specialist states in a supporting letter [F2] \" this kind of research\u000a        helps SEPA to carry out its duties (such as protecting and improving the\u000a        environment)...We are also pleased to see that sections of the PM2.5\u000a      in Scotland report have been referenced in several internal and\u000a        external reports.\"\u000a    O3 The research (sect 2(C), [6]) has led to new\u000a      public health recommendations to raise public awareness of the adverse\u000a      health effects of surface O3, and to strengthen warning systems\u000a      with targeted ozone alerts for high risk groups. It forms part of the\u000a      evidence presented in 2012 to the Dept of Health and the Health Protection\u000a      Agency for their plans for preparedness and mitigation of health effects\u000a      from air pollution and climate change.[S6] Air Pollution and Climate\u000a      Change Group Leader at Public Health England confirmed, in a supporting\u000a      letter \"The Health Protection Agency...commissioned the research\u000a        presented ... The research showed that present-day ozone-related\u000a        mortality in the UK is estimated to be up to around 11,900 premature\u000a        deaths per year, and ... increase of around 500 additional premature\u000a        deaths due to increasing surface ozone in a higher-temperature\u000a        future...The output and recommendations in this report are helping\u000a        inform policy options and preparedness actions for the future impacts of\u000a        ozone on the population...Dr Heal led a team that carried out this\u000a        excellent research work ...\"[F3]\u000a    ","ImpactSummary":"\u000a    Impact type: Public Policy\u000a    Significance: The research provided evidence for formulation of\u000a      government policies to ameliorate poor air quality, to which fine\u000a      particulate matter (PM2.5), O3 and NO2\u000a      are the most important contributors; PM2.5 alone reduces\u000a      average life expectancy in the UK by 6 months and costs &#163;9bn-&#163;20bn a year.\u000a      The research has been incorporated into UK national guidance and\u000a      policy-evidence documents for Defra, the Health Protection Agency, and the\u000a      Environment Agencies.\u000a    Beneficiaries are the public and the environment.\u000a    Research; date; attribution: EaStCHEM research (1995-2011) (a)\u000a      established reliable techniques to measure NO2 for a national\u000a      protocol, and (b) quantified the impact of pollutant emissions on PM2.5\u000a      and O3 concentrations, and on hospital admissions and deaths.\u000a      Heal (EaStCHEM) led the research and wrote, collaboratively in some cases,\u000a      the reports and the work cited.\u000a    Reach: UK wide.\u000a    ","ImpactType":"Political","Institution":"\u000a    EaStCHEM\u000a    ","Institutions":[{"AlternativeName":"Edinburgh (University of)","InstitutionName":"University of Edinburgh","PeerGroup":"A","Region":"Scotland","UKPRN":10007790},{"AlternativeName":"St Andrews (University of)","InstitutionName":"University of St Andrews","PeerGroup":"B","Region":"Scotland","UKPRN":10007803}],"Panel":"B         ","PlaceName":[],"References":"\u000a    Underpinning research has been published in international,\u000a        high-quality, peer reviewed, journals and reports, and receives\u000a        citations from across the research area: Atmospheric Environment is\u000a        one of the top journals in the field of air quality research.\u000a    \u000a[1] * Heal, M. R., Cape, J. N. (1997) A numerical evaluation\u000a      of chemical interferences in the measurement of ambient nitrogen dioxide\u000a      by passive diffusion samplers, Atmospheric Environment 31, 1911-1923. doi:10.1016\/S1352-2310(97)00025-3.\u000a      [34 cits, JIF 3.1]\u000a    \u000a\u000a[2] * Heal, M. R., O'Donoghue, M. A., Cape, J. N. (1999)\u000a      Overestimation of urban nitrogen dioxide by passive diffusion tubes: a\u000a      comparative exposure and model study, Atmospheric Environment 33, 513-524.\u000a      doi:10.1016\/S1352-2310(98)00290-8.\u000a      [39 cits, JIF 3.1]\u000a    \u000a\u000a[3] Hamilton, R. P., Heal, M. R. (2004) Evaluation of method of\u000a      preparation of passive diffusion tubes for measurement of ambient nitrogen\u000a      dioxide, Journal of Environmental Monitoring 6, 12-17. doi:10.1039\/b311869j.\u000a      [6 cits, JIF 2.00]\u000a    \u000a\u000a[4] * Heal, M. R., Naysmith, P., Cook, G. T., Xu, S.,\u000a      Raventos, D. T. and Harrison, R. M. (2011) Application of 14C\u000a      analyses to source apportionment of carbonaceous PM2.5 in the\u000a      UK, Atmospheric Environment 45, 2341-2348.\u000a      doi:10.1016\/j.atmosenv.2011.02.029. [18 cits, JIF 3.1]\u000a    \u000a\u000a[5] Laxen, D., Laxen, K., Heal, M. R., Vieno, M., Bigg, M. (2012) PM2.5\u000a      in Scotland. A report for the Scottish Environment Protection Agency. http:\/\/www.sepa.org.uk\/air\/idoc.ashx?docid=56d39371-fccd-4a80-8389-30e109d22c01&amp;version=-1\u000a      [The output of a consultancy contract awarded to the author team through\u000a      competitive tender].\u000a    \u000a\u000a[6] Heal, M. R., Doherty, R. M., Heaviside, C., Vieno, M., Stevenson, D.\u000a      S., Vardoulakis, S. (2012) Health effects due to changes in air pollution\u000a      under future scenarios, in Health Effects of Climate Change in the UK\u000a      2012: Current evidence, recommendations and research gaps, (ed.\u000a      Vardoulakis, S. and Heaviside, C.), Health Protection Agency, UK. ISBN\u000a      978-0-85951-723-2. http:\/\/www.hpa.org.uk\/webc\/HPAwebFile\/HPAweb_C\/1317135969235.\u000a      [An anonymously peer-reviewed chapter; 4 reviewers selected by the HPA.]\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    [S1] Heal's research underpins his membership of the UK government's Air\u000a      Quality Expert Group in 2001-2009 and 2012-current.\u000a      http:\/\/archive.defra.gov.uk\/environment\/quality\/air\/airquality\/panels\/aqeg\/publications\/membership-aqeg.pdf.\u000a    NO2\u000a    [F1] A corroborating letter is provided by the Senior Air Quality\u000a      Consultant, AEA Technology plc., Gemini Building, Harwell, Didcot, OX11\u000a      0QR.\u000a    [S2] Measurement recommendations: Diffusion tubes for ambient NO2\u000a      monitoring: practical guidance for laboratories and users. report\u000a      no. AEAT\/ENV\/R\/2504, 2008, by the Defra Working Group (of which Heal was\u000a      an invited member). AEA Energy &amp; Environment, Didcot, UK. http:\/\/uk-air.defra.gov.uk\/reports\/cat05\/0802141004_NO2_WG_PracticalGuidance_Issue1a.pdf.\u000a      Heal was also acknowledged particularly for input on diffusion tube\u000a      analysis (p37).\u000a    [S3] The effect of improved measurements: Investigation of the\u000a        effects of harmonising diffusion tube methodology, Report no.\u000a      AEAT\/ENV\/R\/3122, 2011. Loader, A., Willis, P. And Targa, J., AEA Group,\u000a      Didcot, UK. http:\/\/uk-air.defra.gov.uk\/reports\/cat05\/1108030957_Harmonisation_Follow-Up_Report_issue_2.pdf.\u000a    PM2.5\u000a    [S4] Fine particulate matter (PM2.5) in the\u000a        United Kingdom. 2012, report no. PB13837. A report by the Air\u000a      Quality Expert Group, prepared for Department for Environment, Food and\u000a      Rural Affairs, Scottish Government, Welsh Government and Department for\u000a      Environment Northern Ireland http:\/\/uk-air.defra.gov.uk\/library\/reports?report_id=727.\u000a    [S5] PM2.5 in the UK, ER12, 2010.\u000a      Laxen, D., Moorcroft, S., Marner, B., Laxen, K., Boulter, P., Barlow, T.,\u000a      Harrison, R.M., and Heal, M.R. Scotland &amp; Northern Ireland Forum for\u000a      Environmental Research Report ER12. pp.212.\u000a      http:\/\/www.sniffer.org.uk\/Resources\/ER12\/Layout_Default\/0.aspx?backurl=http.\u000a    [S6] PM2.5 in Scotland. Laxen, D.,\u000a      Laxen, K., Heal, M.R., Vieno, M., and Bigg, M. A report for the Scottish\u000a      Environment Protection Agency, 2012\u000a     http:\/\/www.sepa.org.uk\/air\/idoc.ashx?docid=56d39371-fccd-4a80-8389-30e109d22c01&amp;version=-1.\u000a    [F2] Corroborating evidence of expert advice provision to the environment\u000a      agencies in letter from The Local Air Quality Management Specialist,\u000a      Scottish Environment Protection Agency.\u000a    O3 and public health\u000a    [S7] Health effects due to changes in air pollution under future\u000a        scenarios, Heal, M. R., Doherty, R. M., Heaviside, C., Vieno, M.,\u000a      Stevenson, D. S. and Vardoulakis, S.. Chapter 3 in Health Effects of\u000a        Climate Change in the UK 2012: Current evidence, recommendations and\u000a        research gaps, ed. Vardoulakis, S. and Heaviside, C., Health\u000a      Protection Agency, UK. ISBN 978-0-85951-723-2. 2012. http:\/\/www.hpa.org.uk\/webc\/HPAwebFile\/HPAweb_C\/1317135969235.\u000a    [F3] Corroboration of expert advice provision on the potential\u000a        current and future health effects of O3 in the\u000a        UK:, Group Leader, Air Pollution and Climate Change, Public Health\u000a      England.\u000a    ","Title":"\u000a    Air Quality; measurement, standardisation, and quantification of airborne\u000a      contaminants\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Background: Air pollution is the environmental factor with the\u000a      greatest impact on health in the EU, with 16-30% and 15-17% of the EU\u000a      urban pollution estimated to be exposed to levels of PM2.5 and\u000a      O3 greater than the EU limit values.[EEA,\u000a        2012]. Air quality in Europe &#8212; 2012 report. EEA Report No 4\/2012,\u000a      European Environment Agency] In the UK, poor air quality is estimated to\u000a      reduce average life expectancy by ~6 months [COMEAP,\u000a        2010]. The mortality effects of long-term exposure to particulate\u000a      air pollution in the United Kingdom, UK Department of Health Committee on\u000a      the Medical Effects of Air Pollution] and cost &#163;9bn-&#163;20bn in adverse human\u000a      health impacts alone.[EAC,\u000a        2010].'Air Quality' House of Commons Environmental Audit Committee,\u000a      5th report] NO2 is the pollutant causing the\u000a      greatest number of failures of air quality standards in the UK. Heal's\u000a      group (EaStCHEM) has led air pollution research on all three of the most\u000a      important air pollutants; NO2, PM2.5 and O3.\u000a    (A) Measurement of ambient NO2 by passive\u000a        diffusion tube; improved accuracy and quantification of errors\u000a    Measurement of ambient NO2 by passive diffusion tube is widely\u000a      used in the UK as part of air quality assessments required by law. From\u000a      1995 onwards, research led by the Heal group (EaStCHEM) showed that this\u000a      method is subject to inaccuracies, in particular overestimation caused by\u000a      the within-tube reaction between co-diffusing NO and O3 to form\u000a      additional NO2, and an effective shortening of the assumed\u000a      diffusion path length caused by wind turbulence across the entrance of the\u000a      tube. Through field deployments and numerical modelling these biases were\u000a      quantified for locations of varying ambient chemical and meteorological\u000a      conditions.[1,2] Parallel research defined optimal methods for the\u000a      adsorbent preparation and post-exposure chemical analysis.[3] This\u000a      research was initiated in collaboration with Prof. Cape of the NERC Centre\u000a      for Ecology &amp; Hydrology and Honorary EaStCHEM professor but was\u000a      subsequently carried out entirely in the Heal group. The work led to more\u000a      accurate and reliable measurements of atmospheric NO2\u000a      concentration and Heal's methods are now incorporated into protocols\u000a      applied to measurements of NO2 for statutory air quality\u000a      assessments in all urban areas in the UK (estimated &gt;139,000 NO2\u000a      measurements costing &#163;0.5 M annually).[S1]\u000a    (B) Characterisation of sources of airborne particulate matter (PM)\u000a    Research led by the Heal group (EaStCHEM) in 2007-09 quantified the\u000a      proportions of contemporary and fossil carbon in samples of PM2.5\u000a      via accelerator mass spectrometric determination of the carbon-14\u000a      radioisotope. A key finding was that around half the carbon was shown to\u000a      be contemporary rather than fossil, which was higher than anticipated.[4]\u000a      This finding has been important for informing PM2.5 reduction\u000a      policy actions.\u000a    Research carried out in 2012 for the Scottish Environment Protection\u000a      Agency, SEPA, (in collaboration with Dr Vieno from the Centre for Ecology\u000a      &amp; Hydrology) used an atmospheric chemistry transport model to quantify\u000a      the sensitivity of components of PM2.5 in Scotland to\u000a      reductions of primary PM2.5 or gaseous inorganic precursors (SO2,\u000a      NOx, NH3) from industry and shipping within or\u000a      outside of Scotland.[5] A key finding is that reductions in these\u000a      components are most sensitive to reductions in ammonia emissions\u000a      regionally but that the greatest reductions in population exposure are\u000a      achieved nationally by reductions in primary PM2.5 emissions.\u000a      These results are being used by SEPA and the Scottish Government to\u000a      develop policy on reduction of PM2.5 in Scotland.\u000a    (C) Quantification of the current and potential future UK health\u000a        burden from exposure to ambient ozone\u000a    Research led by the Heal group in 2011 used an atmospheric chemistry\u000a      transport model to produce time-series of hourly surface O3\u000a      concentrations at 5 km spatial resolution across the UK for the\u000a      present-day and for possible future scenarios of different precursor\u000a      emissions and increased temperatures from climate change. The O3\u000a      concentrations were used to calculate numbers of regionally-disaggregated\u000a      deaths and hospital admissions that may be attributable to O3\u000a      currently and in the future.[6] The research shows that over a time\u000a      horizon of a few decades policy actions that reduce man-made emissions to\u000a      the atmosphere can have substantially greater health benefits than adverse\u000a      impacts through O3 via climate change but that the O3\u000a      health benefits are extremely sensitive to the exact trends in the\u000a      man-made emissions that are followed.\u000a    People:\u000a    Heal, M. R.: PI who led the research in EaStCHEM, Sept. 1994 to date.\u000a      Hamilton, R.P, O'Donoghue, M.A.; PhD students in the Heal group.\u000a      Doherty, R.D., Stevenson, D.S.; Naysmith, P., Cook, G. T., Xu, S.,\u000a      Raventos, D. T., Harrison, R. M., Bigg, M.; collaborating staff in other\u000a      departments and UK academic institutions.\u000a      Cape, J.N., Vieno. M.; staff at the Centre for Ecology and Hydrology,\u000a      Edinburgh (CEH) (Cape was also an Honorary Professor in EaStCHEM (now\u000a      retired)).\u000a      Laxen, D., Laxen, K., Heaviside, C., Vardoulakis, S.; staff at non-HEI\u000a      institutions (consultancy and public sector).\u000a    "},{"CaseStudyId":"35255","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1733045","Name":"Malaysia"},{"GeoNamesId":"3077311","Name":"Czech Republic"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"3017382","Name":"France"},{"GeoNamesId":"798544","Name":"Poland"},{"GeoNamesId":"1605651","Name":"Thailand"},{"GeoNamesId":"660013","Name":"Finland"},{"GeoNamesId":"2802361","Name":"Belgium"}],"Funders":[],"ImpactDetails":"\u000d\u000a    The grants from ITI Techmedia specified that the arising IP portfolio was\u000d\u000a      to be owned and developed by them for the benefit of the Scottish economy.\u000d\u000a      This responsibility passed onto SE on their amalgamation. M&#246;lnlycke Health\u000d\u000a      Care AB (a world leading manufacturer of wound care products and a major\u000d\u000a      service provider to the healthcare sector with annual sales which have\u000d\u000a      grown rapidly from &#163;536M in Q4 2007 to &#163;932M in 2012 of which ~40%\u000d\u000a      currently derives from its Wound Care Division) recognised the pressing\u000d\u000a      requirement for rapid and sensitive technologies suitable for PoC testing.\u000d\u000a      The opportunity for rapid detection of MRSA was verified by ZinC (a health\u000d\u000a      innovation, growth and market strategy consultancy) in 2008 \"as part\u000d\u000a        of the Scottish Enterprise ITI Scotland Chronic Wound Care Programme.\u000d\u000a        Using our Health Opportunity Design&#174; methodology, ZinC uncovered a\u000d\u000a        $4.3bn global opportunity for chronic wound infection. Prompt, MRSA\u000d\u000a        detection, at the point-of-care, was deemed the most prescient\u000d\u000a        opportunity in a product development roadmap, devised by ZinC, that\u000d\u000a        encompassed a series of increasingly complex technologies to target not\u000d\u000a        just MRSA but other critical bacterial infections, and to meet the\u000d\u000a        prioritized and precisely defined unmet needs of a global wound care\u000d\u000a        practitioner base.[S1] In April 2012, the global PoC diagnostics\u000d\u000a      market was estimated to be in excess of $4.3B and was forecast to grow to\u000d\u000a      $7B by 2018, with infectious diseases being the most dynamic sector [S2,\u000d\u000a      S3]. M&#246;lnlycke Healthcare AB has ~7000 employees and manufacturing plants\u000d\u000a      in Belgium, the Czech Republic, Finland, France, Malaysia, Thailand,\u000d\u000a      Poland, the UK and the US. A route to establishing a competitive presence\u000d\u000a      in the global diagnostics market was therefore a priority for M&#246;lnlycke.\u000d\u000a    Seeing the opportunity that the IP and associated UoE expertise\u000d\u000a      presented, M&#246;lnlycke Healthcare AB secured an exclusive license from SE in\u000d\u000a      2012 (details commercially confidential) and established a new subsidiary,\u000d\u000a      MHC Scotland Ltd in the BioQuarter in Edinburgh [S4], to develop this\u000d\u000a      technology for the diagnostics market. The Head of Chemical Sciences at SE\u000d\u000a      has said \"The Edinburgh University research team were key in delivering\u000d\u000a        a positive outcome from the programme due to their acknowledged\u000d\u000a        world-class capabilities in the field of small-scale surface detection\u000d\u000a        technologies in general and your [EaStCHEM] expertise in electrochemical\u000d\u000a        detection in particular. This progress enabled the developed detection\u000d\u000a        technology and associated IP to be attractive to a world class\u000d\u000a        healthcare company (M&#246;lnlycke Health Care) and was the reason this\u000d\u000a        company chose to set up M&#246;lnlycke Health Care Scotland (MHS) in the\u000d\u000a        BioQuarter in Edinburgh\".[F1] The CEO of M&#246;lnlycke Health Care AB,\u000d\u000a      has confirmed the value to the company in 2012 [S2] \"We are delighted\u000d\u000a        to be expanding our capabilities and product offering in close\u000d\u000a        collaboration with Scottish Enterprise and the University of Edinburgh.\u000d\u000a        This initiative marks our entry into the diagnostic market. We are very\u000d\u000a        proud to be extending our offering of efficient infection control and\u000d\u000a        prevention solutions that make life easier and safer for health care\u000d\u000a        professionals and patients.\"\u000d\u000a    The central importance of the \"innovative technology platform\" developed\u000d\u000a      by the underpinning research is confirmed by M&#246;lnlycke Healthcare AB [S2,\u000d\u000a      S3] and by SE; their Director of Commercialisation has stated [S2] \"...we\u000a        have been able to identify and secure the opportunity for M&#246;lnlycke\u000d\u000a        Health Care to develop its innovative commercial product based on our\u000d\u000a        platform technology at the Edinburgh BioQuarter in Scotland.\" The\u000d\u000a      Managing Director MHC Scotland Ltd [F2] has said \"The innovative\u000d\u000a        detection technology...uses Electrochemical Impedance Spectroscopy (EIS)\u000d\u000a        to identify and quantify biomarkers that show the presence of pathogens,\u000d\u000a        such as Methicillin-resistant Staphylococcus aureus (MRSA). Current MRSA\u000d\u000a        screening often involves centralised laboratory facilities that can take\u000d\u000a        up to 48 hours to process results, during which time MRSA can spread. By\u000d\u000a        using EIS we will be able to offer point of care testing (PoCT).\"\u000d\u000a      [S3] The impact deriving from the underpinning research is therefore\u000d\u000a      directly to M&#246;lnlycke Health Care AB as evidenced by formation of a\u000d\u000a      significant new business venture and alteration of business practice,\u000d\u000a      through the adoption and commercialisation of our new technology platform.\u000d\u000a    Further evidence of the link between research and impact through company\u000d\u000a      formation and commercialisation is the strong Human Capital transfer from\u000d\u000a      UoE to MHC Scotland Ltd. Since 2012, Till Bachmann, the project manager\u000d\u000a      for the ITI Programmes in UoE has been employed both in UoE and part-time\u000d\u000a      on a consultancy basis as the Scientific Programme Director for MHC\u000d\u000a      Scotland Ltd. Of the 8 personnel in MHC Scotland Ltd, 4 (Bachmann, PDRAs\u000d\u000a      Ciani and Schulze, Henihan) were UoE personnel working on the ITI\u000d\u000a      programmes whilst a fifth (Kaatz) is an EaStCHEM postdoctoral worker from\u000d\u000a      Mount's group with expertise in bioelectrochemistry and impedance.\u000d\u000a      Formation of MHC Scotland Ltd represents the first inward investment to\u000d\u000a      the BioQuarter and an important part of Scottish Enterprise's delivery\u000d\u000a      plan for economic benefit from the life sciences, as evidenced by the Head\u000d\u000a      of Chemical Sciences at SE; \"As you know, Chemical Sciences are at the\u000d\u000a        heart of Scotland's economy, and chemistry is indeed the `science at the\u000d\u000a        centre'. It also plays a key underpinning role with other key sectors\u000d\u000a        e.g. life sciences, energy, chemicals and electronics. The research\u000d\u000a        carried out at the University of Edinburgh which M&#246;lnlycke Healthcare is\u000d\u000a        commercialising is a prime example of the synthesis of research and\u000d\u000a        technology excellence that Scottish Enterprise is supporting and\u000d\u000a        promoting globally.\" [F1].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Research; date; attribution:\u000d\u000a    Since 2005, EaStCHEM research expertise in electrochemistry and in\u000d\u000a      sensing and detection, in partnership with University of Edinburgh\u000d\u000a      researchers and expertise from the associated disciplines of medicine,\u000d\u000a      engineering and physics and funded by the Scottish Intermediary Technology\u000d\u000a      Institute (now Scottish Enterprise, SE) has formed a multidisciplinary\u000d\u000a      team and developed the research outputs and novel platform technologies\u000d\u000a      with enhanced detection characteristics (sensitivity, specificity, ability\u000d\u000a      to handle clinical samples, rapid time-to-result) applicable to\u000d\u000a      point-of-care diagnosis of wound infection state.\u000d\u000a    Significance: This technology was exclusively licensed from SE by\u000d\u000a      M&#246;lnlycke Health Care AB in 2012. M&#246;lnlycke Health Care AB also\u000d\u000a      established a new subsidiary, MHC Scotland Ltd in the BioQuarter in\u000d\u000a      Edinburgh, to develop this technology, marking their entry into the\u000d\u000a      multibillion dollar global point of care diagnostics market, as well as\u000d\u000a      employing 5 UoE researchers.\u000d\u000a    Reach: M&#246;lnlycke Health Care AB is a leading innovator in\u000d\u000a      infection control in hospitals having ~7000 employees worldwide and with\u000d\u000a      manufacturing plants in 9 countries.\u000d\u000a    Beneficiaries: The impact deriving from the underpinning research\u000d\u000a      is to M&#246;lnlycke Health Care AB as evidenced by formation of a significant\u000d\u000a      new business venture and alteration of business practice, through the\u000d\u000a      adoption and commercialisation of our new technology platform and the\u000d\u000a      employment of 5 UoE staff from the research programme as human capital in\u000d\u000a      MHC Scotland Ltd.\u000d\u000a    ","ImpactType":"Economic","Institution":"\u000d\u000a    EaStCHEM\u000d\u000a    ","Institutions":[{"AlternativeName":"Edinburgh (University of)","InstitutionName":"University of Edinburgh","PeerGroup":"A","Region":"Scotland","UKPRN":10007790},{"AlternativeName":"St Andrews (University of)","InstitutionName":"University of St Andrews","PeerGroup":"B","Region":"Scotland","UKPRN":10007803}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    Underpinning research has been published in international,\u000d\u000a        high-quality, peer reviewed, journals and reports, and receives\u000d\u000a        citations from across the research area: these are the top journals in\u000d\u000a        the field of biosensors research.\u000d\u000a    \u000a[1] The stability and characteristics of a DNA Holliday junction switch\u000d\u000a      A. R. Mount, C. P. Mountford, S. A. G. Evans, T. J. Su, A. H. Buck, P.\u000d\u000a      Dickinson, C. J. Campbell, L. M. Keane, J. G. Terry, J. S. Beattie, A. J.\u000d\u000a      Walton, P. Ghazal, J. Crain, Biophys. Chem. 2006, 124,\u000d\u000a      214-221. DOI:\u000d\u000a        10.1016\/j.bpc.2006.03.020 [4 cits, JIF: 2.1]\u000d\u000a    \u000a\u000a[2] Electrochemical control of a DNA Holliday Junction nanoswitch by Mg2+\u000d\u000a      ions E.E. Ferapontova C.P. Mountford, J. Crain, A.H. Buck, P. Dickinson,\u000d\u000a      J.S. Beattie, P. Ghazal, J.G. Terry, A.J. Walton, A.R. Mount, Biosensors\u000a        &amp; Bioelectronics 2008, 24, 422-428.\u000d\u000a      http:\/\/dx.doi.org\/10.1016\/j.bios.2008.04.021\u000d\u000a    \u000a\u000a[3] * Development of immunosensors for direct detection of three wound\u000d\u000a      infection biomarkers at point of care using electrochemical impedance\u000d\u000a      spectroscopy I. Ciani, H. Schulze, D. K. Corrigan, G. Henihan, G. Giraud,\u000d\u000a      J. G. Terry, A. J. Walton, R. Pethig, P. Ghazal, J. Crain, C. J. Campbell,\u000d\u000a      T. T. Bachmann and A. R. Mount, Biosensors &amp; Bioelectronics, 2012,\u000d\u000a      31, 413. DOI:\u000a        10.1016\/j.bios.2011.11.004 [8 cits, JIF:5.39]\u000d\u000a    \u000a\u000a[4] * Impedimetric detection of single-stranded PCR products derived from\u000d\u000a      methicillin resistant Staphylococcus aureus (MRSA) isolates D. K.\u000d\u000a      Corrigan, H. Schulze, G. Henihan, I. Ciani, G. Giraud, J. G. Terry, A. J.\u000d\u000a      Walton, R. Pethig, P. Ghazal, J. Crain, C. J. Campbell, A. R. Mount and T.\u000d\u000a      T. Bachmann, Biosensors &amp; Bioelectronics, 2012, 34,\u000d\u000a      178. DOI:\u000d\u000a        10.1016\/j.bios.2012.01.040 [3 cits, JIF: 5.39]\u000d\u000a    \u000a\u000a[5] * Development of a PCR-free electrochemical point of care test for\u000d\u000a      clinical detection of methicillin resistant Staphylococcus aureus\u000d\u000a      (MRSA) D. K. Corrigan, H. Schulze, G. Henihan, A. Hardie, I. Ciani, G.\u000d\u000a      Giraud, J. G. Terry, A. J. Walton, R. Pethig, P. Ghazal, J. Crain, C. J.\u000d\u000a      Campbell, K. E. Templeton, A. R. Mount and T. T. Bachmann, Analyst, 2013,\u000d\u000a      DOI: 10.1039\/c3an01319g\u000d\u000a    \u000a\u000a[6] Detecting analyte e.g. protease used for diagnosing impaired wound\u000d\u000a      healing, involves applying alternating voltage to analyte and determining\u000d\u000a      identity and\/or quantity of analyte from electrochemical impedance\u000d\u000a      spectrometry data, A. R. Mount, M. Khondoker, I. Ciani, T. Bachmann, P.\u000d\u000a      Ghazal; 2011, WO 2011069997-A2; WO2011069997-A3; EP2510342-A2;\u000d\u000a      US2012285829-A1; CN102753965-A; JP2013513790-W\u000d\u000a    \u000aKey Grants\u000d\u000a      2003-2007 &#163;1.48M. \"Genomic Nanoprocessors\" One of only 6 \"Beacon Projects\"\u000d\u000a      funded by the then DTI as part of their multi-million pound 'Harnessing\u000d\u000a      Genomics' programme to ensure that the UK's world-leading bioscience\u000d\u000a      R&amp;D base was capable of being commercialised by a thriving\u000d\u000a      biotechnology sector.\u000d\u000a      Principal Investigators: Mount (EaStCHEM), Crain, Ghazal, and Walton, all\u000d\u000a      UoE academics.\u000d\u000a    2005-2009 &#163;10.2M ITI Techmedia Biosensing Platform; competitively\u000d\u000a      tendered; Consortium = The original UoE \"Beacon\" award group of PIs, plus\u000d\u000a      Till Bachmann (project manager) and Partners Axis-Shield, Haptogen Ltd.\u000d\u000a      and Lab901 Ltd.\u000d\u000a    2009-2011 &#163;7.9M. ITI Techmedia Chronic Wound Care (CWC) programme.\u000d\u000a      competitively- tendered; Consortium = The original UoE \"Beacon\" award\u000d\u000a      group of PIs, plus Till Bachmann and SME Partners D3 Technologies (Now\u000d\u000a      Renishaw Diagnostics), Zisys and Mologic.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"10","Level2":"4","Subject":"Medical Biotechnology"},{"Level1":"3","Level2":"1","Subject":"Analytical Chemistry"},{"Level1":"11","Level2":"9","Subject":"Neurosciences"}],"Sources":"\u000d\u000a    [S1] http:\/\/www.zinc-healthcare.com\/blogpost\/achieving-success-in-health-innovation-through-a-focus-on-care-pathways\u000d\u000a      which corroborates the economic significance of the Scottish Enterprise\/\u000d\u000a      ITI Chronic Wound care programme which is underpinned by UoE research led\u000d\u000a      by EaSTCHEM.\u000d\u000a    [S2] Press release [dated 11 December 2012] (cached website pdf supplied)\u000d\u000a      which contains quoted market data from Original source ISBN: GDME0147\u000d\u000a      Point-of-Care Diagnostics &#8212; Global Pipeline Analysis, Competitive\u000d\u000a      Landscape and Market Forecasts to 2018. It also includes statements from\u000d\u000a      CEO of M&#246;lnlycke Health Care AB and Director of Commercialisation, SE.\u000d\u000a    [S3] http:\/\/www.molnlycke360.com\/joining-the-fight-against-superbugs\/\u000d\u000a      contains the quote include in section 4 from Managing Director, MHC\u000d\u000a      Scotland Ltd.\u000d\u000a    [S4] Edinburgh BioQuarter Q4 newsletter Dec 2012;\u000d\u000a      http:\/\/www.edinburghbioquarter.com\/news\/item\/m-lnlycke-locates-new-subsidiary-at-edinburgh-bioquarter\/,\u000d\u000a      which corroborates the establishment of MHC Scotland Ltd in the Edinburgh\u000d\u000a      BioQuarter.\u000d\u000a    [F1] Head of Chemical Sciences at Scottish Enterprise corroborating the\u000d\u000a      importance of the MHC Scotland Ltd\/UoE development programme to the\u000d\u000a      Scottish life sciences industry.\u000d\u000a    [F2] Managing Director, MHC Scotland Ltd will corroborate all M&#246;lnlycke\u000d\u000a      Healthcare AB and MHC Scotland Ltd related statements.\u000d\u000a    ","Title":"\u000d\u000a    Wound Care; Point of Care Diagnostic Platforms for fast detection of\u000d\u000a      unlabelled infection biomarkers result in establishment of M&#246;lnlycke\u000d\u000a      Health Care AB in Scotland\u000d\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    Background\u000d\u000a    In 2003, EaStCHEM research expertise in electrochemistry and in sensing\u000d\u000a      and detection (led by Mount) played a central role in a University of\u000d\u000a      Edinburgh (UoE) multidisciplinary (with physics, medicine and electronic\u000d\u000a      engineering) programme to produce a novel DNA nanoswitch platform\u000d\u000a      technology. Competitively funded as one of only six national DTI Beacon\u000d\u000a      projects in Harnessing Genomics, this work produced a new type of DNA\u000d\u000a      nanoswitch, based on the Holliday Junction (HJ), that used a combination\u000d\u000a      of binding and conformational switching to enable specific label-free\u000d\u000a      detection of synthetic and cellular DNA and RNA (Anal. Chem. 2007, 79,\u000d\u000a      4724-28). In this work we led the physicochemical characterisation [1] and\u000d\u000a      surface functionalised electrode development required to produce a\u000d\u000a      platform technology with electrochemical control [2] and interrogation of\u000d\u000a      HJs anchored to a silicon substrate in a label-free detection device.\u000d\u000a    A significant output was a UoE multidisciplinary team of researchers\u000d\u000a      capable of developing specific healthcare sensing\/detection platforms.\u000d\u000a      Exploiting this, in 2005 the team won competitive funding from ITI\u000d\u000a      Techmedia for four years to develop a Biosensor Platform for diagnosis and\u000d\u000a      treatment of infectious diseases. (ITI, the Intermediary Technology\u000d\u000a      Institute, was the publicly funded organisation established to lever\u000d\u000a      Scotland's research excellence, funding early stage technology R&amp;D\u000d\u000a      programmes to develop market-driven intellectual property (IP) for the\u000d\u000a      benefit of the Scottish economy. It is now part of Scottish Enterprise\u000d\u000a      (SE), Scotland's economic, enterprise, innovation and investment agency).\u000d\u000a      In this award, which involved working with specific industrial partners,\u000d\u000a      the UoE research programme was the majority of the &#163;10.2M total funding,\u000d\u000a      and involved the development and combination of sensors, microsystems, and\u000d\u000a      custom and high density bioarray \/ microarray platforms. The aim was to\u000d\u000a      develop theranostic platforms, each of which combined the measurement and\u000d\u000a      analysis of specific diagnostic data to reduce the cost and complexity and\u000d\u000a      increase the speed and accuracy of disease diagnosis. Our work resulted in\u000d\u000a      four patents on the development of electrochemical detection and the\u000d\u000a      combination of electrochemical and optical detection for enhanced\u000d\u000a      sensitivity (WO2008084114-A1; WO2008090229-A1; WO2009112537-A1;\u000d\u000a      WO2009141180-A1).\u000d\u000a    Evidence of the success of this UoE research programme was the award of a\u000d\u000a      further &#163;7.9M SE\/ITI Techmedia R&amp;D programme in Chronic Wound Care in\u000d\u000a      2009. This exploited EaStCHEM-led expertise in the development of\u000d\u000a      electrochemical detection and the design of specific probe sensing\u000d\u000a      modified electrode layers for specific label-free target detection. It\u000d\u000a      also utilised electrochemical impedance spectroscopy (EIS, in which\u000d\u000a      EaStCHEM through the Mount group has particular expertise) as a detection\u000d\u000a      method. The majority of this funding was again to UoE, to develop a point\u000d\u000a      of care diagnostic device using multiparameter EIS detection that could be\u000d\u000a      readily applied to diagnose and monitor wound infection both in a clinical\u000d\u000a      environment and in the community. The programme focused on\u000d\u000a      diabetes-related chronic wounds e.g. diabetic foot ulcers, although the\u000d\u000a      technology platform was also intended to be applicable to other major\u000d\u000a      wound categories and other markets. Our research outputs developed methods\u000d\u000a      for rapid detection [6] and satisfied the requirements for point of care\u000d\u000a      (PoC) testing by producing rapid, sensitive and specific label free EIS\u000d\u000a      detection from clinically relevant samples of: three biomarkers diagnostic\u000d\u000a      of wound infection [3]; the antibiotic-resistant mecA gene\u000d\u000a      sequence in DNA fragments produced by PCR; and an MRSA specific assay\u000d\u000a      which did not require polymerase chain reaction (PCR) amplification of the\u000d\u000a      target DNA [5]. Along with the development of a mini-potentiostat system,\u000d\u000a      this enables MRSA diagnosis in less than an hour [5]. Systematic\u000d\u000a      optimisation of e.g. probe chemistry, electrode film structure and DNA\u000d\u000a      fragmentation protocols were key in optimising assay performance.\u000d\u000a    Research Team;\u000d\u000a      A.R. Mount: Group leader, EaStCHEM, Senior Lecturer 2003-, Reader 2005-,\u000d\u000a      Professor 2012-. EaStCHEM PDRAs: Ciani, Corrigan, Evans, Ferapontova. C.\u000d\u000a      Campbell (now Senior lecturer in EaStCHEM).\u000d\u000a      Crain, Walton, Ghazal and their respective groups: collaborators\u000d\u000a        working in the UoE during the period that the underpinning research was\u000d\u000a        performed. All outputs published by UoE.\u000d\u000a    "},{"CaseStudyId":"35256","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":[],"ImpactDetails":"\u000a    Results of the MIDAS group on the quantification of contamination levels\u000a      on 'clean' surgical instruments have been used to formulate, and are\u000a      continuing to influence, government policy. As a minimum estimate, this\u000a      policy helps the work of 20,000 NHS sterile services hospital staff and\u000a      contributes to the health and safety of all patients who now undergo\u000a      surgery, and the technology has been considered at an operation level at\u000a      the Home Office for use in the aftermath of a CBRN incident. The new\u000a      EFSCAN technology is in the final stages of commercialisation.\u000a    1. Public NHS policy: surgical equipment contamination monitoring and\u000a        decontamination\u000a    The MIDAS group's research findings described in section 2 have been used\u000a      in the formulation of 2012 Department of Health policy. The 2012\/13 policy\u000a      framework, CFPP-01-01 (Choice Framework for Local Policy Procedures for\u000a      Decontamination) is the code of practice for the management and\u000a      decontamination of surgical instruments that is adopted throughout the\u000a      NHS, as required by the Health and Social Care Act 2008 with regard to NHS\u000a      Decontamination (Sterile Services; Parts E and work acknowledged in Parts\u000a      A and B) facilities.[S1]\u000a    CFPP-01-01 explicitly cites the researchers and describes the studies\u000a      completed by the MIDAS group: Part A, see text on P8, paragraph 2.40\u000a      (section on 'Protein quantification using epifluorescence scanning'), p29,\u000a      paragraph A1 (chapter on 'Inactivation of prions using novel technologies'\u000a      describing 'instrument exposure to cold plasma' and further references on\u000a      p38, paragraph A86. It also cites the report 'ESAC-Pr: New\u000a      Technologies Working Group Report on Prion Inactivating Agents' written by\u000a      the working group (2008), of which R. Baxter is a member.[S2] This report\u000a      includes citations and references to the MIDAS research on pps\u000a      8,20,21,26,27,29.\u000a    2. Health\u000a    MIDAS has extended the technology through research trials currently\u000a      underway with Edinburgh Royal Infirmary, Ninewells (Dundee), Glasgow\u000a      Dental Hospital. The consultant microbiologist, leading the work says \"The\u000a        introduction of new detection technology, such as EFSCAN, is essential\u000a        to drive improvements in the standards of decontamination of medical\u000a        instruments throughout the Health Service\".[F1] Data obtained in\u000a      these projects will inform supplements to CFPP-01-01[S1] with regard to\u000a      defining maximum permissible levels of protein contamination on\u000a      reprocessed surgical devices and driving the adoption of new detection\u000a      technology (such as EFSCAN) when commercial systems become available. A\u000a      letter of support from a DoH Senior Principal Research Officer states \"We\u000a        will continue to use the outputs from this study as we develop aspects\u000a        of the CFPP in future and anticipate that successful commercialisation\u000a        of your technology for assessment of instrument decontamination will\u000a        make it available to NHS Trusts for their surgical sterilisation\u000a        departments\".[F2]\u000a    The CONTEST funded research demonstrated the efficacy of the EFSCAN\u000a      technology for both detection and decontamination of material from\u000a      possessions and equipment clean-up after a CBRN incident. In a\u000a      corroborating letter, the DoH CBRN Research Manager states \"There is a\u000a        clear concept of use of the research findings, namely to detect\u000a        contamination and provide clean possessions and other sensitive items in\u000a        the aftermath of a CBRN incident... results from the projects have been\u000a        considered at an operational level at the Home Office\".[F3]\u000a    3. Economic: commercialisation of EFSCAN for detection of\u000a        contamination\u000a    Through Edinburgh Research Innovation, MIDAS exploited the IP developed\u000a      in the 2002-8 research. Working with Edinburgh Biosciences, a\u000a      proof-of-concept EFSCAN instrument for hospital Sterile Services\u000a      Departments use was constructed in 2011-12. In early 2013, Edinburgh\u000a      BioSciences was awarded a SMART:SCOTLAND grant of &#163;100k by Scottish\u000a      Enterprise to develop and bring the EFSCAN system to market by the end of\u000a      2013. Edinburgh Biosciences UK has four salaried people now developing the\u000a      EFSCAN proof-of-concept design into commercial prototypes for manufacture\u000a      and marketing. Two are PhD level engineers, one Masters (mechanical\u000a      engineering); and an electronic engineer (honours degree). The Edinburgh\u000a      Biosciences CEO said \"Following the successful development of a\u000a        proof-of-concept instrument, Edinburgh Biosciences Ltd. sees commercial\u000a        exploitation of this instrument as a key element of its business launch\u000a        plan. As the reliability and performance characteristics of the system\u000a        are confirmed, marketing and sales of the instrument will expand\u000a        internationally from a UK base. The US is a target market given that\u000a        awareness of the problems of contamination of surgical instruments is\u000a        already in the public domain\".[F4]\u000a    A portable `hand-held' fluorescence detector for fast detection of\u000a      biomolecules on surfaces, in the context of homeland security, has also\u000a      been developed.\u000a    The press (Telegraph, Guardian, Scotsman newspaper articles; BBC News and\u000a      radio, and specialist publications) note the value to public and the\u000a      profession, and cite MIDAS's work directly. Examples include BBC\u000a      reports,[S3],[S4] and an Association for Perioperative Practice report\u000a      which cites [S1], stating \"The prevention of infection is one of the\u000a        fundamental principles of patient care...The effective decontamination\u000a        of surgical instruments is critical in the management of healthcare\u000a        associated infection and patient safety; therefore it is essential that\u000a        practices and processes applied to thorough decontamination of all\u000a        surgical instruments is of the highest quality and reflects modern day\u000a        standards\".[S5]\u000a    ","ImpactSummary":"\u000a    Impact type: Public Policy; Health (and related economic);\u000a          Economic.\u000a    Significance: the research of the MIDAS (Medical Instrument\u000a      Decontamination and Screening) group has been used to formulate Department\u000a      of Health (DH) policy with respect to both the standard of contamination\u000a      monitoring and the quality of instrument decontamination procedures. The\u000a      Code of Practice CFPP 01-01, 2012 advocates the adoption of MIDAS's\u000a      technology throughout the NHS. With effect from July 2012, this is\u000a      contributing to reducing cancelled operations, 126,000 p.a., due to dirty\u000a      instruments, minimising the risk of new cases of terminal, Transmissible\u000a      Spongiform Encephalopathy (TSE) diseases, and reversal of the fear-driven,\u000a      growing trend towards disposable instruments (at an estimated cost of ca\u000a      &#163;7bn worldwide). As a minimum estimate, this policy helps the work of\u000a      20,000 NHS sterile services hospital staff and contributes to the health\u000a      and safety of all patients who now undergo surgery. Edinburgh Biosciences\u000a      Ltd is employing four staff (2 PhD level) to manufacture and market\u000a      MIDAS's new decontamination monitoring instrumentation.\u000a    Research; date; attribution: Between 2002 and 2008 the Baxter and\u000a      Jones groups developed and reported new methods to quantify and remove\u000a      residual protein contamination on `cleaned' hospital instruments. They set\u000a      up MIDAS, the Medical Instrument Decontamination and Screening group, to\u000a      develop and apply these methods for in situ, quantitative,\u000a      ultra-sensitive detection of surface-bound, biological contamination on\u000a      medical devices and for the removal of this contamination to levels below\u000a      the limit of detection.\u000a    Reach: The code of practice is currently in force at the UK level.\u000a      Edinburgh Biosciences is commercialising decontamination monitoring\u000a      systems for an international market.\u000a    ","ImpactType":"Political","Institution":"\u000a    EaStCHEM\u000a    ","Institutions":[{"AlternativeName":"Edinburgh (University of)","InstitutionName":"University of Edinburgh","PeerGroup":"A","Region":"Scotland","UKPRN":10007790},{"AlternativeName":"St Andrews (University of)","InstitutionName":"University of St Andrews","PeerGroup":"B","Region":"Scotland","UKPRN":10007803}],"Panel":"B         ","PlaceName":[],"References":"\u000a    The MIDAS group has been funded by a series of grants from the Department\u000a      of Health, as well as funding from the Home Office. The journal articles,\u000a      together with official reports, have informed Department of Health policy\u000a      with regard to decontamination of surgical instruments.\u000a    Publications (Underpinning research has been published in\u000a        international, high-quality, peer reviewed, academic journals and\u000a        receives citations from across the research area; A number of other\u000a        (non-peer reviewed) articles have been published in the popular medical\u000a        literature, accessible to a wide range of health professionals.)\u000a    \u000a[1] * Quantitative Analysis of Residual Protein Contamination on\u000a      Reprocessed Surgical Instruments; R. L. Baxter, H.C. Baxter, G. A.\u000a      Campbell, K. Grant, A.C. Jones, P.R. Richardson, A.G. Whittaker, J.\u000a        Hosp. Infection, 2006, 63, 439-44. doi:10.1016\/j.jhin.2006.03.011.\u000a      25 cits, JIF 2.9.\u000a    \u000a\u000a[2] In Situ Detection of Residual Protein Contamination on\u000a      Surgical Instruments for On-the-Spot Monitoring of Decontamination. H.C.\u000a      Baxter, A.C. Jones, R.L. Baxter, Am. J. Infection Control, 2012,\u000a      40, e166-8. doi:10.1016\/j.ajic.2012.04.296.\u000a      0 cits, JIF 2.7.\u000a    \u000a\u000a[3] * Plasma cleaning of Dental Instruments; A.G. Whittaker, E.M. Graham,\u000a      R.L. Baxter, A.C. Jones, P.R. Richardson, G. Meek, G.A. Campbell, A.\u000a      Aitken, H.C. Baxter; J. Hosp. Infection, 2004, 56,\u000a      37-41. doi:\u000a        10.1016\/j.jhin.2003.09.019. 28 cits, JIF 2.9.\u000a    \u000a\u000a[4] * Application of epifluorescence scanning for monitoring the efficacy\u000a      of protein removal by RF gas-plasma decontamination. H.C. Baxter, P.R.\u000a      Richardson, G.A. Campbell, V.I. Kovalev, R. Maier, J.S. Barton, A.C.\u000a      Jones, G. DeLarge, M. Casey, R.L. Baxter. New J. Phys. 2009,\u000a      11, 115028-42. doi:10.1088\/1367-2630\/11\/11\/115028.\u000a      3 cits, JIF 4.1.\u000a    \u000aPatents\u000a    [5] R.L. Baxter, H.C. Baxter, A.C. Jones, G.A. Whittaker, G.A. Campbell,\u000a      H. Halouani, P.R. Richardson, The University of Edinburgh: `Latent\u000a      Fluorescent Probes' 2008, WO\/2008\/047129.\u000a    [6] R.L. Baxter, H.C. Baxter, The University of Edinburgh: `Plasma\u000a      Cleaning Methods for Medical, Surgical and Dental Instruments'. 2006,\u000a      WO\/2006\/079801.\u000a    Grants Awarded (all peer reviewed)\u000a    &#8226; Cleaning and Monitoring of Protein Contamination of Surgical\u000a      Instruments and Medical Devices (RL Baxter, HC Baxter, AC Jones &amp; G\u000a      Whittaker, Department of Health, 2002-6, &#163;1,220k).\u000a    &#8226; Removal of Infective Protein Residues from Medical Instruments (RL\u000a      Baxter, HC Baxter, AC Jones, Department of Health, 2006-7, &#163;130k).\u000a    &#8226; Evaluation of gas-plasma decontamination for TSE inactivation (RL\u000a      Baxter, HC Baxter, AC Jones, Department of Health, 2007-8, &#163;72k).\u000a    &#8226; High-Level Decontamination using RF Gas-Plasma (RL Baxter, HC Baxter,\u000a      AC Jones, Home Office, 2008-10, &#163;120k).\u000a    &#8226; Ultra-sensitive detection of specific biomolecules on surfaces (RL\u000a      Baxter, HC Baxter, AC Jones, Home Office, 2008-10, &#163;120k).\u000a    &#8226; Assessment of EFSCAN technology for detection of residual protein\u000a      contamination on surgical instruments (RL Baxter, HC Baxter, AC Jones,\u000a      Department of Health 2011, &#163;100k).\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"8","Subject":"Medical Microbiology"},{"Level1":"11","Level2":"9","Subject":"Neurosciences"}],"Sources":"\u000a    [S1] Choice Framework for local Policy and Procedures (CFPP) 01-01. March\u000a      2013 &#8212; 'Management and decontamination of surgical instruments used in\u000a      acute care'. https:\/\/www.gov.uk\/government\/publications\/management-and-decontamination-of-surgical-instruments-used-in-acute-care.\u000a\u0009  (Section E as well as\u000a      acknowledgements in Section A and B)\u000a    [S2] 'ESAC-Pr: New Technologies Working Group Report on Prion\u000a      Inactivating Agents' (August 2008.http:\/\/webarchive.nationalarchives.gov.uk\/20130107105354\/http:\/www.dh.gov.uk\/prod_consu\u000am_dh\/groups\/dh_digitalassets\/@dh\/@en\/documents\/digitalasset\/dh_086803.pdf.\u000a    [F1] A corroborating letter is provided by the microbiology consultant,\u000a      based at Glasgow Dental Hospital, responsible for decontamination in NHS\u000a      Glasgow and Clyde Hospital, who led the study using EFSCAN on \"Reducing\u000a      the risk of vCJD by improving the cleaning of neurosurgical instruments\",\u000a      funded by the Scottish Government.\u000a    [F2] A corroborating letter from the Senior Principal Research Officer,\u000a      Department of Health Policy Research Programme.\u000a    [F3] A corroborating letter from the CBRN Research Manager, Research\u000a      &amp; Development Division, Department of Health.\u000a    [F4] A corroborating letter from the CEO of Edinburgh Biosciences.\u000a    [S3] Surgery patients at risk from CJD, 2011: http:\/\/www.bbc.co.uk\/news\/health-12898082.\u000a    [S4] Unsafe surgical instruments delay Glasgow operations, 2013:http:\/\/www.bbc.co.uk\/news\/uk-\u000a        scotland-21760110.\u000a    [S5] Report from the Association for Perioperative Practice http:\/\/www.afpp.org.uk\/news\/resources\/decontamination).\u000a    ","Title":"\u000a    MIDAS: Monitoring and Decontamination of Hospital Medical Instruments;\u000a      New Ultra-Sensitive Methods and New Government Guidelines\u000a    ","UKLocation":[{"GeoNamesId":"2648579","Name":"Glasgow"},{"GeoNamesId":"2650225","Name":"Edinburgh"}],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Background:\u000a    Effective instrument decontamination significantly reduces the\u000a      unnecessary burden of cancelled surgical procedures and the waste\u000a      generated by use of disposable items.\u000a    Three per cent (ca. 126,000 operations) of all operations carried\u000a      out annually in the UK have to be cancelled due to instrument\u000a      cleaning\/failure problems. In the US 34 million surgical operations are\u000a      carried out each year, with a similar cancellation rate. There is\u000a      currently great concern about healthcare-associated infection, and its\u000a      negative impact on the public perception of the NHS. Lack of confidence in\u000a      decontamination is leading to increased use of disposable surgical\u000a      instruments. The global market for disposable hospital supplies is\u000a      currently ca &#163;7bn with expected 6 % annual growth. [GlobalData\u000a      report, Mar 2013].\u000a    The inability of conventional instrument decontamination methods to\u000a      inactivate prion proteins, the infective agents of Transmissible\u000a      Spongiform Encephalopathy (TSE) diseases such as Creutzfeld- Jacob Disease\u000a      (CJD) has been a recent focus of public and professional concern. By 2009,\u000a      there were 61 worldwide confirmed cases of iatrogenic CJD, i.e. that\u000a      contracted by transmission during surgery, particularly in neuro- and\u000a      eye-surgery. [http:\/\/www.patient.co.uk\/doctor\/Creutzfeldt-Jakob-\u000a        Disease.htm; The\u000a        National Creutzfeldt-Jakob Disease Surveillance Unit (NCJDSU)].\u000a    Research:\u000a    Recognising that improvements in quality assurance and efficacy of\u000a      cleaning of medical instruments would reduce hospital-acquired infections\u000a      and cancelled operations the MIDAS (Medical Instrument Decontamination and\u000a      Screening) project was set up by Baxter, Baxter, and Jones (all EaStCHEM)\u000a      in 2002. With core funding from the Department of Health (DoH) its remit\u000a      is the invention, evaluation and application of new methods for\u000a      decontamination of medical devices and for the detection of biological\u000a      material on surfaces.\u000a    The group carried out the first quantitative survey of protein\u000a      contamination levels on `cleaned' hospital instruments (DoH report\u000a      December 2003; published 2006).[1] They then developed a series of\u000a      `latent' fluorescent probes and protocols for in situ labelling of\u000a      protein residues on surfaces. They developed a new epifluorescence\u000a      scanning technique, EFSCAN, to measure these fluorescent, labelled\u000a      residues, pushing the level of detection of proteins on surfaces down to ca.\u000a      100 attomoles mm-2 [2] The new technique was fast and\u000a      quantitative, and exceeded the sensitivity of the commonly used ninhydrin\u000a      swab test by more than 5 orders of magnitude, and was patented.[5]\u000a    In parallel, the group developed RF gas-plasma methods for direct\u000a      oxidation and elimination of proteins, including transmissible spongiform\u000a      encephalopathy (TSE) infective tissue, from metal surfaces of medical\u000a      instruments.[3] Recognising that this method is capable of eliminating the\u000a      risk of iatrogenic CJD transmission between patients by surgery, this RF\u000a      method was patented.[6]\u000a    The proven combination of gas plasma removal, and epifluorescence\u000a      scanning to confirm decontamination,[4] led to the work with Edinburgh\u000a      BioSciences to develop EFSCAN technology into a device.\u000a    Two further research projects were initiated in 2008 arising from funding\u000a      from CONTEST, the UK Government's counter-terrorism strategy program on\u000a      the detection and decontamination of toxins and biological agents:\u000a      `High-Level Decontamination using RF Gas-Plasma' and `Ultra-sensitive\u000a      Detection of Specific Biomolecules on Surfaces'. These provided robust\u000a      evidence that toxins and biological agents can be detected and effectively\u000a      cleaned from the surface of personal possessions and sensitive equipment\u000a      in the context of CBRN (chemical, biological, radiological, and nuclear)\u000a      clean-up, for example, the demonstration of Bacillus spp spore\u000a      inactivation by gas-plasma treatment (2008).\u000a    People:\u000a    Prof R.L. Baxter, from 05\/80 - 08\/12 retirement; Dr H.C. Baxter, from\u000a      05\/98 - 06\/12 retirement; Prof A.C. Jones, from 01\/89 to date: MIDAS PIs\u000a      with complementary expertise in biological chemistry, transmissible\u000a      spongiform encephalopathy (TSE), and spectroscopy research.\u000a    A.G. Whittaker, E.M. Graham, P.R. Richardson, G. Meek, G.A. Campbell, K.\u000a      Grant, H. Halouani: PhD students, PDRAs, and research fellows in the\u000a      research groups of the PIs. A. Aitken and M. Casey are collaborating\u000a      medical experts at the University of Edinburgh, G. Meek is a collaborating\u000a      Dental Surgeon, J.S. Barton, R. Maier and V.I Kovalev are collaborators at\u000a      Heriot Watt University, and G. DeLarge is an industrial collaborator in a\u000a      RF gas plasma cleaning company (Plasma-Etch).\u000a    "},{"CaseStudyId":"35257","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2077456","Name":"Australia"}],"Funders":["Biotechnology and Biological Sciences Research Council","Royal Society"],"ImpactDetails":"\u000a    Ingenza is an industrial biotech company spun out from EaStCHEM research,\u000a      which employs 34 people and had a turnover last year of &#163;2.7M. [F1] It is\u000a      based in Roslin BioCentre, a science park in Midlothian for\u000a      research-intensive and commercial life-science related SMEs. Ingenza was\u000a      set up to optimise and exploit the new robust, general, and scalable\u000a      biocatalysis platform technology described above. The new screening\u000a      methods for strain-engineering developed in the research has helped the\u000a      company expand its portfolio of biocatalysed transformations and\u000a      engineered production microbes into other industry sectors, with\u000a      wide-ranging catalysed transformations for polymers, biofuels, feedstocks,\u000a      nutrition and other applications. These enabling technologies have helped\u000a      establish Ingenza as the leading UK industrial biotechnology and synthetic\u000a      biology company. As a direct result, Ingenza's staff has grown 2-fold in\u000a      the past 4 years and revenues have grown 5-fold. The President of Ingenza,\u000a      in a corroborating letter, states \" Turner's group conducted important\u000a        research at the School of Chemistry between 2001 and 2003...This work\u000a        was an important foundation on which we originally built Ingenza's\u000a        business base...Since that time Ingenza has evolved and diversified into\u000a        the leading industrial biotechnology and synthetic biology company in\u000a        the UK with global reach in its customer base and technology\u000a        implementation...I can attest to direct linkage between research ...and\u000a        the significant societal and economic impacts that followed the spinning\u000a        out of Ingenza and its ongoing expansion\" [F1]. The Life Sciences\u000a      Director at Scottish Enterprise said \"The company ... is a great\u000a        example of Scotland's thriving life sciences sector\" [S2].\u000a    Economic:\u000a    In the financial year 2012-2013 Ingenza turned over &#163;2.7M and expects to\u000a      continue strong and profitable growth as its capabilities and interface\u000a      with multiple market sectors expand. Ingenza's revenue growth reflects the\u000a      unique capabilities of the company's technology in a challenging economic\u000a      climate and its adaptability to other industries' awareness and uptake of\u000a      sustainable manufacturing practices. Total turnover for 2008-July 2013 =\u000a      &#163;7M. [F1]\u000a    a. Development of bioprocess routes to pharmaceuticals\/chemical\u000a        building blocks Industrial biotechnology as a means to produce\u000a      platform chemicals, polymer or important drug intermediates is of high and\u000a      increasing value. Enzyme expertise (engineering and catalysis optimisation\u000a      by directed evolution) has been applied to the large-scale manufacture of\u000a      pharmaceutical intermediates. The value of sales for 2008-July 2013 is\u000a      &#163;3M. [F1]\u000a    b. Provision of process development and bioprocess optimisation for\u000a        other industries The enabling technologies developed in Section 2\u000a      are being used much more broadly by Ingenza for bioprocess optimisation\u000a      and supply of improved production microbes, to provide large industries\u000a      with new, sustainable manufacturing processes from renewable rather than\u000a      petrochemical feedstocks. For example, multi-year partnerships have been\u000a      established with leading global companies, such as Lucite International,\u000a      the world's leading manufacturer of poly-methylmethacrylate [S3]. Ingenza\u000a      piloted one of its improved biofuel strains with another end-user in the\u000a      US at full production scale of 2.4 million litres; the Ingenza President\u000a      can provide information on the number and range of other companies that\u000a      have benefitted. A major two-year development programme employing five\u000a      people at Ingenza to work with Invista, one of the world's largest\u000a      integrated producers of polymers and fibres (10,000 employees in 20\u000a      countries), has also just completed successfully, with ten people starting\u000a      on this project in the near future as a result of the expansion of the\u000a      project. The Ingenza President can provide corroboration on this [F1]. The\u000a      President of Invista is quoted in the most recent press announcement \"We\u000a        see Ingenza's capabilities as very complementary to our own and are\u000a        pleased to announce this extended collaboration.\" [S4]\u000a    In a corroborating letter, the co-founder of Ingenza, who recently moved\u000a      to Australia to be involved in new biotechnology start-up initiatives\u000a      writes \"The deracemisation research and the interest that was\u000a        generated by the high impact publications in Nick Turner's group was\u000a        really the foundation of Ingenza ... and the interest that was generated\u000a        by the high impact publications. As well as the research, the School of\u000a        Chemistry really supported Ingenza in those first few years in an\u000a        operational sense and that support was key to starting the company on a\u000a        strong footing...The ongoing relationship with the School of Chemistry\u000a        has also been important for Ingenza... The international impact of the\u000a        published research from Prof Turner's lab meant that Ingenza had a\u000a        standing on the world stage from day one to the present day, with the\u000a        majority of company's business coming from abroad.\" [F2]\u000a    Human Capital:\u000a    Ingenza's scientific team spans the disciplines of molecular biology,\u000a      biochemistry, enzymology, fermentation science and synthetic organic\u000a      chemistry, and has recruited and trained numerous scientists, including 12\u000a      scientists trained to PhD or post-doctoral level at Edinburgh University.\u000a      Currently 34 staff are employed, 12 of whom have PhDs.[F1]\u000a    There is also strong R+D collaboration with EaStCHEM staff, with joint\u000a      awards from TSB, SPARK, ERA-NET, and collaborative PhD students. Ingenza\u000a      has engaged with the Government's Modern apprentice scheme since 2009,\u000a      winning 'Small Employer of the Year 2011' at the Scottish Modern\u000a      Apprenticeship Awards.[S4] In 2012 Scottish Minister for Youth Employment,\u000a      said \"I commend Ingenza for their forward thinking approach in\u000a        fostering a new generation of young scientists, and offering up some\u000a        excellent opportunities for training in this exciting sector\".[S5]\u000a    Impact Development Timeline:\u000a    2002 First paper and patent; Ingenza launched and incubated within\u000a      School of Chemistry.[F1]\u000a    2003 The Edinburgh (University) technology fund invested &#163;25,000\u000a      in Ingenza for a 5% stake; Ingenza won &#163;120,000 funding from the Scottish\u000a      Executive, Scottish Enterprise and the Royal Society of Edinburgh.\u000a    2005 Scottish Enterprise helped Ingenza with direct funding\u000a      (&#163;20,000) to offset costs of new business development. This helped Ingenza\u000a      to establish its initial base of customers and strategic partners.\u000a    2007 Commercialisation partnership established with Richmond\u000a      Chemical Corporation.\u000a    2008-2010 Awarded 2 new SMART awards and 3 Technology Strategy\u000a      Board grant awards, two in partnership with the University of Edinburgh,\u000a      totalling in excess of &#163;1M. Receives two Biosciences KTN SPARK Awards.\u000a    2011 1) A multi-year bioprocess development agreement is signed\u000a      with Lucite International for bio-manufactured monomers.[S3] 2) Awarded\u000a      over &#163;500k from TSB for three new biotechnology projects on Industrial\u000a      Biotechnology and the commercial application of high-throughput genome\u000a      sequencing, demonstrating Ingenza's diversity and leading position in\u000a      industrial biotechnology. 3) Ingenza named 'Small Employer of the Year\u000a      2011'[S4] for its technical apprenticeship scheme. 4) 5 people at Ingenza\u000a      are employed to work on a large bioprocess development project for\u000a      Invista.\u000a    2012 1) Opening of a new GMP compatible clean room with additional\u000a      local council investment of &#163;50,000.[S6] 2) Ingenza is featured case study\u000a      in Scottish Parliament Life Sciences event.[S7]\u000a    2013 Currently 34 staff employed [F1], Current turnover in excess\u000a      of &#163;2.7 M.\u000a    ","ImpactSummary":"\u000a    Impact: Economic. Ingenza is a profitable SME based\u000a      in Roslin, Scotland, with 34 (12 PhD-level) staff, and a turnover of &#163;2.7M\u000a      in 2012-13.\u000a    Significance: Ingenza Ltd is an established industrial\u000a      biotechnology (IB) and synthetic biology (SB) company which incorporated\u000a      in September 2002. Its combination of synthetic organic chemistry with\u000a      efficient methods of genetic screening, fermentation and engineered\u000a      microbial strains is used to develop competitive and scalable industrial\u000a      bioprocesses for pharma, chemicals, energy, natural product and other\u000a      industry sectors.\u000a    Beneficiaries are Ingenza's customers (commercial and the public)\u000a      and its employees.\u000a    Research; date; attribution: In 2002 the Turner group (University\u000a      of Edinburgh, UoE) published in Angew. Chem. a new strategy of\u000a      integrated chemo- and enzymatic catalysed routes to high-value chiral\u000a      compounds that offered dramatic improvements over existing technologies\u000a      (high yield and enantiomeric excesses often &gt; 99.9%).\u000a    Reach: Ingenza now has moved from a focus on fine chemicals to\u000a      establish long term technology development and licensing agreements with\u000a      global leading end-users in the chemicals, polymers, biofuels, food and\u000a      biologics sectors, for example in the sustainable manufacture of\u000a      poly-methylmethacrylate with Lucite International.\u000a    ","ImpactType":"Technological","Institution":"\u000a    EaStCHEM\u000a    ","Institutions":[{"AlternativeName":"Edinburgh (University of)","InstitutionName":"University of Edinburgh","PeerGroup":"A","Region":"Scotland","UKPRN":10007790},{"AlternativeName":"St Andrews (University of)","InstitutionName":"University of St Andrews","PeerGroup":"B","Region":"Scotland","UKPRN":10007803}],"Panel":"B         ","PlaceName":[],"References":"\u000a    Publications: Underpinning research has been published\u000a        in international, high-quality, peer reviewed, academic journals and\u000a        receives citations from across the research area.\u000a    \u000a[1] * Deracemisation and stereoinversion of alpha-amino acids using D-amino\u000a      acid oxidase and hydride reducing agents. T. M. Beard, N.J. Turner, Chem.\u000a        Commun., 2002, 246-7. doi:10.1039\/b107580m.\u000a      46 cits, JIF 6.4.\u000a    \u000a\u000a[2] Stereoinversion of &#946;- and &#947;-substituted &#945;-amino acids using a\u000a      chemo-enzymatic oxidation-reduction procedure. A. Enright, F.-R.\u000a      Alexandre, G. Roff, I.G. Fotheringham, M.J. Dawson, N.J. Turner, Chem.\u000a        Commun. 2003 2636-7. doi:\u000a        10.1039\/B309787K. 18 cits, JIF 6.4.\u000a    \u000a\u000a[3] * Deracemization of alpha-methylbenzylamine using an enzyme obtained\u000a      by in vitro evolution. M. Alexeeva, A. Enright, M. J. Dawson, M.\u000a      Mahmoudian, N. J. Turner, Angew. Chem., Int. Ed., 2002, 41,\u000a      3177-80. doi:10.1002\/1521-3773(20020902)41:17&lt;3177::AID-ANIE3177&gt;3.0.CO;2-P\/abstract.74cits, JIF 13.7.\u000a    \u000a\u000a[4] Identification of broad specificity P450(CAM) variants by primary\u000a      screening against indole as substrate. A. Celik, R.E. Speight, N.J.\u000a      Turner, Chem. Commun. 2005, 3652-54. doi:10.1039\/B506156C.\u000a      18 cits, JIF 6.4.\u000a    \u000a\u000a[5] * Chemo-Enzymatic Synthesis of Unnatural Amino Acids in\u000a      Asymmetric Synthesis and Application of &#945;-Amino Acids. I. V. Archer, S. A.\u000a      Arnold, R. Carr, I. V. Fotheringham, R. E. Speight, P. P. Taylor. ACS\u000a        Symposium series. 2009, Vol. 1009, ch 20, p. 322-336.ISBN13:\u000a      9780841269743 eISBN: 9780841224841 Eds. V. A. Soloshonok and K.\u000a      Izawa. [peer-reviewed book chapter] http:\/\/pubs.acs.org\/doi\/abs\/10.1021\/bk-2009-1009.ch020.\u000a    \u000aFirst patent:\u000a    [6] Patent with GSK (industrial collaborators at the time) M. V.\u000a      Alexeeva, A. Enright, N. J. Turner, M. Mahmoudian, R. M. Thornley\u000a      (WO.2003.080855.A2, GB0206415.2, filed 19 March 2002); `enzymatic\u000a      deracemisation of amines'.\u000a    Key Grants:\u000a    Dec 2001: Ligand discovery at Edinburgh University funded by Cyclacel (UK\u000a      industry) (&#163;702,360). Jan 2002: Development of enantioselective amine\u000a      oxidases for application in the deracemisation of racemic chiral amines,\u000a      BBSRC (&#163;124,027).\u000a    July 2009: SMART R&amp;D: A new scalable biocatalytic technology to\u000a      produce enantiomerically pure Unnatural Amino Acids (&#163;475,108).\u000a    July 2010: To develop an improved bedside diagnostic (&#163;69,747).\u000a    Nov 2010: Two Biosciences KTN SPARK Awards: Improved fed-batch\u000a      fermentation protocols and Genome sequencing of improved yeast for biofuel\u000a      applications (&#163;5k each).\u000a    March 2011: TSB 100970 (with Edinburgh and Aberdeen Universities): Mining\u000a      new enzymes in the rumen for biomass processing and chiral synthesis\u000a      (&#163;360,336).\u000a    August 2011: TSB 100962 (with Edinburgh University). Adapted yeast for\u000a      superior carbon conversion (&#163;578,890).\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"},{"Level1":"6","Level2":"1","Subject":"Biochemistry and Cell Biology"},{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"}],"Sources":"\u000a    [F1] Letter corroborating the link between EaStCHEM research and Ingenza;\u000a      President of Ingenza. Can be contacted to corroborate staff numbers,\u000a      turnover and sales\u000a    [S1] Scottish Enterprise support for Ingenza, http:\/\/news.ingenza.com\/?p=354,\u000a      includes a quote from their Life Sciences Director\u000a    [S2] 2011 Ingenza and Lucite International in multi-year bioprocess\u000a      development agreement.\u000a      http:\/\/news.ingenza.com\/?p=331.\u000a    [F2] Corroborating support letter from the co-founder of Ingenza [now\u000a      Business Manager, Australian Institute for Bioengineering and\u000a      Nanotechnology].\u000a    [S3] Press release from Invista Intermediates &#8212; extension of\u000a      collaboration set up before July 2013 (includes quote from company\u000a      President)\u000a    [S4] 2011 Small Employer of the Year (Skills Development Scotland)\u000a      http:\/\/news.ingenza.com\/?p=340\u000a    [S5] Visit to Ingenza from Scottish Minister for Youth Employment http:\/\/news.ingenza.com\/?p=377\u000a    [S6] 2012 Ingenza new clean room with council investment:\u000a      http:\/\/www.midlothian.gov.uk\/press\/article\/402\/50_000_council_loan_sets_midlothian_biotechnolog\u000a        y-business_ingenza_ltd_on_expansion_drive).\u000a    [S7] Scottish Parliament -Life Sciences event http:\/\/www.lsscommunity.com\/profiles\/blogs\/life-sciences-scotland-exhibition-at-the-scottish-parliament.\u000a    ","Title":"\u000a    Ingenza Ltd; Technologies for new Catalysts and Products across the\u000a      Industrial Biotechnology Spectrum\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    The Turner group in EaStCHEM developed the simultaneous use of a highly\u000a      selective oxidase biocatalyst and a chemical reducing agent or catalyst,\u000a      to prepare a huge variety of enantiopure chiral amines in high yield and\u000a      optical purity.\u000a    In the key paper in 2002 [1] they demonstrated the deracemisation of the\u000a      amino acid DL-proline using commercially available D-amino acid oxidase\u000a      (DAAO) and three equivalents of NaCNBH4, a reducing agent of\u000a      sufficient water stability to be enzyme-compatible, yielding L-proline in\u000a      99% yield and 99 % ee (enantiomeric excess), achieving a 94 % conversion\u000a      of racemate to chiral amino acid after hydrolysis.[1] Previous dynamic\u000a      kinetic resolutions have been hampered by the harsh conditions required to\u000a      racemise amines. They extended this to a range of amino acids using\u000a      commercially available oxidase enzymes.[2]\u000a    Another key advance was the use of cloned microbial genes and the\u000a      development of in-vitro evolution of enzymes. Working in collaboration\u000a      with GSK, an enzyme from a gene maoN that oxidised simple\u000a      aliphatic amines was identified that showed a clear preference for the\u000a      oxidation of L-&#945;-methylbenzylamine over D-&#945;-methylbenzylamine. The group\u000a      optimised this using random mutagenesis and in vitro and in\u000a        situ selection, and colorimetric solid phase screening, to generate\u000a      new biocatalysts and commercially important targets (starting with chiral\u000a      amines) of interest to pharmaceutical industry customers.[3]\u000a    The Turner group recognised three key points of the new method that led\u000a      them to protect the work [6] and then spin-out Ingenza: (i). The high\u000a      selectivity of an enzyme allows enantiomeric excesses of &gt;99.9 %. (ii)\u000a      It converts all the potential substrate into the desired enantiomer\u000a      product, compared with a standard enzyme-catalysed kinetic resolution of a\u000a      chiral racemate. (iii). It does not require the harsh conditions required\u000a      to racemise amines that alternative transition-metal catalyst routes to\u000a      develop dynamic kinetic resolutions have.\u000a    Further UoE research to develop high throughput screening techniques [4]\u000a      enabled a large number of solid phase screening capabilities to address\u000a      problems faced by the biopharma industry. For example, novel screen\u000a      calibration approaches allowed the development of colorimetric oxidase\u000a      based protein fusion systems to identify the top 50 out of a\u000a      500,000-member library of candidates for a key therapeutic target.[5]\u000a    Key researchers:\u000a    Prof Nick Turner, EaStCHEM School of Chemistry, University of Edinburgh\u000a      10\/1998-09\/2004. The other co-authors are PDRAs and PhD researchers in the\u000a      Turner group, and industry collaborators. Enright was a collaborator in\u000a      Strathclyde at the time of patent filing.\u000a    Dr Ian Fotheringham, co-founder of Ingenza in 2002, now President.\u000a      Glasgow PhD, biocatalysis history with Monsanto.\u000a    Dr Robert Speight co-founder. Hired as a PDRA in 2000 to work in\u000a      Professor Turner's lab, UoE. Awarded an RSE enterprise fellowship in 2002.\u000a    "},{"CaseStudyId":"35258","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"2510769","Name":"Spain"},{"GeoNamesId":"1835841","Name":"South Korea"}],"Funders":["Engineering and Physical Sciences Research Council","Medical Research Council","Royal Society"],"ImpactDetails":"\u000a    The new chemical reagents for transfection described and protected\u000a      (above) were licenced to Deliverics, a new company which specialises in\u000a      cellular delivery products and technologies, spun out of EaStCHEM in\u000a      November 2010. Deliverics used the IP in both the in vitro reagent\u000a      market as well as having longer-term interests in in vivo uses.\u000a      These unique, chemical-based, biodegradable transfection reagents have\u000a      broken into both the \"research tool\" (reagent) and the \"RNAi therapeutics\"\u000a      (drug delivery) markets, delivering economic, human capital, and potential\u000a      health benefits.\u000a    A. Economic: spin-out of the company Deliverics\u000a    The significance of Deliverics' commercialised biodegradable\u000a      transfection reagents impacts on both the \"research tool\" and the \"RNAi\u000a      therapeutics\" markets and arises from their ability to out-perform\u000a      existing materials, without the immunogenicity, manufacturing issues, and\u000a      carcinogenicity previously seen for current viral vectors used as delivery\u000a      agents. This presents a wide ranging ability to deliver nucleic acids into\u000a      cells and tissues for biological applications.[S1]\u000a    The reach of the company is international, despite its youth. It\u000a      has an international customer base, including specially appointed\u000a      distributors in Spain (Albyn Medical), S. Korea (CoreSciences), and US\u000a      (Galen).The customer base (20 research groups and 10 companies) spans 5\u000a      countries. at Scottish Enterprise Enterpreneurial Support Manager has\u000a      said, \"There is significant scope for Deliverics to expand its\u000a        distribution network overseas. We're very positive about the future and\u000a        looking forward to working with them as they continue to grow.\"[S2]\u000a    The turnover of the new company is &#163;330k to date.[F1]\u000a    Deliverics Ltd has so far launched the following products:[F1]\u000a    - SAFEctinTM is a biodegradable transfection kit.\u000a    - SAFEctinTM-STEM is targeted at the stem cell market, a\u000a      market estimated at &#163;100M pa. This reagent offers over 90% transfection\u000a      efficiency of RNA into stem cells in a simple, one-step protocol.\u000a    - New SAFEctin beta product, developed with TSB grant &#8212; out performing\u000a      SAFEctin, SAFEctin STEM, HappyFect and LipoFectamine 2000 in siRNA\u000a      delivery, and showing &gt;70% transfection efficacy in notoriously\u000a      difficult cell types such as human fibrosarcoma HL116, primary mouse\u000a      lobular breast cancer cells, mouse embryonic limb cells and primary human\u000a      monocytes.\u000a    Client testimonies:\u000a    '[Text removed for publication].' [S3]\u000a    'The product that Deliverics has developed is a simple one-step\u000a        protocol that is easy to perform and produces very high transfection\u000a        efficiencies of our embryonic stem cells. During use, cells exhibited\u000a        high levels of expression and remained healthy. I think this is a great\u000a        product that will become market-leader over time.'[F2]\u000a    B. Human Capital:\u000a    Deliverics employs 5 people (4 PhD level).\u000a    C. Impact Development Timeline:\u000a    2008 Unciti-Broceta and Bradley awarded \"Proof of Concept\" grant (&#163;250K)\u000a      from Scottish Enterprise to develop patent [5] into a commercial product.\u000a    4\/2010 Deliverics Ltd spun-out. Registered in Companies House, #SC377672.\u000a    11\/2010 (1) University of Edinburgh licenses patents [5] and [6] to\u000a      Deliverics Ltd.\u000a      (2) Venture funding of &#163;275K raised [S4]. Company valuation of &#163;705K.\u000a      (3) First product, SAFEctin Transfection Reagent, launched.\u000a      (4) Dr Asier Unciti-Broceta awarded Nexxus `Young Life Scientist of the\u000a      year'.\u000a    2011 (1) Second core product, SAFEctin STEM launched.[S5]\u000a      (2) Internationalisation begins: Albyn Medical S.A. appointed as\u000a      distributor of Deliverics products in Spain. CoreSciences appointed as\u000a      distributor of Deliverics products in South Korea. Distribution deal in\u000a      the US with Galen Laboratory Supplies, giving access to the &#163;130m US\u000a      transfection reagent market, a market with 8 % annual growth.[S6]\u000a      (3) Deliverics wins `Nexxus Most Promising Young Life Science Company of\u000a      the Year'[S7]\u000a      (4) SE SMART: SCOTLAND Feasibility Study awarded for RNA transfection and\u000a      new transfection product for stem cells (SMART ref 10-9174; &#163;63K; 2011).\u000a      (5) TSB Feasibility Study awarded to develop new protein delivery\u000a      technology (TSB ref 130436 and 130436; &#163;50K; 2011 &amp; 2012).\u000a    2012 (1) TSB Smart PoC grant awarded (to develop in vivo\u000a      transfection reagent prototype) (TSB ref 710195; &#163;60K; 2012).\u000a      (2) TSB Collaborative R&amp;D Grant awarded (TSB ref 101229; &#163;94K; 2012);\u000a      TSB Collaborative R&amp;D Grant awarded to joint consortium of AvantiCell,\u000a      Deliverics, and Synpromics (&#163;263K, 2012).[S8]\u000a      (3)Deliverics CSO Dr Unciti-Broceta receives Royal Society of Chemistry\u000a      Young Industrialist of the Year Award.\u000a    ","ImpactSummary":"\u000a    Impact: Economic. The EaStCHEM spin-out company\u000a      Deliverics has commercialised biodegradable transfection reagents for both\u000a      the \"research tool\" and the \"RNAi therapeutics\" markets (globally valued\u000a      at &#163;400M and &#163;4 billion respectively). Beneficiaries are the\u000a      pharmaceutical and biotechnology sectors, and clinicians. The turnover\u000a      since 2010\/11 is &#163;330k and the company currently has five employees.\u000a    Significance: Deliveric's agents out-perfom existing materials in\u000a      term of efficacy and reduced levels of toxicity. They are not hampered by\u000a      the immunogenicity, manufacturing issues, and carcinogenicity previously\u000a      seen for viral vectors used as delivery agents. This presents a wide\u000a      ranging ability to deliver nucleic acids into cells and tissues for\u000a      biological applications.\u000a    Research; date; attribution: EaStCHEM research (2008) led by\u000a      Bradley reported a family of non-viral DNA delivery agents that offered a\u000a      highly-efficient and non-toxic method of delivering siRNA\/DNA into\u000a      mammalian cells and tissues. Development and patenting of this technology\u000a      led to the spin-out of Deliverics Ltd. in 2010.\u000a    Reach: International customer base (20 research groups and 10\u000a      companies) including specially appointed distributors in Spain (Albyn\u000a      Medical), South Korea (CoreSciences), and US (Galen).\u000a    ","ImpactType":"Technological","Institution":"\u000a    EaStCHEM\u000a    ","Institutions":[{"AlternativeName":"Edinburgh (University of)","InstitutionName":"University of Edinburgh","PeerGroup":"A","Region":"Scotland","UKPRN":10007790},{"AlternativeName":"St Andrews (University of)","InstitutionName":"University of St Andrews","PeerGroup":"B","Region":"Scotland","UKPRN":10007803}],"Panel":"B         ","PlaceName":[],"References":"\u000a    A. Key papers: Underpinning research has been published in\u000a        international, high-quality, peer reviewed, academic journals and\u000a        receives citations from across the research area:\u000a    \u000a[1] *Tripod-like cationic lipids as novel gene carriers; A.\u000a      Unciti-Broceta, E. Holder, L.J. Jones, B. Stevenson, A.R. Turner, D.J.\u000a      Porteous, A.C. Boyd, M. Bradley, J Med Chem. 2008, 51,\u000a      4076-4084 doi:10.1021\/jm701493f.\u000a      15 cits, JIF 5.6.\u000a    \u000a\u000a[2] *Safe and efficient in vitro and in vivo\u000a      gene delivery: Tripodal Cationic Lipids with Programmed Biodegradability,\u000a      A. Unciti-Broceta, L. Moggio, K. Dhaliwal, L. Pidgeon, K. Finlayson, C.\u000a      Haslett, M. Bradley, J. Mat. Chem, 2011, 2154-2158.\u000a      doi:10.1039\/C0JM03241G. 5 cits, JIF 6.1.\u000a    \u000a\u000a[3] *Solid-Phase Synthesis of Arginine-Based Double-Tailed Cationic\u000a      Lipopeptides: Potent Nucleic Acid Carriers. A. Liberska, A. Lilienkampf,\u000a      A. Unciti-Broceta, M. Bradley. Chem. Comm. 2011, 47,\u000a      12774-12776. doi:10.1039\/C1CC15805H.\u000a      4 cits, JIF 6.4.\u000a    \u000a\u000a[4] A. Unciti-Broceta, J. J. D&#237;az Moch&#243;n, R. M. Sanchez-Martin &amp; M.\u000a      Bradley. The Use of Solid Supports to Generate Nucleic Acid Carrier, Acc.\u000a        Chem. Res. 2012, 45, 1140-1152. doi:10.1021\/ar200263c.\u000a      5 cits, JIF 20.8.\u000a    \u000aB. Key patents:\u000a    [5] Cationic Lipids, Inventors: Unciti-Broceta A.; Bradley M.. Priority\u000a      Date: 19\/10\/2007. Published as WO2009050483.\u000a    [6] Cationic Lipids: second generation compounds, Inventors:\u000a      Unciti-Broceta A.; Liberska A.; Bradley M.. Priority date: 18\/05\/2010.\u000a      Published as WO2011144892.\u000a    C. Key Grants:\u000a    (i) Bradley, MRC\/EPSRC G0401194 `High Throughput Chemical Biology &#8212;\u000a      Transfection Microarrays and Combinatorial Chemistry' &#163;263,990 (2005).\u000a    (ii) Unciti-Broceta &amp; Bradley, Scottish Enterprise proof-of-concept\u000a      award (10-CHM-001) `Non-Toxic DNA Delivery' &#163;248,187 (2008).\u000a    (iii) Bradley, MRC G0801908, Multiplexed in vivo optimisation of\u000a      non-toxic gene transfer agents' &#163;646,272 (2009).\u000a    (iv) Venture funding &#163;205K (2010).\u000a    ","ResearchSubjectAreas":[{"Level1":"10","Level2":"4","Subject":"Medical Biotechnology"},{"Level1":"11","Level2":"15","Subject":"Pharmacology and Pharmaceutical Sciences"}],"Sources":"\u000a    [F1] Testimony from Deliverics' CSO confirming corroboration of turnover\u000a      and product range.\u000a    [F2] Testimony from Head of Production and Quality Control at R\u000a      Biomedical (Deliverics customer)\u000a    [S1] Deliverics' website http:\/\/www.deliverics.com\/home\/index.php\/aboutus.\u000a    [S2] Scottish Enterprise press release on Deliverics (quote from their\u000a      Entrepreneurial Support Manager, High Growth Start-up unit on company's\u000a      rate of growth).\u000a    [S3] [Text removed for publication] Deliverics customer showing efficacy\u000a      of Deliverics products (results from pages 13 onwards).\u000a    [S4] The Scotsman: `New spin-out wins early stage funding' (website\u000a      tinyurl\u000a      http:\/\/tinyurl.com\/nzg6vzk).\u000a    [S5] Deliverics' Press release on Safectin STEM launch, Aug 2011.\u000a    [S6] Deliverics' $200M USA distribution deal, Oct 2011 (Lifescience\u000a      Scotland tinyurl\u000a      http:\/\/tinyurl.com\/o6svk3k).\u000a    [S7] Press release on Deliverics' 2011 Nexxus Award (Scottish Life\u000a      Science Business award).\u000a    [S8] Synpromics website announcing collaborative TSB award with\u000a      Deliverics and Avanti (tiny url\u000a      http:\/\/tinyurl.com\/nd5tukc.\u000a    ","Title":"\u000a    Deliverics; non-viral, non-toxic DNA delivery agents for cells and\u000a      tissues\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Background: The delivery of nucleic acids into cells is a\u000a      requisite for numerous biological \/ biomedical applications, ranging from\u000a      therapeutic (e.g. corrective gene therapy, gene silencing therapy, etc.)\u000a      to routine in vitro cell-based assays. Due to the founding role of\u000a      DNA and RNA molecules in all cellular processes, their transport into\u000a      cells is restricted by the cell membrane. Many different physical,\u000a      chemical and biological approaches have been explored for the cell\u000a      delivery of nucleic acids, with viral vectors being the most efficient one\u000a      both therapeutically or as a research-enabling tool. However, due to the\u000a      limitations of viral agents (antigenicity, risk of mutagenesis, production\u000a      costs, etc.), chemical delivery systems represent an attractive\u000a      alternative but have serious toxicity issues. Most chemical transfection\u000a      technologies are based on the use of large surfactants \/ polycationic\u000a      molecules with the ability to complex nucleic acids into liposome-like\u000a      particles and carry them into cells via endocytosis.\u000a    Research Following their move to EaStCHEM in 2005, the Bradley\u000a      group attracted significant support from the MRC and EPSRC (2005-2008\u000a      &amp; 2009-2012) as well as from Scottish Enterprise (2008-2010), to\u000a      develop non-toxic cationic lipids and dendrimers as DNA\/RNA carriers [1].\u000a      In early development work, two families of transfection reagents, based on\u000a      the rational assembly of naturally-occurring components such as amino\u000a      acids, lipids and non-toxic linkers stood out.[2,3]\u000a    This novel non-viral chemical approach offered a highly-efficient and non-toxic\u000a      method to:\u000a    a. Deliver nucleic acids (siRNA\/DNA) to a wide range of\u000a        mammalian cell lines and tissues that cannot be transfected without\u000a      toxicity by existing commercial non-viral materials such as embryonic stem\u000a      cells.\u000a    b. Deliver gene therapy drugs with high efficiency, e.g. for the\u000a      delivery of RNAi-based therapeutics, an emerging application within the\u000a      Bio-Pharmaceutical sector. Gene therapy drugs have not yet been approved\u000a      in Europe or USA because of lack of safety and efficiency; however the\u000a      in-built degradation propensity of these reagents confers upon them the\u000a      ability to metabolize into natural products and enhance nucleic acid\u000a      release within the cell thus improving the delivery process.\u000a    For the latter, preliminary in vivo assays demonstrated the\u000a      ability of compounds to transfect mouse lung with no obvious signs of\u000a      toxicity, attracting early interest from major market players such as\u000a      Merck and Silence Therapeutics Plc. Therapeutic relevance for this is for\u000a      genetic diseases such as cystic fibrosis (annual treatment cost per\u000a      patient up to &#163;160,000, 9000 sufferers in the UK, 40,000 in the US) and\u000a      viral infections such as influenza (annual cost to the US economy up to\u000a      &#163;110bn, based on average 200,000 hospitalisations and 41,000 deaths).\u000a    The new series of biodegradable delivery reagents were patented in 2007\u000a      [5] and the spin-out company Deliverics Ltd created in 2010 for\u000a      their commercialization. Preliminary in vivo assays demonstrated\u000a      their ability to transfect DNA plasmids into mouse lung [2]. Improved in\u000a        vivo biodegradable reagents were then developed in the Bradley group\u000a      [3,4] and patented in 2010.[6] Their subsequent research and development\u000a      led to water-based formulations (SAFEctinTM product series)\u000a      that allow a one-step `mix &amp; go' procedure. Ongoing research shows\u000a      outstanding transfection performance including with difficult-to-transfect\u000a      and sensitive cells. Additional in vivo assays have demonstrated\u000a      their ability to transfect siRNA and miRNA in mouse lung and skin\u000a      xerographs (unpublished data by Deliverics) with no signs of toxicity.\u000a    The unique selling points that distinguish the reagents from existing\u000a      platforms, and have allowed the research commercialisation are:\u000a    in vitro\u000a    \u000a      High efficiency transfection (comparable\/better than gold-standard\u000a        commercial products, Lipofectamine2000 and Effectene) in a variety of\u000a        mammalian cells, including stem cells.\u000a      Non-toxic.\u000a      Ease of use (no requirement for later removal, enabling a simple,\u000a        one-step protocol).\u000a    \u000a    in vivo\u000a    \u000a      Cationic lipids specifically designed to be metabolised in vivo\u000a        rendering them non-toxic and safe for clinical applications (e.g.\u000a        multiple dosing).\u000a      The combination of reduced toxicity and increased transfection\u000a        efficiency makes the compounds particularly amenable for in-vivo\u000a        application.\u000a    \u000a    Additionally, they do not incur the expensive and difficult 'Good\u000a      Manufacturing Process' requirements of viral production.\u000a    Key people who led the research\u000a    Professor Mark Bradley 2005 to date (EaStCHEM); Dr A. Unciti-Broceta 2005 - 2010 (EaStCHEM).\u000a    Research team members: A. Liberska, A. Lilienkampf, L. Moggio, L.\u000a      Pidgeon, A.R. Turner (EaStCHEM PhD and PDRAs) E. Holder, L.J. Jones, B.\u000a      Stevenson, D.J. Porteous, A.C. Boyd, K. Dhaliwal &amp; C. Haslett (College\u000a      of Medicine and Veterinary Medicine, UoE). Our embedded business\u000a      development executive Dr Keith Finlayson was involved throughout the\u000a      process from application to now and continues to liaise with the company\u000a      in managing the patent portfolio for both parties ensuring a productive\u000a      relationship is maintained.\u000a    "},{"CaseStudyId":"35261","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2921044","Name":"Germany"},{"GeoNamesId":"1814991","Name":"China"},{"GeoNamesId":"3017382","Name":"France"},{"GeoNamesId":"1861060","Name":"Japan"}],"Funders":["Royal Society"],"ImpactDetails":"\u000d\u000a    The work at St Andrews has impacted on the materials, battery,\u000d\u000a      electronics and automotive industries here in the UK and worldwide,\u000d\u000a      bringing economic, consumer and environmental benefits globally. The\u000d\u000a      beneficiaries are wide-ranging: [text removed for publication]. In\u000d\u000a      addition, the [text removed for publication] nanostructured\u000d\u000a      electrodes have had particularly strong impact on companies ([text\u000d\u000a        removed for publication]) that are targeting the automotive industry\u000d\u000a      and there are vehicles that now contain this technology ([text removed\u000d\u000a        for publication]). Finally, the development of the lithium-air\u000d\u000a      battery has had significant impact on several companies, who are looking\u000d\u000a      to develop very high power 3rd generation lithium battery\u000d\u000a      materials [S2, S5].\u000d\u000a    A. Economic Impact. The concepts described in the research above\u000d\u000a      have had significant impact on a number of different areas of lithium\u000d\u000a      battery technology but in particular it has impacted on the development of\u000d\u000a      2nd generation rechargeable Li-ion batteries produced by all\u000d\u000a      the major battery manufacturers globally, [text removed for\u000d\u000a        publication].\u000d\u000a    The discovery and synthesis of layered LiMnO2 (LMO) as a\u000d\u000a      positive electrode for lithium batteries [text removed for\u000d\u000a        publication] to reduce cost and improve safety. These materials are\u000d\u000a      manufactured worldwide, as are the batteries that use them as positive\u000d\u000a      electrodes. The value of the lithium battery market is estimated at $12\u000d\u000a      billion per annum (approx. 4 billion cells) and the Mn based share at ~40%\u000d\u000a      [S6]. [text removed for publication]\u000d\u000a    The University of St Andrews patented the original work and the IPR was\u000d\u000a      licensed to Nissan Chemicals for a significant period. However, it is the\u000d\u000a      general concept that has had the most impact. The wealth of possible\u000d\u000a      combinations of elements in mixed metal Li(Mn1-xMx)O2\u000d\u000a      materials means that each company has developed their own particular\u000d\u000a      electrode. [text removed for publication].\u000d\u000a    The director of LIB Battery Consultants LTD, writes that Peter Bruce's\u000d\u000a      work on \"...manganese-based lithium oxides has made a major impact in\u000d\u000a        the field. His work on the spinel materials laid the foundations for\u000d\u000a        their later use as cathodes in lithium ion batteries for automotive\u000d\u000a        applications, for example in the Nissan leaf and Vauxhall Ampera.\"\u000d\u000a      [Reference S1]\u000d\u000a    II. The hierarchical approach to lithium-ion battery electrode design,\u000d\u000a      combining, nano and micron scales, demonstrated by Bruce, is being\u000d\u000a      exploited in the fabrication of titanate anodes for lithiumion batteries [text\u000d\u000a        removed for publication]. The advantage is that the batteries can be\u000d\u000a      safely charged and discharged at higher rates than traditional lithium-ion\u000d\u000a      batteries, because the nanostructure enhances the charge\/discharge rates,\u000d\u000a      while the hierarchical structure ensures that the electrode is more dense\u000d\u000a      than a simple powder of nanoparticles, thus delivering high volumetric\u000d\u000a      capacity. Nanostructured lithium titanate batteries account for only a\u000d\u000a      small percentage of the total lithium battery market as yet, but their\u000d\u000a      market share is predicted to increase over the next ten years\u000d\u000a      substantially.\u000d\u000a    III. The theoretical energy density (storage) of the lithium-air battery\u000d\u000a      is 10 times greater than lithium-ion batteries of today and greater than\u000d\u000a      Li-ion batteries can ever achieve. As such, lithium-air could deliver the\u000d\u000a      Holy Grail in the automotive industry of an electric vehicle with a 500km\u000d\u000a      driving range. Bruce's pioneering studies in 2006 led directly to an\u000d\u000a      explosion of interest in the Li-air battery, not only in academic research\u000d\u000a      but also within industry. The major current impact (2009 onwards) of this\u000d\u000a      relatively recent research advance is on companies, who are actively\u000d\u000a      developing the concepts behind the lithium-air battery. The Economist [See\u000d\u000a      reference S2] reported that the advances \"..that Dr Bruce's team has\u000d\u000a        designed can be a mere one-eighth to one-tenth the size and weight of\u000d\u000a        modern batteries, while still carrying the same charge. Making such a\u000d\u000a        battery is also expected to be cheaper. Lithium cobalt oxide accounts\u000d\u000a        for 30% of the cost of a lithium-ion battery. Air, however, is free.\"\u000d\u000a      Since then major automotive companies around the world are pursuing the\u000d\u000a      technology. Examples of companies developing the Li-air battery are, IBM,\u000d\u000a      Toyota\/BMW, CEA (France), BASF\/Bosch Germany, Volkswagen, Samsung. IBM has\u000d\u000a      announced they will demonstrate a prototype in 2014, [See corroborative\u000d\u000a      references S5, S9].\u000d\u000a    B. Policy Impact\u000d\u000a    A significant role as advocate and advisor to industry and Government has\u000d\u000a      arisen from the research on lithium batteries at St Andrews. Bruce has\u000d\u000a      appeared before a Parliamentary Select Committee. Importantly, Bruce\u000d\u000a      Chaired a Royal Society of Chemistry committee that produced a report on\u000d\u000a      Energy Storage, [text removed for publication].\u000d\u000a    C. Societal Impact\u000d\u000a    Lithium batteries have become firmly entrenched in consumer goods over\u000d\u000a      the last decade. As such the impact of the fundamental research described\u000d\u000a      above and its subsequent exploitation has played an important part in the\u000d\u000a      impact of 2nd generation lithium batteries on society across\u000d\u000a      the world. For the LMO battery technology the impact has allowed safer\u000d\u000a      power tools and medical device batteries, and nanostructured electrode\u000d\u000a      batteries are breaking into the electric vehicle market. [text removed\u000d\u000a        for publication].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Impact: The impact reported here is on the development of new\u000d\u000a      generations of lithium battery technologies, and is primarily economic,\u000d\u000a      with beneficiaries ranging across all the major battery manufacturers in\u000d\u000a      Asia, Europe and the Americas. Consumers and society at large have been\u000d\u000a      impacted significantly through the introduction of new, safer battery\u000d\u000a      technologies and the environment has been impacted through significant\u000d\u000a      replacement of toxic cobalt by safer manganese.\u000d\u000a    Significance: [text removed for publication].\u000d\u000a    St Andrews research on nanostructured [text removed for publication]\u000d\u000a      electrodes has led to the development of a new generation of lithium\u000d\u000a      batteries [text removed for publication]. These are particularly\u000d\u000a      aimed at the vehicle market, [text removed for publication].\u000d\u000a      Publication of a paper on the Lithium-air battery in 2006 resulted in an\u000d\u000a      explosion of interest by companies worldwide (e.g. IBM, Toyota, Samsung)\u000d\u000a      in this transformational energy storage technology.\u000d\u000a    Attribution and dates: The work was done in the laboratories of\u000d\u000a      Professor Peter Bruce, and was completed between 1996 and the present day,\u000d\u000a      and the impact is still ongoing.\u000d\u000a    Reach: The research has had global impact. The companies that have\u000d\u000a      exploited the concepts [text removed for publication] are based in\u000d\u000a      Asia (Japan, China), Europe and North America, and the impact on the\u000d\u000a      consumer is also global in reach.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    EaStCHEM\u000d\u000a    ","Institutions":[{"AlternativeName":"Edinburgh (University of)","InstitutionName":"University of Edinburgh","PeerGroup":"A","Region":"Scotland","UKPRN":10007790},{"AlternativeName":"St Andrews (University of)","InstitutionName":"University of St Andrews","PeerGroup":"B","Region":"Scotland","UKPRN":10007803}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    \u000a1. Synthesis of layered LiMnO2 as an Electrode for\u000d\u000a      Rechargeable Lithium Batteries, A. R. Armstrong and P. G. Bruce, Nature,\u000d\u000a      381, 499-500 (1996). DOI: 10.1038\/381499a0 (cited 863\u000d\u000a      times)\u000d\u000a    \u000a\u000a2. TiO2-B Nanowires, A. R Armstrong, G. Armstrong, J. Canales\u000d\u000a      and P. G. Bruce, Angew. Chem. Int. Ed., 43, 2286-2288\u000d\u000a      (2004). DOI: 10.1002\/anie.200353571 (cited 418 times)\u000d\u000a    \u000a\u000a3. Synthesis of Ordered Mesoporous Li-Mn-O Spinel as a Positive Electrode\u000d\u000a      for Rechargeable Lithium Batteries, F. Jiao, J. Bao, A. H. Hill, P. G.\u000d\u000a      Bruce, Angew. Chem. Int. Ed., 47, 9711-9716 (2008). DOI: 10.1002\/anie.200803431\u000d\u000a      (cited 94 times)\u000d\u000a    \u000a\u000a4. The Rechargeable Li2O2 Electrode for Lithium\u000d\u000a      Batteries, T. Ogasawara, A. Debart, M. Holzapfel and P. G. Bruce, J Am\u000d\u000a        Chem. Soc., 128, 1390-1393(2006). DOI: 10.1021\/ja056811q\u000d\u000a      (cited 334 times)\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"9","Level2":"12","Subject":"Materials Engineering"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"}],"Sources":"\u000d\u000a    F1 Corroborative Letter from director of LIB Battery Consultants LTD, [text\u000a        removed for publication]\u000d\u000a    S2 The Economist: Air Power http:\/\/www.economist.com\/node\/14299690\u000d\u000a      which corroborates the Bruce contribution to the lithium air battery.\u000d\u000a    [text removed for publication]\u000d\u000a    S4 Toshiba Lithium titanate SCIB technology\u000d\u000a      http:\/\/www.toshiba.com\/ind\/product_display.jsp?id1=821\u000d\u000a    S5 Announcement of Toyota\/BMW lithium air battery:\u000d\u000a      http:\/\/paultan.org\/2013\/01\/25\/toyota-bmw-jointly-research-lithium-air-batteries-fuel-cell-system-and-sports-car-also-on-the-cards\/\u000d\u000a    S6 Lithium Battery market http:\/\/www.frost.com\/prod\/servlet\/press-release.pag?docid=274194514\u000d\u000a    S7 Explanation of lithium manganese oxide battery and major uses\u000d\u000a      http:\/\/batteryuniversity.com\/learn\/article\/types_of_lithium_ion\u000d\u000a    S8 Report that Toshiba SCIB lithium titanate battery will be used in the\u000d\u000a      Mitsubshi electric vehcle\u000d\u000a      http:\/\/www.engadget.com\/2011\/06\/16\/toshiba-scib-to-be-used-in-mitsubishi-i-miev-recharge-to-80-per\/\u000d\u000a    S9 Announcement of IBM lithium-air battery protoytype\u000d\u000a      http:\/\/www.bloomberg.com\/news\/2013-02-21\/lithium-air-battery-gives-ibm-hope-of-power-without-fires.html\u000d\u000a    S10. Royal Society of Chemistry: Electrochemical Energy Storage: a vision\u000d\u000a      for the future, 2010. Corroborating the new policy initiative from BIS.\u000d\u000a    http:\/\/news.bis.gov.uk\/Press-Releases\/Multi-million-boost-for-UK-electric-vehicle-battery-technology-67f95.aspx\u000d\u000a    ","Title":"\u000d\u000a    New Generation Rechargeable Lithium Batteries\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    The discovery of Lithium Manganese Oxide Electrode Materials First\u000d\u000a      generation lithium-ion batteries used LiCoO2 as the positive\u000d\u000a      electrode material. Cost, safety and limitation of the quantity of Li that\u000d\u000a      could be reversibly extracted from LiCoO2 to 0.5 Li per formula\u000d\u000a      unit, defined the need for new lithium intercalation hosts as cathodes.\u000d\u000a      Prof. Bruce, a researcher at the University of St Andrews since 1991, was\u000d\u000a      the first to synthesise layered LiMnO2 (Nature, 1996 [1]) with\u000d\u000a      the structure of LiCoO2 but replacing Co by Mn, resulting in\u000d\u000a      lower cost, improved safety and the ability to extract more Li than the\u000d\u000a      LiCoO2 material. LiMnO2 had been targeted for\u000d\u000a      several years by many groups but had not been prepared successfully. [text\u000d\u000a        removed for publication].\u000d\u000a    The key breakthrough in this research was the Bruce group's\u000d\u000a      novel approach to the synthesis, which involved the formation of a\u000d\u000a      different material, NaMnO2, in the first instance, followed by\u000d\u000a      an ion exchange step to replace the Na with Li [1] He further showed (in\u000d\u000a      2002) that partial replacement of Mn by other ions, including Ni and Al,\u000d\u000a      improved stability. [text removed for publication]. The work on\u000d\u000a      LMO electrode materials is protected in a series of patents (see for\u000d\u000a      examples WO 97\/26683 and WO 2003\/009407).\u000d\u000a    Nanostructured Electrodes for Lithium Batteries Transforming the\u000d\u000a      rate at which Li-ion batteries can be charged\/discharged is essential for\u000d\u000a      their use in electric vehicles (for so-called regenerative breaking). To\u000d\u000a      attack this issue Bruce, in the early years of the 21st\u000d\u000a      century, pioneered nanostructured intercalation electrodes, including TiO2(B)\u000a      nanowires\/nanotubes and mesoporous LiMn2O4 as anodes\u000d\u000a      and cathodes respectively (2004\/2008) [2,3]. He demonstrated that the\u000d\u000a      combination of length scales in one material (micrometre, nanometre and\u000d\u000a      atomic) endows materials with superior properties, and hence performance,\u000d\u000a      compared with micron-sized particulate electrodes when used in lithium-ion\u000d\u000a      batteries. [text removed for publication]. IPR is covered in US\u000d\u000a      12\/857.431 and a Canadian patent application number CA 2.675.302.\u000d\u000a    The Lithium Air Battery Bruce is a pioneer of the rechargeable\u000d\u000a      non-aqueous lithium-air battery (2006) [4], with a theoretical energy\u000d\u000a      density 10 times greater than lithium-ion batteries of today and greater\u000d\u000a      than lithium-ion batteries can ever achieve. He demonstrated that such a\u000d\u000a      battery could be repeatedly recharged. By carrying out fundamental studies\u000d\u000a      of the oxygen reduction mechanism at the positive electrode, he not only\u000d\u000a      changed understanding of the science underpinning the non-aqueous\u000d\u000a      lithium-air battery but also identified the crucial role of electrolyte\u000d\u000a      stability. As a result of Bruce's work, many organisations are developing\u000d\u000a      prototype lithium-air batteries. IPR in this area includes\u000d\u000a      (PCT\/JP2009\/066856 and PCT\/JP2010\/059494).\u000d\u000a    The quality of Bruce's research in developing new concepts in solid state\u000d\u000a      electrochemistry has been recognised by many international prizes, these\u000d\u000a      include the Galileo Gallilei Award of the Electrochemical (Italy, 2012),\u000d\u000a      the Arfvedson Schlenk Award of the German Chemical society (Germany 2011),\u000d\u000a      the Carl Wagner Memorial Award of the US Electrochemical Society (2011),\u000d\u000a      and the Akzo Nobel Science Award (UK, 2012) for `outstanding\u000d\u000a        contributions' to electrochemistry and lithium battery technology.\u000d\u000a      These awards recognised the impact Bruce's research has had on the\u000d\u000a      technology as well as the quality of his underpinning research.\u000d\u000a    "},{"CaseStudyId":"35262","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2963597","Name":"Ireland"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":[],"ImpactDetails":"\u000a    Ramage's innovations in synthesis and purification of long polypeptides\u000a      rapidly established\u000a      Albachem as a world leader in the supply of chemically synthesised\u000a      immunomodulatory proteins.\u000a      The subsequent synthesis of biologically active peptides that afforded\u000a      insights into the structure-\u000a      function relationships of antimicrobial peptides [3], cytokines [4], and\u000a      the ubiquitination process [5]\u000a      demonstrated to the world the usefulness of Albachem's procedures. The\u000a      Almac group (at that\u000a      time CSS) noticed Albachem's success and recognising the future earnings\u000a      potential, acquired\u000a      Albachem - thus taking a \"quantum leap into protein synthesis\".[S1] \"The\u000a        Albachem acquisition\u000a        allowed Almac to add very significant synthetic chemistry expertise to\u000a        its core competencies and,\u000a        critically, to establish a position at the interface between chemistry\u000a        and biology. Access to\u000a        Ramage's innovations transformed [Almac's] market differentiation by\u000a        allowing provision of\u000a        specialist services to its clients worldwide with a focus on the\u000a        pharmaceutical industry\".[S2]\u000a    1. Economic:\u000a    The skills and expertise resident in Albachem and derived from Ramage's\u000a      original research, were\u000a      key [S3] to the Almac group's subsequent success in worldwide protein and\u000a      peptide sales (&gt; &#163;6M\u000a      revenue in REF period attributed to the technology described in Professor\u000a      Ramage's papers, not\u000a      including revenue generated through Almac's GMP capability that was built\u000a      on technical expertise\u000a      flowing from Albachem[S4]). Elaboration of the methodologies described in\u000a      Section 2 for the\u000a      chemical synthesis of long polypetides allows Almac to produce proteins in\u000a      high yield and purity.\u000a      Almac has made over 7000 peptides. Almac can also make polypeptides with\u000a      non-natural amino\u000a      acids that offer new research avenues to their customers. They specialise\u000a      in chemically\u000a      synthesised cytokines. There are &gt;60 of these in their catalogue with\u000a      biotinylation and site-specific\u000a      fluorescent labelling or PEGylation available. \"A legacy of a research\u000a        focus developed at ...\u000a        Edinburgh and in Albachem is our ongoing development of protocols for\u000a        synthesis of chemokines...\u000a        As well as being long polypeptides, chemokines are challenging to\u000a        manufacture because they\u000a        contain ... cysteines that form disulfide bridges following oxidation.\u000a        Starting from methods that are\u000a        founded on Ramage's original technologies, we have robust laboratory\u000a        protocols that have been\u000a        applied to several GMP campaigns on a range of chemokine products.\"\u000a      [S4] In effect, Albachem\u000a      became the specialist R&amp;D arm of the Almac group that offers protein\u000a      and peptide services. \"it is\u000a        easy to trace a clear pathway from research carried out in Professor\u000a        Ramage's lab in the early\u000a        1990s, through the spinning out of Albachem and its eventual acquisition\u000a        by Almac, to significant\u000a        past, present and future economic and health benefit impacts\".[F1]\u000a    Almac is nowadays a global-reach company with 3300 staff (2000 in UK) and\u000a      a &#163;300M turnover\u000a      with &#163;14.3M profit in 2012 and total profits 2008-12 of &#163;55M based on\u000a      sales to 600 companies\u000a      including all the market leaders. Peptide-based therapeutics represents\u000a      the fastest-growing class\u000a      of new drugs, accounting for ~2% of drugs on the market, but comprisin&#285;50%\u000a      of drugs in the\u000a      pipelines of major drug manufacturers. The market for peptide drugs is\u000a      growing by 7.5% annually\u000a      and will be more than $13 billion this year.\u000a    2. Human Capital:\u000a    A total of 14 Almac employees (eight PhD level) remain in Gladsmuir, East\u000a      Lothian, Scotland, while\u000a      large-scale GMP polypeptide manufacture occurs in a dedicated facility\u000a      established (2006) by\u000a      Almac in Craigavon, employing a further 14 people. In the REF period \"we\u000a        have trained many\u000a        chemists in peptide synthesis, in both full-time appointment and on\u000a        placements generating\u000a        significant human capital contribution to the economy\".[F1]\u000a    If it were not for Ramage's pioneering work with Tbfmoc, Almac &#8212; who\u000a      employ people around the\u000a      world &#8212; would have looked overseas when it chose to buy into the protein\u000a      synthesis business. They\u000a      may have not been able to make such rapid inroads into the market and\u000a      certainly would not be\u000a      employing any researchers in Scotland.\u000a    Impact Development Timeline:\u000a    1994 Albachem spun out from Ramage's research. Distinguishes itself by\u000a      its unique capacity to\u000a      produce cytokines.\u000a    2002 Current Operations Manager (PhD, University of Edinburgh 1995) joins\u000a      Albachem.\u000a    2004 CSS\/Almac acquires and expands Albachem.[S3]\u000a    2005 The Almac Group further expands peptide synthesis efforts,\u000a      introduces GMP.\u000a    2006 Almac establishes a dedicated facility in Craigavon, employing a\u000a      further 14 staff.\u000a    2007 Almac announces' `First in Man' approach to peptides, embraces\u000a      development of peptide\u000a      synthesis, full analytical support, and GMP [batch production, and CMC\u000a      (Chemistry,\u000a      manufacturing and controls) documentation].[S1]\u000a    2008 The current Almac Operations becomes Senior Group Leader in protein\u000a      synthesis at\u000a      Almac.[S4]\u000a    2013 Almac is fully established as a global-reach company with 3300 staff\u000a      (2000 in UK), &#163;275M\u000a      turnover and &#163;15M profit.\u000a    ","ImpactSummary":"\u000a    Impact: EaStCHEM spin out Albachem (1994), subsequently\u000a      incorporated into the Almac group,\u000a      enabling the latter company to become a world leader in the provision of\u000a      chemically synthesised\u000a      proteins.\u000a    Significance: Chemical synthesis is competitive with recombinant\u000a      methods for commercial\u000a      production of the therapeutic polypeptides that represent ~50% of drugs in\u000a      big pharma pipelines\u000a      and have a market value in 2008 of over $13B. The value attributable to\u000a      Ramage's methods for\u000a      polypeptide syntheses over the REF period is estimated at approximately\u000a      &#163;6M.\u000a    Beneficiaries: Drug manufacturers, contract research\u000a      organisations, patients, clinicians.\u000a    Research: Studies (1993-6) led by Ramage (at the University of\u000a      Edinburgh) on new methods for\u000a      high-yield total syntheses and purification of long polypeptides.\u000a    Reach: Almac's protein-manufacturing team remains in the UK with\u000a      24 staff members. The Almac\u000a      Group, headquartered in N. Ireland, has 3300 employees globally (1300\u000a      outside UK) and sells to\u000a      600 companies worldwide.\u000a    ","ImpactType":"Technological","Institution":"\u000a    EaStCHEM\u000a    ","Institutions":[{"AlternativeName":"Edinburgh (University of)","InstitutionName":"University of Edinburgh","PeerGroup":"A","Region":"Scotland","UKPRN":10007790},{"AlternativeName":"St Andrews (University of)","InstitutionName":"University of St Andrews","PeerGroup":"B","Region":"Scotland","UKPRN":10007803}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"3345440","Name":"Craigavon"}],"References":"\u000a    Underpinning research has been published in international,\u000a        high-quality, peer reviewed, academic\u000a        journals and receives citations from across the research area:\u000a    \u000aJournal articles\u000a      [1] * Affinity purification of synthetic peptides and proteins on porous\u000a      graphitized carbon\u000a      A. R. Brown, S. I. Irving, R. Ramage\u000a      Tet. Letters 1993, 34, 7129-7132. doi:10.1016\/S0040-4039(00)61617-9.\u000a      26 cits, JIF 2.4.\u000a    \u000a\u000a[2] * (17-tetrabenzo[a,c,g,i]fluorenyl)methylchloroformate (tbfmocCl) a\u000a      reagent for the rapid and\u000a      efficient purification of synthetic peptides and proteins\u000a      A. R. Brown, S. I. Irving, R. Ramage, G. Raphy\u000a      Tetrahedron, 1995, 51, 11815-11830. doi:10.1016\/0040-4020(95)00743-R.\u000a      17 cits, JIF 2.8.\u000a    \u000a\u000a[3] * A solid phase approach to quinolones using the DIVERSOMER&#174;\u000a      technology.\u000a      A. A. MacDonald, S. H. DeWitt, E. M. Hogan, R. Ramage\u000a      Tet. Letters, 1996, 37, 4815-4818. doi:10.1016\/0040-4039(96)00944-6.\u000a      45 cits, JIF 2.4.\u000a    \u000a\u000a[4] The total chemical synthesis of monocyte chemotactic protein-1\u000a      (MCP-1).\u000a      A. R. Brown, M. Covington, R. C. Newton, R. Ramage, P. Welch\u000a      J. Pept. Sci. 1996, 2, 40-46. doi:10.1002\/psc.46.o.\u000a      8 cits, JIF 2.1.\u000a    \u000a\u000a[5] Inhibition of the ubiquitin-proteasome system in Alzheimer's disease\u000a      Y. A. Lam, C. M. Pickart, A. Alban, M. Landon, C. Jamieson, R. Ramage, R.\u000a      J. Mayer, R. Layfield.\u000a      Proc. Natl. Acad. Sci, USA. 2000, 97, 9902-9906. doi:10.1073\/pnas.170173897.\u000a      198 cits, JIF 9.7.\u000a    \u000aPatent\u000a      [6] US Patent No: 6,566,520, 'Support for synthesis and purification of\u000a      compounds' filed 1999,\u000a      issued 2003). S. H. DeWitt, A. A. MacDonald, R. R. Ramage.\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"},{"Level1":"6","Level2":"1","Subject":"Biochemistry and Cell Biology"},{"Level1":"6","Level2":"5","Subject":"Microbiology"}],"Sources":"\u000a    [S1] A 'First in Man' approach to peptides, article containing 'quantum\u000a      leap' quote.\u000a      http:\/\/www.avakado.eu\/dev\/node\/417.\u000a    [S2] 'Integrating Technologies for Complete Chemical Synthesis'. Article\u000a      highlights the importance\u000a      of Ramage\/Albachem to protein synthesis in Almac http:\/\/www.almacgroup.com\/wp-content\/uploads\/Integrating_Technologies.pdf.\u000a    [S3] 'Broadening the Custom Synthesis portfolio'. Article explains how\u000a      crucial Albachem was seen\u000a      to be by CSS (CSS became part of Almac) http:\/\/www.almacgroup.com\/wp-content\/uploads\/SP2_S_Barr_profile_July_20051.pdf.\u000a    [S4] 'Modern Perspectives on Peptide Synthesis'. Article by current Almac\u000a      Operations Manager in\u000a      his capacity as leader of protein synthesis for Almac. http:\/\/www.almacgroup.com\/wp-content\/uploads\/Modern-Perspectives-on-Peptide-Synthesis.pdf.\u000a    [F1] Comments in corroborating letter made by the Operations Manager for\u000a      Almac.\u000a    \u000a    ","Title":"\u000a    Albachem: Commercialisation of the chemical synthesis of biologically\u000a      active\u000a      human proteins\u000a    ","UKLocation":[{"GeoNamesId":"2650225","Name":"Edinburgh"}],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Proteins and polypeptides are attractive research tools and therapeutic\u000a      agents. They combine\u000a      biological activity, low toxicity and high selectivity. But they are\u000a      expensive. While solid-phase\u000a      peptide synthesis was already a routine procedure, the cumulative outcome\u000a      of sub-100% yields for\u000a      each of many steps in the process had limited the length of peptides that\u000a      could be produced and\u000a      purified in useful quantities to &lt; 50-60 amino acid residues. Most\u000a      biologically or clinically interesting\u000a      proteins are bigger. Furthermore, many proteins of interest to\u000a      biotechnology and pharmaceutical\u000a      companies contain disulfide bonds, creating additional challenges for\u000a      synthesis.\u000a    Professor Robert Ramage, FRS, of EaStCHEM recognised an unmet need for\u000a      total protein\u000a      synthesis using solid-phase chemistry as a versatile alternative to\u000a      recombinant gene expression.\u000a      From 1993-5 the Ramage group published, [1, 2] and patented [6] new\u000a      solid-phase and protecting\u000a      group methodologies for peptide synthesis. The work allowed the total\u000a      synthesis of hitherto\u000a      inaccessible long polypeptides. He demonstrated the usefulness of these\u000a      techniques by\u000a      manufacturing biologically active proteins that provided detailed insights\u000a      into structure-function\u000a      relationships.[3-5]\u000a    Ramage recognised that resolution of the product from acetylated\u000a      truncated peptides was key. He\u000a      researched methods for derivatising the peptide N terminus with a\u000a      removable tag for affinity\u000a      purification on a solid support. He introduced the base-labile\u000a      N(f061)-protecting group,\u000a      tetrabenzo[a,c,g,i]fluorenyl-17-methoxycarbonyl (Tbfmoc) for affinity\u000a      purification on porous\u000a      graphitised carbon.[1,2] In a key paper, he described a convenient\u000a      synthesis of Tbfmoc and its\u000a      application to the production of proteins containing up to 85 amino acids.\u000a      The hydrophobicity of\u000a      Tbfmoc was further exploited to simplify peptide purification by\u000a      reverse-phase HPLC. The Ramage\u000a      group showed that Tbfmoc could be added directly to the N terminus rather\u000a      than being\u000a      incorporated as a Tbfmoc-Gly(cine)-OH. Thus, crucially, any peptide could\u000a      be made with retention\u000a      of its native N-terminal residue. This discovery was patented (US Patent\u000a      No: 6,566,520, 2003) [6]\u000a      and paved the way for the spin out of Albachem (1994). The University\u000a      supported Albachem by\u000a      contributing infrastructure, funding, collaborations and technical\u000a      assistance to transfer crucial\u000a      knowhow from academia into the commercial environment. Albachem remained\u000a      within the\u000a      University until 2002.\u000a    The utility of Tbfmoc was dramatically demonstrated in the production of\u000a      a biologically active\u000a      cytokine (monocyte chemoattractant protein 1, MCP-1). This contained 76\u000a      residues and two\u000a      disulfide bonds.[4] Critically, Tbfmoc was removable under mild\u000a      conditions, preserving the nascent\u000a      protein product in a reduced state (-SH). Subsequent oxidative folding\u000a      yielded the correct disulfide\u000a      pattern and fully active cytokine. Albachem thus demonstrated to the world\u000a      its capability of\u000a      producing large quantities of purified cell-signaling proteins. This\u000a      established its credentials as a\u000a      world-leader. Cumulatively, the 1993, 1995 and 1996 papers underpinned\u000a      Albachem's\u000a      establishment, subsequent growth and assimilation into CSS that later\u000a      became the Almac group.\u000a    The Ramage group's work expanded protein therapeutics by facilitating\u000a      access to multiple-gram\u000a      quantities of material suitable for use in laboratories, animal models and\u000a      humans. Future\u000a      prospects are exciting. Routine recombinant methods for protein\u000a      production, besides being\u000a      expensive, provide little flexibility for new developments because the\u000a      building blocks are\u000a      constrained to genetically encoded amino acids. No such limitations apply\u000a      to synthetic proteins of\u000a      the kind accessible via strategies based on Tbfmoc and its\u000a      successors that can incorporate a vast\u000a      range of chemistries.\u000a    Key researchers:\u000a    R. R. Ramage: PI, lead inventor on patents, from 09\/84 to retirement in\u000a      09\/01.\u000a    A. R. Brown, S. I. Irving, G. Raphy, C. Jamieson: PhD students and PDRAs\u000a      in Ramage group.\u000a    Y. A. Lam, C. M. Pickart: collaborators, School of Public Health, Johns\u000a      Hopkins Univ., USA.\u000a    A. Alban, M. Landon, R. J. Mayer, R. Layfield: collaborators in\u000a      University of Nottingham Medical\u000a      School.\u000a    "},{"CaseStudyId":"35405","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"6251999","Name":"Canada"},{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"6252001","Name":"United States"}],"Funders":["Engineering and Physical Sciences Research Council","Royal Society"],"ImpactDetails":"\u000a    The Chemistry Department's outreach and public engagement activities are\u000a      strongly connected to its exceptional research. Almost all academic staff\u000a      have an accessible talk on their research suitable for a range of\u000a      audiences. Public lectures introduce audiences to the fundamental ideas of\u000a      chemistry in engaging ways, in an effort to reduce the marginalisation of\u000a      chemistry within society and promote general public interest in chemistry.\u000a      UCL researchers' ability to engage non-specialist audiences in their\u000a      research has led to further invitations to present on chemistry more\u000a      broadly.\u000a    Promotion of chemistry to school pupils: The department has been\u000a      extensively involved in The Training Partnership's A-level student lecture\u000a      programme. Since 2008, 15 sell-out lectures, on topics such as atmospheric\u000a      and ice chemistry, have been given to nearly 14,000 pupils (underpinned\u000a      by, for example, outputs 1,2,5). The Training Partnership said: \"The\u000a        fact that UCL speakers have taken part on several, and in numerous cases\u000a        many, occasions indicates a high level of approval from students and\u000a        teachers... [The] chemistry department has performed a service of\u000a        inestimable value not just to chemistry but ultimately to developing the\u000a        nation's skill base and potential for knowledge-driven growth.\" [a]\u000a    The Chemistry Department regularly holds lectures for schools attracting\u000a      400 pupils per year from more than 45 schools. Since 2008, this series has\u000a      included lectures to inform pupils about its research on atmospheric\u000a      chemistry (Rowley, output 5), nanomaterials (e.g. output 9), and materials\u000a      design and prediction (Catlow, Lewis, output 6). Eight schools have found\u000a      the talks so useful that they have attended more than four lectures. Talks\u000a      have also regularly been delivered to A-level students through the UCL\u000a      Science Centre, with 16 such talks each delivered to between 300-500\u000a      students in the REF period. Talks to individual schools, often\u000a      demonstration lectures, are increasingly done by postgraduate students\u000a      speaking about research in their supervisor's area. This provides pupils\u000a      with the chance to talk to real researchers of a similar age to their own.\u000a    The department's success in introducing its research in schools led to\u000a      invitations to present on chemistry as a wider subject. For example,\u000a      Sella's lecture, \"How the Zebra got its Stripes\", about the crucial role\u000a      of chemical feedback mechanisms in natural pattern formation that also\u000a      asks profound questions about faith, has been given to over 38,000 GCSE\u000a      students at 26 GCSE ScienceLive events held since December 2008. GCSE\u000a      ScienceLive, which takes place across the UK, is a day-long event\u000a      consisting of talks from the country's most prestigious scientists to\u000a      inspire GCSE students to continue to study science. Participant feedback\u000a      includes: \"Before I had attended Science Live I had only chosen to\u000a        attend for the chance to miss a day of school (...) I also had no idea\u000a        what career path I was going to choose. But after your words on why I\u000a        should become a scientist (which shook my religious beliefs, which I\u000a        adhere [to] with conviction) I've decided that you are right, and\u000a        consequently for work experience placements I am visiting both Norwich\u000a        University Hospital and hopefully something else science-related. Thank\u000a        you so, so much.\" [b]\u000a    Stimulation of public interest and engagement in science: Sella\u000a      has spearheaded much of the outreach work, with the EPSRC awards\u000a      specifically enabling him to promote chemistry and establish himself as\u000a      the UK's foremost public exponent of chemistry. The success of Sella's\u000a      fellowship is highlighted by an article in New Scientist: \"It has often\u000a      been said that chemistry needs a champion in the mould of Brian Cox or\u000a      Richard Dawkins. That is starting to happen with the arrival of such\u000a      popularisers as Andrea\u000a        Sella of University College London\" [n]. As a result, he has not\u000a      simply presented science directly related to his own research (e.g. a\u000a      video on didymium, which is composed of rare earth metals, has been\u000a      watched over 21,000 times since December 2012 [c]), but because of this\u000a      underpinning research he has also been instrumental in bringing a broad\u000a      range of the department's chemistry to a wider audience, through regular\u000a      radio and TV appearances.\u000a    The department's research on thermodynamic properties of matter including\u000a      phase diagrams [output 4] led to Sella contributing to BBC Four's The\u000a        Secret Life of Ice in October 2011, which had 0.47m viewers in the\u000a      UK [j]. It also aired in 8 countries, including the USA, Canada and\u000a      Australia, helping promote chemistry among a global public audience. In\u000a      late 2012, this contribution was developed into a demonstration lecture\u000a      called Strange Ice, which has been delivered to 2,700 sixth-form\u000a      pupils through the Training Partnership's \"Chemistry in Action\" events,\u000a      and audiences at Cambridge, Cheltenham and Edinburgh Science festivals.\u000a      The Training Partnership stated \"the feedback on the most recent UCL\u000a      presenter, Sella in autumn 2012 and spring 2013 for `Strange Ice', ranged\u000a      from `outstanding' to `motivating' and `exceptional'\" [a].\u000a    The platform created by presenting departmental research, combined with\u000a      Sella's ability to translate complex subjects for the public, led to\u000a      repeat invitations to act as consultant and contributor on major\u000a      television and radio productions. This has included ongoing collaboration\u000a      with, among others, the BBC. For example, he acted as consultant and\u000a      recorded demonstrations for the award-winning documentary The Secret\u000a        Life of Chaos, again utilising his expertise in thermodynamics\u000a      [output 4], presented by Jim Al-Khalili and first broadcast on BBC Four in\u000a      Jan 2010 (0.53m viewers [j]). The programme won the Best Film prize at the\u000a      International Science Film Festival 2010 and the Association of British\u000a      Science Writers' best scripted television programme award [d]. A senior\u000a      BBC producer confirms Sella's important contribution to programmes across\u000a      the entire spectrum of BBC broadcasting: \"He is terrific at translating\u000a      the complex and intangible into focused, accessible information which can\u000a      be incorporated into science programmes to make them multi-textured,\u000a      fascinating and entertaining to a wide variety of audiences.\" [i]\u000a    Sella also contributed to and appeared on the BBC Four 3-part series Chemistry:\u000a        A Volatile History in January 2010, which he ensured contained an\u000a      appropriate mixture of historical context and scientific rigour. This\u000a      series holds the record for the highest audience of any science series on\u000a      BBC Four and was consistently one of the channel's top 2 broadcasts\u000a      throughout the series, demonstrating that the public engaged with the\u000a      topic (0.74m viewers tuned in to the first episode) [j]. It was nominated\u000a      for a 2010 Specialist Factual BAFTA [h]. It also aired in the USA. Online\u000a      comments were positive, including: \"I learnt more in these 4 viewings\u000a        than during 3 years of weekly chemistry lessons at college\"; \"Superb.\u000a        The opening episode of this series was simply excellent, with an\u000a        engaging presenter, well demonstrated experiments and evocative\u000a        locations\", and \"If only all chemistry lessons were this good at\u000a        school, we'd all become scientists\" [f]. His other work has included\u000a      contributions to the BBC Four 2-part series Everything and Nothing\u000a      (March 2011, 0.43m viewers); the 3-part Science and Islam (Jan\u000a      2009, up to 0.42m viewers per episode); the BBC Two 6-parter The Story\u000a        of Science: Power, Proof and Passion (May 2010, 1.56-2.25m viewers\u000a      per episode); and Channel 4's Heston's Tudor Feast (March 2009,\u000a      2.6m viewers) [j]. A BBC presenter noted that without Sella's\u000a      \"fundamental\" input, many science series \"wouldn't make it to screen\" and\u000a      was a crucial source for promoting science to young children: without it,\u000a      \"there would be little chemistry and much smaller audiences on [CBBC]\"\u000a      [o].\u000a    Presentations to general audiences: Sella's engagement activities\u000a      extend beyond his media outreach, with talks to the general public, such\u000a      as contributions to the Cheltenham Science Festival. Between 2008 and\u000a      2013, he delivered 24 presentations and 4 discussions to audiences of up\u000a      to 600 members of the public per session. These talks consistently drew on\u000a      departmental research; for example he curated a discussion between Dr\u000a      Lewis and architect Magnus Larsson to draw attention to the parallels\u000a      between deliberate design of porous structures such as zeolites and the\u000a      design of large-scale structures in which bacteria transform sand into\u000a      sandstone. He brought superhydrophobic surfaces [output 8], supercooled\u000a      water [outputs 1,2], phase diagrams and high- pressure science [output 4]\u000a      to this and other Science Festivals, as part of presentations including\u000a      the Overambitious Demo Challenge, Molecular Mastery, The Science of\u000a        Cocktails, and Mercury: Window on the Invisible. His talk Chemistry\u000a        and Architecture was underpinned by Catlow and Lewis's work into\u000a      computer-aided materials design [output 6]. A Festival organiser confirms\u000a      that Sella's events \"all received good feedback from members of the\u000a      audience... The comments included how enthusiastic Andrea is and how it\u000a      has motivated them to learn more or increased their understanding of the\u000a      topic. The style of his events, which often include demonstrations, also\u000a      helps to draw in audiences that might not want to attend debate or lecture\u000a      style events\" [g].\u000a    Since 2009 UCL researchers have been involved in Bright Club, a monthly\u000a      comedy event based on the participants' research (including the work of\u000a      Rowley and Parkin), run by the UCL Public Engagement Unit. Bright Club\u000a      brings researchers to a new audience: 20-50 year olds who have no existing\u000a      relationship with academia. The reach of these events is increased further\u000a      by free podcasts available on iTunes. Sella has also played an important\u000a      part in the science-based comedy event Festival of the Spoken Nerd\u000a      (FoTSN), performing to over 1,200 people over the past three years. One of\u000a      the organisers of FoTSN says: \"The chemistry demos are without a doubt the\u000a      most talked-about part of the show on the night, on social media, and for\u000a      days afterwards.\" [e]\u000a    Online outreach activities: The department has also undertaken a\u000a      number of online activities to engage the public with its research,\u000a      helping reach a far wider, international audience. For example, a 2009\u000a      collaboration with Sciencefilms and Labreporter led to the development of\u000a      six \"Lab Report\" short videos on CVD, atmospheric chemistry and\u000a      carbon-carbon bonds. These videos were posted on YouTube and had, as of 31\u000a      July 2013, been viewed some 25,000 times [m]. Meanwhile, Hirjibehedin\u000a      instituted a citizens' science project titled Feynman's Flowers,\u000a      which uses online participatory methods to educate the public about\u000a      molecular spintronics; the project webpage received around 1,800 unique\u000a      visitor hits from almost 80 countries since Sept 2012 [k].\u000a    The interfaces, catalytic and environmental group's exhibit on the\u000a      properties of water at the nanoscale, at the 2010 Royal Society Summer\u000a      Science Exhibition, included a free iPhone game called Waterfall that\u000a      users in 73 countries downloaded 4,265 times. During the impact period,\u000a      the 25+ videos on the group's YouTube channel were collectively viewed\u000a      110,000 times [l].\u000a    ","ImpactSummary":"\u000a    The UCL Department of Chemistry has for many years run a far-reaching\u000a      programme of outreach and public engagement that has deep roots in the\u000a      department's research programme. Its schools outreach work has promoted\u000a      chemistry and science among secondary school children, while contributions\u000a      to blogs, newspapers, radio, and television have engaged diverse audiences\u000a      from primary school children to the elderly. Millions of people have\u000a      viewed television contributions, while tens of thousands have been reached\u000a      in theatres and science fairs, with positive reviews and feedback\u000a      confirming a stimulation of public interest in, and understanding of,\u000a      chemistry.\u000a    ","ImpactType":"Societal","Institution":"\u000a    University College London\u000a    ","Institutions":[{"AlternativeName":"University College London","InstitutionName":"University College London","PeerGroup":"A","Region":"London","UKPRN":10007784}],"Panel":"B         ","PlaceName":[],"References":"\u000a    References [1], [3] and [6] best demonstrate the research quality.\u000a    \u000a[1] A one-dimensional ice structure built from pentagons, J.\u000a      Carrasco, A. Michaelides, M. Forster, S. Haq, R. Raval and A. Hodgson, Nature\u000a        Mater. 8, 427-431 (2009). doi.org\/bmw9jq\u000a    \u000a\u000a[2] Proton ordering in cubic ice and hexagonal ice; a potential new\u000a        ice phase&#8212;XIc, Z.\u000a        Raza, D.\u000a        Alf&#232;, C. G. Salzmann, J.\u000a        Klime&#353;, A. Michaelides and B.\u000a        Slater, Phys. Chem. Chem. Phys., 13, 19788-19795 (2011). doi.org\/fjjrv6\u000a    \u000a\u000a[3] (PhTe) 3 - : The\u000a        Anionic Tellurium Analogue of I 3 -\u000a      A. C. Hillier, S. Liu, A. Sella and M. R. J. Elsegood, Angew. Chem.\u000a        Int. Ed. 38, 2745-2747 (1999). doi.org\/bsfdxb\u000a    \u000a\u000a[4] Pressure-induced transformations and superconductivity of\u000a        amorphous germanium, O. I. Barkalov, V. G. Tissen, P. F. McMillan,\u000a      M. Wilson, A. Sella and M. V. Nefedova, Phys. Rev. B, 82, 020507\u000a      (2010). doi.org\/fvthph\u000a    \u000a\u000a[5] Ab initio investigations of the potential energy surfaces of the\u000a        XO+HO2 reaction (X=chlorine or bromine), N. Kaltsoyannis and D. M.\u000a      Rowley, Phys. Chem. Chem. Phys., 4, 419-427 (2002). doi.org\/cb5hgd\u000a    \u000a\u000a[6] De novo design of structure-directing agents for the synthesis of\u000a        microporous solids, D. W. Lewis, D. J. Willock, C. R. A. Catlow, J.\u000a      M. Thomas and G. J. Hutchings, Nature, 382, 604-607 (1996). doi.org\/dqqdhf\u000a    \u000a\u000a[7] Quantum engineering at the silicon surface using dangling bonds,\u000a      S.\u000a        R. Schofield, P. Studer,\u000a      C.\u000a        F. Hirjibehedin, N.\u000a        J. Curson, G.\u000a        Aeppli, D.\u000a        R. Bowler, Nature Communications, 4, 1649, (2013). doi.org\/pt5\u000a    \u000a\u000a[8] Water droplet bouncing &#8212; a definition for superhydrophobic\u000a        surfaces, C. R. Crick, I. P. Parkin, Chem. Commun., 47,\u000a      12059-12061 (2011). doi.org\/b8dtsp\u000a    \u000a\u000a[9] An investigation into the effect of thickness of titanium dioxide\u000a        and gold-silver nanoparticle titanium dioxide composite thin-films on\u000a        photocatalytic activity and photo-induced oxygen production in a\u000a        sacrificial system, S. Kundu, A. Kafizas, G. Hyett, A. Mills, J.\u000a      Darr, I. P. Parkin, J. Mater. Chem., 21, 6854-6863 (2011). doi.org\/fmjsdv\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"7","Subject":"Theoretical and Computational Chemistry"}],"Sources":"\u000a    [a] For corroboration of the impact of the A-level lecture series, see\u000a      the statement from the Training Partnership. Available upon request.\u000a    [b] A compilation of feedback from members of the public corroborates\u000a      that demonstrations stimulated public interest is available on request.\u000a    [c] Royal Institution Didymium video received 21,000 views between Dec\u000a      2012 and 31 July 2013:\u000a      http:\/\/youtu.be\/6Ul8CmUkO4E\u000a    [d] The Secret Life of Chaos, winner of Best Film at the\u000a      International Science Film Festival, 2010,\u000a      http:\/\/bit.ly\/1akaMbO, and Association\u000a      of British Science Writers award: http:\/\/bit.ly\/17nyio2\u000a    [e] FoTSN statement confirms Sella's work stimulated public interest in\u000a      chemistry. Copy available.\u000a    [f] Positive reviews of Chemistry: A Volatile History, http:\/\/bit.ly\/1atf6BM\u000a    [g] Statement from Cheltenham Science Festival Assistant confirms that\u000a      festival audiences have commented how Sella's demonstrations increased\u000a      their understanding. Available on request.\u000a    [h] 2010 Specialist Factual Bafta Award nomination for Chemistry: A\u000a      Volatile History:\u000a      http:\/\/awards.bafta.org\/award\/2010\/television\/specialist-factual\u000a    [i] A statement from a Senior BBC Producer corroborates Sella's\u000a      contribution to programmes across the BBC for a range of audiences.\u000a      Available on request.\u000a    [j] Viewing figures for all TV programmes from BARB. Available on\u000a      request.\u000a    [k] Feynman's flowers http:\/\/bit.ly\/1eZr355.\u000a      Usage data, Google Analytics. Available on request.\u000a    [l] Viewing figures for ICE YouTube page from YouTube. http:\/\/www.youtube.com\/icelcn\u000a    [m] Lab Report videos on YouTube: http:\/\/www.youtube.com\/sciencefilms\u000a    [n] RSC President quote in New Scientist, 24 January 2012, http:\/\/bit.ly\/1hFQnlt\u000a    \u000a    ","Title":"\u000a    Increasing public understanding of chemistry\u000a    ","UKLocation":[{"GeoNamesId":"2641181","Name":"Norwich"},{"GeoNamesId":"2653261","Name":"Cheltenham"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    The impact of the Chemistry Department's school outreach work and public\u000a      engagement activities is underpinned by research carried out in the\u000a      department by a number of academic staff.\u000a    One strand has examined important phenomena in surface-, materials- and\u000a      nano-science. Since 2006, researchers have used concepts from quantum to\u000a      statistical mechanics to apply and develop methods and computer\u000a      simulations to study, for instance, chemical reactions at surfaces and\u000a      processes of environmental relevance. Much of this research is carried out\u000a      with leading experimentalists across the world, and in recent years water\u000a      and ice have been a major focus of the work. Breakthroughs in this area\u000a      include the discovery of the first extended ice-like structure built\u000a      exclusively from water pentagons (in collaboration with colleagues at the\u000a      University of Liverpool) [1], and theoretical studies of new phases of ice\u000a      [2].\u000a    Professor Sella (Professor of Chemistry, at UCL since 1990) has worked on\u000a      the synthesis of molecular rare earth complexes and their electronic\u000a      structure [3]. His expertise in synthesis of air sensitive complexes has\u000a      led to collaborative projects with Professor McMillan on tetrelide systems\u000a      and their behaviour under high pressure. These systems have led to the\u000a      preparation of amorphous phases of the group 4 elements, work that has\u000a      uncovered superconductivity in germanium at high pressure [4]. For this,\u000a      the synthesis and initial high-pressure studies were carried out at UCL,\u000a      with the measurement of conductivity done by collaborators in Russia. In\u000a      2007, Sella was awarded an EPSRC Senior Media Fellowship &#8212; awarded to\u000a      enable leading academic researchers to advance public engagement with the\u000a      physical science &#8212; to be a champion for chemistry nationally, with a focus\u000a      on energy issues; this was extended in 2010.\u000a    Another aspect of UCL's research, led by Dr Rowley (Senior Lecturer)\u000a      since 1998, has focused on studying fundamental gas phase free radical\u000a      reactions. These reactions have potential impact on atmospheric\u000a      composition and therefore environmental effects including ozone depletion,\u000a      air quality and global warming. Specifically, reactions of peroxy radicals\u000a      and the unexpected effects of water vapour on reactions of these species\u000a      have been elucidated, giving a better description of atmospheric oxidation\u000a      and therefore pollutant removal mechanisms [5]. In addition, reactions of\u000a      chlorine and bromine monoxide species have been characterised, which has\u000a      led to a better quantitative understanding of halogen mediated atmospheric\u000a      ozone loss.\u000a    The work of Professor Catlow and Dr Lewis [6] uses computational methods\u000a      to understand the structure and synthesis of complex materials, and to\u000a      subsequently synthesise new materials with specific properties. The\u000a      research covers a range of solids with application as catalysts, sensors\u000a      and ceramics; the present focus is on microporous materials.\u000a    Dr Hirjibehedin's research at UCL since 2007 centres on understanding the\u000a      electronic and magnetic properties of nanoscale structures. It explores\u000a      how they might be used to make the smallest possible devices for\u000a      information processing, data storage, and sensing using low-temperature\u000a      scanning tunnelling microscopes [7]. STM is used to image individual atoms\u000a      and molecules on surfaces; to probe structural, electronic, and magnetic\u000a      properties; and even to arrange atoms and molecules into new\u000a      configurations.\u000a    Further research on the structure of surfaces has established a new scale\u000a      of superhydrophobicity. This is based simply upon the number of times\u000a      water droplets bounce on the surface which is dependent on the surfaces\u000a      microstructure [8]. Work has also focused on the use of CVD to create TiO2\u000a      layers doped with nano-particles for photocatalytic water reduction and\u000a      oxidation [9].\u000a    "},{"CaseStudyId":"37314","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255147","Name":"Asia"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"1269750","Name":"India"}],"Funders":["Biotechnology and Biological Sciences Research Council"],"ImpactDetails":"\u000d\u000a    This very recent work has informed the public about the scientific basis\u000d\u000a      of the reported activity of peptide-based skincare treatments, with high\u000d\u000a      levels of media coverage stimulating public interest and awareness of the\u000d\u000a      underpinning science. This is important since many previous cosmetic skin\u000d\u000a      care claims have been based on absent or insubstantial scientific\u000d\u000a      evidence. The work has already had substantial impact on industry &#8212; the\u000d\u000a      UK-based SME Forme Laboratories has, for example, launched a new\u000d\u000a      skincare product for menopausal women, \"Stratum C\", based on this work. Procter\u000a        and Gamble has experienced increased sales of \"Olay Regenerist\", an\u000d\u000a      existing product range containing the key KTTKS peptide, and other\u000d\u000a      companies in the cosmetics field have sought collaboration with Prof.\u000d\u000a      Hamley. Between 2010 and 2013, the research conducted at Reading received\u000d\u000a      considerable media attention in popular science magazines, national\u000d\u000a      newspapers, national radio, industry publications and women's magazines.\u000d\u000a      The media linked this rigorous, independent science with existing products\u000d\u000a      in the multi-million pound skincare market, bringing genuine evidence of\u000d\u000a      product efficacy to fact-hungry consumers. This not only increased public\u000d\u000a      awareness of the science, but has had a major impact on the entire\u000d\u000a      skincare industry.\u000d\u000a    Informing the public through media\u000d\u000a      Hamley's research publications [1 - 6] generated a series of media\u000d\u000a      publications that reached millions of people in the UK and across the\u000d\u000a      world. Examples include:\u000d\u000a    \u000d\u000a      \"The nano-secret of youthful skin\", New Scientist (21 November\u000d\u000a        2010) [Online audience of over 2.3 million unique users]\u000d\u000a      Macrae, F. &amp; Kisiel, R., \"Anti-wrinkle creams that really\u000d\u000a        work...but only with a magic ingredient\", Daily Mail (6 March\u000d\u000a        2013) [42 million UK unique browsers\/month; 129 million unique browsers\u000d\u000a        worldwide]\u000d\u000a      \"Scientists find `miracle ingredient' in anti-wrinkle creams\", Huffington\u000a          Post UK (7 March 2013) [4.8 million unique users]\u000d\u000a      \"Research proves Matrixyl CAN make you look younger!\", Woman\u000d\u000a          Magazine [over 600,000 people weekly &#8212; print, online and social\u000d\u000a        media]\u000d\u000a      \"Key to tissue growth may be in anti-wrinkle cream\", Phys.org\u000d\u000a        (1 November 2010) [&gt;1.5 million unique monthly users]\u000d\u000a      \"Scientists claim to discover \"anti-wrinkle secret\", ITV News\u000d\u000a        (6 Mar 2013) [1.5 million unique monthly users]\u000d\u000a      \"Anti-wrinkle creams actually work!\", The Times of India (20\u000d\u000a        Mar 2013) [average daily readership over 7.6 million]\u000d\u000a      \"There's the rub with anti-wrinkle creams\", The Australian Weekend\u000d\u000a          Magazine (6 Apr 2013) [weekly readership ~700,000]\u000d\u000a      \"Research suggests a specific peptide has enhance anti-ageing\u000d\u000a        properties\", CosmeticsDesign- Europe.com (7 March 2013)\u000d\u000a        [highest-read European news website in the cosmetics industry]\u000d\u000a      BBC Radio 4 &#8212; You and Yours, 21 Jun 2013\u000d\u000a    \u000d\u000a    The Daily Mail and ITV News both quoted the Fashion and Beauty Editor of\u000d\u000a      the Press Association as saying: `Anti-ageing creams frequently boast\u000d\u000a        about being packed full of peptides, but aren't specific as to which\u000d\u000a        one. Now the secret's out and there's some scientific evidence for its\u000d\u000a        collagen- boosting properties, women will be rushing to find out if it's\u000d\u000a        in their anti-ageing potion. It's likely that brands with products that\u000d\u000a        do contain Matrixyl will start shouting about it too if the \"miracle\"\u000d\u000a        peptide becomes the new buzz word in beauty. There was a stampede at\u000d\u000a        Boots in 2007 for No 7 Protect &amp; Perfect Beauty Serum after a BBC2\u000d\u000a        Horizon programme scientifically backed the [Matrixyl containing] lotion.....'.\u000d\u000a      [a]\u000d\u000a    Media attention leads to increased sales of existing skin products\u000d\u000a      The UK skincare market was valued at more than &#163;1.7 billion in 2011 and is\u000d\u000a      predicted to be worth more than &#163;1.9 billion by the end of 2016. Facial\u000d\u000a      care is worth 58.8% of the total skincare market value [Datamonitor &#8212;\u000d\u000a      \"Skincare in the UK to 2016\" published 22\/11\/2012]. Consumers are becoming\u000d\u000a      more appearance conscious, with a 7% increase between 2008 and 2011 in the\u000d\u000a      number of global consumers attaching importance to \"looking good\"\u000d\u000a      [Datamonitor &#8212; \"The Future of Skincare: Consumption trends and product\u000d\u000a      preferences\", published 07\/10\/2011]. Within such a competitive and\u000d\u000a      high-value industry, every market advantage is of huge benefit to\u000d\u000a      manufacturers.\u000d\u000a    As a result of the media attention, several women's magazines ran\u000d\u000a      articles that promoted skin products containing the `miracle ingredient',\u000d\u000a      Matrixyl, including Cosmopolitan [b] and Woman [c] , with\u000d\u000a      the latter referring directly to the research at Reading.[6]\u000d\u000a    One of the products mentioned is the Olay brand, a global market leader\u000d\u000a      [d], produced by Procter and Gamble (P&amp;G). Following the research\u000d\u000a      publication [6] and the associated media coverage, P&amp;G benefitted from\u000d\u000a      a significant boost in sales of this product in the UK. Exact sales\u000d\u000a      figures are confidential, but a spokesperson from the Procter and Gamble\u000d\u000a      London Innovation Centre [d,e] said there was a \"noticeable increase in\u000d\u000a        sales\", as quoted below :\u000d\u000a    \"The Molecular Pharmaceutics paper and subsequent mention in the Daily\u000d\u000a        Mail (Anti-wrinkle creams that really work\") led to a high level of\u000d\u000a        media interest and actual coverage across print and online publications\u000d\u000a        and social media platforms such as Twitter. The specific mention of an\u000d\u000a        Olay Regenerist product containing Matrixyl led to a noticeable increase\u000d\u000a        in sales of this product.\"\u000d\u000a        \"The fact that the original Molecular Pharmaceutics paper appeared in a\u000d\u000a        peer-reviewed science publication certainly gave great credibility to\u000d\u000a        the following media coverage, although none of the mentioned cosmetic\u000d\u000a        products had been part of the research. Media and consumers alike are\u000d\u000a        hungry for independent, believable information and we have seen direct\u000d\u000a        correlations between media coverage and sales numbers in this particular\u000d\u000a        case as well in previous examples. This is way [sic] research\u000d\u000a        partnerships and scientific credentialling are key strategies for Olay\u000d\u000a        and other P&amp;G businesses.\"\u000d\u000a    Industry invests in research and development and new products\u000d\u000a      The research has also impacted on small and medium enterprises working in\u000d\u000a      the skin care area. Forme Laboratories was recently established by a team\u000d\u000a      of entrepreneurs. Hamley's research influenced their approach to\u000d\u000a      developing a new range of skin care products, Stratum C, which are\u000d\u000a      scientifically formulated for the skin of menopausal women using Matrixyl.\u000d\u000a      Hamley is featured on the company website, explaining the science behind\u000d\u000a      their products [f]. The CEO of Forme Laboratories [g] stated that Hamley's\u000d\u000a      research findings [6] stimulated their investment in the development of\u000d\u000a      new products and further research:\u000d\u000a    \"We became aware of the work of Professor Hamley and the University of\u000d\u000a        Reading on peptides and collagen production through the online coverage.\u000d\u000a        This contributed to the development of a new product called StratumC\u000d\u000a        aimed directly at menopausal women to stimulate collagen growth during a\u000d\u000a        period of compromised cellular function. We hope to use the basic\u000d\u000a        science as a foundation for further research and to optimise the product\u000d\u000a        with the help of Professor Hamley and the University.\"\u000d\u000a    Stratum C products are manufactured in the US, and are available online\u000d\u000a      from the UK-based Forme Laboratories, with a full treatment regime for\u000d\u000a      three months costing &#163;120.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    The multi-million pound skincare industry has benefitted greatly from\u000d\u000a      research carried out since 2009 at Reading, demonstrating for the first\u000d\u000a      time that an ingredient in some anti-ageing face creams can genuinely\u000d\u000a      increase the amount of collagen produced by skin cells, thereby removing\u000d\u000a      the appearance of wrinkles. The research investigated the nanostructure of\u000d\u000a      the lipopeptide known as Matrixyl and how changes to its environment and\u000d\u000a      composition affect its structure and activity. These findings received\u000d\u000a      widespread media coverage in the UK and abroad, leading to noticeable\u000d\u000a      increases in sales of Matrixyl-containing products by Procter and Gamble\u000d\u000a      and enhancing the business of the UK-based SME Forme Laboratories,\u000d\u000a      who have developed a new line of effective skincare products for\u000d\u000a      menopausal women, based on the Reading results.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    University of Reading\u000d\u000a    ","Institutions":[{"AlternativeName":"Reading (University of)","InstitutionName":"University of Reading","PeerGroup":"B","Region":"South East","UKPRN":10007802}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    (Citations retrieved from Scifinder on 24\/10\/13)\u000d\u000a    Publications have been internally reviewed and assessed as of at least 2*\u000d\u000a      quality. Outputs marked as * are suggested to assessed quality of\u000d\u000a      research:\u000d\u000a    \u000a[1] Castelletto, V., Hamley, I.W., Perez, J., Abezgauz, L. &amp; Danino,\u000d\u000a      D. (2010) Fibrillar superstructure from extended nanotapes formed by a\u000d\u000a      collagen-stimulating peptide. Chem.l Commun., 46 (48): 9185 -\u000d\u000a      9187. DOI: 10.1039\/c0cc03793a. (Cited 18 times).\u000d\u000a    \u000a\u000a[2] Dehsorkhi, A., Castelletto, V., Hamley, I.W. &amp; Lindner, P. (2012)\u000d\u000a      Influence of a non-ionic amphiphile copolymer on the self-assembly of a\u000d\u000a      peptide amphiphile that forms nanotapes. Soft Matter, 8 (33):\u000d\u000a      8608-8615. DOI: 10.1039\/c2sm25990g.\u000d\u000a    \u000a\u000a[3] *Castelleto, V., Hamley, I.W., Adamcik, J., Mezzenga, R. &amp;\u000d\u000a      Gummel, J. (2012) Modulating self- assembly of a nanotape-forming peptide\u000d\u000a      amphiphile with an oppositely charged surfactant. Soft Matter, 8\u000d\u000a      (1): 217-226. DOI: 10.1039\/c1sm06677c. (Cited 20 times).\u000d\u000a    \u000a\u000a[4] Dehsorkhi, A., Castelletto, V., Hamley, I.W., Adamcik, J. &amp;\u000d\u000a      Mezzenga, R. (2013) The effect of pH on the self-assembly of a collagen\u000d\u000a      derived peptide amphiphile. Soft Matter, 9 (26):6033- 6036. DOI:\u000d\u000a      10.1039\/c3sm51029h.\u000d\u000a    \u000a\u000a[5] Palladino, P., Castelletto, V., Dehsorkhi, A., Stetsenko, D. &amp;\u000d\u000a      Hamley, I.W. (2012) Conformation and Self-association of peptide\u000d\u000a      amphiphiles based on the KTTKS Collagen sequence. Langmuir 28\u000d\u000a      (33): 12209 - 12215. DOI: 10.1021\/la302123h. (Cited 4 times).\u000d\u000a    \u000a\u000a[6] *Jones, R.R., Castelletto, V., Connon, C.J. &amp; Hamley, I.W. (2013)\u000d\u000a      Collagen stimulating effect of peptide amphiphile C16-KTTKS on\u000d\u000a      human fibroblasts. Mol. Pharmaceutics, 10 (3): 1063-1069. DOI:\u000d\u000a      10.1021\/mp300549d. (Cited 1 time).\u000d\u000a    \u000aGrants: This work was funded by BBSRC grants to Prof. Hamley:\u000d\u000a      BB\/I008187\/1 \"Polymeric Templates for Corneal Stem Cells\" (with Dr Che\u000d\u000a      Connon) and BB\/J019836\/1 \"Smart Materials for Wound Healing: A New Fast\u000d\u000a      Acting In Situ Method to Treat Skin and Eye Wounds\" (with Prof. Adrian\u000d\u000a      Williams and Dr Che Connon).\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"6","Level2":"1","Subject":"Biochemistry and Cell Biology"},{"Level1":"11","Level2":"15","Subject":"Pharmacology and Pharmaceutical Sciences"}],"Sources":"\u000d\u000a    [a] MacRae, F. &amp; Kisiel, R. (5 March 2013) \"Anti-wrinkle creams that\u000d\u000a      really work....but only with a magic ingredient\", Daily Mail &lt;http:\/\/www.dailymail.co.uk\/health\/article-2288955\/Anti-wrinkle-creams-really-work--magic-ingredient.html&gt;\u000d\u000a    [b] (2013) \"Cosmo's 10 best wonder creams\", Cosmopolitan\u000d\u000a      &lt;http:\/\/www.cosmopolitan.co.uk\/beauty-hair\/news\/trends\/beauty-products\/the-best-day-night-creams-wonder-creams?click=main_sr#fbIndex1&gt;\u000aEvidence\u000a      that the world's number one woman's magazine was promoting products\u000d\u000a      containing Matrixyl, with direct mention of this ingredient and reference\u000d\u000a      to supporting science behind it.\u000d\u000a    [c] (2013) \"Research proves Matrixyl CAN make you look younger!\", Woman\u000d\u000a      &lt;http:\/\/www.womanmagazine.co.uk\/beauty\/hot-new-beauty-buys\/research-reading-university-matrixyl-anti-ageing-olay-no7ou-look-younger\/&gt;.\u000a      Promotes Matrixyl-containing products and refers directly to research by\u000d\u000a      the University of Reading.\u000d\u000a    [d] P&amp;G (2 January 2013) \"Olay Regenerist\", P&amp;G connect +\u000d\u000a        develop stories\u000d\u000a      &lt;http:\/\/pgconnectdevelop.netcrafters.com\/home\/stories\/other-case-studies\/20130102-olay-regenerist.html&gt;.\u000aEvidence\u000a      that this matrixyl-containing product is a leading product.\u000d\u000a    [e] Scientific Communications, Global Olay and EMEA Skin Care, Procter\u000d\u000a      and Gamble London Innovation Centre.\u000d\u000a    [f] \"How Stratum C works\", Stratum C, The Science &lt;http:\/\/www.stratumc.com\/the-science\/&gt;\u000aLinks\u000a      Hamley's research directly to this new product line of skincare for\u000d\u000a      menopausal women.\u000d\u000a    [g] Director, Forme Laboratories &#8212; Contact details provided.\u000d\u000a    ","Title":"\u000d\u000a    Collagen Stimulating Lipopeptides for Cosmetic Applications\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2643743","Name":"London"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    Background\u000d\u000a      Ian Hamley, Diamond Professor of Physical Chemistry (2005-present), has\u000d\u000a      been investigating the nanostructure of the lipopeptide C16-KTTKS\u000a      (Matrixyl) since 2009. Matrixyl is an ingredient found in a number of\u000d\u000a      commercial face-creams and Hamley's group has demonstrated its ability to\u000d\u000a      increase the amount of collagen produced by fibroblasts &#8212; cells found in\u000d\u000a      connective tissues such as skin &#8212; by 70%. Collagen is the principal\u000d\u000a      protein that contributes to the strength and elasticity of skin.\u000d\u000a    While Hamley's research on C16-KTTKS has inherent implications\u000d\u000a      for skin-care products, his primary interest is in the development of next\u000d\u000a      generation biomaterials for assisting wound healing and regenerative\u000d\u000a      medicine, focusing on strategies to increase production of collagen, the\u000d\u000a      main structural protein in mammalian connective tissue. The peptide KTTKS\u000d\u000a      has been previously shown to promote and stimulate collagen production. In\u000d\u000a      2000, a French biotechnology company (Sederma) added a 16-carbon lipid\u000d\u000a      chain to KTTKS to confer enhanced stability in vivo, and thus increase its\u000d\u000a      bioavailability by increasing resistance to enzymatic degradation. This lipopeptide\u000d\u000a      or peptide amphiphile, (PA) C16KTTKS, was registered\u000d\u000a      under the trade name Matrixyl.\u000d\u000a    Investigating the nanostructure of Matrixyl\u000d\u000a      The way in which molecules of Matrixyl-like peptides aggregate depends\u000d\u000a      upon the length of the lipid tail and the surrounding chemical\u000d\u000a      environment, both of which can influence peptide activity. In 2009, Hamley\u000d\u000a      and Castelletto (Research Fellow at Reading, 2005-present) began studying\u000d\u000a      the nanostructure of Matrixyl to better understand its mode of action.\u000d\u000a      Despite its widespread commercial use, no previous studies of the\u000d\u000a      physico-chemical properties of Matrixyl had been undertaken. Castelletto\u000d\u000a      and Hamley (at Reading) led the research, although some experiments were\u000d\u000a      also carried out in specialist facilities at the Israel Institute of\u000d\u000a      Technology (Technion). Techniques including atomic force microscopy and\u000d\u000a      pyrene fluorescence microscopy were used to reveal the aggregated\u000d\u000a      nanostructure of Matrixyl. In 2010, the team reported that, unlike\u000d\u000a      compounds of similar size that form cylindrical nanostructures, Matrixyl\u000d\u000a      forms flattened aggregates termed \"nanotapes\".[1] The molecules were\u000d\u000a      stacked in a way that suggested the structure itself may be important in\u000d\u000a      stimulating collagen production.\u000d\u000a    How the chemical environment influences structure\u000d\u000a      In skincare products, Matrixyl is formulated with surfactants such as\u000d\u000a      emulsifiers or dispersants, and it was of fundamental interest to\u000d\u000a      understand how these materials affect self-assembly of Matrixyl and\u000d\u000a      ultimately its biomedical activity. Between 2011 and 2012, Hamley's group\u000d\u000a      demonstrated that a non-ionic polymeric surfactant (Pluronic P-123) can be\u000d\u000a      used to prepare solutions of Matrixyl without disrupting its self-assembly\u000d\u000a      characteristics or altering its activity. [2] They also examined the\u000d\u000a      influence of the anionic surfactant SDS on Matrixyl, finding that, due to\u000d\u000a      electrostatic forces, different nanostructures are formed depending on the\u000d\u000a      amount of SDS added, resulting in modification of its macroscopic\u000d\u000a      characteristics such as a change in morphology from sol to gel. [3] In\u000d\u000a      2013, the team found that changes in pH also affected self-assembly of\u000d\u000a      Matrixyl. At pH2, the Matrixyl formed spherical micelles with the\u000d\u000a      hydrophobic tails inside, whilst at pH3, they assembled into tape-like\u000d\u000a      structures and, at pH4, they formed right-hand twisted fibrous structures.\u000d\u000a      [4]\u000d\u000a    Modifying the lipid tail\u000d\u000a      The Reading group also investigated how the length of the lipid tail\u000d\u000a      altered the self-assembly of Matrixyl-type peptide amphiphiles, using\u000d\u000a      techniques including circular dichroism and small angle X-ray scattering,\u000d\u000a      to understand how tail length affected their physico-chemical properties.\u000d\u000a      They found that skin-permeability increased with longer lipid tails, with\u000d\u000a      a C14 tail formulation estimated to be 3.8 times less permeable\u000d\u000a      than a C16 tail and a C16 tail 3.8 times less\u000d\u000a      permeable than a C18 tail. [5] Therefore it seemed possible at\u000d\u000a      this stage that a PA with a longer lipid tail could have an enhanced\u000d\u000a      collagen-stimulating effect due to a higher skin-permeability, with\u000d\u000a      implications not only in regenerative medicine but also for the skin-cream\u000d\u000a      industry.\u000d\u000a    Proving that Matrixyl stimulates collagen production\u000d\u000a      In 2013, Hamley and colleagues reported that Matrixyl stimulates collagen\u000d\u000a      production in human skin and corneal cells in a concentration-dependent\u000d\u000a      manner, indicating that self-assembly and collagen production are\u000d\u000a      interrelated. [6] The finding was based on nanostructural analyses carried\u000d\u000a      out by Roanne Jones (PhD student, 2010-2013) who was co-supervised by\u000d\u000a      Hamley and Dr Che Connon (Lecturer\/Associate Professor in Pharmacy,\u000d\u000a      2007-date) at Reading. This was the first independent demonstration of the\u000d\u000a      stimulation of collagen production by C16-KTTKS \/ Matrixyl.\u000d\u000a    "},{"CaseStudyId":"37317","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"2921044","Name":"Germany"},{"GeoNamesId":"3017382","Name":"France"}],"Funders":["Engineering and Physical Sciences Research Council","Royal Society"],"ImpactDetails":"\u000d\u000a    The UK government is committed to delivering a mixture of energy sources\u000d\u000a      that will provide a secure, affordable, low-carbon supply of electricity\u000d\u000a      in the future. Given finite fossil-fuel resources, the pressing need to\u000d\u000a      reduce carbon emissions worldwide and the inadequacy of alternative means\u000d\u000a      of electricity generation, such as wind and wave power, nuclear power\u000d\u000a      represents a major viable source of electricity. In 2012, nuclear energy\u000d\u000a      accounted for 19% of electricity supply (Digest of UK Energy Statistics\u000d\u000a      2013, Department of Energy and Climate Change). Given the UK's target of\u000d\u000a      reducing emissions of greenhouse gases to 20% of their 1990 levels, by\u000d\u000a      2050, nuclear energy is expected to become increasingly important. By\u000d\u000a      2050, up to 49% of the UK's electricity generation could be provided by\u000d\u000a      nuclear power (House of Lords report on Nuclear Research and Development\u000d\u000a      Capabilities, 2011).\u000d\u000a    The UK currently has about 4.7 million cubic metres of nuclear waste, of\u000d\u000a      which 1000 cubic metres is classified as high-level radioactive waste\u000d\u000a      (Radioactive Wastes in the UK, 2010 Inventory, Nuclear Decommissioning\u000d\u000a      Authority). This will grow as the UK invests in new nuclear build. The UK,\u000d\u000a      along with France, currently reprocesses its spent nuclear fuel to recover\u000d\u000a      unused uranium and plutonium, which can then be used again as fuel. The\u000d\u000a      residual waste contains highly radioactive minor actinides (americium,\u000d\u000a      curium and neptunium) as well as corrosion products and non-radioactive\u000d\u000a      fission products such as lanthanides. Whilst comprising less than 0.1% of\u000d\u000a      the mass of the spent fuel, the minor actinides constitute the major\u000d\u000a      long-term hazard, posing extreme, long-term storage problems. They emit\u000d\u000a      highly penetrating gamma-radiation and generate large amounts of heat,\u000d\u000a      requiring deep geological storage for more than 300,000 years. Reducing\u000d\u000a      this nuclear-waste burden would make nuclear power far more sustainable.\u000d\u000a      One approach to this is through the development of strategies to separate\u000d\u000a      (partition) and inactivate (transmute) the highly radioactive minor\u000d\u000a      actinides.\u000d\u000a    The group in Reading developed the CyMe4BTP ligand during the PARTNEW\u000d\u000a      programme (2000 - 2003, budget &#8364;2.2M, 10 partners) and this led to the\u000d\u000a      EUROPART (budget &#8364;6M, 26 partners) and ACSEPT programmes (budget &#8364;9M, 34\u000d\u000a      partners). During these programes, further research at Reading led to the\u000d\u000a      discovery of the CyMe4BTBP and CyMe4BTPhen ligands. Within EUROPART and\u000d\u000a      ACSEPT, partner organisations including the French Atomic Energy\u000d\u000a      Commission were involved in assessing the minor-actinide selectivity of\u000d\u000a      the ligands and in measuring their rates of actinide extraction, stripping\u000d\u000a      qualities, solvent loading and hydrolytic and radiolytic stability. The\u000d\u000a      European Commission continues to support this work through the SACSESS\u000d\u000a      programme (&#8364;5.5M, 24 partners).[a] The ligands developed at Reading have\u000d\u000a      been shown to be highly selective for extraction of the minor actinides\u000d\u000a      (relative to the lanthanides), and they also exhibit significant stability\u000d\u000a      under the extremely radioactive and highly acidic reprocessing conditions.\u000d\u000a      Furthermore &#8212; and crucially in terms of impact &#8212; the CyMe4BTBP ligand has\u000d\u000a      been shown by workers at the European Commission's Joint Nuclear Research\u000d\u000a      Centre in Germany to effectively \"clean up\" real nuclear reprocessing\u000d\u000a      waste.[b]\u000d\u000a    The success of the work to develop selective extractants has impacted on\u000d\u000a      French nuclear policy, as noted in the \"National Plan for Management of\u000d\u000a      Radioactive Materials and Nuclear Waste 2013-2015\" where it is stated (p.\u000d\u000a      214) in Section 4.2. \"Separation of minor actinides\":\u000d\u000a    \"Research has led to the development of specific extractants and methods\u000d\u000a      of separation, successfully tested on the laboratory scale for each\u000d\u000a      process considered: extraction of Americium (EXAM), extraction of\u000d\u000a      Americium and Curium (SANEX) and group extraction of all actinides\u000d\u000a      (GANEX)\". \"In the period 2013-2015 a full scale experiment should be\u000d\u000a      pursued, from the extraction of several kg of spent fuel obtained from\u000d\u000a      actual, current processing operations, right through to the production of\u000d\u000a      pure pellets of Americium dioxide, AmO2. This experiment will\u000d\u000a      test, across several nuclear laboratories, the sequence of the various\u000d\u000a      unit operations (separation, isolation, conversion to oxide, pellet\u000d\u000a      fabrication), and also various related operations including the management\u000d\u000a      of effluents and by-products.\"[c]\u000d\u000a    For use in an industrial setting, these ligands need to be synthesised on\u000d\u000a      a tonne scale. The Reading group has developed a scalable synthesis of the\u000d\u000a      CyMe4-diketone, a key precursor to all of the ligands, demonstrating for\u000d\u000a      the first time the potential for large-scale industrial production of\u000d\u000a      these compounds. This led to the filing of a patent [d] and the licensing\u000d\u000a      of intellectual property in this patent from the University of Reading to\u000d\u000a      TechnoComm Ltd, a company specialising in technology commercialisation in\u000d\u000a      the chemical sciences.[e] The CyMe4-BTP, CyMe4BTBP and CyMe4-BTPhen\u000d\u000a      ligands are now manufactured and sold by TechnoComm Ltd.[f] These ligands\u000d\u000a      have been purchased for process evaluation by leading national and\u000d\u000a      international nuclear centres such as the NNL (UK), the European\u000d\u000a      Commission Joint Research Centre (Germany), and the Idaho and Oak Ridge\u000d\u000a      National Laboratories (USA), demonstrating that these organisations\u000d\u000a      recognise the potential of the new compounds for effectively treating\u000d\u000a      nuclear waste.\u000d\u000a    Funding to develop a full-scale industrial process for separating minor\u000d\u000a      actinides from nuclear reprocessing waste awaits EU approval. However, the\u000d\u000a      demonstration that CyMe4BTBP shows excellent efficiency and selectivity\u000d\u000a      for the minor actinides on real nuclear reprocessing waste has provided\u000d\u000a      first proof of concept for industrial scale chemical partitioning of the\u000d\u000a      minor actinides and demonstrates the potential to revolutionise nuclear\u000d\u000a      waste management. Not only does it promise to dramatically reduce the\u000d\u000a      levels of radiotoxicity and waste-heat production, but it also paves the\u000d\u000a      way to more efficient use of geological nuclear-waste repositories. This\u000d\u000a      will help to make nuclear power more sustainable, strengthening its role\u000d\u000a      as a genuine alternative to fossil fuels and helping the UK government to\u000d\u000a      meet its 2050 greenhouse-gas emission targets. Reading's position within\u000d\u000a      UK partitioning and transmutation capability has been recognised in a\u000d\u000a      report by the Select Committee on Science and Technology.[g]\u000d\u000a    ","ImpactSummary":"\u000d\u000a    The research groups of Professor Laurence Harwood and Dr Michael Hudson\u000d\u000a      (now retired) at the University of Reading have developed new and highly\u000d\u000a      selective extractants for spent and reprocessed nuclear fuels. These novel\u000d\u000a      extractants remove specifically the components in nuclear waste that have\u000d\u000a      the highest levels of long-term radioactivity. The extracted components\u000d\u000a      (minor actinides) may subsequently be converted &#8212; \"transmuted\" &#8212; into\u000d\u000a      elements with greatly reduced radioactivity. Storage times for high-level\u000d\u000a      nuclear waste can thus be reduced by a factor of a thousand, typically\u000d\u000a      from 300,000 to 300 years. This significant advance in the management of\u000d\u000a      nuclear waste means that next-generation nuclear power production will be\u000d\u000a      safer, more economical and more sustainable, as well as increasing the\u000d\u000a      wider acceptance of nuclear power as a viable alternative to fossil fuels.\u000d\u000a      The newly-developed extractants are now available commercially through\u000d\u000a      TechnoComm Ltd.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    University of Reading\u000d\u000a    ","Institutions":[{"AlternativeName":"Reading (University of)","InstitutionName":"University of Reading","PeerGroup":"B","Region":"South East","UKPRN":10007802}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"5596512","Name":"Idaho"}],"References":"\u000d\u000a    Key outputs include one Patent Cooperation Treaty (PCT) application and\u000d\u000a      five papers published in internationally renowned, peer-reviewed journals.\u000d\u000a      As further indication of the \"quality\" of these publications, the number\u000d\u000a      of times each paper has been cited is given in parentheses (retrieved from\u000d\u000a      Scifinder on 23\/10\/13):\u000d\u000a    \u000a[1]. M. J. Hudson et al., \"The coordination chemistry of\u000d\u000a      1,2,4-triazinyl bipyridines with lanthanide(III) elements &#8212; implications\u000d\u000a      for the partitioning of americium(III)\", Dalton Trans., 1675\u000d\u000a      (2003). DOI: 10.1039\/b301178j. (Cited 42 times).\u000d\u000a    \u000a\u000a[2]. M. J. Hudson et al., \"New Bis-triazinyl Pyridines for\u000d\u000a      Americium(III) Extraction\", New J. Chem. 8, 1171 (2006). DOI:\u000d\u000a      10.1039\/B514108G. (Cited 79 times).\u000d\u000a    \u000a\u000a[3]. L. M. Harwood et al., \"The Separation of Americium(III) from\u000d\u000a      Europium(III) by Two New 6,6'-Bis(triazinyl)-2,2'-bipyridines in Different\u000d\u000a      Diluents\", Solvent Extr. Ion Exch. 29, 551 (2011).\u000d\u000a      DOI:10.1080\/10496475.2011.556989.\u000d\u000a    \u000a\u000a[4]. F. W. Lewis et al., \"Highly Efficient Separation of\u000d\u000a      Actinides from Lanthanides by a Phenanthroline-Derived Bis-Triazine\u000d\u000a      Ligand\", J. Am. Chem. Soc. 133, 6950 (2011). DOI:\u000d\u000a      10.1021\/ja203378m. (Cited 36 times). This paper was accompanied by an\u000d\u000a        article in Chemistry World News on the Royal Society of Chemistry\u000d\u000a        website\" (www.rsc.org\/chemistryworld\/News\/2011\/August\/09081101.asp)\u000d\u000a    \u000a\u000a[5]. L. M. Harwood, M. J. Hudson and F. Lewis (co-inventors), \"Synthesis\u000d\u000a      of Ligands for use in Actinide Extraction\", PCT application number\u000d\u000a      WO2001\/077081 (2011); http:\/\/www.google.com\/patents\/US20120264935.\u000d\u000a    \u000a\u000a[6]. F. W. Lewis et al., \"Synthesis and Evaluation of Lipophilic\u000d\u000a      BTBP Ligands for An\/Ln Separations in Nuclear Waste Treatment: Effect of\u000d\u000a      Alkyl Substitution on Extraction Properties and Implications for Ligand\u000d\u000a      Design\", Eur. J. Org. Chem. 8, 1509 (2012). DOI:\u000d\u000a      10.1002\/ejoc.201101576. (Cited 7 times).\u000d\u000a    \u000aGrants: (i) M. J. Hudson, PARTNEW, European Union, 2000-2003, &#163;216,000.\u000d\u000a      (ii) M. J. Hudson, EUROPART, European Union, 2004-2006, &#163;214,000. (iii) L.\u000d\u000a      M. Harwood, ACSEPT, European Union, 2009-2011, &#163;265,000. (iv) L. M.\u000d\u000a      Harwood, MBase, EPSRC, 2010-2014, &#163;149,000. (v) L. M. Harwood, SACSESS,\u000d\u000a      European Union, 2013-2015, &#163;149,000.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"},{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"},{"Level1":"9","Level2":"4","Subject":"Chemical Engineering"}],"Sources":"\u000d\u000a    [a]. Chef de Project (SACSESS), Commissariat &#224; l'&#201;nergie Atomique,\u000d\u000a      Marcoule. (information on budgets and partners involved in the PARTNEW,\u000d\u000a      EUROPART, ACSEPT and SACSESS consortia). (Contact details provided\u000d\u000a      separately)\u000d\u000a    [b]. D. Magnusson et al, \"Demonstration of a SANEX process in\u000d\u000a      centrifugal contactors using the CyMe4-BTBP molecule on a genuine fuel\u000d\u000a      solution\", Solvent Extraction and Ion Exchange, 27, 97, (2009).\u000d\u000a      DOI:10.1080\/07366290802672204.\u000d\u000a    [c] Translated from \"Plan national de gestion des mati&#232;res et des d&#233;chets\u000d\u000a      radioactifs 2013-2015\", Le minist&#232;re de l'Ecologie, du D&#233;veloppement\u000d\u000a      durable et de l'Energie, Paris, 2013.\u000d\u000a    See: http:\/\/www.developpement-durable.gouv.fr\/Publication-du-Plan-National-de.html\u000d\u000a    [d]. L.M. Harwood, M. J. Hudson and F. Lewis, GB 09 22 588.9, 2010;\u000d\u000a      WO2001\/077-81, 2011.\u000d\u000a    [e]. Contact: CEO of TechnoComm Ltd. (http:\/\/www.technocomm.co.uk).\u000a      Full details of purchasing establishments and quantities sold are\u000d\u000a      commercially sensitive.\u000d\u000a    [f]. Technocomm Ltd http:\/\/www.technocomm.co.uk\/page15.html\u000d\u000a    [g]. Oral and written evidence to the Select Committee on Science and\u000d\u000a      Technology \"Inquiry on Nuclear Research and Development Capabilities\" 24\u000d\u000a      May 2011, page 190.\u000d\u000a    See: http:\/\/www.parliament.uk\/business\/committees\/\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Development of New Chemical Methods for Waste Management in Future\u000d\u000a      Nuclear Fuel Cycles\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    Much of the uranium and plutonium in spent nuclear fuel can be recovered\u000d\u000a      and re-used for power generation. However, 3% of the residual waste from\u000d\u000a      current nuclear fuel cycles is extremely radiotoxic and must be stored for\u000d\u000a      some 300,000 years before it can be considered safe. This long-term\u000d\u000a      radiotoxicity arises from the presence of highly radioactive minor\u000d\u000a      actinides (americium, curium and neptunium), though these constitute less\u000d\u000a      than 0.1% of the spent fuel. If these active components can be separated\u000d\u000a      from the accompanying lanthanides, they can be converted to short-lived or\u000d\u000a      non-fissile elements by neutron bombardment, a process known as\u000d\u000a      \"transmutation\", in the next generation of nuclear reactors (\"Generation\u000d\u000a      IV\"). Such reactors are due for deployment between 2020 and 2030 and\u000d\u000a      represent major advances in sustainability, safety, resilience and\u000d\u000a      economics. Transmutation of the minor actinides will reduce waste-storage\u000d\u000a      times a thousand-fold, to only some 300 years. However, separation of the\u000d\u000a      minor actinides from the accompanying lanthanides is essential for\u000d\u000a      transmutation to succeed, as the lanthanides preferentially absorb\u000d\u000a      neutrons in the reactor, so acting as \"neutron poisons\".\u000d\u000a    The challenge of separating very similar chemical species in nuclear\u000d\u000a      waste is made even more difficult by the operating conditions under which\u000d\u000a      it must be carried out: strong radioactive flux and extreme acidicity. In\u000d\u000a      2003, it was shown by researchers at the University of Reading, working\u000d\u000a      with the French Atomic Energy Commission, that bis(triazinyl)-pyridine\u000d\u000a      ligands (BTPs) can selectively extract minor actinides from lanthanides,\u000d\u000a      with a selectivity of around 30:1. However, while these BTPs provided good\u000d\u000a      selectivity under laboratory conditions, they proved unstable under the\u000d\u000a      conditions experienced during nuclear waste reprocessing.[1]\u000d\u000a    Building on this discovery, University of Reading researchers then went\u000d\u000a      on to develop stable extractant molecules that can separate the\u000d\u000a      minor actinides from the chemically very similar lanthanides in nuclear\u000d\u000a      waste. Since 2000, Dr M. J. Hudson (Lecturer\/Reader 1972-2005), Dr C. E.\u000d\u000a      Boucher (Ph.D. student, 2000-2003), Dr T. A. Youngs (Ph.D. student,\u000d\u000a      2000-2004), Dr M. R. St. J. Foreman (PDRA, 2001-2007), Dr F. W. Lewis\u000d\u000a      (PDRA, 2008-2012) Dr A. W. Smith (PDRA, 2013 &#8212; present) and Prof. L. M.\u000d\u000a      Harwood (Professor of Organic Chemistry, 1995 &#8212; present) have carried out\u000d\u000a      this research.\u000d\u000a    The research undertaken at the University of Reading has led to the\u000d\u000a      design and synthesis of a new series of selective extractants. The first\u000d\u000a      of these, dubbed CyMe4BTP was shown to be stable under typical nuclear\u000d\u000a      reprocessing conditions (high radioactive flux and acidity) and, moreover,\u000d\u000a      showed an unexpectedly high minor-actinide selectivity of 5000:1 relative\u000d\u000a      to lanthanides.[2] Subsequent research by the group led to a\u000d\u000a      second-generation ligand, CyMe4BTBP, which achieved the desired\u000d\u000a      minor-actinide separation from actual downstream reprocessing waste [3],\u000d\u000a      enabling the establishment of Europe's first practical Separation of\u000d\u000a      Actinides and Extraction (SANEX) process. Finally, a third-generation\u000d\u000a      ligand, CyMe4BTPhen, has most recently been developed, which is\u000d\u000a      structurally pre-organised and shows considerably faster rates of\u000d\u000a      extraction. The new ligand achieves high levels of extraction in only 15\u000d\u000a      minutes, as opposed to several hours for CyMe4BTBP, whilst maintaining\u000d\u000a      stability and selectivity.[4]\u000d\u000a    The work at Reading University has been funded by the European Union\u000d\u000a      through four programmes (PARTNEW, 2000-2003; EUROPART, 2004-2007; ACSEPT,\u000d\u000a      2008-2012; and SACCSESS, 2013-2015), with combined budgets of over &#8364;22M,\u000d\u000a      and involving more than 30 research institutes throughout Europe and\u000d\u000a      leading European nuclear-research centres (Commissariat &#224; l'&#201;nergie\u000d\u000a      Atomique, Marcoule, France; National Nuclear Laboratory, Sellafield, UK;\u000d\u000a      Karlsruhe Institute of Technology, Karlsruhe, Germany).\u000d\u000a    "},{"CaseStudyId":"37331","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2963597","Name":"Ireland"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":[],"ImpactDetails":"\u000a    Medical devices are a $434 billion market worldwide, and coating systems\u000a      for use in medical devices reached a market value of ~$5.3 billion\/year in\u000a      2012 (Medical Market Outlook Report, Espicom Business Intelligence, 2013).\u000a    Given the very recent date of the fundamental research that underpins the\u000a      technology, it is remarkable that it has already led to new products which\u000a      are now being marketed actively by Biointeractions Ltd. Economic impacts\u000a      of this work include the generation of new capital investment by\u000a      Biointeractions and 3 new staff positions within the company.\u000a    New capital investment by BioInteractions, resulting from this work, has\u000a      included the purchase of a Sono-Tek, ultrasonic spray stent-coating\u000a      platform and the renting of clean room facilities for the coating of\u000a      stents for human implantation, with 1000 stents having being coated at a\u000a      cost of &#163;200 per stent. Moreover, the polymer technology developed for\u000a      coating coronary stents, as described above (Adapt&#8482;)[a],[b] has very\u000a      recently been adapted &#8212; with a partner company &#8212; for use in implantable\u000a      glucose sensors and catheters.[c] The glucose sensors, using the Adapt&#8482;\u000a      polymer coating system under license from BioInteractions, will allow the\u000a      partner company to market an improved device with extended implantation\u000a      lifetime. The range of clinical applications for such implantable devices\u000a      is very significant, providing a significantly larger potential market for\u000a      the commercialisation of the technology. A partnership agreement is\u000a      expected to be in place by the end of 2013, but details are commercially\u000a      sensitive and so are confidential at present. The licensing agreement is\u000a      expected to generate income of ~&#163;150K\/year from 2016 onwards.[d] The\u000a      projected incomes from the lubricating coating system for catheters\u000a      (Assist&#8482;)[c] developed from the Adapt&#8482; technology, are &#163;176K in 2015 and\u000a      &#163;590K in 2017.[d]\u000a    The second-generation coating system developed through the follow-up KTP\u000a      programme requires approval for medical use in humans. BioInteractions is\u000a      currently involved in the initial stages of clinical evaluation, and a\u000a      partnership has been agreed with IsleChem LLC that will allow production\u000a      of the materials on the scale needed for full clinical evaluation. The\u000a      further capital investment required to bring this novel material to a\u000a      point where BioInteractions can realise their investment through a\u000a      technology licensing agreement is around &#163;100K.[d] The company has heavily\u000a      promoted this system as a base material for the development of contact\u000a      lenses with long residence times in the eye, and the technology is also\u000a      being applied to implantable stents for long-term use: in this case,\u000a      revenue is expected to be generated within 6 years. These developments\u000a      have led BioInteractions to increase the size of their research team by\u000a      150%.[e]\u000a    Biointeractions Ltd have actively promoted the products and technologies\u000a      that arose from the research described here. Since 2008, the company has\u000a      presented these new polymer technologies at 18 major international\u000a      biomedical-device trade shows (often represented by the former KTP\u000a      Associates): UK Biomaterials, Liverpool, 2008; Medical Device &amp;\u000a      Manufacturing (MD&amp;M), Minneapolis, 2008; MEDTEC Ireland, Galway, 2009;\u000a      MD&amp;M, Minneapolis, 2009; Polymeric Biomaterials, Reading, 2010; UK\u000a      Biomaterials, Glasgow, 2010; MD&amp;M West, Anaheim, 2010; MD&amp;M East,\u000a      New York, 2010; MD&amp;M, Minneapolis, 2010; Compamed (Medica),\u000a      D&#252;sseldorf, 2010; MD&amp;M West, Anaheim, 2011; MD&amp;M East, New York,\u000a      2011; Compamed (Medica), D&#252;sseldorf, 2011; US Biomaterials, Florida, 2011;\u000a      MD&amp;M West, Anaheim, 2012; MD&amp;M East, Philadelphia, 2012;\u000a      Biointerfaces, Dublin, 2012 and MD&amp;M West, Anaheim, 2013.\u000a    ","ImpactSummary":"\u000a    Biomedical devices that need to be implanted into the body typically\u000a      experience the so-called foreign-body reaction: proteins adhere to the\u000a      surface of the devices, leading to rapid loss of function and, eventually,\u000a      to a requirement for replacing the device. Between October 2006 and\u000a      September 2011, The University of Reading, in collaboration with the UK\u000a      SME BioInteractions Ltd., developed and evaluated a range of new\u000a      polymers for coating implantable biomedical devices, especially coronary\u000a      stents and catheters. The result was a coating system that can deliver a\u000a      drug controllably over a pre-defined period, leading to the commercial\u000a      biomaterials platforms AdaptTM and AssistTM. This\u000a      work resulted in capital investment by Biointeractions Ltd and a\u000a      substantial increase in their research staffing.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Reading\u000a    ","Institutions":[{"AlternativeName":"Reading (University of)","InstitutionName":"University of Reading","PeerGroup":"B","Region":"South East","UKPRN":10007802}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"5128638","Name":"New York"},{"GeoNamesId":"4155751","Name":"Florida"},{"GeoNamesId":"2964574","Name":"Dublin"},{"GeoNamesId":"2934246","Name":"Dsseldorf"},{"GeoNamesId":"4560349","Name":"Philadelphia"},{"GeoNamesId":"5037649","Name":"Minneapolis"},{"GeoNamesId":"2964180","Name":"Galway"},{"GeoNamesId":"2964574","Name":"Dublin City"}],"References":"\u000a    This research has been internally assessed as of at least 2* quality.\u000a    \u000a[1] Rhodes, A.; Onis, S. J.; Sandhu, S.; Mckendrick. J. E. U.S. Patent\u000a      Application number US20090253733. Preparation of Rapamycin Carbonate\u000a      Esters via Lipase-catalysed Condensation Reaction as Anti-tumour and\u000a      Anti-bacterial Agents (2009).\u000a    \u000a\u000a[2] Sandhu, S.; Raisin-Dadre, F.; Mckendrick, J. E.; Rhodes, A.; Onis, S.\u000a      J., PCT Int. Appl. WO 2012175923 A1. Biomimetic Ampholyte Compounds\u000a      Comprising Phosphate and Quaternary Ammonium groups and Polymers Made\u000a      Therefrom (2012). Also published as U.S. Patent Application US 20130053470\u000a      A1 (2013).\u000a    \u000aGrants: (i) \"Synthesis and characterisation of biocompatible\u000a      bioabsorbable polypeptide analogues\", KTP 796, &#163;100K (2005-2008); (ii)\u000a      \"Next generation biomimetic non-biological based biomaterials\", KTP 7076,\u000a      &#163;130K (2008-2011).\u000a    ","ResearchSubjectAreas":[{"Level1":"9","Level2":"3","Subject":"Biomedical Engineering"},{"Level1":"3","Level2":"3","Subject":"Macromolecular and Materials Chemistry"},{"Level1":"9","Level2":"12","Subject":"Materials Engineering"}],"Sources":"\u000a    *Contact details provided\u000a    Evidence of the material being brought to market can be obtained from:\u000a    [a]. Biointeractions Ltd: http:\/\/www.biointeractions.com\/adapt.htm\u000a      (Adapt&#8482; technology)\u000a    [b]. Biointeractions Ltd: http:\/\/www.biointeractions.com\/drug_delivery.htm\u000a      (Drug delivery)\u000a    [c]. Biointeractions Ltd: http:\/\/www.biointeractions.com\/assist.htm\u000a      (Assist&#8482; technology)\u000a    [d]. The CEO of BioInteractions Ltd*.\u000a    [e]. The KTP Associate working on KTP grant No. 796 (now a staff member\u000a      at Biointeractions)*. This scientist was one of the Biointeractions team\u000a      who won Best Biotechnology Award 2008 in the area of cardiovascular\u000a      research (Medical Futures Innovation Award): http:\/\/www.medicalfutures.co.uk\/2008.php\u000a    [f]. The first KTP research collaboration was judged by the KTP\u000a      sponsorship panel to be so successful that it warranted publication of a\u000a      case study: See: http:\/\/www.reading.ac.uk\/web\/FILES\/ktc\/BioInteractions_Ltd.pdf\u000a    \u000a    ","Title":"\u000a    Biocompatible polymer coatings for the long-term implantation of\u000a      biomedical devices in humans\u000a    ","UKLocation":[{"GeoNamesId":"2644210","Name":"Liverpool"},{"GeoNamesId":"2648579","Name":"Glasgow"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"},{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Drug-eluting stents (DESs) &#8212; the use of which is regulated by the\u000a      National Institute for Health and Care Excellence &#8212; represent a major\u000a      treatment option for arterial coronary disease. DESs enable controlled\u000a      drug-release from an implanted device (a stent) whose main function is to\u000a      open up a partially-blocked artery. Substantial savings can be made if\u000a      stent replacement is avoided within the first 3 years after initial\u000a      implantation: up to &#163;5000 per patient is saved if no re-stenting procedure\u000a      is required in this period. However, most polymers used in coatings suffer\u000a      from protein absorption and foreign-body rejection problems, and so need\u000a      to be replaced earlier than this. Also, because most drugs are\u000a      hydrophobic, and the polymer coatings generally used as in situ\u000a      drug-delivery vehicles are not readily permeable to water, the majority of\u000a      the drug remains encapsulated in the polymer and so is never delivered to\u000a      the surrounding tissue. To address these issues, the research team set out\u000a      to develop a more effective coating system for coronary stents that would\u000a      allow efficient delivery of drugs into the bloodstream from the surface of\u000a      the stent. Key targets were (a) to develop a material that allows complete\u000a      release of the chosen therapeutic agent in a controlled manner, whilst (b)\u000a      presenting a non-thrombogenic (i.e. non-protein-absorbing) surface to the\u000a      blood vessel. Achieving these goals was seen as essential to the success\u000a      of an advanced DES.\u000a    The research team [University of Reading and BioInteractions Ltd., funded\u000a      by the Knowledge Transfer Partnership (KTP) programme], developed a series\u000a      of polymer coatings containing hydrophilic subunits that were already\u000a      approved for human use (so avoiding potential regulatory hurdles). The\u000a      polymers were optimised to deliver over 80% of the encapsulated drug in a\u000a      30-day time window, and to ensure that no delamination of the polymer\u000a      coating from the surface of the stent occurred. Thermomechanical analysis\u000a      of the new polymers revealed that they are elastomeric and highly flexible\u000a      (glass transition below room temperature). A low glass transition improves\u000a      the rate of release of the drug: polymers with glass transition\u000a      temperatures higher than ambient are rigid and so display a less\u000a      satisfactory release profile. In fact, elution studies for the drugs\u000a      paclitaxel and sirolimus demonstrated that 100% of the encapsulated drug\u000a      was delivered from the new coating over a 30-day time period. The elution\u000a      rate was further controlled by varying the ratio of hydrophilic to\u000a      hydrophobic subunits in the polymer, allowing drug release for up to 10-\u000a      15 days, and also by varying the structure of the drug via an\u000a      enzyme-mediated modification, which allowed drug elution to be extended to\u000a      around 30 days. The cytostatic drug sirolimus is also known as rapamycin,\u000a      and the KTP programme led to the development of modified versions of\u000a      rapamycin (carbonate esters) that are more suited to polymer-based release\u000a      applications.[1] These technologies (trademarked as AdaptTM)\u000a      have now been commercialised by BioInteractions Ltd.\u000a    Further development was carried out by Dr Rasin-Dadre (KTP Associate and\u000a      PhD student 2008- 2011) as part of a follow-up collaboration between The\u000a      University of Reading and BioInteractions Ltd. Development of one of the\u000a      polymer technologies resulting from the first KTP led to the creation of a\u000a      second-generation material with a substantially greater hydrophilic\u000a      character.[2] The new polymer material contains a component that mimics\u000a      the structure of the outer wall of cells and so is better tolerated by\u000a      biological systems in terms of the foreign-body reaction. The surface of\u000a      this second-generation polymer is remarkably resistant to protein and\u000a      cellular deposition because it promotes the formation of an extensive\u000a      hydration layer that inhibits such deposition. Hence, the new material is\u000a      highly biocompatible and its ability to retain a clean surface allows\u000a      continuous elution of nonpolar drug substances. Apart from greater utility\u000a      for the purposes of generating drug releasable stents, this new material\u000a      has a potentially wide range of applications for any biomedical devices\u000a      that need to be implanted in the body. A partnership between\u000a      BioInteractions Ltd and a custom synthesis laboratory (IsleChem LLC; USA)\u000a      will produce these materials at large scale for clinical evaluation. In\u000a      particular, the main focus of product development from this technology is\u000a      the manufacture of contact lenses for ocular drug delivery and of coatings\u000a      for long-term implantable catheters (Assist&#8482;).\u000a    The project was developed by Simon Onis (Biology specialist,\u000a      BioInteractions, 2006 - present), Alan Rhodes (KTP Associate and PhD\u000a      student, 2006-2008; BioInteractions Senior Scientist, 2008 - present),\u000a      Fanny Raisin-Dadre (KTP Associate and PhD student, 2008 - 2011;\u000a      BioInteractions Research Scientist, 2011 - present), John Mckendrick\u000a      (Lecturer\/Associate Professor in Chemistry 2000 - present; academic\u000a      supervisor to AR and FRD), Shivpal Sandhu (Research Director,\u000a      BioInteractions, 2006 - 2008) and Ajay Luthra (CEO, BioInteractions, 2006\u000a      - present).\u000a    "},{"CaseStudyId":"38357","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6251999","Name":"Canada"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":[],"ImpactDetails":"\u000a    Cardiome Pharma, a Canadian pharmaceutical company, recognised in 2003\u000a      that the team\u000a      at QUB had the ability to deliver kilogram quantities, to GMP standard, of\u000a      a chiral\u000a      intermediate required for an alternative chemoenzymatic route to their new\u000a      drug candidate\u000a      RSD1235 for a clinical trial for the treatment of atrial fibrillation by\u000a      intravenous injection. Atrial\u000a      fibrillation, which is linked with strokes, is the most common form of\u000a      irregular heartbeat, with an\u000a      estimated nine million sufferers worldwide and established drugs for\u000a      restoring normal heart\u000a      rhythms are limited by either modest efficacy and\/or side effects.\u000a    After investing more than CAN $1M prompted by research in two seminal\u000a      publications by\u000a      the Queen's group (Reference 1, J. Am. Chem. Soc., 1994, 116, 1147;\u000a      Reference 2, J.\u000a      Chem. Soc., Chem. Commun. 1995, 117 in section 3), during 2004 QUB\u000a      was employed to\u000a      deliver 5 kg of an enantiopure bioproduct and develop the synthetic\u000a      chemistry used in the first\u000a      synthetic steps toward RSD1235 (Reference 1 in section 5). Using\u000a      this alternative improved\u000a      chemoenzymatic route, Cardiome ultimately prepared 1 kg of homochiral\u000a      RSD1235 to GMP\u000a      standard required for clinical trials based on the material and routes\u000a      Queen's provided\u000a      (Reference 2 in section 5). As a result of the clinical trials, in\u000a      2009 Merck signed a licensing\u000a      agreement with Cardiome worth up to 600 million dollars to help rapidly\u000a      get the drug to\u000a      market (Reference 3 in section 5). RSD 1235 has completed clinical\u000a      trials, is now marketed as\u000a      Vernakalant and in September 2010 was approved for use in over ten\u000a      European countries and\u000a      other areas under the trade name Brinavess (Cardiome\/Merck). Vernakalant\u000a      is currently in\u000a      phase 3 clinical trials for FDA approval for use in the USA and is\u000a      currently being evaluated by\u000a      the National Institute for Health and Clinical Excellence, NICE, as a\u000a      prescription drug for NHS\u000a      use in the UK (Reference 4 in section 5).\u000a    Secondly, Almac Sciences have over the past five years developed an\u000a      increasing biocatalytic\u000a      capability within their business facilitated by the research undertaken in\u000a      Queen's led by Boyd\u000a      and Stevenson. Many of the initial bioproducts marketed by Almac\u000a      SelectAZyme, and new\u000a      projects undertaken for external customers, were solely based on the\u000a      biocatalytic pathways,\u000a      enzymes, expertise and facilities used for the formation of polyoxygenated\u000a      cyclohexanes from\u000a      aromatics developed in Queen's which are utilized as precursors in\u000a      synthetic routes to\u000a      bioactive materials, such as the influenza drug Tamiflu (Reference 5 in\u000a        section 5). The\u000a      development of the routes for commericalisation was undertaken through a\u000a      collaboration between\u000a      the two groups of researchers (Reference 6 in section 5). This\u000a      area is now growing into other\u000a      markets significantly and the biocatalysis group in Almac now employ 30\u000a      staff including 15 PhD\u000a      graduates from QUB trained in Boyd and Stevenson's groups. The\u000a      biocatalysis group operates as\u000a      a multi-million revenue provider for Almac providing solutions to\u000a      customers through the application\u000a      of enzymes.\u000a    Therefore, this biocatalysis research has led to a number of economic and\u000a      health related\u000a      impacts whose beneficiaries are primarily the industrial partners and the\u000a      resultant economic\u000a      benefits to the general public as well as the new development of\u000a      treatments used in general\u000a      practice worldwide.\u000a    ","ImpactSummary":"\u000a    Queen's University Belfast has developed a number of biocatalytic\u000a      processes for the production of\u000a      pharmaceutical intermediates which have been applied commercially. The\u000a      most significant\u000a      involved Vernakalant, a new drug for treatment of the most common form of\u000a      irregular heartbeat,\u000a      now available in the EU, and currently awaiting approval in the USA and\u000a      Canada. In addition, QUB\u000a      has sold &#163;300,000 worth of bioproducts and through the collaborations with\u000a      Almac Sciences\u000a      facilitated the initiation of their biocatalysis business which currently\u000a      is a multi-million revenue\u000a      earner for Almac Sciences and employs 30 staff, including 15 PhD graduates\u000a      from the Queen's\u000a      group.\u000a    ","ImpactType":"Technological","Institution":"\u000a    Queen's University, Belfast\u000a    ","Institutions":[{"AlternativeName":"Queen's University Belfast","InstitutionName":"Queen's University Belfast","PeerGroup":"A","Region":"Northern Ireland","UKPRN":10005343}],"Panel":"B         ","PlaceName":[],"References":"\u000a    * signify the references\u000a      which best indicate the quality of the underpinning research\u000a    \u000a*1. Boyd, D. R.; Sharma, N. D.; Barr, S. A.; Dalton, H.; Chima, J.;\u000a      Whited, G.; Seemayer,\u000a      R., Chemoenzymatic Synthesis of the 2,3-Cis-Dihydrodiol and 3,4-Cis-Dihydrodiol\u000a      Enantiomers\u000a      of Monosubstituted Benzenes. J. Am. Chem. Soc. 1994, 116, (3), 1147-1148.\u000a      (DOI: 10.1021\/ja00082a053)\u000a    \u000a\u000a2. Allen, C. C. R.; Boyd, D. R.; Dalton, H.; Sharma, N. D.; Brannigan,\u000a      I.; Kerley, N. A.; Sheldrake,\u000a      G. N.; Taylor, S. C., Enantioselective bacterial biotransformation routes\u000a      to cis-diol metabolites of\u000a      monosubstituted benzenes, naphthalene and benzocycloalkenes of either\u000a      absolute\u000a      configuration. J. Chem. Soc., Chem. Commun. 1995, (2), 117-118. (DOI:\u000a      10.1039\/c39950000117)\u000a    \u000a\u000a3. Parales, R. E.; Resnick, S. M.; Yu, C. L.; Boyd, D. R.; Sharma, N. D.;\u000a      Gibson, D. T.,\u000a      Regioselectivity and enantioselectivity of naphthalene dioxygenase during\u000a      arene cis-\u000a      dihydroxylation: Control by phenylalanine 352 in the alpha subunit. J.\u000a      Bacteriol. 2000, 182,\u000a      (19), 5495-5504. (DOI: 10.1128\/JB.182.19.5495-5504.2000))\u000a    \u000a\u000a*4. Boyd, D. R.; Sharma, N. D.; Malone, J. F.; Allen, C.C.R . New\u000a      families of enantiopure\u000a      cyclohexenone-cis-diol, o-quinol dimer and hydrate metabolites from\u000a      dioxygenase-\u000a      catalysed dihydroxylation of phenols, Chem. Commun.,2009, 3633-3635 (DOI:\u000a      10.1039\/b905940g).\u000a    \u000a\u000a*5. Boyd, D. R.; Sharma, N.D.; Acaru, C.; Malone, J.F.; O'Dowd, C.R.\u000a      Allen,; C. C.R.;\u000a      Stevenson, P.J., Chemoenzymatic synthesis of carbasugars (+)-pericosines\u000a      A-C from diverse\u000a      aromatic cis- dihydrodiol precursors, Org. Lett. 2010, 12,\u000a      2206-2209 (DOI: 10.1021\/ol100525r)\u000a    \u000a\u000a6. Boyd, D. R.; Sharma, N. D.; Sbircea, L. ; Murphy, D. ; Belhocine, T.;\u000a      Malone, J. F.; James, S.\u000a      L.; Allen C. C. R. ; Hamilton, J. T. G.; Azaarene cis-dihydrodiol-derived\u000a      2,2'-bipyridine ligands for\u000a      asymmetric allylic oxidation and cyclopropanation, Chem. Commun., 2008,\u000a      5535-5537 (DOI:\u000a      10.1039\/b814678k). See also \u000a      http:\/\/www.rsc.org\/Publishing\/Journals\/cc\/News\/B814678K_Boyd_B812366G_James.asp\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"},{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"}],"Sources":"\u000a    1: Letter of support from Cardiome:by Senior Director, Research\u000a      (Chemistry)\u000a      \"The route employing the cis-dihydrodiol as starting material was\u000a      sufficiently promising that\u000a      the process was optimized and demonstrated in the production of 1kg of\u000a      cGMP vernakalant\u000a      starting from 5kg of the cis-diol produced by Professor Boyd and\u000a      his colleague Chris Allen\".\u000a    2: The Cardiome request for chlorobenzene cis-dihydrodiol (5kg\u000a      fermentation product) for\u000a      1kg GMP manufacture of RSD1235 by Raylo and a possible advantage of the\u000a      new\u000a      chemoenzymatic route based on an earlier (1 kg) delivery :-\u000a    \"Not only has the new route of manufacture for RSD1235 been shown to be\u000a      feasible on tens\u000a      of gram scale by Raylo, but a significant improvement in yield from 40% to\u000a      65-70% for the last\u000a      critical displacement step has been made by Raylo and Medichem.\"\u000a    3: Merck &amp; Co. announces $600-million licensing agreement for\u000a      Cardiome's vernakalant (www.firstwordpharma.com\/node\/359114)\u000a    4: NICE &#8212; Health Technology Appraisal for Vernakalant for the treatment\u000a      of recent onset\u000a      atrial fibrillation (http:\/\/guidance.nice.org.uk\/TA\/Wave26\/7\/DraftScope\/pdf\/English)\u000a    5: Almac.SelectAZyme brochure offering a new range of single enantiomer\u000a      substituted\u000a      benzenecis-diols.\u000a    6: Letter of support from Almac Sciences Ltd by Head of Biocatalysis\u000a      &amp; Isotope Chemistry.\u000a    ","Title":"\u000a    Biocatalysts for industrial and medical applications\u000a    ","UKLocation":[{"GeoNamesId":"2655984","Name":"Belfast"}],"UKRegion":[{"GeoNamesId":"2641364","Name":"Northern Ireland"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    The research at Queen's supervised by Boyd (now Emeritus Professor) and\u000a      Stevenson has led\u000a      to an understanding of the remarkable potential of a range of biocatalysts\u000a      which produce\u000a      single enantiomer polyoxygenated products from aromatic substrates. From\u000a      1993, Boyd, in\u000a      collaboration with Dalton (Warwick), who supplied the initial enzymes\u000a      (toluene dioxygenase\u000a      mutant strains), developed the synthesis of the cis-dihydrodiols\u000a      from monosubstituted benzenes\u000a      which were used as intermediates for the synthesis of Vernakalant (Figure\u000a      1).\u000a    \u000a    Figure 1 Reaction scheme for the formation of cis-dihydrodiols\u000a      from monosubstituted\u000a      aromatics leading to the formation of Vernakalant\u000a    \u000a\u0009Importantly, the ability to translate the fundamental research into a\u000a      commercial success, was due\u000a      to the Queen's group enabling the determination of structure,\u000a      configuration and enantiopurity of\u000a      these novel bioproducts (References 1 and 2 in section 3). Through\u000a      this knowledge, the scope and\u000a      diversity of the bioproducts produced has been expanded significantly and\u000a      the limitations of the\u000a      substrates able to be biotransformed alleviated by the use of manipulation\u000a      of the biocatalyst\u000a      employed. The identification of the latter was critical and the Queen's\u000a      group led the search for\u000a      new enzymes through development of recombinant strains within Biological\u000a      Sciences in Queen's\u000a      (Kulakov and Allen) as well as with Gibson (University of Iowa) developing\u000a      naphthalene and\u000a      biphenyl dioxygenases. This research included the first example of\u000a      site-directed mutagenesis\u000a      being used to modify dioxygenase regio- and stereo-selectivity (Reference\u000a      3 in section 3). From\u000a      these new catalytic systems, previously unknown families of enantiopure\u000a      metabolites with novel\u000a      structures, such as sulfoxide diols, arene-derived triols and tetrols,\u000a      cyclohexenone cis-diols, arene\u000a      oxides and hydrates, with virtually all the products of the biocatalytic\u000a      reactions being single\u000a      enantiomers, were developed (Reference 4 in section 3).\u000a      Furthermore, empirical models\u000a      were devised to allow prediction of the preferred products formed and the\u000a      absolute configurations\u000a      of new bio-products. In addition, this research has contributed to an\u000a      understanding of why\u000a      polycyclic aromatic hydrocarbon (PAH) pollutants are human carcinogens;\u000a      mammalian redox\u000a      enzymes (monooxygenases) play a key role in turning PAHs into arene oxide\u000a      and diol epoxide\u000a      metabolites that interfere with DNA replication.\u000a    From the knowledge and fundamental understanding of the biocatalytic\u000a      pathways, and the\u000a      manipulation of the conditions used for the reaction and separation\u000a      processes, as well as\u000a      the analytical techniques established, commercialisation of the\u000a      bioproducts has been achieved.\u000a      This understanding has led to the utilisation of a wide range of\u000a      substrates which had previously\u000a      been intractable and, therefore, the selective and efficient production of\u000a      a large number of\u000a      desirable pharmaceuticals and fine chemicals in an economic process.\u000a      Applications of its\u000a      enantiopure bioproducts have been made in the synthesis of natural\u000a      products including\u000a      pericosines (see reference 5 in section 3) and epibatidine,\u000a      unnatural products, such as\u000a      carbasugars and chiral ligands, for example, bipyridines (see reference 6\u000a      in section 3),\u000a      aminoalcohols and phosphines\/phosphine oxides.\u000a    "},{"CaseStudyId":"38358","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"3996063","Name":"Mexico"},{"GeoNamesId":"2921044","Name":"Germany"},{"GeoNamesId":"1605651","Name":"Thailand"},{"GeoNamesId":"1733045","Name":"Malaysia"},{"GeoNamesId":"1643084","Name":"Indonesia"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Science and Technology Facilities Council"],"ImpactDetails":"\u000d\u000a    QUB and PETRONAS in a unique partnership have developed a novel mercury\u000d\u000a      removal technology HycaPure Hg&#8482; based on ionic liquids which offers\u000d\u000a      advantaged performance and flexibility to treat a full range mercury types\u000d\u000a      and gas composition (Figure 1). The first full-scale HycaPure Hg&#8482; units\u000d\u000a      containing 1 and 15 tons of absorbent were installed at a PETRONAS gas\u000d\u000a      processing plant in Malaysia in Oct 2011 and have been successfully\u000d\u000a      producing ethane for PETCHEM and sales-quality gas since commissioning\u000d\u000a      (references 1-4 in section 5). The mercury content has been\u000d\u000a      consistently below the legal safe limits, with no excursions. The new\u000d\u000a      technology has a number of benefits over the competing commercial systems,\u000d\u000a      e.g. the kinetics of mercury absorption are 10-20 times faster, allowing\u000d\u000a      the operating plant to cope with large spikes of mercury with no risk to\u000d\u000a      the downstream plant, and the mercury absorption capacities of the new\u000d\u000a      materials are 2-3 times better on a volume\/volume (reactor) basis. The new\u000d\u000a      system is a direct retrofit to commercial plants and installs without any\u000d\u000a      additional costs or modification to procedures (see PETRONAS' Technology\u000d\u000a      Products and Technical Solutions literature).\u000d\u000a    A typical medium-sized mercury removal unit contains around 15 tons of\u000d\u000a      material, and costs in the order of US$180,000 per fill. By comparison,\u000d\u000a      the increased absorption capacity of HycaPure Hg&#8482; materials represents a\u000d\u000a      potential cost saving of over 20% per vessel, and with a market size\u000d\u000a      running into hundreds of thousands of tons, this new technology is not\u000d\u000a      only efficient but highly competitive.\u000d\u000a\u000d\u000aFigure 1 Development of the mercury capture technology\u000d\u000afor natural gas clean up in conjunction with PETRONAS\u000d\u000a\u000d\u000a    The potential market for our SSIL technology in the hydrocarbon industry\u000d\u000a      is huge: MRUs are required in almost every gas and oil terminal and\u000d\u000a      refinery\/petchem complexes in addition to the produced waters from\u000d\u000a      drilling platforms. Mercury contamination ranges from 0.02 micrograms per\u000d\u000a      cubic metre in the Gulf of Mexico to more than 100 in Europe, South\u000d\u000a      America, Gulf of Thailand, Malaysia and Indonesia. In extreme cases, such\u000d\u000a      as in North Germany, levels can reach 5000 micrograms per cubic metre.\u000d\u000a    Even 1 ppm of mercury contamination has significant cumulative effects if\u000d\u000a      we consider a typical plant processes 2000 tons every day. In addition to\u000d\u000a      its well-documented health and environment effects, mercury also damages\u000d\u000a      industrial facilities through corrosion, such as embrittlement of\u000d\u000a      aluminium heat exchangers with catastrophic consequences. Hg is also a\u000d\u000a      strong catalyst poison for downstream units.\u000d\u000a    The current technologies used to remove mercury are chemically-modified\u000d\u000a      activated carbons (with sulphur for gas treatment, and potassium iodide\u000d\u000a      for liquid hydrocarbon treatment) and more expensive technologies, such as\u000d\u000a      silver-impregnated molecular sieves and mixed metal sulphide\/oxide\u000d\u000a      scrubbers. But there are issues with these technologies when it comes to\u000d\u000a      efficiency, the removal of all types of mercury species, robustness when\u000d\u000a      other contaminants are present in the feed and the ability to deal with\u000d\u000a      fluctuating mercury levels. The HycaPure Hg&#8482; is proving robust and durable\u000d\u000a      in operation. The technology is being extended to other gas treatment\u000d\u000a      facilties in PETRONAS facilities and licensing\/manufacturing partners are\u000d\u000a      planning to launch the product globally in 2014. .\u000d\u000a    The (anticipated) greater life-time of HycaPure Hg&#8482; scrubbers will lead\u000d\u000a      to lower total volumes of hazardous mercury-contaminated waste for\u000d\u000a      post-unit remediation and reduced frequency of scheduled scrubber\u000d\u000a      replacement, along with reduced occupational exposure to mercury. The\u000d\u000a      issue of mercury exposure was recently recognised by governments in a\u000d\u000a      global, legally-binding treaty to prevent emissions and releases, the\u000d\u000a      Minamata Convention on Mercury.\u000d\u000a    The impact of this work was recently recognised in the Government's Great\u000d\u000a      British Innovation Vote in March 2013 (reference 5 in section 5).\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Queen's University's Ionic Liquids Laboratory (QUILL) has developed an\u000d\u000a      ionic liquid technology for removing mercury, a toxic, corrosive\u000d\u000a      contaminant naturally present in hydrocarbon reserves, with the national\u000d\u000a      oil and gas company Petroliam Nasional Berhad (PETRONAS).The technology\u000d\u000a      has been successfully installed in 1-and 15-ton units in two PETRONAS gas\u000d\u000a      processing plants in Malaysia. The process, marketed as HycaPure Hg&#8482;,\u000d\u000a      captures all mercury species present in natural gas and has up to 3 times\u000d\u000a      higher capacity than competing state-of-the-art commercial alternatives.\u000d\u000a      This technology represents a significant improvement towards ensuring the\u000d\u000a      health and safety of workers, process plant and the environment.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    Queen's University, Belfast\u000d\u000a    ","Institutions":[{"AlternativeName":"Queen's University Belfast","InstitutionName":"Queen's University Belfast","PeerGroup":"A","Region":"Northern Ireland","UKPRN":10005343}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    * signify the references which best indicate the quality of the\u000d\u000a      underpinning research\u000d\u000a    Key references from the investigators, demonstrating the strength and\u000d\u000a      depth of fundamental research underpinning the design, understanding and\u000d\u000a      application of ionic liquid materials.\u000d\u000a    \u000a1. Influence of chloride, water, and organic solvents on the physical\u000d\u000a      properties of ionic liquids, KR Seddon, A Stark, MJ Torres, Pure Appl.\u000d\u000a      Chem., 2000, 72, 2275, DOI: 10.1351\/pac200072122275. This is a key paper\u000d\u000a      which demonstrated to the ionic liquid research community the importance\u000d\u000a      of understanding and maintaining knowledge of the purity of ionic liquid\u000d\u000a      systems.\u000d\u000a    \u000a\u000a2. The phase behaviour of 1-alkyl-3-methylimidazolium tetrafluoroborates;\u000d\u000a      ionic liquids and ionic liquid crystals, JD Holbrey, KR Seddon, J. Chem.\u000d\u000a      Soc., Dalton Trans., 1999, 2133, DOI: 10.1039\/a902818h. This fundamental\u000d\u000a      study demonstrates the effects of systematic structural changes on the\u000d\u000a      thermophysical properties of ionic liquid systems.\u000d\u000a    \u000a\u000a3. Efficient, halide free synthesis of new, low cost ionic liquids:\u000d\u000a      1,3-dialkylimidazolium salts containing methyl-and ethyl-sulfate anions,\u000d\u000a      JD Holbrey, WM Reichert, RP Swatloski, GA Broker, WR Pitner, KR Seddon, RD\u000d\u000a      Rogers, Green Chem., 2002, 4, 407, DOI: 10.1039\/b204469b. New ionic\u000d\u000a      liquids were described prepared using simple, clean and halide-free\u000d\u000a      syntheses.\u000d\u000a    \u000a\u000a*4. Desulfurisation of oils using ionic liquids: selection of cationic\u000d\u000a      and anionic components to enhance extraction efficiency, JD Holbrey, I\u000d\u000a      Lopez-Martin, G Rothenberg, KR Seddon, G Silvero, X Zheng, Green Chem.,\u000d\u000a      2008, 10, 87, DOI: 10.1039\/b710651c. The paper applied analysis of\u000d\u000a      structure-activity relationships to determine the `best' cations to use in\u000d\u000a      the design of ionic liquids for desulfurisation of diesel fuel.\u000d\u000a    \u000a\u000a*5. Small angle neutron diffraction from 1,3-dimethylimidazolium\u000d\u000a      chloride, C. Hardacre, J. D. Holbrey, S. E. J. McMath, D. T. Bowron, and\u000d\u000a      A. K. Soper, J. Chem. Phys., 2003, 118, 272, DOI: 10.1063\/1.1523917. This\u000d\u000a      paper was the first to demonstrate the use of neutron scattering (using\u000d\u000a      STFC large-scale facilities at ISIS) to directly visualise ionic liquid\u000d\u000a      structure. This allows us to uniquely link bulk properties of ionic liquid\u000d\u000a      systems with their behaviour at the atomic level.\u000d\u000a    \u000aThe materials that form the basis of the HycaPure&#8482; technology are\u000d\u000a      proprietary knowledge and form a suite of 4 patents the most relevant\u000d\u000a      being:\u000d\u000a    *6. Process for removing metals from hydrocarbons, M. Abai, M. Atkins, K.\u000d\u000a      Y. Cheun, J. D. Holbrey, P. Nockemann, K. R. Seddon, G. Srinivasan, Y.\u000d\u000a      Zou, World Patent Application PCT\/WO 2012\/046057 A2\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"},{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"}],"Sources":"\u000d\u000a    \u000d\u000a      The contribution of QUB, through the partnership with PETRONAS, is\u000d\u000a        acknowledged in a letter of corroboration from the Head of Technology\u000d\u000a        Management Department of Technology &amp; Engineering Division,\u000d\u000a        PETRONAS.\u000d\u000a      The PETRONAS Laboratory at the QUILL (Queen's University Ionic Liquids\u000d\u000a        Laboratories) Research Centre was officially opened by The Northern\u000d\u000a        Ireland Assembly Minister for Employment and Learning who recognised it\u000d\u000a        as \"an exemplar of industry and academic collaboration, not just for\u000d\u000a        Northern Ireland but for the United Kingdom as a whole.\"\u000d\u000a        (http:\/\/www.northernireland.gov.uk\/index\/media-centre\/newsdepartments\/news-del\/news-del-april-2008\/news-del-170408-minister-opens-new.htm\u000a          and Petronas 2009 Annual Financial Statement, page 68 (www.petronas.com.my\/investor-relations\/Documents\/annual-report\/AnnualReport_FinancialStatement_2009.pdf)\"\u000d\u000a      \u000d\u000a      2011 Annual Financial Statement (www.petronas.com.my\/investor-relations\/Documents\/annual-report\/AnnualReport_FinancialStatement_2011.pdf)\u000d\u000a        Notes the collaboration with QUB and the first commercial commission of\u000d\u000a        HycaPure Hg&#8482; at PETRONAS Gas Bhd (PGB).\u000d\u000a      Strategic presentations describing the technology at the International\u000d\u000a        Gas Union Research Conference (19-21 Oct 2011, Seoul, Korea; http:\/\/www.igrc2011.com\/programme),\u000a        EUCHEM 2012 (5-10 Aug 2012, Celtic Manor, Wales; http:\/\/www.euchem2012.org\/index.php\/scientific-programme)\u000d\u000a        and Green Solvents (7-10th October 2012, Boppard, Germany;\u000d\u000a        http:\/\/events.dechema.de\/events\/en\/gsfs2012.html).\u000d\u000a      Listed in the Government's Great British Innovation Vote, March 2013\u000d\u000a        http:\/\/www.topbritishinnovations.org\/FutureInnovations\/IonicLiquid.aspx\u000a\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Mercury capture technology for the global petroleum industry\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    QUILL was the first research centre to focus on the development of ionic\u000d\u000a      liquids (liquid salts) and is now recognised as the world-leader in new\u000d\u000a      applications, notably in green chemistry. We drew on our expertise to\u000d\u000a      design an entirely new ionic liquid based approach to remove mercury from\u000d\u000a      natural gas supplies, a feat that has much broader applications. The\u000d\u000a      underpinning research has been performed since the formation of QUILL in\u000d\u000a      1999 to now. Over this period of time a significant understanding of the\u000d\u000a      controlling features of ionic liquids was determined from a fundamental\u000d\u000a      perspective. This included the phase behaviour of ionic liquids and the\u000d\u000a      effect of anion and cation structure as well as new synthetic methods for\u000d\u000a      the production of low cost ionic liquids and the effect of impurities\u000d\u000a      (halide and water, for example) on physicochemical properties of the\u000d\u000a      materials (references 1-5 in section 3). Due to the large number\u000d\u000a      of ionic liquid systems possible, predictive methods for the determination\u000d\u000a      of both chemical interactions and physical property determination were\u000d\u000a      also formulated (references 4 and 5 in section 3). Using this\u000d\u000a      understanding and a knowledge of the requirements of the challenge &#8212;\u000d\u000a      notably the need to extract inorganic, organic, and elemental forms of\u000d\u000a      mercury from natural gas streams on an industrial scale, and the need for\u000d\u000a      rapid capture kinetics in order to protect down-stream facilities from\u000d\u000a      spikes in mercury content, Seddon, Nockemann and Holbrey led the team\u000d\u000a      which targeted the design, synthesis and testing of ionic liquid materials\u000d\u000a      at laboratory scale. Following the initial screening, the Queen's team\u000d\u000a      successfully incorporated the active ionic liquids into porous solids\u000d\u000a      without leaching. Finally, the composition of the solid-supported ionic\u000d\u000a      liquid (SSIL) was optimised as a direct retrofit to existing mercury\u000d\u000a      scrubbers with no added investment required (reference 6 in section 3).\u000a      In partnership with PETRONAS, the optimised SSIL was scaled-up and\u000d\u000a      validated at pilot scale and subsequently scaled up to 15 tons of\u000d\u000a      adsorbent providing the first commercial charge to treat natural gas at an\u000d\u000a      on shore PETRONAS gas processing plant.\u000d\u000a    "},{"CaseStudyId":"38359","Continent":[],"Country":[],"Funders":[],"ImpactDetails":"\u000d\u000a    Research by the Queen's team led by Bell and Fletcher has changed the\u000d\u000a      working practice of the Forensic Science Agency in Northern Ireland, FSNI,\u000d\u000a      in their analysis and case evidence accumulation in serious crime\u000d\u000a      investigations. The new methods adopted have led to reduced analysis time\u000d\u000a      and an increased ability to track distribution and supply of drugs.\u000d\u000a      Following the research undertaken at Queen's, FSNI invested in a &#163;50K in a\u000d\u000a      Raman spectrometer suitable for drugs analysis, which was funded by the\u000d\u000a      Government's Assets Recovery Agency.\u000d\u000a    In 2004 they began profiling ecstasy tablets for drugs intelligence\u000d\u000a      purposes i.e. to detect common sources and patterns of distribution and\u000d\u000a      supply. In 2008 FSNI adopted Raman spectroscopy as the technique of choice\u000d\u000a      for the initial characterisation of all bulk white powders and\u000d\u000a      tablets submitted to the Alcohol, Drugs and Toxicology section (Figure 1).\u000d\u000a      At that time these types of samples constituted around 40% of the drugs\u000d\u000a      casework at FSNI, therefore, in approximately 500 cases per annum the\u000d\u000a      techniques based on the QUB methods supported prosecutions for\u000d\u000a      supply\/possession.(reference 1 in section 5)\u000d\u000a\u000d\u000aFigure 1 High throughput drug analysis-tablets being analysed in a Raman spectrometer as used in FSNI\u000d\u000a\u000d\u000a    Similarly, the research on forensic analysis of household paint by QUB\u000d\u000a      led directly to the Physical Evidence section of FSNI purchasing and\u000d\u000a      validating dedicated Raman and IR microscopes for paint evidence\u000d\u000a      examination in 2008. (reference 2 in section 5) Paint evidence is\u000d\u000a      usually only examined in \"serious cases\" that include murder, rape and\u000d\u000a      assaults, numbering up to 200 each year. This allowed the laboratory to\u000d\u000a      stop investing in pyrolysis GC-MS as their confirmatory technique, leading\u000d\u000a      to substantial savings in equipment estimated as &#163;75K. A newspaper report\u000d\u000a      of the crucial part paint evidence played in the first murder\u000d\u000a      investigation using the method is given as reference 5 in section 5.\u000d\u000a      As part of the long term rollout of the Raman method, since 2010 every\u000d\u000a      paint casework sample which is submitted to the laboratory is subjected to\u000d\u000a      Raman analysis (reference 2 in section 5). Again, as for the\u000d\u000a      ecstasy work, the rationale is that Raman analysis increases the\u000d\u000a      throughput and decreases the cost of hundreds of examinations per annum.\u000d\u000a      The total number of paint examinations to date is 947.\u000d\u000a    The most recent impact of this Queen's research has been on\u000d\u000a      &#946;-ketophenethylamine \"Legal Highs\" (also known as \"cathinones\"). This\u000d\u000a      new generation of synthetic psychotropic drugs was widely available\u000d\u000a      through the internet until 2010 when legislation made supply and\u000d\u000a      possession an offence. Due to their relative novelty and the potential to\u000d\u000a      make hundreds of variants of cathinones, FSNI had problems characterising\u000d\u000a      many of these until work carried out by Fletcher and Bell in 2010 on\u000d\u000a      identifying the novel variants in seized samples. This had the immediate\u000d\u000a      effect of allowing criminal prosecutions which had been stalled until then\u000d\u000a      due to lack of evidence to proceed (reference 3 in section 5). As\u000d\u000a      a result of the work at Queen's, the Director of Public Prosecutions has\u000d\u000a      been able to allow the first criminal trials and convictions have been\u000d\u000a      obtained. This work is now being extended through a FSNI-based trial on\u000d\u000a      the use of the vibrational analysis method developed by QUB for high\u000d\u000a      throughput screening of suspected cathinones seized by the postal\u000d\u000a      authorities.\u000d\u000a    The work on cathinones has allowed the FSNI laboratory to establish a\u000d\u000a      strategy for reacting quickly to the appearance of new classes of\u000d\u000a      synthetic drugs and the corresponding legislation which follows. This is\u000d\u000a      important because the frequency with which new classes of abused\u000d\u000a      substances appear is increasing, as is the speed at which they are adopted\u000d\u000a      to become global problems. (reference 3 in section 5).\u000d\u000a    The impact of this work is being extended beyond FSNI. Firstly, the\u000d\u000a      cathinone trial has been extended to the \"Celtic Fringe\" group of\u000d\u000a      government forensic laboratories which include Scottish and Eire labs\u000d\u000a      (reference 4 in section 5). In addition, the Palestinian National\u000d\u000a      Authority are in the process of purchasing a Raman system for routine drug\u000d\u000a      analysis for their new forensic laboratories due to be completed 2013\u000d\u000a      (reference 1 in section 5). The FBI in the United States has been\u000d\u000a      investigating the use of Raman spectroscopy for paint examination using a\u000d\u000a      sample library supplied by QUB (reference 6 in section 5) and in a\u000d\u000a      recent publication described the QUB series of paint papers as \"important\u000d\u000a      to the forensic community because they provide data to support the highly\u000d\u000a      discriminating nature of comparative paint examination\" (reference 7 in\u000a        section 5). All the above clearly shows the global impact of the\u000d\u000a      research undertaken given its widespread adoption.\u000d\u000a\u0009  Whilst the immediate\u000d\u000a      beneficiaries of the research are the forensic science agencies, the work\u000d\u000a      also has significant societal benefit in providing more robust analysis\u000d\u000a      methods which can be performed rapidly and routinely. This combination\u000d\u000a      allows a wider range of samples to be examined and the creation of\u000d\u000a      patterns of behaviour which will lead to prosecution and convictions.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Techniques that can produce detailed chemical information rapidly and\u000d\u000a      non-destructively for many forensic applications have been developed by\u000d\u000a      Queen's University Belfast based on Raman analysis. The techniques have\u000d\u000a      been adopted by the Forensic Science laboratory in Northern Ireland (FSNI)\u000d\u000a      to trace the source of seized drugs, identify novel psychoactive\u000d\u000a      substances (\"legal highs\") and study paint evidence. More than 2000 cases\u000d\u000a      of supply\/possession of ecstasy drugs, 947 paint casework samples and 100\u000d\u000a      'legal highs' have been analysed. Other law enforcement agencies are now\u000d\u000a      adopting the methods developed at Queen's.\u000d\u000a    ","ImpactType":"Legal","Institution":"\u000d\u000a    Queen's University, Belfast\u000d\u000a    ","Institutions":[{"AlternativeName":"Queen's University Belfast","InstitutionName":"Queen's University Belfast","PeerGroup":"A","Region":"Northern Ireland","UKPRN":10005343}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    * signify the references which best indicate the quality of the\u000d\u000a      underpinning research\u000d\u000a    \u000a*1 \"Rapid analysis of ecstasy and related phenethylamines in seized\u000d\u000a      tablets by Raman spectroscopy\", Bell, S.E.J., D.T. Burns, A.C. Dennis, and\u000d\u000a      J.S. Speers, Analyst, 125, 541-544, 2000. DOI:10.1039\/a908091k\u000d\u000a    \u000a\u000a*2 \"Tracking the distribution of \"ecstasy\" tablets by Raman composition\u000d\u000a      profiling: A large scale feasibility study\", Bell, S.E.J., L.J. Barrett,\u000d\u000a      D.T. Burns, A.C. Dennis, and S.J. Speers, Analyst, 128, 1331-1335, 2003.\u000d\u000a      DOI: 10.1039\/b308312h Note resulting news coverage: Test to link drug to\u000d\u000a      dealers (BBC) http:\/\/news.bbc.co.uk\/1\/hi\/northern_ireland\/3222061.stm\u000d\u000a      Fast way to find out what's in a tab of E (New Scientist)\u000d\u000a      http:\/\/www.newscientist.com\/article\/mg18024162.700-fast-way-to-find-out-whats-in-a-tab-of-e.html\u000d\u000a    \u000a\u000a3 Development of sampling methods for Raman analysis of solid dosage\u000d\u000a      forms of therapeutic and illicit drugs\", Bell, S.E.J., J.R. Beattie, J.J.\u000d\u000a      McGarvey, K.L. Peters, N.M.S. Sirimuthu, and S.J. Speers, Journal of Raman\u000d\u000a      Spectroscopy, 35, 409-417, 2004. DOI 10.1002\/jrs.1160\u000d\u000a    \u000a\u000a*4 \"Raman Spectroscopy for Forensic Examination of&#160; &#946;-Ketophenethylamine\u000d\u000a      \"Legal Highs\": Reference and Seized Samples of Cathinone Derivatives\",\u000d\u000a      Samantha P. Stewart; Steven E. J. Bell*; Nicholas C. Fletcher; Samira\u000d\u000a      Bouazzaoui; Yen Cheng Ho; S. James Speers and K. Laota Peters. Front cover\u000d\u000a      \"Feature Article\" Analytica Chimica Acta, 711, 1-6, 2012. DOI\u000d\u000a      10.1016\/j.aca.2011.10.018.\u000d\u000a    \u000a\u000a5 \"Rapid forensic analysis and identification of \"lilac\" architectural\u000d\u000a      finishes using Raman spectroscopy\", Bell, S.E.J., L.A. Fido, S.J. Speers,\u000d\u000a      and W.J. Armstrong, Applied Spectroscopy, 59, 100-108, 2005. DOI\u000d\u000a      10.1366\/0003702052940404\u000d\u000a    \u000a\u000a6 \"Forensic analysis of architectural finishes using Fourier transform\u000d\u000a      infrared and Raman spectroscopy, Part II: White paint\", Bell, S.E.J., L.A.\u000d\u000a      Fido, S.J. Speers, W.J. Armstrong, and S. Spratt, Applied Spectroscopy,\u000d\u000a      59, 1340-1346, 2005. DOI 10.1366\/000370205774783232\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"3","Level2":"1","Subject":"Analytical Chemistry"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"3","Subject":"Macromolecular and Materials Chemistry"}],"Sources":"\u000d\u000a    Letters from the appropriate users are available as follows:\u000d\u000a    \u000d\u000a      Ecstasy analysis at FSNI by Operations Director and Head of Alcohol,\u000d\u000a        Drugs and Toxicology (ADT) at FSNI during the time period when the\u000d\u000a        method was adopted.\u000d\u000a      Paint analysis at FSNI by Principal Scientific Officer and Lead\u000d\u000a        Scientist at FSNI, in charge of Physical Methods section during the time\u000d\u000a        period.\u000d\u000a      Cathinone characterisation and screening by Senior Scientist and\u000d\u000a        Department Head ADT (Alcohol Drugs and Toxicology) in FSNI.\u000d\u000a      Cathinone screening The Forensic Science Laboratory, Dublin by\u000d\u000a        Director of Operations, Forensic Science Laboratory, Garda HQ, Dublin.\u000d\u000a    \u000d\u000a    Other sources\u000d\u000a    \u000d\u000a      http:\/\/www.belfasttelegraph.co.uk\/news\/local-national\/shirley-finlay-murder-trial-paint-flakes-link-accused-to-body-scene-court-told-28477121.html\u000d\u000a      Copy of E-mail from FBI Laboratory, Quantico confirming supply of\u000d\u000a        samples.\u000d\u000a      Analysis and Discrimination of Single-Layer White Architectural Paint\u000d\u000a        Samples\", D. M. Wright, M. J. Bradley and A. Hobbs Mehltretter, Journal\u000d\u000a          of Forensic Sciences, Volume 58, p 358-364, March 2013.\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Practical Raman chemical analysis for forensic applications\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2655984","Name":"Belfast"}],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"},{"GeoNamesId":"2641364","Name":"Northern Ireland"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    Raman spectroscopy is a powerful method for characterising materials;\u000d\u000a      however, due to the cost and lack of background information it has not\u000d\u000a      been used for routine analysis of forensic samples. In 1999, the Queen's\u000d\u000a      team led by Bell recognised the potential of Raman as a method to analyse\u000d\u000a      for drugs of abuse, specifically ecstasy. In collaboration with the\u000d\u000a      Forensic Science Agency in Northern Ireland, Bell's group demonstrated,\u000d\u000a      for the first time, the use of Raman spectroscopy for the identification\u000d\u000a      of ecstasy and related drugs.[see reference 1 in section 3] In\u000d\u000a      addition, the method was sensitive enough to identify the cutting agents\u000d\u000a      as well as the drug present in a wide range of seized samples thus\u000d\u000a      providing critical information on the particular blend in order to\u000d\u000a      discriminate between different batches of tablets that had been seized in\u000d\u000a      raids. The ability to link a single ecstasy tablet to the dealer in less\u000d\u000a      than a minute had great potential for drugs intelligence work since it\u000d\u000a      allowed distribution pathways to be tracked and a large scale pilot study\u000d\u000a      on seized samples was performed. [see reference 2 in section 3]\u000d\u000a      This led to work which established the method for moving Raman from a\u000d\u000a      specialist university laboratory method to routine tool for high\u000d\u000a      throughput drugs analysis.[reference 3 in section 3]\u000d\u000a    This work was extended to the identification of cathinones, a family of\u000d\u000a      once `legal highs' which was banned in 2010, by Bell and Fletcher in\u000d\u000a      Queen's. Here the Raman methods were supplemented by NMR and mass\u000d\u000a      spectroscopy techniques in order to identify which of the many potential\u000d\u000a      drug compounds from this family were actually being distributed. Queen's\u000d\u000a      synthesised reference samples of important cathinones to provide standard\u000d\u000a      samples which were used to populate a materials library and to allow the\u000d\u000a      relationship between structure and spectra to be determined.[see reference\u000d\u000a      4 in section 3].\u000d\u000a    Work on paint analysis followed a similar pattern, with initial studies\u000d\u000a      in 2005 on what information the spectra could provide followed by a\u000d\u000a      demonstration of how those data could be used to provide discrimination\u000d\u000a      between real world samples.[references 5,6 in section 3] In\u000d\u000a      particular, analysis of white paints was important since they are common\u000d\u000a      in forensic casework but difficult to discriminate using standard methods.\u000d\u000a    "},{"CaseStudyId":"38360","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1861060","Name":"Japan"},{"GeoNamesId":"2215636","Name":"Libya"},{"GeoNamesId":"1227603","Name":"Sri Lanka"}],"Funders":["Royal Society"],"ImpactDetails":"\u000a    Based on the seminal research undertaken by\u000a      de Silva, Roche developed, in conjunction with\u000a      QUB, a blood analyser which was commercialised\u000a      and has been the market leader in point-of-care\u000a      analyzers ever since (Figure 2). Throughout the\u000a      period 2008-13 this R&amp;D programme has led to\u000a      sales of US$50M of the diagnostic cassettes\u000a      used in the OPTI device) (see reference 1 in\u000a        section 5) clearly demonstrating economic impact of\u000a      the fundamental research undertaken in QUB.\u000a\u000aFigure 2 OPTI cassettes sold by Optimedical Inc\u000a(www.optimedical.com). The black spots carry the\u000aappropriate sensor molecules covalently attached.\u000a\u0009  \u000a    As well as economic impact, the formulation of these sensors has had wide\u000a      spread health benefits\u000a      worldwide. \"The sensors are used in various locations within hospitals,\u000a      emergency centers,\u000a      ambulances, helicopters, airplanes, pulmonary centres and in any location\u000a      where time critical\u000a      diagnostic testing is needed.\" (see reference 2 in section 5). For\u000a      example, they monitor blood for\u000a      levels of common salt components such as sodium, potassium and calcium\u000a      rapidly allowing\u000a      emergency units to arrange for a certain type of blood with the necessary\u000a      salt levels to be ready\u000a      following transport of a patient from triage to hospital, for example. The\u000a      ability to analyse the blood\u000a      rapidly (within 30 s) has also changed the working patterns of health\u000a      professionals, for example,\u000a      in Japan, general practitioners use the device to give patients results in\u000a      their surgeries rather than\u000a      have to send away blood samples for analysis. In addition, the technology\u000a      is so robust that\u000a      paramedics in ambulances in Sri Lanka used the Optimedical analyzer during\u000a      the civil war,\u000a      which ended in 2009, when casualties were a daily occurrence. These\u000a      devices have recently\u000a      been used in a similar vein in Libya (see reference 3 in section 5).\u000a      Furthermore, the technology\u000a      has been adapted for veterinary treatments and is incorporated into the\u000a      IDEXX VetLab Suite\u000a      demonstrating the breadth of the impact delivered (see reference 4 in\u000a        section 5).\u000a    The high quality fundamental research undertaken in the area of PET\u000a      fluorescent sensors by de\u000a      Silva in QUB has had significant economic impact benefiting both the\u000a      companies involved as well\u000a      as the wider economy. Importantly, there have also been health and\u000a      societal benefits to the\u000a      development of the OPTI blood analyser in terms of speed of the analysis\u000a      which has resulted in\u000a      patients' peace of mind and more importantly efficient life saving\u000a      transfusion of compatible blood\u000a      aiding the recovery of patients globally.\u000a    In 2008 Prof de Silva won the Royal Society of Chemistry's Award for\u000a      Sensors sponsored by GE\u000a      Healthcare for his contribution towards 'switch and tell' sensor\u000a      molecules, the invention of\u000a      molecular logic and the industrial impact of the research undertaken\u000a      (reference 5 in section 5).\u000a    ","ImpactSummary":"\u000a    Research on fluorescent PET sensors by de Silva at Queen's University\u000a      Belfast was directly, and\u000a      collaboratively, built into the Roche\/Optimedical OPTI blood electrolyte\u000a      analyser, which has had\u000a      sales of US$50M in the past five years equating to 10 million sensors\u000a      sold. The market for this\u000a      sensor is global and it is used every day worldwide in hospital critical\u000a      care units, ambulances,\u000a      general-practice surgeries and veterinary care, often in life or death\u000a      circumstances. The research,\u000a      therefore, has led to both economic impact as well as significant health\u000a      benefits.\u000a    ","ImpactType":"Technological","Institution":"\u000a    Queen's University, Belfast\u000a    ","Institutions":[{"AlternativeName":"Queen's University Belfast","InstitutionName":"Queen's University Belfast","PeerGroup":"A","Region":"Northern Ireland","UKPRN":10005343}],"Panel":"B         ","PlaceName":[],"References":"\u000a    *Signify the references\u000a      which best indicate the quality of the underpinning research\u000a    \u000a*1. Fluorescent switches with high selectivity towards sodium ions:\u000a      correlation of ion-induced\u000a      conformation switching with fluorescence function. A.P. de Silva, H.Q.N.\u000a      Gunaratne, T.\u000a      Gunnlaugsson and M. Nieuwenhuyzen, Chem. Commun. 1996, 1967, DOI:\u000a      10.1039\/cc9960001967.\u000a    \u000a\u000a*2. New Fluorescent Model Compounds for the Study of Photoinduced\u000a      Electron Transfer: The\u000a      Influence of a Molecular Electric Field in the Excited State. A.P. de\u000a      Silva, H.Q.N. Gunaratne, J.-L.\u000a      Habib-Jiwan, C.P. McCoy, T.E. Rice and J.-P. Soumillion, Angew. Chem.\u000a        Int. Ed. Engl. 1995, 34,\u000a      1728, DOI: 10.1002\/anie.199517281.\u000a    \u000a\u000a3. A molecular photoionic AND gate based on fluorescent signalling. A.P.\u000a      de Silva, H.Q.N.\u000a      Gunaratne and C.P. McCoy, Nature 1993, 364, 42, DOI:\u000a      10.1038\/364042a0.\u000a    \u000a\u000a*4. Switching between molecular switch types by module rearrangement: Ca2+-enabled,\u000a      H+-driven\u000a      `Off-On-Off', H+-driven YES and PASS 0 as well as H+,\u000a      Ca2+-driven AND logic operations. J.F.\u000a      Callan, A.P. de Silva and N.D. McClenaghan, Chem. Commun. 2004,\u000a      2048, DOI:\u000a      10.1039\/b405909c.\u000a    \u000a\u000a5. Membrane Media Create Small Nanospaces for Molecular Computation. S.\u000a      Uchiyama, G.D.\u000a      McClean, K. Iwai and A.P. de Silva, J. Am. Chem. Soc. 2005, 127,\u000a      8920, DOI:\u000a      10.1021\/ja0513638.\u000a    \u000a\u000a6. Direct detection of ion pairs by fluorescence enhancement. A.P. de\u000a      Silva, G.D. McClean and S.\u000a      Pagliari, Chem. Commun. 2003, 2010, DOI: 10.1039\/b305262a.\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"7","Subject":"Theoretical and Computational Chemistry"},{"Level1":"3","Level2":"3","Subject":"Macromolecular and Materials Chemistry"}],"Sources":"\u000a    \u000a      Supporting letter from Optimedical Company (which is the current name\u000a        of the Roche\/AVL\u000a        Division) by Senior Scientist.\u000a      http:\/\/www.optimedical.com\/\u000a      http:\/\/www.optimedical.com\/news\/2011\/OPTI_Medical_Analyzers_In_Libya.pdf\u000a      http:\/\/www.idexx.com\/view\/xhtml\/en_us\/corporate\/investors\/annual-review\/2009\/2009-opti-medical.jsf\u000a      http:\/\/www.rsc.org\/ScienceAndTechnology\/Awards\/Archive\/SensorsAward\/Index.asp\u000a    \u000a    ","Title":"\u000a     Utilisation of Fluorescent PET (Photoinduced Electron Transfer) Sensor\u000a      Molecules in Blood Analysis\u000a    ","UKLocation":[{"GeoNamesId":"2655984","Name":"Belfast"}],"UKRegion":[{"GeoNamesId":"2641364","Name":"Northern Ireland"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    De Silva in QUB has been the pioneer of research into fluorescent PET\u000a      (photoinduced electron\u000a      transfer) sensors as a technique to target species such as protons, sodium\u000a      and calcium that are\u000a      crucial in many biological and medical contexts. The research at QUB which\u000a      started in 1993,\u000a      developed an understanding of the mechanism associated with PET sensors\u000a      (references 1 and 2\u000a      in section 3), based on Nobel Prize winning Marcus Theory which\u000a      explains the rates of the electron\u000a      transfer reactions. The mechanistic understanding obtained allowed the\u000a      design of a modular\u000a      sensor consisting of a fluorescent unit and a receptor unit joined through\u000a      a spacer molecule (Figure\u000a      1). When optically excited, this allows the transfer of an electron\u000a      to\/from the fluorescent unit from\/to\u000a      the receptor, as occurs in plant photosynthesis, so that fluorescence is\u000a      killed off. When the\u000a      receptor captures a suitable cation, however, such as sodium, the\u000a      increased positive charge\u000a      prevents the electron transfer, allowing fluorescence. Additionally, the\u000a      research demonstrated that\u000a      changes in conformation caused by species occupying the receptor can\u000a      enhance the fluorescence\u000a      switching effect. Critically, as a result of the understanding formulated\u000a      by the Queen's group, the\u000a      combination of components has been able to be manipulated to selectively\u000a      detect analytes at\u000a      concentrations as low as 10-7 M, thus enabling, for example pH,\u000a      calcium, sodium and potassium\u000a      ion concentration to be determined from the same sample in a flow through\u000a      system via a number of\u000a      sensors in series. Furthermore, the Queen's group OFF state PET\u000a      developed the fluorescent PET sensors to be designed so\u000a      that a substantial number of other cationic, anionic and\u000a      neutral species are also accommodated to trigger Spacer Receptor\u000a      fluorescence leading to the technology to be transferred to a\u000a      commercial process and the design of sensors and devices\u000a      for much wider applications, for example in the field of\u000a      molecular logic based computation (reference 3 in section\u000a      3), of which the initial sensors acted as YES gates. Other\u000a      molecules, which behaved as AND gates, (references 3-6 in\u000a      section 3) also emerged. From this research, Unit\u000a      Roche\/Optimedical collaborated with the Queen's team to hf06e hf06e'\u000a      develop commercial sensors for sodium, potassium and\u000a      calcium which were tested in collaboration with scientists at\u000a      AVL Bioscience Corporation, Roswell, GA leading to the\u000a      final OPTI blood electrolyte analyser product.\u000a\u000aFigure 1 Mechanism of\u000aPET sensor action\u000a\u0009  \u000a    "},{"CaseStudyId":"38628","Continent":[],"Country":[],"Funders":["Royal Society"],"ImpactDetails":"\u000a    Traditional metal processing techniques involve strong mineral acids and\u000a      bases. These processes evolve large volumes of aqueous effluent which must\u000a      be treated before emission and this can be a significant environmental\u000a      hazard. The processes also have inherently poor power inefficiency due to\u000a      the electrochemical instability of water. Scionix Ltd was formed as a\u000a      University spin-out (1999) to commercialise ionic liquid technology as an\u000a      alternative and currently holds 4 key patents [1]. Scionix Ltd. is now one\u000a      of the world's major producers and innovators in the field of ionic\u000a      liquids [2], disseminating technologies and techniques which\u000a      simultaneously benefit industries such as electronics manufacturing,\u000a      aerospace engineering, metal finishing and surface coatings. These\u000a      benefits include reduced energy costs, reduced environmental emissions and\u000a      reduced user hazard. Each process is underpinned by recycling protocols\u000a      and economic evaluations. Typically the company produces 1000 to 3000 kg\u000a      of ionic liquids p.a. which is significant for such a nascent technology.\u000a      The company has developed several commercial scale processes in\u000a      collaboration with UoL and the end users. These include chromium plating\u000a      [text removed for publication] electropolishing (Rolls Royce, Anopol and\u000a      Northbridge Motorsport) and silver plating (P W Circuits) and each process\u000a      delivers environmental and efficiency improvements over the aqueous\u000a      process.\u000a    Rolls Royce, PWCircuits and [text removed for publication] were engaged\u000a      through industry briefing events organised by national\/international trade\u000a      associations (Institute of Material Finishers\/ European Institute of\u000a      Printed Circuit Boards). The technology was showcased through the Ionic\u000a      Liquid Demonstrator which is an industry facing showcase based at UoL\u000a      containing six pilot plants each using &gt; 50 kg of ionic liquids [3].\u000a      Since its opening in June 2009 more than 25 businesses have used the Ionic\u000a      Liquids Demonstrator Unit including Dow, MacDermid, HydroQuebec and\u000a      Silberline. All have trialled new processing techniques with their\u000a      products including printed circuit boards, batteries and colloidal\u000a      dispersions. Prototype materials, devices and processes have been\u000a      produced. A European consortium POLYZION used the facilities and was\u000a      successful in developing rechargeable zinc batteries with a specific\u000a      current density of 1000 W kg-1, excellent cycleability\u000a      (&gt;1000 cycles) and a large open circuit potential (~1.9V) [4].\u000a    Chromium Plating: Chromium is the industry standard for hard metal\u000a      coatings and is currently solely carried out using highly carcinogenic\u000a      chromic acid. The establishment of the first Cr(III) route to hard chrome\u000a      is a significant development. The process developed with [text removed for\u000a      publication] is coating steel tubes with hard chromium using a novel\u000a      rotating electrode arrangement to decrease the volume of ionic liquid\u000a      needed and further improve the safety of the plating process. The\u000a      exclusive license signed between [text removed for publication] and\u000a      Scionix sees private sector investment of &gt;2M Euro. The original work\u000a      in this area led to Abbott being awarded the Industry and Green Medals by\u000a      the Royal Society of Chemistry [5, 6].\u000a    Electropolishing: Rolls-Royce Aerospace was assisted by Ryder\u000a      working at their Derby site (originally under the auspices of the Royal\u000a      Society Industry Fellowship scheme (2010-2012) and then under a HEIF\u000a      funded Fellowship). He developed a new approach to superalloy processing\u000a      using electrochemical etching. To deliver the impact it was necessary to\u000a      understand the role of ionic liquids in electrolytic removal of oxide\u000a      films and dissolution of metals from Ni super alloy castings. The\u000a      mechanism of scale formation was elucidated in collaboration with Rolls\u000a      Royce. The surface chemistries, morphologies and mathematical modelling of\u000a      the cooling process were also studied in high temperature melts.\u000a    The scale removal is greatly simplified using ionic liquids and is not\u000a      possible from conventional aqueous acid electrolytes. Typically these\u000a      parts are deployed in the Trent series of engines that power Boeing and\u000a      Airbus passenger aircraft. The project succeeded in streamlining\u000a      production of the blade components by scale removal (using ionic liquids)\u000a      prior to the expensive heat-treatment and annealing processes. This cannot\u000a      currently be achieved because alternative techniques for scale removal,\u000a      before heat-treatment, cause solid state recrystallisation in the alloys\u000a      producing grain boundaries that lead to stress fractures. Rolls Royce\u000a      Aerospace has now embarked on a technology readiness pathway leading to\u000a      the use of Leicester's ionic liquids technology. The company is now\u000a      collaborating with Ryder to solve specific production problems associated\u000a      with surface scale in engine production parts, with a view to fully\u000a      implementing ionic liquids technology in its production processes.\u000a    Silver Plating: Since October 2009, PW Circuits of Leicester has\u000a      operated a full coating process developed by the Leicester Ionic Liquids\u000a      Group based on an 8 tank line using c.a. 1 tonne of ionic liquid. Simple\u000a      immersion of a copper coated printed circuit board in a mixture of\u000a      ethylene glycol and choline chloride with silver chloride produces boards\u000a      which not only meet all industry requirements but actually improve over\u000a      existing techniques in functions such as solderability. The liquid\u000a      developed significantly reduced the cost of immersion coating as it used a\u000a      less expensive silver salt than the current industry standard. The quality\u000a      of the product in terms of its solderability and resistance to tarnishing\u000a      was independently verified by the European Institute of Printed Circuits\u000a      [7].\u000a    The processes commercialised to date and their key impacts are listed\u000a      below and many of the impacts have been independently verified. [8]\u000a    \u000a      \u000a        \u000a          Process\u000a              (Users)\u000a          Current\u000a              Technology Issues\u000a          Impact\u000a              of New Technology\u000a        \u000a        \u000a          Chromium plating [text removed for publication]\u000a          chromic acid (carcinogenic)\u000a          Three-fold decrease in power consumption\u000a            Uses CrCl3\u000a        \u000a        \u000a          Electropolishing (Rolls\u000a              Royce, Anopol, Northbridge Motorsport)\u000a          H2SO4, H3PO4, HF, chromic acid\u000a          Safe in contact with skin\u000a            Four-fold decrease in power consumption\u000a            Metal recoverable\u000a            Greatly decreased failure rate (superalloys)\u000a        \u000a        \u000a          Silver Plating (PWCircuits)\u000a          Acid based &#8211; leads to board failure through track\u000a            etching\u000a            Silver cyanide complexes\u000a          Reduced cost (uses silver nitrate)\u000a            Reduced light sensitivity\u000a            Non-acidic &#8211; no track etching\u000a            Improved solderability\u000a        \u000a      \u000a    \u000a    ","ImpactSummary":"\u000a    Ionic liquids (liquid salts) offer a more energy efficient and\u000a      environmentally sustainable method of coating and processing metals than\u000a      other more traditional methods. The generic technology developed at\u000a      Leicester for plating and etching metals significantly decreases the power\u000a      consumption, uses less hazardous chemicals and produces less aqueous\u000a      waste. Many of the current acid-based liquids are restricted by\u000a      legislation. The spin-out company, Scionix Ltd has developed numerous\u000a      processes for metal processing through collaborative grants with the\u000a      University of Leicester and the end users. Probably the largest impact has\u000a      been through the development of a breakthrough technology for the\u000a      electroplating of chromium removing the use of carcinogenic chromic acid.\u000a      In April 2013 [text removed for publication] (one of the world's largest\u000a      steel producers) signed an exclusive license with Scionix Ltd for [text\u000a      removed for publication] using the ionic liquid technology developed at\u000a      the University.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Leicester\u000a    ","Institutions":[{"AlternativeName":"Leicester (University of)","InstitutionName":"University of Leicester","PeerGroup":"A","Region":"East Midlands","UKPRN":10007796}],"Panel":"B         ","PlaceName":[],"References":"\u000a    \u000a1) Novel Solvent Properties of Choline Chloride\/ Urea Mixtures\" A. P. Abbott,\u000a      G. Capper, D. L. Davies, R. Rasheed and V. Tambyrajah Chem.\u000a        Commun, 2003, 70-71.\u000a    \u000a\u000a2) \"Deep Eutectic Solvents Formed Between Choline Chloride and Carboxylic\u000a      Acids\" A. P. Abbott, D. Boothby, G. Capper, D. L. Davies,\u000a      R. Rasheed and V. Tambyrajah J. Am. Chem. Soc. 2004, 126,\u000a        9142 Refs 1 and 2 are the standard citation for what DESs are. There\u000a      have been in excess of 300 publications in the field of DESs since 2008,\u000a      all of which built upon the original Leicester publication. (1) and (2)\u000a      have received over 500 citations.\u000a    \u000a\u000a3) Model for the Conductivity of Ionic Fluids Based on an Infinite\u000a      Dilution of Holes\" A. P. Abbott, Chem. Phys. Chem.\u000a      2005, 6, 2502-2505 Paper that proposed a new model\u000a      for mass transport in ionic liquids.\u000a    \u000a\u000a4) \"Ionic liquids form ideal solutions\", A.P. Abbott, G. Frisch,\u000a      H. Garrett, and J. Hartley, Chem Commun, 2011, 47(43),\u000a      11876-11878.\u000a    \u000a\u000a5) \"Ionometallurgy: Designer Redox Properties for Metal Processing\", A.P.\u000a        Abbott, G. Frisch, S.J. Gurman, A.R. Hillman, J. Hartley, F.\u000a      Holyoak and K.S. Ryder, Chem. Commun., 2011, 47, 10031.\u000a    \u000a\u000a6) Electrodeposition of Metals from Ionic Liquids, F. Endres, A. P. Abbott,\u000a      and D. MacFarlane (Eds.) Wiley VCH 2008 This is the standard book on metal\u000a      deposition in ionic liquids. A second edition is currently being written.\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"},{"Level1":"3","Level2":"7","Subject":"Theoretical and Computational Chemistry"}],"Sources":"\u000a    1) International Patents WO2000 056700; WO 2001 022670; WO 2001 022638;\u000a      WO 2007 003956\u000a    2) www.scionix.co.uk\u000a    3) http:\/\/www.ionmet.eu\/fileadmin\/ionmet\/Dissemination\/IONMET_brochure_200711.pdf\u000a    4) http:\/\/www.le.ac.uk\/ebulletin-archive\/ebulletin\/news\/press-releases\/2000-2009\/2009\/06\/nparticle.2009-06-01.html\u000a    5) http:\/\/www.polyzion.eu\/\u000a    6) June 2007 Royal Society of Chemistry - Green Chemistry Medal to Prof\u000a      Abbott\u000a    7) June 2008 Royal Society of Chemistry - Industrial Chemistry\u000a      Lectureship to Prof Abbott\u000a    8) http:\/\/pcb007.com\/pages\/columns.cgi?clmid=26&amp;artid=54911&amp;_pf_=1\u000a      Review of the silver plating process by the silver plating process and the\u000a      dissemination event by the EIPC (Printed circuit board Trade Body)\u000a    9) http:\/\/www.pfonline.com\/articles\/are-ionic-liquids-the-future-of-the-surface-treatment\u000a    ","Title":"\u000a    Leaner, Greener Material Processing using Ionic Liquids\u000a    ","UKLocation":[{"GeoNamesId":"2644668","Name":"Leicester"},{"GeoNamesId":"2651347","Name":"Derby"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Origins: Leicester has developed a series of ionic liquids based\u000a      on eutectic mixtures of quaternary ammonium salts with either metal salts\u000a      or hydrogen bond donors (Abbott and Davies (1999-present)). The research originated from a consultancy for Johnson Matthey\u000a      in 1997 on the electrodeposition of aluminium alloys using traditional\u000a      chloroaluminate based ionic liquids. The original patents covered over 106\u000a      liquids and it was immediately clear that the almost limitless\u000a      formulations had significant commercial application. This led directly to\u000a      the formation of a University of Leicester spinout company, Scionix Ltd.,\u000a      in 1999. A joint venture model was adopted with a partner who has the\u000a      capacity to manufacture the liquids on the multi-tonne scale (Whyte\u000a      Chemicals). Customers range from academic groups through to large scale\u000a      industry (see below). The term Deep Eutectic Solvents (DESs) was coined to\u000a      differentiate them from ionic liquids with discrete anions. The advantages\u000a      of these liquids are that they can be easily prepared in bulk, they are\u000a      comparable in cost to bulk molecular solvents, and can be prepared from\u000a      bulk commodity chemicals such as choline chloride with hydrogen bond\u000a      donors such as glycerol, and urea which have negligible ecotoxicity [1,2].\u000a      The unusual solvent properties make them ideal for metal processing\u000a      applications such as metal deposition, dissolution or recycling. The\u000a      Leicester Group of Abbott, Davies, Frisch, and Ryder have\u000a      published 75 papers on DESs covering topics such as metal deposition and\u000a      dissolution, mass transport and redox properties. This has been pertinent\u000a      to all of the metal deposition and dissolution processes developed to date\u000a      by helping design liquids specific to each application.\u000a    Fundamental Studies: To be able to design and apply a new class of\u000a      liquids Abbott and Ryder developed fundamental new insight\u000a      into the viscosity, conductivity and mass transport in all types of ionic\u000a      liquids [3]. It was shown by the Leicester group that the large ion size\u000a      means that mass transport is limited by the availability of holes for ions\u000a      to move into. This means that viscosity can be modelled using hole theory\u000a      and conductivity can be modelled using a Nernst Einstein model because the\u000a      holes are effectively at infinite dilution. It was shown that classical\u000a      diffusion does not occur in ionic liquids with ions moving by a series of\u000a      jumps between suitably sized voids. It was also shown that some liquids\u000a      form ideal solutions allowing concentration effects of redox potentials to\u000a      be modelled [4]. This has led to the development of liquids with some of\u000a      the lowest viscosities and highest conductivities yet reported and these\u000a      are being applied to the latest generation of liquids for chromium\u000a      plating.\u000a    In addition Abbott, Ryder and Frisch coined the term Ionometallurgy\u000a      to describe the dissolution and selective recovery of metals using ionic\u000a      liquids [5]. They produced the first galvanic series in an ionic liquid\u000a      and showed that in some ionic liquids metal salts form ideal solutions.\u000a      This has allowed the first standard redox potentials to be determined\u000a      which were shown to be related to speciation in different ionic liquids.\u000a      This has helped with the development of a new class of liquids which do\u000a      not involve quaternary ammonium salts which is now being exploited for\u000a      aluminium electrodeposition through an EU project.\u000a    Since 2009 the group has been engaged in detailed studies of surface\u000a      morphology and chemistry using a unique combination of electrochemical\u000a      acoustic resonator as well as X-ray techniques and liquid phase probe\u000a      microscopy to understand the correlations between macroscopic effects such\u000a      as surface finish, brightness and appearance with the microscopic\u000a      environment at the electrochemical interface. This environment encompasses\u000a      the molecular structure of metal ions in the liquids as well as complex\u000a      kinetic phenomena such as electrochemical nucleation and growth. Both of\u000a      these can be affected by addition of molecular ligands that are known\u000a      colloquially as levellers and brighteners in the metal finishing industry.\u000a      In 2010 these facilities were augmented by holographic microscopy (giving\u000a      orders of magnitude faster data acquisition) and in 2012 optical profiling\u000a      for non-contact characterisation. This has informed the development of\u000a      novel brighteners for use in electroplating baths [6].\u000a    Developing Impact: Most of the ionic liquid based metal plating\u000a      processes were initially developed through the Leicester group who\u000a      instigated a consortium consisting of 33 partners for the EU-funded\u000a      IONMET project (EU, FP7 contract No.: 515743) between 2008 and 10. This\u000a      covered not only the fundamental aspects of deposition mechanism but also\u000a      developed additives to make electroplate brighter. It was able to produce\u000a      efficient, environmentally-compatible techniques for depositing thin\u000a      layers of metals such as copper, nickel, aluminium and silver together\u000a      with alloys such as Zn\/Sn. Other outputs were developed through two\u000a      further EU grants, 6 TSB grants, a Royal Society Industry Fellowship\u000a      (Ryder) Rolls-Royce) and a KTP grant all of which involved industrial\u000a      partners such as Corus, Rolls Royce, Anopol Ltd and CTech.\u000a    "},{"CaseStudyId":"38821","Continent":[],"Country":[],"Funders":["Engineering and Physical Sciences Research Council","Royal Society"],"ImpactDetails":"\u000a    The impact achieved from these research findings has been through\u000a      significantly influencing the policies and priorities of the world's most\u000a      active space agencies in terms of the scientific objectives of their space\u000a      exploration programmes, in mission design and on the instrumentation\u000a      carried on spacecraft. Leading individuals at the European and US agencies\u000a      (ESA and NASA) have confirmed that Smith and Sims' findings on\u000a      low-temperature gas-phase chemistry and kinetics have made a material\u000a      contribution to their understanding of interstellar chemistry and thus\u000a      helped determine the approach to current and planned exploratory missions.\u000a    The impact extends into the decision-making and practice of the world's\u000a      foremost space agencies. It has influenced how these agencies\u000a      conceptualise their missions, deploy very large sums of public money and\u000a      plan their future programmes. Given the length of time involved in\u000a      planning and executing space missions, any significant impact is likely to\u000a      be visible across a longer period than a five year window; nevertheless,\u000a      it can been seen here that although these impacts started prior to 2008,\u000a      they have continued to be important to the current Rosetta mission, as\u000a      well as on the Herschel mission which launched in 2009 and to ongoing work\u000a      in the development phase of further planetary exploration.\u000a    Impact on Missions Probing the Interstellar Medium\u000a    Our Sun was formed from the condensation of an interstellar cloud,\u000a      complete with all the complex molecules that it contained, about 4.5\u000a      billion years ago. The proto-solar nebula then evolved into the Solar\u000a      System. Exploration of the Solar System and the understanding of Earth's\u000a      place in it, including its evolution and biosphere, are fundamental\u000a      rationales for ESA and NASA. Such exploration is extremely expensive &#8212; a\u000a      typical interplanetary mission can cost 1bn Euro &#8212; and is only undertaken\u000a      with a thorough analysis of the mission's scientific objectives and\u000a      feasibility. Indeed the planning, design and development stages typically\u000a      span a decade or more prior to the actual operational phase.\u000a    Knowledge of the types of complex molecules formed within interstellar\u000a      clouds serves as an important starting point in the search for organics\u000a      and ultimately life elsewhere in the Solar System. ESA's infrared\u000a      astrophysics missions [ISO (1995-1998) and Herschel (2009 - 2013)]\u000a      together with NASA's Spitzer mission (2003-2012) were the pathfinders for\u000a      establishing the detailed organic component of the interstellar medium,\u000a      with their observations informed by the published research conducted at\u000a      UoB into reaction rates at low temperatures. Professor R. E. Griffiths,\u000a      the Program Scientist for Physics of the Cosmos at NASA has stated: \"This\u000a        work, exemplified by that performed by Smith and Sims, is seminal to our\u000a        understanding of the low-temperature reactions which lead to the\u000a        production of complex molecules within interstellar clouds, molecules\u000a        which are evidenced by observations made using instruments on space\u000a        telescopes\". [source 1]\u000a    A Rosetta Mission Project Scientist, Rita Schulz (see below) also\u000a      confirmed that the Herschel Space Observatory, launched in 2009, has the\u000a      study of the low temperature chemistry of complex organics in molecular\u000a      clouds as a key objective, and that this is a further example of a mission\u000a      where benefits will rely on this research.\u000a    Impact on Comet Missions: ESA's Rosetta mission\u000a    Having knowledge of the composition of interstellar clouds allows\u000a      designers of Solar System exploration missions to include instrumentation\u000a      that can search for these various species on or in planetary and smaller\u000a      bodies (asteroids, comets, moons). It is here that the published work of\u000a      Smith\/Sims has had the most impact, affecting instrument design,\u000a      spacecraft operations and instrument configurations during the exploration\u000a      phase. Building on the results from ESA's GIOTTO mission, the Rosetta\u000a      mission to rendezvous and land on a comet in 2014 has the study of these\u000a      complex organics as a key objective.\u000a    The Rosetta spacecraft will be the first to undertake the long-term\u000a      exploration of a comet at close quarters and also the first mission to\u000a      land on a comet. The craft comprises a large orbiter, which is designed to\u000a      operate for a decade at large distances from the Sun, and a small lander.\u000a      The craft carries a total of 21 instruments (11 in the Orbiter, 10 on the\u000a      Lander) designed to complete the most detailed study of a comet ever\u000a      attempted. [source 2] Three of these instruments carry out activities that\u000a      draw significantly on the work at Birmingham.\u000a    [text removed for publication] the Rosetta Mission Project Scientist\u000a      confirmed the contribution of the Birmingham research to the Rosetta\u000a      mission as follows: \"Three mass spectrometers, two on the Lander (COSAC\u000a        and PTOEMY) and one on the Orbiter {COSIMA), are designed to study\u000a        in-situ the composition of comet refractories specifically focussing on\u000a        organic macromolecules. They will measure molecular numbers of CHON\u000a        particles from which certain chemical groups may be identified. However,\u000a        to be able to conclude on a specific derivate or clearly attribute the\u000a        results to specific organic molecules, laboratory measurements are\u000a        required that allow to determine th probability of their synthesis in a\u000a        low temperature environment.\u000a    Important work was done at Birmingham University's School of Chemical\u000a        Sciences on low-temperature gas-phase chemistry and kinetics. Many of\u000a        the ion-neutral and neutral-neutral processes studied and reaction rates\u000a        determined by Smith, Sims and Rowe have been particularly helpful in\u000a        view to understanding interstellar chemistry and its relations to\u000a        volatiles in comets. I believe that without the research work from\u000a        Birmingham University over the past some twenty years we would have a\u000a        poorer Rosetta mission &#8212; particularly as much of it was conducted during\u000a        the mission's critical design and build phase in the 90's. Furthermore\u000a        on arrival at our target comet the past efforts of the School of\u000a        Chemical Sciences related to low temperature reaction rates will be\u000a        invaluable in interpreting the chemistry that will be underway as our\u000a        comet makes its way ever closer to our sun.\" [source 3]\u000a    Impact on Planetary Missions: Mars and the Jovian moons\u000a    Comets are one end of the exploration spectrum. Planetary bodies,\u000a      particularly Mars and the moons of Jupiter such as Europa and Ganymede,\u000a      are the other and have recently become centre of attention. Current and\u000a      planned missions to Mars by NASA, ESA and the Russian Space Agency RKA\u000a      have the search for life, extinct or extant, as a key aim, with complex\u000a      organic molecules now a precursor in that search. The same can be said of\u000a      the study of the Jovian moons, a mini solar-system in its own right.\u000a      Mission designers, instrument developers and spacecraft\/payload operations\u000a      all have the work of Smith and Sims at the UoB underpinning their\u000a      scientific objectives.\u000a    [text removed for publication] the former Head of ESA's Science\u000a      Technology and Future Science Missions Department, has confirmed the\u000a      continuing impact of the Birmingham research on these programmes as\u000a      follows: \"... future missions in their early preparatory phases such as\u000a        the exploration of the Jovian moon Europa or Exoplanet characterisation,\u000a        instrument and mission design will again be influenced by the search for\u000a        organic molecules. Without the research of Smith and Sims, these mission\u000a        concepts would be much more limited. But now the search for complex\u000a        organics and potential bio-chemical signatures is on the agenda. In\u000a        short, studies of the constituents of the interstellar medium and the\u000a        exploration of our solar system owe a debt to the work of Smith and\u000a        Sims. Without their research we would still be designing missions with\u000a        for astronomy a mainly exploratory focus and for the solar system an\u000a        emphasis on geophysics. This readjustment of the scientific objectives\u000a        will have far reaching implications on mission design, instrument\u000a        complement and ultimately cost.\" [source 4]\u000a    NASA and ESA are currently pursuing separate missions (JUNO and JUICE\u000a      respectively) to the Jovian system acting as precursors with a key\u000a      long-term science objective to search for evidence of life &#8212; indeed JUICE\u000a      will search for evidence of habitability on these moons. If one of these\u000a      missions does discover biological signatures this will have a profound\u000a      impact on mankind's place in the Solar System and the Universe. While the\u000a      goal of these major missions is such a return, they are underpinned by the\u000a      fundamental scientific research on low temperature reaction rates and\u000a      species production conducted by Smith, Sims and their co-workers.\u000a    ","ImpactSummary":"\u000a    The spectroscopic observation in the interstellar medium (ISM) of an\u000a      increasing number of molecules has demonstrated the presence of a rich\u000a      chemistry, especially in the low temperature (ca. 10 K) environment\u000a      of dense interstellar clouds. Understanding this chemistry requires the\u000a      combined efforts of modellers and laboratory scientists. In the 1990's,\u000a      research at the University of Birmingham pioneered a series of unique\u000a      measurements in which rate coefficients for reactions were measured at\u000a      temperatures down to as low as 13 K. These results have made a significant\u000a      impact on the world leading space agencies (NASA and ESA), who have\u000a      benefited from this research through gaining a better understanding of\u000a      interstellar chemistry. Mission priorities and instrument design have been\u000a      influenced by this improved understanding with three (out of a total of\u000a      21) instruments carried by NASA's Rosetta comet-rendezvous mission\u000a      designed to carry out activities that draw significantly on the Birmingham\u000a      findings. This demonstrates the impact on the allocation of budgets by\u000a      these agencies and their scientific aims. The detection of molecules and\u000a      the study of their formation are now viewed as top priorities, which\u000a      ultimately impacts on the search for bio-signatures and life elsewhere in\u000a      the Solar System.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Birmingham\u000a    ","Institutions":[{"AlternativeName":"Birmingham (University of)","InstitutionName":"University of Birmingham","PeerGroup":"A","Region":"West Midlands","UKPRN":10006840}],"Panel":"B         ","PlaceName":[],"References":"\u000a    Professors Smith and Sims have published 39 joint papers, working\u000a      together since ~1990 to develop the CRESU (Cinetique de Reaction en\u000a      Ecoulement Supersonique Uniforme) apparatus to study the kinetics of\u000a      reactions between neutral species at temperatures down to 10 K in the gas\u000a      phase. For example:\u000a    \u000a[1] I. W. M. Smith, E. Herbst and Q. Chang, \"Rapid neutral-neutral\u000a        reactions at low temperatures: a new network and first results for TMC-1\",\u000a      Mon. Not. R. Astronom. Soc., 2004, 350, 323. (118\u000a      citations)\u000a    \u000a\u000a[2] D. Chastaing, P. L. James, I. R. Sims and I. W. M. Smith, \"Neutral-neutral\u000a        reactions at the temperatures of interstellar clouds: Rate coefficients\u000a        for reactions of atomic carbon, C(3P), with O2,\u000a        C2H2, C2H4\u000a        and C3H6 down to 15 K\",\u000a      Phys. Chem. Chem. Phys., 1999, 1, 2247. (68\u000a      citations)\u000a    \u000a\u000a[3] I. R. Sims, J. L. Queffelec, D. Travers, B. R. Rowe, L. B. Herbert,\u000a      J. Karthauser, and I. W. M. Smith, `Rate constants for the reactions of CN\u000a      with hydrocarbons at low and ultra-low temperatures', Chem. Phys.\u000a        Lett. 1993, 211, 461-468. (176 citations)\u000a    \u000a\u000a[4] I. R. Sims, J. L. Queffelec, A. Defrance, C. Rebrion-Rowe, D.\u000a      Travers, P. Bocherel, B. R. Rowe and I. W. M. Smith, \"Ultralow\u000a        temperature kinetics of neutral-neutral reactions: the technique and\u000a        results for the reactions CN + O2 down to 13 K\u000a        and CN + NH3 down to 25 K\", J. Chem.\u000a        Phys., 1994, 100, 4229. (157 citations)\u000a    \u000a\u000a[5] I. R. Sims and I. W. M. Smith, \"Gas-phase reactions and energy\u000a        transfer at very low temperatures\", Ann. Rev. Phys. Chem., 1995,\u000a      46, 109. (83 citations)\u000a    \u000a\u000a[6] D. Chastaing, P. L. James, I. R. Sims and I. W .M. Smith, \"Neutral-neutral\u000a        reactions at the temperatures of interstellar clouds Rate coefficients\u000a        for reactions of C2H radicals with O2,\u000a        C2H2, C2H4\u000a        and C3H6 down to 15 K\",\u000a      J. Chem. Soc. Faraday Discuss., 1998, 109, 165. (81\u000a      citations)\u000a    \u000aMuch of the work at the UoB was supported by EPSRC research grants in the\u000a      1990s, e.g. GR\/J87503\/01 \"Reactive and Inelastic Processes In\u000a        The Gas-Phase At Ultra-Low Temperatures\", &#163;353k. The UoB\/Rennes team\u000a      was awarded one of the first Descartes prizes for this work, and Professor\u000a      Smith was awarded the Royal Society of Chemistry Polanyi and Tilden\u000a      Medals.\u000a    References 3, 4 and 5 best indicate the quality of the underpinning\u000a      research.\u000a    ","ResearchSubjectAreas":[{"Level1":"2","Level2":"2","Subject":"Atomic, Molecular, Nuclear, Particle and Plasma Physics"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"7","Subject":"Theoretical and Computational Chemistry"}],"Sources":"\u000a    \u000a      Corroborating statement received from Program Scientist for the\u000a        Physics of the Cosmos, Astrophysics Division, Science Mission\u000a        Directorate, NASA HQ, Washington DC 20546, USA\u000a      http:\/\/www.esa.int\/Our_Activities\/Space_Science\/Rosetta\/Lander_Instruments\u000a      Statement from Rosetta Mission Project Scientist, Directorate of\u000a        Science and Robotic Exploration, European Space Agency, ESTEC, Keperlaan\u000a        1, 2201 AZ Noordwijk The Netherlands dated 10\/7\/2012\u000a      Corroborating statement from former Head of ESA's Science Technology\u000a        and Future Science Missions Dept (2000-2007) dated 29\/4\/13\u000a    \u000a    ","Title":"\u000a    Astrochemistry: a network of gas-phase reactions used in\u000a        low-temperature interstellar chemistry by the world's leading space\u000a        agencies\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Between 1990-2002, Ian Smith (FRS, Mason Professor of Chemistry,\u000a      University of Birmingham (UoB), up until his retirement in 2002) and Ian\u000a      Sims (EPSRC Advanced Fellowship and then Senior Lecturer, School of\u000a      Chemistry, UoB, up until his move to Rennes as an EU Marie-Curie Chair in\u000a      2003) developed a technique for the study of bimolecular reactions between\u000a      neutral species at much lower temperatures than hitherto studied. This\u000a      technique had originally been developed to study reactions between cations\u000a      and stable molecules. Since they show zero or even negative dependence of\u000a      the rate constant with temperature (Langevin 1905), they proceed at the\u000a      same or higher rate at very low temperatures as they do at room\u000a      temperature. Such reactions had always been assumed to be the primary\u000a      building blocks for molecules in the ISM, where the temperature can be as\u000a      low as 5 K. The primary (and surprising) finding of the Smith\/Sims\u000a      research was that there are a significant number of neutral-neutral\u000a      reactions that also proceed rapidly at these very low temperatures, with\u000a      the result that all the old models for the chemistry of the ISM have had\u000a      to be re-assessed and re-written. Whereas it was not unexpected that\u000a      reactions between two open-shell free radicals (e.g. N + OH &#8594; NO +\u000a      H) are rapid at low temperatures, a remarkable and unexpected finding was\u000a      that these rapid neutral-neutral reactions include an atom or a molecular\u000a      free radical reacting with a `stable' molecule (e.g. CN + C2H2\u000a      &#8594; HC3N + H). [Refs 3 and 4] Some of this research was carried\u000a      out in collaboration with Dr Bertrand Rowe, Universit&#233; de Rennes \/ CNRS\u000a      Rennes, France.\u000a    This research has deep and rather far-reaching implications. For example\u000a      the European Space Agency's (ESA) GIOTTO space mission performed the first\u000a      comet encounter with Halley's Comet in 1986 and discovered a large number\u000a      of complex carbon-based molecules (CHON or Carbon Hydrogen Oxygen and\u000a      Nitrogen particles). Only after the work of Smith\/Sims did astrochemists\u000a      understand how these molecules might be synthesised. There is a particular\u000a      interest in these species because they may have contributed to the start\u000a      of life on Earth &#8212; and, possibly other planets such as Mars and the Jovian\u000a      moons such as Europa. ESA, supported with some instrumentation from NASA,\u000a      quickly developed the Rosetta mission to rendezvous with and land on a\u000a      comet to study, in part, these CHON particles and the complex chemistry\u000a      underway at low temperatures &#8212; the goal being nothing less than to\u000a      determine the content and nature of the molecules present in comets.\u000a    It is clear that our understanding of how these CHON molecules form, both\u000a      in comets and in molecular clouds, is of fundamental importance to\u000a      modelling the evolution of the universe and in particular our solar system\u000a      and its associated biological evolution. ESA Solar System exploration\u000a      missions are built around four axioms: science objectives, design,\u000a      development and operations, all of which are underpinned by the work of\u000a      Smith, Sims and co-workers. Indeed specific past papers (see below) from\u000a      the UoB School of Chemistry dealing with reaction rates at these very low\u000a      temperatures have been particularly useful in shaping the Rosetta and\u000a      JUICE missions in this area of science. In addition two of ESA's\u000a      astrophysical missions, Infrared Space Observatory (ISO) &amp; Herschel,\u000a      have also benefited from this work (for scientific publications arising\u000a      from ISO, see: http:\/\/iso.esac.esa.int\/science\/publications.html).\u000a    To the present day, the UoB, including the Physical and Theoretical\u000a      Chemistry Research Unit, continues with experimental physical chemistry\u000a      research, including gas phase work (e.g. Tuckett, School of Chemistry and\u000a      Mayhew, School of Physics).\u000a    "},{"CaseStudyId":"38822","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2658434","Name":"Switzerland"}],"Funders":["Engineering and Physical Sciences Research Council","Royal Society"],"ImpactDetails":"\u000a    The impact from MOLPRO in the REF window has been primarily economic and\u000a      can be quantified through sales of MOLPRO to academia and industry\u000a      throughout the REF window, as follows (data provided by Cardiff\u000a      University): &#163;1,783,714 (January 2008 &#8212; July 2013). The main\u000a      contributors to the economic impact are academic users but just over 10%\u000a      have been commercial users and companies, contributing &#163;203,480,\u000a      as of 31 July 2013. These include organisations such as Cilag AG (a Swiss\u000a      pharmaceutical firm), BASF, Hitachi, Nissan Chemical Industries, DE Shaw\u000a      Research (a computational biochemistry research company) and Schrodinger\u000a      (a software company).\u000a    Evidence for the impact of MOLPRO on facilitating research by commercial\u000a      users includes that from BASF. BASF conducts research into fields such as\u000a      theoretical chemical modelling as part of its ongoing product development\u000a      process, which requires a high-performance computing (HPC) platform. A\u000a      Group Leader in Quantum Chemistry at BASF and current user of MOLPRO\u000a      states:\u000a    \"MOLPRO and in particular its capability for very accurate\u000a        computations on large molecules, has become a valuable tool for\u000a        estimating thermochemical and kinetic data for substances and reactions\u000a        involved in our development of new materials and processes.\"\u000a    Further evidence of the importance of MOLPRO to BASF comes from a 2009\u000a      INTEL document describing a project in which MOLPRO, as a \"key\u000a      application\", was test run on an INTEL Xeon processor 5500 series, with\u000a      the new platform driving improvements in time performance of the program.\u000a    Furthermore, a user at DE Shaw Research, has written the following\u000a      related to their work on drug design:\u000a    \"The issue of force field accuracy is even more critical in our work\u000a        on problems of drug design, which require a very accurate description of\u000a        protein-small molecule interactions. Here we are taking the approach of\u000a        developing new force fields from scratch, adding force field components\u000a        to account for polarization, charge penetration, and other physical\u000a        effects not typically included in existing biomolecular models. We have\u000a        used MOLPRO extensively to generate the data necessary for fitting these\u000a        more complex biomolecular and small molecule force fields. The wide\u000a        variety of methods available in, and performance and flexibility of, the\u000a        MOLPRO software make it key to our force field development efforts in\u000a        general, and to the development of improved force fields for small\u000a        molecules in particular. We expect these projects &#8212; in which MOLPRO\u000a        plays an important role &#8212; to help foster collaborations with industry in\u000a        the area of drug development.\"\u000a    The role of the Birmingham-based research to this impact is shown by its\u000a      important contribution to the current MOLPRO package, as evidenced as\u000a      follows:\u000a    (i) UoB research [Refs 1, 3 and 4] being highlighted in the recent review\u000a      article on Molpro [Ref 5], in particular DF-LMP2, which is used to \"speed\u000a        up the treatment of exchange, using localized orbitals, and local\u000a        subsets of fitting functions for each orbital product. In large\u000a        molecules, this can significantly increase efficiency without much\u000a        affecting accuracy\".\u000a    (ii) UoB research being cited in the current version of the Molpro manual\u000a      (see www.molpro.net) where it is\u000a      written: \"...The heart of the program consists of the\u000a        multiconfiguration SCF, multireference CI, and coupled cluster routines,\u000a        and these are accompanied by a full set of supporting features. The\u000a        package comprises.... local density fitting methods, as\u000a        described in [Ref 4]...\". Also it is written: \"...Depending on\u000a        which programs are used, the following references should be\u000a        cited....Density fitting methods: DFT, Poisson fitting: [Ref 2]...\u000a        DF-MP2, DF-LMP2: [Ref 4]...\"\u000a    ","ImpactSummary":"\u000a    Work at Birmingham by Peter Knowles and Fred Manby on improving the\u000a      efficiency of calculating integrals for so-called ab initio\u000a      calculations, widely used in computational chemistry, has led to a novel,\u000a      fast algorithm for the accurate calculation of molecular energies and\u000a      structures. It contains a level of theory, known as MP2, widely used in\u000a      modelling by industry (pharmaceutical and chemical) as well as in\u000a      academia. The new local approximation of the method, DF-LMP2, was\u000a      developed at Birmingham and implemented in the MOLPRO package that has\u000a      been sold worldwide, generating economic impact. A major attraction of the\u000a      package is that MOLPRO can do a range of calculations efficiently, MP2\u000a      being one of them.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Birmingham\u000a    ","Institutions":[{"AlternativeName":"Birmingham (University of)","InstitutionName":"University of Birmingham","PeerGroup":"A","Region":"West Midlands","UKPRN":10006840}],"Panel":"B         ","PlaceName":[],"References":"\u000a    Papers published by the Birmingham team:\u000a    \u000a[Ref 1]. Poisson equation in the Kohn-Sham Coulomb problem. Manby, F. R.;\u000a      Knowles, P. J.; PHYSICAL REVIEW LETTERS, 2001, 87, 163001.\u000a      DOI: 10.1103\/PhysRevLett.87.163001.\u000a      (40 citations)\u000a    \u000a\u000a[Ref. 2]. The Poisson equation in density fitting for the Kohn-Sham\u000a      Coulomb problem. Manby, F. R.; Knowles, P. J.; Lloyd, A. W.; JOURNAL OF\u000a      CHEMICAL PHYSICS, 2001, 115, 9144-9148. DOI:\u000a      10.1063\/1.1414370.\u000a      (60 citations)\u000a    \u000a\u000a[Ref 3]. Automatic code generation in density functional theory. Strange,\u000a      R.; Manby, F. R.; Knowles, P. J.; COMPUT PHYS COMMUN, 2001, 136,\u000a      310-318. DOI: 10.1016\/S0010-4655(01)00148-5.\u000a      (11 citations)\u000a    \u000a\u000a[Ref 4]. Fast linear scaling second-order Moller-Plesset perturbation\u000a      theory (MP2) using local and density fitting approximations. Werner, H.\u000a      J.; Manby, F. R.; Knowles, P. J.; JOURNAL OF CHEMICAL PHYSICS, 2003,\u000a      118, 8149-8160. DOI: 10.1063\/1.1564816.\u000a      (311 citations)\u000a    \u000aA recent review article on MOLPRO that cites Birmingham work:\u000a    \u000a[Ref 5]. Molpro: a general-purpose quantum chemistry program package.\u000a      Werner, H-J; Knowles, P. J.; Knizia, G.; Manby, F. R.; Schutz, M.; WILEY\u000a      INTERDISCIPLINARY REVIEWS: COMPUTATIONAL MOLECULAR SCIENCE, 2012,\u000a      2, 242-253.\u000a      (86 citations)\u000a    \u000aGrants:\u000a    Fred Manby: Royal Society Fellowship, 2000-2008. This was awarded to\u000a      Manby while he was in Birmingham and he took it to Bristol when he moved\u000a      there in April 2001.\u000a    EU &#8212; Research Training Network: THEONET II &#8212; Theoretical Studies of\u000a        Electronic and Dynamical Processes in Molecules and Clusters\u000a      (HPRN-CT-1999-00005) 2000-2004. This successful RTN, involving 11 research\u000a      groups in nine countries, including the University of Birmingham from the\u000a      UK, was funded by the European Commission and was aimed at extending the\u000a      successes of first-principle computational chemistry. As outlined in the\u000a      article by the coordinator P. Rosmos in Molecular Physics, 2004,\u000a      102, 2165-2166, it directly supported the training of a number of\u000a      post-doctoral researchers and published more than 300 research papers.\u000a    References 1, 2 and 4 best reflect the quality of the underpinning\u000a      research. A recent review from Cardiff (ref 5) cites the Birmingham ref 4\u000a      as being important for the current programme.\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"7","Subject":"Theoretical and Computational Chemistry"},{"Level1":"2","Level2":"2","Subject":"Atomic, Molecular, Nuclear, Particle and Plasma Physics"},{"Level1":"10","Level2":"6","Subject":"Computer Hardware"}],"Sources":"\u000a    \u000a      Corroborating email from Peter Knowles stating the current income from\u000a        Molpro in the REF window, dated 4th April 2013.\u000a      Corroborating emails and spreadsheet from administrator at Cardiff\u000a        University detailing contribution from non-academic licence holders\u000a      Molpro users manual, Version 2012.1\u000a      Corroborating email from Principal Scientist, Group Leader Quantum\u000a        Chemistry, BASF, Ludwigshafen, Germany, dated 8th October\u000a        2013 and commercial document from INTEL, Blueprint for High\u000a          Performance.\u000a\u000a      Corroborating email from DE Shaw Research, dated 11th\u000a        October 2013\u000a    \u000a    Copies of all these sources are held by the University\u000a    ","Title":"\u000a    MOLPRO &#8212; A Quantum Chemistry Package\u000a    ","UKLocation":[{"GeoNamesId":"2653822","Name":"Cardiff"}],"UKRegion":[{"GeoNamesId":"2634895","Name":"Wales"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    MOLPRO is a complete system of ab initio programs for molecular\u000a      electronic structure calculations. As distinct from other commonly used\u000a      quantum chemistry packages, the emphasis is on highly accurate\u000a      computations, with extensive treatment of the electron correlation\u000a      problem.\u000a    MP2 (M&#248;ller-Plesset perturbation theory to second order) is widely used\u000a      to include \"dynamic correlation\" in the calculation of molecular energies,\u000a      which needs to be performed for accurate results. The standard methods\u000a      scale poorly so can only be applied to small molecules. At Birmingham,\u000a      Manby (funded by a Royal Society Fellowship) and Knowles developed\u000a      density-fitting methods suitable for Hartree-Fock and Kohn-Sham (density\u000a      functional theory, DFT) calculations. Two papers were published together\u000a      on this work (Manby and Knowles PRL (01) 87: 163001, [Ref 1] Manby,\u000a      Knowles and Lloyd JCP (01) 115: 9144 [Ref 2]) as well as a paper on\u000a      automatic code generation in DFT [Ref 3].\u000a    In 2001, Manby left for the University of Bristol and continued this work\u000a      together with Knowles at Birmingham. They then combined it with so-called\u000a      linear scaling methods that are efficient for calculating the\u000a      wavefunctions of large molecules and this led to the DF-LMP2 method\u000a      (Werner, Manby and Knowles JCP (03) 118: 8149. [Ref 4]). This work\u000a      facilitates an approach for the modelling of larger molecules using\u000a      accurate ab initio or quantum mechanical (QM) methodologies that\u000a      can then be coupled with faster, but generally less accurate, molecular\u000a      mechanical (MM) methodologies. The significance of this paper can be seen\u000a      by it having &gt;300 citations. The work was implemented in MOLPRO 2003\u000a      when it was hosted and licensed from the University of Birmingham and is\u000a      an integral part of the MOLPRO package (see Section 4). The evidence for\u000a      the continuing academic importance of this DF-LMP2 work (detailed in Ref\u000a      4) and its role in the MOLPRO package is evidenced by recent papers and\u000a      review articles on the use of computational models to study large\u000a      biological molecules:\u000a    Banas et al in a review on RNA catalysis in Methods\u000a      (2009), 49, 202-216 state: \"...Another, very different and so far less\u000a        popular approximation is local treatment of orbitals; for example, MP2\u000a        method with this local approximation is abbreviated as LMP2 (see, e.g.\u000a        Ref [4]). Methods based on local treatment of orbitals are efficient for\u000a        very large molecules....\"\u000a    Aldulaijan et al in studies on peptide binding interactions in Journal\u000a        of Molecular Graphics and Modelling (2010), 29, 240 state: \"....Density\u000a        fitted, local MP2 (DF-LMP2) makes use of the local nature of electron\u000a        correlation to further reduce the computational resources required for\u000a        MP2 calculations.[Ref 4] Importantly for the study of non-covalent\u000a        interactions, this also effectively eliminates basis set superposition\u000a        error (BSSE), thereby removing the need for potentially expensive\u000a        counterpoise corrections....\"\u000a    A seminal review on QM\/MM Methods for Biomolecular Systems by\u000a      Senn and Thiel in Angew. Chem. Int. Ed. (2009), 48, 1198 states:\u000a      `...The recent development (refs including Ref 4] of linear-scaling\u000a        local correlation methods (e.g., LMP2, LCCSD) has significantly extended\u000a        the size of systems that can be treated with such methods, up to several\u000a        tens of atoms. The superior accuracy of high-level ab initio methods can\u000a        now therefore also be exploited for biomolecular QM\/MM studies,\u000a        certainly at the level of energy calculations at fixed geometry (i.e.,\u000a        single points)...\"\u000a    In 2003, Knowles left Birmingham for Cardiff University. By that time\u000a      MOLPRO was already established as a licensed programme, with income having\u000a      generated ca. &#163;250k for the university between 1996 and 2003. The\u000a      licensing arrangements for MOLPRO as a semi-commercial program were\u000a      transferred to Cardiff upon Knowles' departure. Theoretical and\u000a      computational chemistry continues to be a strength at Birmingham, now led\u000a      by the groups of Johnston, Winn and Worth, with Worth and Winn current\u000a      users of MOLPRO.\u000a    In 2012, an overview of the current MOLPRO package by Knowles, Manby and\u000a      co-workers was published [Ref 5]. For further details on MOLPRO, see: http:\/\/www.molpro.net\u000a    As a measure of its continuing importance, the EPSRC UK National Service\u000a      for Computational Chemistry Software (NSCCS) lists MOLPRO as one of 12\u000a      pieces of software that are quantum chemistry programs, with it being one\u000a      of the leading choices for general purpose calculations of this type (MOs,\u000a      energies, structures, etc.).\u000a    "},{"CaseStudyId":"38823","Continent":[{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6252001","Name":"United States"}],"Funders":["Royal Society"],"ImpactDetails":"\u000a    The fundamental discovery of molecularly engineered selectivity in\u000a      boronic acid sugar recognition\u000a      at Birmingham by Prof James has been used by GlySure, an\u000a      Oxfordshire-based company, to\u000a      provide the novel chemistry for measuring blood glucose in new glucose\u000a      recognition technology\u000a      designed for use in hospital intensive care units. Information published\u000a      on GlySure's website, and\u000a      also confirmed by the company to the University, proves that this novel\u000a      chemistry is crucial to the\u000a      technology that unpins their business.\u000a    The impact to July 2013 is evidenced in both commercial and health terms.\u000a      GlySure was founded\u000a      in 2006 as a new venture to develop the Birmingham invented glucose\u000a      recognition technology.\u000a      Since 2008 it has raised &#163;9.5m venture capital investment for this purpose\u000a      and had 30 employees\u000a      in June 2013 (increased from 16 in 2012), with the company's activities\u000a      wholly focused on this\u000a      device. Positive results of clinical trials, which began in 2010, have\u000a      been reported by the company.\u000a      GlySure's focus is now working on achieving regulatory approval in Europe,\u000a      and the company has\u000a      reported that it expected to begin CE mark trials in 2013. GlySure\u000a      have reported that the worldwide\u000a      market opportunity for Tight Glycaemic Control in hospital intensive care\u000a      units is more than\u000a      $2billion.\u000a    Tight glycaemic control in intensive care units\u000a    The value of intensive insulin therapy in reducing mortality and\u000a      morbidity in patients being treated\u000a      in intensive care units was identified in a landmark clinical study of\u000a      more than 1,500 patients in a\u000a      surgical intensive care unit reported in the New England Journal of\u000a        Medicine in 2001. [source 1] A\u000a      factor hampering implementation of this approach has been the absence of a\u000a      practical method of\u000a      achieving continuous monitoring of patient's glucose levels in an\u000a      intensive care unit. Clinicians\u000a      face difficulties in implementing this extent of tight glycaemic control\u000a      through traditional finger-prick\u000a      blood samples: taking blood samples in this way is resource-intensive for\u000a      nursing staff; provides\u000a      intermittent rather than continuous measurement; patients can be left with\u000a      sore fingers and hands.\u000a    A number of companies, mainly in the US, have tried to find solutions to\u000a      this issue over the last\u000a      decade, often trying to apply approaches from the diabetes industry to\u000a      intensive care purposes, as\u000a      described in a 2012 article in the medical business press. However, none\u000a      have been successful in\u000a      bringing a product to market. GlySure is a new entrant to this\u000a      market, and has used the findings\u000a      from the Birmingham research as a crucial feature of a novel method\u000a      designed specifically for\u000a      intensive case applications. [source 2]\u000a    GlySure's monitoring system\u000a    The GlySure system comprises two main parts; a monitor and a sterile\u000a      disposable set (which\u000a      includes a fibre-optic sensor and integrated calibration module). The\u000a      sensor interfaces with the\u000a      patient's pre-existing intravascular line (arterial or venous) without\u000a      disrupting the clinician's ability\u000a      to monitor pressure, draw blood or administer medication through those\u000a      lines. The sensor contains\u000a      fluorescent indicator chemistry (invented in Birmingham), which produces a\u000a      signal that is\u000a      proportional to the glucose concentration in the patient's blood.\u000a    The sensor is a sterile single-use device. Its fluorophore-receptor\u000a      indicator chemistry is patent\u000a      protected and under exclusive world-wide licence to GlySure. The\u000a      reversible nature of the glucose-fluorophore\u000a\u0009  bond enables monitoring throughout the patient's length of\u000a      stay with the same sensor.\u000a      GlySure argue that their technology exceeds the requirements of\u000a      clinicians, while also significantly\u000a      reducing time and cost.\u000a    Birmingham's contribution to GlySure's system\u000a    GlySure were recommended to consider the Birmingham findings by\u000a      James and subsequently\u000a      obtained a licence from Beckman Coulter Inc. (the original owners\u000a      of the patent) to utilise them in\u000a      their product. In 2012, GlySure purchased this patent from Beckman\u000a        Coulter, underlining the\u000a      importance of this to their activity.\u000a    Glysure's Chief Technology Officer has confirmed that the\u000a      Birmingham discovery is making a\u000a      distinct and material contribution to their product, and that that these\u000a      findings have enabled them to\u000a      develop a sensor that is highly selective to glucose in a biological\u000a      environment [the blood of\u000a      critically ill patients] that abounds with both exogenous and endogenous\u000a      potential interferents. This\u000a      selectivity facilitates the use of a continuous sensor over many hours\u000a      whilst maintaining its\u000a      accuracy. [source 3]\u000a    The importance of the discovery made at Birmingham to this device is\u000a      described on the GlySure\u000a      website, which says: The core to this technology is the\u000a        fluorescent\/receptor glucose indicator\u000a        chemistry. This chemistry is structured to be selective for glucose and\u000a        is immobilised into an optical\u000a        cell that is micro machined into the fibre itself. The selectivity for\u000a        glucose is imparted by the\u000a        specifically configured diboronic acid receptor that is covalently\u000a        linked to the fluorophore and forms\u000a        part of the single molecule indicator chemistry. This\u000a        fluorophore-receptor indicator chemistry is\u000a        covered by US patent 6,387,672 B1 which is owned by GlySure. [source\u000a      4]\u000a    Economic impact\u000a    GlySure, which is focused on exploiting the market potential of\u000a      this innovatory technology, is based\u000a      in Oxfordshire and by June 2013 had grown to 30 employees. The company has\u000a      attracted a total\u000a      of &#163;12.5 million venture capital investment since its formation in 2006,\u000a      including a &#163;7 million\u000a      investment in 2012 to be used to complete the necessary clinical trials as\u000a      part of obtaining\u000a      regulatory approval for the glucose monitoring system in Europe and the\u000a      USA. Investors include\u000a      Amadeus Capital Partners, Delta Partners and Morningside\u000a        Venture, all of whom have wide\u000a      experience of backing successful technology enterprises. [source 5] The\u000a      company has reported\u000a      that &#163;9.5m of this investment has been achieved since January 2008, a\u000a      large increase on the &#163;3m\u000a      achieved in the first two years of operation. [source 3]\u000a    In June 2013, GlySure announced the appointment of a new\u000a      executive chairman with extensive\u000a      experience of the medical diagnostics and devices industry to support its\u000a      commercialisation\u000a      programme. [source 6]\u000a    Health impact\u000a    GlySure have reported on a series of trials of their device, with\u000a      information on these on their\u000a      website and presented industry conferences in 2012 and 2013 [source 7].\u000a      These reports say that\u000a      early trials in human serum plasma and whole blood confirmed that the\u000a      sensor can measure\u000a      glucose levels effectively and accurately, with this later validated in in\u000a        vivo models. Human trials\u000a      began in late 2010. [source 8] In January 2012, GlySure reported\u000a      that they had completed initial\u000a      human trials on over 90 intensive care patients and provided examples from\u000a      these trials of\u000a      successful continuous measurement throughout a patient's intensive care\u000a      treatment of more than\u000a      70 hours. [source 9]\u000a    The company have informed the University that the trials have shown\u000a      benefits including reduced\u000a      patient morbidity, a reduced length of stay in intensive care by around 18\u000a      hours and a saving in\u000a      nursing costs of around $1000 per patient. [source 3]\u000a    In March 2013, Glysure reported that it expected to begin\u000a      European CE mark trials later that year\u000a      (the completion of patient enrolment was confirmed on its website in\u000a      October 2013) and had\u000a      obtained ISO 13485 certification of its quality management system, which\u000a      was an important\u000a      foundation for these next round of trials. [source 10]\u000a    ","ImpactSummary":"\u000a    GlySure, an Oxfordshire-based company, has developed a continuous\u000a      blood-glucose monitoring\u000a      system using an intravascular, optical fluorescence-based sensor to\u000a      support clinical\u000a      implementation of Tight Glycaemic Control and Intensive Insulin Therapy. A\u000a      novel, highly selective\u000a      chemosensor for glucose developed in the School of Chemistry at the\u000a      University of Birmingham\u000a      made a crucial contribution to Glysure's development of this new medical\u000a      technology. To date, this\u000a      activity has achieved economic impact, including &#163;9.5 million of venture\u000a      capital investment in\u000a      GlySure since 2008 and 30 jobs created at the company, and has\u000a      demonstrated impact on health\u000a      through the results of clinical trials of the device in intensive care\u000a      units. If the company is\u000a      successful in achieving European and US regulatory approvals for the\u000a      device, its introduction could\u000a      improve patient outcomes as studies have shown that tighter control can be\u000a      valuable in reducing\u000a      morbidity and mortality amongst intensive care unit (ICU) patients.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Birmingham\u000a    ","Institutions":[{"AlternativeName":"Birmingham (University of)","InstitutionName":"University of Birmingham","PeerGroup":"A","Region":"West Midlands","UKPRN":10006840}],"Panel":"B         ","PlaceName":[],"References":"\u000a    \u000a[1] Novel fluorescence sensor for 'small' saccharides, T. D. James, H.\u000a      Shinmori, S. Shinkai, Chem.\u000a        Commun., 1997, 71 (29 citations) DOI: 10.1039\/A606552J\u000a    \u000a\u000a[2] Exploitation of a novel `on-off' photoinduced electron-transfer (PET)\u000a      sensor against\u000a      conventional `off-on' PET sensors, H. Kijima, M. Takeuchi, A. Robertson,\u000a      S. Shinkai, C. Cooper,\u000a      T. D. James, Chem. Commun., 1999, 2011 (27 citations) DOI:\u000a      10.1039\/A906825B\u000a    \u000a\u000a[3] Synthesis and evaluation of D-glucosamine-selective fluorescent\u000a      sensors, C. R. Cooper, T. D.\u000a      James, J. Chem. Soc., Perkin Trans. 1, 2000, 963 (65\u000a      citations) DOI: 10.1039\/a909145i\u000a    \u000a\u000a[4] A molecular colour sensor for monosaccharides, C. J. Ward, P. Patel,\u000a      P. R. Ashton, T. D.\u000a      James, Chem. Commun., 2000, 229-230 (57 citations) DOI:\u000a      10.1039\/A909204H\u000a    \u000a\u000a[5] A bis-boronic acid modified electrode for the sensitive and selective\u000a      determination of glucose\u000a      concentrations: H.-C. Wang, H. Zhou, B. Chen, P. M. Mendes, J. S. Fossey,\u000a      T. D. James, Y.-T.\u000a      Long, Analyst, 2013, 138, 7146 DOI: 10.1039\/c3an01234d\u000a    \u000a[6] Glucose selective SPR-based bis-boronic acid surface sensor: A.\u000a      Stephenson-Brown, H.-C.\u000a      Wang, P. Iqbal, J. A. Preece, Y.-T. Long, J. S. Fossey, T. D. James, P. M.\u000a      Mendes, Analyst, 2013,\u000a      138, 7140 DOI: 10.1039\/c3an01233f\u000a    (Citations as recorded on Scopus as at 14th October 2013).\u000a    References 1, 2 and 3 best indicate the quality of the underpinning\u000a      research.\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"},{"Level1":"3","Level2":"1","Subject":"Analytical Chemistry"},{"Level1":"6","Level2":"1","Subject":"Biochemistry and Cell Biology"}],"Sources":"\u000a    [1] G. van den Berghe et al, \"Intensive insulin therapy in critically ill\u000a      patients\", New England\u000a        Journal of Medicine, 2001, 345(19), 1359-67\u000a    [2] \"Tight Glycemic Control: Critical Care's Balancing Act\", In Vivo,\u000a      September 2012, pp 44-48\u000a    [3] Information provided to the University by Chief Technology Officer,\u000a      GlySure Ltd, email dated\u000a      24th Jan 2013\u000a    [4] see: http:\/\/www.glysure.com\/technology\/platform-technology\/\u000a    [5] GlySure press notice, 9\/1\/2012, \"GlySure Secure &#163;7 million in Series\u000a      C Financing Round\"\u000a    [6] PR Newswire 26\/6\/13, \"GlySure appoints William Moffitt as Executive\u000a      Chairman\"\u000a    [7] GlySure press notice 20\/3\/12 and 25\/9\/12; PR Newswire, 26\/3\/13\u000a    [8] GlySure press notice 5\/1\/12, \"Prototype Clinical Trials\"\u000a    [9] Clinical trial details: Snapshot of cases from Glysure human clinical\u000a      trials &#8212; January 2012\u000a    [10] GlySure press notice 5\/3\/13, \"GlySure Earns ISO 13485 Certification\"\u000a    ","Title":"\u000a    Continuous Blood Glucose Monitoring for Tight Glycaemic Control\u000a    ","UKLocation":[{"GeoNamesId":"2655603","Name":"Birmingham"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    The importance of carbohydrate research at Birmingham may be traced back\u000a      many years\u000a      (Haworth Nobel Prize 1937). In the modern era, carbohydrate chemistry has\u000a      continued in the\u000a      School of Chemistry (SoC) though supramolecular recognition chemistry\u000a      (James and currently\u000a      Fossey, appointed 2008) and synthetic chemistry (Cox, appointed 1999).\u000a    Professor T. D. James (Royal Society Research Fellow, School of\u000a      Chemistry, University of\u000a      Birmingham, Oct 1995 &#8212; Aug 2000, now at University of Bath) undertook\u000a      research in boronic acid-based\u000a      carbohydrate recognition chemistry at Birmingham (see references listed in\u000a      section 3). His\u000a      work uncovered the requirements for high glucose selectivity amongst his\u000a      saccharide sensors.\u000a    Boronic acids reversibly and covalently bind to diols (including sugars);\u000a      this reversibility is ideal for\u000a      a continuous sensing ensemble, yet specificity between different sugars is\u000a      not high. Indeed among\u000a      common monosaccharides, fructose has the highest binding affinity for\u000a      simple aryl boronic acids.\u000a      To engineer a boronic acid construct with non-typical binding affinity\u000a      (i.e. glucose selective)\u000a      required the combination of two boronic acid groups into one molecular\u000a      sensor. Thus, through\u000a      judicious molecular positioning of two boronic acid groups, a two-point\u000a      and highly specific binding\u000a      to glucose is possible.\u000a    James' research into saccharide sensors was developed in collaboration\u000a      with Beckman Coulter\u000a        Inc., who funded a research project led by James at Birmingham on\u000a      this topic (Development of\u000a        Particulate Fluorescent Receptors for Clinical Analyses, Beginning with\u000a        Glucose, Sept 1999 to Aug\u000a      2000, award value: &#163;59,843). The research led to a patent filed in\u000a      December 2000 [patent 1,\u000a      details given below]. James and Arimori (Research Fellow, SoC, University\u000a      of Birmingham, Jan\u000a      2000 &#8212; Aug 2000) are recorded as the inventors on this patent. James'\u000a      research that contributed to\u000a      this patent was substantially undertaken whilst he was at Birmingham.\u000a      However, the terms of the\u000a      contract with Beckman Coulter meant that the research outputs\u000a      directly related to that patent were\u000a      not published until after he had left the University.\u000a    James continued this research after leaving Birmingham to join the\u000a      University of Bath where he is\u000a      currently a Professor in the Department of Chemistry. The fundamental\u000a      discovery of molecularly\u000a      engineered selectivity in boronic acid sugar recognition in Birmingham by\u000a      James has been used\u000a      directly by industrial partners and has inspired subsequent research in\u000a      Birmingham (Fossey,\u000a      Lecturer since October 2008, who worked with James at Bath before joining\u000a      Birmingham) and at\u000a      Bath. Recently Fossey, James and collaborators at GlySure have been\u000a      granted a further patent\u000a      (patent 2) on the implementation of glucose selective sensors for use in\u000a      intravascular blood-glucose\u000a      sensing. This recent work complements the suite of patents (and academic\u000a      papers) that\u000a      result from the original research at Birmingham and forms part of the\u000a      intellectual property\u000a      foundation of GlySure, who also acquired patent 1 from Beckman Coulter.\u000a      Two recent papers (5\u000a      and 6) use the exact same glucose sensor in the first published \"device\u000a      format\".\u000a    Patent 1: \"Photo-induced electron transfer fluorescent sensor\u000a      molecules\". Inventors: S. Arimori\u000a      and T. D. James. Applicant: Beckman Coulter Inc., US Patent, Publication\u000a      &amp; Grant no.:\u000a      US6387672; Priority date = 4\/12\/2000; Granted = US (May 2002)\u000a    Patent 2: \"Indicator system for fibre optic sensor\". Inventors: B.\u000a      C. Crane, T. James, J. Fossey and\u000a      P. N. Barwell. Applicant: Lightship Medical Ltd. Published under = WO\/\u000a      2011\/101624, Aug 2011;\u000a      Priority date = 19\/2\/2010; Filed in EP(2011704829) AU (2011217066) JP\u000a      (2012553391)\u000a    "},{"CaseStudyId":"39091","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"2661886","Name":"Sweden"},{"GeoNamesId":"294640","Name":"Israel"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"1814991","Name":"China"},{"GeoNamesId":"6252001","Name":"United States"}],"Funders":[],"ImpactDetails":"\u000a    Gun crime is on the increase across the world. Conventional technology to\u000a      visualise fingerprints on spent shell casings produced poor results\u000a      because of vaporisation of the sweat deposits during the firing process.\u000a      Fingerprint recovery rates were traditionally low (&lt;10%). The UoA's new\u000a      technology solves this problem, revealing previously undetectable\u000a      fingerprints on metal objects.\u000a    These technologies have economic and societal impact of substantive reach\u000a      and significance:\u000a    \u000a      improved fingerprint recovery rates which have helped police forensic\u000a        departments worldwide solve recent homicide investigations and re-open\u000a        previously closed \"cold\" cases.\u000a      development of new forensic products by commercial partners, now being\u000a        sold to forensic practitioners worldwide, stimulating the economy.\u000a      new policies and processes for forensic practitioners, which are now\u000a        standard operational procedure for police forces across the UK.\u000a    \u000a    1. Helping to tackle gun crime and further homicide investigations\u000a    The corrosion enhancement technology has been used in many\u000a      homicide investigations including Kingsland, GA; Killeen, TX; North\u000a      Richland Hills, TX; Tinley Park, IL; Marin County, CA [1,2]. It has been\u000a      used to examine evidence in more than 100 criminal cases in the US, UK and\u000a      Europe, including re-examination of evidence in a number of \"cold\" cases.\u000a      In 2012, evidence from the corrosion enhancement technique was heard [Bond]\u000a      and accepted by the Superior Court of the State of California, setting a\u000a      precedent in the US legal system [1,2].\u000a    2. Development of new forensic products\u000a    a) Consolite Forensics\u000a      The localised corrosion enhancement technology has been patented\u000a      [3] and commercialised with UK industrial partner Consolite\u000a      Forensics [4] through consultancy (Bond and Hillman;\u000a      2011-2013). The research helped the company develop the CERA LT, a new\u000a      optical system to recover fingerprints from gun cartridges, offering a\u000a      quick and simple to use product with a fully integrated high resolution\u000a      camera. The product is now commercially available for &#163;50,000 per unit.\u000a      The company launched the product in the summer of 2013, making its first\u000a      sale to the Granite Falls Police Department, Michigan USA. The product is\u000a      currently being trialled in other crime labs worldwide.\u000a    b) Foster and Freeman\u000a      Following patent filing [5], a similar commercialisation\u000a      partnership has been adopted to transfer the electrochromic polymer\u000a      film technology, with one of the world's foremost forensic science\u000a      equipment suppliers, Foster and Freeman [6]. A prototype instrument\u000a      developed via this partnership was undergoing testing as of July 2013. The\u000a      immediate target is to improve fingerprint detection on stainless steel, a\u000a      common material for knives; knife crime is a major area of concern in the\u000a      UK where guns are less readily available.\u000a    3. New processes, procedures and training for forensic practitioners\u000a      Historically, gun crime has been less prevalent in the UK than the US, but\u000a      a range of terrorist, drugs and organized crime threats make this a key\u000a      target for UK policing. Widespread uptake of the electrochromic\u000a        polymer fingerprint enhancement technology in the UK will benefit\u000a      from interactions with the Home Office (formerly HOSDB, now CAST). As a\u000a      result, both the corrosion and the electrochromic technologies have now\u000a      been incorporated as standard operational practice for police forces\u000a      across the UK through inclusion in the Home Office Fingerprint Manual\u000a      [7,8]. The research has given forensic practitioners new options for the\u000a      investigation of crime. The substantive impact of the localized\u000a        corrosion technology has been underpinned by Bond providing\u000a      consultancy training on the technology for practitioner organisations\u000a      (2009-2013) at: Home Office Biometrics Group; European Network of Forensic\u000a      Science Institutes; National Forensic Academy (Knoxville, TN); Southern\u000a      Californian Association of Fingerprint Examiners, Californian Department\u000a      of Justice; Santa Clara County Crime Laboratory, California; American\u000a      Association of Crime Scene Reconstruction; No. 1 Forensic Institute,\u000a      Beijing, China, with approximately 150 practitioners trained at each of\u000a      the seven events, reaching more than 1,000 in total.\u000a    Additional technology transfer activity and widening impact\u000a      Collaboration with the US Naval Criminal Investigative Service (NCIS)\u000a      (2012-13) by Bond involved pseudo-operational trials of pipe bomb\u000a      fragments being sent to the University for fingerprint analysis and the\u000a      identification of fingerprints using these techniques. This represents a\u000a      natural expansion of the localised corrosion technology from shell\u000a      casings to other metals that have been subject to environmental extremes,\u000a      such as bomb fragments.\u000a    Dissemination has included Regional Development Agency Awards (Innovation\u000a      Fellowship and Follow-on Fund), practitioner-based conferences\u000a      (Iinternational Fingerprint Research Group: Sweden (2011) and Israel\u000a      (2013); Home Office meetings (2010-13)), extensive media coverage [9,10]\u000a      (including America's Most Wanted and CrimeWatch) and briefings to Police\u000a      Forces (invited events at the University 2011, 2012 and 2013, involving\u000a      the Forensic Science Special Interest Group of the Technology Strategy\u000a      Board).\u000a    Fingerprint corrosion on metal was recognised by Time Magazine as one of\u000a      the 50 best inventions of 2008 [9] and by BBC Focus Magazine (2009) as one\u000a      of the inventions most likely to change the world in 2009 and its\u000a      description by a detective from the North Richland Hills Police Department\u000a      as \"The new DNA\" [1].\u000a    The interdisciplinary nature of this field has been recognized via the\u000a      establishment (2012) of the Alec Jeffreys Forensic Science Institute\u000a      (AJFSI), led by Chemistry. This Institute has been created to fulfil the\u000a      need to bring together academics across diverse disciplines to tackle\u000a      current and emerging problems in forensic science.\u000a    ","ImpactSummary":"\u000a    Fingerprints remain the most conclusive means of linking an offender to a\u000a      crime scene. Conventional visualization techniques require the sweat\u000a      deposit to be largely retained and thus have low success rates. We have\u000a      developed technologies to visualize fingerprints on metals after the sweat\u000a      deposit has been substantively lost, deliberately removed or\u000a      environmentally degraded. One technology uses microscale corrosion\u000a      caused by the sweat deposit; it has been used in solving gun crimes. A\u000a      second technology uses trace residual sweat deposit as a template to\u000a      direct electrochromic polymer deposition to bare metal between the\u000a      ridge deposits. These have been adopted in the new Home Office\u000a      Fingerprinting Manual and licensed to UK forensic providers.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Leicester\u000a    ","Institutions":[{"AlternativeName":"Leicester (University of)","InstitutionName":"University of Leicester","PeerGroup":"A","Region":"East Midlands","UKPRN":10007796}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"5332921","Name":"California"},{"GeoNamesId":"5001836","Name":"Michigan"}],"References":"\u000a    \u000a1) Imaging fingerprint corrosion of fired brass shell casings, J.W. Bond,\u000a      Rev. Sci. Instrum., 80(7), 2009, 075108 DOI: 10.1063\/1.3183578\u000a    \u000a\u000a2) On the electrical characteristics of latent finger mark corrosion of\u000a      brass, J.W. Bond, J. Phys. D, 41(12), 2008, 125502. DOI:\u000a      10.1088\/0022-3727\/41\/12\/125502\u000a    \u000a\u000a3) High resolution imaging of latent fingerprints by localized corrosion\u000a      on brass surfaces, A.J. Goddard, A.R. Hillman, J.W. Bond, J. For. Sci.,\u000a      55(1), 2010, 58-65. DOI: 10.1111\/j.1556-4029.2009.01217.x\u000a    \u000a\u000a4) Electrochromic enhancement of latent fingerprints on stainless steel\u000a      surfaces, A.L. Beresford, A.R. Hillman, Anal. Chem., 82(2), 2010, 483-486.\u000a      DOI: 10.1021\/ac9025434\u000a    \u000a\u000a5) Electrochromic enhancement of latent fingerprints by\u000a      poly(3,4-ethylenedioxythiophene), R.M. Brown, A.R. Hillman, Phys. Chem.\u000a      Chem. Phys., 14(24), 2012, 8653-8661. DOI: 10.1039\/c2cp40733g\u000a    \u000a\u000a6) Physical characterization and recovery of corroded fingerprint\u000a      impressions from post-blast copper pipe bomb fragments, J.W. Bond, J.\u000a      Forensic Sci. 58, 2013, 776-781.\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"9","Level2":"12","Subject":"Materials Engineering"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"}],"Sources":"\u000a    \u000a      Contact details for Detective at North Richland Hills Police, Texas,\u000a        USA\u000a      Contact details for Inspector at Marin County District Attorney's\u000a        Office, San Rafael, CA. USA\u000a      Patents: GB2008\/001261 Fingerprint detection method and apparatus\u000a        (2008). GB 0819445.8 Fingerprint detection (2008)\u000a      Contact details for Managing Director of Consolite Forensics and also\u000a        http:\/\/www.consolite.co.uk\/Forensics\/CERALTmachine.html\u000a\u000a      Electrochromic latent fingerprint enhancement patent: PCT application\u000a        number: PCT\/GB2010\/050479 (filing date 22 March 2010).\u000a      Contact details for Managing Director of Foster and Freeman (Evesham,\u000a        Worcs)\u000a      Contact details for Home Office Scientific Development Branch, UK Home\u000a        Office\u000a      Fingerprint Manual: https:\/\/www.gov.uk\/government\/publications\/fingermark-visualisation-manual-notice-of-publication\u000a\u000a      \u000ahttp:\/\/www.time.com\/time\/specials\/packages\/article\/0,28804,1852747_1854195_1854178,00.html:\u000a      http:\/\/www.bbc.co.uk\/news\/science-environment-23136589\u000a    \u000a    ","Title":"\u000a    New crime detection technologies for law enforcement agencies\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Fingerprint recovery rates on ballistics are extremely low due to\u000a      vaporisation of sweat deposits during the firing process. Motivated by\u000a      this, Dr John Bond (then working at Northamptonshire Police but\u000a      also an Honorary Fellow of the University since 2007) and Professor\u000a        Robert Hillman undertook collaborative research blending interfacial\u000a      science and forensic expertise (2008-13). Their shared interests in\u000a      interfacial chemistry and surface analysis were focused on\u000a      characterization of thin films generated by and\/or directed by fingerprint\u000a      deposition. Fundamentally, this presents materials imaging challenges in\u000a      terms of 3D control of surface composition and properties at micro- and\u000a      nano-scales. With adequate control of the spatial resolution of these\u000a      processes, the uniqueness of the fingerprint can be preserved and captured\u000a      via permanent surface structures attributable to contact between the\u000a      finger and the substrate. This strategy was explored and exploited in two\u000a      ways: (i) using localised corrosion under the fingerprint ridges\u000a      to generate surface oxides with semiconducting properties and (ii) using\u000a      the fingerprint deposit as an insulating (inert) template to direct\u000a      electrochemically-driven deposition of electrochromic polymers to\u000a      regions of bare metal between the fingerprint ridges.\u000a    Localized corrosion strategy: Bond and Hillman showed that\u000a      fingerprint deposits on metals could, on relatively short timescales,\u000a      generate sufficient corrosion for the fingermark to be visualized long\u000a      after the fingerprint residue was removed or lost. Exploitation required\u000a      understanding and optimization of the underlying interfacial processes.\u000a      Topological and compositional imaging (from micro- to nano-scales) by\u000a      Hillman provided morphological insights into fingermark development,\u000a      veracity and sharpness [1,2]. Application to brass surfaces\u000a      (representative of bullet casings) revealed that oxide corrosion products\u000a      formed Schottky barrier diodes [1], whose electronic properties could be\u000a      exploited to bind coloured particulates electrostatically. Materials\u000a      property studies [3] revealed that Schottky barrier formation requires\u000a      dominance of one corrosion product (copper oxide or zinc oxide); chloride\u000a      concentration is a key determinant. Where neither oxide dominates, optical\u000a      interference effects attributable to the oxide layer permit non-invasive\u000a      visualization by colour mapping.\u000a    Electrochromic polymers: Hillman exploited the insulating\u000a      nature of the fingerprint deposit as a \"mask\" to direct the\u000a      electrochemical deposition of coloured electroactive polymers onto the\u000a      bare metal between the ridge deposits. The key fundamental feature is that\u000a      minute (nanometre) amounts of insulating material can (locally) prevent\u000a      the electron transfer required for electropolymerization, contrasting\u000a      favourably with the larger amounts of residual deposit required for the\u000a      physical \/chemical binding strategies of conventional latent fingerprint\u000a      enhancement methods (e.g. powders and cyanoacrylate polymerization). In a\u000a      totally novel extension, the use of electrochromic polymers (from\u000a      thiophene-, aniline- or pyrrole-based monomers) permits subsequent\u000a      manipulation of optical density and colour via applied potential [4,5],\u000a      providing excellent contrast on metals (Au, Pt, Pb, Ni, steel, brass) with\u000a      diverse surface chemistries, optical properties and operational\u000a      significance (precious objects, weapons, tools, metal theft). The\u000a      performance of the electrochromic technology has been explored for\u000a      fingerprint sweat deposits on metal subjected to diverse environmental\u000a      conditions (heat, immersion in water, soap and solvent treatment) and in\u000a      operationally significant scenarios found to be favourable over\u000a      conventional methodologies. (Image right shows a fingerprint on\u000a        stainless steel, left for 7 days under ambient conditions before\u000a        treatment involving electrodeposition of an electrochromic polypyrrole\u000a        film).\u000a    \u000a    \u000a    \u000a    "},{"CaseStudyId":"40238","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"2658434","Name":"Switzerland"}],"Funders":["Natural Environment Research Council"],"ImpactDetails":"\u000a    Monitoring of atmospheric concentrations of gases is important in\u000a      assessing the impact of\u000a      international policies related to the atmospheric environment and sources\u000a      (Section 5) are indicated\u000a      in brackets. The work carried out at Bristol provides, for the first time,\u000a      an independent scientific\u000a      verification of UK emissions (a) submitted by Parties to the\u000a      Convention reporting under the\u000a      UNFCCC and its Kyoto Protocol. A verification section written by O'Doherty\u000a      is included in the\u000a      UNFCCC documentation (b). The UK, Australia and Switzerland are the\u000a      only countries to provide\u000a      such verification. This type of research was identified as an area of\u000a      importance at the UNFCCC,\u000a      Conference of the Parties (COP15), the Copenhagen Accord, where parties\u000a      were urged to \"ensure\u000a        sustained long-term operation of essential in situ networks through\u000a        provision of necessary\u000a        resources\".\u000a    Long-term monitoring of this kind is similarly important in assessing the\u000a      impact of international\u000a      policies related to control measures on chlorofluorocarbons (CFCs), halons\u000a      and\u000a      hydrochlorofluorocarbons (HCFCs) introduced under the Montreal Protocol of\u000a      Substances that\u000a      Deplete the Ozone Layer. The effect of worldwide CFC controls can be seen\u000a      by decreases in the\u000a      long-term concentrations. Continued monitoring is required to assess the\u000a      overall success of the\u000a      Protocol leading to the recovery of the ozone layer, and the implications\u000a      for atmospheric levels of\u000a      replacement compounds such as HFCs (c).\u000a    The UK and international GHG reduction commitments, of which the\u000a      Bristol-led measurements\u000a      provide independent verification, translate into sector and company level\u000a      obligations which impact\u000a      across all regions of the UK. For example, there are a number of GHG\u000a      reporting schemes\u000a      applicable to businesses operating in the UK, such as the EU Emissions\u000a      Trading System and the\u000a      CRC Energy Efficiency Scheme (a).\u000a    The atmospheric observations have helped DECC prioritise research to\u000a      improve the GHG\u000a      inventory. For example, emissions derived from measurements of N2O\u000a      have resulted in a large\u000a      research programme in Defra to better understand agricultural emissions\u000a      that result from the\u000a      application of man-made fertilizers. This gas is a potent GHG, with the\u000a      fourth largest climate effect\u000a      after CO2, CH4 and CFC-12 (d).\u000a    The information derived from this research will continue to inform\u000a      governments responsible for\u000a      formulating policies on climate change mitigation and adaption. In\u000a      addition, a much wider range of\u000a      organisations that are responsible for planning climate-sensitive\u000a      activities and investments will\u000a      benefit. For example, NERC recently funded an &#163;8.1m programme, \"Greenhouse\u000a      gas emissions\u000a      and feedbacks\" (O'Doherty and Rigby are co-investigators of\u000a      this multi-University consortium), to\u000a      increase the UK's ability to measure and predict sources and sinks of the\u000a      major anthropogenic\u000a      greenhouse gases. The DECC Network forms a central part of this national\u000a      consortium (e).\u000a    Identification by AGAGE, of new ozone-depleting or global-warming\u000a      substances of potential policy\u000a      interest have been provided to DECC\/Defra. For example, the analysis of\u000a      unregulated compound\u000a      NF3 (a powerful GHG showing a steady growth in the atmosphere)\u000a      was used by DECC as an\u000a      evidence base for international negotiations. NF3 was\u000a      subsequently included in the list of possible\u000a      new Kyoto Protocol gases due to its rapidly rising concentration and high\u000a      global-warming potential.\u000a    The Mace Head measurements have been used in a large number of\u000a      publications. This is widely\u000a      regarded as the `Gold Standard' dataset of European measurements. As such,\u000a      it has been central\u000a      to many European Union projects on verification of GHG emissions, such as\u000a      CarboEurope,\u000a      NitroEurope, Geomon, Eurohydros, ICOS, ACTRIS and InGOS. The work detailed\u000a      in this\u000a      document continues to play a key role in the WMO Assessments of Ozone\u000a      Depletion for which\u000a      O'Doherty served as a lead author in the 2010 report and O'Doherty\u000a      and Rigby will serve as\u000a      contributing authors in 2014. The University of Bristol also plays a key\u000a      role in IPCC Assessment\u000a      Reports with O'Doherty being a contributor to the 2007 report\u000a      Working Group 1, Chapter 2 and\u000a      Rigby being a contributor to the 2013 report. Of the first nine\u000a      figures and tables in Chapter 2 of the\u000a      2007 report, seven showed, or were in part based on, AGAGE data (f).\u000a    The Bristol researchers are continuing to communicate the importance of\u000a      global and regional GHG\u000a      emissions verification to policymakers at the highest level. The work of O'Doherty\u000a      and the ACRG\u000a      featured prominently in a recent Parliamentary Office of Science and\u000a      Technology POSTNote, to be\u000a      read by members of parliament, entitled \"Reporting Greenhouse Gas\u000a      Emissions\" (g).\u000a    ","ImpactSummary":"\u000a    Successful policy formulation and effective action on ozone depletion and\u000a      climate change, both of\u000a      which have profound environmental implications, depend on the availability\u000a      of credible data on\u000a      atmospheric gases. Research conducted in the School of Chemistry at the\u000a      University of Bristol\u000a      between 1992 and 2013 has played a leading role in global efforts to\u000a      achieve reliable, long-term\u000a      measurement of climatically important gases such as CO2, CH4\u000a      and N2O. When combined with\u000a      models of atmospheric gas transport, these observations provide an\u000a      independent means of\u000a      assessing natural and man-made emissions. This work is used by the UK's\u000a      Department of Energy\u000a      and Climate Change (DECC) for monitoring compliance with international and\u000a      domestic legislation,\u000a      identifying priorities for improving inventory accuracy, assessing the\u000a      UK's progress towards targets\u000a      set in the Montreal and Kyoto Protocols, evaluating the impact of policy,\u000a      and informing international\u000a      negotiations. These data have been central to recent World Meteorological\u000a      Office (WMO) Scientific\u000a      Assessments of Ozone Depletion produced between 2007 and 2010 and to the\u000a      Nobel Prize-winning\u000a      Inter Governmental Panel on Climate Change (IPCC) Assessment of Climate\u000a      Change\u000a      published in 2007.\u000a    ","ImpactType":"Environmental","Institution":"\u000a    University of Bristol\u000a    ","Institutions":[{"AlternativeName":"Bristol (University of)","InstitutionName":"University of Bristol","PeerGroup":"A","Region":"South West","UKPRN":10007786}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"6077243","Name":"Montral"}],"References":"\u000a    Publications\u000a    \u000a(1) Global and regional emissions of HFC-125 (CHF2CF3)\u000a      from in situ and air archive\u000a      atmospheric observations at AGAGE and SOGE observatories, S. O'Doherty, D.\u000a      M.\u000a      Cunnold, B. R. Miller, J. M&#252;hle, A. McCulloch, P.G. Simmonds, A. J.\u000a      Manning, S. Reimann,\u000a      M. K. Vollmer, B. R. Greally, R. G. Prinn, P. J. Fraser, L. P. Steele, P.\u000a      B. Krummel, B. L.,\u000a      Dunse, L. W. Porter, C. R. Lunder, N. Schmidbauer, O. Hermansen, P. K.\u000a      Salameh, C. M.\u000a      Harth, R. H. J. Wang and R. F. Weiss, J. Geophys. Res., 2009, 114,\u000a      D23304, DOI:\u000a      10.1029\/2009JD012184.\u000a    \u000a\u000a(2) A new analytical inversion method for determining regional and\u000a      global emissions of\u000a      greenhouse gases: sensitivity studies and application to halocarbons, A.\u000a      Stohl, P. Seibert,\u000a      J. Arduini, S. Eckhardt, P. Fraser, B. R. Greally, M. Maione, S.\u000a      O'Doherty, R. G. Prinn, S.\u000a      Reimann, T. Saito, N. Schmidbauer, P. G. Simmonds, M. K. Vollmer, R. F.\u000a      Weiss, and Y.\u000a      Yokouchi, Atmos. Chem. Phys., 2009, 9, 1597-1620, DOI:\u000a      10.5194\/acp-9-1597-2009.*\u000a    \u000a\u000a(3) A 15 year record of high-frequency, in situ measurements of\u000a      hydrogen at Mace Head,\u000a      Ireland, A. Grant, C. S. Witham, P. G. Simmonds, A. J. Manning, and S.\u000a      O'Doherty, Atmos.\u000a        Chem. Phys., 2010, 10, 1203-1214, DOI:\u000a      10.5194\/acp-10-1203-2010.\u000a    \u000a\u000a(4) Inverse modelling of European CH4 emissions\u000a      2001-2006, P. Bergamaschi, M. Krol, J. F.\u000a      Meirink, F. Dentener, A. Segers, J. van Aardenne, S. Monni, A. T.\u000a      Vermeulen, M. Schmidt,\u000a      M. Ramonet, C. Yver, F. Meinhardt, E. G. Nisbet, R. E. Fisher, S.\u000a      O'Doherty, and E. J.\u000a      Dlugokencky, J. Geophys. Res., 2010, 115, D22309, DOI:\u000a      10.1029\/2010JD014180.\u000a    \u000a\u000a(5) Ozone Depleting Substances (ODSs) and Related Chemicals,\u000a      Chapter 1 in Scientific\u000a      Assessment of Ozone Depletion: 2010, S. A Montzka and S. Reimann\u000a      (Coordinating Lead\u000a      Authors), A. Engel, K. Kruger, S. O'Doherty, W.T. Sturges, Global\u000a        Ozone Research and\u000a        Monitoring Project-Report, 2011, No.52, 516, World\u000a      Meteorological Organization, Geneva,\u000a      Switzerland.\u000a      (http:\/\/www.wmo.int\/pages\/prog\/arep\/gaw\/ozone_2010\/documents\/chapter1.pdf).*\u000a    \u000a\u000a(6) Estimating UK methane and nitrous oxide emissions from 1990 to\u000a      2007 using an inversion\u000a      modelling approach, A. Manning, S. O'Doherty, A. R. Jones, P. G. Simmonds\u000a      and R. G.\u000a      Derwent, J. Geophys. Res., 2011, 116, D0230, DOI:\u000a      10.1029\/2010JD014763.*\u000a    \u000aGrants\u000a    2013-2017 Natural Environmental Research Council (NERC), Greenhouse gAs\u000a      Uk and Global\u000a      Emissions (GAUGE), &#163;974,180 (of &#163;3m consortium proposal); Co-I\u000a      O'Doherty.\u000a    2012-2017 Towards treaty verification for non-CO2 greenhouse\u000a      gases, NERC Advanced\u000a      Research Fellowship, &#163;460,196; PI is Rigby.\u000a    2011-2015 EU, InGOS, &#8364;518,225; PI is O'Doherty.\u000a    2011-2014 Department of Energy and Climate Change (DECC), Extension of\u000a      Long-Term\u000a      Atmospheric Measurements of Trace Gases, &#163;1,901,000; PI is\u000a      O'Doherty.\u000a    2011-2016 National Space and Atmospheric Administration (NASA), AGAGE\u000a      Collaborative\u000a      Project, $712,049; PI is O'Doherty.\u000a    2010-2011 Department of Energy and Climate Change (DECC), Extension of\u000a      Long-Term\u000a      Atmospheric Measurements of Trace Gases, &#163;230,000; PI is\u000a      O'Doherty.\u000a    2009-2014 National Oceanic and Atmospheric Administration (NOAA), AGAGE\u000a      Measurements\u000a      in Barbados, $325,666; PI is O'Doherty.\u000a    2008-2011 Irish EPA, Measurement of Trace Gases at Carnsore Point, &#8364;564,860;\u000a      PI is\u000a      O'Doherty.\u000a    2007-2010 Department of Energy and Climate Change (DECC), Measurements at\u000a      Mace Head,\u000a      &#163;623,244; PI is O'Doherty.\u000a    2006-2009 EU, Eurohydros, &#8364;124,000; PI is O`Doherty.\u000a    2005-2008 NERC; Surface Ocean &#8212; Layer Atmosphere Study (SOLAS), &#163;165,395;\u000a      PI is\u000a      O'Doherty.\u000a    2005-2007 Defra, Advanced Global Atmospheric Gases Experiment (AGAGE), &#163;282,469;\u000a      Principal Scientist is O'Doherty.\u000a    2005-2009 Marie Curie Action, Early Stage Training, BREATHE, &#8364;1,064,360;\u000a      Co-PI is\u000a      O'Doherty.\u000a    2003-2007 National Aeronautics and Space Administration (NASA), Advanced\u000a      Global\u000a      Atmospheric Gases Experiment (AGAGE), $490,551; Principal\u000a      Scientist is\u000a      O'Doherty.\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"},{"Level1":"4","Level2":"1","Subject":"Atmospheric Sciences"}],"Sources":"\u000a    (a) Annual and final reports written for DECC are made public and\u000a      can be accessed from the\u000a      DECC website (https:\/\/www.gov.uk\/government\/publications\/uk-greenhouse-gas-emissions-monitoring-and-verification\/)\u000a      and also Met Office website\u000a      (http:\/\/www.metoffice.gov.uk\/atmospheric-trends\/).\u000a      (Champion)\u000a    (b) UNFCCC UK National Inventory Submission (NIR), Section 1.6.2\u000a      and Annex 10.\u000a      (http:\/\/unfccc.int\/national_reports\/annex_i_ghg_inventories\/national_inventories_submissions\/items\/6598.php).\u000a      (Champion)\u000a    (c) Data from the AGAGE network are available at the Carbon\u000a      Dioxide Information Analysis\u000a      Center (CDIAC); this is the primary climate-change data and analysis\u000a      centre of the US\u000a      Department of Energy (http:\/\/cdiac.ornl.gov\/).\u000a      Data are also made available to the World\u000a      Data Centre for Greenhouse Gases; this is a WDC under the GAW programme\u000a      (http:\/\/ds.data.jma.go.jp\/gmd\/wdcgg\/).\u000a      (Prinn and Weiss)\u000a    (d) DECC's Earth Observation strategy:\u000a      (http:\/\/www.gov.uk\/government\/publications\/earth-observation-strategy).\u000a      (Champion)\u000a    (e) Greenhouse gases UK project website (http:\/\/www.greenhouse-gases.org.uk).\u000a      (Prinn,\u000a      Champion)\u000a    (f) Data from AGAGE is included in World Meteorological\u000a      Organisation (WMO) Scientific\u000a      Assessment of Ozone Depletion and Intergovernmental Panel on Climate\u000a      Change (IPCC)\u000a      assessments; these documents can be accessed from the following websites:\u000a      (http:\/\/www.ipcc.ch\/publications_and_data\/publications_and_data_reports.shtml)\u000a      (http:\/\/www.wmo.int\/pages\/prog\/arep\/gaw\/ozone_2010\/ozone_asst_report.html).\u000a      (Reimann,\u000a      Prinn)\u000a    (g) The work at Mace Head has been selected by the Parliamentary\u000a      Office of Science and\u000a      Technology for inclusion in POSTNOTE No. 420, Jan. 2013 \"Reporting GHG\u000a      Emissions\"\u000a      (http:\/\/www.parliament.uk\/briefing-papers\/POST-PN-428).\u000a      (Champion)\u000a    (h) Statements about the importance of the funded work can be\u000a      obtained from different\u000a      agencies: DECC ((Champion), NASA (Prinn and Weiss), NOAA (Butler).\u000a    \u000a    ","Title":"\u000a    CH1: Bristol Research Influences Global Response to Ozone-Depleting\u000a        and Greenhouse Gases.\u000a    ","UKLocation":[{"GeoNamesId":"2654675","Name":"Bristol"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    The work carried out at the University of Bristol's Atmospheric\u000a        Chemistry Research Group\u000a      (ACRG) furthers understanding of emissions of climatically important gases\u000a      at both regional and\u000a      global scales. Globally, the analysis of long-term measurements of key\u000a      radiatively and chemically\u000a      active gases in the atmosphere generates insights into the role of these\u000a      gases in global climate\u000a      change and ozone depletion in the stratosphere. The observatories making\u000a      these long-term (1987-present),\u000a      high-frequency measurements are part of an internationally recognised\u000a      global network of\u000a      10 observing stations called the Advanced Global Atmospheric Gases\u000a        Experiment (AGAGE).\u000a      O'Doherty, Professor of Atmospheric Chemistry, and head of the ACRG\u000a      measurement group is a\u000a      Co-Investigator of the AGAGE programme and lead scientist in charge of two\u000a      of the AGAGE\u000a      stations, Mace Head in Ireland and Ragged Point in Barbados. Since joining\u000a      the network in 1991,\u000a      O'Doherty has pioneered novel analytical techniques that now make\u000a      AGAGE the only global\u000a      network capable of measuring the full suite of substances regulated under\u000a      the Montreal and Kyoto\u000a      Protocols. Funded through a NERC Advanced Fellowship, Rigby (also\u000a      in the ACRG) is developing\u000a      methods for understanding global greenhouse gas emissions using AGAGE\u000a      observations and\u000a      chemical transport models.\u000a    The scientific highlights of Bristol's involvement with AGAGE, which are\u000a      important in furthering our\u000a      understanding of changes in global atmospheric composition, are summarised\u000a      below, with links to\u000a      the scientific outputs listed in Section 3 in brackets:\u000a    \u000a      The determination, from atmospheric observations, of global and\u000a        regional rates of emission\u000a        and destruction of natural and anthropogenic compounds that contribute\u000a        to climate change\u000a        and stratospheric ozone depletion (1-6).\u000a      Improved accuracy in our understanding of the global distributions and\u000a        temporal behaviours of\u000a        natural and anthropogenic gases in the global atmosphere (1-3,5).\u000a      The identification and accurate measurement of new greenhouse gases\u000a        and ozone-depleting\u000a        substances in the global atmosphere (eg the recently discovered\u000a        SO2F2, and high accuracy\u000a        measurement of NF3, C4F10, C5F12,\u000a        C6F14, C7F16 and C8F18)\u000a        (1,5).\u000a      Quantification of the oxidising capacity of the troposphere (5).\u000a    \u000a    The information derived from observational networks such as AGAGE has\u000a      resulted in regulation of\u000a      the production and use of ozone-depleting substances (ODSs) under the\u000a      Montreal Protocol. The\u000a      rate of recovery of the ozone layer will depend critically on the rate of\u000a      decrease of ODSs, which will\u000a      be measured and interpreted by the AGAGE global network.\u000a    To support global climate legislation, it has been recognised that we\u000a      must develop the capability to\u000a      monitor greenhouse gas (GHG) emissions at national scales. The School of\u000a      Chemistry at Bristol, in\u000a      collaboration with the Met Office, is at the very forefront of this\u000a      effort. The UK DECC Network, led\u000a      by O'Doherty and funded by DECC, is a unique national GHG\u000a      monitoring system, comprising four\u000a      stations (with two more being added in 2013) making high-frequency\u000a      measurements of key\u000a      atmospheric trace gases. Since 2010, GHGs have been measured at tall-tower\u000a      sampling sites at\u000a      Tacolneston (Norfolk, UK), Angus (Dundee, Scotland) and Ridge Hill\u000a      (Hereford, UK),\u000a      complementing the long-term record from Mace Head in Ireland. Analysis and\u000a      interpretation of\u000a      these observations using state-of-the-art \"inverse\" modelling techniques\u000a      enables the independent\u000a      assessment of the UK's adherence to the Montreal Protocol as implemented\u000a      by the Environmental\u000a      Protection (Controls on Ozone-Depleting Substances) Regulations (2011).\u000a      Furthermore, it\u000a      improves emissions estimation to UK Devolved Administration (DA) level and\u000a      provides verification\u000a      of the UK GHG emission inventories submitted annually to the United\u000a      Nations Framework\u000a      Convention on Climate Change (UNFCCC) under the Kyoto Protocol.\u000a    "},{"CaseStudyId":"40239","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255147","Name":"Asia"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"3355338","Name":"Namibia"},{"GeoNamesId":"2186224","Name":"New Zealand"},{"GeoNamesId":"2562770","Name":"Malta"},{"GeoNamesId":"1814991","Name":"China"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"953987","Name":"South Africa"},{"GeoNamesId":"2077456","Name":"Australia"}],"Funders":["Research Councils UK","Engineering and Physical Sciences Research Council","Natural Environment Research Council","Royal Society"],"ImpactDetails":"\u000a    Pancost and Shallcross recognised that through Bristol\u000a      ChemLabS, this research could serve as a powerful mechanism for engaging\u000a      students with chemistry as it: (i) highlights the importance of chemistry\u000a      in addressing some of the greatest societal challenges and (ii) inspires a\u000a      passion for all science through the innate interdisciplinarity of the\u000a      work. Thus, research has driven one of the world's most ambitious school\u000a      engagement efforts, co-ordinated by Shallcross and Harrison\u000a      (School of Chemistry Director of Outreach). ChemLabS has therefore\u000a      leveraged the quality, societal relevance and unique interdisciplinary\u000a      aspects of climate change research to inspire and motivate students to\u000a      become better engaged with their environment and pursue further education\u000a      and careers in science. The specific research components that inform\u000a      ChemLabS' outreach are the use of state-of-the-art analytical chemistry to\u000a      make sensitive measurements of gases in the atmosphere, the application of\u000a      physical and chemical principles to the modelling of atmospheric\u000a      chemistry, the chemistry underpinning air pollution and catalytic cycles,\u000a      and the use of paleoclimatic archives to determine the sensitivity of\u000a      global temperatures to pCO2. This research is presented\u000a      by a combination of: (i) research presentations\/events by Shallcross,\u000a        Pancost and members of their research groups and (ii) the `Pollutant's\u000a        Tale', lecture demonstration which incorporates research results\u000a      from Pancost and Shallcross.\u000a    ChemLabS activity that has derived primarily from this research during\u000a      the impact period of 2008- 2013 is oulined below.\u000a    \u000a      \u000aPancost and Shallcross and members of their research\u000a        groups, working with the Director of Outreach, Harrison, have\u000a        delivered more than 1,000 presentations to over 400 schools in the UK,\u000a        reached over 250,000 students and thousands of teachers, delivered\u000a        outreach in 15 countries (including Australia, China, New Zealand,\u000a        Singapore and South Africa), and run activities ranging from lectures to\u000a        research conducted with students and resulting in co- authored papers (a).\u000a      Bristol ChemLabS has delivered over 100 public lectures, engagement\u000a        activities at many UK festivals, including the Bristol Festival of\u000a        Nature (which draws more than 20,000 attendees and for which Pancost\u000a        served as a Steering Group member), the 2008 RS Summer Science\u000a        Exhibition, numerous regional and national science festivals (eg\u000a        Cheltenham), the RS Warm Climates of the Past discussion meeting in\u000a        2011, regular presentations at international science festivals (eg\u000a        National Science Weeks in South Africa, 2008-2012; Namibia, 2011;\u000a        Jersey, 2008 and 2010; Malta 2011\/12) and at international science\u000a        centres (eg Sci-Bono, Johannesburg).\u000a    \u000a    Crucially, to facilitate the continued teaching of such material,\u000a      ChemLabS has conducted extensive follow-up activity, including writing\u000a      articles, contributing to textbooks and training teachers. The team: (i)\u000a      organises the annual Festival of Contemporary Science that always features\u000a      climate change and atmospheric chemistry research and has been attended by\u000a      more than 200 school teachers, (ii) has run a Teachers' Master's Course\u000a      since 2005 that features climate change research as an example of How\u000a      Science Works, established the RCUK course for teachers on Climate Change,\u000a      a course that continued to be delivered through the UK Science Learning\u000a      Centre Network (145 times with approximately 1,200 attendees), and\u000a      regularly updates CHeMneT members (Bristol ChemLabS' teacher network),\u000a      (iii) trains overseas colleagues and postgraduates to present this work\u000a      across the world, with lecture demonstrations in South Africa to nearly\u000a      1,000 students per month at four centres and (iv) has written 15\u000a      publications directed at school teachers or students [eg Science in\u000a      Schools, Chemistry Review, Education in Chemistry, Physics Education,\u000a      School Science Review (b)]. See www.chemlabs.bris.ac.uk\/outreach\/recent_events.html\u000a      for full reports of ChemLabS's outreach events.\u000a    The impact of this activity has been profound and is demonstrated by the\u000a      following:\u000a    \u000a      Publications which have been widely accessed; the climate change and\u000a        atmospheric chemistry articles in Science in School alone have been\u000a        downloaded over 250,000 times.\u000a      The translation of articles into nine languages, most commonly\u000a        Spanish.\u000a      The impact on student training in the UK, which is demonstrated by\u000a        funding from industry to deliver these activities in their communities,\u000a        including: (i) EDF Energy who have funded ChemLabS to develop the\u000a        company's long-term interests in Somerset by `building up enthusiasm\u000a          for science in order to up skill the local communities in STEM\u000a          subjects' (c) supported by six atmospheric and climate\u000a        change chemistry lectures; and (ii) the AstraZeneca Science Teaching\u000a        Trust (AZSTT), which has engaged ChemLabS to deliver demonstrations on\u000a        climate change across the UK.\u000a      The impact on international student training, illustrated by the\u000a        uptake of our material by South African institutions, including: (i) the\u000a        Chemistry Department at Rhodes University, and (ii) The Sci-Bono Science\u000a        Centre, Johannesburg, which has had its demonstrators trained by\u000a        ChemLabS to deliver `A Pollutant's Tale', during Earth Science\u000a        Week in 2011 and the National Science Week in 2012.\u000a      The use of our articles by a UK examination board within Post 16\u000a        examinations 2012\/13.\u000a      The recognition of ChemLabS' outreach work through many awards to Shallcross\u000a        and Harrison and the outreach team, including more than 10\u000a        national and international awards from the RS, the RSC, the Royal\u000a        Meteorological Society (both Outreach and research) and The Bank of\u000a        America (d).\u000a    \u000a    In addition, the quality and range of the impact of this research is\u000a      documented by hundreds of collected testimonials from teachers and\u000a      research at Master's level (e). Bristol ChemLabS has quantified the\u000a      impact with respect to: (i) uptake of this research in course curricula\u000a      and teaching, (ii) its effect on students' cognition, (iii) how it has\u000a      changed students' educational choices and (iv) cultural changes in\u000a      developing countries. With respect to (i), ChemLabS' teaching has now been\u000a      incorporated into UK national exam boards' coursework. Moreover, in one-\u000a      to two-year follow-up studies with 60 of the teachers who attended\u000a      ChemLabS' 2010 national teacher training day (the Festival of Contemporary\u000a      Science), 100% declared it either `very good' or `good' in terms of\u000a      usefulness to their teaching practice (f). With respect to (ii),\u000a      Bristol ChemLabS has studied the impact of its engagement activity on UK\u000a      school's understanding atmospheric chemistry (g). In terms of\u000a      (iii), via repeated visits and interactions with some schools, ChemLabS\u000a      has been able to study how its outreach activity has transformed students'\u000a      educational choices, eg the team has been visiting the Crypt\u000a      School in Gloucestershire for five years resulting in an increase from 5\u000a      to 60 students opting to study chemistry at A-Level, (h). Finally,\u000a      in terms of (iv), papers on the use of these climate-based educational\u000a      resources in the South African context are being published (i).\u000a    Overall, the impact of outreach on students, teachers and participating\u000a      postgraduates has been the subject of 15 papers published (j),\u000a      forming the basis of three postgraduate master's level theses where\u000a      Bristol ChemLabS has demonstrated that students' understanding of the\u000a      science underpinning climate change has been improved, that teachers'\u000a      confidence in teaching these topics has been increased and that student\u000a      aspirations have been raised.\u000a    ","ImpactSummary":"\u000a    Bristol ChemLabS (part of the School of Chemistry) has used School of\u000a      Chemistry research on the atmosphere (air quality, atmospheric chemistry\u000a      and the history of greenhouse gases on Earth) to enhance dramatically the\u000a      quality and uptake of chemistry education in the UK and approximately 20\u000a      other nations. This radical advance has been achieved through ChemLabS'\u000a      outreach activity, which has involved running more than 1,200 events for\u000a      over 250,000 students over the past six years (and over 1,000 events since\u000a      2008). ChemLabS' atmospheric chemistry education packages are now being\u000a      delivered in other countries, its textbooks\/articles have been taken up\u000a      across Europe, and it has trained more than 500 teachers directly. As a\u000a      result of its activities, which are grounded in rigorous research, Bristol\u000a      ChemLabS has been able to document increased interest in science and\u000a      higher uptake at post-16 level.\u000a    ","ImpactType":"Societal","Institution":"\u000a    University of Bristol\u000a    ","Institutions":[{"AlternativeName":"Bristol (University of)","InstitutionName":"University of Bristol","PeerGroup":"A","Region":"South West","UKPRN":10007786}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"993800","Name":"Joburg"},{"GeoNamesId":"993800","Name":"Johannesburg"},{"GeoNamesId":"1880252","Name":"Singapore"}],"References":"\u000a    Publications\u000a    \u000a(1) Alkenone and boron-based Pliocene pCO2\u000a      records, O. Seki, G. Foster, D. N. Schmidt, A. Mackensen, K. Kawamura and\u000a      R. D. Pancost, EPSL, 2010, 292, 201-211. Listed in REF 2.*\u000a    \u000a\u000a(2) Increased terrestrial methane cycling at the Palaeocene-Eocene\u000a      thermal maximum, R. D. Pancost, et al., Nature, 2007, 449,\u000a      332-335. doi:10.1038\/nature06012.*\u000a    \u000a\u000a(3) Large terrestrial and marine carbon and hydrogen isotope\u000a      excursions in a new Paleocene\/Eocene boundary section from Tanzania, L.\u000a      Handley, P. N. Pearson, P. R. Bown and R. D. Pancost, EPSL 2008,\u000a      275, 17-25, doi:10.1016\/j.epsl.2008.07.030.\u000a    \u000a\u000a(4) Introduction to the DAPPLE Air Pollution Project, D.\u000a      Shallcross et al., Sci. Tot. Env. 2004, 332,\u000a      139-153, doi:10.1016\/j.scitotenv.2004.04.020.\u000a    \u000a\u000a(5) Dispersion Experiments in Central London: The 2007 DAPPLE\u000a      project, D. E. Shallcross et al., Bull. Amer. Meteor. Soc.\u000a      2009, 90, 955-969. http:\/\/dx.doi.org\/10.1175\/2009BAMS2638.1.*\u000a    \u000a\u000a(6) Use of Reactive Tracers To Determine Ambient OH Radical\u000a      Concentrations: Application within the Indoor Environment, I. R. White, D.\u000a      Martin, M. P. Mu&#241;oz, F. K. Petersson, S. J. Henshaw, G. Nickless, G. C.\u000a      Lloyd-Jones, K. C. Clemitshaw and D. E. Shallcross, Env. Sci. Tech.\u000a      2010, 44, 6269-6274. DOI: 10.1021\/es901699a.\u000a    \u000aGrants (examples only):\u000a    (a) Pancost (2006-2008) An integrated study of the Middle\u000a        Miocene, NERC, &#163;110k.\u000a    (b) Pancost and Seki (2006-2007) Fellowship, Japan Society\u000a      for Promotion of Science, ~&#163;100k.\u000a    (c) Pancost (2010-2013) Timing, causes and consequences of the\u000a        decline in Pliocene pCO2, NERC, &#163;490k.\u000a    (d) Pancost (2012-2015) Terrestrial methane cycling during the\u000a        Paleogene, NERC, &#163;900k.\u000a    (e) Simmonds and Shallcross (1999-2002) URGENT Programme,\u000a      NERC, &#163;274k.\u000a    (f) Shallcross (2002-2006) DAPPLE, EPSRC, &#163;157k.\u000a    (g) Shallcross (2006-2009) DAPPLE2, Home Office, &#163;266k.\u000a    (h) Shallcross (2010-2011) PFC tracer development, DSTL, &#163;56k.\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"},{"Level1":"4","Level2":"2","Subject":"Geochemistry"},{"Level1":"4","Level2":"1","Subject":"Atmospheric Sciences"}],"Sources":"\u000a    (a) Smoke is in the air: How fireworks affect air quality. Science\u000a        in School, 2011, 21, 47-51. http:\/\/www.scienceinschool.org\/2011\/issue21\/fireworks\u000a    (b) Eg Climate Change modelling in the classroom, Science\u000a        in School 2008, 9, 28-33, and Climate Change: Outreaching to\u000a      School Students and Teachers in Handbook of Climate Change Mitigation,\u000a      Springer 2012, D.E. Shallcross and T. G. Harrison.\u000a    (c) Letter from EDF available on request.\u000a    (d) List of awards for ChemLabS outreach (or co-ordinators): (i)\u000a      2010 Times Higher Education Outstanding ICT Initiative of the Year Award,\u000a      (ii) 2010 Royal Society's Hauksbee Award, (iii) 2009 Highly Commended BITC\u000a      Education Award, (iv) 2009 Big Tick Education Award, (v) 2009 Royal Met.\u000a      Soc. Michael Hunt Award, (vi) 2008 RSC Tertiary Education Award, (vii)\u000a      2006 SCI Science Education Award, (viii) 2005 RSC Higher Education Award,\u000a      (ix) 2005 RSC Schools Education Award, (x) HEA National Teaching\u000a      Fellowship.\u000a    (e) Testimonials archived at: http:\/\/www.chemlabs.bris.ac.uk\/outreach\/Outreach%20Feedback.pdf\u000a    (f) Feedback from teachers who have adopted our materials in\u000a      courses or who have attended Festival of Contemporary Science, RCUK\u000a      courses, MSURE course and CHeMneT are available [see also testimonials\u000a      under (e)].\u000a    (g) S. R. Glover first year transfer report research in Chemistry\u000a      Outreach for PhD thesis 2011.\u000a    (h) Letters from Head of Crypt School and Cheltenham Ladies\u000a      College, available on request.\u000a    (i) An impact assessment of atmospheric chemistry demonstrations\u000a      in Western Cape schools, S. N. Sunassee, et al., Acta\u000a        Didactica Naponcensia 2012, 5(4) http:\/\/dppd.ubbcluj.ro\/adn\/article_5_4_5.pdf.\u000a    Publications on the benefits of engagement:\u000a    The advantages perceived by schoolteachers in engaging their students in\u000a      university-based chemistry outreach activities, J. Tuah, T. G. Harrison\u000a      and D. E. Shallcross, Acta Didactica Napocensia 2009, 2,\u000a      31-44, and a review of the use of demonstration lectures in the promotion\u000a      of positive attitudes towards, and the learning of science with reference\u000a      to a `A Pollutant's Tale', a demonstration lecture on air quality\u000a      and climate change, J. Tuah, T. G. Harrison and D. E. Shallcross, Romanian\u000a        Journal of Education 2010, 1, 93-102. \u000a    ","Title":"\u000a    CH2: Climate Change and Air Quality: Interdisciplinary Research that\u000a        is Transforming the Teaching of Chemistry across the World\u000a    ","UKLocation":[{"GeoNamesId":"2654675","Name":"Bristol"},{"GeoNamesId":"2653261","Name":"Cheltenham"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Pancost (Professor of biogeochemistry, 2000-present; Organic\u000a      Geochemistry Unit, OGU) and Shallcross (Professor of atmospheric\u000a      chemistry, 1999-present; Atmospheric Chemistry Research Group, ACRG) have\u000a      spent the past 15 years studying human impacts on the atmosphere and the\u000a      corresponding effects of carbon dioxide, methane and trace gases on the\u000a      Earth's climate. This work has been conducted as a central part of the\u000a      Bristol Global Change Research Theme, incorporating collaborations with\u000a      other chemists [Evershed, O'Doherty, Rigby,\u000a        Simmonds (UoB Senior Research Fellow)]. Collectively, OGU and ACRG\u000a      atmosphere and trace gas work is represented by over 200 highly cited\u000a      publications, of which a selection led by Pancost and Shallcross\u000a      are listed below. Its larger relevance is reflected in its policy impact;\u000a      the air quality research has been used by the UK Home Office and Ministry\u000a      of Defence to update their emergency-response models, and the\u000a      palaeoclimate research will be cited in the forthcoming Intergovernmental\u000a      Panel on Climate Change report.\u000a    One aspect of this research is the development of geochemical tools for\u000a      the reconstruction of past pCO2 levels and\u000a      temperatures, which is at the centre of assessing how carbon dioxide and\u000a      other greenhouse gases affect climate (1-3). The work illustrates\u000a      that throughout geological history, climate sensitivity (especially in\u000a      polar regions) is either at the high end of, or greater than, that assumed\u000a      for most climate models. For example, the Bristol researchers showed that\u000a      the Pliocene, widely considered an ideal analogue for anticipating future\u000a      warming (including by the IPCC), was characterised by pCO2\u000a      levels similar to those we had already achieved in 2000 but also by global\u000a      temperatures that were 3&#186;C warmer than those of today (1). Such\u000a      work will be included in the next IPCC report, an achievement facilitated\u000a      by Pancost co-hosting international workshops on pCO2\u000a      reconstruction at Bristol Zoo in 2010 and a Royal Society (RS)-funded\u000a      Kavli Meeting in 2011.\u000a    Related research has been led by Shallcross and is focussed on\u000a      air quality and pollutant dispersion and transformation (DAPPLE project,\u000a      2002-09) (4-6). Novel inert gas-phase tracers have been developed\u000a      that allow the characterisation of air flow and dispersion of pollutants\u000a      within the urban environment. These experiments have shown that robust,\u000a      simple models can be used for emergency-response planning, that pollution\u000a      from moving sources penetrates much further into the urban environment\u000a      than that from stationary sources and that outdoor pollution enters the\u000a      indoor environment in greater quantities than first thought and remains\u000a      there for longer than predicted. These findings, together with extensive\u000a      chemical modelling, have allowed us to build a more complete picture of\u000a      the complex urban environment and the chemical and physical\u000a      transformations that take place therein.\u000a    These are just two examples of the extensive research conducted on how\u000a      greenhouse gases (GHGs) are produced, behave in the atmosphere and affect\u000a      the Earth's climate, and how pollutants move and are transformed in the\u000a      urban environment. Additional research areas include investigating the\u000a      methane cycle in modern and ancient soils, wetlands and marine sediments,\u000a      quantifying trace GHGs in the atmosphere and understanding and\u000a      characterising pollutant transformation in the urban environment (5).\u000a    "},{"CaseStudyId":"40240","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2921044","Name":"Germany"},{"GeoNamesId":"2782113","Name":"Austria"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Engineering and Physical Sciences Research Council","Royal Society"],"ImpactDetails":"\u000d\u000a    Introduction\u000d\u000a    The algorithms driving dS are taken from software and methods developed\u000d\u000a      by Glowacki in order to understand the fundamentals of chemical\u000d\u000a      reaction dynamics and energy transfer in liquids. This research occurred\u000d\u000a      as part of the EPSRC Programme Grant employing Glowacki, through\u000d\u000a      collaborations with Orr-Ewing and Ashfold. The exceptional\u000d\u000a      performance of the dS software benefits from a suite of GPU-accelerated\u000d\u000a      algorithms, developed by Glowacki in collaboration with\u000d\u000a      McIntosh-Smith and Tew, a resident at the Pervasive Media Studio in\u000d\u000a      Bristol.\u000d\u000a    Impact: Public Audiences\u000d\u000a    Glowacki recognised that combining his fast MD algorithms with\u000d\u000a      3D-depth sensors could facilitate an immersive, interactive molecular\u000d\u000a      dynamics experience. This led him to develop an integrated\u000d\u000a      software\/hardware system that functions as an installation piece for\u000d\u000a      cultural institutions. dS's sonic and graphic tools may be used by a range\u000d\u000a      of non-specialists, including artists, educators, and hobbyists. This has\u000d\u000a      facilitated the development of `Hidden Fields' (HF) the world's first\u000d\u000a      dance show based on molecular dynamics (1), which Glowacki\u000d\u000a      developed along with an interdisciplinary team including Tew,\u000d\u000a      choreographer Laura Kriefman, musician Joseph Hyde (Professor, Bath Spa\u000d\u000a      University), music technologist Thomas Mitchell (Senior Lecturer, UWE), a\u000d\u000a      team of five professional dancers, and film-makers Nathan Hughes and Jacob\u000d\u000a      Parish. To date, over 20,000 people have attended dS and HF events (2).\u000a      Web statistics show well over 40,000 hits for related content (3),\u000d\u000a      and `Googling' `danceroom spectroscopy' gives more than 200 pages of hits.\u000d\u000a      Notable live events include (2):\u000d\u000a    \u000d\u000a      Shambala Arts Festival: Aug 2011, 2000 participants, mostly a young,\u000d\u000a        arts-oriented audience (2).\u000d\u000a      Bristol's Arnolfini: July 2012, 2000 participants, a wide\u000d\u000a        cross-section of the public, spanning all ages with a range of interests\u000d\u000a        (2).\u000d\u000a      London 2012 Cultural Olympiad: Aug 2012, 2000 participants, spanning\u000d\u000a        all ages with a range of interests.\u000d\u000a      London's Barbican Arts Centre: Nov 2012, 2000 participants with\u000d\u000a        interests in art and technology (4).\u000d\u000a      London's Big Bang science\/engineering fair: Mar 2012, 6000\u000d\u000a        participants, children and families interested in science (5).\u000d\u000a      New York City's World Science Festival: June 2013, 1000 participants,\u000d\u000a        children and families interested in science (2).\u000d\u000a      The Bristol Old Vic theatre, in collaboration with violinist Nicola\u000d\u000a        Benedetti as part of the Bristol Proms: Aug 2013, classical music\u000d\u000a        audience (2).\u000d\u000a    \u000d\u000a    Following the tremendous audience response dS and HF received at the\u000d\u000a      London 2012 Olympics and the Barbican Arts Centre, NVIDIA and Arts Council\u000d\u000a      England have provided nearly &#163;70k in funding to support algorithm\u000d\u000a      development and an international tour of dS and HF in 2013\/14 (6).\u000d\u000a      The momentum associated with this tour has led to a further &#163;75k of\u000d\u000a      funding from The Royal Society of Chemistry, EPSRC, University of the West\u000d\u000a      of England, and the Watershed Arts Trust to support a danceroom\u000d\u000a      Spectroscopy festival, (7) with events aimed at year-9 school\u000d\u000a      children, university students, artists, and the general public. Upcoming\u000d\u000a      performances of dS in 2014 will include the ZKM Centre for Art &amp; Media\u000d\u000a      (Karlsruhe), and London's Barbican.\u000d\u000a    dS is profoundly cross-disciplinary, combining physics, chemistry,\u000d\u000a      computer science, human-computer interaction, art, and music. It thus\u000d\u000a      offers a brilliant \"way in\" to complex chemistry and physics for people\u000d\u000a      who are often hard to reach, eg teenagers, clubbers,\u000d\u000a      festival-goers, and those interested in art. The majority of dS\u000d\u000a      participants indicate that they come from arts backgrounds, with little\u000d\u000a      exposure to science. Written feedback obtained over 21-22 July 2012 at the\u000d\u000a      Arnolfini suggests that dS sparks interest in science and the way that\u000d\u000a      scientists think. Example quotes of respondent's impressions having seen\u000d\u000a      dS\/HF include:\u000d\u000a    \u000d\u000a      \"[dS made me think about] how we interact with all the matter\u000d\u000a          constantly surrounding us.\"\u000d\u000a      \"Science has never been so spellbinding.\"\u000d\u000a      \"[dS\/HF] can teach science in an innovative and creative way.\"\u000d\u000a      \"Whether dance or science dS is totally absorbing and utterly\u000d\u000a          wonderful.\"\u000d\u000a      \"[dS\/HF] makes me think about how I might be influencing everything\u000d\u000a          around me.\"\u000d\u000a      \"an amazing fusion of science and art, something I have never seen\u000d\u000a          before.\"\u000d\u000a      \"just because we cannot see [things] does not mean they are not\u000d\u000a          there. There is more to the universe than meets the eye.\"\u000d\u000a    \u000d\u000a    Impact: Cultural, Artistic, and Media Sectors\u000d\u000a    dS and HF have resulted in a number of awards and award nominations\u000d\u000a      including (8):\u000d\u000a    \u000d\u000a      `Best Digital Innovation 2012' from the UK Royal Television Society.\u000d\u000a      Honorable mention for the Prix Ars Electronica (amongst the most\u000d\u000a        presitigious global awards in digital art).\u000d\u000a      University of Bristol 2013 Public Engagement Award.\u000d\u000a      Nominee for 2013 UK Media Innovation Awards\u000d\u000a    \u000d\u000a    There have been many opportunties for exposure to dS via media outlets.\u000d\u000a      For example, dS was highlighted by the newly appointed chair of Arts\u000d\u000a      Council England, Sir Peter Bazalgette, during his inaugural lecture in\u000d\u000a      March 2013, Glowacki has conducted radio interviews for both BBC\u000d\u000a      Radio Bristol and Monocle-24 (a London-based radio station), dS has been\u000d\u000a      written up in the press at least 35 times, including a range of popular\u000d\u000a      science outlets including Physics World (Institute of Physics), Chemistry\u000a        World (Royal Society of Chemistry), New Scientist, and The\u000a        Guardian (8,9).\u000d\u000a    dS's impact on the UK's cultural, artistic, and media sectors has been\u000d\u000a      strengthened considerably through connections to Bristol's Pervasive Media\u000d\u000a      Studio (Watershed) (10) and Arnolfini Art Gallery, who together\u000d\u000a      provided over &#163;35k of in-kind support for dS development during 2010 to\u000d\u000a      2012. For example, dS's recent London premier at the Barbican has provided\u000d\u000a      excellent exposure for both these institutions within the UK creative\u000d\u000a      technology sector. The Watershed have recently used dS as a \"Talent\u000d\u000a      Development Case Study\" detailing successful examples of\u000d\u000a      cross-fertilization between media organizations and the academic sector\u000d\u000a      and in collaboration with the Institute of Physics, dS's inspired the\u000d\u000a      Pervasive Media Studio to initiate a public communication of science\u000d\u000a      residency.\u000d\u000a    Impact: Non-Academics\u000d\u000a    dS and HF have had substantial impact on Glowacki's non-academic\u000d\u000a      collaborators. Following dS\/HF success:\u000d\u000a    \u000d\u000a      Kriefman has enjoyed significant exposure, with invitations to conduct\u000d\u000a        workshops in collaboration with premier UK dance institutions including\u000d\u000a        the Royal Academy of Dance (London) and Northern Ballet.\u000d\u000a      Tew has boosted his international reputation as a generative digital\u000d\u000a        artist. He was awarded a Pervasive Media Studio residency, which led to\u000d\u000a        his participation in a MADE commission to work on a multi-site European\u000d\u000a        digital art project entitled \"Me and My Shadow\".\u000d\u000a      Hughes and Parish have produced a series of high-impact legacy film\u000d\u000a        documents detailing the groundbreaking collaboration that has resulted\u000d\u000a        in dS\/HF. For example, a dS mini-doc was recently shortlisted for a\u000d\u000a        $100k \"Forward Focus\" prize sponsored by GE (11).\u000d\u000a      The professional dancers who performed in HF have gained valuable\u000d\u000a        experience at the collaborative frontiers of art and science, and learnt\u000d\u000a        strategies for incorporating technology into arts practice. They have\u000d\u000a        improved their ability to engage public audiences in bringing hydbrid\u000d\u000a        forms of art to nontraditional audiences.\u000d\u000a    \u000d\u000a    Impact: Commercial\u000d\u000a    dS has momentum for expansion into commercial sectors, with an initial\u000d\u000a      focus on education. It has resulted in the first ever real-time 360&#176;, 3d\u000d\u000a      depth-capture system and yielded a state-of-the-art, GPU accelerated\u000d\u000a      framework for carrying out quantum molecular dynamics. To exploit these\u000d\u000a      opportunities, Glowacki formed a spin-out company, Interactive\u000d\u000a      Scientific Ltd. (12) with a projected turnover of approximately\u000d\u000a      &#163;150k expected during 2013\/14.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    danceroom Spectroscopy (dS) is a cutting-edge, interactive public\u000d\u000a      engagement project that allows people to literally step into an\u000d\u000a      interactive molecular dynamics simulation. It has its origins in\u000d\u000a      fundamental research carried out to understand ultrafast chemical dynamics\u000d\u000a      in liquids. On a large scale, dS impact has arisen from its deployment in\u000d\u000a      premier cultural settings in the UK and internationally, eg the\u000d\u000a      London 2012 Olympics, London's Barbican Arts Centre, Ars Electronica\u000d\u000a      (Austria), ZKM (Germany), and the World Science Festival (New York City).\u000d\u000a      Statistics indicate well over 60,000 people have so far experienced dS,\u000d\u000a      with audiences spanning ages from 3 to 73, and attracting those with a\u000d\u000a      variety of interests including science, technology, art and education.\u000d\u000a      Within the cultural and media sectors, dS has received several awards and\u000d\u000a      substantial press attention, all of which has proven beneficial to several\u000d\u000a      non-academic collaborators and partner institutions. The substantial\u000d\u000a      momentum and opportunities available from dS are also being commercially\u000d\u000a      exploited through a spin-out company called Interactive Scientific Ltd.\u000d\u000a    ","ImpactType":"Societal","Institution":"\u000d\u000a    University of Bristol\u000d\u000a    ","Institutions":[{"AlternativeName":"Bristol (University of)","InstitutionName":"University of Bristol","PeerGroup":"A","Region":"South West","UKPRN":10007786}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"5128581","Name":"New York City"}],"References":"\u000d\u000a    Publications:\u000d\u000a    \u000a(1) The photodissociation of iodine monochloride at 235 nm. L. J.\u000d\u000a      Rogers, M. N. R. Ashfold, Y. Matsumi, M. Kawasaki and B. J. Whitaker, Chem.\u000a        Phys. Lett., 1996, 258, 159-63. DOI:\u000d\u000a      10.1016\/0009-2614(96)00617-3\u000d\u000a    \u000a\u000a(2) Ion imaging studies of the Cl (2PJ) and\u000d\u000a      Br (2PJ) atomic products resulting from BrCl\u000d\u000a      photodissociation in the wavelength range 235-540 nm. M. J. Cooper, P. J.\u000d\u000a      Jackson, L. J. Rogers, A. J. Orr-Ewing, M. N. R. Ashfold and B. J.\u000d\u000a      Whitaker, J. Chem. Phys. 1998, 109, 4367-77. DOI: http:\/\/dx.doi.org\/10.1063\/1.477039.\u000d\u000a    \u000a\u000a(3) Ultrafast energy flow in the wake of solution-phase\u000d\u000a      bimolecular reactions. D. R. Glowacki, R. A. Rose, S.J. Greaves, A. J.\u000d\u000a      Orr-Ewing, and J. N. Harvey, Nature Chemistry, 2011, 3,\u000d\u000a      850-855. doi:10.1038\/nchem.1154.*\u000d\u000a    \u000a\u000a(4) Vibrationally Quantum-State-Specific Reaction Dynamics of H\u000d\u000a      Atom Abstraction by CN Radical in Solution. S. J. Greaves, R. A. Rose, T.\u000d\u000a      A. A. Oliver, D. R. Glowacki, M. N. R. Ashfold, J. N. Harvey, I. P. Clark,\u000d\u000a      G. M. Greetham, A. W. Parker, M. Towrie, and A. J. Orr-Ewing, Science,\u000d\u000a      2011, 331, 1423-1426. DOI:10.1126\/science.1197796 *\u000d\u000a    \u000a\u000a(5) Danceroom Spectroscopy: Interactive Quantum Molecular Dynamics\u000d\u000a      Accelerated on GPU Architectures using OpenCL. D. R. Glowacki, P. Tew, T.\u000d\u000a      Mitchell, J. Hyde, J. Price, and S. McIntosh-Smith, URL: UK\u000a        Many Core Development Conference 2012 (UKMAC '12).\u000d\u000a    \u000a\u000a(6) Sculpting Molecular Dynamics in Real-Time using Human Energy\u000d\u000a      Fields. D. R. Glowacki, P. Tew, T. Mitchell, L Kriefman, J. Hyde, L. J.\u000d\u000a      Malcolm, J. Price, and S. McIntosh-Smith, in Molecular\u000a          Aesthetics ISBN: 9780262018784 (MIT Press). Can be supplied by\u000d\u000a      the UoB to the REF Panel on request *\u000d\u000a    \u000aGrants:\u000d\u000a    (a) Ashfold (Bristol component), Imaging Network for the Direct\u000d\u000a        Visualisation of Chemical Dynamics: IMAGINE, EU (ERBEMRXCT970110),\u000d\u000a      1998-2001, &#8364;184,730.\u000d\u000a    (b) Ashfold (Bristol component), Product Imaging and Correlation:\u000d\u000a        Non-Adiabatic Interactions in Chemistry; PICNIC, EU\u000d\u000a      (HPRN-CT-2002-00183), 2002-5, &#8364;163,573.\u000d\u000a    (c) Ashfold, Orr-Ewing (Bristol component), Marie Curie Initial\u000d\u000a        Training Network: Imaging and Control in Chemistry: ICONIC, EU,\u000d\u000a      2009-13, &#8364;613,545.\u000d\u000a    (d) Orr-Ewing, Ashfold, et al., Portfolio Partnership LASER,\u000d\u000a      EPSRC GR\/S71750\/01, 2003-8, &#163;3,060,014.\u000d\u000a    (e) Orr-Ewing, Ashfold, et al., New Horizons in Chemical and\u000d\u000a        Photochemical Dynamics, EPSRC EP\/G00224X\/1,\u000d\u000a      2008-13, &#163;5,934,426.\u000d\u000a    (f) Glowacki, Ashfold, et al., danceroom Spectroscopy:\u000d\u000a        Collectively Generating Music from Movement, EPSRC, EP\/I017623\/1\u000d\u000a      &#163;20,000.\u000d\u000a    (g) Glowacki, EPSRC Pathways to Impact Funding, University of Bristol,\u000d\u000a      &#163;37,000.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"2","Level2":"2","Subject":"Atomic, Molecular, Nuclear, Particle and Plasma Physics"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"7","Subject":"Theoretical and Computational Chemistry"}],"Sources":"\u000d\u000a    (1) Hidden Fields video trailer: http:\/\/vimeo.com\/48764930\u000d\u000a    (2) List of all past dS events: http:\/\/danceroom-spec.com\/events\/\u000d\u000a    (3) dS project website: http:\/\/danceroom-spec.com\/\u000d\u000a    (4) Emma Ridgeway, Barbican art director: emma.ridgway@barbican.org.uk\u000d\u000a    (5) Big Bang Video doc: http:\/\/www.chm.bris.ac.uk\/~chdrg\/educationTrailer.mov\u000d\u000a    (6) Arts Council Funding:www.lottery.culture.gov.uk\/GrantDetails.aspx?ID=22473758&amp;DBID=AE\u000d\u000a    (7) www.watershed.co.uk\/news\/first-danceroom-spectroscopy-festival-announced\/;\u000d\u000a      www.theguardian.com\/science\/small-world\/2013\/oct\/25\/danceroom-spectroscopy-invisible-\u000a        world-visible\u000d\u000a    (8) RTS award: http:\/\/www.bristol.ac.uk\/news\/2013\/9200.html,\u000d\u000a      Prix Ars Electronica: http:\/\/prix2013.aec.at\/prixwinner\/11898\/,\u000d\u000a      University of Bristol public engagement award: http:\/\/www.bristol.ac.uk\/news\/2013\/9429.html.\u000d\u000a    (9) List of over 35 dS press stories: http:\/\/danceroom-spec.com\/press\/.\u000d\u000a    (10) Dick Penny, director of Watershed Media Centre: dick@watershed.co.uk,\u000d\u000a      Clare Reddington, director of Pervasive Media Studio: clare.reddington@watershed.co.uk.\u000d\u000a    (11) Forward focus semifinalist video: http:\/\/vimeo.com\/51890018.\u000d\u000a    (12) Interactive Scientific website: http:\/\/www.interactivescientific.com\/.\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    CH3: danceroom Spectroscopy: International Cultural Impact and Public\u000d\u000a        Engagement at the frontiers of Science, Technology, and Art\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2643743","Name":"London"},{"GeoNamesId":"2654675","Name":"Bristol"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    This impact emerged from a fusion of two distinct research strands at\u000d\u000a      Bristol:\u000d\u000a\u0009  Strand 1 concerns the School of Chemistry Laser\u000d\u000a      Group (Professors Mike Ashfold and Andrew Orr-Ewing) who were amongst the\u000d\u000a      first in the UK to use digital imaging methods to investigate gas phase\u000d\u000a      reaction dynamics. They introduced two methods (`event counting' and\u000d\u000a      `centroiding') in order to improve image resolution and alleviate a range\u000d\u000a      of problems that arise from using position sensitive detectors. The\u000d\u000a      methodology was first demonstrated in 1996 and reported in detail in 1998\u000d\u000a      (1,2). Such developments and the science they have enabled have\u000d\u000a      ensured membership in three successive EU Marie Curie Training Networks\u000d\u000a      devoted to developments and applications of imaging methods in\u000d\u000a      contemporary reaction dynamics (a-d) and event counting is now a\u000d\u000a      standard feature in the software supplied with CCD cameras provided for\u000d\u000a      imaging applications. Imaging methods are now being developed further\u000d\u000a      through a Knowledge Training Partnership with Photek Ltd, and were a key\u000d\u000a      tool within a recent EPSRC Programme Grant (e).\u000d\u000a    Strand 2 is an extensive set of Molecular Dynamics (MD)\u000d\u000a      simulation software programs developed by Glowacki, a Royal\u000d\u000a      Society URF (since October 2013) who has recently been appointed to a\u000d\u000a      proleptic lecturership in the School of Chemistry. From June 2009 to Sept\u000d\u000a      2013, Glowacki was employed as a PDRA on the aforementioned EPSRC\u000d\u000a      Programme Grant (e), where he was encouraged to work with a very\u000d\u000a      high degree of autonomy. Glowacki's software programs were\u000d\u000a      developed to understand hitherto unrecognised details of the mechanisms\u000d\u000a      for chemical reactions in liquids revealed by ultrafast laser experiments\u000d\u000a      performed by Laser Group at the Rutherford Appleton Laboratory's ULTRA\u000d\u000a      facility carried out during 2010\/11. Specifically, Glowacki\u000d\u000a      collaborated closely with Orr-Ewing and Ashfold to show\u000d\u000a      that chemical reactions in liquids give rise to products with significant\u000d\u000a      quantum state excitation (3,4). Through the extensive conversations\u000d\u000a      that arose as a result of this collaboration, Glowacki became\u000d\u000a      aware of the in-house experience with imaging methods, and recognised the\u000d\u000a      possibility of combining real-time imaging methodology with his molecular\u000d\u000a      dynamics algorithms to build a real-time interactive system. This inspired\u000d\u000a      Glowacki to investigate combining his MD methods with 3D imaging\u000d\u000a      technology. These efforts were initially funded via an EPSRC\u000d\u000a      public engagement grant awarded in October 2010 (f), and EPSRC\u000d\u000a      Pathways to Impact funding in 2011 (g). The most significant\u000d\u000a      complication arose from the computational requirements of such a system\u000d\u000a      which dramatically exceeded what could be accomplished with standard\u000d\u000a      single-core processing methods. As a result, Glowacki began\u000d\u000a      conversations with McIntosh-Smith (Senior Lecturer, UoB Department of\u000d\u000a      Computer Science) with expertise in high-performance computing. This\u000d\u000a      collaboration, initiated in early 2012, led to a set of GPU-accelerated\u000d\u000a      algorithms for performing real-time interactive molecular dynamics (5,6)\u000d\u000a      and now forms the foundation of the dS system.\u000d\u000a    "},{"CaseStudyId":"40243","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2510769","Name":"Spain"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2658434","Name":"Switzerland"}],"Funders":["Natural Environment Research Council","Royal Society"],"ImpactDetails":"\u000a    Chemical archaeology\u000a      Evershed began to combine chemistry and archaeology to capture\u000a      public interest and stimulate\u000a      chemistry education in the 1990s and has continued to evolve this to the\u000a      present day via the full\u000a      range of mechanisms. The combination regularly attracts students not\u000a      normally inspired to study\u000a      chemistry:\u000a    School and college educational outreach\u000a    \u000a      Presentations to schools by Evershed and his team have a\u000a        profound impact on students\u000a        and teachers, with the latter recognising the value of conveying the\u000a        ideas of chemistry\u000a        through case studies drawn from ancient human societies from across the\u000a        world (a).\u000a        Formalisation of this is evidenced by inclusion of Evershed's work on\u000a        the chemistry of food\u000a        residues in ancient pottery in the Nuffield GCSE Chemistry textbook.\u000a        First published in\u000a        2006, this text is used by most OCR GCSE Science (TFCS) students\u000a        [estimated by OUP to\u000a        be ca. 75% of those students, &gt;20,000 students p.a., based on market\u000a        share (b)].\u000a      \u000aEvershed's work has contributed to more than 20 documentaries\u000a        broadcast worldwide\u000a        most recently: The Making of the Fittest: Got Lactase? The\u000a          Co-evolution of Genes and Culture\u000a        by HHMI (c). On the 1st October, since\u000a        posting in March 2013 the film had 43,429 stream\u000a        attempts and 21,483 downloads.\u000a      Members of his team (Cramp and Salque as PhD students\u000a        and Gill as PDRA) authored\u000a        educational articles in the RSC's journal Catalyst circulation\u000a        10,000 (d).\u000a\u000a    \u000a    Public outreach events\u000a    \u000a      \u000aEvershed and his team have promoted the wider interest in\u000a        chemistry through archaeology\u000a        via &gt;50 community events, public outreach activities and\u000a        presentations to local interest\u000a        groups throughout the UK, e.g. 'Set7', 'Chemistry Alive', 'Scientific\u000a        Power to the People',\u000a        ChemSix, 1996, University of Bath Millennium lecture Series (2\u000a        invitations), University of\u000a        Bristol Centenary celebrations and Open Days, Discover 2010, Oxford May\u000a        Music Festival\u000a        2011, and the Bristol Festival of Nature 2011-2013. A highlight of this\u000a        activity was the\u000a        group's participation in the 2009 Royal Society Summer Science\u000a        Exhibition (RSSSE) (e,f)\u000a        attended by &gt;5000 school\/college students, members of the public of\u000a        all ages and\u000a        backgrounds, and academics\/educators of all types (school teachers to\u000a        FRS).\u000a      Developed in 2009 `The Palaeodetective' display as an outreach\u000a        tool. Central to the display\u000a        is a computer game played on touch-screens, enabling users to learn\u000a        about ancient worlds\u000a        through `cases' drawn from the group's work. The game is designed for\u000a        any age and\u000a        appeals to many interests. The exhibit originally created for RSSSE 2009\u000a        has been re-used\u000a        over a dozen times, including at Festivals and University Open Days, and\u000a        is available to\u000a        teachers online (e). This game has now been played by thousands\u000a        of children and adults.\u000a      \u000aDunne from Evershed's group represented the University\u000a        of Bristol in the 2013 `Soapbox\u000a        Science Event', promoting women in science, presenting an informal\u000a        interactive street talk\u000a        \"Milking it\" at the South Bank, based on her archaeological\u000a        chemistry research (g).\u000a    \u000a    Media interactions and engagement\u000a    \u000a      \u000aEvershed's research has generated over 10 press releases, he\u000a        has given over 50\u000a        interviews to print and radio media and contributed to 12 documentaries.\u000a      \u000aEvershed's media engagement has resulted in vast coverage of\u000a        his research in the\u000a        national and international media, including, for example, over 100\u000a        newspaper and\u000a        magazine publications and nearly two dozen national and international\u000a        interviews.\u000a      Typing \"Evershed ancient dairying\" into Google gives\u000a        &gt;100,000 hits referring extensively to\u000a        his group's work in a diversity of sources from across the world.\u000a    \u000a\u0009In this respect his work continually reinforces the importance of\u000a        chemistry in understanding the\u000a        origins of humankind.\u000a    Detection of vegetable oil fraud\u000a      In 1996 Evershed collaborated with the Leatherhead Food Research\u000a      Association (representing a\u000a      consortium of food producers comprising FOSFA, International, Unilever\u000a      Research, Bedford, UK,\u000a      and Nestec Ltd., Lausanne, Switzerland). The Bristol-based PhD student (Woodbury)\u000a      developed a\u000a      new method for detecting the adulteration of corn oil which was\u000a      incorporated into the CODEX\u000a      Standard for Named Vegetable Oils (CODEX-STAN 210-1999) (h). The\u000a      CODEX was published in\u000a      1999, but remains the UK (and international) standard for detecting\u000a      vegetable oil adulteration,\u000a      thereby protecting consumers' economic and health interests through the\u000a      REF period. Evershed's\u000a      methodologies predate the recent horse meat debacle, emphasising the need\u000a      for the use of\u000a      sophisticated analytical methods to ensure the quality of the food we\u000a      consume. Although such\u000a      frauds are rarely injurious to human health they raise moral concerns,\u000a      however, the famous\u000a      \"Spanish Toxic Oil Syndrome\" resulted in 600 deaths, emphasising the need\u000a      for constant vigilance.\u000a    Murder case\u000a      Approached by the Metropolitan Police, Evershed's team rapidly\u000a      reconfigured their methodologies\u000a      to provide unequivocal evidence that led to an immediate confession and\u000a      subsequent murder\u000a      conviction (i). The methods employed were published (6) with\u000a      the agreement of the Metropolitan\u000a      Police in 2009 to provide an exemplar for others to follow. The case\u000a      rested on the substantial\u000a      stable isotope database built on Evershed's archaeological\u000a      chemical research, bolstered by\u000a      further samples provided by the \"Body Farm\", made famous by\u000a      Patricia Cornwall's novel of the\u000a      same name.\u000a    ","ImpactSummary":"\u000a    Evershed and his research group in The School of Chemistry,\u000a      University of Bristol, have\u000a      pioneered a suite of novel molecular and stable isotope analytical\u000a      chemical techniques for\u000a      provenancing amorphous organic residues in archaeology, particularly for\u000a      the elucidation of\u000a      ancient diet and the origins of agriculture. Their on-going research\u000a      continuously achieves impact\u000a      worldwide at all levels. Impact has been actively enhanced via the\u000a      involvement of Evershed and\u000a      his entire team in hundreds of public engagement activities (art\/science\u000a      exhibitions and festivals,\u000a      personal presentations, media interviews\/articles\/documentaries), school\u000a      and college educational\u000a      outreach activities (teacher\/student conferences, items\/articles in the\u000a      educational literature and\u000a      contributions to educational films\/documentaries). Critically, their\u000a      `fingerprinting' methods have\u000a      found application in detecting food fraud in the vegetable oil trade,\u000a      protecting the human population\u000a      worldwide from consuming impure corn oil for ca. 15 years to the present\u000a      day. Most poignantly,\u000a      when called upon, their methods were pivotal in solving a murder case for\u000a      the Metropolitan Police.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Bristol\u000a    ","Institutions":[{"AlternativeName":"Bristol (University of)","InstitutionName":"University of Bristol","PeerGroup":"A","Region":"South West","UKPRN":10007786}],"Panel":"B         ","PlaceName":[],"References":"\u000a    Publications\u000a    \u000a(1) Direct demonstration of milk as an element of archaeological\u000a      economies, S. N. Dudd and\u000a      R. P. Evershed, Science 1998, 282, 1478-148, DOI:\u000a      10.1126\/science.282.5393.1478.*\u000a    \u000a\u000a(2) Earliest date for milk use in the Near East and southeastern\u000a      Europe linked to cattle herding,\u000a      R. P. Evershed, S. Payne, A. G. Sherratt, M. S. Copley, J. Coolidge, D.\u000a      Urem-Kotsu, K.\u000a      Kotsakis, M. &#214;zdo&#287;an, A. &#214;zdo&#287;an, O. Nieuwenhuyse, P. M. M. G. Akkermans,\u000a      D. Bailey,\u000a      R.-R. Andeescu, S. Campbell, S. Farid, I. Hodder, N. Yalman, M.\u000a      &#214;zbara&#351;an, E. Bicakci, Y.\u000a      Garfinkel, T. Levy and M. M. Burton, Nature 2008, 455,\u000a      528-531, DOI:\u000a      10.1038\/nature07180.\u000a    \u000a\u000a(3) Purity assessments of major vegetable oils based on 03b413C\u000a      values of individual fatty acids,\u000a      S. E. Woodbury, J. B. Rossell and R. P. Evershed, Journal of the\u000a        American Oil Chemists\u000a        Society, 1998, 75, 371-379. DOI: 10.1021\/ac00111a029.*\u000a    \u000a\u000a(4) First dairying in the green Sahara in the 5th\u000a      millennium BC. J. Dunne, R.\u000a        P. Evershed, M.\u000a        Salque,\u000a      L.\u000a        Cramp, S.\u000a        Bruni, K.\u000a        Ryan, S.\u000a        Biagetti and S.\u000a        di Lernia.\u000a       Nature 2012, 486, 390-394. DOI: 10.1038\/nature 11186.\u000a    \u000a\u000a(5) Earliest evidence for cheese making in the sixth millennium bc\u000a      in northern Europe M.\u000a        Salque,\u000a      P.\u000a        I. Bogucki, J.\u000a        Pyzel, I.\u000a        Sobkowiak-Tabaka, R. Grygiel, M.\u000a        Szmyt and R.\u000a        P. Evershed,\u000a      Nature, 2013, 493, 522-525. DOI:10.1038\/nature11698.\u000a    \u000a\u000a(6) Identification of a disinterred grave by molecular and stable\u000a      isotope analysis, I. D. Bull, R.\u000a      Berstan, A. Vaas and R. P. Evershed, Science &amp; Justice, 2009,\u000a      49, 142-149, DOI:\u000a      10.1016\/j.scijus.2009.01.016.*\u000a    \u000aGrants\u000a    &#8226; Analysis of organic residues in Iron Age\/Roman pottery from Stanwick\u000a      (RAP). (PI) English\u000a      Heritage 1993-1995. &#163;19k.\u000a    &#8226; Experimental approaches to the study of organic residues in\u000a      archaeological ceramics. (PI)\u000a      SERC 1992-1995. &#163;71k.\u000a    &#8226; Detecting vegetable oil adulteration using irm-GC\/MS. (PI)\u000a      Leatherhead Food Research\u000a      Association 1994-1997. &#163;30k.\u000a    &#8226; New criteria for the identification of animal fats from prehistoric\u000a      pottery. (PI) NERC 1995-\u000a      1998. &#163;123k.\u000a    &#8226; Was dairying an important element of animal husbandry in prehistoric\u000a      Britain? (PI with\u000a      Straker and Payne) NERC\/English Heritage. 1998-2001. &#163;207k.\u000a    &#8226; The emergence of dairying in early farming practices of the Fertile\u000a      Crescent (PI with\u000a      Sherratt and Payne) Leverhulme Trust. 2002-2005. &#163;161k.\u000a    &#8226; Horse specialisation and pastoralism in the prehistoric Eurasian Steppe\u000a      [co-PI with\u000a      Outram(Exeter)] NERC 2005-2009. &#163;256k.\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"1","Subject":"Analytical Chemistry"},{"Level1":"4","Level2":"2","Subject":"Geochemistry"}],"Sources":"\u000a    (a) Example of educational outreach impact arising from Evershed\u000a      and his team's\u000a      archaeological chemistry research embedded in the School of Chemistry's\u000a      ChemLabs\u000a      wider outreach activity coordinated by Tim Harrison, Bristol ChemLabS\u000a      School Teacher\u000a      Fellow.\u000a    (b) Email letter from Barry Stone, Senior Editor, Education\u000a      Division, Oxford University Press\u000a      confirming the widespread use of the TWENTY FIRST CENTURY SCIENCE textbook\u000a      by\u000a      GCSE students.\u000a    (c) Dated pdf of webpage screen shot including link (http:\/\/www.hhmi.org\/biointeractive\/making-fittest-got-lactase-co-evolution-genes-and-culture)\u000a      to an educational film produced\u000a      by John Rubin for the Howard Hughes Medical Institute (HHMI) that arose\u000a      directly from the\u000a      research and features Evershed and colleagues discussing the relationship\u000a      between his\u000a      archaeological chemistry findings the evolution of lactase persistence.\u000a    (d) Pdfs of 2 educational articles in Catalyst arising\u000a      from research generated through outreach\u000a      and engagement activities.\u000a    (e) Examples of public engagement activity arising from Evershed\u000a      and his team's\u000a      archaeological chemistry research, and the web link to the Palaeodetective\u000a      educational\u000a      game played by thousands of visitors to exhibitions and festivals attended\u000a      by his team and\u000a      now available on-line.\u000a    (f) Pdf of leaflet distributed during 2009 Royal Society Summer\u000a      Science Exhibition showing the\u000a      central role played by archaeological chemistry research in this event.\u000a    (g) Pdf of link to blog in The Independent arising from\u000a      2013 Soapbox Science event\u000a      highlighting the importance of women in science.\u000a    (h) CODEX Standard for Named Vegetable Oils (CODEX-STAN 210-1999).\u000a      Only three peer\u000a      reviewed journal papers are cited (page 11) in the CODEX and all are the\u000a      work of\u000a      Evershed's group in collaboration with LHFRA on the authentication of\u000a      vegetable oils using\u000a      fatty acids in conjunction with stable carbon isotope analyses. Copy of\u000a      report to LHFRA\u000a      RESEARCH REPORT No. 755 by Evershed's PhD student Woodbury is available on\u000a      request.\u000a    (i) Pdf of letter from DCI Ephgrave, The Metropolitan Police,\u000a      London, confirming our role in\u000a      providing evidence to secure the murder conviction; they are also cited on\u000a      page 143 of Bull\u000a      et al. (2009).\u000a    ","Title":"\u000a    CH6: Molecular and Isotope `Fingerprinting' to Enhance Food Quality\u000a        Assurance, Forensic\u000a        Approaches and Wider Public Interest in Chemistry through Archaeology\u000a    ","UKLocation":[{"GeoNamesId":"2644726","Name":"Leatherhead"},{"GeoNamesId":"2656046","Name":"Bedford"},{"GeoNamesId":"2654675","Name":"Bristol"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Evershed joined the School of Chemistry as Lecturer in 1993, was\u000a      promoted to a personal Chair\u000a      of Biogeochemistry in 2000, and elected Fellow of the Royal Society in\u000a      2010. He is one of the\u000a      pioneers of the use of cutting-edge chromatographic and mass spectrometric\u000a      approaches for\u000a      interrogation, at the molecular level, of organic residues\u000a      preserved in archaeological materials. His\u000a      group's discoveries have provided unequivocal evidence for the widespread\u000a      occurrence of\u000a      biomolecules of both original and modified structures in a variety of\u000a      amorphous organic\u000a      archaeological deposits, human, plant and animal remains, sediments and\u000a      artefacts. Critically, his\u000a      team were the first to recognise in the 1990s the hitherto untapped\u000a      potential of the compound-\u000a      specific stable carbon isotope ratio technique to archaeological science.\u000a      These approaches have\u000a      been widely adopted by not only archaeologists but researchers in a wide\u000a      variety of other fields.\u000a      Notably, Evershed and a PhD student (Woodbury) working with\u000a      the food industry (primarily\u000a      Rossell, Leatherhead Food Research Association, LFRA) provided one of the\u000a      first examples of the\u000a      use of these methodologies to detect food fraud; most importantly they\u000a      developed and applied a\u000a      highly robust method (e.g. (3) and references therein) which has\u000a      been adopted as the standard\u000a      method (INTERNATIONAL CODEX) for detecting commercial vegetable oil\u000a      adulteration to the\u000a      present day. Recognising the wider utility of their approach, and when\u000a      called upon, they applied\u000a      the technique (with Bull and Berstan, Bristol) with the\u000a      Metropolitan Police to secure a murder\u000a      conviction (6).\u000a    The Bristol group led by Evershed has continued to develop the\u000a      archaeological applications of\u000a      these techniques very extensively, to show how molecular and isotopic\u000a      information contained in\u000a      such residues can answer fundamental questions concerning early\u000a      agriculture and ancient diet,\u000a      specifically concerning man's relationships with the domesticated animals.\u000a      The following high\u000a      profile studies underpin the impact of this research. A landmark paper\u000a      appeared in Science in 1998\u000a      (1) and led to a series of papers culminating in a report in Nature\u000a      (2) of the earliest chemically-based direct proof of milk use, from the oldest pottery in Europe\u000a      and the Near East, dating to\u000a      nearly 9,000 years ago. This had major ramifications for our understanding\u000a      of the production and\u000a      processing of this key staple by early pastoralists, who overcame the\u000a      health impacts of lactose\u000a      intolerance by processing milk to resduce the lactose content of the dairy\u000a      products they consumed.\u000a      This is further emphasised in two recent high profile papers in Nature\u000a      which demonstrated the first\u000a      evidence for dairying in Saharan Africa (4)&#8224; and for\u000a      cheese-making in northern Europe (5)&#8224;, both\u000a      around 7,500 years ago. These studies are exemplars of the chemical and\u000a      stable isotope\u000a      `fingerprinting' concept which links environmental and metabolic isotope\u000a      signals to specific lipid\u000a      structures, and underpins the wider application of these approaches in the\u000a      food quality assurance\u000a      and forensic fields. These far reaching applications have stimulated\u000a      worldwide public and\u000a      academic interest and provide the basis for the diverse impacts listed in\u000a      Section 4.\u000a    &#8224;These two articles have been viewed nearly 30,000 times on the journal\u000a      website since their publication\u000a    "},{"CaseStudyId":"40244","Continent":[],"Country":[],"Funders":["Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000a    There are three sites of impact:\u000a    AstraZeneca\u000a    This company can now identify ligands for transition metal catalysis\u000a      (mostly with Pd, Rh, Ru and Ir) more efficiently. The Ligand Knowledge\u000a      Base principal component analysis feeds into a Design of Experiment\u000a      programme that defines the `chemical space' within which ligands will be\u000a      tested and how most efficiently to explore this space. This could not be\u000a      done well previously because there were no 'coordinates' for the ligand\u000a      space (unlike, for example, the parameterisations available for solvents).\u000a      AstraZeneca estimated at the end of Phase 2, that this advance has already\u000a      led to about &#163;250k cost saving and it anticipates on-going savings will be\u000a      in the region of millions of pounds, through faster development of\u000a      scale-up processes with reduced development time and costs and ultimately\u000a      a reduction in manufacturing costs with the potential to reduce the\u000a      environmental impact of their processes.\u000a    The impact of these developments were recognised in the form of an\u000a      AstraZeneca Science &amp; Technical Award (to Murray and Osborne) in\u000a      October 2010. The award nomination read \"The design and application of\u000a        high quality ligand descriptors in this way is a scientific breakthrough\u000a        and leading academics refer to this innovation as `revolutionary'. This\u000a        capability is now in routine operation and supporting Discovery in\u000a        gaining access to high value areas of chemical space\". Murray,\u000a      quoted in an internal AstraZeneca document announcing the award, suggested\u000a      that savings derived from the breakthrough are \"estimated at around\u000a        $200k per project to produce 60 kilos of drug substance for a clinical\u000a        trial. This saving would rise with a market launch to $2.5m for 600\u000a        kilos or $25m for six tonnes\", (a).\u000a    CatSci Ltd\u000a    this company, which predominantly arose from activities conducted in the\u000a      labs of Murray at AZ under the auspices of the Ligand Knowledge Base\u000a      programme, has a mission \"To establish new and improved chemical\u000a        reactions and processes through a world-leading understanding and\u000a        application of transition metal catalysis\". A major component in the\u000a      portfolio of services offered by CatSci is \"Optimisation of processes\u000a        through predictive catalysis: Identification and development of\u000a        an optimised catalytic process and for the interrogation of reaction\u000a        space in line with Quality by Design principles delivered through\u000a        exploiting unique predictive catalysis techniques\". These techniques\u000a      derive directly from Phases 1 and 2 of the collaboration, and solely use\u000a      the Ligand Knowledge Base descriptors and principal component\u000a      analysis-derived ligand maps developed at Bristol. Initial investment in\u000a      facilities has been &#163;0.52m in equipment and 5 staff, with &#163;1.2m of\u000a      business already secured. Further investment by the Welsh Government has\u000a      been made in a CatSci-University of Bristol collaborative project to\u000a      develop an improved ligand screening protocol for homogeneous catalysis,\u000a      integrating fully the computational evaluation of catalyst properties with\u000a      CatSci's high-throughput automated catalyst screening and analysis\u000a      facilities. Focusing on the need to ensure 'manufacturability' in the\u000a      chemical industries, this two-year project aims to deliver efficient,\u000a      stable and selective catalysts that are economically viable for process\u000a      scale-up and discovery (b).\u000a    Phosphonics Ltd\u000a    Concepts arising during the initial phases of the research led to the\u000a      design of unique `catalyst capture\/release' technology. This concept is\u000a      now being studied in the School of Chemistry and made ready for the market\u000a      by Phosphonics via a collaboration supported by the TSB\/EPSRC through the\u000a      Technology Strategy Board \"Sustainable Manufacturing for the Process\u000a        Industry\" programme. This &#163;700k project (\"Recyclable Catalyst\u000a        Technology for Cross-Coupling Reactions at Manufacturing Scale\")\u000a      draws together Phosphonics, CatSci, Syngenta, AstraZeneca, Albany\u000a      Molecular Research and the University of Bristol, to explore and design\u000a      novel functionalised silica materials that allow purification of reaction\u000a      products by temporary capture of the Pd catalyst in heterogeneous form,\u000a      capable of triggered release back in an active form into solution. The\u000a      technology will be employed in semi-continuous format, with application\u000a      possible across multiple process industries. Initial applications towards\u000a      the manufacture of pharmaceuticals &amp; agrochemicals will be a\u000a      demonstrable output during 2013-2015 (c).\u000a    ","ImpactSummary":"\u000a    The selection of ligand(s) for the transition metal complexes that are\u000a      frequently employed as catalysts for the production of fine chemicals is a\u000a      key activity ultimately governing the financial viability of the process.\u000a      Traditionally, the method for discovery of ligands with the appropriate\u000a      balance of cost and efficiency has been achieved empirically via\u000a      screening. This Impact Case Study reports on the development of a novel\u000a      methodology for the qualitative and quantitative analysis and prediction\u000a      of the effect of ligand structure on the catalytic activity of\u000a      late-transition metals. It has been applied in process and discovery\u000a      chemistry in pharmaceutical and agrochemical industries in the UK (and\u000a      beyond). The analysis allows rapid, and therefore cost efficient,\u000a      identification of ligands and catalysts with the potential to bypass\u000a      intellectual property issues.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Bristol\u000a    ","Institutions":[{"AlternativeName":"Bristol (University of)","InstitutionName":"University of Bristol","PeerGroup":"A","Region":"South West","UKPRN":10007786}],"Panel":"B         ","PlaceName":[],"References":"\u000a    \u000a(1) Development of a ligand knowledge base, Part 1: Computational\u000a      descriptors for phosphorus donor ligands, N. Fey, A. Tsipis, J. N. Harvey,\u000a      A. G. Orpen, and R. A. Mansson, Chem. Eur. J. 2006, 12,\u000a      291-302, DOI: 10.1002\/chem.200500891.\u000a    \u000a\u000a(2) Computational Descriptors for Chelating P,P- and P,N-Donor\u000a      Ligands, N. Fey, J. N. Harvey, G. C. Lloyd-Jones, P. l. Murray, A. G.\u000a      Orpen, R. Osborne and M. Purdie, Organometallics 2008, 27,\u000a      1372-1383, DOI: 10.1021\/om700840h.*\u000a    \u000a\u000a(3) Counterintuitive Kinetics in Tsuji-Trost Allylation: Ion-pair\u000a      Partitioning and Implications for Asymmetric Catalysis, L. A.\u000a      Evans, N. Fey, J. N Harvey, D. Hose, G. C. Lloyd-Jones, P. Murray, A G.\u000a      Orpen, R. Osborn, G. J. J. Owen-Smith, and M. Purdie, J.\u000a        Am. Chem. Soc., 2008, 130, 14471-14473, DOI:\u000a      10.1021\/ja806278e.\u000a    \u000a\u000a(4) The Newman-Kwart Rearrangement of O-aryl thiocarbamates:\u000a      Substantial Reduction in Reaction Temperatures via Pd Catalysis, J. N.\u000a      Harvey, J. Jover, G. C. Lloyd-Jones, J. D. Moseley, P. Murray and J. S.\u000a      Renny, Angew. Chem., Int. Ed., 2009, 48, 7612-7615, DOI:\u000a      10.1002\/anie.200903908.\u000a    \u000a\u000a(5) Expansion of the Ligand Knowledge Base for Monodentate P-Donor\u000a      Ligands, J. Jover, N. Fey, J. N. Harvey, G. C. Lloyd-Jones, A. G. Orpen,\u000a      G. J. J. Owen-Smith, P. M. Murray, D. R. J. Hose, R. Osborne, and M.\u000a      Purdie, Organometallics, 2010, 29, 6245-6258, DOI:\u000a      10.1021\/om100648v.*\u000a    \u000a\u000a(6) Expansion of the Ligand Knowledge Base for Chelating P,P-Donor\u000a      Ligands (LKB-PP), J. Jover, N. Fey, J. N. Harvey, G. C. Lloyd-Jones, A. G.\u000a      Orpen, G J. J. Owen-Smith, P. Murray, D. R. J. Hose, R. Osborne, and M.\u000a      Purdie, Organometallics, 2012, 31, 5302-5306, DOI:\u000a      10.1021\/om300312t.*\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"3","Level2":"1","Subject":"Analytical Chemistry"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"3","Subject":"Macromolecular and Materials Chemistry"}],"Sources":"\u000a    (a) For AstraZeneca, Dr Mark Purdie, AstraZeneca Macclesfield.\u000a      Project manager for the collaboration into predictive catalysis with\u000a      Bristol (Phases 1 and 2) and Christina Fr&#246;jd, publication of internal (AZ)\u000a      document online regarding AZ Science and Technical Award, October 25th\u000a      2010.\u000a    (b) For CatSci, Dr Jonathan Moseley, Research Director of CatSci\u000a      Ltd. (Phases 1, 2 and 3).\u000a    (c) For Phosphonics, Dr Robin Wilkes, Business Director,\u000a      Pharmaceuticals &amp; Fine Chemicals, Phosphonics Limited.\u000a    ","Title":"\u000a    CH7: Design and Application of a Tool for the Qualitative and\u000a        Quantitative Analysis and Prediction of the Effect of Ligand Structure\u000a        on the Catalytic Activity of Metal Complexes\u000a    ","UKLocation":[{"GeoNamesId":"2654675","Name":"Bristol"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    \u000a      The underpinning research was carried out in the period 2003 to 2013.\u000a      Key Researchers were Lloyd-Jones, Orpen, Harvey,\u000a        Fey, Paul Murray (AstraZeneca and CatSci Ltd) and Bob Osborne\u000a        (AstraZeneca catalyst discovery).\u000a    \u000a    The impact followed on from pure research in the instigation and development\u000a    of a `Ligand Knowledge Base' by Orpen, Fey and Harvey\u000a    (1). The Ligand Knowledge Base aims to capture the properties of\u000a    donor ligands coordinating to transition metal centres by way of a\u000a    collection of up to 29 descriptors. The descriptors evaluated and used are\u000a    computationally-derived from a range of coordination environments in order\u000a    to maximise their transferability and hence utility for the investigation of\u000a    the ligands. These descriptors are analysed using different statistical\u000a    approaches, both individually to determine their chemical context, and\u000a    collectively by principal component analysis thereby allowing the derivation\u000a    of maps of `ligand space' for different ligand sets.\u000a    Lloyd-Jones acted as a consultant to AstraZeneca Process Research\u000a      and Development during 2003-2010. Through discussion with Process Research\u000a      and Development scientists at the AstraZeneca Avlon and Charnwood sites,\u000a      it became evident that catalyst discovery and optimisation for medicinal\u000a      chemistry projects and scale-up, predominantly involving Pd-based systems,\u000a      was heavily dependent on, or influenced by, statistical or anecdotal\u000a      approaches. It was proposed that with funding from AstraZeneca, the Ligand\u000a      Knowledge Base could: (i) be substantially increased in ligand class,\u000a      ligand space, and ligand population density and (ii) be applied to model\u000a      systems for the types of Pd-coupling process that were of interest to\u000a      AstraZeneca so that the feasibility of qualitative and quantitative\u000a      analysis and prediction of the effect of ligand structure on the catalytic\u000a      activity could be explored. Between 2006 and 2010 AstraZeneca provided\u000a      &#163;763k to fund this research in the laboratories of Lloyd-Jones and\u000a      Orpen, Harvey and Fey at Bristol (2). In\u000a      parallel, AstraZeneca invested &#163;1m in the provision of a semi-automated\u000a      catalyst testing facility at Avlon to service catalytic reactions in\u000a      projects within the company that were proving unreliable or low-yielding\u000a      for drug discovery or for scale-up for clinical trials.\u000a    A successful proof of concept emerged from the Bristol-based four-year\u000a      fully-funded \"Phase 1\" study (2006-2010) in terms of: (i) approximate\u000a      prediction of relative activity for various ligands in a model allylation\u000a      reaction (3), and (ii) successful application of the Ligand\u000a      Knowledge Base-based ligand map (4) to a number of active projects\u000a      within AstraZeneca, leading to vastly improved ligand choice for a\u000a      scale-up process (see Section 5, Source 1).\u000a    A second phase (\"Phase 2\", 2010-2012) of underpinning research was\u000a      supported by a Knowledge Transfer Partnership grant of &#163;116k that allowed\u000a      the laboratory-based postdoc (Gareth Owen-Smith) from Phase 1, to develop\u000a      the application of the Ligand Knowledge Base for amination reactions at\u000a      AstraZeneca, by working full-time at Avlon in their semi-automated\u000a      catalyst testing facility. This led to a number of improvements in the way\u000a      in which data were collected for qualitative and quantitative analysis of\u000a      ligand effects in rate (5); it also allowed the Ligand Knowledge\u000a      Base-analysis methodology to be disseminated to all of the other chemistry\u000a      sites at AstraZeneca in the UK and Sweden.\u000a    During the period of the Knowledge Transfer Partnership grant, and based\u000a      on the extensive experience in catalyst development generated by\u000a      collaboration with the Bristol based team during Phases 1 and 2 (6),\u000a      Murray established \"CatSci\" in May 2011 (see section 5, Source 2). This\u000a      spin-out from AstraZeneca was established as a start-up company based in\u000a      Cardiff which has led to a third phase (\"Phase 3\", 2012-2014) of\u000a      underpinning research being supported (&#163;175k) by a Welsh Government\u000a      \"Research, Development and Innovation Grant\" in collaboration with CatSci\u000a      to support Fey in a project to link calculated catalyst property\u000a      descriptors with optimally designed catalyst screening data, and thus to\u000a      develop novel catalysts. This project is allowing CatSci to more\u000a      effectively apply its expertise in the development and optimisation of\u000a      transition-metal catalysed reactions, and thus assist in the efficient\u000a      evolution of this industrial spin-out activity.\u000a    "},{"CaseStudyId":"41642","Continent":[],"Country":[],"Funders":["Natural Environment Research Council"],"ImpactDetails":"\u000a    Impact on the EU regulation of endocrine-disrupting chemicals    \u000a    The contamination of water sources is a serious threat to the environment\u000a      and to human health.\u000a      Our finding that fish can accumulate &#339;strogenic and anti-androgenic\u000a      contaminants that can\u000a      impact on their fertility and health, and that many of these compounds\u000a      persist in the\u000a      environment, has been cited in a European Environment Agency Technical\u000a      report [see Section\u000a      5, C1, which cites Hill's publications R2, R3 and R5 above]. This EEA\u000a      report has provided\u000a      evidence that has underpinned EU policy on endocrine-disrupting chemicals\u000a      and their regulation\u000a      &#8212; specifically the proposal by the European Commission to regulate levels\u000a      of &#339;strogens in\u000a      surface waters under recent revisions to the Water Framework Directive\u000a      (2000\/60\/EC) [C2].\u000a      Some of our work cited in the report was presented in informal meetings\u000a      with the UK\u000a      Environment Agency.\u000a    A further report by the Institute of Environment and Sustainability, of\u000a      the Joint Research Centre\u000a      of the European Commission, cited work by Hill's group on the\u000a      identification of anti-androgenic\u000a      structures in wastewater effluents (see C3 which cites Hill's publication\u000a      R4 listed above). The\u000a      report collated information on chemical analytical methods for the new\u000a      proposed Priority\u000a      Substances under revisions of the European Water Framework Directive\u000a      legislation [C2].\u000a    Impact on the development of in vivo fish-screening\u000a          assays by the EU\u000a    Hill's identification of anti-androgenic contaminants in UK effluent has\u000a      also been cited by the\u000a      Environment Directorate Chemicals Committee as evidence for the need for in\u000a        vivo fish-screening\u000a      assays which, as a consequence, have now been developed by the EU [C4,\u000a      which\u000a      cites Hill's publication R3].\u000a     Impact on the regulation of Nonylphenol in California\u000a    Finally, our work on the toxicokinetics of the endocrine-disrupting\u000a      chemical, nonylphenol, in fish\u000a      has informed the risk assessment of this compound, which has influenced\u000a      state policy and\u000a      regulation in California [see C5 which cites Hill's publication R1].\u000a    The beneficiaries of this impact are thus governmental organisations\u000a      responsible for\u000a      environmental policy, the environment and human health and, through them,\u000a      populations living\u000a      under their regulations.\u000a    ","ImpactSummary":"\u000a    The contamination of water sources is a serious threat to the environment\u000a      and to human health.\u000a      Endocrine-disrupting chemicals (EDCs) cause sexual dysfunction in fish,\u000a      potentially affecting the\u000a      health of fish populations in the UK and abroad. Prof. Hill's research has\u000a      used bioassays combined\u000a      with chemical fractionation and mass-spectrometry profiling techniques to\u000a      identify endocrine-disrupting\u000a      chemicals present in wastewater effluents that are discharged into the\u000a      environment and\u000a      that can bio-accumulate in fish. This has enabled international and\u000a      governmental organisations to\u000a      assess the risk of chemical discharges to the environment, to develop\u000a      tests to monitor the toxicity\u000a      of these newly-discovered EDCs, and to inform policy decisions on\u000a      environmental protection and\u000a      conservation.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Sussex\u000a    ","Institutions":[{"AlternativeName":"Sussex (University of)","InstitutionName":"University of Sussex","PeerGroup":"B","Region":"South East","UKPRN":10007806}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"5332921","Name":"California"}],"References":"\u000a    \u000aR1 Smith, M.D. and Hill, E.M. (2004) `Uptake and metabolism of\u000a      technical nonylphenol and its\u000a      brominated analogues in the roach (Rutilus rutilus)', Aquatic\u000a        Toxicology, 69(4): 359&#8212;70.\u000a    \u000a\u000aR2 Gibson, R., Smith, M.D., Spary, C.J., Tyler, C.R. and Hill,\u000a      E.M. (2005) `Mixtures of estrogenic\u000a      contaminants in bile of fish exposed to sewage treatment effluents', Environmental\u000a        Science\u000a        and Technology, 39(8): 2461&#8212;71.\u000a    \u000a\u000aR3 Hill, E.M., Evans, K.L., Horwood, J., Rostkowski, P., Oladapo,\u000a      F.O., Gibson, R., Shears, J.A.\u000a      and Tyler, C.R. (2010) `Profiles and some initial identifications of\u000a      (anti)androgenic\u000a      compounds in fish exposed to wastewater treatment works effluents', Environmental\u000a        Science\u000a        and Technology, 44(3): 1137&#8212;43.\u000a    \u000a\u000aR4 Rostkowski, P.; Horwood, J.; Shears, J. A.; Lange, A.; Oladapo,\u000a      F. O.; Besselink, H. T.;\u000a      Tyler, C. R.; Hill, E. M. (2011) `Bioassay-Directed Identification of\u000a      Novel Antiandrogenic\u000a      Compounds in Bile of Fish Exposed to Wastewater Effluents'. Environmental\u000a      Science and\u000a      Technology. 45, (24), 10660-10667.\u000a    \u000a\u000aR5 Peck, M., Gibson, R.W., Kortenkamp, A. and Hill, E.M. (2004)\u000a      `Sediments are major sinks of\u000a      steroidal estrogens in two United Kingdom rivers', Environmental\u000a        Toxicology and Chemistry,\u000a      23(4): 945-52.\u000a    \u000aOutputs R1, R2 and R3 best indicate the quality of the underpinning\u000a      research.\u000a    Outputs can be supplied by the University on request.\u000a    Relevant grants\u000a    &#8226; February 2008&#8212;February 2010: NERC, &#163;296,727.\u000a      The Significance of Antiandrogens in Disrupting Sexual Function in Wild\u000a        Fish in UK Rivers.\u000a    &#8226; February 2009&#8212;July 2013: EU Interreg, &#163;619,159.\u000a      DIESE: Determination of Pertinent Indicators for Environmental\u000a        Monitoring: A Strategy for\u000a        Europe.\u000a    &#8226; June 2005&#8212;June 2008: Environment Agency, &#163;35,163.\u000a      Analyses of Fish Bile Samples.\u000a    &#8226; October 2007&#8212;March 2009: Environment Agency, &#163;6,000.\u000a      Analysis of Archived Fish Samples &#8212; A Scoping Study.\u000a    ","ResearchSubjectAreas":[{"Level1":"5","Level2":"2","Subject":"Environmental Science and Management"},{"Level1":"3","Level2":"1","Subject":"Analytical Chemistry"},{"Level1":"6","Level2":"2","Subject":"Ecology"}],"Sources":"\u000a    C1 The Impacts of Endocrine Disrupters on Wildlife, People and\u000a        their Environments: The\u000a        Weybridge+15 (1996-2011) Report. European Environment Agency\u000a      Technical Report No.\u000a      2\/2012, ISSN 1725-2237, 10 May 2012.\u000a    C2 Proposal for a Directive of the European Parliament and of the\u000a      Council amending Water\u000a      Framework Directives 2000\/60\/EC and 2008\/105\/EC as regards priority\u000a      substances in the\u000a      field of water policy. Brussels, 31 January 2012. COM(2011) 876 final\u000a      2011\/0429 (COD).\u000a    C3 Analytical Methods for the new proposed Priority Substances of\u000a      the European Water\u000a      Framework Directive (WFD). Revision of the Priority Substance List (2012).\u000a      JRC Technical\u000a      Report. Ed. Robert Loos. European Commission &#8212; DG Joint Research Centre,\u000a      Institute for\u000a      Environment and Sustainability &#169; European Union, 2012.\u000a    C4 Peer Review Report of the Validation of the 21-Day\u000a        Androgenised Female Stickleback\u000a        Screening Assay. Series of Testing and Assessment, No 127.\u000a      Environment Directorate\u000a      Chemicals Committee and Working Party on Chemicals, Pesticides and\u000a      Biotechnology.\u000a      ENV\/JM\/MONO (2010)18. Revised August 2011.\u000a    C5 Toxicological Profile for Nonylphenol. Integrated Risk\u000a      Assessment Branch, Office of\u000a      Environmental Health Hazard Assessment, California Environmental\u000a      Protection Agency.\u000a      September 2009.\u000a    ","Title":"\u000a    Detecting sex-changing chemicals in the environment\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Prof. Hill's work was the first to discover that endocrine-disrupting\u000a      chemicals can bio-concentrate in\u000a      the bile of fish many thousand-fold, allowing the identification and\u000a      bio-monitoring of trace amounts\u000a      of contaminants in surface waters [see Section 3, R1]. This has enabled\u000a      the identification of\u000a      hormone replacement chemicals as environmental oestrogens [R2].\u000a    Prof. Hill's group has also used bioassay-directed fractionation and\u000a      mass-spectrometry analytical\u000a      techniques to identify the structures of novel anti-androgenic\u000a      contaminants present in wastewater\u000a      effluents [R3, R4]. These contaminants, such as triclosan and\u000a      chlorophenes, are present in\u000a      household disinfectant agents and have not previously been recognised to\u000a      contain anti-androgen\u000a      activity.\u000a    In additional work, the use of bioassay-directed fractionation and\u000a      identification techniques has led\u000a      to the discovery of environmental oestrogens accumulating in river\u000a      sediments at sites below\u000a      wastewater discharges, raising concerns over the persistence in the\u000a      environment and impacts on\u000a      organisms in the water system [R5].\u000a    This research on the identification of new contaminants with\u000a      endocrine-disrupting activity has\u000a      raised concerns that aquatic animals are exposed to complex mixtures of\u000a      chemicals that target\u000a      their reproductive health and fertility. This work has been supported in\u000a      the UK by the Environment\u000a      Agency and government research councils (NERC), and in Europe under the EU\u000a      Interreg\u000a      programme.\u000a    Professor E.M. Hill held the positions of Senior Lecturer, Reader and,\u000a      laterly, Professor at the\u000a      University of Sussex, during the period of this work, and &#8212; as group\u000a      leader &#8212; initiated and\u000a      supervised this work, heading a team of postdoctoral researchers (Peck,\u000a      Gibson and Rostkowski),\u000a      PhD students (Evans, Smith and Oladapo) and a technician (Horwood).\u000a    "},{"CaseStudyId":"41643","Continent":[{"GeoNamesId":"6255150","Name":"South America"},{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"3895114","Name":"Chile"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"3865483","Name":"Argentina"}],"Funders":["Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000a    As part of the EPSRC CASE award and the current TSB-funded second stage\u000a      of the PpTek-Sussex\u000a      collaboration, close examination of the current technology and processes\u000a      that are\u000a      deployed in the UK biogas market by PpTek (which currently has an 80 per\u000a      cent market share)\u000a      was undertaken. In 2008, PpTek's technology was adequate to remove\u000a      siloxanes from the\u000a      relatively consistent composition of biogas emitted from landfills. As a\u000a      result of Sussex research, a\u000a      new process has been developed which allows expansion of PpTek's\u000a      commercial activity to biogas\u000a      sources with more chemically difficult and variable gas compositions\u000a      emitted from an&#230;robic\u000a      digesters and sewage treatment works. Previously, application of this\u000a      technology in these chemical\u000a      conditions was problematic and, in some cases, required the replacement of\u000a      parts under a\u000a      contractual obligation.\u000a    There are a number of beneficial outcomes from the Sussex research work\u000a      that has been brought\u000a      to market through PpTek. One beneficial impact is that 81 additional\u000a      biogas installations have been\u000a      deployed on sites that generate on average 2-3 MW of green energy per year\u000a      each, enabling the\u000a      UK to better meet its target under the Climate Change Act of 2009 [see\u000a      Section 5, C1].\u000a    There are also economic benefits in a number of areas, such as growth in\u000a      turnover, increased\u000a      graduate-level employment with accompanying HMRC returns, reduction in the\u000a      balance sheet\u000a      provision PpTek has to make for replacement parts, increased income from\u000a      servicing and\u000a      expansion of the client base overseas.\u000a    In 2008, the turnover of PpTek was &#163;910,000. In 2013\/14, turnover will\u000a      rise to &#163;3M &#8212; an increase of\u000a      233 per cent. The company has grown from 3 employees to 15, all of whom\u000a      are employed as\u000a      engineers working on product development or electronic\/process\u000a      engineering. This expansion in\u000a      staff numbers at the company has had a substantial effect on the benefits\u000a      to HMRC [TEXT REMOVED FOR PUBLICATION]\u000a    According to the Technical Director [C1], the changes that have effected\u000a      this increase have\u000a      depended critically on the research and analysis conducted by Sussex and\u000a      would not have been\u000a      possible in its absence. Following analysis of biogas at Sussex, the\u000a      company has been able to\u000a      successfully deploy its technology into some highly contaminated landfill\u000a      sites by filtering some\u000a      components from the gas before the siloxanes removal system, thus avoiding\u000a      media failure before\u000a      end-of-life expectancy. In 2008, PpTek was required to make financial\u000a      provision for the failure or\u000a      recall of part of their systems [TEXT REMOVED FOR PUBLICATION] for the five UK\u000a      installations. By 2012,\u000a      provision by PpTek had fallen to [TEXT REMOVED FOR PUBLICATION] for 11 units installed.\u000a    This fall in the provision is due to the analysis at Sussex and in\u000a      particular the complex analysis of\u000a      the compounds blinding the media from the incoming biogas. The resulting\u000a      changes in processes\u000a      and equipment design by PpTek has enabled them to argue scientifically the\u000a      case that the cause\u000a      of failure was the species contained in the biogas stream and not the\u000a      failure of the media. In\u000a      product design, PpTek have been able to reduce the amount of media used in\u000a      each system, giving\u000a      savings in its large systems [TEXT REMOVED FOR PUBLICATION].\u000a    Similar improvements have taken place in the income derived from\u000a      servicing installations:\u000a      [TEXT REMOVED FOR PUBLICATION]. Without the ability to deploy on progressively more\u000a      chemically difficult\u000a      sites, these increases would not have materialised. As of June 2013, PpTek\u000a      purification systems\u000a      are now deployed in sites owned by CLP Envirogas (Bolton), Southern Water\u000a      (Worthing), Wessex\u000a      Water (Bath), Coxhoe Landfill (Durham), United Utilities (Manchester) and\u000a      Severn Trent Water\u000a      (Nottingham), amongst others.\u000a    The collaborative research between PpTek and Sussex formed the technical\u000a      core of negotiations\u000a      with [TEXT REMOVED FOR PUBLICATION] in 2012-13, the result of which was the award of contracts\u000a      to PpTek with a\u000a      value in excess of &#163;1M during 2012-13, where four systems were sold\u000a      [TEXT REMOVED FOR PUBLICATION]\u000a      Chile, [TEXT REMOVED FOR PUBLICATION], and two systems to [TEXT REMOVED FOR PUBLICATION] in\u000a      Argentina\u000a      [TEXT REMOVED FOR PUBLICATION]. Importantly, these contracts are serviced in South\u000a      America and constitute\u000a      the first expansion of PpTek outside the UK and into South America.\u000a    ","ImpactSummary":"\u000a    The an&#230;robic production of gas from waste &#8212; or biogas &#8212; is an important\u000a      renewable energy source\u000a      and means to prevent the release of methane, which is a powerful\u000a      greenhouse gas. Exploitation of\u000a      biogas is hampered by traces of siloxanes and H2S, which damage\u000a      engines through the formation\u000a      of SiO2, SO2 and H2SO4 during\u000a      combustion. Research at Sussex in collaboration with PpTek Ltd\u000a      (engineers of purification technology) has expanded the scope of current\u000a      purification technology,\u000a      meaning that biogas systems can be installed in a range of new sites. This\u000a      has led to a strong\u000a      increase in the commercial activity of the company, with turnover\u000a      increasing from &#163;910,000 in 2008\u000a      to &#163;1.95m in 2012-13 and half year figures suggest turnover of at least\u000a      &#163;3m 2013-14 with &#163;4.3m\u000a      predicted for 2014-15.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Sussex\u000a    ","Institutions":[{"AlternativeName":"Sussex (University of)","InstitutionName":"University of Sussex","PeerGroup":"B","Region":"South East","UKPRN":10007806}],"Panel":"B         ","PlaceName":[],"References":"\u000a    \u000aR1 Bedi, J.S., Lester, D.W., Fang, Y.X., Turner, J.F.C., Zhou, J.,\u000a      Alfadul, S.M., Perry, C. and\u000a      Chen, Q. (2013) `Electrospinning of poly(methyl methacrylate) nanofibers\u000a      in a pump-free\u000a      process', Journal of Polymer Engineering, 33(5): 453-461.\u000a    \u000a\u000aR2 Al-Abdullah, Z.T.Y., Shin, Y., Kler, R., Perry, C., Zhou, W.\u000a      and Chen, Q. (2010) `The\u000a      influence of hydroxide on the initial stages of anodic growth of TiO2\u000a      nanotubular arrays',\u000a      Nanotechnology, 21(50): 505-601.\u000a    \u000a\u000aR3 Papageorgiou, C., Beglitis, N.S., Pang, C.L., Teobaldi, G.,\u000a      Cabailh, G., Chen,Q., Fisher, A.J.,\u000a      Hofer, W.A. and Thornton, G. (2010) `Electron traps and their effect on\u000a      the surface chemistry\u000a      of TiO2(110)', Proceedings of the National Academy of\u000a        Sciences of the United States of\u000a        America, 107(6): 2391-6.\u000a    \u000a\u000aR4 Shahzad, N. and Chen, Q. (2013) `Nanofibers: a simple and\u000a      practical way forward for air\u000a      pollution abatement', Materials Science Forum, 756(): 225-30.\u000a    \u000aOutputs R2 and R3 best indicate the quality of the underpinning research.\u000a    Outputs can be supplied by the University on request.\u000a    Grants awarded\u000a    EPSRC CASE Award: Photocatalytic Oxidation of Volatile Organic\u000a        Compounds in Doped Zeolites\u000a      EPSRC Reference EP\/H501614\/1\u000a      October 2009-September 2014\u000a      Total award value: &#163;195,882\u000a    PpTek CASE Award (industry element): Photocatalytic Oxidation of\u000a        Volatile Organic Compounds in\u000a        Doped Zeolites\u000a      October 2009-March 2013\u000a      Total award value: &#163;21,765\u000a    TSB Award with PpTek: A Green Approach to Biogas Purification with\u000a        Nanomaterials\u000a      TSB reference 101255\u000a      1 October 2012-30 September 2015\u000a      Total award value: &#163;216,600\u000a    ","ResearchSubjectAreas":[{"Level1":"9","Level2":"7","Subject":"Environmental Engineering"},{"Level1":"9","Level2":"4","Subject":"Chemical Engineering"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"}],"Sources":"\u000a    C1 Technical Director, PpTek Ltd.\u000a    C2 Engineering Director, PpTek Ltd.\u000a    ","Title":"\u000a    Improvements to biogas extraction\u000a    ","UKLocation":[{"GeoNamesId":"2643123","Name":"Manchester"},{"GeoNamesId":"2655237","Name":"Worktown"},{"GeoNamesId":"2650628","Name":"Durham"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    The strong relationship between Chen and Turner at Sussex and PpTek Ltd\u000a      is based on research\u000a      to underpin the development and deployment of the photocatalytic\u000a      purification of biogas streams\u000a      for renewable energy generation. Collaborative research between PpTek and\u000a      Sussex has been\u000a      focused on deploying an optimised photocatalytic system as the successor\u000a      technology for PpTek's\u000a      current absorption process. Such an approach has many advantages, not\u000a      least in the energy\u000a      requirement for purification, which will be much lower than the current\u000a      thermal-regeneration\u000a      methods. The capture of solar energy by semiconductors, whereby\u000a      hole-electron pairs are\u000a      generated and can then be used, either as charge carriers for electricity\u000a      generation or directly\u000a      harnessed in chemical transformations, is well known. Optimisation of the\u000a      spectrum captured,\u000a      through a combination of the control of morphology at the nanoscale,\u000a      layering or doping, is an\u000a      attractive method of effecting the redox transformations of components of\u000a      gas streams. Moreover,\u000a      in an industrial setting where gas flows are of the order of 103\u000a      m3 hr-1 and where the duty cycle of a\u000a      catalytic bed is measured in days or months, the physical nature of the\u000a      catalyst is critically\u000a      important. Focusing on TiO2 as a base material for the\u000a      morphological manipulation of the band gap\u000a      and chemical doping, Turner and Chen have developed and optimised the\u000a      generation of physically\u000a      robust mats and beds of nanofibres [see Section 3, R1] that display strong\u000a      photocatalytic\u000a      properties. This applied and collaborative research is based on\u000a      more-fundamental studies of\u000a      nanostructured TiO2 [R2] and its photocatalytic properties\u000a      [R3,R4].\u000a    Initially funded by EPSRC through a CASE award to PpTek and Sussex, we\u000a      demonstrated the\u000a      oxidative power of TiO2 in the removal of volatile organic\u000a      compounds from a gas stream under\u000a      laboratory conditions. This EPSRC-funded work secured the basis for a\u000a      grant from the Technology\u000a      Strategy Board (TSB) for the production of a pilot-scale prototype that\u000a      will be capable of operating\u000a      under the conditions in the field and over a variety of different biogas\u000a      sources &#8212; including sewage\u000a      plants, digestors and landfill sites.\u000a    A key strand of both the EPSRC- and the TSB-funded research has been an\u000a      analysis of the\u000a      current processes of purification and regeneration, as the successor\u000a      technology under\u000a      development must be deployed with minimum disruption to the current\u000a      installations. The results of\u000a      this process of research and analysis have directly affected PpTek's\u000a      current practice and the\u000a      current IP under development has been a significant asset in adding value\u000a      to the company, leading\u000a      to acquisition talks with a major multinational that are currently\u000a      on-going.\u000a    "},{"CaseStudyId":"42242","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2658434","Name":"Switzerland"}],"Funders":["Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000d\u000a    Background\u000d\u000a    Argenta came into being when a team of two dozen highly experienced\u000d\u000a      scientists from the former Aventis Pharmaceuticals (formerly Rh&#244;ne-Poulenc\u000d\u000a      Rorer) Research Centre in Dagenham, led by Dr Christopher Newton set out\u000d\u000a      to raise money to become a pharmaceutical contract research organisation\u000d\u000a      (CRO). Argenta Discovery was formed through a merger with an\u000d\u000a      Imperial-founded spin-out company, ChemMedICa, in addition to the\u000d\u000a      scientific know-how generated and working relationships formed between\u000d\u000a      Imperial and Rh&#244;ne-Poulenc Rorer forged through the TeknoMed project.\u000d\u000a      Argenta Discovery was fully funded in 2000 with &#163;7.2m of private\u000d\u000a      investment. Aventis assisted the fledgling company by allowing the team to\u000d\u000a      use the Dagenham facility whilst the Argenta Harlow laboratories were\u000d\u000a      constructed, by awarding the first large research contract to Argenta, and\u000d\u000a      by allowing the purchase of all of the equipment at the closing Dagenham\u000d\u000a      site (http:\/\/www.imperial.ac.uk\/college.asp?P=2146).\u000a      Two Imperial scientists trained in the Barrett laboratories during the\u000d\u000a      TeknoMed Project, Drs. Jullian Henschke and Ray Boffey joined Argenta in\u000d\u000a      its early stages and, later, Drs. Fabien Roussel, Robert Pace, and Sarah\u000d\u000a      Major joined the company having gained PhD\/postdoctoral training in the\u000d\u000a      Barrett group. In 2007, Argenta signed the largest-ever pre-clinical deal\u000d\u000a      worldwide with AstraZeneca for the co-development of new therapeutic\u000d\u000a      agents for respiratory diseases. This collaboration with up-front and\u000d\u000a      milestone payments is potentially worth in excess of $500M plus royalties.\u000d\u000a    Scientific impact\u000d\u000a    The research carried out at Imperial College led to the highly favourable\u000d\u000a      environment in which ChemMedICa and, subsequently, Argenta came into\u000d\u000a      being, and has had wide impact in the chemical sciences. Taken together,\u000d\u000a      publications in learned journals have been cited 500 times, with 100 of\u000d\u000a      these citations during 2008-present.\u000d\u000a    Commercial impact\u000d\u000a    Argenta Discovery continues to be very successful in both highly\u000d\u000a      profitable CRO work and in the discovery of new drugs to address unmet\u000d\u000a      medical need in respiratory disease, including chronic obstructive\u000d\u000a      pulmonary disease (COPD) (see: Current Opinion in Pharmacology 2009,\u000d\u000a      9 231). This has led to the granting of a substantial number of patents:\u000d\u000a    Argenta patents, 2008&#8212;\u000d\u000a    WO 2010015818 (Feb 11 2010), WO 2009060209 (May 14 2009), WO 2009060203\u000d\u000a      (May 14 2009), WO 2009013444 (Jan 29 2009), WO 2008122784 (Oct 16 2008),\u000d\u000a      WO 2008119917 (Oct 9 2008), WO 2008096094 (Aug 14 2008), WO 2008017824\u000d\u000a      (Feb 14 2008), WO 2008017827 (Feb 14 2008)\u000d\u000a    In addition, Argenta has entered into major collaborations with global\u000d\u000a      pharmaceutical and biotechnology companies including Aventis, Lundbeck,\u000d\u000a      GSK, Novartis, Genentech, Domantis, Pharmagene.\u000d\u000a    In 2010, Argenta Discovery sold the contract business and company name\u000d\u000a      for &#8364;16.5 million [A] in cash to Biofocus Galapagos to form Biofocus\u000d\u000a      Galapagos Argenta. At the time, Argenta had 140 employees. The combined\u000d\u000a      division is \"one of the world's largest drug discovery service\u000d\u000a        organizations, with 390 employees, an estimated &#8364;70 million in annual\u000d\u000a        turnover and significant profitability\" [A]. The acquisition also\u000d\u000a      added additional capacity and drug discovery capabilities to the Galapagos\u000d\u000a      Group. Argenta's respiratory development programs continued as a\u000d\u000a      new privately held company, Pulmagen Therapeutics [A]. Reporting on the\u000d\u000a      deal, Onno van de Stolpe, CEO of Galapagos said: \"today's [2010]\u000d\u000a        acquisition of the services division of Argenta, one of premier players\u000d\u000a        in the segment, creates a true powerhouse in the drug discovery services\u000d\u000a        market. It also provides Galapagos R&amp;D with additional capacity,\u000d\u000a        capabilities and access to respiratory models for our internal R&amp;D\u000d\u000a        efforts\" [A]. Galapagos acquired Argenta Discovery's \"medicinal\u000d\u000a        chemistry, computational chemistry, ADME [absorption, distribution,\u000d\u000a        metabolism, and excretion] and biology activities as well as the\u000d\u000a        respiratory models and pharmacokinetics operations through a &#8364;16.5\u000d\u000a        million cash payment, approximately 4.7 x EBIT or 1.2 x annual revenue\"\u000d\u000a      [A]. The Group's combined service division operations, which will operate\u000d\u000a      under the BioFocus and Argenta brand names, were expected to achieve &#8364;70\u000d\u000a      million in 2010 revenues (including ~&#8364;11 million in service contracts by\u000d\u000a      Galapagos) [A]. Post-acquisition, \"Galapagos' service division\u000d\u000a        operations will employ 390 staff in the UK, Switzerland and the US\"\u000d\u000a      [A].\u000d\u000a    In 2011 Argenta signed an integrated service agreement with Pulmagen\u000d\u000a      Therapeutics: \"Galapagos NV (Euronext: GLPG) announced today that its\u000d\u000a        service division Argenta has signed a subcontracting agreement with\u000d\u000a        Pulmagen Therapeutics Limited to perform integrated services on two\u000d\u000a        respiratory projects. Under the terms of the agreement, Argenta will be\u000d\u000a        eligible to receive up to &#163;6 million (&#8364;7 million) in fee-for-service\u000d\u000a        payments over two years, with the possibility to extend\" [B].\u000d\u000a\u0009\u0009Also\u000d\u000a      in 2011, Argenta and BioFocus announced a two-year extension of a drug\u000d\u000a      discovery collaboration with Genetech: \"Galapagos NV (Euronext: GLPG)\u000d\u000a        announced today that its service division Argenta has extended its\u000d\u000a        integrated contract drug discovery agreement with Genentech, a member of\u000d\u000a        the Roche Group (SIX: RO, ROG; OTCQX: RHHBY). Total potential value of\u000d\u000a        the contract extension is up to &#163;21.5 million (&#8364;23.4 million). This is\u000d\u000a        the third such extension since the agreement was announced in December\u000d\u000a        2005. The agreement covers a number of drug discovery programs that\u000d\u000a        utilize Argenta's expertise in computer-aided drug design (CADD),\u000d\u000a        medicinal chemistry, in vitro biology and screening to discover new\u000d\u000a        chemical entities acting against undisclosed drug targets defined by\u000d\u000a        Genentech\" [C].\u000d\u000a    Biofocus Galapagos Argenta continued to expand and is now a significant\u000d\u000a      employer of PhD organic chemists in the UK (2010 CRO turnover &gt;&#8364;135M\u000d\u000a      [A]). The clinical development of several potential new medicines to treat\u000d\u000a      COPD, asthma, allergic diseases and cystic fibrosis is currently being\u000d\u000a      taken forward in phases 1 and 2 by Pulmagen Therapeutics, the company\u000d\u000a      which owns the complete drug pipeline from Argenta Discovery [D, E]. This\u000d\u000a      activity too has led to the granting of patents:\u000d\u000a    Argenta-AZ patents\u000d\u000a    WO 2009139709 (Nov 19 2009), WO 2009138707 (Nov 19 2009), WO 2009139710\u000d\u000a      (Nov 19 2009), WO 2010019099 (Feb 18 2010), WO 2010018352 (Feb 18 2010),\u000d\u000a      WO 2008149110 (Dec 11 2008), WO 2008149053 (Dec 11 2008), WO 2008096127\u000d\u000a      (Aug 14 2008), WO 2008096129 (Aug 14 2008), WO 2008096136 (Aug 14 2008),\u000d\u000a      WO 2008096126 (Aug 14 2008)\u000d\u000a    Argenta-Pulmagen patents\u000d\u000a    WO 2008135537 (Nov 13 2008)\u000d\u000a    ","ImpactSummary":"\u000d\u000a    The growth and performance of Biofocus Galapagos Argenta (BGA) and\u000d\u000a      Pulmagen Therapeutics (PT) are underpinned by research from the\u000d\u000a      Imperial-based TeknoMed project that started in 1997. BGA was formed in\u000d\u000a      2010 through the acquisition of Argenta Discovery (AD) by Biofocus\u000d\u000a      Galapagos for &#8364;16.5 million and is one of the world's largest drug\u000d\u000a      discovery service organisations with 390 plus employees and turnover of\u000d\u000a      &#8364;135 million [section 5, A]. PT was formed as a separate company to own\u000d\u000a      the complete AD drug pipeline. It develops new medicines to treat asthma,\u000d\u000a      cystic fibrosis and allergic diseases. In 2011 BGA signed agreements with\u000d\u000a      PT for an initial &#163;6million fee and with Genentech for &#163;21.5million.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    Imperial College London\u000d\u000a    ","Institutions":[{"AlternativeName":"Imperial College London","InstitutionName":"Imperial College London","PeerGroup":"A","Region":"London","UKPRN":10003270}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    (* References that best indicate quality of underpinning research)\u000d\u000a    Research publications\u000d\u000a    \u000a[1] C.P. Ball, A.G.M. Barrett, A. Commer&#231;on, D.\u000d\u000a        Comp&#232;re, C. Kuhn, R.S. Roberts, M.L. Smith,\u000d\u000a      and O. Venier, \"Chameleon catches in combinatorial chemistry:\u000d\u000a        Tebbe olefination of polymer supported esters and the synthesis of\u000d\u000a        amines, cyclohexanones, enones, methyl ketones and thiazoles\", Chemical\u000a        Communications (18) 2019 (1998). DOI,\u000d\u000a      21 citations (as at 4\/7\/13)\u000d\u000a    \u000a\u000a[2] A.G.M. Barrett, M.L. Smith and F.J. Zecri, \"Impurity\u000a        annihilation; a strategy for solution phase combinatorial chemistry with\u000d\u000a        minimal purification\", Chemical Communications (21) 2317\u000d\u000a      (1998). DOI, 22\u000d\u000a        citations (as at 4\/7\/13)\u000d\u000a    \u000a\u000a[3] C.P. Ball, A.G.M. Barrett, L. Poitout, M.L.\u000a        Smith and Z.E. Thorn, \"Polymer backbone disassembly:\u000d\u000a        polymerisable templates and vanishing supports in high loading parallel\u000d\u000a        synthesis\", Chemical Communications (22) 2453 (1998). DOI,\u000d\u000a      16 citations (as at 4\/7\/13)\u000d\u000a    \u000a\u000a[4] *A.G.M. Barrett, S.M. Cramp, R.S. Roberts, and F.J.\u000a        Zecri, \"Horner-Emmons Synthesis with Minimal Purification using\u000d\u000a        ROMPGEL: A Novel High Loading Matrix for Supported Reagents\", Organic\u000a        Letters 1 (4) 579 (1999). DOI,\u000d\u000a      46 citations (as at 4\/7\/13)\u000d\u000a    \u000a\u000a[5] *A.G.M. Barrett, R.S. Roberts and J. Schr&#246;der,\u000d\u000a      \"Impurity Annihilation: Chromatography-Free Parallel Mitsunobu\u000d\u000a        Reactions\", Organic Letters 2 (19) 2999 (2000). DOI,\u000d\u000a      49 citations (as at 4\/7\/13)\u000d\u000a    \u000a\u000a[6] *A.G.M. Barrett, B.T. Hopkins and J. Kobberling,\u000d\u000a      \"ROMPgel Reagents in Parallel Synthesis\", Chemical Reviews 102\u000d\u000a      (5) 3301 (2002). DOI,\u000d\u000a      83 citations (as at 4\/7\/13)\u000d\u000a    \u000aGrant Support\u000d\u000a    [G1] Rh&#244;ne Poulenc Rorer, \"TeknoMed Project\", PI: A.G.M. Barrett,\u000d\u000a      1\/1\/1997-31\/12\/1999, $6M ($4M to Imperial College)\u000d\u000a    [G2] EPSRC, GR\/M98968\/01,\u000d\u000a      \"ROMPgel And related supports In combinatorial chemistry\", PI: A.G.M.\u000d\u000a      Barrett, 01\/10\/00 - 30\/09\/03, &#163;189,491\u000d\u000a    [G3] EPSRC, GR\/M76959\/01,\u000d\u000a      \"Chameleon catches in combinatorial chemistry\", PI: A.G.M. Barrett,\u000d\u000a      01\/01\/00 - 31\/12\/02, &#163;182,825\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"},{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"},{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"}],"Sources":"\u000d\u000a    [A] \"Galapagos Acquires Argenta Discovery's Service Operations\" press\u000d\u000a      release, 2\/2\/10\u000d\u000a      http:\/\/www.argentadiscovery.com\/news\/archive,galapagos-acquires-argenta-discoverys-service-operations_5.htm\u000d\u000a      (archived at https:\/\/www.imperial.ac.uk\/ref\/webarchive\/3mf\u000d\u000a      on 4\/7\/13)\u000d\u000a    [B] \"Argenta Signs Integrated Services Agreement with Pulmagen\u000d\u000a      Therapeutics\" press release, 28\/6\/11, http:\/\/www.argentadiscovery.com\/news\/press,argenta-signs-integrated-services-agreement-with-pulmagen-therapeutics_85.htm\u000d\u000a      (archived at\u000d\u000a      https:\/\/www.imperial.ac.uk\/ref\/webarchive\/4mf\u000d\u000a      on 4\/7\/13)\u000d\u000a    [C] \"Argenta and BioFocus announce two-year extension of drug discovery\u000d\u000a      collaboration with Genentech\" press release, 18\/8\/11, http:\/\/www.argentadiscovery.com\/news\/press,argenta-and-biofocus-announce-twoyear-extension-of-drug-discovery-collaboration-with-genentech_86.htm\u000d\u000a      (archived at https:\/\/www.imperial.ac.uk\/ref\/webarchive\/5mf\u000d\u000a      on 4\/7\/13)\u000d\u000a    [D] \"Argenta Signs Integrated Services Agreement with Pulmagen\u000d\u000a      Therapeutics\" press release, 28\/6\/11, http:\/\/www.mvmlifescience.com\/news\/default.asp?aid=118\u000d\u000a      (archived at\u000d\u000a      https:\/\/www.imperial.ac.uk\/ref\/webarchive\/7mf\u000d\u000a      on 4\/7\/13). Full PDF available here.\u000d\u000a    [E] \"Pulmagen Therapeutics Update on Clinical Pipeline\", More News -\u000d\u000a      28\/6\/2011, http:\/\/www.mvmlifescience.com\/portfolio\/detail.asp?pid=6\u000d\u000a      (archived at\u000d\u000a      https:\/\/www.imperial.ac.uk\/ref\/webarchive\/6mf\u000d\u000a      on 4\/7\/13) \u000d\u000a    ","Title":"\u000d\u000a    C1 &#8212; The Founding of Argenta Discovery and Pulmagen Therapeutics\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2647461","Name":"Harlow"},{"GeoNamesId":"2651621","Name":"Dagenham"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    In 1997, in collaboration with the University of Cambridge and\u000d\u000a      Rh&#244;ne-Poulenc Rorer, Tony Barrett started the TeknoMed Project, a major,\u000d\u000a      Imperial-based research programme on drug-design using combinatorial\u000d\u000a      chemistry (CC) and rapid parallel synthesis [G1]. Following further grant\u000d\u000a      support from EPSRC [G2, G3] key outcomes from the collaboration with\u000d\u000a      Rh&#244;ne-Poulenc Rorer were the discovery and development at Imperial of a\u000d\u000a      range of new techniques for parallel synthesis [1-6] and the training of\u000d\u000a      16 postdoctoral medicinal chemists in the methods of parallel synthesis.\u000d\u000a      The new techniques embodied methods for purification-minimised parallel\u000d\u000a      synthesis, which are crucial in the early stages of drug discovery.\u000d\u000a      Parallel, or high-throughput, synthesis renders routine the exploration of\u000d\u000a      extended areas of chemical space in the search for new medicinal\u000d\u000a      molecules, to an extent which was previously unviable because of the time\u000d\u000a      and resources needed. The most significant of these methods is the use of\u000d\u000a      ring-opening metathesis polymerisation (ROMP) for the fabrication of\u000d\u000a      polymer-supported reagents and catalysts: ROMPgels and ROMPspheres. This\u000d\u000a      innovative synthesis methodology enables the fabrication of novel, highly\u000d\u000a      functionalised polymeric supports by simple and efficient methods which\u000d\u000a      use readily available precursors. These functional polymers are used in\u000d\u000a      fundamentally important organic synthesis reactions such as alkene\u000d\u000a      formation and nucleophilic displacement, with the undesired by-products\u000d\u000a      being easy to separate from the soluble desired products simply by virtue\u000d\u000a      of being chemically attached to the insoluble polymeric material, which is\u000d\u000a      removed by filtration at the end of the process. This approach facilitates\u000d\u000a      parallel synthesis, in which multiple versions of a generic chemical\u000d\u000a      structure may be made simultaneously using automated and semi-automated\u000d\u000a      techniques. The research on ROMPgels was described as being of\u000d\u000a      \"outstanding interest,\" (Flynn, D.L.; Hanson, P.R.; Berk, S.C.; Makara,\u000d\u000a      G.M. Current Opinion in Drug Discovery and Development 2002,\u000d\u000a      5, 571) and was highlighted in Chemical and Engineering News\u000d\u000a      (Borman, S. Chem. Eng. News 2002, No. 11, p. 43).\u000d\u000a    In a related method, a polymer-supported transition metal catalyst which\u000d\u000a      promotes the joining together of two alkenes to make a new, more complex\u000d\u000a      alkene together with ethylene as a volatile by-product was developed. The\u000d\u000a      transition metal catalyst is again immobilised by chemical attachment to\u000d\u000a      an insoluble polymeric support. One of the alkenes in solution reacts with\u000d\u000a      the solid-supported catalyst to form a first reactive intermediate in\u000d\u000a      solution, which then combines with the second alkene to give the desired\u000d\u000a      product alkene, together with a second reactive intermediate. This second\u000d\u000a      intermediate recombines with the polymeric support to give ethylene gas,\u000d\u000a      regenerating the solid-supported catalyst. The active transition metal\u000d\u000a      catalyst immobilised on the polymeric support is thus released temporarily\u000d\u000a      into solution, where it affects the synthesis of the desired alkene prior\u000d\u000a      to recapture by the polymer. This release-and-catch concept was termed\u000d\u000a      `boomerang' catalysis, and is significant in that it minimises transition\u000d\u000a      metal contamination of the alkene products.\u000d\u000a    Finally, polymer-supported esters were converted into highly reactive\u000d\u000a      alkenes, which entered into reaction sequences for the formation of\u000d\u000a      all-carbon cyclic compounds as well as sulfur-containing heteroaromatic\u000d\u000a      substances. Product purity was enhanced by being able to wash away\u000d\u000a      impurities and by-products at each stage of the sequence.\u000d\u000a    The research and outputs described above and in section 3 arose entirely\u000d\u000a      out of Imperial research [2, 3, 5, 6] or collaboration with Rh&#244;ne-Poulenc\u000d\u000a      Rorer [1, 4].\u000d\u000a    Key personnel:\u000d\u000a    A.G.M. Barrett, Professor of Synthesis, Director of the Wolfson Centre\u000d\u000a      for Organic Chemistry in Medical Science, Imperial College London,\u000d\u000a      1993-present\u000d\u000a    "},{"CaseStudyId":"42243","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Biotechnology and Biological Sciences Research Council","Engineering and Physical Sciences Research Council","Royal Society"],"ImpactDetails":"\u000a    1) Company Development\u000a    As a direct result of research carried out at Imperial College, a company\u000a      with twelve years' operational history has been established in Central\u000a      London, generating more than &#163;3.4M over the 2008-2013 REF period (&gt;\u000a      &#163;1.2M equity, &gt; &#163;1.5M contract and &gt; &#163;660K grant funding) in inward\u000a      investment for the UK. MV has provided &gt; 50 person years of employment\u000a      for its own, primarily PhD-level, UK graduates and it has also supported\u000a      training activities, paying MBA fees for one of its Principal Scientists,\u000a      a CASE studentship at Imperial College, and a contribution to EPSRC KTS\u000a      project costs for two postdoctoral researchers seconded from Imperial\u000a      College and a Principal Scientist seconded to Imperial College. This\u000a      represents a direct economic impact through investment funding for new\u000a      activities, jobs created and protected, and turnover associated with new\u000a      and improved services.\u000a    MV has additionally been an important component in developing momentum\u000a      for the creation of a UK Plastic Electronics industry [A], being one of\u000a      two Plastic Electronics companies based in Central London. In 2008 MV was\u000a      starting to be recognized as a \"successful multi-million pound\u000a        enterprise\" [B], being the focus of an article in The Engineer [C]\u000a      and a September 2008 visit by Phil Willis MP, then Chair of the House of\u000a      Commons Innovation, Universities and Skills (IUSS) Committee, as part of\u000a      the Committee's Engineering Inquiry [D, B]. In August 2008, joint\u000a      development partner Acrongenomics (an investment and commercialization\u000a      company listed on the USA Nasdaq) took a &#163;1.1M equity position in MV [E].\u000a      Commenting on the deal Platon Tzouvalis, President of Acrongenomics, said,\u000a      \"This is a great day for our company. This agreement with Molecular\u000a        Vision is a major milestone for Acrongenomics, since it marks our\u000a        substantial sharing in everything that this technology has to\u000a        offer...This will allow Acrongenomics and Molecular Vision to focus on\u000a        the goals of developing the technology and bringing great products to\u000a        the market, thus increasing our shareholder value and substantially\u000a        contributing to the betterment of the healthcare system in general\"\u000a      [E].\u000a    In February 2009, Peter Woodford, a diagnostics industry veteran of 35\u000a      years standing, including 15 years with Roche Diagnostics, joined the\u000a      company as Chairman saying \"I am excited by the clear potential of\u000a        Molecular Vision's technology platform\" [F]. In September 2009 MV\u000a      raised an additional &#163;2m from Imperial Innovations and other investors\u000a      including Acrongenomics to further the commercial development of the\u000a      BioLED technology platform [G]. A significant contract with \"a global\u000a        cosmetic company\" was also announced in 2009 [G]. In 2010 MV\u000a      launched the development of its CardioPlex fluorescence based triple test\u000a      for cardiac markers myoglobin, CK-MB and troponin-I, concluding a\u000a      successful demonstration in 2011. In 2011, Imperial Innovations invested a\u000a      further &#163;750k and MV announced the appointment of Chris Hand as CEO [H].\u000a      In 2012, Abingdon Health Group (AHG) led a &#163;3M investment round in which\u000a      it acquired a 50.1% stake in MV. As part of the same deal, Imperial\u000a      Innovations invested in AHG, widening its portfolio of healthcare sector\u000a      investments [I]. Recently, agreements have been put in place with a\u000a      leading European pharmaceutical company and a large multi-national\u000a      chemical company to co-develop point-of-care diagnostic tests in the UK\u000a      [J].\u000a    2) Health Care Benefits\u000a    MV has pioneered a novel microanalysis technology that offers a step\u000a      change opportunity for point- of-care in-vitro diagnostics. In particular,\u000a      MV's BioLED platform provides a simple-to-use, portable, low-cost, rapid,\u000a      quantitative diagnostic tool. It allows efficient, accurate, multi-analyte\u000a      measurement in a generic format that can utilize absorption, turbidity,\u000a      fluorescence, phosphorescence and chemiluminescence detection schemes with\u000a      existing assays on blood, saliva and urine samples and at the cost of a\u000a      few dollars, i.e. some 1000-times lower than the typical bench-top readers\u000a      with which it competes in terms of sensitivity and accuracy. The\u000a      availability of such devices as routine tools in general practice would\u000a      directly address key objectives of health providers in the UK, Europe and\u000a      the US, notably: (i) reduced treatment time; (ii) improved quality of\u000a      treatment; (iii) reduced inequality of treatment by extending facilities\u000a      available to remote surgeries; and (iv) improved ongoing care via\u000a      home-based preventative and post-treatment monitoring of at-risk patients\u000a      [K]. The BioLED platform has the potential to become a de facto\u000a      standard for medical testing and the significance of this disruptive\u000a      technology was recognized by AHG in March 2012 when they acquired a\u000a      majority shareholding in MV. Abingdon founder Dr Chris Hand commented \"This\u000a        is an important step towards our strategy of creating a fully\u000a        functional, specialist diagnostics business. Early detection is critical\u000a        for improved treatment outcomes and there is a significant need for\u000a        simple, faster and more accurate point of care tests. Working with some\u000a        of the world's leading experts we are developing disruptive technologies\u000a        and are well placed to take a share of the US$11.2bn global\u000a        immunodiagnostics market\" [I]. In a later comment for Wired\u000a      Magazine, in which MV technology featured as \"One of the Big Ideas for\u000a      2012\", he added \"If you can test someone in an ambulance on their way\u000a        to hospital, or in A&amp;E, that's a big benefit. It's all about getting\u000a        care to the patient more quickly and efficiently\" [L]. In a letter\u000a      Dr Hand states \"I believe that the Molecular Vision technology offers\u000a        us a current and future competitive advantage in the diagnostics sector.\u000a        It allows us to expand current markets, and with similarities to our\u000a        previous activities at Cozart, allows us to create new, currently\u000a        untapped markets for the benefits of the user, the patient and the\u000a        healthcare system\" [J].\u000a    In addition to the medical diagnostics market, the BioLED technology is\u000a      also suited to environmental testing including water quality ($4Bn\u000a      market), homeland security\/biodefence including pathogen detection ($8Bn\u000a      market), veterinary testing including bovine TB ($2Bn market) and\u000a      substances of abuse testing ($2Bn market) [M].\u000a    ","ImpactSummary":"\u000a    Molecular Vision Ltd (\"MV\"), which was spun-out of Imperial Innovations,\u000a      develops simple-to-use, point-of-care diagnostic devices (known as the\u000a      BioLED&#8482; platform) that quickly produce lab-quality information from a\u000a      single sample of bodily fluids. Since 2008 MV has validated the platform,\u000a      including demonstration of its CardioplexTM triple test for\u000a      myoglobin, CK-MB and troponin-I in a serum sample, and undertaken\u000a      &gt;&#163;1.5M of contract work for a variety of customers including\u000a      Acrongenomics Inc, Microfluidic ChipShop and L'Oreal; addressing analysis\u000a      problems relating to kidney and cardiac health, pathogen identification\u000a      and cosmetics. During the REF period the Company has generated a total of\u000a      over &#163;3.4m in investment, contract revenue and non-UK grant funding and\u000a      created greater than 50 man years of UK employment, primarily at the PhD\u000a      level. Abingdon Health Group acquired a majority stake in MV in 2012 as\u000a      part of its strategy to create a fully integrated business in the UK that\u000a      is able to compete in the large and global immunodiagnostics market.\u000a    ","ImpactType":"Technological","Institution":"\u000a    Imperial College London\u000a    ","Institutions":[{"AlternativeName":"Imperial College London","InstitutionName":"Imperial College London","PeerGroup":"A","Region":"London","UKPRN":10003270}],"Panel":"B         ","PlaceName":[],"References":"\u000a    (* References that best indicate quality of underpinning research)\u000a    N.B. publication of journal articles was generally delayed to accommodate\u000a      patent protection and technology development projects.\u000a    \u000a[1] O. Hofmann, X. Wang, J.C. deMello, D.D.C. Bradley, A.J. deMello,\u000a      \"Towards Microalbuminuria Determination on a Disposable Diagnostic\u000a        Microchip with Integrated Fluorescence Detection Based on Thin-film\u000a        Organic Light Emitting Diodes\", Lab. Chip, 5, 863-868 (2005). DOI,\u000a      47\u000a        citations (as at 21\/7\/13).\u000a    \u000a\u000a[2] * O. Hofmann, X.H. Wang, A. Cornwell, S. Beecher, A. Raja, D.D.C.\u000a        Bradley, A.J. de Mello &amp; J.C. de Mello, \"Monolithically\u000a        Integrated Dye-doped PDMS Long-pass Filters for Disposable On-chip\u000a        Fluorescence Detection\", Lab. Chip, 6, 981-987 (2006). DOI,\u000a      71 citations (as at 21\/7\/13).\u000a    \u000a\u000a[3] * X.H. Wang, O. Hofmann, R. Das, E.M. Barrett, A.J. de Mello,\u000a        J.C. de Mello, and D.D.C. Bradley, \"Integrated thin-film\u000a        polymer\/fullerene photodetectors for on-chip microfluidic\u000a        chemiluminescence detection\", Lab. Chip, 7, 58- 63 (2007). DOI,\u000a      44 (as at 21\/7\/13).\u000a    \u000a\u000a[4] M. Yamazaki, O. Hofmann, G. Ryu, L. Xiaoe, T. K. Lee,\u000a      A. J. deMello and J. C. deMello, \"Non-emissive colour filters\u000a        for fluorescence detection\", Lab Chip, 11, 1228-1233 (2011). DOI,\u000a      4 citations (as at 21\/7\/13).\u000a    \u000a\u000a[5] * J. Huang, P. F. Miller, J. S. Wilson, J.C. de Mello, A.J. de\u000a        Mello, D.D.C. Bradley, \"Investigation of the Effects of Doping\u000a        and Post-Deposition Treatments on the Conductivity, Morphology, and Work\u000a        Function of Poly(3,4-ethylenedioxythiophene)\/Poly(styrene sulfonate)\u000a        Films\", Adv. Funct. Mater., 15, 290-296 (2005). DOI,\u000a      137 citations (as at 21\/7\/13).\u000a    \u000a\u000a[6] J. Huang, R. Xia, Y. Kim, J. Dane, O. Hofmann, X. Wang, A.\u000a      Mosley, A.J. de Mello, J.C. de Mello, D.D.C. Bradley, \"Patterning\u000a        of Organic Devices by Interlayer Lithography\", J. Mat. Chem., 17,\u000a      1043-1049 (2007). DOI, 34\u000a        citations (as at 21\/7\/13).\u000a    \u000aGrants:\u000a    [G1] EPSRC, GR\/R58949\/01,\u000a      `Polymeric Detection System for Microanalysis', 01\/04\/02-31\/03\/05, PI: AJ\u000a      de Mello, Co-Is: Bradley and J de Mello, &#163; 521,390.\u000a    [G2] BBSRC SBRI, 147\/SBRI9689, `A low cost point-of-care test kit for\u000a      microalbuminuria`, 2003- 2005, PI-Bradley, &#163;270K.\u000a    [G3] Royal Society Brian Mercer Award for Innovation, `Novel Patterning\u000a      Processes for Nano- Scale Organic Semiconductor Devices',\u000a      01\/02\/07-31\/12\/09, PI: Bradley, Co-I: J de Mello, &#163;250K.\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"9","Level2":"15","Subject":"Interdisciplinary Engineering"},{"Level1":"2","Level2":"99","Subject":"Other Physical Sciences"}],"Sources":"\u000a    [A] Pages 8 &amp; 58, 2012 UK Plastic Electronics: Capability Guide, http:\/\/ukplasticelectronics.com\/wp-\u000a        content\/uploads\/2012\/09\/PE_CapabilityGuide_V1prJun12.pdf (archived here).\u000a    [B] Institute of Physics response to a House of Commons IUSS Committee\u000a      Inquiry on plastic electronics engineering, 14th March 2008 (available here).\u000a    [C] `Doctor on a Chip' article, The Engineer, 19\/5\/08, http:\/\/www.theengineer.co.uk\/news\/doctor-\u000aon-a-\u000a        chip\/306204.article (archived at https:\/\/www.imperial.ac.uk\/ref\/webarchive\/bhf\u000a      on 22\/4\/13); See also Medgadget Portable Diagnostic Technology from UK'S\u000a      Molecular Vision 28th May 2008: http:\/\/www.medgadget.com\/2008\/05\/portable_diagnostic_technology_from_uks_molecular_vision.html\u000a      (archived at https:\/\/www.imperial.ac.uk\/ref\/webarchive\/chf\u000a      on 22\/4\/13)\u000a    [D] House of Commons IUSS Committee, `Engineering: turning ideas into\u000a      reality' report, http:\/\/www.publications.parliament.uk\/pa\/cm200809\/cmselect\/cmdius\/50\/50i.pdf\u000a      (archived here).\u000a    [E] Reuters article, 21\/5\/08, `Acrongenomics Increases its Shareholding\u000a      in and Restructures Relationship with Molecular Vision', http:\/\/uk.reuters.com\/article\/2008\/08\/21\/idUS224476+21-\u000a        Aug-2008+BW20080821 (archived at https:\/\/www.imperial.ac.uk\/ref\/webarchive\/hhf\u000a      on 22\/4\/13)\u000a    [F] Reuters article, 23\/2\/09, `Acrongenomics` Business Associate\u000a      Molecular Vision Ltd Appoints Peter Woodford as Chairman', http:\/\/www.reuters.com\/article\/2009\/02\/23\/idUS221627+23-Feb-\u000a        2009+BW20090223 (archived at https:\/\/www.imperial.ac.uk\/ref\/webarchive\/ghf)\u000a    [G] Reuters article, 22\/10\/09, `Acrongenomics maintains its stake in\u000a      Molecular Vision', `http:\/\/uk.reuters.com\/article\/2009\/10\/22\/idUS194327+22-Oct-2009+BW20091022\u000a      (archived at https:\/\/www.imperial.ac.uk\/ref\/webarchive\/khf\u000a      on 22\/4\/13)\u000a    [H] OSA Direct newsletter, 2\/2\/11, `Molecular Vision receives further\u000a      investment and appoints Dr Chris Hand as Chief Executive Officer', http:\/\/www.osadirect.com\/news\/article\/433\/\u000a      (archived at https:\/\/www.imperial.ac.uk\/ref\/webarchive\/l8f\u000a      on 19\/11\/13)\u000a    [I] Manufacturing Chemist article, 26\/3\/12, `Abingdon Health raises &#163;3m',\u000a      http:\/\/www.manufacturingchemist.com\/news\/article_page\/Abingdon_Health_raises_3m\/76983\u000a      (archived at https:\/\/www.imperial.ac.uk\/ref\/webarchive\/ykf\u000a      on 22\/5\/13)\u000a    [J] Letter from CEO of Abingdon Health, 24\/5\/13 (available on request\u000a      from Imperial)\u000a    [K] `Technology', Molecular Vision website, http:\/\/www.molecularvision.co.uk\/show.php?page=20&amp;subnav=9\u000a      (archived at https:\/\/www.imperial.ac.uk\/ref\/webarchive\/zkf\u000a      on 22\/5\/13)\u000a    [L] Wired magazine, 3\/1\/12, `25 big ideas for 2012: The lab on a postage\u000a      stamp', http:\/\/www.wired.co.uk\/magazine\/archive\/2012\/01\/features\/the-lab-on-a-postage-stamp\u000a      (archived at https:\/\/www.imperial.ac.uk\/ref\/webarchive\/nhf\u000a      on 22\/4\/13)\u000a    [M] `Applications', Molecular Vision website, http:\/\/www.molecularvision.co.uk\/show.php?page=21&amp;subnav=10\u000a      (archived at https:\/\/www.imperial.ac.uk\/ref\/webarchive\/1kf\u000a      on 22\/5\/13) \u000a    ","Title":"\u000a    C2 - The BioLEDTM microanalysis technology: Molecular Vision\u000a      Ltd\u000a    ","UKLocation":[{"GeoNamesId":"2643743","Name":"London"},{"GeoNamesId":"2657780","Name":"Abingdon"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    MV was founded in 2001 to develop and commercialize instrumented,\u000a      lab-on-a-chip, microanalysis systems invented at Imperial College London\u000a      by Professors Andrew and John de Mello (Chemistry Department) and Donal\u000a      Bradley (Physics Department). This innovation was informed by long-term\u000a      research undertaken by Bradley and John de Mello on organic light emitting\u000a      diodes (OLEDs) and photodiodes (OPDs) and by Andrew de Mello on\u000a      microfluidic chip structures. The resulting Imperial College intellectual\u000a      property (IP), focused on the combination of OLEDs and OPDs with\u000a      microfluidic structures, is protected by granted patents including GB\u000a      2369428, US 6,995,348 and EP 1336089, assigned to MV by Imperial\u000a      Innovations.\u000a    Initial research at Imperial College underpinning the BioLED technology\u000a      was funded by EPSRC [G1] and by MV, supported by a BBSRC Small Business\u000a      Research Initiative grant [G2]. This involved both Imperial College and MV\u000a      staff and Imperial students using facilities in the College. It proved the\u000a      principle of the BioLED platform and demonstrated the competitive\u000a      performance of OLED and OPD instrumented microfluidic structures. The\u000a      first application of polymer OLEDs as light sources for microchip based\u000a      fluorescence detection, the fabrication of dye-doped microfluidic\u000a      structures that integrate an efficient long-pass filter function and the\u000a      use of polymer OPDs as detectors for microscale chemiluminescence resulted\u000a      from this work [1-3].\u000a    By mid-2006, MV had signed a development contract with Acrongenomics Inc\u000a      to work on kidney function, cardiac markers and sexually transmitted\u000a      diseases, with an initial focus on the detection of microalbuminuria (a\u000a      kidney disorder). It had also moved into the Imperial Bioincubator to\u000a      establish its own &gt; &#163;275K R&amp;D facilities to develop BioLED\u000a      prototypes and test them on bodily fluids. Bradley and Andrew de Mello\u000a      were appointed Founder Directors and John de Mello Chief Scientific\u000a      Officer (CSO), later joining the MV Board also. Close research\u000a      collaborations between the founders and MV have continued until the\u000a      present day and resulted in a further 2 BioLED focused journal papers\u000a      (DOI: 10.1016\/j.snb.2004.10.005 and 10.1039\/b313503a, 133 ISI citations).\u000a      These address the use of polymer OPDs as detectors for microscale\u000a      chemiluminescent antioxidant capacity screening (2009) and an optimized\u000a      system for fluorescence immunoassays for cardiac markers myoglobin and\u000a      CK-MB as an early diagnostic of myocardial infarction (2011). Additional\u000a      work and publications between Imperial and MV have covered the development\u000a      of low cost, high performance optical filter technology for use with\u000a      diode-based sensors, see e.g. [4]. MV also secured NHS Health Technology\u000a      Device funding for collaboration with Imperial, Acrongenomics and Pearson\u000a      Matthews &#8212; a design development company specializing in the healthcare\u000a      sector &#8212; to develop prototype diagnostic devices. A PDA-based USB powered\u000a      demo was shown in early 2007 and a battery powered version with a built-in\u000a      display followed late the same year. Eight conference papers also resulted\u000a      from the BioLED focused research at Imperial between 2004 and 2008.\u000a    A second strand of research concerned materials development and\u000a      fabrication methods for OLED and OPD devices, respectively vapour-phase\u000a      polymerized poly(3,4-ethylenedioxythiophene) (VPP- PEDOT) as an\u000a      ITO-replacement electrode and interlayer lithography [5,6]; funded by\u000a      [G1]. The resulting fabrication IP was the subject of a patent filing\u000a      GB\/GB0523437.2 that was successfully licensed (July 2007) to MV for use in\u000a      the medical diagnostic sector. This research underpinned the development\u000a      of flexible substrate devices that enabled the participation of MV in\u000a      contract work for Microfluidic ChipShop and sub-contracted work for\u000a      Cambridge Display Technology (TSB OPALS project). In 2007, a Royal Society\u000a      Brian Mercer Award for Innovation to Bradley and John de Mello [G3]\u000a      co-funded a project with MV and Imperial Innovations to develop further\u000a      the interlayer lithography method and a stamp transfer printing process\u000a      that had been developed by Bradley and co-workers in the physics\u000a      department. The Brian Mercer Award also supported development of the\u000a      VPP-PEDOT electrode system. Eight additional papers (137 citations)\u000a      resulted.\u000a    Key personnel:\u000a    &#8226; Prof Andrew de Mello, RF, lecturer then Prof of Chemical Nanosciences\u000a      Imperial College London, 1997-2011 (with Chemistry) and 2013-present (with\u000a      the Faculty of Medicine)\u000a    &#8226; Prof John de Mello, Prof of Nanomaterials, Imperial College London,\u000a      2000-present\u000a    &#8226; Prof Donal Bradley, currently Vice-Provost (Research), Imperial College\u000a      London, 2000-present\u000a    "},{"CaseStudyId":"42244","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000a    The academic work of Gibson and Marshall revealed that the properties of\u000a      PLA could be improved by using catalysts to promote the formation of\u000a      stereoregular PLA, greatly increasing the potential applications for PLA.\u000a      On this basis a business plan was constructed and funding secured leading\u000a      to the formation of Plaxica in 2008 [B]. Marshall resigned his lectureship\u000a      position in December 2009 to join the Company full-time (Gibson having\u000a      previously taken a visiting professorship at Imperial when he joined BP as\u000a      their Chief Chemist in 2008). The basis of Plaxica's technology is\u000a      fully-owned by the Company. Nonetheless, the insight into the market and\u000a      the understanding of the capabilities arose from academic work at Imperial\u000a      over a number of years, and ultimately proved necessary when seeking funds\u000a      for the launch of the spin-out company.\u000a    Plaxica is a process technology licensing company. It develops,\u000a      demonstrates and designs process plants for the production of the key\u000a      intermediates, especially L- and D- lactic acids and lactides, for\u000a      stereocomplex polylactic acid (PLA) &#8212; a high performance biopolymer made\u000a      from non-food renewable materials, such as cellulosic based materials.\u000a      Plaxica's technology allows high performance PLA to replace traditional\u000a      polymers produced from oil. It has a flexible approach to how it interacts\u000a      with licensees, recognising that a successful biopolymers operation\u000a      requires technology in the areas of feedstock production and conversion,\u000a      intermediates production and polymerisation. Plaxica focuses on the\u000a      ability to credibly scale up the chemical processes developed on a lab\u000a      scale. Using a multidisciplinary team of chemists, process engineers and\u000a      technical consultants the team works to deliver the correct balance of\u000a      innovation, capital and operating costs. Before the launch of Plaxica, the\u000a      UK had no commercial interest in the production of PLA, though several\u000a      distributors could supply it.\u000a    Plaxica was formed to commercialise strong IP in low cost, high\u000a      performance bioplastics. The product is a greener, cleaner and stronger\u000a      form of plastic made from natural feedstock and can be used for a variety\u000a      of applications including for example, fibres and packaging. It is \"developing\u000a        next generation biopolymers that will be both cheaper to produce and\u000a        have improved properties compared with first generation biopolymers. The\u000a        novel chemistry underpinning this technology came from research by\u000a        Professor Vernon Gibson FRS and Dr Ed Marshall at Imperial College\u000a        London. Plaxica's technology uses sustainable feedstocks to produce a\u000a        biopolymer known as polylactic acid (PLA) using more energy-efficient\u000a        processes, to produce a stronger, higher-quality polymer. The result\u000a        should be a low-cost, environmentally-friendly biopolymer for use in\u000a        applications as diverse as packaging, textiles, electronics and\u000a        automobile parts\" [C].\u000a    Since its formation in 2008 Plaxica has had several successful funding\u000a      rounds and key milestones. Imperial Innovations funded the initial launch\u000a      of the company in 2008. A project involving Plaxica, Imperial and\u000a      Holloid Plastics Ltd won funding for the High Value Manufacturing\u000a      Technology Strategy Board in September 2009 [D], leading to\u000a      conditions for the successful injection moulding of stereocomplex PLA. In\u000a      October 2009 Plaxica received &#163;1m in equity funding from Imperial\u000a      Innovations, the Carbon Trust Investments Ltd and the National Endowment\u000a      for Science, Technology and the Arts (NESTA) [C]. Commenting on the\u000a      investment the CEO of Imperial Innovations Group plc, Susan Searle, said \"Existing\u000a        plastics are no longer sustainable because of the oil they use and the\u000a        waste they leave. This investment will help Plaxica develop a low-cost\u000a        and environmentally friendly alternative for a wide range of industrial\u000a        and consumer applications\" [C]. Rachael Nutter, Investment Manager\u000a      at Carbon Trust Investment Partners LLP commented \"The rapidly growing\u000a        market for bioplastics and Plaxica's position as a leader in this field\u000a        have made it an exciting company to invest in. Plaxica has the potential\u000a        to transform the cost and carbon footprint of PLAs and develop new\u000a        applications for this polymer\" [C]. This equity investment allowed\u000a      Plaxica to \"continue developing processes aimed at reducing PLA\u000a        production costs to the point where it can compete with mass volume\u000a        oil-based plastics\" [C]. In 2010 Plaxica announced that it\u000a      raised a further &#163;3 million in a Series A financing in which all existing\u000a      institutional investors participated. The funds were used to accelerate\u000a      development and scale up of the company's next generation PLA technology\u000a      [E]. The funding consists of &#163;1.2m Imperial Innovations) and &#163;1.8m from\u000a      other existing shareholders [E]. In 2011 Plaxica completed a &#163;5m\u000a      round in Series B financing with investment from Imperial Innovations,\u000a      Invesco Perpetual and NESTA Investment [F]. In 2010, Plaxica began to rent\u000a      space in the Wilton Research Centre on Teesside to focus on process\u000a      development, scale-up and demonstration. By September 2012 the\u000a      demonstration facility had entered the commissioning phase [20\/9\/12\u000a      announcement, G]. By May 2013 \"Plaxica [had] demonstrated the\u000a        production of extremely high purity D-lactic acid from a racemic lactic\u000a        acid feedstock, validating [their] Optipure enantiomer separation\u000a        technology\" [30\/5\/13 announcement, G] and had attracted commercial\u000a      interest from a number of clients and partners, especially in South East\u000a      Asia and North America [H]. The product quality exceeded industry\u000a      standards for polymer-grade lactic acid which was \"an important\u000a        milestone in the validation of Plaxica's low cost technology for the\u000a        production of lactic acid\" [30\/5\/13 announcement, G]. In total\u000a      Plaxica has raised almost &#163;10m in investment in the 2008-2013 REF period.\u000a      It continues to attract investment as demonstrated by the recent &#163;8M\u000a      Series C financing round [10\/9\/13 announcement, G, H].\u000a    Plaxica currently employs 27 people covering R&amp;D, engineering, plant\u000a      operation and commercial functions. This includes 18 people in Wilton in\u000a      the North East of England. Since 2008 Plaxica have employed 25 UK\u000a      graduates in STEM subjects [H]. Further support is provided as required\u000a      from a retained team of ca. 10 consultants (industry and academic\u000a      experts).\u000a    The construction of a pilot demonstration facility in Teesside\u000a      demonstrates Plaxica's commitment to creating jobs and revenue within the\u000a      UK. Examples of the local press include:\u000a    \u000a      \"The licensing company, which develops transformational biopolymer\u000a          technology, only moved into the Wilton Centre 18 months ago but has\u000a          already had to take another laboratory and a large open plan office,\u000a          in addition to its existing lab and two small offices.\" [I]\u000a      \"A technology and licensing company is doubling the size of its\u000a          Teesside operation with the launch of a pilot plant that will\u000a          demonstrate the conversion of bio-renewables into polymers using\u000a          break-through technology.\" [J]\u000a      \"Steve Duffield, accommodation manager at The Wilton Centre, said:\u000a          `The speed of Plaxica's progress is very impressive. It is an ideal\u000a          operation to have at the Centre, complementing other organisations\u000a          also here.'\" [K]\u000a    \u000a    Imperial Innovations, one of the major investors in Plaxica make the\u000a      following statement about the company: \"Plaxica is developing a new\u000a        generation of biopolymers derived from renewable resources. Plaxica's\u000a        polymers are a range of polylactic acid based materials which have\u000a        improved physical properties compared with first generation biopolymers.\u000a        In addition, they have a smaller environmental footprint, and are fully\u000a        recyclable and cost competitive with current oil-based alternatives.\u000a        First generation PLA is by far the most successful biopolymer to date,\u000a        with 25% of the biopolymer market. Plaxica's second generation PLA is\u000a        expected to combine the advantages of biopolymers with the mechanical\u000a        and thermal performance of petrochemical derived plastics and is\u000a        expected to develop a market much larger than that of existing\u000a        biopolymers. Given Plaxica's PLA's improved physical properties, its\u000a        applications will expand beyond the currently limited range of\u000a        applications for which first-generation PLAs can be used... Plaxica's\u000a        second generation PLA polymers are likely to compete effectively with\u000a        conventional oil-derived products such as PET, polypropylene and\u000a        polystyrene in applications ranging from textiles to automotive,\u000a        electronics, household goods and packaging. Plaxica's technology is\u000a        particularly suited to the use of sugars derived from cellulosic\u000a        feedstocks &#8212; which are normally waste products and do not, in general,\u000a        take food out of the supply chain\" [L]. They make the following\u000a      statement about the global polymers market: \"The global polymers market\u000a        is worth more than $400 billion in annual sales and has grown at an\u000a        average of 3.5% per year over the last two decades. The current\u000a        biopolymers market is in excess of $2 billion per annum and is growing\u000a        at more than 10% per year. PLA has 40% of this market, at some $800m,\u000a        and this is forecast to grow to $1bn by 2012\" [L].\u000a    The impact offered by Plaxica is nicely summed up by the CEO: \"Economically\u000a        Plaxica has grown quickly to employ a critical mass of scientist and\u000a        engineers... The emphasis on biopolymers from non-food sources such as\u000a        cellulose has clear societal and environmental impacts, and the focus on\u000a        using bioplastics in durable applications such as automotive interiors\u000a        demonstrates a sustainable advantage not offered by current PLA\u000a        materials\" [H]. Unfortunately, due to \"commercial sensitivities\u000a        in the highly competitive PLA marketplace\", Plaxica are \"unable\u000a        to be more forthcoming with details of the impact already realised by\u000a        the company\" [H].\u000a    ","ImpactSummary":"\u000a    Plaxica is a spin-out from, and based, at Imperial College London with\u000a      economic, societal and environmental impacts. Launched in 2008, Plaxica is\u000a      a process technology licensing business which is tackling the barriers\u000a      that currently prevent a wider acceptance of bioplastics; specifically\u000a      improving properties, decreasing cost and using non-food feedstocks to\u000a      manufacture the biopolymer poly(lactic acid), PLA. Plaxica's technology\u000a      uses sustainable feedstocks to produce PLA using more energy-efficient\u000a      processes, to produce a strong, high-quality polymer, the result of which\u000a      is a low-cost, environmentally-friendly biopolymer for use in applications\u000a      including textiles, packaging, and automobile parts. In the REF period\u000a      Plaxica has raised &#163;10m from investors such as Imperial Innovations,\u000a      Invesco Perpetual and NESTA Investments. The market pull for biorenewable\u000a      materials from consumers is strong and the EU predicts that PLA will\u000a      substitute &gt;10% of the existing market for petrochemical polymers and\u000a      forecasts a market &gt;$15b [A].\u000a    ","ImpactType":"Technological","Institution":"\u000a    Imperial College London\u000a    ","Institutions":[{"AlternativeName":"Imperial College London","InstitutionName":"Imperial College London","PeerGroup":"A","Region":"London","UKPRN":10003270}],"Panel":"B         ","PlaceName":[],"References":"\u000a    (* References that best indicate quality of underpinning research)\u000a    \u000a[1] *A.P. Dove, V.C. Gibson, E.L. Marshall, H.S. Rzepa, A.J.P. White\u000a        and D.J. Williams, \"Synthetic, structural, mechanistic and\u000a        computational studies on single-site beta-diketiminate tin(II)\u000a        initiators for the polymerization of rac-lactide\", J. Am. Chem.\u000a      Soc.,128, 30, pp9834-9843 (2006). DOI,\u000a      81 citations (as at 5\/9\/13)\u000a    \u000a\u000a[2] C.K.A. Gregson, V.C. Gibson, N.J. Long, E.L. Marshall, P.J.\u000a        Oxford and A.J.P. White, \"Redox control within single-site\u000a        polymerization catalysts\", J. Am. Chem. Soc., 128, 23, pp 741-7411\u000a      (2006). DOI, 74\u000a        citations (as at 5\/9\/13)\u000a    \u000a\u000a[3] P. Hormnirun, E.L. Marshall, V.C. Gibson, R.I. Pugh and A.J.P.\u000a        White, \"Study of ligand substituent effects on the rate and\u000a        stereoselectivity of lactide polymerization using aluminium salen-type\u000a        initiators\", PNAS, 103, 42, pp 15343-15348 (2006). DOI,\u000a      58 citations (as at 5\/9\/13)\u000a    \u000a\u000a[4] *E.L. Marshall, V.C. Gibson and H.S. Rzepa, \"A\u000a        computational analysis of the ring-opening polymerization of rac-lactide\u000a        initiated by single-site beta-diketiminate metal complexes: defining the\u000a        mechanistic pathway and the origin of stereocontrol\", J. Am. Chem.\u000a      Soc., 127, 16, pp 6048-6051 (2005). DOI,\u000a      90 citations (as at 5\/9\/13)\u000a    \u000a\u000a[5] *P. Hormnirun, E.L. Marshall, V.C. Gibson, A.J.P. White and D.J.\u000a        Williams, \"Remarkable stereocontrol in the polymerization of\u000a        racemic lactide using aluminium initiators supported by tetradentate\u000a        aminophenoxide ligands\", J. Am. Chem. Soc ., 126, 9, pp 2688-2689\u000a      (2004). DOI, 231\u000a        citations (as at 5\/9\/13)\u000a    \u000a[6] Patent WO2002038574\u000a        A1, \"Diamido alkoxide complexes as polymerization initiators of\u000a        lactides\", Inventors: AP Dove, VC Gibson, EL Marshall, Applicant: AP\u000a      Dove, VC Gibson, EL Marshall, Imperial Innovations, Publication date:\u000a      16\/5\/02\u000a    Grants:\u000a    [G1] EPSRC GR\/N64892\/01,\u000a      \"New initiators for the controlled ring-opening polymerisation (ROP) of\u000a        lactides and lactones\", PI: V Gibson, 27\/09\/00-26\/09\/02, &#163;121,867\u000a    [G2] EPSRC GR\/N12084\/01,\u000a      \"P4:Polymers properties &amp; polymerisation processes\", PI: JS\u000a      Higgins (Chem Eng, Imperial), co-I: V Gibson, 01\/02\/01-31\/07\/04,\u000a      &#163;1,089,242\u000a    [G3] EPSRC GR\/R24838\/01,\u000a      \"Cationic metal alkoxides bearing weakly coordinating anions-new\u000a        catalysts for small molecule and polymer synthesis\", PI: V Gibson,\u000a      22\/10\/01-21\/10\/03, &#163;126,061\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"},{"Level1":"3","Level2":"3","Subject":"Macromolecular and Materials Chemistry"},{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"}],"Sources":"\u000a    [A] `Product overview and market projections of emerging bio-based\u000a      plastics', PRO-BIP 200, Final report, June 09 (archived here)\u000a    [B] http:\/\/www.plaxica.com\/about\/about-us\/\u000a      (archived here\u000a      on 16\/9\/13)\u000a    [C] http:\/\/www.nesta.org.uk\/press_releases\/assets\/features\/plaxica_secures_1m_funding_to_develop_next_generation_renewable_polymers\u000a      (archived here\u000a      on 16\/9\/13)\u000a    [D] http:\/\/www.prw.com\/subscriber\/newsmail2.html?id=1254997521\u000a      (archived here\u000a      on 16\/9\/13)\u000a    [E] http:\/\/www.plasteurope.com\/news\/detail.asp?id=217107\u000a      (archived here\u000a      on 16\/9\/13)\u000a    [F] http:\/\/www.imperialinnovations.co.uk\/news-centre\/news\/imperial-innovations-leads-5m-investment-plaxica\/\u000a      (archived here\u000a      on 16\/9\/13)\u000a    [G] http:\/\/www.plaxica.com\/news-2\/\u000a      (archived here\u000a      on 16\/9\/13)\u000a    [H] Letter from CEO Plaxica Ltd, 1\/11\/13 (available on request)\u000a    [I] http:\/\/www.wiltoncentre.com\/news\/2012\/03\/16\/Plaxica-pilot-plant-plans-lead-to-expansion.html\u000a      (archived here\u000a      on 16\/9\/13)\u000a    [J] http:\/\/www.thejournal.co.uk\/business\/business-news\/plaxica-set-double-size-teesside-4412986\u000a      (archived here\u000a      on 16\/9\/13)\u000a    [K] http:\/\/www.thenorthernecho.co.uk\/business_all\/9581859.Plaxica_scheme_to_create_plastic_from_plants\/\u000a      (archived here\u000a      on 16\/9\/13)\u000a    [L] http:\/\/www.imperialinnovations.co.uk\/ventures\/portfolio\/plaxica\/#\u000a      (archived at here\u000a      on 16\/9\/13)\u000a    ","Title":"\u000a    C3 - Plaxica: Transformational Biopolymer Technology\u000a    ","UKLocation":[{"GeoNamesId":"2643743","Name":"London"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Plaxica's two academic founders, Prof Vernon Gibson and Dr Ed Marshall\u000a      have a strong track record in the design and development of homogeneous\u000a      catalysts for the production of polymers, with a particular focus on\u000a      stereoselective polymerisations. Forging close industrial links in the\u000a      past, they developed a range of polymerisation catalysts including\u000a      examples for polyolefins, acrylics, styrenics and polyesters. Aspects of\u000a      this work have been performed in collaboration with a number of\u000a      multinational chemical companies including BP and BASF.\u000a    Gibson and Marshall started to examine polymers from renewable resources\u000a      in the late 1990s and between 2000 and 2006 produced a number of academic\u000a      publications and patents (e.g. [6]) in the field of stereoselective\u000a      catalysts for the production of poly(lactic acid), PLA. Even from an early\u000a      point in their research Gibson and Marshall realised the need to relate\u000a      their research to real world commercial-type operations, and therefore\u000a      published a number of reports exploring the use of well-defined molecular\u000a      analogues of the industry standard catalyst, stannous octanoate [1].\u000a      Further stand out publications include the first detailed theoretical\u000a      basis for stereoselectivity in lactide polymerisation catalysts (a\u000a      computational study carried out in collaboration with Prof, Henry Rzepa at\u000a      Imperial) [4], and a redox-active catalyst the activity of which can be\u000a      attenuated by the oxidation state of the pendant ligand (work carried out\u000a      with Prof. Nick Long at Imperial) [2]. PLA already had a significant\u000a      profile aided by a number of desirable quantities, including\u000a      biorenewability and biocompatibility and being compostable (according to\u000a      EU and ASTM guidelines). The construction of a 140ktpa plant in Nebraska\u000a      by a Cargill-Dow JV (NatureWorks) was seen as further evidence of the\u000a      promise of PLA.\u000a    The team successfully applied for public funds [G1-G3], but industrial\u000a      support for work on PLA was less straightforward to secure. In the early\u000a      2000's, it was thought that PLA suffered from a number of commercial\u000a      deficiencies e.g. its relatively low thermal stability (it deforms at ca.\u000a      50-55&#176;C), and hydrolytic instability. Its cost of manufacturing was also\u000a      higher than that of the plastics it was predicted to compete most closely\u000a      with e.g. PET, polyethylene terephathlate and PS, polystyrene.\u000a    Significantly, Gibson and Marshall's previous academic work had revealed\u000a      that the properties of PLA could be improved by using catalysts to promote\u000a      the formation of stereoregular PLA. With this advance, thermal stability,\u000a      for example, could be increased to &gt;100&#176;C, greatly increasing the\u000a      potential applications for PLA. Particular success was found with several\u000a      families of aluminium catalysts, some of which led to PLA with melting\u000a      points approaching 200&#176;C [3, 5]. These important and commercially-relevant\u000a      findings in the mid-2000s spawned the idea of Plaxica.\u000a    Key personnel:\u000a    \u000a      Dr E.L. Marshall, Lecturer in Green Chemistry, Imperial College London\u000a        (2005-2009), then Director of Research, Plaxica Ltd (2010-present)\u000a      Prof V.C. Gibson, Chair of Polymer Chemistry and Catalysis then Chair\u000a        of Inorganic Chemistry, Imperial College London (1995-10\/2008), Visiting\u000a        Professor, Department of Materials, Imperial College London,\u000a        (11\/2008-present)\u000a    \u000a    "},{"CaseStudyId":"42245","Continent":[{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"102358","Name":"Saudi Arabia"}],"Funders":["Biotechnology and Biological Sciences Research Council"],"ImpactDetails":"\u000d\u000a    The formation of Bio Nano Consulting arose from the realisation that\u000d\u000a      combining the expertise at Imperial College (A Cass in nanobiotechnology\u000d\u000a      and diagnostics, Tim Jones in nanomaterials) with that at UCL (G Aeppli in\u000d\u000a      nanofabrication and M Horton in nanomedicine), and drawing on the National\u000d\u000a      Physical Laboratory's metrology resources, would present a unique offering\u000d\u000a      in Bionanotechnology to provide services to the UK's biomedical sector.\u000d\u000a      Imperial College and UCL had already jointly established the London Centre\u000d\u000a      for Nanotechnology (LCN) in 2003 and discussions had started on how to\u000d\u000a      build on the academic excellence of the LCN to enhance its interactions\u000d\u000a      with industry. A call for proposals in Micro and Nanotechnology\u000d\u000a      Manufacturing Facilities by the Department of Trade and Industry in 2004\u000d\u000a      led to a successful bid by the consortium of the 3 organisations (late\u000d\u000a      2005) [grant G1]. The company was incorporated in October 2007, appointing\u000d\u000a      the experienced Dr David Sarphie as CEO, who had \"over a decade's worth\u000d\u000a        of senior management expertise in drug delivery, diagnostics and\u000d\u000a        medical-device companies\" [A]. Following a total investment in\u000d\u000a      infrastructure, instrumentation and working capital of &#163;5m from the\u000d\u000a      Technology Strategy Board (TSB) and London Development Agency (LDA), it\u000d\u000a      was officially launched in April 2008 [A, B] as a \"specialist product\u000d\u000a        development consultancy applying nanotechnology tools to address\u000d\u000a        real-world problems from the biomedical industry\" [B].\u000d\u000a    In 2010, following steady growth in the business, Lord Alec Broers\u000d\u000a      accepted the role of Chairman. By late 2010, BNC announced the completion\u000d\u000a      of its publically funded phase of corporate development. To \"mark the\u000d\u000a        company's transition to a self-supporting and revenue-funded\u000d\u000a        organisation, BNC...acquired new expanded offices in central London to\u000d\u000a        meet the increasing demand for its services and specialist expertise\"\u000d\u000a      [C]. At that time BNC had \"completed 22 projects for 16 life science\u000d\u000a        and high-technology sector companies\" and, as an indication of its\u000d\u000a      continued success, \"already [had] a further 10 projects actively in\u000d\u000a        progress\" [C].\u000d\u000a    As a not-for-profit company, wholly owned by Imperial College London and\u000d\u000a      University College London, the business has focussed on applying expertise\u000d\u000a      in bio- and nanotechnology in the two universities to provide technical\u000d\u000a      consulting services to UK and overseas companies and institutions. It\u000d\u000a      offers four main services: consultancy services, project management\u000d\u000a      services, contract research and development, and open access to\u000d\u000a      instrumentation [D]. The BNC business model is to be a `labless' company,\u000d\u000a      employing scientist and engineers, as well as project managers, who will\u000d\u000a      deliver the project objectives and who carry out the research in\u000d\u000a      collaborating academic institutions (Imperial and UCL). In doing so, it\u000d\u000a      pays bench fees and equipment access charges to the Universities. Over the\u000d\u000a      assessment period, the company has diversified both its client base and\u000d\u000a      the type of projects that it has taken on. It currently employs 8 people\u000d\u000a      (7 PhD scientists\/engineers with backgrounds in chemistry, materials\u000d\u000a      science and the life sciences) and has employed a yearly average of 13\u000d\u000a      people over the 2009-2012 period [Item 3, E, F, G]. It has generated &#163;6M\u000d\u000a      worth of revenues from both UK and overseas clients since 2008. During the\u000d\u000a      2009- 2012 period, total revenues exceeded &#163;4.6M of which 78% was\u000d\u000a      attributable to overseas clients [Item 2, E, F, G].\u000d\u000a    BNC's business model of working closely with academic groups has resulted\u000d\u000a      in &#163;2.8M of the revenues being returned to the Universities through bench\u000d\u000a      fees and equipment access payments, as described above [Item 5\/`Research\u000d\u000a      and development expenditure', E, F, G]. The company has filed 8 patent\u000d\u000a      applications and is actively negotiating exploitation agreements for\u000d\u000a      several of these. In total, the company has had approximately 14 domestic\u000d\u000a      and international clients including: Oxford Immunotec Ltd., Applied Nano\u000d\u000a      Detectors Ltd, Lockheed-Martin Inc., Vestergaard Frandsen, Targanta\u000d\u000a      Therapeutics Inc., Linde A.G., King Abdulaziz University, [text removed\u000d\u000a      for publication] [H]. The nature of the consultancy has been quite varied\u000d\u000a      as is demonstrated in the examples below.\u000d\u000a    Oxford Immunotech Ltd: In the work with Oxford Immunitech Ltd, an\u000d\u000a      international medical diagnostics company, that commenced in 2008, BNC\u000d\u000a      applied \"its expertise in nano- characterisation to assist Oxford\u000d\u000a        Immunotec in a project related to its novel Enzyme-Linked ImmunoSPOT\u000d\u000a        (ELISPOT) system...Oxford Immunotec [were] commercialising a diagnostic\u000d\u000a        test to detect tuberculosis (TB) based on its patented T-SPOT\u000d\u000a        technology, effectively providing a new way to diagnose and monitor this\u000d\u000a        deadly disease\" [I]. By collaborating with Oxford Immunotec, BNC\u000d\u000a      facilitated the development of precise, accurate techniques to diagnose\u000d\u000a      and monitor infection and disease. It developed and successfully\u000d\u000a      transferred a method that allowed the client to implement an improved QC\u000d\u000a      process for one of its bought-in assay components.\u000d\u000a    King Abdulaziz University (KAU), Saudi Arabia: In 2009 BNC was\u000d\u000a      chosen to \"lead the UK arm of a collaboration with [KAU] in a\u000d\u000a        multi-million pound environmental nanotechnology endeavour. The\u000d\u000a        agreement, worth in excess of &#163;2 million over two years for BNC and its\u000d\u000a        London partners,... [utilised] the expertise of the London Centre for\u000d\u000a        Nanotechnology (LCN...on two important projects looking at the\u000d\u000a        applications of nanotechnology to environmental issues: `nano-catalysts\u000d\u000a        for wastewater treatment' and `nano-catalysts for the synthesis of fine\u000d\u000a        chemicals'\" [J]. In 2012, a further contract was signed with KAU \"for\u000a        two collaborative research projects in the field of environmental\u000d\u000a        nanotechnology... worth &#163;1 million over two years for BNC and its London\u000d\u000a        partners...The aim of each project will be to develop new classes of\u000d\u000a        multifunctional nanomaterials that can pave the way for more sustainable\u000d\u000a        and energy-efficient processes\" [K]. The work with KAU has resulted\u000d\u000a      in 6 patents being filed and 10 publications (as of June 2013). The\u000d\u000a      patents and publications were a direct result of BNC enabling an on-going,\u000d\u000a      collaboration with Prof Milo Shaffer's group at Imperial.\u000d\u000a    Targanta Therapeutics Inc (Now part of the Medicines Company):\u000d\u000a      Targanta Therapeutics Inc. approached BNC in 2008 for help in elucidating\u000d\u000a      the mechanism of action of one its antibiotics (oritavancin), where the\u000d\u000a      lack of a defined mechanism was seen as a barrier to obtaining FDA\u000d\u000a      approval [L, M]. This project built on the BNC's experience with other\u000d\u000a      antibiotics. BNC researchers \"spearheaded the development of the\u000d\u000a        label-free detection of antibiotic-mucopeptide interactions using\u000d\u000a        cantilever arrays, achieving 100 pM sensitivity...This technique is now\u000d\u000a        being made available on a commercial basis for the assessment of\u000d\u000a        drug-target interaction for a broad range of other antibiotics and drugs\u000d\u000a        under development\" [N]. This \"novel technique exploiting\u000d\u000a        nanotechnology used in the micro-electronics industry presents the\u000d\u000a        opportunity to speed up the discovery process for antibiotics and other\u000d\u000a        pharmaceutical products, as well as many other diagnostic and\u000d\u000a        therapeutic processes\" [L]. Commenting on the project Dr David\u000d\u000a      Sarphie, CEO of the BNC said, \"We are thrilled to be working with a\u000d\u000a        company of the quality of Targanta Therapeutics and to assist them in\u000d\u000a        advancing their understanding of the mechanism of action of this new\u000d\u000a        antibiotic drug candidate. This further establishes the BNC as a leader\u000d\u000a        in applying cantilever-array technology to the assessment of drug-target\u000d\u000a        interaction. In addition, it further demonstrates the important role\u000d\u000a        that the BNC plays in the rapidly expanding bio-nanotechnology sector\"\u000d\u000a      [M].\u000d\u000a    Linde A.G.: Working with Linde A.G., the company developed a\u000d\u000a      method for separating carbon nanotubes that was very successful. The head\u000d\u000a      of nanotechnology at Linde testifies: \"Bio Nano Consulting facilitated\u000d\u000a        a program of collaborative work to advance a UCL\/Imperial technology for\u000d\u000a        the separation of carbon nanotubes from academic research to the point\u000d\u000a        of commercialization. The team at BNC managed the overall project,\u000d\u000a        organised regular meetings and ensured that all milestones and report\u000d\u000a        deadlines were met in accordance with the agreed schedule...the\u000d\u000a        responsiveness was vastly superior compared to similar projects at other\u000d\u000a        institutions...Overall the project was a great success and resulted in\u000d\u000a        not only the commercialisation of the technology, but the establishment\u000d\u000a        of a new business entity in our company\" [O]. Linde subsequently\u000d\u000a      spun out a company to develop this work further.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Bio Nano Consulting (http:\/\/www.bio-nano-consulting.com)\u000d\u000a      was established as an operating business in 2007 through a joint venture\u000d\u000a      between Imperial College London and UCL, whose formation was underpinned\u000d\u000a      by research produced by Professor Tony Cass's group at Imperial. The\u000d\u000a      company is the first consultancy in Europe to focus on the increasingly\u000d\u000a      important intersection between bio- and nanotechnology, and it facilitates\u000d\u000a      the development and commercialisation of new biomedical and\u000d\u000a      nanotechnology-based techniques. Since its start-up, the company has\u000d\u000a      attracted numerous clients across the aerospace and diagnostics sectors,\u000d\u000a      including Lockheed-Martin and [text removed for publication]. The\u000d\u000a      company's activities have generated &#163;6M worth of revenue and it has a\u000d\u000a      growing portfolio. The company, which is based in London, currently has 8\u000d\u000a      full time employees.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    Imperial College London\u000d\u000a    ","Institutions":[{"AlternativeName":"Imperial College London","InstitutionName":"Imperial College London","PeerGroup":"A","Region":"London","UKPRN":10003270}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    (* References that best indicate quality of underpinning research)\u000d\u000a    \u000a[1] Halliwell, C. M., Simon, E., Toh, C. S., Bartlett, P. N.,\u000d\u000a      &amp; Cass, A. E., \"Immobilisation of lactate dehydrogenase on\u000d\u000a        poly (aniline)-poly (acrylate) and poly (aniline)-poly (vinyl\u000d\u000a        sulphonate) films for use in a lactate biosensor\". Analytica Chimica\u000d\u000a      Acta, 453 (2), 191-200 (2002). DOI.\u000d\u000a      Times cited: 37 (as at 6\/3\/13)\u000d\u000a    \u000a\u000a[2] *Wada, A., Mie, M., Aizawa, M., Lahoud, P., Cass, A. E.,\u000d\u000a      &amp; Kobatake, E., \"Design and construction of glutamine binding\u000d\u000a        proteins with a self-adhering capability to unmodified hydrophobic\u000d\u000a        surfaces as reagentless fluorescence sensing devices\", J. Am. Chem.\u000d\u000a      Soc., 125 (52), 16228-16234 (2003). DOI.\u000d\u000a      Times cited: 26 (as at 6\/3\/13)\u000d\u000a    \u000a\u000a[3] *Topoglidis, E., Cass, A. E., Gilardi, G., Sadeghi,\u000a        S., Beaumont, N., &amp; Durrant, J. R., \"Protein\u000d\u000a        adsorption on nanocrystalline TiO2 films: an immobilization strategy for\u000d\u000a        bioanalytical devices\", Anal. Chem., 70 (23), 5111-5113\u000d\u000a      (1998). DOI. Times\u000d\u000a        cited: 140 (as at 6\/3\/13)\u000d\u000a    \u000a\u000a[4] Topoglidis, E., Cass, A. E., O'Regan, B., &amp; Durrant,\u000a        J. R., \"Immobilisation and bioelectrochemistry of proteins on\u000d\u000a        nanoporous TiO2 and ZnO films\", J.\u000d\u000a      Electroanalytical Chem., 517(1), 20-27 (2001). DOI.\u000d\u000a      Times cited: 155 (as at 6\/3\/13)\u000d\u000a    \u000a\u000a[5] *Topoglidis, E., Campbell, C. J., Cass, A. E.,\u000d\u000a      &amp; Durrant, J. R., \"Factors that affect protein adsorption\u000d\u000a        on nanostructured titania films. A novel spectroelectrochemical\u000d\u000a        application to sensing\", Langmuir, 17 (25), 7899-7906\u000d\u000a      (2001). DOI. Times\u000d\u000a        cited: 112 (as at 6\/3\/13)\u000d\u000a    \u000a[6] Patent, PCT Int. Appl., EP\u000a        1071945 B1, \"Biochemical devices and their methods of manufacture\",\u000a      Inventors: Cass, A. E., Durrant, J. R., Gilardi, G.,\u000d\u000a      Applicant: Imperial College\u000d\u000a    Grants:\u000d\u000a    [G1] DTI, \"A Bionanotechnology Centre\", &#163;3.74m (Imperial College element\u000d\u000a      &#163;1.5m), 2005- 2010, PI: Tony Cass\u000d\u000a    [G2] BBSRC, E11939,\u000d\u000a      \"A novel strategy for bioanalytical and biocatalytic devices : biomolecule\u000d\u000a      immobilisation on nanoporous TiO2 electrodes\", 10\/04\/2000 - 10\/04\/2003,\u000d\u000a      &#163;191,904, PI: Prof J. Durrant, Co-Is: Prof A Cass, Prof G Gilardi\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"},{"Level1":"3","Level2":"1","Subject":"Analytical Chemistry"}],"Sources":"\u000d\u000a    [A] http:\/\/medicalphysicsweb.org\/cws\/article\/research\/33933\u000d\u000a      (Archived at\u000d\u000a      https:\/\/www.imperial.ac.uk\/ref\/webarchive\/fmf\u000d\u000a      on 10\/6\/13)\u000d\u000a    [B] http:\/\/www.bio-nano-consulting.com\/NewsAndEvents\/Archive%20-%202008\/LaunchofBioNanoConsulting.aspx\u000d\u000a      (Archived at\u000d\u000a      https:\/\/www.imperial.ac.uk\/ref\/webarchive\/cmf\u000d\u000a      on 10\/6\/13)\u000d\u000a    [C] http:\/\/www.mtbeurope.info\/news\/2010\/1011038.htm\u000d\u000a      (Archived at\u000d\u000a      https:\/\/www.imperial.ac.uk\/ref\/webarchive\/gmf\u000d\u000a      on 10\/6\/13)\u000d\u000a    [D] http:\/\/www.bio-nano-consulting.com\/ServicesAndExperts\/OurServices.aspx\u000d\u000a      (archived at\u000d\u000a      https:\/\/www.imperial.ac.uk\/ref\/webarchive\/qmf\u000d\u000a      on 11\/6\/13)\u000d\u000a    [E] Bio Nano Annual Report, year ending 31 July 2010 (available here)\u000d\u000a    [F] Bio Nano Annual Report, year ending 31 July 2011 (available here)\u000d\u000a    [G] Bio Nano Annual Report, year ending 31 July 2012 (available here)\u000d\u000a    [H] CEO, Bio Nano Consulting\u000d\u000a    [I] http:\/\/www.azonano.com\/news.aspx?newsID=7023\u000d\u000a      (Archived at\u000d\u000a      https:\/\/www.imperial.ac.uk\/ref\/webarchive\/hmf\u000d\u000a      on 10\/6\/13)\u000d\u000a    [J] http:\/\/www.bio-nano-consulting.com\/NewsAndEvents\/Archive%202009\/Saudi%20Contract.aspx\u000d\u000a      (Archived at\u000d\u000a      https:\/\/www.imperial.ac.uk\/ref\/webarchive\/kmf\u000d\u000a      on 11\/6\/13)\u000d\u000a    [K] http:\/\/www.bio-nano-consulting.com\/NewsAndEvents\/News\/New%20KAU%20contract.aspx\u000d\u000a      (Archived at https:\/\/www.imperial.ac.uk\/ref\/webarchive\/lmf\u000d\u000a      on 11\/6\/13)\u000d\u000a    [L] http:\/\/www.mtbeurope.info\/content\/ft1106001.htm\u000d\u000a      (Archived at\u000d\u000a      https:\/\/www.imperial.ac.uk\/ref\/webarchive\/pmf\u000d\u000a      on 11\/6\/13)\u000d\u000a    [M] Bio Nano Press release, 'Bio Nano Consulting commences first\u000d\u000a      pharmaceutical project' 17\/1\/08, (available here)\u000d\u000a    [N] http:\/\/www.bio-nano-consulting.com\/SuccessStories\/SuccessStories\/TargantaTherapeutics.aspx\u000d\u000a      (Archived at\u000d\u000a      https:\/\/www.imperial.ac.uk\/ref\/webarchive\/nmf\u000d\u000a      on 11\/6\/13)\u000d\u000a    [O] http:\/\/www.bio-nano-consulting.com\/Testimonials\/Testimonials\/Linde%20AG.aspx\u000d\u000a      (Archived at\u000d\u000a      https:\/\/www.imperial.ac.uk\/ref\/webarchive\/mmf\u000d\u000a      on 11\/6\/13)\u000d\u000a    ","Title":"\u000d\u000a    C4 &#8212; Bio Nano Consulting: a successful bio and nanotechnology consultancy\u000d\u000a      business\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2643741","Name":"City of London"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    The establishment of Bio Nano Consulting (BNC) was a direct consequence\u000d\u000a      of a DTI grant [G1] under the Micro and Nanotechnology Manufacturing\u000d\u000a      Initiative Capital Facilities programme in the specific area of\u000d\u000a      bionanotechnology (awarded in 2005). Its remit was to help UK industry in\u000d\u000a      de- risking new micro- and nanotechnology enabled biomedical devices,\u000d\u000a      especially in the diagnostics sector.\u000d\u000a    In a series of papers, the Cass group at Imperial College demonstrated\u000d\u000a      that the use of protein design and engineering, often in combination with\u000d\u000a      nanostructured surfaces, could lead to novel sensor designs. The use of\u000d\u000a      engineered extensions (`tags') to enzymes was shown to enhance their\u000d\u000a      immobilisation on sensor surfaces. This work was in collaboration with the\u000d\u000a      Universities of Warwick, Southampton and Texas (Austin) [e.g. 1]. A\u000d\u000a      related collaboration with Prof E. Kobatake's group at the Tokyo Institute\u000d\u000a      of Technology, funded by JSPS and BBSRC, was also focussed along the same\u000d\u000a      lines [2]. Most of the research prior to this used very non-specific and\u000d\u000a      poorly controlled chemistry to attach enzymes to surfaces, often resulting\u000d\u000a      in significant and variable loss of function. Our work on engineered tags\u000d\u000a      showed how they could be used to develop a more rational approach. In\u000d\u000a      addition, the attachment of enzymes to nanostructured metal oxide surfaces\u000d\u000a      was being investigated, through collaboration with Prof James Durrant and\u000d\u000a      funded by the BBSRC [G2], and it was shown that a functional coupling\u000d\u000a      between the hard and soft materials could be achieved [3-5]. The unique\u000d\u000a      properties of the metal oxides meant that both optical and electrochemical\u000d\u000a      signal transduction schemes could be used, so yielding a flexible design\u000d\u000a      strategy. This resulted in the grant of a patent [6] with Cass, Durrant\u000d\u000a      and Gilardi as inventors. These papers and the patent established the\u000d\u000a      advantages of using engineered proteins with nanomaterials in producing\u000d\u000a      novel diagnostic devices, as well as demonstrating the expertise of the\u000d\u000a      Cass group in this area. It was this proven, internationally recognized\u000d\u000a      expertise that led directly to the establishment of BNC and the early\u000d\u000a      contracts that it won with diagnostics companies.\u000d\u000a    The personnel contributing to this research programme at Imperial were\u000d\u000a      Academic staff members Prof A.E. Cass (1983-present), Prof James Durrant\u000d\u000a      (1993-present), Prof Gianfranco Gilardi (Reader 1993-2011 then Visiting\u000d\u000a      Professor 2011-present), and research associate Catherine Halliwell\u000d\u000a      (1998-2002). The primary collaborators were the group of Prof E Kobatake\u000d\u000a      (Tokyo), Prof P.N. Bartlett (University of Southampton). In the\u000d\u000a      collaboration with Southampton, the contribution of the Cass group was to\u000d\u000a      carry out all the protein engineering work and to characterise the\u000d\u000a      engineered proteins in terms of their biochemical properties.\u000d\u000a      Incorporating these engineered proteins into electrically conducting\u000d\u000a      polymers and demonstrating the sensing aspects was done both at Imperial\u000d\u000a      and in Southampton. Collaborating with the Tokyo group, we had already\u000d\u000a      cloned, engineered and fluorescently labelled the glutamine binding\u000d\u000a      protein and this knowledge and materials (plasmids) were sent to Tokyo,\u000d\u000a      where the new tag was attached and the behaviour of the immobilised\u000d\u000a      protein characterised.\u000d\u000a    "},{"CaseStudyId":"42246","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"1605651","Name":"Thailand"},{"GeoNamesId":"1327865","Name":"Myanmar"},{"GeoNamesId":"1835841","Name":"South Korea"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"1814991","Name":"China"},{"GeoNamesId":"1861060","Name":"Japan"}],"Funders":["Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000a    The impact of the Imperial College Chemistry Department led research on\u000a      solvent effects on east Asian lacquer has been significant and far\u000a      reaching.\u000a    Impact on the V&amp;A\u000a    It allowed accurate risk-benefit analysis that underpinned the use of\u000a      solvents for cleaning, removal of degraded Western varnish and\u000a      consolidation of the light-damaged surface of Mazarin Chest [A].\u000a      Treatments based on this research stabilised this object for an estimated\u000a      50-100 years and allowed it to travel to exhibitions in Japan and the USA\u000a      in 2008-9, with combined attendances of more than 200,000 (Kyoto National\u000a      Museum &gt;67,000; Suntory Museum of Art, Tokyo &gt;36,000; J. Paul Getty\u000a      Museum &gt;100,000) [B]. The promotional material for the Getty Museum\u000a      visit, 3\/3\/09-24\/5\/09, described the conservation treatment as having been\u000a      \"Backed by thorough scientific and art historical research\" [C, p4\u000a      of exhibition brochure]. In October 2009 the Chest was returned to\u000a      permanent display in the V&amp;A's Toshiba Gallery of Japanese Art to\u000a      coincide with the staging of the international conference, `Crossing\u000a      Borders: The Conservation, Science and Material Culture of East Asian\u000a      Lacquer' [2]. There were around 3,000,000 visitors to the V&amp;A in South\u000a      Kensington in both 2012\/13 and 2011\/12 (the V&amp;A does not count visitor\u000a      numbers to individual permanent galleries).\u000a    The V&amp;A is home to one of the most significant collections of\u000a      Japanese lacquer in any Western collection. It is also home to smaller\u000a      collections of Chinese, Korean, Burmese and Thai lacquer. The knowledge\u000a      and experience gained though the collaboration with Prof Welton and the\u000a      Imperial Chemistry Department have been applied to all subsequent\u000a      conservation treatments of East Asian lacquer at the V&amp;A [D]. The\u000a      beneficiaries of this impact were the V&amp;A and its audiences (UK and\u000a      international) through improved preservation and presentation of East\u000a      Asian lacquer objects that form part of the UK national art collection.\u000a    Impact on the British Museum\u000a    The research on the solvent effects on East Asian lacquer has also had an\u000a      impact on the conservation department at the British Museum. The British\u000a      Museum has 3,245 objects in its collection that are catalogued as\u000a      containing a variety of lacquer, many of which had been waxed or recoated\u000a      prior to their donation. The museum testifies that (i) the \"research\u000a        undertaken at Imperial College in collaboration with the V&amp;A,\u000a        published in East Asian Lacquer: Material Culture, Science and\u000a        Conservation in 2011, has been crucially important in outlining the\u000a        possible effects of a variety of solvents on these coatings and on the\u000a        lacquer\", (ii) it has \"proved to be an excellent reference point\"\u000a      and (iii) is always recommended as required reading before students\u000a      approach the cleaning of a lacquer object [F]. In conjunction with the\u000a      museum's own increased awareness of the material history of their\u000a      collections, \"the work undertaken at Imperial College in collaboration\u000a        with the V&amp;A has changed the way [they] clean East Asian lacquer\"\u000a      [F].\u000a    Impact on UK and international curation and conservation of East Asian\u000a        lacquer\u000a    Imperial College Chemistry Department undertook a survey of conservators,\u000a      curators and scientists in May-June 2013 to assess the impact of Carolyn\u000a      McSharry and Prof Welton's research into the solvent effects on East Asian\u000a      lacquer [E]. The survey was posted on 11 May 2013 on the Conservation\u000a        Distlist, which includes conservators from several specialities,\u000a      scientists, curators, archivists, librarians and academics from a number\u000a      of disciplines; the survey was also posted on the more specialised Lacquer\u000a        Distlist.\u000a    Reach of solvent research impact: There were more than 100\u000a      respondents of whom 80% identified themselves as curators or conservators\u000a      working with East Asian lacquer. Respondents worked in 17 countries,\u000a      though the UK and US predominated. 50% were based in public institutions,\u000a      25% in universities and 25% in private practice. They represented a very\u000a      experienced field of experts, with 79% having at least 5 years, and 63%\u000a      with more than 10 years of experience in their discipline (i.e. curation,\u000a      conservation, science or teaching) [E].\u000a    Significance of solvent research impact:\u000a    72% of respondents overall were aware of the Imperial Chemistry\u000a      Department's collaborative research on the solvent effects on lacquer.\u000a      Within this group:\u000a    \u000a      93% of respondents rated solvent effects on lacquer research as very\u000a        important or important to them (68% very important; 25% important).\u000a      92% indicated that the research on solvent effects had changed their\u000a        understanding of lacquer a lot (47%) or some (45%). None said their\u000a        understanding had not changed at all.\u000a      75% said that it had changed their practice a lot (13%) or some (62%)\u000a      74% said they use or refer to this research a lot (32%) or some (42%)\u000a        when teaching or mentoring\u000a      80% recommend the 2011 paper [3] to others (39% a lot; 41% some).\u000a      Of the 50% of respondents who worked in public institutions\/museums,\u000a        100% of the UK respondents and 89% of the international respondents\u000a        rated the solvent research as very important or important. Impact on UK\u000a        and international public institutions was substantial for a change in\u000a        knowledge (92%); 50% used the research for teaching and mentoring and\u000a        88% recommended the research to others. This impact was reflected in the\u000a        conservation of objects held in public institutions &#8212; 89% of UK\u000a        institutional respondents involved in the treatment of lacquer objects\u000a        said all of their conservation treatments had been influenced by the\u000a        solvent effects research, the remaining 11% said up to 2\/3 of their\u000a        treatments had been influenced. 29% of international institutional\u000a        respondents reported that all of their treatments had been influenced\u000a        and 41% said that up to 1\/3 of their treatments had been influenced.\u000a    \u000a    Respondents were invited to comment on the solvent effects on lacquer\u000a      research. The following is a sample of the comments received:\u000a    (i) `The results were eye-opening. Extremely important research which\u000a        will change the way we approach degraded lacquer treatments' and `It\u000a        has done so much to influence our thinking about the treatment of\u000a        lacquer. It brought together the different approaches in a discussion\u000a        which we can all benefit from' (National Maritime Museum).\u000a    (ii) `This is very important and curators need to understand this\u000a        process and effect as well' (British Museum).\u000a    (iii) `Should be required reading'\u000a    Comments such as (i), (ii), and (iii) touch on the legacy impact of the\u000a      research. Although experienced specialist lacquer conservators may have\u000a      understood many of the findings already (reflected in the 25% who said\u000a      their practice had not changed very much), they had gained this knowledge\u000a      through (unpublished) trial and error tests. As many solvents cause\u000a      permanent damage to lacquer, the publication of the article [3] allows all\u000a      conservators, regardless of their relative experience, the opportunity to\u000a      make informed judgements without the necessity of damaging valuable\u000a      objects in the process of gaining empirical knowledge.\u000a    Respondents were also invited to comment on the Mazarin Chest project\u000a      more generally and the following is a sample of the comments received:\u000a    (i) `The project has been very influential in our lacquer research at\u000a        the Getty. The Crossing Borders symposium was exceptional in its breadth\u000a        and quality of presentations. The book is an excellent summary of the\u000a        symposium, standing as an important resource for those not fortunate\u000a        enough to attend, and is a ready reference for us in our work. I commend\u000a        all of you for having the courage to inquire about the impact that the\u000a        project has had on the field, because few institutions dare to take that\u000a        type of risk. In conclusion, I consider the Mazarin chest project to be\u000a        a smashing success that sets the bar for other collaborative projects\u000a        very high indeed. I applaud all who have been involved!' and `I\u000a        believe the Mazarin chest conservation project is one of the best and\u000a        most influential project in the lacquer conservation field' (Getty\u000a        Museum, USA)\u000a    (ii) `As noted previously, the project gave validity (in my eyes) to\u000a        the use of urushi-based treatments where appropriate (and with\u000a        appropriate training) &#8212; no other major museum has published urushi-based\u000a        treatments (or possibly undertaken them) so this was a significant\u000a        moment in the history of lacquer conservation in the West' (National\u000a      Gallery of Victoria, Australia).\u000a    (iii) `Japanese conservators have been using methods without thinking\u000a        very much. Mazarin Chest project made us to re-think about these\u000a        good-old methods are suitable or not for particular purposes' (Kogei\u000a      Sozai Kenkyujo, Japan)\u000a    Many of the survey comments also referred very positively to the effort\u000a      made by the Imperial\/V&amp;A team to publicise and disseminate the\u000a      research, including the widely heralded dual language English\/Japanese\u000a      website for the project [A, B].\u000a    ","ImpactSummary":"\u000a    A model of collaborative research excellence describes the work led by\u000a      Imperial College on the conservation of the Mazarin Chest. Renowned as one\u000a      of the finest pieces of Japanese export lacquer in the world, the Mazarin\u000a      Chest is viewed by over 3 million people per year in London's V&amp;A\u000a      museum. Its preservation has allowed it to travel and culturally enrich\u000a      global audiences, most recently at exhibitions in USA and Japan. The\u000a      research on the solvent effects on the preservation of Asian lacquerware\u000a      is universally recognized as changing the working practice of conservators\u000a      and curators and is now well established in the teaching and mentoring of\u000a      heritage organisations around the world.\u000a    ","ImpactType":"Cultural","Institution":"\u000a    Imperial College London\u000a    ","Institutions":[{"AlternativeName":"Imperial College London","InstitutionName":"Imperial College London","PeerGroup":"A","Region":"London","UKPRN":10003270}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"1857910","Name":"Kyoto"}],"References":"\u000a    (* References that best indicate quality of underpinning research)\u000a    \u000a[1] *L. Crowhurst, P. R. Mawdsley, J. M. Perez-Arlandis, P. A. Salter,\u000a        T. Welton, `Solvent-solute interactions in ionic liquids',\u000a      Phys. Chem. Chem. Phys., 5, 2790-2794 (2003). DOI,\u000a      351 citations (as of 1\/7\/13).\u000a    \u000a\u000a[2] *T. Welton, `Solvent effects on East Asian lacquer',\u000a      Lecture presented at `Crossing Borders &#8212; The Conservation, Science and\u000a      Material Culture of East Asian Lacquer' Conference, Victoria and Albert\u000a      Museum, 30-31\/10\/09. [N.B. This was a (sold out) conference attended by an\u000a      international audience of 150 conservators, curators and students].\u000a    \u000a\u000a[3] *Carolyn McSharry, Rupert Faulkner, Shayne Rivers, Milo\u000a        S.P. Shaffer and Tom Welton, `Solvent effects on East\u000a        Asian lacquer (Toxicodendron vernicifluum)', in S. Rivers, R.\u000a      Faulkner and B. Pretzel (eds), `East Asian Lacquer: Material, Culture,\u000a      Science and Conservation', London, Archetype Publications, ISBN: 9781904982609\u000a      (2011). [N.B. Publication of this peer reviewed dual language publication\u000a      was funded by the Getty Foundation.]\u000a    \u000aGrants:\u000a    [G1] Arts and Humanities Research Board Collaborative Doctoral Award\u000a      (CDA), `Conserving Tangible and Intangible Cultural Heritage:\u000a      Removing Degraded Western Varnish from photo-degraded Japanese Lacquer',\u000a      2005-08, PI: Prof T. Welton, award covered Imperial fees for three years,\u000a      plus &#163;14,500 per annum maintenance.\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"21","Level2":"2","Subject":"Curatorial and Related Studies"}],"Sources":"\u000a    [A] The Conservation of the Mazarin Chest website at the V&amp;A,\u000a      http:\/\/www.vam.ac.uk\/page\/c\/conservation-of-the-mazarin-chest\/(archived\u000a      at\u000a      https:\/\/www.imperial.ac.uk\/ref\/webarchive\/1nf\u000a      on 16\/7\/13)\u000a    [B] The Mazarin Chest project website at the V&amp;A,\u000a      http:\/\/www.vam.ac.uk\/content\/articles\/t\/mazarin-chest-conservation-project\/\u000a      (archived at\u000a      https:\/\/www.imperial.ac.uk\/ref\/webarchive\/znf\u000a      on 12\/7\/13)\u000a    [C] J. Paul Getty Museum `Tales in Sprinkled Gold: Japanese Lacquer for\u000a      European Collectors', March 3-May 24 2009, exhibition\u000a      website:http:\/\/www.getty.edu\/art\/exhibitions\/japanese_lacquer\/\u000a      (archived at\u000a      https:\/\/www.imperial.ac.uk\/ref\/webarchive\/2nf\u000a      on 16\/7\/13) and exhibition brochure,\u000a      http:\/\/www.getty.edu\/art\/exhibitions\/japanese_lacquer\/lacquer_brochure.pdf\u000a      (archived here)\u000a    [D] Senior Conservator, Victoria &amp; Albert Museum, South Kensington\u000a    [E] Impact of the Mazarin Chest Survey, Imperial College 2013 (survey\u000a      results available on request).\u000a    [F] Letter from the Keeper of Conservation and Scientific Research, The\u000a      British Museum, 14\/10\/13 (letter available from Imperial on request) \u000a    ","Title":"\u000a    C5 &#8212; Impact of research on the solvent effects on East Asian lacquer by\u000a      Imperial College chemistry department on the conservation of decorative\u000a      art objects\u000a    ","UKLocation":[{"GeoNamesId":"2643743","Name":"London"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    The original underpinning research quantified the polarity (i.e.\u000a      solvent-solute interactions) of various solvents. It was carried out\u000a      within the Imperial Chemistry Department in 2001-2002 by Dr (now\u000a      Professor) T. Welton, Imperial PDRA P. A. Salter (EPSRC, 2000-2002) and\u000a      three Imperial College students, L. Crowhurst, P. Mawdsley (both EPSRC DTA\u000a      funded) and J. M. Perez-Arlandis (EPSRC DTA CASE studentship with Kodak)\u000a      within the Imperial Chemistry Department. This research produced the 2003\u000a      paper `Solvent-solute interactions in ionic liquids' by Crowhurst\u000a      et al. [1] which formed part of the citation for Prof Welton's 2007 RSC\u000a      Sir Christopher Ingold Lectureship.\u000a    The paper describes solvent-solute interactions in ionic liquids and\u000a      molecular solvents and how alternative methodologies give different\u000a      results, demonstrating the importance of the solute in determining the\u000a      observed solvent effects. This is an important consideration for\u000a      understanding how solvents interact with any given material's chemical\u000a      structure. This is a vital consideration when using solvents in\u000a      conservation treatments.\u000a    In 2004 this paper brought Prof Welton's research to the attention of\u000a      Shayne Rivers, a senior conservator in the conservation department of the\u000a      Victoria and Albert Museum, London, a UK non-departmental public body\u000a      funded by the Department of Culture, Media and Sport and the world's\u000a      largest museum of decorative arts and design. Ms Rivers was co-managing a\u000a      V&amp;A project to conserve the Mazarin Chest, the most important example\u000a      of Japanese export lacquer in the world, with an estimated value of &#163;10-15\u000a      million. This object, the centrepiece of the V&amp;A's Japanese\u000a      collection, had been removed from display in 1999 due to its damaged and\u000a      unstable condition. It had become clear that knowledge of the solvent\u000a      effects on Asian lacquer was insufficient to allow the Chest to be cleaned\u000a      without significant risk of permanent damage to, or loss of, the\u000a      decoration, where most of the aesthetic, historic and technical value of\u000a      this unique object is located. Ms Rivers contacted Prof Welton to ask him\u000a      to assist her.\u000a    As a result, in 2005 Prof Welton and Ms Rivers established an AHRB funded\u000a      Collaborative Doctoral Award entitled `Conserving Tangible and Intangible\u000a      Cultural Heritage: Removing Degraded Western Varnish from photo-degraded\u000a      Japanese Lacquer' [G1]. This was designed to guide Ms Rivers' conservation\u000a      practice by using quantitative scientific evidence of the effects of\u000a      solvents on these materials to identify whether, and if so which, solvent\u000a      treatments have the potential to remove degraded western varnish without\u000a      damaging underlying photo-degraded Japanese Lacquer. The research was\u000a      carried out from 2005-8 in the Imperial Chemistry Department with joint\u000a      supervision by Chemistry Department staff (Prof. T. Welton and Dr &#8212; now\u000a      Prof &#8212; M. Shaffer), V&amp;A curatorial (Dr R. Faulkner) and conservation\u000a      (S. Rivers) staff.\u000a    Key findings of this research were presented at an international\u000a      conference in 2009 [2] and published in English and Japanese in 2011 [3].\u000a      The Imperial research provided detailed information on the swelling and\u000a      leaching effects of a range of solvents used by conservators when cleaning\u000a      and stabilising Asian lacquer during conservation treatments. It\u000a      established, for the first time, which solvents could be used without\u000a      causing damage to Asian lacquer and the risks involved if less benign\u000a      solvents were required. It also emphasised that due to the kinetics of the\u000a      swelling process, the technique used by the conservator may be as\u000a      important as solvent choice, reinforcing the inextricable\u000a      inter-relationship between chemistry and individual conservation practice.\u000a    "},{"CaseStudyId":"42247","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"1814991","Name":"China"},{"GeoNamesId":"1861060","Name":"Japan"},{"GeoNamesId":"2921044","Name":"Germany"},{"GeoNamesId":"3017382","Name":"France"},{"GeoNamesId":"1835841","Name":"South Korea"}],"Funders":["Engineering and Physical Sciences Research Council","Royal Society"],"ImpactDetails":"\u000d\u000a    The work carried out at Imperial between 1994 and 1999 was the basis of\u000d\u000a      the initial patent [3], applied for in 1995. This patent, which was\u000d\u000a      assigned to Nanoco from Imperial, was the first in the Nanoco IP portfolio\u000d\u000a      as described in Nanoco's 2009 admission document to AIM, the London Stock\u000d\u000a      Exchange's international market for smaller growing companies: `Nanoco's\u000a        earliest patent family dates back to 1995 and contains granted patents\u000d\u000a        in the US, Germany, France and the UK relating to the use of metal\u000d\u000a        complexes to produce nanocrystalline material known as the Single Source\u000d\u000a        Precursor technology. The Single Source Precursor technology was\u000d\u000a        developed by Professor Paul O'Brien while he was at Imperial College,\u000d\u000a        London and all IP was subsequently assigned to Nanoco' [A, p24].\u000d\u000a    This Imperial research provided the backbone for the spin-out of the\u000d\u000a      company which occurred in 2001 after Prof. O'Brien had moved to the\u000d\u000a      University of Manchester. Further patents did not follow until 2004 after\u000d\u000a      Nanoco had been running for 3 years, and as such, the initial patent can\u000d\u000a      be viewed as the cornerstone of Nanoco's commercialisation strategy and\u000d\u000a      the emergence of Nanoco in general. A letter from the Non-Executive\u000d\u000a      Chairman of the Nanoco Group confirms the role of the Imperial research in\u000d\u000a      the early life of the company [B].\u000d\u000a    Highlights of post 2008 impact\u000d\u000a    In 2008 Nanoco won the UK Trade &amp; Industry Business\u000d\u000a      Innovation Award in the category of Clean Technologies [C], signed a\u000d\u000a      distribution agreement with Japan-based Kisco, a major electronics\u000d\u000a      materials supplier, and signed a supply and licence agreement with a major\u000d\u000a      Japanese LED manufacturer [D].\u000d\u000a    In 2009, in addition to successfully floating on AIM (AIM:NANO)\u000d\u000a      [A], Nanoco signed a joint development agreement with Japan based Fine\u000d\u000a      Polymers (owned by Kisco) to service the LED markets outside Japan [D].\u000d\u000a      Revenues in the year to 31 July 2009 were &#163;1.99 million, comprising of\u000d\u000a      milestone payments from strategic partners and income from the sale of\u000d\u000a      products by distribution partners. The company's cash, and cash\u000d\u000a      equivalents, at the financial year's end (7\/2009) were &#163;6.59 million [D].\u000d\u000a    2010 saw a joint development agreement signed with a major\u000d\u000a      Japanese electronics company for LED backlighting of televisions and a\u000d\u000a      joint development agreement signed with Tokyo Electron for a photovoltaic\u000d\u000a      film, marking the first agreement in the solar power sector [E]. In terms\u000d\u000a      of manufacturing, significant progress was made with procurement of a new\u000d\u000a      production facility in Runcorn, Cheshire as the company's first commercial\u000d\u000a      production plant and the addition of a series of scale-up reactors,\u000d\u000a      critical for the progression of quantum dots from very small scale\u000d\u000a      laboratory manufacture to mass production, in the Manchester headquarters.\u000d\u000a      Turnover for the year (to 7\/2010) was &#163;2.9 million [E].\u000d\u000a    In 2011 the Runcorn production facility was designed and built on\u000d\u000a      time and on budget. 1kg of red CFQDs were produced at Runcorn and shipped\u000d\u000a      to a Japanese LED customer triggering a $2 million payment [F].\u000d\u000a      Manufacturing quantum dots on this scale was a world-first technical\u000d\u000a      achievement and underlined the scalability of Nanoco's technology. A\u000d\u000a      follow-on product development agreement, worth $800,000, was signed with a\u000d\u000a      major Japanese company whose products include LCD TVs [F, G]. This\u000d\u000a      agreement, which followed an 18 month JDA, focused on the final steps in\u000d\u000a      combining CFQD into an LCD TV for commercial launch [F]. A JDA was signed\u000d\u000a      with one of the world's largest lighting companies in August 2011 for use\u000d\u000a      of QDs in general lighting [G]. The company's cash, and cash equivalents,\u000d\u000a      at the financial year's end (7\/2011) were &#163;17.1million, up from &#163;5.68M the\u000d\u000a      previous year, and its turnover &#163;2.6 million [F].\u000d\u000a    In January 2012 Nanoco received a $1 million payment from major\u000d\u000a      Japanese LED corporation for achieving the specified performance criteria\u000d\u000a      for green QDs and in May 2012 it received $2 million payment for the\u000d\u000a      delivery of 1kg of the green QDs, a major technical achievement. These\u000d\u000a      payments follow similar payments achieved for the successful development\u000d\u000a      and delivery of red quantum dots in 2011. This Japanese corporation is now\u000d\u000a      working to incorporate the Company's CFQD directly onto LEDs for small\u000d\u000a      size LCD displays [H]. Following significant technical progress achieved\u000d\u000a      during the year a further thin film solar development agreement was signed\u000d\u000a      with Tokyo Electron. In October 2012, Nanoco signed a follow-on joint\u000d\u000a      development agreement with Osram, one of the world's largest lighting\u000d\u000a      companies [G]. Production scale-up plans were also on track in 2012 with\u000d\u000a      the production capacity design of an upgraded Runcorn lab increased to\u000d\u000a      400kg a year, reflecting a greater projected demand for quantum dots [I,\u000d\u000a      J]. Turnover for the year was &#163;2.95m and the company's cash, and cash\u000d\u000a      equivalents, at the financial year's end (7\/2012) were &#163;15.5 million [H].\u000d\u000a    In January 2013 Nanoco announced a worldwide licensing agreement\u000d\u000a      with the Dow Electronic Materials division of the Dow Chemical Company\u000d\u000a      [G]. Under the terms of the agreement, Dow will have exclusive worldwide\u000d\u000a      rights for the sale, marketing and manufacture of Nanoco's CFQDs for use\u000d\u000a      in electronic displays such as TVs, computer screens, tablets and\u000d\u000a      smartphones. Nanoco will receive royalty payments from Dow related to its\u000d\u000a      sales of CFQDs. Dow's experience of manufacturing scale-up was a key\u000d\u000a      component of the licensing agreement and it is expected that full\u000d\u000a      commercial production will begin in 2014 [G]. Following the announcement\u000d\u000a      of the \"transformational global licensing agreement\" with Dow,\u000d\u000a      Nanoco shares rose more than 21 per cent [K].\u000d\u000a    As of January 2013 Nanoco employed 78 staff at its Manchester\u000d\u000a      headquarters and Runcorn plant [G]. By November 2013, the market\u000d\u000a      capitalization of Nanoco was approximately &#163;340 million [B].\u000d\u000a    Selected highlights of technological impact\u000d\u000a    Nanoco is \"the only company in the world that has managed to\u000d\u000a        manufacture quantum dots without the use of cadmium, a toxic chemical\u000d\u000a        effectively banned from most consumer products\" [L]. Nanoco's main\u000d\u000a      US rivals, Nanosys and QD Vision, use the heavy metal &#8212; \"the presence\u000d\u000a        of which in the environment, even in small quantities, can potentially\u000d\u000a        be harmful to human health\" [J] This gives the company a \"dominant\u000d\u000a      position in a potentially huge global market for quantum dot technology\"\u000d\u000a      [J]. In many regions of the world there is now, or soon to be, legislation\u000d\u000a      to restrict and in some cases ban heavy metals in many household\u000d\u000a      appliances such as IT &amp; telecommunication equipment, lighting\u000d\u000a      equipment, and electrical and electronic tools. In Europe, the restricted\u000d\u000a      metals include cadmium. There are similar regulations in place or soon to\u000d\u000a      be implemented worldwide including China, Korea, Japan and the US. Nanoco\u000d\u000a      has developed and is currently extending the range of restricted metal\u000d\u000a      free quantum dots [M].\u000d\u000a    Quantum dots prepared by Nanoco have numerous optical and structural\u000d\u000a      advantages over traditional dyes, phosphors and fluorophores, and the\u000d\u000a      scale up of high quality materials afforded by the single source route\u000d\u000a      pioneered at Imperial allows the materials to realistically be used in\u000d\u000a      application. The use of Nanoco's green and red emitting quantum dots, when\u000d\u000a      applied to a blue emitting LED are the basis of extremely efficient\u000d\u000a      sold-state lighting; whereas traditional light bulbs are up to 5%\u000d\u000a      efficient with a life time of 500 hours, quantum dot\/LED lighting is\u000d\u000a      suggested to be over 60% efficient with a life time of 50,000 hours [N].\u000d\u000a      Similarly, Nanoco's QDs are to be incorporated into organic LEDs, which\u000d\u000a      have benefits including improved energy efficiency, lower cost and\u000d\u000a      improved display quality whilst removing the need for filters or\u000d\u000a      backlights.\u000d\u000a    Future impact\u000d\u000a    The Quantum Dot and Quantum Dot Display markets, worth $150.1 million in\u000d\u000a      2012, are anticipated to reach $6.4 billion by 2019 as technology matures\u000d\u000a      and is designed into products [O].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    The research on the use of single source precursors in quantum dot\u000d\u000a      synthesis undertaken by Professor Paul O'Brien in the Department of\u000d\u000a      Chemistry at Imperial College between 1994 and 1999 resulted in papers and\u000d\u000a      a patent which led to the formation of Nanoco Group PLC, currently a\u000d\u000a      world-leader in the supply of quantum dots (QDs). Quantum dots have\u000d\u000a      applications in backlighting for LCD displays, LED general lighting and\u000d\u000a      thin film solar cells. Nanoco was listed on AIM on the London Stock\u000d\u000a      Exchange in 2009 and by January 2013 Nanoco employed 78 people, had annual\u000d\u000a      revenue of &#163;3 million, and had signed agreements with several major\u000d\u000a      companies in the US and Japan including Dow Chemical, Osram and Tokyo\u000d\u000a      Electron.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    Imperial College London\u000d\u000a    ","Institutions":[{"AlternativeName":"Imperial College London","InstitutionName":"Imperial College London","PeerGroup":"A","Region":"London","UKPRN":10003270}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    (* References that best indicate quality of underpinning research)\u000d\u000a    \u000a[1] * T.Trindade and P.O'Brien, `A single source\u000d\u000a        approach to the synthesis of CdSe nanocrystallites', Adv. Mater., 8,\u000d\u000a      161-163 (1996). DOI,\u000d\u000a      121 citations (as of 26\/2\/13)\u000d\u000a    \u000a\u000a[2] * T. Trindade, P. O'Brien and Xiao-mei Zhang,\u000d\u000a      `Synthesis of CdS and CdSe nanocrystallites using a novel\u000d\u000a        single-molecule precursors approach', Chem. Mater., 9, 523-530\u000d\u000a      (1997). DOI, 205\u000d\u000a        citations (as of 26\/2\/13)\u000d\u000a    \u000a[3] * Patent: PCT Int. Appl., P.O'Brien, and T.Trindade,\u000d\u000a      `Process for preparing a nanocrystalline material', EP\u000a        0 850 194 B1, 1997, 28 pp.\u000d\u000a    \u000a[4] N. Revaprasadu, M. A. Malik, P. O'Brien, G.\u000d\u000a      Wakefield, `A simple route to synthesise nanodimensional CdSe-CdS\u000d\u000a        core-shell structures from single molecule precursors', Chem.\u000d\u000a      Commun., 1573-1574 (1999). DOI,\u000d\u000a      37 citations (as of 4\/7\/13)\u000d\u000a    \u000a\u000a[5] M. Green and P. O'Brien, `A novel metalorganic\u000d\u000a        route for the direct and rapid synthesis of monodispersed quantum dots\u000d\u000a        of indium phosphide', J. Chem. Soc. Chem. Commun., 2459-2460 (1998).\u000d\u000a      DOI, 32 citations (as\u000d\u000a        of 26\/2\/13)\u000d\u000a    \u000a\u000a[6] M.A. Malik, P. O'Brien, G. Wakefield and N.\u000a        Revaprasadu, `A novel route for the preparation of CuSe and\u000d\u000a        CuInSe2 nanoparticles', Mat. Res. Soc.\u000d\u000a      Symp. Proc., 536, 371-377 (1999). DOI,\u000d\u000a      89 citations (as of 26\/2\/13)\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"},{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"},{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"}],"Sources":"\u000d\u000a    [A] Nanoco Group PLC, Admission to AIM document, 2009 (available here).\u000d\u000a    [B] Letter from Non-Executive Chairman, Nanoco Group plc, 4\/11\/13 (letter\u000d\u000a      available from Imperial on request)\u000d\u000a    [C] Clean Technology award, 2008 http:\/\/www.nanotech-now.com\/news.cgi?story_id=31228\u000d\u000a      (archived here\u000d\u000a      on 10\/7\/13)\u000d\u000a    [D] Nanoco Group PLC, Annual Report and Accounts, 2009 (available here)\u000d\u000a    [E] Nanoco Group PLC, Annual Report and Accounts, 2010 (available here)\u000d\u000a    [F] Nanoco Group PLC, Annual Report and Accounts, 2011 (available here)\u000d\u000a    [G] Nanoco Group PLC, Interim Report For the six months ended 31 January\u000d\u000a      2013 (available here)\u000d\u000a    [H] Nanoco Group PLC, Annual Report and Accounts, 2012 (available here)\u000d\u000a    [I] \"Nanoco performance triggers 1m dollar payment \", Manchester Evening\u000d\u000a      News article, 31\/1\/12, http:\/\/www.manchestereveningnews.co.uk\/business\/innovation\/nanoco-group-continues-to-build-momentum-873420\u000d\u000a      (archived here\u000d\u000a      on 10\/7\/13)\u000d\u000a    [J] \"Nanoco strives to join up the `quantum dots'\", FT article, 15\/10\/12,\u000d\u000a      http:\/\/www.ft.com\/cms\/s\/0\/47cae7c6-1492-11e2-8cf2-00144feabdc0.html#axzz2Ydiga9dT\u000d\u000a      (archived here\u000d\u000a      on 10\/7\/13)\u000d\u000a    [K] \"Yesterday's trading: Footsie climbs as company earnings buoy\u000d\u000a      investor mood; Nanoco rockets after Dow deal\", Daily Mail article,\u000d\u000a      23\/1\/13, http:\/\/www.thisismoney.co.uk\/money\/article-2267143\/MARKET-REPORT-Nanoco-rockets-Dow-deal.html#ixzz2YeQhl6YJ\u000d\u000a      (archived here)\u000d\u000a    [L] FE Trustnet.com article, 26\/6\/13, http:\/\/www.trustnet.com\/News\/435479\/fidelitys-stock-picks-for-a-high-growth-investor\/2\/1\/\u000d\u000a      (archived here)\u000d\u000a    [M] Nanoco Cadmium-free quantum dots \"CFQD&#8482;\" webpage,\u000d\u000a      http:\/\/www.nanocotechnologies.com\/content\/AdvancedMaterials\/CadmiumFreeQuantumDotsQFQDHeavyMetalFree.aspx\u000d\u000a      (archived here\u000d\u000a      on 10\/7\/13)\u000d\u000a    [N] Nanoco Solid State lighting webpage,\u000d\u000a      http:\/\/www.nanocotechnologies.com\/content\/CommercialApplications\/Lighting.aspx\u000d\u000a      (archived here\u000d\u000a      on 10\/7\/13)\u000d\u000a    [O] PR Newswire article, 25\/6\/13, http:\/\/www.prnewswire.com\/news-releases\/quantum-dot-and-quantum-dot-display-qled-market-shares-strategies-and-forecasts-worldwide-nanotechnology-2013-to-2019-212987981.html\u000d\u000a      (archived here)\u000d\u000a    ","Title":"\u000d\u000a    C6 - Nanoco: a successful quantum dot nanotechnology company\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2643743","Name":"London"},{"GeoNamesId":"2643123","Name":"Manchester"},{"GeoNamesId":"2638960","Name":"Runcorn"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    The underpinning research on single source precursors, the key technology\u000d\u000a      on which the company Nanoco Group PLC was based, was developed at Imperial\u000d\u000a      College London by Professor Paul O'Brien during the period 1994 -1999.\u000d\u000a      Specifically, Tito Trindade carried out the key seminal work on the use of\u000d\u000a      group 2 and group 4 metal diselenocarbamates and dithiocarbamates as\u000d\u000a      precursors for the organometallic synthesis of quantum dots [1,2]. Prior\u000d\u000a      to this work, the only published and available precursor system for the\u000d\u000a      preparation of high quality semiconductor nanoparticles were metal alkyls,\u000d\u000a      silylated chalcogens and phosphorus-chalcogen compounds. This limited the\u000d\u000a      synthesis of quantum dots to expert organometallic chemistry laboratories,\u000d\u000a      and the yield of the reactions using these precursors was often extremely\u000d\u000a      low.\u000d\u000a    The use of simple cadmium dithiocarbamates (which could be prepared in\u000d\u000a      air under ambient conditions using commercially available starting\u000d\u000a      materials) lead to the routine synthesis of CdS nanoparticles, bypassing\u000d\u000a      the need for (CH3)2Cd and S(SiCH3)2,\u000d\u000a      both highly volatile and noxious compounds. Subsequently, the use of\u000d\u000a      single source precursors allowed for the scale-up of quantum dot\u000d\u000a      synthesis, with several grams of CdS being prepared in early 1996 by Mark\u000d\u000a      Green (PhD student, funded by an EPSRC CASE award, with British Telecom).\u000d\u000a      This was at the time, the largest yield of quantum dots prepared in the\u000d\u000a      world via a single organometallic reaction, opening the way for potential\u000d\u000a      commercialisation. Likewise, the preparation of gram scale amounts of\u000d\u000a      CdSe, the standard quantum dot material, was also achieved by the O'Brien\u000d\u000a      group using a range of cadmium diselenocarbamates during this period.\u000d\u000a    The initial work was protected by a key patent [3], `Process for\u000d\u000a        preparing a nanocrystalline material', which became the basis for\u000d\u000a      Nanoco. The patent, filed at Imperial College in 1995, was assigned to\u000d\u000a      Nanoco in 2005 and became the first in a series of patents which were\u000d\u000a      later filed through Nanoco.\u000d\u000a    The use of simple quantum dots in various applications is however limited\u000d\u000a      by their air sensitivity, and for use in for real-life applications, a\u000d\u000a      further inorganic shell is often required. The O'Brien group also reported\u000d\u000a      the first preparation of core\/shell particles using single source\u000d\u000a      precursors (published in 1999) [4].\u000d\u000a    The other key family of semiconducting materials are the III-Vs, such as\u000d\u000a      InP, and this was also prepared by single source precursors (published\u000d\u000a      1998) [5]. These materials are notable for not possessing cadmium, and in\u000d\u000a      the case of InP, have been highlighted as the next generation of\u000d\u000a      biological labels after the initial work on CdSe-based quantum dots raised\u000d\u000a      questions regarding toxicity. Likewise, the O'Brien group was the first\u000d\u000a      group to work on CuInS2 and CuInSe2 quantum dots\u000d\u000a      (published 1999), again prepared by single source precursors [6]. Nanoco\u000d\u000a      now works extensively on cadmium-free quantum dots (CFQDs).\u000d\u000a    Key personnel:\u000d\u000a    \u000d\u000a      Paul O'Brien, Sumitomo\/STS Professor of Inorganic Chemistry and PI,\u000d\u000a        Imperial College (1994 - 1999), Sumitomo\/STS Visiting Professor of\u000d\u000a        Materials Chemistry, Imperial College (1999-2002)\u000d\u000a      Tito Trindade, PhD student (1993-1996, Junta Nacional de Investiga&#231;&#227;o\u000d\u000a        Cientif&#237;ca e Tecnol&#243;gica Praxis XXI program)\u000d\u000a      Mark Green, PhD student (1995 -1998, EPSRC CASE award with British\u000d\u000a        Telecom), RA (1998-1999)\u000d\u000a      Neerish Revaprasadu, PhD student (1996 -1999, Royal Society, Africa\u000d\u000a        Outreach Programme).\u000d\u000a    \u000d\u000a    "},{"CaseStudyId":"42295","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Research Councils UK","Biotechnology and Biological Sciences Research Council"],"ImpactDetails":"\u000a    Background\u000a    The forestry and timber processing sector as a whole contributes about\u000a      &#163;2,000M per year to the UK economy and supports about 40,000 jobs. Of the\u000a      2.5 million tonnes of UK timber harvested annually, approximately\u000a      one-third is of suitable quality for transformation into\u000a      construction-grade sawn products. The remainder is used for paper,\u000a      chipboard, and biofuel, commanding a price about half that of timber for\u000a      construction [1]. The carbon in these other products is returned to the\u000a      atmosphere within 1-10 years, compared to 50-100 years for timber used to\u000a      build houses [2]. Consequently, there are both financial and environmental\u000a      reasons to channel the maximum possible percentage of UK timber into the\u000a      construction industry. To satisfy the UK Building Regulations, timber has\u000a      to meet the C16 quality specification. In practice the limiting C16\u000a      requirement for Sitka spruce, the prevalent conifer species in the UK, is\u000a      its stiffness: hence the relevance of the WestCHEM research.\u000a    Path to impact\u000a    From the outset of the SIRT Project in 2004, its research and KE goals\u000a      were planned together by a management board with majority industrial\u000a      representation. KE was implemented through industry workshops and the\u000a      Forestry Commission's simple but efficient system of Information Notes for\u000a      forest managers. Since 2004, four Glasgow PhDs have been co-funded by the\u000a      Forestry Commission and one part-time PhD student, a professional timber\u000a      buyer, is fully funded by Egger Forestry Ltd.\u000a    Nature of the Impact\u000a    Acoustic tools for measuring timber quality in the forest\u000a    Acoustic technology based on the WestCHEM research described above and\u000a      adapted for commercial use [Sources 3 and 4] was adopted in 2011 by James\u000a      Jones Ltd for measuring stiffness in standing trees [Source 5]. James\u000a      Jones Ltd is the second largest sawmilling company in the UK. Sawmillers\u000a      purchase standing timber, which is then felled, transported, and processed\u000a      prior to machine grading. Normally about 10% of sawn products fail to meet\u000a      the C16 grading standard and must be diverted to pulping or biomass fuel\u000a      [Source 3]. The costs (and embodied energy) of transporting, sawing, and\u000a      kiln-drying these outgrades are then wasted, amounting to about &#163;6M\/year\u000a      UK-wide [Sources 1and 6]. Selecting parcels of standing trees that will\u000a      give a low outgrade percentage is a crucial skill of timber buyers. James\u000a      Jones Ltd is now using acoustic measurements as a decision support tool\u000a      alongside the traditional, empirical skills of their buyers [Source 5]. In\u000a      these circumstances it is difficult to quantify the gain, but a realistic\u000a      estimate is a 1% reduction in outgrades, leading to a saving of about\u000a      &#163;0.4M since the adoption of the technology.\u000a    A further advance in profitability would be possible if individual logs\u000a      of high or low stiffness, rather than stands of trees, could be identified\u000a      at felling and consigned directly to the sawmill or elsewhere. Acoustic\u000a      devices attached to the harvesting machinery are under development by the\u000a      spin-out company Timber Sonics, started up in 2011 by Shaun Mochan, a\u000a      Forestry Commission researcher who was on sabbatical in WestCHEM in 2007.\u000a    Genetically improved Sitka spruce\u000a    Before the study of P. McLean under Jarvis's supervision, it was assumed\u000a      that the stiffness of Sitka spruce wood was controlled mainly by density,\u000a      and that fast growing tree genotypes would produce low-density timber of\u000a      poor stiffness that would not meet the C16 specification for construction\u000a      purposes. The WestCHEM research showed that, although low density is\u000a      indeed connected with fast growth, stiffness need not be. Cellulose\u000a      orientation is much more important than density in determining the\u000a      stiffness of the wood [Source 7]. It is, therefore, possible to combine\u000a      fast growth, straight stems (giving improved out-turn at the sawmill), and\u000a      stiff timber (due to good cellulose orientation). These findings were\u000a      disseminated informally to the forest industry in 2006-2007 [Source 8] and\u000a      a Forestry Commission Information Note followed in 2008 [Source 9]. The\u000a      private forestry sector has enthusiastically adopted improved planting\u000a      stock and the large forestry company UPM Tilhill is planting improved\u000a      material almost exclusively. Across both public and private sectors,\u000a      improved stock now accounts for over 80% of new planting [Source 10] and\u000a      around 50M improved trees have been planted since 2008. The change has\u000a      been driven by the predicted increase in total wood volume as well as\u000a      increased sawlog output, but it would have been inhibited if the\u000a      perception that improved trees would fail to produce construction-grade\u000a      timber had persisted [Source 10].\u000a    The economic benefits are difficult to estimate when trees take typically\u000a      40 years to mature and when there are uncertainties concerning the\u000a      influence of the biomass energy market and the restructuring of UK\u000a      forests. However, at harvest the improved trees planted between 2008 and\u000a      2013 are expected to yield 15M m3 of additional sawlogs [Source\u000a      9], leading to an increase of &#163;75M in the market value of these trees at\u000a      harvest if calculated at today's prices [Source 1]. The increase in total\u000a      yield at harvest is predicted to be 12M m3 [Sources 9,10],\u000a      equivalent to 7M tonnes of fixed CO2, while about 8M tonnes of\u000a      CO2 equivalent will be locked up for the lifetime of the\u000a      buildings incorporating the additional sawn timber [Source 2].\u000a    ","ImpactSummary":"\u000a    The forestry and timber-processing sector contributes about &#163;2,000M per\u000a      year to the UK economy. There are significant benefits to be gained by\u000a      converting the maximum possible percentage of UK wood into construction\u000a      timber products because the highest returns in terms of price and\u000a      environmental impact are achieved with construction grade timber. WestCHEM\u000a      research has contributed to the development of acoustic tools that allow\u000a      construction-grade timber to be identified in the forest. This research\u000a      also led to changes in UK Forestry Commission planting policy, with\u000a      `improved' stock now accounting for &gt;80% of new planting across both\u000a      public and private sectors, yielding an estimated increase of &#163;75M in the\u000a      market value of these trees.\u000a    ","ImpactType":"Technological","Institution":"\u000a    WestCHEM\u000a    ","Institutions":[{"AlternativeName":"Glasgow (University of)","InstitutionName":"University of Glasgow","PeerGroup":"A","Region":"Scotland","UKPRN":10007794},{"AlternativeName":"Strathclyde (University of)","InstitutionName":"University of Strathclyde","PeerGroup":"B","Region":"Scotland","UKPRN":10007805}],"Panel":"B         ","PlaceName":[],"References":"\u000a    Key references to the research are [3] and [4], which are submitted in\u000a      REF2 and [6] which describes the path to impact.\u000a    \u000a[1] M. Jarvis, Cellulose stacks up. Nature 426, 611-612\u000a      (2003). (doi:10.1038\/426611a)\u000a    \u000a\u000a[2] A.&#352;turcov&#225;, I. His, D.C. Apperley, J. Sugiyama &amp; M.C. Jarvis.\u000a      Structural details of crystalline cellulose from higher plants. Biomacromolecules\u000a      5, 1333-1339 (2004). (doi: 10.1021\/bm034517p)\u000a    \u000a\u000a[3] A.N. Fernandes, L.H. Thomas, C.M. Altaner, P. Callow, V.T. Forsyth,\u000a      D.C. Apperley, C.J. Kennedy and M.C. Jarvis. Nanostructure of cellulose\u000a      microfibrils in spruce wood. Proceedings of the National Academy of\u000a        Sciences of the USA, 108, E1195-E1203 (2011). (doi: 10.1073\/pnas.1108942108)\u000a    \u000a\u000a[4] C. Altaner &amp; M.C. Jarvis. Modelling polymer interactions of the\u000a      `molecular Velcro' type in wood under mechanical stress. Journal of\u000a        Theoretical Biology 253, 434-445 (2008). (doi: 10.1016\/j.jtbi.2008.03.010)\u000a    \u000a\u000a[5] D.J. Cosgrove and M.C. Jarvis. Comparative structure and biomechanics\u000a      of plant primary and secondary cell walls. Frontiers in Plant\u000a        Physiology 3, 204-209 (2012). (doi: 10.3389\/fpls.2012.00204)\u000a    \u000a\u000a[6] J. Moore, B. Gardiner, D. Ridley-Ellis, M. Jarvis, S. Mochan, and E.\u000a      MacDonald, Getting the most out of the United Kingdom's timber resource. Scottish\u000a        Forestry, 63, 3-8 (2009). (http:\/\/eprints.gla.ac.uk\/38551\/)\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"6","Level2":"1","Subject":"Biochemistry and Cell Biology"},{"Level1":"7","Level2":"5","Subject":"Forestry Sciences"},{"Level1":"6","Level2":"99","Subject":"Other Biological Sciences"}],"Sources":"\u000a    [1] Forestry Commission, 2012. Coniferous\u000a        Standing Sales Price Index for Great Britain.\u000a    [2] Carbon\u000a        Benefits of Timber in Construction. Forestry Commission Scotland,\u000a      2006.\u000a    [3] S. Mochan, J. Moore and J Connelly. Using\u000a        acoustic tools in forestry and the wood supply chain. Forestry\u000a      Commission Technical Note, 2009.\u000a    [4] B. Gardiner &amp; J Moore. Implications\u000a        for forecasting stiffness. Private Sector Production Forecasting\u000a      Meeting, Edinburgh, 9 March 2009.\u000a    [5] Information from Harvesting and Operations Manager, James Jones and\u000a      Sons Ltd, who is willing to be contacted for corroboration if required.\u000a    [6] Forestry Commission. Forestry\u000a        Statistics 2013.\u000a    [7] J.P. McLean, R. Evans and J.R. Moore. Predicting the longitudinal\u000a      modulus of elasticity of Sitka spruce from cellulose orientation and\u000a      abundance. Holzforschung 64, 295-500 (2010). (doi:\u000a      10.1515\/HF.2010.084)\u000a    [8] BBSRC\u000a        Annual Report 2006-7 p.15.\u000a    [9] S. Mochan, S. Lee and B. Gardiner. Benefits\u000a        of improved Sitka spruce: volume and quality of timber. Forestry\u000a      Commission Research Note, 2008.\u000a    [10] S. Lee &amp; G Watt. Choosing\u000a        Sitka spruce planting stock. Forestry Commission Practice Note, 2012\u000a    ","Title":"\u000a    Listen to the trees: Improving the timber supply chain in the UK\u000a    ","UKLocation":[{"GeoNamesId":"2648579","Name":"Glasgow"}],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Context\u000a    Most of the underpinning research and its transformation into impact were\u000a      carried out within the Strategic Integrated Research in Timber (SIRT)\u000a      project, a collaboration between the Forestry Commission, Edinburgh Napier\u000a      University, and the University of Glasgow (WestCHEM), initiated by a\u000a      Scottish Funding Council strategic grant (2003-2007) and continuing to the\u000a      present with funding from industry, RCUK, and the European Commission. The\u000a      aims of the SIRT Project are to understand wood structure and its\u000a      relationship with timber performance, and to promote the use of UK-grown\u000a      Sitka spruce in the construction industry. SIRT spans from molecules to\u000a      trees and from the forest to the building site. WestCHEM's contribution\u000a      stems from previous BBSRC-funded research on cellulose structure\u000a      (2000-2003) including novel spectroscopic and scattering methods to probe\u000a      disorder and mechanical function.\u000a    Key Research Findings\u000a    Wood is a composite material based on cellulose fibres (microfibrils)\u000a      embedded in a matrix of other carbohydrate polymers and lignin. WestCHEM\u000a      research led to the determination of the structure of the cellulose\u000a      microfibrils [1-3] and their interconnection through disordered interfaces\u000a      with other wood polymers [3,4]. Under tension, wood can stretch by two\u000a      mechanisms. One is by elastic stretching of the cellulose fibres\u000a      themselves, when they are well aligned with the grain in the stiffest and\u000a      strongest wood. The other is a time-dependent, slip-stick mechanism termed\u000a      `molecular Velcro' [4]. Using the metaphor of microfibrils as two pieces\u000a      of Velcro and of hydrogen-bonded, non-cellulosic polymers as the hooks and\u000a      loops between them, tensile force detaches the connections from the\u000a      disordered microfibril surfaces [3], allowing the microfibrils to slide\u000a      until the `Velcro' re-attaches and restores the original strength of the\u000a      structure [4].\u000a    The progressive transition between these two stretching mechanisms\u000a      explains the steep and near-linear dependence of wood stiffness on\u000a      cellulose orientation [5], a key element in the impact of the research on\u000a      the genetic improvement of trees. Previously it had been thought that\u000a      stiffness was controlled more by density, which decreases in fast growing\u000a      trees. In 2004-2007 WestCHEM researchers collected a large body of x-ray\u000a      data on microfibril orientation in Sitka spruce trees of varying genotype\u000a      and showed that fast growing trees do not necessarily suffer the penalty\u000a      in stiffness that had previously been assumed [6].\u000a    The other key development was the introduction of acoustic methods for\u000a      measuring wood stiffness in standing trees. In principle, the stiffness of\u000a      the wood is proportional to the square of the speed of a sound wave\u000a      travelling between two probes attached at different heights on the side of\u000a      the tree. However, the acoustic frequency is so high that part of the\u000a      `molecular Velcro' component is too slow to be captured. The standing-tree\u000a      acoustic stiffness therefore differs from the bending stiffness measured\u000a      by the standard machines used to grade commercial timber. In addition, the\u000a      dominant path of the sound wave is just under the bark, where the\u000a      cellulose is better oriented, and the wood is therefore stiffer than in\u000a      the rest of the tree. Both problems led to scepticism about acoustic\u000a      methods when these were first introduced. However, understanding how wood\u000a      stretches encouraged the WestCHEM group to persist and find practical\u000a      solutions. The ratio of acoustic to bending stiffness was quantified by\u000a      laboratory-scale calibration on well-characterised material, and detailed\u000a      measurements and modelling of the radial variation of microfibril\u000a      orientation, density, and stiffness allowed the properties of timber sawn\u000a      from any point within a tree to be predicted from measurements at its\u000a      surface [6]. The WestCHEM researchers who carried out these experiments\u000a      were members of the SIRT field teams that did the first successful\u000a      standing-tree acoustic surveys in the UK [6].\u000a    Key Researchers\u000a    Dr Michael Jarvis (appointed 1979, now Reader) led a group that included\u000a      Clemens Altaner (SIRT RF 2004-07); Shaun Mochan (visiting researcher on\u000a      sabbatical from the Forestry Commission, 2007) and 5 PhD students funded\u000a      or co-funded by the forestry industry (2004-2013).\u000a    "},{"CaseStudyId":"42296","Continent":[],"Country":[],"Funders":[],"ImpactDetails":"\u000a    In 2011, the U.S. Drug Discovery company, Serometrix, was attracted by\u000a      the University's championing of our computer technology for the\u000a      accelerated discovery of allosterically acting drugs. The company operates\u000a      internationally between other university research teams and the very large\u000a      pharmaceutical companies to identify promising drug leads. At the time,\u000a      the company was focused on developing drugs for the lowering of\u000a      cholesterol levels and had been working on one particular protein target.\u000a      This target was proving intractable to the usual drug discovery process\u000a      and Serometrix had already concluded that some kind of \"shapeshifting\"\u000a      (i.e. allosterically acting) drug was required.\u000a    When we were invited to analyse the target, the company already had its\u000a      own confidential direct experimental data about the location of sites\u000a      where small molecules could bind and produce \"shapeshifting\" (i.e. they\u000a      challenged us with a \"blind trial\"). On receiving our theoretical\u000a      predictions as to suitable site locations (calculated by our technology in\u000a      seconds) and comparing them with their own findings (achieved after\u000a      significant expenditure of their time and money on conventional\u000a      investigation), the company immediately opened negotiations with the\u000a      university to develop a research contract, exclusively license our\u000a      technology and obtain more calculations on other targets (our technology\u000a      is applicable to all 86,000 structures in the Protein Data Bank). The CEO\u000a      of the company said at the time of the initial trial work (Source 1):\u000a    \"What I find extremely exciting about this entire process is that if\u000a        you look at the time required to identify the spot to begin working,\u000a        through to our current understanding as of today &#8212; it is mind boggling!\u000a        If you compare what we have jointly accomplished with these tools, as\u000a        compared to any other drug discovery platform known to man at this time,\u000a        we may have just improved the efficiency of this process by several\u000a        orders of magnitude. It is clear to me that your program is providing\u000a        accurate predictions about regions where these sites might exist.\"\u000a    Since then, the company has concluded our technology is \"best in class\"\u000a      (Source 3) and has:\u000a    \u000a      Contracted with the University of Strathclyde for exclusive access to\u000a        the technology (Sources 3, 6 and 7). The contract and license includes a\u000a        multi-million buyout option and requires the university to provide the\u000a        company with secure on-line access to the technology for 20 years.\u000a      Used its exclusive access to the new technology to help secure U.S.\u000a        venture capital funding of $228k in June 2012 (Source 4) and pursued\u000a        discussions leading to further venture capital funding, final agreement\u000a        for which is expected to be concluded shortly (Source 2).\u000a      Hired a new Business Development Manager and Medicinal Chemist to take\u000a        full advantage of our technology as quickly as possible (two further\u000a        appointments are due in late 2013).\u000a      Applied the technology to accelerate progress on its current portfolio\u000a        of drug targets with the intention of eventually applying it to all\u000a        proteins of interest as drug targets (including revisiting those that\u000a        have been previously investigated by the pharmaceutical industry).\u000a      \"Shaved years off\" the first stage of its core discovery process and\u000a        reduced its planned number of early trial compounds \"from millions to\u000a        hundreds\" (Source 3).\u000a      Discovered new active lead compounds via the first site predictions\u000a        provided by the university in 2011. This work is focused on PCSK9, a\u000a        high value commercial target for treatment of hypercholesterolemia and\u000a        arthrosclerosis (Source 2).\u000a      More widely, the company has established primary areas of therapeutic\u000a        interest including oncology, cardiovascular, metabolic, central nervous\u000a        system and infectious disease and have identified opportunities for the\u000a        following families of compounds (Source 5):\u000a      \u000a        SX-ARPC is a novel family of AR pathway antagonists that have\u000a          potential as a novel therapeutics for Prostate Cancer.\u000a        SX-RDS1 is a novel set of DNA repair inhibitors discovered to\u000a          enhance the effectiveness of radiation therapy in a non-toxic manner.\u000a        SX-HIV1 is a family of retroviral integrase inhibitors with\u000a          applications for a range of human retroviruses including HIV.\u000a      \u000a    \u000a    Drug site predictions from our technology have been used by the company\u000a      to fashion actual drug lead compounds that target the sites. This means\u000a      that the company's employees and their collaborators are now actively\u000a      engaged in experimental work for which both the direction and application\u000a      have been determined by our technology. Their intention is to develop drug\u000a      leads that can be licensed forward to the larger companies and then pursue\u000a      new targets\/leads. As this collaboration matures, the reach will extend\u000a      beyond the company to larger concerns and eventually to those who will\u000a      benefit from the drugs.\u000a    Our tool for the discovery of drugs that \"shapeshift\" their molecular\u000a        targets is showing how to up-regulate and down-regulate\u000a      protein\/enzyme action without abolishing it, and this is a\u000a      paradigm shift from classic drug action. The newer drugs can also be much\u000a        more selective amongst a family of related targets because they are\u000a      not restricted to highly conserved sites, leading to lower dosing\u000a      requirements and fewer toxic side-effects. This innovative industrial\u000a      collaboration and on-line service comes at a time when much of the drug\u000a      discovery industry is embroiled in a continuing saga of expensive failure\u000a      and temptation to fraud through its adherence to conventional wisdom in\u000a      terms of drug action.\u000a    By helping to automate the process, bringing costs down and prompting\u000a      production of less risky drugs, our technology breaks the current log-jam\u000a      in the drug discovery market and makes it more likely that small market\u000a      drugs (i.e. for small groups of sufferers or developing world populations)\u000a      will become viable.\u000a    ","ImpactSummary":"\u000a    A computer technology has been invented to accelerate drug discovery. It\u000a      predicts locations in disease-associated biomolecules where drug molecules\u000a      could bind, induce shape changes, and thereby bring the activity of the\u000a      biomolecule under control. A U.S. drug discovery company, Serometrix, has\u000a      exclusively licensed this technology and incorporated it within their core\u000a      discovery process. The impact upon them has been:\u000a    \u000a      A step change in their technical approach towards small molecule drug\u000a        discovery,\u000a      Attraction of $227k venture capital funding for the new company\u000a        direction,\u000a      Expansion of workforce (four new personnel by end of 2013),\u000a      \"Shaving years off\" their discovery development programme,\u000a      Promising new drug leads,\u000a      Planned reduction of early trial compounds \"from millions to\u000a        hundreds\".\u000a    \u000a    ","ImpactType":"Technological","Institution":"\u000a    WestCHEM\u000a    ","Institutions":[{"AlternativeName":"Glasgow (University of)","InstitutionName":"University of Glasgow","PeerGroup":"A","Region":"Scotland","UKPRN":10007794},{"AlternativeName":"Strathclyde (University of)","InstitutionName":"University of Strathclyde","PeerGroup":"B","Region":"Scotland","UKPRN":10007805}],"Panel":"B         ","PlaceName":[],"References":"\u000a    The three references that best illustrate the quality of the research are\u000a      numbers 2, 4 and 5 below.\u000a    \u000a[1] Foci of amino acid residue conservation in the 3D structures of the\u000a      Kunitz BPTI inhibitors. Cardle, L. &amp; Dufton, M. (1997) Protein\u000a        Engineering, 10, 131-136. DOI:10.1093\/protein\/10.2.131\u000a    \u000a\u000a[2] Evolutionary trace analysis of the Kunitz\/BPTI family of proteins.\u000a      Pritchard, L. &amp; Dufton, M. (1999) Journal of Molecular Biology,\u000a      285, 1589-1607. DOI: 10.1006\/jmbi.1998.2437. ISSN: 0022-2836\u000a    \u000a\u000a[3] Do proteins learn to evolve? The Hopfield Network as a basis for the\u000a      understanding of protein evolution. Pritchard, L. &amp; Dufton, M. (2000)\u000a      Journal of Theoretical Biology, 202, 77-86. DOI:\u000a      10.1006\/jtbi.1999.1043\u000a    \u000a\u000a[4] Evaluation of a novel method for the identification of coevolving\u000a      protein residues. Pritchard, L., Bladon, P., Mitchell, J. &amp; Dufton, M.\u000a      (2001) Protein Engineering, 14, 549-555. DOI:\u000a      10.1093\/protein\/14.8.549\u000a    \u000a\u000a[5] Simple intrasequence difference (SID) analysis: an original method to\u000a      highlight and rank sub-structural interfaces in protein folds. Pritchard,\u000a      L., Cardle, L., Quinn, S. &amp; Dufton M. (2003) Protein Engineering,\u000a      16, 87-101. DOI: 10.1093\/proeng\/gzg012\u000a    \u000a\u000a[6] SID Technology software, as reported in: The Drug Discovery Portal: A\u000a      Computational Platform for Identifying Drug Leads from Academia. Clark,\u000a      R., Johnston, B., Mackay, S., Breslin, C., Robertson, M., Sutcliffe, O.,\u000a      Dufton, M., &amp; Harvey, A. (2010) Current Pharmaceutical Design,\u000a      16, 1697-1702. DOI: 10.2174\/138161210791164018\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"6","Level2":"1","Subject":"Biochemistry and Cell Biology"},{"Level1":"11","Level2":"15","Subject":"Pharmacology and Pharmaceutical Sciences"}],"Sources":"\u000a    \u000a      Statement from the CEO of US drug discovery company Serometrix\u000a        corroborates his comments following the initial trials undertaken.\u000a      Statement from the CEO of Serometrix corroborates the claims regarding\u000a        the company's licencing and implementation of the technology within the\u000a        company including initial drug targets, impact on company activities and\u000a        benefits arising.\u000a      \u000ahttp:\/\/www.strath.ac.uk\/press\/newsreleases\/headline_737125_en.html\u000a        corroborates the partnership between the university and Serometrix and\u000a        the comments by the Serometrix CEO on the impact that the technology has\u000a        on their business.\u000a      Who Got Funded web-site (www.whogotfunded.com)\u000a        corroborates the venture capital funding raised by Serometrix in June\u000a        2012 (Registration is required to access this web-site; a print out of\u000a        the relevant information is available from the university).\u000a      \u000ahttp:\/\/www.serometrix.com\/pipeline.html\u000a        corroborates the company's primary areas of therapeutic interest.\u000a      \u000ahttp:\/\/pharma.financialexpress.com\/latest-updates\/2574-scientists-from-university-of-\u000a        strathclyde-invents-technology-to-treat-major-illnesses\u000a        corroborates the take-up of the technology by Serometrix.\u000a      \u000ahttp:\/\/drugdiscovery.pharmaceutical-business-review.com\/news\/strathclyde-researchers-invent-\u000a        computer-program-for-drug-discovery-280813\u000a        corroborates the take-up of the technology by Serometrix.\u000a    \u000a    ","Title":"\u000a    A unique computer technology for the accelerated discovery of drugs\u000a        that \"shape-shift\" proteins refocuses and expands a U.S. Drug Discovery\u000a        company\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Context\u000a    Proteins are a major class of biomolecule that are central to virtually\u000a      all life processes. Our aim was to learn more about protein evolution and\u000a      how shape and function might be predictable through analysis of the\u000a      growing databases of sequence and 3D structure. We investigated a range of\u000a      contrasting theoretical approaches to the data analysis as reported in\u000a      references 1-4. The outcomes eventually led us to focus on the information\u000a      content of just the three-dimensional path adopted by the molecular\u000a      backbone in the folded protein. These fold shapes encode the fundamental\u000a      characteristics relevant to maintaining functional capability, molecular\u000a      responsiveness and adaptability through the evolutionary process. From the\u000a      very large range of possible chain fold shapes, only relatively few have\u000a      persisted in living organisms, apparently only those fit and \"smart\"\u000a      enough for purpose.\u000a    The originality of this investigation lay in its focus purely upon the\u000a      enduring characteristics of the chain folding shapes rather than on the\u000a      atomic detail of the amino acid residue chemistries along their length.\u000a    Key findings\u000a    Our results from this research strategy in the late 1990s\/early 2000s\u000a      indicated that a computer technology for predicting important interactive\u000a      sites in proteins from the chain-fold motif alone was possible.\u000a      The first attempt at a systematic algorithm for site location in enzymes\u000a      based on the new principle was published in 2003 (Reference 5).\u000a      Subsequently, after the prototype program was modified, refined and\u000a      extended in its analytical procedure, given a versatile graphical user\u000a      interface and made able to process large numbers of protein structures\u000a      (achieved through collaboration with Dr John Wilson in the Department of\u000a      Computer and Information Science at Strathclyde), it was realised that the\u000a      output from the program was also succeeding in predicting additional sites\u000a      where small molecule binding was known to induce changes in protein shape\u000a      that regulated activity. As no reliable method existed for predicting\u000a      sites for shape-altering drugs (also describable as \"shapeshifting\",\u000a      topomorphic or allosteric drugs), it was realised that our technology,\u000a      would have considerable commercial value as an aid to industrial drug\u000a      discovery, and also be a game-changer in terms of the discovery logic and\u000a      the quality of the end product.\u000a    The majority of small molecule drugs on the market are competitive\u000a      of a protein's key functional site and basically stop the protein working\u000a      altogether. However, shape-shifting drugs can bind away from the key site\u000a      (i.e. they are termed non-competitive or uncompetitive) and exert more\u000a      subtle influences on the bioactivity, bringing about only small,\u000a      non-critical, changes to the shape of the key site. Subtle adjustment of\u000a      such sites is the way natural evolution adjusts protein activity via\u000a      side-chain mutations remote from active sites, while natural allosteric\u000a      effectors exert remote control of the sites during the lifetime of the\u000a      protein. Put simply, it is like the difference between an on\/off switch\u000a      and a dimmer switch in lighting control.\u000a    This computer technology was one of the very first to offer a readily\u000a      accessible solution to the problem of systematically detecting\u000a      shapeshifting sites in proteins. The desirability of moving towards drugs\u000a      that have an allosteric\/topomorphic action has only come to the fore in\u000a      the last few years as successful examples of such drugs have been brought\u000a      to market. Thus our technology was brought to fruition at a key point in\u000a      the changing strategic direction of the drug discovery industry. After a\u000a      long period of testing, refinement and preparation for high throughput\u000a      industrial use, the technology was publicised (Reference 6) and championed\u000a      with support from the University's Research and Knowledge Exchange\u000a      Services.\u000a    Key researchers\u000a    Lead researcher: Dr Mark Dufton, Senior Lecturer, WestCHEM (appointed\u000a      1984, Senior Lecturer from 1994 &#8212; present).\u000a    Collaborating researcher: Dr John Wilson, Senior Lecturer, Department of\u000a      Computer and Information Science, University of Strathclyde (appointed\u000a      1985, Senior Lecturer from 2002 &#8212; present).\u000a    "},{"CaseStudyId":"42297","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2921044","Name":"Germany"}],"Funders":[],"ImpactDetails":"\u000d\u000a    From research to impact\u000d\u000a    XstalBio Ltd was formed as a spin-out company in 2004 to license,\u000d\u000a      commercialise, and extend the\u000d\u000a      intellectual property associated with the protein and vaccine\u000d\u000a      stabilisation technology. XstalBio's\u000d\u000a      technology adds therapeutic value, accelerates the development, and\u000d\u000a      extends the life-cycles of\u000d\u000a      protein-based drugs as well as enabling new product opportunities. The\u000d\u000a      company targets the\u000d\u000a      $50bn currently spent per annum by the pharmaceutical industry on\u000d\u000a      biopharmaceutical product\u000d\u000a      development. XstalBio markets its expertise and technology to these pharma\u000d\u000a      companies with the\u000d\u000a      aim of enabling development of improved formulation and delivery methods\u000d\u000a      for new candidate\u000d\u000a      biologic drugs and vaccines.\u000d\u000a    In an internationally competitive market, XstalBio has succeeded in\u000d\u000a      selling contracts for access to\u000d\u000a      its Intellectual Property Portfolio for over 8 years and has continuously\u000d\u000a      developed the patented\u000d\u000a      technology to meet the new challenges facing the biopharmaceutical\u000d\u000a      industry. These contracts,\u000d\u000a      worth &#163;2.2M over the period 2008-2012, are underpinned by option license\u000d\u000a      agreements taken out\u000d\u000a      on the WestCHEM owned patents. An early client was Boehringer Ingelheim\u000d\u000a      who subsequently\u000d\u000a      licensed the stabilisation technology from XstalBio, primarily for\u000d\u000a      delivery of biologics by inhalation.\u000d\u000a      As part of this license agreement the two companies co-developed and built\u000d\u000a      a dedicated GMP\u000d\u000a      compliant pilot plant for inhalation dry powders, which was commissioned\u000d\u000a      in Biberach, Germany in\u000d\u000a      2008 at cost of &#8364;5M.\u000d\u000a    Development programmes have also been carried out with, or are on-going\u000d\u000a      with, other major\u000d\u000a      pharmaceutical companies including [text removed for publication] with\u000d\u000a      most contracts being with\u000d\u000a      biologic drug development groups from outside the UK. The specific details\u000d\u000a      of these are subject to\u000d\u000a      stringent commercial confidentiality agreements but in general the role of\u000d\u000a      XstalBio is to accelerate\u000d\u000a      development, enhance therapeutic value, or manage the life-cycle of the\u000d\u000a      biopharmaceutical by\u000d\u000a      providing innovative dry powder formulations which improve the overall\u000d\u000a      product profile.\u000d\u000a    Type of Impact\u000d\u000a      An important impact of the original research has been economic with the\u000d\u000a      launch and growth of a\u000d\u000a      sustainable UK based SME with global reach in the pharmaceutical industry.\u000d\u000a      In the period 2008-2012,\u000d\u000a      the company made international sales of its Intellectual Property of &#163;2.2M\u000d\u000a      and employed 8\u000d\u000a      full-time research and development scientists at BSc and PhD level. The\u000d\u000a      company has also\u000d\u000a      supported and trained 3 PhD CASE studentships based at WestCHEM and the\u000d\u000a      London School of\u000d\u000a      Pharmacy.\u000d\u000a    Vaccines and medicines based on biomolecules will be major engines of\u000d\u000a      growth in the\u000d\u000a      pharmaceutical industry over the coming decades. The significant payments\u000d\u000a      by international\u000d\u000a      companies to XstalBio for access to its IP portfolio demonstrate that its\u000d\u000a      biologic formulation and\u000d\u000a      drug delivery technologies lie at the commercial cutting-edge and are\u000d\u000a      impacting on the direction\u000d\u000a      taken by top ten pharmaceutical companies in developing the next\u000d\u000a      generation of biologic\u000d\u000a      medicines.\u000d\u000a    Unmet product and process needs that XstalBio Technology is being used to\u000d\u000a      address include:\u000d\u000a    \u000d\u000a      Delivery by inhalation with a dry powder inhaler requires sensitive\u000d\u000a        biologics to be processed\u000d\u000a        into particles in the size-range of 3-5 microns with no loss of tertiary\u000d\u000a        structure or bioactivity.\u000d\u000a        Techniques such as milling cannot be used and spray-drying produces\u000d\u000a        extremely moisture-sensitive\u000d\u000a        powders which require expensive protective packaging. The impact of\u000d\u000a        XstalBio's\u000d\u000a        PCMC technology in this field was recognised by Boehringer Ingelheim and\u000d\u000a        resulted in a\u000d\u000a        licensing agreement and significant investment in a GMP compliant\u000d\u000a        manufacturing facility\u000d\u000a        (estimated &#8364;5M),\u000d\u000a      Shipping and storage of biomolecules without the need for continuous\u000d\u000a        refrigeration is a major\u000d\u000a        goal for organisations and companies that intend to supply diagnostics,\u000d\u000a        biological medicines\u000d\u000a        and vaccines in challenging environments such as remote regions in the\u000d\u000a        developing world.\u000d\u000a        XstalBio PCMC dry powders remain stable at high temperatures and in\u000d\u000a        humid conditions and\u000d\u000a        therefore offer considerable cost savings to its partners. Boehringer\u000d\u000a        Ingelheim has noted these\u000d\u000a        more efficient and cost effective manufacturing opportunities compared\u000d\u000a        with conventional\u000d\u000a        methods:\u000d\u000a    \u000d\u000a    \"Particularly with regard to cost-effectiveness, precipitation methods\u000d\u000a        are attractive. An\u000d\u000a        interesting method is the protein-coated microcrystals (PCMC) technology\u000d\u000a        that stabilises\u000d\u000a        biomolecules on crystalline surfaces by co-precipitation during rapid\u000d\u000a        solvent exchange\"\u000d\u000a    \u000d\u000a      Administration of therapeutic proteins at very high concentration by\u000d\u000a        subcutaneous delivery\u000d\u000a        would provide an alternative to lengthy infusions, reducing resource use\u000d\u000a        (time in clinic) and\u000d\u000a        improving quality of life for patients with chronic conditions. As was\u000d\u000a        demonstrated with a Pfizer\u000d\u000a        candidate human monoclonal antibody, the patented stabilising additives\u000d\u000a        prevent aggregation\u000d\u000a        and conserve bioactivity. Because the dry mAb powders can also be\u000d\u000a        rapidly reconstituted to\u000d\u000a        very high protein concentration (&gt;200mg\/ml) they are providing\u000d\u000a        industry with a radical\u000d\u000a        alternative to concentrating by TFF which becomes very difficult at high\u000d\u000a        viscosities.\u000d\u000a      Tuneable drug delivery kinetics: Slowing the release of therapeutic\u000d\u000a        proteins without covalent\u000d\u000a        modification is desirable. Use of a calcium phosphate shell allows\u000d\u000a        release of proteins from\u000d\u000a        PCMCs to be tuned from hours to days.\u000d\u000a    \u000d\u000a    The collaboration with Boehringer Ingelheim illustrates how the XstalBio\u000d\u000a      technology has had an\u000d\u000a      impact on a client's R&amp;D strategy and investment. Boehringer Ingelheim\u000d\u000a      has stated publicly that\u000d\u000a      \"Boehringer Ingelheim believes that the collaboration with XstalBio\u000d\u000a        will provide improved methods\u000d\u000a        for the formulation and delivery of biomolecules. The technology\u000d\u000a        provides a highly differentiated\u000d\u000a        method for preparing biomolecules as stable, solid formulations, with\u000d\u000a        the particles capable of being\u000d\u000a        engineered for delivery in a range of formulations via various routes of\u000d\u000a        administration. Both\u000d\u000a        partners will jointly develop and scale-up the PCMC technology for GMP\u000d\u000a        manufacturing at Pilot\u000d\u000a        scale.\"\u000d\u000a    The publication of the 6 filed and licensed patent families impacts on\u000d\u000a      the overall knowledge base\u000d\u000a      and direction of the pharmaceutical industry. This is evidenced by the\u000d\u000a      presence of 11 patent filings\u000d\u000a      from other companies, including BASF, Novo Nordisk, Boheringher Ingelheim,\u000d\u000a      Lek, Taisho\u000d\u000a      Pharmaceutical Co. Ltd and Domin&#243; &#8212; Ind&#250;strias Cer&#226;micas that reference\u000d\u000a      the technology and\/or\u000d\u000a      patents.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    A novel self-assembly process, developed at WestCHEM was shown to provide\u000d\u000a      a step-change for\u000d\u000a      stabilising proteins as dry powders. The spin-out company, XstalBio, was\u000d\u000a      created in 2004 and\u000d\u000a      licensed the patented technology with the aim of developing it for\u000d\u000a      delivery and formulation of\u000d\u000a      therapeutic biomolecules and vaccines. Over the period 2008-2012, eight\u000d\u000a      leading international\u000d\u000a      pharmaceutical and animal health companies paid XstalBio over &#163;2.2M for\u000d\u000a      access to its IP portfolio\u000d\u000a      and to undertake evaluation studies with candidate biomedicines and\u000d\u000a      vaccines. XstalBio employed\u000d\u000a      8 highly skilled research scientists over this period and 4 further patent\u000d\u000a      families were generated.\u000d\u000a      Boehringer Ingelheim licensed the technology for application to its\u000d\u000a      therapeutic biomolecules and in\u000d\u000a      collaboration with XstalBio built a dedicated &#8364;5M pilot plant for\u000d\u000a      manufacture of inhalable dry\u000d\u000a      powders.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    WestCHEM\u000d\u000a    ","Institutions":[{"AlternativeName":"Glasgow (University of)","InstitutionName":"University of Glasgow","PeerGroup":"A","Region":"Scotland","UKPRN":10007794},{"AlternativeName":"Strathclyde (University of)","InstitutionName":"University of Strathclyde","PeerGroup":"B","Region":"Scotland","UKPRN":10007805}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"2949423","Name":"Biberach an der Ri"}],"References":"\u000d\u000a    References 1-3 (highly cited primary papers) best exemplify the quality\u000d\u000a      of the body of research.\u000d\u000a    \u000a[1] Practical route to high activity enzyme preparations for synthesis in\u000d\u000a      organic media. Partridge,\u000d\u000a      J.; Halling, P. J.; Moore, B. D., Chem. Commun., 1998,\u000d\u000a      841-842; DOI: 10.1039\/A800408K\u000d\u000a    \u000a\u000a[2] Enzyme-coated micro-crystals: a 1-step method for high-activity\u000d\u000a      biocatalyst preparation.\u000d\u000a      Kreiner, M.; Moore, B. D.; Parker, M. C., Chem. Commun., 2001,\u000d\u000a      1096-1097; DOI:\u000d\u000a      10.1039\/B100722J\u000d\u000a    \u000a\u000a[3] Control of enzyme activity in organic media by solid-state acid-base\u000d\u000a      buffers. Zacharis, E;\u000d\u000a      Moore, B.D.; Halling, P. J., J. Am. Chem. Soc., 1997, 119,\u000d\u000a      12396-12397; DOI:\u000d\u000a      10.1021\/ja972635c\u000d\u000a    \u000a\u000a[4] Ex vivo perfusion bioassay: an excellent technique to measure the\u000d\u000a      bioactivity of inhalable\u000d\u000a      insulin coated microcrystals. Ross A. C.; Steve H. N.; Partridge J.; Moore\u000d\u000a      B. D.; Flores M. V.;\u000d\u000a      Parker M. C.; Brown A. J.; Hillier C.; Coleman J., Abstracts of the\u000d\u000a        AAPS 2002;\u000d\u000a      http:\/\/abstracts.aaps.org\/published\/ContentInfo.aspx?conID=32975\u000d\u000a    \u000a\u000a[5] Formulation of the adenylate cyclase toxin of Bordetella pertussis as\u000d\u000a      protein-coated\u000d\u000a      microcrystals. Khosravani A.; Parker M. C.; Parton R.; Coote J., Vaccine.\u000d\u000a      2007, 25, 4361-4367;\u000d\u000a      DOI: 10.1016\/j.vaccine.2007.03.035\u000d\u000a    \u000a\u000a[6] Dry powder therapeutic mAb formulations with enhanced temperature\u000d\u000a      stability. Gebbie, W.;\u000d\u000a      Davidson, K.; Partridge, J.; Vos, J., Moore, B. D.; Abate, J.; Kirchhoff,\u000d\u000a      C., AAPS National\u000d\u000a        Biotechnology Conference 2009;\u000d\u000a      http:\/\/abstracts.aaps.org\/published\/ContentInfo.aspx?conID=19420\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"6","Level2":"1","Subject":"Biochemistry and Cell Biology"},{"Level1":"11","Level2":"15","Subject":"Pharmacology and Pharmaceutical Sciences"},{"Level1":"3","Level2":"3","Subject":"Macromolecular and Materials Chemistry"}],"Sources":"\u000d\u000a    1. The Non-Executive Chairman of XstalBio will corroborate the company's\u000d\u000a      client base and that\u000d\u000a      XstalBio's technology is being applied to solving a range of\u000d\u000a      biopharmaceutical product\u000d\u000a      challenges for those clients.\u000d\u000a    2. www.xstalbio.com\/technology &amp; bioresearchcentral.pharmaloco.com\/company\/XstalBio\/index.html\u000d\u000a      will corroborate the claims that XstalBio's technology is being applied to\u000d\u000a      solving a range of\u000d\u000a      biopharmaceutical product challenges for its clients.\u000d\u000a    3. \u000d\u000ahttp:\/\/formulation.org.uk\/index.php?option=com_content&amp;view=article&amp;id=279&amp;Itemid=223\u000d\u000a      will corroborate the claim that collaboration between XstalBio and Pfizer\u000d\u000a      has improved stability of\u000d\u000a      human monoclonal antibody formulations.\u000d\u000a    4. \u000d\u000ahttp:\/\/www.boehringer-ingelheim.ca\/en\/news\/press_releases\/2006\/16_may_2006.html\u000d\u000a      will corro-borate\u000d\u000a      Boehringer Ingelheim's relationship with XstalBio\u000d\u000a    5. \"Development of a pilot-scale manufacturing process for protein-coated\u000d\u000a      microcrystals (PCMC):\u000d\u000a      Mixing and precipitation &#8212; Part I\", C. K&#246;nig, K. Bechtold-Peters, V. Baum,\u000d\u000a      T. Schultz-Fademrecht,\u000d\u000a      S. Bassarab, K.-J. Steffens, Eur. J. Pharm. Biopharm. 2012, 80,\u000d\u000a      490-498 (DOI:\u000d\u000a      10.1016\/j.ejpb.2011.11.012) will corroborate the claim that XstalBio and\u000d\u000a      Boehringer Ingelheim\u000d\u000a      have established a pilot-scale manufacturing process which will provide\u000d\u000a      improved methods for\u000d\u000a      the formulation and delivery of biomolecules.\u000d\u000a    6. World Intellectual Property Organisation (http:\/\/patentscope.wipo.int\/),\u000d\u000a      will corroborate filing of\u000d\u000a      the following patents by B.D. Moore et al. at Strathclyde:\u000d\u000a      Rapid Dehydration of Proteins WO\/2000\/069887; Pharmaceutical\u000d\u000a      Composition\u000d\u000a      WO\/2004\/062560; Process for Preparing Microcrystals\u000d\u000a        WO\/2006\/010921; Precipitation\u000d\u000a      Stabilising Compositions WO\/2008\/132439; Slow Release Compositions\u000d\u000a      WO\/2009\/077732;\u000d\u000a      Method for preparing amorphous precipitated protein particles WO\/2013\/093524\u000d\u000a    ","Title":"\u000d\u000a    Therapeutic protein and vaccine stabilisation technology with global\u000d\u000a        reach across the pharmaceutical industry\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2643743","Name":"London"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    Context\u000d\u000a      Medicines based on biomolecules, including vaccines, are currently the\u000d\u000a      major engines of growth in\u000d\u000a      the pharmaceutical industry, with sales predicted to increase from ~$130bn\u000d\u000a      in 2012 to ~$280bn in\u000d\u000a      2022. The in vivo activity of biomolecules such as enzymes,\u000d\u000a      monoclonal antibodies, and vaccines\u000d\u000a      is determined by the tertiary structure, i.e., the\u000d\u000a      three-dimensional conformation. This means that\u000d\u000a      biologic drugs are much less stable and therefore harder to formulate and\u000d\u000a      administer than\u000d\u000a      traditional small molecule drugs.\u000d\u000a    Research by the research groups of BD Moore (Senior Lecturer and Reader,\u000d\u000a      WestCHEM), PJ\u000d\u000a      Halling (Professor, WestCHEM) and MC Parker (Lecturer, WestCHEM) aimed to\u000d\u000a      facilitate the\u000d\u000a      transfer of active enzymes from aqueous to organic media to harness their\u000d\u000a      catalytic power in\u000d\u000a      organic synthesis. A key observation was that dehydration processes other\u000d\u000a      than lyophilisation\u000d\u000a      resulted in much better retention of enzyme catalytic activity and\u000d\u000a      excellent preservation of protein\u000d\u000a      tertiary structure in the dry state (1). The wider importance of this\u000d\u000a      finding was recognised and the\u000d\u000a      innovative stabilisation technology was translated into commercial\u000d\u000a      formulation of therapeutic\u000d\u000a      biomolecules and vaccines.\u000d\u000a    Key Findings\u000d\u000a      The pathway of transferring an enzyme from aqueous solution into\u000d\u000a      non-aqueous media is found to\u000d\u000a      be critical in maintaining catalytic activity and surprisingly,\u000d\u000a      conventional protein drying methods\u000d\u000a      such as lyophilisation give very poor results. Moore and Parker discovered\u000d\u000a      and patented (\"Rapid\u000d\u000a      Dehydration of Proteins\", WO0069887) a much more successful\u000d\u000a      process based on co-precipitation\u000d\u000a      of enzymes with an inorganic salt by addition of an aqueous mixture to an\u000d\u000a      excess of water-miscible\u000d\u000a      solvent (2). This method was designed to rapidly dehydrate the enzyme, as\u000d\u000a      the water dissolved\u000d\u000a      into the solvent, but the additional bonus was that it also resulted in\u000d\u000a      spontaneous formation of\u000d\u000a      microcrystals of the salt coated with protein. Self-assembly of these\u000d\u000a      protein-coated microcrystals\u000d\u000a      (PCMCs) was found to be applicable to all enzyme classes tested and the\u000d\u000a      process coupled with\u000d\u000a      control of protonation state (3) are recognised as benchmark methods for\u000d\u000a      preparing biocatalysts for\u000d\u000a      use in non-aqueous media. The high catalytic activity of enzymes on dry\u000d\u000a      PCMC particles was\u000d\u000a      postulated to be because an unusually high proportion of protein molecules\u000d\u000a      retained a native\u000d\u000a      tertiary conformation in the dry state. This was subsequently proven to be\u000d\u000a      the case by solid-state\u000d\u000a      circular dichroism spectroscopy and active site-titrations in dry solvent.\u000d\u000a    The excellent retention of protein native structure in PCMCs was\u000d\u000a      recognised to have applications\u000d\u000a      beyond biocatalysis and applied research at WestCHEM explored their\u000d\u000a      potential use as a platform\u000d\u000a      for delivery of therapeutic biomolecules by inhalation (4). This research\u000d\u000a      identified a novel method\u000d\u000a      for forming free-flowing dry powders by supercritical fluid carbon dioxide\u000d\u000a      extraction of suspensions\u000d\u000a      of PCMC in solvent. The formulations and process were patented\u000d\u000a      (\"Pharmaceutical Composition\",\u000d\u000a      WO2004062560) in conjunction with an alternate continuous flow\u000d\u000a      process for precipitating PCMC\u000d\u000a      particles (\"Process for Preparing Microcrystals\",\u000d\u000a\u0009  WO2006010921). A range of physiologically\u000d\u000a      acceptable water-soluble crystals, including amino-acids and sugars, were\u000d\u000a      investigated with the\u000d\u000a      aim of preparing PCMC particles in the size-range 3-5 &#181;m suitable for\u000d\u000a      delivery to the lung. Dry\u000d\u000a      powders of model proteins with promising aerodynamic properties were\u000d\u000a      identified and found to be\u000d\u000a      unusually stable to high temperature and humidity meaning they could be\u000d\u000a      stored without requiring\u000d\u000a      refrigeration or an inert atmosphere. These properties are highly\u000d\u000a      desirable for formulation and\u000d\u000a      delivery of biologic drugs and vaccines (5).\u000d\u000a    The spin-out of XstalBio in 2004 provided access to much more\u000d\u000a      aggregation-sensitive proteins\u000d\u000a      such as humanised monoclonal antibodies supplied by commercial partners,\u000d\u000a      and stimulated further\u000d\u000a      improvements to the technology. In research directed by Moore,\u000d\u000a      zwitterionic additives were\u000d\u000a      identified which disrupted aggregation of precipitated protein on exposure\u000d\u000a      to polar solvents and\u000d\u000a      enabled them to be incorporated onto the outer surface of the particles in\u000d\u000a      a native quaternary state\u000d\u000a      (6). These additives were patented (\"Precipitation Stabilising\u000d\u000a      Compositions\", WO2008132439) and\u000d\u000a      the technology has been successfully applied to the formulation of over\u000d\u000a      ten therapeutic monoclonal\u000d\u000a      antibodies in development by pharmaceutical companies.\u000d\u000a    It was also shown that a double decomposition process could be carried\u000d\u000a      out in a polar organic\u000d\u000a      solvent between (i) phosphate salts that have been co-immobilised with\u000d\u000a      biomolecules on the\u000d\u000a      crystal surface and (ii) calcium chloride dissolved in the solvent. The\u000d\u000a      resultant outer shell of\u000d\u000a      sparingly aqueous-soluble calcium phosphate can be used to tune the rate\u000d\u000a      at which biomolecules\u000d\u000a      are released back into aqueous solution. Patented in 2008 (\"Slow Release\u000d\u000a      Compositions\",\u000d\u000a      WO2009077732) these findings have led to the development of vaccines in\u000d\u000a      which both antigens\u000d\u000a      and toll-like receptor agonists are co-immobilised on slow-release\u000d\u000a      particles, resulting in enhanced\u000d\u000a      innate and adaptive immune responses. These are being exploited in\u000d\u000a      temperature stable vaccines\u000d\u000a      for treatment of helminths in livestock and in vivo trials are\u000d\u000a      on-going in collaboration with the\u000d\u000a      Moredun Research Institute. All of the patents filed have been licensed to\u000d\u000a      XstalBio Ltd.\u000d\u000a    Key Researchers\u000d\u000a      Barry D Moore, (employed at WestCHEM from January 1991, Senior Lecturer\u000d\u000a      from April 1997 and\u000d\u000a      Reader from June 2002); Marie Claire Parker, (employed as Lecturer at\u000d\u000a      WestCHEM from 1997-2005,\u000d\u000a      and currently Honorary Research Fellow); Peter Halling, (employed at\u000d\u000a      WestCHEM since\u000d\u000a      August 1983, Professor since August 1990).\u000d\u000a    "},{"CaseStudyId":"42298","Continent":[{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1605651","Name":"Thailand"},{"GeoNamesId":"1733045","Name":"Malaysia"}],"Funders":[],"ImpactDetails":"\u000d\u000a    The overarching impact arising from the research lies in the enhanced\u000d\u000a      capabilities of law enforcement agencies to deal with illicit drug\u000d\u000a      production, and the influencing of policy and analytical processes to\u000d\u000a      address the new legal high compounds that are emerging on the\u000d\u000a      international stage with associated major societal health and wellbeing\u000d\u000a      consequences. The impact is most easily broken down into three main areas.\u000d\u000a    1. New capability for law enforcement agencies by provision of new\u000d\u000a          tools to identify specific manufacturing routes of illicit drugs and\u000d\u000a          link this back to criminal intelligence data\u000d\u000a    Illicit drug production is a major issue affecting every country in the\u000d\u000a      world with clandestine manufacturing methods and locations constantly\u000d\u000a      changing and developing in their sophistication. The production of\u000d\u000a      precursors for illicit drugs takes place mainly in South East Asia and\u000d\u000a      specifically Malaysia. In 2011, over 1000 kg of methylamphetamine and\u000d\u000a      364,000 ecstasy tablets were seized by the Royal Malaysian Police with a\u000d\u000a      combined estimated street value in excess of $105M. This indicates the\u000d\u000a      scale of the problem for one specific country.\u000d\u000a    The engagement process for this research was as follows: The research\u000d\u000a      published by WestCHEM on the chemical characterisation and classification\u000d\u000a      of ecstasy tablets prompted the Royal Malaysian Police to fund two PhD\u000d\u000a      research students to study at WestCHEM over a five-year period. This\u000d\u000a      provided sustained training in core research methods within this area and\u000d\u000a      the development of a research legacy to advance this field through\u000d\u000a      transfer back to Malaysia. During this time, profiling of\u000d\u000a      methylamphetamine prepared by 8 synthetic routes was developed using GCMS,\u000d\u000a      IRMS, and ICPMS with multivariate data interpretation.\u000d\u000a    The new analytical methodologies, databases, and data analysis approaches\u000d\u000a      developed at WestCHEM have now been implemented in Malaysia on a daily\u000d\u000a      operational basis by the Royal Malaysian Police. The implementation of the\u000d\u000a      research findings has allowed identification of precursor chemicals and\u000d\u000a      the synthetic route used in the production of methylamphetamine. This has\u000d\u000a      provided the Royal Malaysian Police with a new capability leading to\u000d\u000a      enhanced sophistication of investigations, the development of new police\u000d\u000a      intelligence, and the increased ability to secure convictions.\u000d\u000a    The majority of the impact from this research has taken place to date\u000d\u000a      within Malaysia, however, there is also collaborations with the United\u000d\u000a      States Drug Enforcement Agency (USDEA) in the area.\u000d\u000a    Further external engagement followed successful publications in the area\u000d\u000a      of illicit drug synthesis and the Thai Government funded a postdoctoral\u000d\u000a      researcher to be based at WestCHEM to investigate the development of a\u000d\u000a      rapid semi-quantitative presumptive test to allow the determination of the\u000d\u000a      concentration of an illicit drug present within street-seized samples. The\u000d\u000a      test is based on simple colorimetric analysis subsequently recorded using\u000d\u000a      a smartphone with GPS to relay information relative to the point of\u000d\u000a      seizure of the materials. [text removed for publication]\u000d\u000a    2. Rapid identification of legal highs for use in criminal\u000d\u000a          prosecutions\u000d\u000a    The emergence of legal highs as an area of significant concern has led to\u000d\u000a      the increased awareness of the need for rapid and accurate identification\u000d\u000a      of such compounds. One of the stumbling blocks to addressing rapidly\u000d\u000a      changing legislations in this area has been the lack of `gold standards'\u000d\u000a      for each the legal high compound, which are required to facilitate robust\u000d\u000a      and accurate verification and validation of analytical methodologies\u000d\u000a      suitable for use in criminal court cases. The research process involved\u000d\u000a      collaboration between WestCHEM and the Scottish Police Authority Forensic\u000d\u000a      Sciences (SPAFS) to address this crucial issue by synthesising and\u000d\u000a      characterising legal high standards which were subsequently used in\u000d\u000a      verification of analytical methodologies for compound identification in an\u000d\u000a      operational context. The impact of these analytical methodologies as a\u000d\u000a      general cathinone screen in forensic casework in Scotland has involved the\u000d\u000a      analysis of 900 samples associated with criminal and morbid toxicology\u000d\u000a      cases, resulting in the detection of legal high drugs in 21 of those\u000d\u000a      samples, covering 11 different `New Psychoactive Substances' (NPS).\u000d\u000a    In recognition of the impact of this research, this new approach was\u000d\u000a      nominated for a Scottish Police Authority award. One judge commented:\u000d\u000a    `[This is ..]..a good example of a project based on analysis of\u000d\u000a        existing local data in a way which promotes a new look at a national\u000d\u000a        priority area. As well as creating opportunities for closer partnership,\u000d\u000a        working with health and voluntary agencies it has identified means of a\u000d\u000a        more focused service provision in relation to drug misuse.'\u000d\u000a    A second judge added:\u000d\u000a    `This project will be a valuable support to the new single [police]\u000d\u000a        service.'\u000d\u000a    3. New UN protocol for identification of seized materials\u000d\u000a    As a result of the WestCHEM research profile in the area of legal high\u000d\u000a      drug identification, Professor Nic Daeid was invited to develop a new\u000d\u000a      protocol for legal high characterisation for the United Nations Office of\u000d\u000a      Drugs and Crime (UNODC). This activity further extended an on-going\u000d\u000a      relationship and consultancy between Professor Nic Daeid and the UNIODC.\u000d\u000a      The UNODC manuals are developed by `scientific experts recognised for\u000d\u000a        their exceptional contribution to knowledge and\/or the promotion of best\u000d\u000a        practice in the area of interest' and are used by forensic science\u000d\u000a      laboratories across the globe as the accepted industry standard. During\u000d\u000a      the REF assessment period, the WestCHEM research published has influenced\u000d\u000a      the preparation of the guidance manual, `UNODC Recommended Methods for the\u000d\u000a      Analysis of Synthetic Cathinones in Seized Materials', which is expected\u000d\u000a      to be published in early 2014.\u000d\u000a    These three different areas of impact arising from the research detailed\u000d\u000a      in Section 2 show the degree of reach and also the societal significance\u000d\u000a      of the impact that has been achieved.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Global drug crime involving the illicit production of synthetic drugs and\u000d\u000a      the emergence of new legal highs has a detrimental effect on our society\u000d\u000a      and its citizens at all levels. In order to address this global problem,\u000d\u000a      research was conducted that resulted in three significant impacts over the\u000d\u000a      assessment period. These were:\u000d\u000a    (1) New capability for law enforcement agencies by provision of new tools\u000d\u000a      to identify specific manufacturing routes of illicit drugs and link this\u000d\u000a      back to criminal intelligence data,\u000d\u000a    (2) Improvement in the accuracy and reliability of identification of\u000d\u000a      legal highs for use by legal practitioners, and\u000d\u000a    (3) The influencing of policy and protocol for the United Nations Office\u000d\u000a      on Drugs and Crime on addressing legal high drug identification.\u000d\u000a    The research has underpinned the implementation of new analytical\u000d\u000a      methodologies now routinely used in Malaysia and in over 900 drug sample\u000d\u000a      identification cases in Scotland alone across the assessment period.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    WestCHEM\u000d\u000a    ","Institutions":[{"AlternativeName":"Glasgow (University of)","InstitutionName":"University of Glasgow","PeerGroup":"A","Region":"Scotland","UKPRN":10007794},{"AlternativeName":"Strathclyde (University of)","InstitutionName":"University of Strathclyde","PeerGroup":"B","Region":"Scotland","UKPRN":10007805}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    Key references to the work are 1, 2, and 4.\u000d\u000a    \u000a[1] Classification of ecstasy tablets with the application of chemometric\u000d\u000a      procedures and artificial neural network algorithms, R.J.H. Waddell, N.\u000d\u000a      Nic Da&#233;id &amp; D. Littlejohn, Analyst, 2004, 129, 3,\u000d\u000a      235-240, DOI: 10.1039\/b312336g\u000d\u000a    \u000a\u000a[2] Emerging Use of Isotope Ratio Mass Spectrometry as a Tool for\u000d\u000a      Discrimination of 3,4-Methylenedioxymethamphetamine by Synthetic Route,\u000d\u000a      H.A.S. Buchanan, N. Nic Da&#233;id, W. Meier-Augenstein, H.F. Kemp, W.J. Kerr,\u000d\u000a      &amp; M. Middleditch, Anal. Chem., 2008, 80, 9, 3350-3356.\u000d\u000a      DOI: 10.1021\/ac702559s\u000d\u000a    \u000a\u000a[3] Characterization of Route Specific Impurities Found in\u000d\u000a      Methamphetamine Synthesized by the Leuckart and Reductive Amination\u000d\u000a      Methods, V. Kunalan, N. Nic Da&#233;id, W.J. Kerr, H.A.S. Buchanan &amp; A.\u000d\u000a      McPherson, Anal. Chem., 2009, 81, 17, 7342-7348. DOI: 10.1021\/ac9005588\u000d\u000a    \u000a\u000a[4] Synthesis, full chemical characterisation and development of\u000d\u000a      validated methods for the quantification of (&#177;)-4'-methylmethcathinone\u000d\u000a      (mephedrone): A new `legal high' ,E.Y. Santali, A-K Cadogan, N. Nic Da&#233;id,\u000d\u000a      K.A. Savage &amp; O.B. Sutcliffe, J. Pharmaceutical and Biomedical\u000d\u000a        Analysis, 2011, 56, 2, 246-255. DOI: 10.1016\/j.jpba.2011.05.022\u000d\u000a    \u000a\u000a[5] Rapid and semi-quantitative presumptive tests for opiate drugs, A. A.\u000d\u000a      Choodum &amp; N. Nic Da&#233;id, Talanta, 2011, 86, 284-292,\u000d\u000a      DOI: 10.1016\/j.talanta.2011.09.015\u000d\u000a    \u000a\u000a[6] Investigation of the reaction impurities associated with\u000d\u000a      methylamphetamine synthesised using the Nagai method, V. Kunalan, W.J.\u000d\u000a      Kerr &amp; N. Nic Da&#233;id, Anal. Chem., 2012, 84, 13,\u000d\u000a      5744-5752. DOI: 10.1021\/ac3009302\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"3","Level2":"1","Subject":"Analytical Chemistry"},{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    [1] Statement from a Chemist in the Narcotic Section, Royal Malaysian\u000d\u000a      Police Forensic Science Laboratory, corroborates the operational\u000d\u000a      implementation of the drug profiling methodologies within the Royal\u000d\u000a      Malaysian Police Forensic Services. (section 4 point 1)\u000d\u000a    [2] Statement from the Team Manager, Toxicology, Scottish Police\u000d\u000a      Authority Forensic Services, corroborates the use of analytical methods\u000d\u000a      developed with Strathclyde for the analysis of legal high compounds.\u000d\u000a      (Section 4 point 2).\u000d\u000a    [3] Scottish Government, Scottish Police Authority Award nominations\u000d\u000a      available at http:\/\/www.scotland.gov.uk\/Resource\/0041\/00414520.pdf\u000d\u000a      (Section 4 point 2).\u000d\u000a    [4] Statement from the Chief of the Laboratory &amp; Scientific Section,\u000d\u000a      Division of Policy Analysis, UNODC, Vienna corroborates development of\u000d\u000a      Legal high UNODC manual. (Section 4 point 3). \u000d\u000a    ","Title":"\u000d\u000a    Illicit drug analysis as a tool to combat global organised crime\u000d\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    Context\u000d\u000a    The architecture behind the global production of illicit synthetic drugs\u000d\u000a      is complex and multi-faceted. It involves a series of autonomous chemical\u000d\u000a      production phases, each servicing the supply of the next and is overarched\u000d\u000a      by connection to complex organised crime networks. The normal phases of\u000d\u000a      illicit drug production include: chemical synthesis of pre-precursor\u000d\u000a      materials followed by synthesis of the desired compound through a variety\u000d\u000a      of routes; sample dilution with `cutting' agents; and finally introduction\u000d\u000a      of the illicit drug samples into the dealer\/user distribution networks.\u000d\u000a      Due to the differences in chemical synthesis deployed, `families' of\u000d\u000a      impurities and side products become associated with these illicit drugs\u000d\u000a      and can be used to profile and map which synthetic route has been used.\u000d\u000a      Additionally, and in some circumstances, the chemical synthesis route\u000d\u000a      categorisation can be tentatively aligned to a geographical area. An\u000d\u000a      extension of characterising illicit drug production is the ability to\u000d\u000a      rapidly identify and quantify the controlled materials at point of\u000d\u000a      seizure. This pervasive problem can be a barrier to successful litigation\u000d\u000a      and investigative work particularly in, but not limited to, developing\u000d\u000a      countries where access to rapid response forensic science services can be\u000d\u000a      restricted.\u000d\u000a    Recent attempts to circumvent the criminality relating to illicit drugs\u000d\u000a      have seen the rapidly growing emergence of so called `legal high'\u000d\u000a      compounds. Many of these compounds circumvent the existing drug\u000d\u000a      legislation and pose a significant risk to the general population. Methods\u000d\u000a      to identify accurately the presence of such materials are vital to allow\u000d\u000a      the development of the legal framework surrounding these contentious\u000d\u000a      compounds. One of the major challenges to the legal environment is that\u000d\u000a      the compounds emerge into society so rapidly and thus to identify them\u000d\u000a      accurately is very difficult. To overcome this, the legal highs in\u000d\u000a      question need to be synthesised in a pure and accurate form to allow\u000d\u000a      standardised analytical methodologies to be verified and validated for use\u000d\u000a      within law enforcement.\u000d\u000a    Key Researchers\u000d\u000a    WestCHEM academics have been involved in the preparation,\u000d\u000a      characterisation, and continued development of analytical methods for the\u000d\u000a      investigation of synthetic controlled drugs since 2006. Professor Niamh\u000d\u000a      NicDaeid (appointed June 1994, Senior Lecturer from April 2001, Reader\u000d\u000a      from April 2009 and Professor from September 2011) is one of the leading\u000d\u000a      authors in the world in this area and has led the research since 2006.\u000d\u000a      Prof William Kerr (appointed as Lecturer, WestCHEM, October 1989, Senior\u000d\u000a      Lecturer from April 1997 and Professor of Organic Chemistry from April\u000d\u000a      2002), has been involved in supporting the synthetic phase of the work\u000d\u000a      (2006-2011) and Dr Oliver Sutcliff (Lecturer WestCHEM from September\u000d\u000a      2007-January 2012, and holding non-salaried Visiting Scholar appointment\u000d\u000a      since then) has been directly involved in the legal high research\u000d\u000a      (2010-2012).\u000d\u000a    Key Research Findings\u000d\u000a    The identification and characterisation of synthetic routes for\u000d\u000a          illicit drug production\u000d\u000a      The disruption of the clandestine manufacture of illicit materials,\u000d\u000a      primarily the manufacture of amphetamine type stimulants, such as\u000d\u000a      3,4-methylenedioxymethylamphetamine (ecstasy) and methylamphetamine, is\u000d\u000a      vital in attempting to control and restrict these illicit materials. The\u000d\u000a      large-scale production, distribution and sale of such drugs is estimated\u000d\u000a      to be worth hundreds of billions of dollars per annum and affects\u000d\u000a      over 315 million people worldwide. To address this, a body of research\u000d\u000a      undertaken at WestCHEM from 2006 onwards developed chemical analytical\u000d\u000a      methods for synthetic illicit drugs for use by global law enforcement\u000d\u000a      agencies. More specifically, the research focused on the preparation of\u000d\u000a      ecstasy and methylamphetamine under precisely controlled synthetic\u000d\u000a      conditions. This facilitated the understanding of the chemical signature\u000d\u000a      data derived from three complementary instrumental techniques, GCMS, IRMS,\u000d\u000a      and ICPMS for these compounds (1,2,3,6). The understanding of the derived\u000d\u000a      data has been reinforced by multivariate chemometric techniques that\u000d\u000a      included the novel application of artificial neural networks (1). The\u000d\u000a      outcome from the research was a framework for the development of a\u000d\u000a      structured and focused approach that allowed specific samples to be\u000d\u000a      classified according to their synthetic methodology of production.\u000d\u000a    In parallel, point of seizure identification and quantification of\u000d\u000a      illicit drugs was also researched. This resulted in a very simple field\u000d\u000a      test using a semi-quantitative approach (5), which is currently being\u000d\u000a      linked to a smartphone using GPS positioning of the point of\u000d\u000a      interrogation. This research has focused on both opiate drugs as well as\u000d\u000a      amphetamine-type stimulants given their global prevalence.\u000d\u000a    The identification of legal highs\u000d\u000a      Legal highs are predominantly cathinone based synthetic compounds designed\u000d\u000a      to give a similar physiological effect to an illicit drug, but without the\u000d\u000a      criminal implications. Many compounds have not been fully tested in terms\u000d\u000a      of their short- and long-term health implications and the ability of\u000d\u000a      healthcare and law enforcement agencies to deal with this problem is\u000d\u000a      significantly compromised by their inability, in some cases, to identify\u000d\u000a      the legally controlled component. In order to address this, a body of\u000d\u000a      research to synthesise specific legal high compounds with very high purity\u000d\u000a      was undertaken coupled with the investigation and characterisation of\u000d\u000a      these materials using analytical methodologies (4). Without these `gold\u000d\u000a      standard' legal high calibration samples, the analytical methodologies\u000d\u000a      could not have been developed.\u000d\u000a    "},{"CaseStudyId":"42300","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000d\u000a    From research to impact\u000d\u000a      EPSRC and industrially funded research at WestCHEM, including an EPSRC\u000d\u000a      CASE studentship\u000d\u000a      (2002-2005) with Carron Phoenix Ltd, resulted in the development of novel\u000d\u000a      polymer\u000d\u000a      nanocomposite formulations with mechanical, thermal, and barrier\u000d\u000a      properties superior to the base\u000d\u000a      polymers. Of particular relevance to the company, acrylic formulations\u000d\u000a      with enhanced rheological\u000d\u000a      control had been developed that offered the potential of significant\u000d\u000a      benefits to Carron Phoenix Ltd\u000d\u000a      in terms of process flexibility, enhanced product performance, and reduced\u000d\u000a      wastage. This led to\u000d\u000a      the creation of one major Knowledge Transfer Partnership (KTP)\u000d\u000a      collaboration and a follow-on\u000d\u000a      Short KTP (sKTP) collaboration between the company and the University,\u000d\u000a      over the period 2004 to\u000d\u000a      2010, established with the aim of introducing this nanocomposite\u000d\u000a      technology to the company's\u000d\u000a      product and processes (&#163;268k funding in total). This allowed the company\u000d\u000a      to sustain its position in\u000d\u000a      the designer kitchen market worldwide.\u000d\u000a    The KTP associates were embedded in the company to undertake the process\u000d\u000a      and product\u000d\u000a      development work, supported by the WestCHEM academic partners. The\u000d\u000a      associates also made\u000d\u000a      frequent use of specialised WestCHEM facilities. The programme began with\u000d\u000a      a full evaluation of\u000d\u000a      the chemical processing practices, as well as material and energy audits.\u000d\u000a      The detailed\u000d\u000a      understanding of the mixing, reaction characterisation, heat and flow\u000d\u000a      properties was also\u000d\u000a      completed. This led to a radically new approach being devised for all\u000d\u000a      aspects of the process\u000d\u000a      operation, including the reallocation of labour, reduced process times,\u000d\u000a      increased mould tool usage\u000d\u000a      and major capital investment in automation.\u000d\u000a    In view of the highly competitive and financially lucrative market for\u000d\u000a      high-end kitchen products and\u000d\u000a      the propensity to replicate the product by other manufacturers, Carron\u000d\u000a      Phoenix and WestCHEM\u000d\u000a      took the mutual decision not to protect IP through patenting, instead\u000d\u000a      choosing to retain key\u000d\u000a      knowledge in-house but publicising the relevant technological development\u000d\u000a      by way of a conference\u000d\u000a      presentation and refereed journal publication [6] to prevent other\u000d\u000a      manufacturers patenting the\u000d\u000a      process.\u000d\u000a    Nature of the Impact\u000d\u000a    Improved manufacturing process\u000d\u000a      The KTP projects consolidated the findings of the preliminary research by\u000d\u000a      providing a full\u000d\u000a      evaluation of the chemical processing practices as well as material and\u000d\u000a      energy audits. From a\u000d\u000a      detailed understanding of the mixing, reaction characterisation, heat and\u000d\u000a      flow properties, a radically\u000d\u000a      new approach was devised for all aspects of the process operation,\u000d\u000a      including the reallocation of\u000d\u000a      labour, reduced process times, increased mould tool usage, and major\u000d\u000a      capital investment in\u000d\u000a      automation (Source 1).\u000d\u000a    Process acceleration and automation created new challenges in terms of\u000d\u000a      control of the flow\u000d\u000a      behaviour of the composite sink formulation during the final curing step.\u000d\u000a      In particular, more rapid\u000d\u000a      heating rates led to greater sedimentation of the fillers resulting in\u000d\u000a      product defects. Detailed and\u000d\u000a      extensive chemical and processing studies were required in terms of\u000d\u000a      formulation, cure\u000d\u000a      characteristics, flow and thermal properties of the nanoclay materials.\u000d\u000a      This provided the necessary\u000d\u000a      platform for the development of a completely new process with the\u000d\u000a      successful commercial\u000d\u000a      production of high-end designer synthetic kitchen sinks sold worldwide.\u000d\u000a      The research enabled the\u000d\u000a      team to identify a suitable type and concentration of nanoclay filler and\u000d\u000a      rheology modifier to allow\u000d\u000a      control of (a) the mixing and distribution of materials, (b) the effective\u000d\u000a      transfer of the mix, and (c)\u000d\u000a      heating and curing rate, to produce synthetic sinks free from warpage and\u000d\u000a      surface blemishes and\u000d\u000a      thus reduce wastage from spoiled products. Prior to this project, it had\u000d\u000a      been necessary to re-work\u000d\u000a      moulded kitchen sinks in such a way as to avoid warpage and product\u000d\u000a      spoilage. The company is\u000d\u000a      forthright in its acknowledgement of the criticality of the new\u000d\u000a      formulation:\u000d\u000a    \"The nanoclay influenced the processability significantly and enabled\u000d\u000a        us to introduce\u000d\u000a        the new process technology with its significant savings. No nanoclay &#8212;\u000d\u000a        no new process\u000d\u000a        at that time, it is as \"simple\" as that\" (Source 2, Head of R&amp;D,\u000d\u000a      Carron Phoenix Ltd)\u000d\u000a    Production efficiency and cost savings\u000d\u000a      The implementation of the changes to the process enabled by the new\u000d\u000a      nanocomposite formulation\u000d\u000a      resulted directly in considerable production efficiency gains through the\u000d\u000a      reduction of raw materials\u000d\u000a      wastage, the reduction in manufacturing time and the significant reduction\u000d\u000a      of landfill costs of failed\u000d\u000a      and out-of-spec products. These savings alone amounted to in excess of &#163;1M\u000d\u000a      annually,\u000d\u000a      significantly in excess of the 25% target defined for the project. The\u000d\u000a      Franke PL Colour's\u000d\u000a      Sustainability Report 2011 notes that:\u000d\u000a    \"Our production processes mainly use electricity and natural gas. We\u000d\u000a        have experienced that\u000d\u000a        the combination of process and technological improvements result in\u000d\u000a        major energy savings\u000d\u000a        [...] In Falkirk, United Kingdom, the energy required for the moulding\u000d\u000a        of granite composite\u000d\u000a        could be reduced by 20 % per annum with an innovative process called\u000d\u000a        \"Rapid Energy\u000d\u000a        Distribution\" (Source 3 p.19)\u000d\u000a    Competitive advantage to the company\u000d\u000a      By creating superior high-quality products and reducing production costs,\u000d\u000a      the research outcomes\u000d\u000a      from this project have enabled the company to maintain its international\u000d\u000a      business and market\u000d\u000a      share in the higher-end designer kitchen sinks. The company has been able\u000d\u000a      to use these efficiency\u000d\u000a      savings to sustain its drive to maintain the economic viability of the\u000d\u000a      Falkirk site relative to other\u000d\u000a      competitive options. In 2010, Franke PL Colour, the parent company,\u000d\u000a      subsequently established\u000d\u000a      Carron Phoenix in Falkirk as the Group Competence Centre for composite\u000d\u000a      sink technology, due in\u000d\u000a      part to the strong research and development brought about by the\u000d\u000a      incorporation of nano-composite\u000d\u000a      technology. This has secured both major employment for 170 workers in the\u000d\u000a      composite sink\u000d\u000a      division at the Falkirk site and retained the associated supply chain\u000d\u000a      infrastructure supporting further\u000d\u000a      employment locally and nationally (Source 4).\u000d\u000a    Investment\u000d\u000a      The successful research outcomes from this project were further supported\u000d\u000a      by internal company\u000d\u000a      investments securing significant investment in new automated production\u000d\u000a      facilities with a capital\u000d\u000a      investment of approximately &#163;4M. These were installed in 2008 and 2009 to\u000d\u000a      incorporate\u000d\u000a      the new nanocomposite technology with the production and sale of over one\u000d\u000a      million kitchen sinks\u000d\u000a      by Carron Phoenix. This resulted in generating income in excess of &#163;50M\u000d\u000a      for the company as well\u000d\u000a      as generating support for the associated supply chain involved and\u000d\u000a      contributing to the UK economy\u000d\u000a      generally.\u000d\u000a    On-going collaboration\u000d\u000a      The Carron Phoenix company remains in regular contact with researchers at\u000d\u000a      WestCHEM using\u000d\u000a      facilities such as the Advanced Materials Research Laboratory. Schaschke\u000d\u000a      and Liggat provide\u000d\u000a      training courses on polymer chemistry and process technology for company\u000d\u000a      staff. Skilled\u000d\u000a      researchers from WestCHEM have transferred to posts in the industry; a PhD\u000d\u000a      graduate from the\u000d\u000a      Liggat research group, and an MEng graduate Chemical &amp; Process\u000d\u000a      Engineering have been\u000d\u000a      employed by Carron Phoenix since 2012.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Significant economic impact was achieved as a result of research into\u000d\u000a      polymer nanocomposites\u000d\u000a      and their formation, conducted at WestCHEM from 2000 to 2010.\u000d\u000a      Collaboration over the six-year\u000d\u000a      period 2004-2010 with Carron Phoenix Ltd, the world's largest manufacturer\u000d\u000a      of composite `granite'\u000d\u000a      kitchen sinks, led to nanocomposite technology being incorporated into\u000d\u000a      over one million sinks,\u000d\u000a      generating income for the company in excess of &#163;50M from 2007 to the\u000d\u000a      present day. Considerable\u000d\u000a      production efficiency gains saved in excess of &#163;1M annually through the\u000d\u000a      reduction in\u000d\u000a      manufacturing time, the reduction of raw materials wastage, and the\u000d\u000a      reduction in landfill costs (and\u000d\u000a      commensurate environmental benefit) for failed and out-of-spec products.\u000d\u000a      In addition, a &#163;4M\u000d\u000a      capital investment by the company at the Falkirk plant was secured,\u000d\u000a      enabling the company to\u000d\u000a      sustain its leading position in the designer kitchen sink market. With the\u000d\u000a      site consequently\u000d\u000a      designated as the parent company's competency centre for composite sink\u000d\u000a      technology,\u000d\u000a      employment for 170 workers was secured.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    WestCHEM\u000d\u000a    ","Institutions":[{"AlternativeName":"Glasgow (University of)","InstitutionName":"University of Glasgow","PeerGroup":"A","Region":"Scotland","UKPRN":10007794},{"AlternativeName":"Strathclyde (University of)","InstitutionName":"University of Strathclyde","PeerGroup":"B","Region":"Scotland","UKPRN":10007805}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    References 1, 2, and 4 best exemplify the quality of the body of\u000d\u000a      research. Reference 6 is included\u000d\u000a      in REF2.\u000d\u000a    \u000a[1] Study of the factors influencing the exfoliation of an organically\u000d\u000a      modified montmorillonite in\u000d\u000a      methyl methacrylate\/poly(methyl methacrylate) mixtures. M. McAlpine, N. E.\u000d\u000a      Hudson, J. J.\u000d\u000a      Liggat. R.A. Pethrick, D. Pugh, and I. Rhoney, Journal of Applied\u000d\u000a        Polymer Science, 2006, 99,\u000d\u000a      2614-2626. DOI: 10.1002\/app.22582\u000d\u000a    \u000a\u000a[2] Influence of the epoxy structure on the physical properties of epoxy\u000d\u000a      resin nanocomposites, S.\u000d\u000a      McIntyre, I. Kaltzakorta, J.J. Liggat, R.A Pethrick, and I. Rhoney, Industrial\u000d\u000a        and Engineering\u000d\u000a        Chemistry Research, 2005, 44, 8573-8579. DOI: 10.1021\/ie048835w\u000d\u000a    \u000a\u000a[3] Properties of epoxy nanoclay system based on diaminodiphenyl sulfone\u000d\u000a      and diglycidyl ether of\u000d\u000a      bisphenol F: influence of post cure and structure of amine and epoxy. S.E.\u000d\u000a      Ingram, J.J. Liggat\u000d\u000a      and R.A. Pethrick, Polymer International 2007, 56, 1029-1034. DOI:\u000d\u000a      10.1002\/pi.2237\u000d\u000a    \u000a\u000a[4] Some factors influencing exfoliation and physical property\u000d\u000a      enhancement in nanoclay epoxy\u000d\u000a      resins based on diglycidyl ether of bisphenol A and F; S. Ingram, I.\u000d\u000a      Rhoney, J.J. Liggat, N.E.\u000d\u000a      Hudson and R.A. Pethrick, Journal of Applied Polymer Science,\u000d\u000a      2007, 106, 5-19.\u000d\u000a      DOI: 10.1002\/app.25474\u000d\u000a    \u000a\u000a[5] Effects of organically modified clay loading on rate and extent of\u000d\u000a      cure in an epoxy\u000d\u000a      nanocomposite system, S.E. Ingram, R.A. Pethrick, and J.J. Liggat, Polymer\u000d\u000a        International,\u000d\u000a      2008, 57, 1206 - 1214. DOI: 10.1002\/pi.2452\u000d\u000a    \u000a\u000a[6] Influence of clay type on the enhancement in physical properties of in\u000d\u000a        situ polymerised\u000d\u000a      poly(methyl methacrylate) nanocomposites, S. Ingram, H. Dennis, I. Hunter,\u000d\u000a      J.J. Liggat, C.\u000d\u000a      McAdam, R.A. Pethrick, C. Schaschke, and D. Thomson, Polymer\u000d\u000a        International, 2008, 57,\u000d\u000a      1118-1127. DOI: 10.1002\/pi.2453\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"3","Level2":"3","Subject":"Macromolecular and Materials Chemistry"},{"Level1":"9","Level2":"12","Subject":"Materials Engineering"},{"Level1":"9","Level2":"13","Subject":"Mechanical Engineering"}],"Sources":"\u000d\u000a    [1] The KTP programme was assessed on a quarterly basis by and minutes of\u000d\u000a    these meeting are\u000d\u000a    held by the West of Scotland KTP Centre, 50 George Street, Glasgow G1 1QE\u000d\u000a    0141 548 2430.\u000d\u000a    www.ktpws.org.uk\u000d\u000a    [2] Head of R&amp;D, Carron Phoenix Ltd, has provided a statement, and\u000d\u000a      can be contacted to confirm\u000d\u000a      company perspective on the impact of the research, including quantitative\u000d\u000a      estimates of the\u000d\u000a      benefits.\u000d\u000a    [3] http:\/\/www.franke.com\/content\/dam\/frankegroup\/pdf\/publications\/Sustainability_Report_2011.pdf\u000d\u000a      provides evidence of increased efficiency and cost savings at the Falkirk\u000d\u000a      site\u000d\u000a    [4] Commercial &amp; Product Support Manager, Carron Phoenix Ltd, can be\u000d\u000a      contacted to confirm\u000d\u000a      company perspective on the impact of the research, including quantitative\u000d\u000a      estimates of the\u000d\u000a      benefits.\u000d\u000a    ","Title":"\u000d\u000a    Multi-million pound sales and efficiency gains through formulation\u000d\u000a        development and process optimisation\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2649723","Name":"Falkirk"}],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    Context\u000d\u000a      Carron Phoenix Ltd, based in Falkirk and part of the Swiss Franke PL\u000d\u000a      Colour Group, is the world's\u000d\u000a      largest manufacturer of composite kitchen sinks. Prior to our engagement\u000d\u000a      with the company, their\u000d\u000a      manufacturing (moulding) process was energy- and labour-intensive with\u000d\u000a      variable product quality,\u000d\u000a      and represented a significant cost to the company in terms of down-time,\u000d\u000a      remedial work, wastage\u000d\u000a      and disposal costs. There were also significant licensing costs. With\u000d\u000a      major financial concerns, the\u000d\u000a      company sought expertise to increase efficiency and reduce wastage costs\u000d\u000a      together with the\u000d\u000a      development of new products for the market.\u000d\u000a    Key Researchers\u000d\u000a      Since about 2000, the research groups of Richard Pethrick (appointed 1969,\u000d\u000a      promoted to\u000d\u000a      Professor in Physical Chemistry in 1984, retired in 2008 but maintains\u000d\u000a      research interests as non-salaried\u000d\u000a      research professor) and John Liggat (appointed 1994, promoted to Senior\u000d\u000a      Lecturer in\u000d\u000a      2003 and to Reader in Physical Chemistry in 2009), developed expertise on\u000d\u000a      the preparation and\u000d\u000a      evaluation of polymer nanocomposites, particularly by dispersion of\u000d\u000a      functionalised nanoclays, that\u000d\u000a      underpins the success of this project. This knowledge and understanding,\u000d\u000a      together with the\u000d\u000a      complementary expertise of chemical engineer, Carl Schaschke (appointed\u000d\u000a      1990, promoted to\u000d\u000a      Senior Lecturer in 2001, to Reader in 2006 and to Professor in Chemical\u000d\u000a      &amp; Process Engineering in\u000d\u000a      2010), were crucial in transforming the technology at Carron Phoenix,\u000d\u000a      resulting in the impacts\u000d\u000a      described here.\u000d\u000a    Key Research Findings\u000d\u000a      The most significant findings from this extensive research base in terms\u000d\u000a      of this impact case study\u000d\u000a      include:\u000d\u000a    (i) Detailed understanding of how to control and utilise the rheological\u000d\u000a      changes that occur in\u000d\u000a      monomer systems when generating nanocomposites through in situ\u000d\u000a      polymerisation [1, 6];\u000d\u000a    (ii) Understanding of what process factors, such as mixing regimes and\u000d\u000a      additives, optimise the\u000d\u000a      nanocomposite dispersion in the first instance [1, 4];\u000d\u000a    (iii) Identification of the chemical and physical property benefits, such\u000d\u000a      as reduced cure time,\u000d\u000a      increased glass transition temperature and accelerated crystallisation,\u000d\u000a      that can result from\u000d\u000a      effective nanocomposite formulation [2-6];\u000d\u000a    (iv) Knowledge of how different modifiers and the extent of surface\u000d\u000a      treatment for the\u000d\u000a      montmorillonite and sepiolite range of organically modified clays affected\u000d\u000a      the morphology of\u000d\u000a      the dispersion in polymerisable solvents and how this subsequently\u000d\u000a      affected rheology, cure\u000d\u000a      chemistry, and post-cure properties [1,6];\u000d\u000a    (v) Identification of effective mixing regimes and the use of coupling\u000d\u000a      agents to control the\u000d\u000a      dispersions [1].\u000d\u000a    The initial interaction (2002) with Carron Phoenix was through an EPSRC\u000d\u000a      CASE studentship\u000d\u000a      beginning our formal partnership and identifying the value of nanoclay\u000d\u000a      dispersions to the company\u000d\u000a      and some of the specific outputs from this research with are included in\u000d\u000a      [6]. Together, these\u000d\u000a      research outputs were crucial in allowing Carron Phoenix in conjunction\u000d\u000a      with their WestCHEM\u000d\u000a      partners to develop, implement, and fully optimise a new faster production\u000d\u000a      process. Initially, the\u000d\u000a      implementation of more rapid heating rates (an imperative for increased\u000d\u000a      efficiency) led to an\u000d\u000a      unwanted greater sedimentation of the fillers resulting in product\u000d\u000a      defects. Detailed and extensive\u000d\u000a      chemical and processing studies, informed by the earlier research base,\u000d\u000a      were required in terms of\u000d\u000a      formulation, cure characteristics, rheological, and thermal properties of\u000d\u000a      the nanoclay materials.\u000d\u000a      From these studies an innovative nanocomposite rheology modifier was\u000d\u000a      developed, based on the\u000d\u000a      earlier research-led formulations, which provided the required\u000d\u000a      anti-sedimentation controls without\u000d\u000a      adversely affecting the material flow behaviour or cure chemistry. Without\u000d\u000a      this additive, the new\u000d\u000a      cost effective process technology could not have been implemented. The\u000d\u000a      additive was also\u000d\u000a      incorporated into the standard process leading to much reduced rework and\u000d\u000a      wastage.\u000d\u000a    "},{"CaseStudyId":"42301","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2661886","Name":"Sweden"}],"Funders":[],"ImpactDetails":"\u000d\u000a    Process from research to impact\u000d\u000a    The original idea and research arose from Kerr at WestCHEM. Initial\u000d\u000a      results with a WestCHEM-funded\u000d\u000a      PhD student led to interest from AstraZeneca who then decided to\u000d\u000a      collaborate with Kerr,\u000d\u000a      through funding an additional PhD student to work on the project at\u000d\u000a      WestCHEM. The success of\u000d\u000a      those two students' research and frequent interactions between the Kerr\u000d\u000a      group and AstraZeneca\u000d\u000a      then led to immediate and extensive testing of the methodology at WestCHEM\u000d\u000a      and also within the\u000d\u000a      company on many of its drug candidate compounds.\u000d\u000a    Type(s) of impact\u000d\u000a    Process improvements\u000d\u000a    The Global Head of Isotope Chemistry at AstraZeneca explicitly indicates\u000d\u000a      the quantitative\u000d\u000a      difference that these catalysts are making within their drug discovery and\u000d\u000a      development\u000d\u000a      programmes. In drug candidate compounds that are susceptible to HIE\u000d\u000a      reactions (about one-third\u000d\u000a      of all their drug candidates), 90% now use the Kerr catalysts while 10%\u000d\u000a      still use the older Crabtree\u000d\u000a      catalysts. Since these studies underpin the development of all of the\u000d\u000a      AstraZeneca drug candidates,\u000d\u000a      it is clear that the new catalysts have a pervasive and significant\u000d\u000a      influence on the development of\u000d\u000a      new medicines within this multinational company. Of course, since\u000d\u000a      AstraZeneca were parties in the\u000d\u000a      original collaboration first published in 2008, it is to be expected that\u000d\u000a      they would still have a lead in\u000d\u000a      applying it to their work.\u000d\u000a    New product ranges\u000d\u000a    An extension of the impact has been the adoption of the new catalysts as\u000d\u000a      commercial products by\u000d\u000a      Strem Chemicals. They have marketed and sold the catalysts since October\u000d\u000a      2012 and in the 9\u000d\u000a      months since launch, [text removed for publication]\u000d\u000a    Reach and significance\u000d\u000a    Labelled compounds form an essential part of drug discovery and\u000d\u000a      development within the\u000d\u000a      pharmaceutical industry, allowing a rapid understanding of the metabolism\u000d\u000a      of candidate drugs, and\u000d\u000a      discrimination between candidates that can be progressed and those that\u000d\u000a      must be rejected. Efforts\u000d\u000a      to improve the efficiency are important; efficiency gains of 10% in the\u000d\u000a      study of the pharma-cokinetics\u000d\u000a      of candidate drugs would bring savings of the order of $100M per drug.\u000d\u000a      (Source 6).\u000d\u000a    The pharmaceutical industry is now applying the new technology directly\u000d\u000a      to its pipeline of\u000d\u000a      pharmaceutical candidates, with AstraZeneca in the lead, but with uptake\u000d\u000a      gathering pace globally.\u000d\u000a      At present, the principal impact is on operational efficiencies and cost\u000d\u000a      reductions for the\u000d\u000a      pharmaceutical companies, but the impact passes to the population at large\u000d\u000a      through the provision\u000d\u000a      of safer, more effective medicines at lower cost and with less\u000d\u000a      environmental impact.\u000d\u000a    The Global Head of Isotope Chemistry, AstraZeneca (Source 1) notes:\u000d\u000a    `The Kerr catalysts are now `state of the art' in this area of\u000d\u000a        labelling. Indeed, on analysing our\u000d\u000a        internal data for the past 15 months (Jan. 2012 - March, 2013), within\u000d\u000a        our global drug\u000d\u000a        discovery programmes at AstraZeneca, of the tritiation by isotope\u000d\u000a        exchange, 90% of all\u000d\u000a        compounds investigated were labelled with the Kerr-type catalysts. I\u000d\u000a        would predict that this\u000d\u000a        level of impact will continue within our company and will be replicated\u000d\u000a        within similar\u000d\u000a        organisations internationally.'\u000d\u000a    The former Associate Director of Isotope Chemistry, AstraZeneca, M&#246;lndal,\u000d\u000a      Sweden, currently an\u000d\u000a      independent consultant, (Source 2) says:\u000d\u000a    `These new catalysts have changed the map for the isotope chemist\u000d\u000a        world-wide and\u000d\u000a        especially in the pharma business. The Kerr catalysts have been\u000d\u000a        transformational in that they\u000d\u000a        have delivered notable efficiency savings, with tritiation cycle times\u000d\u000a        down from approximately\u000d\u000a        3 weeks to less than 1 week; as well as these time savings, the use of\u000d\u000a        these catalysts at\u000d\u000a        such low loadings has significantly reduced (radioactive) waste. These\u000d\u000a        catalysts are now\u000d\u000a        available from a commercial supplier and all chemists can use them very\u000d\u000a        easily. Moreover,\u000d\u000a        they are shelf stable and, based on the confidence delivered by their\u000d\u000a        efficiencies, D tests are\u000d\u000a        now often discarded in drug projects, with the experimentation going\u000d\u000a        directly to the `hot'\u000d\u000a        process on the T manifold.' (D = deuterium; T = tritium).\u000d\u000a    Further impact has arisen and continues to increase from the business of\u000d\u000a      Strem Chemicals who\u000d\u000a      now manufacture and sell the catalysts. The Chief Operating Officer, Strem\u000d\u000a      Chemicals (Source 3)\u000d\u000a      reports:\u000d\u000a    `The commercial availability of Prof. Kerr's novel iridium complex\u000d\u000a        technology for the R&amp;D\u000d\u000a        community is significantly increasing the adoption, and future potential\u000d\u000a        use, of his associated\u000d\u000a        catalysis methods in industry in the widest sense and especially within\u000d\u000a        pharmaceutical\u000d\u000a        companies. We have already seen interest and direct purchases from a\u000d\u000a        series of drug\u000d\u000a        companies and others in evaluating the technology in their direct\u000d\u000a        business-aligned\u000d\u000a        applications.'\u000d\u000a    Within the first year, Strem Chemicals' products were purchased by [text\u000d\u000a      removed for publication]\u000d\u000a      thereby extending the beneficial reach of Kerr's catalysts.\u000d\u000a    The application of the new catalysts within the pharmaceutical industry\u000d\u000a      ultimately impacts on\u000d\u000a      mankind, since we are dependent on the development of safe and effective\u000d\u000a      medicines at\u000d\u000a      reasonable cost and without detrimental effect on safety or the\u000d\u000a      environment. Use of the Kerr\u000d\u000a      catalysts is helping to speed up drug discovery and development, allowing\u000d\u000a      a rapid understanding\u000d\u000a      of the metabolism of candidate drugs, and discrimination between\u000d\u000a      candidates that can be\u000d\u000a      progressed and those that must be rejected.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Labelled compounds form an essential part of drug discovery and\u000d\u000a      development within the\u000d\u000a      pharmaceutical industry. Novel iridium catalysts, developed by Kerr at\u000d\u000a      WestCHEM since 2008,\u000d\u000a      have introduced a step-change in the ability to label pharmaceutical\u000d\u000a      candidate compounds with\u000d\u000a      radioactive (tritium) or non-radioactive (deuterium) isotopes.\u000d\u000a    The catalysts are applicable to specific types of compounds that comprise\u000d\u000a      approximately one-third\u000d\u000a      of all drug candidates. Advantages of the catalysts include greater\u000d\u000a      efficacy (less catalyst needed\u000d\u000a      and higher yield of labelled product, giving cost savings), greater speed\u000d\u000a      (efficiency savings), and a\u000d\u000a      significant decrease in radioactive waste compared with previous methods\u000d\u000a      (environmental and\u000d\u000a      safety benefits).\u000d\u000a    Even since 2008, their adoption within the pharmaceutical industry has\u000d\u000a      been extremely rapid; e.g.,\u000d\u000a      the multinational pharmaceutical company AstraZeneca now applies the Kerr\u000d\u000a      methodology to 90%\u000d\u000a      of their relevant candidate compounds. Additional impact has been achieved\u000d\u000a      by Strem Chemicals\u000d\u000a      who have been manufacturing and marketing the catalysts worldwide since\u000d\u000a      October 2012. Even in\u000d\u000a      that very short period, multiple sales have been made on three continents\u000d\u000a      providing economic\u000d\u000a      benefit to the company.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    WestCHEM\u000d\u000a    ","Institutions":[{"AlternativeName":"Glasgow (University of)","InstitutionName":"University of Glasgow","PeerGroup":"A","Region":"Scotland","UKPRN":10007794},{"AlternativeName":"Strathclyde (University of)","InstitutionName":"University of Strathclyde","PeerGroup":"B","Region":"Scotland","UKPRN":10007805}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    References 1, 2 and 5 best illustrate the quality of the research. Paper\u000d\u000a      1 is submitted as part of\u000d\u000a      REF2.\u000d\u000a    \u000a[1] Highly active iridium(I) complexes for catalytic hydrogen isotope\u000d\u000a      exchange, J. A. Brown, S.\u000d\u000a      Irvine, A. R. Kennedy, W. J. Kerr, S. Andersson and G. N. Nilsson, Chem.\u000d\u000a        Commun., 2008,\u000d\u000a      1115-1117. DOI: 10.1039\/B715938B\u000d\u000a    \u000a\u000a[2] The development and use of novel iridium complexes as catalysts for\u000d\u000a      ortho-directed hydrogen\u000d\u000a      isotope exchange reactions, G. N. Nilsson and W. J. Kerr, J. Label.\u000d\u000a        Compd. Radiopharm.,\u000d\u000a      2010, 53, 662-667. DOI: 10.1002\/jlcr.1817\u000d\u000a    \u000a\u000a[3] Highly Active Iridium(I) Complexes for Catalytic Hydrogen Isotope\u000d\u000a      Exchange, (conference\u000d\u000a      abstract at major international meeting) W. J. Kerr, S. Irvine, J. A.\u000d\u000a      Brown, S. Andersson &amp; G. N.\u000d\u000a      Nilsson. Abstracts of Papers of the American Chemical Society, 2007,\u000d\u000a      234, 79-ORGN; IDS\u000d\u000a      Number: V12JA; ISSN: 0065-7727\u000d\u000a    \u000a\u000a[4] Highly Active Iridium(I) Complexes for Catalytic Hydrogen Isotope\u000d\u000a      Exchange and Selective\u000d\u000a      Hydrogenation, J. A. Brown, S. Irvine, A. R. Kennedy, W. J. Kerr, S.\u000d\u000a      Andersson and G. Nilsson,\u000d\u000a      J. Label. Compd. Radiopharm., 2009, 52, 210-211. DOI: 10.1002\/jlcr.1590\u000d\u000a    \u000a\u000a[5] Application of neutral iridium(I) N-heterocyclic carbene complexes in\u000d\u000a      ortho-directed hydrogen\u000d\u000a      isotope exchange, A. R. Cochrane, S. Irvine, W. J. Kerr, M. Reid, S.\u000d\u000a      Andersson and G. N.\u000d\u000a      Nilsson, J. Label. Compd. Radiopharm. 2013, 56,\u000d\u000a      451-454. DOI: 10.1002\/jlcr.3084\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"15","Subject":"Pharmacology and Pharmaceutical Sciences"},{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"}],"Sources":"\u000d\u000a    [1] Letter from Global Head of Isotope Chemistry, AstraZeneca R&amp;D\u000d\u000a      corroborates the impact\u000d\u000a      within AstraZeneca.\u000d\u000a    [2] The Chief Operating Officer, Strem Chemicals can be contacted\u000d\u000a      to provide information on\u000d\u000a      sales of the iridium catalysts.\u000d\u000a    [3] Statement from the former Associate Director of Isotope\u000d\u000a        Chemistry, AstraZeneca, M&#246;lndal,\u000d\u000a        Sweden (currently an independent consultant) corroborates the impact\u000d\u000a      of the catalysts in\u000d\u000a      isotope chemistry in the pharmaceutical business.\u000d\u000a    [4] Publications mentioned under section 3 above.\u000d\u000a    [5] www.pharmaceutical-drug-manufactures.com\u000d\u000a      (access date: October 2010) gives the value of\u000d\u000a      the global pharmaceutical market in 2010 and estimates it for 2013.\u000d\u000a    [6] High Clinical Trials Attrition Rate Is Boosting Drug Development\u000d\u000a      Costs, Lang, L.\u000d\u000a      Gastroenterology 2004, 127, 1026, reports the\u000d\u000a      savings of $100 Million per drug that could be\u000d\u000a      achieved with a 10% efficiency gain in the study of pharmacokinetic\u000d\u000a      studies;\u000d\u000a      (DOI:10.1053\/j.gastro.2004.08.066)\u000d\u000a    [7] Synthesis of ximelagatran, melagatran, hydroxymelagatran, and\u000d\u000a      ethylmelagatran in H-3 labeled\u000d\u000a      form, R. Simonsson, G. Stenhagen, C. Ericsson, and C. S. Elmore, J.\u000d\u000a        Label. Compd.\u000d\u000a        Radiopharm., 2013, 56, 334-337, shows a real\u000d\u000a      industrial example of the use of one of the Kerr\u000d\u000a      catalysts within an AZ drug discovery programme (DOI: 10.1002\/jlcr.3028)\u000d\u000a    ","Title":"\u000d\u000a    Improved drug discovery and development through use of novel iridium\u000d\u000a        catalysts\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    Context\u000d\u000a    The design of drugs, with optimal potency and pharmacokinetic properties,\u000d\u000a      as well as increased\u000d\u000a      safety profile, poses a major challenge for pharmaceutical laboratories.\u000d\u000a      Attrition, or high failure\u000d\u000a      rate, has emerged as a central problem in modern drug development. This\u000d\u000a      contributes to an\u000d\u000a      average cost of $1.7 billion for developing a new chemical entity (NCE)\u000d\u000a      into a marketable drug.\u000d\u000a      The really expensive failures are those that fail late in the testing\u000d\u000a      process and so it is vital to get as\u000d\u000a      much information about candidate medicines as early as possible. Efforts\u000d\u000a      to improve efficiency are\u000d\u000a      of high interest to the pharma industry with gains of 10% in the study of\u000d\u000a      the pharmacokinetics of\u000d\u000a      candidate drugs resulting in savings of the order of $100M per drug. This\u000d\u000a      has heightened the\u000d\u000a      importance of absorption, distribution, metabolism, excretion, and\u000d\u000a      toxicology (ADMET) studies.\u000d\u000a      ADMET studies require the use of radiolabelled compounds. These labelled\u000d\u000a      compounds are most\u000d\u000a      conveniently made by taking the unlabelled drug candidate and introducing\u000d\u000a      the label in a single\u000d\u000a      step by hydrogen isotope exchange (HIE) through C-H activation on an\u000d\u000a      aromatic ring ortho- to a\u000d\u000a      substituent that can interact with a suitable catalyst. This method of\u000d\u000a      labelling applies to one-third of\u000d\u000a      all drug candidates.\u000d\u000a    Prior to the WestCHEM research, the industry standard for this operation\u000d\u000a      was Crabtree's catalyst,\u000d\u000a      also an iridium complex. This catalyst has a number of significant\u000d\u000a      disadvantages:\u000d\u000a    \u000d\u000a      Dichloromethane is usually the only solvent tolerated by this\u000d\u000a        catalyst, but many drug\u000d\u000a        candidates are insoluble in that solvent,\u000d\u000a      Bulky substituents near the site of the hydrogen to be exchanged\u000d\u000a        inhibit the process,\u000d\u000a      Inactive iridium dimers and trimers form from Crabtree's complex,\u000d\u000a        compromising its longevity,\u000d\u000a      Many substituents on the drug candidate do not deliver any appreciable\u000d\u000a        degree of labelling,\u000d\u000a      Although nominally a catalyst, high loadings of Crabtree's complex (in\u000d\u000a        many cases, more than\u000d\u000a        100 mole%) are often required, and\u000d\u000a      These high loadings normally lead to a lack of labelling\u000d\u000a        regioselectivity.\u000d\u000a    \u000d\u000a    Key findings\u000d\u000a    In the original WestCHEM paper published in 2008 [1], practical and\u000d\u000a      convenient methods were\u000d\u000a      developed for the preparation of novel iridium complexes, with the key\u000d\u000a      attribute that they\u000d\u000a      possessed both bulky N-heterocyclic carbene and bulky phosphine\u000d\u000a      ligands. Kerr (Professor,\u000d\u000a      WestCHEM) predicted and then demonstrated that these complexes show\u000d\u000a      exceptional activity in\u000d\u000a      hydrogen isotope exchange processes. Previous efforts by other research\u000d\u000a      teams to prepare similar\u000d\u000a      compounds had failed, but through two PhD projects at WestCHEM, Kerr\u000d\u000a      discovered an approach\u000d\u000a      that was successful and convenient. The research for the initial\u000d\u000a      publication was carried out with\u000d\u000a      deuterium (non-radioactive isotope of hydrogen) but with clear\u000d\u000a      applicability to tritium (radioactive\u000d\u000a      isotope of hydrogen) and with the stated aim of addressing important\u000d\u000a      studies of metabolism of drug\u000d\u000a      candidates within the pharmaceutical industry.\u000d\u000a    The interaction with AstraZeneca (at M&#246;lndal in Sweden) triggered through\u000d\u000a      the funding of the\u000d\u000a      second PhD project mentioned above, led to easy further development and\u000d\u000a      transfer of the\u000d\u000a      technology between WestCHEM and M&#246;lndal. Specifically, application to the\u000d\u000a      use of tritium labelling\u000d\u000a      could be more conveniently carried out at the industrial site, which had\u000d\u000a      appropriate safety\u000d\u000a      measures to routinely produce radioactively labelled compounds. In 2010,\u000d\u000a      an overview was\u000d\u000a      published by Nilsson (AstraZeneca) and Kerr [2] showing the development of\u000d\u000a      the collaboration. By\u000d\u000a      2010, three novel air-stable complexes showed great promise, providing\u000d\u000a      effective labelling in short\u000d\u000a      times (hours rather than days) at low loading (usually 0.5 % catalyst\u000d\u000a      loading) to an extended list of\u000d\u000a      substituents with tolerance of a wider list of solvents than could be used\u000d\u000a      for Crabtree's complex,\u000d\u000a      and with excellent selectivity in the site of labelling (through\u000d\u000a      5-membered metallacycle\u000d\u000a      intermediates over slower labelling through 6-membered metallacycle\u000d\u000a      intermediates). Labelling of\u000d\u000a      typical complex drug molecules bearing multiple substituents was\u000d\u000a      demonstrated. Most\u000d\u000a      impressively, the clean reactions seen with the new complexes averted the\u000d\u000a      serious problems of\u000d\u000a      radioactively labelled waste that had arisen with the Crabtree complex. A\u000d\u000a      representative assay in\u000d\u000a      the 2010 overview paper showed that at least 16 radiolabelled products\u000d\u000a      were formed on a\u000d\u000a      particular drug candidate using Crabtree's catalyst, compared with just\u000d\u000a      the single desired product\u000d\u000a      using the new catalyst regime.\u000d\u000a    Key researchers\u000d\u000a    William J Kerr (appointed as Lecturer, WestCHEM, October 1989, Senior\u000d\u000a      Lecturer from April 1997\u000d\u000a      and Professor of Organic Chemistry from April 2002).\u000d\u000a    "},{"CaseStudyId":"42302","Continent":[],"Country":[],"Funders":["Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000a    WestCHEM develops software to support high-throughput systems\u000a      At the same time that the precursor to PolySNAP, the SNAP-1D software\u000a      package, was being\u000a      developed at WestCHEM to facilitate an integrated approach to full x-ray\u000a      powder-diffraction pattern\u000a      analysis, the pharmaceutical industry was developing automated\u000a      crystallisation systems using\u000a      robotics, and was beginning to generate large volumes of one-dimensional\u000a      diffraction patterns.\u000a      However, there was no software available to process, classify, and\u000a      visualise such data. PolySNAP\u000a      was written under contract from Pfizer specifically to address this\u000a      problem. It was the first software\u000a      to do this and used novel statistics and visualisation methods. Data\u000a      visualisation is a vital\u000a      component of handling large amounts of data. With PolySNAP, time\u000a      expenditure was reduced from\u000a      days to seconds for &gt;100 data sets. It is an almost impossible task to\u000a      classify large data sets\u000a      without these techniques and so any investment in the new robotic hardware\u000a      would have been\u000a      pointless. The software was described by one Pfizer employee as \"like\u000a      having a new spectroscopic\u000a      method made available\". A confidential list of PolySNAP users up to 2010\u000a      is available, which\u000a      contains 72 users with commercial licences (Source 2). The software was\u000a      the property of Glasgow\u000a      University until 2010 when Professor Gilmore retired, at which time it was\u000a      sold to Bruker.\u000a    PolySNAP supplied worldwide with Bruker diffractometers\u000a      Bruker purchased the rights to the program from Pfizer in 2002-2003 for ca.\u000a      &#163;125k (the same as\u000a      the original cost to Pfizer) and started to market PolySNAP commercially\u000a      under licence from\u000a      Glasgow University (Source 1). Until 2010, license fees to the University\u000a      totalled &#163;84,164 (from\u000a      2008 &#163;37,894) (Source 3). Bruker continued to develop this software and\u000a      Gilmore set up a limited\u000a      company partly for this purpose (Allander Science Ltd.) and continues to\u000a      act as a consultant to\u000a      Bruker. Dr Dong was employed full-time by Bruker during the assessment\u000a      period. The\u000a      development of PolySNAP also led to a free computer program called dSNAP\u000a      that uses the same\u000a      ideas to classify and visualise the results of searches on the Cambridge\u000a      Structural Database (see\u000a      below).\u000a    New versions of the software were released: PolySNAP-2, PolySNAP-M, and\u000a      the latest PolySNAP-3.\u000a      PolySNAP-3 is unique in that it allows data from multiple sources,\u000a      techniques or data collection\u000a      strategies to be incorporated into the analysis. For example, data from\u000a      powder diffraction can be\u000a      combined with differential scanning calorimetry and Raman data to give a\u000a      combined analysis and\u000a      more accurate classifications of samples [5, 6]. This method is proving so\u000a      important that Bruker are\u000a      currently extending it to include x-ray fluorescence data in the new\u000a      releases of PolySNAP. It saves\u000a      money because it releases the time of highly paid scientific staff and it\u000a      is also objective, avoiding\u000a      the risk that exists with this sort of data that interpretation can become\u000a      subjective.\u000a    The relationship between Bruker and the University continued until 2010\u000a      when Prof Gilmore\u000a      retired. At that point, Bruker paid the equivalent of two years' license\u000a      fees (&#8364;30k) to purchase the\u000a      software outright. PolySNAP continues to be a part of the company's\u000a      development plan (Source 4).\u000a      Current list price when PolySNAP is purchased separately is &#8364;2,700, and\u000a      approximately 120 have\u000a      been sold since 2004, while Bruker also offers another version, m-SNAP, at\u000a      a list price of &#8364;5,000.\u000a      PolySNAP continues to be sold in combination with all Bruker x-ray powder\u000a      diffractometers.\u000a    PolySNAP utilised across industry and education\u000a      Although the impact beyond the sale of the software is very difficult to\u000a      quantify, the beneficiaries of\u000a      this software are many:\u000a    \u000a      The pharmaceutical industry: Most large pharmaceutical companies use\u000a        PolySNAP: Novartis,\u000a        AstraZeneca, Pfizer, Roche, Syngenta, Sanofi Aventis, and many smaller\u000a        companies. It\u000a        dramatically reduces both the timescale and the reliability of sample\u000a        screening allowing even\u000a        very large datasets (&gt;100,000 samples) to be pre-screened in minutes\u000a        to find the subset of\u000a        patterns most relevant to a given target. Prior to PolySNAP, such\u000a        searches would have used\u000a        reduced patterns in which the powder data are presented as a small set\u000a        of intensities and\u000a        positions for the top 5-10 peaks. PolySNAP was the first program to use\u000a        the full measured data\u000a        in all its analysis steps. High-throughput data are of poor quality and\u000a        using traditional reduced\u000a        patterns is ineffective at best and often worthless.\u000a      Mining industry: e.g., companies such as Anglo Platinum and Mintek in\u000a        southern Africa, where\u000a        PolySNAP software is used to assess the quality of ore samples prior to\u000a        processing into pure\u000a        metals, and to group huge quantities of materials of different origin.\u000a        The software allows the\u000a        companies to carry out rapid comprehensive assessments of ore\u000a        variability in terms of bulk\u000a        mineralogical composition and facilitating decision-making.\u000a      Materials Science: identifying new materials, studying phase changes\u000a        with temperature and\u000a        pressure, simple quantitative analysis of mixtures.\u000a      Forensic science: e.g. South African Police Force have used PolySNAP\u000a        to match samples from\u000a        crime scenes with a database of known samples. It is especially valuable\u000a        when used with\u000a        mineral theft.\u000a    \u000a    A Principal Scientist, Materials Science, at AstraZeneca explains the\u000a      value of PolySNAP (Source\u000a      5):\u000a    \"Identification of a suitable solid form for development of a\u000a        crystalline material still remains a\u000a        great challenge for the pharmaceutical industry. Due to the different\u000a        physical properties (e.g.,\u000a        dissolution, stability) of different polymorphs, extensive screening is\u000a        performed during the\u000a        early stages of development to ensure the solid form architecture of the\u000a        proposed molecule\u000a        is fully understood and there have been a number of costly issues where\u000a        compounds have\u000a        had to be reformulated due to changes of form after launch.\u000a    In screening for different solid forms, both manual and automated\u000a        technologies have been\u000a        utilised and a number of high throughput platforms have been developed\u000a        that utilise common\u000a        analytical techniques, e.g., PXRD for analysis of solid form. These\u000a        techniques yield large\u000a        quantities of analytical data which is quite difficult to comprehend and\u000a        can rapidly overwhelm\u000a        operators with excessive data. [...] PolySNAP utilises a wide range of\u000a        mathematical\u000a        techniques to help manage large data sets and successfully guides the\u000a        scientists into not\u000a        only the presence of the different forms but, more importantly, how\u000a        these forms have been\u000a        manufactured and hence how they can be controlled. It provides a range\u000a        of pattern-matching\u000a        methods and allows the user to have full control over understanding the\u000a        date avoiding `black\u000a        box' type results leaving the operator in control and reducing large\u000a        datasets to a much\u000a        smaller number of samples which require interpretation by scientists.\u000a        The results from\u000a        PolySNAP allow rapid identification of `safe' areas of working (e.g.,\u000a        solvents, temperature,\u000a        concentrations, etc.) and where further understanding is required. Most\u000a        recently, the extra\u000a        dimension of adding the capability of other analytical data (e.g.,\u000a        spectroscopic) has provided\u000a        further confidence and opportunities in the pattern matching.\"\u000a    A one-month trial version of the PolySNAP software is available from\u000a      WestCHEM, accompanied by\u000a      a tutorial and trial data (Source 6).\u000a    Visualising the Cambridge Structural Database with dSNAP\u000a      The WestCHEM research that led to PolySNAP also underpinned a free\u000a      computer program called\u000a      dSNAP (Source 7) that classifies and visualises the results of searches on\u000a      the Cambridge\u000a      Structural Database (CSD), a repository of over 500,000 crystal structures\u000a      derived from x-ray and\u000a      neutron diffraction. The CSD is by far the most important source of\u000a      structural data for small\u000a      molecules, but while it is easy to search this database, it can be a\u000a      problem to interpret the results.\u000a      dSNAP is an important tool for this. dSNAP simplifies the problem using\u000a      the same methodology as\u000a      PolySNAP: it clusters the search results into groups that are very similar\u000a      and thus allows the user\u000a      to treat the group as a single entity so reducing the number of structures\u000a      that need to examined.\u000a      Additional tools are provided to assist in this. A confidential list of\u000a      166 licensed dSNAP users up to\u000a      2010 is available (Source 2).\u000a    ","ImpactSummary":"\u000a    PolySNAP is an extensive commercial computer program developed at\u000a      WestCHEM to process and\u000a      classify large volumes of crystallographic and spectroscopic data. It is a\u000a      market-leading product\u000a      sold and supported by Bruker Corporation (a manufacturer of scientific\u000a      instruments for molecular\u000a      and materials research selling products world-wide) and is used in\u000a      laboratories throughout the\u000a      world supporting business in the pharmaceutical, materials, mining,\u000a      geology, and polymer science\u000a      sectors. The PolySNAP software was and continues to be sold in combination\u000a      with all Bruker x-ray\u000a      powder diffractometers.\u000a    ","ImpactType":"Technological","Institution":"\u000a    WestCHEM\u000a    ","Institutions":[{"AlternativeName":"Glasgow (University of)","InstitutionName":"University of Glasgow","PeerGroup":"A","Region":"Scotland","UKPRN":10007794},{"AlternativeName":"Strathclyde (University of)","InstitutionName":"University of Strathclyde","PeerGroup":"B","Region":"Scotland","UKPRN":10007805}],"Panel":"B         ","PlaceName":[],"References":"\u000a    References 2, 3 and 5 best illustrate the quality of the research:\u000a    \u000a[1] `High-throughput powder diffraction. I. A new approach to qualitative\u000a      and quantitative powder\u000a      diffraction pattern analysis using full pattern profiles', C.J. Gilmore,\u000a      G. Barr, and J. Paisley, J.\u000a        Appl. Cryst. (2004), 37, 231-242. (doi: 10.1107\/S002188980400038X)\u000a    \u000a\u000a[2] `High Throughput Powder Diffraction: II Applications of Clustering\u000a      Methods and Multivariate\u000a      Data Analysis', G. Barr, W. Dong and C.J. Gilmore, J. Appl. Cryst.\u000a      (2004), 37, 243-252. (doi:\u000a      10.1107\/S0021889804000391)\u000a    \u000a\u000a[3] `High-throughput powder diffraction. III. The application of\u000a      full-profile pattern matching and\u000a      multivariate statistical analysis to round-robin-type data sets', Gordon\u000a      Barr, Wei Dong,\u000a      Christopher Gilmore and John Faber J. Appl. Cryst. (2004), 37,\u000a      243-252. (doi:\u000a      10.1107\/S0021889804013743)\u000a    \u000a\u000a[4] `High Throughput Powder Diffraction: IV Cluster Validation using\u000a      Silhouettes and Fuzzy\u000a      Clustering', G. Barr, W. Dong, and C.J. Gilmore, J. Appl. Cryst.\u000a      (2004), 37, 874-882.\u000a      (doi:10.1107\/S0021889804020990)\u000a    \u000a\u000a[5] `High Throughput Powder Diffraction V: The Use of Raman Spectroscopy\u000a      with and without X-ray\u000a      Powder Diffraction data', G. Barr, G. Cunningham, W. Dong, C.J. Gilmore\u000a      and T. Kojima, J.\u000a        Appl. Cryst. (2009), 42, 706-714. (doi: 10.1107\/S0021889809022924)\u000a    \u000a\u000a[6] `PolySNAP3: a computer program for analysing and visualizing\u000a      high-throughput data from\u000a      diffraction and spectroscopic sources', G. Barr, W. Dong and C.J. Gilmore,\u000a      J. Appl. Cryst.\u000a      (2009), 42, 965-974. (doi: 10.1107\/S0021889809025746)\u000a    \u000aPolySNAP was developed using grants to Prof Gilmore from Ford Motor\u000a      Company (2000), Pfizer\u000a      (2003, 2004, 2005), Bruker, the Cambridge CDC (2006), and EPSRC\u000a      (`Adventurous Research in\u000a      Chemistry', 2006) for a total value of &#163;712k.\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"3","Subject":"Macromolecular and Materials Chemistry"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"1","Level2":"4","Subject":"Statistics"}],"Sources":"\u000a    [1] Evidence of use of software by Bruker: Bruker website http:\/\/www.bruker.com\/en\/products\/x-ray-diffraction-and-elemental-analysis\/x-ray-diffraction\/xrd-software\/applications\/xrd-software-applications\/polysnap.html\u000a    [2] A confidential list of PolySNAP users up to 2010 is\u000a      available. [To be treated as commercially\u000a      sensitive] The list also contains 166 licenced dSNAP users up to 2010.\u000a      This software is free,\u000a      and is now downloadable without a licence, so users after 2010 are not\u000a      registered on the\u000a      spreadsheet.\u000a    [3] There is a confidential spreadsheet of royalty income from\u000a      Bruker arising from sales of the\u000a      PolySNAP software up to 2010. [To be treated as commercially sensitive]\u000a    [4] Product Manager XRD at Bruker AXS GmbH in Karlsruhe Germany can be\u000a      contacted to\u000a      confirm the value of PolySNAP to Bruker products.\u000a    [5] Statement from Principal Scientist, Materials Sciences, AstraZeneca\u000a      R&amp;D provides evidence of\u000a      the value of PolySNAP in materials analysis\u000a    [6] A one-month trial version of the PolySNAP software can be downloaded\u000a      by sending an e-mail\u000a      to snap@chem.gla.ac.uk. The\u000a      program comes with a tutorial and trial data.\u000a    [7] The dSNAP software can be downloaded from:\u000a      http:\/\/www.chem.gla.ac.uk\/snap\/PolySNAP_index.html\u000a    ","Title":"\u000a    PolySNAP Computer Software for enhanced processing and classifying\u000a        of crystallographic and spectroscopic data\u000a    ","UKLocation":[{"GeoNamesId":"2648579","Name":"Glasgow"}],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Context\u000a      The research undertaken at WestCHEM addresses the problem of analysing\u000a      large quantities data\u000a      from x-ray powder diffraction and one-dimensional spectroscopic data, in\u000a      particular, from Raman\u000a      and IR spectroscopy [1,5]. In commercial research settings, it is now\u000a      routine to collect thousands of\u000a      x-ray powder-diffraction patterns in a day using crystallisation robots\u000a      and a fast powder\u000a      diffractometer. Many pharmaceutical and materials laboratories carry out\u000a      such work routinely, one\u000a      example being in the pharmaceutical industry where companies need to find\u000a      all the possible\u000a      polymorphs of a drug candidate both to protect their intellectual property\u000a      and to ensure that more\u000a      efficacious forms are not excluded. Using crystallisation robots,\u000a      thousands of potential polymorphs\u000a      are crystallised in small quantities and subjected to x-ray powder\u000a      diffraction and, if possible, to\u000a      Raman spectroscopy.\u000a    Key Research Outcomes\u000a      The motivation for the research carried out at WestCHEM was to explore\u000a      ways to classify the data\u000a      automatically and to provide associated data visualisation tools. The\u000a      PolySNAP software classifies\u000a      the patterns automatically using cluster analysis and multivariate\u000a      statistics showing groups of\u000a      patterns that are similar and thus belong to the same polymorph as well as\u000a      highlighting new\u000a      patterns that do not match the library of known forms [2-4]. From its\u000a      first release, PolySNAP's\u000a      approach has been revolutionary in that it uses every measured data point,\u000a      whereas previously\u000a      software used only the heights and positions of the top 5-10 peaks [6].\u000a      This makes it far more\u000a      robust in its statistics especially with regard to poor quality data,\u000a      which are common in high-\u000a      throughput studies.\u000a    The WestCHEM research has led to a new integrated approach to full\u000a      powder-diffraction pattern\u000a      analysis. It incorporated wavelet-based data pre-processing, parametric\u000a      and non-parametric\u000a      statistical tests for full-pattern matching, and singular-value\u000a      decomposition to extract quantitative\u000a      phase information from mixtures. Every measured data point is used in both\u000a      qualitative and\u000a      quantitative analyses. The success of this new integrated approach was\u000a      demonstrated through\u000a      examples using several test data sets [6].\u000a    Key researchers\u000a      The initial research was carried out at WestCHEM under a grant from the\u000a      Ford Motor Company\u000a      (USA and Germany) starting in 2000. Major developments were commissioned\u000a      by Pfizer in Kent\u000a      and involved Professor Chris Gilmore (Prof at WestCHEM 1973-2010) along\u000a      with Dr Gordon Barr\u000a      (PDRA at WestCHEM 2002-10), and Dr Wei Dong (PDRA at WestCHEM 2003-07).\u000a      Grants and\u000a      other income continued from various sources until 2010 including an EPSRC\u000a      Adventurous\u000a      Research in Chemistry grant (2006).\u000a    "},{"CaseStudyId":"43001","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"2921044","Name":"Germany"},{"GeoNamesId":"1861060","Name":"Japan"}],"Funders":["Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000d\u000a    Research at Southampton that gave rise to a unique high-throughput\u000d\u000a      solid-state synthesis methodology, has led to the creation of a dynamic\u000d\u000a      spin-out company, Ilika Technologies plc [5.1]. The company has\u000d\u000a      accelerated the development of the clean technologies of the future, in\u000d\u000a      collaboration with leading multinationals, and boosted the global\u000d\u000a      competitiveness of the UK economy. Based on Southampton's patented\u000d\u000a      methodology [Section 3], Ilika's work is focused on next-generation\u000d\u000a      applications for the high-growth industries of clean energy and\u000d\u000a      electronics, driving forward innovation to reduce reliance on the world's\u000d\u000a      diminishing supply of hydrocarbon fuels and cutting carbon emissions.\u000d\u000a    Clean technology: Governments have introduced incentives to\u000d\u000a      stimulate the development of electric vehicles (EVs), but mass-market\u000d\u000a      roll-out is being hindered by inadequate battery performance. Ilika's\u000d\u000a      technology, which allows rapid synthesis and screening of new cell\u000d\u000a      chemistries, has increased the energy capacity and charge rates of solid\u000a        state lithium-ion batteries, a market set to be worth $32 billion a\u000d\u000a      year by 2018. In a significant collaboration with Toyota, who since 2008\u000d\u000a      have invested ~&#163;4 million revenue directly into this research [5.1,\u000d\u000a        5.2], Ilika has also filed 9 patents in the period 2008-13 to\u000d\u000a      facilitate further advances in EV through the creation of new battery\u000d\u000a      materials and compositions [5.3]. These are being integrated into\u000d\u000a      batteries for future generations of Toyota's hybrid vehicles, also\u000d\u000a      offering very significant safety benefits over liquid electrolyte\u000d\u000a      batteries. Reducing catalyst materials costs is a key driver in delivering\u000d\u000a      Toyota's vision for fuel cell hybrid vehicle roll-out. Mr Taniguchi\u000d\u000a      (Toyota) states, \"Ilika's fuel cell catalyst formulation is key to\u000d\u000a          Toyota's strategy for cost reduction\", while according to Mr\u000d\u000a      Okajima (Project Manager, Toyota's Frontiers &amp; Advanced Engineering\u000d\u000a      Strategy Department, R&amp;D Management Centre, Japan), \"Ilika's\u000d\u000a          high through-put techniques are essential to overcome some of the\u000d\u000a          technological barriers we face in the development of leading-edge\u000d\u000a          technologies\" [5.4, 5.5]. Ilika has also made an\u000d\u000a      impact in other areas of the automotive industry, working with CeramTec to\u000d\u000a      develop more environmentally-friendly lead-free piezoelectrics in sensors\u000d\u000a      and actuators used for triggering airbags and in fuel injection systems.\u000d\u000a      These are now in use in several German automotive vehicle brands [5.4].\u000d\u000a    The International Energy Agency estimates that by 2020 hydrogen fuel cell\u000d\u000a      vehicles will be responsible for 10% of the new car market, achieving an 8\u000d\u000a      million tonne reduction in UK CO2 emissions between 2010-2020.\u000d\u000a      The prohibitive cost of Proton Exchange Membrane (PEM) fuel cells has\u000d\u000a      hindered the growth of this industry. Ilika has worked with Japanese\u000d\u000a      chemicals and materials company Asahi Kasei to develop unique palladium\u000d\u000a      alloy (Pd\/Co\/W) electrocatalysts [5.1] which are ~70% cheaper than\u000d\u000a      `standard' platinum catalysts, making the market penetration of fuel cell\u000d\u000a      vehicles more viable. Ilika has been awarded 3 Carbon Trust Grants to take\u000d\u000a      this work forward (total: ~&#163;438k), plus &#163;150k equity investment in 2012 [5.1,\u000d\u000a        5.6].\u000d\u000a    The future of hydrogen as an energy source is very dependent on the\u000d\u000a      ability to store it safely. Current solutions consume large amounts of\u000d\u000a      energy and raise safety concerns. Ilika worked with Shell to develop a\u000d\u000a      solid metal hydride [5.1, 5.3, 5.4], which is currently being\u000d\u000a      scaled-up and commercialised with Sigma Aldrich, a US-based specialist\u000d\u000a      chemicals company.\u000d\u000a    Digital memory: Phase change memory (PCM) is an emerging\u000d\u000a      technology expected to replace flash in solid-state memory for computers,\u000d\u000a      smart phones, etc., due to its higher performance and capacity to\u000d\u000a      extend battery life. In 2008 Ilika began collaborating with NXP\u000d\u000a      Semiconductors [5.1, 5.3] to optimise new PCM materials through\u000d\u000a      its high throughput screening technology. These are now being used by NXP\u000d\u000a      in embedded memory applications [5.6].\u000d\u000a    Biomaterials: Research into polymers, carried out by Bradley at\u000d\u000a      Southampton, with researchers at the Universities of Edinburgh and\u000d\u000a      Sheffield, produced biomedical applications. This led to the founding of Altrika\u000d\u000a        Ltd in 2009 [5.7], a wholly-owned subsidiary of Ilika,\u000d\u000a      marketing cell-based skin regeneration therapies to treat burns and\u000d\u000a      hard-to-heal wounds. In 2011, its Myskin&#174; and Cryoskin&#174;\u000d\u000a      products were being sold to seven NHS trusts, leading to accelerated\u000d\u000a      recovery, reduced scarring, reduced time in hospital and increased quality\u000d\u000a      of life for ~50 patients with particularly severe burns. In December 2012,\u000d\u000a      Altrika was sold to Adiposet Ltd. [5.7], providing them with\u000d\u000a      quality systems and licenses-to-operate from the Human Tissue Authority\u000d\u000a      and Medicines and Health products Regulatory Agency, for expanding its\u000d\u000a      cell bio-processing and bio-banking projects. This strategic decision\u000d\u000a      enabled Ilika to focus on its core cleantech programmes, now 90% of its\u000d\u000a      business.\u000d\u000a    Economic Impact: The direct economic impact on the UK economy is\u000d\u000a      through the formation of a PLC which now employs 35 staff (doubling since\u000d\u000a      2007), including 25 skilled scientists. Its annual turnover has increased\u000d\u000a      from &#163;0.97m (2007) to &#163;2.01m (2012), growing ~25% pa since 2008. Ilika,\u000d\u000a      listed in The Guardian Clean Tech 100, attracts inward investment into the\u000d\u000a      UK, with 83% of its revenue from international companies. It was floated\u000d\u000a      on the Alternative Investment Market of the London Stock Exchange in 2010\u000d\u000a      [5.8] at a market capitalisation of &#163;18.7m and raised ~&#163;5.2m, with\u000d\u000a      a further &#163;5m in May 2012 [5.1, 5.3, 5.9]. Ilika received the New\u000d\u000a      Energy Awards University Spin-out of the Year in 2012 [5.10]. Its\u000d\u000a      business is supported by sales offices in Japan, USA and Germany.\u000d\u000a    Fostering the Impact: Essential to the realisation of the impact\u000d\u000a      was the involvement of the University of Southampton's Centre for\u000d\u000a      Enterprise &amp; Innovation (CEI), which assisted with the protection and\u000d\u000a      exploitation of the IP. Company incubation was supported via\u000d\u000a      SETsquared (Southampton, Surrey, Bath, Bristol &amp; Exeter Universities).\u000d\u000a      Southampton Chemistry fostered Ilika's success by reducing Hayden's\u000d\u000a      workload to enable him to commit 50% of his time as CSO (2005-present).\u000d\u000a      According to Graeme Purdy (CEO, Ilika), \"Brian's role is extremely\u000d\u000a        valuable to Ilika, both in a business development capacity and in\u000d\u000a        providing scientific and technical leadership and credibility with\u000d\u000a        customers\" [5.4]. Ilika occupied research and office space\u000d\u000a      in Chemistry before relocating to the University of Southampton Science\u000d\u000a      Park in 2007. Graeme adds, \"Southampton Chemistry was critical in\u000d\u000a        nurturing Ilika's growth through structured access to space and a close\u000d\u000a        cooperation in the early days of the company\". Ilika continues to\u000d\u000a      hold a facilities agreement with the University, enabling them to access\u000d\u000a      specialist equipment on a commercial basis.\u000d\u000a    Strong collaborations between Southampton Chemistry and Ilika have also\u000d\u000a      continued through industrial CASE studentships, MChem placements, academic\u000d\u000a      consultancies and joint patents. Southampton Chemistry also trained many\u000d\u000a      of the scientists employed by Ilika.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    The unique application of combinatorial chemistry in materials science at\u000d\u000a      Southampton has directly underpinned the success of University spin-out,\u000d\u000a      Ilika Technologies. Since 2008, the breadth of applications of the\u000d\u000a      research has allowed Ilika:\u000d\u000a    \u000d\u000a      to form a partnership, worth around &#163;4m, with Toyota in the\u000d\u000a        development of battery materials for electric vehicles\u000d\u000a      to optimise new phase change memory materials now used by NXP in\u000d\u000a        embedded memory applications, and\u000d\u000a      to create and sell a subsidiary, Altrika Ltd, that has provided\u000d\u000a        cell-based skin regeneration therapies to 50 severe burn victims.\u000d\u000a    \u000d\u000a    Between 2008 and 2012, Ilika enjoyed considerable growth, doubling\u000d\u000a      employment to 35 staff, increasing turnover by approximately 25% annually,\u000d\u000a      and floating on the AIM with a market capitalisation of &#163;18.7 million.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    University of Southampton\u000d\u000a    ","Institutions":[{"AlternativeName":"Southampton (University of)","InstitutionName":"University of Southampton","PeerGroup":"A","Region":"South East","UKPRN":10007158}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    (the best 3 illustrating the quality of work are starred)\u000d\u000a    \u000a*[3.1] S. Guerin, B. E. Hayden, J. Comb. Chem. 8\u000d\u000a      (2006) 66-73. \"Physical vapor deposition method for the\u000d\u000a        high-throughput synthesis of solid-state material libraries\".\u000d\u000a    \u000a\u000a*[3.2] K. Brace, B. E. Hayden, A. E. Russell, J. R. Owen, Adv.\u000d\u000a        Mater. 18 (2006) 3253-3257. \"A parallel optical screen\u000d\u000a        for the rapid combinatorial electrochromic analysis of electrochemical\u000d\u000a        materials\".\u000d\u000a    \u000a\u000a*[3.3] S. Guerin, B. E. Hayden and D. C. A. Smith, J. Comb.\u000d\u000a        Chem. 10 (2008) 37&#8212;43. \"High-Throughput Synthesis and\u000d\u000a        Screening of Hydrogen-Storage Alloys\".\u000d\u000a    \u000a\u000a[3.4] M. S. Beal, B. E. Hayden, T. Le Gall, C. E. Lee, X. Lu, M.\u000d\u000a      Mirsaneh, C. Mormiche, D. Pasero, D. C. A. Smith, A. Weld, C. Yada, S.\u000d\u000a      Yokoishi, ACS Comb. Sci. 13 (2011) 375-381. \"High\u000d\u000a        Throughput Methodology for Synthesis, Screening, and Optimization of\u000d\u000a        Solid State Lithium Ion Electrolytes\".\u000d\u000a    \u000a\u000a[3.5] M. Mirsaneh, B. E. Hayden, E. Furman, S. Perini, M. T.\u000d\u000a      Lanagan, I. M. Reaney, Appl. Phys. Lett. 100 (2012)\u000d\u000a      082901. \"High dielectric tunability in lead niobate pyrochlore films\".\u000d\u000a    \u000a\u000a[3.6] M. Chang, M. S. Chen, A. David, S. Gandikota, S. Ganguli, B.\u000d\u000a      E. Hayden, S. Hung, X. Lu, C. Mormiche, A. Noori, D. C. A. Smith, C. J. B.\u000d\u000a      Vian, J. Appl. Phys. 113 (2013) 034107. \"Novel metal\u000d\u000a        gates for high k applications\".\u000d\u000a    \u000aFunding: EPSRC projects (i) GR\/M88365\/01 (&#163;5.95m) JIF:Combinatorial\u000a        Centre of Excellence (July 00-June 04) PI:Bradley; (ii) GR\/R50639\/01\u000d\u000a      (&#163;198k) Combinational Screening and Characterisation of Platinum Based\u000d\u000a        PEM Fuel Cell Catalysts (Feb 02-Feb 05) PI:Hayden; (iii)\u000d\u000a      EP\/C003039\/1 (&#163;16k) Electrocatalysis on Supported Metal and Alloy\u000d\u000a        Particles of Controlled Particle Size (Dec 04-Nov 05), PI:Hayden;\u000d\u000a      (iv) EP\/F015631\/1 (&#163;93k) High Throughput Synthesis of PbnNb2O5+n\u000d\u000a      Pyrochlore-Structured Tunable Thin Films (Feb 08-Jan 09) PI:Hayden.\u000d\u000a    Patents based on underpinning research prior to Ilika\u000d\u000a      being founded: S. Guerin and B. E. Hayden, \"Vapour deposition Method\",\u000d\u000a      US patent 8163337 (filed UK 2003, granted US 2012); J. R. Owen, P. N.\u000d\u000a      Bartlett, B. E. Hayden, A. E. Russell and K. M. Brace, \"Electrochemical\u000d\u000a        cell for testing the electrocatalytic behavior of multiple materials\",\u000d\u000a      US patent 8,083,913 (filed UK 2003, Granted US 2011, Europe 2013).\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"3","Subject":"Macromolecular and Materials Chemistry"},{"Level1":"3","Level2":"7","Subject":"Theoretical and Computational Chemistry"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"}],"Sources":"\u000d\u000a    [5.1] Ilika plc web-site: www.ilika.com\u000d\u000a      (includes Company History; Annual Reports; Edison Investment Research\u000d\u000a      Report; press releases)\u000d\u000a    [5.2] Press releases &#8212; Ilika-company partnerships: Toyota: http:\/\/www.ilika.com\/Toyota-Motor-Corporation-Japan-Contract-Renewal.aspx;\u000d\u000a      http:\/\/www.ilika.com\/Ilika-and-Toyota-Extend-Partnership.aspx;\u000d\u000a      http:\/\/www.ilika.com\/Solid%20State%20Battery%20Development.aspx\u000d\u000a      Ceramtec:\u000d\u000a      http:\/\/www.ilika.com\/Ilika%20and%20Ceramtec%20enter%20into%20Joint%20Development%20Project.aspx;\u000d\u000a      Sigma-Aldrich: http:\/\/www.ilika.com\/hydrogen-Storage-Collaboration-with-Sigma-Aldrich-Materials-Science.aspx;\u000d\u000a      Toshiba:\u000d\u000a      http:\/\/www.ilika.com\/New%20contract%20with%20Toshiba.aspx;\u000d\u000a      Energizer:\u000d\u000a      http:\/\/www.ilika.com\/Joint%20Development%20agreement%20with%20Energizer.aspx;.\u000d\u000a    [5.3] Ilika patent holdings.\u000d\u000a    [5.4] Corroborating contact, Chief Executive Officer, Ilika plc.\u000d\u000a    [5.5] Alternative corroborating contact, Chairman, Ilika plc.\u000d\u000a    [5.6] Carbon Trust press releases: http:\/\/www.ilika.com\/Ilika-awarded-Carbon-Trust-Research-and-Development-Grant.aspx;\u000d\u000a      http:\/\/www.ilika.com\/Carbon-Trust-Grant-and-New-Customer-Contract-for-Battery-Materials-Screening.aspx;\u000d\u000a      http:\/\/www.ilika.com\/Carbon%20Trust%20Investment.aspx;\u000d\u000a      Carbon Trust grant award information: 2007\/10: &#163;166,788; 2010\/11: &#163;98,281;\u000d\u000a      2011\/12: &#163;173,110. Total: ca. &#163;438k, plus &#163;150k equity investment in 2012.\u000d\u000a    [5.7] Altrika Ltd web-site: http:\/\/www.altrika.com\/;\u000d\u000a      Adiposet Ltd. acquisition of Altrika:\u000d\u000a      http:\/\/www.adiposet.com\/adiposet-news\/;\u000d\u000a      2010 &#8212; Altrika Ltd awarded &#163;100k TSB funding, winning the healthcare\u000d\u000a      category of the competition for Disruptive Solutions, for its development\u000d\u000a      work on a spray formulation of its Cryoskin&#174; donor skin cell product, http:\/\/www.altrika.com\/altrika-awarded-100000-funding-by-the-technology-strategy-board.aspx;\u000d\u000a      2011 &#8212; Altrika Ltd leads consortium awarded &#163;452k grant by TSB for further\u000d\u000a      developing its cell labelling technology, http:\/\/www.altrika.com\/Altrika%20grant%20award%20and%20new%20JDP.aspx\u000d\u000a    [5.8] London Stock Exchange announcement:\u000d\u000a      http:\/\/www.londonstockexchange.com\/exchange\/prices-and-markets\/stocks\/summary\/company-summary.html?fourWayKey=GB00B608Z994GBGBXASQ1;\u000d\u000a      flotation: http:\/\/www.ilika.com\/Ilika-Announces-Successful-Completion-of-IPO-on-AIM.aspx\u000d\u000a    [5.9] Summary of Ilika's key financial data since 2007;\u000d\u000a    [5.10] New Energy Award 2012 &#8212; press release:\u000d\u000a      http:\/\/www.ilika.com\/Ilika%20wins%20New%20Energy%20Award.aspx\u000d\u000a    ","Title":"\u000d\u000a    08-01 Ilika plc: Driving Global Innovation in Next Generation Materials\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2650225","Name":"Edinburgh"},{"GeoNamesId":"2637487","Name":"Southampton"},{"GeoNamesId":"2654675","Name":"Bristol"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"},{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    The use of combinatorial chemistry, i.e. the rapid synthesis of large\u000d\u000a      numbers (libraries) of related molecules or materials, in industry, has\u000d\u000a      traditionally been associated with drug discovery and catalysis in\u000d\u000a      pharmaceutical companies. The recognition that the technique could be\u000d\u000a      applied to materials science to create new functional solid-state\u000d\u000a      materials with tuneable properties and applications spanning the\u000d\u000a      electronics, energy and polymers sectors gave rise to a significant body\u000d\u000a      of multidisciplinary research at the University of Southampton's School of\u000d\u000a      Chemistry.\u000d\u000a    Mark Bradley, Professor of Combinatorial Chemistry until 2005, led a\u000d\u000a      successful bid to the UK Joint Infrastructure Fund (JIF) for funding of &#163;6\u000d\u000a      million in 2000 to establish a Combinatorial Centre of Excellence at\u000d\u000a      Southampton. Brian Hayden, Professor of Physical Chemistry, and Dr Samuel\u000d\u000a      Guerin, then a Postdoctoral Research Fellow until 2005, now Senior\u000d\u000a      Scientist at Ilika, worked together in the Centre to develop new\u000d\u000a      combinatorial approaches to solid state materials discovery based on\u000d\u000a      vacuum-deposited thin films on silicon micro-fabricated structures for\u000d\u000a      synthesis, characterisation and screening of these materials [3.1,\u000d\u000a        3.2, 3.3]. Professor Bradley also developed combinatorial synthetic\u000d\u000a      and screening methodologies for bio-polymer materials.\u000d\u000a    Projects to prepare and screen supported heterogeneous catalysts and\u000d\u000a      electrocatalysts were implemented with support from Johnson Matthey, a\u000d\u000a      world leader in advanced materials technology, General Motors, who were\u000d\u000a      keen to explore advances in electrocatalysts for use in electric vehicles,\u000d\u000a      and the EPSRC. Initial work centred on the synthesis and screening of\u000d\u000a      metal alloys, and doped oxide materials.\u000d\u000a    This high throughput methodology was then extended to the synthesis of\u000d\u000a      supported nanoparticles, most significantly allowing the characterisation\u000d\u000a      of particle size and support effects in electrocatalysis, and\u000d\u000a      demonstrating close analogies to heterogeneous catalysis. A range of other\u000d\u000a      functional materials were synthesised and characterised, including\u000d\u000a      piezoelectric perovskite metal oxides, metal hydrides and chalcogenide\u000d\u000a      alloys used for phase change memory applications that are destined to\u000d\u000a      replace flash memory. The high throughput physical vapour deposition (PVD)\u000d\u000a      methodology was used to directly synthesise mixed metal hydrides, which\u000d\u000a      are required for a high capacity, energy efficient and safe method of\u000d\u000a      reversibly storing hydrogen.\u000d\u000a    The key research outcome was the successful application of\u000d\u000a          combinatorial, high-throughput discovery tools to a much wider range\u000d\u000a          of materials, including polymers and solid state materials.\u000d\u000a      The IP obtained through this large multidisciplinary project led to the\u000d\u000a      founding of a University spin-out company, Ilika Plc. in 2004 by\u000d\u000a      Hayden, Bradley and Guerin. The research resulted in several key patents\u000d\u000a      and papers [3.1, 3.2, 3.3] and, in particular, the workflow for\u000d\u000a      solid-state materials discovery (Hayden and Guerin) and bio-active polymer\u000d\u000a      libraries and workflow (Bradley).\u000d\u000a    With the founding of Ilika, Hayden and Bradley became consultants, and\u000d\u000a      Hayden was appointed Chief Scientific Officer (CSO) in 2004, a position he\u000d\u000a      still holds alongside that of Professor of Physical Chemistry at the\u000d\u000a      University. Guerin was appointed as a Research Scientist at Ilika in 2005,\u000d\u000a      where he is now Senior Scientist. The areas of high throughput methods and\u000d\u000a      materials discovery have continued to feature strongly in Professor\u000d\u000a      Hayden's research in Chemistry at Southampton [3.4, 3.5, 3.6] with\u000d\u000a      considerable funding from EPSRC and industry for a range of different\u000d\u000a      projects. Bradley moved to become Professor of High-Throughput Chemical\u000d\u000a      Biology at the University of Edinburgh in 2005, subsequent to the\u000d\u000a      formation of Ilika.\u000d\u000a    "},{"CaseStudyId":"43002","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"6251999","Name":"Canada"}],"Funders":[],"ImpactDetails":"\u000d\u000a    After the development of the new Scorpion Primers technology in\u000d\u000a      collaboration with Professor Brown (Southampton Chemistry), two scientists\u000d\u000a      from AstraZeneca (Little and Whitcombe &#8212; key contacts) left the company to\u000d\u000a      set up an SME; DxS Ltd, in Manchester in 2001 (and acquired by\u000d\u000a      Qiagen in 2009) [5.1, 5.2]. DxS began developing mutation\u000d\u000a      detection products including an assay for 29 epidermal growth factor\u000d\u000a      receptor (EGFR) mutations. This led to a range of research products (EGFR,\u000d\u000a      KRAS, BRAF, PI3K, T315I), a selection of which progressed into TheraScreen\u000d\u000a      CE-marked diagnostic kits. In January 2008 DxS launched its first\u000d\u000a        companion diagnostic product to allow European sales of Amgen's\u000d\u000a        colorectal cancer drug, Vectibix&#174;. Vectibix was initially rejected\u000d\u000a      by the European Medicines Agency (EMA) on the basis of limited efficacy.\u000d\u000a      Amgen then used the DxS kit to stratify the population on the basis of\u000d\u000a      KRAS mutation status and Vectibix was approved by EMA for the KRAS\u000d\u000a      wild-type population. Further diagnostic products followed, with the EGFR\u000d\u000a      kit being used to establish the mutation status of non-small cell lung\u000d\u000a      cancer tumours, to determine likely response to Iressa&#174; or Tarceva&#174;.\u000d\u000a    DxS was acquired by QIAGEN N.V. for US$120m in 2009 [5.1, 5.2].\u000d\u000a      QIAGEN, the world-leading provider of assay technologies, is listed on\u000d\u000a      NASDAQ and the Frankfurt stock exchanges and operates more than 30\u000d\u000a      subsidiaries in 18 countries. The acquisition of DxS was described by\u000d\u000a      QIAGEN's CEO as \"strategically a highly important transaction\" and \"a\u000d\u000a        key element\" in its aim to \"lead in molecular diagnostic-based\u000d\u000a        prevention, profiling and personalised healthcare\" [5.2].\u000d\u000a      The sale was recognised as the \"Transaction of the Year\" (2010) at the\u000d\u000a      Mediscience Awards, London [5.3]. It also benefited the UK\u000d\u000a      economy, with QIAGEN establishing a Centre of Excellence in Pharma\u000d\u000a      Partnering at DxS's Manchester headquarters. The workforce expanded\u000d\u000a        from 67 (2009) to ~160 (2012) after a move to a purpose-fitted facility\u000d\u000a        on the Manchester Science Park in 2010. The success of the DxS\u000d\u000a      assays has led to the growth of QIAGEN's personalized healthcare\u000d\u000a      portfolio, which now makes US$100 million of sales annually (Peer Schatz,\u000d\u000a      CEO, QIAGEN N.V.) [5.4].\u000d\u000a    In the US, Food and Drug Administration (FDA) approval requires\u000d\u000a      diagnostic assays be associated with a clinical trial. DxS had been\u000d\u000a      approached by drug companies Amgen, BMS Lilly and Boehringer Ingelheim to\u000d\u000a      provide companion diagnostic assays for use in their clinical trials. This\u000a        led to the approval (July 2012) of the KRAS kit in the US for use with\u000d\u000a        the colorectal cancer drug, Erbitux&#174; [5.5]. The US market for this\u000d\u000a      drug is expected to be in the region of US$20 million. The EGFR kit was\u000d\u000a      submitted to the FDA in November 2012 for use with the Boehringer\u000d\u000a      Ingelheim non-small cell lung cancer drug, Afatinib; approval was\u000d\u000a        received in July 2013.\u000d\u000a    The EGFR and KRAS kits are now being used worldwide by hospital\u000d\u000a      laboratories, central testing facilities and clinical research\u000d\u000a      organisations. In the US the KRAS assay is being offered by Lab21, Inc,\u000d\u000a      The Mayo Clinic, Applied Diagnostics, Inc, Boyce and Bynum Pathology\u000d\u000a      Laboratories. In January 2013 Clarient also began offering the assay\u000d\u000a        [5.6]. The CEO of Clarient, Carrie Eglinton Manner, stated: \"We\u000d\u000a        believe precision medicine is the new direction in diagnosing and\u000d\u000a        treating cancer and Clarient uses state-of-the-art diagnostic\u000d\u000a        technologies like the therascreen KRAS test to bring clarity and\u000d\u000a        precision to physicians to assist them in making better treatment\u000d\u000a        decisions for their patients. Clarient's comprehensive offering and fast\u000d\u000a        turnaround time coupled with our experience with the therascreen KRAS\u000d\u000a        test permits us to provide a higher level of performance. Also, the fact\u000d\u000a        that it is FDA approved provides Clarient with additional assurance of\u000d\u000a        its quality and reliability.\" [5.6].\u000d\u000a    On-going development of the companion diagnostic portfolio is clear from\u000d\u000a      the agreement between QIAGEN and Eli Lilly, signed in February 2013,\u000d\u000a      to develop companion diagnostics for drugs for all therapeutic areas of\u000d\u000a      interest [5.7]. A further expansion of the biomarker portfolio is\u000d\u000a      evidenced by agreements and licences to develop assays for glioblastoma,\u000d\u000a      lymphoma and rheumatoid arthritis, in deals with Insight Genetics, Drug\u000d\u000a      Response Dx, InsermTransfert, Columbia University and the BC Cancer\u000d\u000a      Agency, Canada [5.4].\u000d\u000a    Since 2001 Professor Brown has continued to work on Scorpion design with\u000d\u000a      DxS and later QIAGEN on a consultative basis. Since 2005 this has mainly\u000d\u000a      been channelled through ATDBio (a spin-out company founded by Tom Brown)\u000d\u000a      for the provision of specialist advice and custom oligonucleotides [5.8].\u000d\u000a    David Whitcombe (co-founder of DxS) has stated \"Not only was\u000d\u000a        Professor Brown instrumental in the initial development of Scorpions\u000d\u000a        (suggesting and supplying appropriate blocking and quenching groups, and\u000d\u000a        also creating monomer phosphoramidites), but as the technology matured,\u000d\u000a        he was able to advise and assist on the high quality manufacture of\u000d\u000a        Scorpion constructs. In addition, his group were highly engaged in the\u000d\u000a        investigation of the properties and performance of these molecules. This\u000d\u000a        enabled DxS to move into the manufacture of high quality and high value\u000d\u000a        Diagnostic tests with significant clinical benefits for large numbers of\u000d\u000a        cancer sufferers. Ultimately it was the utility and quality\u000d\u000a          of these tests that underpinned the sale of DxS for US$120m\" [5.9].\u000d\u000a    This is supported by Steve Little (co-founder of DxS), who states that \"The\u000a        core technology used by DxS was Scorpions and, following the\u000d\u000a        acquisition, the technology continues to be used in an expanded range of\u000d\u000a        personalised medicine products provided by QIAGEN. Scorpions\u000d\u000a          technology now supports annual sales of around US$100m.\u000d\u000a      The input of Professor Tom Brown in providing chemistry expertise was\u000d\u000a        central to the success of the Scorpions technology.\" [5.10].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Research from Professor Tom Brown's group in Chemistry at Southampton has\u000d\u000a      made a major contribution towards tackling the issue of ineffective drug\u000d\u000a      therapies using Scorpion Primer Technology. Originally commercialised\u000d\u000a      through DxS Ltd., the major impacts derived since 2008 include:\u000d\u000a    \u000d\u000a      DxS launching, in 2008, its first companion diagnostic product to\u000d\u000a        allow European sales of Amgen's colorectal cancer drug, Vectibix&#174;;\u000d\u000a      The acquisition of DxS by QIAGEN N.V. for US$120 million in 2009;\u000d\u000a      FDA approval in 2012 of the KRAS kit for use with the colorectal\u000d\u000a        cancer drug, Erbitux&#174;;\u000d\u000a      FDA approval in 2013 of the EFGR kit for use with the non-small cell\u000d\u000a        lung cancer drug, Afatinib;\u000d\u000a      A 230% increase in QIAGEN staff based at the Manchester site between\u000d\u000a        2009 and 2012;\u000d\u000a      Current annual sales of Scorpion Primer diagnostics are around US$100\u000d\u000a        million.\u000d\u000a    \u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    University of Southampton\u000d\u000a    ","Institutions":[{"AlternativeName":"Southampton (University of)","InstitutionName":"University of Southampton","PeerGroup":"A","Region":"South East","UKPRN":10007158}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    (the best 3 illustrating the quality of work are starred)\u000d\u000a    Papers:\u000d\u000a    \u000a*[3.1] Whitcombe D., Theaker J., Guy S.P., Brown T., Little S.\u000d\u000a      `Detection of PCR products using self-probing amplicons and fluorescence'.\u000d\u000a      Nature Biotechnol. 1999, 17, 804-807\u000d\u000a    \u000a\u000a*[3.2] Thelwell N., Millington S., Solinas A., Booth J., Brown T.\u000d\u000a      `Mode of action and application of Scorpion primers to mutation\u000d\u000a      detection'. Nucleic Acids Res. 2000, 28,\u000d\u000a      3752-3761.\u000d\u000a    \u000a\u000a*[3.3] Solinas A., Brown L.J., McKeen C., Mellor J.M., Nicol\u000d\u000a      J.T.G., Thelwell N., et al. `Duplex Scorpion primers in SNP analysis and\u000d\u000a      FRET applications'. Nucleic Acids Res. 2001, 29,\u000d\u000a      art. no.-e96.\u000d\u000a    \u000a\u000a[3.4] McKeen, C. M.; Brown, L. J.; Nicol, J. T. G.; Mellor, J. M.,\u000d\u000a      Brown, T. `Synthesis of fluorophore and quencher monomers for use in\u000d\u000a      Scorpion primers and nucleic acid structural probes'. Org. Biomol.\u000d\u000a        Chem. 2003, 1, 2267-2275.\u000d\u000a    \u000a\u000a[3.5] May, J. P.; Brown, L. J.; van Delft, I.; Thelwell, N.;\u000d\u000a      Harley, K, Brown. T. `Synthesis and evaluation of a new non-fluorescent\u000d\u000a      quencher in fluorogenic oligonucleotide probes for real-time PCR'. Org.\u000d\u000a        Biomol. Chem. 2005, 3, 2534-2542.\u000d\u000a    \u000aPatents filed prior to DxS being founded:\u000d\u000a    `Methods for detecting target nucleic acid sequences', US patent number\u000d\u000a      US6326145, Applicant: Zeneca Ltd.; Inventors: D. M. Whitcombe, J. Theaker,\u000d\u000a      N. J. Gibson and S. Little (filed 1999, granted 2001);\u000d\u000a      `Fluorophore\/quencher labelled oligonucleotides', Applicant: Zeneca Ltd.;\u000d\u000a      Inventors: N. J. Gibson and T. Brown, UK patent number GB2337992B (filed\u000d\u000a      1999, granted 2001).\u000d\u000a    Funding for the underpinning research and studentships was\u000d\u000a      provided through industrial contributions from the collaborating partner,\u000d\u000a      AstraZeneca Diagnostics.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"6","Level2":"4","Subject":"Genetics"}],"Sources":"\u000d\u000a    [5.1] Qiagen company web-site: http:\/\/www.qiagen.com\/\u000d\u000a      , main information under section on Molecular Diagnostics: http:\/\/www.qiagen.com\/Products\/Lab-Focus\/Molecular-diagnostics\u000d\u000a    [5.2] Press releases announcing acquisition of DxS by Qiagen: http:\/\/www.qiagen.com\/About-Us\/Press-Releases\/PressReleaseView\/?PressReleaseID=268&amp;lang=EN;\u000d\u000a      http:\/\/www.genomeweb.com\/dxpgx\/qiagen-acquires-uks-dxs-deal-worth-130m\u000d\u000a    [5.3] QIAGEN's acquisition of DxS Ltd. in 2010 was recognized as\u000d\u000a      the \"Transaction of the Year\" at the annual Mediscience Awards (London),\u000d\u000a      the largest annual gathering of publicly quoted healthcare, biotech and\u000d\u000a      life science companies in Europe: http:\/\/www.qiagen.com\/About-Us\/Who-We-Are\/Awards-and-Partnerships\/Awards-and-Recognitions\/\u000d\u000a    [5.4] QIAGEN Sales and Expansion of biomarker portfolio: http:\/\/www.qiagen.com\/About-Us\/Press-Releases\/PressReleaseView\/?PressReleaseID=414&amp;lang=EN\u000d\u000a    [5.5] Press release on the market size for Erbitux: http:\/\/www.genomeweb.com\/mdx\/fda-clears-qiagen-kras-test-cdx-erbitux\u000d\u000a    [5.6] Press release announcing Clarient to offer KRAS assay: http:\/\/www.qiagen.com\/About-Us\/Press-Releases\/PressReleaseView\/?PressReleaseID=404&amp;lang=EN\u000d\u000a    [5.7] QIAGEN-Eli Lilly agreement: http:\/\/www.genomeweb.com\/pcrsample-prep\/qiagen-eli-lilly-enter-cdx-deal\u000d\u000a    [5.8] ATDBio web-site: http:\/\/www.atdbio.com\/\u000d\u000a    [5.9] Corroborating contact, ex-AstraZeneca collaborator and\u000d\u000a      co-founder of DxS.\u000d\u000a    [5.10] Corroborating contact, ex-AstraZeneca collaborator and\u000d\u000a      co-founder of DxS and ex-Vice President QIAGEN.\u000d\u000a    ","Title":"\u000d\u000a    08-02 Scorpion Primers and the Advance of Medical Diagnostics\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2637487","Name":"Southampton"},{"GeoNamesId":"2643743","Name":"London"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    The prescription of ineffectual drug therapies is a recurring problem in\u000d\u000a      global healthcare, putting patients' lives at risk and wasting vast sums\u000d\u000a      of health service money. Around 90% of drugs are effective on only 30-50%\u000d\u000a      of individuals and inappropriate drug treatments can lead to distressing\u000d\u000a      side effects. A colossal US$350bn of the US$770bn global annual drugs\u000d\u000a      sales in 2008 was spent on ineffective medicines.\u000d\u000a    Rapid and accurate analysis of specific DNA sequences can identify groups\u000d\u000a      of patients that are most likely to respond positively to a particular\u000d\u000a      drug, thereby enabling improved and cost-effective care. The need to\u000d\u000a      invent a more effective method of genetic analysis drove a body of\u000d\u000a      research, from 1998 to 2003, by a team in the University of Southampton\u000d\u000a      Chemistry Department, led by Tom Brown [3.1, 3.2 ,3.3]. Brown was\u000d\u000a      a Professor of Biological Chemistry in Southampton Chemistry (until\u000d\u000a      October 2013) and was also the founder of three biotech companies: Oswel,\u000d\u000a      ATDBio and PrimerDesign. Brown's group specialises in nucleic acids\u000d\u000a      chemistry, in particular structure-function relationship, DNA sequence\u000d\u000a      recognition and the application of oligonucleotide chemistry to genetic\u000d\u000a      analysis, diagnostics and therapeutics.\u000d\u000a    The work was conducted in Southampton, mainly by three PhD students under\u000d\u000a      Brown's supervision: Antonio Solinas, Lynda Brown and Jamie Nicol. In\u000d\u000a      collaboration with Dr David Whitcombe and Dr Steve Little at AstraZeneca\u000d\u000a      Diagnostics, the research programme produced an entirely original method\u000d\u000a      of genetic analysis that was particularly suitable for real-time PCR-based\u000d\u000a      diagnostics. AstraZeneca and Oswel Research Products, a company\u000d\u000a      specialising in the synthesis of chemically modified and complex\u000d\u000a      oligonucleotides and their analogues, DNA, RNA and PNA, funded the\u000d\u000a      projects jointly. Oswel was founded by Brown and at the time was based in\u000d\u000a      the University of Southampton.\u000d\u000a    Brown's primary contribution was to provide the unique chemical expertise\u000d\u000a      necessary to construct the complex modified oligonucleotides that form the\u000d\u000a      basis of the technology. Beginning with the analysis of genes involved in\u000d\u000a      breast cancer susceptibility, the group developed bi-functional molecules\u000d\u000a      in which a primer is covalently linked to the probe, which is held in a\u000d\u000a      scorpion-shaped tail (see Figure). The molecules also contain a\u000d\u000a      fluorophore and a quencher. During the Scorpion polymerase chain reaction\u000d\u000a      (PCR), in the presence of the target, the fluorophore and the quencher\u000d\u000a      separate, leading to an increase in the fluorescence emission, which can\u000d\u000a      be detected and measured in the reaction tube.\u000d\u000a    Mechanistic studies followed to test the performance of these systems.\u000d\u000a      Compared with dual-labelled probes, the uni-molecular mechanism acts\u000d\u000a      around four times faster in solution, for instantaneous fluorescence in\u000d\u000a      real-time PCR. Its other key advantages, over standard PCR probes that\u000d\u000a      existed at the time, are enhanced sensitivity, simplified assay design,\u000d\u000a      high signal-to-noise ratio and greater specificity.\u000d\u000a\u0009  (a)\u000d\u000a\u0009  (b)\u000d\u000a    \u000d\u000a    Figure: (a) illustrating the key elements of a Scorpion primer and (b)\u000d\u000a        how it functions.\u000d\u000a    \u000d\u000a    The research resulted in several highly cited publications, e.g. [3.1]-[3.5].\u000d\u000a      AstraZeneca filed a US patent for the Scorpion Primers technology\u000d\u000a      in 1999; a UK patent for \"Fluorophore\/quencher labelled oligonucleotides\"\u000d\u000a      was filed in the same year.\u000d\u000a    "},{"CaseStudyId":"43209","Continent":[{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6252001","Name":"United States"}],"Funders":[],"ImpactDetails":"\u000d\u000a    \"I am delighted to confirm the essential role of Chemistry research in\u000d\u000a        the formation and growth of Atlas Genetics. Atlas is building a world\u000d\u000a        class diagnostics company based on technology for the electrochemical\u000d\u000a        detection of specific sequences of DNA. The underpinning research was\u000d\u000a        carried out in collaboration with Professor Frost [and team] in the\u000d\u000a        Chemistry Department at Bath\" [A]\u000d\u000a    Impacts from this work: company, investment, people and a new\u000d\u000a        technology\u000d\u000a    \u000d\u000a      A spin-out or new business has generated revenue or profits (Atlas\u000d\u000a          Genetics; &gt;&#163;18M new investment in REF period)\u000d\u000a      Highly skilled people having taken up specialist roles that draw on\u000d\u000a        their research (Atlas staff expansion from 12 to 36, largely in\u000d\u000a          technical scientific roles, including three recruited from Bath at\u000d\u000a        doctoral level)\u000d\u000a      A new diagnostic or medical technology has been developed (the io&#8482;\u000d\u000a        platform &amp;trade trialled in the USA and EU; successful clinical\u000d\u000a          trialling)\u000d\u000a    \u000d\u000a    Economic, Wealth and Opportunity Creation\u000d\u000a      The research carried out in Bath Chemistry, and the development of the key\u000d\u000a      technology of the electrochemical sensor [B], resulted in the formation\u000a        of Atlas Genetics in 2005, to exploit commercially the technology\u000d\u000a      originating from the University of Bath. Atlas was launched with &#163;500k\u000d\u000a      initial funding, 50% of which came from the Sulis Seedcorn Fund,\u000d\u000a      established by the University of Bath to provide support for new\u000d\u000a      businesses. Prior to the REF period, in 2007 Atlas completed Series A\u000d\u000a      financing of &#163;2 million and the company relocated from the University to a\u000d\u000a      2,500 sq. ft. site on a business park close to Bath (Trowbridge,\u000d\u000a      Wiltshire). The number of full time staff increased to 12 and a commercial\u000d\u000a      programme to develop the Atlas system io&#8482; was initiated.\u000d\u000a    Atlas [C] is currently venture capital funded and to date has\u000d\u000a          raised ca. &#163;22m, including a &#163;16.9M investment in July\u000d\u000a        2011, specifically to develop the io&#8482; system and a\u000d\u000a      molecular Chlamydia test. Atlas investors include YFM, South West Ventures\u000d\u000a      Fund, Finance South West Growth Fund, Braveheart Ventures, Sulis\u000d\u000a      Investment Management Fund, GEIF Ventures, Consort Medical plc, Novartis\u000d\u000a      Venture Funds, Life Sciences Partners, BB Biotech Ventures and Johnson\u000d\u000a      &amp; Johnson Development Corporation and private investors [D]. Atlas has\u000d\u000a      recently expanded its office and laboratory provision to 9,500 sq. ft. and\u000d\u000a      currently employs a total of 36 permanent staff, representing an increase\u000a        of 24 in the REF period, the majority of whom have higher education\u000d\u000a      qualifications in science (MSc\/PhD), engineering (BEng\/MEng) or business\u000d\u000a      (MBA).\u000d\u000a    The company has continued to invest in the research and development of\u000d\u000a      new reagents and electrochemistry technology with the establishment of a\u000d\u000a      new post for a senior chemist, who spends 3 days\/week at Bath and 2\u000d\u000a      days\/week at Atlas. Professors Frost and Marken are both engaged as\u000d\u000a      consultants by Atlas Genetics.\u000d\u000a    The Route to Clinical Implementation\u000d\u000a      Atlas' proprietary io&#8482; system enables the sensitivity and\u000d\u000a      accuracy of laboratory testing to be achieved in a point-of-care\u000d\u000a      environment. The io&#8482; system will initially be launched for the\u000d\u000a      testing of Chlamydia [E], allowing clinicians to test and treat patients\u000d\u000a      in a single appointment. Around 40 million tests are carried out for this\u000d\u000a      and related diseases in Europe and the US every year. According to the\u000d\u000a      European Centre for Disease Prevention and Control and the World Health\u000d\u000a      Organisation [F], Chlamydia is the most frequently reported bacterial\u000d\u000a      sexually transmitted infection (STI), causing an estimated 92 million new\u000d\u000a      cases of genital Chlamydia infection annually and prevalence rates in\u000d\u000a      young people between 5-10% [F]. Rapid diagnosis is key to preventing\u000d\u000a      disease spread. The electrochemical technology at the core of the Atlas io&#8482;\u000d\u000a      tests offer a time-to-result turnaround of less than 30 minutes, which is\u000d\u000a      within the acceptable waiting period for a point-of-care diagnostic test\u000d\u000a      result. The \"test and treat\" approach offers significant benefits to the\u000d\u000a      wider population and could include a decrease of onward transmission and\u000d\u000a      new infections. To establish the validity of the prototype assays, Atlas\u000d\u000a      have collaborated with Professor Charlotte Gaydos of the Johns Hopkins\u000d\u000a      University Medical School (Baltimore, USA; [G]) to evaluate the io&#8482;\u000d\u000a      system technology for Chlamydia detection on 306 patient samples,\u000d\u000a      showing a sensitivity of 98.1% and specificity of 98.0% using the\u000d\u000a      prototype io&#8482; Chlamydia trachomatis assay. This is\u000d\u000a      comparable with that of existing commercial nucleic acid amplification\u000d\u000a      tests (the slower, lab-based and non-point of care, tests Gen-Probe Aptima\u000d\u000a      Combo 2&#8482; and the Roche Cobas Amplicor&#8482; were used as\u000d\u000a      comparator tests). [H, I]. These impressive clinical test results\u000d\u000a        support the adoption of the Atlas io&#8482; tests in clinical\u000d\u000a        environments.\u000d\u000a    Clinical trials with Public Health England (PHE) for the Atlas io&#8482;\u000d\u000a      platform and Chlamydia detection product commence in late 2013 with final\u000d\u000a      formal clinical evaluation in March 2014. The platform launches in Europe\u000d\u000a      with CE certification in 2014, followed by roll-out in the US.\u000d\u000a    Technology for Widening Diagnostic Reach: The in vitro\u000d\u000a      diagnostics (IVD) market is $42 billion and growing at 6% annum, the most\u000d\u000a      rapidly growing areas are molecular diagnostics (valued at $3b and growing\u000d\u000a      at 15% pa) and the point-of-care market (valued at $2.5b and growing at\u000d\u000a      12% pa); the WHO estimates that 499 milliion new STI infections occur each\u000d\u000a      year [J]. Due to the platform nature of the io&#8482; system,\u000d\u000a      Atlas have developed the technology (by commissioning of new bespoke\u000d\u000a      Chemistry from Bath [A]) for a panel of other tests in development to\u000d\u000a      expand their STI test portfolio, including, a duplex test for\u000d\u000a      Chlamydia\/Gonorrhoea (anticipated clinical trials in 2014) and Trichomonas\u000d\u000a      (the most prevalent curable STI in the world, causing an estimated 248\u000d\u000a      million new cases annually of genital T. vaginalis infection). The\u000d\u000a      Atlas io&#8482; Trichomonas vaginalis prototype test has been\u000d\u000a      evaluated at the Johns Hopkins University Medical School. In this\u000d\u000a      published study [G], clinical sample testing demonstrated a sensitivity of\u000d\u000a      95.5% and specificity of 95.7%; these are comparable with that of existing\u000d\u000a      central laboratory nucleic acid amplification tests used for screening\u000d\u000a      patients for T. vaginalis. In 2010 Atlas started work on an\u000d\u000a      immunoassay programme to expand the capabilities of the electrochemical\u000d\u000a      detection platform with a Regional Development Agency grant for the\u000d\u000a      development of a Syphilis assay. The development of redox-active\u000d\u000a      substrates for electrochemical immunoassays and a novel method for signal\u000d\u000a      amplification are being carried out by a directly-funded PhD student in\u000d\u000a      the Frost group at Bath. Atlas is also developing a rapid test cartridge\u000d\u000a      for Methicillin Resistant Staphylococcus Aureus (MRSA) for\u000d\u000a      near-patient testing in high dependency and intensive care units, and\u000d\u000a      other targeted clinical settings. This test further expands the scope for\u000d\u000a      the Atlas electrochemical detection method by employing the technology in\u000d\u000a      a quantitative PCR (qPCR) based system.\u000d\u000a    Key Impacts Summary\u000d\u000a      2008 &#8212; Establishment of io&#8482; platform , capability for\u000d\u000a      implementation of a range of tests\u000d\u000a      2011 &#8212; Additional &#163;18.4M (&#163;1.5M in March; &#163;16.9 M in July) series B\u000d\u000a      venture capital and strategic investment for Atlas; growth to 25 full-time\u000d\u000a      positions\u000d\u000a      2011 &#8212; Successful clinical sample testing of Chlamydia trachomatis\u000d\u000a      test on io&#8482; System in collaboration with Johns Hopkins,\u000d\u000a      University Hospital, USA.\u000d\u000a      2013 &#8212; New office and laboratory provision for Atlas and strategic\u000d\u000a      expansion to 36 permanent staff\u000d\u000a      2013 &#8212; Successful clinical sample testing of Trichomonas vaginalis\u000d\u000a      test on io&#8482; System in collaboration with Johns Hopkins,\u000d\u000a      University Hospital, USA.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    This case study outlines the impact in generating investment in a\u000d\u000a      spin-out SME and in developing a technology for clinical diagnosis based\u000d\u000a      on chemistry research carried out in Bath. The research led to a spin-out\u000d\u000a      company, Atlas Genetics, which has raised over &#163;18M funding in the REF\u000d\u000a      period specifically to develop the Atlas io&#8482; platform, novel\u000d\u000a      technology for rapid (&lt;30 minute) and robust detection of infectious\u000d\u000a      diseases suitable for point-of-care. The investment has created new jobs\u000d\u000a      for highly skilled workers at the cutting-edge of medical diagnostics,\u000d\u000a      with Atlas currently employing 36 staff. The io&#8482; platform has\u000d\u000a      been fully developed and has undergone successful clinical tests on\u000d\u000a      multiple infections (based on bespoke Chemistry developed at Bath) prior\u000d\u000a      to clinical trialling and rollout in Europe and the United States.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    University of Bath\u000d\u000a    ","Institutions":[{"AlternativeName":"Bath (University of)","InstitutionName":"University of Bath","PeerGroup":"B","Region":"South West","UKPRN":10007850}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"4347778","Name":"Baltimore"}],"References":"\u000d\u000a    \u000a[1] S. C. Hillier, S. E. Flower, C. G. Frost, A. T. A. Jenkins, R. Keay,\u000d\u000a      H. Braven &amp; J. Clarkson (2004). Electrochem. Commun., 6,\u000d\u000a      1227 ; [5-year I.F. = 5.1]. An electrochemical gene detection assay\u000d\u000a        utilising T7 exonuclease activity on complementary probe-target\u000d\u000a        oligonucleotide sequences. [DOI: http:\/\/dx.doi.org\/10.1016\/j.elecom.2004.09.019]\u000d\u000a    \u000a\u000a[2] S. C. Hillier, S. E. Flower, C. G. Frost, A. T. A. Jenkins, R. Keay,\u000d\u000a      H. Braven &amp; J. Clarkson (2004). Bioelectrochemistry, 63,\u000d\u000a      307. An electrochemical study of enzymatic oligonucleotide digestion.\u000d\u000a      [DOI: http:\/\/dx.doi.org\/10.1016\/j.bioelechem.2003.10.028]\u000d\u000a    \u000aIndustrial\/Translation Funding\u000d\u000a    [3] Teaching Company Scheme Programme grant (Frost, with Molecular\u000d\u000a      Sensing plc), 2001-2003 (&#163;94k); Knowledge Transfer Partnership Programme\u000d\u000a      grant (Frost, with Molecular Sensing plc, UK) 2005-2008 (&#163;151k); Great\u000d\u000a      Western Research (Frost, with Atlas Genetics plc, UK) 2008-2011 (&#163;55k)\u000d\u000a    [4] Atlas Genetics Industrial Secondment (Frost), 2009-2010 (&#163;24k); Atlas\u000d\u000a      Genetics Industrial Funding (Frost), 2011-2014 (&#163;206k)\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"1","Subject":"Analytical Chemistry"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"}],"Sources":"\u000d\u000a    [A] Letter of evidence of impact, CEO, Atlas Genetics\u000d\u000a    [B] IP\/patents\u000d\u000a      O H Braven, R Keay (Molecular Sensing), S E Flower (Bath), Protease\u000d\u000a        detection assay, 2005, WO 2005\/005657; Patent (Molecular Sensing,\u000d\u000a      now held by Atlas Genetics)\u000d\u000a      http:\/\/worldwide.espacenet.com\/publicationDetails\/biblio?DB=EPODOC&amp;II=3&amp;ND=3&amp;adjacent=true&amp;locale=en_EP&amp;FT=D&amp;date=20101223&amp;CC=US&amp;NR=2010320093A1&amp;KC=A1\u000d\u000a      ; B Marsh, J Sharp (Atlas Genetics), S E Flower, C G Frost (Bath), Novel\u000a        ferrocene labels for electrochemical assay and their use in analytical\u000d\u000a        methods, 2012, PCT Patent 2012\/085591 (Atlas Genetics)\u000d\u000a      http:\/\/worldwide.espacenet.com\/publicationDetails\/biblio?DB=EPODOC&amp;II=8&amp;ND=3&amp;adjacent=true&amp;locale=en_EP&amp;FT=D&amp;date=20120628&amp;CC=CA&amp;NR=2822477A1&amp;KC=A1\u000d\u000a    [C] Atlas Genetics: http:\/\/www.atlasgenetics.com\/\u000d\u000a    [D] Capitalisation\u000d\u000a      http:\/\/www.atlasgenetics.com\/announcements\/atlas-ltd-completes-16-9-million-series-b-financing-led-by-novartis-venture-funds\u000d\u000a      \"Atlas Genetics Ltd completes &#163;16.9M series B financing led by Novartis\u000d\u000a      Venture Funds\"\u000d\u000a    [E] Broader publicity for Atlas Genetics STD testing\u000d\u000a      http:\/\/www.telegraph.co.uk\/women\/sex\/9740518\/20-minute-sex-disease-test-could-curb-infections.html\u000d\u000a    [F] ECDC and WHO Statistics on occurrence of STI\u000d\u000a      ECDC Guidance, Chlamydia control in Europe, Stockholm, June 2009, ISBN\u000d\u000a      978-92-9193-165-1 [DOI: 10.2900\/11364]; World Health Organisation Global\u000d\u000a      prevalence and incidence of selected curable sexually transmitted\u000d\u000a      infections. Geneva: WHO, WHO\/HIV_AIDS\/2001,02\u000d\u000a    [G-I] Clinical references\u000d\u000a      [G] Successful clinical testing of the device for Chlamydia testing has\u000d\u000a      been carried out at Johns Hopkins University Hospital, Baltimore, USA\u000d\u000a      http:\/\/www.hopkinsmedicine.org\/Medicine\/std\/awards\/\u000d\u000a    [H] Pearce D M, Shenton D P, Holden J, Gaydos C A (2011) Evaluation\u000d\u000a        of a novel electrochemical detection method for Chlamydia trachomatis:\u000d\u000a        Application for point-of-care diagnostics. IEEE Trans. Biomed.\u000d\u000a      Engin. 58: 755-758; Pearce DM, Styles DN, Hardick JP &amp; Gaydos CA\u000d\u000a      (2013) [DOI: 10.1109\/TBME.2010.2095851]. A new rapid molecular\u000d\u000a        point-of-care assay for Trichomonas vaginalis: preliminary performance\u000d\u000a        data. Sex. Transm. Infect.; Published Online First: April 20, 2013.\u000d\u000a      [DOI:10.1136\/sextrans-2012-051000]\u000d\u000a    [I] Successful prototype test for the sexually transmitted infection\u000d\u000a      (STI\/STD), Trichomonas vaginalis (T. vaginalis), on Atlas\u000d\u000a      rapid POC io&#8482; molecular diagnostic platform.\u000d\u000a      http:\/\/www.atlasgenetics.com\/announcements\/successful-evaluation-of-trichomonas-vaginalis-poc-test-on-atlas-io-system-in-collaboration-with-joh\u000d\u000a    [J] WHO Fact Sheet on Sexually Transmitted Infections\u000d\u000a      http:\/\/www.who.int\/mediacentre\/factsheets\/fs110\/en\/index.html\u000d\u000a    ","Title":"\u000d\u000a    Atlas Genetics &#8212; \"Test and Treat\" diagnostics for infectious diseases\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2635427","Name":"Trowbridge"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    The group of Professor Chris Frost synthesises organic and biomolecular\u000d\u000a      systems with potential sensing applications, aligned with the Bath\u000d\u000a      Chemistry Sensing &amp; Healthcare theme. Fast and accurate detection of\u000d\u000a      DNA is an important sensing methodology for a wide range of biological\u000d\u000a      targets, especially pathogens. Although existing DNA sensor technology is\u000d\u000a      largely based on fluorescence detection, other sensor transduction\u000d\u000a      paradigms are known including electrochemistry. The detection of specific\u000d\u000a      oligonucleotide sequences using electrochemistry has significant\u000d\u000a      advantages: no need for optical sample transparency; direct signal\u000d\u000a      read-out; ease of miniaturisation and device manufacture.\u000d\u000a    In the Bath research that underpins this Impact Case Study, an\u000d\u000a      oligonucleotide detection assay was developed based on electrochemical\u000d\u000a      detection, with an assay based on the appearance of a distinct\u000d\u000a      electrochemical signal when an electronic label (based on ferrocene) is\u000d\u000a      cleaved from an oligonucleotide probe. The higher diffusion mobility and\u000d\u000a      enhanced access of the enzymatically cleaved ferrocene label to the\u000d\u000a      electrode surface results in an increase in ferrocene oxidation current.\u000d\u000a      The labelled oligonucleotide probe is designed with a complementary\u000d\u000a      sequence to a unique section of the target DNA and since cleavage of the\u000d\u000a      label from the probe and appearance of a signal occurs only when the\u000d\u000a      target is present, this allows the sensing of any particular\u000d\u000a      oligonucleotide sequence [1, 2]. The ferrocene labels were designed and\u000d\u000a      prepared in Bath and the initial research generated key intellectual\u000d\u000a      property (detailed below) for a relatively simple, potentially widely\u000d\u000a      applicable assay for detecting DNA targets with no surface modification\u000d\u000a      required, followed up by collaborative knowledge transfer funding [3].\u000d\u000a    This research led to the launch of a University spin out Atlas Genetics\u000d\u000a      Ltd, a diagnostic company developing ultra-rapid point-of-care tests for a\u000d\u000a      range of infectious diseases based on the described ferrocene reagents and\u000d\u000a      electrochemical assay. The technology comprises a low cost instrument (the\u000d\u000a      io&#8482; platform) and a disposable test-specific cartridge to which\u000d\u000a      an unprocessed clinical sample is added and which offers fluidic and\u000d\u000a      temperature control, end-point electronics and software that can be\u000d\u000a      automatically processed without user intervention. All reagents required\u000d\u000a      to perform the test are located on the cartridge in an ambient-stable\u000d\u000a      format. The platform nature of the technology allows detection of multiple\u000d\u000a      pathogens or sequences (multiplexing), offering up to 20 tests per\u000d\u000a      cartridge. To achieve this requires multiple ferrocene labels that produce\u000d\u000a      unique electrochemical signals and the chemical functionality on ferrocene\u000d\u000a      can be modified by synthesis to tune the oxidation potential. The\u000d\u000a      successful ongoing development of novel multiplex ferrocene labels for the\u000d\u000a      Atlas io&#8482; detection system has been led by Frost at Bath and\u000d\u000a      funded by AtlasGenetics [4].\u000d\u000a    Timeframe: The relevant initial work was carried out in 2001-2005,\u000d\u000a      with initial publication in 2004 and subsequently developed further with\u000d\u000a      Atlas Genetics, forming the subject of patent applications and continued\u000d\u000a      collaborative funding to fund further label development.\u000d\u000a    Key Researchers\u000d\u000a      Professor Chris Frost (Lecturer, now Professor, at Bath since 1996;\u000d\u000a      synthesis of sensor molecules; lead academic)\u000d\u000a    Dr Toby Jenkins (Lecturer, now Reader, 2000-), Prof Laurie Peter (1990-),\u000d\u000a      Prof Frank Marken (Lecturer, now Professor 2004-) (electrochemistry and\u000d\u000a      prototype device implementation)\u000d\u000a    S C Hillier (2001-05), J Sharp (2009-2012) (PhDs in Frost group); S E\u000d\u000a      Flower (PDRA in Frost research group, 2001-2003)\u000d\u000a    "},{"CaseStudyId":"43210","Continent":[{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1269750","Name":"India"}],"Funders":["Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000a    \"[Our] development of medical devices for glucose detection, inward\u000a        investment in our company and successful clinical trialling of these\u000a        devices ... has relied heavily on the underpinning developments from\u000a        [Bath] Chemistry research, and on our ongoing interactions in\u000a        translating [this] into forms appropriate for commercialisation and\u000a        clinical implementation.\" [A]\u000a    Impacts from this work: company, investment, people, new technology,\u000a        clinical testing\u000a    \u000a      A spin-out or new business has generated revenue or profits (GlySure\u000a          Ltd; &#163;13.5M new investment in REF period directly attributed to\u000a        the Bath research [A])\u000a      Highly skilled people having taken up specialist roles that draw on\u000a        their research (GlySure staff expansion to 30, largely in technical\u000a          scientific roles; including a Senior Chemist at Glysure recruited\u000a        from Bath)\u000a      A new diagnostic or medical technology has been developed and trialled\u000a        with patients (glucose sensor developed; full, successful, clinical\u000a          trials carried out)\u000a    \u000a    Clinical Need, GlySure Ltd, and Economic Impact\u000a    The development of an invasive fibre optic continuous glucose\u000a      sensor\/monitoring system is in direct response to the clinical need\u000a      demonstrated by a seminal clinical study in 2001 [B], which showed that\u000a      continuous intensive administration of insulin (allowing tight glycaemic\u000a      control) reduced patient mortality by 40% and morbidity by 37-46%, the\u000a      latter reducing patient length of stay in the Intensive Care Unit (ICU)\u000a      thus providing economic benefits. GlySure Ltd was founded in 2006 to\u000a      exploit the Bath-developed research [C], with a 20% equity stake held by\u000a      the University of Bath. Based in Abingdon, Oxfordshire, it is a venture\u000a      capital funded company with 30 employees, focused on the development and\u000a      launch of a continuous real time invasive optical glucose sensor utilizing\u000a      fluorescent intensity measurements that allows the development of\u000a      continuous glucose monitoring systems in hospital ICUs. GlySure Ltd was\u000a      the lead organization in partnership with Bath and Gilden Photonics on a\u000a      DTI grant, resulting in new IP filings covering long lifetime dendrimer\u000a      fluorophores and synthesis of an alternative diboronic acid receptor\u000a      structure from the Bath research [D]. The automated and continuous dosing\u000a      and response nature of the GlySure device greatly reduces the nursing\u000a      workload required to implement tight glycaemic control, and helps to\u000a      improve compliance.\u000a    The GlySure target market includes the medical and surgical ICU units of\u000a      acute care hospitals. Global admissions in these units alone are\u000a      approximately 8.6 million per year, representing a market opportunity of\u000a      approximately $1.5 billion for sensors. Initial investments resulted for\u000a      GlySure, to develop and build the Bath chemistry into the glucose sensors,\u000a      which has since been followed, in January and November 2012, by\u000a      further tranches of investment on completion of the initial successful\u000a      clinical trials [E], &#163;13.5M of which directly results from the devices\u000a        developed from the Bath chemistry [A]. GlySure Ltd has thus\u000a      established itself as a secure and expanding UK-based company offering\u000a      highly skilled employment opportunities. GlySure continue to invest in\u000a      Chemistry developments at Bath and have appointed Professor James as\u000a      Scientific Advisor: \"Based at the University of Bath, Dr. James is\u000a        generally accepted as the world's expert in boronic acid fluorophore\u000a        chemistry. He has played a pivotal role in optimising glucose selective\u000a        indicator chemistry for continuous measurement in whole blood\" [F].\u000a    IP Acquisition and Technology Development\u000a    The technology development work has been led from Bath, following the\u000a      development of the initial chemistry by James; GlySure acquired relevant\u000a      IP [C] from the more instrument-focused Beckman Coulter and invested\u000a      direct funding in the James group in Bath to develop the chemistry further\u000a      towards the function and performance of the appropriate sensor molecules\u000a      in the required sensing environment [D] Since 2008, through a series of\u000a      funded industry academic transfer projects [5, above], the chemistry has\u000a      been incorporated into devices ready for implementation in the clinical\u000a      environment. To meet the clinical and commercial need, the technology\u000a      developed by GlySure for ICU applications has required the translation by\u000a      James of the fluorescent\/receptor glucose indicator chemistry developed in\u000a      Bath into an optimised form for in situ sensor operation,\u000a      immobilised into an optical cell that is micro machined into the fibre.\u000a      These sensors have advantage over other existing glucose sensor in terms\u000a      of cost, stability and the ease of the fluorescence measurements, as\u000a      corroborated by advantages highlighted by Senseonics, a US company in this\u000a      domain: \"The fluorescent glucose chemistry is ... not subject to the\u000a      instabilities intrinsic to current protein based glucose sensors...\u000a      Consequently, this technology is expected to be inherently more stable and\u000a      accurate.\" [G].\u000a    Clinical Testing\u000a    Since 2008, GlySure have used the Bath-developed chemistry as a\u000a      fundamental underpinning feature of their sensor device, which is intended\u000a      to act as the active glucose sensor in clinical settings. The sensors were\u000a      tested in vivo (in pigs) in 2008-2009, and the sensors entered\u000a      clinical trials in India in 2010. Successful clinical testing has been\u000a      carried out in the ICU environment and presented at the International\u000a      Symposium on Intensive Care and Emergency Medicine, attracting more than\u000a      2000 physicians, nurses and other healthcare professionals, and the World\u000a      Federation of Societies of Intensive and Critical Care Medicine [H]. Over\u000a      two years of human use trials, the GlySure continuous glucose monitoring\u000a      system has been tested in over 200 intensive care patients to date, in the\u000a      challenging environment of the ICU. The impressive results from these\u000a      clinical trials [H-J] show that the GlySure system is capable of\u000a      monitoring throughout the length of a patient's stay in the ICU.\u000a    Scope for Growth\u000a    In addition to the ICU device described, the fluorescent lifetime glucose\u000a      sensor has been incorporated into a development programme to create a\u000a      small, easy to use continuous glucose sensor for the home diabetic market.\u000a      This lifetime sensor device would allow expansion of the devices into the\u000a      home market which is estimated at &#163;1.5 to &#163;2 billion annually.\u000a    Key Impacts Summary\u000a    2008-2009 - In vivo testing of GlySure device, incorporating\u000a      Bath-developed sensor technology\u000a    2010-2011 - Clinical trials, India; more than 150 patients\u000a    2012 - Clinical Trial outcomes reported, two rounds capitalisation for\u000a      Glysure, &#163;13.5M of which results directly from the Bath chemistry\u000a    2013 - Clinical trials extended to 200 intensive care patients\u000a    2013 - Device enrolled for CE regulatory trial for approval in Europe\u000a    ","ImpactSummary":"\u000a    A commercial continuous glucose sensor\/monitor that provides real time\u000a      data has been developed by GlySure, a venture capital funded company\u000a      founded on the basis of Bath chemistry. The sensor enables Tight Glycaemic\u000a      Control (TGC) for control of glucose levels in patients in Intensive Care\u000a      Units (ICUs), reducing severe hypoglycaemia, glycaemic variability and the\u000a      nursing burden, maximising both patient and economic benefit. This has led\u000a      to (i) &#163;13.5M investment in the company GlySure Ltd directly for\u000a      development of the system based on the Bath chemistry and (ii) successful\u000a      results from full clinical trials of the device, involving more than 200\u000a      ICU patients, prior to CE approval and launch in the EU.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Bath\u000a    ","Institutions":[{"AlternativeName":"Bath (University of)","InstitutionName":"University of Bath","PeerGroup":"B","Region":"South West","UKPRN":10007850}],"Panel":"B         ","PlaceName":[],"References":"\u000a    \u000a[1] S. Arimori, M. L. Bell, C. S. Oh, K. A. Frimat and T. D. James, Chem.\u000a        Commun., 2001, 1836-1837. Modular fluorescence sensors\u000a        for saccharides [DOI: 10.1039\/b105994g]\u000a    \u000a\u000a[2] S. Arimori, M. L. Bell, C. S. Oh, K. A. Frimat and T. D. James\u000a      (2002), J. Chem. Soc., Perkin Trans. 1, 803-808. Modular\u000a        fluorescence sensors for saccharides [DOI: 10.1039\/B108998F]\u000a    \u000a\u000a[3] T. D. James (2007). Top. Curr. Chem., 277, 107-152. Saccharide-selective\u000a        boronic acid based photoinduced electron transfer (PET) fluorescent\u000a        sensors [DOI: 10.1007\/128_2007_110]\u000a    \u000a\u000a[4] R. Nishiyabu, Y. Kubo, T. D. James, and J. S. Fossey (2011). Chem.\u000a        Commun., 47, 1106-1123. Boronic acid building blocks:\u000a        Tools for sensing and separation [DOI: 10.1039\/c0cc02920c]\u000a    \u000a[5] Direct industrial \/ translation funding\u000a\u0009  Total of &#163;344k\u000a      including: EPSRC\/DTI, (DT\/F00267X\/1; with GlySure and Gilden Photonics)\u000a      2007-2009 (&#163;247k); Knowledge Transfer Partnership (KTP) (with GlySure)\u000a      2010-2011 (&#163;47k); Impact Acceleration Account Award (with GlySure) 2013-\u000a      (&#163;50k)\u000a    [6] S.D. Bull, M.G. Davidson, J.M.H. van den Elsen, J.S. Fossey, A.T.A.\u000a      Jenkins, Y.B. Jiang, Y. Kubo, F. Marken, K. Sakuyrai, J.Z. Zhao, T.D.\u000a      James (2013). Acc. Chem. Res., 46, 312-326. Exploiting\u000a        the Reversible Covalent Bonding of Boronic Acids: Recognition, Sensing,\u000a        and Assembly. [ DOI: 10.1021\/ar300130w]\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"3","Subject":"Macromolecular and Materials Chemistry"},{"Level1":"6","Level2":"1","Subject":"Biochemistry and Cell Biology"},{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"}],"Sources":"\u000a    [A] Letter of evidence of impact, CTO and Director, Glysure Ltd\u000a    [B] Van den Berghe et al (2001). New England Journal of Medicine,\u000a      345, 1359-1367. Intensive insulin therapy in critically ill\u000a        patients [DOI:\u000a      \u000a        www.nejm.org\/doi\/full\/10.1056\/NEJMoa011300]\u000a    [C, D]IP\/patents\u000a    [C] M. L. Bell, T. D. James, S. Arimori, Sensor system for\u000a        saccharides, US 7358094 (2008); filed in 2003, with Beckman-Coulter;\u000a      subsequently acquired by GlySure.\u000a      http:\/\/worldwide.espacenet.com\/publicationDetails\/biblio?II=1&amp;ND=3&amp;adjacent=true&amp;locale=en_E\u000a        P&amp;FT=D&amp;date=20041118&amp;CC=WO&amp;NR=2004099778A1&amp;KC=A1\u000a    [D] B. C. Crane, T. D. James, J. S. Fossey, N. P. Barwell, Indicator\u000a        System for Fiber Optic Sensor WO\/2011\/101624 (2011); for chemistry\u000a      developed explicitly in Bath for the Glysure sensor applications\u000a      http:\/\/worldwide.espacenet.com\/publicationDetails\/biblio?DB=worldwide.espacenet.com&amp;II=7&amp;ND\u000a      =3&amp;adjacent=true&amp;locale=en_EP&amp;FT=D&amp;date=20130307&amp;CC=US&amp;NR=2013059394A1&amp;KC=A1\u000a    [E] Capitalisation\u000a    Two major rounds of capitalisation in the REF period:\u000a    http:\/\/www.glysure.com\/media-centre\/press-releases\/new-funding-round\/\u000a      \"GlySure, developer of in-hospital continuous blood glucose monitoring\u000a      systems, today announced\u000a      the close of its &#163;7 million Series C financing round\" (9 January 2012)\u000a    http:\/\/www.glysure.com\/media-centre\/press-releases\/series-c-second-closing\/\u000a      \"Glysure Completes Series C Second Closing for a Total of &#163;8.5M\" (29\u000a      November 2012)\u000a    [F] Quotation taken from GlySure Website listing Professor James\u000a      as Scientific Adviser\u000a      http:\/\/www.glysure.com\/about\/directors-advisors\/\u000a    [G] http:\/\/senseonics.com\/product\/the-sensor\u000a    [H-J]Clinical Trials\u000a      Results presented at ISICEM2012 and WFSICCM clinical conferences, and\u000a      highlighted by the NIHR (National Institute for Health Research) Horizon\u000a      Scanning Centre\u000a    [H] http:\/\/www.glysure.com\/clinical-data\/icu-pilot-trial\/\u000a    [I] ISICEM2012: Mulavisala KP, Gopal P, Crane B et al.\u000a      Preliminary ICU experience of a novel intravascular blood glucose sensor.\u000a      Accuracy of a continuous intravascular glucose monitor in ICU patients.\u000a      32nd International Symposium on Intensive Care and Emergency Medicine\u000a      (ISICEM). March 2012. Poster P175\u000a      http:\/\/www.glysure.com\/media\/14997\/glysure_poster_isicem_final.pdf\u000a    WFSICCM: \u000a       http:\/\/www.glysure.com\/media\/23434\/glysure_poster_durban_2013_updated_v2.pdf\u000a    [J] National Institute for Health Research (NIHR) Horizon Scanning\u000a      Centre, University of Birmingham, May 2013. Glysure intravascular\u000a      continuous glucose monitoring system for glycaemic control in intensive\u000a      care\u000a      http:\/\/www.hsc.nihr.ac.uk\/topics\/glysure-intravascular-continuous-glucose-monitorin\/\u000a    ","Title":"\u000a    GlySure Ltd: a commercial clinical continuous glucose sensor\u000a    ","UKLocation":[{"GeoNamesId":"2657780","Name":"Abingdon"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    The research has been carried out by Professor Tony James, as part of the\u000a      work by his group in the synthesis of a range of organic compounds for use\u000a      in sensing applications. James' work maps to the Sensing &amp; Healthcare\u000a      theme within Bath Chemistry, and is a major component of the CASE\u000a      (Catalysis and Sensing for our Environment) initiative led by Bath.\u000a    The capacity of boronic acid receptors to bind diols effectively in water\u000a      has made boronic acids the receptor of choice in the James group at the\u000a      University of Bath, where he has shown that in order to develop saccharide\u000a      selective receptors systems with two boronic acids must be prepared. Such\u000a      sensors, pioneered at Bath, consist of three components; a receptor, a\u000a      support\/spacer, and a read-out unit. The unique element of selectivity for\u000a      glucose is imparted by the specifically configured diboronic acid receptor\u000a      that is covalently linked to the fluorophore and forms part of the single\u000a      molecule indicator chemistry.\u000a    The James group research has shown that in order to prepare a D-glucose\u000a      selective fluorescence sensor, two boronic acid units (only through two\u000a      point binding can saccharide selectivity be engineered), a hexamethylene\u000a      linker (D-glucose selective spacer) and a fluorophore (read-out) must be\u000a      included [1, 2]. The sensor used in the current system developed by\u000a      GlySure Ltd consists of two boronic acids, hexamethylene linker and\u000a      fluorophore which is then attached to a hydrogel polymer.\u000a    The chemistry has been developed over the last decade [3, 4], and has\u000a      been funded by a combination of research council, direct industry and DTI\u000a      funding [5]. The specific application in glucose sensing that is relevant\u000a      to the commercialisation and clinical implementation has been patented (US\u000a      7358094) and following the purchase of this patent from Beckman-Coulter by\u000a      GlySure Ltd, the continued development of the chemistry has focused on the\u000a      specific requirements of the GlySure sensor system [6].\u000a    The development of these technologies has been furthered, into human\u000a      clinical testing, with GlySure's resources and expertise focused on\u000a      completion of existing fluorescent intensity based measurement systems\u000a      using the Bath chemistry. The targeting of this work towards the GlySure\u000a      sensor has led to Professor James' appointment as Scientific Advisor to\u000a      GlySure Ltd, emphasising the direct link of the Bath-developed chemistry\u000a      to the product.\u000a    Timeframe\u000a    The work relevant to the development of the development of the sensor\u000a      being used by GlySure Ltd in its devices has been carried out in the\u000a      timeframe since 2001. The critical step of incorporating established\u000a      boronic acid sensors into appropriate polymer support matrices and their\u000a      optimisation and development for operation in the responsive flow\u000a      environment was carried out initially between 2002 and 2005. This element\u000a      of the research, crucial to the GlySure technology, resulted in a patent\u000a      filed in 2003 (\"Sensor system for saccharides\"; see Section 5), and has\u000a      been developed subsequently in ongoing research by the James group in Bath\u000a      [6].\u000a    Key Researchers\u000a    Professor Tony James (Bath since 2000; synthesis of sensor molecules and\u000a      support scaffolds; lead academic)\u000a    K. A. Frimat (2008-2012; PhD student in James group); S Arimori\u000a      (2000-2001), S E Flower (20003-2008). N P Barwell (2008-2011); PDRAs in\u000a      James group\u000a    "},{"CaseStudyId":"43211","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2661886","Name":"Sweden"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000a    Impacts from this work: founding and influencing the work of\u000a        charities, public awareness and attitudes, use of research findings by\u000a        clinical practitioners\u000a    \u000a      Enhanced public awareness of a health risk (Outreach and engagement\u000a          with parents &amp; public directly, through the NHS Trust and through\u000a          the media)\u000a      The awareness, attitudes and understanding of (sections of) the public\u000a        have been informed, and their ability to make informed decisions on\u000a        issues improved, by engaging them with research (as above)\u000a      Practitioners have used research findings in the conduct of their work\u000a        (influencing approach taken by clinicians)\u000a      The work of an charitable organisation has been influenced by the\u000a        research (including foundation of a charity, with &#163;1.5M funding)\u000a    \u000a    The need\u000a    Half of all burn injuries occur in children under 16 years old, mostly by\u000a      scalds from hot tea, coffee and bath water. In 2010-2011 the South West UK\u000a      Children's Burn Centre at Frenchay Hospital in Bristol (an NHS Regional\u000a      Centre with a 10 million population catchment area), the main clinical\u000a      partner in this study, treated more than 700 children for serious burn\u000a      injuries. Around 10% of children who are burned become infected, which\u000a      increases the likelihood of scarring and disfigurement and in some cases\u000a      can even cause death. The problem is obtaining clarity in diagnosis, and\u000a      the dressing being developed at Bath provides quick evidence of infection\u000a      without need to remove the dressing, informing clinical decision making.\u000a    Engaging and Influencing Clinicians and Clinical Research\u000a    The development of responsive wound dressings suitable for implementation\u000a      in the clinical environment is a partnership with the clinical community.\u000a      The key direct clinical collaborator is Dr Amber Young, Consultant\u000a      Paediatric Anaesthetist, lead for South-West Burns Unit at Frenchay\u000a      Hospital, but the impact of the work has also been manifest in the reach\u000a      into the mainstream clinical practice community. The concept of using such\u000a      responsive sensors, based on technology being patented by Bath Chemistry\u000a      [A] has also led to substantial influence and attitude changing in the\u000a      broader clinical community. Jenkins is a regular speaker at clinical\u000a      forums, and is a passionate advocate for the role of these advanced\u000a      chemistry solutions in saving lives of vulnerable patients. It is\u000a      extremely unusual for core chemists to be invited into such forums, but\u000a      Jenkins is now a regular invited participant at high profile and\u000a      influential clinical events, for example, the only chemistry plenary\u000a      speaker at the International Society for Burns Injuries in September 2012,\u000a      a large forum of 1250+ practising nurses and doctors investigating the\u000a      latest methods of clinical practice. The high degree of awareness raising\u000a      that Jenkins has managed to achieve is emphasised by his impact at such\u000a      events, where \"his work had a real \"eye-opening\" effect in challenging\u000a        current clinical practice and offering alternative solutions\" [B].\u000a      This is augmented by ongoing interactions with healthcare professionals in\u000a      the British Burns Association and elsewhere. This raising of awareness and\u000a      changing attitudes towards the potential of a system that would aid\u000a      clarity of diagnosis and ease of treatment, has engaged clinicians in this\u000a      debate.\u000a    The research has also made a major contribution to the founding of a\u000a      charity, the Healing Foundation Children's Burns Research Centre [C;\u000a      Jenkins lead academic in the \"Clinical Management\" theme]. The Bath\u000a        research has been used directly to secure at least &#163;1.5M charitable\u000a        funding for the new Centre [B].\u000a    Prototype testing and clinical development\u000a    The development of prototype dressings has been carried out through\u000a      initial ex vivo porcine testing and pre-clinical trials at the\u000a      Blonde-McIndoe Research Foundation, one of the leading charities funding\u000a      clinical work in the remediation of burns injuries, who quote that \"A real\u000a      need therefore exists to develop novel ways to detect and treat burn wound\u000a      infections, and we are working with collaborators at the University of\u000a      Bath and South West Children's Burns Centre, Frenchay Hospital, Bristol to\u000a      develop innovative ways of monitoring infection\" [D]. The manufacturing of\u000a      prototype wound dressings has also been established with industry partners\u000a      (M&#246;lnycke AB Healthcare (Sweden), Hartmann AG (Germany) and Altrika Ltd\u000a      (UK)), translating the research into a viable candidate technology. In\u000a      addition to prototyping, the group are pursuing follow-on implementation\u000a      studies, with publication in clinical journals, establishing a high degree\u000a      of clinical involvement and `buy in' at this early stage, to ensure rapid\u000a      clinical take up of the product when manufactured [E]. Initial direct\u000a        clinical use has also been demonstrated &#8212; having been adopted within\u000a      an NIHR portfolio project [C], an initial cohort of six patients has been\u000a      recruited and used for research-led clinical trials of the effect of burn\u000a      and blister exudates on the Bath-developed prototype wound dressings. This\u000a      was carried out by a charity-funded clinical research nurse whose funding\u000a      resulted from the Bath Chemistry research, providing vital clinical\u000a      information towards wider trialling.\u000a    Community and Media, Raising Awareness and Changing Behaviour\u000a    The Bath research has been instrumental in raising the profile of this\u000a      area. By offering a potentially radical solution to many of the issues of\u000a      diagnosis, it has focused wide attention on the issue of children's burns\u000a      in the region, impacting on education, awareness and attitude changing\u000a      amongst the directly concerned community &#8212; the patients, represented by\u000a      parents and carers of infant burns victims or potential burns victims and\u000a      amongst clinical practitioners: \"it is no exaggeration to say that\u000a        exposure to this research has changed the way in which I think about the\u000a        considerable clinical issues in this challenging area\" [B]. In\u000a      partnership with the South West Children's Burns Centre and the Healing\u000a      Foundation Children's Burns Research Centre, Jenkins and his work have\u000a      been effectively used as a vehicle for publicising the risks of apparently\u000a      innocuous, small volumes of hot liquids to small children [F]. This has\u000a      enabled the development of an educated community of hundreds of\u000a      adults, and of educating children in the risks, through programmes\u000a      of school visits.\u000a    The patients involved represent a group whose injuries stir strong\u000a      emotions and sympathy in the general public. Through a concerted effort\u000a      led by Jenkins and Young, a \"star patient\" (Isambard, who fortunately made\u000a      a full recovery from his dreadful burns injuries) has been used as an\u000a      immediately identifiable vehicle for education, awareness-raising and to\u000a      motivate researchers, clinicians and fund-raisers, through his clinical\u000a      case study:\u000a    Isambard was a 2 year old child who knocked a cup of hot tea over\u000a        himself, causing 32% total body surface area burns (partial thickness).\u000a        He was airlifted to Frenchay hospital and treated. Two days post burn he\u000a        became very pyrexic and non-specifically unwell. Infection was suspected\u000a        and he was brought into the OR. In the OR a `lively' discussion between\u000a        the clinicians took place: should he be treated aggressively, removing\u000a        his dressings &#8212; potentially saving his life but guaranteeing life-long\u000a        scarring, or treated conservatively, leave dressings on and watch and\u000a        wait. In the event the latter approach was used &#8212; with a very good\u000a        outcome, but the decision was not informed by clinical\u000a          knowledge\u000a    The work has had impact far beyond the usual dissemination and has a very\u000a      strong outreach element [G]. This has included articles in magazines such\u000a      as New Scientist, and still more widespread reach and impact in mass\u000a      media, on television and radio, and in national newspapers and news\u000a      outlets (e.g. the Daily Mail and BBC). In addition the BBC recently filmed\u000a      in Jenkins' laboratory, as part of a major piece in the popular, wide\u000a      reach television programme \"Bang Goes the Theory\" [H], which regularly\u000a      attracts total audiences of around 4 million, on the dangers of hot\u000a      drinks, children's burns and newly developed treatments for those injured\u000a      in this way.\u000a    ","ImpactSummary":"\u000a    Half of all burn injuries occur in children and around 10% of children\u000a      who are burnt become infected by disease-causing bacteria that can\u000a      increase the likelihood of scarring and in some cases cause death. Novel\u000a      wound dressing prototypes have been developed using responsive smart\u000a      sensing chemistry. These provide clinical solutions and commercial\u000a      opportunities, have led to the founding of the charity Healing Foundation\u000a      Children's Burns Research Centre with &#163;1.5M of funding, have influenced\u000a      the work of other charities and altered attitudes and practice in clinical\u000a      paediatric burn treatment. The impact has been achieved by development of\u000a      the novel chemistry in partnership with clinicians and practitioners, and\u000a      through extensive engagement with health professionals, well beyond normal\u000a      academic reach, parents and the wider public.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Bath\u000a    ","Institutions":[{"AlternativeName":"Bath (University of)","InstitutionName":"University of Bath","PeerGroup":"B","Region":"South West","UKPRN":10007850}],"Panel":"B         ","PlaceName":[],"References":"\u000a    \u000a[1] J. Zhou, A. L. Loftus, G. Mulley, A. T. A. Jenkins (2010), J.\u000a        Amer. Chem. Soc., 132, 6566-6570. [DOI: 10.1021\/ja101554a].\u000a      A Thin Film Detection \/ Response System for Pathogenic Bacteria\u000a    \u000a\u000a[2] J Zhou, T N Tun, S H Hong, J D Mercer-Chalmers, M Laabei, A E R\u000a      Young, A T A Jenkins (2011). Biosens Bioelectronics, 30,\u000a      67-72 [DOI: 10.1016\/j.bios.2011.08.028]. Development of a prototype\u000a        wound dressing technology which can detect and report colonization by\u000a        pathogenic bacteria\u000a    \u000a[3] Direct industrial \/ translation funding\u000a    Total of &#163;1489k including: (a) Knowledge Transfer Account Award (with\u000a      SWUK Children's Burns Centre) 2010 (&#163;78k), (b) EU FP7 grant Bacteriosafe,\u000a      2010-2014 (&#163;731k); (c) EPSRC Delivery funding 2011 (&#163;40k) and (d) EPSRC\u000a      Healthcare Partnership (with AmpliPhi Biosciences) &#163;640k; (e) Funding for\u000a      a clinical research nurse (James Tudor charity; Young &amp;\u000a      Jenkins), a clinical surgical PhD (Healing Foundation &amp; KOALA\u000a      international network) directly charitably funded to pursue the clinical\u000a      elements of this research.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"},{"Level1":"11","Level2":"2","Subject":"Cardiorespiratory Medicine and Haematology"}],"Sources":"\u000a    [A] IP\/patents\u000a      WO 2013104876 A1, A T A Jenkins, N T Thet, J Mercer-Chalmers, \"Wound\u000a      Dressing\", January 2012 (PCT\/GB2012\/000625)\u000a      http:\/\/worldwide.espacenet.com\/publicationDetails\/biblio?DB=EPODOC&amp;II=12&amp;ND=3&amp;adjacent=tr\u000aue&amp;locale=en_EP&amp;FT=D&amp;date=20130718&amp;CC=WO&amp;NR=2013104876A1&amp;KC=A1\u000a    [B] Clinical Reference:\u000a      Letter of Evidence from Consultant Pediatric Anaesthetist, South West UK\u000a      Children's Burn Centre, Frenchay Hospital, Bristol\u000a    [C] Healing Foundation Children's Burns Research Centre\u000a      http:\/\/www.bristol.ac.uk\/social-community-medicine\/childrens-burns\/\u000a    Jenkins is lead academic in the \"Clinical Management\" strand of the\u000a      Foundation\u000a      http:\/\/www.bristol.ac.uk\/social-community-medicine\/childrens-burns\/people\/\u000a    http:\/\/public.ukcrn.org.uk\/Search\/StudyDetail.aspx?StudyID=13232\u000a      (NIHR portfolio clinical study)\u000a    [D] Blond McIndoe Medical Research Charity\u000a      Wound Assessment Tools\u000a    http:\/\/www.blondmcindoe.org\/wound-assessment-tools.html\u000a    [E] Follow-on clinical development studies\u000a      A T A Jenkins and A Young (2010). Expert Reviews of Anti-Infection\u000a        Therapies, 8, 1063-1065 [DOI: 10.1586\/eri.10.98]. Smart\u000a        dressings for the prevention of infection in paediatric burns patients\u000a    M Laabei, AER Young, ATA Jenkins (2012). Pediatric Infectious Disease\u000a        Journal, 31, E73-E77 [DOI: 10.1097\/INF.0b013e3182493b21]. In\u000a        Vitro Studies of Toxic Shock Toxin-1-secreting Staphylococcus aureus and\u000a        Implications for Burn Care in Children\u000a    [F-H] Broader Publicity, Awareness raising, Behaviour influencing\u000a      [F] North Bristol NHS Trust: Focuses on the collaboration between Jenkins\u000a      and clinician Young\u000a      http:\/\/www.nbt.nhs.uk\/news-media\/latest-news\/revolutionary-burns-dressing-could-save-young-lives\u000a      http:\/\/www.nbt.nhs.uk\/news-media\/video-gallery\/childrens-burns-research\u000a    [G] Popular and mass media coverage\u000a      http:\/\/www.newscientist.com\/article\/dn19158-nanoparticle-bandages-could-detect-and-treat-infection.html\u000a      - 9 July 2010\u000a      http:\/\/www.dailymail.co.uk\/sciencetech\/article-1293052\/Smart-bandage-fights-infection-using-tiny-glowing-capsules-antibiotics.html\u000a      http:\/\/www.bbc.co.uk\/news\/10550239\u000a      8 July 2010 - \"Bath Uni developing new bandage to help fight\u000a      infection\"; Isambard as a case study\u000a    [H] BBC TV film, \"Bang Goes the Theory\", March 2013\u000a    ","Title":"\u000a    Changing Clinical Approaches for Treatment of Burns in Children\u000a    ","UKLocation":[{"GeoNamesId":"2654675","Name":"Bristol"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    The research, carried out in the group of Dr Toby Jenkins in the\u000a      Department of Chemistry at the University of Bath, maps onto the Sensing\u000a      &amp; Healthcare theme in Bath Chemistry. It targets improved human health\u000a      by cutting the risk of microbial infection in burns, wounds and damaged\u000a      skin, especially in clinical environments, and by speeding diagnosis of\u000a      infection. Burn infection can be especially difficult to diagnose since\u000a      the primary method of determining infection, raised body temperature, has\u000a      limited utility in burn patients due to resetting of the bodies thermal\u000a      regulatory system post burn. Typically the only way to diagnose infection\u000a      is to expose the wound to allow examination by swabbing and\u000a      microbiological analysis; this process takes time (typically 24 hours) and\u000a      dramatically increases the danger of severe infection, scarring, and the\u000a      consequent, potentially fatal, side effects, such as sepsis and toxic\u000a      shock syndrome (especially in children). The research, carried out since\u000a      2007, targets this vital clinical issue, by developing responsive wound\u000a      dressings for burn victims, particularly children.\u000a    The research uses phospholipid vesicles dispersed in a composite hydrogel\u000a      matrix, which retain some characteristics of eukaryotic cell membranes.\u000a      The vesicles encapsulate a self-quenched non-toxic dye (fluorescein),\u000a      which is released following the degradation of the lipid vesicles by\u000a      bacterial virulence factors including Phenol Soluble Modulins (PSMs) from\u000a      S. aureus and rhamnolipids from P. aeruginosa, which are\u000a      key infection agents. Release of the dye into the surrounding matrix\u000a      causes fluorescence `switch on', clearly observable by eye and a key paper\u000a      has been published which focuses on the sensor detection \/ response\u000a      chemistry underpinning the developments being implemented [1].\u000a    In the development phase building on this initial sensor chemistry,\u000a      laboratory scale prototype dressings have been developed with vesicle\u000a      compositions that optimise stability and toxin sensitivity; the vesicles\u000a      are stable in wound exudate taken from patients in clinical environments,\u000a      and at the pH range and temperature range expected in the burn environment\u000a      [2]. The dressings therefore give a clear visible indication of infection\u000a      in situ without need to remove the dressing and this is key to its\u000a      benefits in the clinical environment.\u000a    An essential component of this research programme is an absolute focus on\u000a      clinical need, and manufacturability, and this has been supported by\u000a      direct industrial and translation funding [3]. A range of working\u000a      prototypes are available for in-vivo studies on murine and porcine\u000a      models, while manufacturing partners are engaged with small scale, GMP\u000a      compliant production. The research is also being targeted at better\u000a      understanding of mechanisms of bacterial toxicity, with a particular focus\u000a      on infection within paediatric burns, as noted below.\u000a    Timeframe: Research commenced in 2007, with initial key\u000a      publication in 2010 and subsequently developed in partnership with\u000a      clinicians at Frenchay Hospital in Bristol and the South-West Children's\u000a      Burns Centre, and clinical charity research partners.\u000a    Key Researchers\u000a    Dr Toby Jenkins (Lecturer, now Reader; Bath since 2000; anti-microbials,\u000a      functional wound dressing development; lead academic)\u000a    Dr J. Mercer-Chalmers (Bath 1998-2012; PDRA and Research Manager;\u000a      research translation)\u000a    Dr N.T Thet (2008-2013; PhD then PDRA); S Hong (2010-2013; PhD).\u000a    "},{"CaseStudyId":"43212","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1814991","Name":"China"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"1269750","Name":"India"},{"GeoNamesId":"2750405","Name":"Netherlands"},{"GeoNamesId":"2921044","Name":"Germany"}],"Funders":["Engineering and Physical Sciences Research Council","Royal Society"],"ImpactDetails":"\u000d\u000a    Impacts from this work: Adoption of new products and processes, wealth\u000d\u000a        generation from Intellectual Property transfer and environmental\u000d\u000a        benefits\u000d\u000a    \u000d\u000a      The performance of an existing business has been improved through the\u000d\u000a        introduction of new products, processes or services &#8212; Plastics\u000d\u000a          manufacturing\u000a\u000d\u000a      A sector has adopted a new or significantly changed technology or\u000d\u000a        process, including through acquisition and\/or joint venture &#8212; Intellectual\u000d\u000a          Property transferred (raising &#163;4.6M) and implemented\u000a\u000d\u000a      Highly skilled people having taken up specialist roles that draw on\u000d\u000a        their research &#8212; PhD Researchers from the programme of work\u000d\u000a        underpinning this Case Study joined IBM, Johnson Matthey, Cyton\u000d\u000a          Biosciences, EPSRC and Pfizer\u000a\u000d\u000a      The environment has been improved through the introduction of new\u000d\u000a        product(s), process(es) &#8212; Elimination of heavy metals in industrial\u000d\u000a          catalysts and enhancement of processes for manufacture of degradable\u000d\u000a          materials from renewable resources\u000a\u000d\u000a    \u000d\u000a    The Catalyst Industry\u000d\u000a      Catalysis is a major UK industry strength and wealth generator for the\u000d\u000a      economy, and a key component of cleaner, more sustainable manufacturing\u000d\u000a      processes for a wide range of products. The development of new catalysts\u000d\u000a      can lead to more efficient, sustainable, cost-effective processes; those\u000d\u000a      developed in Bath have been translated rapidly and effectively into\u000d\u000a      industrial processes. This direct reach into major players in the global\u000d\u000a      plastics industry underpins the impact of this work.\u000d\u000a    The Bath chemistry, the intellectual property pathway and product\u000d\u000a        development\u000d\u000a      Three classes of titanium and zirconium catalysts for plastics manufacture\u000d\u000a      have been developed at Bath and patented, covering manufacturing processes\u000d\u000a      for the important polymers poly(ethylene terephthalate) (PET),\u000d\u000a      poly(urethane) (PU) (with plastics markets worth $23B and $33B,\u000d\u000a      respectively, in 2010) and, more recently, towards use in improved\u000d\u000a      processes for poly(lactic acid) (PLA). Crucially, these catalysts are\u000d\u000a      based on titanium and zirconium rather than tin, antimony or mercury, thus\u000d\u000a      eliminating the environmentally unfriendly heavy metals from\u000d\u000a      the catalysts used in these large-scale industrial polymerisation\u000d\u000a      processes.\u000d\u000a    Demonstrating the impact of this work involves a detailed following of\u000d\u000a      the original Bath-invented intellectual property but also derivative\u000d\u000a      patents and processes advanced by the partner industries and their\u000d\u000a      successors (ICI Synetix, Johnson Matthey; [A]). The impact outlined here\u000d\u000a      focuses on PET and PU. Developing commercial applications of the third\u000d\u000a      strand of Bath Group 4 catalysts (for PLA manufacture) is more recent,\u000d\u000a      with patent applications in 2006 (Johnson Matthey; [A]) and a recent\u000d\u000a      collaboration with Corbion Purac leading to implementation of\u000d\u000a      Bath-developed benign tin-replacement catalysis for pilot scale PLA\u000d\u000a      manufacture and patent filing in 2013 [A].\u000d\u000a\u0009A critical element of the Bath\u000d\u000a      research is not only the specific catalysts developed in the published\u000d\u000a      work but the fact that these innovations, and the sharing of the\u000d\u000a      intellectual property with Johnson Matthey, through extensive\u000d\u000a      collaboration and a Royal Society Industry Fellowship for Davidson,\u000d\u000a      resulted in the methodology from Bath heralding a new, more sophisticated\u000d\u000a      molecular approach to catalyst design in the PET and PU areas, thereby\u000d\u000a          influencing the development of the whole metal alkoxide Johnson\u000d\u000a          Matthey catalyst portfolio. The Bath-developed materials have\u000d\u000a      been described as \"first in class\", and have also resulted in the\u000d\u000a      establishment of rigorous molecular design process in the industrial\u000d\u000a      environment [B]:\u000d\u000a    \"In addition to the specific catalysts and IP ..., the methodology\u000d\u000a        from Bath influenced the whole JM Ti- and Zr alkoxide catalyst\u000d\u000a        portfolio, including establishing the rigorous molecular design of these\u000d\u000a        families of materials, and the Bath Chemistry and materials are\u000d\u000a        acknowledged as being \"first in class\" in this area.... there is thus no\u000d\u000a        doubt that many of these developments including the whole VertecTM\u000d\u000a        and SnapcureTM portfolio can be linked directly\u000d\u000a        to the Bath research.\"\u000d\u000a    In March 2011 Dorf Ketal, an Indian Chemicals company\u000d\u000a        who are one of the largest in the world, purchased PET and PU catalyst\u000d\u000a        intellectual property from Johnson Matthey in a &#163;4.6M\u000d\u000a      transaction [C]; this income can be directly\u000d\u000a          attributable to the Bath research [B]. Due to the high value\u000d\u000a      of the product portfolio, the sale of the order book was blocked by the UK\u000d\u000a      Office of Fair Trading [D]. The intellectual property covered titanium\u000d\u000a      citrate-based Vertec catalysts first characterised by Bath that are used\u000d\u000a      in PET manufacture and the titanium alkoxide 'Snapcure' catalysts\u000d\u000a      developed from Bath chemistry and used in PU manufacture. Dorf Ketal\u000d\u000a      rebranded these products as part of their Unilink range and they are now\u000d\u000a      manufactured at their new Mundra plant in India:\u000d\u000a    From Dorf Ketal release [E]: \"the plant will produce up to\u000d\u000a        10,000 metric tons of the industry's broadest portfolio of titanates\u000d\u000a        annually, making it the largest facility of its kind in the world. The\u000d\u000a        Mundra plant joins the company's recently expanded Dadra plant in\u000d\u000a        shipping TYZOR&#174;, and VERTEC&#8482; organic titanates worldwide...In April\u000d\u000a        2011, the company acquired the patents, trademarks and related\u000d\u000a        intellectual property for VERTEC&#8482; polyester catalysts and SNAPCURE&#8482;\u000d\u000a        polyurethane catalysts\".\u000d\u000a    Implementation in Industrial Processes\u000d\u000a      The titanium citrate-based catalysts first characterised in Bath have\u000d\u000a      successfully replaced antimony in PET fibre and film applications, with\u000d\u000a      initial impact in bottle resin (PET is the main material used in drinks\u000d\u000a      bottles) with significant environmental and process benefits. In addition,\u000d\u000a      the price of antimony catalysts has recently escalated rapidly due to\u000d\u000a      mining restrictions in China such that there is now an additional\u000d\u000a      significant upsurge in take-up of titanium-based catalysts from a cost\u000d\u000a      basis. Large-scale manufacturers have made substantial process\u000d\u000a      improvements in PET manufacture that allow good quality titanium-based\u000d\u000a      PET; Dorf Ketal are supplying to this market. For example, a new\u000d\u000a      ThyssenKrupp Uhde (Germany) process makes PET through a route in which\u000d\u000a      Vertec titanium-based catalysts are the best on the market by far at\u000d\u000a      matching antimony catalyst performance. These PET catalysts are part of\u000d\u000a      the portfolio taken on by Dorf Ketal, to supply some of the largest PET\u000d\u000a      resin plants in the world (&gt;600 tonnes per day currently with up to\u000d\u000a      1500 tpd planned) [B]; conversion in these plants results in substantial\u000d\u000a      reduction in antimony usage.\u000d\u000a    The Snapcure (now Unilink) solution has also been implemented widely for\u000d\u000a      PU [F], with significant trials run with a number of large mercury\u000d\u000a      catalyst users including full scale trials. This new process, based on the\u000d\u000a      molecular design principles introduced by Bath, is increasingly relevant\u000d\u000a      due to the onset of REACH regulations, which are, increasingly, severely\u000d\u000a      restricting the use of mercury.\u000d\u000a\u0009These new Bath-developed catalysts have\u000d\u000a      thus had impact through their adoption in manufacturing processes, as a\u000d\u000a      replacement for undesirable heavy metal catalysts (notably antimony and\u000d\u000a      more recently mercury). In addition to their adoption in manufacturing\u000d\u000a      plants, aspects of these catalysts and associated processes have been sold\u000d\u000a      on internationally, providing evidence that this chemistry is of ongoing\u000d\u000a      value and impact.\u000d\u000a    Key Impacts Timeline\u000d\u000a      2008 &#8212; Snapcure range of products launched by Johnson Matthey\u000d\u000a      2008-2010 - Pilot scale developments of process for various polymerisation\u000d\u000a      products\u000d\u000a      2010 - Large scale implementation of Snapcure catalysis solution for\u000d\u000a      polyurethane\u000d\u000a      2011 - VERTEC portfolio of PET and PU catalyst IP acquired and used by\u000d\u000a      Dorf Ketal, generating &#163;4.6M income from IP sale alone\u000d\u000a      2011 - Dorf Ketal implementing Ti catalysts in PET plant &#8212; branded\u000d\u000a      Unilink, and manufactured at new Mundra plant in India demonstrating\u000d\u000a      increasing global reach and uptake\u000d\u000a      2011-2013 - Molecular design principles applied to new Group 4 metal PLA\u000d\u000a      catalysts trialled with Corbion Purac and patent application filed\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Catalysis is a major UK industry strength and wealth generator for the UK\u000d\u000a      economy. Research carried out in the group of Professor Matthew Davidson\u000d\u000a      in the Department of Chemistry at the University of Bath resulted in the\u000d\u000a      development of titanium and zirconium alkoxide catalysts for use in three\u000d\u000a      industrial polymerisation processes and patented by the UK companies ICI\u000d\u000a      Synetix and Johnson Matthey. Patents have recently also been acquired by\u000d\u000a      the Indian multinational Dorf Ketal and filed by the Dutch multinational\u000d\u000a      Corbion Purac. The research has resulted in the adoption of new catalysts\u000d\u000a      in industry leading to increased turnover, onward dissemination and\u000d\u000a      implementation of the Bath intellectual property. It has also generated\u000d\u000a      &#163;4.6M from sale of intellectual property and an increase in generated\u000d\u000a      sales of new, sustainable titanium catalysts that replace heavy metals\u000d\u000a      such as tin, antimony and mercury in major industrial processes. The\u000d\u000a      intellectual property and process developments have been implemented\u000d\u000a      globally in the poly(ethylene terephthalate) (PET) and poly(urethane) (PU)\u000d\u000a      plastics markets, worth $23B and $33B, respectively, in 2010.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    University of Bath\u000d\u000a    ","Institutions":[{"AlternativeName":"Bath (University of)","InstitutionName":"University of Bath","PeerGroup":"B","Region":"South West","UKPRN":10007850}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"1262497","Name":"Mundra"}],"References":"\u000d\u000a    \u000a[1] M.G. Davidson, C.L. Doherty, A.L. Johnson and M.F. Mahon, Chem.\u000d\u000a        Commun., 2003, 1832-1833. Isolation and characterisation\u000d\u000a        of transition and main group metal complexes supported by\u000d\u000a        hydrogen-bonded zwitterionic polyphenolic ligands. [DOI:\u000d\u000a      10.1039\/b303618a]\u000d\u000a    \u000a\u000a[2] A.L. Johnson, M. G. Davidson, M. D. Lunn, M.F. Mahon, Eur. J.\u000d\u000a        Inorg. Chem., 2006, 3088-3098 (with industrial co-authors,\u000d\u000a      Johnson Matthey). Synthesis, Isolation and Structural Investigation of\u000d\u000a        Schiff-Base Alkoxytitanium Complexes: Steric Limitations of Ligand\u000d\u000a        Coordination. [DOI: 10.1002\/ejic.200600113]\u000d\u000a    \u000a\u000a[3] A.J. Chmura, M.G. Davidson, M.D. Jones, M.D. Lunn, M.F. Mahon, Dalton\u000a        Trans., 2006, 7, 887-889 (with industrial\u000d\u000a      co-authors, Johnson Matthey). Group 4 complexes of amine\u000d\u000a        bis(phenolate)s and their application for the ring opening\u000d\u000a        polymerisation of cyclic esters. [DOI: 10.1039\/b513345a]\u000d\u000a    \u000a\u000a[4] A.J. Chmura, M.G.Davidson, M.D. Jones, M.D. Lunn, M.F. Mahon, A.F.\u000d\u000a      Johnson, P. Khunkamchoo, S.L. Roberts and S.S.F. Wong, Macromolecules,\u000d\u000a      2006, 39, 7250-7257 (with Johnson Matthey co-authors). Group\u000d\u000a        4 complexes with aminebisphenolate ligands and their application for the\u000d\u000a        ring-opening polymerization of cyclic esters. [DOI:\u000d\u000a      10.1021\/ma061028j]\u000d\u000a    \u000a[5] Direct industrial \/ translation funding\u000d\u000a      Total of &#163;954k including: Royal Society Industry Fellowship (M G Davidson)\u000d\u000a      1999-2003 (&#163;250k); Industrial PDRA (ICI Synetix, now Johnson Matthey)\u000d\u000a      2002-2004 (&#163;134k);\u000d\u000a      EPSRC\/TSB Link Project (with ICI Synetix, now Johnson Matthey) 2004-2007\u000d\u000a      (&#163;200k);\u000d\u000a      Knowledge Transfer Account Award and Industrial co-funding (with Purac,\u000d\u000a      now Corbion Purac) 2010-2013 (&#163;270k); Industrially-funded PhD (M Lunn, L\u000d\u000a      Paches), 2001-2008 (&#163;100k).\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"},{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"},{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"}],"Sources":"\u000d\u000a    [A] Patents\u000d\u000a    \u000d\u000a      WO2005035622 (Johnson Matthey PLC, 2005). Catalyst for the\u000d\u000a          Manufacture of Esters, Partridge, McIntosh, Hanratty; Group 4\u000d\u000a        metal hydroxyacid complexes as PET catalysts. http:\/\/www.google.com\/patents\/WO2005035622A1\u000d\u000a        Led directly from the molecular characterization of the ammonium\u000d\u000a        titanium citrate complex described by Davidson &amp; Partridge, Chem.\u000d\u000a          Br. 2002, 38(7), 26 (article can be accessed\u000d\u000a        through http:\/\/opus.bath.ac.uk\/37761\/).\u000d\u000a      WO2003018662 (Johnson Matthey PLC, 2003). Catalysts and Curable\u000d\u000a          Compositions, Davidson, Lunn, Johnson, Stengel; Group 4 metal\u000d\u000a        alkoxide complexes as PU catalysts http:\/\/www.google.com\/patents\/WO2003018662A1\u000a\u000d\u000a      WO2004052980 (Johnson Matthey PLC, 2006). Polymerisation Reaction\u000d\u000a          and Catalyst Therefor; Partridge, Davidson, Eade; covers a range\u000d\u000a        of Group 4 metal alkoxide complexes as ring-opening polymerization\u000d\u000a        catalysts for lactones and lactides.\u000d\u000a        http:\/\/www.google.com\/patents\/WO2004052980A1\u000a\u000d\u000a    \u000d\u000a    All JM intellectual property in this area sold on to Dorf Ketal as part\u000d\u000a      of the IP acquisition [C]\u000d\u000a    \u000d\u000a      EP13166273.6 (Purac Biochem, 2013). Method to Manufacture PLA\u000d\u000a          Using a New Polymerization Catalyst, Chuck, Davidson, Gobius du\u000d\u000a        Sart; filed in May 2013.\u000d\u000a    \u000d\u000a    [B] Letter of evidence of impact, R&amp;D Director, Johnson\u000d\u000a      Matthey Process Technologies\u000d\u000a    [C] Purchase of Intellectual Property by Dorf Ketal,\u000d\u000a      18 April 2011\u000d\u000a      http:\/\/www.reuters.com\/article\/2011\/04\/18\/idUS125100+18-Apr-2011+PRN20110418\u000d\u000a      \"Dorf Ketal Purchases VERTEC&#8482; Patents and Intellectual Property\"\u000d\u000a    [D] UK Office of Fair Trading press release on the proposed\u000d\u000a          sale of business outright to Dorf Ketal, November\/December\u000d\u000a        2010\u000d\u000a      http:\/\/www.oft.gov.uk\/shared_oft\/mergers_ea02\/2010\/Dorf-Ketal.pdf\u000d\u000a    [E] Dorf Ketal Announces Full Production at World's Largest\u000d\u000a          Organic Titanate Plant, 4 May 2011 http:\/\/www.prnewswire.com\/news-releases\/dorf-ketal-announces-full-production-at-worlds-largest-organic-titanate-plant-121228969.html\u000d\u000a    [F] Johnson Matthey Product Case Study\u000d\u000a      SNAPCURE &#8212; Replacing Mercury with Titanium in Catalysts for Polyurethane\u000d\u000a      Elastomers\u000d\u000a      http:\/\/www.matthey.com\/Sustainability2009\/case-studies\/products_cs_24.html\u000d\u000a    ","Title":"\u000d\u000a    Replacement of Heavy Metal Catalysts in the Plastics Industry\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    The research group of Professor Matthew Davidson in the Department of\u000d\u000a      Chemistry at the University of Bath has been exploring the rich chemistry\u000d\u000a      of a range of ligands and their use in the stabilisation of highly\u000d\u000a      reactive Lewis acidic metal centres since 1999-2000. This work has focused\u000d\u000a      on the use of more environmentally friendly metals such as titanium as\u000d\u000a      replacements for heavy metals such as tin, antimony and mercury in areas\u000d\u000a      such as catalysis. The research is aligned to the Catalysis and\u000d\u000a      Sustainable Chemical Technologies research themes within Bath Chemistry.\u000d\u000a    The development of new and increasingly active homogeneous catalysts has\u000d\u000a      been one of the main driving forces behind recent advances in modern\u000d\u000a      organometallic chemistry. One such area has been the need to develop new\u000d\u000a      Lewis acid catalysts to mediate industrial polymerisation processes such\u000d\u000a      as PET and PU manufacture, as well as for the ring-opening polymerisation\u000d\u000a      (ROP) of cyclic esters. The chemistry is motivated by a drive for the use\u000d\u000a      of more sustainable metals in these high-volume manufacturing processes\u000d\u000a      and also by the introduction of a new generation of commercially viable,\u000d\u000a      sustainable degradable plastics available from renewable resources.\u000d\u000a    Chelating N- and O-containing ligands, which are capable of providing a\u000d\u000a      range of stable steric and electronic environments for catalytically\u000d\u000a      active metal centres, have been the subject of considerable research for\u000d\u000a      some time, not least for their ability to bind active metal centres in\u000d\u000a      well-defined environments [1, 2]. This has attracted huge industrial\u000d\u000a      interest, since the area of new catalyst development is highly competitive\u000d\u000a      and requires a continuous process of innovation and materials development,\u000d\u000a      to facilitate both new processes and new target products.\u000d\u000a    The important breakthrough resulting from this underpinning\u000d\u000a      metallo-organic coordination chemistry was the discovery in 2001-2002,\u000d\u000a      during Davidson's time as a Royal Society Industry Fellow with Johnson\u000d\u000a      Matthey (1999-2003), that well-defined molecular titanium-based complexes\u000d\u000a      being developed at Bath were highly effective in replacing the heavier and\u000d\u000a      more toxic metals that were used in PET and PU polymerisation processes,\u000d\u000a      notably tin, antimony and mercury. This initial discovery immediately led\u000d\u000a      to follow-on industrial funding, a detailed understanding of\u000d\u000a      structure-activity relationships for titanium complexes with commercially\u000d\u000a      viable ligands, and the protection of the chemistry though patents led by\u000d\u000a      the industrial partners as detailed below. Subsequent development in\u000d\u000a      Davidson's group and at Johnson Matthey refined the molecular chemistry\u000d\u000a      and processes, leading to functional catalysts that could be implemented\u000d\u000a      in relevant industrial contexts. For example, this work included the\u000d\u000a      synthesis and structural characterisation of a series of Group 4 metal\u000d\u000a      complexes and assessment of their potential as Lewis acid catalysts for\u000d\u000a      polyester synthesis. In this work, a series of ligands were prepared and\u000d\u000a      their Group 4 metal complexes studied, allowing isolation of well-defined\u000d\u000a      titanium and zirconium complexes which were shown to be active catalysts\u000d\u000a      for the ROP of cyclic esters such as 03b5-caprolactone and lactide with\u000d\u000a      excellent levels of conversion and control [3]. This work was subsequently\u000d\u000a      developed further with industrial collaborators and funding [4, 5],\u000d\u000a      exerting influence over the development of the entire Johnson Matthey\u000d\u000a      metal alkoxide catalyst portfolio.\u000d\u000a    Key Researchers\u000d\u000a      Professor Matthew Davidson (Whorrod Professor of Sustainable Chemical\u000d\u000a      Technologies, lead academic; at Bath since 1999)\u000d\u000a      Dr A L Johnson (PDRA, now Lecturer, at Bath 2000-), Dr M D Jones (PDRA,\u000d\u000a      now Senior Lecturer; at Bath 2004-), Dr C J Chuck (Industrial PhD and\u000d\u000a      PDRA, now Whorrod Fellow; at Bath 2004-)\u000d\u000a      Dr E Gullo (Industrial PDRA, 2004-2007); G F Eade (2001-2004), C L Doherty\u000d\u000a      (2004-2007), A L Chmura (2006-2009) (PhD students in Davidson group); M D\u000d\u000a      Lunn (2001-2005), L Paches (2004-2008) (Industrial PhD students in\u000d\u000a      Davidson group)\u000d\u000a    "},{"CaseStudyId":"43305","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1269750","Name":"India"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2658434","Name":"Switzerland"},{"GeoNamesId":"6252001","Name":"United States"}],"Funders":[],"ImpactDetails":"\u000d\u000a    The major impact of research conducted in the Chemistry department\u000d\u000a      relates to commercial impact with regard to the bio-pharmaceutical\u000d\u000a      industry and impact on practitioners and services. The generation of a\u000d\u000a      pure drug was made possible through the development of new synthesis\u000d\u000a      routes that made the launch of phase 2 clinical trials possible. Based on\u000d\u000a      the research outcomes, and as a result of the Phase 2 trials, TauRx was\u000d\u000a      able to raise &#163;320 million in external investment, now employs 17\u000d\u000a      chemists, 5 biologists, and 14 clinicians. In relation to chemistry\u000d\u000a      activities alone TauRx under Storey's supervision is now working in\u000d\u000a      collaboration with 7 companies: Shasun Pharma Solutions (Newcastle upon\u000d\u000a      Tyne, UK), Roberts Chemicals (UK), Lonza Pharma (Visp, Switzerland),\u000d\u000a      Bohinger (USA), Bayer Schering (Berlin), Piramal Healthcare (Newcastle and\u000d\u000a      Berlin), and Almac Sciences (Edinburgh and Craigavon). Through these\u000d\u000a      commercial collaborations, three centres have been established to each\u000d\u000a      manufacture 5 tonnes of the candidate drug as part of the validation\u000d\u000a      campaign based on the patent [4]. Each validation campaign represents an\u000d\u000a      income of &#163;2.5 million for the companies concerned within the REF period.\u000d\u000a      In addition the ongoing manufacture of 400 tonnes between the three sites,\u000d\u000a      to be completed by May 2015 to coincide with completion of the Phase 3\u000d\u000a      trials, represents a total investment already achieved for these companies\u000d\u000a      of approximately &#163;35 million.\u000d\u000a    Shasun Pharma Solutions Ltd has advised that the company had an initial\u000d\u000a      production of 6 metric tonnes of the drug, and has now established a\u000d\u000a      manufacturing capability of 150 metric tonnes per annum, which will\u000d\u000a      potentially increase to 250 metric tonnes per annum. This would see\u000d\u000a      commercial revenues in the longer term reaching several hundreds of\u000d\u000a      millions of pounds. There will also be longer term impact for Shasun UK\u000d\u000a      and Shasun India resulting from increased demand for the drug, both in\u000d\u000a      terms of commercial return and job creation throughout the supply chain\u000d\u000a      [a]. In terms of UK impact the company states \"Should the forecast API\u000d\u000a        demand be recognised, it will not only provide opportunities for Shasun\u000d\u000a        in the UK, but also have significant local impact involving local\u000d\u000a        engineering manufacturing, supply and support requirements for pipework,\u000d\u000a        reactors and filter dryers along with bulk storage tanks and ancillary\u000d\u000a        equipment including increased waste handling and treatment facilities on\u000d\u000a        site. For example, should the API requirement reach 500 metric tonnes\u000d\u000a        per annum, Shashun UK would need to invest in equipment from UK\u000d\u000a        suppliers of up to &#163;10M and procure goods and services from the north\u000d\u000a        East region of up to &#163;5M. Manufacture of the API on this scale could\u000d\u000a        lead to the creation of up to 80 jobs at the Shashun UK site.\" [a]\u000d\u000a    A second manufacturer is Piramal Healthcare (Newcastle upon Tyne, UK).\u000d\u000a      Piramal advise that to meet the requirements of producing tablets at the\u000d\u000a      amounts required for the initial trials the company has engaged nine\u000d\u000a      further employees at its Morpeth facility, with a current project revenue\u000d\u000a      in excess of USD 1 Million for FY 2013 and 2014. The company states that\u000d\u000a      this revenue provides a platform for the company to grow and develop its\u000d\u000a      team. \"Tablet supply is now approaching 1,500,000 with batches released\u000d\u000a        to clinical sites in the UK, Europe, US and Asia, this is truly a\u000d\u000a        program with global reach. We hope very much it will result in a\u000d\u000a        marketed product that provides therapeutic benefits to a patient\u000d\u000a        population that sadly has a current unmet need.\" [b]\u000d\u000a    Supply of raw materials to the drug manufacturers is a crucial component\u000d\u000a      of the impact of the Aberdeen research. Roberts Chemicals Ltd describe the\u000d\u000a      company's role in supply and logistics for procurement of starting\u000d\u000a      materials. \"The financial impact on Roberts is to have enabled\u000d\u000a        strategic growth planning at a very early stage in the company's\u000d\u000a        development. Critically, the company has been able to promote and market\u000d\u000a        its next generation business model much more forcefully than expected.\u000d\u000a        This has led to an international portfolio of users of its business\u000d\u000a        model-cleverly adapted to the current economic downturn. TauRx are about\u000d\u000a        to undertake a large manufacturing validation campaign at three major\u000d\u000a        pharma companies.......Roberts will supply the starting materials for\u000d\u000a        these campaigns\" [c].\u000d\u000a    Looking to the future, a potential longer term impact, resulting from the\u000d\u000a      synthetic and analytical chemistry performed in the Chemistry department\u000d\u000a      under Storey's supervision relates to the clinical trials of the drugs\u000d\u000a      developed. The Birmingham and Solihull Mental Health NHS Foundation Trust\u000d\u000a      has direct clinical experience with methylthioninium chloride (MTC) and\u000d\u000a      leuco-methylthioninium bis(hydromethanesulfonate) (LMTM) drugs developed\u000d\u000a      in the TauRx project, and is involved in clinical trials. The Trust\u000d\u000a      confirms: \"In AD, in addition to extracellular deposition of b-amyloid\u000d\u000a        protein, there is also intracellular aggregation of tau protein. Several\u000d\u000a        lines of evidence indicate that aggregation of tau protein is central to\u000d\u000a        neurodegeneration in AD. .Numerous laboratory studies show that MTC,\u000d\u000a        when administered in various forms, is effective in disaggregating tau\u000d\u000a        protein... Data from a large phase-2 clinical trial of MTC also provides\u000d\u000a        some evidence of benefit in AD. Based on the Phase &#8212; 2 experience TauRx\u000d\u000a        elected to discontinue clinical studies with MTC and develop\u000d\u000a        leuco-methylthioninium bis(hydromethanesulfonate) (LMTM)\" [d]. As a\u000d\u000a      consequence of the success of these Phase 2 trials, a series of Phase 3\u000d\u000a      trials were organised which commenced in November 2012. These involve an\u000d\u000a      international trial of 1,800 patients, with the data release scheduled for\u000d\u000a      May 2015. In the opinion of a leading consultant from the trust, \"if\u000d\u000a        LMTM is shown to have the expected efficacy in the Phase-3 AD and FTD\u000d\u000a        studies then it has the potential to be a `Game Changer' in terms of how\u000d\u000a        we manage these conditions\" [d].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Alzheimer's disease (AD) affects one in seven of the population over 60\u000d\u000a      years of age, and represents an increasing burden on worldwide medical and\u000d\u000a      care resources. Treatments currently available are symptomatic. Despite\u000d\u000a      pharmaceutical industry efforts there has been little indication of a\u000d\u000a      marketable product for long-term treatment.\u000d\u000a    To address this problem, a joint venture was established in 2001 between\u000d\u000a      the University of Aberdeen and TauRx Pharmaceuticals. A team was created\u000d\u000a      of chemists, biologists, animal behaviourists, working together with a\u000d\u000a      clinical trial team. A drug effective against the progress of AD based on\u000d\u000a      the compound methylene blue was synthesised and scaled up within the\u000d\u000a      Chemistry Department (led by Professor John Storey), with a quality that\u000d\u000a      was proved acceptable through successful phase two clinical trials\u000d\u000a      (2006-8), and is now used in phase three clinical trials which are due to\u000d\u000a      complete in 2015. Several other drug candidates have also been developed\u000d\u000a      and evaluated in pre-clinical and phase one clinical studies that show\u000d\u000a      promise. Collaborations with commercial pharmaceutical companies have as a\u000d\u000a      result led to the manufacture of significant quantities of drug medicines\u000d\u000a      for TauRx Pharmaceuticals based on IP generated within the Chemistry\u000d\u000a      Department and these drugs have been used in clinical trials and for named\u000d\u000a      patient supply (c. 60 patients). This has resulted in increased commercial\u000d\u000a      revenue for these companies and the creation of new employment.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    University of Aberdeen\u000d\u000a    ","Institutions":[{"AlternativeName":"Aberdeen (University of)","InstitutionName":"University of Aberdeen","PeerGroup":"B","Region":"Scotland","UKPRN":10007783}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"2950159","Name":"Berlin"}],"References":"\u000d\u000a    \u000a1. T.Rager, A.Geoffroy, R.Hilfiker, J.M.D.Storey, \"The crystalline\u000d\u000a        state of methylene blue: a zoo of hydrates\", Phys.Chem.Chem.Phys.,\u000d\u000a      (2012), 14, pp 8074-8082.,\u000d\u000a    \u000a\u000a2. S.Clunas, J.M.D.Storey, J.E.Rickard, D.Horsley, C.R.Harrington,\u000d\u000a      C.M.Wischik (2010) \"3,6-Disubstituted Xanthylium Salts\"\u000d\u000a      WO\/2010\/067078\u000d\u000a    \u000a\u000a3. C.M.Wischik, J.E. Rickard, C.R. Harrington, D. Horsley, J.M.D. Storey,\u000d\u000a      C. Marshall, J.D. Sinclair, T.C. Baddeley, \"3,7-diamino-10h-phenothiazine\u000a        Salts and their Use\", WO2007\/110627\u000d\u000a    \u000a\u000a4. C.M.Wischik, D.J. Wischik, J.M.D.Storey, C.R.Harrington, \"Therapeutic\u000a        Use of Diaminophenothiazines\": WO2009\/044127\u000d\u000a    \u000a\u000a5. S.J.Kemp, L.J.Storey, J.M.D.Storey, J.E.Rickard, C.R.Harrington,\u000d\u000a      C.M.Wischik, S.Clunas, T.K.Heinrich, \"Ligands for Aggregated Tau\u000d\u000a        Molecules.\" WO\/2010\/034982.\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"3","Level2":"5","Subject":"Organic Chemistry"}],"Sources":"\u000d\u000a    (a) President, Shasun Pharma Solutions Ltd &#8212; this source corroborates the\u000d\u000a      commercial benefits of the research, to one of the drug manufacturers.\u000d\u000a    (b) Clinical Trial Services and Site Project Lead, Piramal Healthcare UK\u000d\u000a      Ltd &#8212; this source corroborates the commercial benefits of the research, to\u000d\u000a      one of the drug manufacturers.\u000d\u000a    (c) Managing Director, Roberts Chemicals Ltd &#8212; This contact corroborates\u000d\u000a      the impact of TauRx in developing a novel API, which was industrialised\u000d\u000a      and transferred to Shasun Pharma for large scale GMP synthesis. It also\u000d\u000a      impacted positively on the Roberts business model.\u000d\u000a    (d) Consultant Psychiatrist, Birmingham and Solihull Mental Health NHS\u000d\u000a      Foundation Trust &#8212; this source offers corroboration of the benefits of the\u000d\u000a      resrearch findings from the perspective of a medical practitioner treating\u000d\u000a      patients.\u000d\u000a    (e) Media reports:\u000d\u000a      Alzheimer's Association, Four Alzheimer's clinical trials address a\u000d\u000a        variety of treatment targets &#8212; amyloid, tau, synapse formation\u000d\u000a      29\/07\/08\u000d\u000a      http:\/\/www.alz.org\/national\/documents\/release_icad_072908_trials.pdf\u000d\u000a      http:\/\/www.express.co.uk\/news\/health\/401853\/New-wonder-pill-could-halt-dementia\u000d\u000a    ","Title":"\u000d\u000a    Development of treatments &amp; diagnostics for Alzheimer's disease\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2650225","Name":"Edinburgh"},{"GeoNamesId":"2637546","Name":"Solihull"},{"GeoNamesId":"2641673","Name":"Newcastle-upon-Tyne"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"},{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    From the outset of the research in 2001, the development of a candidate\u000d\u000a      drug for treatment of AD required an integrated team of medicinal\u000d\u000a      chemists, analytical chemists and scale-up \/ development chemists. Unlike\u000d\u000a      the vast majority of large pharmaceutical companies and academic groups,\u000d\u000a      the Aberdeen team's approach to the Alzheimer's problem was not to use\u000d\u000a      beta amyloid, but rather concentrated on the disaggregation of tau protein\u000d\u000a      &#8212; in 2001 this approach was distinctive and arguably unique.\u000d\u000a    Clinical trials and investigations cannot take place without a fully\u000d\u000a      developed and potentially efficacious drug candidate. The purity of such\u000d\u000a      drugs has to meet the criteria of the Pharmacopeia and competent\u000d\u000a      regulatory authority guidelines for each region. The challenges to be met\u000d\u000a      by the Chemistry team were to discover a suitable drug candidate and\u000d\u000a      follow-on molecules for future clinical development, and to prepare the\u000d\u000a      drug to a purity commensurate with a pharmaceutical product. This required\u000d\u000a      the team to develop a synthesis suitable for scale up, and to develop\u000d\u000a      suitable testing and analytical protocols for both products and\u000d\u000a      impurities. Work continued to then transfer this technology to facilities\u000d\u000a      capable of scale up to Good Manufacturing Practice (GMP) regulations\u000d\u000a      operated in Europe (by Lonza), in the UK (Shasun Pharma Solutions) and in\u000d\u000a      the USA (Bohringer). Working with the team of chemists based in Aberdeen,\u000d\u000a      this material has then been formulated suitable for use as a final\u000d\u000a      pharmaceutical product.\u000d\u000a    A suitable drug candidate was identified early in the project. The\u000d\u000a      molecule in question, methylene blue (methylthioninium chloride), was\u000d\u000a      commercially available as a dye. The quality of this material was very\u000d\u000a      variable and did not meet regulatory standards for an active\u000d\u000a      pharmaceutical ingredient (API). Despite a number of attempts by various\u000d\u000a      chemical companies worldwide over the years to synthesise this molecule to\u000d\u000a      a suitable level of purity in order to treat other medical indications\u000d\u000a      (malaria, cancer staining, urinary tract infection etc.), this goal had\u000d\u000a      proved elusive.\u000d\u000a    The design of a new, efficient and high yielding synthetic approach was\u000d\u000a      therefore required in order to unlock the true potential of this molecule\u000d\u000a      as a drug and to make a clinical trial possible. Two new innovative routes\u000d\u000a      were devised and taken from milligram scale through to 10-litre scale in\u000d\u000a      the laboratories in Aberdeen. This involved the design and establishment\u000d\u000a      of a scale-up laboratory within the Department of Chemistry with 2, 5 and\u000d\u000a      10 litre reactor vessels; such a facility is relatively rare within a\u000d\u000a      Chemistry department. Furthermore, the control and understanding of the\u000d\u000a      polymorphic state of the molecule was a regulatory and key component in\u000d\u000a      the successful use of methylene blue as a drug [1].\u000d\u000a    Early in the project (2003) it became apparent that for TauRx\u000d\u000a      Pharmaceuticals to develop a convincing market position and accrue more\u000d\u000a      value, second generation compounds would also be required. A large number\u000d\u000a      of previously unreported molecules have been prepared which have resulted\u000d\u000a      in a significant patent portfolio [2]. Four of the drug candidates\u000d\u000a      developed have moved into phase 1 preclinical toxicological studies and\u000d\u000a      have already been assessed using a number of highly discriminating animal\u000d\u000a      models. One of these molecules has been fast-tracked through phase one\u000d\u000a      bioequivalence studies and escalating dose \/ tolerability studies in\u000d\u000a      humans. The design of this molecule centred upon developing a stable\u000d\u000a      reduced form of the methylthioninium moiety (methylene white or\u000d\u000a      leuco-methylene blue). The rationale behind this approach was to provide\u000d\u000a      the molecule in a form with greater tolerability, due to fewer haemolytic\u000d\u000a      and other undesirable side effects [3]. In addition, due to higher\u000d\u000a      solubility and other desirable attributes, a far improved pharmacokinetic\u000d\u000a      profile has been obtained [4]. This molecule has been approved worldwide\u000d\u000a      for two large international phase III clinical trials with 1,500 patients\u000d\u000a      which started in November 2012, and a third phase II\/III clinical trial in\u000d\u000a      fronto-temporal dementia.\u000d\u000a    Given the very poor diagnosis of Alzheimer's disease in its early stages\u000d\u000a      based upon standard medical examination, and to complement the development\u000d\u000a      of treatments within the group, the parallel development of a molecular\u000d\u000a      imaging agent for early and accurate diagnosis was considered important.\u000d\u000a      This has involved the synthesis of a wide range of novel heterocyclic\u000d\u000a      systems that contain tracers such that they can be used for MRI or PET\u000d\u000a      visualisation. Progress on this project has been good, with a number of\u000d\u000a      compound classes being identified and tested with one patent filed to date\u000d\u000a      [5]. In order to progress this project it became apparent that\u000d\u000a      collaboration with an industrial partner with radio labelling capabilities\u000d\u000a      and imaging technology would be advantageous. To this end a collaboration\u000d\u000a      with the leading diagnostic imaging group for AD in the world\u000d\u000a      (Bayer-Schering, Berlin) has been established. This collaboration involves\u000d\u000a      chemical discovery, ligand design and labelling methodology being\u000d\u000a      undertaken in the Chemistry department in Aberdeen, and the \"hot\"\u000d\u000a      labelling and animal \/ human imaging taking place in Berlin. The funding\u000d\u000a      for this collaboration has largely come from Bayer-Schering (&#163;405K per\u000d\u000a      annum) but the outcome of this research will result in joint income for\u000d\u000a      both discovery parties.\u000d\u000a    Whilst the development of compounds has been a central theme throughout\u000d\u000a      all the chemistry effort, analysis has played a very important role; both\u000d\u000a      for molecules synthesised, and also when these molecules are tested in\u000d\u000a      animals and\/or humans. Analysis of biological samples is demanding, and\u000d\u000a      new methodology and protocols have been developed, validated and the data\u000d\u000a      obtained used in support of regulatory submissions for clinical trial\u000d\u000a      approvals worldwide. To achieve these outcomes GLP, GCP and GMP\u000d\u000a      laboratories have been set up and accredited by the MHRA in Aberdeen and\u000d\u000a      inspected on three occasions, the only chemistry department in the UK\u000d\u000a      boasting all three accredited analytical laboratories within a university.\u000d\u000a    All Chemistry research activities have taken place in, or have been\u000d\u000a      directed from, the Chemistry Department at the University of Aberdeen, led\u000d\u000a      by Professor John Storey, who joined the University of Aberdeen in 2001,\u000d\u000a      and was promoted to Professor in 2010. Storey is responsible to TauRx\u000d\u000a      Pharmaceuticals for drug synthesis, design and scale up, and leads a team\u000d\u000a      of 17 research fellows and research assistants on this project (as of 31st\u000d\u000a      July 2013).\u000d\u000a    "},{"CaseStudyId":"43306","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1814991","Name":"China"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"1210997","Name":"Bangladesh"}],"Funders":["Biotechnology and Biological Sciences Research Council"],"ImpactDetails":"\u000a    Prior to 2008, research in Aberdeen had already led to verification\u000a      research by the US-EPA\u000a      in the years after 2005. In parallel, Chinese Import Regulations (a) had\u000a      also been revised to\u000a      establish a maximum permissible level of arsenic in grain that could be\u000a      imported. This Chinese\u000a      hygiene regulation established, for the first time, not only a level for\u000a      total arsenic, but also for\u000a      inorganic arsenic in different grain types including rice (0.15 mg\/kg)\u000a      thereby acknowledging the\u000a      different toxicity of the different molecular forms of arsenic in\u000a      foodstuffs. No impact was witnessed\u000a      at that time, however, on the regulatory levels of either the EU or the\u000a      UK. Subsequent research in\u000a      Aberdeen discovered that US rice has high levels of arsenic due to the use\u000a      of arsenic containing\u000a      herbicides on what were cotton fields but later converted in the Central\u000a      Mid-West to rice fields. The\u000a      extremely high arsenic prevalent in Bangladeshi rice grown in the dry\u000a      season was due to irrigation\u000a      using water containing arsenic; and that while rice accumulates large\u000a      levels of arsenic, wheat or\u000a      barley does not because rice is grown in flooded paddy soil, in which a\u000a      different mobile form of\u000a      arsenic occurs which is more easily taken up by the plant.\u000a    Subsequently, and as a result of the Chinese regulation, rice-based\u000a      consumer products\u000a      were analysed in Aberdeen, and it was found that most did not meet the\u000a      Chinese standard. This\u000a      triggered a study by the UK-Food Standard Agency (FSA) to conduct a study\u000a      on rice-based drinks.\u000a      Since the average rice milk had higher levels of inorganic arsenic than\u000a      would be allowed for\u000a      drinking water, public advice was issued in 2009 that children under 4\u000a      should not drink rice milk (b).\u000a      So called \"health foods\" such as bran, analysed in Aberdeen, also showed\u000a      elevated levels of\u000a      arsenic. When the levels of inorganic arsenic in the consumer products\u000a      were combined both with\u000a      consumption data and with the toxicological assessments developed by the\u000a      US-EPA for arsenic in\u000a      water, the predicted excess cancer cases from eating rice were modelled.\u000a      All exceeded the 1 case\u000a      in 10,000 often used as a benchmark for an acceptable level of a\u000a      contaminant in food. As a result\u000a      the FSA began to support Aberdeen's research (see grants listed in section\u000a      3). We investigated\u000a      how the preparation of the rice has an influence on both the toxic form of\u000a      the arsenic, and its\u000a      amount (A). However it was only when the results of an analysis of\u000a      baby-rice formula were\u000a      published (5), which found that a significant number of products (35%)\u000a      from the market did not\u000a      pass the Chinese regulatory limit that European regulatory authorities\u000a      began to pay attention. At\u000a      this point (2009) an expert group of regulators, toxicologists and food\u000a      scientists were contracted by\u000a      the European Food Safety Authority (EFSA) to develop a scientific opinion\u000a      paper related to levels\u000a      of arsenic in foodstuffs, and whether there was scope to regulate it (c).\u000a      This EFSA paper\u000a      highlighted seaweeds and other marine foods, but principally the concern\u000a      was about arsenic, and\u000a      in particular inorganic arsenic, in rice and rice-based products. They\u000a      concluded that there was\u000a      insufficient data available regarding inorganic arsenic in foodstuffs. The\u000a      authorities in their surveys\u000a      only consider the total arsenic content, instead of identifying the\u000a      specific molecular form of arsenic\u000a      that is known to be a carcinogen, and only 2% of data contains the latter\u000a      information. Hence, there\u000a      was a pressing need to show that a robust analytical method existed to\u000a      determine levels of\u000a      inorganic arsenic in rice and rice-based products. Furthermore, it was\u000a      noted at the FAO\/WHO Joint\u000a      Standard Program (2011) \"... that more accurate information on the\u000a        inorganic arsenic content of\u000a        foods as they are consumed is needed to improve assessments of dietary\u000a        exposures of inorganic\u000a        arsenic species. Analytical constraints to achieving this goal include\u000a        the lack of validated methods\u000a        for selective determination of inorganic arsenic species in food\u000a        matrices and the lack of certified\u000a        reference materials for inorganic arsenic in foods. The proportion of\u000a        inorganic arsenic in some\u000a        foods was found to vary widely, indicating that dietary exposures to\u000a        inorganic arsenic should be\u000a        based on actual data rather than using generalized conversion factors\u000a        from total arsenic\u000a        measurements\" (d).\u000a    Parallel to these developments Feldmann had been invited to join a\u000a      discussion group in\u000a      2006 at the EU-JRC, IRMM (Institute of Materials &amp; Measurements) to\u000a      discuss how the lack of\u000a      arsenic speciation data on consumer products could be alleviated These\u000a      discussions resulted in\u000a      the organisation of a world-wide proficiency testing (PT) (e) and the\u000a      development of rice as\u000a      reference material (g) in which inorganic arsenic was certified for the\u000a      first time. The Aberdeen\u000a      researchers surveyed arsenic speciation in different rice products in the\u000a      EU, provided a rice flour\u000a      material, and studied the stability of a homogenised sample which could be\u000a      sent out for worldwide\u000a      PT to more than hundred laboratories to provide information about the\u000a      concentration of arsenic and\u000a      inorganic arsenic in this rice flour. Not only was Feldmann's group chosen\u000a      to provide the rice\u000a      samples, it was also one of the five expert laboratories to identify the\u000a      \"true\" value, and provide data\u000a      for the stability and homogeneity of the arsenic and arsenic speciation of\u000a      the rice sample. Overall\u000a      the proficiency testing was extremely successful, the analytical community\u000a      demonstrating that\u000a      more than 75% of the laboratories were able to analyse rice within an\u000a      acceptable level (e). This led\u000a      to the decision that the introduction of a maximum regulatory level of\u000a      inorganic arsenic in rice\u000a      should not be postponed due to concerns over constraints or validation of\u000a      the analytical chemistry.\u000a    As a result, in 2012 the Joint (FAO\/WHO) Food Standard Program with the\u000a      Codex\u000a      Committee for Contaminants in Foods tabled in their sixth session (26-30\u000a      March) a proposed draft\u000a      maximum level of arsenic in rice and the Food and Drug Administration\u000a      released their preliminary\u000a      data of rice and rice based products (g).\u000a    In parallel Aberdeen worked together with the EU-JRC-IRMM to generate a\u000a      rice flour reference\u000a      material in which not only total arsenic but also its molecular forms\u000a      especially the inorganic arsenic\u000a      were certified. We provided the material and worked as the expert\u000a      laboratory on the certification\u000a      process. The process was successful and the material was released on 28th\u000a      January 2013 (f) in\u000a      which for the first time the molecular forms of arsenic were certified.\u000a      This guarantees that sufficient\u000a      high quality and transparent data for inorganic arsenic in rice and\u000a      rice-based products will be\u000a      produced over the next year to provide confidence for agreement on a\u000a      maximum level of inorganic\u000a      arsenic in rice and rice based product at the EU level and worldwide under\u000a      the leadership of FAO\u000a      of the UN and the WHO (h).\u000a    Claimed impact includes evidence of enhancement of the quality of data\u000a      for contaminants\u000a      in consumer products by the development of an analytical method and\u000a      fostering a general\u000a      acceptance of analytical methods for the carcinogenic chemical form of\u000a      arsenic in foodstuff; public\u000a      health and well-being has improved; and dietary guidelines have changed.\u000a    ","ImpactSummary":"\u000a    This case study describes how basic research to develop analytical\u000a      methodologies for\u000a      measuring inorganic arsenic in food, and its subsequent application to\u000a      rice and rice-based food\u000a      commodities, led directly to proposals to establish global agreements\u000a      describing the maximum\u000a      permissible level of a class I carcinogen, inorganic arsenic, in rice. The\u000a      impact of the research\u000a      conducted in Aberdeen is still to be fully developed, but as a result of\u000a      our research has been\u000a      identified as absolutely pivotal by food standards agencies in China, USA,\u000a      the UK, and the\u000a      European Union, in leading to policy decisions and changes to established\u000a      practice amongst policy\u000a      makers under the leadership of the Food &amp; Agriculture Organisation\u000a      (FAO) of the UN and the\u000a      World Health Organization (WHO).\u000a    ","ImpactType":"Political","Institution":"\u000a    University of Aberdeen\u000a    ","Institutions":[{"AlternativeName":"Aberdeen (University of)","InstitutionName":"University of Aberdeen","PeerGroup":"B","Region":"Scotland","UKPRN":10007783}],"Panel":"B         ","PlaceName":[],"References":"\u000a    \u000a1: J. Feldmann, K. John, P. Pengprecha (2000) Arsenic metabolism\u000a      of a seaweed-eating sheep in\u000a      Northern Scotland using HPLC-ICP-MS, Fresenius Journal of Analytical\u000a        Chemistry 368: 116-121.\u000a      The first paper to identify how arsenic in seaweed in metabolised in a\u000a        mammal. Cit. 65\u000a    \u000a\u000a2: H.R. Hansen, A. Raab, J. Feldmann (2003) New arsenosugar\u000a      metabolite determined in urine by\u000a      parallel use of HPLC-ICP-MS and HPLC-ESI-MS, Journal of Analytical\u000a        Atomic Spectrometry\u000a      18: 474-479.A demonstration of the novel arrangements of two parallel\u000a        mass spectrometer used\u000a        simultaneously for arsenic speciation in a complex matrix separated by\u000a        HPLC. Cit. 43\u000a    \u000a\u000a3. P.N. Williams, A.H. Price, A. Raab, S.A. Hossain, J. Feldmann,\u000a      A.A. Meharg (2005)\u000a      Variation in arsenic speciation and concentration in paddy rice related\u000a        to dietary exposure,\u000a      Environmental Science &amp; Technology 39: 5531-5540. One paper of\u000a      series of publications on\u000a      characterizing arsenic in food-chains originating from Aberdeen was\u000a      identified by Thompson\u000a          Reuters Essential Science Indicators: Essential Science\u000a        Indicators, Nov 2009, Environment &amp;\u000a        Ecology category identified this as the most cited paper in the Fast\u000a        Moving Front \"Arsenic\u000a        speciation\". http:\/\/sciencewatch.com\/dr\/fmf\/2009\/09novfmf\/09novfmfMeha\/\u000a      Cit. 251.\u000a    \u000a\u000a4: A.A. Meharg, P.N. Williams, E. Adomako, Y.Y. Lawgali, C.\u000a      Deacon, A. Villada, R.C.J. Campbell,\u000a      G. Sun, Y.G. Zhu, J. Feldmann, A. Raab, F.J. Zhao, R. Islam, S. Houssain,\u000a      J. Yanai (2009),\u000a      Geographical variation in total and inorganic arsenic content of polished\u000a      (white) rice.\u000a      Environmental Science &amp; Technology 43:1612-1617. extended\u000a        worldwide survey with more than\u000a        900 samples from 10 countries were analysed, Cit. 112\u000a    \u000a\u000a5:A.A. Meharg, G. Sun, P.N. Williams, E. Adomako, C. Deacon, Y.G.\u000a      Zhu, J. Feldmann, A. Raab\u000a      (2008) Inorganic arsenic levels in baby rice are of concern, Environmental\u000a        Pollution 152: 746-749.\u000a      triggered European Food Safety Authority to revisit arsenic levels in\u000a        food. Cit. 36\u000a    \u000a\u000a6: A.A. Meharg, C. Deacon, R.C.J. Campbell, A.M. Carey, P.N.\u000a      Williams, J. Feldmann, A. Raab\u000a      (2008), Inorganic arsenic levels in rice milk exceed EU and US drinking\u000a      water standards Journal\u000a        of Environmental Monitoring10: 428-431. Triggered a response\u000a        from UK Food Standard Agency\u000a        to investigate arsenic in rice milk which followed a recommendation that\u000a        children &lt; 4.5 should not\u000a        drink rice milk. Cit. 23\u000a    \u000aRelevant UK\/EU funding:\u000a      A; 2007-2010 EU Marie Currie Training programme awarded to joined PI\u000a      Feldmann &amp;Meharg\u000a      &#163;148k for arsenic loss from paddy field through biovolatilisation\u000a      B: 2007-2011 BBSRC-DFID awarded to Meharg (PI), Feldmann &amp; Price &#163;650k\u000a      to study genetic\u000a      approaches to lowering inorganic arsenic in rice\u000a      C: 2008 FSA awarded to Meharg&amp; Feldmann &#163;37k to study cooking practice\u000a      affects arsenic\u000a      removal\u000a      D: 2010-2012 FSA awarded to Meharg&amp; Feldmann &#163;120k, to study arsenic\u000a      speciation in\u000a      vegetables\u000a      E: 2012-2013 FSA awarded to Feldmann, Krupp &amp; Meharg &#163;146k to study\u000a      bioimaging of metals in\u000a      fruits, cereals and vegetables in the UK\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"5","Level2":"3","Subject":"Soil Sciences"},{"Level1":"7","Level2":"3","Subject":"Crop and Pasture Production"}],"Sources":"\u000a    a) Chinese Import Regulations (GAIN Report CH5080, GB2715-2005 Hygiene\u000a      Standards for\u000a      Grains, http:\/\/www.fas.usda.gov\/gainfiles\/200510\/146131382.pdf)\u000a    b) The UK Food Standard Agency, Survey of total and inorganic\u000a      arsenic in rice drinks, Food\u000a      Survey Information Sheet 02\/09\u000a      http:\/\/food.gov.uk\/science\/research\/surveillance\/fsisbranch2009\/survey0209\u000a      FSA commissioned two studies one on rice milk and one on baby rice,\u000a        directly following\u000a        publication of Aberdeen studies (6, 7 in section 3) and their findings\u000a        corroborating those of the\u000a        Aberdeen group. It issued public advice for children younger than 4 not\u000a        to drink rice milk\u000a    c) European Food Safety Authority, Panel on Contaminants in the Food\u000a      Chain (2009), Scientific\u000a        Opinion on Arsenic in Food, EFSA Journal 7: 1351.\u000a    d) Joint FAO\/WHO Food Standards Program Codex Comm. for Contaminants in\u000a      Foods (21-25\u000a      Mar 2011) max. level of arsenic in food\u000a      ftp:\/\/ftp.fao.org\/codex\/meetings\/CCCF\/cccf5\/cf05_INF.pdf\u000a    e) European Commission-Joint Research Council -IRMM Report of the seventh\u000a      inter-laboratory\u000a      comparison organised by the European Union- Reference Laboratory for Heavy\u000a      Metals in Feed\u000a      and Food, IMEP 107: total and inorganic arsenic in rice (2010)\u000a      http:\/\/irmm.jrc.ec.europa.eu\/EURLs\/EURL_heavy_metals\/interlaboratory_comparisons\/imep-107\/Documents\/eur24314en.pdf)\u000a      this is the report on the worldwide proficiency test, also\u000a        subsequently published in a scientific paper co-authored by the Aberdeen\u000a        group; M.B. de la\u000a        Calle, H. Emteborg, T.P.J. Linsinger, R. Montoso, J.J. Sloth, R. Rubio,\u000a        M.J. Baxter, J.\u000a        Feldmann, G. Raber (2011) Trends in Analytical Chemistry\u000a      30:641-651.\u000a    f) Joint Research Centre (IRMM) reference material catalogue, reference\u000a      to certificate, origin and\u000a      certification report of the ERM-BC211 (rice):\u000a      (http:\/\/irmm.jrc.ec.europa.eu\/news\/Pages\/1301_ERM-BC211.aspx\u000a    g) Joint FAO\/WHO Food Standards Programme Codex Committee for\u000a      Contaminants in Foods\u000a      (26-30 March 2012) a proposed draft maximum level of arsenic in rice\u000a      (ftp:\/\/ftp.fao.org\/codex\/meetings\/cccf\/cccf6\/cf06_08e.pdf).\u000a    h) FDA releases preliminary data on arsenic levels in rice and rice\u000a      products\u000a      Full data collection to be complete by end of 2012, agency prioritizes\u000a      further assessment to\u000a      provide scientific basis for additional recommendations (9th\u000a      Sept 2012)\u000a      http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm319972.htm\u000a    ","Title":"\u000a    Health policies for levels of inorganic arsenic in rice\u000a    ","UKLocation":[{"GeoNamesId":"2657832","Name":"Aberdeen"}],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Arsenic is regarded as a poison, and in areas where a large population\u000a      has been exposed\u000a      to arsenic-containing water, epidemiological studies have established that\u000a      inorganic arsenic is a\u000a      non-threshold class I carcinogen. All of the arsenic in water is\u000a      inorganic, and its concentration is\u000a      strictly regulated. Since the 1990s, the WHO, the European Union (EU), and\u000a      the competent\u000a      authorities in the USA have established a maximum permissible level of\u000a      inorganic arsenic in\u000a      drinking water of 0.01mg\/l.\u000a    The environmental analytical chemistry group at the University of\u000a      Aberdeen, led by\u000a      Feldmann since 2003 (s), has worked for many years on the molecular forms\u000a      of toxic elements in\u000a      food, including arsenic. The concentration levels of arsenic in different\u000a      food commodities are\u000a      hugely variable. It was well known that seaweed used in Far East cuisine\u000a      had the highest\u000a      concentrations of arsenic, up to a factor 100 times higher than the levels\u000a      permitted by UK\u000a      legislation dating back to 1959 of 1.0 mg\/kg. EU regulations are typically\u000a      more onerous than\u000a      national food policies, and as a result national legislation has long been\u000a      subordinated to EU\u000a      regulation levels although in the case of arsenic, these have never been\u000a      established. In short, no\u000a      maximum level for arsenic in foodstuffs exists. The reason behind this is\u000a      that arsenic can occur in\u000a      foodstuffs in different molecular forms, of which one organoarsenical\u000a      (arsenobetaine) has been\u000a      established to be benign while others, such as arsenosugars, are\u000a      considered to be less toxic than\u000a      inorganic arsenic. Hence introducing a legal limit has been more complex\u000a      than stating a simple\u000a      arsenic concentration level permissible in food commodities, and\u000a      consequently, no levels were\u000a      established for foodstuffs by organisations such as the WHO.\u000a    The research undertaken in Aberdeen focussed initially on determining the\u000a      molecular forms\u000a      in seaweeds, and studied how these are metabolised by mammals. In the\u000a      first stage (1) a group of\u000a      sheep was identified which roam the shoreline of the island North\u000a      Ronaldsay in Orkney and whose\u000a      only source of food is seaweed. Analytical methodologies were developed to\u000a      determine the\u000a      molecular forms of arsenic in the seaweed, and how these are metabolised\u000a      by the sheep. Novel\u000a      arrangements of analytical instrumentation were established by combining\u000a      online liquid\u000a      chromatography with arsenic-specific detectors (an elemental (ICP-MS) and\u000a      molecular mass\u000a      spectrometry (ESI-MS). This hyphenation of mass spectrometers was the\u000a      first of its kind and\u000a      permitted the unambiguous determination of the molecular forms in complex\u000a      matrices such as\u000a      seaweed and urine (2). However, seaweed is not a major food commodity, and\u000a      although extremely\u000a      high concentrations of arsenic were identified, very little is in the form\u000a      of inorganic arsenic, the\u000a      class I carcinogen. Hence new analytical methods were developed which\u000a      allowed the study of rice,\u000a      a food commodity with lower arsenic concentration but consumed in large\u000a      amounts. The reason for\u000a      selecting rice was that it had been shown previously that the drinking\u000a      water in shallow wells in\u000a      Bangladesh contained significant levels of arsenic to which more than 60\u000a      million people are\u000a      exposed. In collaboration with the group of Professor Meharg (School of\u000a      Biological Sciences,\u000a      University of Aberdeen) greenhouse-based experiments were designed to\u000a      study how the irrigation\u000a      of arsenic elevated groundwater would influence the arsenic concentration\u000a      in rice (Abedin et al.\u000a      ES&amp;T 2002). Although the arsenic was two orders of magnitude lower in\u000a      concentration in\u000a      comparison to seaweed, a large proportion of the arsenic was in the\u000a      inorganic form.\u000a    These initial findings provided impetus for further studies, resulting in\u000a      the first paper to\u000a      consider arsenic speciation (the identification of the chemical form of\u000a      arsenic) in rice in a global\u000a      context (3). The findings concluded that arsenic levels in rice produced\u000a      in the USA were much\u000a      higher than in rice from India and Bangladesh and most of the arsenic was\u000a      in the form of inorganic\u000a      arsenic. This work was published in 2005 and attracted not only specialist\u000a      attention from food\u000a      groups and the American Rice Federation, but also generated very\u000a      considerable public awareness\u000a      of the issue. The American Rice Federation accused the research team of\u000a      bad science (Press\u000a      Release USA Today) although the findings were later supported following\u000a      confirmation by research\u000a      on behalf of the US Environmental Protection Agency (US-EPA). The Aberdeen\u000a      paper (3) also\u000a      became the most influential paper related to the research on levels of\u000a      arsenic in rice, cited 251\u000a      times to date(international recognition being identified by Thomson\u000a      Reuters, Essential Science\u000a        Indicators, November 2009: as the most cited paper in the fast\u000a      moving area of \"arsenic\u000a      speciation\"). This was followed up by a world-wide survey of polished\u000a      white rice (4) which showed\u000a      that high-rice consumption in regions with high arsenic in rice revealed\u000a      elevated cancer risks based\u000a      on cancer risk models from US-EPA using inorganic arsenic as the\u000a      contaminant. Application of the\u000a      same methods to rice-based products led to the identification of high\u000a      levels of inorganic arsenic in\u000a      baby rice (5) and rice milk (6).\u000a    "},{"CaseStudyId":"43307","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"289688","Name":"Qatar"},{"GeoNamesId":"2658434","Name":"Switzerland"},{"GeoNamesId":"6251999","Name":"Canada"},{"GeoNamesId":"6252001","Name":"United States"}],"Funders":[],"ImpactDetails":"\u000a    The impact of the research undertaken at Aberdeen relates to\u000a      practitioners and professional\u000a      services, where professional and industry standards have been informed as\u000a      a result of research\u000a      findings. As stated by Professor R. D. Hooton, a world-leading contributor\u000a      to the cement and\u000a      construction industry in Canada: \"... the Chemistry Department at the\u000a        University of Aberdeen has\u000a        made the biggest contributions globally to our understanding of both\u000a        hydration of cements and\u000a        fundamental understanding of durability of cementitious materials for\u000a        use in concrete\" [a].\u000a    The key outcome of the particular research project as described was to\u000a      inform\u000a      international standards beyond the EU. As verified by the Portland Cement\u000a      Association, the\u000a      industry trade association for North America, \"in the last several\u000a        years, the US cement industry has\u000a        made significant progress in its continuing efforts to improve the\u000a        sustainability of the built\u000a        environment, and a key component of that effort has been the development\u000a        of specification\u000a        requirements for Portland-limestone cements. After several years'\u000a        effort, in 2012, US blended\u000a        cement specifications were revised to include cements with up to 15%\u000a        limestone. While other\u000a        research has gone into this effort, a key component of the rationale\u000a        supporting changes to both\u000a        sets of specifications was results of your (Glasser) research related to\u000a        the reactions that limestone\u000a        undergoes during cement hydration, their volumetric changes, and the\u000a        thermodynamic stability of\u000a        the resulting phases. We continue to use the results of this research in\u000a        the on-going educational\u000a        efforts with specifiers, architects and engineers...\" [b]. Dr\u000a      Kosmatka further clarifies the overall\u000a      economic impact implied by the benefits derived from this research: \"It\u000a        is difficult to estimate the\u000a        economic impact of these changes for the concrete construction industry\u000a        in the US. A roughly 10%\u000a        saving with regard to CO2 and other emissions\u000a        and energy has made the industry more efficient as\u000a        well as more sustainable, both of which help the competitiveness in the\u000a        roughly $19 billion (US)\u000a        cement industry\" [b].\u000a    The impact of Glasser's work on the North American cement industry is\u000a      further\u000a      supported by Al Innis, Vice President of Holcim (US), who states \"...The\u000a        work you have done on\u000a        limestone cements has been a key component in having the US standards\u000a        accept blended\u000a        cements containing up to 15% limestone. This change in standards gives\u000a        our industry and Holcim\u000a        (US) in particular the opportunity to provide our customers a higher\u000a        quality product with a lower\u000a        carbon footprint...\" [c].\u000a    In addition, to confirmation of new standards in the USA, specifications\u000a      in Canada\u000a      have also been developed. As Professor Hooton confirms: \"The work by\u000a        Matschei, Lothenbach\u000a        and Glasser has been important for the understanding of\u000a        Portland-limestone cements that led to\u000a        their adoption in cement specifications in Canada (CSA A3000) in 2008\u000a        and in the USA (ASTCM\u000a        C595) in 2012. The use of these cements is now incorporated into the\u000a        Canadian building codes,\u000a        and their use is increasing\" [a].\u000a    Limestone addition to cement contributes to properties through three\u000a      mechanisms:\u000a      particle packing effects which reduce water demand, nucleation effects\u000a      which accelerate hydration\u000a      reactions, and production of carboaluminate phases which reduce porosity.\u000a      According to a 2011\u000a      State of the Art Report from the Portland Cement Association, Glasser's\u000a      work \"provided\u000a        quantitative calculation of the phases that may be present...... a great\u000a        step forward in\u000a        understanding these systems\" [d]\u000a    The thermodynamic models derived from the research have now been\u000a      incorporated\u000a      into the GEMS suite (Gibbs Energy\u000a      Minimization Software for\u000a        Geochemical Modelling), originally\u000a      developed by the Swiss Nuclear Organisation, and now managed by the Paul\u000a      Scherrer Institute.\u000a      Explicitly the research work has been fundamental to the CEMDATA07\u000a      database, included in the\u000a      GEMS TDB software package (GEMS Thermodynamic\u000a      DataBase) [e]. Empa, who\u000a      co-supervised\u000a      the research project, confirm that the Aberdeen research was a fundamental\u000a      component to the\u000a      cement database \"was published in 2007-2009 and based on work carried\u000a        out at Empa\u000a        (Lothenbach et al., 2008; M&#246;schner et al. 2008, 2009; Schmidt et al.\u000a        2008) and a PhD carried out\u000a      both at the University of Aberdeen and at Empa (Matschei et al, 2008)\"\u000a      [f].\u000a    In overall terms, the economic benefit is hard to calculate, although the\u000a      saving in\u000a      CO2 emissions is more straightforward. The world production of\u000a      Portland cement is about 3 x109\u000a      tonnes per year. If one third of this production uses 10% limestone\u000a      replacement, and assuming\u000a      production in efficient equipment, the net saving in CO2\u000a      emissions is of the order of 85 million\u000a      tonnes per year. From this has to be deducted the energy input of\u000a      quarrying and grinding\u000a      limestone, but this is comparatively low (only a few million tonnes per\u000a      year), Thus a reduction of\u000a      the order of 80 million tonnes per year carbon dioxide emission is\u000a      achieved, with considerable\u000a      scope for greater reductions still realisable as the process continues to\u000a      gain traction.\u000a    The International Energy Agency (IEA) has proposed strategies to reduce\u000a      global\u000a      CO2 emissions by 52% from 2007 to 2050 [g]. The so-called Blue\u000a      Map Scenario places different\u000a      requirements on different sectors of the global economy. The cement\u000a      industry is required to reduce\u000a      its CO2 emissions by 22.5% from 2007 to 2050. Limestone\u000a      substitution in Portland cement at levels\u000a      now shown by this work to be safe and reliable will achieve around 1\/6th\u000a      of the 450 million tonnes\u000a      per year reduction in CO2 emissions required.\u000a    Furthermore, the success of this project has led to financial support for\u000a      bolder and\u000a      more radical initiatives for reducing CO2 emissions from the\u000a      cement industry. The Qatar\u000a      Foundation has awarded a US$5.3M grant to the University of Aberdeen\u000a      (together with the\u000a      University of Dundee) to investigate further reductions in the CO2 input\u000a      to structural concrete and\u000a      increased functional performance of products. This project, which\u000a      commenced in September 2012,\u000a      is focussed on indigenous Gulf region resources. The project has at its\u000a      heart development of two\u000a      novel cements: one being a low carbon-input cement base of calcium\u000a      sulphoaluminate, and a\u000a      second carbon-negative cement type.\u000a    ","ImpactSummary":"\u000a    This case study describes the impact on practitioners and services\u000a      through the development of\u000a      new international standards based on research at the University of\u000a      Aberdeen on Portland-limestone\u000a      cements undertaken in 2004-8. The findings of this research have been\u000a      adopted into\u000a      revised international specifications for Portland cement mixtures in the\u000a      European Union, Canada\u000a      and the United States. The findings have also been incorporated into an\u000a      industry standard\u000a      software package (CEMDATA) for modelling thermodynamic properties of\u000a      cement mixture, now\u000a      established as part of the GEMS software suite freely available.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Aberdeen\u000a    ","Institutions":[{"AlternativeName":"Aberdeen (University of)","InstitutionName":"University of Aberdeen","PeerGroup":"B","Region":"Scotland","UKPRN":10007783}],"Panel":"B         ","PlaceName":[],"References":"\u000a    \u000a1. D. Damidot, S.J. Barnett, F.P. Glasser, D.E. Macphee, \"Investigation\u000a        of the CaO-Al2O3-SiO2-CaSO4-CaCO3-H2O\u000a        system at 25 degrees C by thermodynamic calculation\",\u000a      Advances in Cement Research 16, 69-76 (2004)\u000a    \u000a\u000a2. T. Matschei, ; F.P. Glasser, D. Herfort,; B. Lothenbach, \"Relationships\u000a        of Cement Paste\u000a        Mineralogy to Porosity and Mechanical Properties,\" presentation at International\u000aConference\u000a        on Modelling of Heterogeneous Materials with Applications in\u000a        Construction and\u000a        Biomedical Engineering, Prague, Czech Republic, 25-27 June 2007\u000a    \u000a\u000a3. T. Matschei, F.P. Glasser, \"The Influence of Limestone on Cement\u000a        Hydration\", ZKG\u000a      International 59, 78-86, 2006\u000a    \u000a\u000a4. T. Matschei, B. Lothenbach, F. P. Glasser, \"The Role of Calcium\u000a        Carbonate in Cement\u000a        Hydration\", Cement &amp; Concrete Research, 37, 551-558, 2007\u000a    \u000a\u000a5. T. Matschei, B. Lothenbach, F.P. Glasser, \"Thermodynamic Properties\u000a        of Portland Cement\u000a        Hydrates in the System CaO-Al2O3-SiO2-CaSO4-CaCO3-H2O\",\u000a      Cement and Concrete\u000a      Research 37, 1379-1410, 2007.\u000a    \u000a\u000a6. T. Matschei, F.P. Glasser, \"Temperature Dependence of the\u000a        Mineralogy of Portland\u000a        Cement Paste in the presence of Calcium Carbonate\", Cement and\u000a      Concrete Research 40,\u000a      763-777, 2010.\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"9","Level2":"5","Subject":"Civil Engineering"},{"Level1":"9","Level2":"15","Subject":"Interdisciplinary Engineering"},{"Level1":"9","Level2":"14","Subject":"Resources Engineering and Extractive Metallurgy"}],"Sources":"\u000a    a) NSERC\/CAC Industrial research chair in Concrete Durability &amp;\u000a      Sustainability, University of\u000a      Toronto, Canada.\u000a    This source corroborates the impact of the research findings towards\u000a        the development of\u000a        new cement standards in Canada\u000a    b) Vice President Research &amp; Technical Services, Portland Cement\u000a      Association, Illinois, USA\u000a      This source corroborates the impact of the research findings on the\u000a        international cement\u000a        industry, including reference to adoption in cement standards in Canada\u000a        and the USA\u000a    c) Vice President for Quality and Product Performance, Holcim (US) Ltd.\u000a      This source corroborates the application of research findings and the\u000a        impact to an\u000a        international manufacturer of cement products\u000a    d) \"State of the Art Report on the Use of Limestone in Cements at Levels\u000a      up to 15%\",\u000a      P.D.Tennis, M.D.A.Thomas, W.J.Weiss, Portland Cement Association 2011 (Chapter\u000a        2,\u000a        pp11-16, relates to and cites Aberdeen research)\u000a    e) Paul Scherrer Institute, Villigen, Switzerland: http:\/\/gems.web.psi.ch\/publist.html\u000a      The GEMS website explicitly refers to the Aberdeen research publication\u000a        (2007) in its\u000a        Publications of Collaborators and Developers of Specific Databases\u000a    f) Empa, Switzerland: http:\/\/www.empa.ch\/plugin\/template\/empa\/*\/62204\/---\/l=1\u000a      This site explicitly refers to the Aberdeen contribution to the\u000a        CEMDATA07 database.\u000a    g) \"Energy Technology Perspectives 2010, Scenario and Strategies to\u000a        2050\", International\u000a      Energy Agency Paris, ISBN: 978-92-64-08597-8\u000a      This source corroborates the impact of cement production on greenhouse\u000a        gas emissions,\u000a        and the impact of greenhouse gas reductions from a change in\u000a        manufacturing processes.\u000a    \u000a    ","Title":"\u000a    International Standards for Portland-limestone cements\u000a    ","UKLocation":[{"GeoNamesId":"2657832","Name":"Aberdeen"}],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Cement research at Aberdeen began when HFW Taylor was appointed as a\u000a      lecturer about 1950. A\u000a      former student of the late J.D. Bernal FRS, Taylor took inspiration from\u000a      Bernal's polymath\u000a      approach to science and by demonstrating the application of crystal\u000a      chemistry and structure to the\u000a      hydration of cement, gave the subject new directions. Since Taylor's\u000a      retirement about 1985 this\u000a      work has been progressed by F.P. Glasser and D.E. Macphee. The importance\u000a      of the work to\u000a      science and industry has been recognised by (i) major research projects\u000a      from the UK Environment\u000a      Agency (at that time, HMIP and DoE) and the European Union, having as its\u000a      objective providing a\u000a      scientific basis for the immobilisation of nuclear waste in cement. This\u000a      work is frequently cited\u000a      today and forms an integral part of the safety case worldwide for\u000a      radioactive waste immobilisation.\u000a    The specific example of more recent work which has influenced industry\u000a      and which forms the basis\u000a      of this Case Study relates to the use of limestone (calcium carbonate) as\u000a      a reactive supplement for\u000a      Portland cement. Since the 1970's, the cement industry has come under\u000a      increasing pressure to\u000a      reduce its carbon dioxide emissions: one tonne of Portland cement is\u000a      responsible for emission of\u000a      ~850kg CO2 even with the best available abatement technology.\u000a      By 1990 it was accepted on the\u000a      basis of empirical evidence that adding c. 4-6% limestone to cement\u000a      improved its strength and\u000a      decreased product permeability. Up to 10-12% limestone by volume could be\u000a      added without\u000a      reducing properties to below those of equivalent mixes with 100% cement.\u000a      The problem was that\u000a      the evidence was statistical with a reasonable but not totally convincing\u000a      probability. And it was\u000a      insufficient to convince many sceptics of the need for change in an\u000a      industry dominated by\u000a      prescriptive specifications. Nevertheless, since limestone addition to\u000a      cement reduces CO2\u000a      emissions due to cement production (discounting the small energy cost of\u000a      limestone production),\u000a      the drive for the industry to reduce its CO2 emissions meant\u000a      that more convincing evidence for the\u000a      value of limestone addition was needed.\u000a    In 2004 the Glasser group in Aberdeen began a research project dedicated\u000a      to application of\u000a      thermodynamics to cement hydration. The group had done pioneering work on\u000a      the role of calcium\u000a      carbonate in the hydration process [1]. However the lack of a good\u000a      database meant that\u000a      predictions were only semi- quantitative and only a coarse grid of\u000a      relevant systems could be\u000a      calculated. In 2003 Glasser successfully applied to Nanocem (a\u000a      not-for-profit consortium financed\u000a      by the European cement industry) to sponsor a project aimed at improving\u000a      and applying a\u000a      database for cementitious substances. As a demonstration example of the\u000a      power of the new\u000a      database and modern computation methods, calculations were undertaken and\u000a      subsequently\u000a      verified by targeted experiments, on phase relations in the CaO-Al2O3-SiO2-\u000a      CaCO3-CaSO4-H2O\u000a      system at 0-85&#186;C. It was highly relevant because the benefit, if any, of\u000a      adding limestone to cement\u000a      was being hotly debated at the time.\u000a    The calculations showed that the amount of CaCO3 which could\u000a      react with cement at a particular\u000a      temperature was quantitatively related to the Al2O3\/sulphate\u000a      molar ratio of the cement. Diagrams\u000a      were devised allowing the optimum amount of reactive carbonate to be\u000a      predicted from a two-dimensional\u000a      plot requiring as input compositional data obtained from elemental\u000a      analysis of the\u000a      cement. Experimentally, it was shown that the predicted equilibria were\u000a      attained within a few days.\u000a      This work was first reported at a conference [2] and in an industrial\u000a      journal [3], which presented the\u000a      results and explained the basis of the calculation without thermodynamic\u000a      details, in a manner\u000a      accessible to engineers and stakeholders. Two full papers in the journal\u000a      Cement and Concrete\u000a      Research then presented the details of the thermodynamic modelling [4, 5].\u000a      A subsequent paper\u000a      has extended the modelling to include temperature dependence [6].\u000a    The key outcome of this work is that the addition of CaCO3 can\u000a      be optimised on a generic basis so\u000a      as to shift most of the sulphate into ettringite, a low density calcium\u000a      sulphoaluminate hydrate. This\u000a      maximises conversion of liquid water to crystal water, thereby also\u000a      optimising space filling by solids\u000a      and reducing cement matrix porosity. This enables a win-win situation to\u000a      be attained: reducing\u000a      clinker contents, with their high CO2 liberation, and also\u000a      improving product durability in a wide\u000a      range of aggressive service environments.\u000a    Such modification of the hydrate phase assemblage has mainly been used in\u000a      the cement industry\u000a      to maximise CO2 reduction by increasing substitution of cement\u000a      by limestone, while maintaining\u000a      engineering properties such as strength and porosity, to those which would\u000a      be obtained in cement-only\u000a      formulations. This has led the industry to rely less on empiricism and\u000a      more on science-based\u000a      approaches to improve cement properties and reduce emissions.\u000a      Thermodynamic treatments are\u000a      now routinely being extended to optimise production parameters at the\u000a      hydration stage.\u000a    "},{"CaseStudyId":"43402","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"1269750","Name":"India"},{"GeoNamesId":"1861060","Name":"Japan"}],"Funders":["Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000a    A spin out company has been established and a new technology sector\u000a        has been created: There is a clear link between research at\u000a      Loughborough University in electrochemistry and methane and hydrogen-based\u000a      fuel cell power sources. This is evidenced through the involvement of Dr.\u000a      Phil Mitchell, a lecturer in the Department of Chemistry, in the\u000a      underpinning research and his departure from Loughborough University to\u000a      form the spinout company Advanced Power Sources Limited, and subsequently\u000a      Intelligent Energy in 2001. Dr. Jon Moore, was a researcher in the\u000a      Department of Chemistry and is now also with Intelligent Energy. Professor\u000a      Roger Mortimer is a co-author on some of the publications cited in Section\u000a      3 and is still in the Department of Chemistry. Section 3 lists supporting\u000a      evidence in the form of refereed papers, research funding (e.g. EPSRC and\u000a      TSB) and patents. Research in related areas of electrochemistry is\u000a      on-going in the Department of Chemistry (in collaboration with\u000a      Aeronautical &amp; Automotive Engineering) at Loughborough University\u000a      (LU), funded in part by EPSRC.\u000a    Intelligent Energy (IE) has strong links to LU, commencing in the late\u000a      1980s when researchers in the Department of Chemistry collaborated with\u000a      the Department of Aeronautical and Automotive Engineering to create one of\u000a      Europe's first research and development teams working on the development\u000a      of proton exchange membrane (PEM) fuel cell technology. The UK's first\u000a      kilowatt-level PEM fuel cell stack was constructed by the Loughborough\u000a      Univeristy team in 1995, and the commercial implications of the work\u000a      became apparent. A University spin-out company was formed called Advanced\u000a      Power Sources (APS) Ltd. APS was the first company established in the UK\u000a      to specifically address the development and commercialisation of PEM fuel\u000a      cells.\u000a    With respect to the REF Impact timeline, and impact in period since 2008,\u000a      in addition to its head quarters in Loughborough and office in London and\u000a      its operation in the US, Intelligent Energy has representation in Japan\u000a      and in the emerging markets of India. It has been ranked 27th\u000a      in The Times 100 Fastest Growing Technology Companies [5.1] and 15th\u000a      in the Deloitte 2013 Fast 50 list of companies ranked by revenue growth\u000a      driven by technology innovation [5.2].\u000a    Economic Impacts: jobs created, investment raised, evidenced by\u000a        business performance measures: IE currently employs some 350\u000a      personnel [5.3] [5.4] and it is anticipated by the company that\u000a      this will rise to 400. The majority are in the UK (Loughborough), with\u000a      other bases in the US, Japan and India. In 2011\/12, shareholder investment\u000a      was in excess of &#163;100M since incorporation. It had a 269% revenue growth,\u000a      150 patents granted and 298 others pending in 76 patent families filed\u000a      around the world [5.3] [5.4]. The company was valued at $0.5B in\u000a      2012. R&amp;D expenditure accounted for more than 30% of total turnover [5.3]\u000a        [5.4]. Strong links and collaboration exist between LU and IE on\u000a      fluid transport, fuel cell control and system integration, materials and\u000a      reliability [5.3]. The company has conducted numerous projects\u000a      with LU and fully expects such collaborative agreements to continue in the\u000a      future [5.3].\u000a    Intelligent Energy has collaborated with many high profile partners in\u000a      the development of mobile fuel cell power sources, including Peugeot\u000a      Citro&#235;n, Suzuki, Boeing, Airbus, Lotus and others. These collaborations\u000a      have led to the development of the world's first purpose-built motorbike\u000a      with a fuel cell power source, fuel cell aircraft and zero emission road\u000a      vehicles. Technology Strategy Board support for several of these\u000a      collaborations is a measure of the strategic importance of fuel cell\u000a      development to the UK.\u000a    A collaboration with PSA Peugeot Citro&#235;n (one of the world's biggest\u000a      producers of electric vehicles), Prodrive, and Robert Bosch GmbH, funded\u000a      by TSB (H2Origin project), led to the integration of fuel cell technology\u000a      in a standard Peugeot Partner electric van [5.5]. Intelligent\u000a      Energy has worked with LTI Vehicles, Lotus and TRW Conekt to develop a\u000a      zero emission fuel cell hybrid London taxi (also supported by TSB). The\u000a      first vehicle was unveiled in 2010 and a fleet of 100 vehicles were\u000a      available for the 2012 Olympics [5.6]. Collaboration with Boeing\u000a      resulted in the inaugural flight of the world's first manned fuel cell\u000a      aircraft, powered by an IE power source in 2008. [5.7]\u000a    A major collaboration with Suzuki has led to the incorporation of an IE\u000a      fuel cell power source in the world's first fuel cell motorcycle, the\u000a      Burgman Fuel-cell Scooter, which was announced at the 2009 Tokyo motor\u000a      show. The show also previewed the Tokyo Preview: Suzuki SX4-FCV Hydrogen\u000a      Fuel Cell concept car. The Burgman motor cycle was the first fuel cell\u000a      vehicle to receive Whole vehicle Type Approval in the EU in 2011 [5.8].\u000a      This has led on to the first ready to scale fuel cell production line in\u000a      Japan. [5.9]\u000a    The research from the Unit underpinned these impacts. In turn these have\u000a      had demonstrable economic impacts through the creation of a new company in\u000a      a growing business sector, employing hundreds of people and creating new\u000a      business partnerships and markets. In addition, the use of fuel cells has\u000a      an environmental impact through reduction of pollution and emissions.\u000a    ","ImpactSummary":"\u000a    Electrochemistry research in the Department of Chemistry (and associated\u000a      research in Aeronautical and Automotive Engineering) at Loughborough\u000a      University (LU) since 1993 has led directly to the development of a new\u000a      generation of clean power systems based on advanced fuel cell technology.\u000a      This resulted in the creation of a spinout company based on a\u000a      license awarded by LU: Advanced Power Sources Limited (APS) in 1995.\u000a      Intelligent Energy (IE) Limited (founded in 2001 upon the acquisition of\u000a      APS), has a global presence: a workforce of over 350 highly skilled\u000a      employees, significantly advanced technology, and investment in R&amp;D.\u000a      Environment improvements have been achieved through introduction of\u000a      zero-emission fuel cell systems.\u000a    ","ImpactType":"Technological","Institution":"\u000a    Loughborough University\u000a    ","Institutions":[{"AlternativeName":"Loughborough University","InstitutionName":"Loughborough University","PeerGroup":"B","Region":"East Midlands","UKPRN":10004113}],"Panel":"B         ","PlaceName":[],"References":"\u000a    \u000a3.1 Effect of operating pressure on the system efficiency of a\u000a        Methane-fuelled solid polymer fuel cell power source, Virji, MBV;\u000a        Adcock, PL; Mitchell, PJ; Cooley, G. Journal of Power Sources, 71\u000a        (1-2):337-347 1998. DOI:10.1016\/S0378-7753(97)02764-X\u000a    \u000a\u000a3.2 Solid polymer fuel cells for pulse power delivery, Lakeman, JB;\u000a        Mepsted, GO; Adcock, PL; Mitchell, PJ; Moore, JM. Journal of Power\u000a        Sources, 65 (1-2):179-185 1997. http:\/\/dx.doi.org\/10.1016\/S0378-7753(96)02616-X\u000a    \u000a\u000a3.3 Development and characterisation of a novel electrode\u000a      fabrication technique for use in solid polymer fuel cells Foster, SE;\u000a      Mitchell, PJ; Mortimer, RJ; Adcock, PL Editor(s) Attewell, A; Keily, T.\u000a      Power Sources, 15 15407-418 1995. ISBN: 0951232045. ISSN: 0743-7137\u000a    \u000a\u000a3.4 The effects of battlefield contaminants on PEMFC performance, Jon\u000a        M. Moore, Paul L. Adcock, J. Barry Lakeman, Gary O. Mepsted, Journal of\u000a        Power Sources 85, 254-260, 2000. http:\/\/dx.doi.org\/10.1016\/S0378-7753(99)00341-9\u000a    \u000a\u000a3.5 PL Adcock, PJ Mitchell, SE Foster, Electrolytic and fuel cell\u000a      arrangements, US Patent 6,040,075, Loughborough University, 2000\u000a    \u000aResearch funding\u000a    EPSRC Grant GR\/L60074\/01; Carbonaceous bipolar plates for solid polymer\u000a      fuel cells; M. Turpin and P. Mitchell; &#163;233K; 1998-99.\u000a    EPSRC Grant GR\/K59507\/01; Computer modelling of solid polymer fuel cells,\u000a      P. Adcock, P. Mitchell and J McGuirk, &#163;218K, 1996-98.\u000a    EPSRC Grant GR\/K87524\/01; Low cost component design for solid polymer\u000a      fuel cells; P. Mitchell and P. Adcock, &#163;96K, 1996-1998.\u000a    EPSRC Grant GR\/H16575\/01; Design and construction of a solid polymer fuel\u000a      cell based power source and associated processing unit.; P. Adcock and P.\u000a      Mitchell, &#163;183K, 1991-1995.\u000a    Technology Strategy Board funding: Project #210008, (H2Origin); project\u000a      partners: Intelligent Energy Ltd, Prodrive, PSA Peugeot Citro&#235;n and Robert\u000a      Bosch GmbH; Technology Strategy Board investment: &#163;1,717,600, Total\u000a      project investment: &#163;4,090,500.\u000a      http:\/\/www.innovateuk.org\/content\/case-study\/results\/ultra-low-emission-vans-of-the-future.ashx\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"9","Level2":"4","Subject":"Chemical Engineering"},{"Level1":"9","Level2":"12","Subject":"Materials Engineering"}],"Sources":"\u000a    The following sources of corroboration can be made available at request:\u000a    5.1 2013 Tech Track 100 league table\u000a      http:\/\/www.fasttrack.co.uk\/fasttrack\/leagues\/tech100leaguetable.asp?siteID=3&amp;searchName=&amp;yr=2013&amp;sort=num&amp;area1=99\u000a    5.2 Deloitte2013UK Fast 50 winners\u000a      http:\/\/www.deloitte.co.uk\/fast50\/winners\/2013-winners\/index.cfm\u000a    5.3 Letter of Support from Intelligent Energy.\u000a    5.4 Intelligent Energy Annual Report 2012.\u000a    5.5 Ultra-low emission vans of the future, PSA project, joint research\u000a      with Intelligent Energy, http:\/\/www.intelligent-energy.com\/automotive\/case-studies\/psa\u000a    5.6 Fuel Cell Black Cab prototype First Drive,\u000a      http:\/\/www.cleangreencars.co.uk\/jsp\/cgcmain.jsp?lnk=401&amp;featureid=1170\u000a      London black taxi cabs to run on hydrogen by 2012 Olympics,\u000a      http:\/\/www.environmenttimes.co.uk\/news_detail.aspx?news_id=668\u000a    5.7 Boeing project, joint research with Intelligent Energy, 70 kW fuel\u000a      cell system in light aircraft. http:\/\/www.wired.com\/autopia\/2008\/04\/in-an-aviation\/\u000a    5.8 Suzuki Burgman project, joint research with Intelligent Energy, 1.6kW\u000a      fuel cell system in Burgman motor bike.\u000a      http:\/\/www.which.co.uk\/news\/2011\/03\/suzuki-burgman-fuel-cell-scooter-gets-approval-247213\/\u000a    5.9 Intelligent Energy and Suzuki Motor Corporation Announce Completion\u000a      of Ready-to-Scale Fuel Cell Production Line in Japan, http:\/\/www.intelligent-energy.com\/about-us\/media-room\/news\/company-news\/2013\/02\/20\/intelligent-energy-and-suzuki-motor-corporation-announce-completion-of-ready-to-scale-fuel-cell-production-line-in-japan\u000a    ","Title":"\u000a    Intelligent Energy: A $500M Loughborough spin out company\u000a    ","UKLocation":[{"GeoNamesId":"2643743","Name":"London"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000a    The Fuel Cell Group at Loughborough University was formed in 1988 to\u000a      focus on research in fuel cell technology in the Department of Chemistry\u000a      in collaboration with Aeronautical and Automotive Engineering. This led to\u000a      the construction of the first 1 kW proton exchange membrane fuel cell in\u000a      1995, when the spin out company Advanced Power Sources Limited (APS) was\u000a      formed to work on the pre-commercial development of prototype fuel cells.\u000a      Intelligent Energy was formed in 2001 to acquire APS and attract private\u000a      capital investment. Initially a 25 person strong company based in\u000a      Loughborough and London offices, it secured an irrevocable, worldwide\u000a      license to exploit all of both APS's and the University group's fuel cell\u000a      related IP. Key research staff from Loughborough University were involved\u000a      in setting up both companies, including Dr Phil Mitchell and Dr Paul\u000a      Adcock. Dr Mitchell, a lecturer in the Department of Chemistry at the\u000a      beginning of the project, is now Chief Technology Officer and Executive\u000a      Director of Intelligent Energy, is an electrochemist with over 20 years of\u000a      experience in fuel cell and related fields who obtained his BSc and PhD at\u000a      Loughborough University and was a co-leader of fuel cell research at\u000a      Loughborough University. Dr Adcock is Director of Research and Technology,\u000a      heading up teams at Intelligent Energy developing PEM (proton exchange\u000a      membrane) fuel cell stacks and systems, and was also part of the Fuel Cell\u000a      Group at Loughborough University. Additionally, Jon Moore was a researcher\u000a      in the Chemistry Department during this period. He contributed to key\u000a      research findings, and is now the Communications Director for Intelligent\u000a      Energy.\u000a    The research carried out at Loughborough University contributed directly\u000a      to knowledge in the area of fuel cell development at the time. These\u000a      studies were carried out and published in the period 1997-2001. Operating\u000a      pressure has a direct effect on fuel stack efficiency since it increases\u000a      the cell potential. Research at Loughborough showed that a 33% efficiency\u000a      gain was achieved at an operating pressure of 4 bar [3.1]. Solid\u000a      polymer fuel cells are suitable sources for short duration, high power\u000a      pulses, but this requires the cell design, component materials and\u000a      membrane assemblies to be tested. Loughborough research showed that best\u000a      performance was achieved with low equivalent weight, thin membranes with\u000a      high catalyst utilization and optimized flow designs [3.2]. This\u000a      also required new techniques for the fabrication of the electrodes [3.3]\u000a      The effects of contamination of the fuel cell were assessed for common\u000a      pollutants such as carbon monoxide, sulfur monoxide, nitrogen dioxide,\u000a      hydrocarbons, as well as chemical weapons that may be present in a\u000a      battlefield environment [3.4]. At normal concentrations, little\u000a      effect was found for the first class of contaminants, but the chemical\u000a      weapons class had serious effect on performance. These studies were\u000a      carried out in the period 1995-2001. The research also discovered advanced\u000a      humidification techniques that obviate the need for external\u000a      humidification, a major saving in space and weight for the fuel cell\u000a      system package; an extremely important factor in transportation\u000a      applications in 2000.[3.5]\u000a    The papers [3.1-3.4] are in peer reviewed journals or invited\u000a      contributions and [3.5] is an international patent. This meets the\u000a      requirement that the underpinning research is at least of 2* quality. In\u000a      addition, the underpinning grant income outlined below, which led to these\u000a      papers was peer reviewed in competitive responsive mode.\u000a    Key researchers for LU contributing to this project were: Dr. Phil\u000a      Mitchell (PhD and lecturer 1980 until 1998, now Chief Technology Officer\u000a      at IE), Dr Paul Adcock (PhD and Senior Lecturer 1984 until 2001, now\u000a      Director of Research at IE), Dr. Jon Moore (PhD and Research Associate\u000a      1992 until 2001, now Communications Director at IE), Dr. Simon Foster (PhD\u000a      and Research Associate 1993 until 1995, now Technology Specialist at IE),\u000a      Dr. Chris Dudfield (PhD and Research Associate 1993 until 2001, now\u000a      Technical Director: Corporate Development at IE)\u000a    "},{"CaseStudyId":"43428","Continent":[],"Country":[],"Funders":["Natural Environment Research Council"],"ImpactDetails":"\u000d\u000a    The research directly resulted in changes in UK government policy and\u000d\u000a      improved forecasts of air quality made available to the public. In the UK,\u000d\u000a      air pollutants reduce lifespan on average by 8-14 months, and by up to 9\u000d\u000a      years for the most vulnerable groupings, inducing respiratory and\u000d\u000a      pulmonary diseases that affect disproportionately the elderly and\u000d\u000a      children. Health costs are estimated to be &#163;10.7 billion per annum5\u000d\u000a      and are comparable to those of alcohol and drug misuse. Vulnerable people\u000d\u000a      are advised to consult air quality forecasts, as illustrated by the Met\u000d\u000a      Office and Asthma Society:6 \"If you find pollution triggers\u000d\u000a        your asthma, keep well informed about air quality. Ozone can be a\u000d\u000a        problem for some people. Levels are likely to be higher on hot summer\u000d\u000a        days.\" Air pollution also causes ecological damage and reduces crop\u000d\u000a      yields. The connection between heat-waves and air pollution and their\u000d\u000a      impacts on the population reached wide attention during summer 2003, a\u000d\u000a      period that led to several thousand additional deaths throughout Europe\u000d\u000a      attributable to ozone and fine particulates.7 The event\u000d\u000a      catalysed public debate on the effects of air pollution, the possible\u000d\u000a      impacts of a warmer climate and the effectiveness of Government policy for\u000d\u000a      pollution control. In response, DEFRA collaborated with the York team to\u000d\u000a      improve their capability for prediction of air quality. This collaboration\u000d\u000a      began in 2003 and continues, most recently during the heat-wave of July\u000d\u000a      2013.\u000d\u000a    The government has benefited from clear scientific evidence for the\u000d\u000a      causes of continuing peak summertime ozone pollution, and an enhanced\u000d\u000a      appreciation of the limitations of EU control policies in periods of high\u000d\u000a      temperatures. The inclusion of biogenic species in predictive models has\u000d\u000a      provided government with an improved capability to forecast air quality in\u000d\u000a      the short term,8 and provided advice to the public (for example\u000d\u000a      through DEFRA and Met Office air quality forecasts). It has also improved\u000d\u000a      estimates of future changes in air pollution of natural origin and those\u000d\u000a      arising through policy change. There is now a better appreciation of the\u000d\u000a      balance between the effects of natural and man-made emissions on air\u000d\u000a      quality. Since controlling anthropogenic emissions is a costly activity,\u000d\u000a      the benefits of improved prediction are felt in both health and financial\u000d\u000a      domains.\u000d\u000a    Section 2 presented the finding from York that biogenic volatile organic\u000d\u000a      compounds are released in large quantities from vegetation in the UK on\u000d\u000a      hot summer days, promoting rapid photochemical formation of ozone. The\u000d\u000a      natural emissions offset some of the benefits from policies to reduce man-\u000d\u000a      made VOCs from sources such as combustion and solvent usage. York\u000d\u000a      scientists calculated the impacts of biogenics on air quality using their\u000d\u000a      unique measurements and supporting data from other HEIs.\u000d\u000a    The research data collected by York were shared within months with the\u000d\u000a      evidence team at DEFRA, the Government department responsible for ensuring\u000d\u000a      UK compliance with European legislation, and specifically the air quality\u000d\u000a      Directive 2008\/50\/EC. At the same time there was substantial media\u000d\u000a      reporting and debate about the research.9 Peer-reviewed\u000d\u000a      publications from York followed in 2005 and 2006.2,3 These\u000d\u000a      academic publications were then used by DEFRA as a key part of the\u000d\u000a      evidence base that guided the terms of reference for two Government\u000d\u000a      reports. It is through these reports published in 2008 and 2009, and\u000d\u000a      on-going policy recommendations and practice changes, that the impacts of\u000d\u000a      the research in this assessment period are seen.\u000d\u000a    The first DEFRA expert report on the impacts of climate change on air\u000d\u000a      pollution appeared in 200810 and a second reporting on ozone in\u000d\u000a      the UK appeared in 2009.11 In addition, DEFRA called an expert\u000d\u000a      meeting in 2009.12 Both reports made substantial reference to\u000d\u000a      the original underpinning research, highlighting the impacts that this new\u000d\u000a      understanding of natural emissions may have on air quality, and how\u000d\u000a      climate change may exacerbate this process.\" The drought conditions\u000d\u000a        accompanying the episode (summer 2003) decreased deposition of ozone to\u000d\u000a        vegetation, while the high temperatures led to increased emissions of\u000d\u000a        isoprene, a highly reactive volatile organic compound that is emitted\u000d\u000a        from vegetation, and is an ozone precursor. Both of these effects\u000d\u000a        further contributed to the high ozone concentrations.\" 10\u000d\u000a      Both Government reports made reference to the need to improve the\u000d\u000a      representation of biogenic species in UK emissions models in the light of\u000d\u000a      the York research. In 2010, DEFRA tendered for an update of the reporting\u000d\u000a      of natural VOC emissions for the UK, and the models used for national\u000d\u000a      policy development continue to be updated to include this source. This key\u000d\u000a      change to represent natural VOC emissions in the models used by Government\u000d\u000a      for future scenario testing has embedded the original research in all\u000d\u000a      future policy formulations. Specific direct consequences are: (a) DEFRA\u000d\u000a      contracted the consultancy Ricardo-AEA (http:\/\/www.ricardo-aea.com)\u000d\u000a      to include natural emissions in future air quality predictions, work that\u000d\u000a      is on-going; (b) the Met Office is including natural emissions in the\u000d\u000a      models used for their air-quality forecasts for the public (http:\/\/www.metoffice.gov.uk\/guide\/weather\/air-quality).\u000d\u000a    Activities supporting DEFRA air-quality evidence and policy requirements\u000d\u000a      continue to the present. Lewis is a current member of the Government\u000d\u000a      Expert Committee, the Air Quality Expert Group. DEFRA continues to support\u000d\u000a      a range of air pollution and emissions research projects at York Chemistry\u000d\u000a      with Lewis, Lee and Hamilton. In 2012, DEFRA and York created a new\u000d\u000a      permanent staff position split between Whitehall and York to accelerate\u000d\u000a      the translation of NERC air quality science outcomes into government\u000d\u000a      departments (Dr Sarah Moller).\u000d\u000a    Quotations: Dr Tim Murrells, Technical Director, National Atmospheric\u000d\u000a      Emissions Inventory, Ricardo-AEA (05\/04\/13) \"The research project\u000d\u000a        TORCH, led by Prof. Lewis at University of York, provided a very\u000d\u000a        detailed chemical analysis of processes occurring in the UK during very\u000d\u000a        high temperature conditions. The research, and later DEFRA expert\u000d\u000a        publications, highlighted that natural organic emissions of isoprene\u000d\u000a        could elevate UK ozone during very warm weather. In response, there is\u000d\u000a        now a programme of work, commissioned by DEFRA and led by Ricardo-AEA,\u000d\u000a        to provide recommendations on approaches for estimating biogenic\u000d\u000a        emissions inventories and their use in models to support air pollution\u000d\u000a        prediction and forecasting. Ricardo-AEA includes biogenic inventories in\u000d\u000a        its Ozone Source Receptor Model which is used to predict future ozone\u000d\u000a        concentrations in the UK and to inform DEFRA's policies on ozone air\u000d\u000a        quality by predicting the impacts of future changes in precursor\u000d\u000a        emissions. Ricardo-AEA also uses this information in models used for\u000d\u000a        DEFRA's daily forecasts and public alert systems on air pollution for\u000d\u000a        the protection of human health.\"13\u000d\u000a    Dr Chris Jones, Head, Earth System and Mitigation Science, Met Office\u000d\u000a      Hadley Centre (22\/04\/13): \"In part due to NERC-funded TORCH campaign,\u000d\u000a        the Met Office has developed global and regional chemistry climate\u000d\u000a        models which include detailed process-based representations of the\u000d\u000a        dependence of isoprene emissions on temperature and light levels. This\u000d\u000a        emissions scheme will shortly be included in our air quality forecast\u000d\u000a        model which provides daily forecasts of ozone and other pollutants for\u000d\u000a        the UK and has been demonstrated to improve the ability of the model to\u000d\u000a        represent ozone levels during period of elevated pollution. The work\u000d\u000a        carried out during the TORCH campaign both improved our understanding of\u000d\u000a        the role of isoprene in European and UK ozone episodes and also provided\u000d\u000a        a driver to ensure that these processes are fully considered by Air\u000d\u000a        Quality models for the UK. The campaign was therefore a very valuable\u000d\u000a        contribution to improving our understanding of air pollution and in\u000d\u000a        furthering our ability to model future air pollution events.\"13\u000d\u000a    Stephen Elderkin, Deputy Director Analysis and Evidence, DEFRA (1\/10\/13).\u000d\u000a        \"Summer 2003 resulted in a period of poor air quality with impacts on\u000d\u000a        health across Southern England and in many other parts of Europe.\u000d\u000a        Understanding the causes of poor air quality events such as this is of\u000d\u000a        great importance to Defra. The NERC TORCH project has been a\u000d\u000a        particularly useful scientific resource in understanding the detailed\u000d\u000a        chemistry occurring during very high temperature conditions in the\u000d\u000a        UK.....The improvements to model chemistry resulting from the findings\u000d\u000a        of the TORCH campaign on the significance of natural organic emissions\u000d\u000a        have led to an improved ability to forecast high ozone events and\u000d\u000a        therefore provide appropriate guidance and warnings to the public. It\u000d\u000a        has also led to an improvement in our ability to project future\u000d\u000a        concentrations of ozone reducing uncertainty in evidence to support\u000d\u000a        decisions on the scale and nature of measures required to tackle air\u000d\u000a        pollution.\" 13\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Research performed at York during 2003-6 revealed the unexpectedly high\u000d\u000a      level of organic emissions by trees in the UK during the hottest periods,\u000d\u000a      catalysing the formation of smog. This research on causes of summertime\u000d\u000a      air pollution informed UK government policy reports in 2008\/9. It also\u000d\u000a      resulted in on-going changes in modelling of biogenic emissions by DEFRA\u000d\u000a      (Department for Environment Food and Rural Affairs), embedding the\u000d\u000a      knowledge into all future government policy evaluations of air pollution.\u000d\u000a      The Met Office and others have now improved their air quality forecasts\u000d\u000a      provided to the public by adding the effect of natural emissions. The\u000d\u000a      beneficiaries of the York research include government and those people at\u000d\u000a      health risk from low air quality. The impact spans public policy,\u000d\u000a      environmental policy and health.\u000d\u000a    ","ImpactType":"Political","Institution":"\u000d\u000a    University of York\u000d\u000a    ","Institutions":[{"AlternativeName":"York (University of)","InstitutionName":"University of York","PeerGroup":"B","Region":"Yorkshire And Humberside","UKPRN":10007167}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    This research exceeds the quality threshold as is evident from journal\u000d\u000a      quality, number of citations (data from Scopus, November 2013) and\u000d\u000a      recognition in Lewis's Leverhulme Prize and RSC John Jeyes Award.4\u000d\u000a    Research funding to determine atmospheric chemistry of organic\u000d\u000a        compounds in the UK.\u000d\u000a    1. NERC consortium project 2002-2006, part of the Polluted Troposphere\u000d\u000a      Research Programme: Tropospheric Organic Chemistry Experiment (TORCH),\u000d\u000a      NER\/2002\/00498. Principal Investigator A.C Lewis (at University of York),\u000d\u000a      with 15 co-investigators from five UK HEIs. Total grant &#163;975K.\u000d\u000a    Peer-reviewed papers with research outcomes used later as evidence for\u000d\u000a        policy change:\u000d\u000a    \u000a2. J. D. Lee, A. C Lewis, P. S. Monks, M. Jacob, J.\u000a        F. Hamilton, L. J. Carpenter, et al. \"Ozone\u000d\u000a      Photochemistry And Elevated Isoprene During The U.K. Heat Wave Of August\u000d\u000a      2003\". Atmos. Environ. 2006, 40, 7598-7613. DOI:\u000d\u000a      10.1016\/j.atmosenv.2006.06.057. 43 citations.\u000d\u000a    \u000a\u000a3. S. Utembe, M. E. Jenkin, A. C. Lewis, J. R. Hopkins and J.\u000d\u000a        F. Hamilton. \"Modelling The Ambient Distribution of Organic\u000d\u000a      Compounds During The August 2003 Ozone Episode In The Southern U.K\". Faraday\u000a        Discuss. 2005, 130, 311-326. DOI: 10.1039\/b417403h. 29\u000d\u000a        citations. Other evidence of quality: Awards to A.C. Lewis\u000d\u000a    \u000a4. Philip Leverhulme prize in `Ocean, Earth and Atmospheric\u000d\u000a      Science' (2004) - citation: \"Alastair Lewis has used his talent for\u000d\u000a      chemical analysis to open a new area of atmospheric chemistry, devising\u000d\u000a      innovative techniques to measure complex hydrocarbon volatiles both in the\u000d\u000a      unpolluted atmosphere and in urban air. ... They can play an important\u000d\u000a      role in the chemistry of the atmosphere and are involved in the generation\u000d\u000a      of ozone, which is a potential health hazard when it occurs in the lower\u000d\u000a      atmosphere at high concentration. His measurements have helped to show\u000d\u000a      that recent exceptional summer temperatures in the UK have been\u000d\u000a      accompanied by large emissions of carbon volatiles from vegetation,\u000d\u000a      resulting in high ozone levels across the country.\"\u000d\u000a    RSC John Jeyes Award 2012 citation: \"For his significant contributions to\u000d\u000a      our understanding of the atmospheric chemistry, transport and impacts of\u000d\u000a      organic compounds, enabled by his development of novel methods of chemical\u000d\u000a      analysis\".\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"},{"Level1":"9","Level2":"15","Subject":"Interdisciplinary Engineering"},{"Level1":"9","Level2":"7","Subject":"Environmental Engineering"}],"Sources":"\u000d\u000a    \u000d\u000a      www.publications.parliament.uk\/pa\/cm200910\/cmselect\/cmenvaud\/229\/22906.htm#a11\u000d\u000a      \u000awww.asthma.org.uk\/knowledge-bank-pollutants\u000d\u000a        www.metoffice.gov.uk\/guide\/weather\/air-quality#Air-quality-index\u000a\u000d\u000a      J. R. Stedman et al. \"The predicted number of air pollution\u000d\u000a        related deaths in the UK during the August 2003 heatwave.\" Atmos.\u000d\u000a          Env. 2004, 38, 1087. DOI: 10.1016\/j.atmosenv.2003.11.011\u000d\u000a      N. H. Savage et al. \"Air quality modelling using the Met\u000d\u000a        Office Unified Model (AQUM OS24-26): model description and initial\u000d\u000a        evaluation\", Geosci. Model Dev., 2013, 6, 353. DOI:\u000d\u000a        10.5194\/gmd-6-353-2013\u000d\u000a      \u000a. References to public debate (not exhaustive) prior to Government\u000d\u000a          reports and prior to 2008 The Observer. 9\/5\/04. Front-page story\u000d\u000a        `Summer heat to spark killer fog of ozone'. The Daily Telegraph.\u000d\u000a        10\/5\/04. Page 3 \"Heatwave Britain &#8212; when trees turn toxic\". BBC 1 TV\u000d\u000a        News (1pm, 10pm).10\/05\/04. `Summer ozone'\u000d\u000a      Government reports and meetings referencing research (within REF\u000d\u000a        impact period).\u000d\u000a        http:\/\/archive.defra.gov.uk\/environment\/quality\/air\/airquality\/publications\/airqual-matechange\/documents\/summary.pdf\u000d\u000a         . DEFRA, &#8212; `Air Quality and Climate Change &#8212; A UK\u000d\u000a          perspective', Published 2008, ISBN 0-85521-172-5 See for example\u000d\u000a        Section 3 in executive summary (page 3), or chapter 4 on VOCs. (pages\u000d\u000a        102-150) DEFRA, &#8212; Air Quality and Climate Change policymakers'\u000d\u000a          summary', see pages 18-20, Air Quality and Climate Change'\u000d\u000a      \u000ahttp:\/\/archive.defra.gov.uk\/environment\/quality\/air\/airquality\/publications\/airqual-climatechange\/documents\/contents-execsumm.pdf\u000d\u000a        DEFRA, &#8212;`Ozone in the United Kingdom'. Published 2009. ISBN\u000d\u000a        978-0-85521-184-4. See for example DEFRA recommendations relating to\u000d\u000a        reporting of biogenic VOCs in Annex 1 and Annex 2. Policy recommendation\u000d\u000a        specifically associated with biogenic VOCs with reference to this\u000d\u000a        research, also in Executive Summary.\u000d\u000a      DEFRA, &#8212; Expert meeting to consider biogenic emissions and air\u000d\u000a        quality, 2009, see http:\/\/uk-air.defra.gov.uk\/reports\/cat11\/0903231041_Ozone_in_the_United_Kingdom_-_Agenda.pdf\u000d\u000a        , and then subsequent links to presentations including from\u000d\u000a        National Atmospheric Emissions Inventory on updating biogenic inventory.\u000d\u000a      \u000aConfirmatory Letters: from AEA-Ricardo, Met Office and DEFRA\u000d\u000a        are available from University of York.\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Natural organic emissions and summertime UK air quality\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    Ozone in the troposphere is an air pollutant and a greenhouse gas.\u000d\u000a      Moreover, it has been known for 40 years that the action of light on\u000d\u000a      volatile organic compounds (VOCs) in the atmosphere generates ozone at\u000d\u000a      ground level, resulting in \"photochemical smog\". It is a challenge to\u000d\u000a      determine how much ozone will form at a given time, since each VOC has a\u000d\u000a      different ozone-forming potential. We need therefore to know what types of\u000d\u000a      VOCs are present in air, and in what quantities. In 2003, NERC supported a\u000d\u000a      major experimental project1 led by Lewis (also including\u000d\u000a      Carpenter, Hamilton and Lee from York) to take state-of-the-art\u000d\u000a      measurement into the field in the UK to establish which organic compounds\u000d\u000a      were drivers of ozone formation. Other contributing universities were\u000d\u000a      Leeds, UEA, Manchester, Bristol and Imperial. The York team led the\u000d\u000a      consortium and made the measurements of organic emissions, while the other\u000d\u000a      universities provided supporting data. York led the data analysis.\u000d\u000a    Observations of all major VOC classes and other compounds were made\u000d\u000a      during summer 2003 as part of a large collaborative field experiment\u000d\u000a      during the most significant heat-wave for more than a decade. Ozone in SE\u000d\u000a      England exceeded 240 03bcg m-3 on some days, levels reminiscent\u000d\u000a      of the 1970s and early 1980s before the widespread use of catalytic\u000d\u000a      converters in vehicles. This was a highly unexpected level of air\u000d\u000a      pollution since European policy on emissions targets had been assumed to\u000d\u000a      have mitigated against very high ozone episodes. Using data from this\u000d\u000a      field study, the York group published papers in which they determined that\u000d\u000a      during the hottest periods, organic emissions (especially isoprene) from\u000d\u000a      plants rose dramatically leading to a natural contribution to the overall\u000d\u000a      atmospheric VOC loading, in turn Ozone levels during 2003 heat wave\u000d\u000a      generating additional smog which was not accounted for in predictive\u000d\u000a      forecasting models.2,3 This was an unexpected finding since the\u000d\u000a      UK was considered to have negligible isoprene emissions from its plant\u000d\u000a      stock. These publications highlighted for the first time the potential\u000d\u000a      direct impacts of a warmer climate on air quality in the UK and consequent\u000d\u000a      impacts on quality of life. The research models demonstrated the\u000d\u000a      inadequacy of accounting procedures for emissions used by UK government\u000d\u000a      since their methods did not include these natural organic emissions in a\u000d\u000a      representative way.\u000d\u000a    \u000d\u000a    \u000d\u000a    \u000d\u000a    Key researchers\u000d\u000a      Alistair C. Lewis: Started 01\/05\/03 as Reader. Chair since 01\/10\/06\u000d\u000a      Lucy J. Carpenter: Started 01\/09\/2000 as Lecturer A, Chair since 01\/10\/09\u000d\u000a      James D. Lee: Started: 01\/09\/03 as Research Fellow Grade II, Promotion to\u000d\u000a      Grade 8 01\/10\/11\u000d\u000a      Jacqueline F. Hamilton: Started 20\/08\/03 as Post-doc. Appointment to\u000d\u000a      Lecturer from 01\/02\/08\u000d\u000a    "},{"CaseStudyId":"43429","Continent":[{"GeoNamesId":"6255146","Name":"Africa"}],"Country":[{"GeoNamesId":"3374766","Name":"Cape Verde"}],"Funders":["Natural Environment Research Council","Royal Society"],"ImpactDetails":"\u000a    The York research created impact by: (a) measuring changes in\u000a      stratospheric atmospheric\u000a      composition and determining lifetimes of ozone-depleting substances; these\u000a      results are needed by\u000a      UNEP in order to make decisions, especially to provide evidence of policy\u000a      effectiveness and a\u000a      more robust prediction of the likely timescales for ozone hole recovery;\u000a      (b) revealing natural\u000a      halogenated emissions that close the gap between modelled and measured\u000a      stratospheric BrO\u000a      concentrations, providing confidence in the models used to inform UNEP of\u000a      stratospheric halogen\u000a      changes; (c) by serving on the Scientific Assessment Panel (SAP) that\u000a      advises UNEP; (d) by\u000a      proving the value to the UK of long-term background tropospheric\u000a      measurements of trace gases\u000a      and enabling the UK to fulfil its international obligations.\u000a    The SAP is charged with the periodic updating of the scientific\u000a      understanding of the depletion of\u000a      stratospheric ozone as summarised by A.R. Ravishankara (co-Chair of SAP). \"The assessment is\u000a        written and reviewed by leading\u000a        experts in the international\u000a        atmospheric sciences\u000a        community at the request of the\u000a        Parties to the U.N. Montreal\u000a        Protocol [197 countries]. It\u000a        forms the scientific basis for\u000a        decisions that the Parties reach\u000a        with regard to the phaseout of\u000a        ozone-depleting chemicals such\u000a        as the CFCs and other matters\u000a        related to the long-term\u000a        protection of the stratospheric\u000a        ozone layer. As you may know,\u000a        all previous Montreal Protocol\u000a        decisions have been based on\u000a        the science findings of the\u000a        Scientific Assessment Panel....\u000a        For previous assessments, it\u000a        has proven true that the\u000a        participants have found their\u000a        efforts rewarded with increased\u000a        stature and recognition in the\u000a        scientific community. Likewise,\u000a        their supporting institutions\u000a        have received recognition for their leadership in providing world-class\u000a        scientific expertise to the\u000a        international effort.\"5 The Assessment process\u000a      involves scientific research and stakeholders\u000a      including governments and their agencies, research managers, industries\u000a      and the public.\u000a\u000a\u000a\u0009  \u000a    The 2010 Ozone Assessment,6 and two earlier reports, make\u000a    significant reference to the original\u000a    underpinning research undertaken in York, which contributed to a better\u000a    understanding of the\u000a    observed behaviour of ODSs and ozone in the stratosphere and thus to\u000a    continued international\u000a    acceptance of the Montreal Protocol. Bernath and Carpenter also contributed\u000a    substantially as both\u000a    reviewers of the 2010 report and members of the 2010 Scientific Assessment\u000a    Panel.\u000a    York impact on Scientific Assessment Panel &#8212; stratospheric ozone.\u000a      The projections of different\u000a      ozone depleting gases restricted by the Montreal Protocol including CCl4,\u000a      CH3CCl3 and CFC-11,\u000a      and their photochemical products have been evaluated through the ACE\u000a      measurements.\u000a    \u000a      In the 2010 report6 it was noted that CCl4\u000a        declined more slowly than predicted in the 2006\u000a        report; these predictions are very sensitive to the assumed atmospheric\u000a        lifetime. The new\u000a        stratospheric lifetime contributed to the assessment that the problem is\u000a        due to unreported\u000a        emissions, rather than an erroneous lifetime.\u000a      The end product of the destruction of chlorinated gases in the\u000a        stratosphere and lower\u000a        mesosphere is HCl. Observations of HCl reduction in the lower mesosphere\u000a        by ACE contributed\u000a        to the overall assessment of the success of the Montreal Protocol in the\u000a        2010 report.6\u000a\u000a      In relation to natural brominated compounds, the research provided\u000a        emissions estimates,\u000a        hitherto unidentified species, and new understanding of the\u000a        halogen composition and chemistry\u000a        of the stratosphereand troposphere.3,4 The major\u000a        impact is that inclusion of such natural\u000a        bromine species and their chemistry in global models has led to better\u000a        agreement of the model\u000a        with inorganic bromine measurements in the stratosphere, as detailed in\u000a        the 2010 report.6 This\u000a        provides evidence that the policy is effective and improves the robust\u000a        prediction of the\u000a        timescales for ozone hole recovery.\u000a       \u000a      York impact &#8212; tropospheric ozone. Whilst the role of halogen\u000a        chemistry in controlling stratospheric\u000a        ozone has been well known for several decades, the impact on\u000a        tropospheric ozone has been less\u000a        understood. Ozone in the troposphere is important for several reasons;\u000a        it is an air pollutant, a\u000a        greenhouse gas in its own right, and indirectly it controls the lifetime\u000a        of methane, another important\u000a        greenhouse gas. The roles of both ozone and methane as greenhouse gases\u000a        are increasing in\u000a        importance. The new knowledge of halogen-tropospheric ozone processes\u000a        reported by the York\u000a        scientists4 has contributed to policy recommendations; the\u000a        Royal Society Ozone report (2009)7\u000a        used the research to highlight the need to understand and control\u000a        background ozone\u000a        concentrations in relation to air quality. The research was also\u000a        reported widely in the media and\u000a        led to public debate on the potential of natural processes to mitigate\u000a        against air pollution.8\u000a      The research programme4 has achieved long-term impacts\u000a        through the building of experimental\u000a        infrastructure. The proposal for a tropical ocean atmospheric\u000a        observatory was driven by Carpenter\u000a        (York) with Leeds colleagues and resulted in the construction of an\u000a        observatory in Cape Verde\u000a        (www.ncas.ac.uk\/cvao). The\u000a        research demonstrated the value of long-term monitoring of the\u000a        tropical atmosphere.4 As a result, the observatory is now\u000a        supported as a permanent UK\u000a        contribution to the World WMO Global Atmospheric Watch programme (www.wmo.int\/gaw);\u000a        it is\u000a        one of 28 stations worldwide and the only station supported by the UK\u000a        Government. It employs two\u000a        permanent Cape Verdean technicians (one of whom is now enrolled on an\u000a        MSc in Chemistry at\u000a        York) as well as UK researchers. The data generated from it now form\u000a        part of the UK capability to\u000a        meet its obligations on climate change detection under UNFCCC. The\u000a        research continues to\u000a        generate long-term observations of trends in ozone and other gases, and\u000a        these data are\u000a        disseminated to academic and Government users via agencies such\u000a        as the Department of Energy\u000a        and Climate Change (DECC), UNFCCC and WMO. The data alerts the\u000a        government to changes in\u000a        the Atlantic atmosphere arising from pollution episodes or long-term\u000a        changes.\u000a      Quotation from L. Jalkanen Chief, Atmospheric Environment Research\u000a        Division, World\u000a        Meteorological Organization,9 \"The University of York,\u000a          with support from other UK and German and\u000a          Cape Verdean partners, created in 2006 a new observatory in Cape\u000a          Verde. This observatory\u000a          helped GAW fill in an important gap in global observations, providing\u000a          information on changes\u000a          occurring in the tropical North Atlantic marine boundary layer, a\u000a          region sensitive to both natural and\u000a          anthropogenic change. ... The global reach of the GAW programme, and\u000a          its contributor scientists,\u000a          allows it to also influence governmental understanding and policy on\u000a          atmospheric change.\u000a      ","ImpactSummary":"\u000a    The international Montreal Protocol limits the production of\u000a      stratospheric-ozone depleting\u000a      substances that contain chlorine and bromine. York researchers used the\u000a      Atmospheric Chemistry\u000a      Experiment (ACE) satellite to monitor the decay of halogen-containing\u000a      molecules in the\u000a      stratosphere and to re-evaluate their atmospheric lifetimes. This York\u000a      research also determined\u000a      that oceans represent a vast reservoir of organohalogens, which are\u000a      released to air and impact\u000a      significantly on ozone destruction. The research results have been\u000a      incorporated into the\u000a      conclusions of the World Meteorological Organization\/United Nations\u000a      Environment Programme\u000a      (WMO\/UNEP) Scientific Assessments on Ozone Depletion, the pre-eminent\u000a      knowledge base used\u000a      for international policy and domestic legislation. Experimental\u000a      infrastructure created in this York\u000a      research now contributes to UK Government obligations under the United\u000a      Nations Framework\u000a      Convention on Climate Change (UNFCCC) and informs it of long-term\u000a      atmospheric change.\u000a    ","ImpactType":"Political","Institution":"\u000a    University of York\u000a    ","Institutions":[{"AlternativeName":"York (University of)","InstitutionName":"University of York","PeerGroup":"B","Region":"Yorkshire And Humberside","UKPRN":10007167}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"6077243","Name":"Montral"}],"References":"\u000a    This research exceeds the quality threshold as is evident from the\u000a      journal quality, the number of\u000a      citations (citation data from Scopus, November 2013) and recognition in\u000a      prizes.\u000a    Peer-reviewed publications -- Authors at York in bold\u000a    \u000a1. D. Fu, C. D. Boone, P. F. Bernath, D. K. Weisenstein, C. P.\u000a      Rinsland, G. L. Manney, and K. A.\u000a      Walker, First global observations of atmospheric COClF from the\u000a      Atmospheric Chemistry\u000a      Experiment mission, J. Quant. Spectrosc. Radiat. Transfer, 2009, 110,\u000a      974. DOI:\u000a      10.1016\/j.jqsrt.2009.02.018. 5 citations\u000a    \u000a\u000a2. D. Fu, C. D. Boone, P. F. Bernath, K. A. Walker, R. Nassar, G.\u000a      L. Manney, and S. D. McLeod,\u000a      Global phosgene observations from the Atmospheric Chemistry Experiment\u000a      (ACE) mission,\u000a      Geophys. Res. Lett., 2007 34, L17815. DOI:\u000a      10.1029\/2007GL029942. 7 citations\u000a    \u000a\u000a3. L. J. Carpenter, P. S. Liss and S. A. Penkett, Marine\u000a      organohalogens in the atmosphere over\u000a      the Atlantic and Southern Oceans, J. Geophys. Res.- Atm., 2003, 108,\u000a      DOI:\u000a      10.1029\/2002JD002769. 49 citations\u000a    \u000a\u000a4. K. A. Read, , A. S. Mahajan, L. J. Carpenter, M.\u000a        J. Evans, B. V. E. Faria, D. E. Heard, J. R.\u000a        Hopkins, J. D. Lee, S. J. Moller, A. C. Lewis,\u000a      L. Mendes, J. B. McQuaid, H. Oetjen, A. Saiz-Lopez,\u000a\u0009  M.J. Pilling, and J. M. C. Plane, Extensive halogen-mediated ozone\u000a      destruction over the\u000a      tropical Atlantic Ocean, Nature, 2008, 453, 1232. DOI:\u000a      10.1038\/nature07035. 133 citations\u000a    \u000aOther evidence of quality:\u000a    2012 Benedict Spectroscopy Award to P. Bernath: (from Elsevier Press on\u000a      behalf of the Journal of\u000a        Quantitative Spectroscopy and Radiative Transfer) The citation\u000a      states that Bernath \"has also been\u000a      at the forefront of satellite remote sensing experiments, particularly as\u000a      the mission scientist for the\u000a      ACE (Atmospheric Chemistry Experiment) satellite\"\u000a    2009 Alouette Award of Canadian Aeronautics and Space Institute (CASI) to\u000a      P. Bernath for\u000a      developing the ACE satellite and the resulting observations (shared with\u000a      V. Wehrle, G. Rumbold, I.\u000a      Walkty, T. McElroy and M.-A. Soucy)\u000a    2006 Philip Leverhulme prize to L. J. Carpenter &#8212; citation: \"Not only has\u000a      she made pioneering\u000a      measurements [on the chemistry of atmospheric bromine and iodine\u000a      compounds], but she has also\u000a      contributed substantially to the interpretation of the observations to\u000a      shed light on the underlying\u000a      chemistry. These results are of great significance in understanding the\u000a      Earth's climate.\"\u000a    Selected research grants:\u000a    Bernath, 2008-2011, 'VOCs in the Troposphere Retrieved from ACE Satellite\u000a      Measurements',\u000a      NERC, &#163;364,058.\u000a    Bernath, 2011-2013, 'Satellite Observations of Halogen-Containing\u000a      Molecules', NERC, &#163;349,740.\u000a      Carpenter and Lewis, 2005-2008, 'UK SOLAS Atmospheric Observatory at Cape\u000a      Verde', NERC\u000a      SOLAS contract, &#163;572,220.\u000a    Carpenter, 2006-2009, Philip Leverhulme Prize in `Earth Ocean and\u000a      Atmospheric Sciences',\u000a      Leverhulme Trust, &#163;70,000.\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"99","Subject":"Other Chemical Sciences"},{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"}],"Sources":"\u000a      Reports related to policy\u000a      \u000a     Letter from Co-chair Montreal Protocol Scientific Assessment Panel\u000a        WMO\/UNEP Assessment Report on Stratospheric Ozone 2010, Chapter 1\u000a          Ozone-Depleting\u000a          Substances (ODSs) and Related Chemicals,\u000a          http:\/\/ozone.unep.org\/Assessment_Panels\/SAP\/Scientific_Assessment_2010\/00-SAP-2010-Assement-report.pdf\u000a\u000a        Royal Society report \"Ground-level ozone in the 21st century: future\u000a          trends, impacts and policy\u000a          implications\" 2008. http:\/\/royalsociety.org\/policy\/publications\/2008\/ground-level-ozone\u000a          References to public debate (not exhaustive) relating to reference\u000a          4:\u000a        BBC World Service interview given by Prof L J Carpenter (26.06.08,\u000a          Science In Action, \"Low\u000a          level ozone pollution\". http:\/\/worldservice.prototyping.bbc.co.uk\/programmes\/X0901226\u000a          (sign up\u000a          required); The Guardian newspaper online\u000a          (http:\/\/www.guardian.co.uk\/environment\/2008\/jun\/26\/climatechange.pollution?INTCMP=SRCH);\u000a          New Scientist Online (http:\/\/www.newscientist.com\/article\/dn14211-tropical-ocean-sucks-up-vast-amounts-of-ozone.html);\u000a          A solicited Nature News and Views article (von Glasow, Nature,\u000a          2008,\u000a          453, 1195-1196), Nature Reports Climate Change (Newton,\u000a          \"A natural detox\", DOI:\u000a          10.038\/climate.2008.67)\u000a        Letter from Chief, Atmospheric Environment Research Division, WMO,\u000a          Geneva\u000a          Page 4\u000a      \u000a      ","Title":"\u000a    Ozone-depleting halogens in the atmosphere\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Stratospheric ozone protects humankind and its crops from harmful\u000a      ultraviolet radiation.\u000a      Anthropogenic stratospheric ozone destruction is caused mainly by\u000a      long-lived chlorine-containing\u000a      molecules such as CCl4 and chlorofluorocarbons (CFCs), and\u000a      bromine molecules such as halons\u000a      (brominated fluorocarbons) and methyl bromide. The 1987 Montreal Protocol\u000a      on substances that\u000a      deplete the ozone layer and its subsequent amendments have resulted in the\u000a      phasing-out of the\u000a      production of many such chlorine-and bromine-containing species &#8212;\u000a      preventing not only millions of\u000a      cases of skin cancer deaths and cataracts, but also reducing emissions of\u000a      halogenated\u000a      greenhouse gases by the equivalent of more than 10 billion tonnes of CO2\u000a      at the end of 2008. In\u000a      view of the steady progress made under the Protocol, former UN\u000a      Secretary-General Kofi Annan\u000a      called it in 2003 Perhaps the single most successful international\u000a        agreement to date\u000a      (ozone.unep.org\/Publications\/MP_Key_Achievements-E.pdf).\u000a    It is crucial to assess the performance of the Montreal Protocol in\u000a      reducing the concentrations of\u000a      ozone-depleting substances (ODSs) and to monitor the recovery of the ozone\u000a      layer. Therefore,\u000a      every four years the WMO and UNEP publish a report on the ``Scientific\u000a      Assessment of Ozone\u000a      Depletion'', carried out by the Scientific Assessment Panel (SAP). The\u000a      York-based group, led by\u000a      Bernath, contributed to the WMO ozone report by measuring global\u000a      concentration distributions of\u000a      many chlorine-containing molecules using data from the ACE satellite1\u000a      (www.ace.uwaterloo.ca).\u000a    \u000a      UV photodissociation of these molecules forms intermediates such as\u000a        phosgene (Cl2CO) and\u000a        ClFCO 1,2 and leads ultimately to the formation of HCl. ACE\u000a        satellite measurements tested the\u000a        accuracy of chemical models and showed the anticipated decline in HCl\u000a        and other halogenated\u000a        gases due to the implementation of the Montreal Protocol.\u000a      Atmospheric lifetimes are crucial parameters in models and the\u000a        research group determined the\u000a        relative stratospheric lifetime of CCl4 by the method of\u000a        tracer-tracer correlations; there are\u000a        surprisingly large uncertainties in these lifetimes (see 2010 WMO ozone\u000a        report).\u000a      CCl4 is destroyed mainly by photolysis in the stratosphere\u000a        giving phosgene. Fu et al. measured\u000a        the first global distribution of phosgene2 and found that\u000a        concentrations had declined from earlier\u000a        in situ measurements owing to decline in the parent source gases\u000a        CH3CCl3 and CCl4.\u000a      The York group found that the global distribution of FClCO,1\u000a        produced by photolysis of the\u000a        parent CFC-11 (CF3Cl) molecule, agreed well with that\u000a        calculated by an atmospheric model,\u000a        giving confidence in the reliability of the emissions projections and\u000a        the model.\u000a    \u000a    Conventionally, it was thought that anthropogenic bromine compounds in\u000a      the form of halons and\u000a      CH3Br were the sole carriers of bromine into the stratosphere.\u000a      However, calculated stratospheric\u000a      Bry concentrations from measurements of BrO were too\u000a      high by 15-40% to be explained by these\u000a      halocarbons alone. The oceanic and atmospheric measurements of Carpenter\u000a      in York showed that\u000a      emissions of natural bromine compounds including CHBr3 and CH2Br2\u000a      from the marine biosphere,\u000a      especially macroalgae, represent a major global source of bromine.3\u000a      Subsequent model studies\u000a      showed that these emissions were sufficient to explain the discrepancy\u000a      between modelled and\u000a      measured stratospheric BrO concentrations. The York group demonstrated\u000a      that ozone in the\u000a      troposphere was also controlled over wide oceanic areas by natural halogen\u000a      emissions,4  and this\u000a      has led to public and policy debate on the potential contribution of such\u000a      processes to the reduction\u000a      of ground level ozone, a key pollutant (in contrast to the essential\u000a      nature of stratospheric ozone).\u000a    Both the ACE and the tropospheric research are part of multi-centre\u000a      programmes involving\u000a      collaboration of York with other institutes in Canada, USA, Belgium, UK,\u000a      Germany and France.\u000a    Key researchers:\u000a    Peter F. Bernath: Appointed 01\/07\/2006 as Professor,\u000a      Lucy J. Carpenter: Appointed 01\/09\/2000 as Lecturer A, Promotion to Chair\u000a      01\/10\/09\u000a    "},{"CaseStudyId":"43431","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"2510769","Name":"Spain"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"1733045","Name":"Malaysia"},{"GeoNamesId":"2921044","Name":"Germany"},{"GeoNamesId":"6252001","Name":"United States"}],"Funders":["Research Councils UK","Natural Environment Research Council"],"ImpactDetails":"\u000a    The new research has had impacts in the detection of food contaminants.\u000a      As ready meals containing meat have become more popular (now estimated at\u000a      5% of the UK food budget), the potential for fraudulent food labelling has\u000a      increased. The potential for mislabelling came to the fore in 2009 and\u000a      again in 2013. The Food and Environment Research Agency (FERA, an agency\u000a      of DEFRA close to York) guides the science evidence base in the food and\u000a      environment sectors to ensure that UK policy makers are well informed,\u000a      undertaking both surveillance and R&amp;D activities. Its services\u000a      underpin regulatory frameworks as well as supporting religious and\u000a      cultural factors such as food provenance (e.g. halal or kosher).\u000a      Five million people in the UK choose to avoid pig and cow products on\u000a      vegetarian or religious grounds; they include 2.7M Muslims and 817,000\u000a      Hindus.1\u000a    The standard method of identifying the species origin of meat is DNA\u000a      sequencing, but this is not possible on all samples (e.g. gelatin,\u000a      material that has been heated). Moreover, exogenous DNA can be added\u000a      fraudulently to mask endogenous signals. The York team of Collins and\u000a      Thomas-Oates was asked to use ZooMS and other proprietary mass\u000a      spectrometry approaches for collagen identification, to support a Food\u000a      Standards Agency investigation into the use of pig- and cow-derived\u000a      gelatin employed to re-hydrate air-freighted products in foods labelled as\u000a      containing only chicken (the addition of other animal protein to meat\u000a      stated to be from a single source is illegal). They were then approached\u000a      anonymously by an investigative team later revealed to be from the BBC, to\u000a      test chicken breasts supplied to Asian restaurants. As a result of the BBC\u000a      TV investigation (broadcast on 14\/07\/09, entitled `What's really in our\u000a      food?'), Euro Foods Group announced on their website (July 2009) that in\u000a      order to 'eradicate any future question marks and\/or confusion over\u000a      non-chicken protein detection levels in our product range, Euro Foods\u000a      Group has decided to switch to a vegetable derived protein instead, a move\u000a      which was completed by 29th June 2009' (see also minutes 51-52 of\u000a      programme in reference 2). Euro Foods (http:\/\/www.eurofoods.co.uk)\u000a      is the largest supplier of poultry to the Asian market in the UK. The\u000a      discovery of bovine gelatin in chicken was publicised in the UK press (The\u000a        Independent, The Daily Mail, and The Sun), and\u000a      featured in the BBC documentary.2 The research featured in the\u000a      Annual Report of the Chief Scientist of the Food Standards Agency 2009\/10.3\u000a      Dr Shuja Shafi of the Muslim Council of Britain stated that Muslims would\u000a      be extremely annoyed and extremely distressed to learn that chicken sold\u000a      as halal contains protein from prohibited species and they would be\u000a      extremely angry if this turned out to be a deliberate deception as Muslims\u000a      rely heavily on accurate food labelling (minutes 53 -55 of programme in\u000a      reference 2).\u000a    As a consequence of York's work it was evident that a complex process had\u000a      been developed to dupe DNA testing, enabling low-cost (pork and cattle)\u000a      gelatin to be sold as `chicken protein' and used as a plumping agent in\u000a      chicken breast meat. Two factories (in Germany and Spain) that produced\u000a      the plumping agents were raided by local inspectors.\u000a    FERA has worked with the York team to apply the University of York\u000a      methods of analysis based on collagen sequencing to their core business of\u000a      food authentication. Specifically, it has determined the species\u000a      provenance of gelatin and hydrolysed collagen added to chicken fillets,\u000a      so-called chicken-plumping agents. In a DEFRA-funded study (&#163;91k contract,\u000a      01\/03\/11 to 31\/03\/12), it validated the technique against other\u000a      commercially-available approaches (enzyme-linked immunosorbent assay\u000a      (ELISA) and PCR) and found it to be superior, with the alternative\u000a      techniques providing numerous false positive results. This contract\u000a      involved an inter-laboratory trial of the method, including laboratories\u000a      across Europe and in the USA, during which the analytical method was\u000a      transferred successfully to alternative food enforcement laboratories. A\u000a      further DEFRA-funded project (Defra project code FA0126) is transferring\u000a      the method to a wide range of processed foods and pharmaceutical products.\u000a      The method has also been developed and applied to other food matrices for\u000a      FERA customers to screen foods destined for the halal markets and also for\u000a      products such as gelatin capsules (for therapeutic\/supplement\u000a      formulations) aimed at vegetarian customers.\u000a    Since the outbreak of BSE in 1987, the inclusion of animal proteins has\u000a      been banned in animal feeds to prevent cannibalism in the food chain.\u000a      There is scope to relax the extended feed ban, should scientific methods\u000a      be available to first screen animal feeds and then to provide confirmatory\u000a      analysis of positive samples. A method was developed by the York team\u000a      during this partnership to determine the species origin of bone chips\u000a      using the collagen method. This method is currently being reported to the\u000a      EU, and FERA is publicising its availability.\u000a    There is now interest from various laboratories in Europe, as well as key\u000a      government research laboratories to license the method for gelatin\u000a      identification; the US Food and Drug Administration (FDA) is one of six\u000a      partners in this development. Training in the methodology has been\u000a      provided by the York team for FERA and for analytical laboratories from\u000a      across Europe and North America (including the US FDA). The York team made\u000a      species-specific marker peptide sequences available to FERA, that are now\u000a      being used as internal standards in this assay. FERA is also training two\u000a      Malaysian laboratories in the method.\u000a    In 2013, inclusion of horse meat in ready meals affected numerous\u000a      products in the UK and other EU countries. FERA has demonstrated that, as\u000a      expected, York's approach is also able to identify horse gelatin. FERA has\u000a      funding approved to adapt the pork and beef methods for horse gelatin\u000a      (Defra project code FA0126).\u000a    Quotations to support impact:\u000a    Collins was co-opted as a consultant to an EU project SAFEED-PAP, 6th EC\u000a      FP, DG RTD. The archaeological method proved particularly appropriate to\u000a      the detection of animal bone fragments. Dr Ir Vincent Baeten, Head of the\u000a      Food and Feed Unit, EU Reference Laboratory said: \"I have to applaud\u000a        the innovative analytical solution that the Department has proposed for\u000a        detection of animal bone, using protein mass-spectrometry (ZooMS). I\u000a        would like also to recognise the effort made by the Department to adapt\u000a        this method coming from archaeology to feed safety\".4\u000a    Dr Adrian Charlton, Head of Chemical and Biochemical Profiling at FERA\u000a      wrote as follows, corroborating the nature and extent of the collaboration\u000a      with FERA:\u000a    \"FERA's close collaboration with Professors Thomas-Oates and Collins\u000a        have led to a number of technologies that we routinely exploit to\u000a        deliver ongoing project work and to underpin project proposals, papers\u000a        and publicity material. In particular, we have undertaken a number of\u000a        studies to determine peptide sequences that can be used for the species\u000a        origin determination in collaboration with you and your colleagues.\u000a        These projects have led to FERA offering an international service for\u000a        the species identification of gelatin and MBM in food and feed,\u000a        respectively.\"5\u000a    The research undertaken in York has provided the food standards and\u000a      enforcement agencies with the ability to determine the animal source(s) of\u000a      processed foods in which DNA analysis is not possible, by targeting the\u000a      protein which is the principal component of meat. The York methods have\u000a      been adopted by the UK agencies and transferred to equivalent bodies in\u000a      other countries. The need for these analyses has been demonstrated through\u000a      BBC and FSA investigations of fraudulent labelling and further\u000a      disseminated in the press. The importance and broad applicability of these\u000a      approaches has been further highlighted by this year's horsemeat scandal.\u000a    ","ImpactSummary":"\u000a    York's analytical methods have been applied in food authentication,\u000a      traceability and safety and have been shown to be superior to other\u000a      methods. Mass spectrometric methods developed in York for the\u000a      identification of archaeological bone samples rely on analysing surviving\u000a      fragments of the bone protein, collagen. These techniques also identify\u000a      collagen fragments present in gelatin-based plumping agents that retain\u000a      water in meats for human consumption. York's authentication applications\u000a      disclosed the animal species from which the collagen was derived, and\u000a      revealed contamination of chicken with pork-derived plumping agents, a\u000a      significant issue in communities with halal and kosher diets. These\u000a      results have been disseminated by high-profile media reporting, including\u000a      a one-hour BBC special, and the press. The Food and Environment Research\u000a      Agency (FERA, a DEFRA agency) has validated the York analytical method and\u000a      applied it to processed food and pharmaceutical products. An\u000a      inter-laboratory trial transferred the method to other food enforcement\u000a      laboratories across Europe and the USA (including the US FDA). The results\u000a      were highlighted in the press in 2009 and the debate over food\u000a      authentication exploded in 2013 highlighting the economic effects of\u000a      mislabelling. This research therefore has impact on public and commercial\u000a      services as well as public debate.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of York\u000a    ","Institutions":[{"AlternativeName":"York (University of)","InstitutionName":"University of York","PeerGroup":"B","Region":"Yorkshire And Humberside","UKPRN":10007167}],"Panel":"B         ","PlaceName":[],"References":"\u000a    This research exceeds the quality threshold as is evident from the\u000a      journal quality and the number of citations (Scopus 20.9.13).\u000a    Grant:\u000a    Paleoproteomics: a revolution in ancient biomolecular studies?\u000a      (NERC NE\/C511148\/1) project grant to Collins, Thomas-Oates, Genever,\u000a      2006-2008. &#163;192,726.\u000a    Peer-reviewed publications:\u000a    \u000aM. Buckley, A. Walker, S.Y.W. Ho, Y. Yang, C. Smith, P. Ashton, J. Thomas\u000a      Oates, E. Cappellini, H. Koon, K. Penkman, B. Elsworth, D. Ashford, C.\u000a      Solazzo, P. Andrews, J. Strahler, B. Shapiro, P. Ostrom, H. Gandhi, W.\u000a      Miller, B. Raney, M. I. Zylber, M.T.P. Gilbert, R.V. Prigodich, M. Ryan,\u000a      K.F. Rijsdijk, A. Janoo, M.J. Collins, Comment on \"Protein sequences from\u000a      mastodon and Tyrannosaurus rex revealed by mass spectrometry\", Science,\u000a      2008, 319, 33. DOI: 10.1126\/science.1147046. 19 citations\u000a    \u000a\u000aM. Buckley, M.J. Collins, J. Thomas-Oates \"A method of isolating the\u000a      collagen (I) &#945;2 chain carboxytelopeptide for species identification in\u000a      bone fragments\", Anal. Biochem. 2008, 374, 325-334.\u000a      DOI: 10.1016\/j.ab.2007.12.002. 7 citations\u000a    \u000a\u000aM. Buckley, C. Anderung, K. Penkman, B.J. Raney, A., G&#246;therstr&#246;m, J.\u000a      Thomas-Oates, M. Collins \"Comparing the survival of osteocalcin and mtDNA\u000a      in archaeological bone from four European sites\", J. Archaeol. Sci.,\u000a      2008, 35, 1756-1764. DOI: 10.1016\/j.jas.2007.11.022. 16\u000a        citations\u000a    \u000a\u000aM. Buckley, M. Collins, J. Thomas-Oates, J.C. Wilson \"Species\u000a      identification by analysis of bone collagen using matrix-assisted laser\u000a      desorption\/ionisation time-of-flight mass spectrometry\", Rapid Commun.\u000a        Mass Spectrom. 2009, 23, 3843-3854. DOI: 10.1002\/rcm.4316. 35\u000a        citations\u000a    \u000a\u000aM. Buckley, S. Whitcher Kansa, S. Howard, S. Campbell, J. Thomas-Oates,\u000a      M. Collins \"Distinguishing between archaeological sheep and goat bones\u000a      using a single collagen peptide\", J. Archaeol. Sci, 2010, 37,\u000a      13-20. DOI: 10.1016\/j.jas.2009.08.020. 28 citations\u000a    \u000a\u000aK. Korzow Richter, J. Wilson, M. Buckley, N. van Doorn, A. Jones and M.\u000a      Collins \"Fish 'n chips: ZooMS in a 96 well plate format to identify fish\u000a      bone fragments\", J. Archaeol. Sci. 2011, 38, 1502-1510.\u000a      DOI: 10.1016\/j.jas.2011.02.014. 7 citations\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"6","Level2":"1","Subject":"Biochemistry and Cell Biology"},{"Level1":"6","Level2":"4","Subject":"Genetics"},{"Level1":"3","Level2":"1","Subject":"Analytical Chemistry"}],"Sources":"\u000a    \u000a      2011 Census (England and Wales).\u000a      BBC programme http:\/\/www.bbc.co.uk\/programmes\/b00lrjk4#broadcasts\u000a        4 June 2009, The Independent, `Chicken injected with beef waste\u000a        sold in UK'\u000a        http:\/\/www.independent.co.uk\/life-style\/food-and-drink\/news\/chicken-injected-with-beef-waste-sold-in-uk-1696407.html\u000a        5 June 2009 The Mail, `Chicken secretly injected with beef and\u000a        pork products served in UK\u000a        restaurants' http:\/\/www.dailymail.co.uk\/news\/article-1190796\/Chicken-secretly-injected-beef-pork-products-sold-UK-restaurants.html\u000a        17 Sept 2009 The Sun, `Chicken fill it'\u000a        http:\/\/www.thesun.co.uk\/sol\/homepage\/news\/2464679\/Chicken-fill-it.html\u000a\u000a      Annual Report of the Chief scientist of the Food Standards Agency\u000a        2009\/10. p. 66 http:\/\/www.food.gov.uk\/multimedia\/pdfs\/csr0910.pdf\u000a        Also FSA website 4 June 2009 `New study highlights undeclared\u000a        ingredients in chicken products'. http:\/\/webarchive.nationalarchives.gov.uk\/20101224202640\/http:\/food.gov.uk\/news\/newsarchive\/2009\/jun\/chicken\u000a\u000a      Head of the Food and Feed Unit, EU Reference Laboratory.\u000a      Head of Chemical and Biochemical Profiling at FERA.\u000a    \u000a    ","Title":"\u000a    Food security, traceability and authentication\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Professors Matthew Collins (Archaeology) and Jane Thomas-Oates\u000a      (Chemistry) have had a joint programme of work since 2003, using mass\u000a      spectrometry to analyse ancient and other damaged proteins. The protein\u000a      collagen has extraordinary stability due to its three-dimensional\u000a      structure, which has led to the idea that collagen can persist for\u000a      thousands of years essentially intact. However, the structural features\u000a      that make collagen so stable were for a long time also considered to make\u000a      collagen useless as a species indicator. The highly conserved main\u000a      collagen chain is made up largely of a tripeptide repeat\u000a      (glycine-proline-hydroxyproline), while the chain-terminating\u000a      `telopeptides' were believed to be intractable, due to their cross-linking\u000a      that is crucial for collagen fibril formation. In collaborative work, a\u000a      postdoctoral fellow and PhD student (both NERC-funded) in the York\u000a      research groups investigated collagen's preservation and developed\u000a      approaches to its extraction from fossil bones.\u000a    The collaborators have shown that one of the C-terminal\u000a      telopeptides is not involved in cross-linking and has some\u000a      species-diagnostic value. In addition, and more importantly, the groups\u000a      have demonstrated that the `conserved' repetitive collagen backbone\u000a      polypeptides in fact have a good deal of species-specific amino-acid\u000a      sequence variation. The work has shown that collagen can be extracted\u000a      effectively from very small samples of bone and, using the sample handling\u000a      strategies developed in this collaboration, employed to identify\u000a      historical and archaeological bone fragments in the archaeological record.\u000a      In these studies, as in much archaeological research, a broad network of\u000a      collaborators is involved, all studying the same assemblages or samples.\u000a      The role of the York chemists involved mass spectrometry (sample\u000a      preparation, measurement and data analysis).The NERC-funded PhD\u000a      studentship was a CASE Award with Prosper de Mulder, a meat and bone meal\u000a      company, whose interest was in detecting not ancient but heat-treated meat\u000a      and bone meal, and the ability to identify its animal source. The approach\u000a      is similarly applicable to the detection and analysis of gelatin, which is\u000a      produced from the collagen in bone on boiling. One of the outcomes of\u000a      these projects is a rapid, affordable, medium-throughput method for\u000a      detecting and determining the species of origin of archaeological bone\u000a      fragments. The method which York termed Zooarchaeology by Mass\u000a      Spectrometry or ZooMS, has been reported widely (e.g. Chemistry World,\u000a      Nov 2010, 44; Science, 2010, 330, 28-29), and a large\u000a      database of collagen amino acid sequences has been assembled (Figure). Dr\u000a      Julie Wilson (Chemistry and Mathematics) joined the team more recently,\u000a      applying data analysis and pattern recognition methods to the raw spectra,\u000a      allowing species identification where sequence information may not be\u000a      available. The outcomes of the collaboration also led FERA to invite the\u000a      York team to join an EU Framework 6 project (SAFEED-PAP, Jan 2007-Dec\u000a      2009) to determine the species origin of proteins in animal feed (grant of\u000a      &#163;143k).\u000a    \u000a    \u000a    \u000a    Key researchers\u000a    Jane E. Thomas-Oates: Appointed 01\/04\/2002 as Professor of\u000a      Analytical Science\u000a    Julie C. Wilson: Started 01\/10\/93 as Research Fellow (RA1A), then\u000a      RCUK fellow, transfer to Lecturer 01\/07\/2011 (joint Mathematics and\u000a      Chemistry appointment).\u000a    Matthew Collins, Archaeology, started 01\/10\/2003, Reader then Chair, head\u000a      of BioArCh, An interdisciplinary centre between Biology, Archaeology\u000a      and Chemistry\u000a    "},{"CaseStudyId":"43432","Continent":[{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1861060","Name":"Japan"}],"Funders":[],"ImpactDetails":"\u000d\u000a    Worldwide there are some 35 million sufferers of insulin-dependent\u000d\u000a      diabetes. For many years, the adverse symptoms of this condition have been\u000d\u000a      mitigated successfully with regular injections of insulin. Initially these\u000d\u000a      insulins were obtained from bovine and\/or porcine sources, but they did\u000d\u000a      not mimic well actions of endogenous insulin, leading to frequent\u000d\u000a      hypo-glycaemia and other complications. In 1980, the first clinical trials\u000d\u000a      were begun of recombinant insulins obtained by protein engineering\u000d\u000a      methods. From these trials it soon became apparent that the rate of\u000d\u000a      insulin action in vivo was a key factor in the therapeutic\u000d\u000a      potential of the enzyme. The best results were obtained when the insulin\u000d\u000a      injectate contained a mixture of fast-acting and slow-acting insulins,\u000d\u000a      where the latter avoids the need to have regular repeated injections and\u000d\u000a      minimise hypoglycemia, and the former is necessary to treat the rapid rise\u000d\u000a      in blood glucose levels that accompanies ingestion of food.\u000d\u000a    Accordingly recombinant insulin producers concentrated on controlling the\u000d\u000a      rate of action of insulin and its analogues. Amongst these, Novo-Nordisk\u000d\u000a      in collaboration with YSBL, led the way in trying to find a structural\u000d\u000a      rationale for the controlled disaggregation rates of hexameric insulin.\u000d\u000a      YSBL was the world's leading laboratory for insulin structures, and the\u000d\u000a      large majority of the structural work for Novo-Nordisk on insulins from\u000d\u000a      1993 to 2000 was done in conjunction with YSBL. The protein structures\u000d\u000a      published from York are available as coordinates in the Protein Data Bank.7\u000d\u000a      The collaboration between YSBL and Novo-Nordisk was supported by several\u000d\u000a      grants.8 This development programme was highly successful and\u000d\u000a      consequently today Novo-Nordisk is the leading developer and world's\u000d\u000a      largest producer of recombinant insulin for treatment of diabetes.\u000d\u000a    The first new product that came from York structural studies was the\u000d\u000a      aspartate mutant described above.1,2 This fast-acting insulin\u000d\u000a      was launched in 1999, marketed as NovoLog&#174; in the US and\u000d\u000a      Insulin Novorapid&#174; in Europe.9\u000d\u000a    The second development came from the derivatised insulins, which were\u000d\u000a      conceived directly from the structural work described in reference 4\u000d\u000a      above. It was discovered that the attachment of a fatty acid to insulin\u000d\u000a      led to its prolonged action, resulting in just one daily intravenous\u000d\u000a      administration of the hormone. These derivatised insulins received FDA\u000d\u000a      approval in 2005, and are marketed as the product Levemir&#174; (or\u000d\u000a      Insulin Detemir&#174;) and are now the mainstay of Novo Nordisk's\u000d\u000a      insulin products. Its new, improved generation insulin Degludec&#174;\u000d\u000a      was approved by the EU and Chuikyo (Japan) in 2013.\u000d\u000a    Levemir&#174;, NovoRapid and NovoLog&#174; (also marketed as\u000d\u000a      Novomix&#174; in a different formulation) are true blockbuster drugs\u000d\u000a      with billion dollar sales (reference 10). Levemir&#174; had US sales\u000d\u000a      of $1.7 billion in 2012 growing from $756 million in 2008. The\u000d\u000a      corresponding figures for Novolog&#174; are $1.6 billion and $1.1\u000d\u000a      billion, and for Novorapid, $2.7 billion and $1.5 billion. Levemir&#174;\u000d\u000a      and Novolog&#174; are currently number 40 and 42 in the ranking of\u000d\u000a      US drugs by sales. Total worldwide sales of the drugs were $6 billion in\u000d\u000a      2012 (Figure).10\u000d\u000a\u000d\u000aFigure: Worldwide sales of Novorapid, Levemir&#174; and Novomix&#174; (alternative name for Novolog&#174; depending on market), during REF impact period.10\u000d\u000a\u0009  \u000d\u000a    Svend Ludvigsen (Vice-President, Diabetes formulation, biophysics and\u000d\u000a      structure) at Novo Nordisk assesses the impact of York's work as follows:11\u000d\u000a    \"Throughout the years the collaboration with York has been a continuous\u000d\u000a      source of inspiration for the understanding of insulin structure and\u000d\u000a      insulin as pharmaceutical products. The work of Whittingham et al. 1997\u000d\u000a      has provided significant insight into some of the protraction principles\u000d\u000a      of the insulin analog, insulin Detemir, developed into a once daily basal\u000d\u000a      insulin product Levemir&#174;. Novorapid&#174; (US: Novolog&#174;) and Levemir&#174; both have\u000d\u000a      blockbuster status and are used by millions of patients all around the\u000d\u000a      globe.\"\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Insulin derivatives that stem directly from structural work carried out\u000d\u000a      within the York Structural Biology Laboratory (YSBL) are now the standard\u000d\u000a      treatment for insulin-dependent diabetes for some 35 million patients\u000d\u000a      worldwide. The successful development of new insulin drugs hinged upon\u000d\u000a      controlling their speed of action following intravenous administration.\u000d\u000a      This speed of action is controlled by insulin's degree of aggregation,\u000d\u000a      which, in turn, is determined by protein-protein interactions.\u000d\u000a      Understanding, modifying and controlling these interactions depended on\u000d\u000a      detailed structural studies of insulin, insulin mutants and insulin\u000d\u000a      derivatives. The most widely used derivatives were developed following\u000d\u000a      structural work carried out within YSBL in the Department of Chemistry.\u000d\u000a      The research has had economic impact through sales of the insulin drugs\u000d\u000a      (over $6 billion in 2012) and major health impacts on diabetics worldwide.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    University of York\u000d\u000a    ","Institutions":[{"AlternativeName":"York (University of)","InstitutionName":"University of York","PeerGroup":"B","Region":"Yorkshire And Humberside","UKPRN":10007167}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    This research exceeds the quality threshold as is evident from the\u000d\u000a      journal quality and the number of citations. Citations from Scopus\u000d\u000a      (20\/09\/2013). Refereed publications (authors in publications 1-5 are\u000d\u000a      either from YSBL or YSBL and Novo-Nordisk).\u000d\u000a    \u000a1. E. J. Dodson, G. G. Dodson, R. E. Hubbard, P. C. E. Moody, J.\u000d\u000a      Turkenburg, J. L. Whittingham, B. Xiao, J. Brange, Kaarsholm and H.\u000d\u000a      Thogersen, H. \"Insulin assembly: its modification by protein engineering\u000d\u000a      and ligand binding\", Phil. Trans. R. Soc. Lond. A, 1993, 345,\u000d\u000a      153-164. DOI: 10.1098\/rsta.1993.0126. 14 citations.\u000d\u000a    \u000a\u000a2. J. L. Whittingham, D. J. Edwards, A. A. Antson, J. M. Clarkson and G.\u000d\u000a      G. Dodson, \"Interactions of Phenol and m-Cresol in the Insulin Hexamer,\u000d\u000a      and Their Effect on the Association Properties of B28 Pro &#8594; Asp Insulin\u000d\u000a      Analogues\", Biochemistry, 1998, 37, 11516-11523. DOI:\u000d\u000a      10.1021\/bi980807s. 59 citations.\u000d\u000a    \u000a\u000a3. J. L. Whittingham, S. Chaudhuri, E. J. Dodson, P. C. E Moody and G. G.\u000d\u000a      Dodson. \"X-ray Crystallographic Studies on Hexameric Insulins in the\u000d\u000a      Presence of Helix-stabilising Agents, Thiocyanate, Methylparaben, and\u000d\u000a      Phenol\", Biochemistry, 1995, 34, 15553-15563. DOI:\u000d\u000a      10.1021\/bi00047a022. 69 citations.\u000d\u000a    \u000a\u000a4. J. L. Whittingham, S. Havelund and I. Jonassen, \"Crystal Structure of\u000d\u000a      a Prolonged-Acting Insulin with Albumin-Binding Properties\", Biochemistry,\u000d\u000a      1997, 36, 2826-2831. DOI: 10.1021\/bi9625105. 77 citations.\u000d\u000a    \u000a\u000a5. J. L. Whittingham, I. Jonassen, S. Havelund, S. M. Roberts, E. J.\u000d\u000a      Dodson, C.S. Verma, A. J. Wilkinson and G. G. Dodson, \"Crystallographic\u000d\u000a      and Solution Studies of N-Lithocholyl Insulin: A New Generation of\u000d\u000a      Prolonged-Acting Human Insulins\", Biochemistry, 2004, 43,\u000d\u000a      5987-5995. DOI: 10.1021\/bi036163s.  22 citations.\u000d\u000a    \u000a\u000a6. J. G. Menting, J. Whittaker, M. B. Margetts, L. J. Whittaker, G. K.-W.\u000d\u000a      Kong, B. J. Smith, C. W. Watson, L. &#381;&#225;kov&#225;, E. Kletv&#237;kov&#225;, J. Jir&#225;&#269;ek, D.\u000d\u000a      F. Steiner, S. J. Chan, G. G. Dodson, A. M. Brzozowski, M. W. Weiss, C. W.\u000d\u000a      Ward and M. C. Lawrence. \"How insulin engages its primary binding site on\u000d\u000a      the insulin receptor\", Nature, 2013, 493, 241-245. DOI:\u000d\u000a      10.1038\/nature11781. 11 citations. Patent PUV 2012-26680.\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"6","Level2":"1","Subject":"Biochemistry and Cell Biology"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"},{"Level1":"11","Level2":"15","Subject":"Pharmacology and Pharmaceutical Sciences"}],"Sources":"\u000d\u000a    \u000d\u000a      Deposition of coordinates on Protein Data Bank (PDB). http:\/\/www.rcsb.org.\u000d\u000a        22 insulin structures deposited with Whittingham as co-author (1995\u000d\u000a        onwards) such as entries &#8212; 1UZ9, 1ZEG, 3ZU1, 1MPJ\u000d\u000a      Seven successive, uninterrupted, grant renewals from Novozymes and\u000d\u000a        Novo-Nordisk since 1993- 2013, totalling more than &#163;3.4M.\u000d\u000a      NovoLog&#174; and Novorapid&#174; details: www.ukmi.nhs.uk\/NewMaterial\/html\/docs\/insulin.pdf\u000d\u000a        and http:\/\/www.globalrph.com\/rapid-acting-analogues.htm\u000a\u000d\u000a      Sales of insulins from Novo-Nordisk website: www.novonordisk.com\u000d\u000a        e.g. http:\/\/www.novonordisk.com\/images\/investors\/investor_presentations\/2013\/Interim_report\/PR130808_H1_results_UK.pdf\u000a\u000d\u000a      Vice President, Diabetes formulation, structure and biophysics,\u000d\u000a        Novo-Nordisk A\/S\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Short and long-acting insulins for the management of diabetes\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    Background to research. The late GG Dodson FRS played a major role\u000d\u000a      in the initial determination and analysis of the structure of insulin by\u000d\u000a      X-ray crystallography in the Oxford laboratory of Nobel laureate DC\u000d\u000a      Hodgkin. The insulin project moved to York when Hodgkin retired, and over\u000d\u000a      the next twenty years many further structures of native insulin, insulin\u000d\u000a      mutants and insulin derivatives were determined. These structures allowed\u000d\u000a      both academic and industrial scientists to understand how the structure of\u000d\u000a      insulin relates to its biological activity, and how the physico-chemical\u000d\u000a      properties of different preparations of insulin can be engineered to\u000d\u000a      provide therapeutic options.\u000d\u000a    Naturally occurring insulin is stored in the pancreas in crystals, made\u000d\u000a      up of three insulin dimers coordinated by zinc ions. They dissociate into\u000d\u000a      active insulin monomer upon release into the blood stream. A basal level\u000d\u000a      of insulin (pM) is maintained in the blood stream and increases in\u000d\u000a      response to increased glucose in the blood following a meal. The original\u000d\u000a      therapy for Type I diabetics was injection of insulin crystals extracted\u000d\u000a      from pig or cow pancreas. However, it did not reproduce the physiological\u000d\u000a      blood levels of insulin and caused immune responses to foreign hormones.\u000d\u000a      All these led to the long-term complications associated with insulin\u000d\u000a      therapy.\u000d\u000a    From 1984 to 2000, YSBL engaged in a major collaboration on recombinant,\u000d\u000a      novel modified insulins with Novo Nordisk A\/S (www.novonordisk.com).\u000a      The structures of these analogues provided a detailed understanding of the\u000d\u000a      nature of insulin aggregation. The focus of the work in 1993 moved towards\u000d\u000a      the rational design of modified insulins in order to obtain clinically\u000d\u000a      applicable monomeric insulins &#8212; they are now the basis of the modern\u000d\u000a      \"fast-acting\" insulins. Furthermore, structures of insulin crystals with\u000d\u000a      various additives and\/or modifications identified some general principles\u000d\u000a      on how to increase stability of insulin hexamers, leading to the current\u000d\u000a      \"long-lasting\" insulin preparations.\u000d\u000a    Research during period. The key breakthroughs during the\u000d\u000a      assessment period were carried out by J. L Whittingham and R. E. Hubbard\u000d\u000a      with G. G. Dodson:\u000d\u000a    \u000d\u000a      \u000aDesign of rapid-acting monomeric insulins: The crystal\u000d\u000a        structure of insulin hexamers and dimers suggested amino acid mutations,\u000d\u000a        which would lead to a monomeric insulin. The structures of such proteins\u000d\u000a        are reported in references 1 (1993) and 2 (1998). In one of these\u000d\u000a        proteins, B28 proline is mutated to aspartic acid; this is the insulin\u000d\u000a        of the Novo Nordisk product Insulin aspart.&#174;\u000a\u000d\u000a      \u000aIdentifying additives to stabilise insulin preparations:\u000d\u000a        References 2 (1998) and 3 (1995) describe structures of series of\u000d\u000a        preparations in which hexamer formation is stabilised. The structure of\u000d\u000a        a m-cresol-insulin clathrate led to the proposal that mutation\u000d\u000a        to tryptophan at the end of the B chain would disrupt the insulin\u000d\u000a        aggregate. This mutant was found to have improved stability in Novo\u000d\u000a        Nordisk's very complex protein manufacturing processes.\u000d\u000a      \u000aModifications to generate long-active insulins: References 4\u000d\u000a        (1997) and 5 (2004) report the crystal structures of acylated insulins\u000d\u000a        which had been identified by Novo Nordisk as prolonged-acting insulins.\u000d\u000a        The YSBL research suggested that the prolonged action was more likely to\u000d\u000a        be related to the way that these modified insulins aggregated in\u000d\u000a        solution (and in the crystals). These soluble prolonged-acting insulins\u000d\u000a        are significantly better for diabetics than other long-acting insulins.\u000d\u000a    \u000d\u000a    Insulin research in York continues. Throughout the 2000s AM Brzozowski of\u000d\u000a      YSBL worked with an international team on the development of super-active\u000d\u000a      analogues of insulin. These have provided the tools that enabled a\u000d\u000a      breakthrough in 2013 (reference 6) in the determination of the structure\u000d\u000a      of the first insulin receptor-insulin complex. Insights from this work\u000d\u000a      will have an impact in the future on the design of further insulin\u000d\u000a      analogues with the prospect of oral delivery of insulin.\u000d\u000a    Key researchers:\u000d\u000a    G. Guy Dodson FRS, appointed 01\/07\/1976 as Lecturer, Professor from\u000d\u000a      01\/08\/1993, Emeritus Professor from 01\/08\/2005. Died 2012.\u000d\u000a    Roderick E. Hubbard, appointed 01\/10\/1980 as temporary Lecturer,\u000d\u000a      Professor from 01\/10\/1995\u000d\u000a    A. Marek Brzozowski, appointed 06\/04\/1989 as Research Fellow, Reader\u000d\u000a      01\/10\/2002\u000d\u000a    Jean L. Whittingham, appointed 01\/01\/95 as Research Fellow\u000d\u000a    "},{"CaseStudyId":"43572","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":[],"ImpactDetails":"\u000a    Approximately 500,000 people are currently affected by Alzheimer's\u000a      Disease in the UK. An estimated 62,000 people develop the disease each\u000a      year, of which the majority are in the early stages of the disease. Prior\u000a      to the date of onset of the impact (March 2011), the three anti-\u000a      cholinesterase drugs, Aricept (donepezil), Reminyl (galantamine) and\u000a      Exelon (rivastigmine), although clinically approved much earlier, were not\u000a      available on the NHS for early stage Alzheimer's. The decision as to\u000a      whether any treatment is available on the NHS is made by the National\u000a      Institute of Health and Care Excellence (NICE). NICE considered that the\u000a      drugs offered insufficient patient benefit to justify their cost and\u000a      sought additional longer-term clinical data and a rationale for their\u000a      action [9].\u000a    The mechanism of action for the drug galantamine was elucidated by the\u000a      research carried out at Lancaster. NICE eventually reversed their earlier\u000a      decision in Mar 2011 [10] taking into account the additional clinical\u000a      data, the mechanistic rationale for use of galantamine in early\u000a      Alzheimer's (Lancaster research), and in response to pressure from various\u000a      patient and carer groups, clinicians, and most notably from Alzheimer's\u000a      Society [11-13]. There was an additional argument for the reversal of the\u000a      initial decision, namely that the initial economic model used by NICE to\u000a      calculate whether the drugs offered \"value for money\", did not accurately\u000a      reflect the hidden economic costs of care outside of hospital. The\u000a      Alzheimer's Society used Lancaster's research as a part of its campaign,\u000a      generalising the findings to the entire class of anti-cholinesterase drugs\u000a      (galantamine, donepezil, and rivastigmine). The clinical studies revealed\u000a      that patients with \"mild\" i.e. early stage Alzheimer's did indeed benefit\u000a      from these drugs. Lancaster's basic research (in which NMR spectroscopy\u000a      played a crucial role) provided the mechanistic evidence for the disease-\u000a      modifying effects of the drug galantamine, thus rationalising the clinical\u000a      results.\u000a    The policy change by NICE has led to direct impact, enhancing the quality\u000a      of life for 100,000s of Alzheimer's patients (over 300,000 galantamine\u000a      prescriptions alone were dispensed in the UK in 2012 [8]). This in turn\u000a      would have had a substantial, indirect impact on the lives of spouses,\u000a      immediate family, and those involved in caring for the sufferers. The\u000a      impact continues as new patients come into the pool.\u000a    The impact is certainly beyond the UK, though this cannot be\u000a      corroborated. The UK medicines regulatory bodies, which include the\u000a      Medicines and Healthcare Products Regulatory Agency (MHRA) and NICE, are\u000a      seen as important standards across the world. The confidence expressed by\u000a      NICE in the use of galantamine and related drugs in early stage\u000a      Alzheimer's would have enhanced the use of these drugs in other parts of\u000a      the world.\u000a    The interdisciplinary chemistry-biomedical Lancaster research into the\u000a      disease-modifying effects of galantamine was directly funded by the\u000a      Alzheimer's Society over the period 2006-2009. The Society promptly\u000a      recognised the significance of the results that suggested that treatment\u000a      should be initiated at the earliest stages of development of Alzheimer's\u000a      disease. The research and its implications were widely publicised through\u000a      their printed literature and their website [14-16].\u000a    The following quotation from Alzheimer's Society Newsletter `The Journal\u000a      of Quality Research in Dementia' [14] refers directly to the Lancaster\u000a      research:\u000a    \"There is an exciting piece of research from David Allsop's group in\u000a        Lancaster, looking at the potential therapeutic properties of existing\u000a        acetylcholinesterase inhibitors. These drugs are used currently for\u000a        treating symptoms of dementia, but there is lack of substantial evidence\u000a        to show whether or not they may be of therapeutic value in treating\u000a        disease progression. The results of this current study will highlight\u000a        important evidence in putting forward an argument in using these drugs\u000a        in a therapeutic context.\"\u000a    The impact case study is supported by a letter [17] from the former\u000a      Director of Research (2003- 2011) of Alzheimer's Society from which the\u000a      following passage is reproduced:\u000a    \"The Amyloid &#946; aggregation starts in the brain many years before\u000a        symptoms of dementia appear in Alzheimer's disease and the search is\u000a        still on for drugs that can prevent the aggregation early. Prof Allsop's\u000a        research demonstrating that Galantamine had an additional biochemical\u000a        activity of inhibiting this aggregation was an important supporting\u000a        argument at the time of the campaign. It seemed to promise that the drug\u000a        would likely be efficacious in the early stages of disease. Although not\u000a        evidenced at the time, this result made it more likely that some of the\u000a        other cholinesterase inhibitors might also have biochemical effects in\u000a        addition to the inhibition of acetylcholine degradation....Together with\u000a        the critical reviews of existing clinical research it helped win the\u000a        case for people with dementia and their carers.\"\u000a    ","ImpactSummary":"\u000a    The drug galantamine (Reminyl) received approval for the treatment of\u000a      early stages of Alzheimer's disease in 2001. However it was not made\u000a      available on the NHS until March 2011, the effective onset date for the\u000a      impact. The decision as to whether a treatment is available on the NHS is\u000a      made by the National Institute of Health and Care Excellence (NICE), who\u000a      sought additional clinical data and a rationale for the action of the\u000a      drug. The mechanism of action was elucidated by Lancaster researchers that\u000a      included chemists and biomedical scientists. These results were part of\u000a      Alzheimer's Society's campaign to convince NICE to make the drug available\u000a      on the NHS for early stage Alzheimer's. The resulting impact was direct,\u000a      enhancing the quality of life for 100,000s of Alzheimer's patients\u000a      (318,000 galantamine prescriptions were dispensed in the UK in 2012 [8]),\u000a      with indirect impact on spouses, immediate family, and carers. The impact\u000a      continues as new patients come into the pool.\u000a    ","ImpactType":"Health","Institution":"\u000a    Lancaster University\u000a    ","Institutions":[{"AlternativeName":"Lancaster University","InstitutionName":"Lancaster University","PeerGroup":"B","Region":"North West","UKPRN":10007768}],"Panel":"B         ","PlaceName":[],"References":"\u000a    \u000a[1] Moore S. A., Huckerby T. N., Gibson G., Fullwood N. J., Turnbull S.,\u000a      Tabner B. J., El-Agnaf O. M. A., and Allsop D. (2004) Both the D-(+)\u000a        and L-(-) enantiomers of nicotine inhibit A&#946; aggregation and\u000a        cytotoxicity. Biochemistry 43, 819-826. DOI: 10.1021\/bi035728h.\u000a    \u000a\u000a[2] Matharu B., Gibson G., Parsons R., Huckerby T.N., Moore S. A., Cooper\u000a      L. J., Millichamp R., Allsop D. and Austen B. (2009) Galantamine\u000a        inhibits &#946;-amyloid aggregation and cytotoxicity. J Neurol. Sci. 280,\u000a      49-58. DOI: 10.1016\/j.jns.2009.01.024.\u000a    \u000a[3] Alzheimer's Society project grant \"Effects of galantamine\u000a        (Reminyl) and other acetylcholinesterase inhibitors on &#946;-amyloid\u000a        aggregation and toxicity\", David Allsop (PI), with co-applicants\u000a      Thomas Huckerby, Nigel Fullwood and Francis Martin, 2006-2009. &#163;122,000.\u000a      This grant was awarded by Alzheimer's Society in open competition,\u000a      following scientific peer- review and a presentation by David Allsop and\u000a      Thomas Huckerby to an interview panel of fellow scientists and lay members\u000a      of the Society.\u000a    Development \/ background research prior to impact\u000a    \u000a[4] Huckerby T.N. (2002) The keratan sulphates: structural\u000a        investigations using NMR spectroscopy, Progress in Nuclear Magnetic\u000a      Resonance Spectroscopy 40, 35-110. DOI: 10.1016\/S0079-6565(01)00040-1.\u000a    \u000aCurrent research in NMR spectroscopy\u000a    \u000a[5] Lauder R. M., Huckerby T., Nieduszynski I. and Sadler I. H. (2011) Characterisation\u000a        of oligosaccharides from the chondroitin\/dermatan sulphates: 1H and 13C\u000a        NMR studies of oligosaccharides generated by nitrous acid\u000a        depolymerisation, Carbohydrate Research 346, 2222. DOI:\u000a      10.1016\/j.carres.2011.06.033.\u000a    \u000a\u000a[6] Bonhomme C., Gervais C., Folliet N., Pourpoint F., Diogo C. C., Lao\u000a      J., Jallot E., Lacroix J., Nedelec J.-M., Iuga D., Hanna J. V., Smith M.\u000a      E., Xiang Y., Du J. and Laurencin D. (2012) Sr- 87 solid-state NMR as\u000a        a structurally sensitive tool for the investigation of materials:\u000a        antiosteoporotic pharmaceuticals and bioactive glasses, J. Am. Chem.\u000a      Soc. 134, 12611. DOI: 10.1021\/ja303505g.\u000a    \u000a\u000a[7] Middleton D. A., Madine J., Castelletto V. and Hamley I. W. (2013) Insights\u000a        into the molecular architecture of a peptide nanotube using FTIR and\u000a        solid-state NMR spectroscopic measurements on an aligned sample,\u000a      Angewandte Chemie.52, 10537. DOI: 10.1002\/anie.201301960\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"6","Level2":"1","Subject":"Biochemistry and Cell Biology"},{"Level1":"11","Level2":"15","Subject":"Pharmacology and Pharmaceutical Sciences"},{"Level1":"11","Level2":"9","Subject":"Neurosciences"}],"Sources":"\u000a    [8] (a) Prescription Cost Analysis England 2012 report, Health and Social\u000a      Care Information Centre (www.hscic.gov.uk), published 4 April 2013,\u000a      accessible at\u000a      http:\/\/www.hscic.gov.uk\/catalogue\/PUB10610.\u000a    (b) Prescription Cost Analysis Scotland 2012, Information Services\u000a      Division, NHS National Services Scotland, at\u000a      http:\/\/www.isdscotland.org\/Health-Topics\/Prescribing-and-Medicines\/Community-Dispensing\/Prescription-Cost-Analysis\/.\u000a    (c) Prescriptions Cost Analysis Wales 2011, Welsh Government, at\u000a      http:\/\/new.wales.gov.uk\/topics\/statistics\/headlines\/health2012\/1203281\/?lang=en.\u000a    (d) Prescription Cost Analysis Northern Ireland 2012, Business Services\u000a      Organisation,\u000a      http:\/\/www.hscbusiness.hscni.net\/services\/2437.htm.\u000a    Documentation on the new NICE guidelines for AD (March 2011)\u000a    [9] NICE Final Appraisal Determination: Donepezil, galantamine,\u000a      rivastigmine (review) and memantine for the treatment of Alzheimer's\u000a      disease, 26 May 2006, accessible at\u000a      http:\/\/www.nice.org.uk\/nicemedia\/live\/11599\/33725\/33725.pdf\u000a    [10] http:\/\/www.nice.org.uk\/guidance\/index.jsp?action=byID&amp;o=13419\u000a    Alzheimer's Society challenges to NICE recommendations\u000a    [11] http:\/\/www.alzheimers.org.uk\/site\/scripts\/documents_info.php?documentID=461\u000a    [12] http:\/\/www.publications.parliament.uk\/pa\/cm200607\/cmselect\/cmhealth\/503\/503we05.htm\u000a    [13] http:\/\/www.alzheimers.org.uk\/site\/scripts\/news_article.php?newsID=11\u000a    Documented references to Lancaster's research on galantamine by\u000a        Alzheimer's Society\u000a    [14] Alzheimer's Society Quality Research in Dementia, Issue 4, September\u000a      2007\u000a    [15] Alzheimer's Society Quality Research in Dementia Annual Roundup,\u000a      2008-2009\u000a    [16] Alzheimer's Society Quality Research in Dementia, Issue 95, February\u000a      2010\u000a    Letter of support from Alzheimer's Society\u000a    [17] Letter of support from Former Director of Research, Alzheimer's\u000a      Society \u000a    ","Title":"\u000a    Uncovering how the drug galantamine works contributes to its\u000a        availability on the NHS for use in early stage Alzheimer's disease\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Alzheimer's disease (AD) is characterised by dementia involving loss of\u000a      memory, mood changes, and problems with communication and reasoning.\u000a      Pathological changes include a shortage of the transmitter substance\u000a      acetylcholine and the deposition of protein plaques and neurofibrillary\u000a      tangles in the brain, leading to the death of nerve cells and a reduction\u000a      in brain function. The plaques contain a central deposit of the 39-43\u000a      amino acid peptide &#946;-amyloid (or A&#946;), which accumulates in the form of\u000a      numerous `amyloid' protein fibrils. This accumulation is widely thought to\u000a      be an important step in the early stages of development of AD. Inhibiting\u000a      aggregation of A&#946; or blocking its neurotoxic effects are considered to be\u000a      important approaches for developing treatment.\u000a    In 2004, chemists (Thomas Huckerby, Reader in Spectroscopy) and\u000a      biomedical scientists (David Allsop, Chair in Neuroscience; Nigel\u000a      Fullwood, Senior Lecturer; Frances Martin, Senior Lecturer) developed a\u000a      collaborative research programme to investigate potential inhibitors for\u000a      the aggregation of the amyloid peptide A&#946; responsible for plaque formation\u000a      in Alzheimer's disease. This built on Huckerby's long-standing research in\u000a      nuclear magnetic resonance (NMR) spectroscopy with applications to\u000a      biological systems, a notable sustained contribution being structural\u000a      characterisation of polymeric chemical species present in connective\u000a      tissue (see list of references cited in the major review by Huckerby [4]).\u000a      This research continues to thrive [5]. Indeed, NMR spectroscopy is now a\u000a      strategic research area for Lancaster involving significant investment\u000a      with a view to developing an internationally-leading centre for solid\u000a      state NMR. Investment includes two world-class Chair appointments, Mark\u000a      Smith (materials science focus, see e.g. [6]) and David Middleton\u000a      (biomolecular structure and interactions, see e.g. [7]), and University\u000a      commitment to securing a 600 MHz solid-state NMR instrument through\u000a      matched funding.\u000a    The research collaboration initially investigated members of the nicotine\u000a      alkaloid family of chemicals. It was already known that L-(-)-nicotine\u000a      itself was active &#8212; smokers are slightly less susceptible to developing\u000a      Alzheimer's' &#8212; and in \"Alzheimer's\" mice, plaque densities were reduced by\u000a      administration of L-(-)-nicotine. This prompted comparative solution NMR\u000a      studies, combined with other tests which indicated, surprisingly, that the\u000a      enantiomeric D-(+)- form (inactive at nicotinic receptors) showed\u000a      identical binding to histidine residues in the amyloid peptide [1]. Both\u000a      enantiomers inhibited aggregation and reduced the cell toxicity of A&#946;. It\u000a      appeared that this was thus due to weak, relatively non-specific binding,\u000a      possibly involving the anti-oxidant and\/or metal- chelating properties of\u000a      the alkaloid rather than a chiral interaction. Inhibitor studies using NMR\u000a      spectroscopy were then extended to other small molecule species including\u000a      the known Alzheimer's drug, galantamine.\u000a    Galantamine appears to have multiple actions as a drug. It was known to\u000a      have an inhibitory effect on the enzyme acetylcholine esterase (AChE),\u000a      thereby increasing the level of the neurotransmitter acetylcholine in the\u000a      diseased brain to improve memory and cognition. However, the effectiveness\u000a      of galantamine treatment did not entirely correlate with its AChE\u000a      activity, suggesting an additional unknown mechanism of action.\u000a    Lancaster chemistry research on galantamine showed clear\u000a      concentration-dependent inhibition of aggregation of A&#946; by galantamine, in\u000a        vitro. In complementary biological research, various cell toxicity\u000a      assays showed that galantamine also reduced the cytotoxicity induced by\u000a      A&#946;. NMR spectroscopy involving a combination of 1D and 2D approaches was\u000a      employed to identify the locations and 3D-shape of all 16 proton sites to\u000a      reveal the galantamine conformation in solution. Following on, difference\u000a      NMR spectroscopy was employed to ascertain whether galantamine interacted\u000a      with A&#946; in solution. The results (perturbations in the proton shifts)\u000a      revealed a fast- exchange interaction of galantamine with A&#946; involving\u000a      histadine residues on A&#946;, explaining the effects of the drug on A&#946;\u000a      aggregation and toxicity [2]. These results suggest that galantamine may\u000a      not act purely as a symptomatic treatment for AD. The drug possibly had disease-modifying\u000a      effects, due to the neuroprotection afforded against A&#946; aggregation and\u000a      toxicity. A significant inference arising from this research is that the\u000a      drug should be prescribed as early as possible to check or even reverse\u000a      the course of the disease.\u000a    Funding for the research included a Project Grant (&#163;120k) [3] from the\u000a      Alzheimer's Society on which Allsop was the Principal Investigator with\u000a      Huckerby, Fullwood, and Martin as Co- Investigators. Huckerby was assisted\u000a      in the study by a project student, Robert Millichamp. Other researchers at\u000a      Lancaster University included Research Associates Susan Moore and Leanne\u000a      Cooper, who provided electron microscopy expertise and capability.\u000a    Complementary research focussing on the effects of galantamine on\u000a      apoptosis induced by A&#946; in cell models was carried out by Brian Austen and\u000a      his co-workers at St. George's Hospital Medical School, London. This\u000a      contribution is part of the study reported by Matharu et al. 2009 [2].\u000a    "},{"CaseStudyId":"43573","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":[],"ImpactDetails":"\u000a    The new ink formulations were introduced in the Royal Mail processes in\u000a      2006-7, defining the date\u000a      of onset of impact.\u000a    Embedding of Technology: Key to the realisation of the impact of\u000a      this research programme was\u000a      the embedding of the technology developed at Lancaster University into\u000a      Royal Mail Research\u000a      Laboratories. Linda Swanson [1-5] was a PhD student on the programme, who\u000a      was subsequently\u000a      employed by Royal Mail for three years. Paul Brown and Alistair McCabe,\u000a      employed at Royal Mail\u000a      Research Laboratories, were members of the research team [1-5]. The\u000a      research initiated through\u000a      the partnership with Lancaster University was subsequently refined at\u000a      Royal Mail Research\u000a      Laboratories, which led to a further patent [7] where practical ink\u000a      formulations are described which\u000a      include the addition of an opacifying agent (to enhance the fluorescence\u000a      signal on highly coloured\u000a      envelopes and wrappings, and therefore enhancing the reliability of the\u000a      automated barcode\u000a      reading equipment). A further development was to incorporate dyes that\u000a      could be monitored at two\u000a      distinct excitation wavelengths (e.g. 365 nm and 420 nm) which can be\u000a      `read' using a combination\u000a      of UV and visible illumination. Such formulation is typical of what is\u000a      used by Royal Mail to print\u000a      digital postmarks (DPMs) as barcodes on letters and parcels.\u000a    The IMPACT is evident under THREE distinct headings:\u000a    SAFETY &#8212; The earlier formulations, based on formaldehyde (a\u000a      suspected carcinogen), have been\u000a      replaced by safer polyacrylic and later styrene-acrylic resins [7]. The\u000a      principal impact is on the\u000a      safety of Royal Mail workers who operate the barcoding printers where the\u000a      risk of exposure to the\u000a      wet inks is greatest. Other postal workers, such as postmen and women who\u000a      are exposed to the\u000a      cured inks throughout their daily employment, will not be subjected to\u000a      persistent formaldehyde\u000a      outgassing. Neither will the general public be exposed to formaldehyde.\u000a      Safety, of paramount\u000a      importance, is a significant impact that is directly related to the inks\u000a      developed through the\u000a      Lancaster University\/Royal Mail partnership.\u000a    EFFICIENCY &#8212; Royal Mail is characterised by its massive\u000a      daily throughput of letters and parcels\u000a      (typically 58 million items per day [8]). The logistics can only be\u000a      realised in a sensible and cost-effective\u000a      way through the extensive application of intelligent automation.\u000a      Fundamental to the\u000a      automation of postal delivery is the ability to assign each postal item\u000a      uniquely, and with sufficient\u000a      data to ensure accurate delivery to the intended destination. The DPMs, as\u000a      barcodes, are readable\u000a      by intelligent letter sorting machines. Prior to 2006, most mail was still\u000a      hand sorted, which is a\u000a      \"slow and cumbersome process\" [8]. Royal Mail introduced a major\u000a      modernisation programme in\u000a      2006-07, coincident with the updated coding ink formulation [7], [8].\u000a      During this modernisation\u000a      programme, 64 intelligent letter sorting machines were installed, each\u000a      capable of processing up to\u000a      40,000 items of mail per hour [7]. This has also led to the adoption of\u000a      Compact Sequence Sorters\u000a      that are \"walk-sequenced\", so that letters are ordered to minimise the\u000a      travel distance by postmen\u000a      and women. This now accounts for about 75% of all deliveries. This has the\u000a      direct impact of\u000a      reducing the workload of the delivery personnel, and thereby increasing\u000a      efficiency of the delivery\u000a      process. In turn, this efficiency improvement leads to a reduction in\u000a      cost. During the year 2011-12,\u000a      a total of 235 new, refurbished or upgraded process sequencing machines\u000a      were installed across\u000a      the UK Royal Mail network. The coding inks are pivotal to the IMPACT\u000a      achieved in terms of postal\u000a      delivery efficiency.\u000a    FINANCIAL &#8212; Royal Mail has been hit by a general decline in\u000a      mail volumes within the last decade\u000a      due to electronic substitution of paper communication (for example, Royal\u000a      Mail observed a 3.1%\u000a      pa decline in letter volumes between 2005 and 2008). For Royal Mail to\u000a      remain competitive\u000a      alongside the trend towards electronic communication, it has been\u000a      essential to enhance their\u000a      efficiency, as described above. This will continue to be an acute risk for\u000a      Royal Mail, as they predict\u000a      letters will decline 5% pa during the period 2013-18; and 4% pa during\u000a      2018-23 [9]. The UK market\u000a      present and predicted volumes are: 2012 (Letters 13.8 billion; Parcels 1.7\u000a      billion); 2023 (Letters 8.3\u000a      billion; Parcels 2.3 billion) [9]. Recent (2011) revenue figures for Royal\u000a      Mail are &#163;5.2 billion pa [8].\u000a      This is a significant business in its own right that is dependant for\u000a      efficiency upon the coded inks\u000a      developed from the expertise at the University of Lancaster. From a\u000a      societal standpoint, the\u000a      IMPACT is far greater, since the mail volume accounts for vital\u000a      communications within both the\u000a      domestic and business sectors, with a predicted volume in excess of 10\u000a      billion items pa up to\u000a      2023, even in the light of the trend towards electronic communication. The\u000a      recent flotation of Royal\u000a      Mail, the oversubscription of prospective shareholders, and the rapid\u000a      increase of share value by\u000a      48% [10] is clear evidence of a flourishing business with a strong future\u000a      prospect. The IMPACT of\u000a      the coding inks has played a significant part in the success of Royal Mail\u000a      through the facilitation of\u000a      considerable efficiency gains through intelligent automation. This is\u000a      IMPACT that is set to continue\u000a      to deliver for the foreseeable future [9].\u000a    With respect to corroboration, we quote below from a correspondence [11]\u000a      with Linda Swanson\u000a      who contributed to the fundamental research as a PhD student but then went\u000a      onto work for Royal\u000a      Mail and played a key role in embedding the printing inks science and\u000a      technology within Royal\u000a      Mail. She is therefore well placed to corroborate the implementation of\u000a      the technology within Royal\u000a      Mail.\u000a    `the most important and tangible output from this work is the red ink\u000a        which currently appears on letters\u000a        coded by Royal Mail &#8212; this was the ink that was designed and developed\u000a        at Lancaster during that\u000a        project.'\u000a    ","ImpactSummary":"\u000a    Fundamental research in collaboration with Royal\u000a      Mail into luminescence molecules constrained\u000a      within a water-soluble acrylic polymer matrix has\u000a      led to the development of novel, water-soluble, ink-jet\u000a      printable, luminescent inks. These inks are\u000a      employed by Royal Mail for printing coding patterns\u000a      on envelopes that can be read by automatic letter-sorting\u000a      machines. The inks offer excellent\u000a      performance in humid environments, on coloured\u000a      paper, and on paper containing optical brighteners,\u000a      and are safer. Royal Mail delivers, on average, 58 million letters each\u000a      day, representing annual\u000a      revenue of &#163;5.2 billion. The research at Lancaster enabling the innovation\u000a      has a direct impact on\u000a      the commercial performance of Royal Mail, the safety of its employees and\u000a      the public, and\u000a      everyone (commercially and\/or privately) using Royal Mail services to send\u000a      and receive mail\u000a      correctly, quickly, and at a low cost.\u000a    \u000a    \u000a    \u000a    ","ImpactType":"Economic","Institution":"\u000a    Lancaster University\u000a    ","Institutions":[{"AlternativeName":"Lancaster University","InstitutionName":"Lancaster University","PeerGroup":"B","Region":"North West","UKPRN":10007768}],"Panel":"B         ","PlaceName":[],"References":"\u000a    \u000a[1]. Ebdon J. R., Lane A. R., Lucas D. M., Soutar, I. and Swanson L.\u000a      (1995) Luminescence studies\u000a        of polymer matrices. 1. Phosphorescence of benzophenone dispersed in\u000a        poly(methyl\u000a        methacrylate), Polymer, 36, 1577-1584. DOI:\u000a      10.1016\/0032-3861(95)99002-C\u000a    \u000a\u000a[2]. Ebdon J. R., Hunt B. J., Lucas D. M., Soutar I., Swanson L. and Lane\u000a      A. L. (1995)\u000a      Luminescence studies of hydrophobically modified, water-soluble\u000a        polymers. 1. Fluorescence\u000a        anisotropy and spectroscopic investigations of the conformational\u000a        behaviour of copolymers of\u000a        acrylic acid and styrene and methyl methacrylate, Canadian Journal\u000a      of Chemistry, 73, 1982-1994.\u000a      DOI: 10.1139\/v95-245\u000a    \u000a\u000a[3]. Ebdon J. R., Soutar I., Brown P., McCabe A. J., Lane A. R. and\u000a      Swanson L. (1999)\u000a      Luminescence studies of polymer matrices: 2. On the phosphorescence\u000a        characteristics of 2-benzoyl\u000a        naphthalene dispersed in various acrylic polymers, High Perf.\u000a      Polym., 11, 49-62. DOI:\u000a      10.1088\/0954-0083\/11\/1\/005\u000a    \u000a\u000a[4]. Ebdon J. R., Soutar I., Brown P., McCabe A. J., Lane A. R. and\u000a      Swanson L. (1999)\u000a      Luminescence studies of polymer matrices: III. Characterization and\u000a        evaluation of acrylic acid\u000a        based polymers as hosts for a phosphorescent coding system, J.\u000a      Polym. Sci. B. Polym. Phys. Ed.,\u000a      37, 2127-2136. DOI: 10.1002\/(SICI)1099-0488(19990815)37:16\u000a    \u000a\u000a[5]. Ebdon J. R., Lane A. R., Lucas D. M., Soutar I. and Swanson L.\u000a      (1999) Luminescence studies\u000a        of polymer matrices. 4. Phosphorescence of benzophenone dispersed in\u000a        acrylic acid based\u000a        polymer films, High Perf. Polym., 11, 331-341. DOI:\u000a      10.1088\/0954-0083\/11\/3\/308\u000a    \u000a[6]. Brown P. R., Hewison S., Kondratowicz A., Metson C. A. L., Rock J.\u000a      and Scott R. (1998)\u000a      Patents WO19980003596 and EP 0914392B, assigned to the Post Office.\u000a    ","ResearchSubjectAreas":[{"Level1":"3","Level2":"6","Subject":"Physical Chemistry (incl. Structural)"},{"Level1":"3","Level2":"3","Subject":"Macromolecular and Materials Chemistry"},{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"}],"Sources":"\u000a    [7]. GB 2412659 B, 2005, assigned to the Royal Mail\u000a    [8]. Royal Mail Holdings plc, Annual Report and Financial Statements,\u000a      2011-2012.\u000a    [9]. PwC Strategy &amp; Economics, \"The outlook for UK mail volumes to\u000a      2023\", PWC July 2013.\u000a    [10]. http:\/\/www.thisismoney.co.uk\/money\/news\/article-2458523\/Royal-Mail-shares-surge-stand-48-float-price.html\u000a      [accessed 5 Nov 2013]\u000a    [11] Correspondence with respect to the project from a former Royal Mail\u000a      employee associated with\u000a      embedding Lancaster's research within Royal Mail.\u000a    Contact 1: Royal Mail Group Dangerous Goods Advisor, Royal Mail\u000a      Engineering &#8212; can corroborate\u000a      implementation of printing inks technology within Royal Mail\u000a    Contact 2: Former Royal Mail employee (now at Sheffield\u000a      University) &#8212; can corroborate the\u000a      implementation of the technology\u000a    ","Title":"\u000a    Luminescent inks for mail coding and sorting\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000a    In 1987, Dr A. R. \"Tim\" Lane, a Senior Scientist at the Royal Mail\u000a      Research Laboratories,\u000a      approached Dr John Ebdon, Senior Lecturer, Chemistry Department, Lancaster\u000a      University, for help\u000a      in improving the physical and chemical properties of ink-jet printable\u000a      inks used for printing\u000a      machine-readable patterns of dots (representing postal codes) on\u000a      envelopes, enabling the\u000a      envelopes to be automatically sorted. At the time, the inks already in use\u000a      for this purpose were\u000a      based on suspensions of relatively simple phosphors in aqueous solutions\u000a      of amino resins. These\u000a      inks were believed first to dry and then to cure (crosslink) when applied\u000a      to paper, providing a solid\u000a      hydrophobic medium in which phosphorescence could develop and be \"read\"\u000a      when the envelope\u000a      was passed under a UV lamp. There were three problems with the inks: (1)\u000a      the inks contained\u000a      small amounts of free formaldehyde (a suspected carcinogen); (2) they were\u000a      slow to dry\/cure,\u000a      leading to an unacceptable delay before the coding pattern could be read,\u000a      and (3) they performed\u000a      poorly in humid environments.\u000a    The academic outcomes of the project are described in five papers\u000a      published jointly by Royal Mail\u000a      and Lancaster University over the period 1995-1999 [1-5]. These\u000a      demonstrate: (1) that water-soluble\u000a      acrylic polymer solutions, e.g. aqueous solutions of polyacrylic and\u000a      polymethacrylic acids,\u000a      during the process of drying undergo a \"coil-collapse\" process whereby the\u000a      interiors of the polymer\u000a      coils become sufficiently hydrophobic to act as hosts for hydrophobic,\u000a      luminescent materials\u000a      (guests); (2) that in these collapsed coils, luminescence of the guest can\u000a      occur without significant\u000a      quenching, even before the solution has fully dried; (3) that the onset of\u000a      coil-collapse is influenced\u000a      by temperature and pH; and (4) that the hydrophobicity of the collapsed\u000a      coil can be increased by\u000a      the incorporation of small amounts of a hydrophobic monomer, such as\u000a      styrene or methyl\u000a      methacrylate. A further outcome, not published at the time owing to\u000a      commercial sensitivity, was the\u000a      demonstration that a bi-component luminescent system in a polymer matrix,\u000a      in which energy\u000a      transfer to a fluorescent compound occurs, could be used to give long-lived\u000a        red luminescence.\u000a    The fundamental research on the behaviours of water-based polymer systems\u000a      carried out at\u000a      Lancaster, and the more applied aspects researched jointly by Lancaster\u000a      and Royal Mail, led to the\u000a      patenting of polyacrylic acid binders together with various combinations\u000a      of luminescent compounds\u000a      for use in mail coding inks, by Royal Mail in 1998 [6]. These patents\u000a      refer to the environmental\u000a      hazards posed by the earlier amino resin binders and for the desirability\u000a      that the ink should contain\u000a      a long-lived red emitter so as to allow signals to be read (a)\u000a      irrespective of the substrate colour, (b)\u000a      in the presence of a fluorescence background from any optical brighteners\u000a      in the envelope paper,\u000a      and (c) throughout the period during which the coding ink is drying. The\u000a      use of energy transfer to\u000a      achieve long-lived (&gt;500 ms) luminescence is also disclosed.\u000a    "},{"CaseStudyId":"43614","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"798544","Name":"Poland"},{"GeoNamesId":"3017382","Name":"France"},{"GeoNamesId":"3562981","Name":"Cuba"},{"GeoNamesId":"3175395","Name":"Italy"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Natural Environment Research Council"],"ImpactDetails":"\u000a    The University of Leicester aligned its research strengths in atmospheric\u000a      chemistry and earth observation science with emerging economic development\u000a      objectives in Europe and the East Midlands Region. These objectives were\u000a      advanced by promoting the use of satellite data by businesses. The\u000a      partnership of the University of Leicester, European Regional Development\u000a      Fund (ERDF) and East Midlands Development Agency jointly funded a business\u000a      support offer, Global Monitoring for Environment and Security Space\u000a      Technology Exchange Partnership (G-STEP).\u000a    G-STEP is the UK's only academic-business partnership specifically set-up\u000a      to exploit GMES &amp; Copernicus space data and services. It provides a\u000a      shop front to exploit the research of the university in this field. It has\u000a      been at the forefront of heralding the emerging market opportunity in the\u000a      exploitation of satellite-derive data to create new products and services\u000a      leading to business growth and value added.\u000a    The delivery of G-Step has been managed by University of Leicester under\u000a      the direction of Professor Paul Monks. The project has led to a number of\u000a      impacts.\u000a    A) Economic Impact on the Region's Small &amp; Medium Enterprises\u000a        (SMEs)\u000a      The economic impacts have largely been in the growth of the awareness of\u000a      the opportunity provided by satellite data . The project has informed the\u000a      work of 500 hundred businesses and 20 Local Authorities in the UK and\u000a      internationally and has directly supported 40 East Midlands companies\u000a      through its targeted interventions. The development of new\u000a      products\/services and the training of businesses in the use of EO and GIS\u000a      products have led to a net GVA increase within those 40 companies of &#163;950K\u000a      over 4 years. It has further generated &#163;2.9M in investment in the East\u000a      Midlands regional economy (A). Twenty University of Leicester\u000a      graduates have been employed in East Midlands companies where their skills\u000a      and knowledge in this area are put to good use. G-STEP has also assisted\u000a      with the creation of three new businesses, all SMEs working in the area of\u000a      remote sensing.\u000a    B) Policy Impact\u000a      The success of G-STEP has been significant in the identification of\u000a      upstream and downstream Space technologies as a targeted growth sector by\u000a      the Leicester &amp; Leicestershire Local Economic Partnership within its\u000a      strategic economic growth plan for the region (F).\u000a    On a national level, the Government has invested in 7 Catapult\u000a      organisations which aim to exploit areas of technology in which Britain\u000a      has a potential world leading position. The emerging Satellite\u000a      Applications Catapult has reviewed the G-STEP model of SME engagement and\u000a      will use the model to shape its own SME engagement process.\u000a    In Transport Policy, G-STEP has developed two major projects which are\u000a      directly influencing local and regional policy. ITRAQ was an ESA-funded\u000a      collaborative programme (2011-12) which had the former Transport Research\u000a      Laboratory (TRL) as its commercial prime and three local authorities\u000a      involved in the initial system implementation (C). ITRAQ employed\u000a      novel space and ICT solutions to develop active traffic management systems\u000a      that balance the need to reduce congestion with the requirement to improve\u000a      air quality. As air quality becomes an increasingly important issue for\u000a      local authorities worldwide, the product developed as a result of research\u000a      by Monks\/Leigh (UoL) in partnership with De Montfort University and\u000a      marketed by TRL, is expected to have a global market of &#163; several\u000a      millions.\u000a    THE-ISSUE (2011-14, D) is a project for co-ordination and\u000a      exploitation of Research, Technology, Development and Innovation (RTDI) in\u000a      areas related to Traffic, Health and the Environment. The project is led\u000a      from G-STEP with French, Italian and Polish partners, who together support\u000a      over 100 RTD projects (42 in the East Midlands) that use some degree of\u000a      ICT, satellite-derived spatial data infrastructure (SDI) or location and\u000a      timing services from satellites for transport applications in: intelligent\u000a      transport systems; traffic management; intermodal solutions for public\u000a      transport and citizens; freight logistics; and air quality management.\u000a    At an international level, G-STEP has been leading the NEREUS (Network of\u000a      Regions in Europe Using Space) EO\/GMES working group and produced the \"The\u000a      Growing Use of Space Across Europe\" document that was launched at the\u000a      European parliament in October 2012 [B].\u000a    C) Environmental Products\u000a      G-STEP has worked with Havana Energy (a British power-generating company,\u000a      E) and the Cuban Government to develop an `energy map' of several\u000a      regions in Cuba. The work shows the amount of biomass available for use as\u000a      a renewable energy source. Exploiting satellite-derived data to estimate\u000a      the amount of biomass available allows Cuba to plan for the exploitation\u000a      of its own natural resources to meet energy needs. An ancillary output of\u000a      the project is to identify and manage unwanted non-productive invasive\u000a      species of plant which will be replaced by sugar crops. The project is\u000a      funded entirely by Havana Energy. The Cuban Government is delivering\u000a      policy change in agriculture using this product.\u000a    The UK potato and sugar beet industries are worth over &#163;1bn per year.\u000a      HIVACROM (High Value Crop Monitoring, 2012-13) is a TSB-funded partnership\u000a      between G-STEP (Remedios\/Monks; G) and CGI IT UK Ltd which\u000a      developed a proof of concept for a near-real-time, dynamic integrated crop\u000a      monitoring service derived from Earth Observation data which is now\u000a      commercially available.\u000a    ","ImpactSummary":"\u000a    University of Leicester research has developed, with funding from the\u000a      European Regional Development Fund, a business support offer, Global\u000a      Monitoring for Environment and Security (GMES) Space Technology Exchange\u000a      Partnership (G-STEP) &#8212; which has led to a number of impacts:\u000a    Economic impacts via direct support of 40 East Midlands companies,\u000a      including the creation of 3 new businesses, with a &#163;950K GVA (Gross Value\u000a      Added) to the companies and &#163;2.9M in investment in the East Midlands. It\u000a      has led to the employment of 20 Leicester graduates. Policy impacts\u000a      via the Local Economic Partnership which has identified space as one of\u000a      three emerging sectors for focussed development. Nationally, the emerging\u000a      Satellite Applications Catapult has reviewed the G-Step delivery model to\u000a      inform its own operation. Internationally, G-STEP led the NEREUS (Network\u000a      of Regions in Europe Using Space) Earth Observation\/GMES working group and\u000a      produced the \"The Growing Use of Space Across Europe\", launched at the\u000a      European Parliament in 2012.\u000a    Environmental benefits via the development of products which are\u000a      having a positive impact on the environment including satellite enabled\u000a      traffic management tools and high value crop management.\u000a    ","ImpactType":"Economic","Institution":"\u000a    University of Leicester\u000a    ","Institutions":[{"AlternativeName":"Leicester (University of)","InstitutionName":"University of Leicester","PeerGroup":"A","Region":"East Midlands","UKPRN":10007796}],"Panel":"B         ","PlaceName":[{"GeoNamesId":"3553478","Name":"La Habana"}],"References":"\u000a    \u000a1. Monks PS, Beirle S (2011) Applications of Satellite\u000a      Observations of Tropospheric Composition. In: Burrows JP, Platt U, Borrell\u000a      P (eds) Remote Sensing of Tropospheric Composition from Space. Physics of\u000a      Earth and Space Environments. Springer-Verlag Berlin, Berlin, pp 365-449.\u000a      doi:10.1007\/978-3-642-14791-3_8. The development and delivery of this book\u000a      chapter was supported by the EU FPVI ACCENT program &#163;216,000 to University\u000a      of Leicester.\u000a    \u000a\u000a2. Whyte C, Leigh RJ, Lobb D, Williams T, Remedios JJ, Cutter M,\u000a      Monks PS (2009) Assessment of the performance of a compact\u000a      concentric spectrometer system for Atmospheric Differential Optical\u000a      Absorption Spectroscopy. Atmos Meas Tech 2:789-800. Work supported by\u000a      Centre for Earth Observation Instrumentation grant from NERC and DIUS (now\u000a      BIS) for &#163;120,000.\u000a    \u000a\u000a3. Palmer PI, Barkley MP, Monks PS (2008) Interpreting the\u000a      variability of space-borne CO2 column-averaged volume mixing\u000a      ratios over North America using a chemistry transport model. Atmos Chem\u000a      Phys 8 (19):5855-5868. Work originally supported by NERC Centre of\u000a      Excellence grant from CASIX (Centre for Air-Sea exchange) ca. &#163;70,000\u000a      Cited 8 times (ISI 17th Sept 2013).\u000a    \u000a\u000a4. Kramer LJ, Leigh RJ, Remedios JJ, Monks PS (2008)\u000a      Comparison of OMI and ground-based in situ and MAX-DOAS measurements of\u000a      tropospheric nitrogen dioxide in an urban area. J Geophys Res-Atmos 113\u000a      (D16):-. doi:Artn D16s39. Work supported by NERC funding. Cited 20 times\u000a      (ISI 17th Sept 2013).\u000a    \u000a\u000a5. Wilson RC, Fleming ZL, Monks PS, Clain G, Henne S, Konovalov\u000a      IB, Szopa S, Menut L, Have primary emission reduction measures reduced\u000a      ozone across Europe? An analysis of European rural background ozone trends\u000a      1996-2005 Atmos. Chem. Phys., 12, 437-454, 2012. Supported by the\u000a      EU FPV GeoMON program &#163;130,000 to the University of Leicester. Cited 12\u000a      times (ISI, 17th Sept 2013).\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"5","Level2":"2","Subject":"Environmental Science and Management"},{"Level1":"9","Level2":"7","Subject":"Environmental Engineering"},{"Level1":"9","Level2":"14","Subject":"Resources Engineering and Extractive Metallurgy"}],"Sources":"\u000a    A. Third Party Audits &#8212; Verification of G-STEP impacts are\u000a      available through ERDF A13\/A16 audits and final audited report for\u000a      G-STEP1. These provide third party assurance and measure of economic\u000a      outputs and results.\u000a    B. Output from NEREUS (Networks of Regions of Europe Using Space) RTD\u000a        Audit across Europe &#8212; G-STEP &#8212; The Growing Uses of Space across\u000a      Europe\u000a\u0009  http:\/\/esamultimedia.esa.int\/multimedia\/publications\/NEREUS\/\u000a      Major European synthesis of activity led by G-STEP that also details\u000a      G-STEPs reach and impact.\u000a    C. Outputs on Intelligent Traffic Management &#8212; I-Traq, Traffic\u000a      Technology International August\/September 2012, p18. (www.TrafficTechnologyToday.com).\u000a      Full details and final reports from ESA IAP website http:\/\/iap.esa.int\/projects\/transport\/itraq\u000a    D. http:\/\/www.theissue.eu\/\u000a    E. Testimonials &#8212; Testimonials available from customers:\u000a    \u000a      Operations Director, Bluesky International\u000a      Director, Rockkitchenharris\u000a      Agricultural Advisor, Havana Energy\u000a      Environmental Consultant\u000a    \u000a    F. Regional Economic Plan &#8212; LLEP (Leicester and Leicestershire\u000a      Economic Partnership) Economic Growth Plan 2012-2020\u000a      http:\/\/www.llep.org.uk\/index\/downloads\/filename\/img_1343645215_1755.pdf\/catid\/22\/filetitle\/economic-growth-plan.pdf\u000a    G. Grant Support to G-STEP &#8212; Prof. Paul Monks, Prof. John\u000a      Remedios &amp; Prof. Heiko Balzter, G-STEP (GMES Space Technology Exchange\u000a      Programme), East Midlands Development Agency &amp; ERDF, Apr 2009- Mar\u000a      2013, &#163; 1,860,00+&#163;260,515. Follow on program G-STEP2 ERDF - &#163; 679,158 \u000a    ","Title":"\u000a    Supporting regional businesses to use satellite derived data\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000a    Since 1992, the research that underpins G-STEP has been developed by the\u000a      Earth Observation Science (EOS) group at the University of Leicester.\u000a      G-STEP is based in chemistry and its director is from Chemistry (Monks).\u000a      EOS is a multi-disciplinary group, initially founded through a joint\u000a      University\/national (NERC) initiative that has matured into\u000a      internationally leading research making substantial contributions to\u000a      research science, government policy, industrial activity and education of\u000a      the public. The group undertakes fundamental and leading research in\u000a      applied physics, chemistry and geography as well as developing\u000a      technological innovation through the design and production of satellite\u000a      instruments for observing the Earth mainly with funding from NERC, ESA and\u000a      industry. The group exploits EO data for climate change studies, air\u000a      quality, environmental monitoring and mapping applications with everyday\u000a      impact [1]. The quality of the science is evidenced by leading positions\u000a      on international science teams, data exploitation and EC services. The\u000a      major EOS research themes are a) Air Quality (led by Monks\u000a      (Chemistry, 1996- present) with Leigh (Chemistry, 2010- present),\u000a      b) Climate Change (led by Remedios (Physics and Astronomy, 2000 - present)\u000a      c) Land-surface change (led by Baltzer (Geography, 2006 - present) and d)\u000a      Space Technology (led by Monks (Chemistry).\u000a    G-STEP draws from a portfolio of research translating a wide knowledge\u000a      base into industrial impact, within which a key driver is responding to\u000a      company needs and problems, thus making it demand rather than supply led.\u000a      Research that has been translated in G-STEP includes work by Monks\u000a      and Leigh who have developed new technology and measurements from\u000a      space [2, 3], ground [4] and aircraft for validating emissions of criteria\u000a      air pollutants, in particular nitrogen dioxide. Air quality work has\u000a      focussed on quantifying oxidative capacity change in urban and rural\u000a      environments over the last decade [5]. Results have shown that the\u000a      effectiveness of air quality reductions in ozone precursors is being\u000a      masked by a combination of meteorological variability and change in\u000a      background conditions [5]. The work on Air Quality detection and\u000a      attribution [2, 4] is the basis for the intelligent traffic management\u000a      system described latterly. The greenhouse-gas (GHG) from space work [3]\u000a      has quantified regional GHG budgets, and has latterly been translated into\u000a      the policy arena, as has the ozone work [5].\u000a    "},{"CaseStudyId":"43927","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"660013","Name":"Finland"},{"GeoNamesId":"1814991","Name":"China"},{"GeoNamesId":"3077311","Name":"Czech Republic"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"3017382","Name":"France"},{"GeoNamesId":"2661886","Name":"Sweden"}],"Funders":["Engineering and Physical Sciences Research Council","Natural Environment Research Council"],"ImpactDetails":"\u000d\u000a    Research within the Unit principally impacts on national and\u000d\u000a      international policy in respect of safe disposal of radioactive wastes, a\u000d\u000a      problem whose long term global significance cannot be overstated. The\u000d\u000a      scope of expertise within the Radiochemistry Research Group at\u000d\u000a      Loughborough University has ensured that the reach of the impact spans a\u000d\u000a      range of different aspects with international dimension. Examples from\u000d\u000a      four areas are given below, dealing with in turn: design of deep\u000d\u000a      geological repositories for nuclear wastes, the effect of organic matter\u000d\u000a      on radionuclide speciation-solubility, marine discharges, and management\u000d\u000a      of non-nuclear sources of radioactive materials (NORM). Examples from the\u000d\u000a      first three areas contribute to the broader remit of safeguarding the\u000d\u000a      environment, while the final studies show how the Unit has shaped policy.\u000d\u000a    &#8226;Safeguarding the Environment\u000d\u000a    Concerns regarding the efficacy of cement as a backfill for conditioning\u000d\u000a      radionuclides as low solubility, immobile species originally led to an\u000d\u000a      avoidance strategy being implemented in nuclear disposal programmes, for\u000d\u000a      example in Finland and Sweden. Although excluding cement entirely is\u000d\u000a      impossible with a deep geological repository, the apparent dichotomy\u000d\u000a      between approaches in national programmes has been exploited by opponents\u000d\u000a      of nuclear waste disposal (and hence new build) to illustrate the\u000d\u000a      uncertainties in process understanding and supporting technologies.\u000d\u000a      Research carried out at Loughborough University has helped reduce the\u000d\u000a      uncertainty by highlighting where cements can fulfil their design function\u000d\u000a      and where components of the system require modification. Specifically, it\u000d\u000a      has been shown that the presence of organic complexants, either natural\u000d\u000a      (humic\/fulvic acids) [3.3] or anthropogenic [3.2]\u000d\u000a      (cellulose degradation products, superplasticisers) can enhance the\u000d\u000a      mobility of otherwise immobile species. Conversely, species that are\u000d\u000a      routinely treated as unretarded through engineered barriers and host rocks\u000d\u000a      in safety case analyses (e.g. technetium, iodine) have been shown to bind\u000d\u000a      effectively to mineral phases; i.e. existing models are overly\u000d\u000a      conservative. Evidence that these findings impact on future programmes\u000d\u000a        can be found in revised research and implementation programmes, for\u000d\u000a      example consideration of alternative backfill materials (e.g.\u000d\u000a      phosphate-amended cement in the Waste Isolation Pilot Plant, USA;\u000d\u000a      prohibition of superplasticisers in Finland) and manufacture of modified\u000d\u000a      superplasticisers by UK industry (Grace Chemicals). Radio-labelled NOM has\u000d\u000a      been utilised by Loughborough researchers to investigate contaminant\u000d\u000a      transport through a sandy aquifer at the Drigg repository, Cumbria and\u000d\u000a      through the Boom Clay at Mol, Belgium. These studies were used to\u000d\u000a        estimate the importance of organic complexing ligands in facilitating\u000d\u000a        the migration of uranium and plutonium, being cited in Post Closure\u000d\u000a        Safety Cases for each site [5.1], [5.2].\u000d\u000a    David Read, Professor of Radiochemistry at Loughborough University was\u000d\u000a      one of three independent scientists asked to assess the feasibility of\u000d\u000a      technetium abatement technologies on behalf of the Environment Agency.\u000d\u000a      Following acceptance by British Nuclear Fuels Limited of recommendations\u000d\u000a      made by Loughborough University researchers regarding the use of\u000d\u000a      tetraphenylphosphonium bromide (TPPB) as a technetium sequestering agent,\u000d\u000a        a &#163;100m treatment plant was commissioned and discharges of 99Tc\u000a        to the Irish Sea are now reduced by 90% compared to previous levels\u000d\u000a      [5.3]. The corollary was accumulation of a new waste-form\u000d\u000a      whose long-term behaviour when encapsulated in cement was unknown.\u000d\u000a      Fundamental research, commissioned at Loughborough (2004-2011) has\u000d\u000a      established the stability of this waste and shed light on its potential\u000d\u000a      behaviour in the geosphere [3.4, 3.5, 5.4].\u000d\u000a    &#8226; Shaping Policy\u000d\u000a    An enormous volume of radioactive waste is created each year by the\u000d\u000a      production and combustion of fossil fuels and exploitation of industrial\u000d\u000a      minerals. Gross under-estimation of the problem by both industry and\u000d\u000a      Government became apparent during revision of the Environmental Permitting\u000d\u000a      Regulations (EPR) from 2009 onwards. The financial implications of\u000d\u000a      choosing a particular threshold for regulation and clearance of\u000d\u000a      radioactively-contaminated land are enormous and, inevitably, a compromise\u000d\u000a      needs to be reached between the level of environmental protection sought\u000d\u000a      and the finite resources available for remediation. Early drafts of the\u000d\u000a      EPR not only omitted key NORM-producing industries but miscalculated the\u000d\u000a      effect of aggregating progeny radionuclides from the two main natural\u000d\u000a      decay chains (238U and 232Th). The consequence was\u000d\u000a      overly restrictive limits that would have driven many businesses overseas.\u000d\u000a      Input by Loughborough University researchers to consultation documents\u000d\u000a        led to a much improved legislative framework (EPR 2011) [5.5]. The\u000d\u000a      intervention during the formulation of this framework prevented highly\u000d\u000a      damaging changes to Exemption Orders that would have made production of inter\u000a        alia advanced TiO2 and Zr coatings in the UK non-viable.\u000d\u000a      Similar considerations apply to the China Clay industry of SW England\u000d\u000a      where successful remediation of NORM contamination is allowing\u000d\u000a      regeneration of 700ha brownfield land under the Government's EcoTown\u000d\u000a      initiative. This has also impacted European policy; it is noted that China\u000d\u000a      Clay for example, which is also produced in France and the Czech Republic\u000d\u000a      is still not included in the current version of the Basic Safety Standards\u000d\u000a      (EC COM 2012, IAEA 2011) but will be in the next revision following its\u000d\u000a      adoption in the UK. A Loughborough spin-in company (Enviras Limited) was\u000d\u000a      launched in 2011; sited on campus it provides high quality UKAS accredited\u000d\u000a      radiochemical analysis specifically for supporting the remediation of\u000d\u000a      radioactively contaminated land. [5.6]\u000d\u000a    &#8226; Training the Next Generation of Nuclear Specialists\u000d\u000a    The third aspect of the Unit's impact stems from its ability to deliver a\u000d\u000a      strong grounding in radiochemical work for a large number of students both\u000d\u000a      at Undergraduate (e.g. via the 2nd and 3rd year\u000d\u000a      modules \"Radiochemistry\" and \"Physical and Radiochemistry\" respectively)\u000d\u000a      and Postdoctoral levels. Such training has impacted significantly on the\u000d\u000a      effectiveness of bodies such as the Nuclear Decommissioning Authority who\u000d\u000a      currently employ undergraduate and doctoral graduates from the Unit in a\u000d\u000a      range of senior positions. Many other organisations whose activities hinge\u000d\u000a      on radiochemical expertise have employed undergraduate and postgraduate\u000d\u000a      students who have benefited from the research environment in the Unit,\u000d\u000a      through their doctoral work (with17 students engaged in PhD work during\u000d\u000a      the REF period) and undergraduate\/MSc research projects etc.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Research at Loughborough University during the REF period (and extending\u000d\u000a      back at least three decades beyond that) has had a significant impact on\u000d\u000a      national and international policy decisions governing the management of\u000d\u000a      radioactive waste, one of the Grand Challenges facing society. The Unit's\u000d\u000a      research ranges from deep geological disposal to abatement of marine\u000d\u000a      discharges and remediation strategies for industrial radioactive waste,\u000d\u000a      the latter safeguarding the competitiveness of the oil &amp; gas and\u000d\u000a      mineral processing sectors. This input has been crucial for revising the\u000d\u000a      new Environmental Permitting Regulations and International Basic Safety\u000d\u000a      Standards. Many of the Unit's doctoral graduates occupy important\u000d\u000a      decision-making roles at key organisations such as the Nuclear\u000d\u000a      Decommissioning Authority (NDA), Sellafield, Environment Agency, CEA\u000d\u000a      (France) and the International Atomic Energy Agency (IAEA).\u000d\u000a    ","ImpactType":"Political","Institution":"\u000d\u000a    Loughborough University\u000d\u000a    ","Institutions":[{"AlternativeName":"Loughborough University","InstitutionName":"Loughborough University","PeerGroup":"B","Region":"East Midlands","UKPRN":10004113}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    The following publications appear in peer reviewed journals; the journals\u000d\u000a      in question are key international output mechanisms for the radiochemistry\u000d\u000a      discipline in general, covering as they do a range of areas including\u000d\u000a      geochemistry, nuclear science, environmental toxicology and radiological\u000d\u000a      protection.\u000d\u000a    \u000a3.1. M. Felipe-Sotelo, J. Hinchliff, N. Evans, P. Warwick\u000d\u000a      and D. Read. Sorption of radionuclides to a cementitious backfill under\u000d\u000a      near-field conditions.\" Min Mag. 501: 3401-3410 (2012).\u000d\u000a      http:\/\/dx.doi.org\/10.1180\/minmag.2012.076.8.53\u000d\u000a    \u000a\u000a3.2. A. Young, P. Warwick, A. Milodowski and D. Read. \"Behaviour of\u000d\u000a      radionuclides in the presence of superplasticiser.\" Adv. Cem. Res.\u000d\u000a      25: 32-43 (2013).\u000d\u000a      http:\/\/dx.doi.org\/10.1680\/adcr.12.00032\u000d\u000a    \u000a\u000a3.3. N. Maes, L. Wang, T. Hicks, D. Bennett, P. Warwick, A. Hall, G.\u000d\u000a        Walker and A. Dierckx 2006. The role of natural organic matter in the\u000d\u000a        migration behaviour of americium in the Boom Clay &#8212; Part I: Migration\u000d\u000a        experiments. Physics and Chemistry of the Earth 31,\u000a        541-547 (2006).\u000d\u000a        http:\/\/dx.doi.org\/10.1016\/j.pce.2006.04.006\u000d\u000a    \u000a\u000a3.4. P. Warwick, S. Aldridge, N. Evans and S. Vines, The Solubility of\u000d\u000a      Technetium(IV) at High pH. Radiochim Acta 95, 709-716\u000d\u000a      (2007). DOI: 10.1524\/ract.2007.95.12.709\u000d\u000a    \u000a\u000a3.5. S. Aldridge, P. Warwick, N., Evans and S. Vines. Degradation of\u000d\u000a        tetraphenylphosphonium bromide at high pH and its effect on radionuclide\u000d\u000a        solubility. Chemosphere, 66, 672-676 (2007).\u000d\u000a        http:\/\/dx.doi.org\/10.1016\/j.chemosphere.2006.07.088\u000d\u000a    \u000a\u000a3.6. D Read, G.D. Read and M. Thorne. Background in the context of\u000d\u000a        land contaminated with naturally occurring radioactive material. J.\u000a          Rad. Prot. 33: 367-380 (2013). Doi:\u000d\u000a        10.1088\/0952-4746\/33\/2\/367\u000d\u000a    \u000aMajor grants supporting this work include (since 2000):\u000d\u000a    - Migration case study: Transport of radionuclides in a reducing clay\u000d\u000a      sediment (EC ,2000, PW) &#163;135,000\u000d\u000a    - Measurements of radionuclides in decommissioning wastes (Berkeley Tech\u000d\u000a      Cent .2000, PW) R63,584\u000d\u000a    - Further development of STAB (NIREX, 2000, PW) &#163; 62,993; FUNMIG\u000d\u000a      (EU, 2005, PW) &#163;240,864\u000d\u000a    - Analytical development (Magnox, 2006, PW) &#163;85,000\u000d\u000a    - The Chemistry of Technetium with Reference to Geological Disposal)\u000d\u000a      (NNL, 2007, PW) &#163;78,000\u000d\u000a    - Demonstration experiments for chemical containment (NDA, 2008, DR)\u000d\u000a      &#163;429,152\u000d\u000a    - Radionuclide Transport in the Environment (Sellafield, 2008, PW)\u000d\u000a      - &#163;51,000\u000d\u000a    - DIAMOND Superplasticiser Project (EPSRC, 2008 &#8212; DR) &#163;78,429;\u000d\u000a    - Surface modified materials for radionuclide sequestration (NDA, 2011, DR)\u000d\u000a      &#163;80,000;\u000d\u000a    - Migration of radon, 14CO 2 and CH4 through\u000d\u000a      partially saturated media (MEC 2012, DR) &#163;60,000;\u000d\u000a    - Radioactivity in the iron and steel industry (Tata Steel, 2012 DR)\u000d\u000a      &#163;35,000;\u000d\u000a    - NORM in onshore oil &amp; gas production (Aurora Health Physics, 2011 DR)\u000d\u000a      &#163;42,000;\u000d\u000a    - Superplasticisers for applications in nuclear decommissioning and\u000d\u000a      storage (NDA, 2012 DR)\u000d\u000a    - &#163;78,998. Cooperation in education and training In Nuclear Chemistry (EU\u000d\u000a      FP7, 2013 &#8212; DR\/NE) &#163;106,532.\u000d\u000a    - BIGRAD (NERC, 2009 &#8212; NE) &#163;318,354;\u000d\u000a    - SAMPL (NDA, 2010 &#8212; NE) &#163;75,789;\u000d\u000a    - SKIN (EU FP7, 2010 &#8212; NE) &#163;105,814;\u000d\u000a    - AMASS (EPSRC , 2011 &#8212; NE) &#8212; &#163;104,669;\u000d\u000a    - The Impacts of Aqueous Phase Degradation Products from PVC Additives on\u000d\u000a      Radioactive Waste Management (AMEC, 2013 &#8212; NE) &#8212; &#163;45,000;\u000d\u000a    - Decommissioning, Immobilisation and Storage solutions for Nuclear waste\u000d\u000a      inventories) (EPSRC ,2013 &#8212; NE) &#163;352,124;\u000d\u000a    - Long-lived Radionuclides in the Surface Environment (NERC, 2013 &#8212; NE)\u000d\u000a      &#163;406,065\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"9","Level2":"14","Subject":"Resources Engineering and Extractive Metallurgy"},{"Level1":"3","Level2":"1","Subject":"Analytical Chemistry"},{"Level1":"9","Level2":"7","Subject":"Environmental Engineering"}],"Sources":"\u000d\u000a    5.1 \"The 2011 Environmental Saftey Case Near Field\", LLW Repository\u000d\u000a      Limited, LLWR\/ESC\/R(11) 10021 (2011)\u000d\u000a    5.2 \"Review of sorption values for the cementitious near field of a near\u000d\u000a      surface radioactive waste disposal facility; Project near surface disposal\u000d\u000a      of category A waste at Dessel\", NIRAS-MP5-03 DATA-LT(NF), Version 1\u000d\u000a      (2009).\u000d\u000a    5.3 \"An assessment of the availability of Tc-99 to marine foodstuffs from\u000d\u000a      contaminated sediments\", The Centre for Environment, Fisheries and\u000d\u000a      Aquaculture Science, Environment Report RL 09\/08, (2008).\u000d\u000a    [Text removed for publication]\u000d\u000a    5.5 ENVIRONMENTAL PROTECTION, ENGLAND AND WALES;The Environmental\u000d\u000a      Permitting (England and Wales) (Amendment) Regulations 2011.\u000d\u000a    5.6 http:\/\/www.enviras.co.uk\/Recent_Projects.html\u000d\u000a    ","Title":"\u000d\u000a    Radiochemistry at Loughborough: Safeguarding the Environment, Shaping\u000d\u000a        Policy, Training the Next Generation of Nuclear Specialists\u000d\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    The technical prowess and accumulated experience of the radiochemistry\u000d\u000a      group at Loughborough University makes them one of the very few UK centres\u000d\u000a      capable of addressing all aspects of the fundamental research required to\u000d\u000a      direct policy on radioactive waste management. This high level of\u000d\u000a      technical competence is crucial, as any safety case for the disposal of\u000d\u000a      nuclear wastes must be supported by defensible scientific data and\u000d\u000a      principles. In the context of a geological nuclear waste repository,\u000d\u000a      essential components concern the solubility, speciation and retardation of\u000d\u000a      key radionuclides in groundwaters and barrier materials (e.g. cement),\u000d\u000a      since these affect their migration through the terrestrial environment.\u000d\u000a      Loughborough University researchers have played a major role in carrying\u000d\u000a      out research into these essential areas. Thus, following the failure of\u000d\u000a      the nuclear industry body, Nirex, to gain approval for a deep facility at\u000d\u000a      Sellafield, Loughborough University was entrusted with\u000d\u000a      reducing the key uncertainties via a series of projects (2008-2014)\u000d\u000a      supported by the NDA, EPSRC and EU. The output from this ongoing work\u000d\u000a      [3.1, 3.2] continues to determine whether porous cement could\u000d\u000a      be a viable backfill material for this type of waste. Evidence to date has\u000d\u000a      already underpinned policy changes and the reconsideration of current\u000d\u000a      practices. Loughborough University researchers have made substantial\u000d\u000a      contributions in formulating pan-European thermodynamic models of waste\u000d\u000a      disposal systems. Building on the original CHEMVAL geochemical modelling\u000d\u000a      projects, which set standards for numerical approaches, our most\u000d\u000a      significant contribution has been the development of methods for\u000d\u000a      radio-labelling natural organic matter (NOM) and associated thermodynamic\u000d\u000a      models [3.3].\u000d\u000a    Until 2002, Sellafield discharged large volumes of technetium (as 99Tc)\u000a      into the Irish Sea, the isotope subsequently appearing in marine biota,\u000d\u000a      notably Norwegian lobsters. Such was the environmental concern that an\u000d\u000a      important contract to install a natural gas pipeline from Norway to the UK\u000d\u000a      was placed in jeopardy. Loughborough University researchers played a\u000d\u000a      crucial role in assessing the behaviour of the chosen Tc sequestrant,\u000d\u000a      tetraphenylphosphonium bromide (TPPB), and its long-term stability when\u000d\u000a      encapsulated in a cementitious waste form [3.4, 3.5].\u000d\u000a      Large volumes of radioactive waste (NORM) are created each year by the use\u000d\u000a      of fossil fuels and exploitation of industrial minerals. Research at\u000d\u000a      Loughborough University into scale formation coupled with strategies for\u000d\u000a      inhibition and remediation [3.6] generated high level\u000d\u000a      advice to industry and Government.\u000d\u000a    The following members of staff directed the research during this period:\u000d\u000a    Peter Warwick (PE), Professor of Radiochemistry: 1981 - 2010\u000d\u000a      David Read (DR), Professor of Radiochemistry: 2010 &#8212; present. Visiting\u000d\u000a      Professor 2008 - 2010\u000d\u000a      Dr. Nick Evans NE), Research Associate: 2003 - 2007, Lecturer: 2007 - 2011,\u000d\u000a\u0009  Senior Lecturer: 2011 &#8212; present\u000d\u000a    "},{"CaseStudyId":"44016","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Engineering and Physical Sciences Research Council"],"ImpactDetails":"\u000d\u000a    Research by Heggie at Sussex has impacted significantly on generation and\u000d\u000a      interpretation, by the nuclear industry, of Materials Test Reactor data,\u000d\u000a      used to assess reactor lifetime. In particular, Heggie's research has\u000d\u000a      influenced the Core Component Condition Assessment (CCCA); the CCCA is a\u000d\u000a      key component of the safety assessment that comprises elaborate modelling\u000d\u000a      of reactors, including a module (UMAT) that describes the material\u000d\u000a      properties of the graphite moderator as a function of temperature, coolant\u000d\u000a      composition, neutron dose, and applied stresses. The UMAT module relies on\u000d\u000a      constitutive equations that employ the concept of equivalent temperature\u000d\u000a      (Paper 28). However, the Sussex model has demonstrated this concept is\u000d\u000a      inappropriate for reactor graphite temperatures, and contributed to a\u000d\u000a      decision by the nuclear industry to revise it. Without this demonstration,\u000d\u000a      there was a danger that the &#163;22M Materials Test Reactor programme\u000d\u000a      (Blackstone project) would have produced data less relevant to reactor\u000d\u000a      operation.\u000d\u000a    More importantly, in light of the Sussex model, Paper 28 (which employed\u000d\u000a      the equivalent temperature concept) has been replaced by EDF with a new\u000d\u000a      paper (`P28') that uses a new graphite behaviour model (B++) that does not\u000d\u000a      invoke the equivalent temperature concept. See for example\u000d\u000a      DAO\/JIEC\/162\/AGR\/11 J. Smith and B.C. Davies May 2012 and other Graphite\u000d\u000a      Core Committee papers. [C1]\u000d\u000a    `Paper 28' separated `dimensional change' and `irradiation creep' &#8212; the\u000d\u000a      first being a strain that depended on neutron dose and the second being\u000d\u000a      the response of graphite components to applied stresses while under\u000d\u000a      irradiation. The Sussex model attributes the bulk of dimensional change to\u000d\u000a      basal slip, however, a process inherently related to irradiation creep.\u000d\u000a      The implication of this model is that, rather than being two separate\u000d\u000a      physical processes, irradiation creep is best described as dimensional\u000d\u000a      change occurring under applied stresses. The new behaviour model for the\u000d\u000a      core, being one of the 20 or so potentially life-limiting factors, has\u000d\u000a      allowed an extra 48 total reactor-years, so far, of planned life [C1].\u000d\u000a    Calculations to quantify the impact of the Sussex contribution, are based\u000d\u000a      on reference data from the submission by EDF to the Technology Strategy\u000d\u000a      Board for a project on irradiation creep, which was successful in being\u000d\u000a      funded. These calculations are supported by EDF [C1]. The total plant life\u000d\u000a      extension project (PLEX) provides for an extra nine years of life for 14\u000d\u000a      reactors. At &#163;0.5M per day, per reactor, this equates to &#163;23bn at today's\u000d\u000a      prices. Approximately two thirds of this contributes to the UK economy\u000d\u000a      through the nuclear supply chain (i.e. &#163;15bn). Aside from the direct\u000d\u000a      economic effects, there are also, of course, effects on the UK's carbon\u000d\u000a      dioxide emissions, fossil fuel reduction, and energy deficit.\u000d\u000a    An alternative calculation is based on the present annual contribution to\u000d\u000a      UK GDP of the industry, of about &#163;3.3bn, which gives a potential &#163;30bn\u000d\u000a      over nine years at today's prices. So PLEX is worth &#163;15bn-&#163;30bn to the UK\u000d\u000a      economy at today's prices.\u000d\u000a    An understanding of irradiation creep is estimated as contributing\u000d\u000a      (&#163;500M), i.e. 1\/30th of the &#163;15bn. An understanding of creep is not\u000d\u000a      possible without understanding underlying dimensional change and the\u000d\u000a      Sussex work has provided a foundation for understanding dimensional\u000d\u000a      change, which is conservatively 10-20 per cent of the solution [C1]. This\u000d\u000a      gives an impact of the order of &#163;100M at today's prices, with &#163;40M having\u000d\u000a      accrued already and a further &#163;60M over the rest of the period.\u000d\u000a    Undoubtedly, there remains a difference between what might be possible\u000d\u000a      with engineering solutions and what would be acceptable to the nuclear\u000d\u000a      regulator. Increasing the fundamental understanding helps the industry to\u000d\u000a      maximise its use of engineering solutions to reactor life extension.\u000d\u000a    The EPSRC, in its review of the impact of Chemistry, concludes: `the work\u000d\u000a      at the University of Sussex on graphite as a moderator in AGRs is\u000d\u000a      contributing to the better definition of reactor longevity and safety. If\u000d\u000a      the fourteen UK operating AGRs closed unnecessarily early, by perhaps one\u000d\u000a      year, it could lead to losses running into billions of pounds, threaten\u000d\u000a      the UK's carbon dioxide emission targets (linked to reducing fossil fuel\u000d\u000a      dependency) and widen the nation's energy deficit'. [C2]\u000d\u000a    The importance of Heggie's work in this respect is illustrated by regular\u000d\u000a      invitations for dialogue with EDF Energy Nuclear Generation (EDF-E-NG), by\u000d\u000a      Heggie's invited position on the Graphite Core Committee that has advised\u000d\u000a      EDF-E-NG since 2007, and by Heggie's invitation onto the International\u000d\u000a      Atomic Energy Agency (IAEA) Collaborative Research Programme on\u000d\u000a      Irradiation Creep in Graphite [C3]. The understanding of graphite damage\u000d\u000a      is also relevant to the material's use in the design and development of\u000d\u000a      generation IV reactors.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    This research underpins assessments of nuclear reactor longevity and\u000d\u000a      safety and has contributed to EDF's project to extend the life of nuclear\u000d\u000a      reactors by 100+ reactor-years. So far this project has achieved 48 years\u000d\u000a      or nearly &#163;9bn in benefit. The Sussex contribution is accruing value to\u000d\u000a      the UK economy of an estimated &#163;100M at today's prices, with about &#163;40M of\u000d\u000a      that achieved already. Graphite in nuclear reactors is susceptible to\u000d\u000a      neutron damage, and accurate estimations of the rate of graphite damage in\u000d\u000a      reactors are critical to safety and to predicting reactor lifespan.\u000d\u000a      Research from Sussex has developed models for graphite damage that now\u000d\u000a      underpin one component (of six independent components) of the safety\u000d\u000a      assessments conducted by the nuclear industry for Advanced Gas-cooled\u000d\u000a      Reactors. The research demonstrated that a previous model employed for\u000d\u000a      this purpose was invalid, and developed alternative models that have been\u000d\u000a      adopted by the nuclear industry.\u000d\u000a    ","ImpactType":"Economic","Institution":"\u000d\u000a    University of Sussex\u000d\u000a    ","Institutions":[{"AlternativeName":"Sussex (University of)","InstitutionName":"University of Sussex","PeerGroup":"B","Region":"South East","UKPRN":10007806}],"Panel":"B         ","PlaceName":[],"References":"\u000d\u000a    \u000aR1 Telling, R.H., El-Barbary, A., Ewels, C.P. and Heggie, M.I.\u000d\u000a      (2003) `Wigner defects bridge the graphite gap', Nature Materials, 2(5):\u000d\u000a      333-337.\u000d\u000a      http:\/\/www.nature.com\/nmat\/journal\/v2\/n5\/full\/nmat876.html\u000d\u000a    \u000a\u000aR2 Heggie, M.I., Suarez-Martinez, I., Savini, G., Haffenden, G.L.\u000d\u000a      and Campanera, J.M. (2010) `Radiation damage in graphite &#8212; a new model' in\u000d\u000a      Proc. IAEA Consultancy, Solutions for Graphite Waste: A Contribution to\u000d\u000a      the Accelerated Decommissioning of Graphite-Moderated Nuclear Reactors,\u000d\u000a      IAEA-TECDOC-1647, Manchester UK, 39-46.\u000d\u000a      http:\/\/www.pub.iaea.org\/MTCD\/publications\/PDF\/TE_1647_CD\/PDF\/TECDOC_1647.pdf\u000d\u000a    \u000a\u000aR3 Heggie, M.I., Suarez-Martinez, I., Davidson, C. and Haffenden,\u000d\u000a      G. (2011) `Buckle, ruck and tuck: a proposed new model for the response of\u000d\u000a      graphite to neutron irradiation', Journal of Nuclear Materials, 413(3):\u000d\u000a      150-155. http:\/\/dx.doi.org\/10.1016\/j.jnucmat.2011.04.015\u000d\u000a    \u000a\u000aR4 Latham, C.D, Heggie, M.I., G&#225;mez, J.A., Su&#225;rez-Mart&#237;nez, I.,\u000d\u000a      Ewels, C.P. and Briddon, P.R. (2008) `The di-interstitial in graphite',\u000d\u000a      Journal of Physics: Condensed Matter, 20(39) 395220 doi: \u000d\u000a      10.1088\/0953-8984\/20\/39\/395220\u000d\u000a    \u000a\u000aR5 Haffenden G. and Heggie, M. (2010) `Using First Principles\u000d\u000a      Calculations to Estimate Thermal Properties of Graphite and its Defects',\u000d\u000a      in Neighbour, G. (ed.) Securing the Safe Performance of Graphite Reactor\u000d\u000a      Cores. RSC Publishing 185-192. ISBN 978-1-84755-913-5\u000d\u000a    \u000a\u000aR6 Heggie, M.I. (2010) `Carbon in Moderation', Vega Science Trust.\u000d\u000a      http:\/\/www.vega.org.uk\/video\/programme\/316\u000d\u000a    \u000aResearch grants underpinning, and\/or resulting from, underpinning\u000d\u000a        research:\u000d\u000a    &#8226; EPSRC &#163;1.4M Fundamentals of current and future uses of nuclear\u000d\u000a        graphite: EP\/I003312\/1 (15\/09\/2010 to 14\/03\/2014, now extended to\u000d\u000a      14\/9\/14)\u000d\u000a    &#8226; EPSRC The Elementary Carbon project (EP\/G062943\/1, 2009-2010)\u000d\u000a    &#8226; TSB Developing the Nuclear Supply Chain: The influence of Graphite\u000d\u000a        Irradiation on Plant Life Optimisation\u000d\u000a    Outputs R1, R3 and R4 best indicate the quality of the underpinning\u000d\u000a      research.\u000d\u000a    Outputs can be supplied by the University on request.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"2","Level2":"2","Subject":"Atomic, Molecular, Nuclear, Particle and Plasma Physics"},{"Level1":"9","Level2":"12","Subject":"Materials Engineering"},{"Level1":"3","Level2":"2","Subject":"Inorganic Chemistry"}],"Sources":"\u000d\u000a    C1 Group Head, Graphite Core Project Team, EDF Energy.\u000d\u000a    C2 RSC\/EPSRC (2010) Economic Benefits of Chemistry Research to\u000d\u000a        the UK pp76-77\u000d\u000a      http:\/\/www.epsrc.ac.uk\/SiteCollectionDocuments\/Publications\/reports\/ChemistryImpact.pdf\u000d\u000a    C3 Gas-Cooled Reactors Technology, Nuclear Power Technology\u000d\u000a      Development Section, Division of Nuclear Power, Department of Nuclear\u000d\u000a      Energy, International Atomic Energy Agency.\u000d\u000a    C4 Nuclear Inspector, Office for Nuclear Regulation.\u000d\u000a      Can endorse the general impact of the research and the importance of\u000d\u000a      graphite core as being the most probable life limiting factor for AGR\u000d\u000a    C5 Poulter, L. (2012). The role of graphite in nuclear power\u000d\u000a        stations.\u000d\u000a      http:\/\/news.hse.gov.uk\/onr\/2012\/10\/onr-regulates-graphite-in-nuclear-reactors\/\u000d\u000a      This explains why it's vital to monitor the continued use of graphite, as\u000d\u000a      reactors reach the end of their planned operation.\u000d\u000a    ","Title":"\u000d\u000a    Extending nuclear reactor life by research into radiation damage in\u000d\u000a      graphite\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Chemistry","UnderpinningResearch":"\u000d\u000a    The safe provision of electrical power is critical to the social and\u000d\u000a      economic infrastructure of the UK and worldwide. It is an ambition of EDF\u000d\u000a      Energy Nuclear Generation (EDF-E-NG), formally British Energy, to achieve\u000d\u000a      an extra 100 reactor-years from existing Advanced Gas-cooled Nuclear\u000d\u000a      Reactors, which equates to &#163;60 billion of additional power output at\u000d\u000a      today's retail prices. Whereas a design life of 25 years invoked very\u000d\u000a      conservative models of graphite behaviour and lifespan following neutron\u000d\u000a      damage in nuclear reactors, the safety assessment for plant extension\u000d\u000a      requires a more precise model that must be supported by new experiments\u000d\u000a      for the neutron doses experienced in the extended lifetime. Such a model\u000d\u000a      has emerged, in part, from the research programme on nuclear graphite at\u000d\u000a      Sussex.\u000d\u000a    Radiation damage changes the shape and size of the crystallites that\u000d\u000a      comprise graphite, a process known as dimensional change, which in turn\u000d\u000a      degrades the mechanical properties of the graphite. The primary focus is\u000d\u000a      on neutron damage, such as atomic displacement damage in which neutrons\u000d\u000a      collide with atoms in the graphite lattice, both creating a `vacancy' (a\u000d\u000a      `point defect') and displacing an atom into another position. Some of the\u000d\u000a      displaced atoms find another vacancy to fill. However, those that do not,\u000d\u000a      come to rest in non-ideal locations; that is, not along the symmetrical\u000d\u000a      lines of the lattice. Because these atoms, known as interstitial atoms,\u000d\u000a      are not in the ideal location they have an energy (Wigner energy)\u000d\u000a      associated with them. When large amounts of interstitial atoms have\u000d\u000a      accumulated they pose a risk of releasing all of their energy suddenly,\u000d\u000a      creating a temperature spike. Sudden unplanned increases in temperature\u000d\u000a      can present a large risk for certain types of nuclear reactors with low\u000d\u000a      operating temperatures and were the indirect cause of the Windscale fire\u000d\u000a      in 1957, the worst nuclear incident in British history.\u000d\u000a    The existing consensus for radiation damage considers the aggregation of\u000d\u000a      interstitial atoms into discs\/sheets of new graphite (graphene) between\u000d\u000a      existing layers, and the aggregation of vacancies into lines, making a\u000d\u000a      slot in the graphite. The Sussex nuclear graphite programme started with\u000d\u000a      discovering in 1997 that the interstitial atoms bonded neighbouring layers\u000d\u000a      together covalently (this is the so-called `spiro'-structure). A whole\u000d\u000a      class of cross-linking defects between graphite layers were found [See\u000d\u000a      Section 3, R1]. It became apparent from research in Sussex that the\u000d\u000a      assumed extreme mobility of interstitial atoms was incorrect and\u000d\u000a      longstanding theories of dimensional change were incomplete [R2]. Archival\u000d\u000a      research confirmed quantitative inadequacies in the theory and so a new\u000d\u000a      theory was proposed, by Heggie and colleagues, with the most important\u000d\u000a      component being reported in 2007 [R2]. The new theory does not rely on the\u000d\u000a      movement of vacancies and interstitial atoms and on the formation of new\u000d\u000a      graphite sheets, but argues that `basal slip' is promoted by neutron\u000d\u000a      collisions, resulting in buckling and folding of existing graphite layers\u000d\u000a      [R6]. This theory is supported experimentally, and has been refined by\u000d\u000a      Heggie and co-workers with improved simulations and diffractograms [R3 and\u000d\u000a      R2]. In the context of the science of radiation damage, this is a paradigm\u000d\u000a      shift, and the description of buckling and folding in layered materials\u000d\u000a      such as graphite is new and fundamental.\u000d\u000a    Key researcher: Malcolm Heggie at Sussex 1\/1\/96 to 30\/9\/2012.\u000d\u000a    "}]